<SEC-DOCUMENT>0000875045-22-000025.txt : 20220720
<SEC-HEADER>0000875045-22-000025.hdr.sgml : 20220720
<ACCEPTANCE-DATETIME>20220720162442
ACCESSION NUMBER:		0000875045-22-000025
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220720
DATE AS OF CHANGE:		20220720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		221094477

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6,d:ae1758f0b07f4108915caecfff327c7a--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:biib="http://www.biogenidec.com/20220630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8xLTEtMS0xLTEwNjUwMg_0a25c26e-e9c8-4e89-966f-69ed4e7c9a8f">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8yLTEtMS0xLTEwNjUwMg_ef8d72ee-5f5c-4109-bc81-d6f80473e5bc">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8zLTEtMS0xLTEwNjUwMg_db9e2284-e5c1-4e66-bd65-993415e9dda5">2022</ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV80LTEtMS0xLTEwNjUwMg_8a269a95-4d70-4dda-b6fb-8731d7c3211a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV81LTEtMS0xLTEwNjUwMg_c50ec29d-f9c2-4559-9217-7b108480c6f1">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV82LTItMS0xLTEwNjUwMg_185ec485-4e30-4dae-a657-8c3f5d0b23e6">145,113,047</ix:nonFraction><ix:nonNumeric contextRef="ied71ea253e4b4771947185eb41d0c454_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82NC9mcmFnOjM3ZDIzMGY5MmY2NzQ1ZTU4Nzc3OWZkYjFkZThiMzQ2L3RhYmxlOjFlNDE4ZTA1OWQyMzQxMzhiMmI0NmMyYTZiM2JhY2MzL3RhYmxlcmFuZ2U6MWU0MThlMDU5ZDIzNDEzOGIyYjQ2YzJhNmIzYmFjYzNfMS0xLTEtMS0xMDY1MDI_c1bab225-0a1d-4845-a51e-7d4f11a37275">4</ix:nonNumeric><ix:nonNumeric contextRef="i68ece7d88a2540288a7a78a56600747f_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82NC9mcmFnOjM3ZDIzMGY5MmY2NzQ1ZTU4Nzc3OWZkYjFkZThiMzQ2L3RhYmxlOjFlNDE4ZTA1OWQyMzQxMzhiMmI0NmMyYTZiM2JhY2MzL3RhYmxlcmFuZ2U6MWU0MThlMDU5ZDIzNDEzOGIyYjQ2YzJhNmIzYmFjYzNfMi0xLTEtMS0xMDY1MDI_eeae9b2a-3502-4348-b143-9d8e53f547f9">28</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNS0xLTEtMS0xMDY1MDI_40122220-72c2-44eb-82b1-166676fe7965">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNi0xLTEtMS0xMDY1MDI_d78febbd-bec9-4c28-9a9d-15336229bfa8">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNy0xLTEtMS0xMDY1MDI_a3112499-02e1-458b-8934-f3f487425b87">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfOC0xLTEtMS0xMDY1MDI_3fb5f975-60a4-48b0-9d46-714f3ada8f4c">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfOS0xLTEtMS0xMDY1MDI_2ae24171-2259-464c-83fa-1c1c8d22ef1e">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0324ddb09a434fee859e03396262f145_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfMTAtMS0xLTEtMTA2NTAy_9f5de7bb-26ea-4c3e-86e3-b58b2b08666c">3.250</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RleHRyZWdpb246NTM4NmQ3MjZiNGU2NGExZjljMmFjMTI5ZDIyNWJjZGZfOQ_dcc81b75-939e-42ff-9ff6-9dc15fa131e3">0</ix:nonFraction><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMzAvZnJhZzoxNWRkNTIxOTgxMGI0Y2MwODZiMjNhMWRiN2EzYjlmZS90ZXh0cmVnaW9uOjE1ZGQ1MjE5ODEwYjRjYzA4NmIyM2ExZGI3YTNiOWZlXzM2Nw_fb9f081a-f28b-4500-aa41-1374f80a6092" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1009614648486a8d4885185901e0da_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f0875c34f74569ad7173f706002116_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852ff350063140c2bb0be923b3509114_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i10419c7fca6040f5b7f54c27a139c129_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12af56ba242049728b6eb6a1d817a8b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7eba8131b2470f979b8859ac26fa65_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655d8f6be57b43f8a4aff100977af6ba_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4021ecec514c33b4f46028ea027777_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0383fdaa1a45b2990dc160ac25e8e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609e4fab86de4ca682e02c1766083dab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f53af952a05400eb5a03b652b2a5224_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25bd83dbf18a47969953f960652b7ca8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f48125dbb64c14aa174f438eb3b529_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a7a040013e4e578186caffe27ff784_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a5574cfc654102a3578daabb6da090_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200e14d4b78f4812b17968b9f9d1aea2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5245b9a67e8448b39d74a04b7e9b1de1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ba7d8360a14679a9369e90b81fc882_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281cd7edebd843fe95c846ccd0a8fbe2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15182190caca498b8e52572e96ba2eba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d420575ff241bcb18f34eca21efd56_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3891d530ed41ce9c40c01229b3ecde_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67c4af1889714ce0862fe75007a47c79_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0a37bdf69449ddaf16a60e03e555ae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b532043d004077960b4e7717b3606f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6736d3935f8c47758cb22a7798dd423d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3383d03c85d343899a6760bb144c07cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47198f9003784e62a2d403aa1634c0cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35827c831ea64be78954e395e1202d2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf823cd6b2f40d2a0cc0697e0186894_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc3332cac8046689fcf7638658efa23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea41407ff6964211a00be80476455624_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75454f1173a447139f1217b1ed46d9fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d0784f479f4fc880cb5813d70f6f6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d4c7b0576941b3878692efd86da487_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e6f5e180744036ba354c330621db30_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bd31dba4354e46bc9629fe6a03d388_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368ea118836f487388ce043a695cadcd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25d30d01e8e4db4b897cf36867a25e6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbb659071554201aaf22eccd009353e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea5cd790d23403096957d2bd80ac925_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb06f06c308249beb439d90fa38b3553_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b352f1e386449dba581418fff17ab7a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6703a3087e48768722c1c0f8e42a83_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9aca39866e45a586dd764d86c5ed26_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab659fae07d74a4f8df69f5e986830f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420d4dc476054e95991acdec07455f64_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1857ee2b87204f6d8d339cd56a32cca7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d979b13ecb40159fab297299c33759_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656fd73a858a4b54b51b65e3c1349710_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c0db0e45a843e093aa8601c3e476f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ab97abf7474573a44451ecae9b1c59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88b9101790d4b0f86a212c7e9a96706_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14bbc79f38b047a0a22a8ba1a14f35ea_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052eecd99d764d54aa68dbdd7ecc39a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bf6535ed584cc8b7699690ed33169c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib469a3e9386544858caebbc51fee96a5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1fbe3fefed437397ee703a9770abfd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if28bf8793bb647839d1579d8c2459b62_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i776b02f0e19a4bf1a200745fd79fec21_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332047e2daed45c5b00fd02fa57e3838_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a38dad3f363459ea85b6ba15b99fd86_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2455559f227c4f65a8e32a02250a6b37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e9662a1a044772a5c48f8eb3e4d351_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1552de9fe9a4d07bfa00d31cdf4cddb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea743edaf2fd4b7097146dfcb59ebcc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0faea6ed6246d5afbb055c576af9f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d0c433f57848faa5d9ff27e1571aa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe70259be16496eb27510a3d1a37162_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7705963176451eab777349e7f86df3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2150fda458e94f098288538ad0da1347_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298109b8168d4593a326a064ab5b4deb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbabe3e8841e43538325df1464a51f39_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab1d1f75f7b44e8878daeee3d01001d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00b516da2954357b5eb349ac6097259_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9742df769c7c419e858e70601aff7144_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3c8021fc79f6416686d187243973ea45_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bce0582b9234dbbac96a00b848486a2_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3729e3a50004440ba3134a7803d8b293_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc13fd60c8140859d72089cfe8c306f_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42c682634844c03b11c37f7325f453e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb2cf98fd9549a4b68f0d966327fbfd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bbffe1fc2c4ff4bec0eda9713c2a71_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb931292e9944a83b4a28788d901981a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093f59a249e8425e8dc9546e07b5d4b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb54803dffa43a8b5c152bf9bca7854_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc97f4c706c4df984f6691e843d75ee_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af09c4bc4774ceb8b2aea7ec735f424_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2801f94f42429ca36d1bfeafd776fc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cec06562a4b4440bbb60cef5c0e756c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57475280b3bd4e4f8735035f66af5da2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae64ec1886f4842b346a20565644a07_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd18c1f363643da8e1eee2a47998423_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e50d0bd0f744b5ba53de911cb87f81c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5c3899b1854563ad3c2273433e9b88_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007d608c419b478cba33ba05d07aced0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d12a48ae2a54cd9bb4249844b6f04e1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8f3d7a22d664d38ae15146f61f0f1c7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie099d88fe35a436897378cba2f7f09f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bacccfe4b440259bfddc3e626a3be8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd6a55e7a084e99a824039b5136eb48_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f0b5ae9f1c4ab88664e67c1b9d51a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie863f266caf446248389f5d655c80f07_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0877cfe46ef448c8c7131bfa2927823_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf00ad995134f4cb48df2bd2c51a7e9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5a7668e3e149bb9288945e1b644d4c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70f6702bb4646988e0ca53e9412cd4d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439dde2be341406fa6edfa8d2a5fa6f9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81b6c4e8b0846d2977a5e818273a87c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d118c84efd5442395adffb3dccb0b7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549b6fd3d1344466adcf7f2de11e4565_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc8989f45f1472695f8f6ed83d3dbf1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ed02e892e14d0eaf6fee39773e7d02_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2c705401ea4f62a8a0412004a979dc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e8eb6c75ee484da1a9b2899bf4079f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e7d54a466a485cb541688829066e26_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9874f7ddd2cc4c1598811a920b86b7d7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd19d0a1a1bb4808875dccbdcf6b2e0c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669f2e9eba26433a84e680686bb0cf63_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4a8e4a5df14221807d09956dafea13_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2360a519c23e4144ab123af88aa77ea6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b67a35dc2b4011989ac9568e54000e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e14405a5204b01a6ec0d2b6f80a62f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89841ea93b374be7b061906d6d41e52f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f2ed1ce3a14b0990001afc1dd6c491_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f89510757554e059925b2ada6c7f286_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1389917b17d40cab84d0dea445f439f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66eadafd646d481f90ae1525ff408940_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26206d0cd7764127b07966be5f7b1a7b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246f3bb8b3b94d7a85b72b22eb167658_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18509476d6e74f7a8ad9b9e79de07e3a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ccb1c80bf9489c82bec10e689c3e90_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a2594f184f4ac9b8cbc8aad0760336_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66d9f7c4dc24480aeac96e047fbb0e3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db865d77b6d42dbb986db32acfa75e6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4237b443b36c423e87d4bba35a59f794_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47841ad34b76402897680f541339e3a0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b428dc01d34c3bbe3425f599b4d465_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24d8e1260d54752840a81ca4bdcf3fc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibac58ba74b4a4daab4732d74461adb12_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a6246e1af94484ac63941a25f762a8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b30f603f0e4af5b617750440ab03a1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787e3c6fe03d41b1af6a449e9505be82_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6ba2438bad4f1a9522748b9f8c53b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900bd71ac7a447f2877d1c9ef20a5d79_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d48220f13a42a9ab30ced0e8f1e5be_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb64f28ce22a4e32865b37fc103092bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5191eac6bdab406a954232524744f872_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd597660d69548fab84a62c47780e0a4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35a86579b2d4ccab8f3d3435b134d6e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64518c9cf9e49b0a60aaee3bd5ed703_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a92ffd45f3464b9fda8ccf988fe123_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358cd1acfeee460987aedecf5fb632f2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05e0a33bc5c4413a51ea40bba76c6c5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4508944e934b4c8cb245dc13c3967cfb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475aa3cb324a442da54be389e9f9aec0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236b9b5fed79407ea79107fdd77e4910_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3d0fc0b8224db6a7dfe05c6ee94f16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804d63c72cb74d8a825d0c9196678307_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c59c486765442ab29490107dc4c833_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad386a522eeb41e08b1ab49a0355313c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d98e5ebbda3474a97b1805fe5acad43_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1952410e30f040bc853466b15fdacad3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984ae54db252428cb8f595d9cb4150d9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9acb352dfec4b54bba68898daf102aa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2567373127054bc2a8607a8a0c8a7edd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c6c1e9fba1448c8ff10e9636557a4d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3588cab2b9054d38bac088fe429cc890_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7181656e80b44d28b2579ef54642c184_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7a5aef1a14499eb4bc5e66e0ff9e05_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5196d39fc34746f686749f922c1eddd3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034c5f0e4d404907bd5ac516daf28b53_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49329c17755547ba919fa1dda7c1f8d6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b838ba43c36477982d17fb691b3234a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae90209eddb94ce18a41953fa15d38c1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d5f94ef9b9a43dc8d2c2d02fdcb2722_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed83b378cc4447ba4b164ca7ba2461e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b56cabf17a421f85d3d4f832e08a91_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib039450f31374b54b85c6aededf4648d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611d28129d4e4e0599f6a9f56f89224e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3c484378104076849db738ae2ec70c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7866e70096134bd6b4a49b4aa53f2d04_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98bbb070b1424fc2a3a3f4bf953dc517_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248c0445077b45aa86eba19f300d0882_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfd10449e7548ffbe44b55fae3c44b5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b5463a749b4240884bb2801739ef29_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c2fc38dd6440378e0da306d5634c8a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c752409708d47fb98286c2172136b6c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d293f205e034c3fa4e0b605f6b06cb8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b96e7b13fe4cf899501970595d616e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ef2831201c483a816e081f25fe77b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic75cc49ce6a3424a8ebc26ac92c41122_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45191a6585d342b19254212fbe8438cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99502a8cfb3f45729909de9e9445521e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9efe3047c104850b8e5e3f237c83105_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ac3e997349402c8283ff022c717a94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9cd308b36c74ad58f3c697827421153_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa62803e94f241bc8d51d00489520d62_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1762fc48b1448f996169dd0486ad6d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df119b80ffc480e8399e35f9caf0122_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cff98a2974c4e18b7621008c47bf431_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe712ea06fb4478e9e58e6a0e0bdc3be_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c298411b25d4e859abbd71121626990_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e803d9462d4f58ae2c9c760329e8e6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593120b1e8584eb3b206a368abb95161_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6113e46ab14f91972e94233f927582_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide944bcb2c8349cf9c7f53fda13e0687_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ccd22804b741a38a553424e98761d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4b3c8eb21445db8b85f3ee7225cc7d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c97e3c0924c4cdca1b9f1a53282f87c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb92748d73344c199c4d746141d7e10_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8feeefdefc47759f3ad172a5d47c38_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf198850c37f48fe8acdfb3a8d10b2b7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48eec3c9dd8649e994f055ef1a743d24_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfa09326e424881b32a983586469855_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e6c0ccdcca4ea08f4fbcc8304df01e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909ed281083841ad97422e6d8e9b5fa2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1b8097922a4bfc8460acc93072bf50_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff32cab6555f4e67aa1cc62da2fe2381_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d6bc8eecef46c88940df4fee6d8925_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0039988350a4be2b2d710515403df71_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83629e3f3364efa9bef8fbc4e846597_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide698acf03b8401b9aef8d55660fcfab_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516625dc60d343959f4510e766fb1c31_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674aeedb6b6245808af71c103fe19496_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534264b1291c4344a70276b5e63a6910_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc015931c1d4d2db4fba3c31bd94986_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if805be58b48f48e48afc88306089f798_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4006bfbe38034523a41e0e68251e4252_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeedfc78a95049649dab7ec26f21d7ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0b53fa1b874bc596af922c5d3014db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c6e75fff5d48ae9c25b00d31fe330f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dfa622b4e2449e8b118649dadcb3f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i845528c074714b90896d3a1a295e2d20_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa23d5be5be49e894fcbc5ff00c4c1d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a07137c98dd4524ada1101807817e84_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ff46c84eb64c11aa952fd2ef0f8162_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746834edaf31484b8281cd357d15cf15_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie414fbe6060f4736819d0c0a26db0825_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb013e9fb28748ec96b5bd3dbcd9cb36_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98657545c7442f69f64e667dcb30fef_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if081f6ddaa644634a85c1c8e772b6984_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d58cea04d384f9e962f42524c6c6618_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e33e4e8358e4adda4f14ec95348140d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9743755e37fa419da373d722f34ee542_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2fcbeae88249a4bcd644491e34cbff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic01db06835d64a3183e66267859801c6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350ceaa6094d41beb6a43612a28b3522_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8767bf21797c4edd9ed6d33237556b82_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a4b565eb6a4894a23a82cad310d92d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8586bda14db4b688d52c294e041530e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1be940b30cb4fe585cc5a760d23fa93_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa0b6d1982040c4b2eec5d12980a8f6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a76cce432a4940a7ee77404de33976_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i267202cf4eae44a18487d9728c2731e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id895b207466d40dc95e4ccc4a5a688cd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddce2d7962540e6ac7f7d0e98e969a8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb00137c6dbf40a19194ed758485a9ad_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5b6eaefce44a1a8296fbd9fad4e46e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8cf5e156d34a85b0e5038f75d9a1ba_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf550338832a4a30b4fdd8fec9c03a94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f6509df9234368ac66c5aee7ff2450_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39db4e78f61d4e84a1a5f31a5027bbfb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6154029d154694ad802b0c0880d594_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848c2181fc424e8a9cb106ef8274e8a6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41610ed9f98048e6b4b8084998674df6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272a454e80394786a9fd2275a5ba02e0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5bc86475c9b4c89ab084e88ce485ca1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb45edccfc854e13b231619881ae3579_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ff50cb600c4fa6a01c0a4495b88c78_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0863cb79da9045349bba7df17125e957_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e411c18d6544dc871cf730df065633_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5acd41d895754f3ab16a2ad37d6b762c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20bdbb4b6e064fc0af141d9e1a0fb2b2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68dfb47e453249e6afb959fc861e7025_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f28371d51c34038bc9822ac4d4329ea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1ac54ae2734b5f9a4178272d59b625_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b44e06b1074fe69c010ee1a0eeacc9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9427ad614e3477597e42639edc85a11_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391f039c06924c07919d530cf6d2dab3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c880de17294fb3ae9accb52a1997c4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05034b4dab44684bb680a5b424b3f61_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5991f123dec64a919280b85ffc4ab06e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411f9e9067594525b9d4f01a9b27f61f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e83afbbe2445c19ca3bd556f42beb1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6a7d87e2f44c0db0cd331472ab5e2c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaecbfefdeba441fafd2b18f0f37475a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6647a216d66c4d41a03fe12ef97207e6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0008cbf40274fbeb37cbbc7833e345b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1e43eb20404d65a4905d84c981be83_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63936ee597c4dcbb4c197c6cd02228d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35fad63758942b88c0a4d638d35855b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2f580e87294d6dbdf0e82006621e05_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ebb2e335574f1286e06fa26a183500_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2099c0e56b54466bb5a80bc17980d728_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012225e935554e759f4d02bd7f455af3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i544c9b9c3c2441c5857dc27ac5202a31_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59cb8ca63113417198b368e0ac0ee147_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd081a6a3bb5485b83c7166fa8c55471_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic484bc958fa842c3893a6412ac12e08c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc85bed201b940878824eb131a5d746d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b7e31d17f240a4bfc8076fc48a942c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d66fca5ded45e297765f1b445f6c92_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2d9158b11645f5828f271820b2dde2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d6c18c9bc14e658bc749d15f2cc080_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b0b386d72c42c7829f67584a538904_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b21651141942a69478099c2ccff90f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e2e6376f304466973b1a306132b804_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a0c596128542549c311e01f527d415_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadcd9c4eb7aa4d43a9535edcf11234db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15237bd167748dc8935bb2db5aadd11_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be79ed31c744ac0b8ce99f0b7505404_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab432a874db444408172f33c16977803_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43bad9cb88d740469bbafb0fb0cf0cee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33934bee3c5143dd99f1d517165ead05_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if642314400ad46ce8997912ff65d7344_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f09e81766c42e2bbbe9c2a856ada30_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3b5523cb8f4e5288c2afa798269171_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if88580276d234ac794a107b535d8a45b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d27d16a0e37434c878cd333a5be7789_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb9e7fc3fdf4dc9a9ee227b36aeed4c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86078aa510454a67ac821f531e00d16a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2407978bb6bb465a9a11b59c52630feb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a019fd8fe4f425ab48dd67d22d37e0e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a2d4a8e1514e098184d910e5f41721_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03d8681da5c48ed823c595e3df9cae4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a918b8fbaf4a098bb0923df21e1a68_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9895041a5d4fbf93cb82132c5fdbc5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39f35171ae547d68317e335f6bc8cc8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LecanemabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690a67cc5731414a8f9aa06c53540e02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c5095f62ab4c62ba0b2a1719784d97_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635b802dc41d46298f9d8608e9935a23_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08cc12b77134a85b0419098882728db_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a40683af9114b76a6f0f696d7c173ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c90e8d925d40afa3e544318c2a8632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d560d86969470286de95947d4488f4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50f82f106e724d23928e954b5d6e3aca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15444f937e5a42c6928f7d30caa9be5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7072613f54844e3ba4de934782cd9535_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d589ef9b9024af5845103efc8018806_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57322b393335447fa049a18be91e5f26_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86265989727740ada4d3803a06691ae4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf09d1ffde3467f9d51fd1d72e55232_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cb1609479343309a6ca0ff24c5fca5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035bd9bd822646e3ba8f72fa5b2ecab5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie430205c0e8642b399f6ac098c948e1d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502f935fe0b441bfbca01d697b55e5c7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab21929ee2b44bd3a5f7fcac80a7717a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied71ea253e4b4771947185eb41d0c454_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ece7d88a2540288a7a78a56600747f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9311db8dab450889a2d4bef745e3db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6986e53f6f514bc497305cf50bf1d99d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529693e18f9d4940a0dc51a9656b8e81_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5410a4b7463e4871ba2258c342695d0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e760801b4e427c8d09b34b65881a0e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaae543901cf4bf0b0aaf47b428c3c49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf903905566403e92f0306b14f21dfe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc363fb469e473aaecac4cf8e63ef86_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86003e21d714ef8a56c54bdd2b57d52_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d547ff00df40f989fae1a81b0cda41_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8467e688e67c4414ae5b2d512e027882_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d5a87c8222b415e99b23eb87ba7b373_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e25682c306442281fbd9b9e82f381c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439c2171b7ad4a428141db883360f934_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a56b8cc106475483c716145966db29_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9074ac7fc541f5890093a94bed4d8e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11ecccfe2884f3db642f3f076602bf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1825b81a7ec14bec968fb3cd13c00522_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314a58abcbd64561923d0f9981338f6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id49be596d72642af812e59dd50890f35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f635edc8a2430189c968b78a9e8cb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4316a770d24b4d87b85ca16f1e2d0f5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b362d0ab3134007a6f2417677122114_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b867d694211492a993655d5fb259d85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1446517efc4d939297638bd36ea497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia741396d8ac949ab9d5894b778f1505e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03963bc9f9074822b67815b3e793e1da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e334b59f08464daa0d2d2f402ad4b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca26b7ffe0540fc80c3f59dfb576259_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129644619e6d4f278f61964c9e9f3d66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bc38e16d5946d6982b6c3c72a07586_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580eba0699d7484880390868de30783e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ac8144dad34592a0e0d767e503cd0c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia788a53d2f44480a9c09cb836102cf88_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b2d699c7994b058ffdc0a2973fe76a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7f7781b1e446cc8b8a3b615a223395_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd86bc5c7e44ed5a9d043c911ec35d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae70c7addbd245e88b9cf036469b0e00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2546b8d042464cf18732132087c7837b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1b24834b7c453f887f7958431a260f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749156c0d2244797891329da8f801076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e095c97d47740e5afa1a5c72b4c260c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c33ec33ac24977b3efeb593adf8673_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5363dbf017c244debdb2e7604c5291cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbcb087e76943ca97d22fd15915d974_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd69aba81534dac91205bace6805330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0324ddb09a434fee859e03396262f145_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e56bad4fc89492691617ec7457815b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207ad38739a54d138f6be5e688458503_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5238704ed54c3bb7e1f6928897e2c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1febee2fa143e5976b10c5f25675f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157163fe40884091bf7820d01b3e22e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5386dbc2d85346818db10319e0a45e26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c9f2c4702549599568d0e5eb9618b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb4076d18da4ad79a95ee670fa15bb9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef3bd0aea29473b9ec52de86adeb7c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d591f719add4db891a44f2be40ad81c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36d266508c34afbaaaeb0f53bd98cce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae46d4e5ae24b1f999399ec074184ab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c0efb74abe649dc92a1800ec298d90d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09e47414ccf4f6b88062930b82b2a81_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16498989190e4b99abd2625557d367dd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a33bb7bfab44b49a33909b6a68a094_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0dbe89693034b608f02372c6ae74cf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140bb6501b0449349963095a4992952e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769b78fc374145a2b38b4bb257858d1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90787041e4c649eabc5e9f60954a4d29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992615614bce4506b32f63aabda86d0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73106cc97da45d0a1aa9b8366bb2add_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d0bd51bc4647dfb2a191cad3986b16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab0561efd9a429f84f8b4296c82c73e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff853fccd14442ebbb17ab9ef5e1c4be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d6800eb2c74fba819c1b070cefdc3b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c0ffa95ac44d50a2d00434ffc62f9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921449c1dcd64ae094a4e7206755b28f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a4214140a84299923a095d0db68a81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753e77cb96eb44eb91792a859ab31f61_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cb17acde494685b6ba5f5809b645d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7766088e60b94262b048c5f32da60dbf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199c91171d3f4a2382e5d5cd3f00f2f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacc3061343b44129f16a08974a6b548_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff5ba68900c43e69eec8d505e93c934_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ecadcec54794963b50463bd915d2bc9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe39514eee6e4adc9af02f16e10ee4f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7533348289c643f4870127b69ce2e844_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5cb29af1d6742908ff898b5ebf574cf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfba5b1866a471cabbde592da7a1247_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e00dff9ecc46b9bdb7d69718e8e77a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0466df147d7942408c489858f169de93_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26725a695f2b478788a442808ce1beee_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2ff89e7330400e967da0afcc3e2d99_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e91a04e7eea4c38b6cb6751d4043a2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1bde062c47d49a8a7f0277989d627c9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743019f676ee466795fa568ff3243842_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb90f3ecd54b4e76b9e9bd9dbdbfe5af_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b82baa8ea8543bda12f9f9de5c4af65_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8929791e27f944c09502d04a25c1b021_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c78831bea640a7b02cdd4181f233cf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa592716840490d9b21fa9dd5a26334_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75940771ad54dec84714d53bc3a845a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6cecc0a55d14fafbfae04ffa644a385_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ca7beff5f2474b9d401734f8a1ec03_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e235045cf98490f8a1e30fcda5c5e48_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de48898e11f44699c3ee51c8d39f207_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f3f785472d4636b331649fe366628f_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e750febc54343bc90f1a684d4d68e95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f906803044b470f81de0eefb5dba012_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74799976f1b24216a03f17304e960c0c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b1a6af29424cb4aa2a50fd11bfc322_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d5ef31f0fa47a39e2dd83dd2bfe19a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575d79eb11134ef993a7f0b1f6d269e3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc4c2d8c7e943a895789a1697167962_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02689d9b0b44614b294b3f29ca4964e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cefa532629b41e3b9dc278f0f0761e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6092dc9afba6475196a6884c6298c6f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic958db40215b499a9247ed982bcb0126_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b36ca2852634efd80fe1a2529739a5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0857062bc899445982d736bffcb52e46_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c530cc918fe4a479490cc9b9876a764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd7a423894c0434db231ce4133ce2fc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1d25a8fbe4414ba423291d19d37d5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb798cbcdc26425ca390649668ae6b38_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926408e195f24642b73de23a766b86b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70908e6791334ae48472963b146ee23a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af4d136402048959dd3e0e8e44a22bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7da619d63a94a4591936365ba7bb51f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8fa50adcc4464c39a7eefd4680d1765c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaefaf11247247fabd1fe4cc79c22821_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0043843f37f44a84bcc5be0643dee99c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b4c6baf27c4eba8805276bb5e93dc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ad03e37af84a41bf8a69fdca5275ba_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5299d1d7822041d3b1817887dbd46432_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45416e1b26f14f8cb98e144608a14a4a_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dde4b51293471682782551de32cb29_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012f5bd22d3246cab5a94a0bed345c02_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f30485bd8748f68ef275fcb514e0b7_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a73135034a4df7a82a111ed6759cd0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ce2898f9b84c02bac44cbb9b1e0305_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764a683e6bcc4b34bf7d9c79615d5377_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fab60076437436eb30238de33b462fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2094119ab54aaf9f28c105672c9bb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182bc48d598f48999740017707097224_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443555b494964780923c6389a3abfb01_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e893ee39104e1b816e93ed8a47ede9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia28fc04646c349038aaaf67a779b66d3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d16f8649274ffb8a001d8f59f22062_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie252dc547f144a40a6ac6f848a877b7d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7eb2c1a6e246ada70e7f900be38d88_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe2a159169d54d4286b3396de8a76082_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia331bc87e6e54c62a0a9e2f8480cea82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a78abae937b4e9484720512244a264b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4702937641c1484bb3d3617fa0ba60d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e1d4e25ace4b32b9de201f21da7db8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5920e9a8348d4b0184a94d22f70f6368_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812b8492c7e14121b9c263880e2c112c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe2d434e7672451886a60cab65f8b82c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1938ff3b65564001bf3b50000b46d67e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bdeffc2747242298d5c74ba9260545b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec879dd434784246ba9689b7523432b6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced58bff08fe424fb838818157ecd374_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7ab9eec76f415b9754dece93693c29_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b10142df3b467e8bdcbcc59ff9e2e6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e16fe28452c4b27a1b2a84884bb91f2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34aa5eb01fc941468970bfd540a717af_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d9e723dce441e9bca32cefeba7912d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef3a7fd90234f2892d851bd89cb2861_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd50768ee6b486a869faf383cfec503_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c42c98806743678d857956f14b201c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05576bec60da463ba40fa81a1d5d6213_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49a0c322d4a4fa6ad316e2dbcd57859_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769f963dcd104808b7f557b5bcf509fc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82614881b654024a0f966982a2e1643_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064f6c79792847f38bbef18be71b042b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i935112ef58c34d998257dbf55b14da22_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1fbb5461ad43bea5769749d280c2c6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59078147fa6f488c8239e033a6fdf63a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9be70de8b546c1876a1ef6efccb2b6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca4330df54e4589a400fd134a2fa6be_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430d8a3876b04d60b0a0e1af9b6f9375_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4c31bfbdd74c94810389e9eb943e18_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e723dda18e341ab87f7edde733b2a16_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaaccf079a49488eb79a43457781b779_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404f8659b4894301b106514d8921df0f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726ad69e44e74f18812d926508d81057_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib613e85a78bc4456893a2ad6a58b3db5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c01771898e4c6a8325194d609c2081_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ac757a014e4f9d8ee4cc1b9b4d3350_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7dc5fd89d04e4c8378db999b2eda6e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0768cf5b82344dfeb26a9db8c6655c34_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie432e10abc0b47dd9185ef700519fae8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eccf41bcd3b4ecba3d2a095e0239516_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da564986d004bf6bbea566000fdb4f4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34df8b39629d46e3a1d76df662efe1ac_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4242bcb1bf68441e915043a252b28f3e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c11788c3f940898950aac7349449bc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2087847394724417ae5cd7671bef7634_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e3f4c497b04721b2a471a9d1462e90_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e6a4109ed149448f4eb38f7f7a6fe0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd85c59952834082adcd0bda1c3bc397_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c78200de99d4a8992ff379211c1b05c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598d5781ec294abb97c2fd87cab72371_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb25232bfbb143b2a5469052ea1aacbb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070778a5f6bf479290bc275c09f5d25d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c2f4968e7d449bbcdba9e0686e5349_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4229db4a3b479c9d2a9fb092797c6f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4787bd92caad430eade94b63652c8eae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f165e7c3e24de78375b532ed70ebc6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id383c4b3624c4a3084db5066645c15a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0b80c4d4a24c59870003ff1526e308_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03333ee45c754e49b0aae5e5249ab285_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d41849f5c049ef858c1b655ecdb83d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1703619476c5469fb6eae667c889633f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd736af6b0704581966ceb888e962dc1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafdb9d7e53324279ba0597cb20081464_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af51832291c4232b19c5319e421ca32_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e91b63836f40969d01256870c0e4e2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ef6923e0fd491fb74d065e645dbbce_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc7449e1d4248ee94e3a7a6a2b8c0e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc0bc45a8f34476bd5ce77c28c035ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78027a673ba84f59a729646c29056ff0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95e48bbaf4a4e799a9ebda77407ebe7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03a4083cbe14980afe9873df6e01157_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fdad13d37214d518d991982787c19e3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231f21da54f240e09322a7c8c9ff9b00_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ccab6bc98574047b1778979662e99de_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie326ff087126492b947c8a627fa90a72_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33450308aef4ad29feeb06170373827_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f3123780b4402a90c954338e97580c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5e346af48c4d1ca76de22d3af2bb36_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1166a4ed6a348088b5ef0d2b05a70c1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8a39607aa44c739f29386c64f8a2bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6766574fbd894502b558478062716387_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e9b008911d4b25964bc84cba645427_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311cc627d4884000b967bc589ce09d88_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if756749af2de4c4e957db16b485d5427_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e194ceae6f64b65b2349e8df6ab64e9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ab1ddc9657403a8db302457fb46496_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b2b113cfdd420ebfc7941cfaba6661_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89906910d5954e76b7d9d286e110f422_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd95981381d46b7a30d0a586d846fb5_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i994f69bbb09645ee8a7918008c471ef6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c39215e3534c88835566c3e470d890_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce6fe69e35a448dbd457279465a317b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b272d435084dce9cd4a8f7830ba08a_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1139e7fad6c40f48deba330c854be64_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261e664559194dcfb968a0ed63765c2b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a36bcdc40354faeb9b03f0586021c98_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iae1758f0b07f4108915caecfff327c7a_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE2_d7d55a05-8e7b-4be8-9a35-e863c851f5dc">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2RkNzcyZWJlZGY4NDQ3Zjg0ZTIyZDMxMmVjMWQ5NzkvdGFibGVyYW5nZTozZGQ3NzJlYmVkZjg0NDdmODRlMjJkMzEyZWMxZDk3OV8wLTAtMS0xLTEwNjUwMg_fc2810cf-9781-4cd0-b9b6-cae8bb6ca8cd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18xMjM_5219da45-eb68-4ec7-bfcb-058f3717f7f6">June 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6YjBhMTc0YzFiY2NmNDIwZTg0ZTlmYzMzNDcwNGVlNDEvdGFibGVyYW5nZTpiMGExNzRjMWJjY2Y0MjBlODRlOWZjMzM0NzA0ZWU0MV8wLTAtMS0xLTEwNjUwMg_76a45a24-8836-41fb-a1a0-c4f390e05943">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEw_4b2b46c0-2578-493b-a3b4-8771d496363e">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20220630_g1.jpg" alt="biib-20220630_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEx_d6e372a6-109e-4e27-9002-f0cf800e36b5">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2Q4MjY4YjZiZGY4NDllNzhiNGIyNzI4YmU1MThmNjUvdGFibGVyYW5nZTozZDgyNjhiNmJkZjg0OWU3OGI0YjI3MjhiZTUxOGY2NV8wLTAtMS0xLTEwNjUwMg_80ba2d7c-5a8d-4d60-b47d-442899c7b712">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2Q4MjY4YjZiZGY4NDllNzhiNGIyNzI4YmU1MThmNjUvdGFibGVyYW5nZTozZDgyNjhiNmJkZjg0OWU3OGI0YjI3MjhiZTUxOGY2NV8wLTItMS0xLTEwNjUwMg_f3d45009-b5de-4c84-809f-b98fcd601072">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE3_ed9fb133-d484-4392-afe5-e6e1c510ab6a">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA2_5318afdd-9c0a-448e-b3f9-1bcb7005d7ad">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEy_8a55ebd9-1ba9-46e8-b6f0-d4fc4713deee">MA</ix:nonNumeric> <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA3_068d166f-7012-4e86-8577-779847a95c30">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEz_caa52318-189c-4916-a3fa-ff06f52d1b51">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA4_a5b9e824-c7ca-4fbb-8564-460a3b70febb">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTAtMS0xLTEwNjUwMg_b57e0440-2741-4f30-b4dd-0ee77d7cf026">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTItMS0xLTEwNjUwMg_95590b8c-5f3e-4b73-8b0f-312f56b637bf">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTQtMS0xLTEwNjUwMg_3e3743e6-f7b4-4b35-b575-636e74890b21">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA5_42afeee1-fdb5-448f-b78c-5aecf410b1e3">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE0_39ade907-5d95-4953-bf1f-edf3862d47bf">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8wLTAtMS0xLTEwNjUwMg_a154dec4-2ebe-441a-a7b5-8dec863af7f3">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8xLTQtMS0xLTEwNjUwMg_b8542a58-3daa-4b75-bf7a-6553f21ad94f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8yLTQtMS0xLTEwNjUwMg_d01f95fd-c1ce-4a54-8be9-a227e90bd4c7">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE1_41e53978-9c9f-4a2b-92a8-ebe16f5b64ef">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of July&#160;19, 2022, was <ix:nonFraction unitRef="shares" contextRef="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18xOTk1_185ec485-4e30-4dae-a657-8c3f5d0b23e6">145,113,047</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended June 30, 2022 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of June 30, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_34">Condensed Consolidated Statements of Equity &#8212; For the Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_37">13</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_133">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_133">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_217">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_217">77</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_220">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_220">79</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_223">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_226">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_226">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_229">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_229">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_232">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_232">96</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_235">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_235">97</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_241">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_241">98</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#8482;, BENEPALI&#8482;, BYOOVIZ&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="iae1758f0b07f4108915caecfff327c7a_16"></div><div style="text-align:center"><span><br/></span></div><div id="iae1758f0b07f4108915caecfff327c7a_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy0xLTEtMS0xMDY1MDI_740a9b0e-a571-4d14-9b26-3adbf54c4efc">2,054.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy0zLTEtMS0xMDY1MDI_3dbcad0d-8721-467b-9971-de97ccad96e9">2,236.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy01LTEtMS0xMDY1MDI_3b9df68b-17a9-4055-b39c-36f6315ba91e">4,121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy03LTEtMS0xMDY1MDI_11e233d9-e90e-4d5d-b6f4-cebd88693e9c">4,447.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC0xLTEtMS0xMDY1MDI_086d1353-f48a-4d3c-b2b6-8ea4e75d3d13">436.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC0zLTEtMS0xMDY1MDI_778a137b-f2ab-45a3-a024-2431428b960c">440.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC01LTEtMS0xMDY1MDI_6491cf43-5530-4604-9c83-b438b873510a">835.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1009614648486a8d4885185901e0da_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC03LTEtMS0xMDY1MDI_9f662bbf-5070-4ee9-994e-c753f6e467b9">829.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS0xLTEtMS0xMDY1MDI_cdd4709b-2c93-40cd-8af2-ef161784a4c7">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS0zLTEtMS0xMDY1MDI_8d9f6bbd-04be-445a-b8bd-d425254aacc5">99.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS01LTEtMS0xMDY1MDI_878ad17a-5002-462c-848c-c00bf93bbbfd">164.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f0875c34f74569ad7173f706002116_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS03LTEtMS0xMDY1MDI_a6c4f5b9-108e-491a-a234-5d821547b77b">192.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi0xLTEtMS0xMDY1MDI_252bfb67-41a1-47b8-9e27-c022e18f9f28">2,589.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi0zLTEtMS0xMDY1MDI_4f7d5fae-f3e3-4001-84b5-27d3e10d4255">2,775.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi01LTEtMS0xMDY1MDI_d0efdaee-5206-46cc-9740-6e548c5d19a2">5,120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi03LTEtMS0xMDY1MDI_5c2e7ea7-7684-4e29-afeb-7d1bfa91601a">5,469.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC0xLTEtMS0xMDY1MDI_5b042497-7a4a-43cc-9662-42b8e8583bc9">484.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC0zLTEtMS0xMDY1MDI_9a4b1be4-5e39-461b-9f59-12cce1a8bdd8">459.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC01LTEtMS0xMDY1MDI_c5269ad9-8b37-49d3-9e62-f1088247560c">1,237.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC03LTEtMS0xMDY1MDI_0283a3f9-284a-4b5c-b4d4-e29578a7fd3b">937.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS0xLTEtMS0xMDY1MDI_89b6e955-ad7a-4c51-9139-d9f6bea2dcc6">528.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS0zLTEtMS0xMDY1MDI_dcbfbda3-7b32-4527-b2a3-b4c9532121ce">585.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS01LTEtMS0xMDY1MDI_04db9713-35dd-4e5e-8d72-3692aef7bfdc">1,080.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS03LTEtMS0xMDY1MDI_6a556878-341a-4ed2-b6fb-86276490e8f8">1,099.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtMS0xLTEtMTA2NTAy_53e7311a-9660-4ef1-93ba-d96528ae3297">572.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtMy0xLTEtMTA2NTAy_0b24f963-93db-408d-865c-b8037fe301ef">637.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtNS0xLTEtMTA2NTAy_f63c1578-d2ff-49ed-972b-d342fbba2ff4">1,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtNy0xLTEtMTA2NTAy_409e19e0-8402-4b0d-a2a4-99ed3cb9f1d0">1,232.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtMS0xLTEtMTA2NTAy_27d7621a-90c4-41eb-9c1e-a19334410445">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtMy0xLTEtMTA2NTAy_09d2be0a-a1c1-4806-8c64-4234621585c4">604.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtNS0xLTEtMTA2NTAy_70744d33-1fd3-4fb7-b8f6-2646c8389db4">134.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtNy0xLTEtMTA2NTAy_a20ba55c-64fc-4c97-a0fe-83a44833fdb9">702.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItMS0xLTEtMTA2NTAy_6c42e508-4a21-4459-af0b-0fc5bc1e9990">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItMy0xLTEtMTA2NTAy_af189703-9fdc-4378-b552-7d7ef83b33e2">15.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItNS0xLTEtMTA2NTAy_4885b701-6f8b-4c79-9dc2-112b7eba93c9">87.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItNy0xLTEtMTA2NTAy_995f8328-1037-44a7-a355-5c5b0cb6bf52">53.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtMS0xLTEtMTA2NTAy_141ebcad-9bb8-41d0-b504-418111a7a034">4.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtMy0xLTEtMTA2NTAy_91cf8a80-2932-49bc-b0db-5d8edd00e34b">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtNS0xLTEtMTA2NTAy_d5298007-4981-4142-84bc-2a5ece3c941e">11.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtNy0xLTEtMTA2NTAy_f93a32b4-784b-4f39-9f6f-e5647ae03497">33.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtMS0xLTEtMTA2NTAy_3fc4c0d5-aaec-4fe1-956a-15c8fc9cd71e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtMy0xLTEtMTA2NTAy_a806854e-8497-4073-9ae3-425e505c6379">18.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtNS0xLTEtMTA2NTAy_9075e630-493d-4877-b05a-20d8ca67f60f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtNy0xLTEtMTA2NTAy_1232349f-b4e5-432e-a7a7-3cd96cb049d6">18.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtMS0xLTEtMTA2NTAy_1b9b5b52-58c0-48b1-9ef9-8316c4af4235">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtMy0xLTEtMTA2NTAy_6326ed62-53d7-4b70-9c39-3163cb5db3b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtNS0xLTEtMTA2NTAy_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c">108.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtNy0xLTEtMTA2NTAy_5de627c0-31d6-4281-a7e5-b4ed37b39cd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMS0xLTEtMTMxMzg5_4b038783-c73a-436c-a12c-6f322c8966a1">428.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMy0xLTEtMTMxMzg5_26b72504-9e10-4d04-8a36-ab9007374eed">96.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNS0xLTEtMTMxMzg5_f1391009-f9da-43fb-8bac-7edc058e1418">165.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNy0xLTEtMTMxMzg5_542d89c4-1cef-4d21-8621-9024f26921aa">410.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMS0xLTEtMTA2NTAy_5d97117b-bdb0-41c0-8ea0-80804fe0cd04">1,319.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMy0xLTEtMTA2NTAy_d9e458d8-83de-4967-ba75-3c11cfc683a9">2,192.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNS0xLTEtMTA2NTAy_b33713de-906f-46d7-acef-fd9300466e16">3,504.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNy0xLTEtMTA2NTAy_b0e498ee-1837-4bee-a938-8bcbcbc9f442">4,419.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktMS0xLTEtMTA2NTAy_dd1debf6-0a00-469d-9a97-8a19ef4128f4">1,269.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktMy0xLTEtMTA2NTAy_5805ef70-765e-4db0-a86e-1198380ce986">582.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktNS0xLTEtMTA2NTAy_93770a4b-7757-44fc-94e5-b238dfb31041">1,616.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktNy0xLTEtMTA2NTAy_eee17cac-ad20-469a-9775-a94ce2524c9f">1,049.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtMS0xLTEtMTA2NTAy_770ed739-3325-4298-bc96-0c84ada72cd1">216.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtMy0xLTEtMTA2NTAy_13d1757a-de59-43c9-bd0f-9d70a161960c">409.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtNS0xLTEtMTA2NTAy_d8a80f94-dae3-4690-8de5-4dbb5576734a">342.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtNy0xLTEtMTA2NTAy_98fab727-9675-401f-a306-485d6c4702d2">364.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtMS0xLTEtMTA2NTAy_2546250b-b456-401f-bd8d-489cadacdc60">5.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtMy0xLTEtMTA2NTAy_2652f7cd-4a64-46f6-a3ce-29bf9e1df019">34.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtNS0xLTEtMTA2NTAy_3fc00b9a-642e-430f-95fc-a03b2f13ec84">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtNy0xLTEtMTA2NTAy_71c6cb88-9b58-4378-af0c-50f89efad3f6">16.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItMS0xLTEtMTA2NTAy_8f2ed7e3-dc4a-4d60-aee5-6ba3f35c7a6b">1,058.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItMy0xLTEtMTA2NTAy_86bcb419-e09c-4caf-921b-2e64413fded2">1,025.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItNS0xLTEtMTA2NTAy_73a044ea-aad1-45fd-af0a-4e55624e2ce4">1,277.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItNy0xLTEtMTA2NTAy_a67ed8f9-3406-4c4d-afd6-25592cef7645">1,430.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtMS0xLTEtMTA2NTAy_285e130d-87a9-4979-80dd-9fd15fb3b6b8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtMy0xLTEtMTA2NTAy_22073884-fc60-4eda-beaa-57b8b2caa3eb">577.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtNS0xLTEtMTA2NTAy_0945e8a1-a152-4225-a285-1216e094f93b">84.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtNy0xLTEtMTA2NTAy_66eea830-9948-443b-bbfa-3c7d493c5827">571.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtMS0xLTEtMTA2NTAy_b3be894f-a7b7-48ed-a34b-f102f30dff42">1,058.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtMy0xLTEtMTA2NTAy_2538cd3a-a0e7-458f-be42-dd5658430d4e">448.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtNS0xLTEtMTA2NTAy_3af3ad3f-9e7b-4b3c-972a-774ab66520b6">1,361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtNy0xLTEtMTA2NTAy_b7d407b8-4693-4113-8b18-bfb5dd7a375d">858.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctMS0xLTEtMTA2NTAy_914c2185-ecf3-474c-951b-67a9b6ef3b75">7.25</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctMy0xLTEtMTA2NTAy_08dc768d-bb6a-4eed-973a-757d51f8456c">3.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctNS0xLTEtMTA2NTAy_6b06c0dd-cf6c-4d32-92f7-f44e7d01d4f2">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctNy0xLTEtMTA2NTAy_55f475bc-a34e-4463-8ab5-9d4517a33ab6">5.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtMS0xLTEtMTA2NTAy_237401c2-ea5f-42b9-b71b-a2dbcf717649">7.24</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtMy0xLTEtMTA2NTAy_64306c28-ee7d-4151-9a54-453a65198690">2.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtNS0xLTEtMTA2NTAy_6925f975-b657-488d-85b8-f38d8efe1ac6">9.27</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtNy0xLTEtMTA2NTAy_54f82b47-528e-474c-afe9-3ad12b3bd4ab">5.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtMS0xLTEtMTA2NTAy_f97c16f6-8084-4256-b6f8-3746b529ae7b">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtMy0xLTEtMTA2NTAy_81e84c82-80a8-4725-be66-23382bc0e6da">149.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtNS0xLTEtMTA2NTAy_35c639fe-0d87-4607-a057-680c4065e9dd">146.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtNy0xLTEtMTA2NTAy_5b5a331a-0d25-4f59-9ec4-044355a314c3">150.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItMS0xLTEtMTA2NTAy_676f8ce1-11b3-4eb5-89ac-339f50b41678">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItMy0xLTEtMTA2NTAy_29113cbb-ebe6-49da-b0b0-4ceffdb35dbc">150.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItNS0xLTEtMTA2NTAy_fb7d1add-e4fd-49dc-b2d9-36dea61642a7">146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItNy0xLTEtMTA2NTAy_000cc38a-6738-4002-8ea8-d05ac542dbd3">151.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi0xLTEtMS0xMDY1MDI_f88097c0-da7b-42e5-99cc-a3b0b508ebbb">1,058.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi0zLTEtMS0xMDY1MDI_7dc4454e-620e-4912-aefc-5f0f1a33e44b">448.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi01LTEtMS0xMDY1MDI_07aa6797-1d4b-48c0-8084-a7e8196645c8">1,361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi03LTEtMS0xMDY1MDI_ffd312f2-3c47-4a9f-bd80-89641872e4a1">858.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC0xLTEtMS0xMDY1MDI_70c34891-7207-46c4-8f2c-128bfbfabfa9">8.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC0zLTEtMS0xMDY1MDI_280090d3-ffdc-4bff-aa14-77117b27b77c">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC01LTEtMS0xMDY1MDI_6e924920-aec1-4a2e-933a-c2cce377bd16">18.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC03LTEtMS0xMDY1MDI_3f0b4728-0df4-4b7b-9bb0-bdefcfe74885">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS0xLTEtMS0xMDY1MDI_8e5cf6c2-58d9-4c56-8ea3-6f43be189766">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS0zLTEtMS0xMDY1MDI_5d02108a-29ee-44e9-af9f-c210129c9d21">11.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS01LTEtMS0xMDY1MDI_a5ce1e5e-6ab0-4f1c-b3f8-e018f6964b30">73.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS03LTEtMS0xMDY1MDI_fb6de167-2640-4bec-b766-c0a75c091edc">138.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi0xLTEtMS0xMDY1MDI_f7205f35-7fca-478e-8729-67ba0b24e179">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi0zLTEtMS0xMDY1MDI_f632f743-c4e5-4fa8-94b3-ccff1e520df7">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi01LTEtMS0xMDY1MDI_d49bc86a-dc55-41e2-b73f-fe28a5220b11">25.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi03LTEtMS0xMDY1MDI_5d168c9a-8566-4b97-97c7-d3bf61b1ed7d">20.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy0xLTEtMS0xMDY1MDI_a38a226a-caba-43d3-8734-233c1a5a631a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy0zLTEtMS0xMDY1MDI_623c67f8-c464-4987-9272-dd6eb0514442">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy01LTEtMS0xMDY1MDI_d44e4c35-0946-4c06-a47d-e15767003367">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy03LTEtMS0xMDY1MDI_1c229f94-570f-4c7f-b2e3-7cb6316107d1">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC0xLTEtMS0xMDY1MDI_23d236ed-dd0e-48d4-805c-f8acd5f314e7">14.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC0zLTEtMS0xMDY1MDI_0f4c6982-a4db-4f7f-8393-be7df396d2fa">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC01LTEtMS0xMDY1MDI_fd37c94e-6884-4657-98cc-da41aa479593">36.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC03LTEtMS0xMDY1MDI_f9a9d292-1403-45f7-9420-8f60eb083dd2">32.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS0xLTEtMS0xMDY1MDI_f6877ed0-b0c7-4a2a-9d11-93a65052177e">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS0zLTEtMS0xMDY1MDI_7631ac47-d627-472b-a0fb-bd66fe679119">2.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS01LTEtMS0xMDY1MDI_88fb0654-cbe8-4c08-bf91-00211f11d8b7">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS03LTEtMS0xMDY1MDI_a53f54d5-ff58-42ff-b51d-65cdabca1789">127.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtMS0xLTEtMTA2NTAy_a980e789-60c3-411c-8b94-98e2d4445a3e">1,062.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtMy0xLTEtMTA2NTAy_1a38ef8a-b726-4fd1-abd6-50b2f5754463">451.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtNS0xLTEtMTA2NTAy_67f19c20-2ddb-4da5-9067-8f1b3821d1a9">1,358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtNy0xLTEtMTA2NTAy_553c34da-5eec-4b16-97e7-10352a7a1e5f">985.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtMS0xLTEtMTA2NTAy_7d8b0b80-bbed-45a8-a849-fca30518d389">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtMy0xLTEtMTA2NTAy_3a0c22d9-b611-4853-8d5f-4078c7e5a896">576.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtNS0xLTEtMTA2NTAy_a968b583-2988-4ab5-875d-2162748261b7">84.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtNy0xLTEtMTA2NTAy_6d2f1bda-0dd0-4b7a-89cb-8b373a5bf43e">572.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItMS0xLTEtMTA2NTAy_2c6a3c15-8294-4578-adea-fafc00e451eb">1,063.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItMy0xLTEtMTA2NTAy_a15c2713-908a-4453-9ade-08502be1ea1e">1,027.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItNS0xLTEtMTA2NTAy_01afa574-5053-491e-b454-07c0c022da76">1,273.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItNy0xLTEtMTA2NTAy_eb20c2dd-0110-48b6-8993-26b123c320bc">1,557.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMy0xLTEtMS0xMDY1MDI_ce568163-38ac-4ec6-9f51-77138fc60f06">2,646.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMy0zLTEtMS0xMDY1MDI_7ddd4e5d-03db-4bd9-9f30-0c3aded4468e">2,261.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNC0xLTEtMS0xMDY1MDI_8e60382c-98f7-447b-ae97-74c01b95c233">2,151.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNC0zLTEtMS0xMDY1MDI_41ec96cc-26f6-4f49-94d0-6d62f580ef51">1,541.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNS0xLTEtMS0xMDY1MDI_f07bc863-9d8f-414f-916e-3c641b4f9238">1,567.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNS0zLTEtMS0xMDY1MDI_26fad047-1a4e-4857-ac34-e1dd99a47f93">1,549.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNi0xLTEtMS0xMDY1MDI_1228e42d-8628-4cab-b5ad-2b4f75945e0e">435.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNi0zLTEtMS0xMDY1MDI_c7f6aedb-52e2-4034-b703-c32e36f0f736">412.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNy0xLTEtMS0xMDY1MDI_d1bc45ac-778a-4ffa-ad6d-84173b58f51c">1,294.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNy0zLTEtMS0xMDY1MDI_b1eb106c-1ab5-4230-b4c5-605c3910fb87">1,351.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOC0xLTEtMS0xMDY1MDI_6efaf9a4-0f82-4608-b468-7ce5701c7fef">1,645.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOC0zLTEtMS0xMDY1MDI_071a8b89-8cec-4df6-8593-c51e549a70ed">740.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOS0xLTEtMS0xMDY1MDI_e4859d6e-d940-4047-b62a-d8d3f26433a5">9,740.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOS0zLTEtMS0xMDY1MDI_ca6b4e5a-7e18-4333-8e7c-46254376dca8">7,856.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTAtMS0xLTEtMTA2NTAy_c37e81c5-b453-411f-ac81-0edf4442fe9a">1,102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTAtMy0xLTEtMTA2NTAy_2d5334ef-a350-441d-b927-86b11781cde5">892.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTEtMS0xLTEtMTA2NTAy_8be31b63-5893-40b8-9fa4-dbac74b97624">3,355.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTEtMy0xLTEtMTA2NTAy_89819675-bb91-4a65-8168-2e93e414f89d">3,416.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTItMS0xLTEtMTA2NTAy_e31a1616-65e1-473b-8b5a-75d80e28ac1d">321.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTItMy0xLTEtMTA2NTAy_89e00683-4daa-4663-922f-033352e92207">375.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTMtMS0xLTEtMTA2NTAy_1474a265-587c-480f-9ac9-7600210c2f1d">2,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTMtMy0xLTEtMTA2NTAy_719f5070-58d4-460a-a600-3a245a8f253a">2,221.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTQtMS0xLTEtMTA2NTAy_3da45500-ca5c-4fce-8652-cd4eab697bbb">5,749.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTQtMy0xLTEtMTA2NTAy_089d50c0-c7d5-458c-8e63-d55ed85b2b1c">5,761.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTUtMS0xLTEtMTA2NTAy_91273ff7-dfa8-4934-932d-854a1f98004c">1,235.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTUtMy0xLTEtMTA2NTAy_429b2314-2a8c-48b1-9a23-fa5cf22320e0">1,415.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTYtMS0xLTEtMTA2NTAy_193566ef-01b5-4eef-b13b-34f2b1f45216">1,500.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTYtMy0xLTEtMTA2NTAy_7019067d-b241-467e-b54f-d62823260602">1,939.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTctMS0xLTEtMTA2NTAy_c2235642-255c-47a0-9566-8193c73b8cc3">25,081.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTctMy0xLTEtMTA2NTAy_83face22-a599-4547-9a42-31c07da0ff2a">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjAtMS0xLTEtMTA2NTAy_1cf25998-3d5b-4f56-93aa-7c4c0faffa85">999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjAtMy0xLTEtMTA2NTAy_bfd0ae17-6f2b-4723-95b7-2ca9ac798bef">999.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjEtMS0xLTEtMTA2NTAy_9c2ec648-1a91-4b4e-b2c3-64eb7c5bcbae">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjEtMy0xLTEtMTA2NTAy_d034a66c-c5b2-4fe5-a542-c69b5ef3595a">174.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjItMS0xLTEtMTA2NTAy_1445c34c-3f54-4ae7-ba04-e0daafcde0ff">434.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjItMy0xLTEtMTA2NTAy_b36aa412-458c-4fbe-8605-4b896af2271e">589.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjMtMS0xLTEtMTA2NTAy_1d4e82b7-fa92-4291-9b86-221a241b6c83">3,298.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjMtMy0xLTEtMTA2NTAy_06689928-4f6c-48ce-bafb-9fc6b670a367">2,535.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjQtMS0xLTEtMTA2NTAy_de3afdd7-d5bf-4ac8-9e1a-18b24c24c28f">5,018.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjQtMy0xLTEtMTA2NTAy_f27a017b-84b9-4f11-bb68-bb07454b7219">4,298.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjUtMS0xLTEtMTA2NTAy_ea8eb751-d679-4a20-a4c2-0d0c643635dd">6,277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjUtMy0xLTEtMTA2NTAy_7aa33ffe-c514-4794-a3bf-dc8e68cdfd93">6,274.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjYtMS0xLTEtMTA2NTAy_5fd459bd-56eb-4dd2-988f-e5d30f43fa22">480.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjYtMy0xLTEtMTA2NTAy_edaae6df-6a79-4c3a-899e-b9a37c9b70a2">694.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjctMS0xLTEtMTA2NTAy_816def96-6b80-470d-9190-12c68c20520e">274.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjctMy0xLTEtMTA2NTAy_b8ff769f-f0be-42ca-851f-a337b2365ba5">330.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjgtMS0xLTEtMTA2NTAy_d8c876d6-39f6-45db-a7fa-1410d0306c29">1,167.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjgtMy0xLTEtMTA2NTAy_b9aa5324-4b4b-4d05-81ed-1b1097bdef16">1,320.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjktMS0xLTEtMTA2NTAy_e496c6b1-9c74-43d8-9e13-422f9cc1b661">13,218.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjktMy0xLTEtMTA2NTAy_b291a270-2b05-49f3-a0c8-0e61f41bece2">12,917.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzAtMS0xLTEtMTA2NTAy_c11e1a9f-c87d-4196-897c-1c7aae10ce13"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzAtMy0xLTEtMTA2NTAy_aaec61c0-73dd-4598-bdcb-1f7394954e95"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzMtMS0xLTEtMTA2NTAy_5d2a7d80-01f4-478c-b31e-ebc40a3b8d32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzMtMy0xLTEtMTA2NTAy_fe173fd0-2bba-4030-bcd6-22ace8756281">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzQtMS0xLTEtMTA2NTAy_7e9a0186-cb91-48b4-a15e-2c250a78555d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzQtMy0xLTEtMTA2NTAy_1a93c8b1-3684-45e2-8401-af00fa3f15ef">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzUtMS0xLTEtMTA2NTAy_f133c4ff-c989-4326-b9f7-58b13626cdb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzUtMy0xLTEtMTA2NTAy_fc3798aa-1741-4237-960a-138cc605e058">68.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzYtMS0xLTEtMTA2NTAy_59840401-5903-4aa1-9a3b-ec445f2eaf16">110.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzYtMy0xLTEtMTA2NTAy_31cea787-6529-404d-95aa-38b72fde1547">106.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzctMS0xLTEtMTA2NTAy_d1757042-fe1e-4841-a768-b1da3e57ea7c">14,959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzctMy0xLTEtMTA2NTAy_f7d0d3f1-5a82-45e7-a7e1-732e42d753ef">13,911.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzgtMS0xLTEtMTA2NTAy_650c5a72-34d8-41c9-b746-017f81900258">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzgtMy0xLTEtMTA2NTAy_9bc4925c-58cb-47c5-9436-2bb36057bfc0">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzktMS0xLTEtMTA2NTAy_050907d5-5c5e-4b82-9b3a-4f620df92c3d">11,872.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzktMy0xLTEtMTA2NTAy_5e88282b-2087-42e6-a4af-bccd92526121">10,896.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDAtMS0xLTEtMTA2NTAy_0b191aae-3134-445d-a079-bb6d734e30a4">9.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDAtMy0xLTEtMTA2NTAy_90b8619c-0c36-4fc1-ade7-b78396f93095">63.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDEtMS0xLTEtMTA2NTAy_85b56cd4-879d-4aff-8802-c68ff957c67f">11,863.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDEtMy0xLTEtMTA2NTAy_b97f2c9a-90fc-438c-8786-17032b57a976">10,959.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDItMS0xLTEtMTA2NTAy_65609c55-a3ca-4cba-a7a5-e4c015d91491">25,081.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDItMy0xLTEtMTA2NTAy_4d0556c6-6704-4ce0-9807-cd0459789318">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMy0xLTEtMS0xMDY1MDI_91317937-3c59-4662-ad02-0f0769977c3b">1,277.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMy0zLTEtMS0xMDY1MDI_5477de2e-01b4-403d-a18d-c795e073a0ea">1,430.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNS0xLTEtMS0xMDY1MDI_668a2724-48f6-47df-9cc8-af8a88df4981">277.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNS0zLTEtMS0xMDY1MDI_7d317cbe-52ab-49a4-b1f5-5707cb1bcc03">219.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNi0xLTEtMS0xMDY1MDI_82d1305d-fd02-4dee-9b40-7e60902f689a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNi0zLTEtMS0xMDY1MDI_5000ff39-ad45-4100-a8ef-8ac0ac8020e7">585.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNy0xLTEtMS0xMDY1MDI_1b2cde6c-4b7d-4531-8d0e-61bdb833e564">305.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNy0zLTEtMS0xMDY1MDI_25f0b9e3-0ece-4356-95d9-c834b69b3066">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOC0xLTEtMS0xMDY1MDI_2e6d13e3-5188-45e1-a587-790ec8d7bd10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOC0zLTEtMS0xMDY1MDI_3d3d561e-0d0a-471c-a8ef-ae0f205fcd92">18.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOS0xLTEtMS0xMDY1MDI_27a4fb17-c49a-4c01-b8e0-23f0098f42da">123.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOS0zLTEtMS0xMDY1MDI_3fa957a7-fb6a-4b8b-b8ae-b3748e6dae2e">124.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTAtMS0xLTEtMTA2NTAy_9adddfbc-4695-4bd3-b3db-e25e629a8cb3">11.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTAtMy0xLTEtMTA2NTAy_e798043a-0999-4382-9f8a-2548c1d97ab8">33.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTEtMS0xLTEtMTA2NTAy_ed3aa5f9-8ca3-460e-9f6d-5855c6600efc">47.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTEtMy0xLTEtMTA2NTAy_c20ff4a3-2f7a-43c0-bdaf-570afa9315f4">622.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTItMS0xLTEtMTA2NTAy_b3fe2f55-d1f6-4d63-9bab-b1613c3098b4">269.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTItMy0xLTEtMTA2NTAy_e4f5e956-60a0-422e-809d-6dd2afa69619">283.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTMtMS0xLTEtMTA2NTAy_9827b8f3-c9a5-4cdb-a9e7-469935ace9e0">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTMtMy0xLTEtMTA2NTAy_c0f242dd-968a-4cb7-a754-179d56b34079">16.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMS0xLTEtMTIwODg4_cabf57cd-0339-46ef-9019-d8f6d6516c5d">1,505.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMy0xLTEtMTIwODg4_b1a79659-58dc-4ddd-83bc-770bcaed2c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMS0xLTEtMTA2NTAy_ce4b55ed-ef8b-4a98-8e19-d3cf1e11eb7e">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMy0xLTEtMTA2NTAy_b61a3676-79a5-41a1-8d52-08e2d4ee921a">104.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTYtMS0xLTEtMTA2NTAy_9a8b73f7-bce5-42de-95bf-9525e7ab702d">67.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTYtMy0xLTEtMTA2NTAy_40f01a9b-a7c6-4d42-ba07-0083645b328b">211.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTctMS0xLTEtMTA2NTAy_855f6388-e152-4b08-aebd-f301b8e88695">23.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTctMy0xLTEtMTA2NTAy_04e5f0c4-32c0-4f10-be4d-71b00d2482dd">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTgtMS0xLTEtMTA2NTAy_62167f05-9f2c-4148-a234-6ac3ee54e1bf">243.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTgtMy0xLTEtMTA2NTAy_f5a0c03a-f5af-41f6-b4bd-30bd49346948">193.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTktMS0xLTEtMTA2NTAy_53394028-6ce3-4f3e-9e57-72b4dba41625">634.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTktMy0xLTEtMTA2NTAy_cc1cd23e-3f0e-4cfe-9bbe-8150b5f67fe4">188.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjAtMS0xLTEtMTA2NTAy_c03ba73f-7ebd-4a57-9cad-01311b46d299">65.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjAtMy0xLTEtMTA2NTAy_658b2113-e2de-4531-8300-c9a89c3a1e00">171.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjEtMS0xLTEtMTA2NTAy_d1112f91-2c18-444c-a044-cc5cf5f500b6">134.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjEtMy0xLTEtMTA2NTAy_b5517605-5612-41d9-be60-9ddd8f147ba6">97.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjItMS0xLTEtMTA2NTAy_e0044f0d-e636-494f-b5ea-2cfa6606d9e1">898.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjItMy0xLTEtMTA2NTAy_15662f79-1a6d-47cd-9d36-8f8985efc993">1,996.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjQtMS0xLTEtMTA2NTAy_fbec1d20-bf3d-4def-b02d-f28be50d753b">94.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjQtMy0xLTEtMTA2NTAy_dcbb6b9e-1fc1-451e-a8fe-25654bf5b4df">164.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjUtMS0xLTEtMTA2NTAy_6b02ec11-e448-41d0-9e79-6a233ee4ac80">1,461.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjUtMy0xLTEtMTA2NTAy_338fe41f-6864-46f2-a41b-0bd96c80f351">1,452.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjYtMS0xLTEtMTA2NTAy_285590cf-1188-4422-a1e1-ac8c5f9442f3">2,311.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjYtMy0xLTEtMTA2NTAy_55e842d8-e6e1-4c60-9006-0c1e343d40b5">1,626.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sale of equity in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMS0xLTEtMTE0Mzkx_8c256366-aac8-4f94-b33c-c92b6e9919f7">990.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMy0xLTEtMTE0Mzkx_f800bcbb-2063-4773-882c-1ecd7c4a15ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMS0xLTEtMTA2NTAy_6aef1fdf-0487-4e4a-a17a-0ecf60074420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMy0xLTEtMTA2NTAy_41328abd-c610-4fdf-810b-8c65dc735352">28.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjktMS0xLTEtMTA2NTAy_8107678e-ccd6-49c1-bc7a-803cb99f666c">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjktMy0xLTEtMTA2NTAy_d1341235-5100-4ab1-9068-b3a714608535">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from the sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzAtMS0xLTEtMTA2NTAy_40fb64c0-2517-4e78-835c-4de73937b1a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzAtMy0xLTEtMTA2NTAy_a9fa9b1b-278e-459b-bf26-bb648adc5c11">91.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzEtMS0xLTEtMTA2NTAy_3e5b1fa2-d0d1-4507-b21b-6c7bb6005525">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzEtMy0xLTEtMTA2NTAy_f6533ee2-b55f-4a58-a231-b97def07b19d">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzItMS0xLTEtMTA2NTAy_c76ea73e-5b33-4c83-8867-013a39267d4f">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzItMy0xLTEtMTA2NTAy_ca75e852-812c-4828-a24b-8fceff1618a6">217.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzQtMS0xLTEtMTA2NTAy_3bd93f9b-0a87-4bba-b1f3-4af74eea74b5">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzQtMy0xLTEtMTA2NTAy_4f38fdf2-88f1-4e3b-bf42-4475b98b8236">1,050.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzUtMS0xLTEtMTA2NTAy_9a379675-e186-4025-b386-0b77cc18b436">11.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzUtMy0xLTEtMTA2NTAy_f53bb67a-886f-48ae-b502-cacb99693c23">14.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid on debt exchange</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzYtMS0xLTEtMTA2NTAy_be1d4d7f-939b-4842-9c4b-ce5012b558de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzYtMy0xLTEtMTA2NTAy_d34734d4-39dc-47b5-842b-b7fe99e0aea0">170.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzktMS0xLTEtMTA2NTAy_88698b80-528e-4aa2-865e-cca837344205">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzktMy0xLTEtMTA2NTAy_e14916d1-05ac-4498-9569-646b70742904">94.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDAtMS0xLTEtMTA2NTAy_821db42d-f3cd-4051-b5c3-dea72aa845ea">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDAtMy0xLTEtMTA2NTAy_c9ac0f90-e635-4fbd-82bc-d68c8ba6c517">20.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDEtMS0xLTEtMTA2NTAy_915d4921-87a9-4f28-a98e-f9a880c41ca7">488.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDEtMy0xLTEtMTA2NTAy_0dec2e99-0b62-403e-9976-4ba8a8413f92">1,349.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDItMS0xLTEtMTA2NTAy_4d8f9f92-16ff-4a56-aca2-c26aa416b86a">455.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDItMy0xLTEtMTA2NTAy_f92e687a-46e7-468d-9464-e814f980e4bf">429.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDMtMS0xLTEtMTA2NTAy_1159fd41-cf2f-4ca4-8715-b30b4081a3b4">70.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDMtMy0xLTEtMTA2NTAy_9fab2740-2ec9-4e05-9127-8944f1b25cd8">18.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDQtMS0xLTEtMTA2NTAy_7eb2b420-af6e-46e3-8b79-4331c6dbf3d0">2,261.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDQtMy0xLTEtMTA2NTAy_5e133283-743f-48c1-a09d-f46521ca3413">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDUtMS0xLTEtMTA2NTAy_2bc39381-5e60-43e3-b47f-d3462436afdf">2,646.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDUtMy0xLTEtMTA2NTAy_960ce799-d52b-4661-b566-a984c28c89ae">1,742.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xLTEtMS0xMDY1MDI_14b25d1d-dfed-49fe-8b6e-e8e31ac8d632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0zLTEtMS0xMDY1MDI_0c81a046-9f49-414e-8bc0-35e1599291a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i655d8f6be57b43f8a4aff100977af6ba_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi01LTEtMS0xMDY1MDI_2ba77a37-eddf-4cca-b2d7-a64ef86d8ad5">171.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655d8f6be57b43f8a4aff100977af6ba_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi03LTEtMS0xMDY1MDI_50b6fd0a-edaa-4fc4-8524-3e180337f428">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4021ecec514c33b4f46028ea027777_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi05LTEtMS0xMDY1MDI_af6f8b81-2233-4b79-a718-c04a359d81e4">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d0383fdaa1a45b2990dc160ac25e8e6_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xMS0xLTEtMTA2NTAy_b8793f6a-e992-4168-b396-0e10733c688f">115.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609e4fab86de4ca682e02c1766083dab_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xMy0xLTEtMTA2NTAy_cceacdfc-d4b6-47a2-9063-7fa45c7fba27">14,215.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xNS0xLTEtMTA2NTAy_c65a809b-5678-4a3a-b487-c9bc938c528e">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xNy0xLTEtMTA2NTAy_a2ef20bc-d1d5-4440-93a1-a36d7bd5691f">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f53af952a05400eb5a03b652b2a5224_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xOS0xLTEtMTA2NTAy_d3ce7b2a-d30d-4278-81c0-fea36320221b">11,242.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25bd83dbf18a47969953f960652b7ca8_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0yMS0xLTEtMTA2NTAy_268200e5-0921-4bcf-b9a1-438f22da7336">21.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f48125dbb64c14aa174f438eb3b529_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0yMy0xLTEtMTA2NTAy_9e7a67f5-c185-4c1e-81db-d317ee0bd173">11,220.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a7a040013e4e578186caffe27ff784_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0xMy0xLTEtMTA2NTAy_bca244a9-74c1-44ba-9f00-b9d24f9ebaad">1,058.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0xOS0xLTEtMTA2NTAy_93a0d6a8-a775-490e-b8a4-4491bca39ead">1,058.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0yMS0xLTEtMTA2NTAy_9b23fbb8-f6c0-4a7d-9524-50faa256c88a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0yMy0xLTEtMTA2NTAy_faf57dbb-65f0-4314-a68d-2cc0c44dc355">1,058.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a5574cfc654102a3578daabb6da090_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0xMS0xLTEtMTA2NTAy_c84d67d5-eccd-4b64-972a-151f74f4e758">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0xOS0xLTEtMTA2NTAy_c045843e-7c9a-4635-b83f-1baf95d66f1f">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0yMy0xLTEtMTA2NTAy_be2b5fba-0f8a-4bf3-8ce9-9fce6187255b">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNi0yMS0xLTEtMTA2NTAy_185c15ee-e95f-4b09-92e1-521f44624767">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNi0yMy0xLTEtMTA2NTAy_28af49a8-3bb4-47ac-8ea7-794c87ad4e6f">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xNS0xLTEtMTA2NTAy_0a16b3cc-f6f3-48d0-8472-8240d058bbac">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xNy0xLTEtMTA2NTAy_9f5348f6-bb0c-48e5-9d24-7e3055d62ec2">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i200e14d4b78f4812b17968b9f9d1aea2_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xOS0xLTEtMTA2NTAy_6fa9a40b-1720-4bad-b02b-be1480d3a75b">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0yMy0xLTEtMTA2NTAy_0c490aa6-fb9a-40e7-af44-72d05dfd4bc6">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5245b9a67e8448b39d74a04b7e9b1de1_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC01LTEtMS0xMDY1MDI_b7d341c4-41f5-4a52-ab99-59e6c41263aa">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34ba7d8360a14679a9369e90b81fc882_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC05LTEtMS0xMDY1MDI_60c63916-3c28-44db-97d3-6f2a0b534534">186.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i281cd7edebd843fe95c846ccd0a8fbe2_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xMy0xLTEtMTA2NTAy_d7a28129-0ea1-407d-b088-725ef2770ca4">313.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xNS0xLTEtMTA2NTAy_5877a858-f317-45f0-afda-4eaaab6d04a0">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xNy0xLTEtMTA2NTAy_3ead3307-94ba-400d-a6d9-b54b593709ab">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0yMy0xLTEtMTA2NTAy_f11a9965-e5cf-44a9-8a47-0a6e3870e098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15182190caca498b8e52572e96ba2eba_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS01LTEtMS0xMDY1MDI_acdb1770-958f-49b4-8788-b25a8753e385">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS05LTEtMS0xMDY1MDI_4040f78f-142b-43db-aa69-c9515278c84f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS0xOS0xLTEtMTA2NTAy_6d58b551-7aee-4033-ae9d-77f90b5c8e88">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS0yMy0xLTEtMTA2NTAy_70a54c6c-e6f9-4fdc-aa55-af97a134e9c9">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15182190caca498b8e52572e96ba2eba_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtNS0xLTEtMTA2NTAy_cb35ca0c-bcf8-4d8b-9ebc-c11a904060f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtOS0xLTEtMTA2NTAy_682cde58-44c1-4caf-9661-37979122d203">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtMTktMS0xLTEwNjUwMg_bc691f4c-340a-4143-aac2-18fdd6968cb6">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtMjMtMS0xLTEwNjUwMg_84f531c7-2c80-404e-a9f9-80ac2841a1b8">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtOS0xLTEtMTA2NTAy_7a0f6e64-ddd1-45ed-8b6c-62a4597ec599">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtMTktMS0xLTEwNjUwMg_8b47d950-d5cf-47f9-95db-95a3b2f67747">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtMjMtMS0xLTEwNjUwMg_c829c3ad-233d-4645-a0e0-3cab30c983b1">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItOS0xLTEtMTA2NTAy_24fe83a7-ca1d-4dc0-a32f-a24cfd5da7ae">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItMTktMS0xLTEwNjUwMg_8a30248d-f3d3-45d6-8f76-29a20a6d6c62">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItMjMtMS0xLTEwNjUwMg_cde72900-c72d-4d33-9061-0e3564cecd36">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMS0xLTEtMTA2NTAy_4d0be2d5-aeab-4c85-9af1-4e54ea36d767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMy0xLTEtMTA2NTAy_2c5c1520-776e-4962-a11e-5fe4bfede821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtNS0xLTEtMTA2NTAy_7ab92f6f-f1d4-4e75-bc3f-086993432400">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtNy0xLTEtMTA2NTAy_f060e94a-db60-41d0-ad39-7327310c64aa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c4af1889714ce0862fe75007a47c79_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtOS0xLTEtMTA2NTAy_4a225158-f9ad-4b28-8cf4-d76799575f53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0a37bdf69449ddaf16a60e03e555ae_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTEtMS0xLTEwNjUwMg_0b27da45-bda8-4de9-95c2-c7f2244efb99">110.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTMtMS0xLTEwNjUwMg_2aaa9a52-0652-42ea-91e5-dfb417623920">14,959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id8b532043d004077960b4e7717b3606f_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTUtMS0xLTEwNjUwMg_ef2c1801-2cbe-45bb-ad1c-2b22cd9b6a09">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8b532043d004077960b4e7717b3606f_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTctMS0xLTEwNjUwMg_306291e0-ca85-49d4-ba91-34d337a91d8e">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTktMS0xLTEwNjUwMg_e796ebd3-9f6a-41da-a09c-4e4dd3acc97c">11,872.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6736d3935f8c47758cb22a7798dd423d_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMjEtMS0xLTEwNjUwMg_01640780-964e-42cc-861d-c25f939278cf">9.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMjMtMS0xLTEwNjUwMg_8f8191d7-2bbb-45cf-8382-97c4f189e642">11,863.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3383d03c85d343899a6760bb144c07cd_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xLTEtMS0xMDY5MTY_d7d4d3d9-254f-473f-8c2f-60b6535f332d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3383d03c85d343899a6760bb144c07cd_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0zLTEtMS0xMDY5MTY_9b9ad3c5-6660-49bc-b569-5286ce0a75b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47198f9003784e62a2d403aa1634c0cd_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi01LTEtMS0xMDY5MTY_93b448bb-e3c3-4350-9a70-69263d9d1cd6">170.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47198f9003784e62a2d403aa1634c0cd_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi03LTEtMS0xMDY5MTY_734bd339-ba81-4229-a7f9-d0f9583d02f9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35827c831ea64be78954e395e1202d2e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi05LTEtMS0xMDY5MTY_45500f5a-c9f9-4c4e-adbb-2475e558ce3f">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cf823cd6b2f40d2a0cc0697e0186894_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xMS0xLTEtMTA2OTE2_a76c6d3a-9d97-4357-8e8b-0d3c0f9fe15c">106.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc3332cac8046689fcf7638658efa23_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xMy0xLTEtMTA2OTE2_a193fab3-7243-4b2a-9fa8-3c6cdbcb590f">13,911.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea41407ff6964211a00be80476455624_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xNS0xLTEtMTA2OTE2_31a7f34a-11c3-4ece-9102-d96923291e36">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea41407ff6964211a00be80476455624_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xNy0xLTEtMTA2OTE2_4060c2a6-b60e-441a-aa4d-396bdbe29dbc">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75454f1173a447139f1217b1ed46d9fa_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xOS0xLTEtMTA2OTE2_4f3dddad-d609-4ba2-b623-ea7d4f169d3b">10,896.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d0784f479f4fc880cb5813d70f6f6c_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0yMS0xLTEtMTA2OTE2_8afb46a2-20b4-48cd-b5ca-a497b6d04790">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0yMy0xLTEtMTA2OTE2_ea992e93-e265-4314-8c45-8de7c7b15042">10,959.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d4c7b0576941b3878692efd86da487_D20220101-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0xMy0xLTEtMTA2OTE2_54077d96-2471-412b-8f22-28df87fba49f">1,361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0xOS0xLTEtMTA2OTE2_43f43648-e46b-480e-97a4-54cd7cdb79db">1,361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0yMS0xLTEtMTA2OTE2_1a954ddd-9ea6-4a51-ae22-2042623b5683">84.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0yMy0xLTEtMTA2OTE2_0971069f-9105-44b1-80fd-56ac33e2a66c">1,277.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bd31dba4354e46bc9629fe6a03d388_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0xMS0xLTEtMTA2OTE2_0883fbc2-fd32-4956-ab5b-2634c9b66649">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0xOS0xLTEtMTA2OTE2_e54efd57-5018-4b5b-a9f3-5f3d95e6afcd">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0yMy0xLTEtMTA2OTE2_8fc5738c-ba59-4e16-9ba3-ad6743efee1e">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNi0yMS0xLTEtMTA2OTE2_88fa97cd-9b00-45c7-9c1b-42c01e3564c1">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNi0yMy0xLTEtMTA2OTE2_ffed1373-aa84-44c5-a648-9f3406b60eb6">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xNS0xLTEtMTA2OTE2_94e37b11-8241-43e4-8332-3c9f630e9274">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xNy0xLTEtMTA2OTE2_bb10d32d-365d-438a-a81d-c8d8aae7bc50">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i368ea118836f487388ce043a695cadcd_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xOS0xLTEtMTA2OTE2_4c78ca83-96ae-4392-bc3a-469b850ff2e7">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0yMy0xLTEtMTA2OTE2_63721e10-067b-416d-abd9-da48bea03a65">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if25d30d01e8e4db4b897cf36867a25e6_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC01LTEtMS0xMDY5MTY_81a4b96c-084c-4071-97b1-2cd3b7897cb9">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bbb659071554201aaf22eccd009353e_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC05LTEtMS0xMDY5MTY_43a137d2-eb4a-4458-8d14-85b272d8b163">186.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifea5cd790d23403096957d2bd80ac925_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xMy0xLTEtMTA2OTE2_904cc854-77c4-4e10-8917-99ca5a50361e">313.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xNS0xLTEtMTA2OTE2_b04f8d4c-12e6-431e-a6ac-b07eb4855911">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xNy0xLTEtMTA2OTE2_058a01f8-501c-49ec-9426-2e28ffe34009">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS01LTEtMS0xMDY5MTY_bee4b808-aff5-4610-b11b-cd505d4dd1e6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS05LTEtMS0xMDY5MTY_df39892c-e2af-42e6-b734-f43195486faf">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS0xOS0xLTEtMTA2OTE2_b35248c7-8604-43f7-b1ea-88792b6878a8">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS0yMy0xLTEtMTA2OTE2_818ee299-ee68-442f-a566-262e64faeae1">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtNS0xLTEtMTA2OTE2_c2640f39-ea19-4201-ae87-aba12fc1f708">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtOS0xLTEtMTA2OTE2_cbf75fc4-e514-4835-9f34-0b6ad13d15fa">40.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtMTktMS0xLTEwNjkxNg_fe4ad154-8ad0-4da6-a81b-4034e23ba303">40.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtMjMtMS0xLTEwNjkxNg_c4596c89-f7be-4326-bd10-f6a86129f9b0">40.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtOS0xLTEtMTA2OTE2_475ade75-f4d1-4fe6-a7d1-041ef457ccbf">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtMTktMS0xLTEwNjkxNg_8906e789-862f-4ae8-9ea9-d136c5360f7e">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtMjMtMS0xLTEwNjkxNg_e4346b32-5037-43b7-af96-116df776e32a">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItOS0xLTEtMTA2OTE2_dcf0e850-41b4-4dd4-b228-f1ccacbaa70f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItMTktMS0xLTEwNjkxNg_df78b43f-1498-4cf1-893e-d718bd6e5be4">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItMjMtMS0xLTEwNjkxNg_a05d613a-cef9-4781-9a61-378c974ef28e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMS0xLTEtMTMxODEz_0ffc7d24-5fa8-4468-8bf4-cbef20f377c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMy0xLTEtMTMxODEz_797c2a2b-017d-4b92-a6d0-464724748eca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtNS0xLTEtMTMxODEz_e3ec9fa9-6c96-4af5-9ae4-b680c7d58c7d">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtNy0xLTEtMTMxODEz_b65c582d-4f08-4063-bd3a-2d004511919a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c4af1889714ce0862fe75007a47c79_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtOS0xLTEtMTMxODEz_c5c27a80-da68-4b44-ab5e-77f1cbcec5e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0a37bdf69449ddaf16a60e03e555ae_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTEtMS0xLTEzMTgxMw_b371572a-3bbd-4526-9ff0-e3334be95aaf">110.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTMtMS0xLTEzMTgxMw_20123e83-befd-4dfd-a020-471ad08a8d54">14,959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id8b532043d004077960b4e7717b3606f_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTUtMS0xLTEzMTgxMw_8271e185-85bb-4076-8e58-bd65bce63710">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8b532043d004077960b4e7717b3606f_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTctMS0xLTEzMTgxMw_a51c3541-44b4-4232-9029-83b16c5c3ecb">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTktMS0xLTEzMTgxMw_056db12e-7d19-4faf-b6cd-d7c6b47922ed">11,872.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6736d3935f8c47758cb22a7798dd423d_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMjEtMS0xLTEzMTgxMw_15fad7ff-fd4f-40fd-a4a5-1bae4bf920a7">9.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMjMtMS0xLTEzMTgxMw_e385edb5-c85f-4bb8-852f-3df62a486eca">11,863.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b352f1e386449dba581418fff17ab7a_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xLTEtMS0xMDY1MDI_5adfbb4d-bba8-42b4-b7c6-d0455b0873fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b352f1e386449dba581418fff17ab7a_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0zLTEtMS0xMDY1MDI_57ba4098-7f42-4b51-92b1-454abb503aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b6703a3087e48768722c1c0f8e42a83_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi01LTEtMS0xMDY1MDI_b17829e3-c132-4074-90eb-efc0861eb2b3">174.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6703a3087e48768722c1c0f8e42a83_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi03LTEtMS0xMDY1MDI_bd34fdef-e73e-4c51-8f32-e4ec15a80879">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9aca39866e45a586dd764d86c5ed26_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi05LTEtMS0xMDY1MDI_fe9b51b2-ac3d-44b3-96ef-5d5f7c59397f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab659fae07d74a4f8df69f5e986830f7_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xMS0xLTEtMTA2NTAy_3c0ec8da-7602-4f96-8ca0-b75e8a875cc7">174.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420d4dc476054e95991acdec07455f64_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xMy0xLTEtMTA2NTAy_422c6fd2-efc0-4ea0-b82f-6953037cb5ca">13,833.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1857ee2b87204f6d8d339cd56a32cca7_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xNS0xLTEtMTA2NTAy_60eb8914-b1e6-40c5-9364-319d07acba81">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1857ee2b87204f6d8d339cd56a32cca7_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xNy0xLTEtMTA2NTAy_13bcc863-7869-4321-bbce-1b39305e3e7d">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d979b13ecb40159fab297299c33759_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xOS0xLTEtMTA2NTAy_f21d9d3c-e936-4ff4-9246-bf869415c917">10,682.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i656fd73a858a4b54b51b65e3c1349710_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0yMS0xLTEtMTA2NTAy_104852e6-c1c1-44d3-9d7a-75f30c8208f3">19.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c0db0e45a843e093aa8601c3e476f1_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0yMy0xLTEtMTA2NTAy_4530d72e-eb7f-4c1a-a0eb-7b12c170da0f">10,663.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0xMy0xLTEtMTA2NTAy_4af0fb9d-6d44-47e7-bc3b-0807a37ac601">448.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0xOS0xLTEtMTA2NTAy_426d22e4-34ae-450e-b475-dd15070f7842">448.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0yMS0xLTEtMTA2NTAy_0d357633-1fde-4969-b674-51d616ad01aa">577.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0yMy0xLTEtMTA2NTAy_04c7bfab-299b-4217-b5ac-6ad66b1615ad">1,025.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ab97abf7474573a44451ecae9b1c59_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0xMS0xLTEtMTA2NTAy_2cdd8b51-5fa0-493d-b4a9-b3adbc95c230">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0xOS0xLTEtMTA2NTAy_bf9c7124-3d2a-499c-9c75-d3a525919d15">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0yMS0xLTEtMTA2NTAy_cf3f4076-640b-4a4f-81d8-59cb09816bef">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0yMy0xLTEtMTA2NTAy_398cbe42-34db-467b-81d7-1a708a3a92f1">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNS0yMS0xLTEtMTA2NTAy_a055e68d-d56e-43e0-86bf-3143ef3e7e2f">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNS0yMy0xLTEtMTA2NTAy_b7989dc8-fffc-4df8-bb8b-9b1b914c9e8e">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNi0yMS0xLTEtMTA2NTAy_9e8cec67-b75f-4adc-b2c7-d70fa4a00f93">5.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNi0yMy0xLTEtMTA2NTAy_f8659276-f8d1-411f-9446-f6e0a5024baa">5.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xNS0xLTEtMTA2NTAy_e8460c74-8704-4bc4-a1d9-bf2582166f1e">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xNy0xLTEtMTA2NTAy_8aeeb3fb-9789-485c-8313-e0804419c7d7">450.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia88b9101790d4b0f86a212c7e9a96706_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xOS0xLTEtMTA2NTAy_bff47f5f-2763-42e1-a7d5-88e6985667c3">450.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0yMy0xLTEtMTA2NTAy_20f497c6-0276-49d2-b34b-f871dc0f2c1a">450.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i14bbc79f38b047a0a22a8ba1a14f35ea_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC01LTEtMS0xMDY1MDI_121b1bd7-ae7e-4923-b344-5b2dcd5a8ed7">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i052eecd99d764d54aa68dbdd7ecc39a1_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC05LTEtMS0xMDY1MDI_545c592e-ca4e-4e1c-8645-380184b23dc8">69.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9bf6535ed584cc8b7699690ed33169c_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xMy0xLTEtMTA2NTAy_6fe6b957-c10d-417d-b37c-4c493433411e">380.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xNS0xLTEtMTA2NTAy_25630b08-c226-40cd-ba2a-e0b59bc32b44">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xNy0xLTEtMTA2NTAy_40f4ba72-4c79-481b-ae9d-711a08d6b969">450.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS01LTEtMS0xMDY1MDI_2790efa6-f194-4cdb-8c5e-16aa7e280a30">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS05LTEtMS0xMDY1MDI_d310163e-0951-45b1-bc00-440de499894a">13.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS0xOS0xLTEtMTA2NTAy_928de169-d3c7-4720-9829-a96fb77c9479">13.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS0yMy0xLTEtMTA2NTAy_162c68d0-36b2-4279-9f62-78ac3e086a82">13.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtNS0xLTEtMTA2NTAy_e16cd5ef-3898-4e62-ac6c-b5e82c7f9d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMTMtMS0xLTEwNjUwMg_1c189e10-dc25-495a-8522-2b2a440c8476">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMTktMS0xLTEwNjUwMg_69cabdbd-bcf0-4c8c-9a43-47ca1379ed61">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMjMtMS0xLTEwNjUwMg_804a1249-6959-4516-9c63-98b35c0833ab">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtOS0xLTEtMTA2NTAy_5c60208b-3f47-4fa8-beb7-5fe06e199a6a">55.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtMTktMS0xLTEwNjUwMg_89743d5d-5a4c-4e9a-b746-9d6874e3460d">55.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtMjMtMS0xLTEwNjUwMg_df990216-f6ba-43c2-aa31-4532aa7b8a18">55.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMS0xLTEtMTA2NTAy_fea6c8ae-3eee-4299-a18c-e816fee3717d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMy0xLTEtMTA2NTAy_81e19a58-2bf8-491c-9917-6c38ea17b276">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtNS0xLTEtMTA2NTAy_4d9d078f-b470-4d10-9d31-ccdb55ad34cf">172.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtNy0xLTEtMTA2NTAy_8b043c9c-63b7-42a5-83d9-f030702dffa4">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28bf8793bb647839d1579d8c2459b62_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtOS0xLTEtMTA2NTAy_60544167-3a5d-4739-a5a6-4a856f28874d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTEtMS0xLTEwNjUwMg_a5bda871-447d-4d1f-a4e9-8a6444c8e69a">171.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTMtMS0xLTEwNjUwMg_eee26a09-e413-4c37-91cb-2f767f0633ae">13,900.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTUtMS0xLTEwNjUwMg_9207fbb1-d5a5-43be-a3b0-a689aeca89df">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTctMS0xLTEwNjUwMg_7897a1ea-613f-4e8f-bf89-b6a0960e1cde">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332047e2daed45c5b00fd02fa57e3838_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTktMS0xLTEwNjUwMg_2bdcd29a-4ea8-488a-be1c-52b00075c731">10,751.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a38dad3f363459ea85b6ba15b99fd86_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMjEtMS0xLTEwNjUwMg_6b97d509-1adf-46c8-a5ba-b9fbe5b1b394">462.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMjMtMS0xLTEwNjUwMg_4a0ef294-8510-4c93-bb66-b6678299b456">11,214.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2455559f227c4f65a8e32a02250a6b37_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xLTEtMS0xMDY5MDE_d7ecff4d-d2e7-46da-9e59-78f3713a3052">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2455559f227c4f65a8e32a02250a6b37_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0zLTEtMS0xMDY5MDE_23b04655-4895-454d-bb6d-3dea898a9f2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi01LTEtMS0xMDY5MDE_cb03e91c-699c-40b2-8024-1722c832ef3f">176.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi03LTEtMS0xMDY5MDE_24328259-d059-4aaf-a0e3-796d67f7807e">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e9662a1a044772a5c48f8eb3e4d351_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi05LTEtMS0xMDY5MDE_9afcd71b-b870-4f83-a42b-3a2f64185afb">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1552de9fe9a4d07bfa00d31cdf4cddb_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xMS0xLTEtMTA2OTAx_455e7709-af2b-4b31-9091-d5f99a3cbe58">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea743edaf2fd4b7097146dfcb59ebcc3_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xMy0xLTEtMTA2OTAx_e4cedec0-be04-4c41-82f1-4162174a06fa">13,976.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7f0faea6ed6246d5afbb055c576af9f3_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xNS0xLTEtMTA2OTAx_8ce37f96-b5a1-411a-86b4-5ad0e4c3846b">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f0faea6ed6246d5afbb055c576af9f3_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xNy0xLTEtMTA2OTAx_ecf0a657-887c-481f-a876-2c46794446cb">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d0c433f57848faa5d9ff27e1571aa6_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xOS0xLTEtMTA2OTAx_7b76ee43-ecaa-4a8d-95b0-a1f739d74eea">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe70259be16496eb27510a3d1a37162_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0yMS0xLTEtMTA2OTAx_0f82f083-3de4-4286-9439-04df73e25567">14.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0yMy0xLTEtMTA2OTAx_48180d85-7128-4614-8206-8cd4c7a7f948">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7705963176451eab777349e7f86df3_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0xMy0xLTEtMTA2OTAx_012cd88e-7668-4455-9b9f-73cb96fcad8b">858.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0xOS0xLTEtMTA2OTAx_d2afe433-4888-48d0-94a8-ccd42e32b4e7">858.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0yMS0xLTEtMTA2OTAx_fd97b13f-cb4e-4827-97b0-57e6c94f010d">571.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0yMy0xLTEtMTA2OTAx_9eb91e52-54a8-4117-b99c-b5790fc4251b">1,430.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298109b8168d4593a326a064ab5b4deb_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0xMS0xLTEtMTA2OTAx_92261b73-79ad-4683-9485-e08040b9f8d3">127.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0xOS0xLTEtMTA2OTAx_32f6c31f-4605-4f96-9f60-8ab5dea18668">127.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0yMS0xLTEtMTA2OTAx_b17e1317-8940-4cad-af13-d118cc02bda4">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0yMy0xLTEtMTA2OTAx_ebd75a44-4b90-4a98-bdea-787144c707e7">127.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNS0yMS0xLTEtMTA2OTAx_aaa75b38-7081-4b90-b5c7-ab068c58d0a9">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNS0yMy0xLTEtMTA2OTAx_3e1e773d-1537-4217-849d-8e6952777deb">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNi0yMS0xLTEtMTA2OTAx_65d98ae2-a95e-4b6d-a544-9a655e687228">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNi0yMy0xLTEtMTA2OTAx_d1ce4bc3-00a3-40bd-93ce-0c41257dbe44">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xNS0xLTEtMTA2OTAx_4661c782-a391-4960-b65a-b81f2f43338d">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xNy0xLTEtMTA2OTAx_406aa724-f4f1-4e02-80b4-45ecafd6b556">1,050.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbabe3e8841e43538325df1464a51f39_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xOS0xLTEtMTA2OTAx_d123df58-5bd1-4f95-93ec-2043cc03ec94">1,050.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0yMy0xLTEtMTA2OTAx_26446715-9ded-4081-8f7c-d7847382ecf4">1,050.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibab1d1f75f7b44e8878daeee3d01001d_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC01LTEtMS0xMDY5MDE_8dd55ec7-80e7-4561-83de-ca9f889702cd">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia00b516da2954357b5eb349ac6097259_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC05LTEtMS0xMDY5MDE_4e41ae86-c167-4ea8-87cb-150fb722e208">163.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9742df769c7c419e858e70601aff7144_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xMy0xLTEtMTA2OTAx_c9e32dc9-9a71-4948-8334-72182f831f90">886.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xNS0xLTEtMTA2OTAx_77b281aa-b01e-4d39-9dd7-0616cfa14574">3.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xNy0xLTEtMTA2OTAx_5076484e-3b88-4b91-91cc-21e8705385ae">1,050.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS01LTEtMS0xMDY5MDE_951223b3-484d-459b-967c-de58c8242711">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS05LTEtMS0xMDY5MDE_60220493-a7dd-471e-a8e6-dbac7ef5b6f3">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS0xOS0xLTEtMTA2OTAx_733183e2-80a6-444f-86eb-85e7eaf42e3f">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS0yMy0xLTEtMTA2OTAx_d19a995a-8d06-4098-aa69-ded21e584646">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtNS0xLTEtMTA2OTAx_a982948e-cde8-4282-86dd-cc7af28fc4f5">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7705963176451eab777349e7f86df3_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMTMtMS0xLTEwNjkwMQ_95def920-7b2a-49ff-8f5c-10d4b3748088">47.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMTktMS0xLTEwNjkwMQ_0f8bf72b-e5b5-4705-845c-0c650ffe1c60">47.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMjMtMS0xLTEwNjkwMQ_39ee899a-4eed-400f-83f0-8901a2610bbf">47.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtOS0xLTEtMTA2OTAx_ec16fbb3-25d2-442a-b694-60bb5a63101f">128.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtMTktMS0xLTEwNjkwMQ_998b2cf1-4917-420e-a0b4-1cd9ce9bf417">128.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtMjMtMS0xLTEwNjkwMQ_f03457e5-a707-4e29-80d4-b36fb03801bc">128.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItOS0xLTEtMTA2OTAx_e3ab490a-8e65-4abb-9cc5-0550e9f5957c">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItMTktMS0xLTEwNjkwMQ_cd5eeac6-f420-42f7-b877-b3f74c81e8a9">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItMjMtMS0xLTEwNjkwMQ_acc1378b-030b-45d7-b999-a31564ba07e6">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMS0xLTEtMTMxODAx_c1fc1d2f-eaea-45d9-9bed-63495a2ca854">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMy0xLTEtMTMxODAx_6543f6bb-674b-4d3c-a0b6-1a179066d912">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtNS0xLTEtMTMxODAx_415927e6-91d7-4743-908d-4d802da3c3b9">172.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtNy0xLTEtMTMxODAx_bfe0fa12-5b4c-4971-b56a-1dc41a1561c2">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28bf8793bb647839d1579d8c2459b62_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtOS0xLTEtMTMxODAx_746a200e-932e-489c-adbe-9b6ee2b0fde6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTEtMS0xLTEzMTgwMQ_f2b47979-f38e-4177-b95f-80dae2a1334a">171.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTMtMS0xLTEzMTgwMQ_d056ad79-d754-49bc-8a36-e1341e89c20e">13,900.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTUtMS0xLTEzMTgwMQ_4a037eb7-a613-45d6-aaad-3f4a3b99e477">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTctMS0xLTEzMTgwMQ_5f16a800-7278-4e4a-8ccd-b6aa19c3f47b">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332047e2daed45c5b00fd02fa57e3838_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTktMS0xLTEzMTgwMQ_499f9f76-dfbc-42c5-835a-2eb0cf1185e5">10,751.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a38dad3f363459ea85b6ba15b99fd86_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMjEtMS0xLTEzMTgwMQ_e1e05d77-cf6f-4641-95f6-f4c0785c09e5">462.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMjMtMS0xLTEzMTgwMQ_992cda22-d559-4540-b6f0-4edb125eae57">11,214.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="iae1758f0b07f4108915caecfff327c7a_40"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODAzOA_ce99c2cb-e44f-4385-ade8-f5fe1128c6e6" continuedAt="i0ecd401e0d7545d18f0b50ad193c2b7a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA4MQ_ccdf9462-d4e5-4c4d-96e0-3dad7e90865e" continuedAt="i86172f8ffe1f4660af31c8085fd548d9" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i86172f8ffe1f4660af31c8085fd548d9" continuedAt="i022b6f655a1f4ab2b23bada0fc7242ec"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i022b6f655a1f4ab2b23bada0fc7242ec"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA0NQ_773e8e35-75b2-4f74-8f38-4ae618118d9f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfNDI5MQ_2517cf27-117c-4102-b0b0-524e5bb5b322">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0ecd401e0d7545d18f0b50ad193c2b7a"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA2NQ_f3f6fe76-0cca-48b8-bb9b-20a40214c3c6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfNDgwMQ_b003055a-8981-4455-91fd-eb46f9fb2f5c">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA4Ng_2cc773ae-1e5e-43dd-bcb0-0b9227f08182" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA2OQ_777a1254-3554-4881-915b-1961585185c6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the Financial Accounting Standards Board issued Accounting Standards Update No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024, and is not expected to have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_46"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMzQ5Mw_5bc55828-e956-452b-9c5c-377304e4831b" continuedAt="i5239df3957be44af8bdb3e7337706833" escape="true">DISPOSITIONS </ix:nonNumeric></span></div><ix:continuation id="i5239df3957be44af8bdb3e7337706833"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDY4NA_c9e0aefc-ddcd-4bbb-b940-e655b42de12c">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDY5Nw_7a21c978-d96f-4ba4-ab49-534bfc1b329b">1.0</ix:nonFraction>&#160;billion in cash at closing and expect to receive approximately $<ix:nonFraction unitRef="usd" contextRef="i0bce0582b9234dbbac96a00b848486a2_I20220131" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcwNQ_74b91707-5750-444f-bcd8-66b6f887893d">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i3729e3a50004440ba3134a7803d8b293_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcxMw_0ebc0d84-6263-4981-9891-fe9599c61249">812.5</ix:nonFraction>&#160;million due at the first anniversary and approximately $<ix:nonFraction unitRef="usd" contextRef="i3fc13fd60c8140859d72089cfe8c306f_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcyMQ_0b3c464b-8df7-4504-812f-a222d66f4d98">437.5</ix:nonFraction>&#160;million due at the second anniversary of the closing of the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $<ix:nonFraction unitRef="krw" contextRef="id42c682634844c03b11c37f7325f453e_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMjc0ODc3OTA4NDIwNA_95ffbf8d-e30e-4cfe-af6d-81e9397a7194">581.6</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recognized a pre-tax gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-8" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MDU3NA_7b8f8f03-b95d-4c99-841b-978b9491ae9e">1.5</ix:nonFraction>&#160;billion related to the transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to net income of approximately $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MTUwNA_be0a21f9-11e4-4445-8d15-20440de7e642">58.9</ix:nonFraction>&#160;million in cumulative translation losses, partially offset by approximately $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MTU3Ng_ccbec429-c472-4849-887c-1e4e523dab20">57.0</ix:nonFraction>&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value based on risk-adjusted discount rates of <ix:nonFraction unitRef="number" contextRef="i2cb2cf98fd9549a4b68f0d966327fbfd_D20220101-20220630" decimals="3" name="biib:OtherAssetsFairValueMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTAyMzA_49516697-e1d1-4596-aaba-465ba20f1e15">3.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i74bbffe1fc2c4ff4bec0eda9713c2a71_D20220101-20220630" decimals="3" name="biib:OtherAssetsFairValueMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTAyMzQ_8f63d0ce-f83d-4dbe-ad4b-7c4b7c8c640c">3.7</ix:nonFraction>% for the first and second payments due, respectively. As of June 30, 2022, the estimated fair values of the first and second payments were approximately $<ix:nonFraction unitRef="usd" contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTE0OQ_42500476-d823-4ac6-bb3c-e6f59571462c">788.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTE4Mw_aaa784e1-accc-4fde-ade9-c6465a134a61">406.8</ix:nonFraction> million, respectively, and have been classified as level 3 measurements reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNTMzNg_00c50cc8-f513-4c3b-96a3-9a140ac3e3e3">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any payments due to us remain outstanding after the second anniversary of the closing of the transaction, we may elect to receive shares of Samsung BioLogics common stock at a <ix:nonFraction unitRef="number" contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430" decimals="INF" name="biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTc2Mw_5c891711-fec0-4c49-9fe6-e7168e5e112a">5.0</ix:nonFraction>% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the three and six months ended June 30, 2022, we recorded a discrete tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630" decimals="-5" name="biib:DiscreteIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNzg3Mw_2e84832a-4d8a-4878-a3e1-87c0e8201e40"><ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" name="biib:DiscreteIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNzg3Mw_433ff21b-a7c7-4fbb-b8ee-dd692d58e626">269.5</ix:nonFraction></ix:nonFraction>&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_49"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTc4OA_5df79605-8acd-48d8-bb32-8f7205907af3" continuedAt="i632f166cfabc4bf4af280422aa228c8f" escape="true">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES </ix:nonNumeric></span></div><ix:continuation id="i632f166cfabc4bf4af280422aa228c8f" continuedAt="i9ea80d50aca84ea29b597ff2d0f49d4c"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNTkz_3aba3de6-061c-4a43-afe8-91099cc65ac5">130.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNTk5_adfdb999-8023-47f3-8d78-db4bff8c327c">150.0</ix:nonFraction>&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTk5NA_1b9b5b52-58c0-48b1-9ef9-8316c4af4235">70.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMjAxMQ_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c">108.7</ix:nonFraction> million, respectively, of pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNzY5_21d50c17-f0a6-4ace-90f3-ab7ef4d352ee">60.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYyOTYwNw_341b08c3-780a-4968-aaf4-d3cfe99ac21a">88.6</ix:nonFraction>&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i9ea80d50aca84ea29b597ff2d0f49d4c"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the six months ended June 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTUxMg_7bb2cdc5-cf4f-4328-a374-1717a053fd8f">10.4</ix:nonFraction>&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recorded other restructuring costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTM2Nw_69606ba6-a436-46d1-bb6b-26336d96b45f"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTM2Nw_c1bdf8b4-5d16-4ece-9b61-9b14d616a3bd">9.7</ix:nonFraction></ix:nonFraction>&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs includes items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTc4MA_d9aed38b-39c4-481f-aab4-ca3673e0da9e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb931292e9944a83b4a28788d901981a_I20211231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMS0yLTEtMS0xMDY1MDI_dc1606bb-bae4-453b-8e39-b6679e5e5267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMi0yLTEtMS0xMDY1MDI_ad96b6e9-21fc-4280-8c1e-1cfdf0f3b37b">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMy0yLTEtMS0xMDY1MDI_153ef6a1-5a3a-4fab-bbea-bd555f043c17">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093f59a249e8425e8dc9546e07b5d4b4_I20220331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNS0yLTEtMS0xMDY1MDI_c0e9d225-b7e5-4b2a-b330-8de3f34ee3e4">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNi0yLTEtMS0xMTI4MDA_817f7b1b-9fac-4dbd-814d-c81d89e7a71d">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNy0yLTEtMS0xMTI4MDA_dafff149-edbb-4629-ba24-b0b6049ff0d5">29.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfOC0yLTEtMS0xMjg5MjY_3d88232b-c4a0-4aef-bee8-6167604d1027">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb54803dffa43a8b5c152bf9bca7854_I20220630" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfOS0yLTEtMS0xMzE4NTg_dcf4c6ab-0250-4640-b6ae-f69f6de6e7d1">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;REVENUE </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcxMQ_889a0763-0206-48e2-8f5a-919f8a4fda3a" continuedAt="i6e263f4517d04a0a89cc374700fc32ac" escape="true"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY5MA_eb1db6fe-6845-45f0-9e93-bd5ee044e0b2" continuedAt="iccb18b2c0bac47a3bba27c99d52780d0" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc97f4c706c4df984f6691e843d75ee_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0yLTEtMS0xMDcxNjM_e77219b7-c7de-45c8-b7c9-023378cece76">120.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af09c4bc4774ceb8b2aea7ec735f424_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC00LTEtMS0xMDcxNjM_4ad4259a-bac5-4848-9828-068c078cedda">277.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2801f94f42429ca36d1bfeafd776fc_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC02LTEtMS0xMzE4ODI_5739e8b4-2275-45b0-8ec0-6df40aaada0f">397.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cec06562a4b4440bbb60cef5c0e756c_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC04LTEtMS0xMDcxOTU_8391f9ab-48ee-4741-b367-a3a518849397">178.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57475280b3bd4e4f8735035f66af5da2_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMC0xLTEtMTA3MTk1_730fc4c6-05c1-4b2e-8952-dc7dfc690791">309.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae64ec1886f4842b346a20565644a07_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMi0xLTEtMTMxODg4_c2931aaa-3af2-4ed7-984b-44f82d81e580">487.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd18c1f363643da8e1eee2a47998423_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0yLTEtMS0xMDcxNjM_9f9e2e4e-bf20-4250-bab0-5d0c01b27515">129.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e50d0bd0f744b5ba53de911cb87f81c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS00LTEtMS0xMDcxNjM_987f7c03-4ff2-4384-a5cd-b63bb66ecbc8">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5c3899b1854563ad3c2273433e9b88_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS02LTEtMS0xMzE4NzM_51b19371-bc0c-487e-86f0-6711037b3cfa">136.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007d608c419b478cba33ba05d07aced0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS04LTEtMS0xMDcyMDM_d2351db1-a3e7-49cb-9ce1-5955590fb8e2">90.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d12a48ae2a54cd9bb4249844b6f04e1_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMC0xLTEtMTA3MjAz_90c323f7-ca38-42f6-8d90-032ed42417fb">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f3d7a22d664d38ae15146f61f0f1c7_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMi0xLTEtMTMxODg4_1626346b-4a87-45bb-974a-0d0bf2d1af72">90.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie099d88fe35a436897378cba2f7f09f5_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0yLTEtMS0xMDY1MDI_429203bb-39ff-47c3-a320-716f89b77ff8">250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bacccfe4b440259bfddc3e626a3be8_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC00LTEtMS0xMDY1MDI_872156b4-744a-4430-b5ed-9771a6109b77">284.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd6a55e7a084e99a824039b5136eb48_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC02LTEtMS0xMDY1MDI_b8a78e42-16ad-4b2b-aafa-4832d65a435f">534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f0b5ae9f1c4ab88664e67c1b9d51a3_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC04LTEtMS0xMDY1MDI_da4c9ceb-619f-4cab-8e18-2ca5feb22e3e">269.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie863f266caf446248389f5d655c80f07_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMC0xLTEtMTA2NTAy_eb1241bb-211e-4557-9820-3ee6f6384bc6">309.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0877cfe46ef448c8c7131bfa2927823_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMi0xLTEtMTA2NTAy_ecf7b297-3b0f-4988-aeaf-ba40a2da6185">578.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf00ad995134f4cb48df2bd2c51a7e9_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0yLTEtMS0xMDcyMjI_e699b82b-4810-45d1-a91a-0188e3fa48e8">171.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5a7668e3e149bb9288945e1b644d4c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy00LTEtMS0xMDcyMjI_2c000893-53e0-41b6-8d59-282605b5510c">87.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70f6702bb4646988e0ca53e9412cd4d_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy02LTEtMS0xMzE4ODQ_7c7f8233-ef99-4003-8b6e-c0cfdb8620a3">258.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439dde2be341406fa6edfa8d2a5fa6f9_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy04LTEtMS0xMDcyNTM_bd1edd5f-892e-4c92-bf71-52f8cbaceb9d">214.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81b6c4e8b0846d2977a5e818273a87c_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMC0xLTEtMTA3MjUz_807604fe-aec9-4d79-b6c5-132901de0821">96.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d118c84efd5442395adffb3dccb0b7c_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMi0xLTEtMTMxODg4_fb2429b0-a36c-4701-9ede-6d25d6fb65ea">310.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549b6fd3d1344466adcf7f2de11e4565_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0yLTEtMS0xMDcyMjI_1a945619-772b-4938-9984-9e182f61c2e6">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc8989f45f1472695f8f6ed83d3dbf1_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC00LTEtMS0xMDcyMjI_7ced6bbc-6ad3-48ef-9422-e856cc5fa890">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ed02e892e14d0eaf6fee39773e7d02_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC02LTEtMS0xMzE4Njg_cd7b5d0b-4b3a-4f42-9c56-007b237c68d3">91.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2c705401ea4f62a8a0412004a979dc_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC04LTEtMS0xMDcyNTM_e9304e37-db2d-428d-b7ef-6725e3528594">43.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e8eb6c75ee484da1a9b2899bf4079f_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMC0xLTEtMTA3MjUz_a383e05e-dede-4f8e-b3ae-83cfb0fabcbe">46.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e7d54a466a485cb541688829066e26_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMi0xLTEtMTMxODg4_94593f2c-69ed-44b6-8bde-039cb354814e">89.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9874f7ddd2cc4c1598811a920b86b7d7_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0yLTEtMS0xMDY1MDI_4bf454e7-8279-4681-9a26-4d3c394378e1">211.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd19d0a1a1bb4808875dccbdcf6b2e0c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS00LTEtMS0xMDY1MDI_dfa53b8c-6b4b-4184-a8ff-7ee539778b39">139.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669f2e9eba26433a84e680686bb0cf63_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS02LTEtMS0xMDY1MDI_6ef7c5d7-2b20-4c66-8ad8-a2b42f590337">350.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4a8e4a5df14221807d09956dafea13_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS04LTEtMS0xMDY1MDI_da13550f-57f3-47a7-ae7b-bf6c8901fcce">257.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2360a519c23e4144ab123af88aa77ea6_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMC0xLTEtMTA2NTAy_093c927c-3968-4270-88c2-7ea325a71c84">143.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b67a35dc2b4011989ac9568e54000e_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMi0xLTEtMTA2NTAy_79c5609b-45af-4cbd-a485-c5704db1491c">400.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e14405a5204b01a6ec0d2b6f80a62f_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0yLTEtMS0xMDY1MDI_c7b56dae-f413-42df-91b0-8d8dbae7fe0d">291.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89841ea93b374be7b061906d6d41e52f_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi00LTEtMS0xMDY1MDI_978b6b96-ba64-4023-9d3d-9ab624b6e2ee">224.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f2ed1ce3a14b0990001afc1dd6c491_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi02LTEtMS0xMDY1MDI_9e4931d4-a393-4cf4-8037-298587223c6c">516.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89510757554e059925b2ada6c7f286_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi04LTEtMS0xMDY1MDI_4f5440bb-102a-4b1d-b809-164b2fc662fd">299.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1389917b17d40cab84d0dea445f439f_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0xMC0xLTEtMTA2NTAy_8dcc34ae-b04b-4a02-8156-7999468641ec">224.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66eadafd646d481f90ae1525ff408940_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0xMi0xLTEtMTA2NTAy_e8c83591-22c3-407b-beb2-18cdb9c9e784">524.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26206d0cd7764127b07966be5f7b1a7b_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0yLTEtMS0xMDY1MDI_7f20c2d4-a793-4d38-9db4-1a3e7674c889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246f3bb8b3b94d7a85b72b22eb167658_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy00LTEtMS0xMDY1MDI_88c4d0fe-7922-42aa-99e7-54cb7fec6217">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18509476d6e74f7a8ad9b9e79de07e3a_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy02LTEtMS0xMDY1MDI_4c03dbbb-2dda-4f3b-b585-ae64367ff7dc">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ccb1c80bf9489c82bec10e689c3e90_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy04LTEtMS0xMDY1MDI_1868b230-1d10-42e6-b8dd-d109cdd74796">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a2594f184f4ac9b8cbc8aad0760336_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMC0xLTEtMTA2NTAy_49d419f5-ee41-432c-9e2a-7cc1a8ea0e33">26.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d9f7c4dc24480aeac96e047fbb0e3_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMi0xLTEtMTA2NTAy_15000c08-c4f0-4e39-b1f4-d5734df8e845">26.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db865d77b6d42dbb986db32acfa75e6_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0yLTEtMS0xMDY1MDI_79b67c76-9295-4976-9bbd-0e248eae4527">753.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4237b443b36c423e87d4bba35a59f794_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC00LTEtMS0xMDY1MDI_eca190c3-58e6-4a3b-b418-17bab4ad6477">672.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47841ad34b76402897680f541339e3a0_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC02LTEtMS0xMDY1MDI_ba746c47-8a5b-4d0e-8ec6-af08acb6f0e3">1,426.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b428dc01d34c3bbe3425f599b4d465_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC04LTEtMS0xMDY1MDI_1079e8cf-ce0b-4211-90b1-e3042cb8290a">826.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24d8e1260d54752840a81ca4bdcf3fc_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMC0xLTEtMTA2NTAy_dcb94655-7d67-4675-aab2-280e419e7b7d">702.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac58ba74b4a4daab4732d74461adb12_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMi0xLTEtMTA2NTAy_6db8497d-9785-4e6f-b39a-e20eed71abe4">1,529.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a6246e1af94484ac63941a25f762a8_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMi0xLTEtMTA2NTAy_78ed68d3-7e6c-4e65-8b15-7956607939e2">139.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b30f603f0e4af5b617750440ab03a1_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtNC0xLTEtMTA2NTAy_d04c9cb2-9b67-43ed-b36d-9d68b4445291">291.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787e3c6fe03d41b1af6a449e9505be82_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtNi0xLTEtMTA2NTAy_c32944f6-85d5-4abc-a2e3-3f6e1fa23ed3">431.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6ba2438bad4f1a9522748b9f8c53b1_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtOC0xLTEtMTA2NTAy_a55e7823-f672-4df3-b0ce-9effff2cabea">149.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900bd71ac7a447f2877d1c9ef20a5d79_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMTAtMS0xLTEwNjUwMg_6022ace7-b058-47a4-83d6-5dc08c4b9fb3">350.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d48220f13a42a9ab30ced0e8f1e5be_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMTItMS0xLTEwNjUwMg_82d250ff-0e7c-4a03-ba3a-f20bd98925a8">499.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb64f28ce22a4e32865b37fc103092bc_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMi0xLTEtMTA2NTAy_fb872379-2756-4d3e-95b1-2ae9ffdf84ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5191eac6bdab406a954232524744f872_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctNC0xLTEtMTA2NTAy_978ac0b6-d291-470e-9b07-8f9bfc1c8c3c">115.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd597660d69548fab84a62c47780e0a4_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctNi0xLTEtMTA2NTAy_f37c6feb-0be0-41a1-abd2-94d91e27e889">115.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35a86579b2d4ccab8f3d3435b134d6e_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctOC0xLTEtMTA2NTAy_7b678c36-e45f-4efa-a883-613163fd491c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64518c9cf9e49b0a60aaee3bd5ed703_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMTAtMS0xLTEwNjUwMg_a2fdeeaf-750e-4d53-bdbd-adcaa5fff38b">121.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a92ffd45f3464b9fda8ccf988fe123_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMTItMS0xLTEwNjUwMg_8a64a4bc-c22d-4ff3-8bfd-70fd6f72b53e">121.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358cd1acfeee460987aedecf5fb632f2_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMi0xLTEtMTA2NTAy_6d5df807-7696-4c0d-bad5-927b8b59c9b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05e0a33bc5c4413a51ea40bba76c6c5_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtNC0xLTEtMTA2NTAy_920204cf-f9ee-4b2c-9bf8-6553f79f2ace">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4508944e934b4c8cb245dc13c3967cfb_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtNi0xLTEtMTA2NTAy_c4a8aa71-a0cc-4add-9803-d66201ee3f19">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475aa3cb324a442da54be389e9f9aec0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtOC0xLTEtMTA2NTAy_d1b495b5-4ee5-4d6f-9c9a-95740a16afb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236b9b5fed79407ea79107fdd77e4910_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMTAtMS0xLTEwNjUwMg_3a8dc33a-55c1-4868-8d35-bb8b079fd1dd">55.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3d0fc0b8224db6a7dfe05c6ee94f16_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMTItMS0xLTEwNjUwMg_c49eb235-acc7-42c4-a013-bf8ec542adb4">55.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804d63c72cb74d8a825d0c9196678307_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMi0xLTEtMTA2NTAy_86492c76-85bc-4d59-8783-70b1c826aa4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c59c486765442ab29490107dc4c833_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktNC0xLTEtMTA2NTAy_e9c6991d-98f7-4ef2-be0e-9d80038208ea">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad386a522eeb41e08b1ab49a0355313c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktNi0xLTEtMTA2NTAy_8df7f28b-4cdc-49da-8804-9a55e4365d29">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d98e5ebbda3474a97b1805fe5acad43_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktOC0xLTEtMTA2NTAy_ad298b53-ac59-465b-b650-2864462a8012">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1952410e30f040bc853466b15fdacad3_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMTAtMS0xLTEwNjUwMg_aace7e14-e753-4780-8dba-7d5370090d45">25.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984ae54db252428cb8f595d9cb4150d9_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMTItMS0xLTEwNjUwMg_43606e7d-581b-4d85-9ac3-91626591ee10">25.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9acb352dfec4b54bba68898daf102aa_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMi0xLTEtMTE1MDg2_a884aeaa-229f-43e9-835b-d7e13f0304b8">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2567373127054bc2a8607a8a0c8a7edd_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNC0xLTEtMTE1MDg2_6ecda5ba-719f-471f-b9aa-585069bab541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c6c1e9fba1448c8ff10e9636557a4d_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjEtNi0xLTEtMTMxODY1_f24c18ca-4703-4bd3-a256-f3ef1efadaee">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3588cab2b9054d38bac088fe429cc890_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtOC0xLTEtMTE1MDkz_adfa745c-eed1-4dc4-9e0c-3a53d4e56b84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7181656e80b44d28b2579ef54642c184_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTAtMS0xLTExNTA5Mw_65b7542f-3df0-4292-981c-91125fd50c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7a5aef1a14499eb4bc5e66e0ff9e05_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjEtMTItMS0xLTEzMTg4OA_d20e57ed-039d-4512-9fb7-59708543dd17">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5196d39fc34746f686749f922c1eddd3_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMi0xLTEtMTA2NTAy_cedea667-160f-4e62-8723-79a8f94e4906">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034c5f0e4d404907bd5ac516daf28b53_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtNC0xLTEtMTA2NTAy_e8b36dad-b0de-4f73-acdd-0c53304a1864">193.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49329c17755547ba919fa1dda7c1f8d6_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtNi0xLTEtMTA2NTAy_1cb0097e-1b1d-4175-9238-3cc7485b1264">194.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b838ba43c36477982d17fb691b3234a_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtOC0xLTEtMTA2NTAy_6d19097e-2a78-49e1-a170-6ecfc9d8ce6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae90209eddb94ce18a41953fa15d38c1_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMTAtMS0xLTEwNjUwMg_42c6fc74-d227-4d00-967d-9d506ab6dade">202.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5f94ef9b9a43dc8d2c2d02fdcb2722_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMTItMS0xLTEwNjUwMg_f690c8ff-06b1-4e75-b9ad-5aa89ad4342f">202.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed83b378cc4447ba4b164ca7ba2461e_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMi0xLTEtMTA2NTAy_95252f2e-3fc0-4e5d-afdc-8535387cf5e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b56cabf17a421f85d3d4f832e08a91_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtNC0xLTEtMTA2NTAy_2a54e839-49c9-40d1-8c5d-15a1078802f8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib039450f31374b54b85c6aededf4648d_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtNi0xLTEtMTA2NTAy_d6416089-68ce-4ee9-a99e-17baca301a00">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611d28129d4e4e0599f6a9f56f89224e_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtOC0xLTEtMTA2NTAy_b33cd1bd-3291-431a-8553-d00fc3902c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3c484378104076849db738ae2ec70c_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMTAtMS0xLTEwNjUwMg_24fd21b4-4cd7-4348-b466-4580ba02f449">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7866e70096134bd6b4a49b4aa53f2d04_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMTItMS0xLTEwNjUwMg_e0faa141-a6bf-4fcb-a280-23ad91a0d901">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98bbb070b1424fc2a3a3f4bf953dc517_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMi0xLTEtMTIyNjky_3179d8e9-280e-4086-a99e-08d4ad81b85b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248c0445077b45aa86eba19f300d0882_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktNC0xLTEtMTIyNjky_9475c5a4-907a-4175-8b13-886551f97fda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktNi0xLTEtMTIyNjky_bc171013-2783-4eb8-aa83-7e3d9d6ecf5c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfd10449e7548ffbe44b55fae3c44b5_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktOC0xLTEtMTIyNjky_a765135d-91c0-4158-b866-3d831673d727">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b5463a749b4240884bb2801739ef29_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMTAtMS0xLTEyMjY5Mg_62d296f2-a129-4661-845b-fa5113036f79">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c2fc38dd6440378e0da306d5634c8a_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMTItMS0xLTEyMjY5Mg_d4461306-6059-4c28-b4b2-a565b64d5922">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c752409708d47fb98286c2172136b6c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMi0xLTEtMTA2NTAy_c98ff1f7-b78f-4384-8236-7f06050a5e99">894.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d293f205e034c3fa4e0b605f6b06cb8_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNC0xLTEtMTA2NTAy_20301e90-ff7f-4523-b46f-afc03ff32f8b">1,160.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNi0xLTEtMTA2NTAy_7f144613-e18c-4d27-9048-0a2b4cd72b4c">2,054.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b96e7b13fe4cf899501970595d616e_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtOC0xLTEtMTA2NTAy_db478d2f-8420-4f18-acc0-593c00d31e21">977.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ef2831201c483a816e081f25fe77b2_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTAtMS0xLTEwNjUwMg_03873e34-dfbd-41d4-8ce9-badcd681d3dc">1,258.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTItMS0xLTEwNjUwMg_7c4481c5-4ada-46b7-bec2-ce4dbf4a2494">2,236.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i6e263f4517d04a0a89cc374700fc32ac" continuedAt="i06aa42c88abe4728b77deeb89494540f"><ix:continuation id="iccb18b2c0bac47a3bba27c99d52780d0"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic75cc49ce6a3424a8ebc26ac92c41122_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0yLTEtMS0xMDczMDc_3fc9c83f-0e60-4774-b419-ace2b6ae3471">237.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45191a6585d342b19254212fbe8438cb_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC00LTEtMS0xMDczMDc_de30d9f1-c820-4934-990d-622b1cb7e24a">570.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99502a8cfb3f45729909de9e9445521e_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC02LTEtMS0xMzE4OTA_0d9d1361-d06f-4c1b-aa56-186f3c86e16a">807.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9efe3047c104850b8e5e3f237c83105_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC04LTEtMS0xMDczMjc_3bef8cd8-de23-4e95-b345-238a61c8a2f5">340.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ac3e997349402c8283ff022c717a94_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMC0xLTEtMTA3MzI3_d527d94a-73e8-45de-85b1-e159fee241c5">626.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cd308b36c74ad58f3c697827421153_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMi0xLTEtMTMxODkw_f1a948de-ca25-4246-8d9f-04a2c0d98de1">966.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa62803e94f241bc8d51d00489520d62_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0yLTEtMS0xMDczMDc_c84e1fcb-7e63-4185-9327-9bc7d633de4a">255.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1762fc48b1448f996169dd0486ad6d_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS00LTEtMS0xMDczMDc_47592c7b-4e24-4c96-83cb-d9a6e878922a">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df119b80ffc480e8399e35f9caf0122_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS02LTEtMS0xMzE4OTA_56b573a8-19d9-4a9c-aa54-1f52dcce42ce">264.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cff98a2974c4e18b7621008c47bf431_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS04LTEtMS0xMDczMjc_4becaac3-ebcd-4e9e-bad9-d68447896ea0">164.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe712ea06fb4478e9e58e6a0e0bdc3be_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMC0xLTEtMTA3MzI3_766b4d23-3942-46cc-b491-61018f85f852">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c298411b25d4e859abbd71121626990_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMi0xLTEtMTMxODkw_57dd2b05-3096-4057-9609-30970c4b77bb">164.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e803d9462d4f58ae2c9c760329e8e6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0yLTEtMS0xMDcwNDk_05d721f9-f14c-4618-b39c-2c870ea34dc3">492.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593120b1e8584eb3b206a368abb95161_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC00LTEtMS0xMDcwNDk_404581c2-504a-4a3e-bdab-5cfe3d6c2312">579.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6113e46ab14f91972e94233f927582_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi02LTEtMS0xMzE4OTA_58d75fe3-baf2-482e-9e9f-9b3715fedd9d">1,072.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide944bcb2c8349cf9c7f53fda13e0687_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC04LTEtMS0xMDcwNTY_f5dace19-7b26-4f00-bcd8-75d6086f3f32">505.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ccd22804b741a38a553424e98761d6_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMC0xLTEtMTA3MDU2_19cec32c-4569-4745-8feb-71f1ecfe47ba">626.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4b3c8eb21445db8b85f3ee7225cc7d_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0xMi0xLTEtMTMxODkw_9f5d7a14-6071-4f66-b19c-efbcd430f66b">1,131.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c97e3c0924c4cdca1b9f1a53282f87c_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0yLTEtMS0xMDczMjk_a787a26d-dbaa-422b-a0d5-324934aa4854">319.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb92748d73344c199c4d746141d7e10_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy00LTEtMS0xMDczMjk_9e81a2de-0dce-4944-9021-759fe84bc028">169.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8feeefdefc47759f3ad172a5d47c38_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy02LTEtMS0xMzE4OTA_0071931b-3ac2-415b-8007-d6c3a78b1a54">488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf198850c37f48fe8acdfb3a8d10b2b7_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy04LTEtMS0xMDczMzE_0e875a65-f10a-44bd-a744-2bb7f087305a">423.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48eec3c9dd8649e994f055ef1a743d24_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMC0xLTEtMTA3MzMx_06813280-9b9a-43d0-8af4-7e385ec55c7f">198.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfa09326e424881b32a983586469855_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMi0xLTEtMTMxODkw_2bf874c7-171e-4fb3-8ffb-2d9bc6b16234">622.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e6c0ccdcca4ea08f4fbcc8304df01e_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0yLTEtMS0xMDczMjk_c149b26b-ac6f-4d18-a1a7-2cd0f255f051">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909ed281083841ad97422e6d8e9b5fa2_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC00LTEtMS0xMDczMjk_88be6a92-a3f2-40a3-bea6-c97dd0d03f48">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1b8097922a4bfc8460acc93072bf50_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC02LTEtMS0xMzE4OTA_0121b86b-248c-42b8-926f-9afa40d16e87">171.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff32cab6555f4e67aa1cc62da2fe2381_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC04LTEtMS0xMDczMzE_51aed4b6-6fff-456b-b79c-6ec7e8467e19">76.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d6bc8eecef46c88940df4fee6d8925_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0xMC0xLTEtMTA3MzMx_41489df5-90d5-4644-bcaa-bd9f8a5cecae">102.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0039988350a4be2b2d710515403df71_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0xMi0xLTEtMTMxODkw_a6d36f7b-ac4a-4f99-8748-bd5365fdf2d7">178.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83629e3f3364efa9bef8fbc4e846597_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0yLTEtMS0xMDcwNjI_5d0d9775-c9b1-44fa-971a-87758b55c251">393.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide698acf03b8401b9aef8d55660fcfab_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS00LTEtMS0xMDcwNjI_17a0318d-fdc8-4c32-8984-0406716b0cca">266.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516625dc60d343959f4510e766fb1c31_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOS02LTEtMS0xMzE4OTA_e4ad0f5b-0398-4e42-9841-5fc2bccf6221">659.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674aeedb6b6245808af71c103fe19496_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS04LTEtMS0xMDcwNjg_b286dcf4-39cc-4efe-b492-236e7be8f49b">499.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534264b1291c4344a70276b5e63a6910_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMC0xLTEtMTA3MDY4_4662cc0f-b5b1-4192-974b-dd7514a4e225">301.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc015931c1d4d2db4fba3c31bd94986_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOS0xMi0xLTEtMTMxODkw_f5a0cbb7-aebf-4a2a-8166-bff84d2bf52e">800.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if805be58b48f48e48afc88306089f798_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0yLTEtMS0xMDcwNzQ_540ffbcc-f154-4dd9-afe1-ecc1fd8197e9">576.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4006bfbe38034523a41e0e68251e4252_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi00LTEtMS0xMDcwNzQ_6bf533e8-5deb-45e4-86eb-7752413d894e">460.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeedfc78a95049649dab7ec26f21d7ed_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTAtNi0xLTEtMTMxODkw_02b2f550-84f5-4850-aa7c-b57adaa93e1e">1,037.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0b53fa1b874bc596af922c5d3014db_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi04LTEtMS0xMDcwODA_079008a5-da63-458d-93b1-a997a7c2b77c">573.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c6e75fff5d48ae9c25b00d31fe330f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0xMC0xLTEtMTA3MDgw_f3ac7032-94cc-4ead-84f8-24541c9d32be">454.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07dfa622b4e2449e8b118649dadcb3f0_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTAtMTItMS0xLTEzMTg5MA_6169acef-b860-4560-9380-a5fffc055d9f">1,027.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i845528c074714b90896d3a1a295e2d20_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0yLTEtMS0xMDcwNzQ_59a8ba1e-1968-4296-8245-e63bc5d18f43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa23d5be5be49e894fcbc5ff00c4c1d_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy00LTEtMS0xMDcwNzQ_6a482f6e-f5f3-45d9-be6b-c5b9d38c6234">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a07137c98dd4524ada1101807817e84_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtNi0xLTEtMTMxODkw_e5cd1bf5-90f6-4b43-8b3c-dc715def2093">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ff46c84eb64c11aa952fd2ef0f8162_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy04LTEtMS0xMDcwODA_01b858ef-e17e-4a00-ad24-b0a2e20b93b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746834edaf31484b8281cd357d15cf15_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMC0xLTEtMTA3MDgw_3d354432-80e2-43da-aa96-abaa77b6ca5f">52.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie414fbe6060f4736819d0c0a26db0825_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMTItMS0xLTEzMTg5MA_fbf6a87f-3844-4736-9ace-84d2ce43ad0c">52.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb013e9fb28748ec96b5bd3dbcd9cb36_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMi0xLTEtMTMxODkw_e00befd4-2652-4d7c-96a9-bd93c40a3dd2">1,462.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98657545c7442f69f64e667dcb30fef_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItNC0xLTEtMTMxODkw_76dc678b-d434-4d89-8b2a-9749ae8dbb3c">1,358.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if081f6ddaa644634a85c1c8e772b6984_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItNi0xLTEtMTMxODkw_29dab2e7-a121-422a-82b6-f0c61830ef3f">2,821.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d58cea04d384f9e962f42524c6c6618_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItOC0xLTEtMTMxODkw_5278de2c-b5ee-4068-8a42-91cc409aab52">1,577.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e33e4e8358e4adda4f14ec95348140d_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMTAtMS0xLTEzMTg5MA_e1e72fa5-0b15-415c-bb22-39072b56b641">1,435.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9743755e37fa419da373d722f34ee542_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMTItMS0xLTEzMTg5MA_bed74c0b-9c12-471e-b3d6-1ab4e74ad747">3,012.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2fcbeae88249a4bcd644491e34cbff_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMi0xLTEtMTA3MDg2_3364ee86-8137-40ad-be6a-a32d8658ccb6">303.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01db06835d64a3183e66267859801c6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtNC0xLTEtMTA3MDg2_f438ca5b-90b7-4bc2-8111-4ae717e99c85">600.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350ceaa6094d41beb6a43612a28b3522_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTUtNi0xLTEtMTMxODkw_a390adcb-0e52-4b44-8412-5f24635ccd6b">903.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8767bf21797c4edd9ed6d33237556b82_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtOC0xLTEtMTA3MDg4_1149e14b-2c02-4c3c-98a4-be1f7115164d">298.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a4b565eb6a4894a23a82cad310d92d_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMTAtMS0xLTEwNzA4OA_1a03dfd6-2b8c-4912-99a8-9fc06f2fe875">722.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8586bda14db4b688d52c294e041530e_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTUtMTItMS0xLTEzMTg5MA_da9d2ec0-b85c-48d3-957d-57e5a3ef0af2">1,020.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1be940b30cb4fe585cc5a760d23fa93_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctMi0xLTEtMTA3MDk0_868e7c62-0e50-4cc2-afeb-832a2c273a3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa0b6d1982040c4b2eec5d12980a8f6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctNC0xLTEtMTA3MDk0_d4d21d2e-fd71-4f14-bb31-707fc9499a27">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a76cce432a4940a7ee77404de33976_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtNi0xLTEtMTMxODkw_3ad4dc32-09e2-4caf-9661-e90db1a4bdbf">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267202cf4eae44a18487d9728c2731e5_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctOC0xLTEtMTA3MTAw_fed7a0b2-0e1d-4338-96b9-27906dadf4cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id895b207466d40dc95e4ccc4a5a688cd_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctMTAtMS0xLTEwNzEwMA_c86a17bb-481b-4cf6-8d7e-ed3ac715ee06">243.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddce2d7962540e6ac7f7d0e98e969a8_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMTItMS0xLTEzMTg5MA_72f424c1-13a2-4b8e-b55e-bdc36ffe4eda">243.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb00137c6dbf40a19194ed758485a9ad_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMi0xLTEtMTA3MDk0_6acb3bb7-3da3-4041-978f-f9f3163c760e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5b6eaefce44a1a8296fbd9fad4e46e_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtNC0xLTEtMTA3MDk0_4091189f-59f2-4e9a-83c9-94ce3853fb10">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8cf5e156d34a85b0e5038f75d9a1ba_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktNi0xLTEtMTMxODkw_6030b4c2-1dfa-4112-82e2-caa9a0246f4a">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf550338832a4a30b4fdd8fec9c03a94_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtOC0xLTEtMTA3MTAw_cfd26702-9d57-47b0-a58d-cd0f463bb7e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f6509df9234368ac66c5aee7ff2450_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMTAtMS0xLTEwNzEwMA_c8464514-7962-426e-b6b7-dfa4313a9543">113.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39db4e78f61d4e84a1a5f31a5027bbfb_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMTItMS0xLTEzMTg5MA_8b0aee5e-8beb-41b0-b713-2bb887047e4f">113.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6154029d154694ad802b0c0880d594_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMi0xLTEtMTA3MDk0_f45930b8-241b-48bb-90c7-3750c3b9ee1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848c2181fc424e8a9cb106ef8274e8a6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktNC0xLTEtMTA3MDk0_7d781fc7-043d-4835-8c84-56330a042593">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610ed9f98048e6b4b8084998674df6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjAtNi0xLTEtMTMxODkw_62fa3ab4-4693-4264-ad9f-1173aa9e80c9">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272a454e80394786a9fd2275a5ba02e0_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktOC0xLTEtMTA3MTAw_8d1115c7-e1ff-48b8-adc9-c9385335fb94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bc86475c9b4c89ab084e88ce485ca1_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMTAtMS0xLTEwNzEwMA_d1005e5d-e381-4316-848e-b15a6209e02b">50.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb45edccfc854e13b231619881ae3579_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjAtMTItMS0xLTEzMTg5MA_2b7980fa-ed57-45ac-83fa-a554f2c35af5">50.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ff50cb600c4fa6a01c0a4495b88c78_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtMi0xLTEtMTE1MTYw_a9e148ac-0610-47c2-845b-dc92421b0e78">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0863cb79da9045349bba7df17125e957_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtNC0xLTEtMTE1MTYw_87f48376-f6ef-45ed-ba52-8aab6120a901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e411c18d6544dc871cf730df065633_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjEtNi0xLTEtMTMxODkw_6d26230b-5015-49bf-97d3-e6ccc1d03622">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acd41d895754f3ab16a2ad37d6b762c_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtOC0xLTEtMTE1MTY2_3ab7aec0-0c1c-4db8-bebb-a8b7b35fc1f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20bdbb4b6e064fc0af141d9e1a0fb2b2_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtMTAtMS0xLTExNTE2Ng_792db46d-9ed8-4a15-87dd-f3bdbe484bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dfb47e453249e6afb959fc861e7025_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjEtMTItMS0xLTEzMTg5MA_f7de5755-23c7-4467-a369-b5968bb32f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f28371d51c34038bc9822ac4d4329ea_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMi0xLTEtMTMxODkw_087fc3a7-6510-4bcf-bce5-d8bb633855b1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1ac54ae2734b5f9a4178272d59b625_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItNC0xLTEtMTMxODkw_9444a7ce-bafa-4422-a976-4f968bd55205">388.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b44e06b1074fe69c010ee1a0eeacc9_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItNi0xLTEtMTMxODkw_425e4ce7-61bd-44c0-8194-01470a680575">388.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9427ad614e3477597e42639edc85a11_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItOC0xLTEtMTMxODkw_d328dbb1-c529-4df5-9a28-b738a98689f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391f039c06924c07919d530cf6d2dab3_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMTAtMS0xLTEzMTg5MA_3b71b87b-5bb0-41cf-87dc-49149f582549">407.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c880de17294fb3ae9accb52a1997c4_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMTItMS0xLTEzMTg5MA_141f0d38-1eab-4a87-a970-0507172ece10">407.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05034b4dab44684bb680a5b424b3f61_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtMi0xLTEtMTA3MTA2_9070e544-3b52-43c7-b7c2-fd79593fa001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5991f123dec64a919280b85ffc4ab06e_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtNC0xLTEtMTA3MTA2_20b778bc-ba0b-4a2b-8b5d-1662599eb7e9">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411f9e9067594525b9d4f01a9b27f61f_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjUtNi0xLTEtMTMxODkw_6b0b2535-58c0-4597-84a1-07175eb623bb">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e83afbbe2445c19ca3bd556f42beb1_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtOC0xLTEtMTA3MTEy_5d50c8eb-a492-4a06-a6bb-86a3c807e503">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6a7d87e2f44c0db0cd331472ab5e2c_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtMTAtMS0xLTEwNzExMg_0ed46021-4251-4426-9970-f2261d22e036">5.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaecbfefdeba441fafd2b18f0f37475a_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjUtMTItMS0xLTEzMTg5MA_efda5b2f-8d7c-49ab-9070-9a5a15c708a9">5.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6647a216d66c4d41a03fe12ef97207e6_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMi0xLTEtMTIyNjQ3_77a6f37e-2213-4a4e-9168-3e25e9735fb3">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0008cbf40274fbeb37cbbc7833e345b_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktNC0xLTEtMTIyNjQ3_884e7905-748d-4c6c-8bd0-c437007ebc26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktNi0xLTEtMTIyNjQ3_26ffaee6-0fbe-4bf9-9deb-4edf0cf0a5eb">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1e43eb20404d65a4905d84c981be83_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktOC0xLTEtMTIyNjQ3_bc698e33-fa26-44c1-80b8-ce69044e8817">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63936ee597c4dcbb4c197c6cd02228d_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMTAtMS0xLTEyMjY0Nw_06903755-93af-494c-982a-d13a876d49c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35fad63758942b88c0a4d638d35855b_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMTItMS0xLTEyMjY0Nw_e435f7e7-50a6-4c95-b6e1-96fcc8d4c8b0">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2f580e87294d6dbdf0e82006621e05_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMi0xLTEtMTMxODkw_e1b21eaf-4380-457d-891a-27d9b31d9af9">1,769.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ebb2e335574f1286e06fa26a183500_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctNC0xLTEtMTMxODkw_729de87c-31ef-4265-929b-7fa4afdaeaf5">2,351.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctNi0xLTEtMTMxODkw_d18f13fa-2ae1-4dc3-8c1d-5063ffd51b89">4,121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2099c0e56b54466bb5a80bc17980d728_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctOC0xLTEtMTMxODkw_970a3eb8-8d17-46e3-b35e-9b54b183d6dc">1,877.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012225e935554e759f4d02bd7f455af3_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMTAtMS0xLTEzMTg5MA_9b723664-4e91-4544-964b-c285160adaa6">2,570.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMTItMS0xLTEzMTg5MA_5ae5da90-6da2-4ae5-ade4-c8701f4a479f">4,447.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjE3_30689567-4c75-48e3-b3fd-7582567cda8b"><ix:nonFraction unitRef="wholesaler" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjE3_cde3c04a-3199-40b9-a2cd-e73357fb3421">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i544c9b9c3c2441c5857dc27ac5202a31_D20220401-20220630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjQ3_d384d381-eb38-4b2f-a016-ceede49379dd">27.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i59cb8ca63113417198b368e0ac0ee147_D20220401-20220630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjU0_f7d3fde9-1c7c-4ca2-8546-523a57444e9f">11.2</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2022, and <ix:nonFraction unitRef="number" contextRef="idd081a6a3bb5485b83c7166fa8c55471_D20220101-20220630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYyOTk5Mg_10d8ed5a-17fd-4ae8-902d-2b7cd48415f7">26.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic484bc958fa842c3893a6412ac12e08c_D20220101-20220630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDAwMA_257c73da-d463-4f37-896d-bde878ac12f9">10.8</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDA5NQ_30689567-4c75-48e3-b3fd-7582567cda8b"><ix:nonFraction unitRef="wholesaler" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDA5NQ_cde3c04a-3199-40b9-a2cd-e73357fb3421">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="ifc85bed201b940878824eb131a5d746d_D20210401-20210630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNzE0_2ba7abd8-649d-4c94-b500-d3dc0ef8525e">30.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i73b7e31d17f240a4bfc8076fc48a942c_D20210401-20210630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNzIx_b213dfd6-fb5a-485f-bdb4-d8cc6a6b77ec">9.9</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i77d66fca5ded45e297765f1b445f6c92_D20210101-20210630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDEzMg_47fbcc6b-76c6-4212-8e3d-e8e876da9867">30.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0e2d9158b11645f5828f271820b2dde2_D20210101-20210630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDE0MA_583e32e6-47af-4287-917e-893eb49b5973">9.6</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2021.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcwMA_a6dbd964-e03b-4f76-89fe-fbeb63120fee" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d6c18c9bc14e658bc749d15f2cc080_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS0yLTEtMS0xMDY1MDI_ee663c4c-e7a0-4eb4-9b55-dcb7b0e97cf1">137.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b0b386d72c42c7829f67584a538904_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS00LTEtMS0xMDY1MDI_f371194b-00e0-4769-87bf-cc757fb470dd">759.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b21651141942a69478099c2ccff90f_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS02LTEtMS0xMDY1MDI_88b03bdf-7973-4a74-86de-2442dbc182c2">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS04LTEtMS0xMDY1MDI_1efe0125-8e18-4c1e-8950-a6c82ea09904">935.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi0yLTEtMS0xMDY1MDI_e5ff1303-db96-4132-8091-c8cc95696e2c">337.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi00LTEtMS0xMDY1MDI_818fb4bf-b844-4c9b-abef-918dc2a67228">1,346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi02LTEtMS0xMDY1MDI_723ec62d-7569-4ed1-8590-fa4351c6a5ea">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi04LTEtMS0xMDY1MDI_a9475636-23a2-47e5-a3fe-934f80dd915c">1,690.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy0yLTEtMS0xMDY1MDI_dd034180-ff1a-4a1a-b2c6-c7c0ea94cbd2">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy00LTEtMS0xMDY1MDI_8eff0bd2-3276-42bc-a714-eccc3b959c0f">58.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy02LTEtMS0xMDY1MDI_411b8848-af49-4fa2-bec1-6f1eca080418">4.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy04LTEtMS0xMDY1MDI_54385c97-cf09-437b-87c9-4c9e375c8c5e">64.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC0yLTEtMS0xMDY1MDI_099382f7-64fd-48f0-bbf1-f768895ac6d4">243.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC00LTEtMS0xMDY1MDI_b9f74850-9a7f-4b82-8fb2-1228a0a77b96">833.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC02LTEtMS0xMDY1MDI_5422df33-2e85-4fa7-9e42-62863bb76bc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC04LTEtMS0xMDY1MDI_ffb735dc-a837-4452-b8b3-84062cb87bdd">1,077.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS0yLTEtMS0xMDY1MDI_ee6bb631-2d7a-4d51-ac02-dad9465177cf">98.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS00LTEtMS0xMDY1MDI_075bd12e-3ad8-4475-b35c-540575ae4085">391.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS02LTEtMS0xMDY1MDI_7bfd3246-a4cc-47f6-80d5-52fd6f38c57b">10.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS04LTEtMS0xMDY1MDI_57c9d6c6-2e31-490c-9978-7aebeec9cdcc">500.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadcd9c4eb7aa4d43a9535edcf11234db_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi0yLTEtMS0xMDY1MDI_b1a6f0ad-4285-44f3-a4cd-c037236a479d">132.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15237bd167748dc8935bb2db5aadd11_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi00LTEtMS0xMDY1MDI_b2e41de1-73c0-4739-9d28-365fb31269c1">822.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be79ed31c744ac0b8ce99f0b7505404_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi02LTEtMS0xMDY1MDI_07b98d5a-dd62-45fa-abec-2db7c62de022">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi04LTEtMS0xMDY1MDI_bfa173af-f411-4df8-8c0e-a4c72186383e">983.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i06aa42c88abe4728b77deeb89494540f"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY5Ng_575ffd3e-ffc3-4b58-8f2c-85f3dda3f906" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab432a874db444408172f33c16977803_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMS0yLTEtMS0xMDY1MDI_0e03f038-b1ea-437f-8457-256f608f8ec3">137.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43bad9cb88d740469bbafb0fb0cf0cee_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMS00LTEtMS0xMDY1MDI_55a935e7-678b-4885-97c5-e0127f2dcfc4">133.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33934bee3c5143dd99f1d517165ead05_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMi0yLTEtMS0xMDY1MDI_ee59b2c0-daa5-462c-90c4-2337dcef3305">846.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if642314400ad46ce8997912ff65d7344_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMi00LTEtMS0xMDY1MDI_526746d5-1585-4750-b659-1aa01c1c8e41">802.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMy0yLTEtMS0xMDY1MDI_63038ff0-d1d3-471c-8d57-1e3c9b4a7d67">983.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMy00LTEtMS0xMDY1MDI_caadd61a-b1e5-4d8b-8215-5ccbc976cc4f">935.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY4Mg_584a84c5-463c-400c-a43b-51701ce61bb3" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi0yLTEtMS0xMDY1MDI_bea823cf-59d3-443e-b09a-f2fc6d005be2">139.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi00LTEtMS0xMDY1MDI_8836f7a5-e0f0-4106-938a-c28316143ba4">178.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi02LTEtMS0xMDY1MDI_45694de6-4d5c-49f9-8bfc-55262faf7bc0">283.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi04LTEtMS0xMDY1MDI_5cd31e20-3056-4093-9f81-27be9ee51647">352.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy0yLTEtMS0xMDY1MDI_8485599c-81c4-4080-a225-be259d97faa6">296.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy00LTEtMS0xMDY1MDI_fe50d9f3-3a77-4cfc-b0e2-69b0b819706e">261.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy02LTEtMS0xMDY1MDI_a4624c8d-7ac7-47af-8a04-f6b84316a0c1">552.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy04LTEtMS0xMDY1MDI_35e94819-27aa-4e1d-9eaa-d04985d7695d">476.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC0yLTEtMS0xMDY1MDI_47c7e836-231a-4bd8-a209-aa989990c0c7">436.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC00LTEtMS0xMDY1MDI_446083fc-bde9-4cd3-b75d-13d2b996ed45">440.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC02LTEtMS0xMDY1MDI_e45aa86b-6fa6-4506-8b05-ab3ae602904e">835.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1009614648486a8d4885185901e0da_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC04LTEtMS0xMDY1MDI_24dfa311-e351-4504-8f4d-cfff39259e66">829.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcyMQ_8bc1ae18-b6f2-44df-a84d-a1e49facae0e" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f09e81766c42e2bbbe9c2a856ada30_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy0yLTEtMS0xMDY1MDI_02155e25-f6ba-4c1c-befd-bfd4f063dd6b">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3b5523cb8f4e5288c2afa798269171_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy00LTEtMS0xMDY1MDI_00a223b7-49f7-4e6d-81ca-2cdce43d3598">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88580276d234ac794a107b535d8a45b_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy02LTEtMS0xMDY1MDI_13eaeb03-23c3-448d-97be-46ad9a27f190">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d27d16a0e37434c878cd333a5be7789_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy04LTEtMS0xMDY1MDI_db82a637-5d78-49fb-973a-6ba32a81d97a">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb9e7fc3fdf4dc9a9ee227b36aeed4c_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi0yLTEtMS0xMDY1MDI_faa208be-642c-4266-90d8-d88a73313e48">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86078aa510454a67ac821f531e00d16a_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi00LTEtMS0xMDY1MDI_f4423de2-b271-412e-8a3c-b38e0c93cd82">6.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2407978bb6bb465a9a11b59c52630feb_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi02LTEtMS0xMDY1MDI_61821f3f-59da-4e41-bb70-7c0c75737f3b">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a019fd8fe4f425ab48dd67d22d37e0e_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi04LTEtMS0xMDY1MDI_70c1eb89-ea6a-4028-9c4e-cbac7b97708f">12.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a2d4a8e1514e098184d910e5f41721_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy0yLTEtMS0xMDY1MDI_91bca108-acb7-43f3-a6e1-d47f6c226e16">81.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03d8681da5c48ed823c595e3df9cae4_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy00LTEtMS0xMDY1MDI_a5a43093-e26e-4c2e-b32c-b7ba5f00e965">87.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a918b8fbaf4a098bb0923df21e1a68_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy02LTEtMS0xMDY1MDI_b49983ac-b12a-4013-884a-79e99a7e5a1f">128.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9895041a5d4fbf93cb82132c5fdbc5_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy04LTEtMS0xMDY1MDI_447289ca-b254-49aa-8489-27acad13309a">170.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC0yLTEtMS0xMDY1MDI_632401a2-ac7b-425c-8bcf-97d86491055f">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC00LTEtMS0xMDY1MDI_68b3ba95-9df6-40df-882c-a0396fc0a27d">99.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC02LTEtMS0xMDY1MDI_eaaf633e-fa00-4259-8bbb-f95222bb0142">164.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f0875c34f74569ad7173f706002116_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC04LTEtMS0xMDY1MDI_8f372499-01e2-419c-9317-4f7319a70805">192.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_58"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;INVENTORY </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTM4OA_ae4d8098-e647-4c0e-835c-658a3d56b7d7" continuedAt="i12b84c76b5384e12ab5f9d2891cfdf31" escape="true"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTM5OA_8548d90f-71a2-4297-b414-6b6777f6cc23" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMS0yLTEtMS0xMDY1MDI_8207240a-4c98-4da7-8498-0d3602472fc3">378.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMS00LTEtMS0xMDY1MDI_6641c799-b194-47f1-b268-8b44d26a3449">349.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMi0yLTEtMS0xMDY1MDI_81497d62-0dda-45a9-ac9c-df246f29a0d5">706.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMi00LTEtMS0xMDY1MDI_91610b28-5a0d-4de5-ada1-a897e8b4be39">814.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMy0yLTEtMS0xMDY1MDI_222db4f8-8f38-42c5-a0f0-73bc0b74856c">209.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMy00LTEtMS0xMDY1MDI_34a1f610-4512-4139-bc54-aa699e9bc061">187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfNC0yLTEtMS0xMDY1MDI_026881ec-cfe1-4bd2-80ca-a2459b398211">1,294.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfNC00LTEtMS0xMDY1MDI_38b8f092-11dd-461f-ab53-67c92955a461">1,351.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of June 30, 2022, includes approximately $<ix:nonFraction unitRef="usd" contextRef="id39f35171ae547d68317e335f6bc8cc8_I20220630" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTA5OTUxMTYyOTY3Nw_531b2e8b-8dac-413e-9cfe-554f527bf4ba">71.5</ix:nonFraction>&#160;million related to lecanemab.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="i690a67cc5731414a8f9aa06c53540e02_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNTg3_b68f7228-21f5-4ba3-bc7b-e654b29204e5">275.0</ix:nonFraction>&#160;million of inventory related to </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i12b84c76b5384e12ab5f9d2891cfdf31"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ic5c5095f62ab4c62ba0b2a1719784d97_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNzU0_4ad9941a-8800-4d74-861d-b550d358dbb9">136.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNzYw_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="i635b802dc41d46298f9d8608e9935a23_D20211001-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfODI4_5200727f-295c-4bf9-a393-cfdc33498f13">120.0</ix:nonFraction>&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ia08cc12b77134a85b0419098882728db_D20211001-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTAyMg_f57a7979-cc38-4bfa-a6c2-67b98e77341c">59.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTAyOA_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June 30, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i3a40683af9114b76a6f0f696d7c173ca_I20211231" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTI2OA_35b649c4-60c6-46c7-9baf-58fa92373a2d">223.0</ix:nonFraction>&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_61"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;INTANGIBLE ASSETS AND GOODWILL </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE3NA_4f9f6745-5831-4922-83d7-1cd8bdacde4f" continuedAt="i37ba3a352c8b414983599bcf0eeb4d75" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE4NA_73cba80e-d200-473b-9a06-c2e73569b06a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi00LTEtMS0xMDY1MDI_f1109da6-ddfc-4856-95ab-62dde744bf00">7,415.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi02LTEtMS0xMDY1MDI_7b4448bc-3cb7-43b0-9bc6-19b0989ff0d3">5,522.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi04LTEtMS0xMDY1MDI_f4bcf4d2-c28d-4f7f-9519-349861101b77">1,892.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xMC0xLTEtMTA2NTAy_3742af8a-fec0-419e-b03f-7ee7ea3ce631">7,413.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xMi0xLTEtMTA2NTAy_0febaf1f-a4fb-47e2-9813-5d09f8f69fc7">5,388.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xNC0xLTEtMTA2NTAy_595c904f-ef1a-43db-a9b4-3ba4e06d3d31">2,024.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d560d86969470286de95947d4488f4_I20220630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy00LTEtMS0xMDY1MDI_7d20e746-eab5-4f32-ac0b-43067cd3c794">119.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d560d86969470286de95947d4488f4_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy02LTEtMS0xMDY1MDI_e05fb0d5-b3df-45ef-9f99-f1bae34d5734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d560d86969470286de95947d4488f4_I20220630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy04LTEtMS0xMDY1MDI_6b49ec70-658e-49ea-9c7d-5e4cc017dc92">119.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xMC0xLTEtMTA2NTAy_c1a27037-1fb4-4761-b699-a93dea98a9a4">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xMi0xLTEtMTA2NTAy_d7b896ac-c421-4f84-82f6-09ff1b788ec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xNC0xLTEtMTA2NTAy_24d7c623-9dd5-462f-a21b-0f2efe86523d">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC00LTEtMS0xMDY1MDI_232a9511-f500-4cde-a1cd-4b7379136373">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC02LTEtMS0xMDY1MDI_97d89b2b-a168-497f-a954-39c8123d34a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC04LTEtMS0xMDY1MDI_e6a8ca1b-5426-4277-998c-e54884e24898">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xMC0xLTEtMTA2NTAy_49d29229-d7b4-47e0-bd4e-8762072b07eb">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xMi0xLTEtMTA2NTAy_4ef4a1de-8e36-40d5-a27a-376e0859f07e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xNC0xLTEtMTA2NTAy_95b895ab-261f-4eb7-b34f-0bd96c5effd2">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS00LTEtMS0xMDY1MDI_0e71d8b1-0f3f-42b6-af7b-128ba61c4cde">7,598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS02LTEtMS0xMDY1MDI_c06b7b72-161c-473d-b25b-d8a9f28393f1">5,522.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS04LTEtMS0xMDY1MDI_c53c1ba5-db74-4b7f-9f9d-d0c220aacd72">2,075.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xMC0xLTEtMTA2NTAy_1db19349-ca40-43da-b87c-1795d48359ea">7,609.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xMi0xLTEtMTA2NTAy_4cd709fe-04fd-4e37-ab3d-5bbc941675dc">5,388.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xNC0xLTEtMTA2NTAy_719f5070-58d4-460a-a600-3a245a8f253a">2,221.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjcw_27d7621a-90c4-41eb-9c1e-a19334410445">67.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMDk5Mw_70744d33-1fd3-4fb7-b8f6-2646c8389db4">134.4</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjg2_09d2be0a-a1c1-4806-8c64-4234621585c4">604.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTAwNQ_a20ba55c-64fc-4c97-a0fe-83a44833fdb9">702.2</ix:nonFraction> million, respectively, in the prior year comparative periods. For the three and six months ended June 30, 2022, we had no impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and six months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021, amortization and impairment of acquired intangible assets reflects a $<ix:nonFraction unitRef="usd" contextRef="i7072613f54844e3ba4de934782cd9535_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTUyOA_1fb393a6-5fc2-4e2a-a3b3-0ec29ba7b8aa"><ix:nonFraction unitRef="usd" contextRef="i2d589ef9b9024af5845103efc8018806_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTUyOA_7760a89a-56af-454c-8aab-0bd6cb5b43be">350.0</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $<ix:nonFraction unitRef="usd" contextRef="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTU0OA_04387fe5-523f-44de-b97f-4859e9177237"><ix:nonFraction unitRef="usd" contextRef="i57322b393335447fa049a18be91e5f26_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTU0OA_eb3cc616-da13-484f-93ce-1bdcb329ccc1">191.6</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets also reflects a $<ix:nonFraction unitRef="usd" contextRef="i86265989727740ada4d3803a06691ae4_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfNDk2_936fb08d-69a7-4dbd-b303-1bbbf3a7a364">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of June 30, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i37ba3a352c8b414983599bcf0eeb4d75" continuedAt="i22ecf1955d8940fa9c96a16c6ccca725"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i86265989727740ada4d3803a06691ae4_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjM1NA_936fb08d-69a7-4dbd-b303-1bbbf3a7a364">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the carrying value associated with the remaining IPR&amp;D intangible asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="iacf09d1ffde3467f9d51fd1d72e55232_I20220630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjUzMw_dd85d0b5-7742-4253-aabe-df9f5217f7a2">119.2</ix:nonFraction>&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial or sooner if there is a reevaluation event and may record an impairment charge related to this asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i7072613f54844e3ba4de934782cd9535_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTkzNg_1fb393a6-5fc2-4e2a-a3b3-0ec29ba7b8aa"><ix:nonFraction unitRef="usd" contextRef="i2d589ef9b9024af5845103efc8018806_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTkzNg_7760a89a-56af-454c-8aab-0bd6cb5b43be">350.0</ix:nonFraction></ix:nonFraction>&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $<ix:nonFraction unitRef="usd" contextRef="ic0cb1609479343309a6ca0ff24c5fca5_I20210331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjU2OA_4459f5f0-9651-46b5-9178-a93823396412">365.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i035bd9bd822646e3ba8f72fa5b2ecab5_I20210630" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjU5MQ_8550d89b-cf78-454a-a95a-968e2883eba6">15.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjQzNQ_04387fe5-523f-44de-b97f-4859e9177237"><ix:nonFraction unitRef="usd" contextRef="i57322b393335447fa049a18be91e5f26_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjQzNQ_eb3cc616-da13-484f-93ce-1bdcb329ccc1">191.6</ix:nonFraction></ix:nonFraction>&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $<ix:nonFraction unitRef="usd" contextRef="ie430205c0e8642b399f6ac098c948e1d_I20210331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjYwOQ_67f7c486-867b-4691-8748-836da8fc45d1">220.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i502f935fe0b441bfbca01d697b55e5c7_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjYyOA_9d6a2828-d0c9-4431-b1c0-08ca39a59014">28.4</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized additional impairment charges related to BIIB111 and BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to <ix:nonFraction unitRef="usd" contextRef="iab21929ee2b44bd3a5f7fcac80a7717a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMzUzMw_39f01559-a3f7-48c8-a22a-08a4e305ddc2">zero</ix:nonFraction>.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE2Ng_60b75e62-f10c-476d-b6dd-cdeaa758da71" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMS0yLTEtMS0xMDY1MDI_ab972535-e0fa-453c-8831-ea1a3915278a">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMi0yLTEtMS0xMDY1MDI_c5541a44-eaff-41b3-a484-3de766ab34ca">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMy0yLTEtMS0xMDY1MDI_0d252c41-d50c-41a1-bda0-3088d063a108">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNC0yLTEtMS0xMDY1MDI_ed44ac3b-7913-4f37-953c-7b126eca3aea">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNS0yLTEtMS0xMDY1MDI_c293bca0-ae85-4164-90ec-b6f0fff0e017">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNi0yLTEtMS0xMDY1MDI_f33ecb1c-64c9-4bd9-b9c1-d29b5e5969b6">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE5OA_7e1a6c19-80e2-4514-954d-15c03ab69ac9" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfMS0yLTEtMS0xMDY1MDI_089d50c0-c7d5-458c-8e63-d55ed85b2b1c">5,761.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfMy0yLTEtMS0xMDY1MDI_59f9448f-16a7-489d-b0a1-447be0a542a8">11.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfNC0yLTEtMS0xMDY1MDI_8a91327c-3401-421a-ab23-9b73ff165665">5,749.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i22ecf1955d8940fa9c96a16c6ccca725" continuedAt="id26de0e877004591919f8e1610028f60"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzAxOA_775c4a87-78e0-4d03-bd4d-6a8deb1c0e5c">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id26de0e877004591919f8e1610028f60">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMzk1MA_fffdede5-218d-48a1-9478-b92abaa6621c" continuedAt="i8de723b6181c4e8a96b6f996be95e8e3" escape="true"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMzk3OQ_3c078a84-e639-4ad3-8b9d-51dc3b6a8749" continuedAt="ia4f69e5582394f55a572accbc7c2fdc3" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy0yLTEtMS0xMDY1MDI_8cd41b7b-e1b5-48f0-b145-c69436dd3625">2,144.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy00LTEtMS0xMDY1MDI_52efda17-e35d-47f0-bd4f-f13c357ea389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy02LTEtMS0xMDY1MDI_4d80ac01-4acb-4f63-976d-9f00e5650db4">2,144.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy04LTEtMS0xMDY1MDI_ad7ff019-cb0a-4050-837c-d9bddd0f64d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529693e18f9d4940a0dc51a9656b8e81_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS0yLTEtMS0xMDY1MDI_140ddaa2-4541-488e-9be9-33bf0ce9ad23">1,890.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5410a4b7463e4871ba2258c342695d0f_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS00LTEtMS0xMDY1MDI_c6f67324-8c44-4f0b-bdaf-de9fa0c2987e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e760801b4e427c8d09b34b65881a0e_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS02LTEtMS0xMDY1MDI_ee0fe996-51a1-471a-a822-8eb671f141d5">1,890.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaae543901cf4bf0b0aaf47b428c3c49_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS04LTEtMS0xMDY1MDI_dc2b607a-888b-4a72-ba3d-37cc1a04db06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf903905566403e92f0306b14f21dfe_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi0yLTEtMS0xMDY1MDI_72cc06ba-be6b-443c-8e55-93aee07dfd82">1,156.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc363fb469e473aaecac4cf8e63ef86_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi00LTEtMS0xMDY1MDI_d386f91e-17bf-4382-935c-750ebbf4a06e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86003e21d714ef8a56c54bdd2b57d52_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi02LTEtMS0xMDY1MDI_d6daecbd-cf23-4418-ab12-5bf668593012">1,156.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d547ff00df40f989fae1a81b0cda41_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi04LTEtMS0xMDY1MDI_25896829-82c7-42e1-9dc3-281fcfe74037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467e688e67c4414ae5b2d512e027882_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy0yLTEtMS0xMDY1MDI_a42e26ce-9195-40c5-88fb-de404bf1c9f3">207.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d5a87c8222b415e99b23eb87ba7b373_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy00LTEtMS0xMDY1MDI_037418e1-b6cb-4acd-8046-8bd04596bc01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e25682c306442281fbd9b9e82f381c_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy02LTEtMS0xMDY1MDI_ef5bd977-fb63-4ef9-be63-586239b3961e">207.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439c2171b7ad4a428141db883360f934_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy04LTEtMS0xMDY1MDI_d413049f-690c-4e32-9b8e-c48a33602987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC0yLTEtMS0xMDY1MDI_edbdb67d-01d4-4bfa-8518-441c02dbf24e">785.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC00LTEtMS0xMDY1MDI_7f3aecf0-32cd-4f27-b384-57c195c43f8a">668.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC02LTEtMS0xMDY1MDI_b1265d8e-ef97-42b1-84e0-8d84bff07e85">116.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC04LTEtMS0xMDY1MDI_4c60f68d-dd47-42bd-87f9-d6dd17b9eb93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtMi0xLTEtMTIzNzUy_42500476-d823-4ac6-bb3c-e6f59571462c">788.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNC0xLTEtMTIzNzUy_92fd6c5f-9f22-4991-9c18-dfea87f1aae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a56b8cc106475483c716145966db29_I20220630" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNi0xLTEtMTIzNzUy_77472494-eda6-449b-ba8a-be8a7d9b704b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9074ac7fc541f5890093a94bed4d8e_I20220630" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtOC0xLTEtMTIzNzUy_adcbf3f1-2485-49bc-98b1-cc892b998f7b">788.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS0yLTEtMS0xMDY1MDI_ac77552e-2591-47f5-9b38-57418c175e4d">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS00LTEtMS0xMDY1MDI_12a4b7cb-23e7-445d-bd5c-d9b529d581fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS02LTEtMS0xMDY1MDI_4f12dacb-2f2d-4e80-a02d-c358974dc163">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS04LTEtMS0xMDY1MDI_28fb0ba0-908c-4e8a-9323-f77d9aa2a969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtMi0xLTEtMTA2NTAy_ff8ca1dc-6cf1-4eeb-adef-fcad58c3c735">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtNC0xLTEtMTA2NTAy_16a2748c-711c-40c1-af0c-2b383e1bb321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtNi0xLTEtMTA2NTAy_ac802843-dbc5-4207-a121-b0a3ed11c469">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtOC0xLTEtMTA2NTAy_674e27d0-5765-4389-b741-9e2c7edc3fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtMi0xLTEtMTIzNzU4_aaa784e1-accc-4fde-ade9-c6465a134a61">406.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNC0xLTEtMTIzNzU4_efa052c0-b642-49ff-b841-ca5d4273c0d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a56b8cc106475483c716145966db29_I20220630" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNi0xLTEtMTIzNzU4_bf90de1d-27e5-40c2-a6ea-f1feaac1c64f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9074ac7fc541f5890093a94bed4d8e_I20220630" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtOC0xLTEtMTIzNzU4_02193ea8-8ce5-4195-b398-57bfb6fb6c16">406.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtMi0xLTEtMTA2NTAy_6618e4dc-4ed9-464b-997a-af0d1889ce52">7,591.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNC0xLTEtMTA2NTAy_6aae2f02-c702-44f4-ba5e-acc3c5df208b">668.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNi0xLTEtMTA2NTAy_ba84701b-369b-4163-9cda-50a6771668ab">5,727.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtOC0xLTEtMTA2NTAy_d5f1e5b8-7af6-4746-857a-91a41a63d4d1">1,194.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtMi0xLTEtMTA2NTAy_2328d95d-cbb8-485a-b47b-2f96db58cb81">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtNC0xLTEtMTA2NTAy_248039c6-6150-483e-9fdc-787a1339302b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtNi0xLTEtMTA2NTAy_2c90bd19-01b0-4842-86a7-55a579a641b2">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtOC0xLTEtMTA2NTAy_293f1ada-e33d-4d0b-bbb7-f4b5a5ada507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtMi0xLTEtMTA2NTAy_a8ba0b5f-f555-45ab-87fb-b44706b76ea4">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtNC0xLTEtMTA2NTAy_f258800b-c094-4a45-a8f3-c0dcf6a4ee6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtNi0xLTEtMTA2NTAy_c99fd124-e33c-4657-875e-c1387fa98e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtOC0xLTEtMTA2NTAy_416bcdad-2730-42f6-86cb-05672027bd38">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtMi0xLTEtMTA2NTAy_65bc936b-6542-4f58-aec4-b1da437d1a0e">220.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNC0xLTEtMTA2NTAy_08a371ef-88c9-44bf-ac34-589da3d8bdb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNi0xLTEtMTA2NTAy_ce45d0b1-8bc9-47a9-a1cd-a7c02ed7267f">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtOC0xLTEtMTA2NTAy_85a6f851-5015-46cb-947b-b97e70bd84aa">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTY0OTI2NzQ2MDE0OA_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia4f69e5582394f55a572accbc7c2fdc3" continuedAt="id496cb0eed054e0289251f7ac258e4cb"><div><ix:continuation id="i8de723b6181c4e8a96b6f996be95e8e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy0yLTEtMS0xMDY1MDI_535b0fbc-20c1-4212-a639-b8d3b3fad1ab">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy00LTEtMS0xMDY1MDI_ef60082a-4721-4a33-b6da-9e6fea144f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy02LTEtMS0xMDY1MDI_eadbf00c-9576-45d8-95e9-768c07fb7aff">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy04LTEtMS0xMDY1MDI_38e0cbfa-bb14-4778-8548-d25556baefd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f635edc8a2430189c968b78a9e8cb3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS0yLTEtMS0xMDY1MDI_e230548d-12af-415e-b37f-5d4ecff8af53">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4316a770d24b4d87b85ca16f1e2d0f5a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS00LTEtMS0xMDY1MDI_996fb5cb-469e-4493-927d-da4c0ff39d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b362d0ab3134007a6f2417677122114_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS02LTEtMS0xMDY1MDI_306c8ca3-c536-407d-85a4-a96868463542">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b867d694211492a993655d5fb259d85_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS04LTEtMS0xMDY1MDI_635ee32b-5333-4331-9bf1-59cc56c37bd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1446517efc4d939297638bd36ea497_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi0yLTEtMS0xMDY1MDI_c0552669-524e-4953-9897-354421b3524c">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia741396d8ac949ab9d5894b778f1505e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi00LTEtMS0xMDY1MDI_ca495866-00ce-48c3-b257-b1602c10b22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03963bc9f9074822b67815b3e793e1da_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi02LTEtMS0xMDY1MDI_cc8874b5-6f30-4594-b627-37f022fe835f">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e334b59f08464daa0d2d2f402ad4b5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi04LTEtMS0xMDY1MDI_3813b960-2ad3-4bfd-a27b-5c65a86b7e6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca26b7ffe0540fc80c3f59dfb576259_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy0yLTEtMS0xMDY1MDI_693891a4-3757-4e52-ae77-1a14894dda81">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129644619e6d4f278f61964c9e9f3d66_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy00LTEtMS0xMDY1MDI_3922eb3f-25d3-4bcd-99e9-9073ef6c2a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bc38e16d5946d6982b6c3c72a07586_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy02LTEtMS0xMDY1MDI_f2e559a0-70a6-463c-a296-4f7119d24c0e">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580eba0699d7484880390868de30783e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy04LTEtMS0xMDY1MDI_ac177d19-e0bf-4006-8897-f2d7b9cf7d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC0yLTEtMS0xMDY1MDI_961bae6c-e626-483a-921e-e25f558be532">1,048.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC00LTEtMS0xMDY1MDI_054193db-6f23-4a3d-8965-7d476bcf7220">181.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC02LTEtMS0xMDY1MDI_24c09f8c-abd9-4cb0-8f71-aaf76c6caf44">866.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC04LTEtMS0xMDY1MDI_336df4f2-cfc6-4959-9ddc-e00f49a13e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS0yLTEtMS0xMDY1MDI_e31b63aa-3ed8-443b-8ea0-d09b7ea00e98">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS00LTEtMS0xMDY1MDI_3ed8e0ca-59e7-44ff-9518-be743f230ea2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS02LTEtMS0xMDY1MDI_821276fd-bc2c-4fc7-b2bb-e7907adf7c20">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS04LTEtMS0xMDY1MDI_561bead1-d4b4-45f2-8603-1c1628538316">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtMi0xLTEtMTA2NTAy_03d11a8f-3948-49f2-93d8-49baaa067073">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtNC0xLTEtMTA2NTAy_a4d4beea-d864-4dbe-aa64-c123ef074e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtNi0xLTEtMTA2NTAy_e70cd97c-7267-4ac8-ad13-e174d344e66a">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtOC0xLTEtMTA2NTAy_a3964826-6cc2-4cae-877c-4db673540f2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtMi0xLTEtMTA2NTAy_799d1119-aea5-4006-b41d-143da66099d0">5,228.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtNC0xLTEtMTA2NTAy_762536f8-d1fd-4b4d-b6e7-1d220423b34d">181.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtNi0xLTEtMTA2NTAy_1f42d6cc-f5d7-4f3b-afe8-188bf2fcc0b8">5,046.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtOC0xLTEtMTA2NTAy_23409b10-304f-4c9c-bcd8-9bc3513fe819">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtMi0xLTEtMTA2NTAy_5d7307f7-a065-4fab-820c-98fca7fd12ed">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtNC0xLTEtMTA2NTAy_7936ab10-f581-4e71-a79d-fdd573ceee67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtNi0xLTEtMTA2NTAy_612f9722-0e17-4c0e-af81-816a4a1026e6">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtOC0xLTEtMTA2NTAy_bdf77963-f037-44a0-a0f0-b9dc49b2c46c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtMi0xLTEtMTA2NTAy_31c8ecec-d915-459e-8ce2-84050967544f">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtNC0xLTEtMTA2NTAy_b873237f-3b5f-4763-88b0-67c0e47d5b48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtNi0xLTEtMTA2NTAy_0f09a6d2-b0f9-479e-8501-4a6e2f6c74ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtOC0xLTEtMTA2NTAy_b6b358f7-3395-4cc0-b35a-844b5f6d549b">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtMi0xLTEtMTA2NTAy_0600a6d8-7480-4be9-953a-748fb18b7ef5">219.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtNC0xLTEtMTA2NTAy_574b95e7-f1da-41d3-8bdf-5e09da702e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtNi0xLTEtMTA2NTAy_d8f96656-57f3-4030-ba2c-eb28937c64c5">10.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49be596d72642af812e59dd50890f35_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtOC0xLTEtMTA2NTAy_d334baca-5c37-4d87-b2b6-7eb26b6b4088">209.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMjgy_5415e3b4-8ab5-446f-83d7-6686cb1640a5"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMjgy_e89d9a22-b64b-4a62-a9a8-e8d4aba65f0a">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of June 30, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents a portion of our investment in the common stock of Sage Therapeutics, Inc. (Sage) and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. This initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 and is reflected as a Level 1 measurement as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial holding period restriction for a portion of our investment in the common stock of Sangamo Therapeutics, Inc. (Sangamo) expired during the second quarter of 2021 and the remaining portion expired during the second quarter of 2022. The holding period restriction for our investment in the common stock of Denali Therapeutics Inc. (Denali) expired during the first quarter of 2022. As of June 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as level 2 instruments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id496cb0eed054e0289251f7ac258e4cb" continuedAt="i63bc10a1bca14c3da49709df30312c07"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfNDk0NzgwMjM0NTEyMQ_45f084e3-25b0-48c1-9c48-c550891bfd53" continuedAt="i52cc4898939749ee8130269be0162835" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy0yLTEtMS0xMDY1MDI_a8ba0b5f-f555-45ab-87fb-b44706b76ea4">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfNS00LTEtMS0xMjE3MTU_31c8ecec-d915-459e-8ce2-84050967544f">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2ac8144dad34592a0e0d767e503cd0c_I20220630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy04LTEtMS0xMDY1MDI_980f4bcf-3b34-41ef-994c-8fb25aee4441">3.96</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia788a53d2f44480a9c09cb836102cf88_I20220630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfOC0xMi0xLTEtMTMxOTE2_d023c34e-5196-4af0-a7f2-8162e3984c53">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29b2d699c7994b058ffdc0a2973fe76a_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy0xMC0xLTEtMTA2NTAy_5e8e51d7-1b23-46f8-959d-6d189f60f42e">1.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from <ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzMzE2Mg_26d4aa40-8205-4e35-bdb5-31e91827b07e">10.9</ix:nonFraction>% to certain probability as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration Obligations</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfNDk0NzgwMjM0NTEyMA_f06d87c6-710c-4411-ab42-e7c0dff894cd" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7f7781b1e446cc8b8a3b615a223395_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi0yLTEtMS0xMjE5MTA_0aaeba29-262b-44ca-a923-45f9b20874ed">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd86bc5c7e44ed5a9d043c911ec35d9_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi00LTEtMS0xMjE5MTA_2174413c-d963-47fe-ad70-0613479a1d22">226.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi02LTEtMS0xMjE5MTA_8a12ef07-cd34-47bf-bf5d-2232f112f6b5">209.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae70c7addbd245e88b9cf036469b0e00_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi04LTEtMS0xMjE5MTA_4ee38905-34d4-46e6-86ef-da69540a89f7">259.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy0yLTEtMS0xMjE5MTA_141ebcad-9bb8-41d0-b504-418111a7a034">4.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy00LTEtMS0xMjE5MTA_91cf8a80-2932-49bc-b0db-5d8edd00e34b">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy02LTEtMS0xMjE5MTA_d5298007-4981-4142-84bc-2a5ece3c941e">11.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy04LTEtMS0xMjE5MTA_f93a32b4-784b-4f39-9f6f-e5647ae03497">33.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS0yLTEtMS0xMjE5MTA_0a1d215a-a120-4689-88fe-494665f485f3">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2546b8d042464cf18732132087c7837b_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS00LTEtMS0xMjE5MTA_49b8e4cf-3915-454e-9279-0be7c0b7f44d">226.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS02LTEtMS0xMjE5MTA_fb0b1bdc-b4c5-427c-a19d-aa7ebd5a3845">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2546b8d042464cf18732132087c7837b_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS04LTEtMS0xMjE5MTA_fc4d20e1-8b97-4dc8-841b-63df95705429">226.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzNTYzNA_bc6dd326-9ce0-4b10-81c8-c576b6483328">197.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzNTY0Mg_00f6cded-836b-4085-b7ce-d1abe00b7497">209.1</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, chang</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i63bc10a1bca14c3da49709df30312c07"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Instruments</span></div><ix:continuation id="i52cc4898939749ee8130269be0162835"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy0yLTEtMS0xMDY1MDI_30bfd345-fd33-47cc-b8c9-45db458b940a">1,001.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy00LTEtMS0xMDY1MDI_fede9ccb-3d2b-4130-a32c-b6a095055683">999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749156c0d2244797891329da8f801076_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy02LTEtMS0xMDY1MDI_eb918e86-0e49-43bc-b5f2-4d4700243730">1,020.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749156c0d2244797891329da8f801076_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy04LTEtMS0xMDY1MDI_43ec3ac0-e47b-4484-aeae-a191b807f6db">999.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC0yLTEtMS0xMDY1MDI_a818f7c1-6812-46bd-88d2-fbcffaae9755">1,730.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC00LTEtMS0xMDY1MDI_8d7d5c53-84cb-4f92-bdb2-6987305bba78">1,743.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC02LTEtMS0xMDY1MDI_eeb3f903-3e91-4170-8c95-507bda026302">1,895.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC04LTEtMS0xMDY1MDI_80390540-df35-442e-bb12-f58268ab4b1e">1,742.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS0yLTEtMS0xMDY1MDI_6023e273-c59f-4df8-acce-330e5ab06ae6">1,232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS00LTEtMS0xMDY1MDI_a75d00b4-d34c-491f-a929-e83cd8286d16">1,492.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c33ec33ac24977b3efeb593adf8673_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS02LTEtMS0xMDY1MDI_0e53db44-922a-45ac-8421-d17d6076fab7">1,475.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c33ec33ac24977b3efeb593adf8673_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS04LTEtMS0xMDY1MDI_778b8332-a88c-4a0e-8282-0e7dc5a3a2ad">1,492.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi0yLTEtMS0xMDY1MDI_e3226d8f-7843-4ddd-936a-44dee9bb6617">1,066.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi00LTEtMS0xMDY1MDI_ccba2e43-52ae-4aab-b17d-d6a566ec757c">1,100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5363dbf017c244debdb2e7604c5291cf_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi02LTEtMS0xMDY1MDI_f04b2bc2-bbb1-4d4d-8fe5-fdfbf7800811">1,463.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5363dbf017c244debdb2e7604c5291cf_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi04LTEtMS0xMDY1MDI_d37885d8-9b33-46ed-a2b9-843965095846">1,099.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy0yLTEtMS0xMDY1MDI_9278909f-f9dd-4442-8d24-60c98aa098e4">1,027.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy00LTEtMS0xMDY1MDI_d041b815-4237-4340-8245-0c3a5ee00cc5">1,473.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd69aba81534dac91205bace6805330_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy02LTEtMS0xMDY1MDI_3d83a9ec-ae34-42f4-bf96-8fb7ee1d0a31">1,457.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd69aba81534dac91205bace6805330_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy04LTEtMS0xMDY1MDI_69633024-801e-4107-9db6-d64d9b7b4dae">1,473.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0324ddb09a434fee859e03396262f145_I20220630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC0yLTEtMS0xMDY1MDI_1e61f103-16f5-4e33-b87a-3948987d3c3f">489.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0324ddb09a434fee859e03396262f145_I20220630" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC00LTEtMS0xMDY1MDI_9ae0cdb8-62af-4695-9ef5-a71aa6d085b1">467.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e56bad4fc89492691617ec7457815b8_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC02LTEtMS0xMDY1MDI_ad57c59c-44b0-4f4f-86c2-6898862563ac">692.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e56bad4fc89492691617ec7457815b8_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC04LTEtMS0xMDY1MDI_468a5de2-3d23-47f4-8181-3dddbd0ada68">466.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS0yLTEtMS0xMDY1MDI_1d14b3a8-0bd0-40b7-a3ea-77c4453fe019">6,546.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS00LTEtMS0xMDY1MDI_f2e50757-acda-45ab-a2d8-2eb808ebe991">7,277.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS02LTEtMS0xMDY1MDI_84bedef3-e229-4b38-b360-2261a5e6d43a">8,004.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS04LTEtMS0xMDY1MDI_874da353-4d8c-49ee-a846-6d4cb1dfb86b">7,273.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The change in the fair value of our Senior Notes as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to December 31, 2021, is related to the increase in U.S. treasury yields and wider credit spreads used to value the notes since December 31, 2021. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_73"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ2Nw_fc76300b-3e03-4697-be1f-0b923555b23f" continuedAt="ic5fbb998b4fd4354b510d23222b8268e" escape="true"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ5MQ_6bf8c50d-d182-48ae-8160-89c4a88913ae" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207ad38739a54d138f6be5e688458503_I20220630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMS0yLTEtMS0xMDY1MDI_31f5f50f-a222-47ed-93fd-9967162449a9">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5238704ed54c3bb7e1f6928897e2c3_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMS00LTEtMS0xMDY1MDI_8ed89030-e82d-4f55-b8c4-2d0e4fb2b97c">247.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1febee2fa143e5976b10c5f25675f0_I20220630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMi0yLTEtMS0xMDY1MDI_0ddc3350-2314-4f03-9a75-7aa8ea2d008d">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157163fe40884091bf7820d01b3e22e7_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMi00LTEtMS0xMDY1MDI_11800465-2f21-4f65-b9ca-6f43d4b44258">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5386dbc2d85346818db10319e0a45e26_I20220630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMy0yLTEtMS0xMDY1MDI_40d1c29e-26bf-4358-8e22-aa2a60402c01">1,764.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c9f2c4702549599568d0e5eb9618b5_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMy00LTEtMS0xMDY1MDI_30d4f8dd-3801-4dd5-86f6-d5df258f1e66">901.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb4076d18da4ad79a95ee670fa15bb9_I20220630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNC0yLTEtMS0xMDY1MDI_ed9b6603-c43a-429a-9d63-65339400e4af">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3bd0aea29473b9ec52de86adeb7c7_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNC00LTEtMS0xMDY1MDI_752b5e45-943f-48fa-84d1-c773e5d1ecca">283.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNS0yLTEtMS0xMDY1MDI_5bc58bfe-49ea-4856-a118-c5d276e3327d">2,144.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNS00LTEtMS0xMDY1MDI_c25e17eb-9da1-49ee-91cc-06553b9e30bc">1,632.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic5fbb998b4fd4354b510d23222b8268e" continuedAt="ic8dcc8c513984af6a23226106b94168a"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ4Mg_c2033e19-f964-4904-9867-beba29adc1b3" continuedAt="if9995df7c7ec4335b2bb1ef3af96ec8e" escape="true">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="if9995df7c7ec4335b2bb1ef3af96ec8e"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC0yLTEtMS0xMDY1MDI_b2096554-f602-415b-9047-2aa5eb08ecd5">1,363.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC00LTEtMS0xMDY1MDI_e5325275-2bc7-40e9-928f-69044d68cb34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC02LTEtMS0xMDY1MDI_a54ddb9c-2122-4c6d-9850-e23136723472">6.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC04LTEtMS0xMDY1MDI_47e515b1-7f48-4a29-b1a6-558106fa6071">1,357.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS0yLTEtMS0xMDY1MDI_8cd3f94b-c7b9-4516-8645-78a6408410b0">540.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS00LTEtMS0xMDY1MDI_04b7d52b-4d59-48a5-a13b-77fc3e0e5c5d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS02LTEtMS0xMDY1MDI_e4d53323-e136-4df4-92aa-95a7da85cf33">7.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS04LTEtMS0xMDY1MDI_6729d127-7559-411f-8543-5cc053a87560">532.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy0yLTEtMS0xMDY1MDI_05d96db5-f7d5-486e-8adf-90050bb193a1">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy00LTEtMS0xMDY1MDI_dacaeac4-2f24-4a50-92db-7a08f78d3c57">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy02LTEtMS0xMDY1MDI_d5a28ec7-0857-4473-828e-ba94deedd173">4.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy04LTEtMS0xMDY1MDI_16026d8c-9239-4a37-af58-97bf5152006a">793.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC0yLTEtMS0xMDY1MDI_75cf8510-762f-465c-bc26-3b8855005a80">367.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC00LTEtMS0xMDY1MDI_5694f117-6bc0-4a11-ad8d-1c7221ad0b53">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC02LTEtMS0xMDY1MDI_705acc75-05d9-4a2a-ad21-155a7a2cff6d">4.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC04LTEtMS0xMDY1MDI_1e32bb13-9be5-4e3d-aece-9b1cc28c104d">363.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtMi0xLTEtMTA2NTAy_a06515bf-58b2-4465-8bc2-403977201f20">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtNC0xLTEtMTA2NTAy_2811073b-ccb9-420b-87e1-8a7620fb05f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtNi0xLTEtMTA2NTAy_5e5c0c45-b209-4636-9e04-d140e7e3e4c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtOC0xLTEtMTA2NTAy_e0becac2-003d-49fe-85d0-68b144e2e31a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtMi0xLTEtMTA2NTAy_a91d4d6a-da6e-4dcb-9bdf-67bf9266c904">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtNC0xLTEtMTA2NTAy_708794c9-d4ba-4f6c-9ff5-fd18fc997bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtNi0xLTEtMTA2NTAy_e559d3e3-f29e-4614-8e88-4fd25b00107c">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtOC0xLTEtMTA2NTAy_44697ccf-130e-42a5-a126-c0edeb1e13eb">206.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItMi0xLTEtMTA2NTAy_70e8a51d-4d33-4103-8f82-fb1a5b4892a9">3,279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItNC0xLTEtMTA2NTAy_3d289515-397e-4c5f-b0e5-e99083566e7c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItNi0xLTEtMTA2NTAy_1427aeef-8065-4e94-844d-2ac567d46614">25.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItOC0xLTEtMTA2NTAy_533e942c-051c-462f-a063-3df3ae51f7aa">3,254.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtMi0xLTEtMTA2NTAy_7a591618-0880-4369-aa95-739c91e3cd8c">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtNC0xLTEtMTA2NTAy_45d10429-8778-4cc0-8354-b574a96033bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630" decimals="-5" sign="-" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtNi0xLTEtMTA2NTAy_72416d13-3c77-4493-a368-5af42423c19a">9.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtOC0xLTEtMTA2NTAy_c6c4c10d-1e49-412d-a301-301b625e2ff4">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16498989190e4b99abd2625557d367dd_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtMi0xLTEtMTA2NTAy_2ae1b8bf-d600-4ca5-b25b-b602240d960c">1,103.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16498989190e4b99abd2625557d367dd_I20220630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtNC0xLTEtMTA2NTAy_c99cce3e-de22-404d-a2dd-0ce5eceba01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16498989190e4b99abd2625557d367dd_I20220630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtNi0xLTEtMTA2NTAy_b18ce7a9-6d9b-4b52-8f1f-c0b53c2a2c73">341.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16498989190e4b99abd2625557d367dd_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtOC0xLTEtMTA2NTAy_081eaf47-0d58-414d-88cc-47718eb09748">761.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctMi0xLTEtMTA2NTAy_c60b12fc-0ce2-4307-8b01-f8a2f6ea851e">1,137.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctNC0xLTEtMTA2NTAy_56c3d778-94a1-4e93-ab4c-81156a4e2399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctNi0xLTEtMTA2NTAy_a6ee8cbe-b398-40f8-acd8-8a03fecb14d0">351.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctOC0xLTEtMTA2NTAy_4da414b6-53eb-48ad-a64a-016805c9d5b0">785.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC0yLTEtMS0xMDY1MDI_31ac29e3-6b2f-4bce-90b5-35de287c63b5">723.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC00LTEtMS0xMDY1MDI_d42ec81b-801a-4ed8-8d92-18c5cc18d78d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC02LTEtMS0xMDY1MDI_436d2ed0-7eb9-4e7b-846b-d7c6f5f95780">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC04LTEtMS0xMDY1MDI_53898ac0-977a-4a84-9f63-f2dd725c5848">723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS0yLTEtMS0xMDY1MDI_f4fbed87-2bc8-4556-be51-8c670268af17">385.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS00LTEtMS0xMDY1MDI_7d6306fc-1053-46a6-80d1-94e0146521c8">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS02LTEtMS0xMDY1MDI_4eded8f0-1133-4ca4-9310-76aab4ed4c03">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS04LTEtMS0xMDY1MDI_9a26b8a1-e0ab-424a-b132-c978696b75e5">384.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140bb6501b0449349963095a4992952e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy0yLTEtMS0xMDY1MDI_570d0b35-cc09-4ff3-b50e-6ac94dc3b39d">817.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140bb6501b0449349963095a4992952e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy00LTEtMS0xMDY1MDI_b7c8c3e2-26db-479a-8681-16b87e851de3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140bb6501b0449349963095a4992952e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy02LTEtMS0xMDY1MDI_e5ca8e77-c7d0-4b4e-a512-f16fa5ff72ee">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140bb6501b0449349963095a4992952e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy04LTEtMS0xMDY1MDI_d9426891-d6a1-4bb4-8cbd-f51aaca60abf">816.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC0yLTEtMS0xMDY1MDI_6478d47f-07fa-4efc-84ed-3d944ce3226c">377.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC00LTEtMS0xMDY1MDI_ac733c32-c3f7-4278-8949-8bb02130f73d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC02LTEtMS0xMDY1MDI_4b53a382-4fb4-4264-9deb-d21e88dac835">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC04LTEtMS0xMDY1MDI_db3caf97-d99a-479f-880f-b27d7b1c388f">376.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtMi0xLTEtMTA2NTAy_3046fcdc-3d9b-44a0-a596-6dcb1173faf0">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtNC0xLTEtMTA2NTAy_c9d72187-67fe-4352-85f4-a9bd0fa3d889">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtNi0xLTEtMTA2NTAy_705ac18a-a34d-4e71-b5bc-924a665a0c33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtOC0xLTEtMTA2NTAy_a561e2ea-14eb-4c63-84e5-cf8512cc85e9">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992615614bce4506b32f63aabda86d0e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtMi0xLTEtMTA2NTAy_0413907e-99a5-414a-aea5-bef4bc606172">131.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992615614bce4506b32f63aabda86d0e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtNC0xLTEtMTA2NTAy_d53723ba-06a3-40a7-b244-f7e273fbf32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i992615614bce4506b32f63aabda86d0e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtNi0xLTEtMTA2NTAy_527c9122-e585-440b-8aad-67889bc337b9">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992615614bce4506b32f63aabda86d0e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtOC0xLTEtMTA2NTAy_eb0af1f7-19de-44fc-9952-cbe99fdeae76">131.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItMi0xLTEtMTA2NTAy_7e286949-efa5-4b32-9579-4e4a35eb73a0">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItNC0xLTEtMTA2NTAy_04325a40-ce74-49b7-9b05-e3be4b3458da">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItNi0xLTEtMTA2NTAy_a11602db-a626-4964-96cb-d7b4420f8823">3.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItOC0xLTEtMTA2NTAy_492bd886-b312-4c72-8fba-1124e4fde17e">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtMi0xLTEtMTA2NTAy_49218ea2-6d4a-4e90-a849-c1936e284663">33.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtNC0xLTEtMTA2NTAy_e7fdecb1-9f60-4b9c-8c25-193d73b1f257">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtNi0xLTEtMTA2NTAy_db98d457-c885-4394-b80b-861dc4619fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtOC0xLTEtMTA2NTAy_7ecac38f-609c-469d-abb5-7eaa426fd709">43.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtMi0xLTEtMTA2NTAy_739fe23c-e43e-4d14-b6ad-a7a54dc40f45">1,133.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtNC0xLTEtMTA2NTAy_78f08b75-29e6-4c39-8532-ceb4e5263e39">151.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtNi0xLTEtMTA2NTAy_154745c7-e8d8-4cf2-bdaf-3bc74e790063">279.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtOC0xLTEtMTA2NTAy_0c32c971-7696-429b-94ea-66f4e3fb973c">1,004.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctMi0xLTEtMTA2NTAy_045ab6a1-6a3c-402e-a913-f3dc9f8364ed">1,167.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctNC0xLTEtMTA2NTAy_1a96fd38-6100-445e-a338-87723648be2a">160.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctNi0xLTEtMTA2NTAy_7eaa718c-d0ee-498a-b5a9-27d7a161027f">279.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctOC0xLTEtMTA2NTAy_7e65bb94-323b-4066-ba48-fb343520e104">1,048.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic8dcc8c513984af6a23226106b94168a"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ3Ng_b4285db9-005f-40a2-86fe-2c777abedf6f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi0yLTEtMS0xMDY1MDI_ee82c496-36ac-454d-9796-89a58c067fa5">2,151.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi00LTEtMS0xMDY1MDI_f2f476f4-765c-4e66-8cb7-7d8ad94b49f5">2,135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi02LTEtMS0xMDY1MDI_61e61dc1-0e28-44c3-a5d3-93aaa9f43885">1,541.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi04LTEtMS0xMDY1MDI_06173a2b-9367-4aad-84f2-d2523ca6ed85">1,541.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy0yLTEtMS0xMDY1MDI_1f7178df-2b6b-4d7e-afae-1ddbf2d92b97">1,089.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy00LTEtMS0xMDY1MDI_4f232374-f279-4d18-9c76-6aefcc4d2731">1,130.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy02LTEtMS0xMDY1MDI_c5b154ed-89ba-46be-9ad6-07430848874d">868.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy04LTEtMS0xMDY1MDI_86dc6923-5f06-4555-991a-1a0f107e450c">870.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC0yLTEtMS0xMDY1MDI_e2b97208-4d87-4a58-ba2f-9a95560c5e0d">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC00LTEtMS0xMDY1MDI_cd1d6460-e375-4c90-b1d4-d4fd7464848a">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC02LTEtMS0xMDY1MDI_86427b61-3a13-44b4-9701-e385e0a605f6">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC04LTEtMS0xMDY1MDI_987effae-90c4-4ed5-bd64-0b1eb09f165f">24.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS0yLTEtMS0xMDY1MDI_051fb93b-c182-4bc3-8938-6810a3226860">3,254.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS00LTEtMS0xMDY1MDI_1f0fbb06-8426-451f-81f2-1e381743e5bb">3,279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS02LTEtMS0xMDY1MDI_21a35d7c-2109-43a4-9781-1f094219fd96">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS04LTEtMS0xMDY1MDI_c54b99d2-c386-43a2-80e6-1249a85ea4fb">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of June 30, 2022 and December 31, 2021, was approximately <ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTAyMw_b06c7beb-5af9-4e9a-85f9-3d0f4ce8ee2b">11</ix:nonNumeric> months and <ix:nonNumeric contextRef="if73106cc97da45d0a1aa9b8366bb2add_D20210101-20211231" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTA5OTUxMTYzMDI3OA_cffa279f-391f-4695-b783-a93bfa6d4f5f">10</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ5NA_20a843ce-f9be-4dff-a8e8-23a81aa08edf" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi0yLTEtMS0xMDY1MDI_79202ec7-9eea-472a-bdeb-b34b12575258">917.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi00LTEtMS0xMDY1MDI_4e96d11b-cfe1-4a91-a14d-29967cf31994">633.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi02LTEtMS0xMDY1MDI_fd45d323-9261-497f-9c29-5fdca6b032ba">1,461.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi04LTEtMS0xMDY1MDI_c61aee43-6240-45b3-8601-cf222bcdc8ea">1,452.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy0yLTEtMS0xMDY1MDI_78a6f575-2bdf-4972-821f-4c314a5bc4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy00LTEtMS0xMDY1MDI_0a89938c-a997-4f90-88a2-bc6d5ff6adde">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy02LTEtMS0xMDY1MDI_c3867e2c-ac53-4cc4-82a6-615e88a3b6a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy04LTEtMS0xMDY1MDI_ab600a1f-5b84-495f-bad4-501751daf411">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC0yLTEtMS0xMDY1MDI_a28a41e1-389b-447e-b814-48b20a89ed6d">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC00LTEtMS0xMDY1MDI_42f8950a-77e9-4fa3-a889-75f12f27a62b">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC02LTEtMS0xMDY1MDI_8a0f6cce-8d00-4a55-b26c-f4638df23c9b">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC04LTEtMS0xMDY1MDI_a1d25da8-8da2-4dae-aa9f-2b42f0ad2eb8">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTQ4NA_24ec6155-03b4-4cf7-ae3d-8597ccf3c9ff">839.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id4d0bd51bc4647dfb2a191cad3986b16_I20211231" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTQ5MQ_11d9b3e7-077d-47df-a092-8e6f7af27597">1,110.3</ix:nonFraction> million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in our strategic investment portfolio for the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, were primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_79"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;DERIVATIVE INSTRUMENTS </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTg5Nw_686adbd2-78cf-4e13-94c8-bbbf23095b25" continuedAt="if7f2f18bcb8647be96baa305e99d752e" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of June 30, 2022 and December 31, 2021, had durations of <ix:nonNumeric contextRef="i3ab0561efd9a429f84f8b4296c82c73e_D20210101-20210930" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNjM2_52e0bbd3-5454-46f5-98a5-ba2c32213b3b">1</ix:nonNumeric> to <ix:nonNumeric contextRef="iff853fccd14442ebbb17ab9ef5e1c4be_D20210101-20210930" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNjQy_974ac3ce-61ea-4254-b0ac-917c00286a28">15</ix:nonNumeric> months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="if7f2f18bcb8647be96baa305e99d752e" continuedAt="idd25f82999264b369b89c3a21040dea6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkyNA_c06e459c-98fe-491f-a71f-ff8c2a70ad56" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d6800eb2c74fba819c1b070cefdc3b_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMi0yLTEtMS0xMDY1MDI_a66764d1-34fc-4782-9c2c-8dbe8d352208">1,285.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c0ffa95ac44d50a2d00434ffc62f9b_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMi00LTEtMS0xMDY1MDI_8096bae9-c9c0-488c-b1a2-cc6c95a820e3">1,828.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921449c1dcd64ae094a4e7206755b28f_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMy0yLTEtMS0xMDY1MDI_4e446546-230c-4a5f-9da3-e3ca33f131b2">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a4214140a84299923a095d0db68a81_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMy00LTEtMS0xMDY1MDI_42721103-454c-475f-befc-692e9d547863">166.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753e77cb96eb44eb91792a859ab31f61_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNC0yLTEtMS0xMDY1MDI_ea9a0c75-0fe1-4e49-acbf-69864d55d604">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cb17acde494685b6ba5f5809b645d2_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNC00LTEtMS0xMDY1MDI_6baa69d2-9400-47bf-adf7-f4899918a27b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7766088e60b94262b048c5f32da60dbf_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNS0yLTEtMS0xMDY1MDI_481601a6-ebe0-4f66-a04f-3aa36d0eab39">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199c91171d3f4a2382e5d5cd3f00f2f6_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNS00LTEtMS0xMDY1MDI_1344dfa0-4713-482e-8d74-0bd2bd99cadc">72.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacc3061343b44129f16a08974a6b548_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNi0yLTEtMS0xMDY1MDI_38c50fd8-81c6-4c10-a7f7-2d96ee7ac828">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff5ba68900c43e69eec8d505e93c934_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNi00LTEtMS0xMDY1MDI_af5354b4-99ee-4553-9163-01f46ebaa528">59.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ecadcec54794963b50463bd915d2bc9_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNy0yLTEtMS0xMDY1MDI_c8016cf9-47c2-40d2-b244-b223858fe28f">1,525.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe39514eee6e4adc9af02f16e10ee4f7_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNy00LTEtMS0xMDY1MDI_7f720ab0-bab9-4e54-beee-b87079b12b7a">2,126.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkwMQ_de244f05-f62d-41a8-80e7-362abbc80052" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMi0yLTEtMS0xMDY1MDI_9f2e37d2-cd42-4105-86ac-9bb596aa31d1">140.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMi00LTEtMS0xMDY1MDI_ad6fa76e-15c3-42bb-b347-0731ff604e67">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMy0yLTEtMS0xMDY1MDI_0531dfb6-acbc-4e22-aa1e-ff4f003d1f0b">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMy00LTEtMS0xMDY1MDI_87f760e7-36c2-4f43-91e1-7852d5ded979">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfNC0yLTEtMS0xMDY1MDI_11b3be11-cb71-4903-8e34-b121e43a64c4">137.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfNC00LTEtMS0xMDY1MDI_dd2cb134-0890-413d-a977-ae365a0a6b62">53.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzkxMg_11b3be11-cb71-4903-8e34-b121e43a64c4">137.6</ix:nonFraction>&#160;million to be settled over the next <ix:nonNumeric contextRef="if5cb29af1d6742908ff898b5ebf574cf_D20220101-20220630" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTg2MQ_eb3f119e-62bd-4713-a51e-f5241ebbacbf">15</ix:nonNumeric> months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i5bfba5b1866a471cabbde592da7a1247_I20220630" decimals="-5" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTg3NA_330a016e-78b1-47cd-81ae-565a90841ac0">133.7</ix:nonFraction> million of these net unrealized gains are expected to be settled over the next <ix:nonNumeric contextRef="ic5e00dff9ecc46b9bdb7d69718e8e77a_D20220101-20220630" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTk0OA_609ff910-ff82-4a0d-abd4-fcaeddcb69ec">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkwNQ_c21824bf-1cb6-4135-ab19-a85337ef76dc" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0466df147d7942408c489858f169de93_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy0yLTEtMS0xMDY1MDI_4616c379-31e7-42a4-9db2-280dd0089b59">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26725a695f2b478788a442808ce1beee_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy00LTEtMS0xMDY1MDI_ccff7d86-0391-4238-a651-4c8f6f5a005a">30.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e2ff89e7330400e967da0afcc3e2d99_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy04LTEtMS0xMDY1MDI_a0784e58-c5c8-4b50-87ed-63f17c280f97">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e91a04e7eea4c38b6cb6751d4043a2a_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy0xMC0xLTEtMTA2NTAy_f67d1d98-825a-404a-9f91-c5e8539fd397">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1bde062c47d49a8a7f0277989d627c9_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC0yLTEtMS0xMDY1MDI_3a787ca8-d07f-4d9b-a2a9-0a0100557cb9">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743019f676ee466795fa568ff3243842_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC00LTEtMS0xMDY1MDI_581dd151-237d-4ba0-a7b0-f8679633c7f9">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb90f3ecd54b4e76b9e9bd9dbdbfe5af_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC04LTEtMS0xMDY1MDI_55cdfca2-7cf7-43b3-9a4e-7820fc9d590c">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b82baa8ea8543bda12f9f9de5c4af65_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC0xMC0xLTEtMTA2NTAy_1fd37743-b19a-4b75-8874-22f0231095ca">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8929791e27f944c09502d04a25c1b021_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS0yLTEtMS0xMDk2OTQ_b5c91257-5e42-4757-87c2-b086ec42d32f">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16c78831bea640a7b02cdd4181f233cf_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS00LTEtMS0xMDk2OTQ_cb821079-f226-42ca-98e4-ef92ef90638e">53.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa592716840490d9b21fa9dd5a26334_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS04LTEtMS0xMDk3NzM_4cc26fcd-1abc-4e02-bc37-7bf4b3213499">7.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia75940771ad54dec84714d53bc3a845a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS0xMC0xLTEtMTA5Nzcz_74b5ce17-8857-4e62-a3e7-7c88bddc1795">3.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6cecc0a55d14fafbfae04ffa644a385_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtMi0xLTEtMTA5Njk0_c2fc00a5-7056-44e8-b74c-58165156245a">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ca7beff5f2474b9d401734f8a1ec03_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtNC0xLTEtMTA5Njk0_fa9d98a5-b017-4c57-a8c6-16806718ff27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e235045cf98490f8a1e30fcda5c5e48_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtOC0xLTEtMTA5Nzcz_a2524504-44ef-435a-970f-c7b39699a840">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de48898e11f44699c3ee51c8d39f207_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtMTAtMS0xLTEwOTc3Mw_0d453c96-4925-43f3-95a1-b1e78908ca7e">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i17f3f785472d4636b331649fe366628f_I20180531" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMjkxMA_b3579220-a663-4607-b024-5fcca6f1170d">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMjkzMA_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130" decimals="-8" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzAyMw_7ad82036-3c71-421d-9ddd-7e97c504f6db">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzA0NA_3802d612-0807-4c22-b388-e7ec4ab80144">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="idd25f82999264b369b89c3a21040dea6" continuedAt="i6c881635aa1d46b9820a26864fb57c85"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzNzQ3Nw_c9e0aefc-ddcd-4bbb-b940-e655b42de12c">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzODA5MA_897ee35b-4163-4c42-84ce-a26f27e77b6c">57.0</ix:nonFraction>&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of our equity interest in Samsung Bioepis we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="i6e750febc54343bc90f1a684d4d68e95_D20210101-20211231" decimals="-5" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzc3Nw_5f34378b-774e-4897-8ed7-3c314defd52f">10.6</ix:nonFraction> million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="i3f906803044b470f81de0eefb5dba012_I20211231" decimals="-5" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNDIyNA_ce36cea2-1c91-424e-b244-59cea775a27f">3.6</ix:nonFraction> million as of December 31, 2021.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkxMQ_fd98563d-95e4-43b5-a2bb-d28031c6a186" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0yLTEtMS0xMDY1MDI_d2ae851e-43e5-4cd5-87c4-d664ea993bb1">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy00LTEtMS0xMDY1MDI_b4b98459-9ee8-480b-9cb5-ab3d40a99db3">2.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy04LTEtMS0xMDY1MDI_5637cb50-ef03-435f-b431-c13eccf8bc98">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xMC0xLTEtMTA2NTAy_ccd6023a-a019-4e1c-9089-59d856276aa4">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74799976f1b24216a03f17304e960c0c_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xNC0xLTEtMTA2NTAy_921e239d-ddce-4b6d-b041-2c56f186957a">3.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b1a6af29424cb4aa2a50fd11bfc322_D20210401-20210630" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xNi0xLTEtMTA2NTAy_293ed262-c87f-4716-9dff-f4bc53194867">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0yLTEtMS0xMDkzOTc_600e39c4-133a-41c4-84b1-2158ff644de6">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC00LTEtMS0xMDkzOTc_d30adfae-6ed3-46e5-b807-98fc54d15d08">21.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC04LTEtMS0xMDk0MDQ_38896ce7-c197-47f1-ba6e-9b798b3957db">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xMC0xLTEtMTA5NDA0_39e35df4-69f6-4f45-ba5d-b13c7aa0ede7">1.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94d5ef31f0fa47a39e2dd83dd2bfe19a_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xNC0xLTEtMTA5NDEw_62985bef-1f91-4dd4-a924-d40ed2de3222">4.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575d79eb11134ef993a7f0b1f6d269e3_D20210101-20210630" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xNi0xLTEtMTA5NDEw_bdb9feca-9968-45c1-bffb-f1ea9ab54d21">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzNzA0NQ_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="i4bc4c2d8c7e943a895789a1697167962_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTEyOA_8513b94a-8ce0-4890-a95d-d5c75c2cf5fc">1,230.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib02689d9b0b44614b294b3f29ca4964e_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTEzNQ_c4473992-8f6b-45ea-8838-2b0ca92e3749">1,268.0</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTE4Mw_99ca5746-4827-449d-b845-55556e93de73">37.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzczNQ_1d4f8718-bbce-4985-9896-72a3bdf2b7dc">49.3</ix:nonFraction>&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2022, respectively, compared to net gains of $<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzc5Mw_c91607b4-57c0-4661-b1ef-e223c38c27c7">4.8</ix:nonFraction>&#160;million and net losses of $<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzgxOQ_dab24aff-52bc-4c40-bcbe-7989a89422c9">12.6</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i6c881635aa1d46b9820a26864fb57c85"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkyNw_538618fb-c693-4a22-b102-6d942e81d45d" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cefa532629b41e3b9dc278f0f0761e4_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMi00LTEtMS0xMDY1MDI_5cebf2f6-b1c4-4020-b639-a9b2060bf6ab">142.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6092dc9afba6475196a6884c6298c6f1_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMi02LTEtMS0xMDY1MDI_14c400f2-5288-432b-a545-00b5e8e8c772">66.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic958db40215b499a9247ed982bcb0126_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMy00LTEtMS0xMDY1MDI_05baff69-1370-497e-b0a0-2b3ddabca0b8">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b36ca2852634efd80fe1a2529739a5c_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMy02LTEtMS0xMDY1MDI_2230f4f2-aac1-49ad-b5f1-8a3cce6e19bb">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0857062bc899445982d736bffcb52e46_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfNC00LTEtMS0xMDY1MDI_15b6193f-bfd0-440d-ad1b-1930d3ad2b14">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c530cc918fe4a479490cc9b9876a764_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfNC02LTEtMS0xMDY1MDI_047d695b-80b3-436c-a4bb-500723fdb590">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7a423894c0434db231ce4133ce2fc3_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfOC00LTEtMS0xMDY1MDI_f50c6f13-af4e-42fb-994d-aeb90cf7ef6a">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1d25a8fbe4414ba423291d19d37d5f_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfOC02LTEtMS0xMDY1MDI_7ab97c50-f191-4708-a119-08146f50c10d">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb798cbcdc26425ca390649668ae6b38_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTYtNC0xLTEtMTA2NTAy_f8a763a6-37c0-475e-9f31-c96d75869546">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926408e195f24642b73de23a766b86b6_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTYtNi0xLTEtMTA2NTAy_ea046686-ce17-4701-92e7-7de7a7de0191">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70908e6791334ae48472963b146ee23a_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTctNC0xLTEtMTA2NTAy_93892902-a7a7-4fad-9110-310f1ee1b8b6">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af4d136402048959dd3e0e8e44a22bc_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTctNi0xLTEtMTA2NTAy_b1bf4f2c-21e7-4649-bd81-c38f0db0bdd0">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzODA4Mg_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_85"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;PROPERTY, PLANT AND EQUIPMENT </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTE2MA_2c29fcbc-2a77-4764-89ff-87bdb287f5ea" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTcx_269b2382-d24e-45cf-93d4-e1715b324424">2,131.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTc4_1fd4ff7a-b789-4430-8b46-148bdf0c4484">2,006.6</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively. For the three and six months ended June 30, 2022, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMjY5_19077e88-bb89-4f56-bb6b-153491de4f5f">67.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA5OTUxMTYyODk0OQ_7c10df8f-0ca3-457f-8abb-4316da92b38f">143.5</ix:nonFraction>&#160;million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMjg0_50e0c6f4-c41c-42bf-be40-3ee79ff9ba38">54.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA5OTUxMTYyOTAxOA_3b14b470-53d6-4c7b-8767-5e14e58c839c">103.5</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="ic7da619d63a94a4591936365ba7bb51f_D20220101-20220630" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNTc0_e5dc664b-1b6a-4777-a584-22227a8b6151">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="i8fa50adcc4464c39a7eefd4680d1765c_D20220101-20220630" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNjQ4_25c28039-4db5-4ba6-b0e2-87fb2289f0d4">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="ibaefaf11247247fabd1fe4cc79c22821_D20220101-20220630" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzA5_3583300a-8f51-4f2d-a051-c477c0b17f71">51,000</ix:nonFraction> square feet of administrative space. As of June 30, 2022 and December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i0043843f37f44a84bcc5be0643dee99c_I20220630" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzg3_73115022-ee48-4f45-9fdb-d629747ad304">691.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i12b4c6baf27c4eba8805276bb5e93dc8_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzk0_c5ec0250-c0db-43a2-a8a5-8ec2680d1472">677.0</ix:nonFraction> million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="i0043843f37f44a84bcc5be0643dee99c_I20220630" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA3MQ_3bcc813e-fbb3-4819-b74a-c81a6db59301">1.2</ix:nonFraction>&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite will be operational during the second half of 2023.</span></div></ix:nonNumeric><div id="iae1758f0b07f4108915caecfff327c7a_88"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEBTEDNESS</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTgwNg_de744866-15a2-4fd8-8914-1a6310ad76f9" continuedAt="i882f67140790408baff99f3f8b361c7c" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i65ad03e37af84a41bf8a69fdca5275ba_I20150915" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU1MQ_c4269836-adb5-43fa-8e47-6cbb435b26ec">1.0</ix:nonFraction>&#160;billion aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU2NQ_c76cc7cf-8331-4df1-80e7-c662bb99fd51"><ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU2NQ_cef9d2f5-e2bf-4578-bea4-110727b64305">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes due September 15, 2022, at <ix:nonFraction unitRef="number" contextRef="i5299d1d7822041d3b1817887dbd46432_I20220915" decimals="INF" name="biib:DebtInstrumentRedemptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU5MQ_cb50925d-1efb-4fe9-b8ae-34f23b36b0f9">99.920</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU3OQ_c76cc7cf-8331-4df1-80e7-c662bb99fd51"><ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU3OQ_cef9d2f5-e2bf-4578-bea4-110727b64305">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our <ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU4OA_c76cc7cf-8331-4df1-80e7-c662bb99fd51"><ix:nonFraction unitRef="number" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU4OA_cef9d2f5-e2bf-4578-bea4-110727b64305">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes prior to their maturity and will recognize a net pre-tax charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i45416e1b26f14f8cb98e144608a14a4a_D20220701-20220731" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDUxNQ_630c2bd3-8076-4524-a202-ff94113c3412">2.4</ix:nonFraction>&#160;million upon the extinguishment of these notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i882f67140790408baff99f3f8b361c7c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income during the third quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMjYx_3c42bef3-665d-4c05-81a3-1ecbad72ca9b">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i28dde4b51293471682782551de32cb29_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMzU0_69e75d1a-c2bc-45c7-b411-dd936e1db445">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i012f5bd22d3246cab5a94a0bed345c02_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfNDI3_1fbed40a-69af-4d89-9eb6-6c042304ca8b">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228" decimals="-5" name="biib:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfNzM4_8ffb18dd-2d54-4d13-8d21-6128b40de145">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfODEx_6456ff70-388d-4451-97b5-64238b81fafd">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfOTYx_bdf27121-0b1e-4eb0-b1e5-bdf8d10b767f">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTQzOQ_3faa3ee2-3ddc-422c-8cf6-c14b251d4ae2">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTYwNA_d1a6cfdd-d0b7-4407-ba37-03baf70ecdc8">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_97"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;EQUITY </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTM4_7fbabc88-6e39-4f02-a420-096d3323b9e7" continuedAt="i2f521376dded4224857e8f0b14a082ff" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i18f30485bd8748f68ef275fcb514e0b7_I20201031" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTEx_010390db-4712-4d4e-bda4-2ef450bd1efa">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyODczNw_8f8fab23-6628-44f8-bd88-a170979ec677">2.4</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyODc5NQ_601d7a32-2406-46e8-a11d-7f7b89e254ce">500.0</ix:nonFraction>&#160;million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTExNw_65ccb61d-a5b2-4417-8e00-eed1ea4a91fe">1.6</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTEyNw_51fb2f38-95b0-4049-8e57-79e7fd6d2c78">3.8</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTE5OA_0839d4b9-cb1b-4fcd-98b1-a6b93e568ebc">450.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTIwNg_c397bde2-bec5-48de-8a9b-9dbedb41cd37">1.1</ix:nonFraction>&#160;billion, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="i85a73135034a4df7a82a111ed6759cd0_I20220630" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfNTg0_389900fc-78df-477d-a5e5-c330aa5f47c3">2.3</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTQ4_8baa1034-a97c-4b05-be8a-337c304ed0d2" continuedAt="i9ed882bfcb3847a4bf71d6dbe9fe1a92" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84ce2898f9b84c02bac44cbb9b1e0305_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0yLTEtMS0xMDY1MDI_fc245c79-198d-42a6-af80-e36e4643c72f">2.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764a683e6bcc4b34bf7d9c79615d5377_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS00LTEtMS0xMDY1MDI_6595a212-a531-4f1b-a6ed-7bf7ac743502">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fab60076437436eb30238de33b462fe_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS02LTEtMS0xMDY1MDI_221a4304-7fed-41a2-9208-92f927b697fd">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad2094119ab54aaf9f28c105672c9bb1_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS04LTEtMS0xMDY1MDI_3e9317c4-bc21-439f-8ed0-795cbe28d568">44.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i182bc48d598f48999740017707097224_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0xMC0xLTEtMTA2NTAy_ccb200dd-0fb7-4e37-a24a-7c75c03119dc">139.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0xMi0xLTEtMTA2NTAy_31cea787-6529-404d-95aa-38b72fde1547">106.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0yLTEtMS0xMDY1MDI_ff40dedb-2926-4894-8e59-7f4aca56e3bf">19.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi00LTEtMS0xMDY1MDI_eb8e0b23-6ef6-4728-ba22-fd0a6c7a8130">129.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi02LTEtMS0xMDY1MDI_884ba03b-348d-4cb7-bdf8-ebe9adc72a07">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi04LTEtMS0xMDY1MDI_86177276-b9e9-4aee-b986-0b4a117b72a5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0xMC0xLTEtMTA2NTAy_da294062-2f7f-4619-8a91-9b044470a7cc">94.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0xMi0xLTEtMTA2NTAy_7aee907e-ea9d-4a1f-9799-a854fb0d9aa6">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0yLTEtMS0xMDY1MDI_77aa4be6-575a-498a-b25e-d786446c8c30">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy00LTEtMS0xMDY1MDI_90bbfd70-ecbd-4cda-b8e5-a8f0228702e5">56.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy02LTEtMS0xMDY1MDI_573dc8b7-a4c6-4fc1-8f25-662be7b72da1">38.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy04LTEtMS0xMDY1MDI_0d41b05b-4e06-462d-ac24-96f52d4b4477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0xMC0xLTEtMTA2NTAy_7dcd70fa-9cef-4dd7-986b-efe2e798a0b2">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0xMi0xLTEtMTA2NTAy_9820659f-6bff-4891-99c7-9cf0a80e9bf4">34.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0yLTEtMS0xMDY1MDI_57f3afa0-dfd3-49c6-913f-d2735db2b20d">18.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC00LTEtMS0xMDY1MDI_527a4bc3-7b9c-445c-adcc-30582ae516c4">73.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC02LTEtMS0xMDY1MDI_d87019fb-8615-4674-9dee-1334f0234d5c">25.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC04LTEtMS0xMDY1MDI_ca51ba32-17e5-4ce5-bc9d-32fe1840805e">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0xMC0xLTEtMTA2NTAy_98e4f3ad-89a8-4e0a-90ef-dfa884b9c268">36.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0xMi0xLTEtMTA2NTAy_f6582f2a-9ea7-445a-bcd7-54a2e5570156">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9e893ee39104e1b816e93ed8a47ede9_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0yLTEtMS0xMDY1MDI_c1946ff7-c261-492f-a54d-717fa08ed5d6">20.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28fc04646c349038aaaf67a779b66d3_I20220630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS00LTEtMS0xMDY1MDI_d99db966-3068-46b6-bc9d-3b81bf0ec6f4">126.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d16f8649274ffb8a001d8f59f22062_I20220630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS02LTEtMS0xMDY1MDI_ca4e9e04-080c-412e-993c-d40ce5de06c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie252dc547f144a40a6ac6f848a877b7d_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS04LTEtMS0xMDY1MDI_85493d25-b564-492f-96f9-9cae4d60afb7">42.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a7eb2c1a6e246ada70e7f900be38d88_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0xMC0xLTEtMTA2NTAy_1cdaf3b5-f404-4719-ac56-136dc631796f">175.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0xMi0xLTEtMTA2NTAy_66ee0996-1c74-4b6b-b7f1-8e4dc474622a">110.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTYyMA_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i2f521376dded4224857e8f0b14a082ff"><div style="margin-top:6pt;text-align:center"><ix:continuation id="i9ed882bfcb3847a4bf71d6dbe9fe1a92"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2a159169d54d4286b3396de8a76082_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0yLTEtMS0xMDY1MDI_719d94a0-e6f1-4fea-9858-53461e19dcca">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia331bc87e6e54c62a0a9e2f8480cea82_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS00LTEtMS0xMDY1MDI_1e050e51-c8f3-4a3a-b72f-2ceb439d2db7">179.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a78abae937b4e9484720512244a264b_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS02LTEtMS0xMDY1MDI_22aa954c-e0dc-4e14-9c06-eacfe2f39e7b">8.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4702937641c1484bb3d3617fa0ba60d1_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS04LTEtMS0xMDY1MDI_7a5e63ff-a646-44f3-984e-c6ee3851a599">66.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85e1d4e25ace4b32b9de201f21da7db8_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0xMC0xLTEtMTA2NTAy_0f6cbff5-33d2-41aa-b7ec-798f0ebb9a68">46.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0xMi0xLTEtMTA2NTAy_2ff5964c-d1c8-4a30-9eee-c20dcd1365a6">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0yLTEtMS0xMDY1MDI_3b48b6e2-9ebd-4957-8732-5c51c3b012f8">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi00LTEtMS0xMDY1MDI_f01e39be-bec9-4aa7-ade0-08ac8cc12710">90.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi02LTEtMS0xMDY1MDI_14296708-e538-420c-bc65-2c14e936a8b2">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi04LTEtMS0xMDY1MDI_48a472f7-bbec-427b-bf7f-5f28732717dd">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0xMC0xLTEtMTA2NTAy_a321aac7-c55c-4ceb-abdf-bda2c0973248">32.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0xMi0xLTEtMTA2NTAy_c3497782-e99c-4ab5-8588-8eaec7d7347a">78.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0yLTEtMS0xMDY1MDI_a74c5bc9-ee3c-4a18-ac0b-5d38ac0a63eb">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy00LTEtMS0xMDY1MDI_5292e089-a4fb-4589-af66-7f0c3513af4f">48.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy02LTEtMS0xMDY1MDI_913c407b-9fb7-4200-81dd-ec839339c51d">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy04LTEtMS0xMDY1MDI_74362644-2539-4c95-aa16-367f5dfb5b30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0xMC0xLTEtMTA2NTAy_0dcd96d3-4f39-4d27-b798-5a9cde8226df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0xMi0xLTEtMTA2NTAy_ba4cd243-8164-4e04-ab95-cde1bb97efd5">49.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0yLTEtMS0xMDY1MDI_cd1c67da-5b99-4824-bc06-f303a6492fee">1.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC00LTEtMS0xMDY1MDI_dbd2c5bb-e753-47c8-809f-ba1d210fb785">138.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC02LTEtMS0xMDY1MDI_79a376cf-756b-48e0-87a7-7100c097a7d0">20.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC04LTEtMS0xMDY1MDI_20129e6d-5b82-4c9a-9765-c076071a214c">2.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0xMC0xLTEtMTA2NTAy_3f89d32c-394b-4205-a2e3-0cb71e47bc81">32.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0xMi0xLTEtMTA2NTAy_81e02ff6-eba9-4a75-a68c-56b27b5bc800">127.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5920e9a8348d4b0184a94d22f70f6368_I20210630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0yLTEtMS0xMDY1MDI_cbde7d9b-7370-406c-9113-066b9b099925">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i812b8492c7e14121b9c263880e2c112c_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS00LTEtMS0xMDY1MDI_bf26aeae-d7ee-4d45-85f7-3e343993b12f">40.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2d434e7672451886a60cab65f8b82c_I20210630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS02LTEtMS0xMDY1MDI_56348970-3d59-471f-8317-43c84f325e76">11.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1938ff3b65564001bf3b50000b46d67e_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS04LTEtMS0xMDY1MDI_520b895b-974f-4676-91b0-143673c975d4">63.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bdeffc2747242298d5c74ba9260545b_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0xMC0xLTEtMTA2NTAy_6051ac56-38b9-4c5d-8783-85ef29c282ef">79.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0xMi0xLTEtMTA2NTAy_d215b349-1d8d-4c76-a849-a24731b83504">171.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTM1_7fa77229-af80-476e-b69f-4affccc34ede" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy0zLTEtMS0xMDY1MDI_fa155031-3eec-4d47-b210-71ab3222e1ec">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec879dd434784246ba9689b7523432b6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy01LTEtMS0xMDY1MDI_2d13d4da-f9a8-407a-b134-f7acd6471123">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy03LTEtMS0xMDY1MDI_1708f1a5-6960-4246-877c-2f2edac128c1">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy05LTEtMS0xMDY1MDI_5d594a2b-329b-46c4-9c9c-ff8b26f2a4cb">0.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC0zLTEtMS0xMDY1MDI_12f6ea72-0e1f-44da-b515-29ce9901d7ba">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec879dd434784246ba9689b7523432b6_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC01LTEtMS0xMDY1MDI_16988caf-2f9e-4362-9684-964d3ccc4ee8">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC03LTEtMS0xMDY1MDI_d2ed686b-fe0f-4cd9-b80a-ab18a54aa439">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC05LTEtMS0xMDY1MDI_8863b78d-032a-41a4-894c-11aa4c4eaede">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi0zLTEtMS0xMDY1MDI_a1a5ce60-fb32-4002-a414-4bce997191eb">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi01LTEtMS0xMDY1MDI_f5139ea9-f27e-466e-a947-84f3a26eb9b4">30.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi03LTEtMS0xMDY1MDI_5c994de6-03f0-4f51-9c5b-f87b0f2b4cdd">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi05LTEtMS0xMDY1MDI_c3049800-f665-4b77-8f6f-34e6f35ecbf0">53.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy0zLTEtMS0xMDY1MDI_89fbf79b-336f-4a47-a9d4-b54ae57c025a">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy01LTEtMS0xMDY1MDI_061dda8e-350f-4197-b3ac-45964e328074">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy03LTEtMS0xMDY1MDI_c96dfb9d-2796-4a7a-8f0a-dd26c94f4a6a">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy05LTEtMS0xMDY1MDI_cb85c491-6f33-4ca5-a12c-c6242cf9f777">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC0zLTEtMS0xMDY1MDI_28c0d4f8-265d-44ef-9b7f-69cf8e3d9545">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC01LTEtMS0xMDY1MDI_f146a503-7852-41bb-8fbf-b6adea96c560">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC03LTEtMS0xMDY1MDI_ffd95543-940c-4154-8601-d1f01c01c6bf">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC05LTEtMS0xMDY1MDI_7b453b71-4619-4749-8f08-3a382bf28ed2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS0zLTEtMS0xMDY1MDI_598a822b-ba34-4027-a98c-2920d6e2e229">4.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS01LTEtMS0xMDY1MDI_36dd36a5-f710-4fc5-91b8-f2cfc85e3bbd">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS03LTEtMS0xMDY1MDI_b6d8359f-1035-4e15-99af-efa2b67ad371">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS05LTEtMS0xMDY1MDI_6bb1a572-6680-4ddd-a202-c4c7fe944e99">5.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7ab9eec76f415b9754dece93693c29_D20220401-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtMy0xLTEtMTA2NTAy_827372ab-34d8-47b8-b2dc-b668e9aea209">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b10142df3b467e8bdcbcc59ff9e2e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtNS0xLTEtMTA2NTAy_325d4433-c3e3-4dba-aa86-50f6cc0aa60f">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e16fe28452c4b27a1b2a84884bb91f2_D20220101-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtNy0xLTEtMTA2NTAy_8dc99271-f218-4a11-9fa5-79d30a81c5ec">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34aa5eb01fc941468970bfd540a717af_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtOS0xLTEtMTA2NTAy_b48c93fe-342e-45fc-b2d3-390b4caaf7c8">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45d9e723dce441e9bca32cefeba7912d_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtMy0xLTEtMTMwMzU5_c2a0fa9a-59c9-499b-83be-150c8626cf91">58.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef3a7fd90234f2892d851bd89cb2861_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNS0xLTEtMTMwMzU5_0faadffc-1c79-4682-a9a4-9f85cb8305ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdd50768ee6b486a869faf383cfec503_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNy0xLTEtMTMwMzU5_445a0e19-8baf-4a3d-9174-3fe4978fccf5">58.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c42c98806743678d857956f14b201c_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtOS0xLTEtMTMwMzU5_89031eab-9aa9-456b-aff8-5d53eb52f121">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05576bec60da463ba40fa81a1d5d6213_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtMy0xLTEtMTA2NTAy_996d9d2a-bb21-49e7-b77a-37e150bed05f">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic49a0c322d4a4fa6ad316e2dbcd57859_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNS0xLTEtMTA2NTAy_09deaa87-de3f-4187-afde-f74ccaba47e1">27.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769f963dcd104808b7f557b5bcf509fc_D20220101-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNy0xLTEtMTA2NTAy_8a1ac859-6c52-4d09-941f-c953cc9abc4d">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia82614881b654024a0f966982a2e1643_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtOS0xLTEtMTA2NTAy_971c41ba-6da5-435f-b9f2-561df97cc397">49.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTY1Nw_eaf44043-7fb2-43b6-994d-a1e086faa999">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_100"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;EARNINGS PER SHARE </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90ZXh0cmVnaW9uOmJlYjI0MGE1YjU5MjQ2MTJiZDQxNzE5ODZlNzg3ODliXzI1Nw_7401577e-0e5b-4f73-9236-2ff344fb19cc" escape="true"><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90ZXh0cmVnaW9uOmJlYjI0MGE1YjU5MjQ2MTJiZDQxNzE5ODZlNzg3ODliXzI2MA_06aa1a9f-20f3-4c47-a688-f8b56ec94a6d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtMi0xLTEtMTA2NTAy_b3be894f-a7b7-48ed-a34b-f102f30dff42">1,058.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtNC0xLTEtMTA2NTAy_2538cd3a-a0e7-458f-be42-dd5658430d4e">448.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtNi0xLTEtMTA2NTAy_3af3ad3f-9e7b-4b3c-972a-774ab66520b6">1,361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtOC0xLTEtMTA2NTAy_b7d407b8-4693-4113-8b18-bfb5dd7a375d">858.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtMi0xLTEtMTA2NTAy_4836b745-ca16-4de6-a091-6322a630e82f">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtNC0xLTEtMTA2NTAy_66711d85-b677-45a7-a479-acc990f19fe7">149.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtNi0xLTEtMTA2NTAy_46cb6ef0-29ea-4e38-bd62-5199149f5618">146.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtOC0xLTEtMTA2NTAy_50d7827b-6d6a-47d8-9747-8972779830f0">150.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i064f6c79792847f38bbef18be71b042b_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtMi0xLTEtMTA2NTAy_e1f8d085-2841-4548-9405-20c37f2d86c6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i935112ef58c34d998257dbf55b14da22_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtNC0xLTEtMTA2NTAy_241c4aa5-aa3d-40ad-85fb-4497dda0bd8e">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe1fbb5461ad43bea5769749d280c2c6_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtNi0xLTEtMTA2NTAy_ccb758bb-d102-45cc-8a87-4d6ae21b5953">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59078147fa6f488c8239e033a6fdf63a_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtOC0xLTEtMTA2NTAy_0a0f1b8b-7dd4-47a5-8aec-348e911e1f37">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied9be70de8b546c1876a1ef6efccb2b6_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktMi0xLTEtMTA2NTAy_1999998f-5805-4741-8c42-bff9b58c332f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ca4330df54e4589a400fd134a2fa6be_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktNC0xLTEtMTA2NTAy_55cd46b2-e3a0-48fd-aeac-c3d17dd2a7bd">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i430d8a3876b04d60b0a0e1af9b6f9375_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktNi0xLTEtMTA2NTAy_8367351e-11d9-4eb5-8386-f8b22de25309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee4c31bfbdd74c94810389e9eb943e18_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktOC0xLTEtMTA2NTAy_4e7a12db-c9d3-4ed8-91c4-afd59c5bcede">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e723dda18e341ab87f7edde733b2a16_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTItMS0xLTEwNjUwMg_bdaf5fae-f3c3-4e5b-bbc0-d8b96e09392b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaaccf079a49488eb79a43457781b779_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTQtMS0xLTEwNjUwMg_7e231cb1-e62d-4bec-a685-15b2e5b0cd06">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i404f8659b4894301b106514d8921df0f_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTYtMS0xLTEwNjUwMg_12281334-f68f-4561-844e-95b0f9586425">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i726ad69e44e74f18812d926508d81057_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTgtMS0xLTEwNjUwMg_f4eddc93-f748-480d-af77-6d37ae651cd7">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTItMS0xLTEwNjUwMg_37b53ba1-529a-437b-a2b8-28f755f80ac6">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTQtMS0xLTEwNjUwMg_1a30c7f0-3d14-4b1a-b17a-a9370e3083ea">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTYtMS0xLTEwNjUwMg_68cfd099-1cc3-42a7-93b7-62600a4ca670">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTgtMS0xLTEwNjUwMg_5359cb84-dd35-4a91-8952-c43a2b30f973">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTItMS0xLTEwNjUwMg_96b74e01-eede-4660-988a-54c7b147831d">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTQtMS0xLTEwNjUwMg_6553bf5f-c5e3-4897-ab5d-34fb53dc2805">150.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTYtMS0xLTEzMTk0Mw_6043c306-5bbc-40a0-88a0-b71b7c215fe1">146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTgtMS0xLTEzMTk0Mw_7ede2052-eca2-4e12-ba68-ffa7f59e8324">151.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_103"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;SHARE-BASED PAYMENTS </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY3Mg_63682b08-9fc2-45f8-b500-55f6603e8101" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY1MQ_20af3933-fcef-4757-bf41-8267ee992055" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib613e85a78bc4456893a2ad6a58b3db5_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItMi0xLTEtMTA2NTAy_41ec3d5e-f69c-466a-bc43-72877d059843">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c01771898e4c6a8325194d609c2081_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItNC0xLTEtMTA2NTAy_0f34cc4f-8dbc-46da-8a4b-188d7c6d9138">19.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ac757a014e4f9d8ee4cc1b9b4d3350_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItNi0xLTEtMTA2NTAy_da72a1d0-a373-4a9c-9d3d-e0b3aee333f7">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7dc5fd89d04e4c8378db999b2eda6e_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItOC0xLTEtMTA2NTAy_63a1849e-4174-4c82-9beb-f67948135131">52.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0768cf5b82344dfeb26a9db8c6655c34_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtMi0xLTEtMTA2NTAy_e7400d60-d90a-49e2-b45a-5cd3af67e43b">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie432e10abc0b47dd9185ef700519fae8_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtNC0xLTEtMTA2NTAy_789bfa85-b8de-4c3a-a979-8d3e4fb9279a">40.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eccf41bcd3b4ecba3d2a095e0239516_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtNi0xLTEtMTA2NTAy_19f87180-ae59-4a37-8966-c66c5edb12e7">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da564986d004bf6bbea566000fdb4f4_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtOC0xLTEtMTA2NTAy_8c7eb7b6-ef0b-4b94-b31f-be92017c0b86">85.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtMi0xLTEtMTA2NTAy_ee317d42-1577-42fe-8a49-3830058b571f">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtNC0xLTEtMTA2NTAy_f9fc723f-1ae6-4f7f-83ac-1ea4e68cb423">59.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtNi0xLTEtMTA2NTAy_23bb314d-c353-4697-a1f4-51588120b04a">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtOC0xLTEtMTA2NTAy_b18455b1-f98f-4e54-876b-4c1cb9a6e7c3">137.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtMi0xLTEtMTA2NTAy_866e7714-8f80-4ec1-81ed-134de95a753d">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtNC0xLTEtMTA2NTAy_b037d017-f6fa-4596-a6ac-d25ebc4e5cc2">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtNi0xLTEtMTA2NTAy_2e0aadc7-5613-4036-9102-a88572558357">5.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtOC0xLTEtMTA2NTAy_88523a2d-f709-439a-96e0-397e04279af5">4.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctMi0xLTEtMTA2NTAy_e8816dd5-f14c-49e3-a4f4-d66bfb8aa3ec">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctNC0xLTEtMTA2NTAy_56764f58-7cee-403e-818b-781017c096a6">57.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctNi0xLTEtMTA2NTAy_af5183e8-95f2-408e-8c38-89ad291330ac">125.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctOC0xLTEtMTA2NTAy_3fa0820f-9acb-47ec-b42c-9edb9ab24cdb">133.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtMi0xLTEtMTA2NTAy_5141fa87-3164-47c3-a4a6-447298f115df">10.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtNC0xLTEtMTA2NTAy_a40f8428-5905-4569-8f7d-0cc590ca3a47">10.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtNi0xLTEtMTA2NTAy_1a77349b-38a7-4107-9c05-76d6012c98a6">23.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtOC0xLTEtMTA2NTAy_504fb566-7d88-40a8-81dc-02ce2ec803c5">24.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34df8b39629d46e3a1d76df662efe1ac_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktMi0xLTEtMTA2NTAy_a3fee7a6-fab9-42a1-b4f9-37d81bbdc182">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4242bcb1bf68441e915043a252b28f3e_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktNC0xLTEtMTA2NTAy_3fc9624d-b180-4f0a-a4f3-142f0fdc8d39">46.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c11788c3f940898950aac7349449bc_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktNi0xLTEtMTA2NTAy_f7c023d9-1cf8-4172-8412-2e6908073639">102.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2087847394724417ae5cd7671bef7634_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktOC0xLTEtMTA2NTAy_842b09cd-79a4-4aab-bb29-c30481a771d9">108.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY2MA_97e45962-e064-4d71-a552-80a1a70164be" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e3f4c497b04721b2a471a9d1462e90_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItMi0xLTEtMTA2NTAy_1a263b83-1f5c-4efb-8e04-6fa96947c329">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e6a4109ed149448f4eb38f7f7a6fe0_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItNC0xLTEtMTA2NTAy_17de2dac-611b-44e8-ab17-34235df359fc">9.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd85c59952834082adcd0bda1c3bc397_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItNi0xLTEtMTA2NTAy_8850d4bb-ab53-4164-b6e5-8feabfe16118">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c78200de99d4a8992ff379211c1b05c_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItOC0xLTEtMTA2NTAy_7ff78f80-aa5d-4082-b395-3f44767384e1">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598d5781ec294abb97c2fd87cab72371_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtMi0xLTEtMTA2NTAy_1c2d3a13-947c-47bf-b7d7-a271e615483e">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb25232bfbb143b2a5469052ea1aacbb_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtNC0xLTEtMTA2NTAy_c575c606-c693-4440-b355-5dabad11e34b">40.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070778a5f6bf479290bc275c09f5d25d_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtNi0xLTEtMTA2NTAy_fd8cd2bc-e992-437c-81d2-007712090aa3">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c2f4968e7d449bbcdba9e0686e5349_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtOC0xLTEtMTA2NTAy_8506aadc-4cb0-4c9d-94c9-48d066e1fba1">83.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4229db4a3b479c9d2a9fb092797c6f_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtMi0xLTEtMTA2NTAy_a0debd36-d311-4085-8181-b0f3d3a9630a">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4787bd92caad430eade94b63652c8eae_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtNC0xLTEtMTA2NTAy_da7a52d5-b22f-4b1b-8c1b-c8459409846c">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f165e7c3e24de78375b532ed70ebc6_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtNi0xLTEtMTA2NTAy_3492ec41-4516-45ca-9d22-5e8d394556a7">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id383c4b3624c4a3084db5066645c15a6_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtOC0xLTEtMTA2NTAy_f1d71ea7-27dd-4ce6-b880-a02fc447a224">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0b80c4d4a24c59870003ff1526e308_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctMi0xLTEtMTA2NTAy_4fc5969c-3970-42de-94ab-95689ca239b7">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03333ee45c754e49b0aae5e5249ab285_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctNC0xLTEtMTA2NTAy_1c39114d-9718-4492-9bf5-0e3112c3dd5b">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d41849f5c049ef858c1b655ecdb83d_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctNi0xLTEtMTA2NTAy_d79d527e-f37f-4ebd-a282-ed07db777c7e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1703619476c5469fb6eae667c889633f_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctOC0xLTEtMTA2NTAy_721bb479-18ae-4261-b451-5b13dd6ec851">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd736af6b0704581966ceb888e962dc1_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtMi0xLTEtMTA2NTAy_0c9eb837-7ee7-45c8-8785-ab23130a184f">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafdb9d7e53324279ba0597cb20081464_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtNC0xLTEtMTA2NTAy_ccbfdb25-1ae4-41e7-b51c-51ebb073ff12">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af51832291c4232b19c5319e421ca32_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtNi0xLTEtMTA2NTAy_79893ee5-b253-415f-8498-ccb1048c021f">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e91b63836f40969d01256870c0e4e2_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtOC0xLTEtMTA2NTAy_e98b8c56-45b3-4c63-84a0-de0622915d36">10.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTItMS0xLTEwNjUwMg_e009a248-e780-4ae4-bbf9-b7473a524bfa">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTQtMS0xLTEwNjUwMg_330da492-15c6-4813-b042-9eb3737c12b4">59.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTYtMS0xLTEwNjUwMg_0eb4d94e-478f-41b4-8a14-7470b33148a6">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTgtMS0xLTEwNjUwMg_25ff75a4-f0f3-46f8-ae67-3d7e3fce67ff">137.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTItMS0xLTEwNjUwMg_7105d0a2-43e6-4e95-8f5d-4701a83af1ab">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTQtMS0xLTEwNjUwMg_0e7c8b28-fa12-4b35-8a3b-9ae23e12a264">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTYtMS0xLTEwNjUwMg_036653d3-5bb9-46c4-9287-565d855c6979">5.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTgtMS0xLTEwNjUwMg_7f0c381a-8646-407e-b6e2-896089987e77">4.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTItMS0xLTEwNjUwMg_52aac256-f6fa-45fe-a034-5184ec2bf915">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTQtMS0xLTEwNjUwMg_d04fd73b-b820-4216-a4cc-ecaa60c3dbd8">57.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTYtMS0xLTEwNjUwMg_ae741ab0-6123-4b23-8d63-3d5513d27d5d">125.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTgtMS0xLTEwNjUwMg_1646892b-b25f-4a9b-b0a4-adb9fa300d92">133.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_106"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;INCOME TAXES</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzM0NjI_cd670749-0cac-4cad-ae9c-1b0cceac8d9d" continuedAt="id4c650d71c46474b9ae9443a214234a0" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzM0ODA_7a5c8fca-2e6a-4231-a38d-04f745a11fa0" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItMS0xLTEtMTA2NTAy_fcb7ce6c-6cda-4138-962f-05a27f774429">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItMy0xLTEtMTA2NTAy_112f522e-e79c-4dd6-a011-0d9ee3a9e369">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItNS0xLTEtMTA2NTAy_3007ce72-e1ce-41dc-ac72-0b3af18bca81">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItNy0xLTEtMTA2NTAy_3e1afdad-0ab4-41dc-992b-7f9290cdd280">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtMS0xLTEtMTA2NTAy_505328ce-83c3-4c24-95bd-fac9fc7c81e7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtMy0xLTEtMTA2NTAy_2971f69e-b41a-4903-80ab-d22836386b65">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtNS0xLTEtMTA2NTAy_155b84ae-2c86-4e9c-a27e-aa84fb351888">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtNy0xLTEtMTA2NTAy_b58324c7-b8f9-4772-b716-cd6a9a20742a">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtMS0xLTEtMTA2NTAy_ded297de-8f47-470f-8da0-bbe315bdede5">3.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtMy0xLTEtMTA2NTAy_bb1497ae-4ed0-43a3-8d85-7bd52c116841">7.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtNS0xLTEtMTA2NTAy_46fe4893-993c-4772-b068-00b735ac9b6f">5.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtNy0xLTEtMTA2NTAy_2431fcc2-3aee-4258-af23-7c08613075d4">9.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtMS0xLTEtMTA2NTAy_0414cd74-5d48-404b-8757-7069127c326c">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtMy0xLTEtMTA2NTAy_cf933cdf-e7a4-48fd-85ae-df0afce88112">2.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtNS0xLTEtMTA2NTAy_65b08941-49d7-464a-a0e4-bdd51f0cfa6a">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtNy0xLTEtMTA2NTAy_1350e55d-e8e3-48aa-985e-44deca9e05bf">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtMS0xLTEtMTA2NTAy_eeaf48b1-1a5a-4c20-8304-dea9786ba5bc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtMy0xLTEtMTA2NTAy_8959143a-7239-4731-82b4-a1d55707c1dd">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtNS0xLTEtMTA2NTAy_da2fd11c-6d2f-4d55-8f02-b2d4f85ccf83">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtNy0xLTEtMTA2NTAy_8bfe5e59-e4b1-4edf-ad05-e2d3fb2d0c3c">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTEtMS0xLTEwNjUwMg_cc279179-e761-4cb9-a063-86a2c24d7a2b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTMtMS0xLTEwNjUwMg_30a5b520-9c3e-48be-97c1-195567ca7db4">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTUtMS0xLTEwNjUwMg_47d8fd67-a60a-4555-beeb-cf2ee4677c71">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTctMS0xLTEwNjUwMg_b684a998-864b-4e88-8f1d-6af4ebc70eb9">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTEtMS0xLTEyOTgxMg_49ea5514-6d04-4119-b75a-9fc7b5eeb39a">3.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTMtMS0xLTEyOTgxMg_c0c7d1ed-074c-4f03-8be7-5234c688176d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTUtMS0xLTEyOTgxMg_7dbc1aee-3a51-486e-99a6-359eccac5e25">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTctMS0xLTEyOTgxMg_22b3ad6c-3d52-43e6-8cdf-2d7de2afb37d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEzMjE4MA_d92ae294-e060-4a18-81ce-c3a79b07e7aa">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEzMjE4MA_b7ce85fb-2750-4c21-8104-0c0ef5248dd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEzMjE4MA_a634b4e5-db62-4da2-b1cc-f36c94b1cbc3">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEzMjE4MA_f1c9dfb7-ed51-4bcd-87ad-f66997f184f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTEtMS0xLTEzMjE4Nw_e323011d-1882-4c0c-ac95-e2bf5638be20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTMtMS0xLTEzMjE4Nw_621bc553-6b2c-4a41-85b7-7bc82f7ab64b">83.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTUtMS0xLTEzMjE4Nw_6ca43db8-5788-4e61-9dcb-1eb814c802c9">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTctMS0xLTEzMjE4Nw_aceb8d9c-d724-4532-b9e2-3414754e8a81">46.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEyOTgxMg_5f1a095d-b04f-4018-ad57-3cd3d6623462">4.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEyOTgxMg_a8073e83-2f7e-4a4a-be77-8f368070082b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEyOTgxMg_df509a9a-b04b-446c-bcbf-e5bafb6cf9a7">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEyOTgxMg_874e8e6a-dac3-4738-a72e-4aea5ffdf47f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTEtMS0xLTEwNjUwMg_ff0fd7a8-7b78-4cbf-9397-e5de4e06970a">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTMtMS0xLTEwNjUwMg_3ed7d2ca-afcb-4f99-9bb7-21a453791a33">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTUtMS0xLTEwNjUwMg_8a7bbeae-3c1c-463c-9661-67d60af54204">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTctMS0xLTEwNjUwMg_af60b237-edbc-4972-9ad0-c77a0af59cfc">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEwNjUwMg_e0266d25-612e-4b6d-85ee-4b8832ec5272">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEwNjUwMg_f78895c3-6524-43aa-b077-3e7a6a30eec4">70.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEwNjUwMg_5c2dac61-8998-4b34-a9d1-4d83ed6bc0b4">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEwNjUwMg_74ae0d4c-fab9-4fe5-9810-e64ff67921f9">34.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the increases in our effective tax rate were primarily due to the overall current year unfavorable tax rate impact on the sale of our equity interest in Samsung Bioepis in April 2022, the litigation agreement in principle and the tax benefit recorded in the second quarter of 2021 related to the Neurimmune SubOne AG (Neurimmune) deferred tax asset matter, as discussed below. These effective tax rate increases were partially offset by the non-cash tax effects of changes in the value of our equity instruments and the current year tax benefits recorded in the second quarter of 2022 related to an international reorganization to align with global tax developments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared with the same period in 2021, our effective tax rate also increased as a result of the Neurimmune valuation allowance recorded in the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzI4NDE_6fd45d02-6f14-4d18-b610-ae68ba08b2d1"><ix:nonFraction unitRef="usd" contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzI4NDE_a84899e0-f424-46c4-8ade-0eea1fc0865f">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzMxMjI_cb9a9ccd-20df-4848-92e0-6d688659b783">390.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzMyNzU_7277a262-d932-4818-baf9-b1f319851af2">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id4c650d71c46474b9ae9443a214234a0" continuedAt="i1dde536a3562461a959f7a4b52c76daa"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i7cc7449e1d4248ee94e3a7a6a2b8c0e6_I20221231" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzI3NDg3NzkwNzgzNjU_5d9de7a4-66b8-458f-b9c7-dcc708f43675">500.0</ix:nonFraction>&#160;million, including approximately $<ix:nonFraction unitRef="usd" contextRef="i4fc0bc45a8f34476bd5ce77c28c035ac_I20221231" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzI3NDg3NzkwNzgzODE_afe2f8ff-637f-45b7-b6b8-e5a3dc79a49a">455.0</ix:nonFraction>&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit</span></div></ix:continuation><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1dde536a3562461a959f7a4b52c76daa">closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w</ix:continuation>e have recorded a full valuation allowance against the relevant deferred tax assets.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_112"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;OTHER CONSOLIDATED FINANCIAL STATEMENT DETAIL </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMTQ_c210e3f0-c801-4e94-b80b-057d4f63f551" continuedAt="id687b3037ea147b7ad6924644d46772a" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMjQ_d5f00e1d-b10f-45e9-b794-79301612c5f0" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItMi0xLTEtMTI2MDI1_7523f6ad-2bf8-40e2-a449-299bde8975f4">1,505.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNC0xLTEtMTI2MDI1_d1a14689-4779-4340-92bf-583e20ee93b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNi0xLTEtMTI2MDI1_efaf9d73-d1a8-495f-a320-ce37702ef9bc">1,505.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItOC0xLTEtMTI2MDI1_a7e19e02-61eb-4ea4-b88f-f99d59933c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtMi0xLTEtMTMwNjY0_7d7d458b-130b-4066-8e53-ad40f24e427f">900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNC0xLTEtMTMwNjY0_ed0f362e-7380-47f8-bf32-a282e5f6e8bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNi0xLTEtMTMwNjY0_91960898-ba14-40be-b48c-0cb7d21b9021">900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtOC0xLTEtMTMwNjY0_9af5c264-1990-4219-bd89-a78c5bb3899e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItMi0xLTEtMTA2NTAy_43ec6b53-06bc-4ba3-afc2-3e7be4412932">12.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNC0xLTEtMTA2NTAy_52924097-b632-45a5-9b4a-23493fff59b5">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNi0xLTEtMTA2NTAy_4c137482-dcdc-4e7f-bce0-1d04bb153959">15.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItOC0xLTEtMTA2NTAy_4bdec16a-53b1-4cdf-a901-ee2200176a3a">5.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtMi0xLTEtMTA2NTAy_6160115e-cb46-4e2f-8dfd-71f7ba5d3706">65.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNC0xLTEtMTA2NTAy_a793421c-7ce3-4bb3-b879-f22d6fd441d4">56.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNi0xLTEtMTA2NTAy_35af5c26-07fe-4732-b73e-9df16e9bd6ba">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtOC0xLTEtMTA2NTAy_63de7274-f9c8-49c6-b8d7-afba9a8e0ed8">121.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtMi0xLTEtMTA2NTAy_e48fc09c-7c76-4881-ba35-87a2b7d60293">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtNC0xLTEtMTA2NTAy_d94fd433-2a13-4150-9ec1-d755a9059d9b">153.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtNi0xLTEtMTA2NTAy_c4e0744e-b605-4371-8f20-ddaeffb7628a">269.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtOC0xLTEtMTA2NTAy_0bf7fe1f-f747-48dd-816c-0c57457a9950">282.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtMi0xLTEtMTA2NTAy_594cf521-50dc-4cad-b488-32758afa37f9">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtNC0xLTEtMTA2NTAy_76ab5b01-bdb6-4cd1-86ef-c76bb333369f">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtNi0xLTEtMTA2NTAy_1b6797a0-9ee9-44e5-bc65-d0fc54c19f8c">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtOC0xLTEtMTA2NTAy_a3242632-daeb-4c07-8241-0eaf21de38ba">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtMi0xLTEtMTA2NTAy_4455ae72-2353-4cc3-9e78-d8432744b736">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtNC0xLTEtMTA2NTAy_86ce69f3-34ec-4ff7-9bb8-81530177f098">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtNi0xLTEtMTA2NTAy_9b88a622-37d5-4de0-84dd-a0ddd3ca1cce">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtOC0xLTEtMTA2NTAy_2b7bc2ca-b0bd-4889-84e7-e0205695a715">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctMi0xLTEtMTA2NTAy_141d4691-1525-4230-927b-4b81d509c6bf">428.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctNC0xLTEtMTA2NTAy_1a860420-8c19-4170-af57-6d1de80c4974">96.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctNi0xLTEtMTA2NTAy_fb02f824-01a3-4d19-bc3d-58ef268f8e81">165.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctOC0xLTEtMTA2NTAy_a8bf830c-7292-4b6a-95ea-08eb99f4fa33">410.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwOTk1MTE2MzExNjY_c9e0aefc-ddcd-4bbb-b940-e655b42de12c">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzQ5NDc4MDIzMzE2NTc_15907a59-f314-4dfc-a134-f09ea70172bd">900.0</ix:nonFraction>&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMDY_f6bc6ea4-f611-4cf4-9927-3e1a20974aa4" continuedAt="i2f62d8ab41f145b4878f28d200139f25" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItMi0xLTEtMTA2NTAy_706bda13-8a41-45a8-b265-cd883096dfc5">77.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItNC0xLTEtMTA2NTAy_e41ee933-09ef-4dbb-b694-37bb6e5b9bd4">154.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItNi0xLTEtMTA2NTAy_1822e4d8-5b22-4a93-b91c-913f4eb8b702">267.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItOC0xLTEtMTA2NTAy_6f07b58b-a605-4eda-8d1f-0d6efc46bd84">281.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtMi0xLTEtMTA2NTAy_a5847d77-03c9-44dd-8a26-4d8322c7f0fd">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtNC0xLTEtMTA2NTAy_1b7c5b8c-65b6-49eb-b67d-e62dc0c224c9">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtNi0xLTEtMTA2NTAy_e6bb6df5-e91f-4505-85b3-bc94ff2465bf">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtOC0xLTEtMTA2NTAy_279256bb-5b77-484a-a9cc-1e407a609db9">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtMi0xLTEtMTA2NTAy_fc3c95e9-3ecb-4a15-a82b-4c0e1263393b">76.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtNC0xLTEtMTA2NTAy_b7f12ddf-95c5-4752-b98a-f561554c5331">153.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtNi0xLTEtMTA2NTAy_dc0d088a-3ba8-4460-a626-3904ac8156a4">267.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtOC0xLTEtMTA2NTAy_8942610c-bcaf-46b3-b92a-f910e3fe59cc">288.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo and Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i78027a673ba84f59a729646c29056ff0_D20220401-20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwOTk1MTE2MzA1MzM_a047a02e-7418-4ae6-b618-021e485e00b3">75.3</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id687b3037ea147b7ad6924644d46772a"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f62d8ab41f145b4878f28d200139f25">The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMzE_ca31d9b6-a289-40e4-9d6e-1e5fab6cacbe" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtMi0xLTEtMTMxNjkx_b8deddd2-0f59-47c5-8dfe-9c1131ea643e">900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtNC0xLTEtMTMxNjkx_6f4c4e1e-9d94-4489-b3f0-824672ed828b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33934bee3c5143dd99f1d517165ead05_I20220630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtMi0xLTEtMTA2NTAy_f14d0131-235c-477a-923a-60d65bf9f482">846.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if642314400ad46ce8997912ff65d7344_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtNC0xLTEtMTA2NTAy_8f8b8e2d-3445-4598-8136-4b45a2eff63e">802.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzItMi0xLTEtMTA2NTAy_b64b7c7c-e640-4310-a5df-3138cba9a100">261.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzItNC0xLTEtMTA2NTAy_3b5d39c8-83e5-4ca6-976f-ea7cf092a352">324.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzMtMi0xLTEtMTA2NTAy_1cda7e8b-bc76-40c7-9b89-9cb32314e553">216.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzMtNC0xLTEtMTA2NTAy_10d06abc-af5f-49f0-8e34-822ef2499471">234.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzQtMi0xLTEtMTA2NTAy_c71de29c-6e55-49cd-b547-701e57eccf95">281.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzQtNC0xLTEtMTA2NTAy_bdf17c3a-a14e-43df-8cc3-a7c8a3ef6c27">345.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzctMi0xLTEtMTA2NTAy_dadbaa29-0aa1-46a5-9649-09db6c130198">793.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzctNC0xLTEtMTA2NTAy_cb711fcf-7481-4a4d-b57e-37bc785830a7">828.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzgtMi0xLTEtMTA2NTAy_382a5aec-fc01-48d3-a4f9-26e61e0d3b98">3,298.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzgtNC0xLTEtMTA2NTAy_334deb3f-1d10-4ab3-bcd3-5c5c5965c319">2,535.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzQ5NDc4MDIzMzE2ODg_fb22b722-e07a-4d3d-b065-7ea951867e47">900.0</ix:nonFraction>&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzg5NQ_d8c876d6-39f6-45db-a7fa-1410d0306c29">1,167.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzkwMg_b9aa5324-4b4b-4d05-81ed-1b1097bdef16">1,320.5</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzk3OQ_e18bd63d-060e-4723-bcc7-780ce2a932a8">499.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzk4Ng_5e793162-bdee-42b8-8e5f-e1c25c849b9d">664.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="iae1758f0b07f4108915caecfff327c7a_115"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;COLLABORATIVE AND OTHER RELATIONSHIPS </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njcy_876c1c69-559c-4453-8633-ee63d98535fc" continuedAt="i7227bac92f4342d4858b430d08e6ffc5" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from <ix:nonNumeric contextRef="if95e48bbaf4a4e799a9ebda77407ebe7_D20220101-20220331" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDI_90567a85-eecb-43fb-981f-34a416b27c34">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDg_32577ec9-4897-4ecd-8e18-8be6ae174045">ten years</ix:nonNumeric>, and we will manufacture the lecanemab drug substance.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7227bac92f4342d4858b430d08e6ffc5" continuedAt="i0d6f06af6fbc42739cec6839630fbc2c"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njk0_6ba370d2-3a67-4475-8f83-09d85df6ecdc" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItMi0xLTEtMTA2NTAy_5c5a86e4-122d-45c4-a54a-db5387d9925c">78.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03a4083cbe14980afe9873df6e01157_D20210401-20210630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItNC0xLTEtMTA2NTAy_1eb11542-181b-4d08-92d1-e23b8c477fa2">62.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItNi0xLTEtMTA2NTAy_ec2c2379-6aa1-4bf9-9322-b9cf86a11d37">155.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdad13d37214d518d991982787c19e3_D20210101-20210630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItOC0xLTEtMTA2NTAy_8594151c-0a14-44c1-ae46-3db6594f1557">117.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtMi0xLTEtMTA2NTAy_b3ce30b4-0fff-4237-adab-4689bd18b038">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03a4083cbe14980afe9873df6e01157_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtNC0xLTEtMTA2NTAy_af45ba32-37a1-4655-bec0-6d39a4d15d96">31.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtNi0xLTEtMTA2NTAy_724d7c3a-0196-45fa-8f4d-8e77c342d279">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdad13d37214d518d991982787c19e3_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtOC0xLTEtMTA2NTAy_fa874574-e6cb-4e5c-8668-79597db9f286">58.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtMi0xLTEtMTA2NTAy_e89522fa-75d1-44ad-a435-2ac5d46fbe47">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtNC0xLTEtMTA2NTAy_4a1ca1f0-b49f-4090-bc8f-e108762e7763">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtNi0xLTEtMTA2NTAy_5120c2b6-2b51-4a2b-a123-b47cc745e78b">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtOC0xLTEtMTA2NTAy_25319eeb-0112-440a-be07-b60d0d6b6661">10.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtMi0xLTEtMTA2NTAy_73dc56c9-3516-43d1-832c-a5be722874dc">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtNC0xLTEtMTA2NTAy_fb3659cf-6ebc-4665-83c7-70f5f12ee585">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtNi0xLTEtMTA2NTAy_c001fbf4-e518-43d5-bdba-bb968ee6f34e">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtOC0xLTEtMTA2NTAy_d77f797e-956f-42fb-bbb0-993820dc29ee">5.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzIwMjU_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $<ix:nonFraction unitRef="usd" contextRef="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzIzNDM_95c0ab1b-f6d8-4a94-ba3a-9d14458899d8">100.0</ix:nonFraction>&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0NTY_5e0b93b2-f2a2-4402-81f0-5f387bfa03b7">45.0</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0Nzg_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0OTQ_95c0ab1b-f6d8-4a94-ba3a-9d14458899d8">100.0</ix:nonFraction>&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $<ix:nonFraction unitRef="usd" contextRef="i231f21da54f240e09322a7c8c9ff9b00_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzMwMzI_fbe206df-3225-4a45-9910-537f16daa1aa">335.0</ix:nonFraction>&#160;million for the period from January 1, 2022 to December 31, 2022. As of June 30, 2022, Eisai's portion of these expenses was approximately $<ix:nonFraction unitRef="usd" contextRef="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDUzMDU_c9339fd2-a8a2-428b-9d79-314787a9ad5d">275.0</ix:nonFraction>&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njky_2813ab9e-7235-4d90-8422-bc21cb603435" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ccab6bc98574047b1778979662e99de_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItMi0xLTEtMTA2NTAy_16c38078-2f71-4d2a-9774-4068fd6b6efb">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItNC0xLTEtMTA2NTAy_fc2ed524-3860-4282-8121-a08c81f48ffa">42.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItNi0xLTEtMTA2NTAy_09343d6f-830e-4c17-b933-20a1a974a5d2">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItOC0xLTEtMTA2NTAy_edca1aa4-ed79-4097-adf1-a09f19f63700">89.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ccab6bc98574047b1778979662e99de_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtMi0xLTEtMTA2NTAy_5df8ae4f-5802-4e5b-9da7-59e13bcc9e77">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtNC0xLTEtMTA2NTAy_43c70e5e-ac17-474d-8229-f7f26c7e28a5">23.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtNi0xLTEtMTA2NTAy_26416ccc-6cff-48d3-bab2-756c82943fdc">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtOC0xLTEtMTA2NTAy_9111d5bc-f5d6-48fa-b5ec-2beee4db42fa">49.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtMi0xLTEtMTA2NTAy_fd4cb46d-42a8-490f-87a7-2fc3e99bf5f6">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie326ff087126492b947c8a627fa90a72_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtNC0xLTEtMTA2NTAy_c96c50f3-3ddc-4cd9-8aa0-003119fe3939">125.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtNi0xLTEtMTA2NTAy_4e729131-a252-41c8-b1cb-bd3cd80d917c">135.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33450308aef4ad29feeb06170373827_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtOC0xLTEtMTA2NTAy_f265293e-5e45-4017-aca0-a24839fa809a">237.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtMi0xLTEtMTA2NTAy_c9f6fa61-5fc8-482a-ab4b-370563d2584d">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie326ff087126492b947c8a627fa90a72_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtNC0xLTEtMTA2NTAy_0f44f9d5-ef48-4348-8d02-0725ce7792bc">67.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtNi0xLTEtMTA2NTAy_8edc778b-2899-46d4-bb63-f25d21305700">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33450308aef4ad29feeb06170373827_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtOC0xLTEtMTA2NTAy_0f20f582-646a-4b5a-abd4-0aa51f21f47a">127.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third-party milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtMi0xLTEtMTA2NTAy_5082d9c4-02b2-4013-8ec3-ad8261c766a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtNC0xLTEtMTA2NTAy_b3fd5df0-b286-4746-a0f0-6d05717e583c">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f3123780b4402a90c954338e97580c_D20220101-20220630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtNi0xLTEtMTA2NTAy_55a74324-4bf6-4035-ae5d-9816c0f7451f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtOC0xLTEtMTA2NTAy_975f27bc-4006-4c41-a2a3-04ce903c7f40">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctMi0xLTEtMTA2NTAy_1f64af70-8bb4-4216-a516-bd8b572eab69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctNC0xLTEtMTA2NTAy_b8ff4403-4981-4c6c-ad5f-51786c186843">45.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f3123780b4402a90c954338e97580c_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctNi0xLTEtMTA2NTAy_7acbd98e-c290-46d3-bffd-953a9e8349cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctOC0xLTEtMTA2NTAy_3d524a80-6eb8-4a0d-830a-e94baafd31bc">45.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0d6f06af6fbc42739cec6839630fbc2c" continuedAt="if64875bf077d4218818e74e1e898bded"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received from Eisai for its <ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzM3NjI_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6b5e346af48c4d1ca76de22d3af2bb36_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQwMTM_b27f05e1-2278-46c7-9f66-ae1a22827816">28.9</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg0MDc_331917b3-5558-4c86-bc58-b818b39cc02e">210.6</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQwMzU_f3f0cb38-ce8e-457b-9ff9-23520125d4c5">45.0</ix:nonFraction>% share of net collaboration losses in the U.S.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to $<ix:nonFraction unitRef="usd" contextRef="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTcxNTA_544308ea-2a02-4cfd-ab96-926277dca7ad"><ix:nonFraction unitRef="usd" contextRef="ie1166a4ed6a348088b5ef0d2b05a70c1_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTcxNTA_6857bc77-6221-4b22-a2c8-bff5e95c9b82">40.1</ix:nonFraction></ix:nonFraction>&#160;million in each of the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQzNTk_971beb38-6dde-4d38-9dd1-b1ccf3f019c1">275.0</ix:nonFraction>&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $<ix:nonFraction unitRef="usd" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="-5" name="biib:CostOfGoodsSoldCapacityCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ1MDY_444714d5-762d-4a79-8e96-ea0281f69e18">45.0</ix:nonFraction>&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ2Njk_5687cfee-0f0d-4fda-91f6-46fbf641ea4e">160.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ2OTE_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ4ODk_63243683-6c4e-4e23-8874-09d7b59428d9">250.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="ide8a39607aa44c739f29386c64f8a2bb_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ4OTY_cebbe120-5241-4556-b3e4-a15ae75dc296">285.4</ix:nonFraction>&#160;million as of June 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzUwMDI_9422b353-77a5-49af-bcb2-8c1d3c4b0cd0">56.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ide8a39607aa44c739f29386c64f8a2bb_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzUwMDk_68cc81cb-55d0-4353-946b-8aca257bedc2">46.5</ix:nonFraction>&#160;million as of June 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItMi0xLTEtMTA2NTAy_aaae7587-2c53-4ca8-8da4-7e97bd87cbbf">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6766574fbd894502b558478062716387_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItNC0xLTEtMTA2NTAy_e4a39a55-5d5d-4dbf-acee-550e628eca2c">16.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e9b008911d4b25964bc84cba645427_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItNi0xLTEtMTA2NTAy_15777019-aba3-431b-8a8f-6646ea58be36">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItOC0xLTEtMTA2NTAy_36249b40-37b0-4f69-b461-8c10c7998e99">33.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtMi0xLTEtMTA2NTAy_b938e436-f2bd-4ade-af9e-89ba9bc2a09c">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6766574fbd894502b558478062716387_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtNC0xLTEtMTA2NTAy_b22672d1-deb0-454b-9907-a6b61ce1d129">8.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e9b008911d4b25964bc84cba645427_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtNi0xLTEtMTA2NTAy_7c5ae784-60fc-46ee-962e-69b1ffc026a8">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtOC0xLTEtMTA2NTAy_2ee6576e-4c73-455e-a71b-e533c6321537">16.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="if64875bf077d4218818e74e1e898bded" continuedAt="iabbac533fcda408aac4c369a3c82530c"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItMi0xLTEtMTA2NTAy_32be4baf-56e5-484b-93d8-4aefdf7c5c11">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItNC0xLTEtMTA2NTAy_a04d9932-5191-480f-891a-bb22c0269ff6">54.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItNi0xLTEtMTA2NTAy_2cdb4020-c44c-4a50-832b-3744dc1e14ba">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItOC0xLTEtMTA2NTAy_5c6d2a66-d00e-4531-bb63-278e12608b5c">93.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtMi0xLTEtMTA2NTAy_51d5b31f-1011-450a-88c7-e7fa79e997df">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtNC0xLTEtMTA2NTAy_1740743c-dc79-4021-851b-f449ff1ef17e">27.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtNi0xLTEtMTA2NTAy_d68e982c-32c7-4021-9a00-eae18d485324">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtOC0xLTEtMTA2NTAy_dc25e0c6-d27c-4680-9b62-2d83defdb968">46.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtMi0xLTEtMTA2NTAy_fe4f4079-38c4-4def-9e68-2f4887f161fa">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtNC0xLTEtMTA2NTAy_512bc838-1ef2-44f8-903b-89093d8b1353">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311cc627d4884000b967bc589ce09d88_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtNi0xLTEtMTA2NTAy_81b775d1-9dee-4fcc-a7f0-174de70d582b">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtOC0xLTEtMTA2NTAy_974feb7b-f9ef-47c8-bd2d-d05b785cf55c">15.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtMi0xLTEtMTA2NTAy_8e5d23ae-9a85-4276-9c81-62b10079dca1">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtNC0xLTEtMTA2NTAy_34d87569-fe78-4424-aee9-23b5e406a890">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311cc627d4884000b967bc589ce09d88_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtNi0xLTEtMTA2NTAy_69e44076-b569-474c-a4bc-d008fed3d6e8">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtOC0xLTEtMTA2NTAy_29df4b99-7a33-4690-8ae2-7d45121acd41">7.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NjU5_c77e35cf-3040-4b56-b6e6-78a24cc7cac4" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItMi0xLTEtMTA2NTAy_5783eb62-fc20-4f9c-97c0-01610201b1f6">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItNC0xLTEtMTA2NTAy_1d48b1e3-c041-4b2e-89d0-0b8e7fa88cf0">10.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if756749af2de4c4e957db16b485d5427_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItNi0xLTEtMTA2NTAy_2ca44996-d503-432a-bd30-a13eaf755d70">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItOC0xLTEtMTA2NTAy_29fd9d32-2c86-4a88-9dda-f51086cca98d">18.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtMi0xLTEtMTA2NTAy_7b95ca07-8d83-44e3-880f-4f79dac57e0a">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtNC0xLTEtMTA2NTAy_6063eaaf-8360-4bf9-9a0f-4fe51398bbf2">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if756749af2de4c4e957db16b485d5427_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtNi0xLTEtMTA2NTAy_0cc58865-3c80-41c2-95bd-4bf5c175eb43">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtOC0xLTEtMTA2NTAy_6bad6503-e871-4b88-946e-0a13327ba9cc">11.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i3e194ceae6f64b65b2349e8df6ab64e9_D20220101-20220630" name="biib:Termofcollaborationagreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NjYz_da388bc4-e2c8-422e-808f-671a4df2b8b8">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItMi0xLTEtMTA2NTAy_afce82f7-fd72-4326-8488-73488e014ccc">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItNC0xLTEtMTA2NTAy_797e91c7-7891-419c-a2ab-33cd94faf446">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItNi0xLTEtMTA2NTAy_d623ee1d-362e-4061-b96e-283d274a04c6">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItOC0xLTEtMTA2NTAy_d4399cb3-4601-43db-af38-2df80411a63e">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtMi0xLTEtMTA2NTAy_e71d14cf-e5c7-4641-9e8e-002cd4369e5f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtNC0xLTEtMTA2NTAy_9b23e84e-86b3-4e8d-abb8-f2a36e8e58e9">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtNi0xLTEtMTA2NTAy_5b309a03-674f-4371-8851-c8ef9fb10b75">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtOC0xLTEtMTA2NTAy_36e00efd-1a93-459f-ad1c-c646ffe5282e">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iabbac533fcda408aac4c369a3c82530c" continuedAt="icdc16cf85ef2430c9f14b1f529c24074"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5Xzk5MTI_59fb0bf9-ebf8-4c83-846b-2020d6e57aab">125.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $<ix:nonFraction unitRef="usd" contextRef="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831" decimals="-5" name="biib:ContingentMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDY2_e660df52-a3b4-4975-a687-83f111a0ce91">812.5</ix:nonFraction>&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i32ab1ddc9657403a8db302457fb46496_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwNjc0_8a832e82-e400-4079-b65d-a6de7bce0b4b">18.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i35b2b113cfdd420ebfc7941cfaba6661_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg0NzQ_2452b977-182a-465c-b520-7809caef02e2">37.5</ix:nonFraction>&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i89906910d5954e76b7d9d286e110f422_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwODQ4_8a22cbc1-ad3c-4b9d-892f-2996d82b2b00">77.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in each of the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTc2NTY_c9e0aefc-ddcd-4bbb-b940-e655b42de12c">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ2MjE_7a21c978-d96f-4ba4-ab49-534bfc1b329b">1.0</ix:nonFraction>&#160;billion in cash at closing and expect to receive approximately $<ix:nonFraction unitRef="usd" contextRef="i0bce0582b9234dbbac96a00b848486a2_I20220131" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ2NzU_74b91707-5750-444f-bcd8-66b6f887893d">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i3729e3a50004440ba3134a7803d8b293_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ3MTU_0ebc0d84-6263-4981-9891-fe9599c61249">812.5</ix:nonFraction>&#160;million due at the first anniversary and approximately $<ix:nonFraction unitRef="usd" contextRef="i3fc13fd60c8140859d72089cfe8c306f_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ3NTI_0b3c464b-8df7-4504-812f-a222d66f4d98">437.5</ix:nonFraction>&#160;million due at the second anniversary of the closing of the transaction.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI1ODcz_00c50cc8-f513-4c3b-96a3-9a140ac3e3e3">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i0dd95981381d46b7a30d0a586d846fb5_I20181107" decimals="-5" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzExODM4_2a881b76-08f6-4560-8318-535734de84ac">675.0</ix:nonFraction> million and related to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i994f69bbb09645ee8a7918008c471ef6_D20220101-20220630" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMDMw_1a3e767a-0214-4c22-b31a-ca1cbae5d6e3">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i89c39215e3534c88835566c3e470d890_D20220101-20220630" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMTk4_f43ee309-ee4b-4f51-917c-4fcfee381fe4">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMjgy_730ce4d5-daa9-4d38-b6c2-5493c5eb5844">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg2NzM_dc576cb8-b4b8-4f9f-8892-5a60e75bd4a5">2.6</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $<ix:nonFraction unitRef="usd" contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMzY2_63f90801-d155-4fc9-acfb-f289194423fd">13.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg3MjY_d8ffc544-ec60-4975-aa5c-2f7c75c78cfb">17.0</ix:nonFraction>&#160;million, respectively, offset by amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNDIy_3ff39b71-6e8f-4bad-a464-fa7d2f283f3f">7.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg3NjA_7fbb97a8-67fb-440a-be20-c742f94dfbf5">14.4</ix:nonFraction>&#160;million, respectively. These amounts reflect our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNTAw_e9feac9c-ee53-43d5-9313-0c98580790c2">34.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg1NTI_90b09031-c809-4e86-9b6f-7e67808b766e">16.1</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating income, net of tax totaling $<ix:nonFraction unitRef="usd" contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNTgz_25f6d243-65dc-4780-958e-fec49323fd5f">41.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg4MjE_e8f12d5f-f4ac-4ca3-a45b-75f6953d0d8b">30.6</ix:nonFraction>&#160;million, respectively, and amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNjMz_881c03a7-97fe-4b6c-9e77-70927858f593">7.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg4NDA_a820b28c-415d-448a-88b6-b0918edacef4">14.5</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="icdc16cf85ef2430c9f14b1f529c24074" continuedAt="i1911854cb1b54ff195f45a43c2d84ce1"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="ifce6fe69e35a448dbd457279465a317b_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNzQ3_9ea34dd2-4a0a-4685-a871-78e90a63f3a5">713.3</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ifce6fe69e35a448dbd457279465a317b_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNzY4_c1ef8905-2f97-4430-9641-0be15c23948a">599.9</ix:nonFraction> million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to <ix:nonFraction unitRef="krw" contextRef="i3c8021fc79f6416686d187243973ea45_I20220630" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NzE4NTA_f5bbef57-bc85-4c1a-ba75-54ea83d9eaf9">zero</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEzNTc2_d2dfd2d0-f68f-4778-a728-eb7c2e6e08cb">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU3ODM_7b75a52e-215c-40a1-b37f-4421ee9a6766">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MDQ0_a2f5b56a-2f98-4e16-bb57-d7bbd99b6540">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MDky_d95b94f7-c0aa-4117-be49-890ca9b0fda3">63.0</ix:nonFraction> million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i78b272d435084dce9cd4a8f7830ba08a_I20200131" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MjA3_f260d952-c261-4c7b-b05c-51456bce2340">37.0</ix:nonFraction> million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $<ix:nonFraction unitRef="usd" contextRef="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630" decimals="-5" name="biib:AccruedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MzQ4_79910970-996f-4f63-85db-1ef975100f88">15.0</ix:nonFraction>&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0NTk0_ccd1d2a8-a37e-4cf3-9a9b-356a886d4151">180.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0Nzkz_3c16a467-14e9-4a63-b272-df9efc6ad56c">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="-5" name="biib:ContractOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0ODQ1_d8a235e3-db4f-4df0-8b6d-93669715e080">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1MzE1_448b4761-fe5b-43b3-9c93-b9ddd999866b">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2022, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NTgx_791fefe2-09f8-4b75-bb2a-068f9a74b517">58.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU2OTk_e706bc1e-5055-4345-8b90-b3bf2fbba8f9">122.7</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NjEy_448b4761-fe5b-43b3-9c93-b9ddd999866b">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NzAx_af80aaf1-38e6-4bc4-88c1-d81a1a61d603">69.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU2NzU_8703e371-87bf-4290-b9dc-68c57205ee01">138.4</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="if1139e7fad6c40f48deba330c854be64_I20220630" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MjE5_c85ef29a-bda6-4517-8345-d0528e82cb91">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MjI2_6b2a503e-1dc0-4b56-a35a-e9551bb14127">4.1</ix:nonFraction>&#160;million as of June 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="if1139e7fad6c40f48deba330c854be64_I20220630" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MzQy_19626a1b-3efb-46ce-8317-7147691a8757">121.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MzQ5_65281d32-32e2-4d6b-82e9-d7a553f79d8f">148.7</ix:nonFraction>&#160;million as of June 30, 2022 and December 31, 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i1911854cb1b54ff195f45a43c2d84ce1" continuedAt="icc5b7ce148b94a91a1282a133fdf4577"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc5b7ce148b94a91a1282a133fdf4577"> to our consolidated financial statements included in our 2021 Form 10-K.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_121"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;INVESTMENTS IN VARIABLE INTEREST ENTITIES </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzQyNTQ_1987706d-235e-468c-a67a-0d9cafe6ac64" continuedAt="i9dda4af7c7044af0bc6bd4267fb30f20" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630" name="biib:CollaborationAgreementTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4Xzc0Mg_b0171aea-e319-4bf6-ab73-4ba622a1a099">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzEwODU_a6483068-e155-4c45-9ac6-e394749d65fd">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzEzMzg_41a09d39-293f-4a54-a19a-e26f3b0c7864">100.0</ix:nonFraction>&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $<ix:nonFraction unitRef="usd" contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE0MzM_41a09d39-293f-4a54-a19a-e26f3b0c7864">100.0</ix:nonFraction>&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i5a36bcdc40354faeb9b03f0586021c98_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE2OTQ_8be9b8a6-56c2-4e97-8baa-4eac79a28020">45.0</ix:nonFraction>&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE3MTY_bd644626-3c0a-4486-b743-28754bd95245">45.0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $<ix:nonFraction unitRef="usd" contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE3MzI_41a09d39-293f-4a54-a19a-e26f3b0c7864">100.0</ix:nonFraction>&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MDE_6fd45d02-6f14-4d18-b610-ae68ba08b2d1"><ix:nonFraction unitRef="usd" contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MDE_a84899e0-f424-46c4-8ade-0eea1fc0865f">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MjY_cb9a9ccd-20df-4848-92e0-6d688659b783">390.0</ix:nonFraction>&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MzM_7277a262-d932-4818-baf9-b1f319851af2">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzM0Mzc_257c5ca7-620a-449a-88e1-64e33a57eeeb">23.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzM0NDQ_86c85f61-4f58-4077-917d-d21433b95027">24.6</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i9dda4af7c7044af0bc6bd4267fb30f20"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></ix:continuation></div><div id="iae1758f0b07f4108915caecfff327c7a_127"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;LITIGATION </span></div><ix:nonNumeric contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzEyNDcw_155e27c8-8f1b-4d4f-b493-9595e8ba3bc0" continuedAt="i8bf85fbacc464313a1b118d264a8ee47" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 (the November 2020 Securities Action) and February 7, 2022 (the February 2022 Securities Action), and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the November 2020 Securities Action, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#8217; fees and costs to the plaintiff. The court has stayed the case pending the resolution of the February 2022 Securities Action. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). Fresenius Kabi later added European Patent 3 145 488 (the EP &#8216;488 Patent, expiring in May 2035) to both actions and no hearing has been set in either.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP &#8216;510 Patent. The EPO has scheduled a hearing on the validity of the EP &#8216;488 Patent for October 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i8bf85fbacc464313a1b118d264a8ee47" continuedAt="ib6035f20cbad4375b11f13e943df2212"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biogen has reached an agreement in principle to resolve previously disclosed litigation pending in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. The litigation was filed by Michael Bawduniak on behalf of the U.S. and certain states and unsealed in 2015. The U.S. has not intervened in the case. The agreement in principle contemplates Biogen making a payment of $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzQ5NDc4MDIzNDE3NTY_03b286c3-b594-4466-b929-e787940399eb">900.0</ix:nonFraction>&#160;million. The agreement in principle does not include any admission of liability and is subject to the negotiation of final settlement documents and agreements with the named government entities. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzYwMzU_0155e341-0999-463f-939c-cdd2abf16dad">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib6035f20cbad4375b11f13e943df2212"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description and in June 2022 we filed a petition for a writ of certiorari to the United States Supreme Court seeking review of the Federal Circuit's decision.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#8216;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for November 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for February 2023.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div id="iae1758f0b07f4108915caecfff327c7a_136"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC). In April 2022 the United States (U.S.) Food and Drug Administration (FDA) approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite will be operational during the second half of 2023. We believe that the Solothurn facility will support our anticipated near-term needs for the manufacturing of biologic assets. If we are unable to fully utilize our manufacturing facilities, due to lower than forecasted demand for our products, we will incur excess capacity charges which will have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, geopolitical events, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2021 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM (aducanumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which we are collaborating on with Eisai Co., Ltd. (Eisai), based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer&#8217;s disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit of ADUHELM, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. ADUHELM product label states that treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population which was studied in clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022 the Centers for Medicare and Medicaid Services (CMS) released a proposed National Coverage Determination (NCD) decision memorandum, stating the proposed NCD would cover FDA approved monoclonal antibodies that target amyloid for the treatment of Alzheimer's disease for people with Medicare only if they are enrolled in qualifying clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue funding certain regulatory and research and development activities for ADUHELM, including the continuation of the EMBARK re-dosing study and the initiation of the Phase 4 post-marketing requirement study, ENVISION. Additional actions regarding ADUHELM may be informed by upcoming data readouts expected for this class of antibodies, as well as further engagement with the FDA and CMS.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of June 30, 2022, Eisai's portion of these expenses was approximately $275.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application (NDA) for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a negative opinion on the MAA for aducanumab in Europe. We sought re-examination of the opinion by the CHMP. In April 2022 we announced our decision to withdraw our MAA for aducanumab in Europe.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive regulatory approval or are unable to successfully commercialize aducanumab in other jurisdictions, our financial condition, business and operations may be adversely affected.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 U.S. federal courts in West Virginia and Delaware entered judgments in favor of the defendants in patent infringement proceedings relating to TECFIDERA Orange-Book listed patents. We appealed both decisions. In late 2021 the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) affirmed the judgment of the West Virginia federal court. The appeals in the actions in Delaware are stayed pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our U.S. TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021 the European General Court annulled the EMA's decision not to validate applications for approval of TECFIDERA generics on the basis that the EMA conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the European Commission (EC) have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021 the CHMP of the EMA issued an ad hoc opinion referencing the General Court&#8217;s decision which concluded that "the totality of the available data cannot establish that [monoethyl fumarate] exerts a clinically relevant therapeutic contribution within FUMADERM," and in May 2022 the EC approved applications to market generic TECFIDERA. Generic TECFIDERA is now for sale in the E.U. and we expect generic sales to have an adverse impact on our TECFIDERA sales in the E.U. and our results of operations. In June 2022 the European Patent Office granted Biogen a patent that relates to TECFIDERA and expires in 2028. We intend to enforce this new patent.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report and the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19 and Other Disruptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conflict in Ukraine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine have resulted in global business disruptions and economic volatility, including sanctions and other restrictions levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor and are currently involved in clinical trials with sites in Ukraine and Russia. The timing and costs of these trials may be impacted as a result of the conflict. For example, the development of orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS, that we are developing with InnoCare has been delayed and will require the establishment of new clinical sites in other geographies.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia. Revenue generated from sales in these regions represented less than 2.0% of total product revenue for the three and six months ended June 30, 2022 and the year ended December 31, 2021.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors such as the COVID-19 pandemic, adverse weather events, geopolitical events, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic and the conflict in Ukraine, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_139"></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $7.24 for the three months ended June 30, 2022, representing a increase of 142.1% compared to $2.99 in the same period in 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended June 30, 2022, compared to the three months ended June 30, 2021, reflects the following:</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,589.1 million for the second quarter of 2022, representing a $185.9 million, or 6.7%, decrease compared to $2,775.0 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $2,054.9 million for the second quarter of 2022, representing a $181.1 million, or 8.1%, decrease compared to $2,236.0 million in the same period in 2021. This decrease was primarily due to a $102.6 million, or 6.7%, decrease in MS product revenue and a $68.6 million, or 13.7%, decrease in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in U.S. TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market and a decrease in Interferon demand due to competition.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in SPINRAZA revenue was primarily due to a decrease in demand as a result of increased competition in certain established markets, particularly Germany, and the timing of shipments, as well as unfavorable pricing and the </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $436.3 million for the second quarter of 2022, representing a $3.7 million, or 0.8%, decrease compared to $440.0 million in the same period in 2021. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hi</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s decrease wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s primarily due to a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39.2&#160;million, or 24.6%, decrease </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in RITUXAN revenue, partially offset by a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$34.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in royalty revenue on sales of OCREVUS. Sales of RITUXAN have been a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dversely affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $97.9 million for the second quarter of 2022, representing a $1.1 million, or 1.1%, decrease compared to $99.0 million in the same period in 2021.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $1,319.6 million for the second quarter of 2022, representing a $873.3 million, or 39.8%, decrease compared to $2,192.9 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in amortization and impairment of acquired intangible assets is primarily due to impairment charges recorded during the three months ended June 30, 2021 totaling $541.6&#160;million.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.27pt">Other (income) expense, net for the second quarter of 2022 reflected a pre-tax gain of approximately $1.5&#160;billion related to the sale of our 49.9%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity interest in Samsung Bioepis, partially offset by a pre-tax charge of $900.0&#160;million related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $898.3 million of net cash flow from operations for the six months ended June 30, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $5,900.8 million as of June 30, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 2.4&#160;million shares of our common stock at a cost of approximately $500.0&#160;million during the second quarter of 2022 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common stock (2020 Share Repurchase Program). Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative and other relationships discussed below, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash at closing and expect to receive approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.3&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash to be deferred over two payments of approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $812.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the first anniversary and approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $437.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the second anniversary of the closing of the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Eisai Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of June 30, 2022, Eisai's portion of these expenses was approximately $275.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022 we extended our supply agreement related to lecanemab from 5 years to 10 years, and we will manufacture the lecanemab drug substance.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our 2022 cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3, Restructuring, Business Transformation and Other Cost Saving Initiatives</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB125 (zuranolone)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022 we and our collaboration partner Sage Therapeutics, Inc. (Sage) initiated a rolling submission of a New Drug Application (NDA) to the FDA for BIIB125 (zuranolone) for the potential treatment of major depressive disorder (MDD). We have submitted the nonclinical module of the NDA to the FDA and plan to submit the remaining components for the MDD filing in the second half of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 we and Sage announced that the Phase 3 SKYLARK Study of zuranolone, which is being evaluated in women with postpartum depression, met its primary and all key secondary endpoints. Subsequently, we decided to submit a single NDA seeking approval of zuranolone for the treatment of both MDD and PPD. We expect to complete the submission of this single NDA in the second half of 2022, and to seek priority review of the filing.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022 we and our collaboration partner Eisai announced the completed submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab, an anti-amyloid antibody candidate for the potential treatment of Alzheimer's disease. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mosunetuzumab</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 our collaboration partner Genentech announced that mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas, was approved in the E.U.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July Genentech announced that the FDA accepted the company's BLA and granted Priority Review for mosunetuzumab, with a PDUFA action date of December 29, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,160.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,589.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,775.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(185.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(107.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,351.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,121.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(326.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,120.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,469.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(348.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(133.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,121.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(326.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20220630_g2.jpg" alt="biib-20220630_g2.jpg" style="height:549px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. During the fourth quarter of 2021 VUMERITY was approved for the treatment of relapsing-remitting MS (RRMS) in the E.U., Switzerland and the United Kingdom (U.K.).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases of 6.9% and 2.4%, respectively, in U.S. Fumarate revenue were primarily due to decreases in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market, partially offset by favorable pricing for TECFIDERA driven by discounts and allowances and increases in VUMERITY sales volumes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the  decreases of 8.2% and 7.4%, respectively, in rest of world Fumarate revenue were primarily due to TECFIDERA pricing reductions in certain European countries, the unfavorable impact of foreign currency </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange and decreases in TECFIDERA demand as multiple TECFIDERA generic entrants entered into markets such as Germany and Canada.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 U.S. federal courts in West Virginia and Delaware entered judgments in favor of the defendants in patent infringement proceedings relating to TECFIDERA Orange-Book listed patents. We appealed both decisions. In late 2021 the Federal Circuit affirmed the judgment of the West Virginia federal court. The appeals in the actions in Delaware are stayed pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our U.S. TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021 the European General Court annulled the EMA's decision not to validate applications for approval of TECFIDERA generics on the basis that the EMA conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021 the CHMP of the EMA issued an ad hoc opinion referencing the General Court&#8217;s decision which concluded that "the totality of the available data cannot establish that [monoethyl fumarate] exerts a clinically relevant therapeutic contribution within FUMADERM," and in May 2022 the EC approved applications to market generic TECFIDERA. Generic TECFIDERA is now for sale in the E.U. and we expect generic sales to have an adverse impact on our TECFIDERA sales in the E.U. and our results of operations. In June 2022 the European Patent Office granted Biogen a patent that relates to TECFIDERA and expires in 2028. We intend to enforce this new patent.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that TECFIDERA revenue will continue to decline in 2022, compared to 2021, as a result of generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volumes in 2022, compared to 2021, mostly due to demand growth in the U.S. and 14 other markets. We are currently working with our contract manufacturing suppliers to address potential supply constraints and have therefore delayed any additional country launches.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20220630_g3.jpg" alt="biib-20220630_g3.jpg" style="height:525px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases of 17.9% and 21.2%, respectively, in U.S. Interferon revenue were primarily due to decreases in Interferon sales volumes of 15.5% and 15.1%, respectively, and decreases in pricing of 2.4% and 6.1%, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the decrease of 2.8% in rest of world Interferon revenue was primarily due to the unfavorable impact of foreign currency exchange. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the decrease of 11.7% was primarily due to decreases in Interferon sales volumes resulting from the continued decline of the Interferon market, unfavorable pricing and the unfavorable impact of foreign currency exchange.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2022, compared to 2021, as a result of increasing competition from other MS products, including biosimilars, and further pricing reductions in certain European markets.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20220630_g4.jpg" alt="biib-20220630_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the decrease of 2.6% in U.S. TYSABRI revenue was primarily due to a decrease in sales volumes, partially offset by an increase in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, U.S. TYSABRI revenue remained flat.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, rest of world TYSABRI revenue remained flat.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI revenue to be relatively flat on a global basis in 2022, compared to 2021, despite increasing competition from additional treatments for MS. We expect to continue to face price reductions in certain European markets. We are also aware of a potential biosimilar entrant of TYSABRI that may enter the market as early as 2023.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20220630_g5.jpg" alt="biib-20220630_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the decrease of 6.4% in U.S. SPINRAZA revenue was primarily due to a decrease in sales volumes resulting from increased competition and unfavorable pricing driven by higher rebates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the increase of 1.7% in U.S. SPINRAZA revenue was primarily due to an increase in sales volumes resulting from favorable channel dynamics in the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases of 16.9% for both periods in rest of world SPINRAZA revenue were primarily due to decreases in pricing of 7.3% and 6.8%, respectively, and decreases in sales volumes of 4.7% and 4.9%, respectively, resulting from increased competition in certain established markets, particularly Germany, and the timing of shipments, as well as the unfavorable impact of foreign currency exchange. The decreases were partially offset by sales volume growth in certain Asian markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. In 2022 we expect that SPINRAZA revenue will be subject to increased competition likely resulting in continued patient discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alzheimer's Disease</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM</span></div><div style="margin-top:6pt"><img src="biib-20220630_g6.jpg" alt="biib-20220630_g6.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI, FLIXABI and BYOOVIZ</span></div><div><img src="biib-20220630_g7.jpg" alt="biib-20220630_g7.jpg" style="height:600px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 BYOOVIZ, a biosimilar referencing LUCENTIS, was approved in the U.S., the E.U. and the U.K. BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022 through major distributors in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases of 4.0% and 4.6%, respectively, in biosimilar revenue were primarily due to decreases in pricing in certain markets and the unfavorable impact of foreign currency exchange, partially offset by increases in sales volumes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate a slight decline in revenue from our biosimilars business in 2022, despite the launch of BYOOVIZ in the U.S., and an anticipated modest </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in sales volumes as we continue to face price reductions in certain markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_148"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20220630_g8.jpg" alt="biib-20220630_g8.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,105.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">953.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n U.S.&#160;product revenue, net were primarily due to decreases in sales volumes of RITUXAN in the U.S. of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.9%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.6%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, primarily due to the onset of competition from multiple biosimilar products</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and decreases in GAZYVA sales volumes of 4.0% and 3.8%, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same pe</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">riods in 2021, the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in collaboration costs and expense were primarily due </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to lower cost of sales, selling and marketing expense and distribution costs related to RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets. Biosimilar products referencing RITUXAN have launched in the U.S. and are being offered at lower prices. This </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, compared to the same periods in 2021, the increases in other revenue from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue recognized on sales of OCREVUS for the three and six months ended June 30, 2022, totaled $291.8 million and $544.1&#160;million, respectively, compared to $257.0&#160;million and $466.3&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20220630_g9.jpg" alt="biib-20220630_g9.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in other corporate revenue were primarily due to lower contract manufacturing revenue related to the timing of batch releases.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_154"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20220630_g10.jpg" alt="biib-20220630_g10.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, reserves for discounts and allowances as a percentage of gross product revenue were 29.2% and 28.1%, respectively, compared to 29.2% and 28.6%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in discounts were primarily driven by decreases in gross sales.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases in contractual adjustments were primarily driven by lower TECFIDERA sales in the U.S., resulting in lower pharmacy rebates, Medicaid rebates and managed care rebates, as well as lower Medicaid rebates in the U.S. driven by a favorable change in estimates for VUMERITY.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(536.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(428.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,192.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(873.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,207.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(567.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(264.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(575.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,504.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,419.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(915.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220630_g11.jpg" alt="biib-20220630_g11.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the increase in product cost of sales was primarily due to product mix and higher cost of sales associated with contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the increase in product cost of sales was primarily due to the write-off of ADUHELM inventory during the first quarter of 2022. During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges. We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the six months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 we recorded approximately $72.0&#160;million of gross idle capacity charges. We have recognized approximately $32.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the six months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases in royalty cost of sales were primarily due to lower royalties payable on lower sales of SPINRAZA, TYSABRI and AVONEX, partially offset by higher royalties payable on higher sales of VUME</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RITY.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="iae1758f0b07f4108915caecfff327c7a_163"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20220630_g12.jpg" alt="biib-20220630_g12.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20220630_g13.jpg" alt="biib-20220630_g13.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the decrease in research and development expense was primarily due to higher milestone payments in 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the decrease in research and development expense was primarily due to higher milestone payments in 2021, partially offset by an increase in spending related to lecanemab, the advancement of BIIB059 (anti-BDCA2) for the potential treatment of systemic lupus erytheatosus (SLE), the development of mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage, the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali Therapeutics Inc. (Denali), and the development of BIIB135 (orelabrutinib) for the potential treatment of MS.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we recorded significant upfront payments related to our new collaborations as part of research and development expense. Excluding upfront payments, we expect our core research and development expense in 2022 to be consistent with 2021 as we continue to invest in our pipeline. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases in spending related to our early stage programs were primarily due to decreases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB112 (cotoretigene toliparvovec) in X-linked retinitis pigmentosa; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by increases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB122 for the potential treatment of Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB135 for the potential treatment of MS; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB059 for the potential treatment of cutaneous lupus erythematosus (CLE).</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, compared to the same period in 2021, the increase in spending associated with our late stage programs was primarily due to an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the increase in spending related to lecanemab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was partially offset by a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the decrease in spending associated with our late stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to lecanemab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to mosunetuzumab.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketed Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the increases in spending associated with our marketed programs were primarily due to increases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of lecanemab in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. In July 2022 Eisai completed the submission of a BLA to the FDA for the accelerated approval of lecanemab.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had approximately $71.5&#160;million of work-in-process inventory related to lecanemab. We plan to continue producing inventory and are also procuring raw materials associated with this production. If the lecanemab Phase 3 study receives a negative readout, or if the program does not receive regulatory approval, we would expect to expense inventory on hand at that time as research and development expense and, under the terms of the collaboration arrangement with Eisai to jointly develop and commercialize lecanemab, we and Eisai would share the costs equally.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_166"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20220630_g14.jpg" alt="biib-20220630_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, selling, general and administrative expense decreased by approximately 10.2% and 2.0%, respectively, primarily due cost-reduction measures realized during 2022, partially offset by gross ADUHELM commercialization expense of approximately $27.0&#160;million and $107.0&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021 reimbursement from Eisai for its share of U.S. ADUHELM selling, general and administrative expense is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 we expect selling, general and administrative costs to decline versus 2021 primarily driven by the implementation of our cost savings initiatives, which include the substantial elimination of our commercial infrastructure supporting ADUHELM as well as other cost-reduction measures.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="iae1758f0b07f4108915caecfff327c7a_169"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220630_g15.jpg" alt="biib-20220630_g15.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the decreases in amortization and impairment of acquired intangible assets were primarily related to impairment charges recorded in 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment charges.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million impairment charge related to BIIB111 for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the carrying value associated with the remaining IPR&amp;D intangible asset </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $119.2&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial or sooner if there is a reevaluation event and may record an impairment charge related to this asset.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $365.0&#160;million to $15.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $191.6&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $220.0&#160;million to $28.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized additional impairment charges related to BIIB111 and BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to zero.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20220630_g16.jpg" alt="biib-20220630_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expense in the U.S. related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized net profit-sharing expense of $58.3 million and $122.7 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to a net profit-sharing expense of $69.9 million and $138.4 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$28.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$210.6&#160;million, respectively, to refl</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ect Eisai's 45.0% share of net collaboration losses in the U.S., compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.1&#160;million in each of the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and six months ended June 30, 2021, we also recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.0%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $100.0&#160;million milestone payment made to Neurimmune related to the launch of ADUHELM in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="iae1758f0b07f4108915caecfff327c7a_178"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20220630_g17.jpg" alt="biib-20220630_g17.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, changes in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charges</span></div><div><img src="biib-20220630_g18.jpg" alt="biib-20220630_g18.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzY0_3aba3de6-061c-4a43-afe8-91099cc65ac5">130.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4Xzcw_adfdb999-8023-47f3-8d78-db4bff8c327c">150.0</ix:nonFraction>&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1ODE_1b9b5b52-58c0-48b1-9ef9-8316c4af4235">70.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1ODk_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c">108.7</ix:nonFraction> million, respectively, of pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1OTg_21d50c17-f0a6-4ace-90f3-ab7ef4d352ee">60.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI2MDY_341b08c3-780a-4968-aaf4-d3cfe99ac21a">88.6</ix:nonFraction>&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the six months ended June 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE5MA_7bb2cdc5-cf4f-4328-a374-1717a053fd8f">10.4</ix:nonFraction>&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recorded other restructuring costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzEwOTk1MTE2Mjg1NDQ_69606ba6-a436-46d1-bb6b-26336d96b45f"><ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzEwOTk1MTE2Mjg1NDQ_c1bdf8b4-5d16-4ece-9b61-9b14d616a3bd">9.7</ix:nonFraction></ix:nonFraction>&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs includes items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div><img src="biib-20220630_g19.jpg" alt="biib-20220630_g19.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the changes in other (income) expense, net primarily reflect a pre-tax gain of approximately $1.5&#160;billion related to the sale of our 49.9%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity interest in Samsung Bioepis during the second quarter of 2022, partially offset by a pre-tax charge in connection with a litigation agreement in principle, as discussed below.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In the period paid, the settlement amount plus all related fees and expenses will have a material adverse impact on our cash flow. For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, net unrealized losses and realized losses on our holdings in equity securities were approximately $76.5 million and $0.7 million, respectively, compared to net unrealized gains and realized gains of approximately $153.9 million and $0.4 million, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo Therapeutics, Inc. (Sangamo) and Denali common stock of approximately $75.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, net unrealized losses and realized losses on our holdings in equity securities were approximately $267.4 million and $0.5 million, respectively, compared to net unrealized losses and realized gains of $288.4 million </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $6.6 million, respectively, in the prior year comparative period. The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_190"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax Provision</span></div><div><img src="biib-20220630_g20.jpg" alt="biib-20220630_g20.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the increases in our effective tax rate were primarily due to the overall current year unfavorable tax rate impact </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the sale of our equity interest in Samsung Bioepis in April 2022, the litigation agreement in principle and the tax benefit recorded in the second quarter of 2021 related to the Neurimmune SubOne AG (Neurimmune) deferred tax asset matter, as discussed below. These effective tax rate increases were partially offset by the non-cash tax effects of changes in the value of our equity instruments and the current year tax benefits recorded in the second quarter of 2022 related to an international reorganization to align with global tax developments. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, our effective tax rate also increased as a result of the Neurimmune valuation allowance recorded in the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 15, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="iae1758f0b07f4108915caecfff327c7a_193"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20220630_g21.jpg" alt="biib-20220630_g21.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. We recognized amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized net income on our investment of $5.9 million and $2.6 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $13.0&#160;million and $17.0&#160;million, respectively, offset by amortization of basis differences totaling $7.1&#160;million and $14.4&#160;million, respectively. These amounts reflect our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating income, net of tax totaling $41.6&#160;million and $30.6&#160;million, respectively, and amortization of basis </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences totaling $7.3&#160;million and $14.5&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_196"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests, Net of Tax</span></div><div><img src="biib-20220630_g22.jpg" alt="biib-20220630_g22.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of our variable interest entity, Neurimmune, as we determined that we are the primary beneficiary.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the changes in net income (loss) attributable to noncontrolling interests, net of tax were primarily due to a deferred tax benefit recorded in the second quarter of 2021, as discussed below.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a deferred tax benefit associated with the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $490.0&#160;million related to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interest, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded a valuation allowance of approximately $85.0&#160;million related to this deferred tax asset. There is an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, the changes in net income (loss) attributable to noncontrolling interests, net of tax were also due to the $100.0&#160;million milestone payment to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 15, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change&#160;%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,646.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,261.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,694.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,277.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,274.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,277.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,740.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,856.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,018.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,298.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,722.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,558.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="iae1758f0b07f4108915caecfff327c7a_202"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$990.3 million in net proceeds received from the sale of our equity interest in Samsung Bioepis;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$898.3 million in net cash flow provided by operating activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$500.0 million used for share repurchases; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$443.2&#160;million in total net payments for income taxes; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$94.8 million used for purchases of property, plant and equipment.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. and other markets will continue to reduce our cash flow from operations in 2022 and will have a significant adverse impact on our future cash flow from operations. During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. In the period paid, the settlement amount plus all related fees and expenses will have a material adverse impact on our cash flow. Additionally, in July 2022 we redeemed our 3.625% Senior Notes due September 15, 2022, with an aggregate principal amount of $1.0&#160;billion.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had cash, cash equivalents and marketable securities totaling approximately $5.9 billion compared to approximately </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.7 billion as of December 31, 2021. The change in cash, cash equivalents and marketable securities at June 30, 2022, from December 31, 2021, was primarily due to proceeds received from the sale of our equity interest in Samsung Bioepis and net cash flow provided by operating activities, partially offset by share repurchases.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of December 31, 2021, include the carrying value of our investment in Samsung Bioepis of $599.9 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.0&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash at closing and expect to receive approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.3&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash to be deferred over two payments of approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $812.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the first anniversary and approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $437.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the second anniversary of the closing of the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. If any payments due to us remain outstanding after the second anniversary of the closing of the transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.088%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new facility is expected to be operational by the end of 2023, with an estimated total investment of approximately $200.0&#160;million. Construction for this new facility began during the fourth quarter of 2021.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$624.6&#160;million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7&#160;million aggregate principal amount of our 2051 Senior Notes and approximately $151.8&#160;million of aggregate cash payments; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$8.9&#160;million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1&#160;million of aggregate cash payments, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of June 30, 2022 and December 31, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of June 30, 2022 and December 31, 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Working capital was $4.7 billion and $3.6 billion as of June 30, 2022 and December 31, 2021, respectively. The change in working capital reflects an increase in total current assets of approximately $1,884.4 million and a increase in total current liabilities of approximately $719.8 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total current assets was primarily driven by the receipt of approximately $990.3 million in cash, net of expenses, and the recording of a receivable from Samsung BioLogics for approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$788.1 million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as part of the sale of our equity interest in Samsung Bioepis in the second quarter of 2022.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in current liabilities was primarily due to an increase in accrued expense and other resulting from a pre-tax charge of $900.0&#160;million in connection with a litigation agreement in principle reached during the second quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.4&#160;million shares of our common stock at a cost of approximately $500.0&#160;million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately 1.6&#160;million and 3.8&#160;million shares of our common stock at a cost of approximately $450.0&#160;million and $1.1&#160;billion, respectively. Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_205"></div></div></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,996.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(488.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,349.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the decrease in net cash flow provided by operating activities was primarily due to to lower net income in 2022, timing of payments and higher net income tax payments in 2022 as compared to the same period in 2021.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the increase in net cash flow provided by investing activities was primarily due to proceeds received from the sale of our equity interest in Samsung Bioepis of $<ix:nonFraction unitRef="usd" contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMDUvZnJhZzphMzIwOWQwNjZhODU0MTM0OGJjMjkwYzMzODJhNzA3OS90ZXh0cmVnaW9uOmEzMjA5ZDA2NmE4NTQxMzQ4YmMyOTBjMzM4MmE3MDc5XzI3NDg3NzkwNzM0MDc_8c256366-aac8-4f94-b33c-c92b6e9919f7">990.3</ix:nonFraction> </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, net of expenses, during the second quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared to the same period in 2021, the decrease in net cash flow used in financing activities was primarily due to a greater number of shares repurchased in 2021 as compared to the comparative period in 2022. Additionally, we executed our Exchange Offer in the first quarter of 2021, which resulted in net cash outflows of $170.0&#160;million.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_208"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. During the fourth quarter of 2021 VUMERITY was approved for the treatment of RRMS in the E.U., Switzerland and the U.K. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net sales of VUMERITY using a royalty rate of 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of June 30, 2022, we could trigger potential future milestone payments to third parties of up to approximately $9.6 billion, including approximately $1.9 billion in development milestones, approximately $0.8 million in regulatory milestones and approximately $6.9 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of June 30, 2022, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $39.7&#160;million in milestones in 2022 under our current agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Tabl</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">e of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $18.8 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of June 30, 2022. We have approximately $986.5 million in cancellable future commitments based on existing CRO contracts as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of June 30, 2022, we have approximately $104.7 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we have accrued income tax liabilities of approximately $558.0&#160;million and $633.0&#160;million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of June 30, 2022, approximately $137.8&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_211"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_214"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2021 Form&#160;10-K.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_217"></div><div style="margin-top:14pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic and the conflict in Ukraine. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of June 30, 2022, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense transactions denominated in foreign currencies in the next 15 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of June 30, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $245.5 million and $333.1 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program was designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of June 30, 2022 and December 31, 2021, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $9.9 million and $14.3 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the COVID-19 pandemic and the conflict in Ukraine, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of June 30, 2022 and December 31, 2021.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Price Risk</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of June 30, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $78.6&#160;million and $104.8&#160;million, respectively.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_220"></div><div style="margin-top:12pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of June 30, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="iae1758f0b07f4108915caecfff327c7a_226"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of June 30, 2022, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_229"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM in the U.S. In addition to risks associated with new products and the other factors described in these Risk Factors, our ability to successfully commercialize ADUHELM may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">concern regarding the accelerated approval of ADUHELM and its data;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain reimbursement for ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the final NCD by CMS for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of market acceptance of ADUHELM.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third-parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third-parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our former joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third-parties over whom we have limited or no control in the development and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing of biosimilars products. If these third-parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. For example, as part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:4pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. The COVID-19 pandemic has caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with a number of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches of our technology systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability, negatively impact our business operations, and/or require replacement of technology and/or ransom payments. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, when they impact vendors, customers or companies, including vendors, suppliers and other companies in our supply chain. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with careless or malicious intent. Geopolitical instability, including that related to Russia's invasion of Ukraine may increase cyber-attacks. Cyber-attacks include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information. Regulators are considering new cyber security regulations. For example, the SEC has proposed amendments to its disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These proposed regulations may impact the manner in which we operate. Failure to comply with new laws may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and other personnel changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management (including our CEO), other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more marketed or late stage programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing internationally;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for ADUHELM, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates including VUMERITY. In some cases, due to the unique manner in which our products are manufactured, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. Furthermore, factors such as the COVID-19 pandemic, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has and could continue to be adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments have implemented and may continue to implement safety precautions. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. Customer-facing professionals interactions in healthcare settings have changed as a result of the COVID-19 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in flexible working arrangements could impact employee retention, employees' productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third-parties we rely on. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third-parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue our existing clinical trials or to initiate new clinical trials has been and may continue to be adversely affected, directly or indirectly, by the COVID-19 pandemic. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, legislation has been enacted aimed at providing emergency assistance and health care for individuals, families and businesses and broadly supporting the U.S. economy. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures and have a financial impact on our business that we cannot predict.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will continue to have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, supply chain and distribution systems, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including in-process research and development (IPR&amp;D) and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, recurring charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings (including those related to the impact of the Tax Cuts and Jobs Act of 2017), adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the second quarter of 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900,000&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.27&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900,000&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,606.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535,074&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.51&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535,074&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435,074&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.33&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.4&#160;million shares of our common stock at a cost of approximately $500.0&#160;million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately 1.6&#160;million and 3.8&#160;million shares of our common stock at a cost of approximately $450.0&#160;million and $1.1&#160;billion, respectively. Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="iae1758f0b07f4108915caecfff327c7a_238"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504522000013/exhibit101letteragreement.htm">Letter regarding employment arrangement of Michel Vounatsos dated May 2, 2022. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022630xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022630xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022630xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="iae1758f0b07f4108915caecfff327c7a_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iae1758f0b07f4108915caecfff327c7a_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July&#160;20, 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2022630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e37d5986043464c813a0b4fcf2d079a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 20, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2022630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0638c85a844847ab92f6a387087febee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 20, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2022630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib703c53dc7584245a072b98edd24f7ba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 20, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 20, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>2410404 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2414408 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>2415409 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2116104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2317303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>2418410 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>2419411 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2120105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2124106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2325305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2426414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2427415 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2429417 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2430418 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2131107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2332306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2433419 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2434420 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2435421 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2436422 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2437423 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2139108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2340307 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2441425 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>2142109 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2443426 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2144110 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2445427 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2146111 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2347308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2448428 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2449429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2450430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2151112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2352309 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2453431 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2154113 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2355310 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2456432 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2457433 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2158114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2359311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2460434 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2461435 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2162115 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2363312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2464436 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2465437 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2166116 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2367313 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2468438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2469439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2170117 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2471440 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2172118 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2473441 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2174119 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>2175120 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>2476442 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentAssetDomain" abstract="true" name="ResearchAndDevelopmentAssetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AccruedMilestonePayments" abstract="false" name="AccruedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" abstract="false" name="PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationInternationalReorganization" abstract="false" name="EffectiveTaxRateReconciliationInternationalReorganization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationLitigationAgreement" abstract="false" name="EffectiveTaxRateReconciliationLitigationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" abstract="false" name="EffectiveTaxRateReconciliationSaleOfSamsungBioepis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherAssetsFairValueMeasurementInput" abstract="false" name="OtherAssetsFairValueMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_WorkforceReductionMember" abstract="true" name="WorkforceReductionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CostOfGoodsSoldCapacityCharges" abstract="false" name="CostOfGoodsSoldCapacityCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DiscreteIncomeTaxExpenseBenefit" abstract="false" name="DiscreteIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CentersForMedicareAndMedicaidServiceMember" abstract="true" name="CentersForMedicareAndMedicaidServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InnoCarePharmaLimitedInnoCareAgreementMember" abstract="true" name="InnoCarePharmaLimitedInnoCareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContingentMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="ContingentMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionRate" abstract="false" name="DebtInstrumentRedemptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LecanemabMember" abstract="true" name="LecanemabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BIIB111AndBIIB112Member" abstract="true" name="BIIB111AndBIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ef4b89e-3505-4aaf-844b-d0a482fd988e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_846edc6a-9824-42bf-add4-226cc320b719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8ef4b89e-3505-4aaf-844b-d0a482fd988e" xlink:to="loc_us-gaap_ProfitLoss_846edc6a-9824-42bf-add4-226cc320b719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_46a6ffb4-c0f4-49b0-9ebb-142d13838bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8ef4b89e-3505-4aaf-844b-d0a482fd988e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_46a6ffb4-c0f4-49b0-9ebb-142d13838bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_371c3da8-cdb6-487e-b546-dd008ec54b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_371c3da8-cdb6-487e-b546-dd008ec54b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_458e184f-368c-4ff3-95cb-c34d0be4c3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_458e184f-368c-4ff3-95cb-c34d0be4c3ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d3095492-4a61-4239-aaac-710604d08b96" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d3095492-4a61-4239-aaac-710604d08b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_cc7997f9-ac92-42f5-b53b-6bff747c7a49" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_biib_Collaborationprofitlosssharing_cc7997f9-ac92-42f5-b53b-6bff747c7a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_e10b4899-7c4d-4d50-bc42-d53c99b07449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_e10b4899-7c4d-4d50-bc42-d53c99b07449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c64430ad-803f-4b4e-a1a7-345ef379b049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c64430ad-803f-4b4e-a1a7-345ef379b049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e8ac2209-2454-4ded-93ca-1fbf80dd0546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e8ac2209-2454-4ded-93ca-1fbf80dd0546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9964c2ec-352d-4593-abab-8f7a1720985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9964c2ec-352d-4593-abab-8f7a1720985a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_af1b8094-648c-4ccd-8853-8ecd4aa3ed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4cf9795e-b9d8-4909-a7ea-cf535148d65c" xlink:to="loc_us-gaap_RestructuringCharges_af1b8094-648c-4ccd-8853-8ecd4aa3ed0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47c53eeb-7f74-4ae4-bc03-d227a57dabbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e458c170-a35d-4b24-8c75-b3c5cb8662d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47c53eeb-7f74-4ae4-bc03-d227a57dabbd" xlink:to="loc_us-gaap_Revenues_e458c170-a35d-4b24-8c75-b3c5cb8662d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3f1130a7-6806-4fa2-a567-d31842f09d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47c53eeb-7f74-4ae4-bc03-d227a57dabbd" xlink:to="loc_us-gaap_CostsAndExpenses_3f1130a7-6806-4fa2-a567-d31842f09d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1f4b3ec4-57ec-4db8-a018-64a6bf98b68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f03262fe-0ace-42a6-b68e-f7b1ad417f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1f4b3ec4-57ec-4db8-a018-64a6bf98b68e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f03262fe-0ace-42a6-b68e-f7b1ad417f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72961a00-ca71-423f-ae67-d111c861e9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1f4b3ec4-57ec-4db8-a018-64a6bf98b68e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72961a00-ca71-423f-ae67-d111c861e9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_cb1196c1-3c68-41df-ae37-987460f90efe" xlink:href="biib-20220630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1f4b3ec4-57ec-4db8-a018-64a6bf98b68e" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_cb1196c1-3c68-41df-ae37-987460f90efe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3931767-a319-40a5-bb4f-65a384ebeb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_82dc0fb6-3bd0-4755-a46a-5c87d9b2f512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3931767-a319-40a5-bb4f-65a384ebeb75" xlink:to="loc_us-gaap_NetIncomeLoss_82dc0fb6-3bd0-4755-a46a-5c87d9b2f512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5bee769e-33a2-494c-8a74-3261a9f79204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3931767-a319-40a5-bb4f-65a384ebeb75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5bee769e-33a2-494c-8a74-3261a9f79204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d06fd249-ab21-45b2-a84d-c58d7b027d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d06fd249-ab21-45b2-a84d-c58d7b027d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_07cbf7e0-e4b7-46db-ac3c-6057bccb1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_07cbf7e0-e4b7-46db-ac3c-6057bccb1e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_37f8e464-b9eb-4817-9d53-afce9268bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_37f8e464-b9eb-4817-9d53-afce9268bab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b2026f0a-f905-42c4-a953-c9f29647a41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b2026f0a-f905-42c4-a953-c9f29647a41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a1c1ce7d-8fc7-4c76-b26f-806cd8f020c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f0fe3472-b277-49ea-aa5e-3d099cfacaad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a1c1ce7d-8fc7-4c76-b26f-806cd8f020c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e21a7dc0-b7b5-40e4-94b9-1d3d88460e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea0f27a4-c6da-4040-bfa2-3363a90156a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e21a7dc0-b7b5-40e4-94b9-1d3d88460e25" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea0f27a4-c6da-4040-bfa2-3363a90156a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cc41821d-eefd-44a5-83fd-e70cc494f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e21a7dc0-b7b5-40e4-94b9-1d3d88460e25" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cc41821d-eefd-44a5-83fd-e70cc494f196" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18a1e831-69d7-40e5-b015-9a71fcfb2fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18a1e831-69d7-40e5-b015-9a71fcfb2fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c54cbf69-ca62-49a9-8958-0f5939f6105a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c54cbf69-ca62-49a9-8958-0f5939f6105a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_33d9c82a-4a5d-4c93-af76-7f1f21f0eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_33d9c82a-4a5d-4c93-af76-7f1f21f0eef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_1e9c5418-0b13-4b84-a24f-b1af28025c1d" xlink:href="biib-20220630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_1e9c5418-0b13-4b84-a24f-b1af28025c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7cf398e3-dceb-456b-a08b-f34a51923629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_us-gaap_InventoryNet_7cf398e3-dceb-456b-a08b-f34a51923629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a8924753-48f0-4111-aff8-861191705302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_78a50b8b-db38-411c-86cb-27a973ee8c7d" xlink:to="loc_us-gaap_OtherAssetsCurrent_a8924753-48f0-4111-aff8-861191705302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_74d03528-6869-4fd5-aee0-49e917a037c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_AssetsCurrent_74d03528-6869-4fd5-aee0-49e917a037c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7aa05549-35e2-41ef-821a-47414e53ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7aa05549-35e2-41ef-821a-47414e53ddb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4679e760-3814-4075-a135-7f4ed790ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4679e760-3814-4075-a135-7f4ed790ff0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_90adf904-2aa6-4cc7-9529-cac87611a68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_90adf904-2aa6-4cc7-9529-cac87611a68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_de223959-9c61-4cf1-93a9-ad764c6844ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_de223959-9c61-4cf1-93a9-ad764c6844ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_08dd3c03-44bc-43d3-adae-7a9408f1e898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_Goodwill_08dd3c03-44bc-43d3-adae-7a9408f1e898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6da8528f-8613-4932-8aed-3051977696dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6da8528f-8613-4932-8aed-3051977696dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f7458a6f-fb9d-4e36-8edd-479790c51823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_179203d7-c412-4ec0-b3ed-4e37db707c33" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f7458a6f-fb9d-4e36-8edd-479790c51823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a17ee0a-b10d-4a0c-bde4-5c78b7b9cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e43f08c-24da-420b-b8b0-5e73b732fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a17ee0a-b10d-4a0c-bde4-5c78b7b9cbc1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e43f08c-24da-420b-b8b0-5e73b732fa93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17d22e78-846d-4d88-a868-4e5e7767879c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a17ee0a-b10d-4a0c-bde4-5c78b7b9cbc1" xlink:to="loc_us-gaap_Liabilities_17d22e78-846d-4d88-a868-4e5e7767879c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cdbe052c-539e-4239-a0bf-e4cab2c9aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a17ee0a-b10d-4a0c-bde4-5c78b7b9cbc1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cdbe052c-539e-4239-a0bf-e4cab2c9aacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_79665efa-86f9-4686-9c98-0280ae1485f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2dea847b-1dd7-41c0-8fea-602911674975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79665efa-86f9-4686-9c98-0280ae1485f8" xlink:to="loc_us-gaap_AccountsPayableCurrent_2dea847b-1dd7-41c0-8fea-602911674975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_b33517bc-ece2-44d3-a33c-a8196e46acae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79665efa-86f9-4686-9c98-0280ae1485f8" xlink:to="loc_us-gaap_TaxesPayableCurrent_b33517bc-ece2-44d3-a33c-a8196e46acae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c5c73deb-1440-4a14-99dc-a7e910aa004b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79665efa-86f9-4686-9c98-0280ae1485f8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c5c73deb-1440-4a14-99dc-a7e910aa004b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_2015b289-6d57-484f-8a80-208aef2bcfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79665efa-86f9-4686-9c98-0280ae1485f8" xlink:to="loc_us-gaap_NotesPayableCurrent_2015b289-6d57-484f-8a80-208aef2bcfad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63be1915-e3e5-4e0a-82c2-e18f943f1f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c928cc2d-f0ec-466c-b6c0-51021092d785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63be1915-e3e5-4e0a-82c2-e18f943f1f4a" xlink:to="loc_us-gaap_StockholdersEquity_c928cc2d-f0ec-466c-b6c0-51021092d785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9f955add-5857-4900-80d2-0fdef75c6629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63be1915-e3e5-4e0a-82c2-e18f943f1f4a" xlink:to="loc_us-gaap_MinorityInterest_9f955add-5857-4900-80d2-0fdef75c6629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_53c52bca-db01-4e0d-bfca-122b690342ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:to="loc_us-gaap_LiabilitiesCurrent_53c52bca-db01-4e0d-bfca-122b690342ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d1e32d7f-1716-4f28-b0c2-63b28ae56898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:to="loc_us-gaap_LongTermDebt_d1e32d7f-1716-4f28-b0c2-63b28ae56898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6111d1a1-07fd-4175-99b1-dc47f01fb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6111d1a1-07fd-4175-99b1-dc47f01fb0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3ce6a38-f400-413d-8ee9-590ab3206ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3ce6a38-f400-413d-8ee9-590ab3206ecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5592a4c3-7e9a-4a07-a559-1b8d734e28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4b68c68-0576-430b-81eb-352bb21b64a8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5592a4c3-7e9a-4a07-a559-1b8d734e28c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_43e2a152-1235-451f-977b-ec087c997a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_PreferredStockValue_43e2a152-1235-451f-977b-ec087c997a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e48462bd-b858-426f-8fee-dcf784ac00d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_CommonStockValue_e48462bd-b858-426f-8fee-dcf784ac00d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_713485a6-de8b-44c0-bbb3-ca12534b4ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_713485a6-de8b-44c0-bbb3-ca12534b4ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_baa8e4dd-c9f8-4918-bc0c-3e8ab50d246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_baa8e4dd-c9f8-4918-bc0c-3e8ab50d246f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1c824678-5572-4075-9fcb-08c5cc493ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1c824678-5572-4075-9fcb-08c5cc493ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_979d93a6-4a52-4b0d-9893-54da1201dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c9d499b-6671-4d0a-9a7f-06b6e056cbd4" xlink:to="loc_us-gaap_TreasuryStockValue_979d93a6-4a52-4b0d-9893-54da1201dd3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e7cdd90-6d1d-4067-ae90-e994f1c7cb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a32ef94f-8e66-421e-b872-c588a48669de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e7cdd90-6d1d-4067-ae90-e994f1c7cb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a32ef94f-8e66-421e-b872-c588a48669de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31c4bb02-cf2b-432e-9141-c9dc1ae299fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e7cdd90-6d1d-4067-ae90-e994f1c7cb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31c4bb02-cf2b-432e-9141-c9dc1ae299fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0e7548d-d383-4a68-b8f2-19fb5df7d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e7cdd90-6d1d-4067-ae90-e994f1c7cb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0e7548d-d383-4a68-b8f2-19fb5df7d80b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0ee30f2a-581e-46ab-906b-7ca7c9778ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0ee30f2a-581e-46ab-906b-7ca7c9778ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97385ce6-dadd-47ab-b0a5-59aeba5acd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97385ce6-dadd-47ab-b0a5-59aeba5acd9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db389be4-02e4-47b7-8829-517cce931761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db389be4-02e4-47b7-8829-517cce931761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_43eedf09-66e2-4e54-9d8d-c90c47193a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_43eedf09-66e2-4e54-9d8d-c90c47193a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_af4ee5ba-8f16-457d-abd1-8837feab7603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_af4ee5ba-8f16-457d-abd1-8837feab7603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ddfd8e01-b071-4e62-a760-d48311317785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ddfd8e01-b071-4e62-a760-d48311317785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_929ae39e-7f28-4a94-ad24-bf507397fa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_929ae39e-7f28-4a94-ad24-bf507397fa8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed1bee43-71a3-411d-be6a-b4a6087678fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_93c827a3-b98d-4f75-8a6d-3f8b126e5b87" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed1bee43-71a3-411d-be6a-b4a6087678fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_de05a2d9-274c-4957-957d-b1bbfea6e5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_de05a2d9-274c-4957-957d-b1bbfea6e5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4909210a-38fa-43e4-aebc-373f38aa1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4909210a-38fa-43e4-aebc-373f38aa1ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cec609e9-0503-4e96-bc39-29f3e9d1454d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_ShareBasedCompensation_cec609e9-0503-4e96-bc39-29f3e9d1454d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8e761242-f698-48d7-ad62-a70d46708350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8e761242-f698-48d7-ad62-a70d46708350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1f45779b-7a21-4a18-add9-ddc100300f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1f45779b-7a21-4a18-add9-ddc100300f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_85d2a385-ea44-4215-80b9-451b62bdb62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_85d2a385-ea44-4215-80b9-451b62bdb62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e2a3570b-a9ed-40f6-8866-296c7af0de30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_ProfitLoss_e2a3570b-a9ed-40f6-8866-296c7af0de30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7dcfe7a6-2c46-414c-9e99-e01fa6fd8702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7dcfe7a6-2c46-414c-9e99-e01fa6fd8702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67c1e649-8090-4b67-8516-a4bf21966dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_67c1e649-8090-4b67-8516-a4bf21966dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b1aeea06-b50e-4e17-b690-97f46ae08e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b1aeea06-b50e-4e17-b690-97f46ae08e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_92217300-8577-444b-b44e-a21630ee296f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_92217300-8577-444b-b44e-a21630ee296f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_7ba2e4a2-ab91-4974-9db7-652d6636cc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_7ba2e4a2-ab91-4974-9db7-652d6636cc2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3b2944a3-334e-4d0c-bd84-0eae735ff516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3b2944a3-334e-4d0c-bd84-0eae735ff516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_07406f83-f18f-4c65-82ff-1f99c2cdbffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_07406f83-f18f-4c65-82ff-1f99c2cdbffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_11d2c4e0-c404-4978-837b-0e7546f59b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_11d2c4e0-c404-4978-837b-0e7546f59b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0674da17-5cc9-415a-820d-786beafa4827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_InventoryWriteDown_0674da17-5cc9-415a-820d-786beafa4827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8e480c73-9316-43b5-9083-821820bc9825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8e480c73-9316-43b5-9083-821820bc9825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7ef5b7a4-6816-4795-a1ba-966f1b4e4733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e179f30-75f0-4e4e-b143-7e9397c61f0e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7ef5b7a4-6816-4795-a1ba-966f1b4e4733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fe14a9dc-b6b0-407a-999c-6ab6353c6189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fe14a9dc-b6b0-407a-999c-6ab6353c6189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f6a42784-3a93-469c-930a-8418f3dc9f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f6a42784-3a93-469c-930a-8418f3dc9f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_08e8b471-82cb-4884-9b0c-ffcf529e0448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_08e8b471-82cb-4884-9b0c-ffcf529e0448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3e4bfdd6-be8f-4023-bc57-8c1c0bc0f1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_3e4bfdd6-be8f-4023-bc57-8c1c0bc0f1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9e331e4f-890f-4ad5-8e6e-996eb907612a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b752f4fe-4c15-433b-80b4-faf3475d15ce" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9e331e4f-890f-4ad5-8e6e-996eb907612a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c482b0b-4cd2-4519-a61e-e74544610275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_3042227d-8baa-467b-93a9-7cbfd5b33116" xlink:href="biib-20220630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4c482b0b-4cd2-4519-a61e-e74544610275" xlink:to="loc_biib_ShareOfCoPromotionProfits_3042227d-8baa-467b-93a9-7cbfd5b33116" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_15b31f6e-bc89-4a53-8f8d-c3b558c3d609" xlink:href="biib-20220630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5e81e87c-78ae-4cd7-a2d2-f25b20fa3337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_15b31f6e-bc89-4a53-8f8d-c3b558c3d609" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5e81e87c-78ae-4cd7-a2d2-f25b20fa3337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_114302d7-0c93-42be-8380-1057f439a00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_15b31f6e-bc89-4a53-8f8d-c3b558c3d609" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_114302d7-0c93-42be-8380-1057f439a00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f974ea84-3457-4303-9232-022ea38007fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_15b31f6e-bc89-4a53-8f8d-c3b558c3d609" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f974ea84-3457-4303-9232-022ea38007fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39c54b16-8a37-48cc-b52f-43dd84765299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7e964460-38e4-4562-a059-cb24c54132e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39c54b16-8a37-48cc-b52f-43dd84765299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7e964460-38e4-4562-a059-cb24c54132e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c24d9a3c-52b8-467b-8000-7518b1938a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39c54b16-8a37-48cc-b52f-43dd84765299" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c24d9a3c-52b8-467b-8000-7518b1938a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81d8dee0-30a1-4eff-97ea-9464f95eab11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6472cca6-f080-4cad-94f2-2a720e7c9adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81d8dee0-30a1-4eff-97ea-9464f95eab11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6472cca6-f080-4cad-94f2-2a720e7c9adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b2a28e30-69bc-4def-b8c5-1a7efceb56f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81d8dee0-30a1-4eff-97ea-9464f95eab11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b2a28e30-69bc-4def-b8c5-1a7efceb56f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4f38d08d-ce17-4a43-a1e2-ccb1a5ef7175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb95f592-c02d-423d-95eb-e5f7edd6aeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f38d08d-ce17-4a43-a1e2-ccb1a5ef7175" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb95f592-c02d-423d-95eb-e5f7edd6aeb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_56cb4b34-a912-4457-8ad5-a9e0031931ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f38d08d-ce17-4a43-a1e2-ccb1a5ef7175" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_56cb4b34-a912-4457-8ad5-a9e0031931ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_565a2675-b5a5-4feb-8677-e819bc39dbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_91128e8b-c87b-47c8-a998-e5bbc51d1bc1" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_565a2675-b5a5-4feb-8677-e819bc39dbe3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_91128e8b-c87b-47c8-a998-e5bbc51d1bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2cf09e17-bd8c-4274-8c7c-82859fd38100" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_565a2675-b5a5-4feb-8677-e819bc39dbe3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_2cf09e17-bd8c-4274-8c7c-82859fd38100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_05b3c216-4bdd-43b9-b920-4432bcee0f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_565a2675-b5a5-4feb-8677-e819bc39dbe3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_05b3c216-4bdd-43b9-b920-4432bcee0f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7c3f3d-5608-46cd-931f-3b90a28ecf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c18f6304-833f-4b3b-a889-44dd9facc920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7c3f3d-5608-46cd-931f-3b90a28ecf32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c18f6304-833f-4b3b-a889-44dd9facc920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_68e70b63-927d-4ca3-a2a0-d05148f0530c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7c3f3d-5608-46cd-931f-3b90a28ecf32" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_68e70b63-927d-4ca3-a2a0-d05148f0530c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b04fb7c1-722a-411b-b1f4-22fff18ce9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7c3f3d-5608-46cd-931f-3b90a28ecf32" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b04fb7c1-722a-411b-b1f4-22fff18ce9cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9cbe05fc-0e9e-4a89-b09a-fe8d2af292c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a662ff85-6088-4333-afa8-2b3e25ca73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9cbe05fc-0e9e-4a89-b09a-fe8d2af292c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a662ff85-6088-4333-afa8-2b3e25ca73a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_53671cd3-9ecf-4229-bfe6-7d2ac90a1494" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9cbe05fc-0e9e-4a89-b09a-fe8d2af292c4" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_53671cd3-9ecf-4229-bfe6-7d2ac90a1494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_68c2ab72-6648-4737-845b-8bb5e73347ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9cbe05fc-0e9e-4a89-b09a-fe8d2af292c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_68c2ab72-6648-4737-845b-8bb5e73347ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0929df07-0ae0-4cf6-b3af-aec3ac2b6520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_de98300a-ee9f-47bd-be5b-232d44d56b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0929df07-0ae0-4cf6-b3af-aec3ac2b6520" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_de98300a-ee9f-47bd-be5b-232d44d56b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fce51f7-7684-439c-88d2-d3c8b6f08c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0929df07-0ae0-4cf6-b3af-aec3ac2b6520" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fce51f7-7684-439c-88d2-d3c8b6f08c0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_14e5b011-296a-4948-b449-df3722a9b7f2" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0929df07-0ae0-4cf6-b3af-aec3ac2b6520" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_14e5b011-296a-4948-b449-df3722a9b7f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44639a0f-08ff-4d95-b328-4cb841d02a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70eeae68-fb51-471e-923b-3ad5f8eab0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44639a0f-08ff-4d95-b328-4cb841d02a3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70eeae68-fb51-471e-923b-3ad5f8eab0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_cce10c3c-e064-40c3-a17a-49bb8af6385a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44639a0f-08ff-4d95-b328-4cb841d02a3d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_cce10c3c-e064-40c3-a17a-49bb8af6385a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e08fe788-c862-4314-842a-e0ba623e0e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_de39fcfe-31b0-4d8b-9d88-2436cf62b106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e08fe788-c862-4314-842a-e0ba623e0e55" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_de39fcfe-31b0-4d8b-9d88-2436cf62b106" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ae1a523e-3e22-4e9b-9436-d2e025eb3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_981c00a9-2894-4992-a580-535a68a19a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ae1a523e-3e22-4e9b-9436-d2e025eb3e09" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_981c00a9-2894-4992-a580-535a68a19a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_e6aa71c7-9b84-40aa-b314-aa445dd94362" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ae1a523e-3e22-4e9b-9436-d2e025eb3e09" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_e6aa71c7-9b84-40aa-b314-aa445dd94362" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_556bf1f0-151b-4ae7-854d-00fe7517f092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_556bf1f0-151b-4ae7-854d-00fe7517f092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_e47a903e-e76c-4bf4-9449-c362ecda5b25" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_e47a903e-e76c-4bf4-9449-c362ecda5b25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5626a092-c655-4260-995e-bf20a994bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5626a092-c655-4260-995e-bf20a994bf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_a8b97feb-4740-49db-a8f5-33847f9eda0d" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_a8b97feb-4740-49db-a8f5-33847f9eda0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_aba3ea5d-60fc-45c6-94dd-f2e7631ab940" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_aba3ea5d-60fc-45c6-94dd-f2e7631ab940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2fcab570-f70e-4bf9-9a23-2f3488a3170c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2fcab570-f70e-4bf9-9a23-2f3488a3170c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_de30a245-226c-408c-ad42-a33d4b035fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_de30a245-226c-408c-ad42-a33d4b035fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dd4da812-758a-4263-8516-d679da9206bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dd4da812-758a-4263-8516-d679da9206bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_b58a820b-63c5-4bdc-8f9d-ef6d5b1562f1" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_b58a820b-63c5-4bdc-8f9d-ef6d5b1562f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_463bb85e-1cc7-48f2-b69a-700fa6ecbde2" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_463bb85e-1cc7-48f2-b69a-700fa6ecbde2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_13aa9f8e-fec4-46fe-8547-bc51518698bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9cf061f6-3680-43bd-b54b-203595ba2e31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_13aa9f8e-fec4-46fe-8547-bc51518698bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6edf220f-fe65-4d78-b6cd-40649a116a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_94d341aa-7f6e-4992-88fd-175dfd79dd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6edf220f-fe65-4d78-b6cd-40649a116a54" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_94d341aa-7f6e-4992-88fd-175dfd79dd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6e5c7370-88ff-4ae9-9c74-9ebc79b89734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6edf220f-fe65-4d78-b6cd-40649a116a54" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6e5c7370-88ff-4ae9-9c74-9ebc79b89734" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="ia81a85447b8d4818968bb2d1812439b6_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bf3e4d69-4cb7-4eda-a78a-df3b2d2c5964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_Revenues_bf3e4d69-4cb7-4eda-a78a-df3b2d2c5964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95dfc6b8-c8d2-4f0d-a51e-14509f56da4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_95dfc6b8-c8d2-4f0d-a51e-14509f56da4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d64462bf-bc90-4ff6-a1ec-aa3cfd6d8e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d64462bf-bc90-4ff6-a1ec-aa3cfd6d8e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9c65726-6ed5-428f-9e18-e5b634e379ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9c65726-6ed5-428f-9e18-e5b634e379ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7240e187-87ea-47ba-804c-25e3597dbbf2" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7240e187-87ea-47ba-804c-25e3597dbbf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9fcffcff-9747-490a-bcf4-a2e25fb975cf" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_biib_Collaborationprofitlosssharing_9fcffcff-9747-490a-bcf4-a2e25fb975cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11bd6657-3816-471f-814f-16237a05c481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11bd6657-3816-471f-814f-16237a05c481" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_5b284e3f-b949-4489-a16a-18f60fbad402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_5b284e3f-b949-4489-a16a-18f60fbad402" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_99918081-2541-4394-8b4d-fdd0bc70b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_RestructuringCharges_99918081-2541-4394-8b4d-fdd0bc70b3c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f8470610-a780-4318-a32d-dda0ab6b8d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f8470610-a780-4318-a32d-dda0ab6b8d75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d4279828-48e2-4777-860a-9c34e5f0591d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_CostsAndExpenses_d4279828-48e2-4777-860a-9c34e5f0591d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cebf6bac-dd97-40da-a84a-76808555ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cebf6bac-dd97-40da-a84a-76808555ca9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c59dd8f-f1d1-49e5-b70f-43587608407f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c59dd8f-f1d1-49e5-b70f-43587608407f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c2afe91-82e8-41c9-9300-46cbeeb9e5b4" xlink:href="biib-20220630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c2afe91-82e8-41c9-9300-46cbeeb9e5b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e7690f0-c05d-4781-8cde-7588c4ebda21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_ProfitLoss_5e7690f0-c05d-4781-8cde-7588c4ebda21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62e07b9f-410f-40a2-803c-1cecffc0204d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62e07b9f-410f-40a2-803c-1cecffc0204d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c810f6b0-4070-413d-9acc-9d439c01921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_NetIncomeLoss_c810f6b0-4070-413d-9acc-9d439c01921c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ba18e6ec-0d52-483e-91fb-026076e0d1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:to="loc_us-gaap_EarningsPerShareBasic_ba18e6ec-0d52-483e-91fb-026076e0d1fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d0b92a51-4bf2-4023-9208-645943d79109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d0b92a51-4bf2-4023-9208-645943d79109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92aaf154-2841-4351-a879-02b96ed635c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92aaf154-2841-4351-a879-02b96ed635c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25029e4c-6107-4119-be4b-828f37063d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25029e4c-6107-4119-be4b-828f37063d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:to="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf491430-ea7e-42d3-aba6-17d46c5c3d7c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:to="loc_srt_ProductsAndServicesDomain_bf491430-ea7e-42d3-aba6-17d46c5c3d7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:to="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e421363c-9c95-4c79-b501-f4eebe6cc650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_us-gaap_ProductMember_e421363c-9c95-4c79-b501-f4eebe6cc650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba03f42b-9d47-43a3-aeaf-e72c47421a36" xlink:href="biib-20220630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba03f42b-9d47-43a3-aeaf-e72c47421a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_403f5f6e-5900-4294-bc42-65effb44c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_403f5f6e-5900-4294-bc42-65effb44c32d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="ib3bd5f5cc7004d7b948e8e7298bebde9_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5ab3636-3489-4523-b942-c3158413ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5ab3636-3489-4523-b942-c3158413ed8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_409d1b6a-b6ec-41e6-9d5e-4cd8d26e40f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_409d1b6a-b6ec-41e6-9d5e-4cd8d26e40f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a0aa3bf7-7327-409b-83e5-0ac7d467ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_ProfitLoss_a0aa3bf7-7327-409b-83e5-0ac7d467ba78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56fdac83-74a6-43ee-9ac3-3e94b4e2d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56fdac83-74a6-43ee-9ac3-3e94b4e2d6e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_e13ea0a9-952d-4689-a88e-c6b3b9e27c0b" xlink:href="biib-20220630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_e13ea0a9-952d-4689-a88e-c6b3b9e27c0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6c4881df-6c8f-43f4-8671-738c358d9c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6c4881df-6c8f-43f4-8671-738c358d9c2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_908bab13-d999-4489-9687-7d60cd27ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_908bab13-d999-4489-9687-7d60cd27ba6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c2bbbb23-ed67-4bed-bea6-93ffd14a9e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c2bbbb23-ed67-4bed-bea6-93ffd14a9e81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_eee2e600-bd1b-4c58-b8c7-d980f764d2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_eee2e600-bd1b-4c58-b8c7-d980f764d2fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_deecbd0e-c9f4-4aad-8545-07950c8a6886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_deecbd0e-c9f4-4aad-8545-07950c8a6886" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a33ed767-5f84-4f91-b145-e1a36487b344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a33ed767-5f84-4f91-b145-e1a36487b344" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_b6b9919a-2210-4706-91ce-ce7117ddc8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_b6b9919a-2210-4706-91ce-ce7117ddc8c7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4357a71-3df8-463b-b376-17c513494f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4357a71-3df8-463b-b376-17c513494f12" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3e7e7b1f-17b4-464e-ae82-fe2a45df04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3e7e7b1f-17b4-464e-ae82-fe2a45df04a8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92fa761f-8934-450a-a234-625aebb02225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92fa761f-8934-450a-a234-625aebb02225" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_27d1646e-8310-4073-aa5d-0a10cb9f5eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockholdersEquityOther_27d1646e-8310-4073-aa5d-0a10cb9f5eb1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f59ba60e-d0e6-4bf8-bd93-e97e0a8c39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c8be526d-b141-4339-abf7-bd9788c78ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_25e78633-2ce7-43f7-a3a8-bcf391e5d778_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_25e78633-2ce7-43f7-a3a8-bcf391e5d778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_dc7414a4-77fe-4e0e-b2a1-2293b815e45f" xlink:href="biib-20220630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_dc7414a4-77fe-4e0e-b2a1-2293b815e45f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_255b1184-0641-438f-821e-ba5656f2082d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:to="loc_us-gaap_EquityComponentDomain_255b1184-0641-438f-821e-ba5656f2082d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:to="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_51f8477d-5612-4648-94d5-efd550c0e577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_PreferredStockMember_51f8477d-5612-4648-94d5-efd550c0e577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d9f31fdd-0c58-4cd0-8068-bf2292c436ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_CommonStockMember_d9f31fdd-0c58-4cd0-8068-bf2292c436ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8094553d-22aa-4a58-b766-626a6c530e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8094553d-22aa-4a58-b766-626a6c530e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98738a17-888d-4692-8457-e53682865f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98738a17-888d-4692-8457-e53682865f23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8523843e-2cae-40dd-9ceb-69c68f7d29fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_RetainedEarningsMember_8523843e-2cae-40dd-9ceb-69c68f7d29fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ddd09d0e-db60-4e0f-8010-cdd4fc0dd02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_TreasuryStockMember_ddd09d0e-db60-4e0f-8010-cdd4fc0dd02d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_67a9d931-5205-4a00-b77d-afe8629c9d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_ParentMember_67a9d931-5205-4a00-b77d-afe8629c9d9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a55e3267-3576-4678-a5ba-50ca0d006c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a55e3267-3576-4678-a5ba-50ca0d006c26" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended" id="i7c10140b905d454a9ca78f883921d863_RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e8b37d98-9776-4c0a-9087-13aa3225c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_RestructuringCharges_e8b37d98-9776-4c0a-9087-13aa3225c9a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_417d7208-ddba-4f6d-b045-ee955f6555c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_SeveranceCosts1_417d7208-ddba-4f6d-b045-ee955f6555c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_d761b892-7f83-472d-9f26-11635dacbbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_d761b892-7f83-472d-9f26-11635dacbbd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_ee4a3518-274e-46eb-9346-df54478cab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_OtherRestructuringCosts_ee4a3518-274e-46eb-9346-df54478cab8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:to="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_add3854e-ac4b-4533-bb7e-77720e2528af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:to="loc_srt_RangeMember_add3854e-ac4b-4533-bb7e-77720e2528af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:to="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e1dfb4a3-0af2-4b8e-8235-8594f4675752" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:to="loc_srt_MinimumMember_e1dfb4a3-0af2-4b8e-8235-8594f4675752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf393b1e-1eaf-4623-90eb-9d8765c4d604" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:to="loc_srt_MaximumMember_cf393b1e-1eaf-4623-90eb-9d8765c4d604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:to="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b68c9595-3455-46d2-ad2a-f485ed2d5fdd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b68c9595-3455-46d2-ad2a-f485ed2d5fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9694e7c6-a594-45a9-8795-28214d52bf6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:to="loc_srt_ScenarioForecastMember_9694e7c6-a594-45a9-8795-28214d52bf6d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended" id="i3bf4e09a5ef9466a905500465068344b_RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c263ab7e-870c-41fd-8ac3-a9e4c3fc3196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringReserve_c263ab7e-870c-41fd-8ac3-a9e4c3fc3196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0a4adcc5-60cc-4840-8a2c-50940b21c814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringCharges_0a4adcc5-60cc-4840-8a2c-50940b21c814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_00f5b841-39e5-4bf9-a205-5bdabaa16b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_PaymentsForRestructuring_00f5b841-39e5-4bf9-a205-5bdabaa16b2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_9b2792fc-7b33-4572-8865-db366f7f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_9b2792fc-7b33-4572-8865-db366f7f3146" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e489c5c2-59d4-426b-96ce-06dffc9fb6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_47da150b-af02-42b3-b299-bc8a72a27093_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_47da150b-af02-42b3-b299-bc8a72a27093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_ea1a89f2-de6f-4bbd-9544-83adab089190" xlink:href="biib-20220630.xsd#biib_WorkforceReductionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:to="loc_biib_WorkforceReductionMember_ea1a89f2-de6f-4bbd-9544-83adab089190" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended" id="i99177baa3e57471280e6b7cd53ed059b_RevenuesRevenuesbyproductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc478635-224b-4c0b-80a9-29f915153f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:to="loc_us-gaap_Revenues_bc478635-224b-4c0b-80a9-29f915153f47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:to="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64809230-aefe-45b2-8607-32b1fd2b0b0a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:to="loc_srt_ProductsAndServicesDomain_64809230-aefe-45b2-8607-32b1fd2b0b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:to="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:href="biib-20220630.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:href="biib-20220630.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:to="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_130b66f8-1487-4e45-ba71-e63c661b3807" xlink:href="biib-20220630.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:to="loc_biib_TECFIDERAMember_130b66f8-1487-4e45-ba71-e63c661b3807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_bd188d96-4ec9-4cbf-b338-dcb57826cd22" xlink:href="biib-20220630.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:to="loc_biib_VUMERITYMember_bd188d96-4ec9-4cbf-b338-dcb57826cd22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:href="biib-20220630.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:to="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_d1bec0b0-0f4e-416a-9569-385882a75c54" xlink:href="biib-20220630.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:to="loc_biib_AVONEXMember_d1bec0b0-0f4e-416a-9569-385882a75c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_f943c262-821a-49a2-9c1f-14baade3a96b" xlink:href="biib-20220630.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:to="loc_biib_PLEGRIDYMember_f943c262-821a-49a2-9c1f-14baade3a96b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_2fa39293-eb0b-4fea-8edd-94c563639bca" xlink:href="biib-20220630.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_TysabriProductMember_2fa39293-eb0b-4fea-8edd-94c563639bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_e076a434-2cf4-4683-8fea-ae4737745d78" xlink:href="biib-20220630.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_FAMPYRAMember_e076a434-2cf4-4683-8fea-ae4737745d78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_4e070a1d-339c-41f5-95f0-da812b4ef8fd" xlink:href="biib-20220630.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_SPINRAZAMember_4e070a1d-339c-41f5-95f0-da812b4ef8fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:href="biib-20220630.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_99243a50-ee2f-4598-af18-d52ebe18e78a" xlink:href="biib-20220630.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_BENEPALIMember_99243a50-ee2f-4598-af18-d52ebe18e78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_9bedb5c7-5475-4dd2-86b9-618a47d20ba8" xlink:href="biib-20220630.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_IMRALDIMember_9bedb5c7-5475-4dd2-86b9-618a47d20ba8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_74c5c536-0f98-454f-ab66-91231cee939c" xlink:href="biib-20220630.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_FLIXABIMember_74c5c536-0f98-454f-ab66-91231cee939c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_0ac9e018-637c-48cb-aba6-1fac239eadd3" xlink:href="biib-20220630.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_BYOOVIZMember_0ac9e018-637c-48cb-aba6-1fac239eadd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_d6a7a0c3-8824-4fb9-9585-1ec01320be0d" xlink:href="biib-20220630.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_FUMADERMMember_d6a7a0c3-8824-4fb9-9585-1ec01320be0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_aa9a9d9f-c97b-4242-bf82-4ccea598a3d0" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_ADUHELMMember_aa9a9d9f-c97b-4242-bf82-4ccea598a3d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ed3ba04-d775-40d2-9979-5414e0ddec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_us-gaap_ProductMember_4ed3ba04-d775-40d2-9979-5414e0ddec9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:to="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e947aa4f-f28b-4713-b36b-2ae327a6c992_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:to="loc_srt_SegmentGeographicalDomain_e947aa4f-f28b-4713-b36b-2ae327a6c992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:to="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6c52be46-fa8c-4da7-8130-42bfc735c6f3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:to="loc_country_US_6c52be46-fa8c-4da7-8130-42bfc735c6f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ec30be2a-e912-4ff2-8611-987316dcf812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:to="loc_us-gaap_NonUsMember_ec30be2a-e912-4ff2-8611-987316dcf812" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="i735f11a82dba4858ae6180bbba87ff6a_RevenuesReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1c8f0a42-4107-4dcb-8663-812151c40885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1c8f0a42-4107-4dcb-8663-812151c40885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2ab5451e-ba45-42a1-be13-68851d5b4ddd" xlink:href="biib-20220630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2ab5451e-ba45-42a1-be13-68851d5b4ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e8ee1cd8-294f-4c2b-993c-f914a4bb2876" xlink:href="biib-20220630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e8ee1cd8-294f-4c2b-993c-f914a4bb2876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f577b1e0-25a4-461f-94a0-114258f72d51" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f577b1e0-25a4-461f-94a0-114258f72d51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d6bb9f3b-1f6c-44e4-a2f6-fc2702396c77" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d6bb9f3b-1f6c-44e4-a2f6-fc2702396c77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab3be22a-6f32-4dde-9c8a-2fced07f26d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d67e7aef-d4c4-412f-9ebf-bccb63558b71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d67e7aef-d4c4-412f-9ebf-bccb63558b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_ee7d3fa3-c9bc-4196-b463-8c1c5f3414c7" xlink:href="biib-20220630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_biib_ReserveforCashDiscountsMember_ee7d3fa3-c9bc-4196-b463-8c1c5f3414c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_d0b59834-a144-4617-87bf-89416d36b1f9" xlink:href="biib-20220630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_biib_ContractualAdjustmentsMember_d0b59834-a144-4617-87bf-89416d36b1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_c3230ee4-d6da-4931-999f-ff400748adea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_c3230ee4-d6da-4931-999f-ff400748adea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="iba52133be63a4f6c83fd21f55c1f3391_RevenuesReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2e9120c-7125-42df-a911-2e4860aca025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2e9120c-7125-42df-a911-2e4860aca025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:to="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4e5d33db-c46a-44c6-b88b-1f6610384dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:to="loc_us-gaap_AccountsReceivableMember_4e5d33db-c46a-44c6-b88b-1f6610384dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_acdfe010-61b7-4fad-88bc-f2e24530c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_acdfe010-61b7-4fad-88bc-f2e24530c788" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="ib2dfe100f03f41c3abf0147152e0a1a9_RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_5097a67a-b05c-4536-a3bc-1a8992ff8765" xlink:href="biib-20220630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_biib_ShareOfCoPromotionProfits_5097a67a-b05c-4536-a3bc-1a8992ff8765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_bad127fe-53e2-4a10-b014-88e88077678b" xlink:href="biib-20220630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_bad127fe-53e2-4a10-b014-88e88077678b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_54d30c5d-6843-4cb9-8bb0-ec9b3f729a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_us-gaap_Revenues_54d30c5d-6843-4cb9-8bb0-ec9b3f729a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:to="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53117658-ae86-47b1-af9f-0491bd6d689f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:to="loc_srt_ProductsAndServicesDomain_53117658-ae86-47b1-af9f-0491bd6d689f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:to="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1efa1651-4a99-43f6-8fac-50516f9daf59" xlink:href="biib-20220630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1efa1651-4a99-43f6-8fac-50516f9daf59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:to="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_4392586d-da35-4222-b56d-32ad7221d10f" xlink:href="biib-20220630.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:to="loc_biib_RocheGroupGenentechMember_4392586d-da35-4222-b56d-32ad7221d10f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" id="i88716a104b6148498127a4298129d6eb_RevenuesOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b85db5ac-27f2-4cc1-9dfd-0b962852ef3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:to="loc_us-gaap_Revenues_b85db5ac-27f2-4cc1-9dfd-0b962852ef3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e569e3a-d362-4629-938b-a330cede39d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e569e3a-d362-4629-938b-a330cede39d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1dbc6f49-a727-4b43-88c2-e9ba93bb861a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1dbc6f49-a727-4b43-88c2-e9ba93bb861a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c2143526-9f11-4363-9bf9-965ecd9a88be_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:to="loc_srt_ProductsAndServicesDomain_c2143526-9f11-4363-9bf9-965ecd9a88be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:to="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f73c6652-fa44-44cb-bd4d-55bdb91c01f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_us-gaap_RoyaltyMember_f73c6652-fa44-44cb-bd4d-55bdb91c01f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_0b401e98-b0f5-4d9f-8470-099e2505656a" xlink:href="biib-20220630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_biib_OthercorporaterevenuesMember_0b401e98-b0f5-4d9f-8470-099e2505656a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4030a79b-7afc-4629-b155-f5829ef5f922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4030a79b-7afc-4629-b155-f5829ef5f922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b3fa6b71-4aec-4f5a-bcb7-9004b3991883_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:to="loc_srt_NameOfMajorCustomerDomain_b3fa6b71-4aec-4f5a-bcb7-9004b3991883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:to="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_49f8aa3b-2998-45f9-be73-25b6672ffee3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_49f8aa3b-2998-45f9-be73-25b6672ffee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_0d141b44-60fd-4a17-8f28-f49acfade8e6" xlink:href="biib-20220630.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:to="loc_biib_ZINBRYTAMember_0d141b44-60fd-4a17-8f28-f49acfade8e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i53dd76b8fcf54ea4812d7d8521e997c0_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ec10bbcc-626f-40c7-9498-3993d7d261b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_us-gaap_Revenues_ec10bbcc-626f-40c7-9498-3993d7d261b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6d8a8ad6-a292-4e4f-8e6a-958bbc8b5464" xlink:href="biib-20220630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6d8a8ad6-a292-4e4f-8e6a-958bbc8b5464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_e6d5ec55-4c41-43cb-9404-84c3990542c9" xlink:href="biib-20220630.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_biib_NumberOfWholesalers_e6d5ec55-4c41-43cb-9404-84c3990542c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:to="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:to="loc_srt_ProductsAndServicesDomain_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:to="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_6fa72a00-3b40-427f-9851-7da8fbd70b77" xlink:href="biib-20220630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:to="loc_biib_OthercorporaterevenuesMember_6fa72a00-3b40-427f-9851-7da8fbd70b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6a4636c5-5373-467b-bb22-dfa03998b7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6a4636c5-5373-467b-bb22-dfa03998b7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:to="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_367c031b-bb4c-4eff-be35-09a69bbacd24_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:to="loc_srt_NameOfMajorCustomerDomain_367c031b-bb4c-4eff-be35-09a69bbacd24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_8074e181-6236-4989-8ae3-cc7899c10b6c" xlink:href="biib-20220630.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:to="loc_biib_DistributorOneMember_8074e181-6236-4989-8ae3-cc7899c10b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_ecdc6e2f-657b-4ffd-812b-b8f222a77113" xlink:href="biib-20220630.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:to="loc_biib_DistributorTwoMember_ecdc6e2f-657b-4ffd-812b-b8f222a77113" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryComponentsofInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended" id="if5a294e1bde24ba096bc996d8a86e39b_InventoryComponentsofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_756b932e-2a84-4a5e-93e0-4e31475ed8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_756b932e-2a84-4a5e-93e0-4e31475ed8bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_29e48b3d-460e-46a6-954a-e44a3edfddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_29e48b3d-460e-46a6-954a-e44a3edfddb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ecca1d6f-b333-49ac-8af2-22a4e38b30c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ecca1d6f-b333-49ac-8af2-22a4e38b30c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9e507bf1-cf56-4289-ba72-ac0ea5cb7df7" xlink:href="biib-20220630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_9e507bf1-cf56-4289-ba72-ac0ea5cb7df7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:to="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6843578-6eaa-442b-a3ea-2c001add2abd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:to="loc_srt_ProductsAndServicesDomain_e6843578-6eaa-442b-a3ea-2c001add2abd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:to="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember_a56ea400-bff5-4b15-a994-ca49911e0b7d" xlink:href="biib-20220630.xsd#biib_LecanemabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:to="loc_biib_LecanemabMember_a56ea400-bff5-4b15-a994-ca49911e0b7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended" id="ibb18badb06084a24a1353a335f6120ee_InventoryNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d837e4cc-9603-4e0e-9c5c-21ab4fde8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_us-gaap_InventoryWriteDown_d837e4cc-9603-4e0e-9c5c-21ab4fde8acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eb9d9550-d44c-40aa-b210-dec2ab4df479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eb9d9550-d44c-40aa-b210-dec2ab4df479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_58ce6f0f-ed10-4c96-8973-1c4de4be1118" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_58ce6f0f-ed10-4c96-8973-1c4de4be1118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_906f7cb4-f2be-4694-8a43-d10f82c00eb5" xlink:href="biib-20220630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_906f7cb4-f2be-4694-8a43-d10f82c00eb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c62a978d-b044-4c3a-afa0-30fab8dfca5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:to="loc_srt_ProductsAndServicesDomain_c62a978d-b044-4c3a-afa0-30fab8dfca5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:to="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_0edf9be0-7a66-4f45-8394-9e625d986366" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:to="loc_biib_ADUHELMMember_0edf9be0-7a66-4f45-8394-9e625d986366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_603cdea1-7615-4839-a2b3-242946deda6b" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:to="loc_biib_EisaiMember_603cdea1-7615-4839-a2b3-242946deda6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ababb62a-5159-4830-9818-5e63abb1afa6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ababb62a-5159-4830-9818-5e63abb1afa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_01a1769c-e036-4d9b-8ee1-0e39a8ba5f8e" xlink:href="biib-20220630.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_01a1769c-e036-4d9b-8ee1-0e39a8ba5f8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i9439042db565459c95ec71ff912d63e5_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f74af85-f551-4056-8f52-bdc5a0074e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f74af85-f551-4056-8f52-bdc5a0074e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b43da980-feae-424c-bffb-058c71a924ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b43da980-feae-424c-bffb-058c71a924ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_43351310-aefc-4c05-97f6-763f8f450aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_43351310-aefc-4c05-97f6-763f8f450aff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84a1b7e6-18ca-4a0b-aeb2-cb2b3f0fba97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84a1b7e6-18ca-4a0b-aeb2-cb2b3f0fba97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_722b80cf-81c1-4da5-9f53-b55b35b3d0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_722b80cf-81c1-4da5-9f53-b55b35b3d0ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_678d2a74-6776-411a-a505-fde633b250f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_678d2a74-6776-411a-a505-fde633b250f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f9cf121-a834-48b6-ba22-8e7d037395b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f9cf121-a834-48b6-ba22-8e7d037395b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_2940da0b-338e-4f5b-a84d-264d7af49674" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_2940da0b-338e-4f5b-a84d-264d7af49674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a74bb58d-a686-4159-a928-04c52d0515c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_9633415e-226e-4a7c-a99c-951665a7dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_9633415e-226e-4a7c-a99c-951665a7dc3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_61a6d0c7-aeac-4f81-bd0e-a5232dd36d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_61a6d0c7-aeac-4f81-bd0e-a5232dd36d21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cb70fedf-f67c-41f5-963a-15723e397ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cb70fedf-f67c-41f5-963a-15723e397ba0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_13676472-4a65-43ff-8475-9e1e3cf41cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_13676472-4a65-43ff-8475-9e1e3cf41cb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bce55de6-c179-46fd-9a5d-0a50897d2fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bce55de6-c179-46fd-9a5d-0a50897d2fda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a86f0fae-3bf6-402e-85d8-2cb238bd375a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a86f0fae-3bf6-402e-85d8-2cb238bd375a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7e7680be-2063-453b-9f6d-a99568671ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7e7680be-2063-453b-9f6d-a99568671ab5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:href="biib-20220630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_89757ae9-5f0d-4954-b0a1-8b3907c24ae4_default" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_89757ae9-5f0d-4954-b0a1-8b3907c24ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_5a66a743-ee93-460e-9be4-fd68ea617c02" xlink:href="biib-20220630.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB111Member_5a66a743-ee93-460e-9be4-fd68ea617c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_9c21edfc-5009-405f-b989-70cf200b7616" xlink:href="biib-20220630.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB112Member_9c21edfc-5009-405f-b989-70cf200b7616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_7dc57b71-d702-4551-b58d-85a30981f333" xlink:href="biib-20220630.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_VixotrigineMember_7dc57b71-d702-4551-b58d-85a30981f333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_07ddb815-5752-476b-b558-a60357222324" xlink:href="biib-20220630.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_TGNMember_07ddb815-5752-476b-b558-a60357222324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_cf3cf213-8efb-4110-97f2-32f5a9542d57" xlink:href="biib-20220630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB111AndBIIB112Member_cf3cf213-8efb-4110-97f2-32f5a9542d57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_792550fe-887e-4bb1-a744-edda9ba1c122" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7706b1a5-927d-4802-8801-34d1ec73b3ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7706b1a5-927d-4802-8801-34d1ec73b3ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_f34d05ce-90f5-4020-b75c-8e3f768df0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_f34d05ce-90f5-4020-b75c-8e3f768df0cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_10bc2ba7-965e-47bc-b19b-21a974e17c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_10bc2ba7-965e-47bc-b19b-21a974e17c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4188251b-8f64-42c7-86c4-68b0ee069a8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4188251b-8f64-42c7-86c4-68b0ee069a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_f94162f3-5195-4252-9998-59797f6ca679" xlink:href="biib-20220630.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:to="loc_biib_OutLicensedPatentsMember_f94162f3-5195-4252-9998-59797f6ca679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d4cd929-f341-440f-addf-634bc74d1656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d4cd929-f341-440f-addf-634bc74d1656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef474d23-953a-477d-a071-54fcd2b25909_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:to="loc_srt_RangeMember_ef474d23-953a-477d-a071-54fcd2b25909_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:to="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d5158a0-1b70-4c97-b19d-8e7bd55f03a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:to="loc_srt_MinimumMember_9d5158a0-1b70-4c97-b19d-8e7bd55f03a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b34b467a-eb39-4f1c-ab0b-d7294433271e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:to="loc_srt_MaximumMember_b34b467a-eb39-4f1c-ab0b-d7294433271e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i7e43ac16f86a41049e9a9f390ff7c74b_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00973dd2-d007-4dbd-9000-eb64bc964e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00973dd2-d007-4dbd-9000-eb64bc964e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af4670c-b029-4ad0-9940-5c71cdab5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af4670c-b029-4ad0-9940-5c71cdab5fea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dfd6397a-dc11-43fa-9413-f05600c1e429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dfd6397a-dc11-43fa-9413-f05600c1e429" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_933ab1c1-e91a-44ae-acce-c1437416dfba" xlink:href="biib-20220630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_933ab1c1-e91a-44ae-acce-c1437416dfba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9df7eac1-29a4-40c6-a23d-c22abba68df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9df7eac1-29a4-40c6-a23d-c22abba68df9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_d4e122f8-193a-412b-b288-a07f63fed511" xlink:href="biib-20220630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_d4e122f8-193a-412b-b288-a07f63fed511" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_53fad40d-620f-4dd5-9162-2626dab26d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_53fad40d-620f-4dd5-9162-2626dab26d4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6c233bd6-bc72-41d0-97f5-087df36f5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6c233bd6-bc72-41d0-97f5-087df36f5eef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1a9dfff0-bb2a-4fc7-ad0b-01e0e8e4a9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1a9dfff0-bb2a-4fc7-ad0b-01e0e8e4a9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fcdfd358-fa44-4ead-9afb-bc47d94fea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fcdfd358-fa44-4ead-9afb-bc47d94fea5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2974f662-79ed-4af5-9a14-b26946560614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2974f662-79ed-4af5-9a14-b26946560614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10f00ca0-f89d-4103-a438-c44f771c4314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10f00ca0-f89d-4103-a438-c44f771c4314" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5a6c914-32ea-4c8f-b32e-04ef3373e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5a6c914-32ea-4c8f-b32e-04ef3373e45a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a47a6016-f28d-49f8-b8c4-c8e731322c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a47a6016-f28d-49f8-b8c4-c8e731322c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_13555b7a-f922-43b3-ac98-6c3cbe2bed73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_13555b7a-f922-43b3-ac98-6c3cbe2bed73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c7cc6ee-0491-4e86-998e-a7cb1de68d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c7cc6ee-0491-4e86-998e-a7cb1de68d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b414fc5c-dc82-479f-998a-17991da3e5fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b414fc5c-dc82-479f-998a-17991da3e5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_18f129cb-663e-4b39-ba71-6ccae2bd29cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_18f129cb-663e-4b39-ba71-6ccae2bd29cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ca16c323-2da8-49de-b60b-a8ae92bb5eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ca16c323-2da8-49de-b60b-a8ae92bb5eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17ba9ef6-224f-4751-b8ee-b030c1b7d9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17ba9ef6-224f-4751-b8ee-b030c1b7d9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b2cc5003-de68-4308-b11d-e3437ee5b954_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b2cc5003-de68-4308-b11d-e3437ee5b954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_27b14c00-6a92-4ada-809f-a4e8b5743652" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_27b14c00-6a92-4ada-809f-a4e8b5743652" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="ib3c225676e8b4e9db2823b6a2e65b343_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eaf7524d-8d50-4f5f-bedb-4bd5b936fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eaf7524d-8d50-4f5f-bedb-4bd5b936fb21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0c46f805-cc1e-44da-aa3b-abb79d356f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0c46f805-cc1e-44da-aa3b-abb79d356f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:to="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7371f81d-ca56-4b15-b0c7-48f06f886337_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:to="loc_srt_RangeMember_7371f81d-ca56-4b15-b0c7-48f06f886337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:to="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c3fdf59f-e586-4afe-96f8-0f451b82ab8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:to="loc_srt_WeightedAverageMember_c3fdf59f-e586-4afe-96f8-0f451b82ab8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_66669a84-cc4a-4a67-af89-a48848430f32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_66669a84-cc4a-4a67-af89-a48848430f32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7b8ae18a-a350-4bb9-ad86-0da6507ae949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7b8ae18a-a350-4bb9-ad86-0da6507ae949" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i3c858dd1ce36429384ba1feb334e827c_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_508e7813-b156-4bd3-8693-6d2a2d441075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_508e7813-b156-4bd3-8693-6d2a2d441075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_532d1a37-e7e4-4ecb-ba57-b92625512df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_NotesPayable_532d1a37-e7e4-4ecb-ba57-b92625512df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_dd084df8-5cdc-412c-8afa-51daae376612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_dd084df8-5cdc-412c-8afa-51daae376612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82159358-db96-499f-851a-a159fc75356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82159358-db96-499f-851a-a159fc75356e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a2600e0d-fda9-4175-a676-d93f17ecf724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a2600e0d-fda9-4175-a676-d93f17ecf724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c1ca22b5-cb43-4534-bcab-e2271e21960e" xlink:href="biib-20220630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c1ca22b5-cb43-4534-bcab-e2271e21960e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_92c7d920-be91-41e8-9b02-bb3af91df6a7" xlink:href="biib-20220630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_92c7d920-be91-41e8-9b02-bb3af91df6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_817599d6-b252-473b-9ca8-013710e04243" xlink:href="biib-20220630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_817599d6-b252-473b-9ca8-013710e04243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8327839a-2996-4b2d-9be4-a66051763660" xlink:href="biib-20220630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8327839a-2996-4b2d-9be4-a66051763660" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_38901288-a273-4517-b2e1-e982fda84c92" xlink:href="biib-20220630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_38901288-a273-4517-b2e1-e982fda84c92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_6244422f-444f-4553-9a0c-b8ccc2df9a2e" xlink:href="biib-20220630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_6244422f-444f-4553-9a0c-b8ccc2df9a2e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="ieb2b090b6ba746b79e61c119ec026bcb_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8a38f31b-421f-48ad-8aeb-4cfa3c8813f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8a38f31b-421f-48ad-8aeb-4cfa3c8813f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27e7a539-b9b5-4720-b159-dc0e88b9117b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27e7a539-b9b5-4720-b159-dc0e88b9117b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f80d64f-71d0-4c0b-ae73-25a1e663faee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7ba6b57-ebf9-497a-8df9-791423209018_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7ba6b57-ebf9-497a-8df9-791423209018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a6bab894-7816-4c07-ae35-5a02906101b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a6bab894-7816-4c07-ae35-5a02906101b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="if2b9cd25667f4e4dac82bb570c59a257_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_132155b2-524a-4ef3-b705-e41c46743dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_132155b2-524a-4ef3-b705-e41c46743dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:to="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8e42d6f4-036c-4b77-a53d-ba64abd5929b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8e42d6f4-036c-4b77-a53d-ba64abd5929b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f59b1dd-b0d5-4efb-91bb-e06ef94d3f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_CommercialPaperMember_4f59b1dd-b0d5-4efb-91bb-e06ef94d3f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_8c50df4e-031a-4612-953e-9756643448a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_8c50df4e-031a-4612-953e-9756643448a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0ab04ea1-50af-4336-adef-675828c679ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0ab04ea1-50af-4336-adef-675828c679ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_3b86b52e-3e20-4947-8294-cc7b42676456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_DebtSecuritiesMember_3b86b52e-3e20-4947-8294-cc7b42676456" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="i2feb1746cfe54f5abbe777d82e6532c4_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0eb6a1ae-caef-4891-843e-36ecc175170b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0eb6a1ae-caef-4891-843e-36ecc175170b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e30d19c-625f-4ed9-bc22-4511eb2b535c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e30d19c-625f-4ed9-bc22-4511eb2b535c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a68b07db-021e-4489-bce6-664aaab64d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a68b07db-021e-4489-bce6-664aaab64d0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_619db90c-f534-4960-8fae-748de527b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_619db90c-f534-4960-8fae-748de527b36b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_50bd1e9e-00b4-4fd5-b1d9-b64e069cb4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_50bd1e9e-00b4-4fd5-b1d9-b64e069cb4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_260f2e0f-032c-4b14-9618-18f2e69ab465" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_260f2e0f-032c-4b14-9618-18f2e69ab465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_d9cfb416-4ded-4b2f-b7ea-e7d1d6f05995" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_d9cfb416-4ded-4b2f-b7ea-e7d1d6f05995" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a9891ffc-0a53-4592-a2d5-37c9f0ba00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a9891ffc-0a53-4592-a2d5-37c9f0ba00dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c348230a-ca90-4c27-9120-421891a7ad35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c348230a-ca90-4c27-9120-421891a7ad35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_dc9ecd78-d524-4be6-9980-52cad970a7d3" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_dc9ecd78-d524-4be6-9980-52cad970a7d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_8222b8e1-0291-4cba-9b11-d6536c0cb903" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_8222b8e1-0291-4cba-9b11-d6536c0cb903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_f46fdfc6-79c2-4715-81db-51638c3c6435" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_f46fdfc6-79c2-4715-81db-51638c3c6435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_9e4110d4-c7a5-466c-b952-0f3d538aa7aa" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_9e4110d4-c7a5-466c-b952-0f3d538aa7aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_31641dc5-7de4-48b2-b6eb-1982f96b6902" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_31641dc5-7de4-48b2-b6eb-1982f96b6902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c3ffec83-d5c6-4c5c-a735-67767152c17b" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c3ffec83-d5c6-4c5c-a735-67767152c17b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_d6c9ff97-73a3-41c6-b438-544f304e43c9" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_EquitySecuritiesCurrentMember_d6c9ff97-73a3-41c6-b438-544f304e43c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_9ac6582d-3430-4546-b50e-3a13efc62c7e" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_9ac6582d-3430-4546-b50e-3a13efc62c7e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="iae81a50da71f4f9d8895b06c0cd338dd_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_c8c0f287-f2df-4327-8f47-107d0a88c223" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:to="loc_biib_StrategicInvestmentPortfolio_c8c0f287-f2df-4327-8f47-107d0a88c223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_526d001c-9b53-46d9-81ba-20ab06529f8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_526d001c-9b53-46d9-81ba-20ab06529f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_62fdf9a7-1c00-4c24-b1ad-e49e26bd48b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_62fdf9a7-1c00-4c24-b1ad-e49e26bd48b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:to="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_523bd9dd-6063-4682-a35f-d2baa04c15c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_523bd9dd-6063-4682-a35f-d2baa04c15c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_0fd4f9ea-5d85-49cf-97b8-8802aa3cc96e" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:to="loc_biib_StrategicInvestmentsMember_0fd4f9ea-5d85-49cf-97b8-8802aa3cc96e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i10292928676c4ba593d2412ac91d726d_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_61a2b4e7-949d-4972-b574-732bcf39f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_61a2b4e7-949d-4972-b574-732bcf39f4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_b14f8e36-5e81-4ad8-a6b4-f05e4c53adf0" xlink:href="biib-20220630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_b14f8e36-5e81-4ad8-a6b4-f05e4c53adf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_361b1f66-7076-4e6c-a442-7830b00d49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_361b1f66-7076-4e6c-a442-7830b00d49b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2be5b199-0fca-4214-a362-5f77faa1e6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2be5b199-0fca-4214-a362-5f77faa1e6fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f7911889-9b17-4fbd-8f39-e194d90a990c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f7911889-9b17-4fbd-8f39-e194d90a990c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72f42ff8-690f-4319-9eff-515a7a7a3be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72f42ff8-690f-4319-9eff-515a7a7a3be9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_96376338-4e5a-442e-aba8-7e258eedb331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_96376338-4e5a-442e-aba8-7e258eedb331" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_dcc3e1b4-2d4a-46be-b32f-256080ba3eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_dcc3e1b4-2d4a-46be-b32f-256080ba3eb2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_645add32-bdd7-4458-a88a-f8dd8e3f3909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_645add32-bdd7-4458-a88a-f8dd8e3f3909" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_396dd322-d49b-41bb-b0d4-964d66de6298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_396dd322-d49b-41bb-b0d4-964d66de6298" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d39b09c9-0563-428a-8f23-d3bdd3c24b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d39b09c9-0563-428a-8f23-d3bdd3c24b75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_81a86cde-25e7-40c9-bc45-209731fff868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_81a86cde-25e7-40c9-bc45-209731fff868" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4e75fc21-c321-4c09-97e3-e331f12c1e4e" xlink:href="biib-20220630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4e75fc21-c321-4c09-97e3-e331f12c1e4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_59be5135-c9bf-480f-94b2-8a643ab0a139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_59be5135-c9bf-480f-94b2-8a643ab0a139" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_c2bad7ae-419e-49df-b5a5-42270698af50" xlink:href="biib-20220630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedGainOnDerivatives_c2bad7ae-419e-49df-b5a5-42270698af50" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_8e00383a-84e1-491a-99fb-c2826c277aaf" xlink:href="biib-20220630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedLossOnDerivatives_8e00383a-84e1-491a-99fb-c2826c277aaf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_7509cdc3-c100-4221-8737-54cb770b7200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_7509cdc3-c100-4221-8737-54cb770b7200" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5eb83a4b-d5f1-4dc0-ae63-84526ef2c697" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5eb83a4b-d5f1-4dc0-ae63-84526ef2c697" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_593f19f6-5185-4bb7-b7e7-16124fb6aa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_593f19f6-5185-4bb7-b7e7-16124fb6aa5f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_104a9739-671c-4ec9-a4f0-ef4e2429afe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_104a9739-671c-4ec9-a4f0-ef4e2429afe3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_df25aab4-5889-4e86-bbce-c9a34157fe33_default" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:to="loc_biib_DerivativeMaturityDomain_df25aab4-5889-4e86-bbce-c9a34157fe33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:to="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_3a2ff8f0-67ab-49cb-9763-e6208907e1ce" xlink:href="biib-20220630.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:to="loc_biib_ShorttermderivativeMember_3a2ff8f0-67ab-49cb-9763-e6208907e1ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9b347030-0606-4327-97e1-36f0504b3266_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9b347030-0606-4327-97e1-36f0504b3266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c7a618d4-b14b-4960-86f7-bbbcbd46e905" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c7a618d4-b14b-4960-86f7-bbbcbd46e905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c9202fb8-9d3d-4005-a962-a5745809fb12_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:to="loc_currency_AllCurrenciesDomain_c9202fb8-9d3d-4005-a962-a5745809fb12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:to="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_ebfb39c5-d298-40d1-b798-9be4d46f2ac6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_EUR_ebfb39c5-d298-40d1-b798-9be4d46f2ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_2ab2d78a-88c0-4084-8f8c-1c551c7aaf84" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_GBP_2ab2d78a-88c0-4084-8f8c-1c551c7aaf84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_d8376201-addd-473f-9a70-37ad54750929" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_CHF_d8376201-addd-473f-9a70-37ad54750929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_3c5f898f-a635-4802-8c7f-6233fb5d0db7" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_JPY_3c5f898f-a635-4802-8c7f-6233fb5d0db7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_06b90780-1110-4c55-bc01-5a9b6c6395e2" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_CAD_06b90780-1110-4c55-bc01-5a9b6c6395e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6ded12a-c99e-47db-aa09-410870f44a5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6ded12a-c99e-47db-aa09-410870f44a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d6433c65-33b2-4b3e-ac67-ba04df68f713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_SalesMember_d6433c65-33b2-4b3e-ac67-ba04df68f713" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_99ae8637-8b39-4488-aa6c-774b8df0ba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_OperatingExpenseMember_99ae8637-8b39-4488-aa6c-774b8df0ba3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3215d33d-0251-4d3e-a626-6f3e94108e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3215d33d-0251-4d3e-a626-6f3e94108e32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ef0f3598-7880-46f4-b061-011ec057103d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ef0f3598-7880-46f4-b061-011ec057103d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_f83b6901-aeb4-4879-bf0d-b40d6fc3824d" xlink:href="biib-20220630.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_biib_CashflowsrevenueMember_f83b6901-aeb4-4879-bf0d-b40d6fc3824d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_aa5231f5-f580-4dc9-80a6-fec74c4226e9" xlink:href="biib-20220630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_biib_CashflowsoperatingexpensesMember_aa5231f5-f580-4dc9-80a6-fec74c4226e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7565c351-0d95-46f5-b587-d2bcbe31a8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7565c351-0d95-46f5-b587-d2bcbe31a8d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5faf0564-5c4b-4694-b690-47e94d296e01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5faf0564-5c4b-4694-b690-47e94d296e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_dc0f88ae-804a-4782-a51b-7b9f1b2e968d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:to="loc_us-gaap_ForeignExchangeContractMember_dc0f88ae-804a-4782-a51b-7b9f1b2e968d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_fe76408f-fe9d-4677-9711-3bc554d209bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_fe76408f-fe9d-4677-9711-3bc554d209bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9bf2d8e9-4ca5-4fda-863c-382778c540a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9bf2d8e9-4ca5-4fda-863c-382778c540a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_52a82b26-22fa-4bc1-9ac5-5332e072a81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_52a82b26-22fa-4bc1-9ac5-5332e072a81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_75640f5a-6956-477e-86cc-8a6dabb61cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_75640f5a-6956-477e-86cc-8a6dabb61cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4c73f041-9635-4c96-abb5-8878708b0495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4c73f041-9635-4c96-abb5-8878708b0495" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8828321b-4859-40c6-bf2a-de3bdb29ea37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:to="loc_us-gaap_HedgingDesignationDomain_8828321b-4859-40c6-bf2a-de3bdb29ea37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:to="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc8f2a72-c22b-484d-a9d5-d61d9bad7b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc8f2a72-c22b-484d-a9d5-d61d9bad7b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_746d0cc2-1791-4f43-a9f9-80bdb7a8fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:to="loc_us-gaap_NondesignatedMember_746d0cc2-1791-4f43-a9f9-80bdb7a8fe43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45547b2b-5b33-43ad-aa7f-201b9541201d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:to="loc_srt_RangeMember_45547b2b-5b33-43ad-aa7f-201b9541201d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:to="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a89562d5-cc8e-46b9-9ef7-0fedbe2b96b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:to="loc_srt_MinimumMember_a89562d5-cc8e-46b9-9ef7-0fedbe2b96b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_230567f7-a09b-4d4c-adf5-fbf02138c6e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:to="loc_srt_MaximumMember_230567f7-a09b-4d4c-adf5-fbf02138c6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca7307a5-096e-4be5-ab61-f278c16c8f51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca7307a5-096e-4be5-ab61-f278c16c8f51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe53b5b5-0f4e-4410-970c-c73f01d276b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe53b5b5-0f4e-4410-970c-c73f01d276b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i455c625b957c44caaf3dec3c7bf89fcc_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_427c1201-7a83-49e0-bc35-0d26c23c6d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_427c1201-7a83-49e0-bc35-0d26c23c6d4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d0db2f75-0c38-490f-b7fb-1dd62e6cb8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_Depreciation_d0db2f75-0c38-490f-b7fb-1dd62e6cb8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8f9407ca-b8d4-447d-8a93-278efd6279a6" xlink:href="biib-20220630.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_biib_NumberOfSquareFeet_8f9407ca-b8d4-447d-8a93-278efd6279a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_cac863f8-b30c-4607-b505-d262d1179f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_ConstructionInProgressGross_cac863f8-b30c-4607-b505-d262d1179f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e22bbd0a-fe83-4401-92c5-7b4a9e29cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e22bbd0a-fe83-4401-92c5-7b4a9e29cddc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:href="biib-20220630.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:to="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_b095a474-8b2a-4ac2-aa9b-e4780630eb7b_default" xlink:href="biib-20220630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:to="loc_biib_FacilityLocationDomain_b095a474-8b2a-4ac2-aa9b-e4780630eb7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:href="biib-20220630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:to="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_7ded2bd5-077b-41d0-a823-855c7d834e02" xlink:href="biib-20220630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:to="loc_biib_SolothurnSwitzerlandMember_7ded2bd5-077b-41d0-a823-855c7d834e02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:href="biib-20220630.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:to="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_97e9347d-9160-4931-a005-78f8a3287174_default" xlink:href="biib-20220630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:to="loc_biib_FacilityTypeDomain_97e9347d-9160-4931-a005-78f8a3287174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:href="biib-20220630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:to="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_fe1f43ce-a5ac-4ce4-9ae9-45458af8a5fc" xlink:href="biib-20220630.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_BiologicsManufacturingMember_fe1f43ce-a5ac-4ce4-9ae9-45458af8a5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_c98ad089-8107-4c40-a4d8-272121d9cdd5" xlink:href="biib-20220630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_c98ad089-8107-4c40-a4d8-272121d9cdd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_ee69a42e-ca98-4e8e-b9ee-a9db931a198c" xlink:href="biib-20220630.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_AdministrativeSpaceMember_ee69a42e-ca98-4e8e-b9ee-a9db931a198c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="ie6e8a12aebdc4e919916a18f07583f81_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a29c8292-670c-42f4-965b-b3cc2388e534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a29c8292-670c-42f4-965b-b3cc2388e534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_b0037829-a508-49b1-be5f-1a914424aa58" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_DebtInstrumentRedemptionRate_b0037829-a508-49b1-be5f-1a914424aa58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3da89e2-4683-47d2-a751-05f59905b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3da89e2-4683-47d2-a751-05f59905b8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_5bb7f2b8-3b46-4456-9000-189adeb00a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_5bb7f2b8-3b46-4456-9000-189adeb00a5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_688e779c-29de-4791-95ff-25be6a6013ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_688e779c-29de-4791-95ff-25be6a6013ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_fefd086a-bd53-49ba-8171-a0e0fd19d7a7" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_fefd086a-bd53-49ba-8171-a0e0fd19d7a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_ac45a702-eab7-4bdf-8fa2-61093c9adb40" xlink:href="biib-20220630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_LongTermDebtExchangedAmount_ac45a702-eab7-4bdf-8fa2-61093c9adb40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c46b816a-cff1-46cb-8fde-09a9ab7d98ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c46b816a-cff1-46cb-8fde-09a9ab7d98ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_35b11c7a-fd28-492e-974c-c2a38f41e6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_RepaymentsOfDebt_35b11c7a-fd28-492e-974c-c2a38f41e6bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_76d8a3b5-b8b5-4c90-9150-44ded96991d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_InterestExpense_76d8a3b5-b8b5-4c90-9150-44ded96991d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a862b59-14b4-4984-9bb3-a4a2dc3b540e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a862b59-14b4-4984-9bb3-a4a2dc3b540e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_663a7be3-8b1b-4e17-84a6-a851ac79aa3f" xlink:href="biib-20220630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_663a7be3-8b1b-4e17-84a6-a851ac79aa3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_8044a6b1-3952-4982-b988-cd2f2b058d3e" xlink:href="biib-20220630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_8044a6b1-3952-4982-b988-cd2f2b058d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3455c224-a372-4907-a056-c90380a68474_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3455c224-a372-4907-a056-c90380a68474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cb51182c-bbea-4b94-9f70-a42d142c3c42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:to="loc_srt_ScenarioForecastMember_cb51182c-bbea-4b94-9f70-a42d142c3c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83a0a033-9ca0-44b2-acb0-3bce8ede4c16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83a0a033-9ca0-44b2-acb0-3bce8ede4c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c89bd82d-0872-41a3-9dba-4a9e7835d410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:to="loc_us-gaap_SubsequentEventMember_c89bd82d-0872-41a3-9dba-4a9e7835d410" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i2bb56cc2a791458cae560a67edf7f306_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_82875fe0-c6bb-456d-b1cd-1b6f083b0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_82875fe0-c6bb-456d-b1cd-1b6f083b0fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7a5efa54-7117-4fc0-b3fa-0ede5fa46cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7a5efa54-7117-4fc0-b3fa-0ede5fa46cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d92b15f-2629-4476-878f-7667f66cbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d92b15f-2629-4476-878f-7667f66cbe66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_cfb94e90-c660-4c70-a323-5382f4e27bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_cfb94e90-c660-4c70-a323-5382f4e27bd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_18c39273-bc79-4685-976f-b02adea6cd52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_18c39273-bc79-4685-976f-b02adea6cd52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_75410e33-6414-4271-8167-bf236f1afe23" xlink:href="biib-20220630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_75410e33-6414-4271-8167-bf236f1afe23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="idcb549576c4c4d898f31f939f8741cd7_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d599361-e571-4a71-8ab3-82a24c3770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d599361-e571-4a71-8ab3-82a24c3770ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6918380d-a965-4aa7-99a6-b94025f55778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d625b16-b2ad-4388-875f-d4e1e0f3ea0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d625b16-b2ad-4388-875f-d4e1e0f3ea0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7736e298-200b-4cae-8fc8-e549cdac66f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7736e298-200b-4cae-8fc8-e549cdac66f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23228c05-60ad-4b81-9a34-b77288966acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23228c05-60ad-4b81-9a34-b77288966acc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dee78076-86f6-46c3-a95e-7b2c4eebf18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_78a69ee0-78e0-4e3f-8ea5-4b0e739eabae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_78a69ee0-78e0-4e3f-8ea5-4b0e739eabae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b715cb09-2100-4c0e-a760-4bdf9e99b13b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:to="loc_us-gaap_EquityComponentDomain_b715cb09-2100-4c0e-a760-4bdf9e99b13b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:to="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d2cd44a5-42c9-4e35-a841-e5889147493b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d2cd44a5-42c9-4e35-a841-e5889147493b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_41d06ed4-6e3f-4dea-b125-f65b2af3ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_41d06ed4-6e3f-4dea-b125-f65b2af3ed56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5c0e5f60-fa7a-413e-9558-b6f44b582cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5c0e5f60-fa7a-413e-9558-b6f44b582cc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ed97fdc1-8c5c-4065-bec6-b3d606744168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ed97fdc1-8c5c-4065-bec6-b3d606744168" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9690aad0-b6b8-44c8-9115-6c3fa22a97dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9690aad0-b6b8-44c8-9115-6c3fa22a97dc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i190d595a92d14218bd16d6caeff3c3de_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1f9a9b1e-d295-4a2f-a1f2-bde5d6d5b558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1f9a9b1e-d295-4a2f-a1f2-bde5d6d5b558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ff7b992-1bd0-4172-848f-a5234165229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ff7b992-1bd0-4172-848f-a5234165229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_17727657-0a14-4a8b-bb01-cef77bf1c3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_Revenues_17727657-0a14-4a8b-bb01-cef77bf1c3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7df09b13-e29a-4d0b-8927-3ae00e4205fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_OperatingExpenses_7df09b13-e29a-4d0b-8927-3ae00e4205fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a489a6ec-db54-49c8-a945-6a9f7d3caebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_NetIncomeLoss_a489a6ec-db54-49c8-a945-6a9f7d3caebf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d94a9d0e-9405-4e42-8dd5-5fbc8c326408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d94a9d0e-9405-4e42-8dd5-5fbc8c326408" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:to="loc_us-gaap_EquityComponentDomain_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:to="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0eb197f8-e4d1-4b5e-9243-80dce48a81fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0eb197f8-e4d1-4b5e-9243-80dce48a81fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe0cbd38-12a2-42ee-a43a-ac7ac194e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe0cbd38-12a2-42ee-a43a-ac7ac194e1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_ba099712-09b8-4b74-a0e2-d9ab2147558d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_ba099712-09b8-4b74-a0e2-d9ab2147558d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f9c4d852-b605-4506-bb8e-5988b08163a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f9c4d852-b605-4506-bb8e-5988b08163a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_9b535d27-d8b7-4752-85dc-7960d40bc401_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_9b535d27-d8b7-4752-85dc-7960d40bc401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9bdaed45-c908-446d-9f0f-b2765edd2d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9bdaed45-c908-446d-9f0f-b2765edd2d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_fd563e0f-19f6-42b4-a1d9-0d086cdbb9f3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_fd563e0f-19f6-42b4-a1d9-0d086cdbb9f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i91cee777e6e549a48b4fd8b4166ad20e_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:href="biib-20220630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1064aee5-83e7-4f7a-aba1-fddd8dda0724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:to="loc_us-gaap_NetIncomeLoss_1064aee5-83e7-4f7a-aba1-fddd8dda0724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b9fba6b-bbcb-4b47-ad45-d23cd73ff49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b9fba6b-bbcb-4b47-ad45-d23cd73ff49d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cb1e146e-908d-4176-bde8-8883d590dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cb1e146e-908d-4176-bde8-8883d590dcda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92239264-08be-4af8-9eea-94f29df1dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92239264-08be-4af8-9eea-94f29df1dca8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd9a9bb4-acd5-436e-a7d5-ec22d15759f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd9a9bb4-acd5-436e-a7d5-ec22d15759f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10825a7d-e72e-4b4b-ae94-fc14b94dc80f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10825a7d-e72e-4b4b-ae94-fc14b94dc80f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_db3b94ca-9350-4a40-abb0-50b5dce7ca65" xlink:href="biib-20220630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_db3b94ca-9350-4a40-abb0-50b5dce7ca65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_364aeb51-ab00-40ab-bdc3-121f4568ce6e" xlink:href="biib-20220630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_MarketStockUnitsMember_364aeb51-ab00-40ab-bdc3-121f4568ce6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_cdbc87f6-c253-4417-a6d7-9c1fd06b0728" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_cdbc87f6-c253-4417-a6d7-9c1fd06b0728" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="ib5cbc03381344e4e8c375c8c60838851_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_775a391d-f4c5-4a0d-b004-cebac68b0210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_775a391d-f4c5-4a0d-b004-cebac68b0210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e4995905-fb2e-47dc-9de1-ccc95d47feb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e4995905-fb2e-47dc-9de1-ccc95d47feb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b836c5ac-0b44-4852-9278-a1449d0d6896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b836c5ac-0b44-4852-9278-a1449d0d6896" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f5b9e627-42e2-4ffa-9351-c3bf28501c23" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f5b9e627-42e2-4ffa-9351-c3bf28501c23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_869a2b98-68b7-4849-b0ff-0763ae223d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_869a2b98-68b7-4849-b0ff-0763ae223d57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c4746bcf-6f0f-475d-b785-0fbd6a1f3500_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c4746bcf-6f0f-475d-b785-0fbd6a1f3500_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e2738901-ad3f-4d49-98ae-d2a6a1b7595d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e2738901-ad3f-4d49-98ae-d2a6a1b7595d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bb91875-8c3f-4af3-b36a-8fa6295a0534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bb91875-8c3f-4af3-b36a-8fa6295a0534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_bf9957ba-823c-4b1e-802b-c47b690d1f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_ParentMember_bf9957ba-823c-4b1e-802b-c47b690d1f7f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="ic1e53b337a924c9c9422899ee0cb71bd_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:href="biib-20220630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_20fe6b3e-d375-4776-af94-8832b35b9067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_20fe6b3e-d375-4776-af94-8832b35b9067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dd29969a-c3af-4617-b919-f1f744031703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dd29969a-c3af-4617-b919-f1f744031703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c4ff7a85-8c9c-417c-b2ef-aca9ae014ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c4ff7a85-8c9c-417c-b2ef-aca9ae014ed5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_bb5dc9cd-e20c-4865-bffe-6a584289a05b" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_bb5dc9cd-e20c-4865-bffe-6a584289a05b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:to="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5705125d-ddb0-45e0-9c34-f5a628564960_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5705125d-ddb0-45e0-9c34-f5a628564960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_38b989ae-f69c-46eb-8ed7-a2f0efc7b055" xlink:href="biib-20220630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_MarketStockUnitsMember_38b989ae-f69c-46eb-8ed7-a2f0efc7b055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_e9144ef1-2699-47b4-8a4b-24d529470eb7" xlink:href="biib-20220630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_e9144ef1-2699-47b4-8a4b-24d529470eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_bcf5e6d8-e1fd-4731-b61b-ab2362ed3221" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_bcf5e6d8-e1fd-4731-b61b-ab2362ed3221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_4ff02fad-3d16-458c-9d40-bcbb28b22c96" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_4ff02fad-3d16-458c-9d40-bcbb28b22c96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_28674568-e52a-4826-8726-d1fefa805ae6" xlink:href="biib-20220630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_28674568-e52a-4826-8726-d1fefa805ae6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i43ac5a6a5d114612bd7816e493f4a13b_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_03628bb5-30fa-4fb8-a5a4-271d1bba9aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_03628bb5-30fa-4fb8-a5a4-271d1bba9aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f52c345f-408c-4ba8-937f-208449bcee74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_EquityMethodInvestments_f52c345f-408c-4ba8-937f-208449bcee74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2513705c-a841-4a28-abdf-c482d059230e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2513705c-a841-4a28-abdf-c482d059230e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cae92cd3-8c09-460f-8e60-b06cb723a422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cae92cd3-8c09-460f-8e60-b06cb723a422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7f00e959-459e-4d9d-825b-0930d89a5b17_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7f00e959-459e-4d9d-825b-0930d89a5b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5525fc55-e044-4656-b879-b5885dcb6854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:to="loc_srt_ScenarioForecastMember_5525fc55-e044-4656-b879-b5885dcb6854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e43cdaac-e807-4993-9b2d-fb0d29a7a14d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e43cdaac-e807-4993-9b2d-fb0d29a7a14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_83cf9b8f-8e1a-48d6-a97d-2b835638e4b5" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_83cf9b8f-8e1a-48d6-a97d-2b835638e4b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f05c4d4-7833-4d70-9c36-40d39add8d94_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:to="loc_srt_ProductsAndServicesDomain_4f05c4d4-7833-4d70-9c36-40d39add8d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:to="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_0b1b79c9-c50e-465f-9022-7bc701ae24bc" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:to="loc_biib_ADUHELMMember_0b1b79c9-c50e-465f-9022-7bc701ae24bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="iaba67f39f7aa4c73bd1bf7403460356d_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a847a05a-8b0b-4809-a67d-a36380906f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a847a05a-8b0b-4809-a67d-a36380906f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_346814e2-8507-41aa-9006-4d7a88325384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_LitigationSettlementExpense_346814e2-8507-41aa-9006-4d7a88325384" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a47a9506-2708-45af-b4ec-31c1566bc50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a47a9506-2708-45af-b4ec-31c1566bc50e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4aee8517-104c-40b4-a471-e91fd32d856e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_InterestExpense_4aee8517-104c-40b4-a471-e91fd32d856e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_49a3474c-bba9-4af3-b14f-d5cc45340d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_49a3474c-bba9-4af3-b14f-d5cc45340d98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ec272fd8-1eee-4fdc-bb88-69c756df234b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ec272fd8-1eee-4fdc-bb88-69c756df234b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_96daa3f0-2a43-43ac-a0bb-edc380504a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_96daa3f0-2a43-43ac-a0bb-edc380504a0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a0e02c0b-d045-4630-b9b5-42ef9281104d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a0e02c0b-d045-4630-b9b5-42ef9281104d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e81de12-e4cf-43fc-9ac4-368e5700a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e81de12-e4cf-43fc-9ac4-368e5700a83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cf37e71-8831-46ed-81c5-8016ab7be18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cf37e71-8831-46ed-81c5-8016ab7be18a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e95becd1-b275-4c5a-b7c2-c9443a1681aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e95becd1-b275-4c5a-b7c2-c9443a1681aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_33311d7d-5615-4696-80a8-4a403aa2f3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_33311d7d-5615-4696-80a8-4a403aa2f3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b35dc459-2e07-45c2-b2eb-2af85e907a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b35dc459-2e07-45c2-b2eb-2af85e907a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee11bfe0-f46d-428b-afb2-c267bf0489e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee11bfe0-f46d-428b-afb2-c267bf0489e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_38235fb0-1a12-4b7c-8894-6088286e9ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_38235fb0-1a12-4b7c-8894-6088286e9ac6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_e84f26d5-9570-47f8-b2b1-a9503f14b24e" xlink:href="biib-20220630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_biib_Collaborationexpensesaccrual_e84f26d5-9570-47f8-b2b1-a9503f14b24e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_202ced45-b8d9-48c4-a8ac-9421c5d8d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_202ced45-b8d9-48c4-a8ac-9421c5d8d3bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6997c888-e317-4c09-abcc-f96d62fb9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6997c888-e317-4c09-abcc-f96d62fb9c39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d3771b13-4d06-429e-a13d-803ebf865eed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d3771b13-4d06-429e-a13d-803ebf865eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2995953a-0449-422e-8489-9fb1c92c4854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2995953a-0449-422e-8489-9fb1c92c4854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:to="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:to="loc_dei_EntityDomain_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:to="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_f4ad7876-ab25-417f-bfce-233257e01861" xlink:href="biib-20220630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_f4ad7876-ab25-417f-bfce-233257e01861" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i61f3295df6f5433a99d520806c58f1e5_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a1db8917-e049-4d23-9a73-64cb0db00103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a1db8917-e049-4d23-9a73-64cb0db00103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e1ee4f43-9682-4343-a45f-c82488da4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e1ee4f43-9682-4343-a45f-c82488da4b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c891bbee-e918-4c38-a1f8-a802c5d28d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c891bbee-e918-4c38-a1f8-a802c5d28d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_43732042-5a15-42a4-b15e-2e8f22a11a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_43732042-5a15-42a4-b15e-2e8f22a11a12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:to="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0cd0590b-8835-4843-aeba-5ee59b74e6bd_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:to="loc_dei_EntityDomain_0cd0590b-8835-4843-aeba-5ee59b74e6bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:to="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_41fd2094-9e26-4586-9c46-042a4d4f2265" xlink:href="biib-20220630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_41fd2094-9e26-4586-9c46-042a4d4f2265" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="icb716f7a9db44115a3314bf8595433e0_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_43d1752d-2376-4ffe-a51f-b21a6308f2e2" xlink:href="biib-20220630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ExpenseIncurredByCollaboration_43d1752d-2376-4ffe-a51f-b21a6308f2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_1e90e203-bd99-4b20-9fd6-41c59ffc8922" xlink:href="biib-20220630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Expenseincurredbythecollaboration_1e90e203-bd99-4b20-9fd6-41c59ffc8922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_4c806d10-25fd-465b-8d34-ea086859d54a" xlink:href="biib-20220630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_4c806d10-25fd-465b-8d34-ea086859d54a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6caff1c5-c7cd-49c4-b666-3c51ef7f674e" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6caff1c5-c7cd-49c4-b666-3c51ef7f674e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_c68ba30f-b076-41c3-b5a4-a213ae0e4912" xlink:href="biib-20220630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_c68ba30f-b076-41c3-b5a4-a213ae0e4912" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_2adae89b-1921-410e-9f6b-57fbba15ce3b" xlink:href="biib-20220630.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_CollaborationAgreementTerm_2adae89b-1921-410e-9f6b-57fbba15ce3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6008cda-5e1e-46d8-bc3d-9717643564fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6008cda-5e1e-46d8-bc3d-9717643564fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_286dc577-00bb-46b2-bfeb-29022c81f3d6" xlink:href="biib-20220630.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Termofcollaborationagreement_286dc577-00bb-46b2-bfeb-29022c81f3d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_ccfa7c57-7ed4-4f47-a101-d12e744af215" xlink:href="biib-20220630.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_ccfa7c57-7ed4-4f47-a101-d12e744af215" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_3518fd97-c305-4f90-8f04-844d8f763d35" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_AdditionalMilestonePayment_3518fd97-c305-4f90-8f04-844d8f763d35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_264f7684-d975-4b6b-aadc-ea401705213f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_264f7684-d975-4b6b-aadc-ea401705213f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ddd1633d-cfa3-4338-942c-2cc85cd6e653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ddd1633d-cfa3-4338-942c-2cc85cd6e653" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_15bde1df-0f43-4054-91f5-95a161ab19c6" xlink:href="biib-20220630.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_15bde1df-0f43-4054-91f5-95a161ab19c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d79efe69-6099-4b6c-8e96-ff2e3d314f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d79efe69-6099-4b6c-8e96-ff2e3d314f7c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_f291e44d-0826-475e-9bfe-ddbdeceab3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_f291e44d-0826-475e-9bfe-ddbdeceab3d3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_1ae3e364-7417-4e0a-84f5-aa251e143efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_AdjustmentForAmortization_1ae3e364-7417-4e0a-84f5-aa251e143efc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_c46c25e5-e954-45dc-bffe-56d570a42b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_DueFromRelatedParties_c46c25e5-e954-45dc-bffe-56d570a42b34" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b4cc4dca-90d2-4ada-8b84-9a09a986f453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b4cc4dca-90d2-4ada-8b84-9a09a986f453" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_25073297-8794-41f1-9184-f44c2be5ca0f" xlink:href="biib-20220630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_25073297-8794-41f1-9184-f44c2be5ca0f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ef2d6def-2e27-4d23-96f9-10c598a597ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ef2d6def-2e27-4d23-96f9-10c598a597ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ce9acbdf-3606-4f3e-a793-007df617ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ce9acbdf-3606-4f3e-a793-007df617ca2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9dc265e5-7ebb-4991-8e19-59ee2a31e023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9dc265e5-7ebb-4991-8e19-59ee2a31e023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894184dc-e9ce-42a3-92d6-c982cac5f9de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894184dc-e9ce-42a3-92d6-c982cac5f9de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_da030b1a-6205-42b1-8576-8d894d0c7f57" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_EisaiMember_da030b1a-6205-42b1-8576-8d894d0c7f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_f968d8d1-33ff-4dd6-9504-a0c1a50fe26d" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_DenaliTherapeuticsIncMember_f968d8d1-33ff-4dd6-9504-a0c1a50fe26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_0f790013-fb2c-4626-af84-96605e501d93" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_80a4353c-037b-4c40-b0b6-57f26d255613" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_80a4353c-037b-4c40-b0b6-57f26d255613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_28af59a6-7046-4c38-aba6-0fefad7cd72c" xlink:href="biib-20220630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SageTherapeuticsIncMember_28af59a6-7046-4c38-aba6-0fefad7cd72c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_40bf0e97-f604-412a-8248-99f56f088549" xlink:href="biib-20220630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_UCBPharmaS.A.Member_40bf0e97-f604-412a-8248-99f56f088549" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_0e3d11d2-1b7f-4a9d-a11b-bd34a56462f4" xlink:href="biib-20220630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_0e3d11d2-1b7f-4a9d-a11b-bd34a56462f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3607c009-96f5-4244-9468-5734300a8beb" xlink:href="biib-20220630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3607c009-96f5-4244-9468-5734300a8beb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_97edcc5f-c3e7-4136-8fa3-0a8327575a68" xlink:href="biib-20220630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_97edcc5f-c3e7-4136-8fa3-0a8327575a68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:to="loc_srt_ProductsAndServicesDomain_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:to="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_73e13d7d-16ae-4276-b630-3c6cfa8240cd" xlink:href="biib-20220630.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:to="loc_biib_E2609andBAN2401Member_73e13d7d-16ae-4276-b630-3c6cfa8240cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c3a65995-0dd6-40c0-b75a-e81172a51d88" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:to="loc_biib_ADUHELMMember_c3a65995-0dd6-40c0-b75a-e81172a51d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77b51ca2-9c01-4e70-8031-a681a1123a17_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77b51ca2-9c01-4e70-8031-a681a1123a17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_01dc9c84-fac0-4b39-b75c-fcacfa1eefa8" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_DenaliTherapeuticsIncMember_01dc9c84-fac0-4b39-b75c-fcacfa1eefa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_38d617bd-4f5b-4d17-8c2f-6c335d57383f" xlink:href="biib-20220630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_38d617bd-4f5b-4d17-8c2f-6c335d57383f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_65c90e82-4170-4151-990b-fab0cbf180ac" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_65c90e82-4170-4151-990b-fab0cbf180ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f79951d-7abb-445c-b69a-8838de2d41fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:to="loc_srt_RangeMember_7f79951d-7abb-445c-b69a-8838de2d41fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:to="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be271ac8-f767-41b5-83c5-f360e609ad24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:to="loc_srt_MaximumMember_be271ac8-f767-41b5-83c5-f360e609ad24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1d6d2680-7f4c-40a2-a17f-a099182dedf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:to="loc_srt_ScenarioForecastMember_1d6d2680-7f4c-40a2-a17f-a099182dedf4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="i910afca844e6491f8671722b61086f66_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_724a5189-59c4-466d-b85c-53e792ffa7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_724a5189-59c4-466d-b85c-53e792ffa7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_b5585dd1-fccf-4202-a1b3-a9f436c5ab28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_b5585dd1-fccf-4202-a1b3-a9f436c5ab28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2ef88b48-3ba3-4d64-8e51-432f8076d26a" xlink:href="biib-20220630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2ef88b48-3ba3-4d64-8e51-432f8076d26a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_049d7573-53b9-4bcf-9511-93fe04ab6fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_049d7573-53b9-4bcf-9511-93fe04ab6fbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4aa89bfc-f6f6-4be4-bbf4-05e2f8c7115f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4aa89bfc-f6f6-4be4-bbf4-05e2f8c7115f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_7d8406e3-0b76-4ed3-846a-740f7966465e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_7d8406e3-0b76-4ed3-846a-740f7966465e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_01ba9e6a-99df-4d9c-bc07-4be9a12ca191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestments_01ba9e6a-99df-4d9c-bc07-4be9a12ca191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_43e5c661-b9e4-467b-9025-5f2d51ca4f0b" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_43e5c661-b9e4-467b-9025-5f2d51ca4f0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ef36c8bb-f87b-474a-b075-c8ab7471e958" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ef36c8bb-f87b-474a-b075-c8ab7471e958" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_55bbbc74-d347-46b5-a6e5-20540d7781ad" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_Collaborationprofitlosssharing_55bbbc74-d347-46b5-a6e5-20540d7781ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_320c3559-549a-4b0f-95db-600700196e5c" xlink:href="biib-20220630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_320c3559-549a-4b0f-95db-600700196e5c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_65a46b40-5fda-4db6-baa1-d37907176a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_65a46b40-5fda-4db6-baa1-d37907176a49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5fb2e3c8-2ea7-4b03-a3cb-9165fd0a1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_5fb2e3c8-2ea7-4b03-a3cb-9165fd0a1f06" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_479119c3-2835-47b9-bf95-bc74871b37dc" xlink:href="biib-20220630.xsd#biib_AccruedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_AccruedMilestonePayments_479119c3-2835-47b9-bf95-bc74871b37dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_30a5b3ea-e70a-4f14-aab6-7bc93ebb43e4" xlink:href="biib-20220630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_30a5b3ea-e70a-4f14-aab6-7bc93ebb43e4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_30951b3b-1d6d-46a5-92a5-517020fb6eec" xlink:href="biib-20220630.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_ContractOptionExerciseFee_30951b3b-1d6d-46a5-92a5-517020fb6eec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_804fc1e5-5218-4e51-9939-c6e129862e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_804fc1e5-5218-4e51-9939-c6e129862e1d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81ddff95-1af4-4d6d-82a6-8422e0014bed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81ddff95-1af4-4d6d-82a6-8422e0014bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_029aee16-47fd-4bac-a34c-2c22e79186c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:to="loc_us-gaap_InventoriesMember_029aee16-47fd-4bac-a34c-2c22e79186c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ca532712-94ab-40ab-bfb9-393331db6918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ca532712-94ab-40ab-bfb9-393331db6918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6530065f-fff1-4659-aafa-8798e88c65c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6530065f-fff1-4659-aafa-8798e88c65c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_4468c164-316a-4eec-b9cd-763a40817a31" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:to="loc_biib_EisaiMember_4468c164-316a-4eec-b9cd-763a40817a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_be313ac6-c342-47a0-a34d-b69f99d0638a" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_be313ac6-c342-47a0-a34d-b69f99d0638a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f1e32644-5ceb-4930-9076-332eceb3fd5e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f1e32644-5ceb-4930-9076-332eceb3fd5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0371cbc0-915e-4f4e-a574-a99b792eb627" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0371cbc0-915e-4f4e-a574-a99b792eb627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21729e86-cb4f-4775-938d-0ec382bb6b45_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:to="loc_srt_ProductsAndServicesDomain_21729e86-cb4f-4775-938d-0ec382bb6b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:to="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c60236ab-1f3c-44e4-b0b9-7f812430f02e" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:to="loc_biib_ADUHELMMember_c60236ab-1f3c-44e4-b0b9-7f812430f02e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede_default" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_45d49bfe-8f03-4774-8cf6-cdb0f41981f5" xlink:href="biib-20220630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_45d49bfe-8f03-4774-8cf6-cdb0f41981f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_a615ca91-ed9c-4983-a1ac-951f741db0a7" xlink:href="biib-20220630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_a615ca91-ed9c-4983-a1ac-951f741db0a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="i891f67443e844c438869b2fbe7b3ef0c_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_9ff46bc2-962c-4b87-b9f7-a9f997fa0a4a" xlink:href="biib-20220630.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_CollaborationAgreementTerm_9ff46bc2-962c-4b87-b9f7-a9f997fa0a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_c9ad35c5-1049-44f6-a35e-12622700da37" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_c9ad35c5-1049-44f6-a35e-12622700da37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_73d05a9b-3ab6-45f1-8739-2440b926c546" xlink:href="biib-20220630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_73d05a9b-3ab6-45f1-8739-2440b926c546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b54dc65-7a53-4892-a4af-ce60e0479795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b54dc65-7a53-4892-a4af-ce60e0479795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_30755e5e-5b72-4f06-b07d-5d02268e9e6d" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_30755e5e-5b72-4f06-b07d-5d02268e9e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_d5ce0222-da6d-4396-afc6-bba0e8deaf40" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_AdditionalMilestonePayment_d5ce0222-da6d-4396-afc6-bba0e8deaf40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_52bcfce1-75b2-4676-8c76-de463818b7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_52bcfce1-75b2-4676-8c76-de463818b7e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_63b41b5f-0180-4d52-bf72-64813ff2fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_63b41b5f-0180-4d52-bf72-64813ff2fe69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8158ec59-c9f6-469b-b5a7-522fdc5fa4c4" xlink:href="biib-20220630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8158ec59-c9f6-469b-b5a7-522fdc5fa4c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0862fb5-c6fb-4c5a-9509-f542407cf40c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0862fb5-c6fb-4c5a-9509-f542407cf40c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_f5e2e156-f026-494e-b6d6-291044c14c90" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:to="loc_biib_EisaiMember_f5e2e156-f026-494e-b6d6-291044c14c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a_default" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_0ef720e0-4468-4b1a-aa0b-2ecdcb3ebdf8" xlink:href="biib-20220630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:to="loc_biib_RegulatoryMilestonesMember_0ef720e0-4468-4b1a-aa0b-2ecdcb3ebdf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9a2148f6-602b-43c8-ab00-2f113648f52f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9a2148f6-602b-43c8-ab00-2f113648f52f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_4f1af972-d622-45b3-875e-8df309b0bc6e" xlink:href="biib-20220630.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:to="loc_biib_NeurimmuneMember_4f1af972-d622-45b3-875e-8df309b0bc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56b59b40-0620-4cf2-b3eb-319ccb2c0b98_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:to="loc_srt_ProductsAndServicesDomain_56b59b40-0620-4cf2-b3eb-319ccb2c0b98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:to="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_b2e465eb-ccf0-4d9e-81ef-85084bf44698" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:to="loc_biib_ADUHELMMember_b2e465eb-ccf0-4d9e-81ef-85084bf44698" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended" id="i5d2c8b4fde8d4157a872ce9f29dddc40_DispositionsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8a08bf7b-04d3-4c87-88b9-a4c5b1165cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8a08bf7b-04d3-4c87-88b9-a4c5b1165cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_52948dff-910b-4a6f-887f-fcf8ef4dfdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_52948dff-910b-4a6f-887f-fcf8ef4dfdbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_9091bd9b-0922-4af3-a164-3e4ceb3d34bd" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_9091bd9b-0922-4af3-a164-3e4ceb3d34bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a606fb2e-dc5f-49ed-b845-a731cb6e3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a606fb2e-dc5f-49ed-b845-a731cb6e3ccf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2fe10129-99dc-43a1-8d40-0febd69cef60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2fe10129-99dc-43a1-8d40-0febd69cef60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6f8e3fa2-ffa8-4334-8817-f2d8ec1b5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6f8e3fa2-ffa8-4334-8817-f2d8ec1b5dc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsFairValueMeasurementInput_58800e56-64f8-48a5-92a6-e4cee8f6253f" xlink:href="biib-20220630.xsd#biib_OtherAssetsFairValueMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_OtherAssetsFairValueMeasurementInput_58800e56-64f8-48a5-92a6-e4cee8f6253f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_22611f3f-5976-4ec8-8400-b4c7c78e0929" xlink:href="biib-20220630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_22611f3f-5976-4ec8-8400-b4c7c78e0929" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_4ff45c7c-463f-477e-83be-0156d1c610eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_4ff45c7c-463f-477e-83be-0156d1c610eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_6303bd5d-df12-4d05-885f-121a2b65a15e" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_AdditionalMilestonePayment_6303bd5d-df12-4d05-885f-121a2b65a15e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_e426f6d6-9f3c-466f-935a-f8cd96ff0931" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_e426f6d6-9f3c-466f-935a-f8cd96ff0931" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit_5ab2b76e-891a-4f5e-83c1-9b31bbc52b83" xlink:href="biib-20220630.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_DiscreteIncomeTaxExpenseBenefit_5ab2b76e-891a-4f5e-83c1-9b31bbc52b83" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbb7a03a-df22-4dc7-8fd8-9cc696158e02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbb7a03a-df22-4dc7-8fd8-9cc696158e02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6582f8f4-c1d6-4617-9871-8005b4a348a3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6582f8f4-c1d6-4617-9871-8005b4a348a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_54ecd7ad-a679-49f9-ac00-171b32a1a3fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_54ecd7ad-a679-49f9-ac00-171b32a1a3fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_e711e306-6d8b-4424-a1de-66959bf2bbac" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_e711e306-6d8b-4424-a1de-66959bf2bbac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_146719f2-e75a-438e-adfb-5cd19439f94a_default" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_146719f2-e75a-438e-adfb-5cd19439f94a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_50ef67ee-d737-4a42-84f9-24486a22b2fe" xlink:href="biib-20220630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_50ef67ee-d737-4a42-84f9-24486a22b2fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_16cd4f4d-8f33-4a57-83ed-c53bafc59632" xlink:href="biib-20220630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_16cd4f4d-8f33-4a57-83ed-c53bafc59632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f00444f5-19cb-4455-ae96-48cdc972b7d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f00444f5-19cb-4455-ae96-48cdc972b7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1e844f26-4632-4db8-a68c-add05342378f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1e844f26-4632-4db8-a68c-add05342378f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be2a7ba-dcc9-4340-aac7-e7d7c463563b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be2a7ba-dcc9-4340-aac7-e7d7c463563b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac89d529-a90e-43cd-92d2-2eac7e810afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac89d529-a90e-43cd-92d2-2eac7e810afd" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_a93da101-82b7-4f46-99c2-cea99ec69ff4_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20220630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_72a3f7ee-db1e-47f8-9602-db87ff277103_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_aeb64ee6-a738-4242-96d4-65c1419f0141_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e1c9794a-4482-49a4-9c90-0c8bd8ebb8a1_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ab4ef122-3cc4-43be-8960-734b3b7681f0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_d489840f-bf95-4c10-b810-f0f26d72e834_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20220630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_aa0836ac-1394-4d43-9e4f-494880daf5cb_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b130a5ee-b7eb-4d2e-a481-765036566f7b_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_17a664ff-fb52-448f-b0af-cc15017bbf9a_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20220630.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_a761b6a8-ffe0-439e-b4c4-cdc52b95fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32be28c1-67c2-48a9-a8ab-bb3034368b3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b75def60-faa7-40d0-b4a4-3ccc3635d2bc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b1a443f-71ad-44aa-bbd6-8d0feb2c2704_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_15213a66-5eb5-4f97-b9a9-a7c7ef53f845_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_34182875-7e5e-4170-a1ae-8d58edfe4150_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_338b72d3-26b3-4c68-acc5-0d0e418c425a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis(1)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_c225c68b-8170-4e6b-bd0e-47838426fe77_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d01cc70e-4bf4-446a-85da-bb457dd965c8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_043a4c86-acaa-4d76-a987-6da67a69b8c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_4674fdc4-a961-44b1-bb54-6676f915f0a0_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20220630.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_954b04d5-0aaa-406e-97a8-ad6dbdd6c7f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_293d9187-eae6-4880-aa16-c6633738d4da_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_52140564-c122-46f2-8f58-d5562c92edec_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_434cab9f-fa64-4171-87a4-57ad1fdca519_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f66b5720-b1ff-43e7-9da2-6c8f0550d073_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_5650532e-a3b2-4e28-9c37-578f88072b65_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7eaf63c8-332a-4879-a0cc-c9f49a7de727_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_aa115474-5897-4760-8955-3a98e39d1894_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_d81a807f-9961-4202-be9e-3164e40e5cd2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_4ab9ff7e-ed5b-4d4a-8671-408112af5e92_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1fda72c9-fe03-4c7d-af8e-3c09f482de96_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4ed4907f-d062-444a-96e6-facb6f379bc1_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_07ef50be-9532-4f64-9975-4753370fa7ec_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3468ba03-9d36-4005-b199-de7785518b2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_9e9efaff-ac2c-4db9-bcf0-74ea0d603234_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20220630.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_d4fbc188-88a1-44d9-b9f2-78f1071cb945_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5852321f-ce1f-4272-ab0e-a2bd772f4f45_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_bf8fbcb9-9975-41f8-ab06-5ad70f96bc9b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_f0f2d830-5b78-4585-a13a-7ec0739da298_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20220630.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_dd3454e1-ced2-400b-b8ee-4fab9b890c38_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11743b4c-5e67-4e1d-b07c-6a2003a8ece0_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1817d624-24bb-44b6-bebf-7ed2d7be4ae9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_48766cb2-2a5e-4d5d-acb0-71073d0eec20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_d4ef2810-2390-4a9c-8c77-4e3f5205dacb_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_62856a85-7024-4052-8fd7-587ab6b1b8d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_0f5335b6-9954-41fa-bd84-4697805ff6de_terseLabel_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_label_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service [Member]</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_documentation_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:href="biib-20220630.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:to="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_441e6cc9-d0b5-4aec-8a57-7c8118686c0b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_43e1bc13-ed39-4d86-9465-76d3e23c0dde_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20220630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_96c68128-f950-423a-ae6d-7fc6f2d7358b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_18d1bfb7-f9b9-46f8-b012-115b2508131b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_1e86c50c-8bc3-4139-bd48-e43ded6b666f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_edced19c-e390-4240-a602-495012956a3c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_f7ee9258-caca-4bc9-a852-3d60c95e670e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation agreement in principle</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_521e99c0-438f-4554-b1fe-608ba4a57b1e_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation agreement in principle</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7d457ab-4a33-4b23-bb26-5606ead20a7a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_fc5975e6-b923-4d8c-9567-00992331c65e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e2ec4dbd-c002-46ad-8dfb-d2cf7f6b3672_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e5319ab0-12b7-4797-b622-d2ee089c3725_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_f3dcac2a-7393-474a-aa4f-0d1ecd871127_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7ab8f3e9-260c-4bdf-b2d9-b2db10b1aa86_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9ee70a0c-da52-42fb-8733-b2193e3e375a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_be0a0834-518b-40e7-9489-cf8aab2576f4_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_109fd220-eb5b-4a73-ac3b-e5d72a812e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_2901b214-aff3-4727-a1a2-dfdbf70dadae_terseLabel_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_label_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement [Member]</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_documentation_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:href="biib-20220630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:to="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_71845c80-80fb-4537-90c2-959ab173976a_terseLabel_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_label_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member" xlink:href="biib-20220630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111AndBIIB112Member" xlink:to="lab_biib_BIIB111AndBIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_236ae7e3-484c-47b0-9100-7bdaf2652610_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:to="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1b411d71-722d-4f87-b870-579360119bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4edb5cec-7cd2-4be2-84fe-8ffd75310ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9211c607-e0f6-4dc6-aa54-6e18cf220a41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_ac8a488b-44cc-4a01-9941-233e3d33c57d_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20220630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_baf25e79-c13e-4e3c-8715-5050e2e94bf2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_eef44e65-56c1-4a22-a61c-fec346982ad1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_15f9b0c4-97cd-4c3f-a06b-e422b02961d7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_54b2b806-f687-46ba-b386-e46c75cd66be_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_665fc773-1c8b-40ba-93d8-d365bfb75db8_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_495d6eb3-f599-4d38-9f09-e3fde56bfbab_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20220630.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_333b7047-aeb2-4a39-a277-1138fb786176_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20220630.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_cacb6eac-0cf2-4806-b231-cc96dc04c1e2_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20220630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_808996e8-6aa2-48e4-abf1-628ce39574a0_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d72259f8-379f-461f-8e21-b21e7da30a34_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_815488e7-2ff1-4c91-8294-4cd8c5a65154_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_9294aa1d-5345-4ecc-9bd7-ab7e7973c899_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a58a166c-e741-4764-a733-03226d5790b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f462f89a-eca5-47f9-bad5-4c526e31b35b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4d115467-b16f-423c-ad08-1ba4455a3fc1_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e52e6b7f-a0e9-4c00-bb71-07123fa12577_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_61341a08-3b8f-4b7d-aef9-1f2bc10dc4ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_62832f65-b2ed-4deb-9391-05e0fd1c13e3_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_6c5914fb-1f0b-48fa-a21d-0e1580b15fcf_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20220630.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8213076b-c587-433d-b307-22be6b9adc42_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_d966a4ea-c9e8-40d6-915a-d44eb54ee446_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20220630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7c91e0fc-0fca-437f-b4f1-8a50e268b070_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_e5e1b036-1f55-4d8e-8a7b-c0560bfcb3b4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_637c315a-4f44-4086-895c-cba5ad85c951_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_b88360b7-df17-4e86-87c2-6157573f06bb_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2f892d01-6211-417d-b75f-679e6a8dbbf1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7897ba32-2fe6-404c-9cde-690cd248a9d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_b293da87-34ef-4356-9cb7-0cd2159a9961_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsFairValueMeasurementInput_86b9430c-88a2-4036-8baf-f2bb3a200bb2_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsFairValueMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value, Measurement Input</link:label>
    <link:label id="lab_biib_OtherAssetsFairValueMeasurementInput_label_en-US" xlink:label="lab_biib_OtherAssetsFairValueMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value, Measurement Input</link:label>
    <link:label id="lab_biib_OtherAssetsFairValueMeasurementInput_documentation_en-US" xlink:label="lab_biib_OtherAssetsFairValueMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsFairValueMeasurementInput" xlink:href="biib-20220630.xsd#biib_OtherAssetsFairValueMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsFairValueMeasurementInput" xlink:to="lab_biib_OtherAssetsFairValueMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_7e407829-6440-40ce-a9f8-287888263fb1_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20220630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69831b32-94e4-4263-b715-a697f905c6f7_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_68e5c41a-bf77-488c-ac79-dc11476cea93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_8de66df8-ec24-41c3-ac12-939e0fc9dd7c_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:to="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4a0cf920-8b7f-4a93-ad62-bc4548f21c3f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_0951bc40-112f-48ae-a0f5-8050325d6081_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0f24b808-da86-4373-ba95-1dd1753f5cf8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_eadcfae7-709f-4c36-9373-c8bbd886f8f2_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20220630.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d850738-47db-4ab9-b5d7-499f715d6cf0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d274ac68-c504-4fac-8de9-ff9d24471f6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7d3a2b38-5571-4d43-8664-aae655fbf7af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ea548c5-55d7-4b03-a1df-c96396357f3b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_4af09e4d-9658-42b9-bc94-a3ac2e2c9419_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20220630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e2ce4827-1a64-493f-8930-84a5c1e295f9_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_997913f4-5344-422b-b3ad-bd78cd677ac9_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_a2832e0e-6d1a-456c-8760-381d0b3a156d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_38a8aada-4fb0-47fe-8dbb-96aba5fc1267_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_f81f8f2f-ae71-4b0b-bbd2-f78a12db5b1a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8578524f-a0a0-44f2-a9e9-615eadcb7649_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ddc70345-c4be-4734-92b5-552be4defbd3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_b389dc2d-7c16-48e0-8abc-205b6ee89a06_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfb477ef-1a7f-4d93-aadc-3c8ca0884b2a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_af2adf68-b7c7-475b-8e3e-1e0497bc9944_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_6b82a127-cd0b-49dc-9c76-8cc13d6dd8b3_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20220630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_ced87b13-ece7-4a31-b842-826c7bc0b513_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_89c7aa5c-39e2-44cc-a43e-a8007cf3c75c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_54b635c7-a754-421b-b28b-62541af84e4b_terseLabel_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete income tax expense (benefit)</link:label>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit" xlink:href="biib-20220630.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscreteIncomeTaxExpenseBenefit" xlink:to="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_14b234b9-4dcf-4432-953b-3ed88abd6517_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20220630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_cbbb91b2-85d5-418e-83e1-e2c0f3954c90_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a8b3ea98-c8ba-4453-930e-30d42a1cc782_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1c97010d-8d5a-4f3f-8cd7-74a806a34790_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_8e0a291e-231f-482a-b66f-54047a66fd75_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_119964f1-368a-457e-849f-4e2b7e510493_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20220630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_6bb54d52-27f3-4b9c-800a-062e10a3f2aa_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_eadcc07f-a424-4eb8-8eaa-95fac18a424f_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_456d8417-6bcd-4a86-b533-1256255dbaf4_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20220630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_5d0ec0ff-9fa7-4728-b2df-ab3da74d007c_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20220630.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_99afee36-558a-4ead-b8ad-d6a24e1f0076_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_2ab66d0d-f824-4ce7-ac14-144f8b52f943_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_b66eb90b-a5cd-4a17-9c76-f37ea5468b7c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_5010ae56-d495-439e-b210-33576bf65bf5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_accbc90a-a7a8-48ca-9540-d08568ad772f_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20220630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_7c231fa0-c5ce-4fe2-9b86-699374a83167_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20220630.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ec6d9af-6dcd-4d11-982e-f016238d61d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ac41842e-0c52-4c7c-a3e6-bc29f22dcb5f_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9c5ea0aa-37eb-4f04-bbd4-135d21abda4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_d0426256-346b-407d-a8fe-9102b3db9758_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20220630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_6fbde193-4686-46d1-ae3c-48cadbf85355_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_291d6989-a3f6-4473-95d8-ce9bcbef4a75_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20220630.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_12ff6b8a-e490-4b69-be1f-f0f02a6b4c39_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ee61b78b-e9d5-4d3d-ada2-08702adfd2c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_b47f3a3f-a43d-4ca2-8596-f306aa1ef4d9_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20220630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_219006e3-551c-43e4-b20f-ca7835d2e23c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_f73fa62b-f8c5-4182-a5ef-e615272c8ef8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f5deb8fa-9534-465b-9a8b-608eb760fc66_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_797ce937-6000-49c9-90fe-fea80b2ab5a9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_31ed7883-6782-4464-95b3-f4a131ce5c5b_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e78795cf-2c94-4900-8d83-0baf17a6910d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_645e6760-f7e7-4e63-b75b-f650acf75463_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_3684f5fc-0fee-49b1-b0c8-e331e25a6a40_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_512659f1-d12a-4d88-b3ce-2fa8db787be2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_052f03c7-8965-4a4e-b5e4-01e6f55bc3e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4259e11c-06d3-4737-a7c6-fa4ac46e84ce_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e0355a73-aa31-4476-ba0a-a4f051ad63b1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e675e452-ac9a-44e8-ae2e-06ec3b0a19be_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5cd518a-fea4-4df7-8b45-8b352f42b951_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_d1b15f21-80ca-4704-a0a4-6046e3a9d729_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_57870611-0ce2-4106-b6a2-6c3e129a5da6_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_eb5b05a8-82af-4587-a089-1dcc01cbe24a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_25b88891-8cc7-44dd-a61e-19b009a6ac0c_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent discount on common shares</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4eab5f12-b7ce-4989-9abc-e879a2a84d0e_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20220630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8bccb234-b481-4171-b6b0-1f5313468a05_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_6490679a-be23-4ef2-b1d8-8db064a46540_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20220630.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_c1e5760d-7fd1-442c-87bd-a83e517e5bf9_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20220630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_0024f8e9-bbc1-43e6-a866-61c39b9b78cf_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_86f6d390-7205-4ace-b991-118f6dfa4871_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b6a02c83-fc11-4e48-9730-12d34f41e605_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7c5e607e-5ced-4d45-8ce2-abb61ae6980e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5678570f-33e5-4a76-9ec4-da58a141086d_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_879176f4-0f17-41c4-b716-f7f7e17a181b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_f6c6f22c-011a-4f1a-aaa5-623bfe22150e_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_fdd89374-5308-42dd-9fe7-fd0cb40b8723_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:to="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4fa066a3-ce89-4938-9a25-dbd77b33d3a6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_41f1774b-8287-49dc-b98e-0e368858c68b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_4955cc49-d14c-4e7c-8fad-191576c1f782_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5164ab1a-1b21-462f-994e-f3fa99ce4903_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_843f4ee8-e2ce-435e-a39e-5b7f80a8e972_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5240390d-1e04-49b8-910b-0a44dea5a59f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1fd87104-45b7-47ef-a820-f7091678110e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_32856028-f172-4c2c-a171-8769dacf15b9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d86f8cb5-c8a7-496b-8321-524ea78026e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a75323d4-733e-42c0-92d7-9866b293a292_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_3a6b81c9-9ceb-4722-bc85-f358d0ef4a51_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20220630.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2aea80fb-b6d3-4736-8abe-7cf7083e86ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_a059a27f-5b86-4587-8784-a6d0c775d713_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_09c9af82-13be-452c-a407-17b8bb2722dc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_f08fb877-847e-40ab-b283-8ff06eb6c2c0_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20220630.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_32e75c2e-1140-45a0-b2f6-a8c359b7d82c_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20220630.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5237de7e-49df-480b-868a-e423ac401266_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_431638b0-e0c5-4bf5-9da3-89f65ceb13ca_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6bcb8579-331e-4720-b169-0a15fc119540_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a138682c-ae87-44e8-9540-891dd71b890e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_236110e3-b7c4-4f8a-ab8b-e185d52bfc3b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_bde31d92-013e-4723-bf68-1a0c015bf54b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_675c5feb-ee7d-45aa-afbb-ed1b64c23a18_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a008ff58-7596-4284-83df-f8f22e3c4231_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_79a1cce2-a332-4dac-9867-7aa804863805_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ab1b6458-44f2-4707-94a6-1614e678ab9e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a2fb5b40-f9e4-42e6-9d75-6a456b2f51d2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cbcec616-d40d-4fd7-8b8d-a8867a780d79_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_896fd0fa-1119-4e8a-ac1e-dd8c900c6565_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_5358d335-3a53-427f-b20e-24d4ddbe9ca6_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a8f44fae-0c8d-4e29-872d-c56d04fd86b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ad9c8b77-acdf-4d2b-ac21-cec07682c939_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_e3a3cf7c-f66a-40d5-a370-cd2b12fac232_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20220630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_c4cf3c6e-87ef-4d55-98db-84cf73995a0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fe765b11-7dd8-4b56-860d-1574d72e88d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_6a97d51b-c526-412d-b27a-c3f96ae02710_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20220630.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cf280e5c-7f90-4b37-b7e1-973a2d10c6a3_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_ecf64a3c-6807-4e64-88f1-612e1631b713_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20220630.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_51327a58-666f-4d31-aef7-7a50ea6c0c78_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_583bdfc5-1517-4ba6-a3bd-26532902575c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f69a5b2f-64c4-4f6f-a71b-84c6e3ecb5a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_db8279f8-49b0-4c71-95a3-40389157ac8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_de57e911-57de-4fd5-b37d-642632580561_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_19473204-941b-4393-aa47-326faf137151_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_43614687-81ad-4c4d-9032-8b7ca7a71b4d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_96a6924b-06e5-42d4-8043-45aaf182d717_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_a1de816e-9cd9-4d22-8b0c-8f1cd1bdb59b_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20220630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c1710b75-15a7-4de0-9e55-ad699fde91a0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_23e0f1a2-184d-45e2-965d-bb53b2516f57_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_5f7d8e6c-3e86-4254-bfb9-be9af1fa1ed5_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_31fdcb0c-8979-4862-a006-bb79e84bd36f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_ee76548d-cafe-46ad-bb6c-a723d869985f_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5d4104e5-c477-41f5-aabc-18e5e33f17f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_d32cdc5e-fb0f-434e-ab29-0d9485a3e657_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20220630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_8d2a4761-0856-4496-a4c4-55163e80ff17_terseLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20220630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_cfd43c74-a9e3-4aa5-90df-d3038e9116dd_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_24265ecb-ce62-4117-9129-1b104911c232_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_692725a0-d5af-47fe-bd02-18b0b0e8e14f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_d8739773-3460-41d9-9b65-3de26f5f28ac_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a51b95f6-d93a-4bd2-9f57-d31722523df8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c8d9f18-b447-4ace-b3b2-98b77c4c9d8e_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_83d9525c-8a66-41de-a05d-310299d3b6c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e66f84d-eb4f-4be5-9205-67668086447e_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_eb4a16c2-712d-40f6-91ef-5796f66593bc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_22ac2863-7400-4c7b-87df-2f1a0ef59cef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_0b7553cd-690c-4ae2-8fd7-581baf2fe318_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_4f347d3a-679c-4e46-9ded-2415dc7bcff8_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20220630.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_738726fd-2704-42ff-b368-68686d525914_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6c52e95c-0781-4471-99d4-d2032f8318ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_512aee00-c1ab-4782-971a-546bd9dbe9d7_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20220630.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_10388b54-bf7f-43b8-ae0d-f51ad3b73985_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20220630.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_74c0816d-6e31-4a15-8151-18cc01342312_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b43094ad-37d9-48e2-b470-aa9d591b7b5e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c1c30b76-35ef-4ed4-9a6d-4c8d538df9c2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7f142aac-40f8-4e96-abe8-14498dcb1535_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_85b3a2fe-927b-4244-8392-c42467c1b405_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_43ef222c-4dc3-45f5-ad7f-8980da4cf72c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c7193020-7ebc-42a0-aaf1-7c6b66bae12b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_457d47a8-a5b0-48c9-b315-fb277c870be0_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_c18b3961-cb68-49f9-a45a-2d5104d8b94a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ffa4fe9f-96ab-4ef3-ac45-ae7e02b19074_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20220630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_177c1543-18ad-4a95-ae3c-008878429e61_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_707fd3d5-864c-4221-bcf2-71d59c5f0974_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20220630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_869c91db-8e22-4efa-af55-7f94abb47214_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20220630.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_35b9ae8a-1177-4c0b-9eac-63135da3c851_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4fb1b2ab-f883-4b2f-88e5-1ae11a98bf00_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_34e183b8-35d3-44a3-acf6-3f63ca5d4f28_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9447d7dc-d71c-4db7-b9a7-643bf14c1250_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_33ba7bc8-9b19-4fe3-847a-40d6c9f94052_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_00b6fa96-803a-4232-af1f-d191f9f597d6_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_56fa05b9-5a9b-4afd-804a-d2648adeb5d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_db9cae3f-f07a-4db3-ac0d-59e402d5cdd7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_4fecf738-1a30-4843-bb41-3c278b1f7d7e_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20220630.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_60d541fa-610d-4041-95a0-7a970a561f7e_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b90a2fc9-b12c-4578-b27b-18c173d862a0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_90e40122-39f5-46a2-91eb-d8845e98d12c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3344410e-8a63-473d-b6ba-6db8cfe791c0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_85651982-69c7-478b-a3f6-aabd4c3ba21d_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_01895e0c-5108-464a-adb8-1c602eebef3a_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20220630.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_0faeef3c-4ae7-4ec6-9450-4a72aac3bdd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_83e26061-d7e4-4c51-8bfb-7246a9966315_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_cc7f3798-3157-4140-8be8-7dada96b13f6_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_711b6ec7-019d-4802-a553-3f931d3f0ced_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_26c9e71e-d0c0-43b7-9c59-bb37b5275643_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_55c16087-12ea-4ccc-b2e0-c8d5b81ddc3a_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_475fd289-e9dc-41cc-a8f2-7ffa692a7ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_a36057d9-b33a-4eb7-b850-eff54e1dea56_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_760000de-483a-4ec5-8ff1-887483953f55_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_cf77d0e8-913d-47eb-b14d-7fe9a299f26d_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_b473df6a-b86e-4cdf-8af8-8572a9d836f0_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20220630.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_81bac42a-f075-4352-9e09-b5f899c6e6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3659da4e-2b40-464c-83ab-4f0d8aeb99e3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_351acab3-a802-42d9-a64e-710f02fdde72_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7b6cb90c-674d-4acd-a4e6-3173a319133c_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ffc07c78-2894-466c-a243-3edbba83ce28_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea3de4f7-f8c1-4f48-9cd9-e50474a7b7c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_443b5d1c-363f-4b93-a6fa-bea113a93558_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_55c22390-1a70-4e96-9622-1fe7832caa60_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_561be999-9599-4bca-8b9c-6d44c3a3722f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_16ecf458-477b-4a69-a783-832239680dec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dcda7575-2189-4e20-95b3-fd66c81e075d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0e6b46e1-a427-414b-a2cb-10f3b1ad8e4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ba09e64e-404b-453d-903f-39f84069c735_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8a89342d-fe29-4095-b86b-94915db89f80_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_7d32de52-d7d5-4d70-8695-103c2cc46d65_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_3f269845-02ad-479d-a7e2-49fd30b62c74_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20220630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_a8567aba-26ca-4630-b080-7822c8a1745d_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_d6321f74-330d-4c4e-a84e-1869393599f0_terseLabel_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent additional milestone payment</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220630.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_94d80c03-a1a0-4a27-aa80-8a28a3fff6c3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_afa200e7-5dfb-4195-97d6-53e2e219723e_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e8585031-f27d-40b7-b8a2-3ba840a55fbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_72766720-9575-4655-8718-1178081dea4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5abf3503-4ccf-4bc3-a498-328263616454_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_4c4748cb-017c-421c-914f-4df0a0fe4efa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_836c5a8b-9708-4c1b-bb0e-90a8e492a576_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9062940a-bff1-4083-a6a5-c63c7bae96b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_e01f2110-d6eb-44bf-8c50-aea9726ae313_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_562267c1-3600-4ea2-81d7-c9e80c89d8b6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_82d7a574-9adb-4550-aa2e-b74028725eaa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9ba08e28-91d0-49f9-9011-7bbbc8f312ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_43d6af75-e5ed-482e-b413-f0e6c9dcbbde_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_56e2871c-7144-4841-b483-5d7af5306818_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20220630.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_f8b0d0e2-912d-492f-940b-89a606ee2a2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4cebf8aa-a737-4766-a1e6-7c64f85994a3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8c58ae11-7b61-4a11-aa25-b1673def319b_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8951c5a-cd77-4212-9056-1552bb1efdcb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_e9cbf935-415f-4ca3-86a1-f0c21e84dbcc_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20220630.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_11dd85c8-18c0-4743-b1d1-c9124e25515e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_393083a3-9b6f-4f26-b293-b31c5fab8288_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_de8a6a0b-7f5e-4b06-8d5d-4ab1a6651c7c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_ee4ef9c3-1ab5-44b9-95f4-b63849f7f6fb_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20220630.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b33b5e8a-e0e4-44f8-8e77-0b8e6714c2bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_01e967b6-2ae8-4d18-a65c-a212e91187fc_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_edf1d6ef-4854-4739-99fa-3f424b84d400_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9ed5fe03-1bc6-44de-9d76-43aeb5f257ef_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_3c116a54-4a4a-4138-aa2c-6ad8d01394dd_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20220630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5f9447ba-ce50-4303-af75-c2157e23aa52_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a2f8a46d-ee25-4f42-8925-5116790bbbe1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1b2d0c87-58c1-4d49-be21-c7e71fb59129_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4b4a6b50-11bd-47ad-a86c-5ed9ac630883_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2087b924-158c-4899-8bf1-e1bbf01cddec_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_56f172d3-60aa-488e-95e4-067742b8c504_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_50c2c872-354f-4801-8b79-3f2241a29343_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_2ac65d4d-8a7e-4134-831f-e7a74a77b36b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_811846a2-c838-4b1a-b7dd-f34dc3c4f69c_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20220630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_97dfac09-4edf-4778-a2f1-85dbfc3b2fe3_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_29e435fc-dcc0-43e3-aa30-acbe1ce735b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_131946c1-32a0-474e-9d46-30cf08f33233_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_1506b0f7-ed3b-4544-9d0d-a2ecf5664073_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20220630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fc725718-8bbf-4cc6-9c0d-8bf1d989fa78_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0b9df912-9b80-450e-b452-a60a3094cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_42b00c44-4047-4624-bc6a-948b37da0dd1_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_5c6f8f88-e706-4360-8c02-069527e002d4_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20220630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_9d3dc0ee-fa19-4c1a-ac3d-66cd6249b5bd_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_1aee1209-b9a4-4e3c-8590-dacb72025902_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_a265d3ee-39e8-481e-b2de-4c9dbed44447_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20220630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LecanemabMember_2bcecd43-861e-4877-b853-a2a9d1360c8d_terseLabel_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab</link:label>
    <link:label id="lab_biib_LecanemabMember_label_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab [Member]</link:label>
    <link:label id="lab_biib_LecanemabMember_documentation_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember" xlink:href="biib-20220630.xsd#biib_LecanemabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LecanemabMember" xlink:to="lab_biib_LecanemabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3661904c-988f-4f63-9775-b66c062a7125_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_21efb6bf-53e8-4032-82f4-f6a88bfd6802_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_6de38995-c388-4ba4-9a16-f242227cccae_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e3b62be8-f7a1-4c49-b701-d7abd116a4d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_a6101615-2df7-452a-abca-21b6b1a12336_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_52514c22-27f6-4121-87a0-265ff0c2f4a5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_c883be76-effc-4681-8d14-06e4257b3aa7_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9eba9b78-cb84-4cf0-9201-3f38ad2fd183_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_8d3f9424-f239-4213-a5b2-09dfe1761f55_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20220630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_db3376a8-22be-4a37-a658-69427f85fa60_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_5295112c-895c-42c5-a4fe-ea5cec887aad_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_f3b4aa53-03f0-445f-ac68-97ed149faec1_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation agreement in principle</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:to="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9636a2da-887f-480c-867e-fc586e2cbf7b_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_a1e179d8-1d6f-439a-ae00-ed9b022627e7_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20220630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_2a117237-570f-40fa-938f-fb448f188a8f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_963dd353-2119-4f69-9a90-2927f2806ee4_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20220630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7ca414f4-a009-4902-8824-6cb1fee77449_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_798c349c-4239-455c-b35a-2f4754265675_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8003eb9e-77a7-4501-9d3d-d400b4e89dc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative used in net investment hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b7ec4ab0-c779-4fa6-938e-35f4e6203f8d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_bd62c3db-e682-42c3-acfb-08c21f330163_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20220630.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ec390e35-cb55-4ca0-b49b-d3420433df8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_1c44fdc5-d23e-4266-b8bc-27c4efb31b4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_de92ca64-60bf-4831-b3ca-319f0a42413b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0feeb830-abd7-48d6-ab12-757069841748_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_ea35f2da-adeb-420a-9a1f-3aab6fb7f8e9_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20220630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_496ffe7d-443e-48af-b9eb-38ddc5bc417e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7fb9eb47-1d12-4db6-a500-d01f1b0af3c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5618f0a-5ad1-4a99-8b24-d3261611fa3b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_47add986-49cf-402f-919a-5b15500f6514_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_0359b7ca-8b39-4811-a482-028cf0ac3ed1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_e9698c60-ba95-43dc-8e0f-734592cba695_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets, receivable</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:href="biib-20220630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_80d7c966-bc0a-487a-a1c4-c09ebd09e5f2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_2bdd078e-c846-4087-8fbd-137475acf2bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_c20851f8-73ab-4f61-a765-196343663e85_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e1918202-7d70-4d70-a9be-0124550eae1c_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bf273a3-4926-482f-bb40-066c832bb58b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60d96ea3-7bc3-42ad-b24c-5f3bde0556bf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09d1c407-789c-428b-842b-f8f890521948_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ada228ce-3f49-499c-8c90-c89fdd983fcc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fdc813a-72f9-4d34-a249-5fe6aea5618d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_389f4885-89a6-47a6-b4f0-3d8328a45222_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a9826bd5-9490-4385-bcc7-5320e1aa3108_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_693b9b54-4377-4b0a-8b4d-24e18e8cb4a5_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20220630.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_cd4ba3b8-460a-44bc-9246-aef45e96387a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2e43e6ed-94e6-416a-a259-d6da05187edb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_093a5fc1-9d67-4d8c-9715-922283ebf255_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cd6cb310-a5ca-4bb6-b74b-983104c60023_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74a4a434-69df-4e42-bb1f-ecdfd96e9281_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3ec26850-56ae-4f12-bd00-add80de778a4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_51c0b72e-de63-4eed-acc5-52d702b49581_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5f6f6fd-8bc4-41e4-ae76-5b37b670287b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_1cb96747-3895-413e-aeb6-07fad16b71cd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d12dbddc-d197-4bbb-9860-57e4ba8c872f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_86897acd-099a-4a11-9821-7fd2d22e1fdb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_a5b3d3d4-4ce2-41a2-9f0b-edd779329b95_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_5b079cd8-9d38-4fee-94da-7a05e7810225_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a77054b3-e726-4930-b61c-a93a7382f1aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ae203cfd-7320-4d40-a737-0b1615225eda_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_aabdddf6-3aaf-412a-82d1-28e3fb5a05a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_d227c71c-c1d2-402c-a36e-680c540d69d4_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20220630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_a2dcfe8f-636b-4103-9485-9f7a63f55974_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, receivable</link:label>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:to="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_e05d079e-39f6-4468-a67e-23f2b7f5b57e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cb2df0bf-d71f-42e8-a301-c3084494ea8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e89358e6-5d38-430b-be4f-28e0e3068e1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_35161bdb-bfce-4112-8133-46896ceb90aa_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_13cf3458-7f69-4d99-8262-db634f5711b0_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20220630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ecc7f8e0-31a2-482e-8a47-da58c4d49d6a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_46422e98-4e58-43b9-9d90-59c0d0a917df_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_63173c72-4a1c-457e-acd6-b9ff2dac5315_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e4c4c7d6-48ea-4729-8947-4a9a34b9dc04_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2fad703e-e241-404c-8b07-b7ea6f0dc1df_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_295dd0cc-85d5-4292-a8f0-293746ba2f85_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_ca3a51e7-b69a-4999-ad4e-1c978d0e8a56_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_87858343-41e3-49c1-84f6-205a56e524c2_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20220630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_a1df73b2-c6fe-4b7d-ad2c-7ee51c47c235_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_b2310c00-a33d-4c2a-bfa7-1f0305d5cd3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_29826a11-6cdd-4814-ae41-e484ce294e0e_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20220630.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6170ca4b-6d0c-4cc2-9854-fbda33fc8fa9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_1c5d154a-12a0-48ca-b2f5-27afd0bef4c0_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20220630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_0a431227-9821-4ece-8caf-a3755bbe6f77_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6abd2c4c-d970-44d4-95b0-27a1126d18a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_51891b6e-18b3-4008-9c8b-3557695c672a_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20220630.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_92727708-2339-4ca5-9960-c242de0f5a7a_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20220630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_e78afeed-b6eb-4904-b737-ab260c35c9b2_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20220630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9d783193-7ab0-427e-bc8a-d30121de5261_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_0dcd4e3d-a05a-4ea5-a106-2e6fa5a16415_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c22f2d40-a55a-4201-a22f-140b08f93691_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_d30ef190-ced0-4b69-b7cd-8a834a4341a0_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20220630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_262490aa-101f-4a13-ad05-aa0a8be2eb60_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f0aa41b8-8b17-4c10-a790-c49266f3c4ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_32d8774d-b5de-458b-ae34-c97938eeb7f3_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20220630.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a78c08db-7fb3-4eba-9ac6-dadd3042d3c0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_05aa54b7-6837-488d-9976-a4684e9e326e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f634246-2a81-4ff4-a589-989e77d5d06d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_c47326f8-1af1-4805-9a9f-bc536dbed03d_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7b29084d-c730-4138-bec3-5364cd246cdc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e765eaa6-6956-4906-b69b-57ad6e685251_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_0ce58d92-3a8e-47ca-8dcf-7405facda689_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b203a318-2ed2-4918-adb5-d5ae736d8347_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c2142c2f-66df-454b-9606-482aa06f446a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_a2a39367-cf66-4e1e-952c-e45ede139f58_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2021</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WorkforceReductionMember_4d0a6839-0cf1-4a80-8d1c-f61430ddba5c_terseLabel_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_label_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction [Member]</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_documentation_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember" xlink:href="biib-20220630.xsd#biib_WorkforceReductionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkforceReductionMember" xlink:to="lab_biib_WorkforceReductionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_fd166715-42c4-4615-b5ad-311ee7fa0c69_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_e91c1121-4915-4088-a0fb-11f502088051_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_440f2012-12eb-437e-9bf3-9355bf40b596_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20220630.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_85329169-4332-438b-b488-795103e4e4ba_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_260f0dce-6845-476e-85eb-321e17901891_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_ea2e440f-9f3f-418b-ad46-0cbfa970b338_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20220630.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_cb533767-e973-4174-9423-a7cf9619be01_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_817ff2e3-4e0f-48a3-b71d-d2c9f94599a6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a127be9f-577f-4a0e-96c0-aef01bae377c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d84c453b-73e5-4f41-85e3-3c987fa523e3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_44560733-3c2d-4a05-9bed-c1326292f8ae_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_8a811624-7ee9-4512-a83e-6ae66ea77f32_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0ff354cf-72f6-4908-bf18-bf7fedd0aabe_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ddb35418-8fd0-49f4-8d0c-1ffe58e062a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_762210d0-6c00-46b3-b13c-747340093975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_933e54dd-2d97-4379-857c-73541599af5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2253e6a9-5985-475d-b983-212c3dbc8a67_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_067f3a15-ce5f-48c0-a408-e0ef6ca10146_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_df726b60-9907-4326-8e02-6c61e324132c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_a16a1f0e-8e31-48c7-a9b6-8256ea848da9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_124cdea6-9120-479b-9aa4-e443f8962a3c_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20220630.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e86eae91-5f05-4f29-b8ba-1680e2e98f2b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_fe3d9d6a-1c15-47f4-8560-42ab9f86b86e_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20220630.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_bcdf2444-2302-4421-85f3-145242c108be_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_10f7ae15-8d26-43cb-b0ec-36da4717b7fa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_b74f9a8e-aada-4197-822a-1e67b479ba18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_98fcf5af-5467-4869-8408-1a5736badbd3_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_6e8a7bb0-59ae-4d9e-bfcb-7b83e8914287_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_00fccabe-5d67-4fb6-82c5-af321e65d42b_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20220630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_e12846ed-8b14-4086-9723-46b822615889_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_bf87f5d7-e751-4387-96e5-2b341cf44a1c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ae7af8f5-b832-4224-99c8-71d9ac4626ae_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_314c5ddb-22a1-453e-9b86-14dbdd48dac5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_5cf067bc-3a22-4a75-9821-e07609c6aaed_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20220630.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c47fe418-9364-462e-8526-00c2fb6e894b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d85827a4-9ec4-4450-ae41-47b5cbc35375_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_09627015-e196-4f20-b4c9-a9ed729c9b09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_eb74016a-ac8c-454c-8f16-ba28b65647de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_83a41902-5933-407d-8591-4b1a9266908a_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20220630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e9abe40-ca59-4910-8925-b4cef6282762_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_dc2d8c4a-8840-4692-916b-7adc1fa2fefb_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20220630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2869f4fc-e054-4265-a88c-e9131b65f483_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_985823ea-09c6-4d4a-97f5-cf7afa17b722_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7c428b9f-258d-4a49-a049-623cd79ee7d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_a7c24d0a-b1ef-4d98-bdbf-88c25a00e20d_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20220630.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_d72f1809-2102-441e-98a5-07f8127d77a6_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_c81aa2e6-e856-48d2-bdae-ff45ef210869_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20220630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_20f49222-fa9a-4c13-832b-a55f2460695a_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20220630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_6a1f7a77-7529-4663-a816-810b087c4b0f_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_33353ebe-01d5-4350-9f09-2e98daed3b88_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_e7ced26a-376f-4cac-92f5-8aed2e85a27f_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6d427cc5-063e-4246-b015-f6167eeeeb4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b69d3b5-27f5-42b9-a700-8a327c3f5d10_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_162570e4-bb50-4d5a-9274-76b93ef7d35c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6389b9ed-4f85-4003-84f1-c87764815980_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e5c77673-cd24-4346-9a0c-2da97b593a39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_8f07deb7-78a6-4c2f-b3ce-db561fa03d81_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7e077b67-b58b-41a6-a705-07213b4ce650_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b78c6c45-5338-4211-8ac2-762b1723ae44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9201d01-a04e-4118-97be-fc8554061e47_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639fc7d9-cb7e-41fe-bdfc-1649e060d0ed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e8bc7607-66bf-4e31-9118-b20d3c90ac17_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_eb9e7acf-d6ef-4a76-9d18-b4a74b2a161d_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20220630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5e8164d2-6d30-484b-9ecf-f1edfa249141_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_608cc069-d722-49ae-b8e8-f17c2a2b0d39_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_d22614de-915f-41bd-99fe-c9d29c13b0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_3cb75bd9-c977-40ab-8bf6-b383b233cc00_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3e56430b-62ba-4f10-835b-27b2ddd5033e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_1eef6e97-ce54-48ea-9b9e-6cf378e64072_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6714de9a-d0f5-42a4-ad21-b5bec68eeb7b_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_b6c48820-83ee-41ae-b44d-e0df65bafc81_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c4952d54-75e5-4dcf-8409-204cae279277_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c27f62f3-d109-4889-b899-7aa6068e8777_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_1b71bdb7-8d0d-4ad7-8b86-4216f456a259_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20220630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3e162d75-06af-439a-bab7-fc24fa3fe8c5_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_86cb2b6d-639b-4c3b-b4ff-b938334940b0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0b22289-78f5-4aec-a240-32fd30201227_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cf3f2c0f-454e-4fbe-9e42-3f945c56aea7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0924054-f1c2-4dca-9c02-c9beb9cbadad_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3cc223c4-5da1-4304-826c-7296f47bdb63_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_ccdc66a7-313a-478b-a55c-50526fb53333_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20220630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_7e2a0090-c2b9-4dae-a043-13135a73adc8_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1142ea40-4dbe-4d3e-b17f-89aa5a06dbf9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_9ace2a12-21f4-4403-8411-3a772afec7db_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4047b0d7-9297-432c-9c14-11d42268d13e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_4936fe00-92a3-4463-ae5f-87933bc647cd_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20220630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_cc0d41cb-a1df-4e75-b3ba-6d24c5de8cbf_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7f49abcb-8cbc-4595-961b-eb218f64678c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_059a2155-2d95-4b4a-b607-8afae3b26d09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_bfc22a53-94ba-4f2b-9cfb-421171aab75f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_b4671b03-da09-4167-9640-6a4489fe10bf_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20220630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_5f407fa9-d45c-4699-948e-88ae09918988_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2cd3efb0-ca63-47f8-9fdc-d85726ab62db_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c8f70343-fa01-4242-a0a8-27066c6e835c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_83af5cdc-465b-4dea-b298-53e332823e53_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_fe7cc7d4-8693-4e66-b1f4-05078de68518_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_0c02f80e-da36-4619-b265-3bed14641855_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20220630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8747ec60-6e7d-43f3-855e-90b5730debd4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1fd2133d-44ec-4836-ae00-387c2696a6e2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_c946357a-a12f-41be-84e6-e3152d618597_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_8938b20f-3dae-4a22-a5a4-7ac12a12d278_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_2e8d2db6-d1ea-437e-8d31-9b4d0c3892e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d3d78b98-8b07-4976-8cef-cd4d7d2aa6b8_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d4d55247-470c-4073-b9cf-46b1cb77af15_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_035fa11e-e937-44aa-a793-2545eacbf4e0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e4486cb0-3d9f-4967-b980-4f02a47c0d40_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_57f43544-f744-44a8-ae6a-0f9269253c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7f364d4c-2c41-47ae-b810-dbb954d28602_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ab4cdc83-4157-4041-93b2-0769740ac00c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_72303914-a061-40b2-9f10-76b969635e1e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_529259da-95e5-4374-bfa7-7a2015c5f47c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_d6af922c-8b8f-4a28-bd92-112087e84ae7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_a859737d-686d-4b3f-9d84-790e2edd69ae_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7a714181-9b01-445a-a39d-d98375a6f44e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aa668745-ff8d-4e17-82ee-b93bb71d6bd1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_bc4ab69a-9401-49aa-9baa-f0ed81bbaaf1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_6e522f23-a159-43e0-a3bc-d7bd1814fb38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_b80d05d2-f830-4f1a-8b0c-7bc3683ed5dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b7d9dc28-70e2-47e0-b9ec-04d2609419d3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_de70965e-4cad-496e-a523-893ec6daacfd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_cb849033-b321-44d4-9071-8dd840606f0f_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20220630.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_07b255e7-a679-42b7-9fb1-e252c354021d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_1dd69dd0-b36a-4c70-94bb-52ca83cb2b1b_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_78e6ed54-65f2-4437-964b-b9c74d0b41d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_e360b531-3e99-4727-9ed6-ee844d3448ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_41188eeb-8a7f-4d38-8edd-5f2e2e7a1b61_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2b3561e4-645e-4a2e-8f00-0dc27a8bd6a0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e34199b-e358-4618-8750-b0a97ea05550_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_10e37829-5b83-4de0-ad4b-a096758a5b46_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_c8cd7065-ff0d-4eca-bf4e-c5d1545579fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_f10960ac-7062-429a-be54-5d6fc69b3505_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_0daf1adf-1d7d-4785-8b01-132f2b322432_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20220630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_8f92bf37-81d6-46ce-9445-b59530668ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_8e1d18d5-3858-47cb-b252-dd0ee76ec137_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20220630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29aea44a-92f6-468b-9218-0a8b1b187ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_32a3249d-e1cb-4e9f-a5c9-8fdeb5ee22cc_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7c51f98a-0cba-47b0-8bfc-15a7dd83bf96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5ea6b484-ebec-46b7-948c-10f0b00a5b42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_34f7d91f-4761-4fb2-88c0-394a09bb91fd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_1b6508eb-192f-4c5d-a7c8-09573e718d71_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_54929490-d6ba-4d22-91e9-69bfc4de2cea_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c84eb859-245b-49bb-aa00-91773feafef9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_aae50a9d-304c-4654-a512-f34e055fcb0c_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_92ed42d9-71c3-4b4c-a45f-f92e71a92d45_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3d199194-f137-4eaf-bea7-0cd300aba01b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fb363ae3-7a5d-4603-8556-5306711d219a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_6596f0bc-5d87-456e-b2b3-87a1835de0fa_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_5da314ea-06e6-43e0-9506-657b897ce354_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20220630.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedMilestonePayments_571b444d-b4eb-4fcf-a627-280ed55cac66_terseLabel_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued milestone payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_label_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_documentation_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments" xlink:href="biib-20220630.xsd#biib_AccruedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedMilestonePayments" xlink:to="lab_biib_AccruedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_f5848072-543f-45a1-a988-fea5003ac941_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20220630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_e7d769f3-350e-4432-903b-020ddfbc056c_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20220630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ec6fddcf-cbc2-4f16-a804-3feb44aab6d7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4a5a0cbe-4195-48fe-bf28-c72c9740d619_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_68796d1b-32e1-4263-930e-e0b082d68f07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ca65e6a4-ce7c-4e5d-ab17-104cef897dc4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b048708-f2b3-4da3-a2a7-9b7a64a23082_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c563de05-b306-40b8-9d2b-e47e02db3562_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e9ac3c95-a7eb-4f32-8673-d9958f0de33f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d52bc624-326d-4cb9-99bf-fd82e8a8a155_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0f34b78c-d12b-409b-bbf4-e190f75e1b2d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fde5c886-eaa9-4f5c-a511-5b6204e812c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_451aa7b4-ab62-43d5-ab2e-29766c490c29_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6f536d8c-fafa-4e2d-bd3d-6a3d65783654_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_73d0e6ee-763c-4976-99ef-7e5ab542b5e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f7fd5bee-96be-4308-964d-8d927d8eb3fc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1092afab-4f7d-40fd-9a00-44458f8e914c_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_0fbca037-cfbe-416a-a2c4-3f103191d5aa_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_efb68b8d-90b8-45e6-87ff-db8270a6f4a5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_a9d374f7-c0c8-4c24-9411-1e80f546e64d_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4ce8c592-4c3a-4fac-a3e6-8376dbb2a936_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_e7f9d3cb-6e36-492b-89da-3ed76b40192c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_9705c050-a7b8-4908-abd0-12b4a78edeec_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_cca3440c-261b-4b70-8716-729bcb1f1c70_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_c3105673-d2f4-4a3d-a9f1-d87fc60fb7ee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_9cdb7535-a6be-437a-b1d5-0e39a3cab129_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_520f98d9-45bc-454b-a9c9-895a343367bf_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_b13e6633-aa63-4811-aaf9-2a529396a5b1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_c9075b1e-c476-4e32-9ba2-cdba44f4f3bb_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20220630.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ace71577-1f44-4d64-b76f-41531ec72a22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f40b0e1d-dbb0-4c5f-8d7e-3481877a290b_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6fa63429-2bcd-430c-924c-83415e9cd957_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_27ad0f8c-2548-4d5e-9351-9f1d1b9adda6_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_77dd8dc7-57a6-431c-a386-711a8c4048a0_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20220630.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2ee7dbbc-4067-4689-af14-93ec0fb7d3c8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_348a0b10-e80c-4781-9156-bc4f615d5676_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20220630.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_895b3c7e-a460-46cc-81d2-5bbf65a82297_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_1bec80ac-025b-41de-ac7c-98d90972f4ef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_523e08e5-ee79-46b6-a3f2-2177a8177918_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20220630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d8adaf8d-cf28-4661-8a41-040e6b49eb61_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_208048c8-eef0-4fbd-b699-69108356ed5f_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6f386482-e545-488e-adec-b6f208f4a062_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_69207364-c5c2-468c-adf1-f8b847e6b1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a2dd7605-a746-4a38-b6c3-d270389b64af_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ba7c5edd-88a1-4db7-a891-bed4c539abe3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8a39b4b5-4e2e-4bc1-a9bb-67cf883fefc3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fea2fb2a-b6c8-4f0d-82b1-89444f075d41_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ad3a6ca-2a28-43b0-99f4-1bfe6cd2bdbf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fffa51ce-99ab-4466-9cde-7f6d0605d06e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_93fcb9b3-8afa-4845-8986-888f7b6fa85b_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20220630.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_50ec6a78-58fe-432f-91db-e740547376cb_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b7ca982a-05d6-4ea6-a250-afdd9a7daf46_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_92703c15-d3e1-46ac-9e1e-6c7774f026bc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_6876c54f-e7bc-43b7-848c-eff896a74179_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_d21e60d0-767f-4806-957f-288e40fd57b2_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d4219dda-bca4-428d-bb80-da7db9419815_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e248c86e-7b29-4f32-bca3-1ac994f6523d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e932e341-5945-48a1-af37-23d8424dd792_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_33dfeed1-330a-4a84-ac6c-252cb3a69ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_037f70f7-d714-4051-89ce-a9a722cc42f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cb293230-cbcf-4b5d-a3ab-f2212ef37d11_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_616770bd-4b49-4c8e-84b4-1ca1b9425b15_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1ba6a6b9-998d-4148-a8df-37e288b0789c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_d39d8b17-d926-44dc-8b45-b33c0e96c47a_terseLabel_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation agreement in principle(1)</link:label>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_26b41271-11a2-4dab-9eb3-6ffb2e91160c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7d63e121-0789-491f-90ec-31648fddf568_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36380996-571a-422e-9a38-409d4940d07f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_0aeda399-8ff4-4fbe-9c62-c7d7af4fe69d_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20220630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_7e222013-83ad-4897-9454-b72bbd06f93c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2a794b6a-0d5c-49b1-8f21-cb7f9552df7c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0210abf3-7618-4179-abc1-0a8b180c97dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_c2bf4985-5344-4a4f-8173-7699ce77c637_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20220630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f0f4d8b2-40d7-4cfd-b0af-ca8b7842b01b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2f4a36bd-ab1e-4abf-8374-cb8f61ac1ce9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_cc06d83a-f3b0-47ff-8570-14dbf87c2ba6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_c9f99847-3980-4330-bc46-e9e8b1072dbc_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_08674032-9557-4592-a675-7f212836573f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_546a6c23-d4a1-4461-bad0-729176453e9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_203447be-6d74-47f7-ab37-98add72ce740_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20220630.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d971ec9a-72d9-4ff5-bb2d-15dbc0d912f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_80cd5157-ebda-4e72-b887-9dcab1f1bcec_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3fb80a73-4906-489f-bc99-c5eb718b9762_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_7a8a35b4-38fc-49b9-8a84-7ba3b5327d59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_7cec17d5-039f-4730-8e2c-41e691f235fd_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e766422a-59c5-4851-afb7-158021232e7c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_46b0963a-e6db-496f-98f1-a39b5bad9816_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20220630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_a68bfc51-97fa-4cf6-84ed-6126477d841a_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d1fbc7ce-48d1-4757-8db1-fa4dfe2b1f68_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba58e512-f954-4986-9e3c-5e4a93e8edcd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_d3b2bae7-92cc-4157-94e0-120686e8c9c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c244d59b-4aa5-4877-be0e-885f670e8896_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_618dfd63-efc9-4dc3-8fc8-4d1ce1343080_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_77e0b862-7751-460e-a441-cd57f2a9a9cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_30a0be54-8777-4a41-86c5-a629a9de6d59_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b084719d-5dc8-463f-a8f3-c1bb6b098c80_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_90aeb0a8-efdf-4731-a4c2-6397cc24a2aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9413c970-d2e3-44ef-b858-c3b0e833272f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_014ad81e-91bc-43fa-bff0-a99445991ff0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_c2bc89f6-fdb2-4cb9-be14-4ad20ab34987_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_359e84c0-3e01-4f57-aa82-df24bbda86a2_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_013b0e78-ffba-4931-92af-9e4830fe0b75_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20220630.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_c1f1f4ba-a609-453f-8a64-d96315ec034c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7cbb3cbf-0527-4354-a071-c8f8e96162d1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b2e631f1-7425-4251-91ec-8572da66e9b8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_db3927e6-5ef6-4d81-bdd6-fe1b44500f96_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_6fa5e592-6056-4218-bd5a-70ad4bd17d74_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_60b70a88-25e6-4ae0-8338-c4c34f9560ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0b0d50ca-753f-4ab5-a4be-a8fb6befad6e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_43be66ef-2b68-494b-bf92-4d3d97f3cb5f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_362379eb-d28f-45ea-9ea4-1898347d0e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_cdf28705-6952-413b-a028-034bda866d54_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20220630.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_4dfe212f-c3e8-4a8a-b973-108a379f3594_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fefd1d46-4c30-414e-8067-eb604f6bdd2e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_f086a362-f1be-4f53-be42-eb88cae09c45_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e2ee0e17-645e-413a-a1fe-2d4b4ed07821_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_bc0ff59a-5b37-47c8-ba2d-5895358befea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_a9a27013-2144-486d-b793-e652001feb23_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fecbe9e0-f211-48c0-91cb-7e21ed9bcc24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_eecf4b08-3386-4950-995c-e7fa672f57a9_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20220630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_2238ce13-37ee-459f-9e0e-e133cba147a3_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20220630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_605150af-9bdd-4379-8d14-4219d25fca87_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_595ffa16-1511-4eaa-b032-c520d270f20f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4c889d91-2fea-407b-b09b-ee5e03fc5fca_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8e8178e0-9b68-493c-8543-6c2aa7cd1d86_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_01efe2f8-914f-4604-a12f-15d244f20977_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_a00a0e6f-a21c-4c26-881b-bec3d5076aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_68e3cb62-fdc6-4a74-b5ea-97d624017c67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5b4e71b2-9e60-43bf-b0c3-176c5c922277_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f421e647-800e-42c9-abf8-3928220f024c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9c261146-ade0-42e4-bc25-3159c98bcbaf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_dfadae8f-bfc5-4084-87ba-a9fbe3afb465_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b2e2d502-b3be-43ad-a903-f7ce0922e872_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9e14d6a5-5ab6-4e85-8ae1-1827a20b9e36_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_ccbad454-2ad3-4ffc-a165-456211582eba_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_7f32199d-9544-415f-862c-adb24f67b67e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ca1ad2db-5d5c-4c8d-9fac-8d08b1f34bd1_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d0b9ea7-be96-4228-a27f-6fd08aad0a9e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_f27477f6-0f01-40c7-86f3-494185800b0d_terseLabel_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_label_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_documentation_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:href="biib-20220630.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:to="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_660fd68c-3a3f-470d-9407-a69325ec7ef9_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_00346d3b-8345-4612-891f-2d77d600eb0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_126fe0d3-bb41-4fc8-9a35-c993efbbfd3c_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a25ee03a-6aa9-4c10-bd58-a3f434b05c69_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_27be0020-9ada-4b6f-b10a-3d195fd92305_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_254d9d55-c129-44db-909b-4d4119c51f05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_0fc5dd48-f13c-4c7b-b40f-cf06d6c7f8bd_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionRate" xlink:to="lab_biib_DebtInstrumentRedemptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4e6d16b6-69d0-45a4-9a80-633f489126e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_9035b6fa-b925-4ebf-b0af-0cce25a314e5_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20220630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_4895c5c9-3124-47ba-b70e-a0d3e7bea826_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_eb95f776-7805-42b8-bd2d-06cfd3533ca6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef8023b4-3a36-4811-ba8e-1ac1dc7e784a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a20c99cf-55c5-4530-844a-24d606af7cf7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_08bdcfaa-7e41-4785-b2a5-99dd2caf5fea_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20220630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d900b755-c546-45dd-a2de-6ae35d334320,g:6e6867d7-3f18-4452-8d19-1c93aac135c6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3f7f16cc-8d3b-4a6c-a428-5b6138236e25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentType_3f7f16cc-8d3b-4a6c-a428-5b6138236e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c943b2df-bd7c-461b-8b2f-5393787c0f70" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentQuarterlyReport_c943b2df-bd7c-461b-8b2f-5393787c0f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_898716b6-b3ba-4181-9d5c-5fb95495d135" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentPeriodEndDate_898716b6-b3ba-4181-9d5c-5fb95495d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_963e4c1c-7fab-493b-81bb-804d5f374447" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentTransitionReport_963e4c1c-7fab-493b-81bb-804d5f374447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9916742f-487a-470f-9889-0e44a306d73d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityFileNumber_9916742f-487a-470f-9889-0e44a306d73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d8f46eed-1c42-48b0-afc3-6979241b70d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityRegistrantName_d8f46eed-1c42-48b0-afc3-6979241b70d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7a6e25eb-0d3a-49c0-9704-663a9c81ef9b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityCentralIndexKey_7a6e25eb-0d3a-49c0-9704-663a9c81ef9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ef91714e-eb0c-443d-9069-ea9c4b2a9e97" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_CurrentFiscalYearEndDate_ef91714e-eb0c-443d-9069-ea9c4b2a9e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1e6d0838-64db-4d18-b1e3-bb841b7380bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentFiscalYearFocus_1e6d0838-64db-4d18-b1e3-bb841b7380bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_08b25624-e7b7-4d78-87f7-a5336c1cad44" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_DocumentFiscalPeriodFocus_08b25624-e7b7-4d78-87f7-a5336c1cad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_030ca264-39eb-4693-9559-4c495e688484" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_AmendmentFlag_030ca264-39eb-4693-9559-4c495e688484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6023e2ee-9577-47a4-be9d-01d0f64bd5eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6023e2ee-9577-47a4-be9d-01d0f64bd5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e19e576e-af4b-42fc-b335-fb79bbfe6756" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityTaxIdentificationNumber_e19e576e-af4b-42fc-b335-fb79bbfe6756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30142c88-9d11-4102-bec8-b6e3da9a2060" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityAddressAddressLine1_30142c88-9d11-4102-bec8-b6e3da9a2060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ea9c636f-fd2c-43b1-ac3c-bd7ea0d16e38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityAddressCityOrTown_ea9c636f-fd2c-43b1-ac3c-bd7ea0d16e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_140611e6-9054-4668-97bf-e91b976d9a6a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityAddressStateOrProvince_140611e6-9054-4668-97bf-e91b976d9a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_24bfb99d-8e5b-43f6-b1f6-3e6fd701413e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityAddressPostalZipCode_24bfb99d-8e5b-43f6-b1f6-3e6fd701413e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9627ea9e-f9c2-4047-a94e-ec1c2efad955" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_CityAreaCode_9627ea9e-f9c2-4047-a94e-ec1c2efad955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3be630b4-f401-433b-b40c-f406aa973cda" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_LocalPhoneNumber_3be630b4-f401-433b-b40c-f406aa973cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2a04ffd2-914b-43ce-8e30-4ff2d10a795e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_Security12bTitle_2a04ffd2-914b-43ce-8e30-4ff2d10a795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a74bf63f-5322-4963-b972-04fa580e26b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_TradingSymbol_a74bf63f-5322-4963-b972-04fa580e26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_eb7215b5-3a2c-4bb4-8e9e-32549f8aebb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_SecurityExchangeName_eb7215b5-3a2c-4bb4-8e9e-32549f8aebb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_14ade5e1-04fe-4092-af89-1757e079d97e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityCurrentReportingStatus_14ade5e1-04fe-4092-af89-1757e079d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1c8cbdbc-a51f-4bad-99ea-c0743a2096a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityInteractiveDataCurrent_1c8cbdbc-a51f-4bad-99ea-c0743a2096a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7fd4340d-969b-4e07-a706-e5ab6b8d3bf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityFilerCategory_7fd4340d-969b-4e07-a706-e5ab6b8d3bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5b0c7c7c-e91c-4ded-a6a5-e4550db04e48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntitySmallBusiness_5b0c7c7c-e91c-4ded-a6a5-e4550db04e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_09708a77-d078-477b-b091-8e04329322f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityEmergingGrowthCompany_09708a77-d078-477b-b091-8e04329322f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0f614f09-cc98-4656-9d1d-94c1b2ac8a92" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityShellCompany_0f614f09-cc98-4656-9d1d-94c1b2ac8a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4cfeca0b-15d7-4c5e-95ff-823f3b02d855" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a96f4890-9c21-4ec1-8082-bef90941ccae" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4cfeca0b-15d7-4c5e-95ff-823f3b02d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b102d567-abd0-44fd-bbfb-d28d04fd7c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b102d567-abd0-44fd-bbfb-d28d04fd7c37" xlink:to="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:to="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bf491430-ea7e-42d3-aba6-17d46c5c3d7c" xlink:to="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e421363c-9c95-4c79-b501-f4eebe6cc650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_us-gaap_ProductMember_e421363c-9c95-4c79-b501-f4eebe6cc650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba03f42b-9d47-43a3-aeaf-e72c47421a36" xlink:href="biib-20220630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba03f42b-9d47-43a3-aeaf-e72c47421a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_403f5f6e-5900-4294-bc42-65effb44c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc4eb77c-cca9-4353-88e0-ff995ad4427d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_403f5f6e-5900-4294-bc42-65effb44c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_701209a0-2ae7-410d-9696-db0013350951" xlink:to="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bf3e4d69-4cb7-4eda-a78a-df3b2d2c5964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_Revenues_bf3e4d69-4cb7-4eda-a78a-df3b2d2c5964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_95dfc6b8-c8d2-4f0d-a51e-14509f56da4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_95dfc6b8-c8d2-4f0d-a51e-14509f56da4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d64462bf-bc90-4ff6-a1ec-aa3cfd6d8e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d64462bf-bc90-4ff6-a1ec-aa3cfd6d8e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9c65726-6ed5-428f-9e18-e5b634e379ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9c65726-6ed5-428f-9e18-e5b634e379ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7240e187-87ea-47ba-804c-25e3597dbbf2" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7240e187-87ea-47ba-804c-25e3597dbbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9fcffcff-9747-490a-bcf4-a2e25fb975cf" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_biib_Collaborationprofitlosssharing_9fcffcff-9747-490a-bcf4-a2e25fb975cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11bd6657-3816-471f-814f-16237a05c481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11bd6657-3816-471f-814f-16237a05c481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_5b284e3f-b949-4489-a16a-18f60fbad402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_5b284e3f-b949-4489-a16a-18f60fbad402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_99918081-2541-4394-8b4d-fdd0bc70b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_RestructuringCharges_99918081-2541-4394-8b4d-fdd0bc70b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f8470610-a780-4318-a32d-dda0ab6b8d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f8470610-a780-4318-a32d-dda0ab6b8d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d4279828-48e2-4777-860a-9c34e5f0591d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3e8cc749-cdcd-4676-9058-4b8fd4b9cd2a" xlink:to="loc_us-gaap_CostsAndExpenses_d4279828-48e2-4777-860a-9c34e5f0591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cebf6bac-dd97-40da-a84a-76808555ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cebf6bac-dd97-40da-a84a-76808555ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c59dd8f-f1d1-49e5-b70f-43587608407f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c59dd8f-f1d1-49e5-b70f-43587608407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c2afe91-82e8-41c9-9300-46cbeeb9e5b4" xlink:href="biib-20220630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c2afe91-82e8-41c9-9300-46cbeeb9e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e7690f0-c05d-4781-8cde-7588c4ebda21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_ProfitLoss_5e7690f0-c05d-4781-8cde-7588c4ebda21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62e07b9f-410f-40a2-803c-1cecffc0204d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62e07b9f-410f-40a2-803c-1cecffc0204d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c810f6b0-4070-413d-9acc-9d439c01921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_NetIncomeLoss_c810f6b0-4070-413d-9acc-9d439c01921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ba18e6ec-0d52-483e-91fb-026076e0d1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:to="loc_us-gaap_EarningsPerShareBasic_ba18e6ec-0d52-483e-91fb-026076e0d1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d0b92a51-4bf2-4023-9208-645943d79109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_060b06dc-56ce-43e3-911e-c4c54fbfb7df" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d0b92a51-4bf2-4023-9208-645943d79109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5543f7d3-513a-4a64-8e53-ce8387595a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92aaf154-2841-4351-a879-02b96ed635c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92aaf154-2841-4351-a879-02b96ed635c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25029e4c-6107-4119-be4b-828f37063d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0ce2124-f7d4-4926-8d36-1487a900dbe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25029e4c-6107-4119-be4b-828f37063d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3026ce0f-3876-4d5a-9446-a2d0fcddbb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01315326-c34d-4b1f-8c3b-cf3af792140d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3026ce0f-3876-4d5a-9446-a2d0fcddbb30" xlink:to="loc_us-gaap_NetIncomeLoss_01315326-c34d-4b1f-8c3b-cf3af792140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3026ce0f-3876-4d5a-9446-a2d0fcddbb30" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f4f01156-3e32-4798-88d4-e2059f913146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f4f01156-3e32-4798-88d4-e2059f913146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dc1e2002-e223-4467-8cad-111830b4f715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dc1e2002-e223-4467-8cad-111830b4f715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3ea9df2f-b108-4858-9273-e5645c0d379f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3ea9df2f-b108-4858-9273-e5645c0d379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5e9364a1-7433-44e1-90a7-6f6f46e7f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5e9364a1-7433-44e1-90a7-6f6f46e7f13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f770f54-6a22-4bd9-96ad-5fa4ffdb3084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f770f54-6a22-4bd9-96ad-5fa4ffdb3084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7f023d8-e004-494f-9e67-33032d5b103c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7f023d8-e004-494f-9e67-33032d5b103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a854e7a1-9209-48ab-a996-804e0a3f3169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a854e7a1-9209-48ab-a996-804e0a3f3169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_92341a02-acd5-4b6a-944b-4cbd95b97fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_92341a02-acd5-4b6a-944b-4cbd95b97fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5bd032e-44f5-49ee-a7d1-5aaec4933643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c7f169f1-ffe4-4371-b302-4a0120f607f2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5bd032e-44f5-49ee-a7d1-5aaec4933643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4312c1ea-0d8a-4bb7-9cf0-e714a78dadda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4312c1ea-0d8a-4bb7-9cf0-e714a78dadda" xlink:to="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_490b8b2c-0172-45c0-83b0-22b55b3ea0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_490b8b2c-0172-45c0-83b0-22b55b3ea0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c3df94e-6f93-4322-bd05-3de48a01a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c3df94e-6f93-4322-bd05-3de48a01a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d58bf54a-0122-4c1c-a8c9-4fb1713d59d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d58bf54a-0122-4c1c-a8c9-4fb1713d59d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_b883dc61-b274-428f-964f-3574091a4d12" xlink:href="biib-20220630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_b883dc61-b274-428f-964f-3574091a4d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_22037a8b-c101-4f5f-bc14-e90ec79f36e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_InventoryNet_22037a8b-c101-4f5f-bc14-e90ec79f36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5105cbf4-2621-4c56-8aa2-d9118444dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_OtherAssetsCurrent_5105cbf4-2621-4c56-8aa2-d9118444dbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_34d5fd80-105a-4d1a-af8b-b84f3875ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3463ad26-353b-4304-b56e-4308a2581b92" xlink:to="loc_us-gaap_AssetsCurrent_34d5fd80-105a-4d1a-af8b-b84f3875ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e4fa7c58-8616-46eb-8a1d-183ebe9c92a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e4fa7c58-8616-46eb-8a1d-183ebe9c92a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f1dad0a-9b9e-4066-8289-6ca9b5515c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f1dad0a-9b9e-4066-8289-6ca9b5515c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0df8d926-a8c4-409b-b8b9-fd193ea5bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0df8d926-a8c4-409b-b8b9-fd193ea5bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3742ab2e-0409-4782-a732-2db233e6ddce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3742ab2e-0409-4782-a732-2db233e6ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d68988d3-3537-4f9e-8a6d-b779e2557db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_Goodwill_d68988d3-3537-4f9e-8a6d-b779e2557db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f41a1e9b-b339-44d9-96b8-1947b7b0cdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f41a1e9b-b339-44d9-96b8-1947b7b0cdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_da0327a8-a4d4-40a2-91c1-fadd7a2c2fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_da0327a8-a4d4-40a2-91c1-fadd7a2c2fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ee9f3bdb-287d-4a2a-986d-6a1c6cdba193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7488d619-f3c4-485b-afdf-e6f23c74542c" xlink:to="loc_us-gaap_Assets_ee9f3bdb-287d-4a2a-986d-6a1c6cdba193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4312c1ea-0d8a-4bb7-9cf0-e714a78dadda" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_40236e4e-93bc-488e-9571-33d997ab4304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:to="loc_us-gaap_NotesPayableCurrent_40236e4e-93bc-488e-9571-33d997ab4304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_638ca4b7-9184-4d2e-86f5-fa21ef0649c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:to="loc_us-gaap_TaxesPayableCurrent_638ca4b7-9184-4d2e-86f5-fa21ef0649c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7c1c3a72-697d-44dd-b694-08e471663345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:to="loc_us-gaap_AccountsPayableCurrent_7c1c3a72-697d-44dd-b694-08e471663345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_73f5753c-484d-487d-9606-e7302fa53b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_73f5753c-484d-487d-9606-e7302fa53b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d6210e5e-6638-4060-9432-ba696964ce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5aec0fc5-5fe5-47ef-834b-a14789e7182a" xlink:to="loc_us-gaap_LiabilitiesCurrent_d6210e5e-6638-4060-9432-ba696964ce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_61dce0f0-2f6a-4cb3-b118-8646c6919f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_LongTermDebt_61dce0f0-2f6a-4cb3-b118-8646c6919f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6e1071f3-2ae6-49a0-9261-13755db067b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6e1071f3-2ae6-49a0-9261-13755db067b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45e69594-cd7a-4656-ba63-f71a5a4705ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45e69594-cd7a-4656-ba63-f71a5a4705ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_444fd467-80c4-4c08-9e9a-03ef7e4b8eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_444fd467-80c4-4c08-9e9a-03ef7e4b8eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c561e377-b6ee-4df7-9824-919b6432fe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_Liabilities_c561e377-b6ee-4df7-9824-919b6432fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_eeea105a-5929-4fe2-90cd-05f103d62647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_CommitmentsAndContingencies_eeea105a-5929-4fe2-90cd-05f103d62647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f432bf72-e8b6-488b-9a64-767661395f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f432bf72-e8b6-488b-9a64-767661395f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f432bf72-e8b6-488b-9a64-767661395f6f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_68caa178-5fba-4ff4-9af3-29800c697a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_PreferredStockValue_68caa178-5fba-4ff4-9af3-29800c697a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5d839894-7928-4dae-985c-60764290f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_CommonStockValue_5d839894-7928-4dae-985c-60764290f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d69ad8e2-40bc-40b9-8bef-9ad05359eedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d69ad8e2-40bc-40b9-8bef-9ad05359eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3de92254-4ba0-4d1b-b41c-3ba0b0d23ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3de92254-4ba0-4d1b-b41c-3ba0b0d23ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_981d67d0-9fc0-43c9-94f7-18ec0128e477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_981d67d0-9fc0-43c9-94f7-18ec0128e477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0a905372-d4ca-4f3a-9973-7573ce223a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_TreasuryStockValue_0a905372-d4ca-4f3a-9973-7573ce223a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9b62a26-b902-44b5-8682-19cbd102f6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8f289359-f6ea-4592-b847-165b5a45c401" xlink:to="loc_us-gaap_StockholdersEquity_e9b62a26-b902-44b5-8682-19cbd102f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9f9322ce-0ffd-471a-96b7-fb1d8b047a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f432bf72-e8b6-488b-9a64-767661395f6f" xlink:to="loc_us-gaap_MinorityInterest_9f9322ce-0ffd-471a-96b7-fb1d8b047a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba418920-0f3d-4c17-9188-5b5ce3e0d262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f432bf72-e8b6-488b-9a64-767661395f6f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba418920-0f3d-4c17-9188-5b5ce3e0d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5519048a-fd1d-40d8-89e9-434ca2d0215d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0c14267-2e66-4523-a2ca-7190c3059c06" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5519048a-fd1d-40d8-89e9-434ca2d0215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0ebd4760-a217-46f4-9da5-3e496869c853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7179edfb-7f82-4f54-987b-dce53a36de78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0ebd4760-a217-46f4-9da5-3e496869c853" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7179edfb-7f82-4f54-987b-dce53a36de78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_daa01c4f-1998-424b-9634-d2cd490dd365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0ebd4760-a217-46f4-9da5-3e496869c853" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_daa01c4f-1998-424b-9634-d2cd490dd365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60422196-4819-4f60-b3b8-40853a914c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60422196-4819-4f60-b3b8-40853a914c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e1faccf8-d57c-48ee-9658-adb7c2203fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60422196-4819-4f60-b3b8-40853a914c9e" xlink:to="loc_us-gaap_ProfitLoss_e1faccf8-d57c-48ee-9658-adb7c2203fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60422196-4819-4f60-b3b8-40853a914c9e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3766ff6e-ecd6-410d-8458-6e1e880c810e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3766ff6e-ecd6-410d-8458-6e1e880c810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ecc68d1d-f76d-4ca6-9f0b-e70d031215de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ecc68d1d-f76d-4ca6-9f0b-e70d031215de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ec775b21-b0e8-4058-b9c2-a3e9f4b32f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_InventoryWriteDown_ec775b21-b0e8-4058-b9c2-a3e9f4b32f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_983c8563-a3bd-4b67-9745-4a71c8501423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_983c8563-a3bd-4b67-9745-4a71c8501423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eb6e681d-84a7-4581-80db-be99f45e6b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_ShareBasedCompensation_eb6e681d-84a7-4581-80db-be99f45e6b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_91f29b1b-fa55-459a-82a8-70451379c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_91f29b1b-fa55-459a-82a8-70451379c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab70cd2f-55d9-48a7-97a7-bd316f2c7558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab70cd2f-55d9-48a7-97a7-bd316f2c7558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_efd6b04c-1bfc-4a03-89a5-e56e38e909a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_efd6b04c-1bfc-4a03-89a5-e56e38e909a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_445f35c2-be6a-49f6-8870-c3195d89a6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_445f35c2-be6a-49f6-8870-c3195d89a6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_4565192f-e03c-4763-a7fc-e819adae4699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_4565192f-e03c-4763-a7fc-e819adae4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_432e8031-553d-49f5-8788-d8442059c500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_432e8031-553d-49f5-8788-d8442059c500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eb25e8fb-787e-483b-bea9-94802b3760cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eb25e8fb-787e-483b-bea9-94802b3760cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9ecc2468-cbf6-4d92-8099-c7fd8daba785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9ecc2468-cbf6-4d92-8099-c7fd8daba785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d739f2be-6a34-4e60-b947-0cfef4ba39c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d739f2be-6a34-4e60-b947-0cfef4ba39c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_876ba88c-8b5d-4ab2-9143-4e374207c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_876ba88c-8b5d-4ab2-9143-4e374207c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f13bdac9-3d45-46b4-94b2-2f1ea97af49e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f13bdac9-3d45-46b4-94b2-2f1ea97af49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_01678354-0947-4927-9419-a8415acea679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b6f8db1-2c0a-4ed8-984a-ccd54edd313f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_01678354-0947-4927-9419-a8415acea679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b85ddc9-46bc-490a-b79b-efe828ff28aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55d49ba6-1ede-4f1d-bcd6-8482ef01830d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b85ddc9-46bc-490a-b79b-efe828ff28aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3eb42d76-1503-40c2-87c5-ef52cf99641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3eb42d76-1503-40c2-87c5-ef52cf99641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b827941c-85cd-44aa-bfd1-8d3e1a364678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b827941c-85cd-44aa-bfd1-8d3e1a364678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_81038f88-766c-4c6e-9cd6-5c93fd11cdea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_81038f88-766c-4c6e-9cd6-5c93fd11cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_120be45b-aa7d-45d3-8fa5-884dc3f7c5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_120be45b-aa7d-45d3-8fa5-884dc3f7c5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e7598631-75f4-45c3-b09d-529517fb2836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e7598631-75f4-45c3-b09d-529517fb2836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1915bb7c-54b5-48f7-a4bc-e584567970fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1915bb7c-54b5-48f7-a4bc-e584567970fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_60fda15b-603c-4753-b2cd-7fbfbc65e47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_60fda15b-603c-4753-b2cd-7fbfbc65e47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_db63d94e-875f-497a-8b94-a868538e1903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_db63d94e-875f-497a-8b94-a868538e1903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca1013bd-47e6-4804-99ef-4dd7b7b5cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15fec1f-4970-4292-96ac-7b2f3dd8e423" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca1013bd-47e6-4804-99ef-4dd7b7b5cf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_974beb7f-445e-4f27-8ed6-e486038086c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_974beb7f-445e-4f27-8ed6-e486038086c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aca531d9-d7a7-492a-90d8-ece614e2bceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aca531d9-d7a7-492a-90d8-ece614e2bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2983ad2f-bdc9-4a6e-8d05-2592aaf70d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2983ad2f-bdc9-4a6e-8d05-2592aaf70d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_e1830edf-5bca-4ae2-8349-0cb3a680789a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_e1830edf-5bca-4ae2-8349-0cb3a680789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_111f39cb-fedc-4003-92e2-1aa0acf46906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_111f39cb-fedc-4003-92e2-1aa0acf46906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aef600c7-a5c2-4071-a260-03cbc051b7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec3e8fbe-a5f5-4d00-88e3-e2e56fb4c354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aef600c7-a5c2-4071-a260-03cbc051b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ba3a0028-0a44-40b7-b4f9-aa1e99412ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ba3a0028-0a44-40b7-b4f9-aa1e99412ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_437ec539-b2fb-491e-894e-4b75c00a000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_437ec539-b2fb-491e-894e-4b75c00a000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f789d98-fb83-40e4-8a2e-1ee20d946aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f789d98-fb83-40e4-8a2e-1ee20d946aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a0756a9-2edb-478c-bffa-366c3cb2c282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4dbdb994-40e3-4a7e-b94e-54b67765cc06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a0756a9-2edb-478c-bffa-366c3cb2c282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e516a3bb-185d-4d39-a300-82fc37db237b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e516a3bb-185d-4d39-a300-82fc37db237b" xlink:to="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_25e78633-2ce7-43f7-a3a8-bcf391e5d778" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_dc7414a4-77fe-4e0e-b2a1-2293b815e45f" xlink:href="biib-20220630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_bed80698-3983-42d9-bfa3-db6666e8eb3b" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_dc7414a4-77fe-4e0e-b2a1-2293b815e45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255b1184-0641-438f-821e-ba5656f2082d" xlink:to="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_51f8477d-5612-4648-94d5-efd550c0e577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_PreferredStockMember_51f8477d-5612-4648-94d5-efd550c0e577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d9f31fdd-0c58-4cd0-8068-bf2292c436ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_CommonStockMember_d9f31fdd-0c58-4cd0-8068-bf2292c436ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8094553d-22aa-4a58-b766-626a6c530e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8094553d-22aa-4a58-b766-626a6c530e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98738a17-888d-4692-8457-e53682865f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_98738a17-888d-4692-8457-e53682865f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8523843e-2cae-40dd-9ceb-69c68f7d29fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_RetainedEarningsMember_8523843e-2cae-40dd-9ceb-69c68f7d29fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ddd09d0e-db60-4e0f-8010-cdd4fc0dd02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_TreasuryStockMember_ddd09d0e-db60-4e0f-8010-cdd4fc0dd02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_67a9d931-5205-4a00-b77d-afe8629c9d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_ParentMember_67a9d931-5205-4a00-b77d-afe8629c9d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a55e3267-3576-4678-a5ba-50ca0d006c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_034111e7-4732-4212-8e31-36f8adab27d9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a55e3267-3576-4678-a5ba-50ca0d006c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43f45219-964e-449f-adb6-0823bae91994" xlink:to="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5ab3636-3489-4523-b942-c3158413ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5ab3636-3489-4523-b942-c3158413ed8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_409d1b6a-b6ec-41e6-9d5e-4cd8d26e40f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_409d1b6a-b6ec-41e6-9d5e-4cd8d26e40f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a0aa3bf7-7327-409b-83e5-0ac7d467ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_ProfitLoss_a0aa3bf7-7327-409b-83e5-0ac7d467ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56fdac83-74a6-43ee-9ac3-3e94b4e2d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56fdac83-74a6-43ee-9ac3-3e94b4e2d6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_e13ea0a9-952d-4689-a88e-c6b3b9e27c0b" xlink:href="biib-20220630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_e13ea0a9-952d-4689-a88e-c6b3b9e27c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6c4881df-6c8f-43f4-8671-738c358d9c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6c4881df-6c8f-43f4-8671-738c358d9c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_908bab13-d999-4489-9687-7d60cd27ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_908bab13-d999-4489-9687-7d60cd27ba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c2bbbb23-ed67-4bed-bea6-93ffd14a9e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c2bbbb23-ed67-4bed-bea6-93ffd14a9e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_eee2e600-bd1b-4c58-b8c7-d980f764d2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_eee2e600-bd1b-4c58-b8c7-d980f764d2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_deecbd0e-c9f4-4aad-8545-07950c8a6886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_deecbd0e-c9f4-4aad-8545-07950c8a6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a33ed767-5f84-4f91-b145-e1a36487b344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a33ed767-5f84-4f91-b145-e1a36487b344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_b6b9919a-2210-4706-91ce-ce7117ddc8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_b6b9919a-2210-4706-91ce-ce7117ddc8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4357a71-3df8-463b-b376-17c513494f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4357a71-3df8-463b-b376-17c513494f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3e7e7b1f-17b4-464e-ae82-fe2a45df04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3e7e7b1f-17b4-464e-ae82-fe2a45df04a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92fa761f-8934-450a-a234-625aebb02225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92fa761f-8934-450a-a234-625aebb02225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_27d1646e-8310-4073-aa5d-0a10cb9f5eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockholdersEquityOther_27d1646e-8310-4073-aa5d-0a10cb9f5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f59ba60e-d0e6-4bf8-bd93-e97e0a8c39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f59ba60e-d0e6-4bf8-bd93-e97e0a8c39d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c8be526d-b141-4339-abf7-bd9788c78ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2decb4e-72d4-49a0-80d7-e9033b1f1468" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c8be526d-b141-4339-abf7-bd9788c78ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3485a854-12bc-4a1a-aff0-4c62d8bba550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a5de051c-37fc-45b9-914e-44b7e5131707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3485a854-12bc-4a1a-aff0-4c62d8bba550" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a5de051c-37fc-45b9-914e-44b7e5131707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20220630.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_f86efb88-fd5c-444b-af47-88917701ec19" xlink:href="biib-20220630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_f86efb88-fd5c-444b-af47-88917701ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c43f40c9-2736-4d9d-add7-8cb1349d0826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c43f40c9-2736-4d9d-add7-8cb1349d0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b7ace617-02e1-4a66-bcea-f72c00d6e83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b7ace617-02e1-4a66-bcea-f72c00d6e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3504e896-d905-4440-a950-1aff4c33883c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:to="loc_us-gaap_UseOfEstimates_3504e896-d905-4440-a950-1aff4c33883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4ea2879-8d68-496c-b08d-977477b4ea60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a26a7a9-24e8-4f2b-a81a-1f0b4736b86c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4ea2879-8d68-496c-b08d-977477b4ea60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_022f52f0-7c09-43cb-8c67-7103760b0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5227f099-c8f2-4d23-bd54-08b8ea24fbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022f52f0-7c09-43cb-8c67-7103760b0015" xlink:to="loc_us-gaap_NumberOfReportableSegments_5227f099-c8f2-4d23-bd54-08b8ea24fbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_c5f5c145-abba-4f66-8fbd-58dba7ebf508" xlink:href="biib-20220630.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022f52f0-7c09-43cb-8c67-7103760b0015" xlink:to="loc_biib_InterestInSubsidiary_c5f5c145-abba-4f66-8fbd-58dba7ebf508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b4f3dce1-51a7-45e6-98fb-d6e63aaa5c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f1371408-92cb-4bff-be6f-08f33366fac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b4f3dce1-51a7-45e6-98fb-d6e63aaa5c0f" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f1371408-92cb-4bff-be6f-08f33366fac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_81a2707d-5f75-4abe-b0c8-d993b9f90e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3fde444b-6148-449c-b542-06c4bc170fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_81a2707d-5f75-4abe-b0c8-d993b9f90e30" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3fde444b-6148-449c-b542-06c4bc170fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5934ff85-8c0f-4ee0-93d0-63365a807879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5934ff85-8c0f-4ee0-93d0-63365a807879" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:to="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_add3854e-ac4b-4533-bb7e-77720e2528af" xlink:to="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e1dfb4a3-0af2-4b8e-8235-8594f4675752" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:to="loc_srt_MinimumMember_e1dfb4a3-0af2-4b8e-8235-8594f4675752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf393b1e-1eaf-4623-90eb-9d8765c4d604" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d278fed-d78c-4e49-917f-23be16e15b08" xlink:to="loc_srt_MaximumMember_cf393b1e-1eaf-4623-90eb-9d8765c4d604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:to="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b68c9595-3455-46d2-ad2a-f485ed2d5fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9694e7c6-a594-45a9-8795-28214d52bf6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8eb06d31-62cb-42a3-b1c4-05a92a17126d" xlink:to="loc_srt_ScenarioForecastMember_9694e7c6-a594-45a9-8795-28214d52bf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_20ea28f5-79a9-40fc-a864-14a0b5a1ce24" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e8b37d98-9776-4c0a-9087-13aa3225c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_RestructuringCharges_e8b37d98-9776-4c0a-9087-13aa3225c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_417d7208-ddba-4f6d-b045-ee955f6555c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_SeveranceCosts1_417d7208-ddba-4f6d-b045-ee955f6555c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_d761b892-7f83-472d-9f26-11635dacbbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_d761b892-7f83-472d-9f26-11635dacbbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_ee4a3518-274e-46eb-9346-df54478cab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4d87ccb1-46b9-4848-9c8c-f761019d4488" xlink:to="loc_us-gaap_OtherRestructuringCosts_ee4a3518-274e-46eb-9346-df54478cab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_065bc4e1-8640-4cd5-b6a2-43a85367ad22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_065bc4e1-8640-4cd5-b6a2-43a85367ad22" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_47da150b-af02-42b3-b299-bc8a72a27093" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_ea1a89f2-de6f-4bbd-9544-83adab089190" xlink:href="biib-20220630.xsd#biib_WorkforceReductionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b5248533-c50e-4bbc-ab3d-e109865afd62" xlink:to="loc_biib_WorkforceReductionMember_ea1a89f2-de6f-4bbd-9544-83adab089190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8b661dbc-2491-45a2-b7bf-598a8d5dbb3c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c263ab7e-870c-41fd-8ac3-a9e4c3fc3196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringReserve_c263ab7e-870c-41fd-8ac3-a9e4c3fc3196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0a4adcc5-60cc-4840-8a2c-50940b21c814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringCharges_0a4adcc5-60cc-4840-8a2c-50940b21c814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_00f5b841-39e5-4bf9-a205-5bdabaa16b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_PaymentsForRestructuring_00f5b841-39e5-4bf9-a205-5bdabaa16b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_9b2792fc-7b33-4572-8865-db366f7f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_9b2792fc-7b33-4572-8865-db366f7f3146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e489c5c2-59d4-426b-96ce-06dffc9fb6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21767f59-c320-443a-afae-6dbfd8bb6eed" xlink:to="loc_us-gaap_RestructuringReserve_e489c5c2-59d4-426b-96ce-06dffc9fb6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20220630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2a74a6a8-9854-4137-b894-8302a854405c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bf7470d1-4e88-44bc-a3b2-4679a6b0f30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2a74a6a8-9854-4137-b894-8302a854405c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bf7470d1-4e88-44bc-a3b2-4679a6b0f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_497769e0-cd87-4bd1-9258-8e43f7989a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_497769e0-cd87-4bd1-9258-8e43f7989a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_e2017941-4a0b-495e-adcf-31ae707ff7ed" xlink:href="biib-20220630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_e2017941-4a0b-495e-adcf-31ae707ff7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ebe55dc2-23e4-4ff5-902e-7f5878984bad" xlink:href="biib-20220630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ebe55dc2-23e4-4ff5-902e-7f5878984bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_c865f881-f214-446d-8e5a-af10cd880ce4" xlink:href="biib-20220630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_c865f881-f214-446d-8e5a-af10cd880ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_69424cc1-6953-4710-8fad-589df1040829" xlink:href="biib-20220630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_592c033d-541c-4c1b-909c-b36c82c20509" xlink:to="loc_biib_OtherrevenuesTableTextBlock_69424cc1-6953-4710-8fad-589df1040829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_4bb4148f-2f0b-449e-b201-a263809f4775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_4bb4148f-2f0b-449e-b201-a263809f4775" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:to="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_64809230-aefe-45b2-8607-32b1fd2b0b0a" xlink:to="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:href="biib-20220630.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:href="biib-20220630.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:to="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_130b66f8-1487-4e45-ba71-e63c661b3807" xlink:href="biib-20220630.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:to="loc_biib_TECFIDERAMember_130b66f8-1487-4e45-ba71-e63c661b3807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_bd188d96-4ec9-4cbf-b338-dcb57826cd22" xlink:href="biib-20220630.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_160e75d8-5260-4c66-90d3-77ad23828acc" xlink:to="loc_biib_VUMERITYMember_bd188d96-4ec9-4cbf-b338-dcb57826cd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:href="biib-20220630.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_0f1e5ca0-3adc-4704-bfe3-f674c8498ebf" xlink:to="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_d1bec0b0-0f4e-416a-9569-385882a75c54" xlink:href="biib-20220630.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:to="loc_biib_AVONEXMember_d1bec0b0-0f4e-416a-9569-385882a75c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_f943c262-821a-49a2-9c1f-14baade3a96b" xlink:href="biib-20220630.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_0ce56c4c-26a0-4230-9b00-f2757fc6da9e" xlink:to="loc_biib_PLEGRIDYMember_f943c262-821a-49a2-9c1f-14baade3a96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_2fa39293-eb0b-4fea-8edd-94c563639bca" xlink:href="biib-20220630.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_TysabriProductMember_2fa39293-eb0b-4fea-8edd-94c563639bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_e076a434-2cf4-4683-8fea-ae4737745d78" xlink:href="biib-20220630.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_FAMPYRAMember_e076a434-2cf4-4683-8fea-ae4737745d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_4e070a1d-339c-41f5-95f0-da812b4ef8fd" xlink:href="biib-20220630.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_SPINRAZAMember_4e070a1d-339c-41f5-95f0-da812b4ef8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:href="biib-20220630.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_99243a50-ee2f-4598-af18-d52ebe18e78a" xlink:href="biib-20220630.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_BENEPALIMember_99243a50-ee2f-4598-af18-d52ebe18e78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_9bedb5c7-5475-4dd2-86b9-618a47d20ba8" xlink:href="biib-20220630.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_IMRALDIMember_9bedb5c7-5475-4dd2-86b9-618a47d20ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_74c5c536-0f98-454f-ab66-91231cee939c" xlink:href="biib-20220630.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_FLIXABIMember_74c5c536-0f98-454f-ab66-91231cee939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_0ac9e018-637c-48cb-aba6-1fac239eadd3" xlink:href="biib-20220630.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_9ce374c2-f5e4-4286-abbb-899cf71341b8" xlink:to="loc_biib_BYOOVIZMember_0ac9e018-637c-48cb-aba6-1fac239eadd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_d6a7a0c3-8824-4fb9-9585-1ec01320be0d" xlink:href="biib-20220630.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_FUMADERMMember_d6a7a0c3-8824-4fb9-9585-1ec01320be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_aa9a9d9f-c97b-4242-bf82-4ccea598a3d0" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_biib_ADUHELMMember_aa9a9d9f-c97b-4242-bf82-4ccea598a3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ed3ba04-d775-40d2-9979-5414e0ddec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea303d02-20da-4afb-9e7f-996d433d7077" xlink:to="loc_us-gaap_ProductMember_4ed3ba04-d775-40d2-9979-5414e0ddec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:to="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e947aa4f-f28b-4713-b36b-2ae327a6c992" xlink:to="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6c52be46-fa8c-4da7-8130-42bfc735c6f3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:to="loc_country_US_6c52be46-fa8c-4da7-8130-42bfc735c6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ec30be2a-e912-4ff2-8611-987316dcf812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4b1a9e96-db4d-40eb-9c0a-b0af4d79e81f" xlink:to="loc_us-gaap_NonUsMember_ec30be2a-e912-4ff2-8611-987316dcf812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46580bd5-99e1-4a89-8747-32c9e12efef9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc478635-224b-4c0b-80a9-29f915153f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5acfec68-0c42-4ba6-85b4-c88c7107f5a9" xlink:to="loc_us-gaap_Revenues_bc478635-224b-4c0b-80a9-29f915153f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_e31bddf5-8822-4299-9a8b-587748688a2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_e31bddf5-8822-4299-9a8b-587748688a2f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d67e7aef-d4c4-412f-9ebf-bccb63558b71" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_ee7d3fa3-c9bc-4196-b463-8c1c5f3414c7" xlink:href="biib-20220630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_biib_ReserveforCashDiscountsMember_ee7d3fa3-c9bc-4196-b463-8c1c5f3414c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_d0b59834-a144-4617-87bf-89416d36b1f9" xlink:href="biib-20220630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_biib_ContractualAdjustmentsMember_d0b59834-a144-4617-87bf-89416d36b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_c3230ee4-d6da-4931-999f-ff400748adea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4c2fc0b-9041-42ec-8fe4-af379f04e600" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_c3230ee4-d6da-4931-999f-ff400748adea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_40bee5ea-06fa-4509-86c1-c4312caef7f3" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1c8f0a42-4107-4dcb-8663-812151c40885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1c8f0a42-4107-4dcb-8663-812151c40885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2ab5451e-ba45-42a1-be13-68851d5b4ddd" xlink:href="biib-20220630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2ab5451e-ba45-42a1-be13-68851d5b4ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e8ee1cd8-294f-4c2b-993c-f914a4bb2876" xlink:href="biib-20220630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e8ee1cd8-294f-4c2b-993c-f914a4bb2876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f577b1e0-25a4-461f-94a0-114258f72d51" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f577b1e0-25a4-461f-94a0-114258f72d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d6bb9f3b-1f6c-44e4-a2f6-fc2702396c77" xlink:href="biib-20220630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d6bb9f3b-1f6c-44e4-a2f6-fc2702396c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab3be22a-6f32-4dde-9c8a-2fced07f26d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c540df12-d6af-4e4b-b3dd-f70f10678950" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab3be22a-6f32-4dde-9c8a-2fced07f26d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_31d87e5c-7f7d-47ce-9f92-ff76aea7cc43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_31d87e5c-7f7d-47ce-9f92-ff76aea7cc43" xlink:to="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2c8c3d81-21cd-43a9-8f09-b7d10aef2f45" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4e5d33db-c46a-44c6-b88b-1f6610384dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:to="loc_us-gaap_AccountsReceivableMember_4e5d33db-c46a-44c6-b88b-1f6610384dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_acdfe010-61b7-4fad-88bc-f2e24530c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f8c15132-b175-471b-84b4-207daa24f11b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_acdfe010-61b7-4fad-88bc-f2e24530c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_88840208-2d71-4331-87f3-83c91f7ea458" xlink:to="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2e9120c-7125-42df-a911-2e4860aca025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf9ac16-d7cf-4de1-bf29-e7818c296160" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2e9120c-7125-42df-a911-2e4860aca025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ecd8ee7-782a-4187-9025-719e9b7c3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ecd8ee7-782a-4187-9025-719e9b7c3cdf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:to="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_53117658-ae86-47b1-af9f-0491bd6d689f" xlink:to="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1efa1651-4a99-43f6-8fac-50516f9daf59" xlink:href="biib-20220630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f499a57f-3f73-4c9b-900f-620ad81df95e" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1efa1651-4a99-43f6-8fac-50516f9daf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:to="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0c2f9799-f6bb-412d-ba3d-f7e47dcb6a5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_4392586d-da35-4222-b56d-32ad7221d10f" xlink:href="biib-20220630.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_affdfc1c-f467-46f4-a634-9e70d0cb19cc" xlink:to="loc_biib_RocheGroupGenentechMember_4392586d-da35-4222-b56d-32ad7221d10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_993f98a4-ec4c-4b1b-bdc6-b89ab3580769" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_5097a67a-b05c-4536-a3bc-1a8992ff8765" xlink:href="biib-20220630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_biib_ShareOfCoPromotionProfits_5097a67a-b05c-4536-a3bc-1a8992ff8765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_bad127fe-53e2-4a10-b014-88e88077678b" xlink:href="biib-20220630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_bad127fe-53e2-4a10-b014-88e88077678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_54d30c5d-6843-4cb9-8bb0-ec9b3f729a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6b4b3c68-3c4f-4c7d-ad1b-dca73c7a6b5c" xlink:to="loc_us-gaap_Revenues_54d30c5d-6843-4cb9-8bb0-ec9b3f729a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_c36843d1-8171-4ca7-b5d2-026268cbcf61" xlink:href="biib-20220630.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_c36843d1-8171-4ca7-b5d2-026268cbcf61" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e569e3a-d362-4629-938b-a330cede39d7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1dbc6f49-a727-4b43-88c2-e9ba93bb861a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8471f3af-32c9-46c0-af14-152260dea5f8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1dbc6f49-a727-4b43-88c2-e9ba93bb861a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c2143526-9f11-4363-9bf9-965ecd9a88be" xlink:to="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f73c6652-fa44-44cb-bd4d-55bdb91c01f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_us-gaap_RoyaltyMember_f73c6652-fa44-44cb-bd4d-55bdb91c01f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_0b401e98-b0f5-4d9f-8470-099e2505656a" xlink:href="biib-20220630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_biib_OthercorporaterevenuesMember_0b401e98-b0f5-4d9f-8470-099e2505656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4030a79b-7afc-4629-b155-f5829ef5f922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b73f79-8a6d-42cd-b6cd-7b62277c717f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4030a79b-7afc-4629-b155-f5829ef5f922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b3fa6b71-4aec-4f5a-bcb7-9004b3991883" xlink:to="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_49f8aa3b-2998-45f9-be73-25b6672ffee3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_49f8aa3b-2998-45f9-be73-25b6672ffee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_0d141b44-60fd-4a17-8f28-f49acfade8e6" xlink:href="biib-20220630.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7c901237-23bf-44ee-87bb-5e242dacdea7" xlink:to="loc_biib_ZINBRYTAMember_0d141b44-60fd-4a17-8f28-f49acfade8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_59c4ef7d-6256-4d43-ae41-7691e0bcb926" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b85db5ac-27f2-4cc1-9dfd-0b962852ef3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e5c8eac2-04da-4ad7-b0eb-a16bff034e3c" xlink:to="loc_us-gaap_Revenues_b85db5ac-27f2-4cc1-9dfd-0b962852ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e19d5d6d-af8a-47b1-b09b-004e37c45a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e19d5d6d-af8a-47b1-b09b-004e37c45a77" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:to="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9a1a54b4-4293-4b27-8fc3-bdef89aad6f4" xlink:to="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_6fa72a00-3b40-427f-9851-7da8fbd70b77" xlink:href="biib-20220630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:to="loc_biib_OthercorporaterevenuesMember_6fa72a00-3b40-427f-9851-7da8fbd70b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6a4636c5-5373-467b-bb22-dfa03998b7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02b1e348-5a85-4921-beea-8ba06d2f82c3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6a4636c5-5373-467b-bb22-dfa03998b7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:to="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_367c031b-bb4c-4eff-be35-09a69bbacd24" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_8074e181-6236-4989-8ae3-cc7899c10b6c" xlink:href="biib-20220630.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:to="loc_biib_DistributorOneMember_8074e181-6236-4989-8ae3-cc7899c10b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_ecdc6e2f-657b-4ffd-812b-b8f222a77113" xlink:href="biib-20220630.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3c397e6f-62d0-40cd-bfdf-8c94a75ad949" xlink:to="loc_biib_DistributorTwoMember_ecdc6e2f-657b-4ffd-812b-b8f222a77113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_038d8ae9-4fa2-42ea-b59b-0b1bb977ecc3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ec10bbcc-626f-40c7-9498-3993d7d261b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_us-gaap_Revenues_ec10bbcc-626f-40c7-9498-3993d7d261b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6d8a8ad6-a292-4e4f-8e6a-958bbc8b5464" xlink:href="biib-20220630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6d8a8ad6-a292-4e4f-8e6a-958bbc8b5464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_e6d5ec55-4c41-43cb-9404-84c3990542c9" xlink:href="biib-20220630.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b98e5557-f5b9-465e-983c-0a84feea8254" xlink:to="loc_biib_NumberOfWholesalers_e6d5ec55-4c41-43cb-9404-84c3990542c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20220630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9eef2561-0c2c-4f51-80c7-24c8337879b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_19e65f50-b159-4b56-88a6-37ee235cd6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9eef2561-0c2c-4f51-80c7-24c8337879b7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_19e65f50-b159-4b56-88a6-37ee235cd6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_46272e58-3d87-4cf7-bd03-cab231d4cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3603ca83-a5a9-4ebb-ad26-11d39ba3b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46272e58-3d87-4cf7-bd03-cab231d4cf8a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3603ca83-a5a9-4ebb-ad26-11d39ba3b86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8d956e82-a3b4-412a-a7f1-e211be428b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8d956e82-a3b4-412a-a7f1-e211be428b83" xlink:to="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:to="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e6843578-6eaa-442b-a3ea-2c001add2abd" xlink:to="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember_a56ea400-bff5-4b15-a994-ca49911e0b7d" xlink:href="biib-20220630.xsd#biib_LecanemabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d8f999ba-c0d2-4abe-97fb-f884d6580fe7" xlink:to="loc_biib_LecanemabMember_a56ea400-bff5-4b15-a994-ca49911e0b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cd2b4e4d-d04d-48c8-bae4-cb9a7b85e2f5" xlink:to="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_756b932e-2a84-4a5e-93e0-4e31475ed8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_756b932e-2a84-4a5e-93e0-4e31475ed8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_29e48b3d-460e-46a6-954a-e44a3edfddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_29e48b3d-460e-46a6-954a-e44a3edfddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ecca1d6f-b333-49ac-8af2-22a4e38b30c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ecca1d6f-b333-49ac-8af2-22a4e38b30c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9e507bf1-cf56-4289-ba72-ac0ea5cb7df7" xlink:href="biib-20220630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_7d415b4b-ef6b-40cc-8c00-c3ab89d144b9" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_9e507bf1-cf56-4289-ba72-ac0ea5cb7df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4aa28a11-10ca-442c-a8b3-3546ed0dddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4aa28a11-10ca-442c-a8b3-3546ed0dddcf" xlink:to="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c62a978d-b044-4c3a-afa0-30fab8dfca5d" xlink:to="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_0edf9be0-7a66-4f45-8394-9e625d986366" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30b8990f-deeb-428e-8c53-5b8e4711088f" xlink:to="loc_biib_ADUHELMMember_0edf9be0-7a66-4f45-8394-9e625d986366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89ccaa28-c8b2-44cf-bcd4-b3f50b3fb518" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_603cdea1-7615-4839-a2b3-242946deda6b" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358aca10-0fe1-4335-ab06-ca00f4077768" xlink:to="loc_biib_EisaiMember_603cdea1-7615-4839-a2b3-242946deda6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ababb62a-5159-4830-9818-5e63abb1afa6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_01a1769c-e036-4d9b-8ee1-0e39a8ba5f8e" xlink:href="biib-20220630.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ed132ff-7b7a-4172-8910-aea3650472eb" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_01a1769c-e036-4d9b-8ee1-0e39a8ba5f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_0a991107-f967-493a-a043-40ba5b8359be" xlink:to="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d837e4cc-9603-4e0e-9c5c-21ab4fde8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_us-gaap_InventoryWriteDown_d837e4cc-9603-4e0e-9c5c-21ab4fde8acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eb9d9550-d44c-40aa-b210-dec2ab4df479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eb9d9550-d44c-40aa-b210-dec2ab4df479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_58ce6f0f-ed10-4c96-8973-1c4de4be1118" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_58ce6f0f-ed10-4c96-8973-1c4de4be1118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_906f7cb4-f2be-4694-8a43-d10f82c00eb5" xlink:href="biib-20220630.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d55b4978-eaf5-49b6-841c-9192ab090f4a" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_906f7cb4-f2be-4694-8a43-d10f82c00eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1cd45d6-b77f-4119-8a35-9ee04f59d380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6ca727a8-4ffa-472c-874d-d16b892a55af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1cd45d6-b77f-4119-8a35-9ee04f59d380" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6ca727a8-4ffa-472c-874d-d16b892a55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b04ab5c-34ef-48f3-8624-b6926461def1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_b7c8a263-8a3a-46c5-a46e-10209ab6b021" xlink:href="biib-20220630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b04ab5c-34ef-48f3-8624-b6926461def1" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_b7c8a263-8a3a-46c5-a46e-10209ab6b021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d753f706-2afd-43ac-98b7-904f278f8057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b04ab5c-34ef-48f3-8624-b6926461def1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d753f706-2afd-43ac-98b7-904f278f8057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_99253fe5-afe8-4818-892f-a5e63caa4ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b04ab5c-34ef-48f3-8624-b6926461def1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_99253fe5-afe8-4818-892f-a5e63caa4ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1a40428-a278-4d1c-b634-10580cde19d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1a40428-a278-4d1c-b634-10580cde19d9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:href="biib-20220630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_89757ae9-5f0d-4954-b0a1-8b3907c24ae4" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_5a66a743-ee93-460e-9be4-fd68ea617c02" xlink:href="biib-20220630.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB111Member_5a66a743-ee93-460e-9be4-fd68ea617c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_9c21edfc-5009-405f-b989-70cf200b7616" xlink:href="biib-20220630.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB112Member_9c21edfc-5009-405f-b989-70cf200b7616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_7dc57b71-d702-4551-b58d-85a30981f333" xlink:href="biib-20220630.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_VixotrigineMember_7dc57b71-d702-4551-b58d-85a30981f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_07ddb815-5752-476b-b558-a60357222324" xlink:href="biib-20220630.xsd#biib_TGNMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_TGNMember_07ddb815-5752-476b-b558-a60357222324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_cf3cf213-8efb-4110-97f2-32f5a9542d57" xlink:href="biib-20220630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_18bef7ae-e8c9-4c8b-bb9f-5ee041412aaa" xlink:to="loc_biib_BIIB111AndBIIB112Member_cf3cf213-8efb-4110-97f2-32f5a9542d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_792550fe-887e-4bb1-a744-edda9ba1c122" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7706b1a5-927d-4802-8801-34d1ec73b3ff" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_f34d05ce-90f5-4020-b75c-8e3f768df0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_f34d05ce-90f5-4020-b75c-8e3f768df0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_10bc2ba7-965e-47bc-b19b-21a974e17c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6c8caff-8137-4f19-986e-16df989543eb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_10bc2ba7-965e-47bc-b19b-21a974e17c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4188251b-8f64-42c7-86c4-68b0ee069a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_f94162f3-5195-4252-9998-59797f6ca679" xlink:href="biib-20220630.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:to="loc_biib_OutLicensedPatentsMember_f94162f3-5195-4252-9998-59797f6ca679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d4cd929-f341-440f-addf-634bc74d1656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a92240e-ccd9-4c1e-b378-afdbca1cffe9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d4cd929-f341-440f-addf-634bc74d1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ef474d23-953a-477d-a071-54fcd2b25909" xlink:to="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d5158a0-1b70-4c97-b19d-8e7bd55f03a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:to="loc_srt_MinimumMember_9d5158a0-1b70-4c97-b19d-8e7bd55f03a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b34b467a-eb39-4f1c-ab0b-d7294433271e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ed49cd81-8536-42bd-95ea-a27af04ed593" xlink:to="loc_srt_MaximumMember_b34b467a-eb39-4f1c-ab0b-d7294433271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1021f12d-4160-48df-89f0-4042aafe095d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f74af85-f551-4056-8f52-bdc5a0074e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f74af85-f551-4056-8f52-bdc5a0074e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b43da980-feae-424c-bffb-058c71a924ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b43da980-feae-424c-bffb-058c71a924ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_43351310-aefc-4c05-97f6-763f8f450aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_43351310-aefc-4c05-97f6-763f8f450aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84a1b7e6-18ca-4a0b-aeb2-cb2b3f0fba97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84a1b7e6-18ca-4a0b-aeb2-cb2b3f0fba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_722b80cf-81c1-4da5-9f53-b55b35b3d0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_722b80cf-81c1-4da5-9f53-b55b35b3d0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_678d2a74-6776-411a-a505-fde633b250f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_678d2a74-6776-411a-a505-fde633b250f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f9cf121-a834-48b6-ba22-8e7d037395b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_585ab056-349d-42c0-96ff-caba272f4d03" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f9cf121-a834-48b6-ba22-8e7d037395b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_2940da0b-338e-4f5b-a84d-264d7af49674" xlink:href="biib-20220630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_2940da0b-338e-4f5b-a84d-264d7af49674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a74bb58d-a686-4159-a928-04c52d0515c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a74bb58d-a686-4159-a928-04c52d0515c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_9633415e-226e-4a7c-a99c-951665a7dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_9633415e-226e-4a7c-a99c-951665a7dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_61a6d0c7-aeac-4f81-bd0e-a5232dd36d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_61a6d0c7-aeac-4f81-bd0e-a5232dd36d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cb70fedf-f67c-41f5-963a-15723e397ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cb70fedf-f67c-41f5-963a-15723e397ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_13676472-4a65-43ff-8475-9e1e3cf41cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_13676472-4a65-43ff-8475-9e1e3cf41cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bce55de6-c179-46fd-9a5d-0a50897d2fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bce55de6-c179-46fd-9a5d-0a50897d2fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a86f0fae-3bf6-402e-85d8-2cb238bd375a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a86f0fae-3bf6-402e-85d8-2cb238bd375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7e7680be-2063-453b-9f6d-a99568671ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1be6ccc6-8f7f-4055-bab7-1f0c33127033" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7e7680be-2063-453b-9f6d-a99568671ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5fa1a13-fa5e-40bf-8597-22c9e5d87be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6195d8fa-3b56-4093-a473-93035beb7d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5fa1a13-fa5e-40bf-8597-22c9e5d87be3" xlink:to="loc_us-gaap_GoodwillRollForward_6195d8fa-3b56-4093-a473-93035beb7d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_357429bb-9648-4adb-a99c-508684aeb06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6195d8fa-3b56-4093-a473-93035beb7d52" xlink:to="loc_us-gaap_Goodwill_357429bb-9648-4adb-a99c-508684aeb06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_a1300bd6-6bd2-411e-89ef-7e70a695d741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6195d8fa-3b56-4093-a473-93035beb7d52" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_a1300bd6-6bd2-411e-89ef-7e70a695d741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e8b8bad-7f5f-496e-a4ca-777faf37de44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6195d8fa-3b56-4093-a473-93035beb7d52" xlink:to="loc_us-gaap_Goodwill_6e8b8bad-7f5f-496e-a4ca-777faf37de44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ac514928-97fd-4c46-bd8b-dbe097e728d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d5fa1a13-fa5e-40bf-8597-22c9e5d87be3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ac514928-97fd-4c46-bd8b-dbe097e728d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_745399c0-c0e1-42cf-8e49-c656a21a384d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4a240c1e-0b1c-438b-becd-889f2aef11c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_745399c0-c0e1-42cf-8e49-c656a21a384d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4a240c1e-0b1c-438b-becd-889f2aef11c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_158a4cd0-d0ef-47b5-8d4b-bf79d55e7a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_35923a11-d611-47ed-907e-7adc0e354c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_158a4cd0-d0ef-47b5-8d4b-bf79d55e7a97" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_35923a11-d611-47ed-907e-7adc0e354c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a5f15abc-7e09-4e02-bb2a-fb124fd38cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_158a4cd0-d0ef-47b5-8d4b-bf79d55e7a97" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a5f15abc-7e09-4e02-bb2a-fb124fd38cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8fd87e1d-5f63-4f4f-bcff-e076248e6cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_158a4cd0-d0ef-47b5-8d4b-bf79d55e7a97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8fd87e1d-5f63-4f4f-bcff-e076248e6cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ea444f29-3c15-4480-85dd-856f84fbb1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea444f29-3c15-4480-85dd-856f84fbb1d2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_56dbe3e7-6156-4da8-8fba-d8b0c36c8df7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5a6c914-32ea-4c8f-b32e-04ef3373e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5a6c914-32ea-4c8f-b32e-04ef3373e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a47a6016-f28d-49f8-b8c4-c8e731322c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a47a6016-f28d-49f8-b8c4-c8e731322c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_13555b7a-f922-43b3-ac98-6c3cbe2bed73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f32dbccd-afda-47fe-b933-fee4253a387a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_13555b7a-f922-43b3-ac98-6c3cbe2bed73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80038f92-b1a8-4ddb-bfc6-0ee34d4f58cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c7cc6ee-0491-4e86-998e-a7cb1de68d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75e1c465-d662-4d41-8273-59ca3991d44e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c7cc6ee-0491-4e86-998e-a7cb1de68d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b414fc5c-dc82-479f-998a-17991da3e5fd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_18f129cb-663e-4b39-ba71-6ccae2bd29cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_18f129cb-663e-4b39-ba71-6ccae2bd29cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ca16c323-2da8-49de-b60b-a8ae92bb5eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ca16c323-2da8-49de-b60b-a8ae92bb5eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_17ba9ef6-224f-4751-b8ee-b030c1b7d9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_29c4a93f-c56f-4fca-b973-82aafad656e3" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_17ba9ef6-224f-4751-b8ee-b030c1b7d9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b2cc5003-de68-4308-b11d-e3437ee5b954" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_27b14c00-6a92-4ada-809f-a4e8b5743652" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5e5fe66c-7d50-4f36-8de5-23d71a066971" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_27b14c00-6a92-4ada-809f-a4e8b5743652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25013fb0-3359-4bf0-83d2-2f0027f3ef72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010d30de-1d22-4004-8ce2-02c151ff38b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00973dd2-d007-4dbd-9000-eb64bc964e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00973dd2-d007-4dbd-9000-eb64bc964e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af4670c-b029-4ad0-9940-5c71cdab5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af4670c-b029-4ad0-9940-5c71cdab5fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dfd6397a-dc11-43fa-9413-f05600c1e429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dfd6397a-dc11-43fa-9413-f05600c1e429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_933ab1c1-e91a-44ae-acce-c1437416dfba" xlink:href="biib-20220630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_933ab1c1-e91a-44ae-acce-c1437416dfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9df7eac1-29a4-40c6-a23d-c22abba68df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9df7eac1-29a4-40c6-a23d-c22abba68df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_d4e122f8-193a-412b-b288-a07f63fed511" xlink:href="biib-20220630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_d4e122f8-193a-412b-b288-a07f63fed511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_53fad40d-620f-4dd5-9162-2626dab26d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_53fad40d-620f-4dd5-9162-2626dab26d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6c233bd6-bc72-41d0-97f5-087df36f5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b874fc42-bdf0-4492-954c-4ff7c666322e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6c233bd6-bc72-41d0-97f5-087df36f5eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_520ce9e0-f7d9-44d4-9d87-397e83960511" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1a9dfff0-bb2a-4fc7-ad0b-01e0e8e4a9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1a9dfff0-bb2a-4fc7-ad0b-01e0e8e4a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fcdfd358-fa44-4ead-9afb-bc47d94fea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fcdfd358-fa44-4ead-9afb-bc47d94fea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2974f662-79ed-4af5-9a14-b26946560614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2974f662-79ed-4af5-9a14-b26946560614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10f00ca0-f89d-4103-a438-c44f771c4314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_204479b9-b200-4ec8-8894-df60255918cd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10f00ca0-f89d-4103-a438-c44f771c4314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f2e18516-42b9-4369-a6a6-6a1a009ea091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_48a37f07-4788-4068-8acf-2723cff29174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2e18516-42b9-4369-a6a6-6a1a009ea091" xlink:to="loc_us-gaap_AssetImpairmentCharges_48a37f07-4788-4068-8acf-2723cff29174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3fa4338c-98ca-44e5-b7cb-57b1b7f8b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2e18516-42b9-4369-a6a6-6a1a009ea091" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3fa4338c-98ca-44e5-b7cb-57b1b7f8b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_b7440b9c-2a1d-43ed-a660-d61cf2ae59ee" xlink:href="biib-20220630.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2e18516-42b9-4369-a6a6-6a1a009ea091" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_b7440b9c-2a1d-43ed-a660-d61cf2ae59ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8f696b61-90e0-4910-b129-1f8e07a37c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8f696b61-90e0-4910-b129-1f8e07a37c5d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:to="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7371f81d-ca56-4b15-b0c7-48f06f886337" xlink:to="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c3fdf59f-e586-4afe-96f8-0f451b82ab8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f40d36e-4555-418a-967f-0b6efeabcf60" xlink:to="loc_srt_WeightedAverageMember_c3fdf59f-e586-4afe-96f8-0f451b82ab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_66669a84-cc4a-4a67-af89-a48848430f32" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7b8ae18a-a350-4bb9-ad86-0da6507ae949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8abfc5b7-9311-451b-b31c-4f3852a4c606" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7b8ae18a-a350-4bb9-ad86-0da6507ae949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1331c8a1-9561-4feb-9aa3-f7019229e9aa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eaf7524d-8d50-4f5f-bedb-4bd5b936fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eaf7524d-8d50-4f5f-bedb-4bd5b936fb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0c46f805-cc1e-44da-aa3b-abb79d356f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b54b9eb-d0bd-4d3e-9465-db5b8acd330c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0c46f805-cc1e-44da-aa3b-abb79d356f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1763d0b5-8ce8-436e-ae14-acd40a52f46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1763d0b5-8ce8-436e-ae14-acd40a52f46a" xlink:to="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2600e0d-fda9-4175-a676-d93f17ecf724" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c1ca22b5-cb43-4534-bcab-e2271e21960e" xlink:href="biib-20220630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c1ca22b5-cb43-4534-bcab-e2271e21960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_92c7d920-be91-41e8-9b02-bb3af91df6a7" xlink:href="biib-20220630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_92c7d920-be91-41e8-9b02-bb3af91df6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_817599d6-b252-473b-9ca8-013710e04243" xlink:href="biib-20220630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_817599d6-b252-473b-9ca8-013710e04243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8327839a-2996-4b2d-9be4-a66051763660" xlink:href="biib-20220630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8327839a-2996-4b2d-9be4-a66051763660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_38901288-a273-4517-b2e1-e982fda84c92" xlink:href="biib-20220630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_38901288-a273-4517-b2e1-e982fda84c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_6244422f-444f-4553-9a0c-b8ccc2df9a2e" xlink:href="biib-20220630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f7211faf-f7dd-4366-82b6-b99322185a0d" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_6244422f-444f-4553-9a0c-b8ccc2df9a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1cc08792-51d9-4e10-bc49-5b19f22a25ba" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_508e7813-b156-4bd3-8693-6d2a2d441075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_508e7813-b156-4bd3-8693-6d2a2d441075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_532d1a37-e7e4-4ecb-ba57-b92625512df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_NotesPayable_532d1a37-e7e4-4ecb-ba57-b92625512df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_dd084df8-5cdc-412c-8afa-51daae376612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_dd084df8-5cdc-412c-8afa-51daae376612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82159358-db96-499f-851a-a159fc75356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc262c1e-8c0c-4911-a8e3-756abb7ff20e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82159358-db96-499f-851a-a159fc75356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3c3f6dca-b86c-4352-97f9-1d2bc92e1f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3c3f6dca-b86c-4352-97f9-1d2bc92e1f45" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d7ba6b57-ebf9-497a-8df9-791423209018" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a6bab894-7816-4c07-ae35-5a02906101b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_43c76dc7-f1a8-4109-9f57-610625b1e506" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a6bab894-7816-4c07-ae35-5a02906101b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1ea27934-0d0b-41cb-825f-17518b6807cc" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8a38f31b-421f-48ad-8aeb-4cfa3c8813f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8a38f31b-421f-48ad-8aeb-4cfa3c8813f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27e7a539-b9b5-4720-b159-dc0e88b9117b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27e7a539-b9b5-4720-b159-dc0e88b9117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f80d64f-71d0-4c0b-ae73-25a1e663faee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_af6db713-133d-4a8c-903c-2eaad0f6cc1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f80d64f-71d0-4c0b-ae73-25a1e663faee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8a534ebb-75b7-469f-af12-b94babebbf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b40b8516-5a30-4cde-a56c-dcc5c77cd106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8a534ebb-75b7-469f-af12-b94babebbf4c" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b40b8516-5a30-4cde-a56c-dcc5c77cd106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecd1f2ff-03e4-4836-9631-daf09cda7eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_30c669f0-0f3d-4186-b4f8-3c33090021a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecd1f2ff-03e4-4836-9631-daf09cda7eda" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_30c669f0-0f3d-4186-b4f8-3c33090021a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bd057421-72d4-4cdf-b6df-e7563e1a0562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecd1f2ff-03e4-4836-9631-daf09cda7eda" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bd057421-72d4-4cdf-b6df-e7563e1a0562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_528e478c-1bce-411a-8ad4-69bfa80689ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecd1f2ff-03e4-4836-9631-daf09cda7eda" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_528e478c-1bce-411a-8ad4-69bfa80689ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_45210e7c-8c3a-4132-983c-8cbead3f3659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecd1f2ff-03e4-4836-9631-daf09cda7eda" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_45210e7c-8c3a-4132-983c-8cbead3f3659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5caf7510-36a4-4d1a-a685-fb11172b50f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5caf7510-36a4-4d1a-a685-fb11172b50f9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:to="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8e42d6f4-036c-4b77-a53d-ba64abd5929b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f59b1dd-b0d5-4efb-91bb-e06ef94d3f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_CommercialPaperMember_4f59b1dd-b0d5-4efb-91bb-e06ef94d3f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_8c50df4e-031a-4612-953e-9756643448a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_8c50df4e-031a-4612-953e-9756643448a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0ab04ea1-50af-4336-adef-675828c679ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0ab04ea1-50af-4336-adef-675828c679ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_3b86b52e-3e20-4947-8294-cc7b42676456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f398044-8fc9-407b-a660-d83163ba771e" xlink:to="loc_us-gaap_DebtSecuritiesMember_3b86b52e-3e20-4947-8294-cc7b42676456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a69043cb-dce8-44ec-9d2a-e5ee18a5477a" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_82f9277c-0366-4b2b-8a4a-cef6800b8956" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_132155b2-524a-4ef3-b705-e41c46743dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_ca8884ed-01c9-4f1a-8e44-0662a74c97ee" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_132155b2-524a-4ef3-b705-e41c46743dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59020408-b91e-4c57-b06b-e52f70cb2449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59020408-b91e-4c57-b06b-e52f70cb2449" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c348230a-ca90-4c27-9120-421891a7ad35" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_dc9ecd78-d524-4be6-9980-52cad970a7d3" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_dc9ecd78-d524-4be6-9980-52cad970a7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_8222b8e1-0291-4cba-9b11-d6536c0cb903" xlink:href="biib-20220630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_8222b8e1-0291-4cba-9b11-d6536c0cb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_f46fdfc6-79c2-4715-81db-51638c3c6435" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_f46fdfc6-79c2-4715-81db-51638c3c6435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_9e4110d4-c7a5-466c-b952-0f3d538aa7aa" xlink:href="biib-20220630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_9e4110d4-c7a5-466c-b952-0f3d538aa7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_31641dc5-7de4-48b2-b6eb-1982f96b6902" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_31641dc5-7de4-48b2-b6eb-1982f96b6902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c3ffec83-d5c6-4c5c-a735-67767152c17b" xlink:href="biib-20220630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c3ffec83-d5c6-4c5c-a735-67767152c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_d6c9ff97-73a3-41c6-b438-544f304e43c9" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_EquitySecuritiesCurrentMember_d6c9ff97-73a3-41c6-b438-544f304e43c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_9ac6582d-3430-4546-b50e-3a13efc62c7e" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b85ec27-ad92-48a7-970f-5e5d6f75f070" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_9ac6582d-3430-4546-b50e-3a13efc62c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1fca881-9c57-412b-adf2-afcb5993a5bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0eb6a1ae-caef-4891-843e-36ecc175170b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0eb6a1ae-caef-4891-843e-36ecc175170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e30d19c-625f-4ed9-bc22-4511eb2b535c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e30d19c-625f-4ed9-bc22-4511eb2b535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a68b07db-021e-4489-bce6-664aaab64d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a68b07db-021e-4489-bce6-664aaab64d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_619db90c-f534-4960-8fae-748de527b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7972c756-41e0-4fd2-aca6-a0397e911901" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_619db90c-f534-4960-8fae-748de527b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05e73bcd-52ca-4cc9-b6b9-37d93f439a7d" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_50bd1e9e-00b4-4fd5-b1d9-b64e069cb4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_50bd1e9e-00b4-4fd5-b1d9-b64e069cb4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_260f2e0f-032c-4b14-9618-18f2e69ab465" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_260f2e0f-032c-4b14-9618-18f2e69ab465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_d9cfb416-4ded-4b2f-b7ea-e7d1d6f05995" xlink:href="biib-20220630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_d9cfb416-4ded-4b2f-b7ea-e7d1d6f05995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a9891ffc-0a53-4592-a2d5-37c9f0ba00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_888c73bb-06f4-4aae-a96e-40e994f9b3c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a9891ffc-0a53-4592-a2d5-37c9f0ba00dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d2dfcd68-0cf1-479e-a9ae-6d1ec3797218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d2dfcd68-0cf1-479e-a9ae-6d1ec3797218" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_92827c65-8c63-4f83-a9d9-f832ce907def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_92827c65-8c63-4f83-a9d9-f832ce907def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_82c6da7b-0d78-4af8-801f-df33c971e2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_82c6da7b-0d78-4af8-801f-df33c971e2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6ccdfdf6-19e3-45ec-9f65-c80b7b0782ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6ccdfdf6-19e3-45ec-9f65-c80b7b0782ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7f1a8359-713e-458b-8de9-3f5a2a054c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7f1a8359-713e-458b-8de9-3f5a2a054c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_42e8fdb2-1de2-42ff-b2c0-14f13aa2da6a" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_42e8fdb2-1de2-42ff-b2c0-14f13aa2da6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_d40074e9-1d55-4321-93ee-ead4e1756ff0" xlink:href="biib-20220630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_d40074e9-1d55-4321-93ee-ead4e1756ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_827e6b3e-7464-4800-b3f2-6f01e12467bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_827e6b3e-7464-4800-b3f2-6f01e12467bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc6d3b60-b9dd-4b5b-9a0a-f31cd66e3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_a309130d-0af9-4894-9950-159a48dd745a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc6d3b60-b9dd-4b5b-9a0a-f31cd66e3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6dd8b501-742c-4311-8bec-267b639dec58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_20b5c232-779f-4af7-a59b-8fc20a711ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6dd8b501-742c-4311-8bec-267b639dec58" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_20b5c232-779f-4af7-a59b-8fc20a711ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2b51243d-0f69-42c0-8afd-adf6a8cb2488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6dd8b501-742c-4311-8bec-267b639dec58" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2b51243d-0f69-42c0-8afd-adf6a8cb2488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_86f79e2b-1a8d-4035-b56f-c4a6cb124934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6dd8b501-742c-4311-8bec-267b639dec58" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_86f79e2b-1a8d-4035-b56f-c4a6cb124934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ccee81b-a54b-4fc6-970e-cd0fb27d5815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_6157214a-0ce6-4ae5-8eed-cb020374f90f" xlink:href="biib-20220630.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ccee81b-a54b-4fc6-970e-cd0fb27d5815" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_6157214a-0ce6-4ae5-8eed-cb020374f90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_235c485b-fe9a-4173-b7bb-51db07bcb1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_235c485b-fe9a-4173-b7bb-51db07bcb1ac" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_526d001c-9b53-46d9-81ba-20ab06529f8a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_62fdf9a7-1c00-4c24-b1ad-e49e26bd48b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8d5c31ca-f023-450a-bbde-a0c5157d3bc4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_62fdf9a7-1c00-4c24-b1ad-e49e26bd48b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:to="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_523bd9dd-6063-4682-a35f-d2baa04c15c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_0fd4f9ea-5d85-49cf-97b8-8802aa3cc96e" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_564b781d-d2b6-4776-ab5a-32c40b08ea49" xlink:to="loc_biib_StrategicInvestmentsMember_0fd4f9ea-5d85-49cf-97b8-8802aa3cc96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7616c6bd-3522-4d0f-aa4f-9f276463fa96" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_c8c0f287-f2df-4327-8f47-107d0a88c223" xlink:href="biib-20220630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c8b6eaf7-e85e-4810-9897-2b372ee16263" xlink:to="loc_biib_StrategicInvestmentPortfolio_c8c0f287-f2df-4327-8f47-107d0a88c223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20220630.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_79de2c46-bcfc-48e4-9f3a-42292d83b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cd0cbd00-587d-4f98-8449-1cb9d1470dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_79de2c46-bcfc-48e4-9f3a-42292d83b3d8" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cd0cbd00-587d-4f98-8449-1cb9d1470dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20220630.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_cfe14113-1e02-4b63-98f8-92ba5882c58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_cfe14113-1e02-4b63-98f8-92ba5882c58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5dd79e7f-39b0-42f4-bbfc-2dc28426c864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5dd79e7f-39b0-42f4-bbfc-2dc28426c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9575490f-8265-4d6c-be64-2cf9255efdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9575490f-8265-4d6c-be64-2cf9255efdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f2903c18-45ab-4f09-8ebc-777639aadd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f2903c18-45ab-4f09-8ebc-777639aadd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_27713fcd-18bf-4c82-84a3-d0f3a3aa659e" xlink:href="biib-20220630.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fcb35bb3-fc5f-4e0c-81a9-3ad5cd77bac3" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_27713fcd-18bf-4c82-84a3-d0f3a3aa659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_24a62764-4b08-48ef-b9e4-7ac308a4de26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_24a62764-4b08-48ef-b9e4-7ac308a4de26" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:href="biib-20220630.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_df25aab4-5889-4e86-bbce-c9a34157fe33" xlink:to="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_3a2ff8f0-67ab-49cb-9763-e6208907e1ce" xlink:href="biib-20220630.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_4e8d507a-8ce9-4fd8-ad52-96f7b86cebf5" xlink:to="loc_biib_ShorttermderivativeMember_3a2ff8f0-67ab-49cb-9763-e6208907e1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b347030-0606-4327-97e1-36f0504b3266" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c7a618d4-b14b-4960-86f7-bbbcbd46e905" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_48abd2a6-e012-4b70-89f1-a7c35ca6a161" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c7a618d4-b14b-4960-86f7-bbbcbd46e905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_c9202fb8-9d3d-4005-a962-a5745809fb12" xlink:to="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_ebfb39c5-d298-40d1-b798-9be4d46f2ac6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_EUR_ebfb39c5-d298-40d1-b798-9be4d46f2ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_2ab2d78a-88c0-4084-8f8c-1c551c7aaf84" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_GBP_2ab2d78a-88c0-4084-8f8c-1c551c7aaf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_d8376201-addd-473f-9a70-37ad54750929" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_CHF_d8376201-addd-473f-9a70-37ad54750929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_3c5f898f-a635-4802-8c7f-6233fb5d0db7" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_JPY_3c5f898f-a635-4802-8c7f-6233fb5d0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_06b90780-1110-4c55-bc01-5a9b6c6395e2" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_845d2b2b-c2d8-4c9a-8bb6-09d8af6b504d" xlink:to="loc_currency_CAD_06b90780-1110-4c55-bc01-5a9b6c6395e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6ded12a-c99e-47db-aa09-410870f44a5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d6433c65-33b2-4b3e-ac67-ba04df68f713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_SalesMember_d6433c65-33b2-4b3e-ac67-ba04df68f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_99ae8637-8b39-4488-aa6c-774b8df0ba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_OperatingExpenseMember_99ae8637-8b39-4488-aa6c-774b8df0ba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3215d33d-0251-4d3e-a626-6f3e94108e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6ad44750-4b39-43de-aaca-046497e743e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3215d33d-0251-4d3e-a626-6f3e94108e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef0f3598-7880-46f4-b061-011ec057103d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_f83b6901-aeb4-4879-bf0d-b40d6fc3824d" xlink:href="biib-20220630.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_biib_CashflowsrevenueMember_f83b6901-aeb4-4879-bf0d-b40d6fc3824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_aa5231f5-f580-4dc9-80a6-fec74c4226e9" xlink:href="biib-20220630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_biib_CashflowsoperatingexpensesMember_aa5231f5-f580-4dc9-80a6-fec74c4226e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7565c351-0d95-46f5-b587-d2bcbe31a8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bed5d1ca-102e-4a6c-af2c-dab90d6376ca" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7565c351-0d95-46f5-b587-d2bcbe31a8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5faf0564-5c4b-4694-b690-47e94d296e01" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_dc0f88ae-804a-4782-a51b-7b9f1b2e968d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:to="loc_us-gaap_ForeignExchangeContractMember_dc0f88ae-804a-4782-a51b-7b9f1b2e968d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_fe76408f-fe9d-4677-9711-3bc554d209bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c478038a-8102-43aa-a38a-5b551c0548da" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_fe76408f-fe9d-4677-9711-3bc554d209bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9bf2d8e9-4ca5-4fda-863c-382778c540a5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_52a82b26-22fa-4bc1-9ac5-5332e072a81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_52a82b26-22fa-4bc1-9ac5-5332e072a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_75640f5a-6956-477e-86cc-8a6dabb61cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_75640f5a-6956-477e-86cc-8a6dabb61cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4c73f041-9635-4c96-abb5-8878708b0495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_98fd47ce-31ad-49ae-863e-37d4811bfb7d" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4c73f041-9635-4c96-abb5-8878708b0495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8828321b-4859-40c6-bf2a-de3bdb29ea37" xlink:to="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc8f2a72-c22b-484d-a9d5-d61d9bad7b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc8f2a72-c22b-484d-a9d5-d61d9bad7b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_746d0cc2-1791-4f43-a9f9-80bdb7a8fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f2f2cdd7-1897-4ef9-8e23-bb758eecbe55" xlink:to="loc_us-gaap_NondesignatedMember_746d0cc2-1791-4f43-a9f9-80bdb7a8fe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45547b2b-5b33-43ad-aa7f-201b9541201d" xlink:to="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a89562d5-cc8e-46b9-9ef7-0fedbe2b96b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:to="loc_srt_MinimumMember_a89562d5-cc8e-46b9-9ef7-0fedbe2b96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_230567f7-a09b-4d4c-adf5-fbf02138c6e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6836e61f-b8a3-4000-9b8a-312c16a2963b" xlink:to="loc_srt_MaximumMember_230567f7-a09b-4d4c-adf5-fbf02138c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe53b5b5-0f4e-4410-970c-c73f01d276b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ca7307a5-096e-4be5-ab61-f278c16c8f51" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe53b5b5-0f4e-4410-970c-c73f01d276b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_106cbfc2-42ac-4863-a965-cbefd8f688c0" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_61a2b4e7-949d-4972-b574-732bcf39f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_61a2b4e7-949d-4972-b574-732bcf39f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_b14f8e36-5e81-4ad8-a6b4-f05e4c53adf0" xlink:href="biib-20220630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_b14f8e36-5e81-4ad8-a6b4-f05e4c53adf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_361b1f66-7076-4e6c-a442-7830b00d49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_361b1f66-7076-4e6c-a442-7830b00d49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2be5b199-0fca-4214-a362-5f77faa1e6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2be5b199-0fca-4214-a362-5f77faa1e6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f7911889-9b17-4fbd-8f39-e194d90a990c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f7911889-9b17-4fbd-8f39-e194d90a990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72f42ff8-690f-4319-9eff-515a7a7a3be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_72f42ff8-690f-4319-9eff-515a7a7a3be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_96376338-4e5a-442e-aba8-7e258eedb331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_96376338-4e5a-442e-aba8-7e258eedb331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_dcc3e1b4-2d4a-46be-b32f-256080ba3eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_dcc3e1b4-2d4a-46be-b32f-256080ba3eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_645add32-bdd7-4458-a88a-f8dd8e3f3909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_645add32-bdd7-4458-a88a-f8dd8e3f3909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_396dd322-d49b-41bb-b0d4-964d66de6298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_396dd322-d49b-41bb-b0d4-964d66de6298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d39b09c9-0563-428a-8f23-d3bdd3c24b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d39b09c9-0563-428a-8f23-d3bdd3c24b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_81a86cde-25e7-40c9-bc45-209731fff868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_81a86cde-25e7-40c9-bc45-209731fff868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4e75fc21-c321-4c09-97e3-e331f12c1e4e" xlink:href="biib-20220630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4e75fc21-c321-4c09-97e3-e331f12c1e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_59be5135-c9bf-480f-94b2-8a643ab0a139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_59be5135-c9bf-480f-94b2-8a643ab0a139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_c2bad7ae-419e-49df-b5a5-42270698af50" xlink:href="biib-20220630.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedGainOnDerivatives_c2bad7ae-419e-49df-b5a5-42270698af50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_8e00383a-84e1-491a-99fb-c2826c277aaf" xlink:href="biib-20220630.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_UnrealizedLossOnDerivatives_8e00383a-84e1-491a-99fb-c2826c277aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_7509cdc3-c100-4221-8737-54cb770b7200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_7509cdc3-c100-4221-8737-54cb770b7200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5eb83a4b-d5f1-4dc0-ae63-84526ef2c697" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5eb83a4b-d5f1-4dc0-ae63-84526ef2c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_593f19f6-5185-4bb7-b7e7-16124fb6aa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_593f19f6-5185-4bb7-b7e7-16124fb6aa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_104a9739-671c-4ec9-a4f0-ef4e2429afe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_9e993652-67b1-4749-9908-321fc9db3047" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_104a9739-671c-4ec9-a4f0-ef4e2429afe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20220630.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e56a7b9-5d67-4443-8a00-0dbbc64a40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a65de30a-a586-47c5-95ae-869c706a8cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e56a7b9-5d67-4443-8a00-0dbbc64a40a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a65de30a-a586-47c5-95ae-869c706a8cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f8cc8aef-705b-4fec-9569-0a701dda859e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f8cc8aef-705b-4fec-9569-0a701dda859e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:href="biib-20220630.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:to="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:href="biib-20220630.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_b095a474-8b2a-4ac2-aa9b-e4780630eb7b" xlink:to="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_7ded2bd5-077b-41d0-a823-855c7d834e02" xlink:href="biib-20220630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_20915b74-f48a-4a9c-9b40-d67a4cd71a9d" xlink:to="loc_biib_SolothurnSwitzerlandMember_7ded2bd5-077b-41d0-a823-855c7d834e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:href="biib-20220630.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:to="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:href="biib-20220630.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_97e9347d-9160-4931-a005-78f8a3287174" xlink:to="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_fe1f43ce-a5ac-4ce4-9ae9-45458af8a5fc" xlink:href="biib-20220630.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_BiologicsManufacturingMember_fe1f43ce-a5ac-4ce4-9ae9-45458af8a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_c98ad089-8107-4c40-a4d8-272121d9cdd5" xlink:href="biib-20220630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_c98ad089-8107-4c40-a4d8-272121d9cdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_ee69a42e-ca98-4e8e-b9ee-a9db931a198c" xlink:href="biib-20220630.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_9f6dde4e-e76a-438a-a92c-852580b606c9" xlink:to="loc_biib_AdministrativeSpaceMember_ee69a42e-ca98-4e8e-b9ee-a9db931a198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3ec6e93-b11f-46f0-938b-890f5f8ec7cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_427c1201-7a83-49e0-bc35-0d26c23c6d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_427c1201-7a83-49e0-bc35-0d26c23c6d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d0db2f75-0c38-490f-b7fb-1dd62e6cb8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_Depreciation_d0db2f75-0c38-490f-b7fb-1dd62e6cb8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8f9407ca-b8d4-447d-8a93-278efd6279a6" xlink:href="biib-20220630.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_biib_NumberOfSquareFeet_8f9407ca-b8d4-447d-8a93-278efd6279a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_cac863f8-b30c-4607-b505-d262d1179f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_ConstructionInProgressGross_cac863f8-b30c-4607-b505-d262d1179f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e22bbd0a-fe83-4401-92c5-7b4a9e29cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7c43e460-0296-4754-bbf1-d18d1fa09831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e22bbd0a-fe83-4401-92c5-7b4a9e29cddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20220630.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5981f4b2-3a12-4f92-815c-9477641050b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eda8d4c2-c2be-4942-bb09-21bd43360fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5981f4b2-3a12-4f92-815c-9477641050b5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eda8d4c2-c2be-4942-bb09-21bd43360fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6c2aa14e-fffc-47ff-80da-c03a01c2fafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6c2aa14e-fffc-47ff-80da-c03a01c2fafa" xlink:to="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a862b59-14b4-4984-9bb3-a4a2dc3b540e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_663a7be3-8b1b-4e17-84a6-a851ac79aa3f" xlink:href="biib-20220630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_663a7be3-8b1b-4e17-84a6-a851ac79aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_8044a6b1-3952-4982-b988-cd2f2b058d3e" xlink:href="biib-20220630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edd761b5-4679-4a9f-8540-160fac669175" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_8044a6b1-3952-4982-b988-cd2f2b058d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3455c224-a372-4907-a056-c90380a68474" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_cb51182c-bbea-4b94-9f70-a42d142c3c42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f8805bff-a781-4bb8-ba89-aa5ee5554f2a" xlink:to="loc_srt_ScenarioForecastMember_cb51182c-bbea-4b94-9f70-a42d142c3c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a0a033-9ca0-44b2-acb0-3bce8ede4c16" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c89bd82d-0872-41a3-9dba-4a9e7835d410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_667449c9-8ce4-4cfb-9036-09e41bbb4481" xlink:to="loc_us-gaap_SubsequentEventMember_c89bd82d-0872-41a3-9dba-4a9e7835d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5884b69a-b769-4cb3-b0ad-72a220591964" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a29c8292-670c-42f4-965b-b3cc2388e534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a29c8292-670c-42f4-965b-b3cc2388e534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_b0037829-a508-49b1-be5f-1a914424aa58" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_DebtInstrumentRedemptionRate_b0037829-a508-49b1-be5f-1a914424aa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3da89e2-4683-47d2-a751-05f59905b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3da89e2-4683-47d2-a751-05f59905b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_5bb7f2b8-3b46-4456-9000-189adeb00a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_5bb7f2b8-3b46-4456-9000-189adeb00a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_688e779c-29de-4791-95ff-25be6a6013ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_688e779c-29de-4791-95ff-25be6a6013ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_fefd086a-bd53-49ba-8171-a0e0fd19d7a7" xlink:href="biib-20220630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_fefd086a-bd53-49ba-8171-a0e0fd19d7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_ac45a702-eab7-4bdf-8fa2-61093c9adb40" xlink:href="biib-20220630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_biib_LongTermDebtExchangedAmount_ac45a702-eab7-4bdf-8fa2-61093c9adb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c46b816a-cff1-46cb-8fde-09a9ab7d98ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c46b816a-cff1-46cb-8fde-09a9ab7d98ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_35b11c7a-fd28-492e-974c-c2a38f41e6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_RepaymentsOfDebt_35b11c7a-fd28-492e-974c-c2a38f41e6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_76d8a3b5-b8b5-4c90-9150-44ded96991d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0535204-4079-4e49-8e7d-d9d82ce3ac57" xlink:to="loc_us-gaap_InterestExpense_76d8a3b5-b8b5-4c90-9150-44ded96991d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20220630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_32920792-5cfa-431f-8481-51f37cd2fa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5bd37ceb-2f43-4a0a-a931-44b2a2f20d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32920792-5cfa-431f-8481-51f37cd2fa87" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5bd37ceb-2f43-4a0a-a931-44b2a2f20d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b48b1ffc-93c5-4bb2-8c2b-58debe4e3c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f38915ae-4582-49d7-9f57-3faeb23524c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b48b1ffc-93c5-4bb2-8c2b-58debe4e3c8b" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f38915ae-4582-49d7-9f57-3faeb23524c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_56718495-ebc2-4c01-874a-eca7e4707076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b48b1ffc-93c5-4bb2-8c2b-58debe4e3c8b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_56718495-ebc2-4c01-874a-eca7e4707076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5f7d7811-34a2-46a4-ae98-56a58ee542ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5f7d7811-34a2-46a4-ae98-56a58ee542ab" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_18c39273-bc79-4685-976f-b02adea6cd52" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_75410e33-6414-4271-8167-bf236f1afe23" xlink:href="biib-20220630.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_381ed390-8854-4518-8fad-7f8ffc6fd59d" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_75410e33-6414-4271-8167-bf236f1afe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_453cc9f5-f148-4148-be1d-71a99940cba3" xlink:to="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_82875fe0-c6bb-456d-b1cd-1b6f083b0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_82875fe0-c6bb-456d-b1cd-1b6f083b0fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7a5efa54-7117-4fc0-b3fa-0ede5fa46cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7a5efa54-7117-4fc0-b3fa-0ede5fa46cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d92b15f-2629-4476-878f-7667f66cbe66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6d92b15f-2629-4476-878f-7667f66cbe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_cfb94e90-c660-4c70-a323-5382f4e27bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee2e8a38-5156-4bbf-9d4a-fb486dfdafda" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_cfb94e90-c660-4c70-a323-5382f4e27bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_093c58e5-f448-46e5-9ea1-5e7cfcb268c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_093c58e5-f448-46e5-9ea1-5e7cfcb268c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b715cb09-2100-4c0e-a760-4bdf9e99b13b" xlink:to="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d2cd44a5-42c9-4e35-a841-e5889147493b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d2cd44a5-42c9-4e35-a841-e5889147493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_41d06ed4-6e3f-4dea-b125-f65b2af3ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_41d06ed4-6e3f-4dea-b125-f65b2af3ed56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5c0e5f60-fa7a-413e-9558-b6f44b582cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5c0e5f60-fa7a-413e-9558-b6f44b582cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ed97fdc1-8c5c-4065-bec6-b3d606744168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ed97fdc1-8c5c-4065-bec6-b3d606744168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9690aad0-b6b8-44c8-9115-6c3fa22a97dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8dfedec-27a3-4757-a18e-7cc8786ffb60" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9690aad0-b6b8-44c8-9115-6c3fa22a97dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_61d502a0-d370-4fed-b2a6-7ea257de2926" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d599361-e571-4a71-8ab3-82a24c3770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d599361-e571-4a71-8ab3-82a24c3770ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6918380d-a965-4aa7-99a6-b94025f55778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6918380d-a965-4aa7-99a6-b94025f55778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d625b16-b2ad-4388-875f-d4e1e0f3ea0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d625b16-b2ad-4388-875f-d4e1e0f3ea0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7736e298-200b-4cae-8fc8-e549cdac66f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7736e298-200b-4cae-8fc8-e549cdac66f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23228c05-60ad-4b81-9a34-b77288966acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23228c05-60ad-4b81-9a34-b77288966acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dee78076-86f6-46c3-a95e-7b2c4eebf18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dee78076-86f6-46c3-a95e-7b2c4eebf18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_78a69ee0-78e0-4e3f-8ea5-4b0e739eabae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f712e5e7-b085-462a-bd40-46e652f03d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_78a69ee0-78e0-4e3f-8ea5-4b0e739eabae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_0cb45faf-edc5-490a-b8bf-b3e88645e8bf" xlink:href="biib-20220630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_0cb45faf-edc5-490a-b8bf-b3e88645e8bf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a16c2e62-30bd-4a3a-a0cc-8a044a24c39f" xlink:to="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0eb197f8-e4d1-4b5e-9243-80dce48a81fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0eb197f8-e4d1-4b5e-9243-80dce48a81fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe0cbd38-12a2-42ee-a43a-ac7ac194e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_fe0cbd38-12a2-42ee-a43a-ac7ac194e1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_ba099712-09b8-4b74-a0e2-d9ab2147558d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_ba099712-09b8-4b74-a0e2-d9ab2147558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f9c4d852-b605-4506-bb8e-5988b08163a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968502c5-097c-4ca9-902d-ae6863bc38e4" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f9c4d852-b605-4506-bb8e-5988b08163a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9b535d27-d8b7-4752-85dc-7960d40bc401" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9bdaed45-c908-446d-9f0f-b2765edd2d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_95b468c3-a403-4e2f-9a5e-7bc08d6654bd" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9bdaed45-c908-446d-9f0f-b2765edd2d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_771b37e5-d7d8-46ac-9bd7-e1fa472dcc7d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_fd563e0f-19f6-42b4-a1d9-0d086cdbb9f3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2da7fc58-160c-47bc-835b-4bcfcf0c5406" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_fd563e0f-19f6-42b4-a1d9-0d086cdbb9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a8367ed0-0a32-4ce6-9684-b08f300e5c74" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1f9a9b1e-d295-4a2f-a1f2-bde5d6d5b558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1f9a9b1e-d295-4a2f-a1f2-bde5d6d5b558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ff7b992-1bd0-4172-848f-a5234165229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ff7b992-1bd0-4172-848f-a5234165229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_17727657-0a14-4a8b-bb01-cef77bf1c3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_Revenues_17727657-0a14-4a8b-bb01-cef77bf1c3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7df09b13-e29a-4d0b-8927-3ae00e4205fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_OperatingExpenses_7df09b13-e29a-4d0b-8927-3ae00e4205fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a489a6ec-db54-49c8-a945-6a9f7d3caebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_NetIncomeLoss_a489a6ec-db54-49c8-a945-6a9f7d3caebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d94a9d0e-9405-4e42-8dd5-5fbc8c326408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a5946e87-b80d-4d57-9f33-b5de15ca6f25" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d94a9d0e-9405-4e42-8dd5-5fbc8c326408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20220630.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a921540-9c16-46fe-a9ce-111107ba06cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c8fecc86-19af-481d-b2ac-18efba4b5f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a921540-9c16-46fe-a9ce-111107ba06cc" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c8fecc86-19af-481d-b2ac-18efba4b5f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20220630.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39814ef4-c0e2-4f6b-8372-c2329b17f999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f53cf060-0f28-4ac0-b48e-d5ce0ee09c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39814ef4-c0e2-4f6b-8372-c2329b17f999" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f53cf060-0f28-4ac0-b48e-d5ce0ee09c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70c5cf76-6559-449e-80bb-694b4fead463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70c5cf76-6559-449e-80bb-694b4fead463" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10825a7d-e72e-4b4b-ae94-fc14b94dc80f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_db3b94ca-9350-4a40-abb0-50b5dce7ca65" xlink:href="biib-20220630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_db3b94ca-9350-4a40-abb0-50b5dce7ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_364aeb51-ab00-40ab-bdc3-121f4568ce6e" xlink:href="biib-20220630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_MarketStockUnitsMember_364aeb51-ab00-40ab-bdc3-121f4568ce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_cdbc87f6-c253-4417-a6d7-9c1fd06b0728" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_718656bd-6a4d-4cd5-b4c4-afb18a044b5b" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_cdbc87f6-c253-4417-a6d7-9c1fd06b0728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1c82fd31-5439-40cd-8909-b77a4ed42546" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:href="biib-20220630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_30b465cd-ec37-481c-9ca0-1ced8e2fc469" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1064aee5-83e7-4f7a-aba1-fddd8dda0724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6bb06950-f070-4b7d-9691-856a64d226c2" xlink:to="loc_us-gaap_NetIncomeLoss_1064aee5-83e7-4f7a-aba1-fddd8dda0724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2ac77b0b-a1ac-430c-9e86-a425ef27899c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b9fba6b-bbcb-4b47-ad45-d23cd73ff49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b9fba6b-bbcb-4b47-ad45-d23cd73ff49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cb1e146e-908d-4176-bde8-8883d590dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cb1e146e-908d-4176-bde8-8883d590dcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92239264-08be-4af8-9eea-94f29df1dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0ac6a783-8048-46ac-9add-68729ab66a13" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92239264-08be-4af8-9eea-94f29df1dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd9a9bb4-acd5-436e-a7d5-ec22d15759f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37390edd-69b7-45da-a302-e3ce25172cd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd9a9bb4-acd5-436e-a7d5-ec22d15759f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20220630.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d21fdbf1-b28f-4cf8-8eda-849a06caa53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4d77fa1-6f8a-45a5-bba6-b03faea011bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d21fdbf1-b28f-4cf8-8eda-849a06caa53a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4d77fa1-6f8a-45a5-bba6-b03faea011bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6401d206-2e9b-4e91-a10f-8240f3c75307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0fc34b41-d28f-44b7-9ece-4a3da90b0001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6401d206-2e9b-4e91-a10f-8240f3c75307" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0fc34b41-d28f-44b7-9ece-4a3da90b0001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b2bbc594-91ed-4c15-9671-0bea9ed0a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6401d206-2e9b-4e91-a10f-8240f3c75307" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b2bbc594-91ed-4c15-9671-0bea9ed0a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f7abdff-161e-43e9-9262-519a671f41d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f7abdff-161e-43e9-9262-519a671f41d6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4746bcf-6f0f-475d-b785-0fbd6a1f3500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e2738901-ad3f-4d49-98ae-d2a6a1b7595d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e2738901-ad3f-4d49-98ae-d2a6a1b7595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bb91875-8c3f-4af3-b36a-8fa6295a0534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bb91875-8c3f-4af3-b36a-8fa6295a0534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_bf9957ba-823c-4b1e-802b-c47b690d1f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da8bd8a-9e8e-43a8-bbcc-5d77f74c0bd8" xlink:to="loc_us-gaap_ParentMember_bf9957ba-823c-4b1e-802b-c47b690d1f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04ab52cf-e1d2-4e07-86e9-d01accda71bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_587bda36-2a9f-4028-a007-f131f293f0a6" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_775a391d-f4c5-4a0d-b004-cebac68b0210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_775a391d-f4c5-4a0d-b004-cebac68b0210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e4995905-fb2e-47dc-9de1-ccc95d47feb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e4995905-fb2e-47dc-9de1-ccc95d47feb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b836c5ac-0b44-4852-9278-a1449d0d6896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b836c5ac-0b44-4852-9278-a1449d0d6896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f5b9e627-42e2-4ffa-9351-c3bf28501c23" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f5b9e627-42e2-4ffa-9351-c3bf28501c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_869a2b98-68b7-4849-b0ff-0763ae223d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_fd40a868-fc4b-49c4-823a-dfb2a6f20c58" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_869a2b98-68b7-4849-b0ff-0763ae223d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220630.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f75b0d-3a0a-41e3-b8fe-3e9d74307ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f75b0d-3a0a-41e3-b8fe-3e9d74307ecf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:to="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5705125d-ddb0-45e0-9c34-f5a628564960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_38b989ae-f69c-46eb-8ed7-a2f0efc7b055" xlink:href="biib-20220630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_MarketStockUnitsMember_38b989ae-f69c-46eb-8ed7-a2f0efc7b055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_e9144ef1-2699-47b4-8a4b-24d529470eb7" xlink:href="biib-20220630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_e9144ef1-2699-47b4-8a4b-24d529470eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_bcf5e6d8-e1fd-4731-b61b-ab2362ed3221" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_bcf5e6d8-e1fd-4731-b61b-ab2362ed3221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_4ff02fad-3d16-458c-9d40-bcbb28b22c96" xlink:href="biib-20220630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_4ff02fad-3d16-458c-9d40-bcbb28b22c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_28674568-e52a-4826-8726-d1fefa805ae6" xlink:href="biib-20220630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b94b1507-6a74-4c18-8c04-5d56a14e5723" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_28674568-e52a-4826-8726-d1fefa805ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_532e8460-6f2a-4acd-bd3e-576169db124d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:href="biib-20220630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1abb5b5a-2fa7-4550-849b-715a9104b222" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_20fe6b3e-d375-4776-af94-8832b35b9067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_20fe6b3e-d375-4776-af94-8832b35b9067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dd29969a-c3af-4617-b919-f1f744031703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dd29969a-c3af-4617-b919-f1f744031703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c4ff7a85-8c9c-417c-b2ef-aca9ae014ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c4ff7a85-8c9c-417c-b2ef-aca9ae014ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_bb5dc9cd-e20c-4865-bffe-6a584289a05b" xlink:href="biib-20220630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_e7c74540-6c02-44ae-87bd-4f917c881b4a" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_bb5dc9cd-e20c-4865-bffe-6a584289a05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6da11429-ae51-497c-a5e0-5991e1b880cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1ee1020b-a5bb-4866-89e2-10df5fdc4a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da11429-ae51-497c-a5e0-5991e1b880cb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1ee1020b-a5bb-4866-89e2-10df5fdc4a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_823486d1-598a-43f0-900e-65ac234aea5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_42dc7c5b-d1e4-49f1-989c-13b8931c42f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_823486d1-598a-43f0-900e-65ac234aea5a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_42dc7c5b-d1e4-49f1-989c-13b8931c42f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7701111f-af17-426b-be2d-dda05c001865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7701111f-af17-426b-be2d-dda05c001865" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7f00e959-459e-4d9d-825b-0930d89a5b17" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5525fc55-e044-4656-b879-b5885dcb6854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f12750eb-5b1d-46e3-b052-40309d1df2ad" xlink:to="loc_srt_ScenarioForecastMember_5525fc55-e044-4656-b879-b5885dcb6854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e43cdaac-e807-4993-9b2d-fb0d29a7a14d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_83cf9b8f-8e1a-48d6-a97d-2b835638e4b5" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ff5222d5-6daf-4c43-a6ef-043d71d031b1" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_83cf9b8f-8e1a-48d6-a97d-2b835638e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4f05c4d4-7833-4d70-9c36-40d39add8d94" xlink:to="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_0b1b79c9-c50e-465f-9022-7bc701ae24bc" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c2d19d4-b70c-45b9-8667-d90656ddf62c" xlink:to="loc_biib_ADUHELMMember_0b1b79c9-c50e-465f-9022-7bc701ae24bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_602256f8-6e08-4f53-bf95-4e24bb393ae6" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_03628bb5-30fa-4fb8-a5a4-271d1bba9aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_03628bb5-30fa-4fb8-a5a4-271d1bba9aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f52c345f-408c-4ba8-937f-208449bcee74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_EquityMethodInvestments_f52c345f-408c-4ba8-937f-208449bcee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2513705c-a841-4a28-abdf-c482d059230e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2513705c-a841-4a28-abdf-c482d059230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cae92cd3-8c09-460f-8e60-b06cb723a422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_198f38bc-22f9-4c9c-a4cf-2e57ece7cfeb" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cae92cd3-8c09-460f-8e60-b06cb723a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b0828880-ba62-4045-85ad-fb1d4eef95a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b0828880-ba62-4045-85ad-fb1d4eef95a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5fbfd769-4455-45f7-a00e-a928fc7b4818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5fbfd769-4455-45f7-a00e-a928fc7b4818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_857ace19-0b4e-4f54-b130-336e7cbedea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_857ace19-0b4e-4f54-b130-336e7cbedea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a839f2c3-74de-42d0-a9e1-c8c1544cfc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a839f2c3-74de-42d0-a9e1-c8c1544cfc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ddf68087-c54e-4130-bd8d-44e24be13671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ddf68087-c54e-4130-bd8d-44e24be13671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_24137a0b-02ff-44f0-9aeb-fd06b7d3d36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_24137a0b-02ff-44f0-9aeb-fd06b7d3d36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_4c7f3f64-ca1d-423b-9591-1d0f405d9d97" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_4c7f3f64-ca1d-423b-9591-1d0f405d9d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_72bab4ea-b0bb-4665-8fc1-d38f9982742d" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_72bab4ea-b0bb-4665-8fc1-d38f9982742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_eb029595-6241-42fd-a426-d4e8f7b14284" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_eb029595-6241-42fd-a426-d4e8f7b14284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_f6ea4a35-41b5-426b-8950-cf85b4c8f45d" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_f6ea4a35-41b5-426b-8950-cf85b4c8f45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_f5c029ba-afc1-46d9-a360-e808a401cc96" xlink:href="biib-20220630.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_f5c029ba-afc1-46d9-a360-e808a401cc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_80c40ac7-2856-4e38-b895-9c37fdbe9751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_80c40ac7-2856-4e38-b895-9c37fdbe9751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_679ebeba-48e3-499e-8d54-9804957c1d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6319ee7d-48f6-4456-81cb-540b84b43099" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_679ebeba-48e3-499e-8d54-9804957c1d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c3ddf8-317d-4802-bfff-985b1832672b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_be760b56-96f7-4b9b-82ab-36edeb16c7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c3ddf8-317d-4802-bfff-985b1832672b" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_be760b56-96f7-4b9b-82ab-36edeb16c7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b0d0e05-96d7-49d9-9d81-c9144c989524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_30176e8d-0d61-4a7e-ac0c-6f1de5b2d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b0d0e05-96d7-49d9-9d81-c9144c989524" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_30176e8d-0d61-4a7e-ac0c-6f1de5b2d3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_5a66acc5-ce9d-4dfd-a602-e6faf26051a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b0d0e05-96d7-49d9-9d81-c9144c989524" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_5a66acc5-ce9d-4dfd-a602-e6faf26051a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7169d185-3a96-47ec-88e0-655f94aaf023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b0d0e05-96d7-49d9-9d81-c9144c989524" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7169d185-3a96-47ec-88e0-655f94aaf023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e33868fa-2dd6-4067-ad65-0c35be9e7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e33868fa-2dd6-4067-ad65-0c35be9e7adb" xlink:to="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d3771b13-4d06-429e-a13d-803ebf865eed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2995953a-0449-422e-8489-9fb1c92c4854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6497f59c-32aa-40be-b117-1ef0093c0700" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2995953a-0449-422e-8489-9fb1c92c4854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:to="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_42f352b0-a0c0-49e2-a6ad-5b25b0a874b7" xlink:to="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_f4ad7876-ab25-417f-bfce-233257e01861" xlink:href="biib-20220630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5dd0df20-9e5b-4f7f-92b0-49d8f744a3d2" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_f4ad7876-ab25-417f-bfce-233257e01861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2e8cea3-ca65-41d4-8aa6-8cb3b15ba0e0" xlink:to="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a847a05a-8b0b-4809-a67d-a36380906f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a847a05a-8b0b-4809-a67d-a36380906f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_346814e2-8507-41aa-9006-4d7a88325384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_LitigationSettlementExpense_346814e2-8507-41aa-9006-4d7a88325384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a47a9506-2708-45af-b4ec-31c1566bc50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a47a9506-2708-45af-b4ec-31c1566bc50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4aee8517-104c-40b4-a471-e91fd32d856e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_InterestExpense_4aee8517-104c-40b4-a471-e91fd32d856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_49a3474c-bba9-4af3-b14f-d5cc45340d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_49a3474c-bba9-4af3-b14f-d5cc45340d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ec272fd8-1eee-4fdc-bb88-69c756df234b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ec272fd8-1eee-4fdc-bb88-69c756df234b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_96daa3f0-2a43-43ac-a0bb-edc380504a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_96daa3f0-2a43-43ac-a0bb-edc380504a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a0e02c0b-d045-4630-b9b5-42ef9281104d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2ae18513-a7d9-4028-8073-90dcc7716bba" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a0e02c0b-d045-4630-b9b5-42ef9281104d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e81de12-e4cf-43fc-9ac4-368e5700a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e81de12-e4cf-43fc-9ac4-368e5700a83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cf37e71-8831-46ed-81c5-8016ab7be18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0cf37e71-8831-46ed-81c5-8016ab7be18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e95becd1-b275-4c5a-b7c2-c9443a1681aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_7988b0f7-1afb-4570-96da-f9987c82130f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e95becd1-b275-4c5a-b7c2-c9443a1681aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b66ab24e-b454-4680-89c1-42313abf7bbb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_33311d7d-5615-4696-80a8-4a403aa2f3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_33311d7d-5615-4696-80a8-4a403aa2f3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b35dc459-2e07-45c2-b2eb-2af85e907a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b35dc459-2e07-45c2-b2eb-2af85e907a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee11bfe0-f46d-428b-afb2-c267bf0489e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee11bfe0-f46d-428b-afb2-c267bf0489e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_38235fb0-1a12-4b7c-8894-6088286e9ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_38235fb0-1a12-4b7c-8894-6088286e9ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_e84f26d5-9570-47f8-b2b1-a9503f14b24e" xlink:href="biib-20220630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_biib_Collaborationexpensesaccrual_e84f26d5-9570-47f8-b2b1-a9503f14b24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_202ced45-b8d9-48c4-a8ac-9421c5d8d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_202ced45-b8d9-48c4-a8ac-9421c5d8d3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6997c888-e317-4c09-abcc-f96d62fb9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a7600aae-641e-467e-b6ef-b205a8c791e5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6997c888-e317-4c09-abcc-f96d62fb9c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6fb1ea7-08c8-4d8f-b5cd-6e961fd95a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6fb1ea7-08c8-4d8f-b5cd-6e961fd95a26" xlink:to="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:to="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0cd0590b-8835-4843-aeba-5ee59b74e6bd" xlink:to="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_41fd2094-9e26-4586-9c46-042a4d4f2265" xlink:href="biib-20220630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ec20b37e-982b-4def-9ee3-76ff1bca392c" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_41fd2094-9e26-4586-9c46-042a4d4f2265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ceca1c4-f0bc-4c15-8c52-d0f48c407947" xlink:to="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a1db8917-e049-4d23-9a73-64cb0db00103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a1db8917-e049-4d23-9a73-64cb0db00103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e1ee4f43-9682-4343-a45f-c82488da4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e1ee4f43-9682-4343-a45f-c82488da4b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c891bbee-e918-4c38-a1f8-a802c5d28d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c891bbee-e918-4c38-a1f8-a802c5d28d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_43732042-5a15-42a4-b15e-2e8f22a11a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9eed0089-51fc-4e9d-81ef-de3bea9166c5" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_43732042-5a15-42a4-b15e-2e8f22a11a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47dc1547-b9af-4914-94f8-5e618d5a0ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8604fead-092d-44c5-8451-c6d9aa767dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47dc1547-b9af-4914-94f8-5e618d5a0ce6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8604fead-092d-44c5-8451-c6d9aa767dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bba2c09-3810-449c-ac97-c602cb8ac1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4ab01de0-94e6-4d6e-b0d2-e450a82da4f9" xlink:href="biib-20220630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bba2c09-3810-449c-ac97-c602cb8ac1e3" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_4ab01de0-94e6-4d6e-b0d2-e450a82da4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_2531cbda-d197-4c41-820c-565bdb066add" xlink:href="biib-20220630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bba2c09-3810-449c-ac97-c602cb8ac1e3" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_2531cbda-d197-4c41-820c-565bdb066add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_e8f82071-a645-480b-8859-9cc0139c35ce" xlink:href="biib-20220630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bba2c09-3810-449c-ac97-c602cb8ac1e3" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_e8f82071-a645-480b-8859-9cc0139c35ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d46fc883-f6c6-49f4-8158-467a30527241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d46fc883-f6c6-49f4-8158-467a30527241" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef2d6def-2e27-4d23-96f9-10c598a597ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ce9acbdf-3606-4f3e-a793-007df617ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ce9acbdf-3606-4f3e-a793-007df617ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9dc265e5-7ebb-4991-8e19-59ee2a31e023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab75ed3e-6fb2-4df9-9502-b2c41371993f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9dc265e5-7ebb-4991-8e19-59ee2a31e023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_894184dc-e9ce-42a3-92d6-c982cac5f9de" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_da030b1a-6205-42b1-8576-8d894d0c7f57" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_EisaiMember_da030b1a-6205-42b1-8576-8d894d0c7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_f968d8d1-33ff-4dd6-9504-a0c1a50fe26d" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_DenaliTherapeuticsIncMember_f968d8d1-33ff-4dd6-9504-a0c1a50fe26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_0f790013-fb2c-4626-af84-96605e501d93" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_80a4353c-037b-4c40-b0b6-57f26d255613" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_80a4353c-037b-4c40-b0b6-57f26d255613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_28af59a6-7046-4c38-aba6-0fefad7cd72c" xlink:href="biib-20220630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SageTherapeuticsIncMember_28af59a6-7046-4c38-aba6-0fefad7cd72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_40bf0e97-f604-412a-8248-99f56f088549" xlink:href="biib-20220630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_UCBPharmaS.A.Member_40bf0e97-f604-412a-8248-99f56f088549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_0e3d11d2-1b7f-4a9d-a11b-bd34a56462f4" xlink:href="biib-20220630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_0e3d11d2-1b7f-4a9d-a11b-bd34a56462f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3607c009-96f5-4244-9468-5734300a8beb" xlink:href="biib-20220630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3607c009-96f5-4244-9468-5734300a8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_97edcc5f-c3e7-4136-8fa3-0a8327575a68" xlink:href="biib-20220630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0cfd015-763c-4de6-ae6c-da47bdae28e6" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_97edcc5f-c3e7-4136-8fa3-0a8327575a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6cd1b8ba-5c8d-47e9-be1e-0d46f0d3c537" xlink:to="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_73e13d7d-16ae-4276-b630-3c6cfa8240cd" xlink:href="biib-20220630.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:to="loc_biib_E2609andBAN2401Member_73e13d7d-16ae-4276-b630-3c6cfa8240cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c3a65995-0dd6-40c0-b75a-e81172a51d88" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8719400c-9268-4cb3-be30-aac39293e979" xlink:to="loc_biib_ADUHELMMember_c3a65995-0dd6-40c0-b75a-e81172a51d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77b51ca2-9c01-4e70-8031-a681a1123a17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_01dc9c84-fac0-4b39-b75c-fcacfa1eefa8" xlink:href="biib-20220630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_DenaliTherapeuticsIncMember_01dc9c84-fac0-4b39-b75c-fcacfa1eefa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_38d617bd-4f5b-4d17-8c2f-6c335d57383f" xlink:href="biib-20220630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_38d617bd-4f5b-4d17-8c2f-6c335d57383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_65c90e82-4170-4151-990b-fab0cbf180ac" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5aea340-170a-47fb-b530-cf231db0ba54" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_65c90e82-4170-4151-990b-fab0cbf180ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f79951d-7abb-445c-b69a-8838de2d41fd" xlink:to="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_be271ac8-f767-41b5-83c5-f360e609ad24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52e2b52b-a1ef-4663-a9e7-c567113062a3" xlink:to="loc_srt_MaximumMember_be271ac8-f767-41b5-83c5-f360e609ad24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7a3299b0-89f9-48f4-b10b-7f1d7f71ea9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1d6d2680-7f4c-40a2-a17f-a099182dedf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ee53229-3a8d-46f8-aee1-b254e3dc965b" xlink:to="loc_srt_ScenarioForecastMember_1d6d2680-7f4c-40a2-a17f-a099182dedf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b084ac61-4cb1-4678-84ff-9c8b1a595a69" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_43d1752d-2376-4ffe-a51f-b21a6308f2e2" xlink:href="biib-20220630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ExpenseIncurredByCollaboration_43d1752d-2376-4ffe-a51f-b21a6308f2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_1e90e203-bd99-4b20-9fd6-41c59ffc8922" xlink:href="biib-20220630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Expenseincurredbythecollaboration_1e90e203-bd99-4b20-9fd6-41c59ffc8922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_4c806d10-25fd-465b-8d34-ea086859d54a" xlink:href="biib-20220630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_4c806d10-25fd-465b-8d34-ea086859d54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6caff1c5-c7cd-49c4-b666-3c51ef7f674e" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6caff1c5-c7cd-49c4-b666-3c51ef7f674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_c68ba30f-b076-41c3-b5a4-a213ae0e4912" xlink:href="biib-20220630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_c68ba30f-b076-41c3-b5a4-a213ae0e4912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_2adae89b-1921-410e-9f6b-57fbba15ce3b" xlink:href="biib-20220630.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_CollaborationAgreementTerm_2adae89b-1921-410e-9f6b-57fbba15ce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6008cda-5e1e-46d8-bc3d-9717643564fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6008cda-5e1e-46d8-bc3d-9717643564fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_286dc577-00bb-46b2-bfeb-29022c81f3d6" xlink:href="biib-20220630.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_Termofcollaborationagreement_286dc577-00bb-46b2-bfeb-29022c81f3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_ccfa7c57-7ed4-4f47-a101-d12e744af215" xlink:href="biib-20220630.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_ccfa7c57-7ed4-4f47-a101-d12e744af215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_3518fd97-c305-4f90-8f04-844d8f763d35" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_AdditionalMilestonePayment_3518fd97-c305-4f90-8f04-844d8f763d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_264f7684-d975-4b6b-aadc-ea401705213f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_264f7684-d975-4b6b-aadc-ea401705213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ddd1633d-cfa3-4338-942c-2cc85cd6e653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ddd1633d-cfa3-4338-942c-2cc85cd6e653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_15bde1df-0f43-4054-91f5-95a161ab19c6" xlink:href="biib-20220630.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_15bde1df-0f43-4054-91f5-95a161ab19c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d79efe69-6099-4b6c-8e96-ff2e3d314f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d79efe69-6099-4b6c-8e96-ff2e3d314f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_f291e44d-0826-475e-9bfe-ddbdeceab3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_f291e44d-0826-475e-9bfe-ddbdeceab3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_1ae3e364-7417-4e0a-84f5-aa251e143efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_AdjustmentForAmortization_1ae3e364-7417-4e0a-84f5-aa251e143efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_c46c25e5-e954-45dc-bffe-56d570a42b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_DueFromRelatedParties_c46c25e5-e954-45dc-bffe-56d570a42b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b4cc4dca-90d2-4ada-8b84-9a09a986f453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b4cc4dca-90d2-4ada-8b84-9a09a986f453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_25073297-8794-41f1-9184-f44c2be5ca0f" xlink:href="biib-20220630.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4081e14-3ee5-4d6f-9ccb-62d070d71d9d" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_25073297-8794-41f1-9184-f44c2be5ca0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d8efc78-1483-4433-b72f-f0c25012d589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d8efc78-1483-4433-b72f-f0c25012d589" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_81ddff95-1af4-4d6d-82a6-8422e0014bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_029aee16-47fd-4bac-a34c-2c22e79186c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:to="loc_us-gaap_InventoriesMember_029aee16-47fd-4bac-a34c-2c22e79186c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ca532712-94ab-40ab-bfb9-393331db6918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_163beae3-c8d1-4f1d-9fda-cf5de588eba5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ca532712-94ab-40ab-bfb9-393331db6918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6530065f-fff1-4659-aafa-8798e88c65c4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_4468c164-316a-4eec-b9cd-763a40817a31" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:to="loc_biib_EisaiMember_4468c164-316a-4eec-b9cd-763a40817a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_be313ac6-c342-47a0-a34d-b69f99d0638a" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86744a16-057f-4fa6-ac41-ed649b3d7d11" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_be313ac6-c342-47a0-a34d-b69f99d0638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f1e32644-5ceb-4930-9076-332eceb3fd5e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0371cbc0-915e-4f4e-a574-a99b792eb627" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4b5d9a54-cfb7-44b8-8b33-2fb30ea48efc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0371cbc0-915e-4f4e-a574-a99b792eb627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_21729e86-cb4f-4775-938d-0ec382bb6b45" xlink:to="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c60236ab-1f3c-44e4-b0b9-7f812430f02e" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22f4baca-befb-41bb-a3af-81e504c8846d" xlink:to="loc_biib_ADUHELMMember_c60236ab-1f3c-44e4-b0b9-7f812430f02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8db2a5fe-ebbb-45d7-a19e-e1695bc4dede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_45d49bfe-8f03-4774-8cf6-cdb0f41981f5" xlink:href="biib-20220630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_45d49bfe-8f03-4774-8cf6-cdb0f41981f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_a615ca91-ed9c-4983-a1ac-951f741db0a7" xlink:href="biib-20220630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_a02c1a90-9b12-418d-8211-e84e6acfe2df" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_a615ca91-ed9c-4983-a1ac-951f741db0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0c05767f-ae16-4c52-b113-1cea2fef156c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_724a5189-59c4-466d-b85c-53e792ffa7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_724a5189-59c4-466d-b85c-53e792ffa7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_b5585dd1-fccf-4202-a1b3-a9f436c5ab28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_b5585dd1-fccf-4202-a1b3-a9f436c5ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2ef88b48-3ba3-4d64-8e51-432f8076d26a" xlink:href="biib-20220630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_2ef88b48-3ba3-4d64-8e51-432f8076d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_049d7573-53b9-4bcf-9511-93fe04ab6fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_049d7573-53b9-4bcf-9511-93fe04ab6fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4aa89bfc-f6f6-4be4-bbf4-05e2f8c7115f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4aa89bfc-f6f6-4be4-bbf4-05e2f8c7115f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_7d8406e3-0b76-4ed3-846a-740f7966465e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_7d8406e3-0b76-4ed3-846a-740f7966465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_01ba9e6a-99df-4d9c-bc07-4be9a12ca191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_EquityMethodInvestments_01ba9e6a-99df-4d9c-bc07-4be9a12ca191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_43e5c661-b9e4-467b-9025-5f2d51ca4f0b" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_43e5c661-b9e4-467b-9025-5f2d51ca4f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ef36c8bb-f87b-474a-b075-c8ab7471e958" xlink:href="biib-20220630.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ef36c8bb-f87b-474a-b075-c8ab7471e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_55bbbc74-d347-46b5-a6e5-20540d7781ad" xlink:href="biib-20220630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_Collaborationprofitlosssharing_55bbbc74-d347-46b5-a6e5-20540d7781ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_320c3559-549a-4b0f-95db-600700196e5c" xlink:href="biib-20220630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_320c3559-549a-4b0f-95db-600700196e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_65a46b40-5fda-4db6-baa1-d37907176a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_65a46b40-5fda-4db6-baa1-d37907176a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5fb2e3c8-2ea7-4b03-a3cb-9165fd0a1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_5fb2e3c8-2ea7-4b03-a3cb-9165fd0a1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_479119c3-2835-47b9-bf95-bc74871b37dc" xlink:href="biib-20220630.xsd#biib_AccruedMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_AccruedMilestonePayments_479119c3-2835-47b9-bf95-bc74871b37dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_30a5b3ea-e70a-4f14-aab6-7bc93ebb43e4" xlink:href="biib-20220630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_30a5b3ea-e70a-4f14-aab6-7bc93ebb43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_30951b3b-1d6d-46a5-92a5-517020fb6eec" xlink:href="biib-20220630.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_biib_ContractOptionExerciseFee_30951b3b-1d6d-46a5-92a5-517020fb6eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_804fc1e5-5218-4e51-9939-c6e129862e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d2e2b148-3c3e-4af9-a733-1f7ea0c89926" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_804fc1e5-5218-4e51-9939-c6e129862e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20220630.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_b39f29f1-a8f3-4266-be77-c02af07923eb" xlink:href="biib-20220630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b523cad2-d62e-48bc-8183-ff9b8b56d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_b39f29f1-a8f3-4266-be77-c02af07923eb" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b523cad2-d62e-48bc-8183-ff9b8b56d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_96d1060c-b37b-4707-9932-55b59256a1ef" xlink:href="biib-20220630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_96d1060c-b37b-4707-9932-55b59256a1ef" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e0862fb5-c6fb-4c5a-9509-f542407cf40c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_f5e2e156-f026-494e-b6d6-291044c14c90" xlink:href="biib-20220630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b233fcf3-db3e-46e2-8ba9-530900dcde16" xlink:to="loc_biib_EisaiMember_f5e2e156-f026-494e-b6d6-291044c14c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_a2d654d3-7f19-4f0a-ac8f-45b420b02f4a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_0ef720e0-4468-4b1a-aa0b-2ecdcb3ebdf8" xlink:href="biib-20220630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_e34a9169-35f4-44cf-8dd6-e988a9c0ff48" xlink:to="loc_biib_RegulatoryMilestonesMember_0ef720e0-4468-4b1a-aa0b-2ecdcb3ebdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9a2148f6-602b-43c8-ab00-2f113648f52f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_4f1af972-d622-45b3-875e-8df309b0bc6e" xlink:href="biib-20220630.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c41ffbfc-3ef8-415a-b230-4e71568557d6" xlink:to="loc_biib_NeurimmuneMember_4f1af972-d622-45b3-875e-8df309b0bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_56b59b40-0620-4cf2-b3eb-319ccb2c0b98" xlink:to="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_b2e465eb-ccf0-4d9e-81ef-85084bf44698" xlink:href="biib-20220630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d304efd8-08c9-4445-8ead-3a608d98f4eb" xlink:to="loc_biib_ADUHELMMember_b2e465eb-ccf0-4d9e-81ef-85084bf44698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_54ac1d30-85b9-45de-adbd-928342938cc2" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_9ff46bc2-962c-4b87-b9f7-a9f997fa0a4a" xlink:href="biib-20220630.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_CollaborationAgreementTerm_9ff46bc2-962c-4b87-b9f7-a9f997fa0a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_c9ad35c5-1049-44f6-a35e-12622700da37" xlink:href="biib-20220630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_c9ad35c5-1049-44f6-a35e-12622700da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_73d05a9b-3ab6-45f1-8739-2440b926c546" xlink:href="biib-20220630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_73d05a9b-3ab6-45f1-8739-2440b926c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b54dc65-7a53-4892-a4af-ce60e0479795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4b54dc65-7a53-4892-a4af-ce60e0479795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_30755e5e-5b72-4f06-b07d-5d02268e9e6d" xlink:href="biib-20220630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_30755e5e-5b72-4f06-b07d-5d02268e9e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_d5ce0222-da6d-4396-afc6-bba0e8deaf40" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_AdditionalMilestonePayment_d5ce0222-da6d-4396-afc6-bba0e8deaf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_52bcfce1-75b2-4676-8c76-de463818b7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_52bcfce1-75b2-4676-8c76-de463818b7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_63b41b5f-0180-4d52-bf72-64813ff2fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_63b41b5f-0180-4d52-bf72-64813ff2fe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8158ec59-c9f6-469b-b5a7-522fdc5fa4c4" xlink:href="biib-20220630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f35e8dfd-9b24-4960-b534-9a614ee284cc" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_8158ec59-c9f6-469b-b5a7-522fdc5fa4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20220630.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_c4491385-3093-459c-ac95-222bc7027a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_0e1ad602-e4f9-4851-bb17-99b795c728a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_c4491385-3093-459c-ac95-222bc7027a94" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_0e1ad602-e4f9-4851-bb17-99b795c728a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20220630.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4807e989-9914-49a9-aa84-74efd871d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_980cf014-d6df-4905-bd4f-accea459f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4807e989-9914-49a9-aa84-74efd871d3f6" xlink:to="loc_us-gaap_LitigationSettlementExpense_980cf014-d6df-4905-bd4f-accea459f79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_0ffb270b-5b3a-4330-a978-25a6d3dfdf94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4807e989-9914-49a9-aa84-74efd871d3f6" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_0ffb270b-5b3a-4330-a978-25a6d3dfdf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_eb8c8e5c-53cd-4a64-8c4d-254b1602360c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4fa923c4-27e1-4eb2-ab61-903dc9f53b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_eb8c8e5c-53cd-4a64-8c4d-254b1602360c" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4fa923c4-27e1-4eb2-ab61-903dc9f53b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20220630.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_74be410b-25b4-442a-be47-f2779f8e3753" xlink:href="biib-20220630.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_99ea07d6-58fa-4702-ae7d-51dab79df2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_74be410b-25b4-442a-be47-f2779f8e3753" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_99ea07d6-58fa-4702-ae7d-51dab79df2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20220630.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_93619303-35c3-43b1-9791-553bb257f474" xlink:href="biib-20220630.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_93619303-35c3-43b1-9791-553bb257f474" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fbb7a03a-df22-4dc7-8fd8-9cc696158e02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6582f8f4-c1d6-4617-9871-8005b4a348a3" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fea4732a-aefb-4691-8b9e-a4b8db28fcd2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6582f8f4-c1d6-4617-9871-8005b4a348a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_54ecd7ad-a679-49f9-ac00-171b32a1a3fd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_e711e306-6d8b-4424-a1de-66959bf2bbac" xlink:href="biib-20220630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3977e6a2-abb0-41f5-921f-208856551b20" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_e711e306-6d8b-4424-a1de-66959bf2bbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:href="biib-20220630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_146719f2-e75a-438e-adfb-5cd19439f94a" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_50ef67ee-d737-4a42-84f9-24486a22b2fe" xlink:href="biib-20220630.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_50ef67ee-d737-4a42-84f9-24486a22b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_16cd4f4d-8f33-4a57-83ed-c53bafc59632" xlink:href="biib-20220630.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_74a9ed38-5be1-4fff-aec5-c64b02a901be" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_16cd4f4d-8f33-4a57-83ed-c53bafc59632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f00444f5-19cb-4455-ae96-48cdc972b7d3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1e844f26-4632-4db8-a68c-add05342378f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b56e7a6d-335a-4fb8-b16d-1701cdbbf618" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1e844f26-4632-4db8-a68c-add05342378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5be2a7ba-dcc9-4340-aac7-e7d7c463563b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac89d529-a90e-43cd-92d2-2eac7e810afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3570f57c-d899-4cf3-a663-b5cf043e6f51" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac89d529-a90e-43cd-92d2-2eac7e810afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37c2d8dd-dc7a-4505-9048-3b29e7f3773d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8a08bf7b-04d3-4c87-88b9-a4c5b1165cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8a08bf7b-04d3-4c87-88b9-a4c5b1165cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_52948dff-910b-4a6f-887f-fcf8ef4dfdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_52948dff-910b-4a6f-887f-fcf8ef4dfdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_9091bd9b-0922-4af3-a164-3e4ceb3d34bd" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_9091bd9b-0922-4af3-a164-3e4ceb3d34bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a606fb2e-dc5f-49ed-b845-a731cb6e3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a606fb2e-dc5f-49ed-b845-a731cb6e3ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2fe10129-99dc-43a1-8d40-0febd69cef60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2fe10129-99dc-43a1-8d40-0febd69cef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6f8e3fa2-ffa8-4334-8817-f2d8ec1b5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6f8e3fa2-ffa8-4334-8817-f2d8ec1b5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsFairValueMeasurementInput_58800e56-64f8-48a5-92a6-e4cee8f6253f" xlink:href="biib-20220630.xsd#biib_OtherAssetsFairValueMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_OtherAssetsFairValueMeasurementInput_58800e56-64f8-48a5-92a6-e4cee8f6253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_22611f3f-5976-4ec8-8400-b4c7c78e0929" xlink:href="biib-20220630.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_22611f3f-5976-4ec8-8400-b4c7c78e0929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_4ff45c7c-463f-477e-83be-0156d1c610eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_4ff45c7c-463f-477e-83be-0156d1c610eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_6303bd5d-df12-4d05-885f-121a2b65a15e" xlink:href="biib-20220630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_AdditionalMilestonePayment_6303bd5d-df12-4d05-885f-121a2b65a15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_e426f6d6-9f3c-466f-935a-f8cd96ff0931" xlink:href="biib-20220630.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_e426f6d6-9f3c-466f-935a-f8cd96ff0931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit_5ab2b76e-891a-4f5e-83c1-9b31bbc52b83" xlink:href="biib-20220630.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22ca9ae3-3029-48ea-a627-a53ee4241ebf" xlink:to="loc_biib_DiscreteIncomeTaxExpenseBenefit_5ab2b76e-891a-4f5e-83c1-9b31bbc52b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20220630_g1.jpg
<TEXT>
begin 644 biib-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
MW(5G6?8/*Z/M<5*W9=7Z+]=EU#)\CQ>95O98:/J^B]7^F[Z'1?\ !#O]A"X\
M&Z8?C'XILFAO]4MVM_#5O,N&AMW&)+L@\@R#*)T^0N>0ZFOT<ID42P1+'&JH
MB *JJ,!0.@ I]?S7G><5LSQDL76W>R[);+^MW=G]$Y+E-++<)'"T>F[[OJ_Z
MV5D%?.__  5A_P"4>OQ+_P"O*W_]*X*^B*^=_P#@K#_RCU^)?_7E;_\ I7!1
MD/\ R,\/_P!?(?\ I2#._P#D78C_  3_ /26?@W1117]7'\OA7[R?\$GO^4>
MOPT_Z\KC_P!*YZ_!NOWD_P""3W_*/7X:?]>5Q_Z5SU^9>*?_ "+:7_7Q?^DR
M/T;PS_Y&-3_ _P#TJ)]$445Y#^W9^TI'^R=^R]XH\8*R_P!J6]O]DTA& ;S+
MV7Y(>#PP4GS&'=8VK\0PN&J8BM&A25Y2:2]6['[1B<1##T95ZKM&*;?HC\_?
M^"WO[=\GCKQC)\'_  Q>D:'H,P?Q%+$W%[>*<K;$]TAX+#H9.HS&"?SSJ;5=
M4N-;U.XO+R>6ZN[R5IYYI&W/*[$LS,3U))))]34-?U-D>4T<MP<,)1Z;ON^K
M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
MF;DGZMWDO6[]#]!R/Q Q&$M1Q,%*G_=2BUZ)6B_2R]3^C^BOE7_@G!_P4ST7
M]MC0FT75(8=#^(.EV_FWEBI_T?4$!P9[<DYP.-R'E=PY8?-7U57XEF&7XC U
MY8;$QY9+^KKNGW/V7 9A0QM!8C#2YHO^K/LPKYW_ ."L/_*/7XE_]>5O_P"E
M<%?1%?.__!6'_E'K\2_^O*W_ /2N"NG(?^1GA_\ KY#_ -*1SYW_ ,B[$?X)
M_P#I+/P;HHHK^KC^7PK]Y/\ @D]_RCU^&G_7E<?^E<]?@W7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\R\4_^1;2_Z^+_ -)D?HWAG_R,:G^!_P#I43Z(K\M?^#A+
MXW->^+_ _P .[>;]S86TFOWR Y5I)&:&#/H55)SCTE'J*_4JOP=_X*P^/Y/B
M'^W[\0IS(TD.EW<6E0J>D8MX8XF ^LBNWU8U\1X;X%5\W]K+:G%R^;M%?FW\
MC[3Q"QCHY5[*.]227RW?Y)?,^=:***_H0_!0K^@3_@G]^SM'^S#^R9X0\,-#
MY.J-:+J&K$C#->S@22@^NS(C!_NQK7XE_L3_  U3XO?M<?#KP[-'YUKJ&O6I
MNH\9WP1R"28?]^T?Z=:_H<K\?\5,PDE1P,7H[R?Y+]3]8\,< FZV-ENK17YO
M] HHHK\;/UP**** ,/XE?#[3?BQ\/=:\,ZS#]HTK7[*6PNDP,F.12I(ST89R
M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
M@K#_ ,H]?B7_ ->5O_Z5P5]$5\[_ /!6'_E'K\2_^O*W_P#2N"OQ/(?^1GA_
M^OD/_2D?LF=_\B[$?X)_^DL_!NBBBOZN/Y?"OWD_X)/?\H]?AI_UY7'_ *5S
MU^#=?O)_P2>_Y1Z_#3_KRN/_ $KGK\R\4_\ D6TO^OB_])D?HWAG_P C&I_@
M?_I43Z(K^<O]J#7/^$G_ &EOB)J6[=_:'B;4KG<5VYWW4K9QVZU_1I7\W?QQ
MB>#XU>,(Y%9'36[U65AAE(G?((KPO"F*]OB'Y1_-GN>)\G['#KSE^2.7HHHK
M]J/QT^J/^"+V@+K7_!0SP?,T;2+IMMJ%UT!53]CFC!.?0R#'?.*_<2OQ1_X(
M;RI%^WOIJLRJTFCWRJ"?O'8#@?@"?PK]KJ_ /$Z3>;Q3Z0C^<C]T\-XI95)K
MK-_E$****_.C] "BBB@ K\C_ /@X3T3R/VE/!.I;1FZ\,_9MV[D^7=3MC';'
MF]>^?:OUPK\H?^#AUA_PN?X=CO\ V+<<?]MZ^X\.Y-9W3MVE^3/B^/XIY--O
MHX_FC\\:***_HP_G\$=HG5E8JRG((."#7]+WAO5&UOPYI]XWE[KRVCG.S[N6
M4-Q[<^M?S0U_25\)+&32_A5X9M9L>;;Z3:Q/@Y&Y84!_45^0>+$5R89];S_]
MM/U?POD^?$KI:'_MQT5?DO\ \%CO^";MW\//%^H?%CP3I\MQX:UB5KG7[.WC
M+'2KEB6>X '2"0Y+'HCD]%8!?UHJIK<]G;:-=2:D]K'IZPN;EKDJ(5CP=Q<M
M\NW&<YXQ7YOP]GV(RK%K$4-4]''I)=O7L^_E='Z'GV24,TPKH5M'NGV??T[H
M_F>HKZ1_X*5:=\![7XPRR?!:^O)?-E8ZI;6L(.B12'))M)2V[&[^!5,0!^1@
M!MKYNK^F\OQGUK#QKJ+CS*]I*S7JC^<,=A?JU>5!R4N5VO%W3]&+%*T$JR1L
MR.A#*RG!4CH0:^V?V7_^"Y7Q(^"^D6^D>,;&W^(FEVRB.*>ZN3;:E&HXP9PK
M"3'7+H6/=J^):*QS+)\'F%/V6,IJ2Z7W7HUJODS7+LUQ> J>TPDW%^6S]4]'
M\T?KMH?_  <'?"FXLE;4O"'Q"M+GO';06=Q&/HS7"'_QVJ7C'_@X5^'=E9,W
MA_P+XTU.XV_*FH/;6,9//!9))B!TYVGJ?3G\EJ*^77ASDBE=PEZ<SM_G^)],
M_$#.7&W.O7E7_#?@?4G[8'_!6SXF_M9:1<:"K6O@_P )W.4FTW2W8R7B?W9Y
MV^9QZJH12.JFOENBBOK<!EN&P5+V.$@H1[+\WU;\V?*X[,,3C*OML5-REW?Z
M=EY(*=:VLE]<QPPQR333,$CC12S.Q.  !U)STKL/@E^SYXT_:-\6QZ)X*\.Z
MEX@OV(#_ &>/]U; G :60X2-?]IR!7ZU?\$\?^"1>@_LJ7%GXM\92V?B;Q]&
M \&U=UCHS>L(8 O*/^>K 8_A"]3XW$'%."RFDW5?-4Z06[]>R\W\K['K9#PS
MC,TJ)4E:'63V7IW?DOG8D_X)$?\ !/B;]E'X=S>+O%EGY7CWQ5 JM _WM'L^
M&$!])'(#2>A5%X*L3]F445_..:9E7S#%2Q>(=Y2^Y+HEY(_H3+<NHX'#1PM!
M>['[V^K?FS\W_P#@XEUTVW@/X7Z7Y@ O+_4+K9SEO*C@7/IQYWZ_6ORSK]-O
M^#C+_FCO_<:_]Q]?F37] ^'\4LBHM=>;_P!+DC\'X[DWG=9/IR_^D1"BBBOL
MSY$**]LTS_@G#\<M;TRWO+7X:>))[6\B6:&18DVR(P!5A\W0@@U8_P"'9WQZ
M_P"B7^)_^_2?_%5YO]LX!.SKP_\  H_YGH+*,<U=49_^ R_R/"Z*]T_X=G?'
MK_HE_B?_ +])_P#%4?\ #L[X]?\ 1+_$_P#WZ3_XJC^VLO\ ^?\ #_P./^8_
M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20220630_g10.jpg
<TEXT>
begin 644 biib-20220630_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45RGQH^./PD_9V^']U\4OC;X^T_PWH-G
M+%%+J&HRD!YI7"10QJ 7EED=E1(D#.[$*JDG%>7_ ++'_!2S]D3]KWQ'+\/_
M (5_$M(_%T5UK ;P7K-G-9:N+33M1DL9+UK2=$EC@=T4JSJI'F!&"R*Z* >]
MT5A?%'XF>!/@M\-?$'Q@^*/B.'1_#7A;1;K5M?U6X5F2SL[>)I9I2$!9@J(Q
MPH+'& "<"MR.1)8UEC.58 J?44 +16#\3OBA\.O@OX"U/XH_%KQMIGASP[HU
MOY^J:SK%VL%O;)D*"SL0,EBJ@=69@H!) KF?@Y^U9\"/CSXBU'P7\.O&-P=?
MTFSAO=1\-Z]H5[H^J0VDI(BNC9ZA##.;=RK!)PAC8J0&)!H ]$HK!^*?Q.\!
M_!3X:>(/C%\4O$D.C^&O"NBW.K:_JMPK,EG9V\32S2E4!9MJ(QPH+'& "2!6
MZK!E#*>",B@!:*P+KXH> K+XH6/P6N?$L*^*-2T"[UNST<(QD>PMI[>":<D#
M:JK+=P* Q!8N=H(1]N_0 45X;^U9_P %+/V%?V(/$6F>$?VJ/VDM"\(:IJUL
M+FTTZ[2>>9;<R>6MQ*EO'(;> N"@FEV1EE8!LJ<>Q^%?%7ACQUX9T_QKX*\0
MV6KZ/J]E%>:5JNFW23V]Y;R('CFBD0E9$92&5E)!!!% %^BBB@ HHHH ****
M "BBB@ HHHH **** "N9^,OQ,L?@W\+M;^*&IZ9->V^BV1N9;6!PKR $# )X
M!YKIJ\H_;G_Y-'\>_P#8!?\ ]#6@#TKPYK,7B/P]8>(8(6C2_LHKA(W.2@=
MP!]QFKM87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
M]#6@#I/AK9^,F^'.@-!K%HJ'1+78K6Y) \E<#K6W]B\;_P#0;LO_  &/^-1?
M"[_DF?AW_L!6G_HE*W: ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !K\[?B\LR_%CQ0MRX:0>(KT2,HP"WGODBOTJK\V/C+_
M ,E@\5_]C+??^E#T <U1110 445X'^T]^U_XH^&VI^)_AM\#OAU'XD\3^%_!
MX\0:_<W^II:V6D6TK2+;[SAGGE<PR$1*H&U,LZ;ER >^45P'P(^-NJ_%^R\4
M?\)1\+]4\':AX3\2MHVI:=K-U!*SNME:W7GI)"S(T++=+M;.2%R0I)4>>_\
M#=9_X53_ ,-/?\*ANO\ A4OVS9_PE7]K+]O^Q>?Y']J?8/+_ ./+=\^[SO.\
MK]YY..* /H&BDCDCFC66*161E!5E.00>A!KS[XJ?'*[\'>/]"^#?P_\ "">(
M_&/B"RNM0M]-GU+[';6=A;E%EN[J<1RM%'YDL42!8W9WD  PKLH!Z%17&? W
MXTZ)\<?"-UK^GZ3=:7J&D:Q=:/XBT2^96FTS4;9]LT#,A*N.5='4X>.1'&-V
M!V= !1110 5]Z_LN6OBQ_@!X8>PU6UCA-BVQ'@)('F/U-?!5?H3^R?\ \F[>
M%?\ L'M_Z->@#K[.T\6I=(]]JUJ\0;]XB6Y!(]C6I110 4444 %%%% !1110
M 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_
M ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'
MQE_Y+!XK_P"QEOO_ $H>OTGK\V/C+_R6#Q7_ -C+??\ I0] '-4444 %?&__
M  4?_94C^(L?BK]I7X!?&:[\(_$3PMX0;3O$UG$OF6.O:85:9+.\B/J"VR5=
MVW'0E%*?9%>)_'_]BW1?C#>^*O&'A;XI^*O"OB3Q3H$6DWUUI>IJ;.>WB5Q%
M'+:RQO$X!DD._;Y@WL%=0<4 8G[%?[17C/\ :(M?B)\&/V@_A#:>$?B)X)U&
M"P\>6>D3;[/4!=6N8+R%^6VR0QC 8L518_F(("^'?M&:9^T%\!_V#=-_X)[V
M7P^M-9UKQ1)%X"\'>)K;5H?(U"PE<J)FM<^>D\=F&,PV>3'L:3SB,*?L'X*?
M 'P3\#+?6+CP_>ZGJFL>)-1%_P")?$NOW@N+_5;@1K$C2N%50J1HJ)&BI&BC
M"J,G*^&?@'X)T+XBR?%_6KG4/$/BLVCVEMKVO7"RR6-JQ!:"VCC5(;9&(&XQ
M1JTFT;V? P =9H6DPZ#HEGH=L[-'96L<$;-U*HH4$_@*\'TI9K?_ (*FZT=4
MSBZ^ VG_ -CD]-D6LW?VD#W#2VQ;V9/:O5_B;\(M(^*6H^&-3U7Q3X@TUO"O
MB.'6;2/0]7>U2\EC5U$-RJ_ZZ [SNC/!P.<9!K?%+X'>'OB?K>B^,X_$6K>'
MO$GAWSUT7Q+H$D"W=O%.JK/ 5N(I898I-B%DDC<;HT889%8 'F/['ZS7'[1G
M[1^JZ9G^QI?B=8PVNW[AO(M"T];LCWW[0?<>U?05<U\)OA-X.^"_@Y/!?@NW
MG\DW<]Y?7E[<&:YO[R>1I9[J>4\R2R2,S,W3G  4 #I: "BBB@ K]"?V3_\
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M )+!XK_[&6^_]*'K])Z_-CXR_P#)8/%?_8RWW_I0] '-4444 %%%% !1110
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M$FT':ZQLRG!R#@@=>*TZQ?B1_P D[U__ + MU_Z):@#X@_X;5_:9_P"BE_\
ME&LO_C-'_#:O[3/_ $4O_P HUE_\9KRRB@#U/_AM7]IG_HI?_E&LO_C-'_#:
MO[3/_12__*-9?_&:\LHH ]3_ .&U?VF?^BE_^4:R_P#C-'_#:O[3/_12_P#R
MC67_ ,9KRRB@#U/_ (;5_:9_Z*7_ .4:R_\ C-'_  VK^TS_ -%+_P#*-9?_
M !FO+** /4_^&U?VF?\ HI?_ )1K+_XS1_PVK^TS_P!%+_\ *-9?_&:\LHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8OQ(_Y)WK_ /V!;K_T2U;58OQ(_P"2=Z__ -@6Z_\ 1+4 ?F;1110
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M)_9/_P"3=O"O_8/;_P!&O0!Z'1110 4444 %%%% !1110 4444 %>4?MS_\
M)H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =)\-?!NE3_  YT"=[F[!?1
M+5B%NF R85K;_P"$'TC_ )^;W_P+:HOA=_R3/P[_ -@*T_\ 1*5NT 8__"#Z
M1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S
M>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_
MS\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M;Q=XV^$_AK6-6L@HL]4U70K>XN(-IW+LDD0LN#R,$8/-=+110 4444 %%%%
M'Z7V7@C239PG[3>?ZI?^7MO2I?\ A!](_P"?F]_\"VK3L?\ CRA_ZY+_ "J6
M@#'_ .$'TC_GYO?_  +:OSM^+T*6WQ8\46\9)6/Q%>JI8Y.!.XY-?I57YL?&
M7_DL'BO_ +&6^_\ 2AZ .:HHHH **** "BBB@ HHHH **** "BBB@ K[U_9<
M\)Z;?_ #PQ=S7%T&DL6)"7+*/]8_0"O@JOT)_9/_ .3=O"O_ &#V_P#1KT =
M?9^$M-L;I+N&XNBT;94/<L1^(K4HHH **** "BBB@ HHHH **** "O*/VY_^
M31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$
MI6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%^)'_)
M.]?_ .P+=?\ HEJVJQ?B1_R3O7_^P+=?^B6H _,VBBB@ HHHH **** "BBB@
M HHHH **** "BBB@#]1['_CRA_ZY+_*I:BL?^/*'_KDO\JEH *_-CXR_\E@\
M5_\ 8RWW_I0]?I/7YL?&7_DL'BO_ +&6^_\ 2AZ .:HHHH **** "BBB@ HH
MHH **** "BBB@ K]"?V3_P#DW;PK_P!@]O\ T:]?GM7Z$_LG_P#)NWA7_L'M
M_P"C7H ]#HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU
M>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%
M:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%^)'_).]?\ ^P+=?^B6K:K%
M^)'_ "3O7_\ L"W7_HEJ /S-HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _4>Q_X\H?\ KDO\JEJ*Q_X\H?\ KDO\JEH *_-CXR_\E@\5_P#8RWW_ *4/
M7Z3U^;'QE_Y+!XK_ .QEOO\ TH>@#FJ*** "BBB@ HHHH **** "BBB@ HHH
MH *_0G]D_P#Y-V\*_P#8/;_T:]?GM7Z$_LG_ /)NWA7_ +![?^C7H ]#HHHH
M **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'
M\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Q?B1_R3O7_^P+=?^B6K:K%^)'_).]?_ .P+
M=?\ HEJ /S-HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4>Q_P"/*'_K
MDO\ *I:BL?\ CRA_ZY+_ "J6@ K\V/C+_P E@\5_]C+??^E#U^D]?FQ\9?\
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M)X4NW"Z):@.K+AAY*\UM_P#"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
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M;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QG\;?\
M@II\7KCXKZI\/_V//V:%\=Z7X(^*^G^!_'7B+4O%5MIR3ZO+!'<SZ9I\4@)E
MFCBG@#SS-#$KOM!?:Q7[,K\IO^"A?["/QF^&G[0"_P#!1#_@D]\=X(_%'B[X
MNZ?!XX^#/BIF?PQXG\1V4LML+ACN1[*Y#PNCL"!(6W"2-68N ?=7P]_;I^'N
MN?L4:I^W)\7?"&M?#KP[X?L]>N_$FC>)HXVU'2(M*O;NUGCFCA9U,^;1OW4;
M/\[!%9^">3TG_@H'XZ\+ZA\,M:_:3_9@O/ 'A/XPZY::+X-UEO%$5_>:;J5Y
M$TEA9ZS:)"@L9;C:8T,$UVBS,D<CH6!/F_P:\;>'/^"XW_!)'XA_#36/AO<?
M"77O%,?B'P9XU\/NBS#P]XFAF?[0^5"?:%^U,L[<*SEW5CNRU>7_ +8WQ*_:
M[_:+^.7[*/\ P3P^(?[/]AHGBS_A9VB^/OB9KFE^)[:_L6TGPW.EU/=VD<7[
M^&UN+I88TENX[=_,=8424EV0 ^J?VLOVO?VH/A'\6M-^#O[*7[!.K_&G46\.
M_P!L^);JW\=Z?X?M=&ADG:"U0RWPVSR3-#<G8AW*L&2,,*9^PK^V?\??VI/'
M/Q+^'GQY_8UG^$>I_#;4--L+V&7Q_9:\+J[N[07AA#V2".-H[>2TD8%R<7<?
M KW/XD?$'PG\)?AWKWQ5\>ZJEAH7AG1;K5=:OI/NV]I;PM--(?941C^%>2_\
M$Z?A]XL\(_LP:;X[^)NE/9>-/B9J=YXZ\:6LW^LM;_593<K9-Z_9+=K:Q'^Q
M9KUZT 7O&_[8VBQ?M!3?LH? [P)>^//'VFZ=!J'BJ"TNTM=*\*6L^3;OJEZP
M;R'F"L8K>&.>X=1YGE"+]Y7LD)E:)6G15<J-ZHVX ]P"0,CWP/I7Y&_L1_#[
MXT^$/^"/_P 3?^"K_@S]ISQ1I7Q9\67?C#XLW]M<7<<FAO/:7%T?[*N[-TVS
M0O;6"6SNQ\Z '$+Q"-17ZF? _P")'_"Y/@KX/^+PT>33O^$J\+Z?K']GS'+V
MOVFVCG\IC@9*[]I^E ' ?'S]K>Z^&WQN\)?LL_"+X;?\)I\2O&.D7VM6NCW&
MLC3M/TK2+-XHI]1U"[$4SP0F:>&&,1P322228";5=EM_LN?M8Z;^T1K/CGX:
M^(? UWX1\??#'7XM)\=>$[N\2Z6V>>W2ZM;JVN$"BYM+B"19(I2D;G#J\<;H
MRCA/V@?@'\8O!O[<_A']O_X(>$(?%YL?AOJ'@7QSX+.J0V=[<:;->P7]M>6$
MEPR0-/%<0NCQ321*\<Y(D#1A7\D_X(V^)OB-^TO\<_VG?^"AGB[P=#H.@?$[
MQ]IOAWP+9V]^EW'=:7X=M9;$WL=Q'^[G26XEN!YD9:,M$X1G0([ 'WE1110
M4444 %8OQ(_Y)WK_ /V!;K_T2U;58OQ(_P"2=Z__ -@6Z_\ 1+4 ?F;1110
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M1JXO[$P_V#HXCG^T"*(R.X'S9C0C:%P0 Q^#OB]!_P $:_@3\6/$7P/^)O\
MP4X_;3L_$_A/4OL'B#3[+QO\1KY;2X\M)0GG6MG)$^8Y(W#([ JZD$@@U]<?
M\$8M5_9KUKX.?$[4?V4?B]\1/'/A)_BY,(_$7Q1N-2EU>:Y&A:,)4=M4CCNR
MBG 7S5!P/ERFTT ?8E>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
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MJ2M==X/\'^%/A]X4TWP+X$\-6.C:+H]C%9Z3I.EVJ06UG;QJ$CABC0!415
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MP31;36H-.2WM(8]TMU)<3CRU57:&,*<%FF7'H>4^!W[47QY^(/QSF^"/Q?\
MV29O <T'A=M;>_D\<V6J 1&X$$2%+93M,C"7;N89$$F,XH ]THHKR']I/]KO
MP[^SOXK\%^"#X2N]=U+Q;XJTO2KB.SN%C32;>]NUM([R=B#P96PD?WI/+E*D
M")R #UZBBB@#]1['_CRA_P"N2_RJ6HK'_CRA_P"N2_RJ6@ K\V/C+_R6#Q7_
M -C+??\ I0]?I/7YL?&7_DL'BO\ [&6^_P#2AZ .:HHHH **** "BBB@ HHH
MH **** "BBB@ K]"?V3_ /DW;PK_ -@]O_1KU^>U?H3^R?\ \F[>%?\ L'M_
MZ->@#T.BBB@ HHHH **** "@@-PP!Y[T44 ?'?BC7/\ @I;\<_B=X\O/V*O%
M/P,^''A/2/&4^DW=YXT\)ZCK.MZWJ%I#!!-=SI;W5M%;(1&D<2MYLCPQ0R;E
M5U1?3OV$? W[5_@;0_B%%^V1\0?"'B?Q9J/Q"^UP:MX(TEK"R>R_L;2XHE^S
MR2RR1.K12 B1V9L!AA64#Y+\8_!K]F?]HW]M'XM>*_C7_P %1_'?P;^(6F^(
M1I#^ OAC\6['PBAT:WB06-Y<*B>;JDLJ%F:YE=_*.;51']F*U].?\$V_A7\*
M?A!X+^(GA?X1_M8^)?C)92?$I[B_\5>+_&(U_4(+IM&TI6LY;X ";8B1LH'W
M%E5.JF@#Z.KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA
M=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ H) &2:*P?BGX%B^
M*'PQ\1_#2?6;K3D\1:#>:8^H638FM1<0O$98SV==^X>X% 'SQJ7_  6<_P""
M=6C?$NZ\ :M^T3IEK86NES77_"8W$$Z:'<S17!@:TMKYHQ!=S[PP587?<PV+
ME\+7O_Q>^,OPM^ ?@2Z^)OQC\<6'A_0[.2**6_OY,!II9%CAAC4 M++)(RHD
M2!G=V554D@5^,7A3XZ>+/^";GB72_P#@G+_P6[^%4$/PL7X-+\.?!OQM\!V'
MVO1[S1Q=HEE=:A'AGTZ>,1J@D9&;S8U?80IF;[U_X+$:G8I\.O@1\4O!=[#X
MA\2^&?V@?#WB#P%X M',C^/KI;>\C.G6SH&2.06T\]W'<28@B:T5Y7C3,B@'
MTG\%OVE?@M^T#/K.G?"_Q=+<:GX<GAA\1:!JVD7>EZII32IYD/VFQO8H;FW$
MB LC21J' )4D XY[XW?MW_LF_LX^*'\(?&CXP6VB75M!#/JL[Z;=SVFCPRMM
MBEU"ZAB>#3HW/W7N7B4CD''-?/7[*'BK7OBW_P %?_BE\4_BY\/M3^%7BFP^
M"6AZ#H'PQ\13VT^HZWHR:E=W3^())[&6>SEC6YN#9I'#/,\15_-\LS1J?4O^
M"F7C'QU\*OV/OB2/@Q^RAJ'Q U#Q9X7U2'6SI(L4M;3S+);5[W48WE%U=HD&
M,QVL%U.Z6WEA!\E 'T#J7BCPUHOAJX\::QXBL;31[2Q>]NM6N;M([:&V5#(T
M[RL0BQA 6+D[0HSG%>;?"/\ ;?\ V7OCEXNL? OPX^)WGZIK&F2:EX>MM3T6
M]TX:]8Q[=]WIKWD,2:E;J'0F:U,L8#J2V&!/S)^T-^SQK_Q3_P"#>ZR_9X_9
M,\:2?% P_!7PS;>']4TURK^,M.L5L99XX@QR&O+2WFB6-CG,X1N<UR7[:W[9
M7[/G[2G[3G[%?P=_9C\0R:CXYE^/%OXA-G:Z9-;7?A[1++1K\:K;7B.BM9RF
M"X2-[24*^W)*_(,@'Z/UY/\ &#]N']ESX$>++[P/\3/B@+74](TN/4_$,&G:
M+>Z@N@V$A8)>:E):0RIIMNVQR)KIHHR$8AL*2/6*_-I_BU\6?@#^U3^VDG[,
MW[+^L_M!0>(KC3M6U6_\/W-I%'X?UU-!M[1_#U^;R6)KQ$MX8+D)8+=2QI=F
M%H0Y3> ?HYHVLZ/XCT>T\0^'M5MK^PO[:.XL;ZRG66&XA=0R21NI*NC*00P)
M!!!%6:^>_P#@D[X3\"> _P#@FK\$/!GPS^+\'CW0]+^'&F6UAXNM8Y$BU$)"
M S)'*!)$JN&012 /&$". RD#Z$H **** "BBB@#SW]J7QQXI^''P0U?Q?X,U
M3['J-K);""X\A)-H>XC1OED5E.58CD=Z^2/^&U?VF?\ HI?_ )1K+_XS7U#^
MV[_R;7KW_76S_P#2J*O@N@#U/_AM7]IG_HI?_E&LO_C-'_#:O[3/_12__*-9
M?_&:\LHH ]3_ .&U?VF?^BE_^4:R_P#C-'_#:O[3/_12_P#RC67_ ,9KRRB@
M#U/_ (;5_:9_Z*7_ .4:R_\ C-'_  VK^TS_ -%+_P#*-9?_ !FO+** /4_^
M&U?VF?\ HI?_ )1K+_XS1_PVK^TS_P!%+_\ *-9?_&:\LHH ]3_X;5_:9_Z*
M7_Y1K+_XS1_PVK^TS_T4O_RC67_QFO+** /4_P#AM7]IG_HI?_E&LO\ XS1_
MPVK^TS_T4O\ \HUE_P#&:\LHH ]^^!O[6'Q_\8_%[P]X7\1^/OM-C?:I'#=0
M?V5:)O0GD;EB##\"#7V=7YV?LS_\E]\)?]AJ'^=?HG0 5B_$C_DG>O\ _8%N
MO_1+5M5B_$C_ ))WK_\ V!;K_P!$M0!^9M?&_P#P4?\ V5(_B+'XJ_:5^ 7Q
MFN_"/Q$\+>$&T[Q-9Q+YECKVF%6F2SO(CZ@MLE7=MQT)12GV17B?Q_\ V+=%
M^,-[XJ\8>%OBGXJ\*^)/%.@1:3?76EZFILY[>)7$4<MK+&\3@&20[]OF#>P5
MU!Q0!E_L+_M.>/?C?<^._AA\=?A)9^#_ (E_#_6;6V\;6FE2>99W[7%N&MKV
M%^6*R0Q#"L6(14^8@@+S7QP^%7PO\&_\%&?@!XX\(?#?0-*UK7[WQ:^NZQIN
MCP076I,-()#7$J*'F(+,07)ZGUKV[X*? 'P3\#+?6+CP_>ZGJFL>)-1%_P")
M?$NOW@N+_5;@1K$C2N%50J1HJ)&BI&BC"J,G.;\3/V:M'^)WQF\'?&^_^)7B
M?3M2\"M>-H-EIC60M5-U"(+@R++:R/)OC&.7^7JNT\T >DUS?Q1^(_AWX3>%
MY?%NL6DUU<2R):Z9IEC&&N]5NVSY-I I(WR.<XR0JC<[%45F'(_M1_!WQ)\9
M--\*Z?X0\3^)=%U+1O%MGJEOJ>@ZV+."%8F_>"[3.;F(QLX$(4[WV!BB%F&1
M\?/V*M)^/_Q.TWXJZA^T1\4?#%]H^GO::5:^#?$4%E;VJR?ZUT!MG;S)  &<
ML254+P!B@#0_9=^#US^SK\)-:U;QY<6Y\0>)O$6I^,/&SV!+P1W]XYEEBAXR
MT<4:QPJV,N(0V 6P/D8^$_B)'_P3GC^*\FIV/_"BUU5?%_\ PJ?[+_Q-O^$8
M^V_;18_VKOV$ XF\CR-VS_1_M&/WE?:7P$_9\TWX#:3J=B/BAXT\97FK72RW
M6L^/-=_M"[6-$"I;HX1%2%?G8(%^]+(23NXY4?L+?"P>$1\)3XO\4GX=K??:
M1\-C?P?V3CSO.^S[O(^U?9O,^;[/]H\K'R;-GR4 >R:=?VNJZ?!JEDY:&YA6
M6%BI&58 @X/3@UY+^RG_ ,5[J'C;]I*X^<>-O$;VV@2'MHFG%[2TV_[$L@N[
MM?:][5ZEXET,>(_#6H>&AJEW8"_L9;87NGR*D]MO0IYD3,K!77.5)! ('!Z5
M!X&\&>'_ (<^"M(^'WA*R%MI6A:7;Z?IMN/^64$,:QQK^"J!0!'\1/&"?#WX
M?Z[X^DT._P!470]&NM0;3-*MS+=78AB:3R84'+R-MVJO=B!7YX?'W]KCX<WW
MPZ\%ZIK_ ($^([^+M1^-OA7Q#XLO[SX:ZI;PM]GOXV%E:M+"N](8E$,,0&^0
M@MM,DKD_?O@#X1Z1\//%WBSQCIWBGQ!?S>+]4CO[RTU?5WN;>R=(EB$=K&W$
M$9"@E1G)]@ (OC-\$O"/QSTO0M(\8W5_%%X?\6Z9XBL383(C-=V-PL\*ON5L
MQEU 8#!(Z$=: .@\)^([+QCX6TSQ=IMK=P6VJZ?#>6\-_:/!/&DJ!U62)P&C
M<!@&1@"IR",BM"BB@#]1['_CRA_ZY+_*I:BL?^/*'_KDO\JEH *_-CXR_P#)
M8/%?_8RWW_I0]?I/7YL?&7_DL'BO_L9;[_TH>@#FJ*** "BBB@ HHHH ****
M "BBB@ HHHH *_0G]D__ )-V\*_]@]O_ $:]?GM7Z$_LG_\ )NWA7_L'M_Z-
M>@#T.BBB@ HHHH **** "BBB@#P7Q+_P2Y_X)U>//B5XJ^,'Q/\ V)?A9XO\
M2^,M734M;UCQAX"T[5)WF6U@M@$>YA=HT*0*Q4'!=Y'/+FNZ_9Y_9:^ /[*&
MA:YX2_9R^%>B>#-#U_Q VM77A_PWI<-E807;6MM;.T-O BI$&2UC8A1RY=OX
MJ\)\??%S_@J=\;_B!XI3]A_2?@'X<\'>%O$EQH":E\64UG4=2U6[M=JW,PMM
M/D@2TA$I9(P\DCR+&),(KJ*]*_8@M/VUK/PSXUB_;L\1^!]3\5GQR3I,OPZM
MKN#2(]+_ ++T[RTABO)))HSYWVDN'=LNS,/E8  'ME>4?MS_ /)H_CW_ + +
M_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_)
M,_#O_8"M/_1*5NT %<O\;_!>L_$GX+^+_AWX<OH;74=?\+ZAIUA<W#LL<,T]
MM)$CL5!8*&8$D D < UU%% 'YQ?M ?L,_P#!3C]J6#4OV7_C=K7PAU#P]XI^
M#8\'>+/B_#!?^?- ;V-Y;F+1WC:-=1(3S$S=^4CXD&-HBKZ+_:%_85U77O#_
M ,#-?_9Q\36.F>*OV=M8BNO T'BAI)+'5++^RY=*N=/NY(E+Q>;:3-BY1':*
M1%;RW&Y#])44 ?.GPG_9?^-/B3]MB;]NO]I*?POI.KZ;\.)/!/@_P9X,U6YU
M*ULK.XO8KV\O+B^N;:U>XFEDM[=$C6WC2)(FYD:0E>U^-$'[9<MEKOAWX$VW
MP\F35;5DT3Q#XHU:\MIM"=X]A9[.&TF341&^95'GVN\$1-MVF9O5J* /)OV5
M?V:+;]B3]CCP7^RY\')4\0?\(#X3M]*TN?7KUK-=2FC7YY9I(XYC ))"[D*C
M[-V "!7/?!']CWQ#IO[16J?MF_M,>.[3Q;\2+K1VT3PQ;:99-;Z/X,T9G622
MRT^.1F>2:9U1KB]D(DF,:*J0QJ(A[U10!Y_>Z7^TVW[3]CK.G^*O!Z_!]?!4
ML.HZ++IUP==?Q ;H&.=)@WDBT%OE2A&_?SR""OB_@K]F']K/]E+XC?%V_P#V
M46^'?B+PY\6_&]QXSCB\>ZU?:?<^&-;NK:""[(6UM+@:G:N]O'.L1>T="SQ^
M805=/JBB@#R7]A?]E/2/V(OV3_!O[+^C>+;C7QX8L9OMNN7-LL+:A>W%S+=W
M5P(E)$2O<3S,L8+;%95W-C)]:HHH **** "BBB@#R?\ ;=_Y-KU[_KK9_P#I
M5%7P77WI^V[_ ,FUZ]_UUL__ $JBKX+H **** .#_:A^+^I? #]G7QK\;-&\
M.'5[OPOX;N]1MM.R0LSQ1EE#D<A 1EB.0H8U\X?!WQS^U%X[\6P_%'X3?M1:
M3X_TK4E\%7&OVD?AJ+[*=/N]0GCOA8B%P;5X8A)N\[S7VJP<AD4K]0?'#XE^
M%_@Y\)=>^)WC>U6;1=&L3<:NC#(^S9 E8C!W (6.W'.,=Z_/?XS_  ]T#]C_
M .,FK?M'_P#!.?XHV6CP7=[X6/\ PK'1M02ZTCQL=2O+B"2*VA#,!(%574Q<
M1IYA390!^BWQ)^(&B?"_P9>>-->2:6.V");V=H@>>]N)'$<-M"N1OEED9(T7
M(RSCD=:\E_8<^+WQN^*<WQ3TSX[W^FR:GX5^)L^DV=KI5NJ0V-O]@LK@6RN
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M.S]F?_DOOA+_ +#4/\Z_1.@ K%^)'_).]?\ ^P+=?^B6K:K%^)'_ "3O7_\
ML"W7_HEJ /S-HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4>Q_X\H?\
MKDO\JEJ*Q_X\H?\ KDO\JEH *_-CXR_\E@\5_P#8RWW_ *4/7Z3U^;'QE_Y+
M!XK_ .QEOO\ TH>@#FJ*** "BBB@ HHHH **** "BBB@ HHHH *_0G]D_P#Y
M-V\*_P#8/;_T:]?GM7Z$_LG_ /)NWA7_ +![?^C7H ]#HHHH **** "BBB@
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MVKKOA=_R3/P[_P!@*T_]$I7@W_!23_D5O"W_ &$+G_T!* ,__AY;_P!45_\
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M (0?2/\ GYO?_ MJQOB'X,TJ'P!KDR7-X2FCW) -TQ'$34 ?G)1110 4444
M%%%% !1110 4444 %%%% !1110!^H]C_ ,>4/_7)?Y5+6%9>"-)-G"?M-Y_J
ME_Y>V]*E_P"$'TC_ )^;W_P+:@#8K\V/C+_R6#Q7_P!C+??^E#U^A_\ P@^D
M?\_-[_X%M7YV_%Z%+;XL>*+>,DK'XBO54L<G G<<F@#G:*** "BBB@ HHHH
M**** "BBB@ HHHH *_0G]D__ )-V\*_]@]O_ $:]?GM7WK^RYX3TV_\ @!X8
MNYKBZ#26+$A+EE'^L?H!0!ZO1679^$M-L;I+N&XNBT;94/<L1^(K4H ****
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M7KW_ %UL_P#TJBKX+K[T_;=_Y-KU[_KK9_\ I5%7P70 4444 %%%% !1110
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M2^^$O^PU#_.OT3H *Q?B1_R3O7_^P+=?^B6K:K%^)'_).]?_ .P+=?\ HEJ
M/S-HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4>Q_P"/*'_KDO\ *I:B
ML?\ CRA_ZY+_ "J6@ K\V/C+_P E@\5_]C+??^E#U^D]?FQ\9?\ DL'BO_L9
M;[_TH>@#FJ*** "BBB@ HHHH **** "BBB@ HHHH *_0G]D__DW;PK_V#V_]
M&O7Y[5^A/[)__)NWA7_L'M_Z->@#T.BBB@ HHHH **** "BBB@ HHHH *\H_
M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
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M "BBB@ HHHH **** "O>/^">/_)<KW_L6I__ $=!7@]>\?\ !/'_ )+E>_\
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MM]<$&8CYOD3IBOH?X7?\DS\._P#8"M/_ $2E>#?\%)/^16\+?]A"Y_\ 0$H
M^2:*** "BBB@ HHHH **** "BBB@ HHHH *]O_8%O;BP^-5Y-;:=+=,?#LX,
M<1&0/.@YY_SS7B%>\?\ !/'_ )+E>_\ 8M3_ /HZ"@#Z\_X275_^A0O?^^EH
M_P"$EU?_ *%"]_[Z6MBB@#Q7]LS6]1O/V=M<M[CPY<VZ-+:9ED9<#_28CVKX
M=K[T_;=_Y-KU[_KK9_\ I5%7P70 4444 %%%% !1110 4444 %%%% !1110!
MVO[.<TEM\=/"T\5NTK)K$16).K<]!7W_ /\ "2ZO_P!"A>_]]+7P)^S/_P E
M]\)?]AJ'^=?HG0!C_P#"2ZO_ -"A>_\ ?2UC?$/Q%JLG@#7(W\)WB!M'N06+
M+@?NFYKL:Q?B1_R3O7_^P+=?^B6H _,VBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#]+[+Q+JPLX1_P (A>?ZI?XE]*E_X275_P#H4+W_ +Z6M.Q_X\H?
M^N2_RJ6@#'_X275_^A0O?^^EKX8^)_P6^*6L?$OQ%J]KX3/E76NW<T>Z]@!V
MM,[#(+\<&OO^O _%?_(TZE_V$)O_ $,UX6>YGB,LIPE22=V][_HT!\O_ /"A
M/BS_ -"I_P"3T'_QRC_A0GQ9_P"A4_\ )Z#_ ..5](45\W_K9F/\D/N?_P D
M!\W_ /"A/BS_ -"I_P"3T'_QRC_A0GQ9_P"A4_\ )Z#_ ..5](44?ZV9C_)#
M[G_\D!\W_P#"A/BS_P!"I_Y/0?\ QRC_ (4)\6?^A4_\GH/_ (Y7TA11_K9F
M/\D/N?\ \D!\W_\ "A/BS_T*G_D]!_\ '*/^%"?%G_H5/_)Z#_XY7TA11_K9
MF/\ )#[G_P#) ?-__"A/BS_T*G_D]!_\<H_X4)\6?^A4_P#)Z#_XY7TA11_K
M9F/\D/N?_P D!\W_ /"A/BS_ -"I_P"3T'_QRC_A0GQ9_P"A4_\ )Z#_ ..5
M](44?ZV9C_)#[G_\D!\W_P#"A/BS_P!"I_Y/0?\ QROL_P#9UD\2>%/@IX>\
M/:EX0NC/:V9639*C#/F,>""0>M<!7N'PV_Y$;3?^N'_LQKVLCSK%9GB94ZL8
MI)7T3[I=6P+%GKVI7-TD$WAFZA5FPTKLN%]S6I117TX!1110 4444 %%%% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
MDF?AW_L!6G_HE*\&_P""DG_(K>%O^PA<_P#H"5[S\+O^29^'?^P%:?\ HE*\
M&_X*2?\ (K>%O^PA<_\ H"4 ?)-%%% !1110 4444 %%%% !1110 4444 %>
M\?\ !/'_ )+E>_\ 8M3_ /HZ"O!Z]X_X)X_\ERO?^Q:G_P#1T% 'VI1110!Y
M/^V[_P FUZ]_UUL__2J*O@NOO3]MW_DVO7O^NMG_ .E45?!= !1110 4444
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E>#?\ !23_ )%;PM_V$+G_ - 2O>?A=_R3/P[_ -@*T_\ 1*5X-_P4D_Y%
M;PM_V$+G_P! 2@#Y)HHHH **** "BBB@ HHHH **** "BBB@ KWC_@GC_P E
MRO?^Q:G_ /1T%>#U[Q_P3Q_Y+E>_]BU/_P"CH* /M2BBB@#R?]MW_DVO7O\
MKK9_^E45?!=?>G[;O_)M>O?]=;/_ -*HJ^"Z "BBB@ HHHH **** "BBB@ H
MHHH **** .Y_9G_Y+[X2_P"PU#_.OT3K\[/V9_\ DOOA+_L-0_SK]$Z "JNN
M_P#(#O/^O23_ -!-6JJZ[_R [S_KTD_]!-9UOX4O1@?/M%%%?C8!1110 444
M4 %%%% !1110 4444 %%%% 'T5#_ *I?]T4ZFP_ZI?\ =%.K]G6P!7@?BO\
MY&G4O^PA-_Z&:]\KP/Q7_P C3J7_ &$)O_0S7R/%W\"EZO\ (#/HHKE_B_\
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M?_VVO8**/]8<X_Y^_P#DL?\ (#Q__AE'_J??_*7_ /;:/^&4?^I]_P#*7_\
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M?XIOM6U"74K[2/$]S//;FTFU"X9[F?SK."&=8KB61HE0;-L<BK7)?LD?"?\
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MGQ7_ &5-=^*UM8:M\)T^,?VK7Y[HI-IS7DNCWBZ+)-G*-"]XT<89OD+3(O\
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MX;_ V(>;I/@"QF^(7BM/X3<_O=/T6!QW#3/J%TOH^EH>:]#_ &?M._:%TOP
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M'9:=H5I,TR6HD.UY+B>0P2LL**!M3+R)N7/T]7Y__P#!6[]B2+XL1^-?VO\
M]E_]H*^\"?%?P7X#?2?&%A"AETWQ/H[(UQ'8:A ?4,Q2==Q7'W2R(8_%P$*%
M3$*-7;YVO=;VUM^MN@'UC^S%^T/K_P"T#9^,8/%WP4UOP'J_@GQBWAW5-&UV
M[MYWEE73[*]^T126[O&\#K>IL8'+*N2$)*+%\4/VM?AQ\,_VEOAE^RI/<P7G
MBSXE3ZE);V$5ZJRV%A96%Q=27DB8)*M)%'"H.W<9'8$^4RGS#_@FM^V1\3_V
MCKSXE_!G]I7X%:?X!^,'PM\065G\1+'1)A+I^IM=6@>TU"WD.6*RP0C"NSLJ
M)'\Y!"KQ_P"T=\$O@Q\/_P#@K/\ LO?$?P%\(O#&B>(O%&H^.I/$VO:1H%M;
M7NKNN@DJUU/&@>X(+,07+8+'U-:+#P6)G3J*UHMI)W5U%M.]]GNMP/HC]I?]
MI;1?V==+\-64?A6]\1^)_&_B6'P_X+\+Z=,D<NHWSQR3,7DD.V&"*&&6:68Y
MV)&<*[%4;-^$O[4&I^)OCKJW[+OQB^',?A+Q[IOAN+Q%96NGZU_:>FZQI+S&
MW:YM+HPP2,8I\1RQRPQ,ADC(WJX:LC]LO]G_ .(OQ)\4_"OX]_!B&PO/%OPB
M\:2ZS9Z'JMX;>#6+&ZL;BPOK02[6$,Q@N"\3L"GF1JK;5<NOBG[-'C;XF_M5
M?\%<_'7QJU3X92^&O"OP=^%W_"!HEQJ=O=RS:WJ%[;:A<QO+:O)!YD,-M"KP
MQR2>694WL'<HBIT:,\.Y=DVW?5.]DK=GITZOL![5\2?VR/$>E?$;QI\/_@?\
M"KSQZWPQTRVO/B'-;:W'9O;//#]HCT^Q1XW%[?\ V;;.86:",++"#-ND"CU7
MX4_%#P1\;/AEX?\ C!\--<34O#_B?1[?4]&OXP0)[:>-9(VP>5.UAE3@@Y!
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M_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\
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M_#;X?>%?A+\.]!^%G@;3A9Z+X:T:UTO2+13Q#:V\2Q1)^"(H_"MJBHYI6MT
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M[)O_ $4;XI_^%L?_ (U7V-10!\<_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\
MT4;XI_\ A;'_ .-5]C44 ?'/_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T
M4;XI_P#A;'_XU7V-10!\<_\ #D+]DW_HHWQ3_P#"V/\ \:KS'X[?\$FOV<OA
M[\2/AIX6T/Q[\1GMO%7B=[#4FNO%[.Z1"$N#&1&-K9'4@U^BE>??&/X,ZG\3
M?'O@#Q?8ZU!:Q^#O$+ZC<PS1L6N%,138I'0Y.>: /GK_ (<A?LF_]%&^*?\
MX6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J^QJ* /CG_AR%^R;_T4;XI_^%L?_C5'
M_#D+]DW_ **-\4__  MC_P#&J^QJ* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\
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M7T3XD^)K2, :IJ.K-;/I^AR.,>:]M DUZZY/E"\ML@&88^SJ "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MRCXZ_P#(W6W_ &#4_P#1DE>KT5Y^9X#^T<*Z/-RZIWM?;YH#YSHKZ,HKYO\
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M%\40\5?"P64%MKMO--"L]NFV>9;=DEB;S%G29H65),.S1L@ /;:*^-_V9/\
M@J8=:_X)6:%_P4:_:6^%'BG3M/C\*Q:YXLDTG2[>1(K9U,CW5M&)P\UM&"J9
M \SC<4P&(]P^+W[8_P +?@CKOPQTGQQHVO+:_%OQ-9^'O"6L6E@DMK_:=U!+
M/!;3XD\R$M%!*^\H4^0C=G H ]8HKPCPO_P44_9V\7>/]+\'Z2^NC2M>\=:A
MX*\/>-YM*V:+JGB*R%Q]ITV&<OO,BM:72+*T:P2/;ND<KOA3Y+_P7.TA)/V6
M_ _BF#5=4M;S2_CUX"6W^PZQ<6\4BS^(["&19HHW6.<%&( D5MN25P230!]H
MT5%>WMGIMG-J.HW4<%O;Q-)//,X5(T499F)X  !))KQ+X$_\%!_@'^T'XJ\+
M>&?!]OXAL(OB!X<N]?\ AKJ^NZ.;6T\6Z9;-")[FR8L7 5;B"01SI#(\4HD1
M&0,P /<J*\R^-_[5_P ,O@;XS\/?"N_T_6_$7C7Q7!<W'AWP5X3TPWFHW=M;
M;/M%TP++%;V\9DC5IIY(X]\B(&+LJGX[_P""9GQC^'_CK]L[]N;QOX/O_'J:
M!9^(/"D+Z?JNGZK<ZSI5TFANE[;QVLZRW(D2Z$^V.-74GF(,A4D _1&BOC7]
MC3]M_P#9Q^&?[*G[/6CZ1\5/B]\1/#OQ9UR?PUX#^)WQ(1;S5-7U(SWT@BU&
M0E)HW*6MQL9X@!%"BD[@17KGQ&_X*!?L^?!OXT>*_@A\7[G5_#5]X/\ A;=_
M$35=6U'3P]@_AZVN%MYKJ*6%W9F65MODE1*<<(<KN /;J*\Z^%_[1NF?$CXB
M:A\*M1^%OC#PKKFGZ);ZPUMXFTV%(Y[.:62*.2*:WFFB=MT3;HM_F1_+YB)N
M4'Q;Q5^W[\2](_X*Q^'_ -@RS_9\\4GPQ/\ "K4?$%YXD2WM)$O[G^U-)M8;
MF+_2 \=G;)<7*S.RAV>50L9$>Y@#ZNHKYRF_X*??L^7W[0_C7]E#P)X+^(GB
MCXA> ;>SN?$'AK1_ UU'*MM<*["XC>[$,;PJ%7]YNVR&:,0F4L0*J?\ !67]
MD'4OAK-\<?".J>)=?\ Z5:Q7'C'QQHWA>XDT_P *!]I:/4MP6:":)6#SPK&\
MELA#SK$K*Q /I>BO(/BC^VS\(/AU\5K/X":!IGB'QOXZO/#W]OGPGX%TK[=<
MVNDE_+6^N)&=(+>)W!6/S)5>8JPB5]K8BT3]O?\ 9G\3?LR>(/VM_#GBG5M0
M\)>$OM\?BF*Q\+7\VJ:/=6)87EI=:>D)NH+B$J?,C>,%!\YPA#4 >R45\W_"
M3_@J9^S'\8]#^'WCG0-/\86'A'XI7=GI_@?QMK7AB2WTK4=3N8B\6G>:26CF
M+*\0=U6!YD,4<KN54X/PY_;_ /B3XY_X*D>//V)=0_9]\4:5X:\'^!M+U"VU
MRYM[1EO)[F[O8VU!F2X+1V3+:B.+(\QG$A:-!M) /JZBO&OA1^V]\,/C)K?A
M"V\'^#_%AT3XA6EQ>> O&,^E1_V5KMK%"9C/%*DK/"'C&^-;A(GE7+(K*K,/
M9: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC#_
M (*+?\EMTO\ [%6#_P!*;FOL^N+^(W[/7P?^+.MQ>(_B!X0_M"]@M5MHIO[0
MN(ML09F"XCD4'EV.<9Y^E 'YST5]\_\ #%7[,W_1-/\ RLWO_P >H_X8J_9F
M_P"B:?\ E9O?_CU '5? S_DB7@[_ +%73_\ TFCKJ:JZ%HFF>&M$L_#FB6WD
M66GVL=M:0[V;RXD4*BY8DG  &22?6K5 !1110!P'[5G[/'A']K7]FGQY^S'X
M[NI;?2?'GA2^T2\N[=0TEJ+B%HQ.@/!>-BKJ#QE!FOE[]AS]I#X_?L=_L^^&
M?V._VYOV9_B9<^+?AUI</AW2?''PY\ :AXET/Q=I]J@AL[V.?3HIFLY6A2,2
MQWBPE7#-G#<?<%% 'QM^T;HGQD;]KK]GW_@H%?? 7Q1-X9\':5XK\/>+O"EA
M:KJFMZ%:ZM'9FVU465F96F97L1%-#;&>58[E6"MLD5=/]EOPCXZ\;?M[_&O]
MO?5?A[XC\*^"-9\!^'?"7A2PUW0;FSU/Q -,DU"ZN=4DT^1!=0J&O1;PI+&L
MSB)SY84IO^MJ* /S9_93L/$7AS]A3]M+0-?^ 'Q+T_4_''QA^*&M:#I%Y\*]
M:BN]>M-6:4:?/!";0/-YR&-< 90 ;P@%9.C:5\9?"'PG_P"";_QOO_V<OBCJ
MR?!O3/[#^)^B6/@*_.LZ1>W'@F32M\EG+&DK0K>.$>X ,0'S;\<U^GE% 'Q)
M=OK^I?\ !=CPU\5]2^"7CR'0K?\ 9BO?#+^)I? 6HRZ;9:U<:_9W0LVOHX&M
MMWD12DRK(8@ 1YGS 'YT^,7BC]L#XSVOPQ^*GQ>_95^-2>*_A3^V#:ZQXL\*
M^'/!-RNAZ-X9AO=1MX+C3(H /[;,L$]M<2W2"YD5VN3FWB*HWZS44 ?)W[:G
M@+XE:=^UO^SA^W)HOPTU[Q!X;^&Z>)M+\;^'=$L#?:KI=OK=C:I'J45I 7>Z
M-O+:+%+';^9+Y=T[1K(%8'V+P5XATSXU:#XQ\4>#?@_J?A^+6=.6RMM;\2^'
M9='U#6Y%AE0-):W,4=U'#%O5$:X5&8F7:@C"22^GT4 ?FY^R[\!/CA^T)_P;
MTZO^P#JGP-\8>!_'^E_ Z[\%BS\=:/\ V;'=:TEM/&J0F1LR6YD6'_20/*99
MP49RKA:_[77Q1^.?QWL_V.=*^&O[&'Q>OF\ ?'+PWKWQ/2X\!7=BV@O;:3?V
M[0AKM8HKF,/-+NNH'DM5\I 9LSQ!_P!*Z* /R8^-/BG]L+XUV/P[^)_Q=_91
M^-47BGX4_MAV.M>)O"7ASP5<#1-'\+P:C>PPW.FQV^/[=>6":"XEN8Q<R*[7
M)S!$55OIK_@M(/&/C+]DKP;X?\%_"'QQK^KW/Q<\%ZU-HWACP=>ZO<6=G8:Y
M8WMX\_V&.9(O+AC<\M\Y4A-YK[-HH Q-=\0ZS<_#F]\5> _#TFH:@^BRW6C:
M5J44EDUS-Y)>*&59E5X"S;58.H9,G(!!%?F#\*_$O[4?C[]HO]C?]K+XL?LP
M_'276O#\?B?1OBS8S^ Y[#3_  SJFHZ0D-O8V6GY1(=-CGB:-=0*&-HS"9[I
MV!"?JS10!\D?&CPIXX^ O_!4G2/VWM5^'GB3Q)X \0? YO 6JW7A#P_<ZQ>^
M'-0M]7?489GL;-)+F2WNDG>-I((Y-CVL7F!58..%_P""8E]\9/$?_!1']KWX
MQ>./V3_'W@+PS\0_$?A:\\':OXJT$6$6IVMCHJ69FVR,)!))M64Q[-T>\I*(
MY$=!]XUYQ\?O!'[3WBO4O"VI?LW?'SP[X,72]4DD\3V'B;P(VMV^MVCQE!$/
M+O+66W=&/F*Z2<D ,"N00#\W/V1/A+\0_&W_  1J_8M^,'P]\&ZEX@'P?^.$
M'C/Q#HVB6AN+Z?2$U#7+&[>W@7Y[B2)+_P _RD!D=865%9RJGKOVA_$7Q(^,
M/_!23QM\9[G_ ()X_%'Q[\'[[]C_ %+P:+:_\%W-@?$EQ-K<5S<VAM[SR)X"
M\"R1QHZ),SH75/+>*5OOO]E3]G'P/^R)^SGX/_9J^'$]S-H_@[1(K"VNKTJ9
M[IAEI;B3: N^21GD;: NYS@ 8%>@T ?#_P#P3A^%?QW^!?[2VM_"_P"'GQ#^
M*'BG]FZ/X=077AA/C3X?O+76?"FN&\"+I%G<ZA!!=W=E]D5G(D600&.%!(2S
M9U?CYI_Q-^&'_!97X8_M"VGP+\:>*/"FL_ 37O!/]K>$]$-Y#IVK2ZUIE[$M
M[("$LX6BMY,3RLL>1C.<U]ET4 ?$7[+-[?>'?^"M7[6/Q8\1_!_Q_8:)XE\+
M>!X/#/B:\^&FL)::I_9=CJ7V^.VF-KMD*/-" JG,K$",2$5XI\ ?"OBW1/\
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ML+\ O'FK^$_BE\!?#&F^'_$^G^&)A86=W9:GJ<MS!?R2A/L$B0W<<OES!7<
MHBM)B,_:]% 'YL?L&_!_XO?!O]H/X2:C^R!X:^+/@OX1^+;'4KWXR_ 7XI>&
M+Z/1_AW<M822Q-H=W?PHT+'4)!";6VEFA>.:20*BKE?TGHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[X@_'WX2_"O6HO#WC
MSQ9]@O)K5;B.'[!/+F(LRALQQL.J,,9SQ]*[&OCS_@H+_P EFTS_ +%B'_TH
MN:]7)L#1S'&JC4;2LWIOIZIG@\1YIB,GRQXBBDY72UO;7T:_,]U_X;(_9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?'G_!07_DLVF?\ 8L0_^E%S
M7V'7CW[0?[)W_"]O&=KXN_X3[^ROLVEI9_9_[*\_=MDD?=N\U,?ZS&,=NO->
MUD.+P^"S!5:TK1L^C?Y7/F^*L!B\RRAT<-'FE=.UTMO5I'Q117TY_P .Y/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20220630_g11.jpg
<TEXT>
begin 644 biib-20220630_g11.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MB@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ_X*>_MP^)/^"<O[(_B#]L"
MR^"L'CG1?"1MW\1:6OBC^S;J.&>ZAMDD@S;3),1).I96,>%!(+'Y:S6_:6_X
M*-7'@,>.]"_X)X^#]3672A?6>F6?QX NKH&/S%B02Z.D8D8$ ;G5<GE@.:\N
M_P"#EG_E"!\>?^P1I'_I[T^O.?V\_BQ_P6"_8[_X)T2?M4^'OCS\%-=T[P-I
M6D:I>:!X?^%NK:/>W%J&AC0/=SZY=QM%'))%+/&(HS+#%*@=-VU@#]%/AMXX
MT[XG?#K0/B3H]I<6]IX@T6UU*U@NXBDL4<\2RJKJ>58!@"#T((K:KXE^.UW\
M>/V M9^ /Q!B_:>\7_$!_'/Q=T'P#\3=+\5SP36FMG5Q) -2LX8XE&G2V]R$
ME6*VV0F#S5=&(5UH?M0C]ICQS_P6(^'/[-?@[]KGQKX6^'7BKX*:_KOBCP[H
M/V&!HVL[[3X$-G/]F,L4LCSH&E=I'2-IA"82X90#[IKS_P"('[0OASPY\%/&
M/QD^'6D3>-U\&KJ4=[I&@7ENDLMW8LZ75L)+AXXU>-XW5\MP48 ,P"FWX#^#
M4W@[X&0? _6OBYXS\2F/2)]/F\8:YK*KKEPL@<><UU;1P[9U5\+*BJPV*V2P
MW'X1_P""1OPNTSX?_P#!*/XO7.F>*O$E\C^*?B;8I;ZWXAN+V.-+;6M6C611
M,S'S7 S)(26D;YF)/- 'V_\ LB_M VG[5_[+/P[_ &G;'PO)HD'Q!\%Z;XAA
MT>:[$[V2W=LDXA,@50Y4/MW!1G&<"O1*_)W]GC7_ (\?L:_\$5?V9OVU=-^/
M_B6_U+3[3X=6>K>%7N(_[$NO#.I7UAIG]G+9[-J2I;7<<GVH'SS<1DE_*/DC
MT70_VE?VI_VN?VP?VA/#-M\/?CI=^"/A/XSC\$^#M.^"_B7PQH_V6^BLH;BZ
MU*^DU34[6XNYI'N(S#&4>S6)!E)'9R #]':\>^//Q\^/7@[XI:-\)/V=?V:;
M;Q_?7.B7&J^(M1U7QFNB6.B0"5(K5'D^RW#2RW#"YV(B<"TD+$97.?\ \$[O
M$?[9_B']F'38OV^/A^VA?$;3-4O;"[GDGTUGUFRBG86>HR1Z;<3VUO+- 8S+
M#'(5659-H5"H'N- 'P/\&O\ @KI^UM\??AQ\8?B7\*_^"<6FZI;_  1^(6N>
M#?%VFK\:8HKNYU'25B>[-FLNF+'+'ME!1GDC+8(P#@'ZO_8Z_:*L_P!KK]E7
MX>?M0Z?X5ET.#Q_X1L=>AT::[%P]DMS"LHB:0*H<J&QN"C..E?"7_!&[_D@/
M_!0+_L\CXI_^DMG7$_LVZ_\ 'C]C;_@AG^SQ^W)I7Q_\2WNJZ)9> (;_ ,*&
MXC&AW7AO4-5L-+.FBSV;5D6UO%E^U9\_[0A;>(L0@ _6RBO@WXO:;^TS\6/^
M"TD_[*UA^V1X^\-_"^[_ &;QXLU+0?#DEC:W$-\=<:R2.UN$MO,A0JJR-(Q>
M;]V4614D9:\!_8I^+O\ P4._:K_8SUKXT^&V_::\0^*WU36M*^$OBK1O$G@B
M+3--ATNZGL+4:E9WFI6C:E<236K/>R75JI<R.+=8D$;$ _7"BOSK_:5_;-_;
MX?Q3^R;^RGXF^#/BGPIXZ^+'AW5]<^-&B_#35M";5HCI%I;F?3=,N]0O4LHT
MFN+@.\J3M/';KB-MY+#U[]BO4OV\M!_:K\6>!/B;\&OB-8_ R\\'V^H^$=9^
M+'B7P[?ZSHVNI<"*XTM9-+U*[GN[26%EN$FN27C>.6,OM,8H ^MJ*\C_ &YO
M$6I^%OV9=>U?2_VBK;X5$7>G177C:;3/MDUK;/?0)/!:P\E[RXB9[:W"J[^?
M/%L1VVJ?'O\ @GI\>O'_ (J_:Z_:*_9EUR;QBWACX?-X2U7P;#X_NOM&JVMO
MJ^GW#RQ/*\DDS1&6S,R)<,9X_M#(P0*L: 'U[17PEJ]I^T=\4?\ @M7XR_9J
MU/\ :U\<V?PJL_@'I'BR3PMH]U;6$L6H7&KWUHD$%U;01S10;+8R,VXSLRHO
MG>7OC;SOPY^W)^U%XA\#Z#^R+!\7[^V\2:A^V?K_ ,&KKXJ2V-J=23P]IL%S
MJBSC,7V?^TI;*.*S68Q$;R\VPN* /L/Q9^V4_A/]O3P;^P]>_![5%_X3+P3J
M_B*P\9RZG;BU9=/>T26!($+2LV;N,%I!$!@[0XYKOOV@_CM\.?V8?@=XL_:'
M^+NJR67AGP7H%SJ^MW$,)DD6W@C+L$0<N[8VJH^\S =Z^']1^#_BGX/?\%\_
M@KIDWQQ\2^*?#E]\!O&4^BZ/XMU%;Z[T>X%WI:W)2Z91/)#,!;LJ2L^QXY=A
M"L$7[3_:C\"?!3XI_L\^,/A=^T=##)X&\3:'-I/B99Y&C7[+<CR#\Z?-&<N"
M)!@H<-D8R #P^;]O[]I[PEH_@KQ]\6/^">>LZ3X3\>^+_#NAZ=J>C_$"PU*[
MT0:QJ-K96]SJMJJ1BW13=(6^S27>&PI(!,B^V_M"_M!6?[/.E>&-5O?A+XZ\
M7#Q1XVT[PVD'@/PZ=2DTQ[QV47]XH=?(L8MN99^=@9?E)(%?FWXPU7_@H)_P
M0(\-Z,WQ<\96W[27['>EZ_I>GG4/$<"IXP^'5N]Y#%92,^/+OX()F@"'&_>L
M:H+90M?6/_!7#XD?&/X2> O@]XR^$'QCUSPN;S]HKP/H6OV&E);>5K.G7^M6
MT$]O.TD+RJI0D?NI(\AF#;@<  ^LZ*_-_P#X+"?%'XT?L*_&[P%^T7X'^/>O
MW'A'XFRWW@.]^'FK_$&;3].TCQ#?0-_9GB)'#"6.S@E!6[16,<4<B2)'N&#]
MO_LQ_!+Q!\ O@]H_P^\:?&CQ3\0M>MK.,:[XP\6ZBTUSJ=T%'F2B//EVZ%L[
M8HP JXR6;+L >'ZK_P %0[;X<?\ !47P[_P3(^.WPAL_#FH>._!UQK_P]\8Z
M?XN%[;:OY3RC[)+ ]K"]M.4M[EL;G4F-55F+C'T'\?/C=\/_ -FOX)>+/V@?
MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
M '>@#Q+2OV'-!T?]LO7?VW[3X]>/CXH\0>$(?#%WI$C:2=,BTR&XFN+>&./^
MS_-!BFN)75S*SG=ARXXKB/"W_!)/X$Z#X3\9^$M>^+?Q$\0+XR^*LGQ*74=4
MU+3X+S0O%C/&PU73I[*R@>WD7RE41DO#L+HT;+(ZM?\ @U_P6!_X)[?'OX]6
M'[-GPX^.SR^*-<CF?PJNI^&=2L++Q(L(S*VF7MS;QV]^% )!AD<.OS)O7FO9
MOCA\??A9^SKX3MO&'Q5\02VD&H:K!I>CV5CIT][>ZI?S$B&TM+6W1YKF9]K$
M)&C$*CN<*C, #Q;0/^"6OPNMOVP_#O[=WC[]H/XL^,?B/X:T*?1K/4M;\26E
MK:RV$CHXMGM--M+6 1JZLVU$02&5S-YOR[?:?VA/@5X#_:;^"GB7X ?%!+U_
M#OBW2WT[6H].O&MYI+9\;T25?FC)'&Y<,,Y!!P0GP.^/_P +/VBO"UWXL^%>
MOS74>F:M/I6M6%_IT]E?:5?P[?-M+NUN$2:VF4,C;)$4E'1URCJQ\8^,O_!8
M?_@GA^S_ /&H_ CXM?'LZ3JL.L1:1J.KMX;U&71-,U&0*4L[K58[=K*VFPPW
M)),#'_RTV4 /U3_@F-X$\;_V/X:^-G[37Q@^(G@C0M4L]1L?AQXU\2V=SI,U
MQ:2K-:M=R16<=[J"QS)'*$N[F9&>-"ZOBNR_;*_8M\*_MK>'?#'A7QM\6_&?
MAFS\*>,=-\4:>GA"73XVFU*PG6XM))6N[.X)6.5%?8NU6(PP8<5Z!\7?C!\,
MO@-\,]7^,?Q?\96>@^&="M/M&J:M>,?+B0L%4 *"SNSLJ(B!G=W55#,P!\M_
M9&_X*5?L<_MP>*?$/@#]G[XFW=QXF\*QQS:]X4\1>&K_ $75+6WD($=Q]DU"
M"&5H6RN)%4J-ZABI8"@#C/CK_P $G_AY^TMXI\6^*_C=^T]\5M??Q=\-+[P)
M/8WDN@_9=,TB\>)[K[%$-)"V]Q*T,9:X&9#Y<?S?NX]GN7[.GP5N/V>/A#H_
MP??XO^+_ !O;Z':QVMAK?CFZM)]1^SQQJD<4DUM;P";:J_ZR16D8DEG8UW%%
M 'CND?L?6^D?M>ZE^V,/VA?B#<:OJOAJ#P_<^%IY-*_L8:=#<S7,,"Q+8"<%
M);B8B3SO,(<AG8  <%\&_P#@DM^S%^S?\#/BI\ _V<=8\3^!=-^+_B34]7\4
M:GH5Q9->VXO8VC>RM'N+65(+:-&98DV,T>YB'W,6/T_10!\=?LS_ /!%_P"#
MO['GA[3=(_9P_:A^,/AF]TSPVOAU=<M]1T2:ZNM(2XN+F&SN%FTIX)_)FNIV
MBG>(W$2R-&DJQG97L%C^PY\(O"W[(^I?L9?"_6_$'A+PUK&FZA::IJVDWL-Q
MJMVU^96OKF6XOH;CS;B=YY9'F=6;<Y(*X&-_]J;]J_X%_L8?"*]^.G[17BVX
MT3PSI\L45U?V^CW5Z4>1UCC!2VBD90SLB;B H+J"1FO1J /E[QI_P2P^'7CG
M]D/P!^Q3J?[2'Q1@\(_#>XT67P_<VEQHJW[KI#6[Z;'-*VF%76!K6)AA%9R#
MYC2# '8:G^P9\/-3_:RTC]LS_A:OCVU\767@ZS\-:[#IVMPVUCXFM+2YDNK9
MK^"*!=SQSS2/^Y,*,',;H\9*5A_M6?\ !6+]A']BOQT?AW^T)\8+S3=1MH8)
M];;2_">IZI;Z%#/Q#)J$]E;RQ6(DX*B9E8JP8#;\U>]:-XT\'^(O!MK\1-!\
M4Z=>:!?:8FHV>MVUXCVD]F\8E2X64'8T1C(<.#M*G.<4 >+? _\ 8(TSX >,
M/BGX\\$_M-?$J;5?BYK0UCQ)=:E_8<GV;41!#;K<VJKIBK&P@MXX@CAX]HR4
M+?-7(_LU?\$I?!_[)'A;PWX/^!?[77QDTNS\*^%Y/#VF)/?:%<!M/:[FNUCE
M272625TFGD*2LID0,5#;68-Z5\%/V[OV9OV@?%]CX(^&_C+47O=;TB75O"LF
MK^&;_3K?Q)IT3(LEYID]W#''J$*F2,EX&<;)(Y/]7+&[+^UI^W9^S1^Q+I.F
M:A\?O&5_:W6MF<Z-HF@>'+[6-2O4A"F>6.TL899O*B#IOE*B--Z!F!=00#K?
MV>_@)\,/V7?@KX<_9^^#&@'3/#'A735LM)LWG:5U0$LSN[$EW=V9V8]68GO6
M5^UE^S;HW[7?P \3?LX>*OB/XG\,Z%XPTFXTKQ#=>$I;..[NK"XB>&>VWW5M
M.J))&[*S(H?!X8<YM_LT_M._ 7]L+X.:5\?OV:_B78>+/"6M*_V'5K .OSHQ
M5XI(Y%62&56!#1R*KJ>H%:GCCXR?#OX<^-/!GP\\7>(%MM8^(&MW&D^%+$1L
MSWES!I]UJ,H^4'8JVUG.Q=L+D(N=SJ" ?//PN_X):ZU\%?AEH'P;^%__  4F
M_:,TCPUX6T6VTC0-*@U/PRRV=E;Q+%#"K/H3.0J*J@L2>.236C^R]_P2Y\ ?
MLF?%C5_C+\/?VE/BIJ6L:]X0L_#VL'Q)?:1=K=PVOVEX+B1AIJR/<B>[N;AI
M2Y,LLK&0.IVU].T4 ?*W@O\ X)(_ OPCX"UOP->?&#XC:S+J?Q7N_B7I7B#4
M=2TZ+4O#WBJYF>:?4K":TL80A=I90T,JRPLDLD;1E'93H^!/^"7?PJ\*_MEV
MG[?'BOX\_%7Q?\2[;PL_AV35-?\ $MM!;3Z:9DG6V:TT^UMH%C21 XCC1$=F
M9I%D9BU?3%% 'S]X1_X)Y^"/A7=ZWI7P'^//Q)^'_A#Q'K]SK.K_  _\*:I8
M)I9N[J0RW;6TEQ92WFG+-(S.R6=S JN[-&(V8FNK^-W['_PT^-&J^#/&5MKF
MN^$/%GP[:<>"/&7A&ZACO]*AGB6&XM@+F*>"XMY8XXP\,\4J$Q1OM#QHR^K4
M4 ?.G[-/_!,_X._LR?M,^./VN]#^*_Q)\3>.OB/9V</C+4?%GBE98-1>U61(
M96MK>&&%2D<AC2-4$4:A1'&F*^BZ** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "OSQUA+R3_@Z;A33YHXIS^P,XAEFB,B(__"8O
MM+*&4L <9 89Z9'6ON?XV>!/$WQ0^#OBGX;^"_B5J7@W6->\/WEAI7BW1XU>
MZT:XEA9([R)6X9XV8. <9*XR.H^?_P!FW]A7XN>'OVU;C]OK]J'XDZ!KOCR+
MX):;\,K!/"UA+!:S6<%_)J%UJ,HF)*S7%PT9$*Y6%8R-\F[*@&'\$/VWOVE?
MBG^QI^T'\8-3B\#6OC+X-?$3QUX<TN>#P]>'3-1BT"25(I9;8WWFHTWE_-MG
MPN[C..>(\9_\%)_VU)_"'[%.L_"GX5_#F[N?VH-"L&\2'5'O@-(O;CP\VJ2S
M6\:2#_1H#F0H\CO*D;1 QLPF'8^-?^"=G[0ND> OC[\!/@!\;_#.B>"OCYK^
MMZ]?:CJNB3RZOX=O-7M%AU&&V*2"&9)I5:6.5PK6YN'^2?:HKG]#_P""<O[7
M?@W3/V0M"M/B5\.=>B_9;LQ#-=S6E_IC^(4_L)]%2$1C[2+=D@<R&?<XE?&(
M85&T@&Q\0?\ @I_XE_8YU+X_>$/VRK+0M;O?@Q\+],^(&E:QX'TF?3(O$6F7
MTEW:I:?9;FYNC;7"7MIY._SW1Q<1OA-K+7$V_P#P5@^-?P]T3X;?$_XE:S\,
M/&>G^,M?TS3O&GP]^'&AZF-;\&17[*BW2W4ES,FK):NZ+<!;:U)3?(G";#V7
M[0'_  3*\>?M5_M7?%KQY\;;GPL_PT^*_P $(/AG>Z1I>J7*ZO86]O?7=Y!J
MD<CVQA:?S;HD0D;4*(?,?:5?V+X(?#?]NCP9H7A;X:?%'XU>!-6TKPW#;V^I
M^,-,\.W,>K^(H+<*JA[>65[>REE"CSI%:<$-)Y:0ED>, ]SKXV_X+::E\2K?
M]@;X@?"_P5\&9+OP;XH\/7-I\2?'-J\$H\(:'.Y_M+54TX,)]0EA@::?RXL'
M(+Y)4JWV37@?[4?P'_:J_: ^%?C/]G'1/BWX4TCPQX[L+S2[[Q9)HTSZQI6E
M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\7V8G0AXM",<=GH46#RH_LJULYF3@"6YF/5B2 ?0U[=P:?9RW]TY6*")I)&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!TGPUL_&3?#G0&@UBT5#HEKL5K
M<D@>2N!UK;^Q>-_^@W9?^ Q_QJ+X7?\ ),_#O_8"M/\ T2E;M &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XUD>/;/QF/ NM&;6;,H-)N=X%L02/
M*;-=?6/\0_\ D0-<_P"P/<_^BFK6C_&CZHQQ'^[S]'^1^;]%%%?LY_-H4444
M %%%% !1110 4444 %%%% !1110!^C=G9>-OLD6-;L\>6O\ R['T^M2_8O&_
M_0;LO_ 8_P"-:EE_QYQ?]<E_E4E?BCW/Z6C\*,?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QK8HI%&/\ 8O&__0;LO_ 8_P"-<_\ %/XDZ;\#_A]JOQ7^
M+_Q2T#PWX;T2V\_5=:U<B&WMDR%&YF/5F9551RS,J@$D ]Q7S5_P5<_9'^-/
M[8O[*D7@[]F[QYIF@?$+PCXUT3QGX)FUZ(OIMWJ>E7:74%M>* 2879/0@,$)
M! (H K?L[_\ !3G]FG]IGXBO\(/ 7QMLK3Q;+KMYIVD>%O$&B7.G:EJJ6T#7
M$MW!:W*)*UN(T<F0J I #8+H&]%^,G[2_@3X"ZWI7A/XC_$J)=<UR":?1_#>
MA^&K[5]5O((=OG7$=C8137#0Q[TWS"/RTWKN89&?@?\ X)K_ /!0'X7?&+]K
M6#]E[_@H-\$[_P"$7[3&@_%/7_$/A;2[F-)M(U6ZGTR2RO;?3=17>LZ^4\DC
M0[ADI#AY3&17O^L>)-&_93_X*V_$/X^_M,WITGP9\1/@YX<TKP!X]U.)AIFE
M3Z;>:E)J&CRW.-EK+.UW;7,:.5$^Q@A=XRH /IGX5_$O2_CCX!T[XI?"#XI:
M#XC\/:M&SZ?J^DXEAFVN4=<@\,CJR,APR.K*P# @>?\ A3]NS]GKQK\6K3X(
M>'OVA-&D\0ZG=W-KHD=QHUW!::Q<6X)G@L+V6);:_EC"L6CMY9&4(Q( 4X\5
M_P""''C_ $GXS>#?VC?C?X#L[N#P)XQ_:F\47_@1+NT> 7%F+>P@N+I(Y K1
MK->Q7DA1@"'9]P#%A5;_ (*>ZC+>_$W]G;]GO5_A)>> ?AGH?QX\*:J/B[<"
MS&D6=S8.)-/T>S@M)9+BUDNIREB)KF&VMXU9T#R&2-6 /=_VN/VY/@!^PEH&
MB^)OVL?V@M%\'V?B*^DL]$>ZTBZN7NYHX_,=4CMHY'^5>2Q&!D<Y(KG?V3_^
M"G/[(W[<?CS4?AE^RM^TSI7BW7-)T@ZGJ-C;^&-1MO(M!*D7F,]S!&G+R* N
M[<>2 0K$>_7_ ,/O!>J>.]-^)VI>'+:?7]&TV[L-*U.52TEI;7+P/<1QY.%\
MQK:#<0,GRE&<#%>%?L4_\7G^-/QB_;-NOWMIXA\4#P3X&F/(&@>'Y9[5Y$/I
M-JTNL2AAP\7V<Y8!30![M]B\;_\ 0;LO_ 8_XUX]X<_;M_9[\6>/;/X=Z!^T
M!I,]WJ>NS:'H^IG0[Q-)U/582XET^TU-XA975VICD4V\4SRAHW&W*D#V;QH-
M,;P=JRZUKQTJS.F3_:]4%P(39Q>6VZ;S&X38,MN/ QFOQ[\(>+_&.K?\$K?V
M>/V5O&/P@U'PM\)-'^*/A2SA_:>D6&+1+K2-.UN&YTS6+6T#G4K.74Y(;:$3
M75M#;QM>M(9W1D+@'Z__ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &79VGBU+I'OM6M7B#?O$
M2W()'L:U*** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_
M;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5
MI_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Q_B'_ ,B!KG_8'N?_ $4U;%8_
MQ#_Y$#7/^P/<_P#HIJUH_P :/JC'$?[O/T?Y'YOT445^SG\VA1110 4444 %
M%%% !1110 4444 %%%% 'Z:67_'G%_UR7^525'9?\><7_7)?Y5)7XH]S^EH_
M"@HHHI%!7DG[7_PI_:$^*7A?PI<?LR?$K0?"WBCPQXWM=;6_\2:?-=V=Q;1P
M7,4UI)#"Z.ZSI,8B0ZE%=G!+(JMZW10!^??PY_X)^?M7_M%?M*^%_BS^V3X<
M^'_A+0/A5\<-5\>^'K7PAJ5WJ6HZYJ4MHEO#BXN+>W%I8 XE9 LDDS0HK; F
MX_5O[3WP\_:6^,>@2_"?X,_%#3/A[HVLVGDZ]X\LQ)=:]:0L666'3K=D6"WF
M9,;+R227RBQ(MV*JU>KT4 <;\!_@'\+_ -F7X)>'_P!GSX'>'$T'PQX7TI;'
M1K. [VB49)D9GR9)7=FD>1\L[NS,26)/B/[4?[+W[3O[:?A'0OV>/C'=>!=#
M\ VWC+1M:\8:]X>U6\N-2\00Z7?PW\%I#92VT<>G":XMH&>3[5<F-%9%#EA(
MOU!10!S/QHL/BCJOP@\4Z5\$-3TRR\977AZ\A\*7VM.ZV=MJ+0NMO+-Y:.WE
MI*49@JDD*0!S57]GSX+>%OV<?@7X0^ G@II'TOP=X<L](LYIN9)U@A6,S2'J
MTCE2[L22S,Q)).:["B@#R'P]\)_CU\3?!'Q<^%/[7'BGPMJGAOQCJ^JZ=X.C
M\&6=Q:W%GX7NK801P7;S,P>\&^;=)&-G((_NK\\Z_P#\$^?VO?BC^Q+X:_X)
MC?%CQ?\ #T?#31;/1=#UOXC:1>WO]NZWH&ES6[PVZZ6]J+>QNIX[6&&2X%Y.
MB9D=(LLJI]R44 %%%% !1110 4444 %%%% !1110 5Y?\?6_:K\4NG@#]F6Z
M\->%FFBW:I\0?%U@^HQV /2.STZ*6(W<^.2\TT4,>Y,"X.^-/4** /C^Z_X)
M?_M"^)[G_A(?'G_!9/\ ::DUEB69_#-UX:TG3PW;;91Z.ZA1_=+'CJ>]=[\'
M_AY^WC^SSK-OI?Q!_: L?CIX-E<1SW>L^&K;1?%&EKT$HDL]MEJ2#C=&8;64
M*&99)GVQ-Q?[37_!2KQ_\ /AAKOC'2OV<K/7=9U;XH+\//@EX;M?&7^F>-]<
M-T]JYD0VH73[>*2*Y9W+R'9:R-A5*,WM/[*WQ=^+'Q4\':QIGQ\^'NB>&/'/
MA+7O[&\5:7X9\0/J>F_:&L[6]CDMKB2&"1D:WO8"5DB1D<NOSA5D< ].KRC]
MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?
MXA_\B!KG_8'N?_135L5C_$/_ )$#7/\ L#W/_HIJUH_QH^J,<1_N\_1_D?F_
M1117[.?S:%%%% !1110 4444 %%%% !1110 4444 ?II9?\ 'G%_UR7^525'
M9?\ 'G%_UR7^525^*/<_I:/PH*^=/&'[?G_"*>+=4\+?\*G^T?V;J,]KY_\
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M^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444
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M/[1'Q\\(?$36=&^(@L['5O ND#3],L[(:'I#Q6<5J)91;[#([%-[9,A;C=@
M'T77E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_D
MF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 55UW_ ) =Y_UZ2?\ H)JU577?^0'>?]>DG_H)K.M_"EZ,#Y]HHHK\; **
M** "BBB@ HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 K\
MZOC!_P E:\4_]C'??^CWK]%:_.KXP?\ )6O%/_8QWW_H]Z^QX0_WBKZ+\S\[
M\0_]TH?XG^2.<K@_C5^SWX1^.5YX>U7Q!XC\0Z3J'A:_EO="U+PWJ[6<]M<2
M1-"7W*#O'ENZE'#1L'(96%=Y17W4X1J1Y9*Z/RZG4J4I\T'9GB7[/'[%7AOX
M->)+?XB^-?B#K_C?Q1IXU.'1=4\07$7EZ5;7MX]Q,MM!!%%%')+F/S9=I=BN
M 53"#U_Q1X>L?%OAG4?"FIO(MMJ=C-:7#0L X21"C%200#ACC(-7J*BG1ITH
M<D5H:5L36KU?:3=W^771=#SVP_9TT#0/V9[#]EWP=X\\3Z%I6F>%[;0;'7M)
MOXH]5@MH8DB#),8BBRLB8+A 1N)7:<$>9?#?_@FSX5^&MQH-K9?M6?&W4M#\
M/7%M):>$]4\;Q-I<T<#*T=O+!%;)OARJ@QY"L!@Y!(/T?142PN'FTW';1>AI
M#'8NG&2C+XG=[:ON>-?M'_L9:/\ M)^.= \>:M\?_B7X4N/#4$BZ1:^"=?@L
MH89I ZR7/S6\CF9HW,>[=PF54#>^[<_9\_9KT_\ 9_;5[L_&+Q]XVOM8,"S:
MGX_\1#4)X(HM^R&$B-%C3,CL0!DELDG QZ3136'HJK[1+WOZ1,L9B94%1<O=
M733O?\]3D_@O\(-'^"'@QO!&A^*O$.L0-J=U>F\\3:P]]<AYYFE9!(_/EJ6(
M5>P'<Y)P+3]F;1[3]IBY_:F'Q-\42:W=>'$T&32Y&L?L T]+A[A(0@M1*-LL
MCMO\S>=V"Q'%>ET5?L:?+%6T6Q"Q%92E*^LM_.X4445H8A7WS^RU_P F_P#A
MC_KP/_HQZ^!J^^?V6O\ DW_PQ_UX'_T8]?*<7?[C#_%^C/O/#[_D:5?\'_MT
M3OZ***_/C]<"BBB@ HHHH *^+_\ @L!X5_9D\4M\)+7]H[_@G/XY_:)8>)M2
M'AK1?!FC6%ZMG<G3I#(ETEY<P#RY(E>5=I/SV2DD;0&^T*\^_:"^&_QN^)-I
MX1A^"'[0S_#N71?'6G:MXFF3PO;:I_;^C0E_M6CD3D?91<!E'VE,R1[/E!W&
M@#\PO^%*?\$[?^E4_P"+_P#X;OP]_P#+>OL?_@C_ *#\+O#7PG^)>D?![]BK
MQ!\ -#C^*\AA^'7B6PBM;F!SH>CE[CRH)98D64_,!'(P/).&+ >1?MG>-_C!
M\$/C_P"*I?BW_P '&?A?X$:/JVK)=^!OAWJ?@OP;/=V6EM;09WF^M_M,@^T_
M:0KMN'EB/+EMV/8O^"17C:+X@_"[XF>)H/VZK7]HM)/BO(B_$VRT>RL8;G;H
M>CC[,L5BJVV(ONYB !.<_-NH ^LJ\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_
M'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "JNN_\@.\_P"O23_T$U:JKKO_ " [S_KT
MD_\ 036=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110!]%0_
MZI?]T4ZFP_ZI?]T4ZOV=; %?G5\8/^2M>*?^QCOO_1[U^BM?G5\8/^2M>*?^
MQCOO_1[U]CPA_O%7T7YGYWXA_P"Z4/\ $_R1SE%%%?>'Y6%%%% !1110 444
M4 %%%% !1110 5]\_LM?\F_^&/\ KP/_ *,>O@:OOG]EK_DW_P ,?]>!_P#1
MCU\IQ=_N,/\ %^C/O/#[_D:5?\'_ +=$[^BBBOSX_7 HHHH **** "BBB@#\
MY]<_:3^#?[./[67Q=\!W7_!-OXC_ !\O;[Q>VJ:Q\3?A;\)H]<-O<SP0L-%U
M"YN_)0SVD(AC18)9E2 P*XBD#I7TA_P3I^+_ (*^-GA+XB>,/!'[)7BGX-0Q
M_$AK:\\+>-/#*:/J5S.NC:4?MDUK&[I'O1HT4JQ#)$K'#,PKQ^P\,_\ !:OX
M;?M(?%JP_9I^&W[/,GPIO?'$FH>%[?XD^*=;M-1FEN;:"XNKF%[*RG00//+)
MN23++.MQM81F-5]]_8EU']LS4_#_ (YF_;@\'^"]%\4)X[9-(@^']U<W&E3:
M6-+T[RY8I[J**:8F8W 9GC4AE9 -J"@#VNO*/VY_^31_'O\ V 7_ /0UKU>O
M*/VY_P#DT?Q[_P!@%_\ T-: .D^&OB+58OASH$2>%+MPNB6H#JRX8>2O-;?_
M  DNK_\ 0H7O_?2U%\+O^29^'?\ L!6G_HE*W: ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6JVL>(M5DTBZC?PG>(&MG!8LN!\IYKH:JZ[_R [S_KTD_]!-9UOX4O1@?/
MM%%%?C8!1110 4444 %%%% !1110 4444 %%%% 'N47B75A&H_X1"\^Z/XEI
MW_"2ZO\ ]"A>_P#?2UK0_P"J7_=%.K]G6P&/_P )+J__ $*%[_WTM?G_ /%B
M1YOBGXEFDB,;-X@O"R-U4F=^#7Z,5^=7Q@_Y*UXI_P"QCOO_ $>]?8\(?[Q5
M]%^9^=^(?^Z4/\3_ "1SE%%%?>'Y6%%%% !1110 4444 %%%% !1110 5]R_
MLSZ]J5K\"?#=O#X9NIE6Q($J,N&_>/TS7PU7WS^RU_R;_P"&/^O _P#HQZ^4
MXN_W&'^+]&?>>'W_ "-*O^#_ -NB=79Z]J5S=)!-X9NH59L-*[+A?<UJ445^
M?'ZX%%%% !1110 4444 ><_&K]L+]DG]FR_M]*_:*_:D^'/@&ZNXO-M+;QKX
MWL-*DF3)&Y%NID++D$9'&0:L?L_?M0? +]JO0M:\6_LY_%?0O&NAZ%KQT>ZU
M_P ,ZM!?6$UVMK;W+K#<0.\<H5+J,,5/#AE/*FO@-_V@/V9/A[^V/\=? 7QF
M_P""2'Q9^+>O6WQ!>:Z^*^A?L^CQ)%>1RV=K+!I\ERZLR?9K>2!(HXRT9@,,
MAV/(Z#ZK_P"";'Q(^"_Q/\%?$77/@;^RGXA^#NFVWQ+>UO\ PKXH\%_\(]>3
M7:Z-I3-=M88'D!T:)5./WBQB3^.@#Z/KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]
MN?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?
M^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JNN_P#(#O/^O23_ -!-6JJZ[_R
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M5_AGG$\Z<[)5W-D ]\KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
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MANHKA[20NC P3B(PRJ "T4LBAE)##LZ "BBB@ HHHH *JZ[_ ,@.\_Z])/\
MT$U:JKKO_(#O/^O23_T$UG6_A2]&!\^T445^-@%%%% !1110 4444 %%%% !
M1110 4444 ?14/\ JE_W13J;#_JE_P!T4ZOV=; %?G5\8/\ DK7BG_L8[[_T
M>]?HK7RYXX^#OPXU'QKK&H7GAW?-/JEQ)*_VR8;F:1B3@/@<FN[!\48#AB3J
M8J,I*>BY4GMKK>43Y3BK(\7GE"G"A**<6V^9M;KR3/FJBOH'_A2/PO\ ^A8_
M\G9__BZ/^%(_"_\ Z%C_ ,G9_P#XNO0_XBSPY_SZJ_\ @,/_ )8?%_\ $/\
M.?\ GY3^^7_R!\_45] _\*1^%_\ T+'_ ).S_P#Q='_"D?A?_P!"Q_Y.S_\
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M17T#_P *1^%__0L?^3L__P 71_PI'X7_ /0L?^3L_P#\71_Q%GAS_GU5_P#
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MZ M>KD=.G6S6E":33OH]5LSP>)ZU;#Y%6J4I.,DE9IV:]Y=4>1?\-D?M(?\
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M3?\ /NI]T?\ Y,^ZJ*^%?^&R/VD/^BC?^4BS_P#C-'_#9'[2'_11O_*19_\
MQFC_ %2S+^>'WO\ ^1#_ (B!DW_/NI]T?_DS[JHKX5_X;(_:0_Z*-_Y2+/\
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M&#Q]^TG^SCKG@+X@>+/BM8>([+Q?\0]+\-:[X+BT&&&WM%U"0Q))I\Z@7#/
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MY$;3?^N'_LQKP^O</AM_R(VF_P#7#_V8U]3PG_OT_P##^J W****^_ ****
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ME_C?Y1/Q[C__ )'4/^O:_P#2I!7Q_P#\%&/#7[)'[3'AOQY\&OBQINFIX_\
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M7[-EH2TGQ+\1Q:=JR*?NZ) IN]3+>B26\)M<_P!Z\3UKTKQ[X^\#_"GP9?\
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M_P /ZL_6?#[_ )%U;_'^B*?_  F/AC_H-0?]]55UGQ;X;ET>[BCUB$LUM(%
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MLHH_XC!_U _^5?\ [F'_ !#K_J*_\D_^W/E.BOJRBC_B,'_4#_Y5_P#N8?\
M$.O^HK_R3_[<^4Z*^K**/^(P?]0/_E7_ .YA_P 0Z_ZBO_)/_MSY3HKZLHH_
MXC!_U _^5?\ [F'_ !#K_J*_\D_^W/E.O<?V ?\ DM=[_P!BY/\ ^CH*[NNS
M^!O_ ".$W_8/?_T-*'XG_P!K_P"Q_5.7VFE_:7M\N17^]';EO W]GX^GB?K'
M-R.]N2U_GS/\CUFBBBI/OSRW]L__ )-TUW_KK:?^E45?#-?<W[9__)NFN_\
M76T_]*HJ^&:_1.$O^1;+_&_RB?CW'_\ R.H?]>U_Z5(****^H/B HHHH ***
M* "BBB@ HHHH **** .V_9O_ .2[>%?^PQ%_.OT"K\_?V;_^2[>%?^PQ%_.O
MT"KX#B__ 'RG_A_5GZSX??\ (NK?X_T055UW_D!WG_7I)_Z":M55UW_D!WG_
M %Z2?^@FOCJW\*7HS[\^?:***_&P"BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "NS^!O_(X3?\ 8/?_ -#2N,KL_@;_ ,CA-_V#W_\
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M%'_$6>(_^?5+_P !G_\ + _XA_DW_/RI]\?_ ) ^?O\ A2/Q0_Z%C_R=@_\
MBZ/^%(_%#_H6/_)V#_XNOH&BC_B+/$?_ #ZI?^ S_P#E@?\ $/\ )O\ GY4^
M^/\ \@?/W_"D?BA_T+'_ ).P?_%T?\*1^*'_ $+'_D[!_P#%U] T4?\ $6>(
M_P#GU2_\!G_\L#_B'^3?\_*GWQ_^0/G[_A2/Q0_Z%C_R=@_^+H_X4C\4/^A8
M_P#)V#_XNOH&BC_B+/$?_/JE_P" S_\ E@?\0_R;_GY4^^/_ ,@?/W_"D?BA
M_P!"Q_Y.P?\ Q='_  I'XH?]"Q_Y.P?_ !=?0-%'_$6>(_\ GU2_\!G_ /+
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M* "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
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MZ3<W7ABT<HS1/'M;=&=RCS"P4\*ZJXY4&NR^(_PE^%?QB\,_\(5\7?AGX?\
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MVJ>,+F:2X1X+.6XRD45ND +^4IG=G8JR+$Q/WU7PA_P5<\(?L-_M>^$_B5\
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MHH **** "BBB@ HHHH **** /HJ'_5+_ +HIU-A_U2_[HIU?LZV *\#\5_\
M(TZE_P!A";_T,U[Y7@?BO_D:=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444
M %%%% !1110 4444 %%%% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\
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MBN%_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\ QJC_ %0_Z?\
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M-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU1_JA_T_P#_ "7_ .V
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M[$A_U2_[HIU?'/\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\
MC5?9K1 ?8U>!^*_^1IU+_L(3?^AFO-?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0
MOV3?^BC?%/\ \+8__&J\G-\J_M6G&//R\KOM?]4!W5%<+_PY"_9-_P"BC?%/
M_P +8_\ QJC_ (<A?LF_]%&^*?\ X6Q_^-5X7^J'_3__ ,E_^V [JBN%_P"'
M(7[)O_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JC_5#_ *?_ /DO_P!L
M!W5%<+_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU1_JA_T
M_P#_ "7_ .V [JBOG?\ 9/\ ^"37[.7QC^&]_P"*?%7CWXC17-OXGU&PC6P\
M7M&ABAF*(2#&?FP.3GFO3O\ AR%^R;_T4;XI_P#A;'_XU1_JA_T__P#)?_M@
M.ZHKA?\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :H_U0_P"G
M_P#Y+_\ ; =U17"_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\ A;'_
M .-4?ZH?]/\ _P E_P#M@.ZKW#X;?\B-IO\ UP_]F-?*O_#D+]DW_HHWQ3_\
M+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5>IE.1?V77E4]IS75MK=4^[[ ?8U
M%?+?PE_X)'?LU_!KXEZ)\5/"_CKXBW&HZ#J"7EG!J7BXRV[R(<@2)Y8WKZC/
M-?4E?0 %%%% !1110 4444 %%%% !1110 4444 %%%% !17)_&SX[?!K]F_X
M>7GQ8^//Q,T;PEX<L61+G5]=OD@A$CG"1J6.7D<_*L:Y9B<*">*X7X-_\%!_
MV/\ X\?$2#X0_#WXPQIXKO+%[W3O#/B/1+[1=0U"V3EYK6WU&""2ZC4<L\2N
MJCDD"@#V:BO!/VE_^"HG_!/_ /8[^(ME\)OVEOVI/#?A/Q#?10RC3K]I7-K%
M*Q6*2Z>)'2SC<@[7G:-6P2"0#7NNFZEIVLZ=;ZOI%_#=VEW"DUK=6THDCFC8
M!E=&4D,I!!!'!!S0!PGASX,ZGHG[27B3XXRZU ]IKGAZSTZ*Q6-A)$T+$ER>
MA!S7H-<5\7OVB_@A\!-4\(Z+\8OB3IWA^Z\>^*K?PWX/@OW8-JFJSAC#:QX!
M^=MAQG S@9RP!YO]K#]NG]DK]AOP[IWBC]JOXWZ5X/MM7EECTJ*[CFGN;PQ*
M&E:*WMTDFD2-64NZH50,NXC<,@'K-%<O\%OC9\)/VC/ACI'QH^!7Q$TKQ7X5
MUZW,^DZ[HMVLUO<H&*MAAT965E93AE965@""*\ET[_@JM_P3OU7]I5?V0;#]
MK/PI)\0Y-4DTN#0?/D"37Z':]E'<E!;R7*M\A@60R!_D*[N* /H*BBB@ HHH
MH **** "BBB@ HHJ'4=1T_2-/GU;5KZ&UM;6%IKFYN)0D<,:@LSLS8"J "23
MP * )J*^<]-_X*U_\$[-5O[2&U_:>TE-.U#4AI^G^*[G3;V'P_=W1<HL4.L2
M0+82L7!4;)SN/ R:[_\ :B_;*_9A_8L\$6OQ$_:?^,6E^$M*O[O[+ISWBR33
MWLVTN8X+>!'FG8("S"-&VJ"3@<T >FUY]\8_@SJ?Q-\>^ /%]CK4%K'X.\0O
MJ-S#-&Q:X4Q%-BD=#DYYJY^SY^T;\"_VKOA5IWQN_9R^*6D>,/"FJ[A9:UHM
MSYD3,IVO&PX:.13PT;A64\$"M;XJ_%/X>_ _X:Z[\8?BQXJM=#\,^&=*FU+7
M=8O"?*L[6%"\DC;020%!X )/0 DXH WZ*X3Q/^T[^S[X*_9]3]JOQ=\7=$TW
MX=2:%;:S%XOO;P1V<EC<(CV\RL?O>:)(PB@%G,BJH+,!7/?LG?MX_LA_MS:-
MJ^M_LI_'72/&">'[M;;7;6T66"[TZ1MVP3VUPD<T0;:^UF0!MC;2=IP >N45
M@?%/XH> O@G\.-<^+GQ2\2PZ/X<\.:9-J&M:G<(S+;6\2EG?:@+,<#A5!9C@
M $D"M^@ HHHH **** "BBB@ HHJ#4]0M])TVXU6ZCG>*U@>61+6UDGE95!)"
M1QJSR-@<*H+,> "2!0!/17C'[-?_  4&_9(_:\^('BSX6?L\_$^YU_Q!X$G6
M#QGIC^%M3LGT2=GD18;DW5M$(92T,P$;$.?*? ^5L1_&+_@H;^R;\!OC)_PS
MY\2_'>M6_C,Z*FL)H&E^ M:U*:2P9S&+I#9V<JO%YBLA=20'4J<,"* /:Z*^
M58?^"V'_  35N?!NL?$:W^/>JR>'O#UW-:Z_KR?#7Q$;+39X2!-%<3C3]D+H
M6 97(*Y&0,U9T3_@L[_P36U[P78_$VW_ &CVM?">HL%L_&.K>#=9L=%?]YY>
M?[0N;-+95W@J6,@ (()X- 'N'[07PSOOC+\%_$7POTS4XK*XUO3FMHKJ="R1
MDD') Y(XKH?"6C2^'/"FF>'IYED>PT^&W>1!@.4C521['%2Z%KVA^*=$L_$O
MAG6;34=-U"UCN;#4+"X6:"YA=0R21R(2KHRD$,"00017*V'[1?P0U3X_ZA^R
MQIWQ)TZ;XA:5X9B\0ZAX41V^U0:9)-Y*7+#&W:9,+C.1N4D ,I(!VM%?/WQO
M_P""JG_!/']F[XV6_P"SM\<OVL?"OAOQ?/-;PR:7J$\FRSDG7="EU<*A@LV=
M2'59WC)4A@-I!KVOQMX[\%?#7P7J?Q'^(7BS3M$T#1;"2^U?6M4O$@M;.VC4
MN\TDCD*B*H)+$X % &M17B7[*/\ P4=_8A_;@UO6O#'[+/[1.B>+-6\/1K+K
M&D01SVUY;PL0%F\BYCCD:$DJ!*JE,LOS?,,^VT %%%% !1110 4444 %%%>(
MZ_\ \%%OV0/"O[4>E?L5^(_B9J%G\4==WMHGA"?P9JZSZA$BRL\\#_9?+F@5
M89F,Z.8@L3DMA20 >W45YI^TQ^U_^SY^Q]HFB>(_VAO&MUH5EXCUI-'T2>W\
M.W^H?:[^16:.U46<$I$KA7*(0"^QMN=IQYC!_P %?_V KKQW<?"ZV^*7B:3Q
M-::<NH77AV/X3^)C?PVC-L6X>W&G>8L1;Y0Y7:3QG- 'TS17RMX$_P""U_\
MP34^*+ZNGPU^/NI^(/\ A'[@0:^=%^''B&Z&ER$L-ER8[ B Y1^'V_<;T->Z
M_ 3]HSX$?M2?#R#XK_LZ_%K0?&?AV>9X5U7P_J"7$:3)C?#)M.8I5R-T;A77
M(R!0!2_9K^#.I_ SP%>^$-5UJ"_DNO$-]J*S6\;*JK/*7"8/< X->@UQ7Q;_
M &B_@A\"-;\'^'/B_P#$G3M OO'WB:+P]X.M;YV#:KJ<JLT=M'@'YF"G!.!G
M SE@#S/[67[=_P"R+^PSH.F^(OVK/CEI/@^#6))4TJ&[CFN+F[\I0TKQV]ND
MDKI&&4O($V)N7<1N&0#UNBN9^#?QG^%'[0OPSTCXR_ _X@Z5XI\*Z];?:-(U
MW1;M9[>Y3<5.UE[JRLK*<,K*RL 00)_%'Q0\!>"_%WAGP'XG\2PVFL>,;ZXL
M_#5@Z,SWTT%K+=S*NT$*$@AD<LV%X SN900#?HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH _/+X_0Q_M!_P#!QQ\(?V?_ (JG[1X0
M^%'[.U_\3?"6BW?-M=^)IM8.EBY:,_+))!;_ +R(G+1,&9=I.3L?\'(GA73-
M/_X)?^)OVG-%U,:+X[^"NO:-XN^''BJ'"W&E:I'J5M#A'Z[98YGB9,[6+)D'
M:*]<_;F_8(\2?M _%?X>?M=?LZ?$FT\$_&?X5/=Q>'-:U.QDN--UK2[M-EWH
M^HQ1.DC6\@Y25&\R!R9$!)Q7QE^T5_P2H_;E\:^(/#VL>/\ P2GB'X-0>+=)
MU;XJ_L]^!?CGJGB*Z\;363RR17T=WXHAM8X")C T]FLT:W219,HECC9@#[%_
M:>3X+>#_ /@GQ\0_&'C'X06^I7WQ:\-.VI>$C:BXO/%7B#5+1+:TTT!\M-,S
MM;VL0/$4<2<JD65[[_@GK^SYXO\ V4/V&/A+^S9X_P#$ U37/!'@#2](U>\2
M4NAN8;=%D2-CR8T8%$/]Q%X'2OF3Q;\-/^"WGQ0_:1/[3OAGX>?LYZ5HFGPR
M0_#/P+\4O$&L3ZAX5A??'+=W TJ.2T.ISQ$+))'+.L$;-!#(5>>2?['_ &<]
M/_:$TWX/:3%^U3X@\,:CX^D,\WB"7P7;31:3"[S.T<%J)QYQBCB,:;Y?G<J6
M.,X !F_M"?LL_"[]IC6OASK?Q*M)99?AA\1+3QGX=$)4?\3&VMKF"+>2#\@^
MTL^!C+(G/%;?B?PY\(_ 7B/6_P!I3QK_ &=IUU9>$Q9ZQXDU294CL=)M7GNG
MR[_+#'F1WD(P&$<9;/EICKJ^0/\ @H/\$/\ @IU\<_BOX8L_V9E^!%S\,-!$
M>H:GX8^)^K:TKZ]JR2!X&NH[&V*M:V[*LB0>85DE"O("(T0 "?\ !&3]G34_
M@E^S3X\\3R>%KKPKHWQ<^,_B;Q]X-\(36QMI?#NAZC,@L+8P$#[*S00I<F#
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MXB?LY_!;XH_L_:I^RUXM^'NF2> ]6\,MH$_AN&T2.VBL##Y2Q1(!B,(H785
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M>%/%?@+PU+K6FW*:197L%T8BI:">*ZAD!1EW#*%&!(.2 5/SY\3/B)_P4R^
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MO[:W[<'PS_9OU;P[_P (\/C%82V6AZ3<0F(8TF&._P#)A4X^SI>FXC&T>6N
MHP,"OOCXI?!GX/\ QQ\/+X1^-?PI\->,-)2=9TTOQ3H5OJ%NLH! D$<Z.H8
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20220630_g12.jpg
<TEXT>
begin 644 biib-20220630_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
MM#^-OBK\ 5>'XN_ _P""_A'XA_"R^MX]TQU#3M>UZ66U4#EQ/ )$$></((<Y
MQ75?%K]K3P)_P5__ &6/!.E_"UDD\&7GPCN?BK\6;))/,6TDM([B+2]#F/0L
MVLVMQ,P(PRZ#(IXE&0#ZO_X)N?MD>)OV_P#]DGPQ^UQJOP<@\$:9XRMY+K0-
M'_X2;^TKG[,LTD.^<BVA2)F,98*ID^5ADJ<J/>*_';_@W9\5?$[]L#]FG1_V
M>-2^,?BGP9X(^"GPN\.V]CI7@O4187>LZKJS7]Z^H7%TJF4Q0QI%#% I$3.)
MS*LF%5?JGX,_M(?M$_%O_@F]^T"/$OQDU&S^(/P6\2^.O"%O\2=%TVQCN-6D
MT0RFUU P2026R2R1>4DRI&%$JR^6(_E"@'W!62OCSP<_CM_ABGB*V/B"/25U
M2320^9DLVE:)9R.R&164$]2K8Z&OS@\'_%?]J;X"_P#!.']ES]OOQK^T_P"+
MO%7BWQ?J?PY@^(&FZI=QOI>J:/KTEG:26XM=FV.XB2\CF%TA$TD\3%W=',==
MU\%/@?HNC?\ !P%\9O$=KX[\9O))\$/"NMRVUSXNNYK=Y9]4UB,V_E.Y5;5%
MC4QVZ@1HQ9E4%F) /HW]D7]LI_VJ/'?Q>\!W?P>U3P?=_"7Q^OA>\AU;4[>X
MEO7:PMKU9\6Y>.,%+I %$DG3)(/RCVZOSE_8\^ GQ"^-/[;/[;YL_P!H/Q;X
M.TJV^,EG'H,/@Z^2TEBU9O#6F;KVX<HQN5C3[.([=_W!/FF1)<IY?+>%O^"A
M'[3'Q,_9)_9Y_;4^.?P\^(6N?"SQ!\)KJ3XLZA\#[B2+5O#WB1;B.*/6[BSM
M'2XFT[9;7K>7#YD499S+%(%C  /U#KRO]MC]H3Q;^R=^RUXW_:9\*_#&U\7I
MX!\-7OB#6-#N/$!TUY=/L[>2XN&AE^SS!I1'&Q5&"AL8W XS;_8Y\:^&_B)^
MRA\./&7A+XWCXEV%[X+TXQ?$'8$;Q"RVZ))?.FU?+DE=6=T*J4<LI52"!Q/_
M  5@_P"46?[2O_9 /&7_ *8[R@#C?@%^VO\ MV?M(_ 3P?\ M&?#C]@;P=_8
M/CCPK8^(-#AO_CFT5S]EN[=)XED0:,5238Z@C<0#GGO7O_[/OQ5U/XV?!O0?
MB7K_ (#O/"NJZA:LFN>&+^X6:;1]0AD:"[LVE0!9?*N(Y8_,4;7"!EX85\%?
ML$?#S_@JSKO_  2G^ A^$G[1GP?@\/R_"GP?+9:+:?"_5+77?[(%K9M);+J;
MZY);K=&U#Q^?]D56<Y58<AD[#P<GQ^^//_!8#XV? 35?VR?&[?"KPU\-_#FL
M6OAS0-1M;&2TU*ZN]2A-O#=6D,<L<,;6LOF*6,SO'$LDK(C1N ?>]>(W'[93
MVG_!0C3_ -@J\^#VJ6[:C\+K_P 9V?C2XU.W^S7,=K?6=H]O% A:7.Z\!+R>
M7@QX"N&##X\^&O[<G[4?Q6\.?"O]C2Z^+U]IWB?Q%^U#X\^&'BOXJP6-JNH3
MZ+X7_M*Y+Q#RO(AO[NWM;:W,PCPI,TB(KE2G1^"OA1XJ^#G_  <+>'M#O/C5
MXC\6>'[G]DS7KO0=.\57JWM[H['Q#I23Q+<E1-/"Y2-T\YI'5C* VW:J@'Z'
M45^3W[-/[2G_  4A_;M_8IU#]L_X;_#_ ./2?$+QE<:QJ'PLE\)Z_P"#(/!^
MB0P7D\%CILUA?:O%+>1$P*EU-=0?:-[S>2R!(S7T9XA^.7[4GQX_:>^ G[&7
MQ)DU'X0W_B/X*:A\0_C'8>&=3@:\EO;673K+^PK2_B:411+=7LDLDT#^:\<$
M861 SE@#V?X,_ME/\6_VS?BS^Q]>?![5- N?A;HF@ZG_ &[J&IV\J:S#J9O1
M&\44)?RD7[$2"[ASO^:-".?;J_/_ /X)X^ /&/PQ_P""RO[77@OQ7\7M6\9P
M6O@3X=MH>H:^\4E_:6+IK#I:3RQHGGM&[2!9'!D:,Q[V=@7;] * "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /$OV_/V&/ 7_  43_9ZU+]E_XN?$_P 9
M>'_".N/$?$%IX,NK&"74DBGBN(HY);FTG9%66%&Q$4+<ABP.*ZW1_P!G/P=+
M^SH_[,'Q4UG4_B%X;NO#;Z#JS^,EM7GU.P>'R&BN#:P01MF,E2P16.<DYYKT
M"B@#P'P%_P $\?AOX6\5^!O$7CGXO_$'Q_9_"^1I?AKH'CC6+6XL_#T_D/;)
M<KY%K#->W$=O(\4<]])<R1AV96#LSG2\4?L1>'/%7[:6@_MQS_&_QU:^(_#G
MAFX\/:=H-H^E_P!D_P!F7$\,]Q;NCV+3MYDEO$Q?S@XV81D'%>V44 %?./PW
M_P"":'PP^#_@OXF?#SX9?&_XF:3HOQ,U35[Z73$UVTGM_#SZI.\]^NFQ3VCQ
MQB61V;,ZSO'N;RV3<V[Z.HH ^5_%'_!)_P"&'BS]A[PK_P $_;_]HWXI1>!?
M![:4-*GM[K15U!H=,FMI]/@DF.F%62"6TA=2$#L01(SC '7WO[!/AG3_ (L:
MU\=_A3\??B#X"\9>+=/LK7QYKOA9M(8>*&M(_*M[F[M;W3KBT6Y2/]WY\$,+
ME $)*JH'O->%2?\ !1K]F*+]L-?V"GO_ !9_PM)]*_M5?#W_  @.J^6=-\PQ
M_;_M7V?[/]FW@IYWF;-WRYW?+0!ZY\/_  1IGPY\(V?@[2=0U&\BM%8O>ZM?
MO=75S*[EY)997)+N[LS'H!G"A5 4:&LV%UJFDW.FV.M7.G33P-'%?V21--;,
M1@2()4>,L.HWHRY'((XJS10!\J?LW?\ !)_P#^RQX(^*_@/X8_M4_%V2U^,G
MB#4=?\83ZM>:'<3#5[\*MY?P-_90$4LJ($((:,#E4# ,%\1_\$F/A9XF_8/\
M/?\ !.R^_:+^*4?@#PT=,33YH+K1EU%K?3KBVN;&W>8Z85*0S6D+@A [$$.[
MKA1]544 >$>'?V$=(T/]L2']MW4/VC?B+JWBY/ J>#Y[+4/[%73[C25O#>")
MXH--C8-Y[%_,1U?G;G;Q4.B?\$^_!GP]\2^)]3^ GQW^(OPWT7QKXBGUWQ3X
M/\(7^G?V;>:C<'-U<1?;+*XN+!IS\TGV.: %R9%VN2]>^UX?\4?^"BG[*7P8
M\977A/XC^,=;T^TT[58=+UKQ</!6JR^'=)OI618[:[UB.V:QMI-TB*PDF41L
MZK(49E! -;X[?L8?!WX\Z9X).IS:UX?U[X:7XO?AWXR\-:EY6K>'Y_(-NYAE
MF65)DDA)CEAN$EBF7_6(^ 1T7PD^"][\-+N]USQ1\9/%_CO6;Z-(6UGQ?/9J
M\$"Y(AAM["VM;6$$G+,D(DD(7S'<1QA>A\?>/O!7PL\$:M\2OB1XIL=#\/Z#
MITU_K.L:G<+#;V=M$A>261VX554$DGTKB/@;^U]\#OVA?$=]X+\!ZKK-GKNG
MZ7;ZI+H'BOPKJ&B7\FG3LRPWT5O?P0R2V[LC+YJ*55P4?:X*T -_; _9+^&O
M[:WP1NO@7\4=7UW3+.35;#5-.UOPOJ(M-1TO4+*ZCNK6[MI61U62.6)6&Y'4
M\@J:Y7X*?\$^OAW\#OVE=;_:LT/XR_$C5O%'BOP[I^F>,H]=\21RV>O360G2
MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%,GGBMH'N9VVI&A9VQG
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M -./_)O_ +4#Z,HKYSHH_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\
M[4#Z,HKYSHH_UO\ ^G'_ )-_]J!]&45\YU[A\-O^1&TW_KA_[,:]3*<]_M2O
M*G[/ELK[WZI=EW W****^@ **** "BBB@ HHKR_X^_LL>#OVH73PW\;?$.LZ
MAX*CBQ/X%T[4YK"QU20]6U!K=UEO(P,!;9G$!R3)'*=AC *7BO\ X*!?L&>!
M/$K^#/''[;?PBT;6(Y/+DTG5?B3I=O<J_3:8I)PP/!XQ7I_AGQ1X9\::%;>*
M/!WB*PU;3+R/?::CIEVD\$Z_WDD0E6'N#7E?A[_@G?\ L ^$M#7PSX8_8?\
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MZ":M55UW_D!WG_7I)_Z":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@
MHHHH **** /HJ'_5+_NBG4V'_5+_ +HIU?LZV *\#\5_\C3J7_80F_\ 0S7O
ME>!^*_\ D:=2_P"PA-_Z&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 44
M44 %%%% !7N'PV_Y$;3?^N'_ +,:\/KW#X;?\B-IO_7#_P!F-?4\)_[]/_#^
MJ W****^_ **** "BBB@ HHHH _/']J/XP_MC^)?'^L?L2? GXG?%#3?B+\2
MOB3+'JOBB3P8(=%^%W@."4R2ZG8:E]C2"XGGM$C6/?/-(MS=O'F)H !]'_\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JKKO\ R [S_KTD_P#035JJNN_\@.\_Z])/_036
M=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110!]%0_P"J7_=%
M.IL/^J7_ '13J_9UL 5X'XK_ .1IU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T
M,U\CQ=_ I>K_ " SZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-I
MO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ?^']4!N4445]^ 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJKKO_(#O/^O23_T$U:JKKO\ R [S_KTD_P#036=;^%+T8'S[1117XV 4444
M%%%% !1110 4444 %%%% !1110!]%0_ZI?\ =%.IL/\ JE_W13J_9UL 5X'X
MK_Y&G4O^PA-_Z&:]\KP/Q7_R-.I?]A";_P!#-?(\7?P*7J_R SZ***^& ***
M* "BBB@ HHHH **** "BBB@ KW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M-_ZX
M?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%% 'YN_M#?$[XX_L4?M7:
M6VI?\$\_BW\1_#C?'74/B#;?$'X->%H]=FU6VO/#&J:8+*^@65);:ZMI[RWM
MXVD_<M:0(PD5D,=?5_["&D_%_4?"'C7XY?&[X4R^ M9^*7CM_$D/@6\OHKFZ
MT.S33-/TRWBN7A)C^T21:<MS(B%A&]RT>YBA)XSX%_'OX>Q?M5_&'4OCC^U^
MVE^)M!UEM'B^$WB#Q'9V.G:%HT:Q366I06SJDLS743^<UXSNN97@&WR-J]U^
MP]\;+/XY>%?&VM^#_'R^+_!6C_$.\TGX?^,DN?M":SIL5K:/*R7(XNT@OI+^
MR6<%C(MDK,\C;I' /;*\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%_
M_0UH [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JNN_\@.\_Z])/_035JJNN_P#(#O/^O23_ -!-9UOX
M4O1@?/M%%%?C8!1110 4444 %%%% !1110 4444 %%%% 'T5#_JE_P!T4ZFP
M_P"J7_=%.K]G6P!7@?BO_D:=2_["$W_H9KWRO _%?_(TZE_V$)O_ $,U\CQ=
M_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH **** "O</AM_P B-IO_ %P_
M]F->'U[A\-O^1&TW_KA_[,:^IX3_ -^G_A_5 ;E%%%??@%%%% !1110 4444
M ?D_XV\&!?VM/CIX,^)'_! F_P#VB-#@^+$VKZ1\0]7A\.W4_P!HNM.T^5[6
M-=4F#&V5/)9&C95"N(GBWQ.[_=/[ /QQ\=_&OX<>)K;QQ^R=J'P53P=XM'A_
M1/ 6I_9/-M;"/2]/N(W_ -#=[<(6NI @B8J$51PP85YG)^T/^V;XU_;S\'W&
M@^+/"N@_ EOBIJ_@"3PVND&YUSQ)?6GAS5KV>^FN7;;8V\5[8"**&-3)*L9D
M=PCJE?0/P'^*WB'X@ZO\0/!/BVTM!J?P_P#'3Z!<7M@I6&^CDTZPU.WE",6*
M.+;48(Y!D@RQ2,N%95 !Z%7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_
M + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %5==_Y =Y_P!>DG_H)JU577?^0'>?]>DG_H)K
M.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O^Z*=
M38?]4O\ NBG5^SK8 KP/Q7_R-.I?]A";_P!#->^5X'XK_P"1IU+_ +"$W_H9
MKY'B[^!2]7^0&?1117PP!1110 4444 %%%% !1110 4444 %>X?#;_D1M-_Z
MX?\ LQKP^O</AM_R(VF_]</_ &8U]3PG_OT_\/ZH#<HHHK[\ HHHH **** "
MBBB@#\H_^"BGPJ\2>._VT-6\5_\ !/FU_:I?Q3X;\0PZA\3)_@U+H:^%[;6C
MI+632QC7I8X3K']F78BE^R;ALDB\P"49K[6_X)AVOP+L/V5K6Q^![>/3)%KM
M\/&Q^+)D/BP^(3(&O3K)DY-X24.5_=&(PF']R8Z\,T:;_@M1\'_VC/C3X=_9
MZ_9G^#NN_"V\^($VH^"9_'/CJ^TV_:2[L[:YNID:"SE6:W:YEE.UE#QR^?&)
M&14V\OX2NO\ @X%^!?PL^*7BZ3]E#X$>)/''C'5M0\2W>J:+\3[Y0EV-/M[*
MTAM-/?3"'\FUL;2-8Y)R9GC9F<&0X /TAKRC]N?_ )-'\>_]@%__ $-:]2L6
MF>RA>Y!\PQ*9,C!W8YX[<UY;^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6
MG_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55UW_
M ) =Y_UZ2?\ H)JU577?^0'>?]>DG_H)K.M_"EZ,#Y]HHHK\; **** "BBB@
M HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 KP/Q7_ ,C3
MJ7_80F_]#->^5X'XK_Y&G4O^PA-_Z&:^1XN_@4O5_D!GT445\, 4444 %%%%
M !1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_P#7#_V8U]3P
MG_OT_P##^J W****^_ **** "BBB@ HHK)\>>"](^(O@[4? ^O7VKVUGJ=LT
M%Q<:#KUWI=Y&I[PW=G+%/ _H\;JP]: +6B^(O#_B2*XF\.Z[9WZ6EY+:73V5
MTDHAN(F*2PN5)VR(P*LIY4C! -5_"WC7PIXVAOIO"FO6]\-,U.?3M16%_FM;
MN%MLD,BGE''!P0,JRL,JRD_DSXF_9R_9H_9$\=>)?@'<_M;?\%!OBYXMLO$E
M[JWB2U^!GC;Q9J*^'[>^F:ZM8M2>SE\D79MY(V8[C/,,2F,"1<_>7_!,3P+^
MR5X1_9H?7_V._&GB?Q)H7BOQ/?:QXAU[QQK-_>ZY>:T2EM=?VBVH8N8[J/[-
M'"\4JHR>2 5SR0#Z(KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]
M#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXS^-O\ P4T^+UQ\5]4^
M'_['G[-"^.]+\$?%?3_ _CKQ%J7BJVTY)]7E@CN9],T^*0$RS1Q3P!YYFAB5
MWV@OM8K]F5^4W_!0O]A'XS?#3]H!?^"B'_!)[X[P1^*/%WQ=T^#QQ\&?%3,_
MACQ/XCLI9;87#'<CV5R'A='8$"0MN$D:LQ< _07]G/\ :ETKX[_LSQ_M+^(O
MA[K7@:U2361JOA[Q.(A?Z5_9M]=6DZ7(B9D60&U=F5695)*AFQN/CO[%/[=G
M[=/[6ESX.\8^+?\ @F'/\/?ASXQT"#6[3QSJWQCTN]9+*XMEGMR+"VA-P9)%
M=/W;B/;D[RI&#5_9!_:-\/?\%6/^"9_C5M:\%7?P8U;68?%'@GXCZ4AB:3PQ
MK/[Z#4IHI&54D8/,TXD=?ON=X8AL\AXI\+?%W_@ES\7?V=_#_@/]JGQW\0_A
MS\1/B!:_#37?!/Q#?3KJ2R\[3;N:PU'3IK6TMVM_(-CLEA^:)XI,A$9 U 'T
M1^T9^UO<?"+XP> _V:/AC\-_^$P^(WQ%@U*]T31[G6!IUA8Z=8+$;N_OKL13
M/!"K7$$2B.&:22290J8#LMK]E/\ :RTS]I2X\<>"M9\#W7A3QQ\,?%7_  CW
MCOPM=7B7*VERUM#=03V]P@47%K/;3Q2Q2E(V(8AHT92H\"_;6L_&7Q4_X*A_
M!#X7_LR:Y8>$_BOX/\ ^(/%>J^.]?T]M0TR+PI/<6EA/I<NGI)"]^]S=_9I%
M*W%N;?[(9 [;S&]O_@EA%JO@/]H#]IOX&_&:ZCUSXPZ9\0M,\0?$'QY8IY5E
MXEL]3TY?[(DMK8Y:P2WM+,VGV1GF*&W,GG2^=NH NZ?_ ,%#/VT?B;\;/%/@
M;]FS_@F=-XR\$>%_B#=^$KGXE7WQBTO2[8W-I*L-Y,;22)[D1PRF13L21F\I
MMH8_+7V"NXJ"X ..0#D9K\Z/VF/V>/BE_P $O/V./'W[;'[,7[<GCS6+SP9K
M6K>.]<\&^)YM+N/#/B$7>JRW^JV)A2T$T#2O<7"QS).9HY-@+LHVU^AVAZI'
MKFBV>MQ6TL*7EK'.L,Z;70.H8*P[$9P1ZT 4_'?COP7\+_!FJ?$7XB^*;#1-
M!T2QDO=7U?4[E8;>SMXU+/+([$!5 !))KBOV.?VEM _;'_9@\%_M0^%=!FTS
M3/&^C+J>G6-Q-YDD<#LP3<=J\E0"1@8SCMFK/[37P!^!'[1/PKOO"7[0/P4\
M(^.M*L8I;ZRTSQCX;M=3M[>Z2&15G2.YC=4D"NX#@!@&(!Y->'?\$)/^4/7[
M._\ V3.Q_DU 'UG1110 4444 %5==_Y =Y_UZ2?^@FK55==_Y =Y_P!>DG_H
M)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O\
MNBG4V'_5+_NBG5^SK8 KP/Q7_P C3J7_ &$)O_0S7OE>!^*_^1IU+_L(3?\
MH9KY'B[^!2]7^0&?1117PP!1110 4444 %%%% !1110 4444 %>X?#;_ )$;
M3?\ KA_[,:\/KW#X;?\ (C:;_P!</_9C7U/"?^_3_P /ZH#<HHHK[\ HHHH
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ME'S/$K-@=R,UY;^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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MW^(_A3QK#K$7B#2W:-I+5;B+5Y))HX)$+O&T1,$GS%68JV.5_P""E'_!-O\
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MUT+X+^+]<^&UK-/XCLO"^H3Z!#;VOGR27J6TC0*L>#YC&0* F#N/&#FNHHH
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M_$5SE%?/?VEF/_/Z?_@3_P P.C_X6U\0?^A@_P#)2+_XBC_A;7Q!_P"A@_\
M)2+_ .(KG**/[2S'_G]/_P "?^8'1_\ "VOB#_T,'_DI%_\ $4?\+:^(/_0P
M?^2D7_Q%<Y11_:68_P#/Z?\ X$_\P.C_ .%M?$'_ *&#_P E(O\ XBC_ (6U
M\0?^A@_\E(O_ (BN<HH_M+,?^?T__ G_ )@='_PMKX@_]#!_Y*1?_$4?\+:^
M(/\ T,'_ )*1?_$5SE%']I9C_P _I_\ @3_S Z/_ (6U\0?^A@_\E(O_ (BC
M_A;7Q!_Z&#_R4B_^(KG**/[2S'_G]/\ \"?^8':^#OB5XUU7Q18Z=?ZUYD,U
MPJR)]FC&1]0N:]7KPSX??\CKIG_7VM>YU]KPQ7KXC"S=6;D^;JV^B[@%5==_
MY =Y_P!>DG_H)JU577?^0'>?]>DG_H)KZ*M_"EZ,#Y]HHHK\; **** "BBB@
M HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 KP/Q7_ ,C3
MJ7_80F_]#->^5X'XK_Y&G4O^PA-_Z&:^1XN_@4O5_D!GT445\, 4444 %%%%
M !1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_P#7#_V8U]3P
MG_OT_P##^J W****^_ **** "BBB@ HHHH _.KXI?\$9_B'^WI\4_&WBK]LW
MX_ZEH'@RS\2>([;X5>%OAUH]CINI0Z?>SN99]4U%H'FO8I96>06)/V=T$+3"
M4DHGT%_P3+_9]^*7[,?P\\?_  E^)_@'X>:&MC\2''AJ?X7^#AH.E:OI0T?2
MXX+[[&'=8KAS'(DP5B@EB<(=H6O*;3Q!\;?B5_P46\*?&+5/VKO$=KX=T7XZ
M:Q\/(/@GH5W';:7;VD/A#6;S[9JR*OFWMU/-;P7D&]EBB@> JC-^\KZ0_99^
M*6L?$+5/BCX6O?%46O6'@;XGW/A_1=;0HS7-N-.T^]>&1T^5WMKB]N+(L/F_
MT/\ >$RB0D ]9KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#
MNOA=_P DS\._]@*T_P#1*5=U_P 4:%X8BCFUR^\A96*QGRF;)'7[H-8/PS\6
M>&X?AQX?AEUB%631+164GH1"G%8GQKUO2M6T^P33KZ.8I,Y8(>G K@S/%5,%
M@9UH)-JV^VZ7D!TW_"VOA]_T,'_DI+_\11_PMKX??]#!_P"2DO\ \17BU%?&
M_P"MF8_R0^Y__) >T_\ "VOA]_T,'_DI+_\ $4?\+:^'W_0P?^2DO_Q%>+44
M?ZV9C_)#[G_\D![3_P +:^'W_0P?^2DO_P 11_PMKX??]#!_Y*2__$5XM11_
MK9F/\D/N?_R0'M/_  MKX??]#!_Y*2__ !%'_"VOA]_T,'_DI+_\17BU%'^M
MF8_R0^Y__) >T_\ "VOA]_T,'_DI+_\ $4?\+:^'W_0P?^2DO_Q%>+44?ZV9
MC_)#[G_\D![3_P +:^'W_0P?^2DO_P 11_PMKX??]#!_Y*2__$5XM11_K9F/
M\D/N?_R0'M/_  MKX??]#!_Y*2__ !%7="\<^%O$MX;#1=4\Z98RY3R'7Y00
M,Y90.XKPFNL^#FI6.E^*I;C4+E8D-DZAG/&=R<?I79@.),=BL;"C.,;2=M$[
M_F![!16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5]J!F?%W_D0+W_ 'HO_1BU
MXQ7K/Q1\2:%J'@F[M++4XI)&:/:BGDXD4UY-7Y[Q7_R,H_X5^<@"BBBOF0"B
MBB@ HHHH **** "BBB@ HHHH V?A]_R.NF?]?:U[G7A'@:X@M/%VGW-S($C2
MY4NQZ 5[+_PF/AC_ *#4'_?5?>\)?[G4_P 7Z(#2JKKO_(#O/^O23_T$U7_X
M3'PQ_P!!J#_OJJNL^+?#<NCW<4>L0EFMI H!ZDJ:^GK?PI>C \/HHHK\; **
M** "BBB@ HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG5EQ>,/# B4'6H?NCO3
MO^$Q\,?]!J#_ +ZK]G6P&E7@?BO_ )&G4O\ L(3?^AFO:O\ A,?#'_0:@_[Z
MKQ+Q++'<>(]0GA<,CWLK(P[@N2#7R/%W\"EZO\@*5%%%?# %%%% !1110 44
M44 %%%% !1110 5[A\-O^1&TW_KA_P"S&O#Z]A\ >)] LO!UA:W6JQ1R)#AD
M8\CDU]3PG_OT_P##^J ZNBJ%MXH\/WDZVMKJL3R.<(BGDFK]??@%%%% !111
M0 4444 ?,?[6O_!'_P#8+_;4^*UO\=/C1\+-3@\90P1V]QXE\)>+=1T2[OH$
MC>)8[E[&>+S\12/$'<%UC<H&"G%>W? CX#?![]F/X3Z-\#?@)\/]/\+^$] M
MS#I.BZ:A$<(9B[L2Q+2.[LSO(Y9W9F9B6))ZZO!/V;?VCOVM/BCXUUR+XY?L
M8S?#_P ,IXWU30?#-Y)XF%]J%Q;6H+0:G<VZ0"*&TN0C['69V5S&A5E<2T >
M]UY1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =K\,+"Q;X:^
M'F:RB).AVA),8Y_<I7/_ !VMK:#3M/,%NB$SODH@&>!72_"[_DF?AW_L!6G_
M *)2N=^/?_(-T[_KN_\ Z"*\?/\ _D45?E^: \RHHHK\O **** "BBB@ HHH
MH **** "BBB@ KL/@E##/XNF2:)7'V!SAER/OI7'UV?P-_Y'";_L'O\ ^AI7
MI9-_R-*/^) >I_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%345^K <M\6;.SA\!WD
MD5K&K!HL,L8!_P!8M>.5[/\ %W_D0+W_ 'HO_1BUXQ7Y[Q7_ ,C*/^%?G( H
MHHKYD HHHH **** "BBB@ HHHH **** -?P"B2>,]-21 RFZ7((R#7M_]G:?
M_P ^,/\ WZ%>)?#[_D==,_Z^UKW.OO>$O]SJ?XOT0$/]G:?_ ,^,/_?H55UR
MPL%T6\9;*$$6LF"(Q_=-:%5==_Y =Y_UZ2?^@FOIZW\*7HP/GVBBBOQL HHH
MH **** "BBB@ HHHH **** "BBB@#Z$BT[3_ "E_T&'[H_Y9"G?V=I__ #XP
M_P#?H5)#_JE_W13J_9UL!#_9VG_\^,/_ 'Z%>$>*55/$^HHB@ 7\P  Z?.:]
M]KP/Q7_R-.I?]A";_P!#-?(\7?P*7J_R SZ***^& **** "BBB@ HHHH ***
M* "BBB@ KVOX<V5E)X(TYY+2)F,'):,$GYC7BE>X?#;_ )$;3?\ KA_[,:^I
MX3_WZ?\ A_5 :Z6-E&P>.SB5AT*Q@$5+117WX!1110 4444 %%%% 'RO^TC_
M ,%,+O\ 9W^%/B?XE2_LYZKKEROQ'B\ _"G0++7[=+KX@^(9+IK06]L-K?98
MEFCG6264946LS!'55+^O?LO?&OX@_&KP3J,WQA^#@\ ^,O#FLG2O%7A6'Q'%
MJ\%G<FUM[N,PWD21BXC:WN[=]QCC8,S*5&W)^._C5X>\2^)/VU]0_:+_ &0/
M^"4^I_%O6? .LWVG6_C7Q5\?CX<T&TUMX5AU"?2M*F-U$MR 3!->K:PL\J2@
M.Y4N?;_^"6WAKXU^'/ 7Q-D^/W[/-Y\-/$&I?%BXOI-"O_B1/XMDN(Y-(TK%
MU_:DP5K@,P= H55A6(1*H$8H ^GZ\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_
M'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E<[\>_P#D&Z=_UW?_ -!%=%\+
MO^29^'?^P%:?^B4KG?CW_P @W3O^N[_^@BO'S_\ Y%%7Y?F@/,J***_+P"BB
MB@ HHHH **** "BBB@ HHHH *[/X&_\ (X3?]@]__0TKC*[/X&_\CA-_V#W_
M /0TKTLF_P"1I1_Q(#UFBBBOU8#FOB[_ ,B!>_[T7_HQ:\8KV?XN_P#(@7O^
M]%_Z,6O&*_/>*_\ D91_PK\Y %%%%?,@%%%% !1110 4444 %%%% !1110!L
M_#[_ )'73/\ K[6O<Z\,^'W_ ".NF?\ 7VM>YU][PE_N=3_%^B *JZ[_ ,@.
M\_Z])/\ T$U:JKKO_(#O/^O23_T$U]/6_A2]&!\^T445^-@%%%% !1110 44
M44 %%%% !1110 4444 ?14/^J7_=%.IL/^J7_=%.K]G6P!7@?BO_ )&G4O\
ML(3?^AFO?*\#\5_\C3J7_80F_P#0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH
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M_8"M/_1*5SOQ[_Y!NG?]=W_]!%>/G_\ R**OR_- >94445^7@%%%% !1110
M4444 %%%% !1110 5V?P-_Y'";_L'O\ ^AI7&5V?P-_Y'";_ +![_P#H:5Z6
M3?\ (TH_XD!ZS1117ZL!S7Q=_P"1 O?]Z+_T8M>,5[/\7?\ D0+W_>B_]&+7
MC%?GO%?_ ",H_P"%?G( HHHKYD HHHH **** "BBB@ HHHH **** -GX??\
M(ZZ9_P!?:U[G7AGP^_Y'73/^OM:]SK[WA+_<ZG^+]$ 55UW_ ) =Y_UZ2?\
MH)JU577?^0'>?]>DG_H)KZ>M_"EZ,#Y]HHHK\; **** "BBB@ HHHH ****
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M\O **** "BBB@ HHHH **** "BBB@ KL_@;_ ,CA-_V#W_\ 0TKC*[/X&_\
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MU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T,U\CQ=_ I>K_ " SZ***^& ****
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MW)TUHT:V#(T2C*@OY?F?QT ?2E>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
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M!Y5B?9TY48S:Y*<O><ZB;O.$GM%*U[:;;GVA_P />?\ JWO_ ,NS_P"Y*/\
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MS_Z%N(_\$U/_ )$/]:^%O^@^C_X-A_\ )'IM%>9?\-F?LM_]%LT3_O\ -_\
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MIU-A_P!4O^Z*=7[(MB@KP/Q7_P C3J7_ &$)O_0S7OE>!^*_^1IU+_L(3?\
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M7DUW;6]U<W$3KI\P>W::9AL92T<JSQB5T1%3Z!_8B\9_M6^.M!\=ZS^U_P#
MG0OA[XC3QZT.FZ+X<UD:G;3:<NE::8[@7ODPFZ+2&92[1J5\OR^D8KT;XB?&
MOX-?"%8&^+'Q;\,>%Q= FV/B+7K>R\['7;YSKN_"H?A)\=O@_P#'FSUC5/@S
M\1='\3V.A:S_ &5J.HZ%J,5W;)=BV@N3$LL3,C$1W,1.#P6(/(- '6UY1^W/
M_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B
M4KG?CW_R#=._Z[O_ .@BNB^%W_),_#O_ & K3_T2E<[\>_\ D&Z=_P!=W_\
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M%[_O1?\ HQ:\8K\^XIXWXTACXQCF>(2Y5I[:IW?]XVCP?PC#X<OH+_N%3_\
MD3S6']CO]E^ $)\$=!.?[]IN_F35F+]E#]FF';L^!GA@[>F_2(F_/(Y_&O0:
M*^4GQAQ=4^+,*[]:M3_Y(WCPSPW#X<%17_<.'_R)P\/[,W[.<!+)\!_!YR/X
M_#=LW\TJS%^SW\ X$\N'X'^$$7^ZOAJU _\ 1==?17-+B3B*?Q8RJ_\ N)/_
M #-XY'DD/APM-?\ ;D?\C\7Z*]H_X=Z?M@?]$A_\K^G_ /R11_P[T_; _P"B
M0_\ E?T__P"2*_U2_P"(D>'?_0XPO_A11_\ DS_/'_47C;_H5XC_ ,$5/_D3
MQ>OL/_@D[X<\/>(/^$^_M[0;*^\G^RO*^V6J2[,_;,XW XS@9^@KR3_AWI^V
M!_T2'_ROZ?\ _)%?3G_!.3]GKXP? ;_A,O\ A:_A#^RO[5_L[[!_Q,+>?S?*
M^T[_ /4R/MQYB=<9SQG!K\G\<..^$,Q\+LPP^6YI0J5Y>RY8TZ].4W:O3;LH
MR<G:*;=ELFWH?H_A+PAQ+@?$'!5\=E]:%)>TYI3I3C%7I5$KN44E=M)7ZVZG
MT'_PKCX>?]"'HO\ X*X?_B:/^%<?#S_H0]%_\%</_P 36S17^?']I9C_ ,_I
M_P#@3_S/[2^HX+_GU'_P%?Y&-_PKCX>?]"'HO_@KA_\ B:/^%<?#S_H0]%_\
M%</_ ,36S11_:68_\_I_^!/_ ##ZC@O^?4?_  %?Y#/ 7PT^'$WC+3HIOA_H
MCJUTH96TJ$@_^.U[;_PI_P"$O_1+O#G_ ()(/_B*\N^'W_(ZZ9_U]K7N=?=\
M*8_'2PE2]67Q?S/LO,/J."_Y]1_\!7^1SO\ PI_X2_\ 1+O#G_@D@_\ B*JZ
MY\(?A,NBWC+\+_#H(M9""-$@X^4_[%=9577?^0'>?]>DG_H)KZ:KCL;[*7[V
M6S^T_P#,/J."_P"?4?\ P%?Y'S)_PKCX>?\ 0AZ+_P""N'_XFC_A7'P\_P"A
M#T7_ ,%</_Q-;-%?CW]I9C_S^G_X$_\ ,/J."_Y]1_\  5_D8W_"N/AY_P!"
M'HO_ (*X?_B:/^%<?#S_ *$/1?\ P5P__$ULT4?VEF/_ #^G_P"!/_,/J."_
MY]1_\!7^1C?\*X^'G_0AZ+_X*X?_ (FOQXK]H*_,?_AWI^V!_P!$A_\ *_I_
M_P D5_6'T8.+<ER;^UO[:Q].CS>PY/;58PO;VW-R\\E>UXWMM=7W1_.?C_PW
MFF:?V;_9>#G5Y?;<WLJ<I6O[*W-R)VO9VOO9V/%Z*]H_X=Z?M@?]$A_\K^G_
M /R11_P[T_; _P"B0_\ E?T__P"2*_J__B)'AW_T.,+_ .%%'_Y,_G+_ %%X
MV_Z%>(_\$5/_ )$]0_X)9?#WP#X]3QXGCKP/H^M+;#2_LXU;3(KD1;OM>[;Y
MBG;G:N<==H]*^KY_V9/V<K@YD^ _A 9&/W?AVV7_ -!05XY_P3D_9Z^,'P&_
MX3+_ (6OX0_LK^U?[.^P?\3"WG\WROM._P#U,C[<>8G7&<\9P:^G*_@+QKXN
MQ.)\3\?7RC,'*@_9<LJ55N#M0II\KA+E=I)IVZIWU/[*\*N&J%#@#!TLSP:C
M67M.95*:4U^]FU=25]K-7Z6MH>=3?LD?LRSG+_ [PX,#^#347^6*IS?L5_LL
M3XW_  5T@8Z;!(O\F%>HT5^:PXTXQI?!F6(7I6J+_P!N/NY\+<,5/BP-%^M*
M'_R)Y%/^P=^R5<#$GP;M!SGY-0NE_E**JM_P3Y_9(W&2W^%CP.3]^'7[\'Z?
MZ_%>ST5V0\1/$"G\.;XI?]S%7_Y,YI<$\&3^++<._P#N#3_^1$C_ ."6/[($
M<:MIOAWQ'9$ ;/LOC/4!L]<9F/7G\Z=_P[#_ &>X>-,\7_$.RQRGV7QW=C8?
M49)YKZ)A_P!4O^Z*=7ZZN->+FO>QU5^LY/\ -LG_ %'X/6V I+TA%?DD?.G_
M  [6^&T/_(._:!^,=F.H%M\0YAAO[W*'GI^5>1>(/V*+2PUZ^M+/]J/XRQB.
M\E4L/'1+/AR,L3%R?>ONBO _%?\ R-.I?]A";_T,U\OQ1QUQ90HTW'%/5O=1
M?3SBP_U)X6Z85+T<E^31X/\ \,B>(XN;3]K?XJKG[WG>(4D_+,?%*/V6OB?!
MS9?MA>/5/3]^\$G'XKU]Z]GHKXW_ (B#Q4_BJP?K0H/\Z;#_ %,X>6U.2]*M
M5?E-'BY_9P^/D/\ QX_MG^)5QPOGZ%:R\>^<9/O1_P *%_:I@_X\?VW+U<?<
M^T>!+&7'URPS7M%%'^O_ !"_BCAWZX/"2_.@P_U-R5;2K+TQ.)7Y54?E;^V1
MH?C#PY^TAXCT7Q]XY_X235H?L?VO6O[,CL_M&;.!E_<QDJFU"J<'G;D\DUYC
M7M'_  4+_P"3P/%__</_ /3?;5XO7^G_  !B*F+X#RJO-)2GAJ$GRQC"-W2@
MWRQBE&*[1BE%+1))6/X XRHPPW&&8TH-M1KUDKMR=E4DM92;E)]W)MMZMMA7
MM'_!/3_D\#PA_P!Q#_TWW->+U[1_P3T_Y/ \(?\ <0_]-]S6'B1_R;O./^P7
M$?\ IF9KP+_R6V5_]A%#_P!.Q/TXHHHK_),_TC"BBB@ KW#X;?\ (C:;_P!<
M/_9C7A]>X?#;_D1M-_ZX?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%
M?)__  40^%G_  4>^*?Q7^&L_P#P3G_: \,_#ZYTC3M?3QSK'BO1AJ5E)!+_
M &:;:V-OL;,[.AD1LH52.3YL-M< ^6O%_P 9_P#@EC:_MI_&_P $_ML?\$_=
M?^+?CG2_'++<?$#4/V=+[QC;"S>UMY+338W:SG-I]G@>-1'$HAD1HYPY>>15
M^N/^"6OB_P#8_P#&7PV^(=[^Q+^S_/\ #7PC;?$Z6VN_#LW@I_#BMJ"Z/I1E
MFCTQX(6M%96B7:4!=D:3I(*\&L_V2O\ @XVT^XNKNP_X*8? B"6^G$]]+#\&
M%5KB41I$)'(7+L(XXTR<G:BCHH%?07_!-KX:_MK?!_P!\2H/^"@_Q6T+Q=XQ
MOOB7-J-OXJT#3EL=/NM*_L?2XH&CAV((A&898V!!^>-SN;.X@'TI7E'[<_\
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MW_\ 0171?"[_ ))GX=_[ 5I_Z)2N=^/?_(-T[_KN_P#Z"*\?/_\ D45?E^:
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M%GX7>'_C-X(N/AUXON[U='OYH?[6M+.94&H6R2*\EG,2I)@F"^7*@P7C9TR
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M11[?F9R>[X,(_>3YK75]=-E_6P'Q4-$MS_P;5'Q__:I_MT_"X_$#^V\CS_\
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MY]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O^Z*=38?]4O\
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MZZ9_U]K7N=?>\)?[G4_Q?H@"JNN_\@.\_P"O23_T$U:JKKO_ " [S_KTD_\
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M)#ZII]G'=75BDMJ9HHI"0KLN[ 4XX.3]*V/^&A?VGO\ I'/\4_RM/_CE>_>
M?^4@GC__ +$32O\ T8U>Z4?ZO9/_ ,^O_)I?Y@?!O_#0O[3W_2.?XI_E:?\
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M  T+^T]_TCG^*?Y6G_QRC_AH7]I[_I'/\4_RM/\ XY7WE17-_J]D_P#SZ_\
M)I?Y@?!O_#0O[3W_ $CG^*?Y6G_QRC_AH7]I[_I'/\4_RM/_ (Y7WE11_J]D
M_P#SZ_\ )I?Y@?!O_#0O[3W_ $CG^*?Y6G_QRL?Q+^U]\>?">KZ1HFN?L ?$
MBUN=<O#:Z;#<RVJO<2A=Q2,!CN;'."1]:_0JO"_VL/\ DMGP/_['N7_TF:C_
M %>R?_GU_P"32_S \!_X:%_:>_Z1S_%/\K3_ ..4?\-"_M/?](Y_BG^5I_\
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M -$I1_J]D_\ SZ_\FE_F!\5?\-"_M/?](Y_BG^5I_P#'*/\ AH7]I[_I'/\
M%/\ *T_^.5]Y44?ZO9/_ ,^O_)I?Y@?!O_#0O[3W_2.?XI_E:?\ QRC_ (:%
M_:>_Z1S_ !3_ "M/_CE?>5%'^KV3_P#/K_R:7^8'P;_PT+^T]_TCG^*?Y6G_
M ,<H_P"&A?VGO^D<_P 4_P K3_XY7WE11_J]D_\ SZ_\FE_F!\I)_P % OVG
MD0+_ ,.N_BGP,?\ '[:4O_#P3]I[_I%U\4__  .M*^K**]H#Y3_X>"?M/?\
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M*;^*/ASK5K9GX&6?P8TO4]&N4TC;+_PD4^IW4,D1N<_.1;VS,T?0"2$\$DL
M>_45\*_M]^(?^"MOPS^%WQ*_;<^"7[0?@3PMX>^&%GJFL:7\&-:\ I?)XCT7
M3!))-->ZJ9Q-!/<PPR311P(BQHT4;DN7=?HBW^-/QC^-O[&7A7XV_LY^#+&Q
M\7?$+PIHVI:%9>* \EKH9U&*"5Y[M4*/,MK%*\AB5D:9H1&&C+[E /8J*^%_
M@U\:O^"@/[+7_!23P9^Q+^UU\>- ^,WA+XO>"=:UKPAXPTWP-#X?U'0;_2C
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M,/$5@S&&;RY)@PTRQF!E5B/]*NHHW3]Q;JUS]??#K]G+]GKX/^!M1^%_PD^
M_@SPMX9UB2635O#OASPO:6-C>O+$L4K36\,:QR%XT5&+*=RJ%.0 *X6#_@FA
M_P $XK:9+FV_X)_?!*.2-@T<B?"G1PRL#D$$6W!% 'LFC:M8Z_I%KKNF/(UM
M>VR3V[2P/&Q1U#*2C@,AP1E6 (Z$ U9HHH **** "BBB@ HHHH *^&/^"_/P
MB^*'B_\ 9;^'/[1'PF\$WWBB_P#V>_CSX8^*6H>%],A,MSJNGZ7),+J**/\
MC=8IS+CKMB?&2<'[GHH ^*?CE_P7'_9M^!7PSMOVD]6\":YK/P:U6Q_XD/Q5
M\.ZMI=]:7]^]H;B"T^Q0W37T7FN#:AY(%\NX&R58UQ(?&O\ @G3\3C_P25_X
M)6?"_P"$_P"TIK7A?PW\:?BIJFL:[H7@;Q?XAATJWL+C4+R6[S>RS,/LEK:P
M20M<,1O5R8(UDG>.-_M_Q#^P%^PKXKUW5_%?B/\ 8R^%5YJ^OVT]OK>L3?#_
M $XWE]',C),LL_D^8^]68-EN0QKE_#/_  2I_P""?NAPJGBC]FC1/'D\-I%9
M6-_\69I_&%W8641<PV5M<:W)=2VUK&9)"L$3+&"[-MRQ) (_^">,_P"RMX7\
M#:U\+?@!^T?X:^*'B?\ M23Q1\4O%7AS5;>\;4=:U265Y;R<VSO';F1H72&W
MWDQ06\48RL8)^B*X_P"#W[/'P _9XTR\T7X ? WP=X&L]1G6?4+3P=X9M-,B
MN957:'D6VC0.P' )!('%=A0!Y[^U!^U)\$_V//A!?_&[X]^-+71M%LY8[>W$
MT\:2ZA>2G;!9VZNRB2:1OE520!RS%45F7PC]B+XE_LU>*_CCKOQB\1?M)_#G
MQ9\</BS;Q1S>'/!GC&TU@^&]"T^.66VTB VSN?(@\V:6>Z8*DUW=N1M5[>)?
MHGXP_L]_ +]H;2K30OC]\#_!_CFQT^X-Q867C#PU:ZG%;2E=IDC2YC<(Q4D;
M@ <<5D_"/]CW]DC]G_Q)-XR^ W[+7PY\$ZQ<636=QJOA'P18:;<RV[.CM"TM
MO"C-&6C1BA."44XR!0!\^?\ !P//!;?\$@/C+-<3)&@L=(R[L !_Q.K =37V
M37+?%CX&_!3X]: GA3XY_!_PMXTTN*42QZ;XL\/VVHVZ.,881W".H/ YQGBM
MKPSX7\,^"M M?"G@WP[8:1I=C$(K+3=,M$M[>W3^ZD: *@YZ  4 7Z*** "B
MBB@ HHHH **** /S?_X.I?!?A-_^"2/B7X^B633O'/PN\5>']:^&_B73[UK6
M_P!)U&35[2TD>WFC(<$V\\Q*J>L:/UC4C[[^#?@CP!\-?A+X9^'_ ,*=#L=-
M\,Z-H5K9Z#8::!]G@M(XE6)8\$Y7:!@Y.>N3G-4OC!^SK^S[^T+86FE_'WX%
M>#?'%K82-)8VWC#PQ::G';.P 9HUN8W"$@#)&,XK0T;X0?"7PY\.U^$'A[X7
M>';#PDELULGA>RT2"+3EA)R8Q;*@B"$DY7;B@#\YO^"%WB#09_V ?VJ]5AUJ
MT>U@_:,^),LUPMPI2.,QPN'9LX"["&R>,'/2M_\ X(-?M-_L\_L[?\$$_@[\
M0OCC\:?#7A?2/#_AG5;C5[O5]7BB^SH-7OFP4+;F<\!44%G) 4$D _8_A_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D
MZ[XX\+^&;Q;#6]4\B5XQ(J>0[94DC.54CJ#5+_A;7P^_Z&#_ ,E)?_B*XOXZ
M_P#(W6W_ &#4_P#1DE<57Q68<1X["8V=&$8VB[:IW_,#VG_A;7P^_P"A@_\
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M:@&YU+5[Z.VMX03@;I)"%7GCDTVT\;^"[_PD/'UCXOTN;0C:&Z&M1:A&UH8
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MWT\17;/,D!>)9) Q57(!X7'VKX2_9O\ V>/ &NZ/XH\"? 7P7HFI^'M$;1M
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M0WEK-&LD4R'NK(RL#W!% &M1110 4444 %%%% !1110 4444 %%%% !1110
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MEU:W6]]#Z3P%HYC7XPKQP5:-*?L)7<H<ZM[2EI;FAK>SO?I:VNB_\/.?V?\
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M26US9W4$R3VUW;SQ$/!/#-''+'(A!5D!]0?$-7_X)2_#/QO^TQ\//VN/B_\
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M=,_:*^,]W<? Z:>#X=7E[XR@\S3](FMOLLNC$1VJ(UHT 6/?M%T%CC"W "*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP<GA3P9X#U7PI-HUWJ%V-0O(=1N;.>:\#+;F.-HC:*J0G<)!G,D>X;/I6B@
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M))Z510 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20220630_g13.jpg
<TEXT>
begin 644 biib-20220630_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
MDF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_
MY)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444
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M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
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M/T"V&I$>*!K<FO-)I<%IEMPT Z4;=FC7_03:^9O&_=0!^T-%?*?_  4_\?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\/+?^J*_^7'_ /<U'_#RW_JBO_EQ_P#W-7RS10!]3?\ #RW_ *HK_P"7'_\
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M K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?]%+_P#*->__ !FC_AM7]F;_ **7_P"4:]_^,U\#44 ??/\ PVK^S-_T4O\
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M_CE\0=;T>/3= 2WU#7[.U2W\4,;2Z5A(\=N@<VC%0OE%<&3Y]V10!]>U^?\
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M-V\*_P#8/;_T:] 'H=%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7
M?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9/CZUGOO NM65K'
MNEFTFY2-<@98Q, ,GWK6JKKO_(#O/^O23_T$T ?G=_PH'XM_]"G_ .3]O_\
M'*/^% _%O_H4_P#R?M__ (Y7TG10!\V?\*!^+?\ T*?_ )/V_P#\<IES^SS\
M4KR![6[\%I+%(I62.2\MV5AZ$%\$5]+44 ?-G_"@?BW_ -"G_P"3]O\ _'*/
M^% _%O\ Z%/_ ,G[?_XY7TG10!\V?\*!^+?_ $*?_D_;_P#QRC_A0/Q;_P"A
M3_\ )^W_ /CE?2=% 'S9_P *!^+?_0I_^3]O_P#'*/\ A0/Q;_Z%/_R?M_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JNN_\@.\_Z])/_035JJNN_P#(#O/^O23_
M -!- '@-%%% !1110 4444 %%%% !1110 4444 %%%% 'T-#_JE_W13J;#_J
ME_W13J "OS8^,O\ R6#Q7_V,M]_Z4/7Z3U\7_$?]F'^V_B'KVM?\)QY7VO6K
MJ?RO[,W;-\S-C/FC.,]<4 >!T5[%_P ,F_\ 4_?^4K_[;1_PR;_U/W_E*_\
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JN
MN_\ (#O/^O23_P!!-6JJZ[_R [S_ *])/_030!X#1110 4444 %%%% !1110
M 4444 %%%% !1110!]#0_P"J7_=%.IL/^J7_ '13J "O!O%7_(SZE_U_S?\
MH9KWFO!O%7_(SZE_U_S?^AF@"A1110 4444 %%%% !1110 4444 %%%% !7M
MOPW_ .1'T[_K@?\ T(UXE7MOPW_Y$?3O^N!_]"- &W1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 55UW_D!WG_ %Z2?^@FK55==_Y =Y_UZ2?^@F@#P&BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *JZ[_R [S_KTD_]!-6JJZ[_ ,@.\_Z])/\ T$T
M> T444 %%%% !1110 4444 %%%% !1110 4444 ?0T/^J7_=%.IL/^J7_=%.
MH *\&\5?\C/J7_7_ #?^AFO>:\&\5?\ (SZE_P!?\W_H9H H4444 %%%% !1
M110 4444 %%%% !1110 5[;\-_\ D1]._P"N!_\ 0C7B5>V_#?\ Y$?3O^N!
M_P#0C0!MT444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>
MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
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M?AO_ ,B/IW_7 _\ H1KQ*O;?AO\ \B/IW_7 _P#H1H VZ*** "BBB@ HHHH
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M5]M^(WQ%\"_"+P'J_P 3_B;XIL]$\/Z#827NL:MJ$P2&U@C4LSL?8#H.2<
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 55UW_D!WG_ %Z2?^@FK55==_Y =Y_UZ2?^
M@F@#P&BBB@#\_O\ @KA^Q'%\6(_&W[7_ .R]^T%?>!/BQX+\!OI/C&PA0RZ;
MXGT9D:XCL-0@/J&8I.NXKC[I9$,?KO\ P35_;)^)_P"T?>?$SX,_M+? K3_
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M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
M^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5==_Y =Y_UZ2?^@FK55==_P"0'>?]>DG_ *": / :
M*** "BBB@ HHHH **** "BBB@ HHHH **** /H:'_5+_ +HIU-A_U2_[HIU
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M%#1LS $,"3MPQ\0_:(LO$7[3_P"TA\!]2^!_PR\5Z7J7P_\ B$VN^+/&^O\
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M"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !577?^0'>?\ 7I)_Z":M55UW_D!WG_7I)_Z": /
M:*** "BBB@ HHHH **** "BBB@ HHHH **** /H:'_5+_NBG4V'_ %2_[HIU
M !7@WBK_ )&?4O\ K_F_]#->\UX-XJ_Y&?4O^O\ F_\ 0S0!0HHHH **** "
MBBB@ HHHH **** "BBB@ KVWX;_\B/IW_7 _^A&O$J]M^&__ "(^G?\ 7 _^
MA&@#;HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU>O*/
MVY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\
MHE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M** "BBB@ HHHH **** "BBB@ KVWX;_\B/IW_7 _^A&O$J]M^&__ "(^G?\
M7 _^A&@#;HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU
M>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%
M:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_(#O/^O23_T$U:JKKO\
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MOYU]Z.RHKC?^&@/A'_T-O_DA<?\ QNC_ (: ^$?_ $-O_DA<?_&Z/];.%O\
MH/H_^#8?_)!]9PW\Z^]'945QO_#0'PC_ .AM_P#)"X_^-T?\- ?"/_H;?_)"
MX_\ C='^MG"W_0?1_P#!L/\ Y(/K.&_G7WH[*BN-_P"&@/A'_P!#;_Y(7'_Q
MNC_AH#X1_P#0V_\ DA<?_&Z/];.%O^@^C_X-A_\ )!]9PW\Z^]'UQ#_JE_W1
M3J9;L'@1U/!0$?E3Z^@W-PKP;Q5_R,^I?]?\W_H9KWFO!O%7_(SZE_U_S?\
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M#3XT**** "BBB@ HHHH **** "BBB@ HHHH _4NQ_P"/*'_KDO\ *I:BL?\
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
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M &,M_P#^E#U^(>-__(MP?^.7Y(\C-_@AZLYJBBBOYT/#"BBB@ HHHH ****
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M36-0FO9S;2J44VBPWMRR%"F8T0 !L MQOP!^-W[3O[ D_P !_P!CK]L#X-^
M;3P9XFM++X?^!?&OPW\4WEY'INK6>F,;2POX+RT@8BYALY1'/$2!)'L:-0P>
M@#ZB^-/[1/P<_9[LM*N?BOXP^PSZ]J!L?#^DV6GW%_J.KW01I#!:65I'+<74
M@16<K%&Y55+' !-6_@U\<?A/^T%X.;QY\'?&MKK>FQ7\]C=O"KQS65Y"VV:U
MN(9566VN(VX>&54D0XW*,U\H?M[>(-5^'/\ P4O_ &;OBQ\,/!]_\2/&-EX;
M\6Z5/\)]$EA341HMVM@UQKUO-=216EM]GFM[>!_M,T(F6[V1N778UO\ X)-7
M]SXN^*_[3WQ6\:Z=)X2\;^*?C+%<>*OA'=$?:?!R0:196ED;ADS%/->VUNEX
MUQ;M);N)@J2R&-S0!VGQ!_X+'_\ !-SX7_'>]_9D\8?M*PQ^/=/UJ/2+KPS8
M>%]5O;@7\FS9;+]FM9%DD)D0!4).6QUXKZ:5@ZAAG!&1D8-?GEX?^(G[>/\
MP2M^"_CG]H;]H;X'_#SQ!\,[GXIZ_P",?'TOA;QC>R>)-(TW5=:FF%X()+,6
MUP+.VFMTDMTFR8[=F65CA:_0JTN[6_M(KZQN$FAGC62&6-LJZD9# CJ"#G-
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M/LDO-6ALM-N;P:7;-G;<7C6\;K9Q':Q$DQ12%8YP#7E_[._@"R\0_MM_%O\
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MA5)P.3TKRKP[^USKT=]X"OOBI\&I_#&A?$Z[CL_"6I?VVEU/!=2V[W%O;ZA
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MJ93_ !Y>GZH]$HHHK^F#Z **** "BBB@ KY*_;HN?VG[3]HSPK/^S]_P3,\
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MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
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MZ>UN)U58B0?.8$((R0?,.TX-<=X1_;L\>Z1\6?AG\,/VF_V;9?A\OQDCN4\
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MP?+M;:) B("Q+,<#EF)9B26)))KHJ "BBB@ HHHH \G_ &W?^3:]>_ZZV?\
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M (4#\6_^A3_\G[?_ ..4?\*!^+?_ $*?_D_;_P#QR@#CJ*['_A0/Q;_Z%/\
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M5[_O1?\ HQ:\;H **** "BBB@ HHHH **** "BBB@ HHHH V/ '_ ".FF_\
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MRBBBOO#\K"BBB@ HHHH **** "BBB@ HHHH *^^?V6O^3?\ PQ_UX'_T8]?
MU??/[+7_ ";_ .&/^O _^C'KY3B[_<8?XOT9]YX??\C2K_@_]NB=_1117Y\?
MK@4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_
M[ +_ /H:T =U\+O^29^'?^P%:?\ HE*Y_P"/'_(.T[_KN_\ (5T'PN_Y)GX=
M_P"P%:?^B4KG_CQ_R#M._P"N[_R% 'FE%%% !1110 4444 %%%% !1110 44
M44 %=C\$/^1OF_Z\'_\ 0TKCJ['X(?\ (WS?]>#_ /H:4 >KT444 <W\6O\
MD0KW_>B_]&+7C=>R?%K_ )$*]_WHO_1BUXW0 4444 %%%% !1110 4444 %%
M%% !1110!L> /^1TTW_K[6O<*\/\ ?\ (Z:;_P!?:U[A0 5C_$/_ )$#7/\
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M4AQXAT;P?>W6F311[FMW6,YG Y!,:[I!D$?)R"*\9^-OA#X;_LO:#\#?B;\
MM4-OK6M_$[PYH%UK$=Z\D_C*PU%O*N?MSLQ-Z[1L;E99=S1O$&4J,@E;$^QD
MU;1)-^C=M.^S_#N/#8'ZQ!/FLY-I:7U23UUT6J[]>Q]?4445U' %??/[+7_)
MO_AC_KP/_HQZ^!J^^?V6O^3?_#'_ %X'_P!&/7RG%W^XP_Q?HS[SP^_Y&E7_
M  ?^W1._HHHK\^/UP**** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\
MT-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5S_QX_Y!VG?]
M=W_D*Z#X7?\ ),_#O_8"M/\ T2E<_P#'C_D':=_UW?\ D* /-**** "BBB@
MHHHH **** "BBB@ HHHH *['X(?\C?-_UX/_ .AI7'5V/P0_Y&^;_KP?_P!#
M2@#U>BBB@#F_BU_R(5[_ +T7_HQ:\;KV3XM?\B%>_P"]%_Z,6O&Z "BBB@ H
MHHH **** "BBB@ HHHH **** -CP!_R.FF_]?:U[A7A_@#_D=--_Z^UKW"@
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M:X-K9WMQ8^6#;Z?=7 6*&?S7<F:%I(HDDW#;TSX#^,O@M_P3EU?X(Z#?O?\
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MC_R=@_\ BZ/^%(_%#_H6/_)V#_XNOH&BC_B+/$?_ #ZI?^ S_P#E@?\ $/\
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MAK0!W7PN_P"29^'?^P%:?^B4KG_CQ_R#M._Z[O\ R%=!\+O^29^'?^P%:?\
MHE*Y_P"/'_(.T[_KN_\ (4 >:4444 %%%% !1110 4444 %%%% !1110 5V/
MP0_Y&^;_ *\'_P#0TKCJ['X(?\C?-_UX/_Z&E 'J]%%% '-_%K_D0KW_ 'HO
M_1BUXW7LGQ:_Y$*]_P!Z+_T8M>-T %%%% !1110 4444 %%%% !1110 4444
M ;'@#_D=--_Z^UKW"O#_  !_R.FF_P#7VM>X4 %5==_Y =Y_UZ2?^@FK55==
M_P"0'>?]>DG_ *":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH
M**** /HJ'_5+_NBG4V'_ %2_[HIU?LZV *_.KXP?\E:\4_\ 8QWW_H]Z_16O
MSJ^,'_)6O%/_ &,=]_Z/>OL>$/\ >*OHOS/SOQ#_ -TH?XG^2.<HHHK[P_*P
MHHHH **** "BBB@ HHHH **** "OOG]EK_DW_P ,?]>!_P#1CU\#5]\_LM?\
MF_\ AC_KP/\ Z,>OE.+O]QA_B_1GWGA]_P C2K_@_P#;HG?T445^?'ZX%%%%
M !1110 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +
M_P#H:T =U\+O^29^'?\ L!6G_HE*Y_X\?\@[3O\ KN_\A70?"[_DF?AW_L!6
MG_HE*Y_X\?\ (.T[_KN_\A0!YI1110 4444 %%%% !1110 4444 %%%% !78
M_!#_ )&^;_KP?_T-*XZNQ^"'_(WS?]>#_P#H:4 >KT444 <W\6O^1"O?]Z+_
M -&+7C=>R?%K_D0KW_>B_P#1BUXW0 4444 %%%% !1110 4444 %%%% !111
M0!L> /\ D=--_P"OM:]PKP_P!_R.FF_]?:U[A0 55UW_ ) =Y_UZ2?\ H)JU
M577?^0'>?]>DG_H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@
M HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 K\ZOC!_P E:\4_]C'??^CWK]%:
M\#\5_P#(TZE_V$)O_0S5+BO_ %5_>^Q]ISZ?%RVMK_+*Y\[Q#D']O4J</:<G
M*V]KWO\ -'R'17U913_XC!_U _\ E7_[F?*_\0Z_ZBO_ "3_ .W/E.BOJRBC
M_B,'_4#_ .5?_N8?\0Z_ZBO_ "3_ .W/E.BOJRBC_B,'_4#_ .5?_N8?\0Z_
MZBO_ "3_ .W/E.BOJRBC_B,'_4#_ .5?_N8?\0Z_ZBO_ "3_ .W/E.BOJRBC
M_B,'_4#_ .5?_N8?\0Z_ZBO_ "3_ .W/E.BOJRBC_B,'_4#_ .5?_N8?\0Z_
MZBO_ "3_ .W/E.OOG]EK_DW_ ,,?]>!_]&/7F5>X?#;_ )$;3?\ KA_[,:3X
MZ_UI_P!F^K^SY?>OS\U^EK<L>_<][A_A;^PL5*M[;GYHVMRVZI_S/L;E%%%(
M^N"BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"3
M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E<_\>/^0=IW_7=_Y"N@^%W_ "3/
MP[_V K3_ -$I7C?[?GCKQ5X'\-^'+CPMJGV5[B^G68^0C[@$4C[ZG'7M7E9Y
MG&&R#*JN/Q";A3LVHV;U:6EVEN^Z,JU6-"FYRV1!17S3_P - ?%S_H;?_)"W
M_P#C='_#0'Q<_P"AM_\ )"W_ /C=?FO_ !&KA;_GS6_\!A_\L.#^UL-V?X?Y
MGTM17S3_ ,- ?%S_ *&W_P D+?\ ^-T?\- ?%S_H;?\ R0M__C='_$:N%O\
MGS6_\!A_\L#^UL-V?X?YGTM17S3_ ,- ?%S_ *&W_P D+?\ ^-T?\- ?%S_H
M;?\ R0M__C='_$:N%O\ GS6_\!A_\L#^UL-V?X?YGTM17S3_ ,- ?%S_ *&W
M_P D+?\ ^-T?\- ?%S_H;?\ R0M__C='_$:N%O\ GS6_\!A_\L#^UL-V?X?Y
MGTM17S3_ ,- ?%S_ *&W_P D+?\ ^-T?\- ?%S_H;?\ R0M__C='_$:N%O\
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MH_ULX6_Z#Z/_ (-A_P#)!]9PW\Z^]'945QO_  T!\(_^AM_\D+C_ .-T?\-
M?"/_ *&W_P D+C_XW1_K9PM_T'T?_!L/_D@^LX;^=?>CLJ*XW_AH#X1_]#;_
M .2%Q_\ &Z/^&@/A'_T-O_DA<?\ QNC_ %LX6_Z#Z/\ X-A_\D'UG#?SK[T>
ME> /^1TTW_K[6O<*^9?A5\:OAEKOQ&T;1]*\2^;<W-\B0Q_8YEW,>@R4 'XU
M]-5Z>!S++LSIN>#K0JQ3LW"2DD^S:;U-(5*=17BT_0*JZ[_R [S_ *])/_03
M5JJNN_\ (#O/^O23_P!!-=-;^%+T99\^T445^-@%%%% !1110 4444 %%%%
M!1110 4444 ?14/^J7_=%.IL/^J7_=%.K]G6P!7@?BO_ )&G4O\ L(3?^AFO
M?*\#\5_\C3J7_80F_P#0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BB
MB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\
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M.G!_[U#U/M>BBBO[//JSR;]M_P#Y-IU__KK9_P#I5%7P17WO^V__ ,FTZ_\
M]=;/_P!*HJ^"*_E_QH_Y*JE_UYC_ .EU#Y[-?]Y7I^K"BBBOR,\P**** "BB
MB@ HHHH **** "BBB@#NOV9?^2_^$O\ L-1?SK]%J_.G]F7_ )+_ .$O^PU%
M_.OT6K^E/!/_ )$6)_Z^?^VQ/>RG^#+U"JNN_P#(#O/^O23_ -!-6JJZ[_R
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M2YK=ODET\W=D2BG"/*M65/B7X?\ B9XHMK/1OA[X^B\,1O*S:GK$6GQW5VJ
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M/1=&=%)*<%+2_*WS23Y>;WK*UG?[2E;W;%U8Q5FNJ"BBBO),CNOV9?\ DO\
MX2_[#47\Z_1:OSI_9E_Y+_X2_P"PU%_.OT6K^E/!/_D18G_KY_[;$][*?X,O
M4*JZ[_R [S_KTD_]!-6JJZ[_ ,@.\_Z])/\ T$U^R5OX4O1GK'S[1117XV 4
M444 %%%% !1110 4444 %%%% !1110!]%0_ZI?\ =%.IL/\ JE_W13J_9UL
M5X'XK_Y&G4O^PA-_Z&:]\KP/Q7_R-.I?]A";_P!#-?(\7?P*7J_R SZ***^&
M **** "BBB@ HHHH **** "BBB@ KW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M
M-_ZX?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%% !1110 5Y1^W/\
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M2LF9WBOP?X2\=Z'-X8\<>%].UG3+C'VC3M5L8[B"7!R-T<@*M@\\BCPIX/\
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MM_V@O%EAX@DT*25K!)[:XCMS%:F55D-N@B"1EU#%%7<,YKZVK2O2="LZ;=[
M%%%%9 ?14/\ JE_W13J;#_JE_P!T4ZOV=; %>!^*_P#D:=2_["$W_H9KWRO
M_%?_ "-.I?\ 80F_]#-?(\7?P*7J_P @,^BBBOA@"BBB@ HHHH **** "BBB
M@ HHHH *]P^&W_(C:;_UP_\ 9C7A]>X?#;_D1M-_ZX?^S&OJ>$_]^G_A_5 ;
ME%%%??@%%%% !1110 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\
MFC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2O"O^"CMK]J\+>&!YFW&H7';/
M\"5[K\+O^29^'?\ L!6G_HE*\/\ ^"B?_(L>&?\ K_N/_0%K2EDN6<15%EV8
M4^>C4TE&\HWM[RUBU):I/1H\+B6O5PV1UJM)VDDK?^!+N?)']D_]/'_CG_UZ
M/[)_Z>/_ !S_ .O5RBN[_B!GA9_T+_\ RK7_ /EI^._ZP9O_ ,_?_)8_Y%/^
MR?\ IX_\<_\ KT?V3_T\?^.?_7JY11_Q SPL_P"A?_Y5K_\ RT/]8,W_ .?O
M_DL?\BG_ &3_ -/'_CG_ ->C^R?^GC_QS_Z]7**/^(&>%G_0O_\ *M?_ .6A
M_K!F_P#S]_\ )8_Y%/\ LG_IX_\ '/\ Z]']D_\ 3Q_XY_\ 7JY11_Q SPL_
MZ%__ )5K_P#RT/\ 6#-_^?O_ )+'_(I_V3_T\?\ CG_UZ/[)_P"GC_QS_P"O
M5RBC_B!GA9_T+_\ RK7_ /EH?ZP9O_S]_P#)8_Y%/^R?^GC_ ,<_^O1_9/\
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M%%% !1110 4444 %%%% 'T5#_JE_W13JQ8O$NK"-1_PB%Y]T?Q+3O^$EU?\
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M&8_^IW_\IO\ ]LH_X9C_ .IW_P#*;_\ ;*/^(B<'?]!7_DE3_P"0#_4[B/\
MY\?^30_^2/*:*]6_X9C_ .IW_P#*;_\ ;*/^&8_^IW_\IO\ ]LH_XB)P=_T%
M?^25/_D _P!3N(_^?'_DT/\ Y(\IHKU;_AF/_J=__*;_ /;*/^&8_P#J=_\
MRF__ &RC_B(G!W_05_Y)4_\ D _U.XC_ .?'_DT/_DCRFBO5O^&8_P#J=_\
MRF__ &RC_AF/_J=__*;_ /;*/^(B<'?]!7_DE3_Y /\ 4[B/_GQ_Y-#_ .2/
M*:*]6_X9C_ZG?_RF_P#VRC_AF/\ ZG?_ ,IO_P!LH_XB)P=_T%?^25/_ ) /
M]3N(_P#GQ_Y-#_Y(\IKW']@'_DM=[_V+D_\ Z.@K$_X9C_ZG?_RF_P#VRO4O
MV1_@W_PK_P")MSK?_"1_:]^C2P^5]C\O&9(CG.\_W>F.]<N-XXX7S#"3PV'Q
M'-.:LER35WZN*7WL]3).%\]PF;4:U:C:,9)M\T7I\I7/I"BBBODC]>/+?VS_
M /DW37?^NMI_Z515\,U]S?MG_P#)NFN_]=;3_P!*HJ^&:_1.$O\ D6R_QO\
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MM/\ T2E<[\>_^0;IW_7=_P#T$5T7PN_Y)GX=_P"P%:?^B4KG?CW_ ,@W3O\
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MD?A?_P!"Q_Y.S_\ Q='_  I'X7_]"Q_Y.S__ !==711_K+Q'_P!!E7_P9/\
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M & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5SOQ[_P"0;IW_ %W?_P!!%=%\+O\
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M))*^PHTX5:T825TVD_1LRKRE"A*4=TG^1^6?_#[/_JV;_P O/_[CH_X?9_\
M5LW_ )>?_P!QU\'T5^Z?\0?\.O\ H!_\JUO_ )8?S[_KUQ5_T$?^20_^1/O#
M_A]G_P!6S?\ EY__ ''1_P /L_\ JV;_ ,O/_P"XZ^#Z*/\ B#_AU_T _P#E
M6M_\L#_7KBK_ *"/_)(?_(GWA_P^S_ZMF_\ +S_^XZ/^'V?_ %;-_P"7G_\
M<=?!]%'_ !!_PZ_Z ?\ RK6_^6!_KUQ5_P!!'_DD/_D3[P_X?9_]6S?^7G_]
MQT?\/L_^K9O_ "\__N.O@^BC_B#_ (=?] /_ )5K?_+ _P!>N*O^@C_R2'_R
M)]X?\/L_^K9O_+S_ /N.C_A]G_U;-_Y>?_W'7P?11_Q!_P .O^@'_P JUO\
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M;_L'O_Z&E=^3?\C2C_B0'K-%%%?JP'-?%W_D0+W_ 'HO_1BUXQ7L_P 7?^1
MO?\ >B_]&+7C%?GO%?\ R,H_X5^<@"BBBOF0"BBB@ HHHH **** "BBB@ HH
MHH V?A]_R.NF?]?:U[G7AGP^_P"1UTS_ *^UKW.OO>$O]SJ?XOT0!7'_ +0_
M_) /'/\ V)VI_P#I))785Q_[0_\ R0#QS_V)VI_^DDE?9X7_ 'JG_B7YF&*_
MW:?H_P C^<.BBBOZ\/Y2"BBB@ HHHH **** "BBB@ HHHH **** /Z8]%_Y
MUI_UZQ_^@BK-5M%_Y UI_P!>L?\ Z"*LU_'LOB9_64?A05X'XK_Y&G4O^PA-
M_P"AFO?*\#\5_P#(TZE_V$)O_0S7QW%W\"EZO\BC/HHHKX8 HHHH **** "B
MBB@ HHHH **** "O</AM_P B-IO_ %P_]F->'U[A\-O^1&TW_KA_[,:^IX3_
M -^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\
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MQT?\/L_^K9O_ "\__N.O/_X@_P"(O_0#_P"5:/\ \L/&_P!>N%?^@C_R2?\
M\B?>%%?!_P#P^S_ZMF_\O/\ ^XZ/^'V?_5LW_EY__<='_$'_ !%_Z ?_ "K1
M_P#E@?Z]<*_]!'_DD_\ Y$^\**^#_P#A]G_U;-_Y>?\ ]QT?\/L_^K9O_+S_
M /N.C_B#_B+_ - /_E6C_P#+ _UZX5_Z"/\ R2?_ ,B?>%%?!_\ P^S_ .K9
MO_+S_P#N.C_A]G_U;-_Y>?\ ]QT?\0?\1?\ H!_\JT?_ )8'^O7"O_01_P"2
M3_\ D3[PHKX/_P"'V?\ U;-_Y>?_ -QT?\/L_P#JV;_R\_\ [CH_X@_XB_\
M0#_Y5H__ "P/]>N%?^@C_P DG_\ (GWA17P?_P /L_\ JV;_ ,O/_P"XZ/\
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M+:_C@<XRR+.C!2<#D>@]*OZI\// &M^"9/AKK7@;1[SPY+:"TET"ZTR*2R>
M  1&!E,908'RXQQTK8HI\\K)7V IZGX<\/:UX>N/"6LZ%97>E7=D]G=:9<VJ
M26\UNR%&A>-@5:,H2I4C!!QC%6+6UM;&UCLK*VCAAAC"0PQ(%5% P% '  '
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M;Q%JUOH6A:=-=WEW*L5M:VZ%GE<G 50.I-5J5U>P[.UPHHHIB"BBB@ HHHH
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M'/FC%V>C6N_5(*X_]H?_ )(!XY_[$[4__222NPKC_P!H?_D@'CG_ +$[4_\
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MW_Z7S5^J^%/^_8G_  Q_,_,/$_\ W/#_ .*7Y(\[HHHK]M/QP**** "BBB@
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MX5_Y*/"_XT?L;1117\O']*'RW_P6<_Y1U^.?^OK2?_3G;5^&]?N1_P %G/\
ME'7XY_Z^M)_].=M7X;U^^>%W_)/5/^OLO_28'X;XE?\ (^I_]>X_^E3"BBBO
MT@_/0HHHH **** "BBB@ HHHH **** /:O\ @G)_R?5\+/\ L<;7_P!"K^@*
MOY_?^"<G_)]7PL_['&U_]"K^@*OPSQ4_Y&U#_!_[<S]I\,O^177_ ,?_ +:@
MKC_VA_\ D@'CG_L3M3_]))*["N/_ &A_^2 >.?\ L3M3_P#222OS;"_[U3_Q
M+\S]$Q7^[3]'^1_.'1117]>'\I#[>XGM)EN;6=XY$;*21L0RGU!'2F444 %%
M%% !1110 4444 %%%% !1110!_3'HO\ R!K3_KUC_P#015FJVB_\@:T_Z]8_
M_015FOX]E\3/ZRC\*"OYU_VO?^3LOBA_V436_P#TOFK^BBOYU_VO?^3LOBA_
MV436_P#TOFK]5\*?]^Q/^&/YGYAXG_[GA_\ %+\D>=UW?P-^!M[\9)M>U6\\
M26^A^'O">C'5/$VNW-L\PM+?S4B14BC^:65Y)$14R 222RJ"1PE>M?LD?M"^
M._V9_$VL>/M#\#Z=XG\-7NF#2O&OAW68@]IJ%C._^JD')0ED^5\$*>""&*M^
MPX^6*CA)/#_'TO9==DWI=K17TO:^A^3X&.&EBHK$?!UW?3=VULGO;6U[:FE^
MT3^S-\./AQX1N?B/\+?C+;ZW86FHZ+I]SHE[I\MMJ5O)?:9)>">13F/RF\E]
MNQW(+%6QLRW'?LV_ #QE^TS\8-)^$G@R&59+Z4O?7Z6QE2PM4&Z6X< CY54$
MX)&YMJYRPKZ2_;>^ _P0^(_PMU_]J;]F?Q?J6F1Z"OAU/'OPXU5RZZ8+FRBC
ML)K>4?ZU C^6-VYL^:=R\J>'_P""6'Q-^)/A_P#:V\*?#S0/B#KECH&L7=X^
MK:'9ZM-%9WK"PGP9H58)(1M7!8'&T>E>%0S/$SX>K8BE)NI"+^-6<6H*5FDK
M/NGLTUKU/;K9=AXY]2P]2*5.<E\#NI)R:NKNZ[/JFGIT/G+2M/?5M4MM*CNK
M>!KJX2)9KN<111EF W.[<(HSDL> ,FO3]1_9R\*:W\,O$GQ%^#?QBA\4-X,C
M@F\4:=+H<MBZ6TLJP"[M2[,;B$2NBL7$4BAU8QXSCRBOHGX!77A7Q;^RU\5?
MAS\*-'O=%\71>%(=9\4ZMJ=^MW%K&CV=U"T]G;A8XOL7[QX9L-YQD$6S>@^]
MZ^95:^'A"I3DTN:*>BM9R2;E?7;;EV>KTV\K+Z5&O.5.:3?+)K>]U%M)6TWW
MONM%KOYM\%O@[X+\?6UWXG^*WQFT_P ">'+.=+8:I=Z9/?3W5RP+>5!;0#?)
MM4;G<E50,F3ET#6?VG?V;-<_9J\7Z9I$_BS3?$>B>(=$AUCPMXFT?=]GU.QE
M+!9 K#=&X*LK1MRI'<$$\CX!\#^)OB7XEMO!GAF-6EE+R/)<3".WM(E7=+<2
MN?EBB1%+.YX54R>E=I^U#\8-%^).M^'/!?@BZEG\+^ ?#%OX>\/W<\1C>^6-
MGDFO&0\IYT\DCJAY5#&IY4FE)XM9G%1G>#3YHV5HK[+3M>[?=V:O9*PXK"O+
MI.4+237+*[NWU35[62[*Z=KMW/,*[O4_@!XRT3]G>P_:-UN&6TTK5_$[:/H\
M,]L5-YL@,LDZ,3RBG"9 (+;AG*$5PE?2OQ+^)OQ(^*?_  36T/6_B?\ $'7/
M$=[:_&Z^M;:[U[5IKR6&!=&M&6)7E9BJ!F8A0< L3CDU>.KXBC4HJG:TII2[
MVL]ONW_I1@J%"M3K.I>\8-KM>ZW^_P#KK\U4445Z!P!7[W?\$MO^3 /AC_V
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M[31R5[=;/9OU^_N,HK:^'O@76/B1XNM/".BR0Q/<;WN+RZ<K!9V\:F2:XE8
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M?"34:JW5U9IIKNFFTUZ/?0****Z3G/:O^"<G_)]7PL_['&U_]"K^@*OY_?\
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MWCKXVZQ^VM\%K?X/:OJ4WAR3PMX5@\!6EG(_V.;3_LENEY&R#Y"@E6ZCG##
M5&5^%X^=_BA\,E^(O[3OCKP?^S/X3NM<TF#Q'J\^@VFBVYFQID,\K*Z!<_NU
MB (/ICN:Y+1_BO\ %+P]X5N? N@?$G7['1+S=]KT:SUF>*UGW<-OB5@C9QSD
M<UFZ!XE\1^%+\ZKX7U^]TVZ,,D)N;"Z>&0QNI5TW(0=K*2I'0@D&HP665<"O
MW;5XPY5IO9WYI>?IU<G?6RK&9E2QK]].TI<SUVTMRQ\OT25M+OV+]GO7/V3[
M7X,Z]X4^,?C_ ,9>'=?UO55BN[OPUX<@OEGTJ-8Y$M]TD\1CW7 9Y  =WD0<
M@!@W?_\ !131_@#8_"KX*S?#7QOXEU#4(_AO:0Z9!JVBQ6\4VD_;-1/VB1DE
M8I/YV5\H KL^;=GBOE&KNK^)/$7B"&RMM>U^]OH]-LQ::='>73RK:VX9F$,8
M8G8@9W;:N!EB<<FM)Y5)YA#$QJRLI.3CI;6/+II?\=B89G%8">'E2C=I)/6^
MDKZZV_#<I4445ZYY(5]O_P#! ?\ Y/5UG_LG=]_Z66-?$%?;_P#P0'_Y/5UG
M_LG=]_Z66-?.<7_\DSBO\#/H.%?^2CPO^-'[&T445_+Q_2A\M_\ !9S_ )1U
M^.?^OK2?_3G;5^&]?N1_P6<_Y1U^.?\ KZTG_P!.=M7X;U^^>%W_ "3U3_K[
M+_TF!^&^)7_(^I_]>X_^E3"BBBOT@_/3[H^$GQX^$/[1GPHUO]G[]NWPL_AG
M5_#/AC3M)A^*FB(OVU+$7MJMK#>QD%9HTD:%C*,DINQM+,[>=?"SX"_%7]G[
M_@I3<_#>Y^(5J=5\$7M]JVM>(Y[-KI+O3HK&2\N':$N&E:>U9E,>\'=*1O&"
MXY;2_P!NW5I;'5KCQU\"_ 6OZO=Z-8Z?8:G>:)(FV.TEMVA6X2*9$N@B0* 9
M5=B50,64%3YY9_M&?&2T^.,G[1Q\9RS>,)]0EO+G5+B%)!.\JLDB/&5V-$T;
M-&8]NS8=N,<5\CALIQ]/ZQ""4(3C)<K?-'G:CK'1M1^+F3TVM'1W^JQ&:8&;
MP\YMSG"47S)<LN1.6DM4G+X;-:[WEJK>T6NM_"GXC?LL_%_0OV8O VI^#%L;
MW3]=\3V.NZRNIOJNCQW8BAMX9A%$+80SW$<IC99&EX_>_NPK>#?"[X=:G\4/
M$:Z2VJQZ=I=A ;G7-;O 3;Z39*P\R=\<GE@%0?-)(ZHH+NH.YXA_:)UN_P#
MNK?#CP7X \-^$-*\0W$,WB*+PY!<[]3\I]\4<CW4\S)$K_.(HRD>X*2I*KCH
M_@Y^V9JGP;^%DGPCMOV>OAAXBTZXU'[=?7/BKP[/=W%W.NX1M(PN%4B-794
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M9_#/_L.ZA_Z)BK[\^%W_ "3/P[_V K3_ -$I7P'_ ,'$7_),_AG_ -AW4/\
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M2_\  9__ "8?\0TR+_GY5^^/_P @?SM?\(_/_P!!C1?_  H+/_X[1_PC\_\
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M5'_#+_[-/_1O'@7_ ,)*S_\ C5?!GW!\8?\ !37_ (*"?L:?M"?L8>*_A/\
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MG_Z#&B_^%!9__':_HE_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\
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M-/\ T;QX%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU1_Q%+B#_GU2_P#
M9_\ R8?\0TR+_GY5^^/_ ,@?A5^Q7XE\*_"3]K#P#\2_B#XPT73]$T3Q);W6
MIWO]L6\ODPJ?F;9$[.V/103[5^P7_#V[_@G1_P!'2:+_ . %Y_\ &:]3_P"&
M7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\ HWCP+_X25G_\:KY/B#B+&\1XB%;$
MQBG%67*FE:]^K9]1D608/A_#RHX>4FI.[YFF[VMT2/+/^'MW_!.C_HZ31?\
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M_P#R!_.U_P (_/\ ]!C1?_"@L_\ X[1_PC\__08T7_PH+/\ ^.U_1+_PR_\
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MO_LT_P#1O'@7_P )*S_^-4?\12X@_P"?5+_P&?\ \F'_ !#3(O\ GY5^^/\
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MY-2BTVXET:T@N+Q8'-I!=7#0Q22@':KR*CE%)P"P5B <[6Q@@$]%?)/['?\
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M@5H?[-GP>TGX.Z#XT\3^)8],,\EQXC\::P=0U;4YYIGFEN+JY*J996>1N<
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MMYID&G76KK;K]HEM(9)98H"^,F-7GF8+T!D8]ZP_@)\!/@]^R_\ "#0?@)\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+K"\.K?$KQ-XPU?4IEDU'Q#XKNH&N9@H(CC6.UA@MH(T!.(X(8U)9G(+NS,
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M$_#+2OC%\(]6N]1\-ZY:I=:/J5WHUW8B]MW4/'/&EU%&[Q.K*RR!=K@Y4D4
M=71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>"^,?\ D;M5_P"PE/\ ^C&KWJO!?&/_ "-VJ_\ 82G_ /1C5\CQ
M;_NU+U?Y 9M:7@[_ )&[2O\ L)0?^C%K-K2\'?\ (W:5_P!A*#_T8M?%X;_>
M8>J_,#WJBBBOV( HHHH ^3?^"[ !_P""/?[1&1_S3*__ )"O3OV+]3O=$_X)
M\?"?6-+T*XU2YL_@WH4UOIEFZ++=NFDP,L*&1E0,Q 4%B%R1D@<USW_!4W]G
M+XZ_M@?L-?$#]E?X +X2@U?Q]H,FCS:IXPUFZM+;3X9&7?*!;6MPTS[0P"'8
M,D$MVKS#PU\-?^"QO@K]DS3_ -F7P;X-_9]TN^TGX=1>&-*\8VGQ3UT7-I+%
M8"TBOTB.@X$BLJRA-V,@#/>@#IO@C^W?\79OVJ/A_P#LJ_M->$/!^C>*/B9\
M-+_Q7;^&_#.K-<7W@^ZLS8M-I&I;G83L8[X%+J-84=K691&5VO7&_P#!0'QU
M^V!H?_!3/]DKX=_"3XE^%M/\(>)=>\52OH>I:/=.]U?VGAG4&\R[EBN%\V!8
MIG\N%57$N)'9]J!>*_9E_P""9G[>?P:\6_LO^/\ Q'XF^#W]H_!+0-?\/>,E
MM-0U:\E\01:O'9_;-<-S);Q-/?R2V:R-!(B+EW)N7W +] _MQ_LK?M ?&#X]
M? 7]I7]F[7O!\6O?!SQ5K%U=:3XWDNH[._L=3TJ;3IV62UC=Q-$)!(B$!7(P
M70<D \U^*O\ P5X\&1_M:_$7]E;P#\9?@CX#/PJALH/$'B/XU>/(].&L:K<P
M?:!86%JLD<ABBC,8FO&9@DD@189-K&O9O^"<W[=_@;_@H?\ LY#XY>$-)M],
MO--\1ZAX=\4Z19:S%J5O8ZK92^7.D%Y"!'=V[ QRQ3H )(IHVPI)4<=X._9+
M_:5_9:_:<^)_QZ_9HD\#^+M&^,MQIVK^+_"'C#7+S01IFOVUHEI-?V5S;6=_
MOBN8HXB]M)&"DD>Y9B&*5]'?#NU^(-KX1M1\4]5TR[UZ3?)?G1;=X[2$LQ*P
MP^82[JBE4\Q\-(5+[8]PC4 \'_:J_;FA^!_[4'@?]E5?&?@WP5J'CGPQJ&JZ
M#XH^(Z3#3-7O;:>WA71;=TEA474@F,I8R,R(J[(9B_R>KZ%J7[07B_\ 9MTK
M69M*\/>$_B?J?A&TGO=/U**74=,TC6)+=&GA812127$,4I=1M="P4'(S7FW[
M8/[-_P 2OVCM<O? /BGX-_"OXG_";6_"BVFJ^"?B-J5Q9R6NK)-.R7UM+#8W
M6W,4JH2 DBLB/&Z%"'[#]AW]G?Q#^R7^R)\//V:_%?Q+N_&&H^"_#%MI=WXC
MO=P>[:-<?*'9F$:C"(&8D(B@DD4 ?*7_  2K^/G[<NO_ /!)?P'\99O#FE?%
M#QMXQ\22):S-.]E]F%[XBNX[_5-1>21M\-N'DG\JW4,4C$2@9W+]!_L4?MDS
M?M)>._BY\%O$5]X;U'Q!\'_%UGH^I>(/!MPSZ7K$-WIUO?07$*M)(T#KYTD$
ML)DDV26SX<AL+\T>"_\ @F-_P4"\!?\ !.71_P!AO2/BW\+I5\!?$&SU'P_;
MM)J<=CXVT&+6IM0GTS6W$1:WCN(I4ADAACG0B)@S2)*47VK]CW]D?]J+X$_M
MG?&+X^_$#5?AN?"GQ>M?#U]-I/AE;T76C7^FZ6FFK8PK(BQR6PBBC87)*,S*
MP^S1!AL +.A_M=?M0?M$_$7XNZ+^R)\-?!,FB_!SQ;)X4N9O'&IW44_BC78+
M*WN[FT@\A=NGP1BZ@B%U()R[ESY(50S> Z/_ ,%YKCQ-X:^$NK:AX1^&7@$?
M'R&ZU;P!JOQ!^)/V6R\/:!90HM[=ZR\D$*?:C>;H+>TMI'$V<M-$$8GC?B9X
M6_;@\;?M<?M!^.?V+/V=Y?&/PW\5>+H="\17/PT_:"L_"8U2\L=-M[74$NH;
MW2[IEOUG\RVDO+&>U?;;QQEB\3.?8/A%^S3XA^*VG? S]L/]DSX-:3\'O&GP
M+L->^'M_\'_%6J+/I-WI"3BSNM+.I6 GVF*XLDG@O8TFRP=98F9F" 'H?[#?
M_!3KP1^U+^T?X\_9"O\ Q?\ #_Q!XI\%:%9Z_I_BKX6^*XM6T3Q%I%Q(T)F3
M8SM97$,P$4UK(\A7S(G61UD^7V/]L[XU>.OV;OV4OB%^T'\.?!.E>(M3\#^#
MM2UY='UG69+"&YCL[62XD7S8X)FW;8SM7: QP"Z [AL?"*3]H346O];^/.F>
M$M&>7RX],\.^$=5N-3BME7<7FEOKBVM6F9R5 1;>-8PA^:0ME>'_ ."E_P#R
MCB_: _[(EXK_ /3/=4 >%>&O^"C_ .UIX(_8[^'7_!0?]ISX$^"M(^'/C"'P
M_/XGT/P_K5U+J_A;3]6E@@M]4>25!%=()+F!YK54C>".1R)9FB(;0\:?MU_M
MR:_^WC\4/V'O@M\!_AE9_P#"#?#_ $WQ7I_CCQ;XMOWL3:W,ETBI=1P6JR1S
M2-  (TW)&B32&:0JD3\!\!?V2/VP_P!KK_@F/\$?V1_CYXG\ 0_#6?PGX0O/
M$WBW1+Z]?6_$&BV26=[;Z:;"2V6&RED\F"&>Z%W."J2,L2F4"/VWX:_LK_M%
MZ-_P4H^*W[4GCO0O <OP_P#B+X"T;PO#96?BB]FU2"+37OW6:2!]/2%O.-Z5
M:,3?NPF0TG2@#S3PA_P5 _:HO/V"[#_@J+XP_9_\'P_"M=.CU?5_"^E:U=RZ
M\/#ZRB.?6H)9(DA;"![I+)T5FMP,SK*?+'M_[1/[8/BOPQ\<_A9^RS^SQX;T
M;6/%WQ6TK5=;M-<\074J:5HVBZ=';M/>2)"/,NI'>[MXXH$:/<79FD14^;Q-
M?^";G[5UO^PS+_P2EL_B+X,7X0R6S^'T^(S7]W_PDL?A)YRQTO\ L[[-]F:Z
M%L39B]^UA=N)?LV[Y#7_ ."I7A7XNZM\>/@#X"_8H^&VC^(?B'X"M-<U^WTK
M3?B!'X;U[2M#%I#IWF6]Y<6=Y;?8WGG@26WN(9!.\,.U&$4KQ@'3:3^WM^VG
M>_&/XK_L]6O[.'PWO_$'P/T2'5_&6K3^/[ZPLM9LK^QGN=*EL(UT^YDBD=[6
MZCGBF)$1@&R242!EYC]FS]NS_@J9^U-\!/@K^T]X%_97^%VF^$/BK! -<_M#
MQ)>/>^%;9K>25M;F3$<<UH3"ZI;))YI$ULS2KYDBPU_V1;/]HFPA^+_P1^(/
M[#MQX%^,_P 2?"\NNW?C#QM\9;7Q%!XLV(FFAKJ^T^S#V*VZRQK!:I91PE/,
M\I5(F(DTW_@GC^V[HG_!/W]G']F2PU[X97.M_!#7=&'BOPMJ/B#49/#?CS2;
M&RDMQ#<RBP$T3>:\=RD+031"6WC+;\#: ?0?[ O[8L/[8W@3QMJ%Q_8DNI_#
MSXF:KX+UK4O#%Z9],U.:T6":.\M6)8K'+;W5NYC+.8W9TWR!0[>4_"[]MK]N
MKX^_M=?'S]E/X?\ P+^&_A]_@CJ>D0_\)'K?B*_OK75O[0TQ+ZVMU$4$+K(R
M2 RR;=MO\H5+K?E>M_8 _9/_ &EOV6?BK\;[_P"*GBCP)JGA?XG_ !+G\<Z7
M+X<AO(KVWOKNPT^VGM9(ILQQP1?82$97D:7S-Q$.W8:G[,/[-W[7'P7_ &LO
MVCOVB?%WACX<7-C\8M9T75/#FFZ;XXOVELY-.T>WTP0W+/I2@+(+<2F1-Q0L
M5V/C=0!YEX?_ ."NGQJ\<?L$3?\ !4KP_P#L[Z3I7PK\/6YE\2^%-:U65]?N
MHK6Z6TU>XM)HE\A5M9TNTB21";H6I8M;>8H'?'_@H7XS^(O[3WC_ /9O^"%]
MX"3Q/\/O$.D6P^'?BR>:WUKQ/HMU;65U/KMA)YJH;>..YN%2-8IM[V9WRP^:
MH'EWA?\ X)M_MKZ/_P $3?%'_!,C4/\ A5K>+]=TW7M+@\10^,-2_LU+?5-2
MO;UYV!TOS0\7VI8Q&%(?:6+I]VKWQY_X)J?M.?MB?"^#X;_M&>%OA'8:]HGB
M+2K_ .''Q<\,^(K^3Q%X#@MY+226.S9M-A:=]T,Y0F>!"+A Z-Y6YP#[\HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHKYW\;?M[_ /"'>,]7\(_\*H^T_P!E:I<6?VC^W=GF^5(R;MOD';G;
MG&3C/4UV8/ 8O'R<:$>9K?5+\VCSLQS7 95",\5/E4M%HW^29]$45\Q_\/&_
M^J.?^7#_ /<]:G@G]O?_ (3'QGI'A'_A5'V;^U=4M[/[1_;N_P KS9%3=M\@
M;L;LXR,XZBNV7#V;PBY.EHO[T?\ ,\R'%W#U2:A&MJ]%[L__ )$^B****\8^
MD"BBB@ HHHH **** "BBB@ HHHH **** /G/Q%_P2<_8-\1?%36OC/#\(M7T
M/7O$FIMJ7B-_!WQ#U[0K35KQCE[BZL].OH+:XD<Y+O)$Q<DEBV37O7A#P?X4
M^'WA>Q\$^!O#=CH^CZ7;+;Z=IFFVRPP6T2C 1$4 *!Z 5I44 %<I\;O@K\._
MVBOA7KGP4^+6FWU]X:\2:;-I^N6&GZY>:<UW:S1M'+"TUG+%*$='964. 0<&
MNKHH YGX._"'P)\!/AEHOP>^&-C?6OA[P[IT-AHUGJ&MW>H26UM%&L<40GNY
M9965455&YS@"NFHHH *\<_:9_8#_ &2_VOO$>B>-OCQ\+)+[Q#X;BDAT+Q1H
M?B+4=$U:RA<Y>%+[3+BWN1$3R8_,V9).,DU['10!PGP(_9H^"W[-6A7&@_!_
MPE-9?;3&=1U+4]8N]3U&^\L$1_:+Z]EFN;@(&8*))&VAFVXR:[NBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OSN^-G_)9O%W_8SW__ *425^B-?G=\;/\ DLWB[_L9[_\
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MA[\-O%OBWQ+XP\'7&D>'M"\'^%;W5;FYN92BJ"MK$_E(,EB\FU0%/)/%>>_
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M@+1?%%I%\(/'/Q*T%M.\3:KI[6,37,=^DD,,L_D7!,*7,T223;';E-AKZJH
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M\*R:R?VD3K7P1U2/P3)#X6TC4(7EOH?"36LFH732Z?'/;WL<>+C?#(8HTS)
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M='EEG33II3*"PN/L/V242-\XD ?.X9H ^FM1_:&^ .D:-8^(]6^./@^UT_5
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MU@&DTH16,,0;3D2\,5W+Y[;P;..-0XD=E^M** "BBB@ HHHH **** "BBB@
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M ((H ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\F\2?#/QO?^(;^^M-$WQ37LLD3_ &F(;E+D@X+9'!KU
MFB@#QG_A5'C_ /Z '_DU%_\ %5=\.?#/QO8>(;"^N]$V10WL4DK_ &F([5#@
MDX#9/ KUFB@ HHHH **** .4^./P.^$G[2GPFUWX%_';P%8>)_"7B6Q-IK>B
M:G&6BN8B0PY!#(RL%=74AT=592K*"/GS5_\ @D?\*_'/@VP^#7QI_:?^-GQ
M^&6G20&+X7^+_&5O+I5S'"X>&"[F@M(K^_A1E0^5=74J-L7>&Q7U=10!XI^T
ME^PE\)OVD_$/PT\8W7BSQ7X*UGX3:G<7/@W5?A_JD>GRVT%Q:&SN;(AHI%%O
M+ 1&0BJZA5,;H1FH+3]A7PQ8_MFG]M^T^.GC]?$O_""+X.316GTQ]+71ENS=
MK!L>Q,[,)R7\UIC*>A<CBO<J* /E?2_^"1O[/C^'_B=X4^(7Q*\?>,+#XJ^.
MD\:ZU%KFHV%O+IGB./[,(-4T^?3[.VFLYX1:6X0JY4"/E3N;/K_PN_9ZUKP'
MXDB\5>.?VC_B#\0;FRMC#I4?B^?3(H+'<-KR+#IEC9QS2LOR^;.LKJ"P1E#O
MN])HH \3^"?[$7ASX'_M-_$?]JG2?C?XZUG7/BI_9O\ PEFE:X^EG3W_ +/M
MFMK/R4@L8I(O+B8KQ)\_5]YYKOOCS\(K7X^?![Q%\&-2\;:WX?LO$^D7&F:C
MJ7ATVHNUMIXFBE6,W4$T:ED=ANV$CJ"#S7744 ?/<?\ P39^!EY^R;X%_9"\
M7>*_%VNZ1\,)-*F^'/BB\U&WM]<\.7&F1+#I]Q;7-G;P*)88UV!F1O,5W67S
M%=E/H7PK^ NK> -=G\5>-OC]XY^(&IO9M:6=WXNETZ%+*!F5G6*WTRSL[<LQ
M5<RO&\N%VAPI*GT*B@#P#X0_\$[OAG\+KWX87/B#XL^._'47P:M)H?AK;>-;
MZQF&C-)9-8F7S+:S@EN9%M'DA5KAY<+(3C>%8=/\?/V//AQ\>?B'X5^-8\2>
M(/"'Q \$QW4'AGQWX/NH(K^VM;D*+FSD2YAGMKJWDV(QBN(955D5T"N-U>L4
M4 >-^,_V)?AW\6?V>?'7[.?QU\?>+_'5A\1]'FTSQ5KGB#4H([^:W=&1%A%G
M!!;6HCW%D6&!%WY=E=F<MQWPV_X)B_#GX=?'7P5^TG+^T7\7M?\ &7@WPA+X
M7FU;7_%D$G]OZ09H9XK2^CBMHT*Q301R P+ TC;O/,V]@?I6B@#Q/XB_L1>'
M/B1^V!X-_;0O_C?XZL/$'@32+[2] T+3GTL:6MG>^1]LBD26Q>9_--M"Q8S;
ME*?(4'%1W7["O@O3/B5XJ^(GPH^,?C[X?P^/M474_'OASP;JEI#8:[?>4D+W
M9\^UFGLKB2*.-))K&6VD?8KEO, >O<** /"_VB_V"_ W[17BCX7>([CXM^-/
M",/P?U^#6O!>D>$&TR.TAO8;>:V221;JQG=P+>>2+R]P3:V=N[YJGB_8@\/1
M_MLC]NUOCEX[?Q1_PA(\)'1&?2O[).D"\^V?9_+%@)L^?\_F^=YF/EW;>*]M
MHH \E_;!_8Z^'G[9W@SPWX7\<>,/%'AN^\&>-;'Q9X1\3>#M1BMM0TG5K194
MBGC,T4T3@QSS1LDL;HRR,"N<$9/[.7[!?PT_9B^-WCOXZ^!/B9X^U"_^([VU
MSXITGQ#XD%W83ZC%;PV[:BL?EAEN)(X(E;YS$@7;%'$ORU[A10!X5\,/V%-&
M^$_[1?Q/_:=\-_M$?$.;Q%\6;;3X?$T%\=&>TA^P6TEM9/;1C3E,30QRMC+,
MKG!D$E<5\,_^"1WP-^%WPGTKX7Z5\9?B1>7/ACQW>^,? _B^\U'34UCPQK%[
M+<RWL]K-;V,4<D=P;NX66WN8YX'2388]H KZJHH ^;/@_P#\$P_A-\)_VQM2
M_;QO_C9\4/%GQ(UGPNF@:QJ7B7Q-"MK=V:3>;&K6EE;V\"!2$ CC18OD#^69
M&DD?VSXT?!KX9_M#_"CQ!\#_ (R^$K?7?"WBC3)=/UO2KHLJW$$@P0&0AD8<
M,KJ0R,JLI! (Z>B@#Y-^)7_!(GX7?&SQE\-O&_QM_:G^-OBJ\^$GB&#5_ 0O
MO%UG:BPDC1DV.]E9027)8&/=/.\ES^Z $P#S"3T/Q7^POX,N/C?KW[1GP<^+
MWC?X8>,/%VGV=GXUU+P3/I\L?B%+1#':R7=OJEG>0-/%&3&MPD:3%,(SLH '
MM]% &+\/? VF_#CPC:>$-+U/4KY+8.TNH:Q?O<W=W*[EY)I97Y9V=F.!A5R%
M55554>.>%O\ @F?^R+X8^+_QN^,K?#S^TKS]H*QM[/XC:3JLBRV$]NEJ;:6.
M&$*/*%PI#S_,3(ZJQ(VC'OM% 'B'P?\ V(K'X.67AWPAI_[2_P 4M:\&>$E@
M3PWX%U[6+&2RLTM\?9HWNHK*/4+M(=J[4N;J93L7>'VC$/Q!_8)\#?$S]KK2
M_P!L/Q-\7/&;ZKI7A"\\+1^% NE/HEQH]W+%+=V<T,M@\TB3/!&68S;P%PK*
M#BO=:* /F_PA_P $Q/@IX7M?!7@O4OB7X_\ $'@#X;:Q;:I\/_AAX@UJVGT;
M0[FU.;(JRVRWMVEJ<&"*[N9XXBD95<Q1E/GO_@K!8_!KXF_\%1OV*_A5XX^-
M[>$M1MM5\;:A::CHOB:&QU+2[M-(MWLYE\S<OSRH$$<R/%,"T;)(K%3^BE%
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MCJ/Q9J_PZU&^L7TF2_2_CU!41OL8NXK?[7#%,8$N%1F5MP(DE#]Y^UI^R_\
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M>)X]9T748Y81/::C87D8 DMYXMWR, \4D4L;9*;F^E: "BBB@ HHHH ****
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M@U&ZDO)[!H+>QN$U.**YGF>-_.M'9'"-M(\RNW_:<_9_^,WQJ;1O 'B;X?\
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M^+/%7P_\-^-+7]JV[^.'PJUO1=8OM5MK>YEBBMVT?48);.U9H);99HY)HGW
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MB?&'P_K=]JWP^U@:KX/GTWQMJVF)IUZ$>/[0(K*ZBCDDV22)ND5B4=E^Z2*
M/-M!_9I_:0\=?M9V?[;OQYTWP/;Z[X)\!7_AOX:?#_P[XGO+JPMI+^>WEO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20220630_g14.jpg
<TEXT>
begin 644 biib-20220630_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
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M[^2?W+_Y(#VFBO%O^%M?$'_H8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*/\
M6S+OY)_<O_D@/::*\6_X6U\0?^A@_P#)2+_XBO5/!&I7NL>%++4M1F\R>:+=
M(^T#)R>P %=^79UA<SJNG2C)-*^J7IT; U:***]@ HHHH **** "BBB@ HHH
MH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH Z3X:^#=*G^'
M.@3O<W8+Z):L0MTP&3"M;?\ P@^D?\_-[_X%M47PN_Y)GX=_[ 5I_P"B4K=H
M Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X
M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MI[V^NY0D4$:C+.S'@ #O7XVDV[("[1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC3J7_80F_P#0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH
M*]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\ A_5 ;E%%
M%??@%%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H
M_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(\7?P*7J_R SZ***^&
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MS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !577?^0'>?]>DG_H)J
MU577?^0'>?\ 7I)_Z":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HH
MHH **** /HJ'_5+_ +HIU-A_U2_[HIU?LZV *\#\5_\ (TZE_P!A";_T,U[Y
M7@?BO_D:=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444
M %%%% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\
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MM?\ ^$+DWS.AMO[<O]WEM.3(T7F^8(V<EC'L)Y- 'O\ 7E'[<_\ R:/X]_[
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M_DI+_P#$4?VEEW_/Z'_@2_S Z.BN<_X6U\/O^A@_\E)?_B*/^%M?#[_H8/\
MR4E_^(H_M++O^?T/_ E_F!T=%<Y_PMKX??\ 0P?^2DO_ ,11_P +:^'W_0P?
M^2DO_P 11_:67?\ /Z'_ ($O\P.CHKG/^%M?#[_H8/\ R4E_^(H_X6U\/O\
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M#_V8UX?7N'PV_P"1&TW_ *X?^S&OJ>$_]^G_ (?U0&Y1117WX!1110 4444
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M)68+)<J&*-@_@>U>P?\ "#Z1_P _-[_X%M7WO"7^YU/\7Z(#8JKKO_(#O/\
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M"-Y /=*\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
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M\>_^0;IW_7=__0171?"[_DF?AW_L!6G_ *)2N=^/?_(-T[_KN_\ Z"*\?/\
M_D45?E^: \RHHHK\O _./X>?M6_M*_ML_&:UU?X1?M8:/X+UWP_\8_$_A>'X
M5S^&HKF+28[#3]26WEUA#(EU<FX^S^8?+DBB3>0@,D):OI+XO?M _'#X(?\
M!++4/VB/B%;06?Q1TSX-0WU];M9JD<7B>33T41^2PP%^W2*NPC&.*^0/VP/@
MW^Q]^V/XU\'?MF?LO?'?3?@G\7H/$^NZ5XH^)'A[78[>;3;K3=/U O#JT095
M>,R6:JSR*KR0..60JM?1/P'_ &A_#_QT_P""17@G]H/_ (*9> K.6P\0Z+ID
M_C;3KWP\\]K=[M3CBM+R:U1"!#*1:W3@KY2I(Q8",$5[F(ITVJ<XQTNDXV]Y
M.[T_O)V]=K[ZAW/[(7PY_:ILO$4OC;XP_P#!1_2_B_H26KVRZ-X=^'NE:9;Q
M7GRY:2YMI)7?:,X0&/D@G(&TM^/'P>_X*'?%CXRZEJ/P/_;)TKX2>"M/T^TM
M=+TX_#BR\07.K7.'DN+QWGE0VZ R1P+'R28'<@!E+><ZW\,?A7\$_P#@K!\(
M/#W[)G@;1?#,^M_#_P 1R_&#1?"&GQ6EI+HL26_]E75Y! JQB47S&.&4KO9&
MG4$JN![S^VO\4O%'PI_9QUV^^'5PJ>,-?>W\.>!\\XUK4ITLK.0@<E(I9EF?
MTCA<D@ D<DG-5X2A9\ZTO&.FMMK6Z;VV=P.$_P"">_C/]I37?@+XP^(/QX^,
M+_%&6+QIK5MX+U.P\+6>C-J6F6$AM%9((24!GN;>Y:-V<AHWA;(!KR?X^?%G
M_@I;^QEXG^'W[0GQ:^-G@SQKX.\7_$32/#/C'X6:/X*%F= 34[@6\4FG:AYK
M3WLD,CHI\Y5$O+!(\X3[!^%'PX\&? #X.>'OA3X79;30?!_AVVTVSDN'"[+:
MVA6,/(QXSM3<S'J22:^5-6_; _8L_:D^*^D?%SX@_M2?#RQ^&WPLUJ74_"6E
M7GC"R%SXCUV%9(5U1K?S/,^S6P:5;5-N^>9_/"[8[9I'1E[2O.:@G#K[JVZ)
M6V;\O79 ?:=?/7[9G[;4'P%\<^$?V=_AQ?\ AD?$/QRLMS:W7C#41;Z3X=TJ
M%E6?5;XAT9T#ND45NKHUQ,P0.@5W7U_QA\9?A3\/O$WAGP9XZ^(&E:/J_C.]
MDL_"NFZE=K#/JEPD?F/%"C8+LJ<D#ID#J0#\M^&OAI\.]6_X+3_$CQ+\<_#&
MG7FL7/P3\/1_"F36;=)5?34NM0&L+;^8"-Z3O;>8%^94G!/RR<X86G#F<ZBT
M2;MWUM^#U?HP/J_X>:3X@T?PI;0>)_B#+XGO)5$LNKO9P6Z2;@#B*.!0JQ=U
M#%VP>7?K6W7RK_P2>DV_#WXLZ9X/<-\.;#X[^(K;X4&!LVBZ*OD>9'9D?+]C
M2_-^D6SY JX7Y0M?5598BG[*LXWV^7X=/0 KL_@;_P CA-_V#W_]#2N,KL_@
M;_R.$W_8/?\ ]#2NS)O^1I1_Q(#UFBBBOU8#FOB[_P B!>_[T7_HQ:\8KV?X
MN_\ (@7O^]%_Z,6O&*_/>*_^1E'_  K\Y %%%%?,@%%%% !1110 4444 %%%
M% !1110!L_#[_D==,_Z^UKW.O#/A]_R.NF?]?:U[G7WO"7^YU/\ %^B *JZ[
M_P @.\_Z])/_ $$U:JKKO_(#O/\ KTD_]!-?3UOX4O1@?/M%%%?C8!1110 4
M444 %%%% !1110 4444 %%%% 'T5#_JE_P!T4ZFP_P"J7_=%.K]G6P!7@?BO
M_D:=2_["$W_H9KWRO _%?_(TZE_V$)O_ $,U\CQ=_ I>K_(#/HHHKX8 HHHH
M **** "BBB@ HHHH **** "O</AM_P B-IO_ %P_]F->'U[A\-O^1&TW_KA_
M[,:^IX3_ -^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_P#R:/X]
M_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*YWX
M]_\ (-T[_KN__H(KHOA=_P DS\._]@*T_P#1*5SOQ[_Y!NG?]=W_ /017CY_
M_P BBK\OS0'F5%%%?EX'EOCS]B3]DCXF^+_#_CKQU^SEX*U+4_#-R\^DW-UX
M8M'*,T3Q[6W1G<H\PL%/"NJN.5!KTN^TW3M3TZ;1]2T^"XM+B%H9[6>(/')&
MPVLC*1AE()!!X(-3T5<JDY))N]M@.8^&GP4^#7P7M+JP^#OPD\,>$X+Z59;Z
M#PSH-O8)<.!@,X@10Y X!.36UK'AKPYXAFL;C7] LKZ33+T7FFO>6J2FTN0C
MH)HBP/ER!)'4.N#AV&<$U=HJ7*3=V]0*?B+P[X?\7Z!?>%/%FA6>J:7J=I):
MZEINHVJ3V]W!(I22*6-P5D1E)5E8$$$@C!KS+3/V"/V%M$U*WUG1OV+?A-:7
MEI.DUI=VOPYTR.6&5&#*Z,L *L" 00<@C->LT54:E2"M%M 9FM^"_!WB75M+
MU[Q'X3TS4+[0[E[C1;V]L(Y9=/F9#&TD#L"8F*,REE()4D=#6=\2O@Y\(OC/
MI4&A?&'X5^&_%EC;3>=;6?B70[>_BBDQC>J3HP5L<9 SBNDHI*4DTT]@*VD:
M/I/A_2K;0M TNVL;&S@6&TL[.!8HH(U&%1$4 *H    P *LT45.X!79_ W_D
M<)O^P>__ *&E<979_ W_ )'";_L'O_Z&E>EDW_(TH_XD!ZS1117ZL!S7Q=_Y
M$"]_WHO_ $8M>,5[/\7?^1 O?]Z+_P!&+7C%?GO%?_(RC_A7YR ****^9 **
M** "BBB@ HHHH **** "BBB@#9^'W_(ZZ9_U]K7N=>&?#[_D==,_Z^UKW.OO
M>$O]SJ?XOT0!577?^0'>?]>DG_H)JU577?\ D!WG_7I)_P"@FOIZW\*7HP/G
MVBBBOQL HHHH **** "BBB@ HHHH **** "BBB@#Z*A_U2_[HIU-A_U2_P"Z
M*=7[.M@"O _%?_(TZE_V$)O_ $,U[Y7@?BO_ )&G4O\ L(3?^AFOD>+OX%+U
M?Y 9]%%%?# %%%% !1110 4444 %%%% !1110 5[A\-O^1&TW_KA_P"S&O#Z
M]P^&W_(C:;_UP_\ 9C7U/"?^_3_P_J@-RBBBOOP"BBB@ HHHH **** "BBB@
M KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._
M]@*T_P#1*5SOQ[_Y!NG?]=W_ /0171?"[_DF?AW_ + 5I_Z)2N=^/?\ R#=.
M_P"N[_\ H(KQ\_\ ^115^7YH#S*BBBOR\ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 5V?P-_P"1PF_[![_^AI7&5V?P-_Y'";_L'O\
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M?]@]_P#T-*]+)O\ D:4?\2 ]9HHHK]6 YKXN_P#(@7O^]%_Z,6O&*]G^+O\
MR(%[_O1?^C%KQBOSWBO_ )&4?\*_.0!1117S(!1110 4444 %%%% !1110 4
M444 ;/P^_P"1UTS_ *^UKW.O#/A]_P CKIG_ %]K7N=?>\)?[G4_Q?H@"JNN
M_P#(#O/^O23_ -!-6JJZ[_R [S_KTD_]!-?3UOX4O1@?/M%%%?C8!1110 44
M44 %%%% !1110 4444 %%%% 'T5#_JE_W13J;#_JE_W13J_9UL 5X'XK_P"1
MIU+_ +"$W_H9KWRO _%?_(TZE_V$)O\ T,U\CQ=_ I>K_(#/HHHKX8 HHHH
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M#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J W****^_ **** "BBB@ HHHH
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M_P"O23_T$U]/6_A2]&!\^T445^-@%%%% !1110 4444 %%%% !1110 4444
M?14/^J7_ '13J;#_ *I?]T4ZOV=; %>!^*_^1IU+_L(3?^AFO?*\#\5_\C3J
M7_80F_\ 0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P
M^&W_ "(VF_\ 7#_V8UX?7N'PV_Y$;3?^N'_LQKZGA/\ WZ?^']4!N4445]^
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M8H_Z.$T7_OW/_P#&Z:__  48_8G1E4_M!Z/\QP,0W!_/$?%']FYC_P ^9_\
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M !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\
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M_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\
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M !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\
M&J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :
MKN:* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JN
MYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[F
MB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:*
M .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH
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M,_B9XAN-.TOPNWB\:3-;VMO;-<7.I.[6TR_9(%55E<E2K3P(HD>55KQW0_\
M@IS^U[X@_;8US]@>P_8&\,_\)SX?\ 6_C"^ED^-A%@=.FN1;($E_L?<9?,/*
ME ,<[NU<_P#\&^7B_P ??M=_L7^'?^"E/[2'BG_A)/B?\1-)?0)]3>U$4>FZ
M3I%[/8QVMN@)"?:)[>:^N'&/-GN2,!(842C\+O\ E9W^*/\ V:/H_P#Z>UH
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MOXG:IXC%K'/K/Q<\9#6+FS@M_-*6]L5AB6&(M-([ +EF())VKCVNBB@#Q?\
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M\0_B7'>Z&TOD/#$\EI%:1"0Q;]\8)VI(B.!E%Q]5444 %%%% !1110 4444
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20220630_g15.jpg
<TEXT>
begin 644 biib-20220630_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D7B
M#XH>.K'7KZRM=<VQ0WDJ1K]FB.%#D 9*^E>NUX'XK_Y&G4O^PA-_Z&:^6XHQ
M&(P]&FZ4W&[>S:Z>0&G_ ,+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\
M$5SE%?&_VEF/_/Z?_@3_ ,P.C_X6U\0?^A@_\E(O_B*/^%M?$'_H8/\ R4B_
M^(KG**/[2S'_ )_3_P# G_F!T?\ PMKX@_\ 0P?^2D7_ ,11_P +:^(/_0P?
M^2D7_P 17.44?VEF/_/Z?_@3_P P.C_X6U\0?^A@_P#)2+_XBC_A;7Q!_P"A
M@_\ )2+_ .(KG**/[2S'_G]/_P "?^8'1_\ "VOB#_T,'_DI%_\ $4?\+:^(
M/_0P?^2D7_Q%<Y11_:68_P#/Z?\ X$_\P.C_ .%M?$'_ *&#_P E(O\ XBC_
M (6U\0?^A@_\E(O_ (BN<HH_M+,?^?T__ G_ )@='_PMKX@_]#!_Y*1?_$5Z
MIX(U*]UCPI9:EJ,WF3S1;I'V@9.3V  KPBO</AM_R(VF_P#7#_V8U])PQB\5
MB,;.-6I*2Y>K;ZKN!N4445]N 4444 %%%% !1110 4444 %>4?MS_P#)H_CW
M_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X
M7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?_
M "-.I?\ 80F_]#->^5X'XK_Y&G4O^PA-_P"AFOD.+OX%+U?Y 9]9'BWP!X$\
M?V8T_P =^"M(UNW$;QB#5]-BN4V. '7;(I&&  ([X&:UZ*^'3:=T!P?P$_9A
M^ /[+_AZZ\,? 3X2Z!X6M+Z]FNKX:+I,-LUQ))-)+^\:-%+A3(RH#D(F%7
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MU]3PG_OT_P##^J ["BLNSM/%J72/?:M:O$&_>(EN02/8UJ5]^ 4444 %%%%
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MH@"BBBOJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\
M(TZE_P!A";_T,U[Y7@?BO_D:=2_["$W_ *&:^0XN_@4O5_D!GT445\, 4444
M %%%% !1110 4444 %%%% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\
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M9_B[_P B!>_[T7_HQ:\8K\]XK_Y&4?\ "OSD 4445\R 4444 %%%% !1110
M4444 %%%% &S\/O^1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_P 7Z( H
MHHKZL HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?\ R-.I
M?]A";_T,U[Y7@?BO_D:=2_["$W_H9KY#B[^!2]7^0&?1117PP!1110 4444
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MMX8U[3YH[J"17C/EW-M,A((:-R Z'YD=ADAB" =#7E'[<_\ R:/X]_[ +_\
MH:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/
MP[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-
M?%W_ )$"]_WHO_1BUXQ7L_Q=_P"1 O?]Z+_T8M>,5^>\5_\ (RC_ (5^<@"B
MBBOF0"BBB@ HHHH **** "BBB@ HHHH V?A]_P CKIG_ %]K7N=>&?#[_D==
M,_Z^UKW.OO>$O]SJ?XOT0!1117U8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>!^*_P#D:=2_["$W_H9KWRO _%?_ "-.I?\ 80F_]#-?(<7?
MP*7J_P @,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&W_(C:;_UP_\
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MQ"KNL4TCJTKHC,@>5@A*[: /9:\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
MDT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXN_P#(@7O^]%_Z
M,6O&*]G^+O\ R(%[_O1?^C%KQBOSWBO_ )&4?\*_.0!1117S(!1110 4444
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M>.6YF#J&$D[Y /% 'N]>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
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M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- %+XN_\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
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M.OO>$O\ <ZG^+]$ 4445]6 4444 %%%% !1110 4444 %%%% !1110 4444
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M^1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_Q?H@"BBBOJP"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\ (TZE_P!A";_T,U[Y7@?B
MO_D:=2_["$W_ *&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%
M% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J
MW****^_ **** "BBB@ KXY_;>_X*XV_[#/[45M\ =9_8S^-'Q4MM3\ VGB"S
MG^"G@@:Y=6,CWMY;2K>1M/$(HR((C&PR2WF ]L?8U>(?'3QG^TO\!?%]Y\5?
MAO\ LZ1_%KP]?VL,6JZ7X9U&UT_Q1IT<)D95@6[>*UU*$&69EC:>WEC9V"^?
MYF$ /R+T/6?^"25CXA\0^-M?_P"""/\ P4+U/7_%'B&^U76=8_X0?7;5YS/<
MRS1P[+;7HXPD,;I @"CY(ESELD_I_P#\$8-3^&.L_P#!.7P3JGP8^&/B'P7X
M5FUSQ0VA>$_%MU+-JFE6_P#PDFI[;>[>9WD,Z\AP[NP;(+N06.$?^"Q/A9)_
M[*E_X)U_M?+J?3^S?^&>M2;+>GVA2;7'/W_.V?[5>F_LZ>/OVF?C!J$?B'6/
MV:F^"O@5;J:\BT?Q/?VEWXDUF6:5IG:6VLGEM=-1I':1R9[B>0NP*0$;R >Z
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX
M=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '-?%W_D0+W_ 'HO_1BUXQ7L_P 7?^1 O?\ >B_]&+7C
M%?GO%?\ R,H_X5^<@"BBBOF0"BBB@ HHHH **** "BBB@ HHHH V?A]_R.NF
M?]?:U[G7AGP^_P"1UTS_ *^UKW.OO>$O]SJ?XOT0!1117U8!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %>!^*_^1IU+_L(3?\ H9KWRO _%?\
MR-.I?]A";_T,U\AQ=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH **** "
MO</AM_R(VF_]</\ V8UX?7N'PV_Y$;3?^N'_ +,:^IX3_P!^G_A_5 ;E%%%?
M?@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/
MX]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-?%W_ )$"]_WHO_1B
MUXQ7L_Q=_P"1 O?]Z+_T8M>,5^>\5_\ (RC_ (5^<@"BBBOF0"BBB@ HHHH
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M#_V8UX?7N'PV_P"1&TW_ *X?^S&OJ>$_]^G_ (?U0&Y1117WX!1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
M'=?"[_DF?AW_ + 5I_Z)2MVN,^&OB+58OASH$2>%+MPNB6H#JRX8>2O-;?\
MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45
MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+
M1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q1
M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_
MPDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45
MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM %+XN_\ (@7O^]%_Z,6O&*]5
M^)NMZC>>"[NWN/#ES;HS1YED9<+^\7TKRJOSWBO_ )&4?\*_.0!1117S(!11
M10 4444 %%%% !1110 4444 ;/P^_P"1UTS_ *^UKW.O!_!,TEMXLL)XK=I6
M2Y4K&G5O85[!_P )+J__ $*%[_WTM?>\)?[G4_Q?H@-BBL?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EKZL#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z
M6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI
M:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -
MBBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6
MC_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_
M .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V*\#\5_P#(TZE_V$)O_0S7LG_"
M2ZO_ -"A>_\ ?2UXQXCD>;Q#?RR1&-FO92R-U4ESP:^0XN_@4O5_D!2HHHKX
M8 HHHH **** "BBB@ HHHH **** "O</AM_R(VF_]</_ &8UX?7KG@/7M2M?
M"%A;P^&;J95AP)49<-R>F:^IX3_WZ?\ A_5 =A1679Z]J5S=)!-X9NH59L-*
M[+A?<UJ5]^ 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^
MW/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K
M3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\7?^1 O
M?]Z+_P!&+7C%>S_%W_D0+W_>B_\ 1BUXQ7Y[Q7_R,H_X5^<@"BBBOF0"BBB@
M HHHH **** "BBB@ HHHH V?A]_R.NF?]?:U[G7AGP^_Y'73/^OM:]SK[WA+
M_<ZG^+]$ 4445]6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M@?BO_D:=2_["$W_H9KWRO _%?_(TZE_V$)O_ $,U\AQ=_ I>K_(#/HHHKX8
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M_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KKSFBOS3_ %ASC_G[_P"2Q_R ]&_X7_\
M]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__ -2E
M_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_ /\
M4I?^3_\ ]KH_X7__ -2E_P"3_P#]KKSFBC_6'./^?O\ Y+'_ " ]&_X7_P#]
M2E_Y/_\ VNC_ (7_ /\ 4I?^3_\ ]KKSFBC_ %ASC_G[_P"2Q_R ]&_X7_\
M]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__ -2E
M_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KKSFBC_6'./\ G[_Y+'_(#Z+1MZ!L=1FE
MIL/^J7_=%.K]-6P!7@?BO_D:=2_["$W_ *&:]\KP/Q7_ ,C3J7_80F_]#-?(
M\7?P*7J_R SZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO_7#_
M -F->'U[A\-O^1&TW_KA_P"S&OJ>$_\ ?I_X?U0&Y1117WX!1110 4444 %%
M%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\
M+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!S7Q=_P"1 O?]Z+_T8M>,5[/\7?\ D0+W
M_>B_]&+7C%?GO%?_ ",H_P"%?G( HHHKYD HHHH **** "BBB@ HHHH ****
M -GX??\ (ZZ9_P!?:U[G7AGP^_Y'73/^OM:]SK[WA+_<ZG^+]$ 55UW_ ) =
MY_UZ2?\ H)JU577?^0'>?]>DG_H)KZ>M_"EZ,#Y]HHHK\; ^8?VR?V]/&?PB
MUKQC\(?V;_A/#XO\9>#/ 2^*/$]WJFLQV6G:%:3-,EJ)#M>2XGD,$K+"B@;4
MR\B;ESZ?^S%^T/K_ .T#9^,8/%WP4UOP'J_@GQBWAW5-&UV[MYWEE73[*]^T
M126[O&\#K>IL8'+*N2$)*+\G?\%;OV)(OBQ'XU_:_P#V7_V@K[P)\5_!?@-]
M)\86$*&73?$^CLC7$=AJ$!]0S%)UW%<?=+(AC]=_X)K?MD?$_P#:.O/B7\&?
MVE?@5I_@'XP?"WQ!96?Q$L=$F$NGZFUU:![34+>0Y8K+!",*[.RHD?SD$*OI
MU*%%X%5*:NUOO=/3ILT[Z6[J_F'I_P 4/VM?AQ\,_P!I;X9?LJ3W,%YXL^)4
M^I26]A%>JLMA865A<74EY(F"2K211PJ#MW&1V!/E,IZWXL^-O%G@7PPE]X#^
M&E]XLUJ\O$M=-TBTN4MXS(P9C)<7#@K;0(J,S2$,> B*\CHC?*?[1WP2^#'P
M_P#^"L_[+WQ'\!?"+PQHGB+Q1J/CJ3Q-KVD:!;6U[J[KH)*M=3QH'N""S$%R
MV"Q]37V9J4>HRZ=<1:/=007;0.+6>YMS+'')@[6=%="Z@X)4,I(XW#J.:M"E
M3C2E'6ZN[]^:2Z=- /)_V>/VJ+WXM_$SQE\ OB7\,9O!?C_P+#8W>KZ*-634
M+2[L+T2FVO;.Z5(S-$S031L'CC='B(9<%2UO]LC]JGPU^QW\!]:^,VM^&[O7
M[RPL;F72/#.FRJESJLL-O+<R(C-D(B003322$$)%#(V&("GQ?]DJU\5?#?\
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M&:]\KP/Q7_R-.I?]A";_ -#-?(\7?P*7J_R SZ***^& **** "BBB@ HHHH
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M;-G">0B_,&49RJ@]S6^&XDP.*Q$:,(RO)VU2M^8'H=%%%?0 <U\7?^1 O?\
M>B_]&+7C%>S_ !=_Y$"]_P!Z+_T8M>,5^>\5_P#(RC_A7YR ****^9 ****
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MXN?\%1?V!?$]C90Z'^TKHL[12NT@^RW2X! Q]Z(5Y6=TZE7*ZD()MNVBU>Z
M["BO%O\ AXI^Q1_T<)HO_?N?_P"-T?\ #Q3]BC_HX31?^_<__P ;K\Y_LW,?
M^?,__ 7_ ) =G^T?\8/!GP!^!GB;XR?$:S6?P]X?TQKK78W7<HLPP69BN#N"
MQEF*X^;&.]?E;^T'\*O#'[!/Q_US]K?_ ()-?&?3M MK_4?!;?\ "F_#^J)>
MZ%\16U>_N[:6"TMP[!9555D0P\11^:8_+K]%M7_;[_81\0:?)I&O?&_PY?6D
MNWS;6\M)98WP0PRK1$'! (]P#7GW@OXH?\$A_AU\8=2^/G@>Z^'.E>+M5MHH
M;G7+#PTD4ZA/-^9'2 ,C.)6#L#EPJ!L[17H8*ACL+&5Z$W?=<KLUIHU;UUWU
MT S?VR? /@KQ3_P5(_9BUSXX:'9WGA2ST3Q;!X8.JQ*]D/%,D=B]LCAQL\YK
M:*Z>$-R7A)3YEK6_9#M[#1O^"BO[1WAOX/00P_#Z"R\,S:M:Z<H6PMO%SQ71
MOUA5/W:S-:C3WN O.\H7^9CGL/&_[:__  3O^)GANX\&_$CXH>#_ !!H]WC[
M5I6MZ4UW;38.1OBEA96P0#R.M'@C]M?_ ()W_#/PW;^#?AO\4/!_A_1[3/V7
M2M$TIK2VAR<G9%%"JKDDDX'4UF\/F+P_LW0G\/+\+M\7-?;?I^-^@$O[5'_%
MW/CM\*/V6;?]Y97&MMXY\9Q#E?[+T62&2UB?M^\U6;3F /WTM9Q@X./5OBK\
M8OA7\#?"Z>-?C%\0=)\-:1)J%O8IJ.LWJ00M<SR".*(,Q W,Q  ^IZ FO*X_
MV\_V!$\32^+(_C)X:76);%+.;51ITHN'MD=G2$R^5N:-7=V"9P"['&2:C\6?
MMP?\$]_'NE+H7CGXL>$]:L5N8KA;/5M,>YB$T3B2*0))$1O1U5E;&58 C!%8
MO 8YJ,70G9;^Z_GT^7R W?CYH'[(/CSXX?#OX:_M&?##0/$OBC5K369/ $?B
M;PTM_;QF%+:2]6-I4:&*8QB)@#B1DCDV\*]>2?\ !-O1]"\'_M#?M+?#SX(6
ML5M\(-#^(.FQ>#;#3@!INGZN^FQOK=K9 ?+'"ERT9:),)',\RJ!R*[7X@_MC
M_P#!.#XM>'F\(_%3XA^"O$VDM,LK:9X@T4WMN9%^ZYCFA9=PR<'&1FK?A/\
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MHKQ;_AXI^Q1_T<)HO_?N?_XW1_P\4_8H_P"CA-%_[]S_ /QNC^S<Q_Y\S_\
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MBW_#Q3]BC_HX31?^_<__ ,;H_P"'BG[%'_1PFB_]^Y__ (W1_9N8_P#/F?\
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MS/\ \!?^0'M-%>+?\/%/V*/^CA-%_P"_<_\ \;H_X>*?L4?]'":+_P!^Y_\
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M"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\
MA)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\ A)6?
M_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\ A)6?_P :
MKQ7]I_\ 9_\ @-H_QA^#5CI/P2\(VL%_XUEBOH;;PW:HEQ']G8[) L8#KGG!
MR*^HZYOQO\*?"/Q!\1>'/%'B.&=KOPMJ37VDF&<HJS%"A+#^(8/2@#*_X9?_
M &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\
M9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#AO^&7_P!F
MG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:* .&_X9?_ &:?
M^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z
M-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#AO^&7_P!FG_HW
MCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:* .&_X9?_ &:?^C>/
M O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"
M_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#YV_;0_9W_ &?] _98
M\;ZSH7P,\'65Y;Z([V]U:>&+2.2)MR\JRQ@J?<5VOPV_9G_9PN_AWH%U=?L_
M>")99=%M7DDD\*6;,[&%2228\DD]Z[GXD?#[PY\5? NI_#OQ=%*^FZM;&"\6
M"4HY0D'AAT/%:6C:5::#H]IH>GJP@LK:." .V2$10JY/<X H X__ (9?_9I_
MZ-X\"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\
M"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\
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M,^-'[-EM\,O&7PNTZUU'R;GQO_:+>(["X=E2_P!/46<(EM0/*WR,RLC7$:%
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MNM=\#Z]I]Q?P:3X9^*MM=>(6MX+B6"4Q6,]G;QS2 PR%8EN-SX 4%F KS?\
MX(9?\F'_ +4W_9R7Q*_E%7IG_!MH0/\ @B-\!23_ ,P/4_\ T\7U 'TU^R1^
MUC\$OVWO@!H'[2O[/GB5]3\,^(87,!N+<PW-I/&[1S6MQ$W,4T4BLCH<\KD%
ME(8\[H7[95KK?_!0;7_V!C\*-8@N="^%=EXV/C&6>/[%<Q7-_+9K:J@^</NB
MD(8G!\N08&T%OES_ (-U[BUUGX9_M/\ C/P<ZMX(U_\ ;+\=7_@"6'F";2V>
MU"R0$<>265PN.,JU??</@WPG;^,;GXA0>'+--=O-,@TZZU=;=?M$MI#)++%
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M2,!(842C\+O^5G?XH_\ 9H^C_P#I[6@#7_9?_P""L?[8W[5GQ5^+?P4\%?\
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M\7>(-"\-VMI?:W*NBP,LEY/%&LERP,CD-(S$%V/<T ?>M%%% !1110 4444
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M^S9\'M)^#N@^-/$_B6/3#/)<>(_&FL'4-6U.>:9YI;BZN2JF65GD;G  &%
M4 =O10 5\Q_M=?\ !,3P]^U]\<M#^/FL?MD_'?P)JOAG2)=/\/V/PU\9VFF6
ME@LW^OFC5K*1_.E 57D+DE%"#"\5].44 >+?LP?L6Z?^R]X*\4>'+#]I/XL>
M.=9\52AKCQM\2O%<>L:O9(D/E0PVTCP+%'%$S2RI&8F7S)I&8,&Q7@'AG_@A
M3X0\':3?>'_#'_!3?]L"PL-5U"ZOM5M+#XPV]NMY<W,C27$TC16"L9)'9BS@
MAR3G(XK[HHH K:-H^F>'M(M= T2RCMK.QMDM[2VB&%BB10J(!Z   ?2K-%%
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MBC4<R?(1E-AYKVRB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20220630_g16.jpg
<TEXT>
begin 644 biib-20220630_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29
M^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_
M + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@?BO\ Y&G4
MO^PA-_Z&:]\KP/Q7_P C3J7_ &$)O_0S7R'%W\"EZO\ (#/HHHKX8 HHJEX>
M\2:!XLTS^V?#.L6]_:&XF@%Q:RAT\R&5XI4R.ZR(Z$=BI':BSL!=HHHH ***
M* "BBB@ HHHH *]P^&W_ "(VF_\ 7#_V8UX?7N'PV_Y$;3?^N'_LQKZGA/\
MWZ?^']4!N4445]^ 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H
M:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O
M_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\
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M=GKVI7-TD$WAFZA5FPTKLN%]S6I7WX!1110 4444 %%%% !1110 5Y1^W/\
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MO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ?^']4!N4445]^ 4444 %%%%
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ME*YWX]_\@W3O^N[_ /H(KHOA=_R3/P[_ -@*T_\ 1*5SOQ[_ .0;IW_7=_\
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M[3W;L?P;\U['^SG^VG\+_P!HK5)O!7_"*>+_  )XTM+4W-[X ^)/AN32-72
M$*T\2.6BO8 S*K3VLLT2LRJ7#$"KOCS]MW]COX9?"_5/C7XZ_:B\!:?X2T35
M1IFK>(9/%5JUK:WQ.!:.Z.0)\_\ ++[_  >.#78>']4^%_QH\+>'_B5X6U+1
MO$VCW*0ZMX8U[3YH[J"17C/EW-M,A((:-R Z'YD=ADAB" =#7E'[<_\ R:/X
M]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4KG?C
MW_R#=._Z[O\ ^@BNB^%W_),_#O\ V K3_P!$I7._'O\ Y!NG?]=W_P#017CY
M_P#\BBK\OS0'F5%%%?EX!1110 4444 %%%% !1110 4444 %=G\#?^1PF_[!
M[_\ H:5QE=G\#?\ D<)O^P>__H:5Z63?\C2C_B0'K-%%%?JP!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>!^*_P#D:=2_["$W_H9KWRO _%?_ "-.I?\ 80F_
M]#-?(<7?P*7J_P @,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&W_(C
M:;_UP_\ 9C7A]>X?#;_D1M-_ZX?^S&OJ>$_]^G_A_5 ;E%%%??@%%%% !111
M0 4444 ?E)\8?%?[+GP,_:N\$^%_VV_V]/V<(O#7[.UM?7?PQ^%#>)6M;[5?
M$MPK)%K'B-2DXMKF*%Y&79%(6GNI;GY2RQU]M?\ !+OQ]I7Q5_8MT#XE:+XF
M\-ZQ;:]XF\47ZZCX-,ITF9I?$6I.WV-I4C=[<,2J.R*650Q'-?('[*G[;D'P
M:\(Z]\,M4_X(C?M">(QHGC;7+$^.?#'PPT6Z;Q/-#J=S'/?W9FOXS]J>99?,
M8/*KN&<, P5?MO\ 8#^(6D?%7]F#3/B!H?P%U3X86^I>)/$;_P#"#:Y8"UO=
M,===OTD%Q"KNL4TCJTKHC,@>5@A*[: /9:\H_;G_ .31_'O_ & 7_P#0UKU>
MO*/VY_\ DT?Q[_V 7_\ 0UH \;\+?MW?M(Z#X8T[0]-_X)J_$S4[:RL(8+?4
M;:\M1'=HB!5E3/.U@ PSV-;6E_M*_%[XV,]AX^_8T^(7@2.P DMKC4=/:^%V
MS<%%%JCE"H .6P#GBOH3X7?\DS\._P#8"M/_ $2E;M<V,PM/&X:5&;:3[;[W
M\P/FK[?J/_0C^+?_  C-2_\ C%'V_4?^A'\6_P#A&:E_\8KZ5HKP?]4\N_GG
M]Z_^1 ^:OM^H_P#0C^+?_",U+_XQ1]OU'_H1_%O_ (1FI?\ QBOI6BC_ %3R
M[^>?WK_Y$#YJ^WZC_P!"/XM_\(S4O_C%'V_4?^A'\6_^$9J7_P 8KZ5HH_U3
MR[^>?WK_ .1 ^:OM^H_]"/XM_P#",U+_ .,4?;]1_P"A'\6_^$9J7_QBOI6B
MC_5/+OYY_>O_ )$#YJ^WZC_T(_BW_P (S4O_ (Q1]OU'_H1_%O\ X1FI?_&*
M^E:*/]4\N_GG]Z_^1 ^:OM^H_P#0C^+?_",U+_XQ1]OU'_H1_%O_ (1FI?\
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MGJGW?9KL!D_\-Z_M'?\ 2/+Q/_X<'0__ )(H_P"&]?VCO^D>7B?_ ,.#H?\
M\D5K52\2>)- \'Z!>>*?%.L6^GZ;I]NT][?7<H2*"-1EG9CP !WKQUQ7F3=E
M"'W/_P"2 K?\-Z_M'?\ 2/+Q/_X<'0__ )(H_P"&]?VCO^D>7B?_ ,.#H?\
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M'!T/_P"2*/\ AO7]H[_I'EXG_P##@Z'_ /)%:U%'^MF8_P D/N?_ ,D!D_\
M#>O[1W_2/+Q/_P"'!T/_ .2*/^&]?VCO^D>7B?\ \.#H?_R16M11_K9F/\D/
MN?\ \D!D_P##>O[1W_2/+Q/_ .'!T/\ ^2*/^&]?VCO^D>7B?_PX.A__ "16
MM11_K9F/\D/N?_R0'/G_ (*!_M/ X_X==_%(^XOK0T?\/!/VGO\ I%U\4_\
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M!U#"2=\@'B@#W>O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
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MY)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D!WG_7I)_Z":M55UW_D!WG_ %Z2?^@FLZW\*7HP/GVBBBOQL HHHH ****
M"BBB@ HHHH **** "BBB@#Z*A_U2_P"Z*=38?]4O^Z*=7[.M@"BBBF 4444
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
MX275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_
M *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?
M_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4
M+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H
M4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z
M6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI
M:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -
MBBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6
MC_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8JKKO
M_(#O/^O23_T$U1_X275_^A0O?^^EJMK'B+59-(NHW\)WB!K9P6++@?*>:SK?
MPI>C \4HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG5B
MQ>)=6$:C_A$+S[H_B6G?\)+J_P#T*%[_ -]+7[.M@-BBL?\ X275_P#H4+W_
M +Z6C_A)=7_Z%"]_[Z6F!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM
M &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]
M]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0
M!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_
M -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM
M &Q1679Z]J5S=)!-X9NH59L-*[+A?<UJ4 %%%% !1110 4444 %%%% !7E'[
M<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:
M?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=
M=_Y =Y_UZ2?^@FK55==_Y =Y_P!>DG_H)K.M_"EZ,#Y]HHHK\; **** "BBB
M@ HHHH **** "BBB@ HHHH ^BH?]4O\ NBG4V'_5+_NBG5^SK8 HHHI@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
MDF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !577?^0'>?]>DG_H)JU577?^0'>?\ 7I)_Z":SK?PI>C ^?:***_&P
M"BBB@ HHHH **** "BBB@ HHHH **** /HJ'_5+_ +HIU-A_U2_[HIU?LZV
M****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =
MU\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-5M8L_&8TBZ,VLV906S[P+8@D;3FNAJKKO\ R [S_KTD_P#036=;^%+T
M8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110![E%9>-O+7&MV>-H_Y
M=C_C3OL7C?\ Z#=E_P" Q_QK6A_U2_[HIU?LZV Q_L7C?_H-V7_@,?\ &C[%
MXW_Z#=E_X#'_ !K8HI@8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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M@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH
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MO_Q=='11_9N7?\^8?^ K_(#G/^%2_#[_ *%__P FY?\ XNC_ (5+\/O^A?\
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M_P#HO6@_]_G_ /B: /5Z*\H_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
M?Y__ (F@#U>BO*/^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\
M^)H ]7HKRC_AN?\ 9'_Z+UH/_?Y__B:/^&Y_V1_^B]:#_P!_G_\ B: /5Z*\
MH_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XF@#U>BO*/^&Y
M_P!D?_HO6@_]_G_^)H_X;G_9'_Z+UH/_ '^?_P")H ]7HKRC_AN?]D?_ *+U
MH/\ W^?_ .)J.;]N_P#9#@>.-_CQHI,C84H9& /N0F%'N<4 >MT5Y1_PW/\
MLC_]%ZT'_O\ /_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q- 'J]%>4?\ #<_[(_\
MT7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q- 'J]%>4?\-S_ +(__1>M!_[_
M #__ !-'_#<_[(__ $7K0?\ O\__ ,30!ZO17E'_  W/^R/_ -%ZT'_O\_\
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M7K0?^_S_ /Q-'_#<_P"R/_T7K0?^_P __P 30!ZO17E'_#<_[(__ $7K0?\
MO\__ ,31_P -S_LC_P#1>M!_[_/_ /$T >KT5Y1_PW/^R/\ ]%ZT'_O\_P#\
M31_PW/\ LC_]%ZT'_O\ /_\ $T >KT5Y);_MW_LAW2&2+X\:* &(Q(9$.1[,
M@./>I/\ AN?]D?\ Z+UH/_?Y_P#XF@#U>BO*/^&Y_P!D?_HO6@_]_G_^)H_X
M;G_9'_Z+UH/_ '^?_P")H ]7HKRC_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1
M_P#HO6@_]_G_ /B: /5Z*\H_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
M?Y__ (F@#U>BO./"G[7?[-/CGQ':>$?"/QCT>_U*_E\JSLX)6+ROC.T97KQ7
MH] !1110 4444 %%%% !1110 4444 8DOPT^'$\K3S_#_1'=V+.[Z5"2Q/4D
M[>33?^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#
M/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@
MHA_^)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH
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M_P#HG>A?^"B'_P")K=HH PO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\
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M_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
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M2?M(_M >+XM#\)^%K'[3JE^Z%V.6"1Q1HOS22R2,D:(O+.Z@=:[ROST_X..
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M/#^DQ*^H>(-2DW?9]/M4)&^5SNP6(2-!))(R1QR.H!QG[ _[</P\_;_^ ?\
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M/X%:'^S9\'M)^#N@^-/$_B6/3#/)<>(_&FL'4-6U.>:9YI;BZN2JF65GD;G
M &%  4 =O10 5\Q_M=?\$Q/#W[7WQRT/X^:Q^V3\=_ FJ^&=(ET_P_8_#7QG
M::9:6"S?Z^:-6LI'\Z4!5>0N244(,+Q7TY10!XM^S!^Q;I_[+W@KQ1X<L/VD
M_BQXYUGQ5*&N/&WQ*\5QZQJ]DB0^5##;2/ L4<43-+*D9B9?,FD9@P;%> >&
M?^"%/A#P=I-]X?\ #'_!3?\ ; L+#5=0NK[5;2P^,-O;K>7-S(TEQ-(T5@K&
M21V8LX(<DYR.*^Z** *VC:/IGA[2+70-$LH[:SL;9+>TMHAA8HD4*B >@  '
MTJS110 4444 %%%% !1110 5@?%/X6?#GXW_  YUKX1?%SP98>(?#/B+3Y+'
M6]%U2 2P7=NXPR,I_,$8((!!! -;]% 'Q!\:_P#@A/\  ?X\_ ,_LK^/?VI?
MC7??#:S4-X:\$ZCXCTZ\M=$FCB>*V>*YGL&OY1 KX2.:ZD0JH1@R$J7^*/\
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MP)I'Q+UC4=7UZZU*_P!$N+N#4;]42[NK>4Z4/+>14&00R*26558[JY?X9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20220630_g17.jpg
<TEXT>
begin 644 biib-20220630_g17.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:XSX:V?C)OASH#0:Q:*AT2UV*UN20/)7 ZUM_8O&_P#T
M&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]
MB\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^
M- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR
M_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;
MLO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+
MQO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]
MB\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT
M ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_
M ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR
M_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&
M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+
MQO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!
ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\
MH_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:
M?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]
MN?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?
M^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPU^SC_T!/$__ (<;7/\ Y-H_ULR[^2?W+_Y(#[HHKX7_ .&&OV<?^@)XG_\
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MM'G243%V/EIOK[/HH **** "BBB@ HHHH *JZ[_R [S_ *])/_035JJNN_\
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MZ[_R [S_ *])/_035JJNN_\ (#O/^O23_P!!-9UOX4O1@?/M%%%?C8!1110
M4444 %%%% !1110 4444 %%%% 'T5#_JE_W13J;#_JE_W13J_9UL 5X'XK_Y
M&G4O^PA-_P"AFO?*\#\5_P#(TZE_V$)O_0S7R/%W\"EZO\@,^BBBOA@"BBB@
M HHHH **** "BBB@ HHHH *]P^&W_(C:;_UP_P#9C7A]>X?#;_D1M-_ZX?\
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M'4,))WR >* /=Z\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
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MR?\ Y]?^32_S \Y_X4!_U-O_ )(?_;*/^% ?]3;_ .2'_P!LKT:BC_5[)_\
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M7F^8(V<EC'L)Y- 'O]>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
M+_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7@?BO_ )&G4O\ L(3?^AFO?*\#\5_\C3J7_80F_P#0S7R'%W\"EZO\
M@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X
M?#;_ )$;3?\ KA_[,:^IX3_WZ?\ A_5 ;E%%%??@%%%% !1110 4444 9?A+
MP7X3\!Z9-HW@WP_:Z;:W&I7>H3P6D017NKJXDN;B8CNTDTLDC'N7-+X2\'>%
M_ FD-H'@_1(-/LGO[N]:VMUPGGW-Q)<SOCL7FED<]LN<8'%?&/A#X<_\%*OV
MS=&N/CAX&_X*H+\)M/O=9O[:'X>^$/@YHFIGP_\ 9[F2#[#>7.J">66]C\L"
M<@1*)=X5 H&?H?\ 8?\ A_\ $7X6_LYV'@/XM?'$_$GQ)8>(_$(U?QLUG#;/
MJ<KZW?2;GAAQ%"Z!A&T48"(T950 H% 'K5>4?MS_ /)H_CW_ + +_P#H:UZO
M7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M
M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP/Q7_ ,C3J7_80F_]#->^
M5X'XK_Y&G4O^PA-_Z&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444
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M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
ML O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5X'XK_ .1IU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T,U\AQ=_
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M>-;O4/A[JEV+V;X=1Z5J<T%I<Q39+Q6URWE1*K85W:5B&8!J^J?V-(+C3/\
M@H-^UWIFK _;+GQ7X1U&!VZR6,GARVAA(_V1);7*?6-J[\51C"K4EH_=NK*V
M\N75=UK^#0%3]MKXF_M;_LC?"O6?VQ?^%U:9JFG>'_$=B+CX5Q^&H/L-]I5Q
MJ,-HMO#=D"[_ +0,<RNLN\Q-,-@@VG-?1_Q1TSXE:UX1ET;X4>)]/T35KJ:.
M,ZUJ%D;H6,!8>;+'!D++-M!"!R$#,&8.%,;_ "U_P5BT'X<7/[+]U^V/X1\8
MWDWC7X<7]KJ/PUMQK-S>:9>Z_#=>5;V+Z0\C6MQ<2S.UMN\G[3$[91XWC!'U
M=<^(M.MO#^G'QM<1Z1/K'E6OD/>%"MU*A_<+*I'SY#*I!!) V\D5RU+>PIS2
MUNULEM;2W6W=[WL]@/"?@!\8/C;X3_;6\7_L5?%KXAIX]L].^'FF^,=!\7R:
M/;V5]:1W%Y<V<FGWJ6JI [;K?S8I$CB)0N&5MH:OH^OC[]GWPGHW[/O_  5-
M\<? [X,7=]JOAOQ9\+;?Q=\0)M:U2?5K[2-=2]2TLDDU"Z>2Y*7-H9V2UFE=
M8Q:%XEC5V#?3OA?XQ?"OQMX_\2_"OPC\0=)U+Q)X-:T'BO0[.]22YTDW41EM
M_/C!S'YD8++GJ :G%07.I06G*GM;MJUTU_K4#Y%^"OB?]L?]K;XN>*O&7@K_
M (*1Z/X/\+6'Q,UO2M)^'&G_  YTB^U"32=+U*6P>9;J>0R+YSVTQ61H7"[@
M<,.*^G_VF;'XC?\ "EM:\3?!V[*>,/#MG)JWAJ%V(BO[JW0R"RG ^]#<*&@?
M@E1+YB8=$9?BO]MWP/\ L*7_ /P3EUO]HS]D/X4>'_#_ (WMO$WE?"W7] \,
M)IWB,^,XM7-JD",T:W3W$EVDJ2H^6DC,A<%<FOT(BOI+#0UU+Q'+!;O#:"6_
M=6_=QD+ESD_PC!Y/85MBFDXU(JR3:MRI/2V]M]^NNX'._ 3XS>$/VBO@CX2^
M//@&5FT;QCX=M-8TX28WI%<0K($?'1UW;6'9E([5UM?+O_!%G2]3TK_@ES\'
M4U.UDA^U>');VSBD7!6TN+RXGMN/3R)(L>V*^HJY,33C2Q$X1V3:^Y@%>N>
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M-=U_PJ7X@_\ 0O\ _DW%_P#%T?\ "I?B#_T+_P#Y-Q?_ !=?'++LR3NJ,_\
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ME/3^[+_(#S_P!\+OAG\*-*ET+X6_#K0O#5E/.9Y[/0-(ALXI)2 "[)"J@L0
M,D9X%6M*\%^#M#\0ZIXNT3PGIEGJVN&$ZWJEK81QW&H&%-D/GR* TNQ"57<3
MM!P,"NV_X5+\0?\ H7__ ";B_P#BZ/\ A4OQ!_Z%_P#\FXO_ (ND\OS-MMTI
MZ_W9?Y >80_ /X%V_P 2&^,=O\%O"2>+W)W^*D\.6HU)LKM.;D1^:<K\OWNG
M%4?VC?AWXI^,/PDU7X/>&M9;2H_%=NVE:UK,,FV:QTZ8%;IX/^F[0EXXVZ1O
M(LAR$VMZ[_PJ7X@_]"__ .3<7_Q='_"I?B#_ -"__P"3<7_Q=4L#FBDI>QGI
MM[LO\@.-\*>%O#W@?POIO@KPCI$.GZ3H]A#8Z986RXCMK>)!''$H[*J*J@>@
MJ_71_P#"I?B#_P!"_P#^3<7_ ,71_P *E^(/_0O_ /DW%_\ %U#R[,F[NC/_
M ,!?^0'.5[A\-O\ D1M-_P"N'_LQKS+_ (5+\0?^A?\ _)N+_P"+KU3P1IM[
MH_A2RTW48?+GABVR)N!P<GN"17TG#&$Q6'QLY5:<HKEZIKJNX&K1117VX!11
M10 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P
M"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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M_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G_P 10!ZU17DO_#=W[(?_ $7C1/\
MOJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$4 >M45Y+_PW=^R'_T7C1/^^I/_ (BC
M_AN[]D/_ *+QHG_?4G_Q% 'K5%>2_P##=W[(?_1>-$_[ZD_^(H_X;N_9#_Z+
MQHG_ 'U)_P#$4 >M45Y+_P -W?LA_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G
M_P 10!ZU17DO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$4
M>M45Y+_PW=^R'_T7C1/^^I/_ (BC_AN[]D/_ *+QHG_?4G_Q% 'K5%>2_P##
M=W[(?_1>-$_[ZD_^(J.7]O7]D"%TC?X[:03(V%VI,P'U(3CZF@#UZBO)?^&[
MOV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XB@#UJBO)?\ AN[]D/\
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MT3_OJ3_XBC_AN[]D/_HO&B?]]2?_ !% 'K5%>2_\-W?LA_\ 1>-$_P"^I/\
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M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5_P#1-/#_ /X)H/\
MXBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\ PJ;X5_\ 1-/#_P#X)H/_ (BC
M_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
MZ)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\
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M_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(KH** .?_X5-\*_^B:>'_\
MP30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_
M\11_PJ;X5_\ 1-/#_P#X)H/_ (BN@HH Y_\ X5-\*_\ HFGA_P#\$T'_ ,11
M_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%
M?_1-/#__ ()H/_B*Z"B@#G_^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\
M_@F@_P#B*Z"B@#YS_8*^'G@#6?@WJMUK'@;1[N5?&^KQK)<Z9%(P1;DA5!92
M< =!VKVS_A4WPK_Z)IX?_P#!-!_\14?PM^%/A'X/>'9_"_@N&=+2XU*XOI!<
M3F1O.F?>YR>V>@[5TE '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__
M  30?_$5T%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\
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MHK!6,DCLQ9P0Y)SD<5]T44 5M&T?3/#VD6N@:)91VUG8VR6]I;1#"Q1(H5$
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M?@K4?".D>/M9\+W&H6QA37O#PMOMMIGJ\7VJ&:(-C(RT;8SD8."-JB@#P?\
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20220630_g18.jpg
<TEXT>
begin 644 biib-20220630_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5%?W7V*QFO=F[R8F?;G&<#.*EJKKO_(#O/^O23_T$U%1N--M=
M@.#_ .%__P#4I?\ D_\ _:Z/^%__ /4I?^3_ /\ :Z\YHK\T_P!8<X_Y^_\
MDL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\ _4I?^3__ -KKSFBC_6'./^?O_DL?
M\@/1O^%__P#4I?\ D_\ _:Z/^%__ /4I?^3_ /\ :Z\YHH_UASC_ )^_^2Q_
MR ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\ D_\ _:Z\YHH_UASC_G[_ .2Q
M_P @/1O^%_\ _4I?^3__ -KH_P"%_P#_ %*7_D__ /:Z\YHH_P!8<X_Y^_\
MDL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\ _4I?^3__ -KKSFBC_6'./^?O_DL?
M\@/1O^%__P#4I?\ D_\ _:Z/^%__ /4I?^3_ /\ :Z\YHH_UASC_ )^_^2Q_
MR ^BT;>@;'49I:;#_JE_W13J_35L 4444P"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !577?^0'>?]>DG_H)JU577?^0'>?\ 7I)_Z":SK?PI>C ^?:**
M*_&P"BBB@ HHHH **** "BBB@ HHHH **** /HJ'_5+_ +HIU-A_U2_[HIU?
MLZV ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H
M:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %5==_Y =Y_P!>DG_H)JU577?^0'>?]>DG_H)K.M_"EZ,#
MY]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O^Z*=38?]4O\
MNBG5^SK8 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 55UW_D!WG_7I)_Z":M55UW_D!WG_ %Z2?^@FLZW\
M*7HP/GVBBBOQL HHHH **** "BBB@ HHHH **** "BBB@#Z*A_U2_P"Z*=38
M?]4O^Z*=7[.M@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]
M_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !577?^0'>?\ 7I)_Z":M55UW_D!WG_7I)_Z"
M:SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH **** /HJ'_5+_NB
MG4V'_5+_ +HIU?LZV ****8!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__
M ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I
M6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5==_Y =Y_UZ2?^@FK55==_Y =Y_P!>
MDG_H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]
M4O\ NBG4V'_5+_NBG5^SK8 HHHI@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^
MW/\ \FC^/?\ L O_ .AK0!TGPU\1:K%\.= B3PI=N%T2U =67##R5YJ;Q1\3
M;WPO#%-=>$9P)6*CSK@)T'; .:T/A=_R3/P[_P!@*T_]$I7._'O_ )!NG?\
M7=__ $$5YN;XBMA<NJ5:3M)6L_FNX$'_  O_ /ZE+_R?_P#M='_"_P#_ *E+
M_P G_P#[77G-%?!_ZPYQ_P _?_)8_P"0'HW_  O_ /ZE+_R?_P#M='_"_P#_
M *E+_P G_P#[77G-%'^L.<?\_?\ R6/^0'HW_"__ /J4O_)__P"UT?\ "_\
M_J4O_)__ .UUYS11_K#G'_/W_P EC_D!Z-_PO_\ ZE+_ ,G_ /[71_PO_P#Z
ME+_R?_\ M=><T4?ZPYQ_S]_\EC_D!Z-_PO\ _P"I2_\ )_\ ^UT?\+__ .I2
M_P#)_P#^UUYS11_K#G'_ #]_\EC_ ) >C?\ "_\ _J4O_)__ .UT?\+_ /\
MJ4O_ "?_ /M=><T4?ZPYQ_S]_P#)8_Y >C?\+_\ ^I2_\G__ +76AX:^+]QX
MEU!K"V\(REEB+GRKH.< @="H]?6O*:[/X&_\CA-_V#W_ /0TKNRW.\TQ&/IT
MZE2\6]=(_P"0'H/_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q17Z !C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
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M_P#H:5Z63?\ (TH_XD!ZS1117ZL 4444 %%%% !1110 4444 %%%% !1110
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MO?!GP]XITWPZ+O6+6T3QRLHUJ[E@U:\@N+W4!,JR"[N9XY;F8.H823OD \4
M>[UY1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_
M[ 5I_P"B4KG?CW_R#=._Z[O_ .@BNB^%W_),_#O_ & K3_T2E<[\>_\ D&Z=
M_P!=W_\ 017CY_\ \BBK\OS0'F5%%%?EX!1110 4444 %%%% !1110 4444
M%=G\#?\ D<)O^P>__H:5QE=G\#?^1PF_[![_ /H:5Z63?\C2C_B0'K-%%%?J
MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5==_P"0'>?]>DG_
M *":M55UW_D!WG_7I)_Z":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@
M HHHH **** /HJ'_ %2_[HIU-A_U2_[HIU?LZV ****8!1110 4444 %%%%
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M]_\ (-T[_KN__H(KQ\__ .115^7YH#S*BBBOR\ HHHH **** "BBB@ HHHH
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M3)M&\&^'[73;6XU*[U">"TB"*]U=7$ES<3$=VDFEDD8]RYI?"7@[POX$TAM
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M3?\ 8/?_ -#2O2R;_D:4?\2 ]9HHHK]6 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JKKO_(#O/^O23_T$U:JKKO\ R [S_KTD_P#036=;^%+T
M8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?\ =%.IL/\
MJE_W13J_9UL 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;J:\BT?Q/?VEWXDUF6:5IG:6VLGEM=-1I':1R9[B>0NP*0$;R >Z5Y1^W/\
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M_P"0'>?]>DG_ *":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH
M**** /HJ'_5+_NBG4V'_ %2_[HIU?LZV ****8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*YWX]_\
M(-T[_KN__H(JY\-?!NE3_#G0)WN;L%]$M6(6Z8#)A6L;XS:#9:/86,EK+.Q>
M9P?.F+=ATS7CY_\ \BBK\OS0'G]%%%?EX!1110 4444 %%%% !1110 4444
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK+L_"6FV-
MTEW#<71:-LJ'N6(_$5J4 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*YWX]_\
M(-T[_KN__H(KHOA=_P DS\._]@*T_P#1*5SOQ[_Y!NG?]=W_ /017CY__P B
MBK\OS0'F5%%%?EX!1110 4444 %%%% !1110 4444 %=G\#?^1PF_P"P>_\
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MH_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2N=^/?_ "#=._Z[O_Z"*Z+X7?\
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[
M5I_Z)2N=^/?_ "#=._Z[O_Z"*Z+X7?\ ),_#O_8"M/\ T2E<[\>_^0;IW_7=
M_P#T$5X^?_\ (HJ_+\T!YE1117Y> 4444 %%%% !1110 4444 %%%% !79_
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MY_UZ2?\ H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH
M^BH?]4O^Z*=38?\ 5+_NBG5^SK8 HHHI@%%%% !1110 4444 %%%% !1110
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M)]JU^/7_  2>T'XT?L*_MZ^ /V.?@#^T;?\ C[X&_$73O'U[J?PSUB]%_/\
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MG'[7?A3Q'XY_9I\8^$?".D2W^I7^CM%9V< !>5]RG:,]^* .J^%W_),_#O\
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MC_AXI^Q1_P!'":+_ -^Y_P#XW1_9N8_\^9_^ O\ R ]IKL_@;_R.$W_8/?\
M]#2OF/\ X>*?L4?]'":+_P!^Y_\ XW72_"G_ (*:?L(^&O$DE_K7[1^BPPM9
ML@?[/<M\Q93C"Q$]C7H95@,=3S*E*=*22>[B[?D!]H45\Y_\/;O^"='_ $=)
MHO\ X 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S7Z6!]&45\Y_\ #V[_ ()T
M?]'2:+_X 7G_ ,9H_P"'MW_!.C_HZ31?_ "\_P#C- 'T917SG_P]N_X)T?\
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M)HO_ '[G_P#C=?E']FYC_P ^9_\ @+_R ]IHKQ;_ (>*?L4?]'":+_W[G_\
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M_P#A[=_P3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P" %Y_\9I@?1E%?.?\
MP]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P  +S_XS0!]&55UO0M$\2Z9
M+HOB/1K74+.;;YUI>VZRQ2;6#+N1@0<, 1D<$ ]J^??^'MW_  3H_P"CI-%_
M\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ ,9H [;P'^PW^R'\+_CCJO[2'P^_
M9Q\%Z/XUUBUA@N_$&G>&;2&Y41^=EHY$C#1NXF82,"#(%0-G8,>K5\Y_\/;O
M^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C- 'T917SC'_P %<O\
M@G-*NY?VH]''./FTZ]'\X*=_P]N_X)T?]'2:+_X 7G_QF@#Z,HKYS_X>W?\
M!.C_ *.DT7_P O/_ (S1_P /;O\ @G1_T=)HO_@!>?\ QF@#Z,HKYS_X>W?\
M$Z/^CI-%_P# "\_^,T?\/;O^"='_ $=)HO\ X 7G_P 9H ^C**^<_P#A[=_P
M3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P" %Y_\9H ^C**\*\ ?\%,/V%OB
MEXUTSX=^ ?VB=)U+6M9NTM=,L(K2Z5IYF.%0%X@H)/J17NM !1110 4444 %
M%%% !1110 4444 <3<?LT?LXWEQ)=W?[/_@B665R\LLGA2S9G8G)))CR23WI
MG_#+_P"S3_T;QX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_P
MR_\ LT_]&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_
M +-/_1O'@7_PDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S
M3_T;QX%_\)*S_P#C5=S10!\N>!_V?_@-<?MU^.?#EQ\$O",FGVW@K3);>P?P
MW:F&*1G;<ZH8]JL>Y R:]J_X9?\ V:?^C>/ O_A)6?\ \:K5TSX4^$=(^*.J
M?&"SAG&M:OIL%C>NTY,9AB)* )V.3U[UTE '#?\ #+_[-/\ T;QX%_\ "2L_
M_C5'_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )*S_^
M-4?\,O\ [-/_ $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_  DK/_XU
M1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\ "2L__C5'
M_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )*S_^-4?\
M,O\ [-/_ $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_  DK/_XU1_PR
M_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\ "2L__C5'_#+_
M .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )*S_^-5XK^T_^
MS_\  ;1_C#\&K'2?@EX1M8+_ ,:RQ7T-MX;M42XC^SL=D@6,!USS@Y%?4=<W
MXW^%/A'X@^(O#GBCQ'#.UWX6U)K[23#.459BA0EA_$,'I0!E?\,O_LT_]&\>
M!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_
M ,)*S_\ C5'_  R_^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"
M2L__ (U1_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/
M_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\
MC5'_  R_^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1
M_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\
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M .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )*S_^-4?\,O\
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M-"XZ,CK&"I]P:Z^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \/\
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M.(XX2K32.LH" 0RLG9^-/VT_V-/#7Q"U+X$>//VB_!%KXDMM&N;W4_#6H:W
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M^G_#_2=9NM9U*ZFEU7Q7XHU)5^V>(=8NF\V\U&X*\>9+*20H^6- D:!4C10
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M[:,_-<73*H^2.>2+V_X:?#/P5\'?A?X;^$_@W3EMM"\'Z'::5HD,[!C;VMK
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M=/B=H?APZ9%8:SXGT3Q+#_;^N0C)N/ME[<6\OFM=.S27#!%,I=P2$=D/O5%
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M%&HYD^0C*;#S7ME% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20220630_g19.jpg
<TEXT>
begin 644 biib-20220630_g19.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M% )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
MVMX%\=?'SX7Z#JNH?:/-34=!FUFSD!>3HZ3>5 I;HPD.>#6Y^V-=7'AG_@K'
M^QOKOAX^5>Z^/B!X>UMHN&N-*.A)J&Q\?>1;NPLV / 9N.6KU?XX?L/?"_XP
M?L81?L5Z;J=]X?T;1]$TJT\'ZQ9E9;K0KG2G@ETR\CW\.\$UK;R8. ^PJ>&-
M8OPS_97^,GB7]IO1/VL?VM/'?AG6->\%>#[OP]X%T7P=I=Q;6%BUZ\#ZEJCF
MXD=S<7 M;>)8P=L$2.N^8R%P ?0=9WC#PEX=\?>$M4\"^+]+2^TG6M.GL-4L
MI&8+<6\T;1R1DJ00&1F&00>>#7BNAZ]^U/\ \/&-8\/I\3-%UOX-O\.O,G\.
M6_AORKOPQKJ3VODB2_#$7#74,MS)Y!&8T@C8A Z&;UWXHP_$NY^'6MV_P:OM
M%M?%<FFRKX>NO$<$LMA#=E2(WG2$J[QJV"54J6 P",Y !\J_\% _A%H_[6/[
M4/[./[-_@#2X?[3^%7Q5TKXJ>*M8M8@%\-Z-IL=PEM;%EQL?4+HQP1PY&^*V
MNGP1!5C]I6ZN/$'_  66_9@\&ZYD:5H_PY^('B+2HW^Y-JJKI5B'P>"\=K>7
M0!'(%P_K7"_L_?L>_P#!:KX2PCPQK/[6WP!:S\0>(DU'X@^,=-^'6JOXEU<N
M\8N;E9KB]:W%SY""*$&'R(4CBCCC2.-$7Z3_ &K/V7==^,WC#X=_'7X4^++'
M0?B+\*=<NK[PM?ZK9O<6-[:7EL;74-,ND1E<0W$10B1#NBF@@E <(8W /)OV
M>;F?PY_P6D_:1\':#SI>N_"CP#XBUF-?NQ:J'U>Q#G' >2UM;<$]2MNG9:D_
MX*L?"WP9X@_8$\2_L(?"OP)I]YXF^-7VGPYX*\.-'O!U"\G-S=ZQ,3EA':%Y
MM1GN&R=\8Y:66-6]4_96_9=\0?!WQQ\1?CY\6?%ECKOQ$^*NL6=UXEO-)LW@
ML;"RLK?[-I^F6J2,SF*",RL9'.Z6:XGDVH'6-/G"+]E7_@MSHWQY\7?'GP_^
MT?\ LTW.I^(G-KI,WB'X?Z[=S:%HZL&BTRU9+^-$BW 2R,$#S2X:0L$B6, ^
MQO"_P1\&Z-\-?!GPV\16YUV#P1;Z<-+N=2RS/<V< BANG7.&D!'F#=G;(%<8
M9%8?-GA7X5V'[0?_  61N_VOO!%FD?A[X0?"B\^'VI^(K==HU[7KN_CNIK%'
M'^NBT^*+$A^ZMS>&,'?!,J^A_M&?"+]O7Q9^Q=8_!W]G[]HWPOI'Q7N]/M+3
MQ/\ $?7]%F$39B/VV>S@M60V\DDG$7/[E')4[U1AQ'['7[.__!3SX1^*?"?@
M[XV?&GX%V?PK\+6DJ#PK\*O .I6-W>GR72&*2>_O+C$8D<3NR@2R/&-SD.^X
M ^N*^,F_;]_:%^%?[1'PG^%W[25C\.=-G^+'Q%U/PR_PWT&=KC7_  G#]FO[
MK2KZZNTO98;I;B*P7>@MX-K7BA6;R'#_ &;7YV^&_P#@DM^VKX6^&_PR\$VW
M[4WP[U#4/@_\=KKQ_P"'O$.K>!KZ2\\2FZ;4%FEUB1;U3)=>5J+J#'C<88]S
M@= #V[_@J=^V)^TC^QAX!^&_C#]G7X9^$_%5UXO^,'A[P=?:7XFOKF%Y1J=V
ML"K;M",1N3E?-?>L98-Y4H!4U;_]MWXI_LR?M*WOP&_;+U;PCJFEW'P9UKXA
MZ1XL\$^'+O3!;PZ/-"NHV$UM<WMV9F$5S%-'.LD88+(K1J0K-N_\%$/V5OCM
M^U9H/PNT#X2:YX4L3X ^+WASQY?7OB6XN5-Z^D78N4LTC@B;8)F !F+'8 0(
MWSD<_P#M!_L3?&K]H7]MKP9^T!XJLO [^!M%^&&O^"?$OA6;6;UKO4K77%M/
MMLB3+:A$\K[-L1"I\U<DM"7Q& ?)W_!63XV?MW_'+_@AWK_[3OB3PS\.K+P9
M\1-$T'5+KP!:Z;>C6O#^D7VHV4MI,VIM=-!>7"![<S0BS@4"20+(?*!D_6*O
MSY_:3_X)7?MP_&__ ()WV_\ P3%T']KGP9IW@O2+/3-,T_QK?>$;F;6]2TG3
MYX)+&RNHEN%A22-8(1+<QD_:/)QY4/FL5^]_"]OXGM/#UG;>--7L-0U9+=1J
M%[I>G/9V\\N/F:."2:9HE)Z*97(_O&@#QG]LZ]^%GP,_94^(P@^&\&M:A\0(
M;S3[/PE#$);GQCKVHVYM8++#DF5I0(XR6.R*WA);9#"2ORY^V7\$/'/[!7_!
MM?KG[-?_  F4ESK'A3X.Z;X7U_6;25MNRYGMK346B8\B)8KBX"9Z1JN>E=U\
M9OV7O^"OWB3]K[5OVBOA9\?/V?!H]E%)8?#G1/&O@C6;Z3PY9/D2RH8+V&,W
M=PNT33;2P51$A6,L']VT[]FGQO\ &O\ 8OUK]F;]N_QKIGC75?&^@ZGIGCG4
M?#6FG3[-HKPRJ([*)B[0K#$\:1LY=]T0=F+$F@#QS_@J#I6G?"W5_P!D/7OA
MWIT6G7OA[]J+PQH6B)9KL,6FWUAJ&GW=JN/^61M)')7IB%3_  U]1^+U^%'P
MPFUW]H?QO-IVCG3_  V(]>\3:A-L2UTRU::XP[L<1QH9978C&>,YVKCP?P-^
MQ7\??%OQ%^$^O_M;_&K0?%FD_ [S;OPA%HFB36L_B'639R6$.LZGYLKI'-%:
M37 6&$%#-<R2[U"I$N5^W]^S5_P46_:"^*_A+4/V;/B_\']*\!^&&CU&X\)?
M$7PQJ>H+JVL))O@N;D6ES )([<JDD,+$H)AYKJ[QPF( D_X)#_L\:]\%_A#\
M2OBMKWA*Y\,CXW_&WQ!\1]+\(W=L8)M$T[4&ACLX9H>/)G>WMH[B6+ ,<EPT
M;<H:\O\ VP?@-I7A?_@MI^QK\<IOB)XOU;4-;\0>.[&/2=7UUI=,TN >$[Z0
MK:6H54A+-C<_+N$4,Q"C'T]^R%X,_;?\-Z=X@U?]N+XR^!O$^LW]Y FAV'PZ
M\-7&FZ9IUI'&=S$74LTTD\DCMO+2% L<84*=V>-_:L_9<_:!^,7[9?P%_:0^
M'%]X.AT?X+:KKE_<:;K>H7:7.M-J>E2Z:\:M%;NML(DE:0,?-WM@%4 )(!]*
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME_X#'_&N&U3XP^*=,U.XTUXX'-O.\1<+C=M8C/3VKU&O _%?_(TZE_V$)O\
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MLK^QEMK6!H!";/9)%\T31R9"JRAJG#PI3I2C9.;VO?HKZ6=K^N@'V;1117&
M5[A\-O\ D1M-_P"N'_LQKP^O</AM_P B-IO_ %P_]F-?4\)_[]/_  _J@-RB
MBBOOP"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
MY-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO;UM?>W_ %W^_KW ****R *]P^&W_(C:;_UP_P#9C7A]>X?#;_D1M-_ZX?\
MLQKZGA/_ 'Z?^']4!N4445]^ 4444 %%%% !1110 4444 %>4?MS_P#)H_CW
M_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X
M7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-
M?(<7?P*7J_R SZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
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MO^CJ_#'_ '\E_P#B*/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B* /?Z*\ _P"'I_\
MP3V_Z.K\,?\ ?R7_ .(H_P"'I_\ P3V_Z.K\,?\ ?R7_ .(H ]_HKP#_ (>G
M_P#!/;_HZOPQ_P!_)?\ XBC_ (>G_P#!/;_HZOPQ_P!_)?\ XB@#W^BO /\
MAZ?_ ,$]O^CJ_#'_ '\E_P#B*/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B* /?Z*\
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MO^CJ_#'_ '\E_P#B* /?Z*\ _P"'I_\ P3V_Z.K\,?\ ?R7_ .(H_P"'I_\
MP3V_Z.K\,?\ ?R7_ .(H ]_HKP#_ (>G_P#!/;_HZOPQ_P!_)?\ XBC_ (>G
M_P#!/;_HZOPQ_P!_)?\ XB@#W^BO /\ AZ?_ ,$]O^CJ_#'_ '\E_P#B*/\
MAZ?_ ,$]O^CJ_#'_ '\E_P#B* /?Z*\ _P"'I_\ P3V_Z.K\,?\ ?R7_ .(H
M_P"'I_\ P3V_Z.K\,?\ ?R7_ .(H ]_HKP#_ (>G_P#!/;_HZOPQ_P!_)?\
MXBC_ (>G_P#!/;_HZOPQ_P!_)?\ XB@#W^BO /\ AZ?_ ,$]O^CJ_#'_ '\E
M_P#B*/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B* /?Z*\ _P"'I_\ P3V_Z.K\,?\
M?R7_ .(H_P"'I_\ P3V_Z.K\,?\ ?R7_ .(H ]_HKP#_ (>G_P#!/;_HZOPQ
M_P!_)?\ XBC_ (>G_P#!/;_HZOPQ_P!_)?\ XB@#W^O _%?_ "-.I?\ 80F_
M]#-,_P"'I_\ P3V_Z.K\,?\ ?R7_ .(JI)XET+QG(WC#POJ<=[IFK,;S3KR'
M.R>"7YXY%SV96!'UKY#B[^!2]7^0#:***^& **** "BBB@ HHHH **** "BB
MB@ KW#X;?\B-IO\ UP_]F->'U:A_X*%_L6?":)?AU\1OVB- TC6]*'E:CIMT
M\@D@<_-M;"$9P0?QKZGA/_?I_P"']4!]!45XOX!_X*)?L3?%'QEIWP^^'_[1
MGA_5=:U:Y$&G:=;/)YD\AZ*N4 SP:]HK[\ HHHH **** "BBB@ HHHH *\H_
M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH T?AS\#O@I??#W
M0;V]^#_A:::;1K5YII?#]LS.QA4EB2F22>236=\5/AW\/_!-E:7'@SP-H^D2
M7$K+.^EZ9%;F0  @,8U&0,]Z[KX7?\DS\._]@*T_]$I7._'O_D&Z=_UW?_T$
M5X^?_P#(HJ_+\T!YE1117Y> 4444 %%%% !1110 4444 %%%% !71_#'PGX5
M\9>(9-*\7^&=/U6U6T:5;;4K))XPX90&"N",@$C/7D^M<Y79_ W_ )'";_L'
MO_Z&E>EDW_(TH_XD!UO_  H/X%_]$6\)?^$Y:_\ QNC_ (4'\"_^B+>$O_"<
MM?\ XW7645^K ><^/_A)\*O"WA2YUSPQ\,O#VG7L)017EAHL$,J9=5.'1 1D
M$@\\@FO.:]G^+O\ R(%[_O1?^C%KQBOSWBO_ )&4?\*_.0!1117S(!1110 4
M444 %%%% !1110 4444 :/A+2M+USQ+9:1K>FV]Y:7$X2XM;J%9(Y5/565@0
MP]C7I_\ PH/X%_\ 1%O"7_A.6O\ \;KSCX??\CKIG_7VM>YU][PE_N=3_%^B
M Y/_ (4'\"_^B+>$O_"<M?\ XW5?5/@;\%++3+B]LO@]X6AFA@=XI8O#]LK(
MP4D,"$R"#SFNTJKKO_(#O/\ KTD_]!-?3UOX4O1@?/M%%%?C8!1110 4444
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M_P#8"M/_ $2E<[\>_P#D&Z=_UW?_ -!%>/G_ /R**OR_- >94445^7@%%%%
M!1110 4444 %%%% !1110 5V?P-_Y'";_L'O_P"AI7&5V?P-_P"1PF_[![_^
MAI7I9-_R-*/^) >LT445^K <U\7?^1 O?]Z+_P!&+7C%>S_%W_D0+W_>B_\
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M_P#)#_[97HU%'^KV3_\ /K_R:7^8'G/_  H#_J;?_)#_ .V4?\* _P"IM_\
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M(#UFBBBOU8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JNN_\
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M(=+M]7\42VMR\JJ+)V!BD*G.Y.X^M>EDW_(TH_XD![%16/\ \(/I'_/S>_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "NS^!O_(X3?\ 8/?_ -#2N,KL_@;_ ,CA-_V#W_\
M0TKTLF_Y&E'_ !(#UFBBBOU8 HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P D
MS\._]@*T_P#1*5SOQ[_Y!NG?]=W_ /0171?"[_DF?AW_ + 5I_Z)2N=^/?\
MR#=._P"N[_\ H(KQ\_\ ^115^7YH#S*BBBOR\ HHHH **** "BBB@ HHHH *
M*** "NS^!O\ R.$W_8/?_P!#2N,KL_@;_P CA-_V#W_]#2O2R;_D:4?\2 ]9
MHHHK]6 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_
M]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E<[\>
M_P#D&Z=_UW?_ -!%=%\+O^29^'?^P%:?^B4KG?CW_P @W3O^N[_^@BO'S_\
MY%%7Y?F@/,JI>)/$F@>#] O/%/BG6+?3]-T^W:>]OKN4)%!&HRSLQX  [U=K
M\L_^"S7Q-T?X8?M&Z]%^VM\/-=U7X1>)?A.FF_"7Q!#'--H6@^*?-G-Q]NBC
M.U+F53 (YY%;RTC&S ,S)^<X/#/%UO9W_P WZ>8'ZF55_MK2?[9_X1T:C";X
M6OVDV@<&18=VT.1V4MD GJ0<9P<>/_L3?!WX>?"/P;XMUSX0?%5O%?@?QKXO
M_P"$B\'WA\53:Q%9V#Z9I]J;:&ZEDD)@6:TF:-%=E1)%4$8P.,_X)]?&#2/&
MG[*>N?M]?%?7XK&+XAZKJOB>[O[Y\1Z7X?MIYH--MP?X8XK&".0J  9IYWQN
MD8F705I-.Z5EMK=]+?)_<!].T5\'@_%+6_\ @K!\ OB_\2KK5=+G\;> /',E
MAX,N9V2/1-+MUTK['#-"#M^V,)Y9IVP2KS^2&9+=&/T1^TK^Q!\*OVPO$<,/
M[1EUK&M^$-/TI8M+\&V7B"]TZU6^9Y#-?3FSFB:XD\OR4B#DK#ME91NDRM3P
M\*4H\\M&KZ*_5JRU5]NZ ]HHKY-_X(Y+\2M/_9K\6^#O%_CO5_%'AGPQ\8/$
MVA?"SQ'KMV;FZU#PQ9W?D6KO.W,X65+F-9.A2-=N%"@?)$7Q!\+?\,N0^&U\
M:1_\-Y'XL"Q>W_M!O^$C_MG^V_,:$\Y_L/\ LS+;/^/+[)VWUM' .5:4%+9I
M;=[ZOLE;5] /UIHHKX^_X*!_M6?$&']HWX?_ + 'P/\ ^$M@UCQCI-SXD\>:
MSX%L%GU?3/#EO)Y(CM'D98K66ZGW0_:Y&40JCE,RO$*Y:%&5>IRQ]?1+=@?7
M\LBPQ-*X8A5)(52QP/0#D_05#I6JZ7KNEV^MZ)J,%Y9WD"36EW:RB2.:-@&5
MT920RD$$$<$&O-_V2/%G[/?BWX4R2_LY6TEMING:Q<:=KMCJ%O<1:G::M!MC
MN8=1%U_I!O%PF]YBSN"C[G5E8\'^S9XRO?A[^VO\9?V1+J8_V3%9Z5\0/!EN
MQS]FM=5>YAU"W3TC&H6<]P!V-\X'"J _8OWUUCKKIUM^H'T979_ W_D<)O\
ML'O_ .AI7&5V?P-_Y'";_L'O_P"AI77DW_(TH_XD!ZS1117ZL 4444 %%%%
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M?+^RX\W-]YGG?:LGR_+\SY*_26BE#%^SFW&/52WZJ_7KOK^@' ?$KXK>+/A
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &79VGBU+I'OM6M7B#?O$2W()'L:U**
M* "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"3
M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E-\?>!O^$XMK>W_ +4^R_9Y&;/D
M;]V1C^\,4[X7?\DS\._]@*T_]$I6[6.(P]'%472JJ\7NO^& \Y_X4!_U-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^
MW/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K
M3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\: /=**\+_X=[_!/_H;?'?\
MX65S_C1_P[W^"?\ T-OCO_PLKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\
M#O?X)_\ 0V^._P#PLKG_ !H ]THKPO\ X=[_  3_ .AM\=_^%E<_XT?\.]_@
MG_T-OCO_ ,+*Y_QH ]THKPO_ (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO
M_P +*Y_QH ]THKPO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^.__"RN?\:
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MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\
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M &._B+9?";]I;]J3PWX3\0WT4,HTZ_:5S:Q2L5BDNGB1TLXW(.UYVC5L$@D
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MQ2\2PZ/X<\.:9-J&M:G<(S+;6\2EG?:@+,<#A5!9C@ $D"M^@ HHHH ****
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M+-A> ,[F4$ WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN6!=^(H@999'(QNVKNSY:8["OC[_ (* _!#_ (*@?&_XQ>&4_9I7X#7/PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20220630_g2.jpg
<TEXT>
begin 644 biib-20220630_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:7\6GQ-\3_&>F2>%VU1[<1QZ;I&D7<MFL$"Y.UKFX@EOKB08,LTZC 2"%$
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M]EF7XJK\(T\?7GVMO%1\+)KA\.WPT1M? YT@:IY/V,WF04\GS=WF@P_ZT&,
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MHKQ'^VA\<=>\8^$O%$VNZ5K.N:IH,S_:)=-_LTQ,HT@)]G6U:95A4*JM<S2
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M?0-2U'14G.C^((0BRVVJZ<\ZAO(FC?F)B[0R))&S-M#MQ7PU_83_ &B/@?\
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MO@_Q7HFB>"/"][;KM3Q2^E&<WNLC'^MA$TJV<$O_ "T2RD=28WC9N]_X*.?
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MGDF>01V\)):.&-&6)-Q9RL8+LS%F(!\\_P#!3C6[OQ'\;_V4/V<9'(TKQO\
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MU7PYX?;5M1MK&:6PTI;I(#>S*A*0B1_ECWL NYN%SD\"OD[X!_MV_&QOVOO
MG[(?[2&I?#>^\2>.OAIJFOZEI/@!)1-X+UG3I+ W.CWDC7MREW^[O\+.H@):
MT9O*VS+L^G/C#X'U?XF_"/Q3\-O#_C6^\-7_ (A\.7VF67B/3/\ CYTJ:>W>
M)+N+!'[R)G$B\CE1R.M?&/P/_P""9?[87PR\>_LU_$/5OCM\+4G^ _A/5/"%
M]IVB>!+V*'5-(O8K))KM6:\XOY&L4D+%1$'FD8K)T8 ] _;O_:__ &M?@-^U
MM^S[^SM^SYX \"ZIIWQHU[6-(O\ 4/$LEX]SIKVFF37ANDCA:-#'$J"5D+%I
MEB>(-"7$R<WX^_X*A>,?V25_:&\)?M6^']$\1Z[\$?!.B>+-%O? ^FSZ7#XI
ML]6>XM;2U%M<W%VUI.M];FW9_.E1EFCD 7#(/0/VKOV7/V@?C'^V1\!?VC_A
MO?>#H-'^"NKZWJ-QINMZA=I<ZTVIZ5-IKQJT5NZVPB29Y Q\W>V 50 EO.?C
MO_P3"^(W[4G[37QL\8_&76/#4'P\^,7PGT_P(;31-4NAK&CKIUW=W=GJL;O;
M^5)/Y]PK^2<*AC3]Y)M(< \M_P""F-Y^W=INK?LCM^T*WPSU/1-;_:R\"-K%
MMX,T:^LKGPWJ NGDCA\ZXO+A-2@(\V(S".U8,D;",B0K'^EM?#O[4?[!/_!1
M/]K5_@M9>.?VK_AGI$7P<^)^B^,I;W3O 5[,?%=]IS,8Y[F WL8M4*L^;6*5
M@SREA,GEHI^WK5;I+6-+V:.281@3211E%9L<D*2Q4$] 2<>IZT ?(7_!5[X2
M^#?%O[ VM_\ !/[X4>!]/N?$OQG:3P[X+\/M%YBQW5Q<BYO-:GSEA'9[I;^:
MX;+&14&6FFC#Y/\ P52\-'P;^SA^SM^SR^I7%]X=UC]I#X;>%_$SWC9.H:?#
MJ$<HCG_O"6>TMU8'J7QWKG;+]E3_ (+?Z%\;O%_QTT/]I+]FBYU?Q-(;:PN=
M?^'VNW4VB:2K;H=,M62_C2.%6_>.0FZ:4[Y"VV,)]%_&_P#9$U;]I?\ 8YL_
MV=OC+\5;B7Q=;VFDW\?Q"TW3HXY;3Q+I\T-Y;ZK# ,(H2]@200@@&/,60"30
M!Y;^UC=7'A7_ (*^?LC:YX<_=7GB7P[\0_#_ (@:+@W.EIIUE?HLF/O+'=VM
MN5SP&E/]ZO>?C/XJ^"_[,?PZ\;_'GQ?X>3R]16.?7(+2U-Q=Z]=^3%96MC#$
M<F>:;;#;0P*/GDD "[I&)X;X6?LM?%W7?VGM/_:[_:M\:^&M5\2>%_!=QX9\
M$:'X/TVX@T[2XKN6";4=0)N9'D:YN6M;9 HPL,4&P-*7=Z\Q_:H_9B_X*K?$
MS]K6T^-OP.^./P*M?"'A>V"^ O"OC[P?J^H-IEV\12?4W^S7<"27C*\D22$,
M(8698PIEF:4 [S_@D3^R9XO_ &(/^"=WPX_9R^($,-MKNEV=[J&L:;:SB2'2
M[G4+^XU![&)APR6YNC &7AO*W#@UXA\//@-I7P?_ .#B8>)X?B)XO\1W_BO]
MDC6KJ^G\6:ZUX+41^*-(2."U3:J6T*@L?+10"S,QRS$GZW_95\*?M/\ A/X8
M/%^U_P#%/PYXK\;7NK7%S=7/@_1)-/TJSMSM2&VMHI7>7:J('9I7=C)))SMV
M@>::S^RY^T#>?\%1=(_;CL;[P</"NF_"6[\ R:%-J%W_ &A+#<ZI:Z@]^'%O
MY:NK6J1BWY# L3*,@* ?2M?(O[.6MW7Q/_X+$?M*:WX@D,G_  K'P!X'\)>&
MHR>+:"^BO=7O7 ]99'M Q[BT0'.T8^NJ^7] \ ZA^S]_P58\3_$B6W8>&?VA
M/A[I5HMZ1E(/$WA\W>+8GLUSIEVTB#N-*GY&%! /4OAA^Q_\!OA/\*_&/P6\
M-^$?-\.>/?$NOZWXJT^\DW+?7&LW4UQ>HVP+B(^<T2H.D:JI)P2?!_V[OA-I
M?[6_[9G[.7P.\":?'_:'P;^(]K\4/&GB"UC'_$@TNVM;J"TTXN,;9-0NGC A
MSS#83R$81,_4?Q>MOBO>_##7;/X%ZIH=CXPFTV1/#E[XEMI9K"WNB,))/'"5
M>1%/S%%(+8QD9R/BW]G']D#_ (+/?!^.S\'^(OVL/@&=(U;Q)%J7Q#\4Z1\/
M-5;Q-K9>2/[7<_:+F]>W%T\*>5&3#Y4"+%''&D<4<:@'V!^T!\$[']H3X97O
MPLU;XB>+?#%GJ(*7NH>"=<.FWSQ%&5HEN%4O&K!N2A5LJ,,.<_-'_!O=9PZ=
M_P $<O@CI]MGRX-&U&./<<G:NK7H&3WZ5]>^*9O%%OX>NYO!6G6%WJHB/V&W
MU2\>WMWD[>9)''(RKWX0DXQQG(\)_P""7'[*WQ8_8A_8M\)?LI?%O7O#VLWG
M@Y+J&VUWP[).L=_'-=SW.YH9D!A9?.V8#R!MN[*YV@ XK7];NOAM_P %QO#F
MDZ3(8['XJ_LW:DNN6T1PLMYH6LVSV=PXZ%EAU>\CW=<,HSA0*^NJ^7_ '@+4
M/C/_ ,%4O%?[3ZV[?\(S\+?A@OP[T&[<92^UF]O8]1U9XCT9((K?3+<N,CS6
MN8SAH7 ^H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "JNC:+I'AW2H-#T'38;.RM8]E
MM:6T82.%!T1%'"J.@4< <# %6J* "BBB@ JM#HNDV^KW&OPZ;"M]=01PW%X(
MQYLD49<QQENI13)(0O0&1R!ECFS10 4444 %%%% !1110 4444 %%%% !111
M0 55U;1=(UZV2SUK38;J*.XBGC2>,,$EC<21R#/1E=596'(*@CD5:HH ****
M "BBB@"KH^BZ1X>TY-)T/38;2VC+,D%O&%4,S%F; ZEF9F)ZDDDY)-6J** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?C+\3+'X-_"[6_BAJ>F37
MMOHMD;F6U@<*\@! P"> >:Z:O*/VY_\ DT?Q[_V 7_\ 0UH [/0+WQ=XDT*R
M\16>IVL,-_:1W,44EOED5U#!20>2 <5<^Q>-_P#H-V7_ (#'_&HOA=_R3/P[
M_P!@*T_]$I6[0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!EV
M=IXM2Z1[[5K5X@W[Q$MR"1[&M2BB@ HHHH **** "BBB@ HHHH *\H_;G_Y-
M'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E
M;M87PN_Y)GX=_P"P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E/C1\<?A)^SM\/[
MKXI?&WQ]I_AO0;.6**74-1E(#S2N$BAC4 O++([*B1(&=V(55).*\O\ V6/^
M"EG[(G[7OB.7X?\ PK^):1^+HKK6 W@O6;.:RU<6FG:C)8R7K6DZ)+' [HI5
MG52/,",%D5T7C?\ @K7^RG^T[^T?\)O 7Q _8S\3:';_ !-^#GQ,L?'7A30_
M%8/]E:_+;6]S;O87!!'EEX[E]DF1M88W1[O-3YS_ ."0'[>G[/7[1WQR@^!O
M[1'PJUGX6?M/^"M=^(DZ^$-?MU,%[:ZIXENK[4H=.O5!6^BMYH5C;!0E[.5E
M5T1F !^CGQ1^)G@3X+?#7Q!\8/BCXCAT?PUX6T6ZU;7]5N%9DL[.WB:6:4A
M68*B,<*"QQ@ G K<CD26-98SE6 *GU%? '_!R;\#]=^)O_!*WXL>,X?VA?'G
MAO3/"_A-KZY\(>&;C3X-.U^1+B(HM^\EG)=O&,\Q17$2-@;E;%??6G?\@^#_
M *XK_(4 35@>%?BAX!\;^*_$W@?PKXEAO=5\&ZE!8>)[.)6#6%S-:0WD43D@
M LUO<0R?*3Q(,X/%7/&>@ZKXH\*:AX=T/QKJ?AN\O;1X;;7M%BM9+NP<C FB
M6[AG@9UZ@2Q2)ZJ1Q7Q!_P $4OA;<?!;XK?M@?#6\^)_BGQI/IW[1S-/XH\:
MWT-QJ>H/+H&DS,\[P10Q$@R%55(T5455"@** /I_X]_MJ_LR_LQZHFB_&OXE
M_P!E77]G?VC=16NC7M\=/L=S)]LNS:0RBRMBR2 3S^7$3&X#?(V/1O#?B3P]
MXQ\/6'B[PCKMGJFE:I9Q7>F:GIURD]O=V\B!XYHI$)61&4AE920000<&O./V
MJ/'_ (Y^!GPE\2?$;X(_LF:M\4_$UU8R,_A[PY/IMK)?21PD1FZDNYXFDCP
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^J0?^7!_P#<]?--%']N9I_S\_"/^0?\0[X._P"@7_R>I_\ )GTM_P /$/\
MJD'_ )<'_P!ST?\ #Q#_ *I!_P"7!_\ <]?--%']N9I_S\_"/^0?\0[X._Z!
M?_)ZG_R9]+?\/$/^J0?^7!_]ST?\/$/^J0?^7!_]SU\TT4?VYFG_ #\_"/\
MD'_$.^#O^@7_ ,GJ?_)GTM_P\0_ZI!_Y<'_W/1_P\0_ZI!_Y<'_W/7S311_;
MF:?\_/PC_D'_ !#O@[_H%_\ )ZG_ ,F?2W_#Q#_JD'_EP?\ W/1_P\0_ZI!_
MY<'_ -SU\TT4?VYFG_/S\(_Y!_Q#O@[_ *!?_)ZG_P F?2W_  \0_P"J0?\
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M@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
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M&_\ EH:/_P#(E'^O>4?R5/NC_P#)!_Q*QX@_]!6%_P# ZO\ \H/W7HK\*/\
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MQJZE%0AS*2?32_ZI+[FS##8^6(Q#HRHSAI>\N6S5[+:3:OTYDMGU5C(HHHK
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M#/\ UX'_ -&/7T?#7^^3_P /ZH_*_%K_ )$=#_KXO_29'>4445]J?S^%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K(^('_ "(>M_\ 8(N?_135KUD?$#_D0];_ .P1
M<_\ HIJBI_#?H=.#_P![I_XE^9^=5%%%?E1_984444 %%%% !1110 4444 %
M%%% !1110!^E%E_QYQ?]<E_E4E1V7_'G%_UR7^525^KK8_BV7Q,*_/3XN?\
M)5O$_P#V,-[_ .CWK]"Z_/3XN?\ )5O$_P#V,-[_ .CWKYCB?^#3]6?KOA%_
MO^*_PQ_-G/4445\>?NH4444 %%%% !1110 4444 %%%% !7WA^S#_P D$\,_
M]>!_]&/7P?7WA^S#_P D$\,_]>!_]&/7T?#7^^3_ ,/ZH_*_%K_D1T/^OB_]
M)D=Y1117VI_/X4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]
M>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"
MM/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5D?$#_D0];_[!%S_ .BFK7K(
M^('_ "(>M_\ 8(N?_135%3^&_0Z<'_O=/_$OS/SJHHHK\J/[+"BBB@ HHHH
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%%
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M59%F/F(S0,XRJRJI+1,P!(#A2<<4U"4DVEL3.M1IR49R2;V3>_IW,>BBBI-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LCX@?\B'K?_8(N?_135KUD?$#_ )$/6_\ L$7/
M_HIJBI_#?H=.#_WNG_B7YGYU4445^5']EDME97>HW<=C86[S32N%BBC7+,QZ
M "HJ]R_9RT6XUKP?:-\-M7M8-?LM>,VOVC%5NKJQVIL\ICR44[LJ,9)Y_A!\
MQ^)?B+5M>U"PMO$6A"PU/3-.^QZC']A6W:243ROO9% PQ61020"2":[*F%5/
M#QJ-[^6G32_==3Q,+F\L7F=7"Q@K0=GK[RWLW&WPNRLTWHT^Z7-T5[CX]U+X
MM6.F7/A;X<^+])N-&TK0X(;G3M+N;22[CCCMXTGE( \W[X<L5.5SSBO+O ?Q
M'U_X;O>7WA40Q7]W$L*WLL"2F&+=N955U*Y8A.<<!3ZY"K8>%&JHR;MU=ORU
MU_ K!9GB,?A)5:4(N6EH\[Z_S^XN5VULE+RN<_17I'Q*^)OC;Q)\*]'TOQEK
M"W5SJE[)J  LX83';1YAB'[M%SN<3$Y_N(:9KFMWOPG\/^$M/\.+&DFH:4NK
M:SNC#+?>;*ZI#*"/GB$<8&P_+EV.,FE+#TU)VD^5).]M=;=+^?<=/,L3*G%2
MI+GE*44E)M>[>[YG%/=6^'>W34\ZHKJ/C/X6TWP9\3]7\/Z,A2SCG66SC)SL
MBE1947/?"N!^%6_A-I]K:Z9XF\?7-M',_A_1A)8K+&&5;J::.&.0J>#LWLP!
M_B"GM4*A+V[I/I>_RW_(Z)9C2_L^.+@KJ:BXK:[G917E=M+R.,HKN?$)F\9_
M!N#QYK$AFU73?$']G7-Z_,ES!+"98_,;J[*T<@#'G# = ,<-45:?LVK.Z:NC
M;"8GZS"5U:46XM7OJO/3=6>W4****S.H_2BR_P"/.+_KDO\ *I*CLO\ CSB_
MZY+_ "J2OU=;'\6R^)A7YZ?%S_DJWB?_ +&&]_\ 1[U^A=?GI\7/^2K>)_\
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MBBB@ K(^('_(AZW_ -@BY_\ 135KUD?$#_D0];_[!%S_ .BFJ*G\-^ATX/\
MWNG_ (E^9^=5%%%?E1_99Z-\(?#&FW.K>&?$6A>+["VU>+5F^UV$]]Y$NP,-
MDB,V%).6&W(;@$ YI?C]XXM_&%GX9M-4U>TU3Q!INFR1:[JUB0\<Q,F8DWC
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MN?\ )5O$_P#V,-[_ .CWKYCB?^#3]6?KOA%_O^*_PQ_-G/4445\>?NH4444
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M\4DNM=TJ%9M8\(ZWIEUI.MZ=&3M#SZ=?10W,:;OE$ACV$C 8T >OUY1^W/\
M\FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z
M)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'Q _Y$
M/6_^P1<_^BFK7K(^('_(AZW_ -@BY_\ 135%3^&_0Z<'_O=/_$OS/SJHHHK\
MJ/[+"BBB@ HHHH **** "BBB@ HHHH **** /THLO^/.+_KDO\JDJ.R_X\XO
M^N2_RJ2OU=;'\6R^)A7YZ?%S_DJWB?\ [&&]_P#1[U^A=?GI\7/^2K>)_P#L
M8;W_ -'O7S'$_P#!I^K/UWPB_P!_Q7^&/YLYZBBBOCS]U"BBB@ HHHH ****
M "BBB@ HHHH *^\/V8?^2">&?^O _P#HQZ^#Z^\/V8?^2">&?^O _P#HQZ^C
MX:_WR?\ A_5'Y7XM?\B.A_U\7_I,CO****^U/Y_"BBB@ HHHH *YO5/A#\.-
M>^(=C\5O$?A.TU+7])@:'1-0U&/SFTI&_P!9]E#Y6W=_XY$ >0*BLS*B*O24
M4 1WEY::?:2W]_=1P001M)--,X5(T49+,3P  "23TKE_$_PV^$GQE&B>-=5T
M73=5N=*F%[X7\26;*;FP=A@RVMU&=T8=<JP1MLB,R.&1F4_!W[7_ .QA\2/B
M9\0-0_9T\8?#GPEX0^$?Q#^)\GBSXW?%R7QI:VM_XVT6"7[3:^&([<E)XBS"
MWMI6+K"(8'D#%[AUKZ%_X)B6W@/2? OQ*\,?"?X3Z-X"\):3\5+BV\,^"- U
M2PNK71[7^R=+D*J-.FEM8&FEDENVAB<A&NVW9<LQ /IBO*/VY_\ DT?Q[_V
M7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^
M29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(^('_(AZW_V"+G_
M -%-6O61\0/^1#UO_L$7/_HIJBI_#?H=.#_WNG_B7YGYU4445^5']EA1110
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MW.CV[ZB-'THS2065U!!-;(5,0*N@W.LCC*N*3XI_MJ?'+0OB_P"+? '[$/\
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
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MIJUZR/B!_P B'K?_ &"+G_T4U14_AOT.G!_[W3_Q+\S\ZJ***_*C^RPHHHH
M**** "BBB@ HHHH **** "BBB@#]*++_ (\XO^N2_P JDJ.R_P"/.+_KDO\
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M_L$7/_HIJBI_#?H=.#_WNG_B7YGYU4445^5']EA1110 4444 %%%% !1110
M4444 %%%% 'Z'V=EXV^R18UNSQY:_P#+L?3ZU+]B\;_]!NR_\!C_ (UJ67_'
MG%_UR7^525^KK8_BV7Q,Q_L7C?\ Z#=E_P" Q_QKX)^*BS+\3_$BW+AI!KUX
M)&48!;SWR17Z'5^>GQ<_Y*MXG_[&&]_]'O7S'$_\&GZL_7?"+_?\5_AC^;.>
MHHHKX\_=0HHHH **** "BBB@ HHHH **** "OMS]FZU\6/\  [PX]CJMK'";
M([$> D@>8W4U\1U]X?LP_P#)!/#/_7@?_1CU]'PU_OD_\/ZH_*_%K_D1T/\
MKXO_ $F1U%G:>+4ND>^U:U>(-^\1+<@D>QK4HHK[4_G\**** "BBB@ HHHH
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M;.T-O BI$&2UC8A1RY=OXJ /0*\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
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M]LS3/VR_#G@GQ]\>/A3^U+HG@FP\$^&KG5?#/ARX\)VU]8:I]EM/M$QUB>X
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M=&VZ(E^Q)T^/RI((5@\B)5*N2REHPH) /UGKXM^-GP?_ ."J%_K'Q ^.\_\
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M_C5>:44?7\=_S]E_X$_\P_U:X<_Z Z7_ (+A_D>E_P##8'[1?_11/_*1:?\
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MB\UJ4:BING7Y9MIQM.RLFN9M7M)6TM*ZNTE9NYYQ1117$>\%%%% ':?LZ_\
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M_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*^2O^"S'[/'_#0?@7P-IO\
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M_L:/^$Z_ZA?_ )'_ /L:\+_B&O&W_0+_ .3T_P#Y,_>O^(V^&'_0?_Y2K_\
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M_P#@J'_R(?Z]\<?]#3$_^#ZO_P D:'_"4Z]_S_?^0E_PH_X2G7O^?[_R$O\
MA6?11_JOPS_T T?_  5#_P"1#_7OCC_H:8G_ ,'U?_DC0_X2G7O^?[_R$O\
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M_P"NMI_Z4Q5\15\/Q)_O\?\ "OS9_0WA/_R3E3_K[+_TF 4445\^?IP4444
M%%%% !1110 4444 %%%% ':?LZ_\ER\+_P#87B_G7WQ7P/\ LZ_\ER\+_P#8
M7B_G7WQ7VG#/^Z3_ ,7Z(_ _%O\ Y'&'_P"O?_MS"L/XG_\ )-/$7_8"N_\
MT2];E8?Q/_Y)IXB_[ 5W_P"B7KZK#_QX>J_,_(J_\"7H_P C\KZ***_HH_!
MHHHH **** "BBB@ HHHH **** "BBB@#]9[#_CQ@_P"N*_R%2U%8?\>,'_7%
M?Y"I:_G![G[^M@K\N_C?_P EI\7_ /8T:A_Z4R5^HE?EW\;_ /DM/B__ +&C
M4/\ TIDK[_@#_>Z_^%?F?#\<?[M1]7^1R]%%%?J!^<!1110 4444 %%%% !1
M110 4444 %?I%^Q]_P FT^$?^P<W_HUZ_-VOTB_8^_Y-I\(_]@YO_1KU\-Q[
M_P BRE_C_P#;6?9\$_\ (QJ?X/U1Z51117Y0?IH4444 %%%% !1110 4444
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M<;0IVG:QX)M?&;X=Z)X.CT7Q'X,\42ZKX>URTDDTB6Y7;+ $DQ)$XZ95FZ@
M$EN.YM_ *72KO6[CPUI-G-;^)-4TZZMM)U>6</! S1-E?*"@JS)N3S-[;=V=
MOI<:,5B_93BM;=7U71^?2^G<Y:N.K2R7ZW0J-\O,[N*6S:?.FKI0LU-12EH[
M:G)>#?"-WXQU26RANH[:"UM)+N_O)@2EO!&,LY Y/8 #DLP'>I_$O@V+2=$L
MO%>AZJ;_ $J^FD@CN'M_*DBGCP6BD3<P5MK*PPQ!#=<@@;GPK*/X \?VUO\
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MP_B?_P DT\1?]@*[_P#1+U]5A_X\/5?F?D5?^!+T?Y'Y7T445_11^"!1110
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MW\;_ /DM/B__ +&C4/\ TIDK]1*_+OXW_P#):?%__8T:A_Z4R5]_P!_O=?\
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M2#MD) !(##L<FN#^)/PYM8/C;J?PX^&%O+J$:ZAY-A#$V]@2H+(6]$)92Q/
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M?B3_ '^/^%?FS^AO"?\ Y)RI_P!?9?\ I, HHHKY\_3@HHHH **** "BBB@
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M **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
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MT1^!^+?_ ".,/_U[_P#;F%8?Q/\ ^2:>(O\ L!7?_HEZW*P_B?\ \DT\1?\
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M5/E^:/L. ?\ DKL+ZR_](D?+5%%%?G9_4@4444 %%%% !1110 4444 %%%%
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MP_B?_P DT\1?]@*[_P#1+U]5A_X\/5?F?D5?^!+T?Y'Y7T445_11^"!1110
M4444 %%%% !1110 4444 %%%% 'ZSV'_ !XP?]<5_D*EJ*P_X\8/^N*_R%2U
M_.#W/W];!7\Z_P"U[_R=E\4/^RB:W_Z7S5_117\Z_P"U[_R=E\4/^RB:W_Z7
MS5^K>%/^_8G_  Q_,_+_ !/_ -SP_P#BE^2/.Z***_;3\<"BBB@ HHHH ***
M* "BBB@ HHHH *_>[_@EM_R8!\,?^P$__I3-7X(U^]W_  2V_P"3 /AC_P!@
M)_\ TIFK\Q\4_P#D2T?^OG_MLC]'\,O^1Q6_Z]O_ -*B>_4445^$G[:%%%%
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M#\6_^1QA_P#KW_[<PK#^)_\ R33Q%_V KO\ ]$O6Y6'\3_\ DFGB+_L!7?\
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MSNBBBOVT_' HHHH **** "BBB@ HHHH **** "OWN_X);?\ )@'PQ_[ 3_\
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M_P!0O_R/_P#8T?\ "=?]0O\ \C__ &-'_$->-O\ H%_\GI__ "8?\1M\,/\
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M .2:>(O^P%=_^B7KXG#_ ,>'JOS/L*_\"7H_R/ROHHHK^BC\$"BBB@ HHHH
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M -+YJ_5O"G_?L3_AC^9^7^)_^YX?_%+\D>=T445^VGXX%%%% !1110 4444
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M_P!))*^+PO\ O5/_ !+\SZ[%?[M/T?Y'\X=%%%?UX?RD%%%% !1110 4444
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M6<_Y1U^.?^OK2?\ TYVU?AO7[YX7?\D]4_Z^R_\ 28'X;XE?\CZG_P!>X_\
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M_P#C5>?T4?5L-_(ON0?6<3_._O9Z!_PU)\=O^AZ_\IEK_P#&J/\ AJ3X[?\
M0]?^4RU_^-5Y_11]6PW\B^Y!]9Q/\[^]GH'_  U)\=O^AZ_\IEK_ /&J/^&I
M/CM_T/7_ )3+7_XU7G]%'U;#?R+[D'UG$_SO[V>@?\-2?';_ *'K_P IEK_\
M:H_X:D^.W_0]?^4RU_\ C5>?T4?5L-_(ON0?6<3_ #O[V>@?\-2?';_H>O\
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MA/Z8]%_Y UI_UZQ_^@BK-5M%_P"0-:?]>L?_ *"*LU_'LOB9_64?A05_.O\
MM>_\G9?%#_LHFM_^E\U?T45_.O\ M>_\G9?%#_LHFM_^E\U?JOA3_OV)_P ,
M?S/S#Q/_ -SP_P#BE^2/.Z***_;3\<"BBB@ HHHH **** "BBB@ HHHH *_>
M[_@EM_R8!\,?^P$__I3-7X(U^]W_  2V_P"3 /AC_P!@)_\ TIFK\Q\4_P#D
M2T?^OG_MLC]'\,O^1Q6_Z]O_ -*B>_4445^$G[:%%%% !1110 4444 %%%%
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M_F;7P62M%-+F33/0S#EJX.-.&]Z:6JL_<L^3^5)_'=N\FK\K31YE\,/A_/\
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MY, ^&/\ V G_ /2F:OP1K][O^"6W_)@'PQ_[ 3_^E,U?F/BG_P B6C_U\_\
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MOQS_ -?6D_\ ISMJ_#>OW(_X+.?\HZ_'/_7UI/\ Z<[:OPWK]\\+O^2>J?\
M7V7_ *3 _#?$K_D?4_\ KW'_ -*F%/M[B>TF6YM9WCD1LI)&Q#*?4$=*917Z
M1N?GNP4444 %%%% !1110 4444 %%%% 'M7_  3D_P"3ZOA9_P!CC:_^A5_0
M%7\_O_!.3_D^KX6?]CC:_P#H5?T!5^&>*G_(VH?X/_;F?M/AE_R*Z_\ C_\
M;4%<?^T/_P D \<_]B=J?_I))785Q_[0_P#R0#QS_P!B=J?_ *225^;87_>J
M?^)?F?HF*_W:?H_R/YPZ***_KP_E(**** "BBB@ HHHH **** "BBB@ HHHH
M _ICT7_D#6G_ %ZQ_P#H(JS5;1?^0-:?]>L?_H(JS7\>R^)G]91^%!7\Z_[7
MO_)V7Q0_[*)K?_I?-7]%%?SK_M>_\G9?%#_LHFM_^E\U?JOA3_OV)_PQ_,_,
M/$__ '/#_P"*7Y(\[HHHK]M/QP**** "BBB@ HHHH **** "BBB@ K][O^"6
MW_)@'PQ_[ 3_ /I3-7X(U^]W_!+;_DP#X8_]@)__ $IFK\Q\4_\ D2T?^OG_
M +;(_1_#+_D<5O\ KV__ $J)[]1117X2?MH4444 %%%% !1110 4444 %>4?
MMS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P
M%:?^B4KX#_X.(O\ DF?PS_[#NH?^B8J^_/A=_P DS\._]@*T_P#1*5\!_P#!
MQ%_R3/X9_P#8=U#_ -$Q5]9P-_R5>&]9?^DR/EN-?^28Q/I'_P!*B?E91117
M],'\Z'O6E_MVZM+8ZM<>.O@7X"U_5[O1K'3[#4[S1)$VQVDMNT*W"13(ET$2
M!0#*KL2J!BR@J?'OB'\0?&/Q6\;ZI\1_B#KLVIZUK-X]UJ5]/@-+*QY.  %
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M\U?JOA3_ +]B?\,?S/S#Q/\ ]SP_^*7Y(\[HHHK]M/QP**** "BBB@ HHHH
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MKX'_ /0W>.__  KYZ/\ AW5\#_\ H;O'?_A7SU[U10!X+_P[J^!__0W>._\
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M _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\
MA7SU[U10!X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7SU[U10!X+_P
M[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\]>]44 >"_\.ZO@?_T-WCO_
M ,*^>C_AW5\#_P#H;O'?_A7SU[U10!X+_P .ZO@?_P!#=X[_ /"OGH_X=U?
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MOO$\TT+,.SH>&'/0U[)110 4444 %%%% !1110 4444 %%%% !1110 4444
M<G\;/CM\&OV;_AY>?%CX\_$S1O"7ARQ9$N=7UV^2"$2.<)&I8Y>1S\JQKEF)
MPH)XKA?@W_P4'_8_^/'Q$@^$/P]^,,:>*[RQ>]T[PSXCT2^T74-0MDY>:UM]
M1@@DNHU'+/$KJHY) KY8^/T,?[0?_!QQ\(?V?_BJ?M'A#X4?L[7_ ,3?"6BW
M?-M=^)IM8.EBY:,_+))!;_O(B<M$P9EVDY.Q_P '(GA73-/_ ."7_B;]IS1=
M3&B^._@KKVC>+OAQXJAPMQI6J1ZE;0X1^NV6.9XF3.UBR9!VB@#WK]I?_@J)
M_P $_P#]COXBV7PF_:6_:D\-^$_$-]%#*-.OVE<VL4K%8I+IXD=+.-R#M>=H
MU;!() ->ZZ;J6G:SIUOJ^D7\-W:7<*36MU;2B2.:-@&5T920RD$$$<$'-?,G
M[3R?!;P?_P $^/B'XP\8_""WU*^^+7AIVU+PD;47%YXJ\0:I:);6FF@/EIIF
M=K>UB!XBCB3E4BRO??\ !/7]GSQ?^RA^PQ\)?V;/'_B :IKG@CP!I>D:O>)*
M70W,-NBR)&QY,:,"B'^XB\#I0!UWQ>_:+^"'P$U3PCHOQB^).G>'[KQ[XJM_
M#?@^"_=@VJ:K.&,-K'@'YVV'&<#.!G+ 'F_VL/VZ?V2OV&_#NG>*/VJ_C?I7
M@^VU>66/2HKN.:>YO#$H:5HK>W22:1(U92[JA5 R[B-PSH?M"?LL_"[]IC6O
MASK?Q*M)99?AA\1+3QGX=$)4?\3&VMKF"+>2#\@^TL^!C+(G/%;?B?PY\(_
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ML[_P36U[P78_$VW_ &CVM?">HL%L_&.K>#=9L=%?]YY>?[0N;-+95W@J6,@
M(()X-?-7_!$33=/UC_@G_P#M7:1J]A#=6EU^T7\3(;JVN(@\<T;)&K(RG(92
M"00>"#7HW_!NMX<\/^,/^"$WP2\)^+-#L]3TO4_#&KVNHZ;J%LLT%U!)JU^K
MQ21N"KHRD@J0002#0!]RZ%KVA^*=$L_$OAG6;34=-U"UCN;#4+"X6:"YA=0R
M21R(2KHRD$,"00017*V'[1?P0U3X_P"H?LL:=\2=.F^(6E>&8O$.H>%$=OM4
M&F23>2ERPQMVF3"XSD;E) #*3\7?\&[5[?>%_@9\??V9M/U*XNO"?P6_:L\:
M>"OA_P"=.T@M=%MYH)H;968DD(\\IZXPX X%?7NE_LL_"_2?VN-9_;1MK27_
M (3'6OA]8>#[F3*B);"UO;J\! QDNTER Q)^[#&.U '#_&__ (*J?\$\?V;O
MC9;_ +.WQR_:Q\*^&_%\\UO#)I>H3R;+.2==T*75PJ&"S9U(=5G>,E2& VD&
MO:_&WCOP5\-?!>I_$?XA>+-.T30-%L)+[5]:U2\2"UL[:-2[S22.0J(J@DL3
M@ 5\O?\ !4'X4?"+0?\ @G1\5?V>/#?PNLM;UWXRC5-'\)^&C$LD^N>+M8:5
MX)\MD[H9V^UM*>+:"R:3*) -OLWPT_9C\.Z/^RS\/?V:_BY.OBR#P7X>\/VE
M[<7N6CU2[TN.W,5Q*K??'VBW2;:W5E7.>E &'^RC_P %'?V(?VX-;UKPQ^RS
M^T3HGBS5O#T:RZQI$$<]M>6\+$!9O(N8XY&A)*@2JI3++\WS#/MM?&/B+X1:
M7\=O^"VWA/X^_#+3HK>W^!_PKU?1/B3XFM(P!JFHZLUL^GZ'(XQYKVT"37KK
MD^4+RVR 9AC[.H **** "BBB@ HHHH *\1U__@HM^R!X5_:CTK]BOQ'\3-0L
M_BCKN]M$\(3^#-76?4(D65GG@?[+Y<T"K#,QG1S$%B<EL*2/;J^.O^"R/["/
MC_\ :I^"^A?'S]EN]72/V@/@=JQ\5?"'6XP US<1@-<:3*3@/!=QIY91B%+B
M/<=A<$ ]Z_:8_:__ &?/V/M$T3Q'^T-XUNM"LO$>M)H^B3V_AV_U#[7?R*S1
MVJBS@E(E<*Y1" 7V-MSM./,8/^"O_P"P%=>.[CX76WQ2\32>)K33EU"Z\.Q_
M"?Q,;^&T9MBW#VXT[S%B+?*'*[2>,YKS'_@F;\6-0_X*WZ9X(_X*F_$_P<VB
M>&M'TZ:T^$/@A[T2K8ZJ$DLM:UJ?:</*9Q<V-J&&8[:*23"O>,L?._"[_E9W
M^*/_ &:/H_\ Z>UH ]@\"?\ !:__ ()J?%%]73X:_'W4_$'_  C]P(-?.B_#
MCQ#=#2Y"6&RY,=@1 <H_#[?N-Z&O=?@)^T9\"/VI/AY!\5_V=?BUH/C/P[/,
M\*ZKX?U!+B-)DQOADVG,4JY&Z-PKKD9 KXD_X)+Z;I^E?\%7O^"A=MIEA#;1
MM\2/"4S1P1!%,DFDW$DCD#^)G9F8]2S$GDFH_@]I.F_L^_\ !RU\1?A%\)K6
M/3_#?Q;_ &7K/Q_XUT6P4);MXAM==;3DOC&ORK(\!;>P 9WE+-DG) /M[XM_
MM%_!#X$:WX/\.?%_XDZ=H%]X^\31>'O!UK?.P;5=3E5FCMH\ _,P4X)P,X&<
ML >9_:R_;O\ V1?V&=!TWQ%^U9\<M)\'P:Q)*FE0W<<UQ<W?E*&E>.WMTDE=
M(PREY FQ-R[B-PSI?M ?LL_"_P#:2\2_#7Q1\1[266X^%OQ!@\8>'?)*C-_#
M9W=M&')!.P?:C)@8R\49[5L^*] ^#WPYUWQ!^TQXY.G:;/9^$UM-<\3:I*JQ
MV6D6C3W+ N_$40,LLCD8W;5W9\M, %KX-_&?X4?M"_#/2/C+\#_B#I7BGPKK
MUM]HTC7=%NUGM[E-Q4[67NK*RLIPRLK*P!! G\4?%#P%X+\7>&? ?B?Q+#::
MQXQOKBS\-6#HS/?306LMW,J[00H2"&1RS87@#.YE!^8_^"+G[.VL? +]F#Q9
MK]WX1N/"^E?%'XP^)O'OA+P5<VIMW\-Z'J5T&T^R: @?9V^S1QS-!@>4UPR$
M!E(KS7]I#X'Z[X*_X+K?LJ?%W7/VA/'GBE?$ME\0X+#PKX@N-/72/#L,6CQR
M!+"&TLX'!8S;7EN))Y76*,%SLH _06BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#YF_;F_8(\2?M _%?X>?M=?LZ?$FT\$_&?X5/=
MQ>'-:U.QDN--UK2[M-EWH^HQ1.DC6\@Y25&\R!R9$!)Q7QE^T5_P2H_;E\:^
M(/#VL>/_  2GB'X-0>+=)U;XJ_L]^!?CGJGB*Z\;363RR17T=WXHAM8X")C
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MTDLC-)+)(?T+HH K:-:7VGZ1:V&IZK)?W,%LD=Q?2Q(C7#A0&D*H JEB"2%
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MEC3R3&7^:0^8#C]WUKZ>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXYZA:^'_ (JZ4O@_1[EK&_&EP7$\UM]IM7:&03F961BZ<C:J;3NW/^"H,/\
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MXBO/"UOI/B#P;JUYN%E<R-9;+:\L79660^3$\?RD,V0K?.WQ2\4>&;/XZ_\
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M.#,%4J<YKZ\^(_[5?A?X:_L;WO[8FM^'KU+"W\#1^(;?06'^EW$LMNLEO8*
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MOB-^U?\ \(+?6O@VWL8M(_X06YU3SHEN[N03^;%,@7+2LNS&1Y><_,,?-/\
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M^K>$O#GCGQKJ6C>+])M-"TJY6>WMM U/54DBFN[61X',E@L;'+*4D;"JP#4
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M:/806EI:PK#:VMM$(XX8U 5415 "J   !P *X:7]E#]EJX\'^(?A[/\ LU>
M'T#Q=J1U'Q7H;^#;$V>M7A<.;B[A\K9<RE@&\R0,V0#G(KD/V9O^"@G[,G[7
M'Q5^(GPI^!OQ,T37+GX=:]'I-[=:=K,$Z:A-]EAGF>W",3)%"TRPO(N5$B.N
M?EKU+P;\3?AM\19=0@^'WQ!T/77TFY^SZHFC:M#=&SFY_=RB-F\M^#\K8/%
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MU7SM7V7^VO\ "GX4>.OBII^K^.OCG_PC-W'X?BACL/\ A&9[WS(Q/.PEWQL
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M JUH7[(?[)WA;QS:?$_PS^R_\.].\2V$*Q6/B&P\%6$-];Q@Y"1SI$)$4'D
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M,P8R-^B+? [X*MX^U3XKM\(/"Q\4ZWI0TO6O$I\/VW]H7]B  +6>XV>9+#@
M>6S%>!Q6/X6_9*_94\#1^'H?!/[,OP^T=/"-_<7OA1=*\&6-N-%N9U"SSV@C
MB'V:2154.\>UG  ).* /EG]OBY^%?A+_ (*[_L>^+_B7-H&FZ>_AKXFK>ZIK
M9@AA9X].TEXP\DN%RJI(RY/ 5B.AKR;]F+X2_'+X]?MZ_MBP^//B'\(HO%8\
M>PZ7'X>^+/P@NO$MP? 3:? VE-:.NM64<>GS;[K?$L+!KA)6D=F(5/T=^(/P
M>^$?Q:DTF7XJ_"SPYXF?0-334=";Q!H=O>G3;Q/NW,!F1O)E':1,,.QK,^+'
M[-7[.7QYNK.^^.7P \$^,YM/0I83>+/"MGJ+6RDY(C-Q&Y0$\X&.: /AK3/V
M1/BI\)_V0_V?O@E\$O\ @H9X5\1?$/P-\3M4U?X):YXK\+S_ /".^(4BL]3C
M_L"XB^VW,[P0V5Q=I!<).\L<=LC1@[ :^@/^"5GQ?_X6W\$?&4.L_LY6GPM\
M4^%OBSKVA^/O#.D:DMYIDFO1R1S7EY83A4\RWG>X\WE599&E1LLI)]R\=_ [
MX*_%+0+#PI\3?@_X6\1Z7I4B2:7INO>'[:\M[-T7:C11RHRQE5X!4# X%:_A
M'P;X0^'_ (>M_"/@/PKINB:39AA::7I%C';6\ 9BS!(XP%7+$DX'))/>@#2H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y$_;[_P"2
MQ:;_ -BS#_Z47%>'5[C^WW_R6+3?^Q9A_P#2BXKPZOS?-O\ D8U?4_JW@O\
MY)7"?X%^;"OT'^"__)'?"?\ V+-A_P"DZ5^?%?H/\%_^2.^$_P#L6;#_ -)T
MKUN&?X]3T7YGQ/B[_P B[#?XW^1TM%%%?9'X0%<S\:#\4/\ A4GB2+X)+:#Q
MC+HMS%X6EU#;]F@U!XRL$TP;K%'(5=P,DJC  D@'IJ* /S<_;!\;_P#!0O\
M9D_:\_9<_9ITG_@HOXAU6T^-_B;6-)\4ZK<?#?PW')9BRL([A9+5%L2$W.Q!
M60R87 SGDT=<\;_\%,?"O_!9'0/^">NK_P#!1K4[GP+XI^#MWXTTW6;;X:^'
MH]6M9X+K[,UM*6LFAD0LI<.J*<,%P-NYN@_X*U:KI=C_ ,%7/^">MO>ZC!#)
M)\2O%>Q)9E4MG2H$& 3SEW11[L!U(KB?VWOAW\,OB_\ \'''PI\#_$OXD>(?
M#EC%^RWJEQ+>^$_B)J'AJ]1_[8E"*;O3KFWG"-\W[O?M?;R#MX /5_VW/VC_
M -HO_@E9X$'[3?CO]JS6/C5HMF1I5]\+-2\-Z)I^HW^H:@LL6D26LUA:Q2+N
MO8/)=660&)YY%!:WV-WNA_!?_@KCK/PF'Q-U_P#;7\':/\3;C33>1?#J#X:V
MT_@^SNF3<NG2S&3^TID5OW;727*$G+B(C"'X^_X*R_L8^ OA9\%8O$7[(WQ+
M\6_%+QX_Q6\)^/-&^'FO?$&^\5ZOJW_",1:A<WL<-Q?7,]R8/L<S,(BS*)D2
M- 7N(TK]'O@S^V_^RA\>O@+I_P"TM\/?CQX9D\'7VGK=2ZK>ZU!;KI^5!>&Z
M$CC[--&3MDCDPR,"" 10!\;?MG?M%_\ !0'X:>//V*/!&C?M'ZGX(U3XYZA:
M^'_BKI2^#]'N6L;\:7!<3S6WVFU=H9!.9E9&+IR-JIM.[<_X*@P_\%#/V.?V
M*/'W[1?P0_X*=:G>^*?!/AR?Q!#H/B[X=^&WAU&QMGB%TJB"QCD5E65<.-RA
MV16 WAAQO_!<*Q\"_&+]JW]@CPQJWBK5]-TWQ3\:;HPW6CZ]>:'J0ADL(PK0
MW%O)#=6TFZ2-<HR."X7@G%6_^"L?[ GPJ_9R_8%_:#_:(\*_%OXDZE.?V>]?
M\-3V/Q$^*6L^)8\75Q93QO ^K7=PULV^VV%8R!)YBY&4&0#G_'W[37_!0+2_
M'_[!7@#1OVX]:MQ^TSX:O)_B%>GP+X>=[:ZBT6VU)9+)388A4O.\91_,^14Y
MW;BWKOQ]_:=_;,_X)C?''X8ZK^T?\8-,^+?P-^)WCBS\&:EXBO/"UOI/B#P;
MJUYN%E<R-9;+:\L79660^3$\?RD,V0K?.WQ2\4>&;/XZ_P#!(/4;OQ%8Q6__
M  B.IS>?)=HJ>6?".G*'W$XVY(&>F2*]*_X+F_%?P#^UMJ/P6_X)C?L^>*K'
MQ9\2/&WQE\/ZYK.FZ!=+=-X;\.Z?.;B[U6\:(M]FC4! N_!DR^W)7! -OX6_
M$K]NGXT?\%9_VA/V*(_V\?$>A^#OAEX;\-ZSX9ELO OAV6\)U.W\V6":26P9
M9%1@0A"JVT@,6(+'%_X*M?$+_@I/^P1^R)\3_P!ISX1?\%!;SQ3:^"O#EK+L
MUCP-X;\W3=7;4].B%O.D-FOF13V5])(  CQ/!$Q+I-M'&^$/@[\&/CC_ ,'"
M?[6FG_%+XP>+_#,>E?#[P+Y$G@OXNZOX5DEE:P&Y)GTR\MFGPNTA)"P7=D ;
MB3G?\%EO#/[.7[*__!'']I/]F3X8_&[5/%=_XKAB\:H/$'BZ77+^R@?6=!M&
M6ZOKF:6>4O.2(3,Q=U5T!;R&- 'KO[8OQ._X*0?L#?L*WG_!0&R_;FT;XBQ^
M$=#T_6?$G@3Q[\-].L+/5K>:2!);>VN].\B6UF_??NV;S@S!5*G.:^O/B/\
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M6=EH1_8-\-_!S4;AI;C_ (28?%S6]5LDC3$?D?93IUM.7)/F[_,V@ )C.3@
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MN[_7#"O_  E*?%Q=3=8D\P#[0-1&I>7"B [_ "-J*/*(% 'WU_P4(_:*\<_
MGPW\+_!OPVUA=)UGXL_&;1/ MOK_ -DCN'TF&Z6XN;BYBBE#1O,+>SF2/S%=
M%DD1F215*-WG[/OAS]H_PC)XM\._'SQ]I?BK3X/$F[P#XAB@2'4KG26MH&*:
ME%!!#;K<1W)N4#0*$>%8F*J^[/R#_P %<OA#\/?'^I_L8ZY\>OA/X1U7Q/J7
M[3/A;1O$4VI:):W)G@DT?6)+BQ+R(Q>V-P WE9*%@IP3@U][^'O#V@>$= L?
M"GA30[/3-+TRSBM--TW3[9(;>TMXT"1PQ1H L:*JA550     !0!REO^TO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^ WP(\&>"8;S'VN+PCX7M--6?'3>+>- V,GK7SC\>?A/^WW\-?#MYXF^&?\
MP4DUS7)-$TF\O/$FB:KX&\,)<P6KV5V+6\B,=BF!'=Q1NR.")H8;A$*R!37B
MG_!/[Q?_ ,%2?VO?^"9'A']ND_\ !2+3M.\6>(O#=[JZZ%XA^%&CMH,;6]Q<
M1B&=X%AN%B80#=*LH*!BP4[<$ ^QM;_X)S?\$]O$NK7&O^(_V$/@UJ%_=RF2
MZO;WX7Z3+-,YZL[M;EF)]2<U'#_P3;_X)V6]E-IMO^P1\%H[>Y9#<6Z?"S2
MDI7.TLHM\-C)QGIDU^?GCG_@JK^V5^T+^QY^Q#^U]\%_BE/\+Y_VBOC9I?P^
M\>^&;7PYIVH6L"37UW:7%[9M>V\DL;%K)WC#NZ[)DR&*EF[_ /X*F?$G_@IO
M^P7_ ,$T?B3^W3;?MS:@GBOPY?V5QI'@M_ ?AZ;3[&SO==M;.&UGE%F9)YXK
M6Y'F2HZH\R,54)A: /N_5?V4OV7-=^%MM\#M;_9L\ WG@JRE62S\'W?@ZQDT
MN!U^ZR6C1&%2.Q"@BJ?PS_8Q_8]^"WBJ+QU\'/V4/AKX2UR"!H(-9\,^!=/L
M+N.)@5*+-!"KA2"00#@@XKXQ_P""D/@#_@N!\#OV>#\=?V$?VX[GQU>Z)I5Q
MJ/B3PCXE^&WA\W5S;QP^<6LW@M(]SA4D41;'=W>,+CYB/3=9_P""BNB_M"?\
M$W_!'QC_ &)_B1?ZG\0/C/I\6C?"998;*2^7Q"8V\\WT1@:!(K$Q3S7K"((L
M5M+Y?S/%D ^COB]^RI^R]^T'J=IK7Q[_ &;O 7C>\T^'RK"[\7^#[+4I;:/<
M6V1M<1.47))P"!DDUV>AZ%HGAC1[;P]X:T:UT[3[*%8;.QL;=888(U&%1$0!
M54#H  !7-_ WP/\ $KX>_#?3O#GQ>^-=_P"/_$4<"'5?$E]H]E8">?8H?RK>
MSBC2*+<&*HWF. <-(^,UUU %77-"T3Q/H]SX>\2Z-:ZCI]["T-Y8WUNLT,\;
M##(Z."K*1P000:X?X6?LD_LI_ R;4+CX)_LR_#WP=)JUJUMJK^%O!=CIYO(2
M03%*8(D\Q#@95LCCI7Q3X>^)'[?WQ>_X+!?&;]A[PW^WUK'AKP1X%\!Z)XET
M1HOAWH%W>A[\*'MWEDM &C1@Q4[=VTJ"206;T;]C#]KS]IVQ_P""C?Q/_P""
M97[3WC3P[X_N?!_@+3O&7AKXBZ!H']E3O9W,XA:QU&U262)+E6961XM@>,;B
M@W   ][T7]@W]AOPV^IR>'?V,OA18-K4+PZPUE\.M,B-_&Q)9)ML \U22<AL
M@Y-=3\//@!\!_A%X4OO ?PG^"?A'PQH>J,[:GHWA[PW:V5I=ETV.9888U20L
MORG<#D<'BM#P=\4_AA\1+N_T_P"'_P 1]!UV?2IO*U.#1M8@NGLY.?DE6-F,
M;<'AL'BH[WXO?";3?&J_#74?BAX=M_$;)&ZZ!/K<"7I61@L9$!?S,,2 #CDD
M =: *7PV_9\^ ?P:O;C4OA!\$/"'A2YNH?*NKCPWX:M;%YH]V_8[01J67<2V
M#QDYZU<^(WP>^$?QAMM.L_BW\+?#GBF'1]3CU'2(O$>AV]\MC>1Y\NYA$R,(
MI5R=LBX89.#7G_[:W[<OP!_8-^&%G\2/CIXST^Q;5]:L])\/:1/J$<-SJMW<
M7,4 2%7.66/S1)(P!$<:L[8 KUC0M?T+Q3H]MXA\,ZU::CI]Y$);2^L+E9H9
MT/1D="58'U!Q0!;KC)?V</V>9_BHOQUG^ W@Q_&Z ;/&+^%[0ZJN%V#%WY?G
M#Y?E^]TXZ5K^+?B=\-O -]I^F>._B%H>BW.KS^1I-OJ^K0VSWLO'R1+(P,C<
MCA<GD5P7[>/[2-W^Q]^Q=\4OVHM-T6'4KSP'X&U+6=/T^Y8B*YN88':&.0J0
M0C2; Q'.TG'- '2_%#]FW]G;XX:KIVN_&GX!^"O%]]I#J^DWGBCPM::A+9,&
MW PO/&QC())!4CDYKL;>WM[2W2TM($BBB0)%%&H544#   X  [5XK^SMX6_:
M]\.^-].U/XG?&_3_ !SX&UCP!;W5Y<:KIEM9:K8>(C*C,EM'96T4)TYX'<@3
M-)/&\*#?('8KZ%J7QV^"&C>*CX%UCXR>%+36UF6(Z/<^(;:.Z$C %4\IG#[C
MD8&,G- &OXH\#>"O' T]?&O@_2]8&D:I#J>E#5-/CN/L5["28KJ+S%/ES)D[
M9%PRY.",TC>!O!+^-1\27\':4?$2Z4=,77SI\?VT6)D$IM?/V^9Y)D <QYV[
M@&QD9K%T7]H3X!^)1>MX<^.'@_4!IMHUUJ)LO$MK+]E@4@-+)MD.Q!D99L 9
MZT>$_P!H+X">/M?C\*>!?C?X0UK5)8VDBTW2?$MK<W#HO+,(XY"Q [G'% $?
MPV_9Q_9Z^#6O:CXJ^$'P'\&>%-4U@'^U]2\-^%[2QN+[+ESYTD$:M+\Q+?,3
MR2>M1W/[,O[-U[\5$^.EY^S[X(E\;Q;?+\8R^$[-M53!R,79C\X8/(^:NIUK
MQ-X;\-?9?^$C\06.G_;;I;:R^VW:1?:)V!*Q)N(WN0#A1DG!XKY4U']L7QYX
M@_X*G_"_X&_"[XX^$O$?PK\8?#;Q5J-]8>';6"YDBU/3)M,0"6]2:3<1]M8^
M6BQ;1@,'X- 'OWA/]ES]F7P%XQU/XB>!?V=? FB^(-:1DUC7=)\(V5M>7ZL"
M&6::.(/*""00Q.035'PE^QG^Q_X!U2VUOP)^RE\-M%O;/4AJ%G>:3X%T^VE@
MNPK(+A'CA!67:[KO!W88C.":\,_X*_?MF^-?V:_V+OB'X]_9<^/'@_2_B)X*
M@T^ZO-)N[>WU*]BMI[^VMF/V9IAY)VSY$DD<B\ ;><CZ\H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'?\ X.#O^3S?#/\ V3"R
M_P#3CJ-?"=?MA_P4'_X)-_\ #=WQGTSXN_\ "_?^$5_L[PQ#H_\ 9_\ PBOV
M[S/+N;F;S?,^U18S]HV[=IQLSGG \)_XAQO^KR/_ #'G_P!\*_*LZX;SK%YK
M5K4J5XR=T^:*_-W/[T\-?&CPTX?X$R_+L?C^2M2IJ,H^RK.SN]+QIN+^39^8
MM?T3?L2_\F9?"/\ [)AH'_IN@KX3_P"(<;_J\C_S'G_WPK]$_@E\./\ A3GP
M8\(_"+^V?[1_X17PQ8:/_:'V?R?M7V:VCA\WR]S;-VS=MW-C.,G&:]KA')LR
MRO$U9XFGRII):Q?7R;/S3Z0?B1P7QQD^"H9)BO;3IU)2DN2I"R<;)^_"*>O:
MYT]%%%?=G\K!1110!^7/_!5;QQXD_P""67_!3CX;?\%2? '@+4=>\/?%?PC?
M?"[XC>'='A+2:EK20O=^'F51P9YIXA:[SC9%%C^(U0_X*-?L[>*_V+OV>OV.
MOC_XT6;6]/\ @A\?;#Q5\>_$>GVS2&.359)I-8UUU4%O(%]<RR-U*K*@Z*2/
MU!\5^!_!7CNWLK3QQX/TO68M-U2WU+3H]5T^.X6UO8'$D%S&)%(2:-P&21<,
MK#((-:%W:6M_:RV-];1S031M'-#,@9)$(P58'@@@X(- 'RG_ ,%1/CC\*?'_
M /P3Y\<_!WX:_$'1?$GB7XY^"-0\&_"_2=!U2*[EUZ_U:TDM(7MQ$S>9!&LQ
MN)9A\D4,4DC,%4FOGC_@I+^QY>?MU_$7]J7X;_";5TA^*?@/P5\./&/POO;*
M9?M>G>(M/?Q!<6NSO&TR[X 3P!<!NPK[V^%W[)7[*OP.\4WGCCX*_LS?#[P?
MK>H(R7^L>%O!ECI]U<J2"5DE@B1W!(!()/(JQX6_9@_9I\#_ !(N_C'X*_9X
M\#:/XOORQOO%6E^$K.WU*X+#:WF7,<0E?()!RQR#0!^7WB']JV3_ (*T?\$U
M?C%^WKXG\/3:+X=^&?[*'BW0K#3;^!H(W\>7_A^X36YX@^"R6L/DV5O)SN_M
M"]3J,5Y7\,_"7PR^,/[0/_!+3P)XX^(^L:+IK_LDZB]YJ/A/Q[>^'[V!DT.V
M"@7NGW$$\(,D3H560!]KHP(W"OV6U[]F+]FOQ5\/&^$7BC]GKP-J7A-]1EU!
MO"]_X3LYM.-W+*\LMP;9XS$97DDD=GV[F:1F))8D\;=?\$VO^"==[%!!>_L#
M?!69+6'RK9)?A9I#"&/<S[%!M_E7<S-@<98GN: /$-8^&'[)W[$ME\4?&7A7
M]I#Q/XCU+XN>![?P]8Z-XQ^*%]XHO%ETNSUN\>6&XU*[GGCA6VNKB:5=XCC2
MU9@-SX/YQ_!O_@G+KGQF_P"#9WP#^T%^SA\2_B#>^*= TB?Q1K_P[NOBMKDW
MACQ;86&I7?V_1Y=*^V?9(ED@C<[88T=I(@N09&-?L98_\$V_^"=FF2/+IO[
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M^,WAO2_!OQ@_9Y\#>*]'T.,)HNE>)?"5G?6VGJ%5 L$4\3+$ JJN% X4#H*
M.I\)W5K?^%M,OK&YCFAFT^%X9HG#*ZE 0P(X((Y!%?F7_P $B?@I\%/A9_P6
MO_;M\!?#O2+:WTSP7JOA:Z\%:2EX7@T-]=L'O==%G#NV0">ZMK,2!%&!;01\
M!%6OTL\$_#WP!\-/"5KX ^''@?1_#^A6,1BLM$T33(K2TMT.<JD,2JB#D\
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M$O+\T<;?,3RBGJ!7HMK:VMC:QV5E;1PPPQA(88D"JB@8"@#@ #@ 4 24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20220630_g20.jpg
<TEXT>
begin 644 biib-20220630_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110
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M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
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MKXW\1^$;WXGVFC69\1W-C9SPZ+J%^BK]I2,',T$,AWA),,T9*N8W"F)N^HH
M^=/#_P"R_P#&?XG?MN>&_P!LW]HN;PQHR_#SP7JOA_P'X/\ ".K7&I+YNIRV
MKWVH75Y/:VI9C'9P11VZP[4'F.9&+!4^BZ** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*
M/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_
M & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MBO[K[%8S7NS=Y,3/MSC.!G%2U5UW_D!WG_7I)_Z":BHW&FVNP'!_\+__ .I2
M_P#)_P#^UT?\+_\ ^I2_\G__ +77G-%?FG^L.<?\_?\ R6/^0'HW_"__ /J4
MO_)__P"UT?\ "_\ _J4O_)__ .UUYS11_K#G'_/W_P EC_D!Z-_PO_\ ZE+_
M ,G_ /[71_PO_P#ZE+_R?_\ M=><T4?ZPYQ_S]_\EC_D!Z-_PO\ _P"I2_\
M)_\ ^UT?\+__ .I2_P#)_P#^UUYS11_K#G'_ #]_\EC_ ) >C?\ "_\ _J4O
M_)__ .UT?\+_ /\ J4O_ "?_ /M=><T4?ZPYQ_S]_P#)8_Y >C?\+_\ ^I2_
M\G__ +71_P +_P#^I2_\G_\ [77G-%'^L.<?\_?_ "6/^0'HW_"__P#J4O\
MR?\ _M='_"__ /J4O_)__P"UUYS11_K#G'_/W_R6/^0'T6C;T#8ZC-+38?\
M5+_NBG5^FK8 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X
M]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%NFJT$-ZT9FBC(FE!17"D2N,?,<^V?LM?\$[-*_9D^)\OQ8U;]L/X\?%._\
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M^MF7?R3^Y?\ R0'M-%>+?\+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
M%/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_
M 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#S
MXP_]^A0!6MO%'A^\G6UM=5B>1SA$4\DU?J)+&RC8/'9Q*PZ%8P"*EH ****
M"BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T
M-: .Z^%W_),_#O\ V K3_P!$I7._'O\ Y!NG?]=W_P#0171?"[_DF?AW_L!6
MG_HE*YWX]_\ (-T[_KN__H(KQ\__ .115^7YH#S*BBBOR\ HHHH **** "BB
MB@ HHHH **** "NS^!O_ ".$W_8/?_T-*XRNS^!O_(X3?]@]_P#T-*]+)O\
MD:4?\2 ]9HHHK]6 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MKKO_ " [S_KTD_\ 035JJNN_\@.\_P"O23_T$UG6_A2]&!\^T445^-@%%%%
M!1110 4444 %%%% !1110 4444 ?14/^J7_=%.IL/^J7_=%.K]G6P!1113 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\.
M_P#8"M/_ $2E<[\>_P#D&Z=_UW?_ -!%=%\+O^29^'?^P%:?^B4KG?CW_P @
MW3O^N[_^@BO'S_\ Y%%7Y?F@/,J***_+P"BBB@ HHHH **** "BBB@ HHHH
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M_!&M0_#[]K;P]X1\56TY\O3/B3\-K6XLXI'' 2_TJYDEDLV;C$L$]Q$26WB
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MJR!6)*DGU&N&<)4YN,MT 5V?P-_Y'";_ +![_P#H:5QE=G\#?^1PF_[![_\
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M=7[.M@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2N=^/?\
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M_P#Z&M '=?"[_DF?AW_L!6G_ *)2N=^/?_(-T[_KN_\ Z"*Z+X7?\DS\._\
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I7._'O_D&Z=_UW?\ ]!%=%\+O^29^'?\
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M )'";_L'O_Z&E>EDW_(TH_XD!ZS1117ZL 4444 %%%% !1110 4444 %%%%
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M %%%% 'Y=_LF3?M@>*/ASJ6D?"W_ (*\?"WX8647C+7;;6?AAJG@2QUJ_P#
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M2U76/$/BBVT25I+*TU'5M4N]4N;:W=P&DAAEO'B1V +K&&(!.*_,7X>_'?\
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MZOPQ_P!_)?\ XBJ5%'^M_P#TX_\ )O\ [4"[_P /3_\ @GM_T=7X8_[^2_\
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MZI\%OV?-%TRXUC5/@_X0AMK2!YKB9_#MKA$4%F8_N^P!KXY<'MNRK?\ DO\
M]L)M15WL?//Q"=_$VM:=\.+5SLN6%UJI4_=MD/W3_O-@?A76HB1J$10JJ,
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M_P!L!X_7/>._"M[JJ0^(O#CB+6-.)>TDZ"5?XHF]589^A/;)KZ!_X4'\"_\
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M.;F=M[?HST1W_#T__@GM_P!'5^&/^_DO_P 11_P]/_X)[?\ 1U?AC_OY+_\
M$52HKPO];_\ IQ_Y-_\ :@7?^'I__!/;_HZOPQ_W\E_^(H_X>G_\$]O^CJ_#
M'_?R7_XBJ5%'^M__ $X_\F_^U N_\/3_ /@GM_T=7X8_[^2__$4?\/3_ /@G
MM_T=7X8_[^2__$52HH_UO_Z<?^3?_:@7?^'I_P#P3V_Z.K\,?]_)?_B*/^'I
M_P#P3V_Z.K\,?]_)?_B*I44?ZW_]./\ R;_[4"[_ ,/3_P#@GM_T=7X8_P"_
MDO\ \11_P]/_ .">W_1U?AC_ +^2_P#Q%4J*/];_ /IQ_P"3?_:@7?\ AZ?_
M ,$]O^CJ_#'_ '\E_P#B*/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B*I44?ZW_ /3C
M_P F_P#M0+O_  ]/_P"">W_1U?AC_OY+_P#$4?\ #T__ ()[?]'5^&/^_DO_
M ,15*O3?!OP<^$7B'PQ9ZSK_ ,*_#=]>7$6Z>[O-#MY99#DC+,R$DX ZFO4R
MG/?[4KRI^SY;*^]^J79=P.6\ _\ !1+]B;XH^,M.^'WP_P#VC/#^JZUJUR(-
M.TZV>3S)Y#T5<H!G@U[17-Z3\&OA!H.HPZQH?PJ\-V5W;OOM[JTT*WCDB;U5
ME0%3[BNDKZ  HHHH **** "BBN/^._B7XW>#_AEJ/B/]GKX3Z)XW\46J>99>
M&=?\7OH<-Z "61;M;2Z"2' "AXPA)^9T'S4 'AO]GWX&^$;2YL?#OPC\.VT=
MYJM[J5T!I,3&6[N[F2YN)6+*26>:61SSU; P  ':_P# /X)>)[6WL];^%'A^
M9+34K34+4KI42-#=6MQ'<6\JLH!5DFBC<$'JH[<5\;_LY?MF_P#!;'QG\!_"
M_BCQ1_P2@\+7^HZCHT<]U>:_^T+!I%Z[L"?WUFNAD6T@S@Q@\$=:^J/V-=+_
M &EM&_9H\+:?^V!>:1-\1$MYV\0#0[QKFW@#7,K6T F9$,[Q6Q@BDE*CS)(W
M?^+- 'IU>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%
M%% !1110!6UG2-.\0:1=:%J]LLUK>6[P7,+='1@58?D:\[_9TU?4?#\>K? O
MQ-=-)J'A*X$=E-)UN=/?YH)!ZX!VG'3"BO3:\L^/MK<^ /$FB?M!Z/ S?V/(
M++Q''$,F;396 )([F-R& ]\G@5WX+]]&6&?VOA_Q+;[]8_-=CRLQ3P\H8V/V
M-)><'O\ ^ Z2]$UU/4Z*CM;JVOK6.]LYUEAFC#Q2(V5=2,@@]P14E<&QZJ::
MN@HHHH YKXN_\B!>_P"]%_Z,6O&*]G^+O_(@7O\ O1?^C%KQBOSWBO\ Y&4?
M\*_.0!1117S(!1110 4444 %%%% !1110 4444 ;/P^_Y'73/^OM:]SKPSX?
M?\CKIG_7VM>YU][PE_N=3_%^B ****^K *\N_:)OKSQ?>:)\ ]"N&2X\3W/F
M:M+&>;?38CNE;V+$;1V.".]>G7-Q!9V\EW=3+'%$A>21S@*H&22>P KR_P#9
M_MY_'GB'7OV@=5A8?VW,;+P^D@P8=-A;"D#MYC@L1ZKGO7?@DJ7-B7]C;_$_
MA^[67R/+S)NOR8..]3?R@OB^_2/_ &]Y'IUA8V>EV,.FZ?;K#;V\2Q01(,*B
M*,*H]@ !4M%%<#;;NSTTDE9!1110,**** "BBB@ HHHH **** $DCCEC:*5
MRL"&5AD$'L:\?TR23]F7Q\OAZZ<CP'XDO#_9LSGY=%O6.3"3_#$_)'8'Z,3[
M#6;XP\(Z#X[\-7GA+Q-8K<65]"8YHSU'HP/9@<$'L0#75A:\:3<*FL);K\FO
M-=/NV;.''86=>*J4G:I#6+_.+_NRV?R:U2-*O _%?_(TZE_V$)O_ $,UUGP<
M\7:]X+\1R? #XE7K37]E"9/#>K2<#5+(=!G_ )ZH!AAUP,\X+'D_%?\ R-.I
M?]A";_T,U\=QM0EAX4HMW5VT^C5M&OZTV-,)BH8NCSI6:T:>\6MT_P"M59K1
MF?1117Y\=04444 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^N'_ +,:\/KW
M#X;?\B-IO_7#_P!F-?4\)_[]/_#^J W****^_ **** "BBB@ HHHH _+7X?>
M%?\ @D=^UIX=\1?M%?MM?MPI<?%73O$6J1>)[B__ &A[[P_)X#N;>[FC6QTZ
MTM;^WBM;>W" 13"-OM 43,\ID)/TG^PI_P %"OV<=>_94\%7/CW]L7PUXEU:
M_P!;ET/P[?:IXCLQK7B&SDUJ73]%NI[9660W5W:FQF<>6K%YV)1>5'E_P=^&
M7_!%/XT_M:^-/V6_ O\ P3-\(^,=<TW_ (27Q!K7Q(\0?!#2[G2-5U.#5H%U
M/3;;5+R+=>7-O=:G'&R(&BA51&9%V*M>V?#G_@G/_P $H_B+X?\ #OQA^"O[
M$/P>TB2UUBRUC0/$?ACX7Z;I6HV%[8WJ3(!)';)/;2QW%OY<D9VNI62-P#N%
M 'TW7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"2
M9^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444
M %%%% !5;6=(T[Q!I%UH6KVRS6MY;O!<PMT=&!5A^1JS133<7="DE)-/8\R_
M9TU?4?#\>K? OQ-=-)J'A*X$=E-)UN=/?YH)!ZX!VG'3"BO3:\L^/MK<^ /$
MFB?M!Z/ S?V/(++Q''$,F;396 )([F-R& ]\G@5Z?:W5M?6L=[9SK+#-&'BD
M1LJZD9!![@BN[&I5>7$QVGOY27Q??\7HSS,MDZ/-@Y/6GMYP?POY:Q?G&_4D
MHHHK@/4.:^+O_(@7O^]%_P"C%KQBO9_B[_R(%[_O1?\ HQ:\8K\]XK_Y&4?\
M*_.0!1117S(!1110 4444 %%%% !1110 4444 ;/P^_Y'73/^OM:]SKPSX??
M\CKIG_7VM>YU][PE_N=3_%^B ***1F55+,P  R23TKZL#S3]I+6M2U/2M,^#
M/ABX*:IXRN_LKR)R;>R7YKB4^VSY?<,WI7H.A:)IOAO1;3P]H]L(;2QMD@MH
MA_"BJ% _(5YK\%5;XG_$77_CU=@O9%CI'A;=T%I$W[R9?^NDF<'J,,*]5KOQ
MG[B$<,OLZR_Q/=?)67K?N>5EW^TU)XQ_;TC_ (([/_MYWEZ-=@HHHK@/5"BB
MB@ HHHH **** "BBB@ HHHH **** .1^,?PMA^)WAR.*QO38:UILPNM!U5.'
MM;A>1R.=K8 8>F#C(%>'>'_&%_XHN[^W\26BVFN65X\>L68_@FW'++_LDY(_
MKU/T_7RU\9/#^I6GC:^\?>$X<ZC9WLRW-NO O8/,.4/JPZ@^WTKR<\^KXW"T
M\%7?*VW[.3VC+M+^[+9O[+M+;FOY6+ISPE;ZY15^DXK[45U7]Z/XJZWM;9HJ
MEX=\0:;XHT>'6]*EW0S+G!ZH>ZD=B#Q5VOS&M1JX>K*E4BU*+::>Z:W3/2IU
M(5::G!W3U3[H****S+"BBB@ HHHH **** "BBB@ KW#X;?\ (C:;_P!</_9C
M7A]>X?#;_D1M-_ZX?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%% 'Y
MM@_\%3OV0/V@_"_@SX;_ /!-VV^+?AGP-X5\5>'/ OC3P[\3M-TFWU*SU74]
M)O;634XKS$UI/;QZ<T=PZ+,L\C^9'RQ2OM?]CWX3^/O@Q^S_ *3X1^+.I:7=
M>++W4M5U[Q8^AJXL8]4U74[K5+R*V\SYS!'/>2QQLX#,B*6 )(KY*_9L_;__
M ."<7[/_ (6\?VG[6W[8.G^'?BGKNLW4OQ6\/_$CQI<B>:;=*D7]E6=Q(4;3
MGMFC-J;!#'+ T))9\U]3_L,>+?&/CO\ 9?\ #WB_QF-;W7]UJ<NA'Q-%)'J;
M:)_:5T-):\67]Z+HZ<+,R^;^]\POYGS[J /6Z\H_;G_Y-'\>_P#8!?\ ]#6O
M5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW
M_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** *VLZ1IWB#2+K0M7M
MEFM;RW>"YA;HZ,"K#\C7G?[.FKZCX?CU;X%^)KII-0\)7 CLII.MSI[_ #02
M#UP#M..F%%>FUY9\?;6Y\ >)-$_:#T>!F_L>067B..(9,VFRL 21W,;D,![Y
M/ KOP7[Z,L,_M?#_ (EM]^L?FNQY68IX>4,;'[&DO.#W_P# =)>B:ZGJ=%1V
MMU;7UK'>V<ZRPS1AXI$;*NI&00>X(J2N#8]5--71S7Q=_P"1 O?]Z+_T8M>,
M5[/\7?\ D0+W_>B_]&+7C%?GO%?_ ",H_P"%?G( HHHKYD HHHH **** "BB
MB@ HHHH **** -GX??\ (ZZ9_P!?:U[G7AGP^_Y'73/^OM:]SK[WA+_<ZG^+
M]$ 5YW^TCXIU6R\(VWP]\*RXUSQ?=C3+#!YBC;_73'V5"<GMN![5Z)7E/PR_
MXNO\9];^,$WSZ7H6[1?#.?NNP.;BX7ZD[0PZJ2.U?<X&,8S=>2TAKZO[*^_?
MR3/,S.<ITXX:#M*J[>D=Y/Y+1?WFCT3P?X6TKP3X6L/"6B1;+73K5((1CDA1
MC<?<G))]2:TJ**XY2E.3E)W;/1A"%."A%62T7H%%%%24%%%% !1110 4444
M%%%% !1110 4444 %>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-
M?(<7?P*7J_R \[UB*7X8^(G\4V,;'1-1E U6!!D6LIX$ZCT/1O\ ]6.RBEBG
MB6>"171U#(ZG(8'H0:;=6MO?6TEG=PK)%*A22-QD,I&"#7(^&[JX^'NOIX$U
M>9GTZ[8G0KN0_=/>W8^HS\OK^.!Y$O\ A<P?-_S$4EKWJ0BM_.<%O_-!7WB[
M^.O^$O$6_P"7,WI_<D^G^&3V[2TVDK=E1117SI[ 4444 %%%% !1110 4444
M %>X?#;_ )$;3?\ KA_[,:\/KW#X;?\ (C:;_P!</_9C7U/"?^_3_P /ZH#<
MHHHK[\ HHHH **** "BBB@#\9_@G\</^"@-W\,[B#]A/X'>)/B7\/O"\CPGX
ML?&+X<65SJW@F^%\R:C%X9MH[F&?Q%:VI,YAA*JT1MQ$LUU\D _07_@D7K>G
M>)?V _"'B+2_C[JGQ2BOM;\2W!^(6M:#+I=UKKOXAU%GN)+.4![8ERP\HA=H
M4 *H  S/V:_V[)/BE^TI<?LO?";]DS6=$^&VD^$-;E\#_$G5-4@M;+Q'<:+?
M:?I]S;6%D TWV17OT"WLA5)/+)C613O'MW[.WB;X;>,OA7!XH^%7AZ72--O=
M9U:2^TJYA$<UEJO]I7(U.&90S*)DOQ=K)M9D\P/M9EP2 =Q7E'[<_P#R:/X]
M_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:P
MOA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !5;6=(T
M[Q!I%UH6KVRS6MY;O!<PMT=&!5A^1JS133<7="DE)-/8\R_9TU?4?#\>K? O
MQ-=-)J'A*X$=E-)UN=/?YH)!ZX!VG'3"BO3:\L^/MK<^ /$FB?M!Z/ S?V/(
M++Q''$,F;396 )([F-R& ]\G@5Z?:W5M?6L=[9SK+#-&'BD1LJZD9!![@BN[
M&I5>7$QVGOY27Q??\7HSS,MDZ/-@Y/6GMYP?POY:Q?G&_4Y[XN_\B!>_[T7_
M *,6O&*]G^+O_(@7O^]%_P"C%KQBOR[BO_D91_PK\Y'J!1117S(!1110 444
M4 %%%% !1110 4444 ;/P^_Y'73/^OM:]SKPSX??\CKIG_7VM>YU][PE_N=3
M_%^B X/]H?QOJ?A/P"=(\,$MKOB&Y32]%C4X;SI>"_L%7)ST!VYZUT7PZ\$:
M9\./!&F>"=) ,.GVJQE\8,C]7<^[,68_6N#\)_\ %W/V@-2\<R?O-&\%*^EZ
M,>JRWSC_ $B4>ZC"?BI%>K5]UB?W%"&'6_Q2]6M%\E^+9Y6"_P!JQ53%O;X(
M>B?O/_MZ7WJ,6%%%%<!ZH4444 %%%% !1110 4444 %%%% !1110 4444 %>
M!^*_^1IU+_L(3?\ H9KWRO _%?\ R-.I?]A";_T,U\AQ=_ I>K_(#/K.\5>&
M=/\ %NBRZ-J((#_-%*OWHG'W77W'_P!;O6C7S_\ \%(/BIXI\!? O1?AWX!U
MNXTO7_BM\0=$\!:7J]I(4FTY=2N0EW=1L.5EBLDNY$8<JZHPZ5\?@YUZ>+A.
MC+EFFFGV:Z_(SJTJ=>FZ=17BU9KR/4OA9\0(?$UM+H-]J4-S?6#.GVJ!]T=Y
M&CE/-1NC?,I!QW'X#KJ\)_:N_9Q_9IU?X5Z5K/Q=FT72/"'P]T[R[/2]?U"*
MTT!(AY44*W2R%8W5 HCB$C;%,Q^4L5*\%_P1Z\8:OXW_ &?_ !CK>EZSJ%[\
M/V^*6K#X/MJM]+<S1^&=D'DHLDQ,K6PN?M@@,AW>0(L?+MKV,QPN&QF%>98:
MT4W:<%]F7=?W9;I=-8WT5^+!SJX>?U6LV[?#)_:79OK)=>ZU[V^LZ*_/W_@K
M1XP\6?&CX!ZOXX\(>)+[3O!'P]^)OA73K"XT^Z:+_A(M;/B73[6\<LA&^TM$
M>:V"DE9+EYB5'V6-G_0*O&J4'3HQFWNVK=K6?Z_(]$*"<#)[>@KY _X*#>(O
M"'AS]JKX*S?M5ZU9V?P$N[77+;71K5P$T6;Q,R6YTQ-5#GRW@,*WQB$V8O.
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MT989_:^'_$MOOUC\UV/*S%/#RAC8_8TEYP>__@.DO1-=3KOB[_R(%[_O1?\
MHQ:\8KV/XIW5M??#>YO;.=989EA>*1&RKJ9$((/<$5XY7Y=Q7IF4?\*_.1ZJ
M::N@HHHKYD HHHH **** "BBB@ HHHH **** -GX??\ (ZZ9_P!?:UZ#\>/B
M!=?#OX=7.H:,ADU>_D2PT.!?O27<IVI@=R.6Q_LUY]\/O^1UTS_K[6MVV_XN
M]^T7)>']YH?P_C,47=9M4E'S'W\M1CU5A[U^D\"TX2H5*E1>[!\S\]%9?-V1
MYV95JD*"I4G:=1\J\K[R_P"W8W?JDNIV7PD^']K\,/A[IO@VW</);0;KR<<F
M:X;YI'SU.6)QGM@=JZ2BBOHJE2=6HYS=VW=G;1HT\/2C2IJT8I)>B"BBBH-
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MX#[W_;R['E8;_:\=/$?9A>$?6_OO[TH_]NON%%%%>H>J%%%% !1110 4444
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M 4G[];?R@M__  )Z>:Y@X&RGZWCWBYKW:>WG)[?<M?6Q;HHHK^>C]?"BBB@
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M8^+OBK-J<7@72UTRYF&HOI]L+F[!ECC:*#9$P;]ZR;LX7<<BN_KYT_:YOO\
M@J?_ ,+;T+1?V%=.^!H\*3>'9Y]<U/XKVFKR3V^HQSHJQ1&PF4%)(I=PRG!@
MDRWS** /@7Q;_P %$_A9\'?&_B#X6_LH?\%E=9\&> [?Q)J, \*^(_V.?$OB
M.]\)SBZE%U9:??K:11O#%<>:D<=Q',( HC#.B!!^AO\ P3.\8_!KQ_\ L5^$
MO%GP!U[7]8\+W-[K*VOB#Q5%)'J>MW*:O>1W>IW22Q1.D]U=)/=.C1QE6G(V
M+C:/'M&\-?\ !P)X=M'T_09/V*+."2[GNI(;;1_%B*TT\SS32$";EGED=V/5
MF=B>2:]S_8#'QI'[,UFO[1=QX7E\<#Q?XI'B:3P6LPTHW7_"0ZCN^RB?,HCQ
M@ 2$N.=Q)S0![-7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H
M:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%%
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M/P^_Y'73/^OM:]SKPSX??\CKIG_7VM>YU]!PE_N=3_%^B/5"BBBOJP"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\C3J7_80F_P#0S7OE
M>!^*_P#D:=2_["$W_H9KY#B[^!2]7^0&?1117PP!1110 4444 %%%% !1110
M 4444 %>X?#;_D1M-_ZX?^S&O#Z]P^&W_(C:;_UP_P#9C7U/"?\ OT_\/ZH#
M<HHHK[\ HHHH **** "OC7_@H%^QY^P=^TO^V)\']'_:Q^!/C[Q=K?BO0]:T
M/0+OPY+JT&CZ>EJL5\9-2N=/N(1;'!E2$R$B1IY!CY<C[*HH _&.Y^#O_!$
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .:^+O_ "(%[_O1?^C%KQBO9_B[_P B!>_[
MT7_HQ:\8K\]XK_Y&4?\ "OSD!%>V5MJ-G+I][$)(9XVCE0]&4C!%<U\,[VYT
MY;SX?ZK*6N=&DVP.W66V;F-OP'!].*ZJN2^(D4OAS5+#XD649/V%O(U-4',E
MJYY/OM8Y'U]JYLG:QD*F6R_Y>V</*I&_+_X&FX>LDWL>7F*>'E#&1^QI+_ ]
M_P#P'27HFNIUM%-BEBGB6>&0.CJ&1E.00>A%.KPVFG9GJ)IJZ"BBBD 4444
M%5]5U.TT;39]6OY-L-M$TDC>P&?SJQ7(_$!V\3Z[IWPXMF)CN&%WJI4_=MT/
M"G_>; _ 5Z.58.&.QL:=1V@KRF^T(J\GZV6G=V74X\?B987#.<%>3LHKO)Z+
MY7W[*[)_A?IEV=,N/%^KQXOM<F^TR _\LXND:?0+S^-=/2*JHH1%  &  . *
M6L\PQD\PQLZ\E:[T71):1BO**22\D7@\-'"8:-).]MWW;U;?FW=OU-GX??\
M(ZZ9_P!?:U[G7AGP^_Y'73/^OM:]SK[#A+_<ZG^+]$=(4445]6 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7@?BO_ )&G4O\ L(3?^AFO?*\#
M\5_\C3J7_80F_P#0S7R'%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ H
MHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\ A_5
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ME$'"AIII'P, ;L  <4 ;M>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
ML O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=KC/AKX-TJ?X<Z!.]S=@OHEJQ"W3
M9,*UM_\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M
M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%
MM1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q
M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
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M44 %%%% !1110 4444 %%%% !1110 5X'XK_ .1IU+_L(3?^AFO?*\#\5_\
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M,5[/\7?^1 O?]Z+_ -&+7C%?GO%?_(RC_A7YR ****^9 **** /G[XQ>#O\
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M'_LQKP^O</AM_P B-IO_ %P_]F-?4\)_[]/_  _J@-RBBBOOP"BBB@ HHHH
M**** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6
M@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#FOB[_R(%[_ +T7_HQ:\8KV?XN_\B!>
M_P"]%_Z,6O&*_/>*_P#D91_PK\Y %%%%?,@%%%% !1110 4444 %%%% !111
M0!L_#[_D==,_Z^UKW.O#/A]_R.NF?]?:U[G7WO"7^YU/\7Z( HHHKZL HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?_(TZE_V$)O\ T,U[
MY7@?BO\ Y&G4O^PA-_Z&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 444
M4 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]</\ V8U]3PG_ +]/_#^J
M W****^_ **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC
M]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_
MZ)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:^+O\ R(%[
M_O1?^C%KQBO9_B[_ ,B!>_[T7_HQ:\8K\]XK_P"1E'_"OSD 4445\R 4444
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MX1^"7[1S?#?P]I&C*B7]GH-OK.JZA>Y95$[ZBDD:VZ*J,Q :>=Y6_>P^7F4
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MPVXS(\-K;O.ZJ/[Q5"![U\/>)_VN?VT_@O\ \$\?"7_!6'XC_%O3M4L]2L=
M\3>,_A!;^'K1-*LO#NJSVP-O872H+W[?;6]VDAGFGEAFDA=1!&)%V 'Z"45X
MA_P4!^(7CCX ?L[ZM^UC\/1<W-U\*H6\1ZYHD3936=!@P^JVA7H9/L:RS0L.
M5N((>J&1']A\,>)="\9^&M/\8>%]2CO=,U:QAO-.O(3E)X)4#QR+[,K CZT
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M^"M*O8M1L-%\N:%PT;_:9#@_0MBMVBBNBC0H8=6I045Y)+\@"BBBM0"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[
M_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA
M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4VLF&P3N'% '@WBQ+G3O^"]/@B_\0Y6QU+]E'Q#:^&7F^X][%XCTJ2]2//\
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MP[M+A"LD?A[3I;BXENV7^$WE_=W$BCG-O;VC\%RJ_05 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\ )H_C
MW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA
M=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^
MP"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=
M_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]8GQ(^'WASXJ^!=3^'?BZ*5]-U:V,%XL$I1RA(/##H>* &_"[_
M ))GX=_[ 5I_Z)2MVO"8_AA^W1I"+I/ACXZ>"H--M0(=.@G\,R.\<"_+&K-N
M^8A0 3W(IW_" _\ !03_ *+_ .!/_"4D_P#BJ /=**\+_P"$!_X*"?\ 1?\
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MJ /=**\+_P"$!_X*"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4D_\
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M_" _\%!/^B_^!/\ PE)/_BJ/^$!_X*"?]%_\"?\ A*2?_%4 >Z45X7_P@/\
MP4$_Z+_X$_\ "4D_^*H_X0'_ (*"?]%_\"?^$I)_\50![I17A?\ P@/_  4$
M_P"B_P#@3_PE)/\ XJC_ (0'_@H)_P!%_P# G_A*2?\ Q5 'NE%>0>!?!O[:
M=AXNL+SX@?&?P?J&BQS@ZC96'AQXII8\'Y4<M\ISCFO7Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /(/!O@7Q=8?MI^-/B!>:#/'HNH
M>#].M;+46 \N6:-V+H.>H!KU^BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\@_:/\"^+O%GQ8^$FM^'-!GN[30_&$EUJT\(!6UA,#*';GIGBO7Z*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \X_:[\*>(_'/[-/C
M'PCX1TB6_P!2O]':*SLX "\K[E.T9[\5U_P^L;O2_ .AZ9J%NT4]OH]M%/$_
M5'6)0RGW!!%;%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >0
M?L4^!?%WP^^$^I:)XTT&?3KN;QAJEU'!< !FADG+(_!Z$<BO7Z** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"?VX_'O
MQ#_:R_X*G_#3_@D[X?\ 'FL^&O ,'PQN_BA\9I?#>J2V-]X@TQ+[^SK+1UNH
M&66"![KYK@1LKR1,%#*,YY/_ (*F?L^^&O\ @E?^SD?^"D?_  3TT-O FL?"
MC5].N_&O@O1M0FCT;QOH$UW%;7=G>VA<PM,JS"6.ZV^<A1L,2PQZ-^W;^SG\
M??A1^W]\-?\ @JW^S%\.KOQQ<>'O!-[X!^+/@326C&IZCX:GN#=P75@LCHD\
MUK=DRM;E@TR85"&%?'W_  49_:#_ &POVI?AK%^Q9\?=7N/#OP)^*?BG0[?X
MB_'WQG\%=;^']OX'M8[HW5QICQZFTHG6X>V@B@O&9(8VE,4TC>:D@ /K#]O7
M_@G[^S'^TO\ L_\ Q$_;5_:"^*WC"/6;3P9>>(O /C+3?&NHZ7%X"L;>Q,]I
M)8V\$Z0JXV">:217>621P6$:QHGT)_P3C\0_'OQ;^P/\'?%'[40N/^%@ZC\.
M=)N?%C7D6RX>\>U1F:9<#;,009%P,2%A@8Q7QY\;_P#@H5X-^,WQ1L_A/I/[
M#/[1/CW]GOP9+:R:5JGPP^$5UJ^C_$*]M9/W)6ZWI'/H]N\2.GEEUO9%1MWV
M>/%U]Z_LY_%_7/CU\'M)^+>O?!WQ/X"DUDSR6_A7QI9BVU:T@69XXFNH 2+>
M61%63RMS%!( 3D$  \Y_;B_9,\;_ +4/BWX%:]X+^(=YH$?PQ^-VF>,->2VU
M*6!=2T^UM;M7M&6/B7?+) "K?+L\P'@FI?VK/^"?WP>_;A\4P6_[45YK>O\
M@C3-'6+2/ VG^)+_ $NT&HO)*9]0N#93Q-<R"+R(X0Y*PXF91NEROO%?&/\
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MTV^L?&6D6FF?"SP=KVEM&]EX=MWE>'5+Z(D![^^\P3 2+OMK9;:#AQ*#@_\
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M81?%'XP?%#6_B/\ $33]+N1/;Z9J6J2(39QRJ2L@CCBB#%25WE]K,N&;ZXH
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M40>+-9FU*\\+Q?VD=.O-)2[G9II;;S<R1)(S&)$"@DLQ;SW]A_XX>(OV<?\
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M_A&/+^TW*1>9]MSMW,!G&SGK7%'/\HG)1535^4O\@.]HHHKV "BBB@ HHHH
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M%0/V7+*TNO&DLWB9OA]8^)CX>OOBRGAN8^&8-16Y^R-&UYU,*W/[AKP(;19
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M";KJ>"\DN5B9HP5W1$K*H=69%4AJ[O\ 9?\ VCO#W[5WP>TGXZ>"O 7BO0]
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MD:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *P+SX8>!M0O);^[T/?+/(TDK_:91N8G). V!R:WZ*QK8>AB$E5@
MI6[I/\P.<_X5+\/O^A?_ /)N7_XNI+/X8>!M/O(K^TT/9+!(LD3_ &F4[6!R
M#@M@\BM^BL5EV7Q=U1C_ . K_( HHHKL **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH X?]I;X6>)_CE\ /&7P8\(>,['P]>^+/#5]HXUK4
M=%?4([1+FW>%I/LZ7$!D*AR0/,49'-9O['?P,\3_ +,/[+?@#]G#Q5X^L?$\
MW@+PAIOAVVUVPT%]-6\M[*UBMHI&@>YN-LA6(%L28))P .*]*HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBN=^(FI?$S3;*V?X9^&M.U*=I2+J/4;PPJB8X((')S5TX.I-132OW
M=E][,ZM14:;FTW;LFW]RU.BHKS'_ (2G]J[_ *)5X8_\'C?X4?\ "4_M7?\
M1*O#'_@\;_"NOZA4_GA_X''_ #.#^U:7_/NI_P""Y?Y'IU?/G[87Q*^._P (
M=>L-=\$>,VM]#U*+R_).FVT@@N$ZKN>,MAEPPR>H;L*[7_A*?VKO^B5>&/\
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MB/7?B9HB^.?$NC7NJ3:>^LP1MI<$/D"(7"LV4DN&N%$,9PT@1V (7GI_V/O
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MM_%FGVD&I:?\,#:K/HDD20LX$TOG2B^8,6%Q&L4F!'&#ZA_P<8?#?P+\0O\
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M>!M.33]$UW1?B+IOP1OF\5:)XK66*2>5K]_$@,NK/>^=;W&8@T[RRQ^4 X0
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M\%^(/C)X5L-9C($FDWGB&VBN4)7<,Q,X<?+STZ<U\7_L0_% Z?\ \%AOC_\
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MPW!/+* D\ E^UFS!S$SPVACW8B)]#_9ZTW1=$_X+*?&_PA\"=/M8? ,GP?\
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M[6/@A^S_ ."?!MWJ:*FI77A7PI9Z=)=J#D+*UO&AD /(#9YJ7Q?^SO\ L_\
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M/?L??LD^$O'EM\4_"G[+?PYTSQ/90I%9^(]/\$6$-_!&BA51+A(A(JA0  &
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M%6-VNGPYSY4 EB81)GG:F!GM7?VMK;6-M'965O'###&$AAB0*J*!@* .  .
M!4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20220630_g21.jpg
<TEXT>
begin 644 biib-20220630_g21.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M% )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29
M^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_
M + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y
M1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I
M_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[
M<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:
M?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<
M_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6
MG_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\
MFC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^
MB4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
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M3_\ AQM<_P#DVC_AAK]G'_H">)__  XVN?\ R;7KE%']I9C_ ,_I_P#@3_S
M\C_X8:_9Q_Z GB?_ ,.-KG_R;1_PPU^SC_T!/$__ (<;7/\ Y-KURBC^TLQ_
MY_3_ / G_F!Y'_PPU^SC_P! 3Q/_ .'&US_Y-K5\'?\ !.#]FOX@ZJ^B3S>-
M],"0&;[1IOQ%U;S#@@;3YUQ(N/FSTSP.>N?1Z[/X&_\ (X3?]@]__0TKT,JQ
M^.J9E2C.K)IO9R=OS \L_P"'/7[,/_10?BG_ .'$NZ/^'/7[,/\ T4'XI_\
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M;1_PPU^SC_T!/$__ (<;7/\ Y-KURBC^TLQ_Y_3_ / G_F!Y'_PPU^SC_P!
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M &EF/_/Z?_@3_P P/(_^&&OV<?\ H">)_P#PXVN?_)M'_##7[./_ $!/$_\
MX<;7/_DVO7**/[2S'_G]/_P)_P"8'D?_  PU^SC_ - 3Q/\ ^'&US_Y-H_X8
M:_9Q_P"@)XG_ /#C:Y_\FUZY11_:68_\_I_^!/\ S \C_P"&&OV<?^@)XG_\
M.-KG_P FT?\ ##7[./\ T!/$_P#X<;7/_DVO7**/[2S'_G]/_P "?^8'D?\
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M.J>.+FXMW< C$D;<.O/0U]&445]N 4444 %%%% !1110!\D?M-?\%*O'_P
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MZ+_T8M>,5^>\5_\ (RC_ (5^<@"BBBOF0"BBB@ HHHH **** "BBB@ HHHH
MV?A]_P CKIG_ %]K7N=>&?#[_D==,_Z^UKW.OO>$O]SJ?XOT0!3)X(KF![:=
M=R2(5=<XR",&GT5]4TFK,#G/^%2_#[_H7_\ R;E_^+H_X5+\/O\ H7__ ";E
M_P#BZZ.BN/\ LW+O^?,/_ 5_D!SG_"I?A]_T+_\ Y-R__%T?\*E^'W_0O_\
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MPA-_Z&:]\KP/Q7_R-.I?]A";_P!#-?(<7?P*7J_R SZ***^& **** "BBB@
MHHHH **** "BBB@ KW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M-_ZX?^S&OJ>$
M_P#?I_X?U0&Y1117WX!1110 4444 %%%% 'Q%XD_X)O?\% 9_P!I;XG_ !J^
M#?\ P5I\3?#30?&GB:.]TGP?I'PRT+4[2V@%E:QL[K>0%1.9DF4RA?,DC2$R
M.[9Q[G^Q)\!/VB/V?_"WC+1?VEOVF[SXMZWK?C9M5L?%^H:!::7,UF=,T^W6
M!K6S58(MDEM,!Y:@,"&(W,Q/R;\5_ ?_  3*_:&_:>^*&F_\%3OCW9VWC3PU
MXC:'PQX%\<_%F[\-:=HOA[R8C97NF6\=Y;1W(N%S-->CS'6=I(=Z"$1CZ)_X
M)=>)M'\1? SQ%:?#;XJ:[XZ^&>D>/+S3_A)XR\1:C+?7&JZ$EM:EBMY-^\O8
M(;]]0M8;ARQDAM8COD&)& /I.O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_
M -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6;\7/"^N^)[&RAT.Q\]HI7:0>:J
MX! Q]XBM+X7?\DS\._\ 8"M/_1*5NUS8S"T\;AI49MI/MOO?S \6_P"%2_$'
M_H7_ /R;B_\ BZ/^%2_$'_H7_P#R;B_^+KVFBO!_U3R[^>?WK_Y$#Q;_ (5+
M\0?^A?\ _)N+_P"+H_X5+\0?^A?_ /)N+_XNO::S[;Q5X;O/%-YX(M=<MI-8
MT[3[:^OM-28&:"VN'GC@F9>H21[6X53T)A<#[IH_U3R[^>?WK_Y$#R;_ (5+
M\0?^A?\ _)N+_P"+H_X5+\0?^A?_ /)N+_XNO9KFYM[.WDN[N=(HHD+RRR,%
M5% R22>  .<U%I&K:;KVE6VMZ/>)<6EY DUK<1'*RQL RNI[@@@@]P:/]4\N
M_GG]Z_\ D0/'O^%2_$'_ *%__P FXO\ XNC_ (5+\0?^A?\ _)N+_P"+KVFB
MC_5/+OYY_>O_ )$#Q;_A4OQ!_P"A?_\ )N+_ .+H_P"%2_$'_H7_ /R;B_\
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MV=/%'[/'P1U";XF1VZ^.?B%XSU?QQX_2TF$D,&K:G<&=K2-QP\=M#]GM%?\
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MO;ZFMA*C'E$ENE!43/GS[]B+_@G6EI^VEJ?_  4*^)7PBO? PTKPHWA/X/>
MM;\3SZQJ.D:4[[Y[^]FEN+A8)Y@!'%902&&UM]RG,DL@3K/^"M>A7?Q0T[X
M?L]Z#&9M4\7_ +2OA2[\B(9>/3]'GDUJ^N/]E4@T]EW'@-+&.K $ ^N****
M"BBB@ HHHH YKXN_\B!>_P"]%_Z,6O&*]G^+O_(@7O\ O1?^C%KQBOSWBO\
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MO&GAE-'U*YG71M*/VR:UC=TCWHT:*58ADB5CAF84 ?1%>4?MS_\ )H_CW_L
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MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
ML!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXN_\
MB!>_[T7_ *,6O&*]G^+O_(@7O^]%_P"C%KQBOSWBO_D91_PK\Y %%%%?,@%%
M%% !1110 4444 %%%% !1110!L_#[_D==,_Z^UKW.O#/A]_R.NF?]?:U[G7W
MO"7^YU/\7Z( HHHKZL HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O _%?_ "-.I?\ 80F_]#->^5X'XK_Y&G4O^PA-_P"AFOD.+OX%+U?Y 9]%
M%%?# %%%% !1110 4444 %%%% !1110 5[A\-O\ D1M-_P"N'_LQKP^O</AM
M_P B-IO_ %P_]F-?4\)_[]/_  _J@-RBBBOOP"BBB@ HHHH ***^3/\ @H=^
MSQ^W7^T1\8/AQ-^P7^V=9_!;4/"^EZZOC+Q++X7M->+P71T[[-:&PNLQL9&@
MDD$C8V"!L')P0#YX?]H#]F3X>_MC_'7P%\9O^"2'Q9^+>O6WQ!>:Z^*^A?L^
MCQ)%>1RV=K+!I\ERZLR?9K>2!(HXRT9@,,AV/(Z#ZK_X)L?$CX+_ !/\%?$7
M7/@;^RGXA^#NFVWQ+>UO_"OBCP7_ ,(]>37:Z-I3-=M88'D!T:)5./WBQB3^
M.OGN'_@G=_P7VMI)IK?_ (.!]+C>XD$D[I^RKX;!D<*JAF(/)VJJY/90.PKW
M[_@G/\%?VL_V9?AO\1K#]O']I6U^)?B74?B3-JMO\06TF#28;[36TG3((C]D
MAQ%:>6\$L11?ERA;)WYH ^E:\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
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M444 %%%% &S\/O\ D==,_P"OM:]SKP?P3-);>++">*W:5DN5*QIU;V%>P?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
M^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &'\1M'U'7O"%UI>E6_FSR-'LC
MWA<X=2>20.@->9?\*E^(/_0O_P#DW%_\77M-%>-F&1X3,JZJU9232MHUY]T^
MX'BW_"I?B#_T+_\ Y-Q?_%T?\*E^(/\ T+__ )-Q?_%U[35#7_%7AOPJMF_B
M37+:Q&H:A%8V)N9@GGW,IQ'"N>KL> .IKA_U3R[^>?WK_P"1 \E_X5+\0?\
MH7__ ";B_P#BZ/\ A4OQ!_Z%_P#\FXO_ (NO::J6.O:+J>I7NCZ=J<,]SIKI
M'J$,+AC;.Z"14?'W6*,K[3SM=&QAE)/]4\N_GG]Z_P#D0/(?^%2_$'_H7_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_\
MR:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4
MK=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110
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MX)Q^%O$6I>(_#USHLWB_7?[32YM9%LKN.*X=;&V6XC^TRQKN-\8XRZHQ"_\
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MNKX'_P#0W>.__"OGH ]ZHKP7_AW5\#_^AN\=_P#A7ST?\.ZO@?\ ]#=X[_\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ />J*\%_X=U? __H;O'?\
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M,'BK4K*,67B::)/*AG*)D#JV.I[UZG_P[J^!_P#T-WCO_P *^>@#WJBO!?\
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M-4^/^H?LL:=\2=.F^(6E>&8O$.H>%$=OM4&F23>2ERPQMVF3"XSD;E) #*2
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MT2EY(&O)9&22!+</'. >V_\ !'WX(Q^"=,^.'[1GAK0&T'P=\</C7J/B_P
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M%^L7-K;64<%];W18"VM9VE9A"4V_(!N!R<8KZ \,7'B:[T"UN/&6D6%AJCQ
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M'X36D_B[PEX9C\9Q:<HN-*TWQ'<2:8URHQA;M[-91&<9R;<E<XPV,D _//\
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MM^*;VVU#4?[7L(K7]S'%I\L:>28R_P TA\P''[OK0!]/4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20220630_g22.jpg
<TEXT>
begin 644 biib-20220630_g22.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
MM#^-OBK\ 5>'XN_ _P""_A'XA_"R^MX]TQU#3M>UZ66U4#EQ/ )$$></((<Y
MQ75?%K]K3P)_P5__ &6/!.E_"UDD\&7GPCN?BK\6;))/,6TDM([B+2]#F/0L
MVLVMQ,P(PRZ#(IXE&0#ZO_X)N?MD>)OV_P#]DGPQ^UQJOP<@\$:9XRMY+K0-
M'_X2;^TKG[,LTD.^<BVA2)F,98*ID^5ADJ<J/>*_';_@W9\5?$[]L#]FG1_V
M>-2^,?BGP9X(^"GPN\.V]CI7@O4187>LZKJS7]Z^H7%TJF4Q0QI%#% I$3.)
MS*LF%5?JGX,_M(?M$_%O_@F]^T"/$OQDU&S^(/P6\2^.O"%O\2=%TVQCN-6D
MT0RFUU P2026R2R1>4DRI&%$JR^6(_E"@'W!62OCSP<_CM_ABGB*V/B"/25U
M2320^9DLVE:)9R.R&164$]2K8Z&OS@\'_%?]J;X"_P#!.']ES]OOQK^T_P"+
MO%7BWQ?J?PY@^(&FZI=QOI>J:/KTEG:26XM=FV.XB2\CF%TA$TD\3%W=',==
MU\%/@?HNC?\ !P%\9O$=KX[\9O))\$/"NMRVUSXNNYK=Y9]4UB,V_E.Y5;5%
MC4QVZ@1HQ9E4%F) /HW]D7]LI_VJ/'?Q>\!W?P>U3P?=_"7Q^OA>\AU;4[>X
MEO7:PMKU9\6Y>.,%+I %$DG3)(/RCVZOSE_8\^ GQ"^-/[;/[;YL_P!H/Q;X
M.TJV^,EG'H,/@Z^2TEBU9O#6F;KVX<HQN5C3[.([=_W!/FF1)<IY?+>%O^"A
M'[3'Q,_9)_9Y_;4^.?P\^(6N?"SQ!\)KJ3XLZA\#[B2+5O#WB1;B.*/6[BSM
M'2XFT[9;7K>7#YD499S+%(%C  /U#KRO]MC]H3Q;^R=^RUXW_:9\*_#&U\7I
MX!\-7OB#6-#N/$!TUY=/L[>2XN&AE^SS!I1'&Q5&"AL8W XS;_8Y\:^&_B)^
MRA\./&7A+XWCXEV%[X+TXQ?$'8$;Q"RVZ))?.FU?+DE=6=T*J4<LI52"!Q/_
M  5@_P"46?[2O_9 /&7_ *8[R@#C?@%^VO\ MV?M(_ 3P?\ M&?#C]@;P=_8
M/CCPK8^(-#AO_CFT5S]EN[=)XED0:,5238Z@C<0#GGO7O_[/OQ5U/XV?!O0?
MB7K_ (#O/"NJZA:LFN>&+^X6:;1]0AD:"[LVE0!9?*N(Y8_,4;7"!EX85\%?
ML$?#S_@JSKO_  2G^ A^$G[1GP?@\/R_"GP?+9:+:?"_5+77?[(%K9M);+J;
MZY);K=&U#Q^?]D56<Y58<AD[#P<GQ^^//_!8#XV? 35?VR?&[?"KPU\-_#FL
M6OAS0-1M;&2TU*ZN]2A-O#=6D,<L<,;6LOF*6,SO'$LDK(C1N ?>]>(W'[93
MVG_!0C3_ -@J\^#VJ6[:C\+K_P 9V?C2XU.W^S7,=K?6=H]O% A:7.Z\!+R>
M7@QX"N&##X\^&O[<G[4?Q6\.?"O]C2Z^+U]IWB?Q%^U#X\^&'BOXJP6-JNH3
MZ+X7_M*Y+Q#RO(AO[NWM;:W,PCPI,TB(KE2G1^"OA1XJ^#G_  <+>'M#O/C5
MXC\6>'[G]DS7KO0=.\57JWM[H['Q#I23Q+<E1-/"Y2-T\YI'5C* VW:J@'Z'
M45^3W[-/[2G_  4A_;M_8IU#]L_X;_#_ ./2?$+QE<:QJ'PLE\)Z_P"#(/!^
MB0P7D\%CILUA?:O%+>1$P*EU-=0?:-[S>2R!(S7T9XA^.7[4GQX_:>^ G[&7
MQ)DU'X0W_B/X*:A\0_C'8>&=3@:\EO;673K+^PK2_B:411+=7LDLDT#^:\<$
M861 SE@#V?X,_ME/\6_VS?BS^Q]>?![5- N?A;HF@ZG_ &[J&IV\J:S#J9O1
M&\44)?RD7[$2"[ASO^:-".?;J_/_ /X)X^ /&/PQ_P""RO[77@OQ7\7M6\9P
M6O@3X=MH>H:^\4E_:6+IK#I:3RQHGGM&[2!9'!D:,Q[V=@7;] * "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /$OV_/V&/ 7_  43_9ZU+]E_XN?$_P 9
M>'_".N/$?$%IX,NK&"74DBGBN(HY);FTG9%66%&Q$4+<ABP.*ZW1_P!G/P=+
M^SH_[,'Q4UG4_B%X;NO#;Z#JS^,EM7GU.P>'R&BN#:P01MF,E2P16.<DYYKT
M"B@#P'P%_P $\?AOX6\5^!O$7CGXO_$'Q_9_"^1I?AKH'CC6+6XL_#T_D/;)
M<KY%K#->W$=O(\4<]])<R1AV96#LSG2\4?L1>'/%7[:6@_MQS_&_QU:^(_#G
MAFX\/:=H-H^E_P!D_P!F7$\,]Q;NCV+3MYDEO$Q?S@XV81D'%>V44 %?./PW
M_P"":'PP^#_@OXF?#SX9?&_XF:3HOQ,U35[Z73$UVTGM_#SZI.\]^NFQ3VCQ
MQB61V;,ZSO'N;RV3<V[Z.HH ^5_%'_!)_P"&'BS]A[PK_P $_;_]HWXI1>!?
M![:4-*GM[K15U!H=,FMI]/@DF.F%62"6TA=2$#L01(SC '7WO[!/AG3_ (L:
MU\=_A3\??B#X"\9>+=/LK7QYKOA9M(8>*&M(_*M[F[M;W3KBT6Y2/]WY\$,+
ME $)*JH'O->%2?\ !1K]F*+]L-?V"GO_ !9_PM)]*_M5?#W_  @.J^6=-\PQ
M_;_M7V?[/]FW@IYWF;-WRYW?+0!ZY\/_  1IGPY\(V?@[2=0U&\BM%8O>ZM?
MO=75S*[EY)997)+N[LS'H!G"A5 4:&LV%UJFDW.FV.M7.G33P-'%?V21--;,
M1@2()4>,L.HWHRY'((XJS10!\J?LW?\ !)_P#^RQX(^*_@/X8_M4_%V2U^,G
MB#4=?\83ZM>:'<3#5[\*MY?P-_90$4LJ($((:,#E4# ,%\1_\$F/A9XF_8/\
M/?\ !.R^_:+^*4?@#PT=,33YH+K1EU%K?3KBVN;&W>8Z85*0S6D+@A [$$.[
MKA1]544 >$>'?V$=(T/]L2']MW4/VC?B+JWBY/ J>#Y[+4/[%73[C25O#>")
MXH--C8-Y[%_,1U?G;G;Q4.B?\$^_!GP]\2^)]3^ GQW^(OPWT7QKXBGUWQ3X
M/\(7^G?V;>:C<'-U<1?;+*XN+!IS\TGV.: %R9%VN2]>^UX?\4?^"BG[*7P8
M\977A/XC^,=;T^TT[58=+UKQ</!6JR^'=)OI618[:[UB.V:QMI-TB*PDF41L
MZK(49E! -;X[?L8?!WX\Z9X).IS:UX?U[X:7XO?AWXR\-:EY6K>'Y_(-NYAE
MF65)DDA)CEAN$EBF7_6(^ 1T7PD^"][\-+N]USQ1\9/%_CO6;Z-(6UGQ?/9J
M\$"Y(AAM["VM;6$$G+,D(DD(7S'<1QA>A\?>/O!7PL\$:M\2OB1XIL=#\/Z#
MITU_K.L:G<+#;V=M$A>261VX554$DGTKB/@;^U]\#OVA?$=]X+\!ZKK-GKNG
MZ7;ZI+H'BOPKJ&B7\FG3LRPWT5O?P0R2V[LC+YJ*55P4?:X*T -_; _9+^&O
M[:WP1NO@7\4=7UW3+.35;#5-.UOPOJ(M-1TO4+*ZCNK6[MI61U62.6)6&Y'4
M\@J:Y7X*?\$^OAW\#OVE=;_:LT/XR_$C5O%'BOP[I^F>,H]=\21RV>O360G2
MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
MVMX%\=?'SX7Z#JNH?:/-34=!FUFSD!>3HZ3>5 I;HPD.>#6Y^V-=7'AG_@K'
M^QOKOAX^5>Z^/B!X>UMHN&N-*.A)J&Q\?>1;NPLV / 9N.6KU?XX?L/?"_XP
M?L81?L5Z;J=]X?T;1]$TJT\'ZQ9E9;K0KG2G@ETR\CW\.\$UK;R8. ^PJ>&-
M8OPS_97^,GB7]IO1/VL?VM/'?AG6->\%>#[OP]X%T7P=I=Q;6%BUZ\#ZEJCF
MXD=S<7 M;>)8P=L$2.N^8R%P ?0=9WC#PEX=\?>$M4\"^+]+2^TG6M.GL-4L
MI&8+<6\T;1R1DJ00&1F&00>>#7BNAZ]^U/\ \/&-8\/I\3-%UOX-O\.O,G\.
M6_AORKOPQKJ3VODB2_#$7#74,MS)Y!&8T@C8A Z&;UWXHP_$NY^'6MV_P:OM
M%M?%<FFRKX>NO$<$LMA#=E2(WG2$J[QJV"54J6 P",Y !\J_\% _A%H_[6/[
M4/[./[-_@#2X?[3^%7Q5TKXJ>*M8M8@%\-Z-IL=PEM;%EQL?4+HQP1PY&^*V
MNGP1!5C]I6ZN/$'_  66_9@\&ZYD:5H_PY^('B+2HW^Y-JJKI5B'P>"\=K>7
M0!'(%P_K7"_L_?L>_P#!:KX2PCPQK/[6WP!:S\0>(DU'X@^,=-^'6JOXEU<N
M\8N;E9KB]:W%SY""*$&'R(4CBCCC2.-$7Z3_ &K/V7==^,WC#X=_'7X4^++'
M0?B+\*=<NK[PM?ZK9O<6-[:7EL;74-,ND1E<0W$10B1#NBF@@E <(8W /)OV
M>;F?PY_P6D_:1\':#SI>N_"CP#XBUF-?NQ:J'U>Q#G' >2UM;<$]2MNG9:D_
MX*L?"WP9X@_8$\2_L(?"OP)I]YXF^-7VGPYX*\.-'O!U"\G-S=ZQ,3EA':%Y
MM1GN&R=\8Y:66-6]4_96_9=\0?!WQQ\1?CY\6?%ECKOQ$^*NL6=UXEO-)LW@
ML;"RLK?[-I^F6J2,SF*",RL9'.Z6:XGDVH'6-/G"+]E7_@MSHWQY\7?'GP_^
MT?\ LTW.I^(G-KI,WB'X?Z[=S:%HZL&BTRU9+^-$BW 2R,$#S2X:0L$B6, ^
MQO"_P1\&Z-\-?!GPV\16YUV#P1;Z<-+N=2RS/<V< BANG7.&D!'F#=G;(%<8
M9%8?-GA7X5V'[0?_  61N_VOO!%FD?A[X0?"B\^'VI^(K==HU[7KN_CNIK%'
M'^NBT^*+$A^ZMS>&,'?!,J^A_M&?"+]O7Q9^Q=8_!W]G[]HWPOI'Q7N]/M+3
MQ/\ $?7]%F$39B/VV>S@M60V\DDG$7/[E')4[U1AQ'['7[.__!3SX1^*?"?@
M[XV?&GX%V?PK\+6DJ#PK\*O .I6-W>GR72&*2>_O+C$8D<3NR@2R/&-SD.^X
M ^N*^,F_;]_:%^%?[1'PG^%W[25C\.=-G^+'Q%U/PR_PWT&=KC7_  G#]FO[
MK2KZZNTO98;I;B*P7>@MX-K7BA6;R'#_ &;7YV^&_P#@DM^VKX6^&_PR\$VW
M[4WP[U#4/@_\=KKQ_P"'O$.K>!KZ2\\2FZ;4%FEUB1;U3)=>5J+J#'C<88]S
M@= #V[_@J=^V)^TC^QAX!^&_C#]G7X9^$_%5UXO^,'A[P=?:7XFOKF%Y1J=V
ML"K;M",1N3E?-?>L98-Y4H!4U;_]MWXI_LR?M*WOP&_;+U;PCJFEW'P9UKXA
MZ1XL\$^'+O3!;PZ/-"NHV$UM<WMV9F$5S%-'.LD88+(K1J0K-N_\%$/V5OCM
M^U9H/PNT#X2:YX4L3X ^+WASQY?7OB6XN5-Z^D78N4LTC@B;8)F !F+'8 0(
MWSD<_P#M!_L3?&K]H7]MKP9^T!XJLO [^!M%^&&O^"?$OA6;6;UKO4K77%M/
MMLB3+:A$\K[-L1"I\U<DM"7Q& ?)W_!63XV?MW_'+_@AWK_[3OB3PS\.K+P9
M\1-$T'5+KP!:Z;>C6O#^D7VHV4MI,VIM=-!>7"![<S0BS@4"20+(?*!D_6*O
MSY_:3_X)7?MP_&__ ()WV_\ P3%T']KGP9IW@O2+/3-,T_QK?>$;F;6]2TG3
MYX)+&RNHEN%A22-8(1+<QD_:/)QY4/FL5^]_"]OXGM/#UG;>--7L-0U9+=1J
M%[I>G/9V\\N/F:."2:9HE)Z*97(_O&@#QG]LZ]^%GP,_94^(P@^&\&M:A\0(
M;S3[/PE#$);GQCKVHVYM8++#DF5I0(XR6.R*WA);9#"2ORY^V7\$/'/[!7_!
MM?KG[-?_  F4ESK'A3X.Z;X7U_6;25MNRYGMK346B8\B)8KBX"9Z1JN>E=U\
M9OV7O^"OWB3]K[5OVBOA9\?/V?!H]E%)8?#G1/&O@C6;Z3PY9/D2RH8+V&,W
M=PNT33;2P51$A6,L']VT[]FGQO\ &O\ 8OUK]F;]N_QKIGC75?&^@ZGIGCG4
M?#6FG3[-HKPRJ([*)B[0K#$\:1LY=]T0=F+$F@#QS_@J#I6G?"W5_P!D/7OA
MWIT6G7OA[]J+PQH6B)9KL,6FWUAJ&GW=JN/^61M)')7IB%3_  U]1^+U^%'P
MPFUW]H?QO-IVCG3_  V(]>\3:A-L2UTRU::XP[L<1QH9978C&>,YVKCP?P-^
MQ7\??%OQ%^$^O_M;_&K0?%FD_ [S;OPA%HFB36L_B'639R6$.LZGYLKI'-%:
M37 6&$%#-<R2[U"I$N5^W]^S5_P46_:"^*_A+4/V;/B_\']*\!^&&CU&X\)?
M$7PQJ>H+JVL))O@N;D6ES )([<JDD,+$H)AYKJ[QPF( D_X)#_L\:]\%_A#\
M2OBMKWA*Y\,CXW_&WQ!\1]+\(W=L8)M$T[4&ACLX9H>/)G>WMH[B6+ ,<EPT
M;<H:\O\ VP?@-I7A?_@MI^QK\<IOB)XOU;4-;\0>.[&/2=7UUI=,TN >$[Z0
MK:6H54A+-C<_+N$4,Q"C'T]^R%X,_;?\-Z=X@U?]N+XR^!O$^LW]Y FAV'PZ
M\-7&FZ9IUI'&=S$74LTTD\DCMO+2% L<84*=V>-_:L_9<_:!^,7[9?P%_:0^
M'%]X.AT?X+:KKE_<:;K>H7:7.M-J>E2Z:\:M%;NML(DE:0,?-WM@%4 )(!]*
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQUXTM9O]9:W^JRFY6R;U^R6[6UB/]BS7KUH ^>/'/_!67]O[P=\&=;_::/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\
M%/XK?#;X'_#[5?BO\7_'&F>&_#>B6WGZKK6KW:PV]LF0HW,W=F9551RS,J@$
MD ]!7S5_P5<_9'^-/[8O[*D7@[]F[QYIF@?$+PCXUT3QGX)FUZ(OIMWJ>E7:
M74%M>* 2879/0@,$)! (H O_ +.W_!4?]C+]IGXBO\(/ 7Q2%IXMEUV\T[1_
M"WB#3KC3M2U5+:!KB6[@M;F-)6MQ&CDR%0%( ;!= VW^UY_P44_8Q_8-N/#U
MI^UG\<K/P?-XJ2[?P_#<:9>73WBVQA$[!;6&0J$-Q""6P#O&,X./AG_@FO\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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MJFE7'E3QM'LDV!L9=0>"".A->9?\+:^(/_0P?^2D7_Q%>B?%W_D0+W_>B_\
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M .UUYS11_K#G'_/W_P EC_D!Z-_PO_\ ZE+_ ,G_ /[71_PO_P#ZE+_R?_\
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M%%% !7@?BO\ Y&G4O^PA-_Z&:]\KP/Q7_P C3J7_ &$)O_0S7R'%W\"EZO\
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
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M -^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\
MZ&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P
M[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\7
M?^1 O?\ >B_]&+7C%>S_ !=_Y$"]_P!Z+_T8M>,5^>\5_P#(RC_A7YR ****
M^9 **** "BBB@ HHHH **** "BBB@#9^'W_(ZZ9_U]K7N=>&?#[_ )'73/\
MK[6O<Z^]X2_W.I_B_1 %%%%?5@%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5X'XK_Y&G4O^PA-_P"AFO?*\#\5_P#(TZE_V$)O_0S7R'%W\"EZ
MO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&W_(C:;_UP_P#9C7A]
M>X?#;_D1M-_ZX?\ LQKZGA/_ 'Z?^']4!N4445]^ 4444 %%%% !117E_P ?
M6_:K\4NG@#]F6Z\->%FFBW:I\0?%U@^HQV /2.STZ*6(W<^.2\TT4,>Y,"X.
M^- #U"BOC^Z_X)?_ +0OB>Y_X2'QY_P63_::DUEB69_#-UX:TG3PW;;91Z.Z
MA1_=+'CJ>]=[\'_AY^WC^SSK-OI?Q!_: L?CIX-E<1SW>L^&K;1?%&EKT$HD
ML]MEJ2#C=&8;64*&99)GVQ, ?0=>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
M)H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\7?\ D0+W_>B_
M]&+7C%>S_%W_ )$"]_WHO_1BUXQ7Y[Q7_P C*/\ A7YR ****^9 **** "BB
MB@ HHHH **** "BBB@#9^'W_ ".NF?\ 7VM>YUX9\/O^1UTS_K[6O<Z^]X2_
MW.I_B_1 %%%%?5@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X
M'XK_ .1IU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T,U\AQ=_ I>K_ " SZ***
M^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO_7#_P!F->'U[A\-O^1&
MTW_KA_[,:^IX3_WZ?^']4!N4445]^ 4444 %%%% !1110!\D?M-?\%*O'_P
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M4?\ 2+EGF$P8L %:-D P@R ?35>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
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MS\WO_@6U'_"#Z1_S\WO_ (%M0!L5X'XK_P"1IU+_ +"$W_H9KV3_ (0?2/\
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M@?BO_D:=2_["$W_H9KWRO _%?_(TZE_V$)O_ $,U\AQ=_ I>K_(#/HHHKX8
MHHHH **** "BBB@ HHHH **** "O</AM_P B-IO_ %P_]F->'U[A\-O^1&TW
M_KA_[,:^IX3_ -^G_A_5 ;E%%%??@%%%% !1110 5Y]^T%\-_C=\2;3PC#\$
M/VAG^'<NB^.M.U;Q-,GA>VU3^W]&A+_:M'(G(^RBX#*/M*9DCV?*#N->@T4
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MQ[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:^+O_ "(%[_O1?^C%
MKQBO9_B[_P B!>_[T7_HQ:\8K\]XK_Y&4?\ "OSD 4445\R 4444 %%%% !1
M110 4444 %%%% &S\/O^1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_P 7
MZ( HHHKZL HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?\
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MI4DR9(W(MU,A9<@C(XR#5C]G[]J#X!?M5Z%K7BW]G/XKZ%XUT/0M>.CW6O\
MAG5H+ZPFNUM;>Y=8;B!WCE"I=1ABIX<,IY4T =]7E'[<_P#R:/X]_P"P"_\
MZ&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P
M[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\7
M?^1 O?\ >B_]&+7C%>S_ !=_Y$"]_P!Z+_T8M>,5^>\5_P#(RC_A7YR ****
M^9 **** "BBB@ HHHH **** "BBB@#9^'W_(ZZ9_U]K7N=>&?#[_ )'73/\
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MB@#Y NOV0O\ @KII]P;#PO\ \%B=$GT[.(YO$W[-NF76H*O8M+:W]K"[=.1
MHSS@]*]#^!_[$7B#PKXFL_B;^U%^U'XT^-7BS3Y5FTR;Q-%::=HNE3+]V:TT
MC3XHK995_AGG$\Z<[)5W-GWRB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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MV?XN_P#(@7O^]%_Z,6O&*_/>*_\ D91_PK\Y %%%%?,@%%%% !1110 4444
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MA;X5_P#!5Z[\,:==>$_VJ?AG::5)80OIEK<^"I'DAMR@,:.W\3!< GN15_\
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M3_X5)_P5]_Z.X^%G_A"R4V7X5_\ !72TB:ZO?VNOA>(8E+RF+P%(S!1R< D
MG';(^HKWVU%78'U=17QU]K_X*$_]'H^&/_#01?\ R=1]K_X*$_\ 1Z/AC_PT
M$7_R=7C?ZPY/_P _?_)9?Y ?8M%?'7VO_@H3_P!'H^&/_#01?_)U'VO_ (*$
M_P#1Z/AC_P -!%_\G4?ZPY/_ ,_?_)9?Y ?8M%?'7VO_ (*$_P#1Z/AC_P -
M!%_\G4?:_P#@H3_T>CX8_P##01?_ "=1_K#D_P#S]_\ )9?Y ?8M%?'7VO\
MX*$_]'H^&/\ PT$7_P G4?:_^"A/_1Z/AC_PT$7_ ,G4?ZPY/_S]_P#)9?Y
M?8M%?'7VO_@H3_T>CX8_\-!%_P#)U'VO_@H3_P!'H^&/_#01?_)U'^L.3_\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
MHE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !577?
M^0'>?]>DG_H)JU577?\ D!WG_7I)_P"@FLZW\*7HP/GVBBBOQL HHHH ****
M "BBB@ HHHH **** "BBB@#Z*A_U2_[HIU-A_P!4O^Z*=7[.M@"BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX
M=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5==_P"0'>?]>DG_ *":M5%?VOVVQFLM^WSHF3=C.,C&:BHG*FTNP'SQ17HW
M_"@/^IM_\D/_ +91_P * _ZFW_R0_P#ME?FG^KV<?\^O_)H_Y@><T5Z-_P *
M _ZFW_R0_P#ME'_"@/\ J;?_ "0_^V4?ZO9Q_P ^O_)H_P"8'G-%>C?\* _Z
MFW_R0_\ ME'_  H#_J;?_)#_ .V4?ZO9Q_SZ_P#)H_Y@><T5Z-_PH#_J;?\
MR0_^V4?\* _ZFW_R0_\ ME'^KV<?\^O_ ":/^8'G-%>C?\* _P"IM_\ )#_[
M91_PH#_J;?\ R0_^V4?ZO9Q_SZ_\FC_F!YS17HW_  H#_J;?_)#_ .V4?\*
M_P"IM_\ )#_[91_J]G'_ #Z_\FC_ )@><T5Z-_PH#_J;?_)#_P"V4?\ "@/^
MIM_\D/\ [91_J]G'_/K_ ,FC_F!Z)#_JE_W13J1%V(%ST&*6OTU; %%%%, H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R
M3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \Q_:?_;!_9_\ V/\ PG;^)_CCXZ33Y=16X&A:+:6DUYJ.
MKR01&62.UM+='FF*H 694*H""Y4'-5?V5OVV_P!FG]L[09]6_9_^*&GZY=:9
MIMA=^(M'@<_:]#:\21H;>[C(!@F(AD_=MAL*&QM="WRK_P %A/V?OVXO"WQ7
MT#_@HQ^PSH.A^-[_ ,'?##7_  ?X\^&'B&]%LVIZ#?-%<37.GSM\L5W&]NC'
M/+K&B@/@QOO?\$8?VROV-?VS/#VK^-?@MIVM>&_BIHW@?POX<^+'@CQ5I/V#
M4K/^SH;I;2X>+'[Y'^TS*LP9LQI"K",J%H ^NQ\7/"MU\7Y/@EI$CWFM6.B1
MZOKBPX\O2[261X[8S-V>=XI_+3^);:9B0%&[B/ '[?/[(WQ0\;:9X"\#_&2V
MO+O7KRYM/#-^VF7<.F>(+BWWF>'3=0EA6TU&2,1R%DMI96 C<D84D?.W[#-Y
MHOQR_9/_ &I_CY\4O'W_  CL/Q'^*WC^VU3Q9-,$;1-$TOS-"M7WL0$2VM-/
M$N,A0S2-P6)KYP\&?$+XB>/?V.OV(/@+\7/@+JGPU\ >%?B9X*:S^.%\81I&
MLIH^U-':RM4<W]@VL,D"J^H6]JD273H6D:2-7 /UXKA/@9^TW\!?VEQXJ;X#
M_$W3_$Z>"?%ESX9\3RZ;O,=CJMND;S6Q=E"NRK+&2R%E^; .0<>>?M@_''27
M\4:1^R#X;^*UCX5UWQCI[WWB?Q#+K$=I-X>\-J_E3W$+NPVW=R^ZUMB.5;S[
M@;A:,C>(?\$7;CX1>'OB7^UC\-?A1J6@P:9IW[1UR-!T;1KN(I#IL7AW08(S
M$B$_N5VB,,/E!&,YH ^[:X[Q+\?_ (/>$_B7IOP8U;QU:OXOU:%9[/POI\<E
MWJ MF?R_M4EO KR0VP<[3<2!85/5Q5']J[XY6?[,7[+WQ&_:0O\ 3Q=Q> ?
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MOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH
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M4W F\V5V#;I,Y9>.!VKU3_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C
M_AWO\$_^AM\=_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z
M&WQW_P"%E<_XT >Z45X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQ
MW_X65S_C0![I17A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M[I17A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'NE%>%_\
M#O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?
M_0V^._\ PLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__
M  LKG_&C_AWO\$_^AM\=_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/
M^'>_P3_Z&WQW_P"%E<_XT >Z45X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\
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MVYM'U?6_V4_CKI'C!/#]VMMKMK:++!=Z=(V[8)[:X2.:(-M?:S( VQMI.TX
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M64)X0T#X:R:C%I$,,<.5>YN;V)KCS99W97*HR1QQ1E%9B^[Y=^'GP)_X+_\
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M?L'^&_V,OVA;OP3J4W@Z\U!M*U[P9K=Y<K?17=_<7K"6*YLX#"R-<%!M9PP
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20220630_g3.jpg
<TEXT>
begin 644 biib-20220630_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ_X*>_MP^)/^"<O[(_B#]L"
MR^"L'CG1?"1MW\1:6OBC^S;J.&>ZAMDD@S;3),1).I96,>%!(+'Y:S6_:6_X
M*-7'@,>.]"_X)X^#]3672A?6>F6?QX NKH&/S%B02Z.D8D8$ ;G5<GE@.:\N
M_P"#EG_E"!\>?^P1I'_I[T^O.?V\_BQ_P6"_8[_X)T2?M4^'OCS\%-=T[P-I
M6D:I>:!X?^%NK:/>W%J&AC0/=SZY=QM%'))%+/&(HS+#%*@=-VU@#]%/AMXX
MT[XG?#K0/B3H]I<6]IX@T6UU*U@NXBDL4<\2RJKJ>58!@"#T((K:KXE^.UW\
M>/V M9^ /Q!B_:>\7_$!_'/Q=T'P#\3=+\5SP36FMG5Q) -2LX8XE&G2V]R$
ME6*VV0F#S5=&(5UH?M0C]ICQS_P6(^'/[-?@[]KGQKX6^'7BKX*:_KOBCP[H
M/V&!HVL[[3X$-G/]F,L4LCSH&E=I'2-IA"82X90#[IKS_P"('[0OASPY\%/&
M/QD^'6D3>-U\&KJ4=[I&@7ENDLMW8LZ75L)+AXXU>-XW5\MP48 ,P"FWX#^#
M4W@[X&0? _6OBYXS\2F/2)]/F\8:YK*KKEPL@<><UU;1P[9U5\+*BJPV*V2P
MW'X1_P""1OPNTSX?_P#!*/XO7.F>*O$E\C^*?B;8I;ZWXAN+V.-+;6M6C611
M,S'S7 S)(26D;YF)/- 'V_\ LB_M VG[5_[+/P[_ &G;'PO)HD'Q!\%Z;XAA
MT>:[$[V2W=LDXA,@50Y4/MW!1G&<"O1*_)W]GC7_ (\?L:_\$5?V9OVU=-^/
M_B6_U+3[3X=6>K>%7N(_[$NO#.I7UAIG]G+9[-J2I;7<<GVH'SS<1DE_*/DC
MT70_VE?VI_VN?VP?VA/#-M\/?CI=^"/A/XSC\$^#M.^"_B7PQH_V6^BLH;BZ
MU*^DU34[6XNYI'N(S#&4>S6)!E)'9R #]':\>^//Q\^/7@[XI:-\)/V=?V:;
M;Q_?7.B7&J^(M1U7QFNB6.B0"5(K5'D^RW#2RW#"YV(B<"TD+$97.?\ \$[O
M$?[9_B']F'38OV^/A^VA?$;3-4O;"[GDGTUGUFRBG86>HR1Z;<3VUO+- 8S+
M#'(5659-H5"H'N- 'P/\&O\ @KI^UM\??AQ\8?B7\*_^"<6FZI;_  1^(6N>
M#?%VFK\:8HKNYU'25B>[-FLNF+'+'ME!1GDC+8(P#@'ZO_8Z_:*L_P!KK]E7
MX>?M0Z?X5ET.#Q_X1L=>AT::[%P]DMS"LHB:0*H<J&QN"C..E?"7_!&[_D@/
M_!0+_L\CXI_^DMG7$_LVZ_\ 'C]C;_@AG^SQ^W)I7Q_\2WNJZ)9> (;_ ,*&
MXC&AW7AO4-5L-+.FBSV;5D6UO%E^U9\_[0A;>(L0@ _6RBO@WXO:;^TS\6/^
M"TD_[*UA^V1X^\-_"^[_ &;QXLU+0?#DEC:W$-\=<:R2.UN$MO,A0JJR-(Q>
M;]V4614D9:\!_8I^+O\ P4._:K_8SUKXT^&V_::\0^*WU36M*^$OBK1O$G@B
M+3--ATNZGL+4:E9WFI6C:E<236K/>R75JI<R.+=8D$;$ _7"BOSK_:5_;-_;
MX?Q3^R;^RGXF^#/BGPIXZ^+'AW5]<^-&B_#35M";5HCI%I;F?3=,N]0O4LHT
MFN+@.\J3M/';KB-MY+#U[]BO4OV\M!_:K\6>!/B;\&OB-8_ R\\'V^H^$=9^
M+'B7P[?ZSHVNI<"*XTM9-+U*[GN[26%EN$FN27C>.6,OM,8H ^MJ*\C_ &YO
M$6I^%OV9=>U?2_VBK;X5$7>G177C:;3/MDUK;/?0)/!:P\E[RXB9[:W"J[^?
M/%L1VVJ?'O\ @GI\>O'_ (J_:Z_:*_9EUR;QBWACX?-X2U7P;#X_NOM&JVMO
MJ^GW#RQ/*\DDS1&6S,R)<,9X_M#(P0*L: 'U[17PEJ]I^T=\4?\ @M7XR_9J
MU/\ :U\<V?PJL_@'I'BR3PMH]U;6$L6H7&KWUHD$%U;01S10;+8R,VXSLRHO
MG>7OC;SOPY^W)^U%XA\#Z#^R+!\7[^V\2:A^V?K_ ,&KKXJ2V-J=23P]IL%S
MJBSC,7V?^TI;*.*S68Q$;R\VPN* /L/Q9^V4_A/]O3P;^P]>_![5%_X3+P3J
M_B*P\9RZG;BU9=/>T26!($+2LV;N,%I!$!@[0XYKOOV@_CM\.?V8?@=XL_:'
M^+NJR67AGP7H%SJ^MW$,)DD6W@C+L$0<N[8VJH^\S =Z^']1^#_BGX/?\%\_
M@KIDWQQ\2^*?#E]\!O&4^BZ/XMU%;Z[T>X%WI:W)2Z91/)#,!;LJ2L^QXY=A
M"L$7[3_:C\"?!3XI_L\^,/A=^T=##)X&\3:'-I/B99Y&C7[+<CR#\Z?-&<N"
M)!@H<-D8R #P^;]O[]I[PEH_@KQ]\6/^">>LZ3X3\>^+_#NAZ=J>C_$"PU*[
MT0:QJ-K96]SJMJJ1BW13=(6^S27>&PI(!,B^V_M"_M!6?[/.E>&-5O?A+XZ\
M7#Q1XVT[PVD'@/PZ=2DTQ[QV47]XH=?(L8MN99^=@9?E)(%?FWXPU7_@H)_P
M0(\-Z,WQ<\96W[27['>EZ_I>GG4/$<"IXP^'5N]Y#%92,^/+OX()F@"'&_>L
M:H+90M?6/_!7#XD?&/X2> O@]XR^$'QCUSPN;S]HKP/H6OV&E);>5K.G7^M6
MT$]O.TD+RJI0D?NI(\AF#;@<  ^LZ*_-_P#X+"?%'XT?L*_&[P%^T7X'^/>O
MW'A'XFRWW@.]^'FK_$&;3].TCQ#?0-_9GB)'#"6.S@E!6[16,<4<B2)'N&#]
MO_LQ_!+Q!\ O@]H_P^\:?&CQ3\0M>MK.,:[XP\6ZBTUSJ=T%'F2B//EVZ%L[
M8HP JXR6;+L >'ZK_P %0[;X<?\ !47P[_P3(^.WPAL_#FH>._!UQK_P]\8Z
M?XN%[;:OY3RC[)+ ]K"]M.4M[EL;G4F-55F+C'T'\?/C=\/_ -FOX)>+/V@?
MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
M '>@#Q+2OV'-!T?]LO7?VW[3X]>/CXH\0>$(?#%WI$C:2=,BTR&XFN+>&./^
MS_-!BFN)75S*SG=ARXXKB/"W_!)/X$Z#X3\9^$M>^+?Q$\0+XR^*LGQ*74=4
MU+3X+S0O%C/&PU73I[*R@>WD7RE41DO#L+HT;+(ZM?\ @U_P6!_X)[?'OX]6
M'[-GPX^.SR^*-<CF?PJNI^&=2L++Q(L(S*VF7MS;QV]^% )!AD<.OS)O7FO9
MOCA\??A9^SKX3MO&'Q5\02VD&H:K!I>CV5CIT][>ZI?S$B&TM+6W1YKF9]K$
M)&C$*CN<*C, #Q;0/^"6OPNMOVP_#O[=WC[]H/XL^,?B/X:T*?1K/4M;\26E
MK:RV$CHXMGM--M+6 1JZLVU$02&5S-YOR[?:?VA/@5X#_:;^"GB7X ?%!+U_
M#OBW2WT[6H].O&MYI+9\;T25?FC)'&Y<,,Y!!P0GP.^/_P +/VBO"UWXL^%>
MOS74>F:M/I6M6%_IT]E?:5?P[?-M+NUN$2:VF4,C;)$4E'1URCJQ\8^,O_!8
M?_@GA^S_ /&H_ CXM?'LZ3JL.L1:1J.KMX;U&71-,U&0*4L[K58[=K*VFPPW
M)),#'_RTV4 /U3_@F-X$\;_V/X:^-G[37Q@^(G@C0M4L]1L?AQXU\2V=SI,U
MQ:2K-:M=R16<=[J"QS)'*$N[F9&>-"ZOBNR_;*_8M\*_MK>'?#'A7QM\6_&?
MAFS\*>,=-\4:>GA"73XVFU*PG6XM))6N[.X)6.5%?8NU6(PP8<5Z!\7?C!\,
MO@-\,]7^,?Q?\96>@^&="M/M&J:M>,?+B0L%4 *"SNSLJ(B!G=W55#,P!\M_
M9&_X*5?L<_MP>*?$/@#]G[XFW=QXF\*QQS:]X4\1>&K_ $75+6WD($=Q]DU"
M"&5H6RN)%4J-ZABI8"@#C/CK_P $G_AY^TMXI\6^*_C=^T]\5M??Q=\-+[P)
M/8WDN@_9=,TB\>)[K[%$-)"V]Q*T,9:X&9#Y<?S?NX]GN7[.GP5N/V>/A#H_
MP??XO^+_ !O;Z':QVMAK?CFZM)]1^SQQJD<4DUM;P";:J_ZR16D8DEG8UW%%
M 'CND?L?6^D?M>ZE^V,/VA?B#<:OJOAJ#P_<^%IY-*_L8:=#<S7,,"Q+8"<%
M);B8B3SO,(<AG8  <%\&_P#@DM^S%^S?\#/BI\ _V<=8\3^!=-^+_B34]7\4
M:GH5Q9->VXO8VC>RM'N+65(+:-&98DV,T>YB'W,6/T_10!\=?LS_ /!%_P"#
MO['GA[3=(_9P_:A^,/AF]TSPVOAU=<M]1T2:ZNM(2XN+F&SN%FTIX)_)FNIV
MBG>(W$2R-&DJQG97L%C^PY\(O"W[(^I?L9?"_6_$'A+PUK&FZA::IJVDWL-Q
MJMVU^96OKF6XOH;CS;B=YY9'F=6;<Y(*X&-_]J;]J_X%_L8?"*]^.G[17BVX
MT3PSI\L45U?V^CW5Z4>1UCC!2VBD90SLB;B H+J"1FO1J /E[QI_P2P^'7CG
M]D/P!^Q3J?[2'Q1@\(_#>XT67P_<VEQHJW[KI#6[Z;'-*VF%76!K6)AA%9R#
MYC2# '8:G^P9\/-3_:RTC]LS_A:OCVU\767@ZS\-:[#IVMPVUCXFM+2YDNK9
MK^"*!=SQSS2/^Y,*,',;H\9*5A_M6?\ !6+]A']BOQT?AW^T)\8+S3=1MH8)
M];;2_">IZI;Z%#/Q#)J$]E;RQ6(DX*B9E8JP8#;\U>]:-XT\'^(O!MK\1-!\
M4Z=>:!?:8FHV>MVUXCVD]F\8E2X64'8T1C(<.#M*G.<4 >+? _\ 8(TSX >,
M/BGX\\$_M-?$J;5?BYK0UCQ)=:E_8<GV;41!#;K<VJKIBK&P@MXX@CAX]HR4
M+?-7(_LU?\$I?!_[)'A;PWX/^!?[77QDTNS\*^%Y/#VF)/?:%<!M/:[FNUCE
M272625TFGD*2LID0,5#;68-Z5\%/V[OV9OV@?%]CX(^&_C+47O=;TB75O"LF
MK^&;_3K?Q)IT3(LEYID]W#''J$*F2,EX&<;)(Y/]7+&[+^UI^W9^S1^Q+I.F
M:A\?O&5_:W6MF<Z-HF@>'+[6-2O4A"F>6.TL899O*B#IOE*B--Z!F!=00#K?
MV>_@)\,/V7?@KX<_9^^#&@'3/#'A735LM)LWG:5U0$LSN[$EW=V9V8]68GO6
M5^UE^S;HW[7?P \3?LX>*OB/XG\,Z%XPTFXTKQ#=>$I;..[NK"XB>&>VWW5M
M.J))&[*S(H?!X8<YM_LT_M._ 7]L+X.:5\?OV:_B78>+/"6M*_V'5K .OSHQ
M5XI(Y%62&56!#1R*KJ>H%:GCCXR?#OX<^-/!GP\\7>(%MM8^(&MW&D^%+$1L
MSWES!I]UJ,H^4'8JVUG.Q=L+D(N=SJ" ?//PN_X):ZU\%?AEH'P;^%__  4F
M_:,TCPUX6T6VTC0-*@U/PRRV=E;Q+%#"K/H3.0J*J@L2>.236C^R]_P2Y\ ?
MLF?%C5_C+\/?VE/BIJ6L:]X0L_#VL'Q)?:1=K=PVOVEX+B1AIJR/<B>[N;AI
M2Y,LLK&0.IVU].T4 ?*W@O\ X)(_ OPCX"UOP->?&#XC:S+J?Q7N_B7I7B#4
M=2TZ+4O#WBJYF>:?4K":TL80A=I90T,JRPLDLD;1E'93H^!/^"7?PJ\*_MEV
MG[?'BOX\_%7Q?\2[;PL_AV35-?\ $MM!;3Z:9DG6V:TT^UMH%C21 XCC1$=F
M9I%D9BU?3%% 'S]X1_X)Y^"/A7=ZWI7P'^//Q)^'_A#Q'K]SK.K_  _\*:I8
M)I9N[J0RW;6TEQ92WFG+-(S.R6=S JN[-&(V8FNK^-W['_PT^-&J^#/&5MKF
MN^$/%GP[:<>"/&7A&ZACO]*AGB6&XM@+F*>"XMY8XXP\,\4J$Q1OM#QHR^K4
M4 ?.G[-/_!,_X._LR?M,^./VN]#^*_Q)\3>.OB/9V</C+4?%GBE98-1>U61(
M96MK>&&%2D<AC2-4$4:A1'&F*^BZ** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "OSQUA+R3_@Z;A33YHXIS^P,XAEFB,B(__"8O
MM+*&4L <9 89Z9'6ON?XV>!/$WQ0^#OBGX;^"_B5J7@W6->\/WEAI7BW1XU>
MZT:XEA9([R)6X9XV8. <9*XR.H^?_P!FW]A7XN>'OVU;C]OK]J'XDZ!KOCR+
MX):;\,K!/"UA+!:S6<%_)J%UJ,HF)*S7%PT9$*Y6%8R-\F[*@&'\$/VWOVE?
MBG^QI^T'\8-3B\#6OC+X-?$3QUX<TN>#P]>'3-1BT"25(I9;8WWFHTWE_-MG
MPN[C..>(\9_\%)_VU)_"'[%.L_"GX5_#F[N?VH-"L&\2'5'O@-(O;CP\VJ2S
M6\:2#_1H#F0H\CO*D;1 QLPF'8^-?^"=G[0ND> OC[\!/@!\;_#.B>"OCYK^
MMZ]?:CJNB3RZOX=O-7M%AU&&V*2"&9)I5:6.5PK6YN'^2?:HKG]#_P""<O[7
M?@W3/V0M"M/B5\.=>B_9;LQ#-=S6E_IC^(4_L)]%2$1C[2+=D@<R&?<XE?&(
M85&T@&Q\0?\ @I_XE_8YU+X_>$/VRK+0M;O?@Q\+],^(&E:QX'TF?3(O$6F7
MTEW:I:?9;FYNC;7"7MIY._SW1Q<1OA-K+7$V_P#P5@^-?P]T3X;?$_XE:S\,
M/&>G^,M?TS3O&GP]^'&AZF-;\&17[*BW2W4ES,FK):NZ+<!;:U)3?(G";#V7
M[0'_  3*\>?M5_M7?%KQY\;;GPL_PT^*_P $(/AG>Z1I>J7*ZO86]O?7=Y!J
MD<CVQA:?S;HD0D;4*(?,?:5?V+X(?#?]NCP9H7A;X:?%'XU>!-6TKPW#;V^I
M^,-,\.W,>K^(H+<*JA[>65[>REE"CSI%:<$-)Y:0ED>, ]SKXV_X+::E\2K?
M]@;X@?"_P5\&9+OP;XH\/7-I\2?'-J\$H\(:'.Y_M+54TX,)]0EA@::?RXL'
M(+Y)4JWV37@?[4?P'_:J_: ^%?C/]G'1/BWX4TCPQX[L+S2[[Q9)HTSZQI6E
M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29
M^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_
M + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_G
M0_; _P"3M/BC_P!E%UO_ -+YJ_HOK^=#]L#_ ).T^*/_ &476_\ TOFKX#CW
M_=:'^)_D?UE]%#_D>YG_ ->X?^E,\ZHHHK\R/[>"BBB@ HHHH **** "BBB@
M HHHH *_?7_@EE_RC]^&'_8!?_TIFK\"J_?7_@EE_P H_?AA_P!@%_\ TIFK
M[?@3_D9U/\'_ +=$_F#Z57_)%8+_ +"%_P"FZA[_ $445^JG\'!1110 4444
M %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"A
MK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?SH?M@?\G:?%'_LHNM_^E\U?T7U_.A^V!_R=I\4?^RBZW_Z7S5\!Q[_ +K0
M_P 3_(_K+Z*'_(]S/_KW#_TIGG5%%;GP[^&GCSXL>)4\(?#KPQ<ZKJ#0O,T%
MN !%$@R\LCL0L<:CEG<A5'4BOS2,93DHQ5VS^VJU:CAZ4JM62C&*NVW9)=VW
MHD8=%>E?&W]DSXX? +3U\0^._"+_ -B22V<$/B&RF2>QFN;BV-PL"31L4=U1
M7R%)QLST92W$>#/!WB;XA>+-.\#>#-(DO]5U:\CM=/LXF ,LKG"KEB .3R20
M .20!5U*%:E4]G.+4NUM3DPN:9;CL'];P]:,Z5K\RDG%)*[N]E9:N^W4S**.
MO2NS\;?L]_&/X=>'/^$K\9>!Y[.SCDACO#]HBDEL))4+Q1W42.9+1W4%E694
M9@"0#BIC3J3BW%-I;^1O6Q>$P]2%.K4C&4](IM)R>FB3WW6W='&45V'P9^ /
MQB_:$\03>&/@WX"O-<O+6 378MRD<=O&2%#22R,L<8+$ ;F&3P,FL_XG_"KX
MC?!;QI=_#OXJ^#K[0M:L2/M.GZA#L=01E6'9E(Y#*2".033=&LJ7M7%\NU[:
M7[7V,HYEET\<\%&M!UDN9PYESJ/=QOS):K6UCGZ*?;V]Q>7$=I:0/++*X2**
M-2S.Q.  !R23VKMO&?[-GQL^'^A7OB+Q7X'>"WTJ6./6TAO8)Y])>0X1+V&*
M1I+-F/R@3JA)XZ\4HTJDXN48MI;Z;%U\;@L-5A3K58QE/X4Y).6J6B;N]6EI
MU:[G#4445!U!7[Z_\$LO^4?OPP_[ +_^E,U?@57[Z_\ !++_ )1^_##_ + +
M_P#I3-7V_ G_ ",ZG^#_ -NB?S!]*K_DBL%_V$+_ --U#W^BBBOU4_@X****
M "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@
M%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_G0_; _Y.T^*/_91=;_]+YJ_HOK^=#]L#_D[3XH_]E%UO_TOFKX#
MCW_=:'^)_D?UE]%#_D>YG_U[A_Z4SSJO</V(?C-\%/AQKOB[X=?M$Z?J:^#_
M (A^%SH>JZSH8S>:2?/BGCN$7!WH'B4N@!R .&QL;P^O0/@KXT^#.@^'_%/A
M3XS^%M:O[;7K.VCTZ\T*>%)],N(IM_V@"4%9/EW(8SMW+(WSH0#7YY@JCI8F
M,TTK7WVV>C\GM\S^PN),'3Q^35*$X3DI<O\ #=IIJ<6IQ;TYH-<ZWORVL]CW
MS]OS]FSXN_"'P//XT\$>+=.\7_"#Q)=Z!/;^(-(G+&"\M-*-M;_:8"<VSR13
MNV,,,-&"P.%.)_P29^(NF^%OVL_#OA-OA=X:U*\UIKV%/$>IQ74E]IT?V&9B
M+8+.L"$[,%VB9\.P# '%5OCW^U#\*-&^$OBKX$? ;4=?UJV\=KX<E\1ZOKT$
M5M#;IIME$L<-M;QR28E:0#S96<?ZH(JD#>?/_P!B?XQ?#G]G[]HK0OC+\3%U
MN6QT(W#K9Z%80S2W#26\L(7,LT00#S V?FSC&.]>O.OAJ6=4JM*5DI)O6ZC[
MSO9OI;7JU>UW8_/<-EF=8[PSQV"QU-RJ2ISC3M%TYU5[&*@YP35I\]Z;3LI*
M"DXQ4K*?]@+PAH/CO]M3X8^%_$T$<UC/XPLWN()1E)1&_F"-@>H8H%([@XKK
MOV5?$&J_%3XC_&^#QO.\Z>*_A;XIU+6A<'</M4"_VC%,V?XDN(4(/49..M>*
M^$/'%U\)?BGI7Q'^&6K3R7'AW6;?4-&N[^S6%VDAD61#)$LC@#<O*AV!'?FO
M3]>_:#^#?A>T^(/B/X)>'->L]=^)=C+87EIJL4*VOAVRN)TGN[>VE21FN_,*
M+$LCQPE(BP*NS;AQX.M2ITXJ3MRRDWYIQ22\]FO^WK[79]#Q#EN/QF-JRHP<
ME6I4H0=OX<XU7.4G>SCI*,_6E;XN5/R2P\1>++OPZOPVTB>=[*]U1+EM.M4)
M-W<[?+BW!>9"H9@@.=IE?'WSGV/]O+XBGQ-JWP]^%^J:HNIZ[\._AY9:!XFU
M4RB5GOU>662V\S)\P6XE6 G)&^.3!(P34_9-^(?[)OPQTO6-?^-(^(:>+)R8
M/#VI^#;*Q9=(A*C?<1M<R@BY;+(K[/W0^=#YA5H^1^.MU^R\PTNR_9JL/&Y1
M?.DUF_\ '+VHFE=M@CCB2U)144*Y+'YB7[!14*]/ 2M43<K75]4D]%;O?7R7
MJSJDX8OBNFI86I&-'G<9\EHRG.%I2<K_  J/N):N4G>R4(MW/V,/'W@;X6_M
M7_#[XA_$I5_L+1_%5I<ZC*\>\0(L@Q,0,DB-L2< GY. 37N?[.GP#^*OPZN_
MCS\3?BF8IO#-O\*?$-O=:^U]'-:^(+BZ 6T>WD5B+A7N#%*)%R%95R0Q /S9
M\3;GX(ZGX[MW^$FG>(]*\-FSM$NEUJ2&ZO$G$:BYD0(41E+[BBEER,9*YP.A
M\8_'?1;'X/\ _#/WP8\/7.D^'KR]BO?%&JW\JMJ'B.YBSY)FV?+#;Q$L8[92
MP5F+L\C8*Z87$4L,FJFO(VXV>[:MVU6B>MM+[MV.3/LIQ^<SC4PB<'B(TX5%
M.*]RG";FVFI+EJ6E**2Y[R<&^51<CS&BBBO)/O@K]]?^"67_ "C]^&'_ & 7
M_P#2F:OP*K]]?^"67_*/WX8?]@%__2F:OM^!/^1G4_P?^W1/Y@^E5_R16"_[
M"%_Z;J'O]%%%?JI_!P4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&
MM>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_
M -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7\Z'[8'_ "=I\4?^RBZW_P"E\U?T7U_.
MA^V!_P G:?%'_LHNM_\ I?-7P''O^ZT/\3_(_K+Z*'_(]S/_ *]P_P#2F>=4
M445^9']O!1110 4444 %%%% !1110 4444 %?OK_ ,$LO^4?OPP_[ +_ /I3
M-7X%5^^O_!++_E'[\,/^P"__ *4S5]OP)_R,ZG^#_P!NB?S!]*K_ )(K!?\
M80O_ $W4/?Z***_53^#@HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7
M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\H_?AA_V 7_ /2F:OQ<_P"&+?VF/^B:_P#E9LO_ (]7[9_\$WO"FO\ @?\
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MO_A'XIY[#0_&$[1#3]2U>V@(-Q;+$)(HA('1))G<*75 WT!_P25^"/P5\(>
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M^U/Y_"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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M ,M#6/\ Y$H_MC*/^@BG_P"!Q_S#_B'7B#_T)\5_X3U?_D#Z=HKYB_X?)?\
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MBOF+_A\E_P $W?\ HXW_ ,M#6/\ Y$H_X?)?\$W?^CC?_+0UC_Y$H_MC*/\
MH(I_^!Q_S#_B'7B#_P!"?%?^$]7_ .0/IVBFP31W$*7$+;DD4,AQC((R*=7I
M'QK33"OST^+G_)5O$_\ V,-[_P"CWK]"Z_/3XN?\E6\3_P#8PWO_ */>OE^)
M_P"#3]6?K_A%_O\ BO\ #'\V<]1117QY^ZA1110 4444 %%%% !1110 4444
M %?>'[,/_)!/#/\ UX'_ -&/7P?7WA^S#_R03PS_ ->!_P#1CU]'PU_OD_\
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M]?1\-?[Y/_#^J/ROQ:_Y$=#_ *^+_P!)D=Y1117VI_/X4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=KD?AGXL\-P_#CP_#+K$*LFB6BLI/0B%.*W/^$Q\,?\
M0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/
M^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK
M-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?
M]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S
M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
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M:Z-8@&:[N$@A#' W.P49_$U]EK+H<G[?C?L"_9XO^%9?;6\$+HGV==@NA!Y
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*X[]H>PL%^
M'CEELH01X.U/!$8_Y])*[>N._:(_Y-_\=?\ 8G:G_P"DDM8XC^!/T?Y'H93_
M ,C2A_CC_P"E(_F\HHHK^>3_ & "GV]Q<6DZ7-K.\4D;;DDC8JRGU!'2F44
MTFK,**** "BBB@ HHHH **** "BBB@#^F71=.T_^QK3_ $&'_CVC_P"60_NB
MK/\ 9VG_ //C#_WZ%,T7_D#6G_7K'_Z"*LU_14?A1_CE4_B/U(?[.T__ )\8
M?^_0K\^?BTJI\5?$R(H 'B"]  '3]^]?H97YZ?%S_DJWB?\ [&&]_P#1[U\S
MQ/\ P:?JS]<\(O\ ?\5_AC^;.>KK/A-\0-=^&VI7FOV6AV^IZ;-;?9=:TZ\7
M,5Q Y^ZWH<CAL'!ZYS@\G6SX2\<:GX.BOK:RL+&Y@U*!8;RWO[42I)&&# 8/
M3Y@#D8(P,$5\I0G[.JI7M;K_ %^)^TYA06)PDJ3@IIVNF[75U?7HTM4^]CTO
MXV>!?!/B+PQ?_%#X;:O<VRV(T\:[X=NCD6PEA58'C;^, -MYR?O'(Z5A_LN^
M)?$>G_%C2O#]AX@O8+"[FF-W8PW;K#,1 ^"Z [6Z#J.PK%\=?%N_\5V#Z%I.
MB66D:=/]G>[M[%&W7,D401#([LS,J_-M7.!G.">:S?A[XZO_ (<>)H/%NDZ5
M975W;!OL_P!N61D0LI4G".N>&/7-=L\316/C5AHDU>W776R\UT[W/ HY7CGP
MY6P=;WI2BU!2:;5X))2>S:E>SU:C;5M#?AWXOE\ >.=*\9PVPF.FWJ3-"3CS
M%!^9<]B1D9[5Z#X%TKP1X6\/>-/BAI?B:2XLO[(N--TFWFLWBD\^[4HJ.3\K
M.J%B0A88&XD< ^5R7=N^H?;%TR!(_,#?9%:3R\?W<EB^/^!9]ZO>(?&6M^)+
M2UTNZ>*&QL019:?:1B.&'/WB%'+,>[L2QP,DXKGH5U16NMKV]6K7_+[D>EF.
M6SQTUR-QYN53>FL4^;EM9ZZM735E)N[T1UG@"2PT;X/^(=8\76\E[HM]J=M9
MPZ=;2B*9KQ5>19A*0PC")N!RK;M^,#&1'\8VAU+PSX1\0Z"AM]"FTR:UTS39
M#NDM)(93YX=_^6A9WW[\+G=C:-M<WX=\;:EX?TN[\/O8VM_IM\Z27.GWR,8S
M(F=D@*,KHP#,,JPR"0<CBF>*?&6J^*Q9VUU#!;6>G0&'3["S0K#;H6+,%!))
M)8DEF)8GJ>E6Z\'AN3RMYWYK[]O+OTZF4,NQ"S7V_3G<KWTY73Y4E'I.Z5Y6
MORW7-9\JM_"?2==USXF:%IGAF_2TU"35(3:74BY6%U8,'([XQG'?&*[RSUOP
M=XO?QU:_#71+C2]1O=*N+J2\NK@21W%K&PEN(HX\ V^_;N&6DP%V9&<UY]JO
MC_7=1\56OC*SAM--OK-8/LS:7:K"J-$ %?:.-W )/?Z<5:O/BCJDEOJ*:5H&
MEZ9/J\1BU2\T^"19+B-B&=/F=EC5B 2(U0'ITXIT:U*E%QOU?3=6MIV??Y=K
M&>.P&,QE:-7EL^6-M=(R4^9\VW/'165M[Z+FNN9HHHKA/H@K[K_9DLK*3X#>
M&GDM(F8V)R6C!)_>/7PI7WA^S#_R03PS_P!>!_\ 1CU]'PU_OD_\/ZH_*_%K
M_D1T/^OB_P#29';I8V4;!X[.)6'0K& 14M%%?:G\_A1110 4444 %%%% !11
M10 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF
M?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7'?M$?\F_\ CK_L3M3_ /226NQKE?CMIUYJ_P $/&6DZ=#YEQ=>%-1A
M@CW ;G:VD51DX R2.O%95]:$O1_D=^5M1S.@WMSQ_P#2D?S:T5ZE_P ,6_M,
M?]$U_P#*S9?_ !ZC_ABW]IC_ *)K_P"5FR_^/5_/WU;$_P C^YG^M7^L.0?]
M!=+_ ,&0_P SRVBO4O\ ABW]IC_HFO\ Y6;+_P"/4?\ #%O[3'_1-?\ RLV7
M_P >H^K8G^1_<P_UAR#_ *"Z7_@R'^9Y;17J7_#%O[3'_1-?_*S9?_'J/^&+
M?VF/^B:_^5FR_P#CU'U;$_R/[F'^L.0?]!=+_P &0_S/+:*]2_X8M_:8_P"B
M:_\ E9LO_CU'_#%O[3'_ $37_P K-E_\>H^K8G^1_<P_UAR#_H+I?^#(?YGE
MM%>I?\,6_M,?]$U_\K-E_P#'J/\ ABW]IC_HFO\ Y6;+_P"/4?5L3_(_N8?Z
MPY!_T%TO_!D/\SRVBO4O^&+?VF/^B:_^5FR_^/4?\,6_M,?]$U_\K-E_\>H^
MK8G^1_<P_P!8<@_Z"Z7_ (,A_F>6T5ZE_P ,6_M,?]$U_P#*S9?_ !ZC_ABW
M]IC_ *)K_P"5FR_^/4?5L3_(_N8?ZPY!_P!!=+_P9#_,_H9T7_D#6G_7K'_Z
M"*LU7TA&CTFUC<89;= 1[[15BOZ%C\*/\B:G\1^H5^>GQ<_Y*MXG_P"QAO?_
M $>]?H77YZ?%S_DJWB?_ +&&]_\ 1[U\QQ/_  :?JS]<\(O]_P 5_AC^;.>H
MHHKX\_=0HHHH **** "BBB@ HHHH **** "OO#]F'_D@GAG_ *\#_P"C'KX/
MK[P_9A_Y()X9_P"O _\ HQZ^CX:_WR?^']4?E?BU_P B.A_U\7_I,CO****^
MU/Y_"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>
M_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *R/B!_R(>M_P#8(N?_ $4U:]9'Q _Y$/6_
M^P1<_P#HIJBI_#?H=.#_ -[I_P")?F?G51117Y4?V6%%%% !1110 4444 %%
M%% !1110 4444 ?I19?\><7_ %R7^525'9?\><7_ %R7^525^KK8_BV7Q,*_
M/3XN?\E6\3_]C#>_^CWK]"Z_/3XN?\E6\3_]C#>_^CWKYCB?^#3]6?KOA%_O
M^*_PQ_-G/4445\>?NH4444 %%%% !1110 4444 %%%% !7WA^S#_ ,D$\,_]
M>!_]&/7P?7WA^S#_ ,D$\,_]>!_]&/7T?#7^^3_P_JC\K\6O^1'0_P"OB_\
M29'>4445]J?S^%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>
MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
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MTJ87OA?Q)9LIN;!V&#+:W49W1AURK!&VR(S(X9&92 =97E'[<_\ R:/X]_[
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M_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH ****
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M:S;P,V3''=6\<ZKGO@.!0!T]%>6_M-?%KQ=X2L=(^$/P9>W?XB^.YI;/PO\
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MRTABO)))HSYWVDN'=LNS,/E8  'ME>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
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MJC_AJ3X[?]#U_P"4RU_^-5Y_11]6PW\B^Y!]9Q/\[^]GH'_#4GQV_P"AZ_\
M*9:__&J/^&I/CM_T/7_E,M?_ (U7G]%'U;#?R+[D'UG$_P [^]GH'_#4GQV_
MZ'K_ ,IEK_\ &J_;O_@FQXAUCQ9^PU\.?$6OWGVB\NM%=YYO+5-Q^T2C.%
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M_P#Z]YO_ "4_NE_\D?KG_$K'A]_T%8K_ ,#I?_*#]U_^'R7_  3=_P"CC?\
MRT-8_P#D2C_A\E_P3=_Z.-_\M#6/_D2OPHHH_P!>\W_DI_=+_P"2#_B5CP^_
MZ"L5_P"!TO\ Y0?NO_P^2_X)N_\ 1QO_ ):&L?\ R)1_P^2_X)N_]'&_^6AK
M'_R)7X444?Z]YO\ R4_NE_\ )!_Q*QX??]!6*_\  Z7_ ,H/W7_X?)?\$W?^
MCC?_ "T-8_\ D2C_ (?)?\$W?^CC?_+0UC_Y$K\***/]>\W_ )*?W2_^2#_B
M5CP^_P"@K%?^!TO_ )0?NO\ \/DO^";O_1QO_EH:Q_\ (E'_  ^2_P"";O\
MT<;_ .6AK'_R)7X444?Z]YO_ "4_NE_\D'_$K'A]_P!!6*_\#I?_ "@_=?\
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M_P!_Y"7_  I?\0>XF_Y_4?\ P*?_ ,K/U+_B8[@?_H'Q/_@%+_Y<=A17'_\
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MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2N5_:*_:V_9\_9.TS3-
M9_: ^(']@6VLSR0Z;)_95W=><Z*&88MHI"N PY; YXK.K6I4*;J59*,5NV[+
M[V=> R_'YIBXX7!4I5:LOAA"+E)V5W:,4V[)-Z+97/1Z*^8O^'R7_!-W_HXW
M_P M#6/_ )$H_P"'R7_!-W_HXW_RT-8_^1*X?[8RC_H(I_\ @<?\SZ?_ (AU
MX@_]"?%?^$]7_P"0/IC[%9_;/[1^R1?:/*\OS_+&_9G.W=UQGG'3-2U\Q?\
M#Y+_ ()N_P#1QO\ Y:&L?_(E'_#Y+_@F[_T<;_Y:&L?_ ")1_;&4?]!%/_P.
M/^8?\0Z\0?\ H3XK_P )ZO\ \@?3M%?,7_#Y+_@F[_T<;_Y:&L?_ ")1_P /
MDO\ @F[_ -'&_P#EH:Q_\B4?VQE'_013_P# X_YA_P 0Z\0?^A/BO_">K_\
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M5^QX?7HVO?!_X:>$]#BD\4?&U;?6WT>WOGT"'PY/(Z-- DR1>;N$>[:ZY)(
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M_P#(EH_]?/\ VV1^C^&7_(XK?]>W_P"E1/?J***_"3]M"BBB@ HHHH ****
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MKV53V?/ROE[VT^\Q^NX-XKZK[2/M+7Y;KFMWY;WMJM;&%1114'2%?<7_  0
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M"X>22<=K_B[OY-ZM;&L<37BVU+>WX*R^:6B>X4445N8!1110!^L]A_QXP?\
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M\K-[_P#'J/\ ABW]F?\ Z)K_ .5F]_\ CU?D7]DXGNOQ_P C^_\ _B)^0?\
M/JK_ . P_P#DSX)HK[V_X8M_9G_Z)K_Y6;W_ ./4?\,6_LS_ /1-?_*S>_\
MQZC^R<3W7X_Y!_Q$_(/^?57_ ,!A_P#)GP317WM_PQ;^S/\ ]$U_\K-[_P#'
MJ/\ ABW]F?\ Z)K_ .5F]_\ CU']DXGNOQ_R#_B)^0?\^JO_ (##_P"3/@FB
MOO;_ (8M_9G_ .B:_P#E9O?_ (]1_P ,6_LS_P#1-?\ RLWO_P >H_LG$]U^
M/^0?\1/R#_GU5_\  8?_ "9\$T5][?\ #%O[,_\ T37_ ,K-[_\ 'J/^&+?V
M9_\ HFO_ )6;W_X]1_9.)[K\?\@_XB?D'_/JK_X##_Y,^":*^]O^&+?V9_\
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MY.MK:ZK$\CG"(IY)J_426-E&P>.SB5AT*Q@$5+7X2?MH4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4KQ7_@H1_R+/AO_K_G_P#0%KVKX7?\DS\._P#8"M/_ $2E
M>*_\%"/^19\-_P#7_/\ ^@+7EYU_R+*GR_-'V' /_)787UE_Z1(^6J***_.S
M^I HHHH **** "BBB@ HHHH **** "O;/V"_^2SWG_8O3_\ HZ"O$Z]L_8+_
M .2SWG_8O3_^CH*[\J_Y&-+U/F>,O^26Q?\ @9]@4445^DG\HGF'[8__ ";S
MKG_76T_]*8J^(J^W?VQ_^3>=<_ZZVG_I3%7Q%7P_$G^_Q_PK\V?T-X3_ /).
M5/\ K[+_ -)@%%%%?/GZ<%%%% !1110 4444 %%%% !1110!VG[.O_)<O"__
M &%XOYU]\5\#_LZ_\ER\+_\ 87B_G7WQ7VG#/^Z3_P 7Z(_ _%O_ )'&'_Z]
M_P#MS"N/_:'_ .2 >.?^Q.U/_P!))*["N/\ VA_^2 >.?^Q.U/\ ]))*^LPO
M^]4_\2_,_(,5_NT_1_D?SAT445_7A_*04444 %%%% !1110 4444 %%%% !1
M110!_3'HO_(&M/\ KUC_ /015FJVB_\ (&M/^O6/_P!!%6:_CV7Q,_K*/PH*
M_G7_ &O?^3LOBA_V436__2^:OZ**_G7_ &O?^3LOBA_V436__2^:OU7PI_W[
M$_X8_F?F'B?_ +GA_P#%+\D>=T445^VGXX%%%% !1110 4444 %%%% !1110
M 5^]W_!+;_DP#X8_]@)__2F:OP1K][O^"6W_ "8!\,?^P$__ *4S5^8^*?\
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M %"__(__ -C1_P 0UXV_Z!?_ ">G_P#)A_Q&WPP_Z#__ "E7_P#E9T%%<_\
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MBM[6$(\K?+.-G=NUIQB]GTT"N/\ VA_^2 >.?^Q.U/\ ]))*["N/_:'_ .2
M>.?^Q.U/_P!))*]3"_[U3_Q+\SX/%?[M/T?Y'\X=%%%?UX?RD%%%% !1110
M4444 %%%% !1110 4444 ?TQZ+_R!K3_ *]8_P#T$59JMHO_ "!K3_KUC_\
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M_P#T-: .Z^%W_),_#O\ V K3_P!$I7BO_!0C_D6?#?\ U_S_ /H"U[5\+O\
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MY_V+T_\ Z.@KORK_ )&-+U/F>,O^26Q?^!GV!1117Z2?RB>/_MY?\FN^(?\
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MM\(4%R(@O 7SM_3C.<<8KD=#T74O$>KV^A:1;^;<W4HCB3< ,GN2>% '))X
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M1YW1117[:?C@4444 %%%% !1110 4444 %%%% !7[W?\$MO^3 /AC_V G_\
M2F:OP1K][O\ @EM_R8!\,?\ L!/_ .E,U?F/BG_R):/_ %\_]MD?H_AE_P C
MBM_U[?\ Z5$]^HHHK\)/VT**** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V
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M36__ $OFK^BBOYU_VO?^3LOBA_V436__ $OFK]5\*?\ ?L3_ (8_F?F'B?\
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M*T_]$I7S]_P4RU.^TWPIX5:RGV%]0N0WR@Y_=IZBOH'X7?\ ),_#O_8"M/\
MT2E?._\ P5!_Y%+PE_V$;G_T6E>UP[AL-C,YI4:\%.#;NI)-/1O5/1GF9SC<
M;EV65,3A*LJ=2-K2C)QDKM+1IIK1M:/8^2/^$IU[_G^_\A+_ (4?\)3KW_/]
M_P"0E_PK/HK]9_U7X9_Z :/_ (*A_P#(GYY_KWQQ_P!#3$_^#ZO_ ,D:'_"4
MZ]_S_?\ D)?\*/\ A*=>_P"?[_R$O^%4K>WN+NX2TM('EEE<)%%&I9G8G
MY))[5VNK?LZ?%S1_#Q\0W/A61TA2YDOX()4DDL8X$5W>=58^4,$\-@@C! )
M.-7A_A*C)*IA*";VO3IJ_P"!M3XTX^K)N&98EI;VK5?_ )(Y?_A*=>_Y_O\
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M***_(3]&/EO_ (+.?\HZ_'/_ %]:3_Z<[:OPWK]R/^"SG_*.OQS_ -?6D_\
MISMJ_#>OWSPN_P"2>J?]?9?^DP/PWQ*_Y'U/_KW'_P!*F%%%%?I!^>A1110
M4444 %%%% !1110 4444 >U?\$Y/^3ZOA9_V.-K_ .A5_0%7\_O_  3D_P"3
MZOA9_P!CC:_^A5_0%7X9XJ?\C:A_@_\ ;F?M/AE_R*Z_^/\ ]M05Q_[0_P#R
M0#QS_P!B=J?_ *225V%<?^T/_P D \<_]B=J?_I))7YMA?\ >J?^)?F?HF*_
MW:?H_P C^<.BBBOZ\/Y2"BBB@ HHHH **** "BBB@ HHHH **** /Z8]%_Y
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M & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I7SO\
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M)ZI_U]E_Z3 _#?$K_D?4_P#KW'_TJ84445^D'YZ%%%% !1110 4444 %%%%
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M%%%%?I!^>A1110 4444 %%%% !1110 4444 >U?\$Y/^3ZOA9_V.-K_Z%7]
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MBF4,K*2C'#*0<$$5@5[HMO'KW_!-F74-4^>;PW\:(K?1Y9.3'%?:5*]Q$I[
MO90.1TSD]37A==&#Q$Z\9J?Q1DXNVSMJGUZ-==SGQ="%"47#:45)7WUT:Z=4
M_D%%%%=AR'],>B_\@:T_Z]8__015FJVB_P#(&M/^O6/_ -!%6:_CV7Q,_K*/
MPH*_G7_:]_Y.R^*'_91-;_\ 2^:OZ**_G7_:]_Y.R^*'_91-;_\ 2^:OU7PI
M_P!^Q/\ AC^9^8>)_P#N>'_Q2_)'G=%%%?MI^.!1110 4444 %%%% !1110
M4444 %?O=_P2V_Y, ^&/_8"?_P!*9J_!&OWN_P""6W_)@'PQ_P"P$_\ Z4S5
M^8^*?_(EH_\ 7S_VV1^C^&7_ ".*W_7M_P#I43WZBBBOPD_;0HHHH **** "
MBBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX
M7?\ ),_#O_8"M/\ T2E? ?\ P<1?\DS^&?\ V'=0_P#1,5??GPN_Y)GX=_[
M5I_Z)2O@/_@XB_Y)G\,_^P[J'_HF*OK.!O\ DJ\-ZR_])D?+<:_\DQB?2/\
MZ5$_*RBBBOZ8/YT"BBB@ HHHH **** "BBB@ HHHH *^W_\ @@/_ ,GJZS_V
M3N^_]++&OB"OM_\ X(#_ /)ZNL_]D[OO_2RQKYSB_P#Y)G%?X&?0<*_\E'A?
M\:/V-HHHK^7C^E#Y;_X+.?\ *.OQS_U]:3_Z<[:OPWK]R/\ @LY_RCK\<_\
M7UI/_ISMJ_#>OWSPN_Y)ZI_U]E_Z3 _#?$K_ )'U/_KW'_TJ84445^D'YZ%%
M%% !1110 4444 %%%% !1110![5_P3D_Y/J^%G_8XVO_ *%7] 5?S^_\$Y/^
M3ZOA9_V.-K_Z%7] 5?AGBI_R-J'^#_VYG[3X9?\ (KK_ ./_ -M05Q_[0_\
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MK;;ZMO5M_P!66RT(K5IUY\TNR2[)+1+^O5ZA1116QD?TQZ+_ ,@:T_Z]8_\
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MQ]V.,C(>2//$?&[PSH_@KXS^+O!OAZW:*PTGQ1J%E8Q-(7*0Q7,B(I8\DA5
MR>37U%\ ]1_86\4_%CX,Z-I/Q8^(=C?Z!KFC+IV@)X0M39R:J]S \\LD_P!J
MW-YMP #)LW+$D2 8B45X_P#M0_#K2O'?[9WBCP#^SM#X@\47NJ>*;Y193Z4L
M=R]^;B9IXHHXW??&I!PY()4$D"O/PF83JYM-5.:,>2]I)J*2EO=I*]M6_E=I
M'=BL!"GE</9\LI<]KQ:<FW';36U]$OG9-F#^S;\)_#7C^X\5^.OB"ER_AGP'
MX6EUO5[:TF\I[Z3S8K>VLQ)@^7YMQ-$&8 D()"/FQ5WXE_#KP5XD_9]T?]I7
MX=>&ET&-O%$_ASQ-H$%U--;6]V(%N;:>W:9WE$<L7FJ4D=RKV[$-M<*O0?LH
MQ76K?#SXV_L_-9R1:_XC\#)+I5BZ$33W.F:C;WLMJJ?>,AAAG(3J?*(QG J+
M4;@>"?\ @G99^&=;4PW_ (W^*HU?2;:48>33["PEMGN .R-/=&-6[F"0#.TX
MNKB*WU]VD[J<(I7T<'&[=MGKSN_]SR(IT*/U%7BK.$I-VU4U*R5^FG*K?WO,
M\,HHHKZ \(]J_P""<G_)]7PL_P"QQM?_ $*OZ J_G]_X)R?\GU?"S_L<;7_T
M*OZ J_#/%3_D;4/\'_MS/VGPR_Y%=?\ Q_\ MJ"N/_:'_P"2 >.?^Q.U/_TD
MDKL*X_\ :'_Y(!XY_P"Q.U/_ -))*_-L+_O5/_$OS/T3%?[M/T?Y'\X=%%%?
MUX?RD%%%% !1110 4444 %%%% !1110 4444 ?TQZ+_R!K3_ *]8_P#T$59J
MMHO_ "!K3_KUC_\ 015FOX]E\3/ZRC\*"OYU_P!KW_D[+XH?]E$UO_TOFK^B
MBOYU_P!KW_D[+XH?]E$UO_TOFK]5\*?]^Q/^&/YGYAXG_P"YX?\ Q2_)'G=%
M%%?MI^.!1110 4444 %%%% !1110 4444 %?O=_P2V_Y, ^&/_8"?_TIFK\$
M:_>[_@EM_P F ?#'_L!/_P"E,U?F/BG_ ,B6C_U\_P#;9'Z/X9?\CBM_U[?_
M *5$]^HHHK\)/VT**** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7K
MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I7P'_P '$7_),_AG
M_P!AW4/_ $3%7WY\+O\ DF?AW_L!6G_HE*^ _P#@XB_Y)G\,_P#L.ZA_Z)BK
MZS@;_DJ\-ZR_])D?+<:_\DQB?2/_ *5$_*RBBBOZ8/YT/H?2OV,/A_X>\+:A
M9?&?XZ6WAOQ8?#&F:S#I\FCW$MGI,-[<6X@-[.@+;FBG4E(HW\L2 ELJ4KQ?
MXK> Y_A7\4?$OPPN=6@OY/#FOWFER7UL"([AK>=XC(F?X6*9'L:^R?A)\>/A
M#^T9\*-;_9^_;M\+/X9U?PSX8T[28?BIHB+]M2Q%[:K:PWL9!6:-)&A8RC)*
M;L;2S.WRY^TK\)?'7[,'[2?B/X8^(/%SWNN>'-961=>M)G62=F"7$5R&R621
ME='/S$JQ/)(S7S648W&5,;4H8J3YU=I67*U[OO0DEMKJG>2YE?N_HLUP>$IX
M2G6PT5R.R;UYD_>]V<6]]-&M'9V[*K\0_@!XR^&/P?\ !/Q;\6PRVD?CN747
MTBPGMBC_ &6U-NJW&2>5D:9PHP/EC# D.,=+\*_V?O@/XA^'%EXY^-G[6-AX
M$N]4N[A=+T4^$KS5)IK6(JGVEC;'$2M+YJ*&&286(SVZ_P#:R\>^.?B5^QU\
M _%OQ&\9ZMK^JSR^*TFU/6]1ENKB15OK=5#22LS$!0  3P!BO%_@M\-[CXO?
M%?0/AM#>"U35M2CAN[UONVEMG=/<-_LQQ*\A]D-=5&MBL3ESJ5:OLW&52[BD
M](3FK+FBULEKRW=O,YJU+#8?,%3I4^=2C3LI-K64(N[Y6GNWI>ROY'1?M,?
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M *"*LU6T7_D#6G_7K'_Z"*LU_'LOB9_64?A05_.O^U[_ ,G9?%#_ +*)K?\
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MG\,_^P[J'_HF*OOSX7?\DS\._P#8"M/_ $2E? ?_  <1?\DS^&?_ &'=0_\
M1,5?6<#?\E7AO67_ *3(^6XU_P"28Q/I'_TJ)^5E%%%?TP?SH>]:7^W;JTMC
MJUQXZ^!?@+7]7N]&L=/L-3O-$D3;':2V[0K<)%,B701(% ,JNQ*H&+*"I\>^
M(?Q!\8_%;QOJGQ'^(.NS:GK6LWCW6I7T^ TLK'DX  4#@!0 %     %8U%<>
M'P&#PDW.E"S?Y::+LM%HM-#KQ&.Q>*@HU9W2_/75]WJ]7W/0O'_[0VJ_$'X.
M^%?@K??#SPY8Z=X-:[;1;W3UO!=*;J599][27+H^]D4\I\N,+M%<Y\/_ (C:
M[\-KG5+_ ,.06WVG5=!N])>YGC9GMX+F/RIFB(8;7:(R19.1LE<8R01@45I#
M"T(4G34?=;;:\V[O[WJS.6)KSJJHY>\DDGY)67W+1!7H/A/]H;5?"/P,\0?
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M?;__  0'_P"3U=9_[)W??^EEC7Q!7V__ ,$!_P#D]76?^R=WW_I98U\]Q?\
M\DSBO\#/>X5_Y*/"_P"-'[&T445_+Q_2A\M_\%G/^4=?CG_KZTG_ -.=M7X;
MU^Y'_!9S_E'7XY_Z^M)_].=M7X;U^^>%W_)/5/\ K[+_ -)@?AOB5_R/J?\
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MYGYAXG_[GA_\4OR1YW1117[:?C@4444 %%%% !1110 4444 %%%% !7[W?\
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M-Z_?/"[_ ))ZI_U]E_Z3 _#?$K_D?4_^O<?_ $J84445^D'YZ%%%% !1110
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M (U1_P .0OV3?^BC?%/_ ,+8_P#QJOL:B@#XY_X<A?LF_P#11OBG_P"%L?\
MXU1_PY"_9-_Z*-\4_P#PMC_\:K[&HH ^.?\ AR%^R;_T4;XI_P#A;'_XU1_P
MY"_9-_Z*-\4__"V/_P :K[&HH ^.?^'(7[)O_11OBG_X6Q_^-5YC\=O^"37[
M.7P]^)'PT\+:'X]^(SVWBKQ.]AJ377B]G=(A"7!C(C&ULCJ0:_12O/OC'\&=
M3^)OCWP!XOL=:@M8_!WB%]1N89HV+7"F(IL4CH<G/- 'SU_PY"_9-_Z*-\4_
M_"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU7V-10!\<_\.0OV3?\ HHWQ3_\
M"V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5?8U% 'QS_P .0OV3?^BC?%/_ ,+8
M_P#QJC_AR%^R;_T4;XI_^%L?_C5?8U% 'QS_ ,.0OV3?^BC?%/\ \+8__&J/
M^'(7[)O_ $4;XI_^%L?_ (U7V-10!\<_\.0OV3?^BC?%/_PMC_\ &J/^'(7[
M)O\ T4;XI_\ A;'_ .-5]C44 ?'/_#D+]DW_ **-\4__  MC_P#&J/\ AR%^
MR;_T4;XI_P#A;'_XU7V-10!\<_\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]
M%&^*?_A;'_XU7V-10!\<_P##D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?
M_A;'_P"-5]C44 ?G_P#M-?\ !(3]FGX4? 3Q3\1?#7C_ .),E_I&EM/:I>^,
M6>)F# ?,HC!(Y]173^"?^"+'[*VO>#-(UR]^(GQ06:]TRWGE6+QH0H9XU8X'
ME<#)KZH_:"^&=]\9?@OXB^%^F:G%97&MZ<UM%=3H62,D@Y(')'%=#X2T:7PY
MX4TSP]/,LCV&GPV[R(,!RD:J2/8XH ^2?^'(7[)O_11OBG_X6Q_^-4?\.0OV
M3?\ HHWQ3_\ "V/_ ,:K[&HH ^.?^'(7[)O_ $4;XI_^%L?_ (U1_P .0OV3
M?^BC?%/_ ,+8_P#QJOL:B@#XY_X<A?LF_P#11OBG_P"%L?\ XU1_PY"_9-_Z
M*-\4_P#PMC_\:K[&HH ^.?\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4_
M_"V/_P :K[&HH ^.?^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_
M ,:K[&HH ^.?^'(7[)O_ $4;XI_^%L?_ (U1_P .0OV3?^BC?%/_ ,+8_P#Q
MJOL:B@#XY_X<A?LF_P#11OBG_P"%L?\ XU1_PY"_9-_Z*-\4_P#PMC_\:K[&
MHH ^.?\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :K[&HH _.
MO]D__@DU^SE\8_AO?^*?%7CWXC17-OXGU&PC6P\7M&ABAF*(2#&?FP.3GFO3
MO^'(7[)O_11OBG_X6Q_^-5]"_LU_!G4_@9X"O?"&JZU!?R77B&^U%9K>-E55
MGE+A,'N <&O0: /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"
MV/\ \:K[&HH ^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8_
M_&J^QJ* /CG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J^Q
MJ* /EOX2_P#!([]FOX-?$O1/BIX7\=?$6XU'0=02\LX-2\7&6W>1#D"1/+&]
M?49YKZDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3^-GQV^#7[-
M_P /+SXL?'GXF:-X2\.6+(ESJ^NWR00B1SA(U+'+R.?E6-<LQ.%!/%<+\&_^
M"@_['_QX^(D'PA^'OQAC3Q7>6+WNG>&?$>B7VBZAJ%LG+S6MOJ,$$EU&HY9X
ME=5')(%?+'Q^AC_:#_X../A#^S_\53]H\(?"C]G:_P#B;X2T6[YMKOQ--K!T
ML7+1GY9)(+?]Y$3EHF#,NTG)V/\ @Y$\*Z9I_P#P2_\ $W[3FBZF-%\=_!77
MM&\7?#CQ5#A;C2M4CU*VAPC]=LL<SQ,F=K%DR#M% 'O7[2__  5$_P""?_['
M?Q%LOA-^TM^U)X;\)^(;Z*&4:=?M*YM8I6*Q273Q(Z6<;D':\[1JV"02 :]U
MTW4M.UG3K?5](OX;NTNX4FM;JVE$D<T; ,KHRDAE((((X(.:^9/VGD^"W@__
M ()\?$/QAXQ^$%OJ5]\6O#3MJ7A(VHN+SQ5X@U2T2VM-- ?+33,[6]K$#Q%'
M$G*I%E>^_P"">O[/GB_]E#]ACX2_LV>/_$ U37/!'@#2](U>\24NAN8;=%D2
M-CR8T8%$/]Q%X'2@#KOB]^T7\$/@)JGA'1?C%\2=.\/W7CWQ5;^&_!\%^[!M
M4U6<,8;6/ /SML.,X&<#.6 /-_M8?MT_LE?L-^'=.\4?M5_&_2O!]MJ\LL>E
M17<<T]S>&)0TK16]NDDTB1JREW5"J!EW$;AG0_:$_99^%W[3&M?#G6_B5:2R
MR_##XB6GC/PZ(2H_XF-M;7,$6\D'Y!]I9\#&61.>*V_$_ASX1^ O$>M_M*>-
M?[.TZZLO"8L]8\2:I,J1V.DVKSW3Y=_EACS([R$8#".,MGRTP 3?!;XV?"3]
MHSX8Z1\:/@5\1-*\5^%=>MS/I.NZ+=K-;W*!BK88=&5E964X965E8 @BO)=.
M_P""JW_!._5?VE5_9!L/VL_"DGQ#DU232X-!\^0)-?H=KV4=R4%O)<JWR&!9
M#('^0KNXK@?^",G[.FI_!+]FGQYXGD\+77A71OBY\9_$WC[P;X0FMC;2^'=#
MU&9!86Q@('V5F@A2Y,&!Y37)0@,I Y;_ (*N?LN?#;XJ?LQ?"S_@F_\  _P;
M9V/B76/'WA^?P";&$>;X1TW2+^VN]2UP-]Z-8K19+<RD@R3ZA#'DO,,@'W31
M110 4444 %%%% !1110 5#J.HZ?I&GSZMJU]#:VMK"TUS<W$H2.&-069V9L!
M5 !))X %35\ _P#!Q+XAU^__ &8?A#^S=!KUWI7AKXY?M+>#_A]\0-0L[AH6
M30;V:>2ZC\Q2"BO]G1&Y *%U/#$$ ]RTW_@K7_P3LU6_M(;7]I[24T[4-2&G
MZ?XKN=-O8?#]W=%RBQ0ZQ) MA*Q<%1LG.X\#)KO_ -J+]LK]F']BSP1:_$3]
MI_XQ:7X2TJ_N_LNG/>+)-/>S;2YC@MX$>:=@@+,(T;:H).!S6O\ $3]G/X+?
M%']G[5/V6O%OP]TR3P'JWAEM G\-PVB1VT5@8?*6*) ,1A%"["H&PHI7!45\
M6?\ !O#XCC^*/_!-+X?_ !W^->L1ZWX@\ 6>O^"M(\<ZQ.&/]@V.J3(DB2.<
M1(T4%O'(X(WK91;R?+% 'VI^SY^T;\"_VKOA5IWQN_9R^*6D>,/"FJ[A9:UH
MMSYD3,IVO&PX:.13PT;A64\$"M;XJ_%/X>_ _P"&NN_&'XL>*K70_#/AG2IM
M2UW6+PGRK.UA0O)(VT$D!0> "3T ).*^5_\ @C[\$8_!.F?'#]HSPUH#:#X.
M^.'QKU'Q?X!\/K;&",:08(+:+4A"0/*-\T$EX%P#Y4T!(!)4?3/[0'P7\)?M
M'? GQG^S[X]$G]B>./"NH:#JS08\Q;>[MW@D9,@@.%D)4]B : *7B?\ :=_9
M]\%?L^I^U7XN^+NB:;\.I-"MM9B\7WMX([.2QN$1[>96/WO-$D810"SF154%
MF KGOV3OV\?V0_VYM&U?6_V4_CKI'C!/#]VMMKMK:++!=Z=(V[8)[:X2.:(-
MM?:S( VQMI.TXZ33/V=?A-IO@;P%\.F\,1W&D_#5K)_"=I<_,EM):6;VEL[+
MC:[1QR$KD?*ZHXPR*1\T_ ;X0Z7\2O\ @L[\5OVV_AEIT=GX5T#X267PSUW4
M[6,)#XF\2QZDU[=2@KQ.;"!+:S:8Y(DDE@SFW=5 /J_XI_%#P%\$_AQKGQ<^
M*7B6'1_#GAS3)M0UK4[A&9;:WB4L[[4!9C@<*H+,<  D@5OU^?7_  <B_ _7
M?B%_P3;\;_$=/VA/'FA:9X5CTJYF\#Z!<:?#I.N3?VM:HK7Y>S>[E5?,R(DN
M8XBT<;%"5R?T%H **** "BBB@ HHHH *@U/4+?2=-N-5NHYWBM8'ED2UM9)Y
M65020D<:L\C8'"J"S'@ D@5/10!XQ^S7_P %!OV2/VO/B!XL^%G[//Q/N=?\
M0>!)U@\9Z8_A;4[)]$G9Y$6&Y-U;1"&4M#,!&Q#GRGP/E;$?QB_X*&_LF_ ;
MXR?\,^?$OQWK5OXS.BIK":!I?@+6M2FDL&<QBZ0V=G*KQ>8K(74D!U*G# BO
MC'_@K#IGB+_@DU^U;I7_  7,^"/ARXOO!VHQ6?A3]J+P9ICHC:OILLJ0:?K,
M2N50W<$S0PY)!8-$F45IGK[&_8L_9\\6^!+/7?VC?CZ+:Y^+OQ1-M>^-9K6Y
M,UOH]K$'^PZ%9L>/LME'*Z;P!Y\TEQ<, 9L* <1#_P %L/\ @FK<^#=8^(UO
M\>]5D\/>'KN:UU_7D^&OB(V6FSPD":*XG&G[(70L RN05R,@9JSHG_!9W_@F
MMKW@NQ^)MO\ M'M:^$]18+9^,=6\&ZS8Z*_[SR\_VA<V:6RKO!4L9  003P:
M^:O^"(FFZ?K'_!/_ /:NTC5["&ZM+K]HOXF0W5M<1!XYHV2-61E.0RD$@@\$
M&O1O^#=;PYX?\8?\$)O@EX3\6:'9ZGI>I^&-7M=1TW4+99H+J"35K]7BDC<%
M71E)!4@@@D&@#[ET+7M#\4Z)9^)?#.LVFHZ;J%K'<V&H6%PLT%S"ZADDCD0E
M71E((8$@@@BN5L/VB_@AJGQ_U#]EC3OB3ITWQ"TKPS%XAU#PHCM]J@TR2;R4
MN6&-NTR87&<C<I( 92?B[_@W:O;[PO\  SX^_LS:?J5Q=>$_@M^U9XT\%?#_
M ,Z=I!:Z+;S030VRLQ)(1YY3UQAP!P*^O=+_ &6?A?I/[7&L_MHVUI+_ ,)C
MK7P^L/!]S)E1$MA:WMU> @8R7:2Y 8D_=AC':@#A_C?_ ,%5/^">/[-WQLM_
MV=OCE^UCX5\-^+YYK>&32]0GDV6<DZ[H4NKA4,%FSJ0ZK.\9*D,!M(->U^-O
M'?@KX:^"]3^(_P 0O%FG:)H&BV$E]J^M:I>)!:V=M&I=YI)'(5$5026)P *^
M7O\ @J#\*/A%H/\ P3H^*O[/'AOX766MZ[\91JFC^$_#1B62?7/%VL-*\$^6
MR=T,[?:VE/%M!9-)E$@&WV;X:?LQ^'='_99^'O[-?Q<G7Q9!X+\/>'[2]N+W
M+1ZI=Z7';F*XE5OOC[1;I-M;JRKG/2@##_91_P""CO[$/[<&MZUX8_99_:)T
M3Q9JWAZ-9=8TB".>VO+>%B LWD7,<<C0DE0)54IEE^;YAGVVOC'Q%\(M+^.W
M_!;;PG\??AEIT5O;_ _X5ZOHGQ)\36D8 U34=6:V?3]#D<8\U[:!)KUUR?*%
MY;9 ,PQ]G4 %%%% !1110 4444 %>(Z__P %%OV0/"O[4>E?L5^(_B9J%G\4
M==WMHGA"?P9JZSZA$BRL\\#_ &7RYH%6&9C.CF(+$Y+84D>W5\=?\%D?V$?'
M_P"U3\%]"^/G[+=ZND?M ? [5CXJ^$.MQ@!KFXC :XTF4G >"[C3RRC$*7$>
MX["X(![U^TQ^U_\ L^?L?:)HGB/]H;QK=:%9>(]:31]$GM_#M_J'VN_D5FCM
M5%G!*1*X5RB$ OL;;G:<>8P?\%?_ -@*Z\=W'PNMOBEXFD\36FG+J%UX=C^$
M_B8W\-HS;%N'MQIWF+$6^4.5VD\9S7F/_!,WXL:A_P %;],\$?\ !4WXG^#F
MT3PUH^G36GPA\$/>B5;'50DEEK6M3[3AY3.+FQM0PS';12285[QECYWX7?\
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MO]HOX(? C6_!_ASXO_$G3M OO'WB:+P]X.M;YV#:KJ<JLT=M'@'YF"G!.!G
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M6$-I9P."QFVO+<23RNL48+G90!^@M%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9*<6WZ),]AHHHKRST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \R_;7_P"3-/BW_P!DQU[_ --T
M]?SP5_0_^VO_ ,F:?%O_ +)CKW_INGK^>"OV_P *O^1?B?\ &OR/QKQ/_P!^
MP_\ A?YA7W3_ ,&_'_)Y?B;_ +)C>_\ IQTZOA:ONG_@WX_Y/+\3?]DQO?\
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MUG^S3X2_:=\ ZO:1Z/XG\+6&LW%LVI0ROI!N;.*[:UN6C8K'-$DRAU."IY(
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MGQ_:^*?!^@:K'8ZE=VK^+TMH+>5D='AM3-=VB2LY\M89SN!1BI]L_8P^*/\
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MA75U87L.I-:_9XIKBR<M;E IQ(&D!!^<@X !]F_!W]FW]G7]G>UN[']G_P"
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M-7OJK>29\QGW"?$G$5:%3+,+.M&*LW%7LWK9GBE?1/\ P3._Y+OJW_8HS_\
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MQO9M2L?V'_A!#<W%H;6XN(OAII2O+ 4"&)F%OED* +M/& !C%0:/_P $Y/\
M@GIX>U*+6?#_ .P?\&;&\MW#P7=G\+])BDC8="K+;@@^X- 'S%_P0$T;Q-X^
M\*_M"?MQ7_AC4-'\._'_ ./^L>*?A[:ZG:/!/=>'U6.&TOFC< IY^V1@".0H
M8$JRD^?>'/@I\%/"'_!UAK%AH&D6T$7B#]F:/X@ZEI"WA%L_B^/59-*34Q;A
MM@NQILMP@?;N"W4[]968_J''''#&L44:JBJ JJ,  = !7G!_8X_9#/Q._P"%
MVG]E;X;_ /"9_;/M?_"7?\(-I_\ :GVCKYWVKR?-W_[6[/O0!U7Q2D^)\7PW
MUV7X*6F@W'B]=*G/AF#Q3<3PZ;)?;#Y*W3P(\J0E]N\QJS!<X!/%>:_LB7O_
M  41O&\0?\-Z^&?@OIRJ+3_A%?\ A4.NZO>F0_OOM/VO^T;6#9C_ $?R_+W9
MS)NQA<^T44 ?G=_P4.U*V_9G_P""T7[+'[:_Q7F32_AE>^%_$7P_UOQ?=-LL
MM"U2\3SK 7<I^6%+A\Q*[$*&5MQ4#->S_P#!0CQW\.?C%=?"S]D7PCJNE^)O
M%/B[XM>%->F\.6<L=T8= T?6;35=0O[I!D1VGDVA@#R85Y;F&(;F<"OIOQ1X
M5\+^./#]WX2\:>&[#6-*OX3%?Z9JEFEQ;W,9ZI)'("KK[$$5R'PR_94_9>^"
MFB:MX9^#7[-W@'PCINOQ-'KNG^&/!UE80:BA5E*SQP1*LP(9@0X((8CO0!^8
M7[+O[,'[/>F_\$5OVT?$.F_#W1$N9?%GQ=DLKU+./?I*Z9=:@=.CM6QFVCMG
MA2>%(RJQRNTB@,Y)]8UV\T;XD?MG_P#!-'X\^*M-TVY\7>+_  'XFEUC7FMH
M_M5^LO@I9V1Y,;I$\R5W"DD N2!R:^U]*_8K_8WT+P9JGPYT3]DOX9V?A[7)
MUFUK0;7P'IT=EJ$@! >>!80DK#<V"P)^8^M0VW[#?[%%G>:/J-G^Q]\+8KCP
M\N- GC^'VFJ^F#@8MV$.8>@^YCH* /SP\"^(O$O@7]C[_@HUX>_9:N["Q^+\
M/QL\?/X1TS16CCUE8!H^ER;[2),2Y""1XM@_UBKM^;%;WP[_ &%=3^,7[#O[
M/OB7X1_MJ? OP5H7A^\\-ZU\+O'7@[X%7D&M+?$Q;K<73>)7^T3WF9;>[C>-
MC,99?,3</E_2#0_@]\(_#'Q"UCXM^&OA9X<T_P 5^(8(H=?\3V.AV\.H:G'$
M (TN+E$$DRH  H=B%P,8K'\,_LN?LR^"OB1/\8_!O[.G@32?%]RTK7/BK3/"
M-E!J4K2#$A:Y2(2L6!(;+<YYS0!\P_"70?!'C?\ X*]?M*:=^T[HNE:E?Z;X
M#\*+\++/Q3;QRQ1^$9;*;^TY+1)@5\M]3%PERRCGR[99#@(*XC_@W&UW]GYO
MV>/C;X-_9P\2Z7=>%=-_:?\ &A\+6>GWJ2>5HS7$(L7502PA:$)Y;'AE ]Z^
MXOBO^S_\!_CS;65E\<O@GX1\9PZ=*TFGP^+/#=KJ*VKL,,T8N(W"$@ $K@G%
M7_ /PJ^%_P *;2]L/A=\-] \-0:E?R7VHPZ!H\%FEU=2,6DGD$*J'D8DEG;+
M$G)- '@G_!02W_8(^._B3P9_P3]_;U\*>&]3TSXKZ3K6H^%U\2WZVN;[2WT^
M,QVDV5>*\,>I,Z-$ZOLAE R"17SC_P $VO"?QR_8=_X*;^)?^":?@3]J/6_C
M'\"+7X0KXLT8>*K]+_5/AW>'4$M;?2I;Q/O131"5XH7VG9%E$41R-+^@OQ$^
M#OPC^+UC_9?Q9^%GASQ1;?99;;[/XBT.WO8_(E:-I8MLR,-CF*(LO1C$A(.T
M8K_"+X$? _\ 9^\.R>$/@-\&O"G@C299S-+I?A'P[;:;;O(1C>8[=$4M@ 9Q
MF@#Y \$:A\)_ O\ P7N^+'_"6W&@:5>ZG^S_ .#)=&%]Y,,UW<R:UK,+- &P
MTDC221H2N6+.HY)%?-?PP_:)^ 7_  L']A?XR_L]:AX5\#_#'6/BCXQ@T6SU
M3Q";GQ!=:==:5J[7=WJ]U+*/+,]Y&DCV[^:5E6%GG+J(T_5O6/@]\(_$7Q&T
MKXP^(/A9X<OO%NA6LEMHGBF\T.WEU'3X),^9%!<LAEA1MQW*C ')R.:YN']C
MK]D:WL[K3[?]ECX<1V]_XCB\07T">![ )<:O&6,>H.HAP]TI=RLYS("QPPR:
M /FK_@M!;>";?4?V4?$WC&VTM+2']KSPK%>:AJ21B-('LM578[OP$9R@P3@D
MCVKRR_T/XI_&W_@N%XP&D_%?X96-C9_ S0;GX!1>/OA]<>)M.O\ 1YY)QK-S
MI2V^K6,4<XN%MTFD7S7>!X!E(Q\_Z(?$OX4_"[XT>$IO /QB^&V@>+-"N)8Y
M;C1?$VCP7]I*\;!T9H9U9&*L P)&00".:H_$OX!? GXS^';/P?\ &'X*^$O%
MFDZ>P:PTOQ+X;M;^VMB%V@QQSQLJ$+QP!QQ0!\(Q_L-W'PD_8U^)_P #H_\
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M:=% H ^T=/\ VAO@#J^BWWB32OCCX/NM.TL(=2O[?Q-:O#:;VVIYKB0K'N/
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MLK#@@@@@CK0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[L_X-\?^3S?$W_9,+W_TXZ=7AY)G,J^;4:?L8*[W7/?\9M?@?I?B7X78+)N
M\PQL,PQ$W3IM\LOJ_*]5H^7#QE;TDGYG[$4445^LG\$A1110!PWB+]F#]FGQ
M?\3K7XV>+/V>/ VJ>,[%D:R\7:CX2LY]3MV10J%+IXC*A50 ,,,  "K?Q=^
M'P(_:!TBWT#X]?!/PCXWL+.4RVEEXO\ #=KJ4,#G&61+B-U4G Y SP*^//\
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M8_XV?L0/^V=KNG^!?"/PHTWQ)X62U\':"U[:WU^4C"R3/8L)H8F$C*A4,P9
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M="VUAV(Z"@#H-'T;2/#NDVV@^']*MK&QLH%AL[*S@6**")1A41% "J
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M#N:179F#D[@S$@Y->FU3\0>(_#WA/2I->\4Z[9:98PE1->ZA=)#$A9@JY=R
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MDKXN^-XOB9\5_P!ESX=>)_$D/E^3X@\0^";"]OH_+QY>V>:)I!MP-N&XP,4
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M&^@:CX5>T2T?PS?Z/!-I[0)C9$;=U,91=HPNW P,#B@#YB_X(2_#/X8^!O\
M@E-\"_$7@'X?Z#H]]XB^%NAW?B&^T?2H;>74[H6B@S7#QJ#-)DM\SDMR>>M+
M_P %HOV=]6^*G[)4?[0GPO\ !]GJ?Q-^ 'B.Q^)7PZ\ZV5Y);G2IDNKFR!P6
M*W-M'-%L'WI/)."47'TS\+_A!\)O@AX67P-\%_A?X=\(:(DS3)H_A?1(-/M5
MD8 ,XB@14#$*H)QDX'I70NB2(8Y$#*PPRL,@CTH _'/7?VQ/#_P\_:X\/_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20220630_g4.jpg
<TEXT>
begin 644 biib-20220630_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX>?!GP[HOBO6_"/Q.TO6/$.G:7'%=WEE:ZWJT5M;R2*-S1Q1Q1JJGA0B@=*
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MQ2M+J5Q%<?-*8)$6)[>/,A9SC(4FOD+X1_\ !/S_ (*%_LI_"73=7_X(Z_\
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M]-T>T:_U;48+6!2 TUS,J("3@ EB!R>*^?\ ]G_X$?\ !0GP9\0M(\3?'/\
MX*!^'/''A6WAD_M'PM8?!*#1YKO= ZQ8O%U&8Q;)&20_NSN"%>-V1\G?LX?L
M(?LV_MC?\%._VU]3_:I^'EIX]T31/B-X>M]#\(^(@9M+L[F;PQ8>???9L[)+
MED6&-97!:)4;RRGF2;@#]."0!DG '4UXI\8/VT?#7PL_:@^!G[-ECX7&M_\
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MXM\0> ;'PA>VLEU&;%;"TN[BZB=(Q'O$IDN9 S%RI4* H()/IE% !7R5:?\
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M%I27*6Q@01AT8BZDWEG<$A<!<'/CGQ(_X)%?"3Q1\5O&/Q4^$7[3/QK^$/\
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M44I$UO;KN5F<EF8Y ( \LC_X([?LCVG_  3';_@D[I%SXIL/AE)#&D]]::E
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M4&G>!O&F@^)]'DTJ[BCEDO-(N$GM5E+QN&B+H Z@*6&<,O6N9^*__!/GP/\
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MGXYBL-%UN^G %U=&*6UEEM)9P,2O:2P%^IYYKL?C#_P3 _9:^*/P0^'GP/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ[X+\1>.M1&H:WH NKRXLY](O+[:'O 6A$\+RYD6-BI9^" #[?HHHH ****
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M+_RB7W_QBC_ANG]E?_HJ7_E$OO\ XQ1_8V<?] ]3_P  E_D']K95_P!!$/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#^)_\ R33Q%_V
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/XG_
M /)-/$7_ & KO_T2];E8?Q/_ .2:>(O^P%=_^B7K;#_QX>J_,RK_ ,"7H_R/
MROHHHK^BC\$"BBB@ HHHH **** "BBB@ HHHH **** /UGL/^/&#_KBO\A4M
M16'_ !XP?]<5_D*EK^<'N?OZV"OR[^-__):?%_\ V-&H?^E,E?J)7Y=_&_\
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MDK]1*_+OXW_\EI\7_P#8T:A_Z4R5]_P!_O=?_"OS/A^./]VH^K_(Y>BBBOU
M_. HHHH **** "BBB@ HHHH **** "OTB_8^_P"3:?"/_8.;_P!&O7YNU^D7
M['W_ ";3X1_[!S?^C7KX;CW_ )%E+_'_ .VL^SX)_P"1C4_P?JCTJBBBOR@_
M30HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
MV 7_ /0UH Z3X:^(M5B^'.@1)X4NW"Z):@.K+AAY*\UM_P#"2ZO_ -"A>_\
M?2U%\+O^29^'?^P%:?\ HE*W: ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:
MV** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?^^EH
M_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH
M Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110
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MS6FL;)[/HFO-69AC:=)1A4II).^W-:Z\I:K==6G]Z"BBBO0. _6>P_X\8/\
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M *P_B?\ \DT\1?\ 8"N__1+UN5A_$_\ Y)IXB_[ 5W_Z)>ML/_'AZK\S*O\
MP)>C_(_*^BBBOZ*/P0Z3X<?%;QE\+[Z>?PQJ2+;WJJFHV%S;1SV]TBG(#Q2
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MK]D[X4>&M:US5Y)ENO$7C;76M-'\/Q(%(EGB@5[J\D<L1'!"J*=C>9-"-I8
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MOZV"OR[^-_\ R6GQ?_V-&H?^E,E?J)7Y=_&__DM/B_\ [&C4/_2F2OO^ /\
M>Z_^%?F?#\<?[M1]7^1R]%%%?J!^<!1110 4444 %%%% !1110 4444 %?I%
M^Q]_R;3X1_[!S?\ HUZ_-VOTB_8^_P"3:?"/_8.;_P!&O7PW'O\ R+*7^/\
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M!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\DS\._\ 8"M/_1*5NUQGPUL_&3?#G0&@UBT5#HEKL5K<D@>2N!UK;^Q>-_\
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MA!M6N8I;:\M99K6\@D1'VRPR-@J0RJ< ^,_!O_@HG_P57^/7PB\+?'+X:_\
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M$/Q@^)?@4?"2WV>!-'^'&N6=CIVFR@!8[E+:>SGC6>- J1R*%,:J N, UO\
M[/\ _P $]M9^ WQ5T[XH7G_!0/\ :,\=QZ>DZMX8^('CJSO=*NO,A>/,T,5C
M$S%-^]<.,.BGG&" ?G'\5/\ @H'^S_\ 'KX;_M1_M8_M)V7Q(T;QGK_PE\6>
M!/@AX(U/X*>*C%X7\.M8SI]HFNETTVD-WJ5P([B>0R[88([:)I%$<@'Z ?\
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M_HH_LG#=W^'^0?VMB>R_'_,^P/\ AJ3X$_\ 0]?^4RZ_^-4?\-2? G_H>O\
MRF77_P :KX_HH_LG#=W^'^0?VMB>R_'_ #/L#_AJ3X$_]#U_Y3+K_P"-4?\
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M [KX7?\ ),_#O_8"M/\ T2E?._\ P5!_Y%+PE_V$;G_T6E?1'PN_Y)GX=_[
M5I_Z)2OG?_@J#_R*7A+_ +"-S_Z+2OH>%?\ D?T/5_\ I+/"XF_Y$=;T7_I2
M/CBBBBOV\_' HHHH **** "BBB@ HHHH **** "OH/\ X)K_ /)?;_\ [%>X
M_P#1]O7SY7T'_P $U_\ DOM__P!BO<?^C[>O%XB_Y$>(_P +/7R'_D<T/\2/
MNFBBBOPD_:3Q_P#;R_Y-=\0_]=K+_P!*X:_/.OT,_;R_Y-=\0_\ 7:R_]*X:
M_/.OUO@/_D3S_P ;_P#28GY=QK_R-H?X%^<@HHHK[4^0"BBB@ HHHH ****
M"BBB@ HHHH [_P#99_Y.)\'?]AV'^=?I;7YI?LL_\G$^#O\ L.P_SK]+:_*^
M/O\ D84O\'ZL_2^"/]QJ_P"+]$%<?^T/_P D \<_]B=J?_I))785Q_[0_P#R
M0#QS_P!B=J?_ *225\7A?]ZI_P")?F?78K_=I^C_ "/YPZ***_KP_E(****
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MM '=?"[_ ))GX=_[ 5I_Z)2OG?\ X*@_\BEX2_["-S_Z+2OHCX7?\DS\._\
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MV-M.1AF!'/IGB:]G^*D_A_QI^SEI7B;X86$FA^'M$\0M:7_ANX;SG-[+%O\
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MFR5<AAM92 3V[' LO 'QF^/WQ8OK:_TJY?7+QS>:M/J,30):QG&99,CY(P,
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M8G_#'\S\P\3_ /<\/_BE^2/.Z***_;3\<"BBB@ HHHH **** "BBB@ HHHH
M*_>[_@EM_P F ?#'_L!/_P"E,U?@C7[W?\$MO^3 /AC_ -@)_P#TIFK\Q\4_
M^1+1_P"OG_MLC]'\,O\ D<5O^O;_ /2HGOU%%%?A)^VA1110 4444 %%%% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
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MK]+:_*^/O^1A2_P?JS]+X(_W&K_B_1!7'_M#_P#) /'/_8G:G_Z225V%<?\
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M2?MH4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4KYW_X*@_\BEX2_P"PC<_^BTKZ
M(^%W_),_#O\ V K3_P!$I7SO_P %0?\ D4O"7_81N?\ T6E?0\*_\C^AZO\
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M'[,%K\9O&T?PFT?5_#7BC2?B'J.G:MX;E,<VFW-NLL@%Y:/''']E^==IMF#
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M>]6OL7C?_H-V7_@,?\:OZ+_R!K3_ *]8_P#T$59K^/9?$S^LH_"C'^Q>-_\
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M]B>]^"O@.ULOASXG\#:O<_#>\O\ PSJ0U&*_^U3Q:QJ$*VFHQK;Q,[R&)O\
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M$Z2VP9=C,0P#$97;DCWOXC>)?BM^T%^P#XM^(/[7_A=M)U'P9K.F1?"W6#I
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MW&O_ "3&)](_^E1/RLHHHK^F#^= HHHH **** "BBB@ HHHH **** "OM_\
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M%%% !1110 4444 %%%% !7V__P $!_\ D]76?^R=WW_I98U\05]O_P#! ?\
MY/5UG_LG=]_Z66-?.<7_ /),XK_ SZ#A7_DH\+_C1^QM%%%?R\?TH?+?_!9S
M_E'7XY_Z^M)_].=M7X;U^Y'_  6<_P"4=?CG_KZTG_TYVU?AO7[YX7?\D]4_
MZ^R_])@?AOB5_P CZG_U[C_Z5,****_2#\]"BBB@ HHHH **** "BBB@ HHH
MH ]J_P""<G_)]7PL_P"QQM?_ $*OZ J_G]_X)R?\GU?"S_L<;7_T*OZ J_#/
M%3_D;4/\'_MS/VGPR_Y%=?\ Q_\ MJ"N/_:'_P"2 >.?^Q.U/_TDDKL*X_\
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M/[+MPF@VWC70KK4O%7C:PTZ&2ZU'5%NY8GL'N'1BB01H@$*E0=[,P8DFL?\
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MT445_7A_*04444 %%%% !1110 4444 %%%% !1110!_3'HO_ "!K3_KUC_\
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MX+.FR52 NUL UE_M:?$SPQ\3M1^&_P"S;I/QIC\2Q>&[BY;Q5\1]0GD:VO\
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MV_Y, ^&/_8"?_P!*9J_!&OWN_P""6W_)@'PQ_P"P$_\ Z4S5^8^*?_(EH_\
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M<S]I\,O^177_ ,?_ +:@KC_VA_\ D@'CG_L3M3_]))*["N/_ &A_^2 >.?\
ML3M3_P#222OS;"_[U3_Q+\S]$Q7^[3]'^1_.'1117]>'\I!1110 4444 %%%
M% !1110 4444 %%%% '],>B_\@:T_P"O6/\ ]!%6:K:+_P @:T_Z]8__ $$5
M9K^/9?$S^LH_"@K^=?\ :]_Y.R^*'_91-;_]+YJ_HHK^=?\ :]_Y.R^*'_91
M-;_]+YJ_5?"G_?L3_AC^9^8>)_\ N>'_ ,4OR1YW1117[:?C@4444 %%%% !
M1110 4444 %%%% !7[W?\$MO^3 /AC_V G_]*9J_!&OWN_X);?\ )@'PQ_[
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M %%_^4__ +<_%FBOVF_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
MPMC_ /&J/^(L_P#4'_Y4_P#N8?\ $+?^HO\ \I__ &Y^+-?;_P#P0'_Y/5UG
M_LG=]_Z66-?8_P#PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
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M?\.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U7Z]_Q%G_J#_\
M*G_W,_*?^(6_]1?_ )3_ /MS\6:*_:;_ (<A?LF_]%&^*?\ X6Q_^-4?\.0O
MV3?^BC?%/_PMC_\ &J/^(L_]0?\ Y4_^YA_Q"W_J+_\ *?\ ]N?BS17[3?\
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M1H8H9BB$@QGYL#DYYKT[_AR%^R;_ -%&^*?_ (6Q_P#C5'_$6?\ J#_\J?\
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MU";2K^WTC4KP,5^SVVJ2VZV-Q(6&U5CG8L2 N217LO[2_P"U=^SI^QU\.?\
MA;'[3/Q:TKPAH37D=G;76I.S27=R^=EO;PQJTMQ,P#$11([D*QQ@$@ ]"KS[
MXQ_!G4_B;X]\ >+['6H+6/P=XA?4;F&:-BUPIB*;%(Z')SS7+?LJ_P#!1']C
M3]M;5M7\-?LW?&VUUO6M B276O#>H:5>Z5JMG$Q 6:2QU"&"Y6(DJ!)Y>S+
M9R17LM[>VVG64VH7LHCA@B:2:0C.U5&2>/84 2T5YCX$_;._9:^)/[,,7[9_
MA3XVZ(WPLFTZXOU\;ZA*UE9+;03/#+*[7*QF-5DC=/F R1QG(SYY^S]_P5U_
MX)U_M0?$VP^#?P;_ &D[.[\2ZQ"\V@:7K.@:EI#:U&@W,UBVH6T"7P"Y;-NT
MGR@GH": /I&BN2^.GQW^#W[,WPIUGXX_'OXAZ;X5\)^'[7[1J^MZK-LB@3(
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MRW"K#*Y8D!<DBOJ"@ HHHH **** "BBB@ HHK@_@Q^TW\"OVA-:\8^&O@_\
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M^.'P_P!+^*WP<\?Z/XH\-:U;^?I.O:#J$=U:7<>2"R21DJV&!4C.000<$$4
M<]^S7\&=3^!G@*]\(:KK4%_)=>(;[45FMXV556>4N$P>X!P:]!KA_P!H?]I'
MX)?LH_#*?XR?M">/K?PUX9MKZULY]5NK>:5$GN9D@@3;"CMEY'10<8&><#FL
MC]J3]L[]F#]BOPC8^-OVG?C!IWA6SU6^%EHT$\4US>:G<XSY-K:6Z27%RX!!
M*Q1L0""<4 >GT5Y%^RI^WC^R3^VW9:O<?LR?&BQ\1W'AZ=(O$&CRV5S8:EI;
M."4^TV-Y%%<P!L':9(U#;6P3@XZ'XI_M/_ #X)_$+P5\)OBG\5-+T?Q-\1M6
M?3?!.A7$C-=:M<HA=UCC0$A54?-(V$4LH+ LH(!WE%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'Y__MF6-G\</^"[O[+WP!^)5HE[
MX0\'?#OQ-\0--T:[7?:WNOQO'9V\[QGY9)+9&:6(D91G+#DT?\%\-.L_ASX;
M_9Y_:^\&6J6WQ ^'O[2'ABU\/ZG;KMN;JPU*=K2_TO<.3#<1/\Z=_+'O7M/[
M?G[#GQ _:)\9_#;]I_\ 9F^)NF>#/C1\&]3O+GP5J^O:?)=:3J=G>PB&^TG4
M8HF61K:=%3]XA\R)E#H,YKXX\)?&?QG^VI_P4B\-?L_?\%7OC;\*_AQKGP&^
M)EKJ/@#X$>$Y;YI/'NO&S273=?6[OUC:YLX1/-Y,,,0;SHY#*0%4, ?>,7P9
M_91_8M\;_%_]O#QKXEM]!O/&RV>H?$'QGXKU5?*L[2QMDMX((Y) /(MU501"
M"09'. 2P%>"_\$=/!7B7QG\5/VC_ -OVQ^']]X,^'_[0'C_3=5^&OA;4K%K2
M>XT^QT];1]=DMB 8&U*7=<;7 =E"NP.]2>,_; _8'_X*J_M(_MLR?&K7M1_9
M\\>_"KPG>QW'PH^%GQ UK7;?3M.N44?\3/4+2TLWCO[X'=L,LDD4(),:*QW#
MZ\_92N/V\YX=<'[<&C?"&S=6MO\ A&1\*=2U2X5EQ+]H^T_;X8]I'[G9LSG,
MF[&%R 6OVTOV2/AU^W)^SQJO[-OQ5GGBT35]3TJ]N9+9%,@:QU&VOD4;N &:
MV"-_LNU/\6_LF_!+Q-^U5X>_;8\965S=>+O!?@Z^T#P])?W@:QTNWNIDFN+J
M*%AB*Y98Q&TZD$Q%D.1T]1KX<_X*R?L;_P#!2/\ ;1\9^&/A[^S_ /$+X81?
M!&WT]9O'W@+Q;K^L:5<^+;[S9?\ 1;NYTVWDD.FB/R28(Y(C*QD$FY @ !SW
M[.FK:'^W-_P69U3]NO\ 9IL@WPK^&OPDO?A]J?Q)LXMEMX[UN;4(YVMK.0<7
MMI8K$<W(RGG/M0LHW5ZOXEE_8<_X(M?L1S^#KFRN;C0KS4KX:;X:N<:IK_CW
M7-1FDE:S1-OF:E>7$DOE_,&Q&%WD(A(U?V1_#'_!2_P!JVG> /C?\-/V:?#?
MPYTC0WM=)TSX37VM">S=$"VT,4%Q:Q0) ,8(4@@ ;17RQ\'OV"O^"V?@O]HW
M5?VPOC/-^RO\4/B?>-+!H'B/Q7XB\2"#PEIS\?8-'M([$16,9'#R@-/+D^9*
M^2* /IG_ ((L_LP_%G]C_P#X)J_#?X&?'#3X].\2VD.H:C?Z!#<>;'H2WVH7
M-['IJMD@_9X[A(3@E=R,%)7%?4U<3^SW+^T;-\+;*3]JVQ\$VWC4S3?VC%\/
M;N\GTL1^8WD^6]Y&DQ;R]N[<H ;.,C%=M0 4444 %%%% !1110 5\)?\'%7B
M;Q%:_P#!.Z'X5Z1K-SING_$[XI^%O!GBC4+.8Q20Z3?:E&MTN]>561$\IO5)
M64\$U]VUY+^W/^Q[\._V]?V6/%G[*_Q.U&]T_3_$UI']FUC3&"W6E7L$R7%K
M>0G^_%/%'(!D!@I4\,: .1_X*!?LO? KQ_\ \$S/B=^S;J_@32+'P=8_"W48
M='TZ&S1+?1S:63O9S0*!B-K>2*.1"/NF,5Y;_P $U/A'X4_;3_9/_9'_ &^_
MVD(=2UKXA^!_A0HT.?4;PO;_ &J[M8;>XU-X6!#74D=NK";(($KXZ\?-'[=G
MQR_X*"^!K+0/^"</_!2O]K#X*?"[X9?$_P )7]CKW[2&B:=J,-UKUE;M##=Z
M4(KD"STS4[RVF=BQDEA">>8QN"1U[U^WQ^Q-^VA^T+\"/A3^S?\ \$X_B9\-
MO#WP!TSPO:6OB7PWK'B'5=-N?$NE101QV>G)?:?;RRQV#P*HE\MHI95)4OM8
MT 4-!U_PY^WU_P %K/ W[1/[+EM%>>!?V<_!OB3P_P#$/XHZ>@^P^)]6U)(8
MX?#]O.O%ZMD4>ZD9"T<4DNW(=N?T#N+>"Z@>UN85DCD0I)&ZY#*1@@CN,5\K
M_L9_#S_@I7\&]7\+_";XD_"+]E[PG\(M#L9;7^R?A/?ZXMY91+"_D):PW-K'
M!CSO+W[F!VEVY;K]5T ?,/A3_@DS^R]H_P"Q!\-_V _$L>K:QX"^&VOZ?K%I
M8RW0C35Y[.]>^2*^C *7%N\[EI(6&UL#N :\6_X*H:YX8_;4_:+^#7_!//\
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M&V.,$B-$'%?HW9_:S:1&_$8G\M?/$))3?CG;GG&<XS0!)1110 4444 %%%%
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M_P $\?V$M7_8\T7QK\0?B_\ %E_B'\7?BQXC77OBAX\;3ELX[VX2(0VUG:P
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MCN9$M''%Y9V2Q%/M(RAF<K&652U>>_MN?L3?"_\ 9S_;D_91^-$?B#Q!XO\
M'_CK]J?S/$'CCQEJ9O+\6?\ 96J2P:9;' 2TL(-^V.WB55X#/O?YJ^L_V/\
MPY_P4D\#>(-.\"?M"?#?]F_PY\-M)T4VNF:=\(;[61<V;1A5MX8H+JUB@2 *
M&! ((PN!7@W[6O[*G_!9']I[XN?"?XCMI'[,NFP_!WXEGQ9H, \7^(2VI$6M
MQ:I#<?\ $M(0;)RQ*$_,N!Q0!^A5%<-^SW<_M*77P\67]JW1_ UCXL^VRAH/
MA[J5Y=Z=]GX\LB2\AAE\S[VX;,#C!-=S0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 53N_#^@W^J6^N7VB6<U[9@BTO);9&E@!Z['(RN
M>^#5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FLZ%H?B.Q
M.E^(=&M+^V9@S6][;K+&2#D':P(R*M(B1H(XT"JHPJ@8 'I2T4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI/8^+Y/#D&MZ?X6T[PUJ.H7^I6LUS+:Q"TBM+>0W4S2PS#R(MTH6)Y&01J7
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MXCX6_8H_Y/+^$G_93M!_].,%?T/U^>'P3_X()_\ "GOC+X1^+G_#5O\ :/\
MPBWB>PU?^S_^$%\G[5]FN(YO*\S[<VS=LV[MK8SG!QBOT/K\V\0,\RO.\90G
M@JG.HQ:>DEK?^\D?HG F39EDV$K0QE/D<I)K6+TM_=;"BBBOSX^["OB'_@XD
M\/:_J_\ P2B\=:_H&AW>HCPMX@\->(M3MK& R2BPL==L;BZE"CDB.!))6]%C
M8]J^WJ;/!!=0/;7,*21R(5DCD4%64C!!!Z@B@#\[_P#@L9^VC^R5^TW_ ,$S
MO$'P3_9U_:/\%^.?%OQCN-%T+X=>&_"?B*WO[_6+NYU.T("6\+M(JH@>21F4
M",(0V#@'KKOPOX?U?_@Y&MO$>J:1!<7ND?L6!M,N)HPS6KR>*Y8W=,_=8H63
M<.=KL.C'/TM\,/V)_P!C/X(^.9OBA\&/V1_ACX0\2W <7'B+POX"T[3[Z4/G
M>&N((5D;=DYRW.3FNW'P^\!#QZ?BH/!&D?\ "4'2!I)\2?V;%]O-@)3,+3[1
MM\SR/-)D\K=LWG=C/- 'Y;?M$@07G_!8*SA4)%_PK+1I?+487>_P^.YL>IP,
MGOBNY^)>NZ)X,_:._P""8'C;Q?K%KI>CP:#XAL9]5U"X6&WCN;GP.$MXFD<A
M5>1E*H"<LW R>*_0'4/@I\&M6;Q4^J?"3PQ<MX[MDM_&YN-!MW/B&%(/LZ1W
MV4_TM%@_=!9=P$?R#Y>*J_$C]GGX _&3X=0?!_XO_ WP?XK\)6OD_9?"WB3P
MS:WVG0^2NV+;;3QM$NQ>%PORC@8H _-K2F\;:'_P7(_:3N=0_;LTOX.W7C[P
M3X)U7X7W^K>'M+OX/$WAZWTV2&Y6QGOSM"PWHF>2.)OG\X2$$+E?+/VE/ ?P
MVB_X)^?'KX\_"7]I76OC9X,O/VI_"OB'XYZC;>#H[+2;NWTR]TY=8DL4M5\F
M]M]D5L\\T.]"UM(2QVL:_6/XA?L?_LE?%OP#H7PJ^*W[+GPZ\3^%_"]M';^&
M?#?B'P387MAI$,<:Q1QVMO-$T=NBQHB*J*H"JH'  KK_  ]X!\"^$O!D'PY\
M*>"M)TSP]:V9M+70=/TV*&RAMR"#"L"*$5,$C:!C!Z4 ?GM_P5?_ &D_V8?B
MY\=OV)?!GPO^*/AGQ7XCF_:E\-Z]8-X<U&&^:VT;[+>Q/</)"S"**66:U5=Q
M E*';N\IMOZ,:E<W-GIUQ>66GR7<T4#O%:1.JM,P!(0%R%!)X!) YY(%><^
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M]F-_V;/%NE^(;[X=?#OQQ>_&#4?#E['<QV6BW]K;0:7;74L1*[I+Y3+'"QW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20220630_g5.jpg
<TEXT>
begin 644 biib-20220630_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M93'/(&DVA0C!B1]<6<CS6<4LARS1J6/N17R#_P %_P"1(_\ @C5^T(TCA0?
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MPV^%%_%>:M\6OB?X&U&'3K4YN=.LM&N8-5UB:2,?-%]C6RD@EW;?+F=(FP[
M'[A\1_'+X.^$?BMX<^!GBCXF:+8>,?%]K>7/A?PS=7Z)>ZI%:('N7@B)W2"-
M2&; X&3V. #PO]JWX>?\%0OB_P"*O$$G[(W[3'A+X1Z3X9MHX_#-KK?@*+7)
M/&%\8$G=[J:691860=Q; 11M-NCFE+%?+0]%_P $O/VO?$_[>7[!'PV_:O\
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M% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\
MH:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?*_[='[1?Q3^$_B/Q=X#U[]G'QIXM^%NM_!R
M[:\\2^%?#7]IQZ-JQ:[C,,\$>;B>*: J6,22B'R4+JJS;J^=/^"'G['LOP<_
M:.^(/[17[/\ \(/%'PR^"'C?X:>&8(?"/B;3YM.36?%449:]U:ST^8B6UMA&
M40,Z1B5YG,:F-5Q^F,T,-Q"]O<1+)'(I5T=<A@>""#U%$$$%K EM;0I''&@6
M.-% 55 P  .@ H ^!/\ @H%^P3X8_P""@WC74_@#\+/V?M6\)Z/XNUFV;XY_
M%NZ>\T>VO;2U=0;:TT_S(TUG494B6&._F@D@MX?G29W6.,>R_P#!1#]E/Q+\
M1?V2O#?AS]FKPA;2>(_@]XS\,>,OAYX92=8(KN30KV&==-5W(5/.M8YK="Y"
MAI$+$*":^F** /D/3M*\4_MJ?\%!OA5^T;I_PM\8>%_ ?P1\(Z]-%>>./"UW
MHMWJGB/688+06T-K>)'*T=K9QW1DN IA=[J-8GDVN4]X^+?QS\-_#>6_\/\
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M:#_UZ'_T-J_0/#O_ )&M7_!_[=$^DX8_WR?^']4=A1117[ ?<!1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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M_?B3_P")KY@HH_XB'G7_ #[I_=+_ .3#_6?'_P L?N?_ ,D?3_\ PU=\+_\
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M6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *+:L<1_N\_1_D9U?X4O1GQ+1117\RGY.%%%% !1110 4444 %%%% !1110
M4444 ?=-K_Q[1_\ 7,?RI],M?^/:/_KF/Y4^OZ>C\*/UM;!7Q;\2/^2B:_\
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M !A\.O L^J'0['+*P@8 1&]D*E4W,1"#YS*V$CEZ;]B[XK:!XY\%S>!_A_\
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MOAYFLHB3H=H23&.?W*5N?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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MZ[??:&$EQ9S33/&D$!A4)$ID=C*A !^E?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M7J$M@]LGAQXKB*9VT]#;K#: M$%5][J%.T'=7ZYZ7I6F:'IEOHNB:=!9V=G
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MHV,H\:LI!4$7Z "BBB@ HHHH *S?&?\ R)^K?]@R?_T6U:59OC/_ )$_5O\
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M7GP"_P"2/:#_ ->A_P#0VKY#KZ\^ 7_)'M!_Z]#_ .AM7Z!X=_\ (UJ_X/\
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MK_IS_P"3?_:GW917PG11_P 1)_ZA?_)__M _UJ_Z<_\ DW_VI]V45\)T4?\
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M?^@FG_X''_,/[0P'_/V/_@2_S.[HKA/^&E_@E_T.O_E-N?\ XW1_PTO\$O\
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M7_I4CX3B;_D81_PK\V%%%%?"GSP4444 %%%% !1110 4444 %%%% '4_!/\
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M7GP"_P"2/:#_ ->A_P#0VK] \._^1K5_P?\ MT3Z3AC_ 'R?^']4=A1117[
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M.:OSGQ&_W3#_ .)_DCY?BC^!3]7^1BT445^3GQ@4444 %%%% !1110 4444
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M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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MA2]&?23^!GX,4445^/GQ(4444 %%%% !1110 4444 %%%% !1110!_01I/\
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MC_\ Y*C=?]@67_T;%7PQ_P /"?\ JD7_ )7_ /[GKZ*_X)D?M5?\+L_:#O\
MPE_P@?\ 9GE>%;FZ^T?VIYV=L]NNW;Y2_P!_.<]NE>UP[E^+I9YAY2CHI+JO
M\SORO#5X9A3DUI?R/O2BBBOW<_1#@?VG?^2+:M_UTM__ $?'7RC7N?\ P4O\
M9>)/ /[&GBKQ5X2U+[)?VT^GB&?R4DVAKZ!6^5P5.02.1WK\L?\ AKO]H?\
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MJ'_I-)74URWQR_Y(IXP_[%;4/_2:2OIJW\*7HSU9_ S\&****_'SXDYSQ_\
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M(JAI""3]XGJ:]/\ AG\)?#/PMAU&72+F^O\ 4=9O!=:UK6K7'G7=_,$"*TC
M* %15545510.%&3FEXV^"NG>./B3X<^)]WXUURSO?"S7!TFVL6M1 #/%Y4N\
M20.S[DXY;CJ,'FM%7HQQ,I0]V+BUUW<;?=?;LBE4@JK<=$TU^%ONN<S^U'\4
MK3P=%HO@?6- \23Z3X@>8ZY>^'M"N;UUM(MFZV_<*QC:8R!-QQB,2X(;::X+
M]FCXV^#?%O[77Q%L- \,>(;./6M,T--/CO?#5Q:I;K;6MSN$N] ( 00$#8WX
M^7.*^EZYWP[\,?#WAGXB>)/B;I\]TVH>*(;&/48Y9%,2"U21(_+ 4%<B1MV2
M<\8Q2I8BA'#3IN+NU:]^O,GM;R[]/,(5*:I.+6MOU3_0\N\1ZAXM_9%L/B1\
M08O#$&M>'-6U.;Q':7']IQV\EG>20QQR6\RR8+(TD:&,Q!W)DV;,@$]3^Q]X
M&\2_#G]FOPGX7\96YAU86,EWJ-NR[3#-<S27+QD=BIE*D=B#71Z]\)_#/BWQ
M39^*/&,]YJPTRY6YTG3+R8?8[.=1@3+$BJ))!U5Y=Y0DE"M7OB'X)L?B/X*U
M'P/J6KZE80:E;^5+>:/>FWN8AD',<@Y4\?B,@\&E4Q$:E)4WNVG)^BLNO1-W
MVN_O%*JI047UM=^FB-6[6Z>UE2QFCCG,;"&26(NBOC@LH92P!Z@$9]1UKQKX
M,0ZOX6_:=\;^&?B5?0:KXIUC0[#5;36[& P6S:4DDL$=JMNS.8#'+YA),DAD
M\W=D8VCU34O"J7^BVVDV^NZC9RV83[+J%O<!IT95*[F,BLLF03D.K DYQD C
M-\%_"K0O!WB/4_&TFIW^K:[J\44-]K.JR1M,8(MWEP(L2)'%&I9CM1%RS%FW
M$YK*E4A"E--[JWGNGOV_JW4F,E&$EW_S.GHHHKG,CUO]@W_D\CX<?]C3;?SK
M]M:_$K]@W_D\CX<?]C3;?SK]M:^ZX4_W2I_B_1'T.3_P)>OZ!7+?'+_DBGC#
M_L5M0_\ 2:2NIKEOCE_R13QA_P!BMJ'_ *325]-6_A2]&>K/X&?@Q1117X^?
M$A1110 4444 %%%% !1110 4444 %%%% ']!&D_\@JV_Z]T_]!%6*KZ3_P @
MJV_Z]T_]!%6*_8UL?;K8*_"G]J'_ ).8^(G_ &/6K_\ I;+7[K5^%/[4/_)S
M'Q$_['K5_P#TMEKY/BS^!2]7^1X^<_PX>IPM%%%?$'@!1110 4444 %%%% !
M1110 4444 %?M+_P3G_Y,F^'O_8&?_T?+7XM5^TO_!.?_DR;X>_]@9__ $?+
M7T_"O^_3_P /ZH];)_\ >)>GZH]KHHHK[T^B"BBB@ HHHH **** "BBB@ KR
MC]N?_DT?Q[_V 7_]#6O5ZBOK"QU2TDT_4[**XMY5VRP3QAT<>A4\$4 8_P +
MO^29^'?^P%:?^B4KXM_X+H_\D^^'_P#V&;W_ -%1UV.K_P#!%3]E/6=6NM7N
M/B#\3XY+NX>9TA\:$(I9BQ"CRN!SP*K_ /#D+]DW_HHWQ3_\+8__ !JN/'X7
MZ[A)4+VYNN_6_D88BC]8HNG>US\M:*_4K_AR%^R;_P!%&^*?_A;'_P"-4?\
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M ,:H_P!4O^GW_DO_ -L']C?]//P_X)^6M%?J5_PY"_9-_P"BC?%/_P +8_\
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M\_#_ ()^6M%?J5_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
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MA#*6AF C8ASY3X'RMB/XQ?\ !0W]DWX#?&3_ (9\^)?CO6K?QF=%36$T#2_
M6M:E-)8,YC%TAL[.57B\Q60NI(#J5.&!% 'M=%?*L/\ P6P_X)JW/@W6/B-;
M_'O59/#WAZ[FM=?UY/AKXB-EIL\) FBN)QI^R%T+ ,KD%<C(&:LZ)_P6=_X)
MK:]X+L?B;;_M'M:^$]18+9^,=6\&ZS8Z*_[SR\_VA<V:6RKO!4L9  003P:
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M91_X*._L0_MP:WK7AC]EG]HG1/%FK>'HUEUC2((Y[:\MX6("S>1<QQR-"25
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M0_4-*^%LG@OQ)\++;P/!H4/C/4O[4MX8+N.Z6];.E^4S,PD4PA@ &4^8=IW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$POAQ\7-<^,7A_0+'P7\.M-TOQ[%KNJQ6DGAO4;"TCMKRTO$E96@DCEB<;7
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20220630_g6.jpg
<TEXT>
begin 644 biib-20220630_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7
MPN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^
M29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
MDF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_
MY)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^
M'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L
M!6G_ *)2MVL+X7?\DS\._P#8"M/_ $2E;M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[
M 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=216]P+R%#=[MR+$Z-(L(#H!*O<_LQ?L0_&W]@'_ ()XZE^S[^R=XA\%:O\
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MAVNF:1I%A#9:7IMC L4%I;1((XH8T7 1%154*.  !0!?HHHH **** "BBB@
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M ,OC_P"X:/\ 6#*/^?O_ )++_(/[2P7\_P"#_P C]"**_/?_ (?O_P#5J_\
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MR\&_\*-^+_@?PC,GCK3[CQ=)XWM&F34?#T9;[=:V@61-ETP:+9(<JN"#C<"
M#XR^*_@/_@F5^T-^T]\4--_X*G?'NSMO&GAKQ&T/ACP+XY^+-WX:T[1?#WDQ
M&RO=,MX[RVCN1<+F::]'F.L[20[T$(C'T3_P2Z\3:/XB^!GB*T^&WQ4UWQU\
M,](\>7FG_"3QEXBU&6^N-5T)+:U+%;R;]Y>P0W[ZA:PW#EC)#:Q'?(,2-X3^
MU%^SO^V1^T_\9O$FJ:E^T_\ LI/X)TK7P?ASI_Q%^#-GXEO;>R:VMY&D::2_
M01NMPT\6 H)$"O\ Q@#W[_@G"GQZL/!OQ"\,_M$?'SPA\1-9T;XB"SL=6\"Z
M0-/TRSLAH>D/%9Q6HEE%OL,CL4WMDR%N-V  ?1=>4?MS_P#)H_CW_L O_P"A
MK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#
MO_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5RWQR_Y(IXP_[%;4/_2:
M2NIKEOCE_P D4\8?]BMJ'_I-)6=;^%+T9,_@9^#%%%%?CY\2%%%% !1110 4
M444 %%%% !1110 4444 ?T$:3_R"K;_KW3_T$58JOI/_ ""K;_KW3_T$58K]
MC6Q]NM@HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD5XVB^(/PN^)GB:#]NJU_:+23XKR(OQ-LM'LK&&YVZ'HX^S+%8JMMB+[N8@
M3G/S;J /K*O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\
ML!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
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M_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444
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MURWQR_Y(IXP_[%;4/_2:2LZW\*7HR9_ S\&****_'SXD**** "BBB@ HHHH
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M/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\
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M]C3;?SK]M:]W*<S_ +4HRGR<MG;>_P"B/0P>*^MP<K6L_4*Y;XY?\D4\8?\
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M]>Z?^@BK%5])_P"05;?]>Z?^@BK%?L:V/MUL%?A3^U#_ ,G,?$3_ +'K5_\
MTMEK]UJ_"G]J'_DYCXB?]CUJ_P#Z6RU\GQ9_ I>K_(\?.?X</4X6BBBOB#P
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MHH **** "BBB@#YS_P""K_\ R8IXP_Z^-,_].%O7X]U^PG_!5_\ Y,4\8?\
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M7XE?L&_\GD?#C_L:;;^=?MK7W7"G^Z5/\7Z(^AR?^!+U_0*Y;XY?\D4\8?\
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MC:[XETQ?#'BFW\1:+J'A/7Y=,O+;4((9XH95GAPX"^>S;00&*J&#(61O3**
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MZ]T_]!%6*KZ3_P @JV_Z]T_]!%6*_8UL?;K8*_"G]J'_ ).8^(G_ &/6K_\
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MZE^WI_T7?_RU]+_^1:^QO^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\
M"V/_ ,:H_L/,/^@R?X__ "0?V?B?^?[_ !_S/CG_ (>I?MZ?]%W_ /+7TO\
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MZ*-\4_\ PMC_ /&J/^'(7[)O_11OBG_X6Q_^-5YO^J7_ $^_\E_^V.7^QO\
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M_P#VP?V-_P!//P_X)]?:3_R"K;_KW3_T$58KXY_X<A?LF_\ 11OBG_X6Q_\
MC5'_  Y"_9-_Z*-\4_\ PMC_ /&J^Q6B/</L:OPI_:A_Y.8^(G_8]:O_ .EL
MM?HA_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R;_T4;XI_^%L?_C5>5FV5_P!J
M4XQY^7E=]K_JCBQF$^MQ2YK6\KGY:T5^I7_#D+]DW_HHWQ3_ /"V/_QJC_AR
M%^R;_P!%&^*?_A;'_P"-5X?^J7_3[_R7_P"V.#^QO^GGX?\ !/RUHK]2O^'(
M7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P!4O^GW_DO_ -L'
M]C?]//P_X)^6M%?J5_PY"_9-_P"BC?%/_P +8_\ QJC_ (<A?LF_]%&^*?\
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M_M@_L;_IY^'_  3\M:_:7_@G/_R9-\/?^P,__H^6O)/^'(7[)O\ T4;XI_\
MA;'_ .-4?\.0OV3?^BC?%/\ \+8__&J]3*LD_LRO*I[3FNK;6ZI]WV.O!X#Z
MI4<N:]U;:WZGV-17RW\)?^"1W[-?P:^)>B?%3POXZ^(MQJ.@Z@EY9P:EXN,M
MN\B'($B>6-Z^HSS7U)7O'HA1110 4444 %%%% !1110 4444 %%%% !1110
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M$_[3O[/O@K]GU/VJ_%WQ=T33?AU)H5MK,7B^]O!'9R6-PB/;S*Q^]YHDC"*
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MAGP'XG\2PVFL>,;ZXL_#5@Z,SWTT%K+=S*NT$*$@AD<LV%X SN900#?HHHH
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M>(-4M$MK330'RTTS.UO:Q \11Q)RJ197OO\ @GK^SYXO_90_88^$O[-GC_Q
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M2*#CC<I9"<,: .L^(G[.?P6^*/[/VJ?LM>+?A[IDG@/5O#+:!/X;AM$CMHK
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MP/[(&G_\%"4E\0:I^WCK'PD1G6UA\*Z+\(HM1:U@1?-,\US+J"K(TCEHE5$
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M3;7OC6:UN3-;Z/:Q!_L.A6;'C[+91RNF\ >?-)<7# &;"^>?\%KOV+_VB_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWQ9\/?AMK'B32]:&E6-W]KGT_3YKD17$-Q \1CE,6'\M489RI7&#VGA7XF^
M_A3X%T[P_P#&/]I;1]2UBQ%M9ZOK?B34M.L)[B]FC\Q$>*%88HG<9*1A 2H_
MBP6(!Z'17F7[3?BO]H'PII?@N\_9\U#X<6[7GQ%TBR\82?$>_N;>)M"FD:.Y
M33S 1OU)F:%;=)/W;,Q!!. >>^%G_!03]F3XR_M;^._V-_AY\3-%U+Q1\/M,
MTN;6?LNLP.'O;MM0\S3XU#;I)[>.Q$DRKGRQ<(&PRL  >W45@W/Q3^&%EXYA
M^&%Y\1]!B\2W$/FV_AZ76(%OI8\9WK 6\QEQSD+BK?B_QKX-^'OA^?Q9X^\6
MZ9H>E6H!N=3UB_CMK>+)P-TDC!5R>.30!IT5\K?L8?M,?&?XN_MX_M+?!;QS
M\2]"\1^$/ 4/@RZ\ 2:!I$=O%%;:II]W=2DRK)*UP24C'F%RI" JJ;B#-_P5
MI_;:\0_L-?L_^%/&7A[Q%I7AL^-?BGH?@V^\>Z_8&ZT_P=:7SR>?J]Q"'02+
M%'"RJ'=8Q)+&7)0,I /J.BOFKX>^'/VY/ 'QV^'S7?[4=G\6/A+XDM[]]>U2
M[\%V5MJEI<"S:6R=+K3A';/8RD/SY"N)%@ F<2E:Z?XH_P#!03]F7X3?M9>#
M/V,?$WQ,T2/QOXOL+V_;3I=9@C;2[6"-&1[@,V4:=Y$2%#@R8<KD(: /;J*P
M[CXF_#:T\<P?#"[^(.AQ>);JW-Q;>'I-6A6^FB ),BP%O,90 26"XXKSO]N/
M]MWX%?L ?L^:Q^T%\=_%=G96EC$8](TJ6^CBN=:OFXALK96.7D=B,X!"+N=L
M*C$ 'L%%81^)_P -!X'/Q-/Q#T(>&Q$93XA_M:'["$#;"WG[O+P&!7.[&1BK
MOA?Q9X6\;Z#;^*O!?B73]7TN[0O:ZEI=XEQ;S*"02DD9*L,@C(/:@#0HKG?!
M/Q>^$_Q*GN+7X<_$_P .^()+5W2ZCT36X+MH61@KAQ$[;2I(!!Z$@'K714 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>>_M;_\ )J7Q._[)[K7_ *0S5Z%7/?%SP'_P
MM/X4^)_AC_:OV#_A(_#U[I?V[R/-^S_:('B\S9N7?MWYV[AG&,CK65:+G1E%
M;M,BHG*#2['X(45^A'_#B#_JZC_RQ_\ [NH_X<0?]74?^6/_ /=U?G/^K^;_
M //K_P FC_F?,?V;C?Y/Q7^9Y[_P1%_Y.M\0?]D]N_\ TNL*_4JOEK]B+_@F
MI_PQO\5M0^)W_"Z?^$C^W^'I=+^P_P#".?8]F^>"7S-_VF3./(QMVC[V<\8/
MU+7V>1X6O@\ J=96E=]G^1[N7T:E##\LU9W"BBBO8.T*_/O_ (+W:7K?@2']
MF?\ ;+N-&NKOP?\ !+]HO1M?^(]S96[2OI6AR!X)]195!)BA+(7QR X/0$C]
M!*9=6MM?6TEE>V\<T,T926*5 RNI&"I!X((X(- 'RI_P4\^/7PF\<?\ !/7Q
MW\+/AG\0=$\3>(_CAX#U/P=\+=)T'58KN7Q!J.K64MI ;<1,QDA3S_/EE7*1
M0Q22,0JDUXY_P3Y_90_9NE_X*=?MS377PD\,WD,7BCPKI$.F3:/ ]I;6]UX6
MLI[X1P%2D9NIG+3D &4Q+OW;:^S_ (7_ +)/[*?P0\5W?COX+_LR_#WPAKFH
M(R7^L^%_!=CI]W<JQR5DF@B5W!/)!)S3?#_[(7[)OA/4M9UCPK^R_P##O3+S
MQ'"8?$-UI_@FPADU2,G)2X9(@9U)[/D4 ?E;X5GT7XA_\$=?V%?B!XX2RU?6
M/"_[6?@[1- U_4%2:ZM+*T\:3V$<<<[Y=1]EM(D8!N5B&<XKZ>^#%_X(\#?\
M%FOVL[6T?PUIOBC4OAK\.Y/!EMJ;0027EZ\.NQL80V&?=*\2N4Y.\ ]:^G%_
M8 _8/30K;PNG[$_PC&F65W]JL].'PWTOR()^?WJ1^1M5^3\P /)YKLX_@9\$
MXO'NE_%2+X/>%E\4:'I']E:)XD7P_;"_T^PP1]D@N-GF108)_=JP7D\4 ?DW
M^PS^Q_\ $']JW_@CS?V/Q1_:A^#OAB]UR\U>[^*WBSQ;\&[Z7Q?X8\817\QN
M+V\U1O$<!CU*TN%1HI6AC"I'  GEX!^G]8\+:J/^"JWP ^&G[6WBN'QAI&E_
MLWW[^!=7UW21:V>N>.X;NSBU*^2UD9UCOCI_[R.(L[Q13W04G#M7UGK/[+G[
M,OB/XFP_&OQ#^SIX$O\ QE;31RV_BV]\(V4NIQ21_P"K=;IHC*K+@;2&R,<5
MM_$OX3?"OXT>&6\%?&+X9^'_ !9HS3I,VD>)M&@O[4R)]US%.C)N&3@XR.U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20220630_g7.jpg
<TEXT>
begin 644 biib-20220630_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ_X*>_MP^)/^"<O[(_B#]L"
MR^"L'CG1?"1MW\1:6OBC^S;J.&>ZAMDD@S;3),1).I96,>%!(+'Y:S6_:6_X
M*-7'@,>.]"_X)X^#]3672A?6>F6?QX NKH&/S%B02Z.D8D8$ ;G5<GE@.:\N
M_P"#EG_E"!\>?^P1I'_I[T^O.?V\_BQ_P6"_8[_X)T2?M4^'OCS\%-=T[P-I
M6D:I>:!X?^%NK:/>W%J&AC0/=SZY=QM%'))%+/&(HS+#%*@=-VU@#]%/AMXX
MT[XG?#K0/B3H]I<6]IX@T6UU*U@NXBDL4<\2RJKJ>58!@"#T((K:KXE^.UW\
M>/V M9^ /Q!B_:>\7_$!_'/Q=T'P#\3=+\5SP36FMG5Q) -2LX8XE&G2V]R$
ME6*VV0F#S5=&(5UH?M0C]ICQS_P6(^'/[-?@[]KGQKX6^'7BKX*:_KOBCP[H
M/V&!HVL[[3X$-G/]F,L4LCSH&E=I'2-IA"82X90#[IKS_P"('[0OASPY\%/&
M/QD^'6D3>-U\&KJ4=[I&@7ENDLMW8LZ75L)+AXXU>-XW5\MP48 ,P"FWX#^#
M4W@[X&0? _6OBYXS\2F/2)]/F\8:YK*KKEPL@<><UU;1P[9U5\+*BJPV*V2P
MW'X1_P""1OPNTSX?_P#!*/XO7.F>*O$E\C^*?B;8I;ZWXAN+V.-+;6M6C611
M,S'S7 S)(26D;YF)/- 'V_\ LB_M VG[5_[+/P[_ &G;'PO)HD'Q!\%Z;XAA
MT>:[$[V2W=LDXA,@50Y4/MW!1G&<"O1*_)W]GC7_ (\?L:_\$5?V9OVU=-^/
M_B6_U+3[3X=6>K>%7N(_[$NO#.I7UAIG]G+9[-J2I;7<<GVH'SS<1DE_*/DC
MT70_VE?VI_VN?VP?VA/#-M\/?CI=^"/A/XSC\$^#M.^"_B7PQH_V6^BLH;BZ
MU*^DU34[6XNYI'N(S#&4>S6)!E)'9R #]':\>^//Q\^/7@[XI:-\)/V=?V:;
M;Q_?7.B7&J^(M1U7QFNB6.B0"5(K5'D^RW#2RW#"YV(B<"TD+$97.?\ \$[O
M$?[9_B']F'38OV^/A^VA?$;3-4O;"[GDGTUGUFRBG86>HR1Z;<3VUO+- 8S+
M#'(5659-H5"H'N- 'P/\&O\ @KI^UM\??AQ\8?B7\*_^"<6FZI;_  1^(6N>
M#?%VFK\:8HKNYU'25B>[-FLNF+'+'ME!1GDC+8(P#@'ZO_8Z_:*L_P!KK]E7
MX>?M0Z?X5ET.#Q_X1L=>AT::[%P]DMS"LHB:0*H<J&QN"C..E?"7_!&[_D@/
M_!0+_L\CXI_^DMG7$_LVZ_\ 'C]C;_@AG^SQ^W)I7Q_\2WNJZ)9> (;_ ,*&
MXC&AW7AO4-5L-+.FBSV;5D6UO%E^U9\_[0A;>(L0@ _6RBO@WXO:;^TS\6/^
M"TD_[*UA^V1X^\-_"^[_ &;QXLU+0?#DEC:W$-\=<:R2.UN$MO,A0JJR-(Q>
M;]V4614D9:\!_8I^+O\ P4._:K_8SUKXT^&V_::\0^*WU36M*^$OBK1O$G@B
M+3--ATNZGL+4:E9WFI6C:E<236K/>R75JI<R.+=8D$;$ _7"BOSK_:5_;-_;
MX?Q3^R;^RGXF^#/BGPIXZ^+'AW5]<^-&B_#35M";5HCI%I;F?3=,N]0O4LHT
MFN+@.\J3M/';KB-MY+#U[]BO4OV\M!_:K\6>!/B;\&OB-8_ R\\'V^H^$=9^
M+'B7P[?ZSHVNI<"*XTM9-+U*[GN[26%EN$FN27C>.6,OM,8H ^MJ*\C_ &YO
M$6I^%OV9=>U?2_VBK;X5$7>G177C:;3/MDUK;/?0)/!:P\E[RXB9[:W"J[^?
M/%L1VVJ?'O\ @GI\>O'_ (J_:Z_:*_9EUR;QBWACX?-X2U7P;#X_NOM&JVMO
MJ^GW#RQ/*\DDS1&6S,R)<,9X_M#(P0*L: 'U[17PEJ]I^T=\4?\ @M7XR_9J
MU/\ :U\<V?PJL_@'I'BR3PMH]U;6$L6H7&KWUHD$%U;01S10;+8R,VXSLRHO
MG>7OC;SOPY^W)^U%XA\#Z#^R+!\7[^V\2:A^V?K_ ,&KKXJ2V-J=23P]IL%S
MJBSC,7V?^TI;*.*S68Q$;R\VPN* /L/Q9^V4_A/]O3P;^P]>_![5%_X3+P3J
M_B*P\9RZG;BU9=/>T26!($+2LV;N,%I!$!@[0XYKOOV@_CM\.?V8?@=XL_:'
M^+NJR67AGP7H%SJ^MW$,)DD6W@C+L$0<N[8VJH^\S =Z^']1^#_BGX/?\%\_
M@KIDWQQ\2^*?#E]\!O&4^BZ/XMU%;Z[T>X%WI:W)2Z91/)#,!;LJ2L^QXY=A
M"L$7[3_:C\"?!3XI_L\^,/A=^T=##)X&\3:'-I/B99Y&C7[+<CR#\Z?-&<N"
M)!@H<-D8R #P^;]O[]I[PEH_@KQ]\6/^">>LZ3X3\>^+_#NAZ=J>C_$"PU*[
MT0:QJ-K96]SJMJJ1BW13=(6^S27>&PI(!,B^V_M"_M!6?[/.E>&-5O?A+XZ\
M7#Q1XVT[PVD'@/PZ=2DTQ[QV47]XH=?(L8MN99^=@9?E)(%?FWXPU7_@H)_P
M0(\-Z,WQ<\96W[27['>EZ_I>GG4/$<"IXP^'5N]Y#%92,^/+OX()F@"'&_>L
M:H+90M?6/_!7#XD?&/X2> O@]XR^$'QCUSPN;S]HKP/H6OV&E);>5K.G7^M6
MT$]O.TD+RJI0D?NI(\AF#;@<  ^LZ*_-_P#X+"?%'XT?L*_&[P%^T7X'^/>O
MW'A'XFRWW@.]^'FK_$&;3].TCQ#?0-_9GB)'#"6.S@E!6[16,<4<B2)'N&#]
MO_LQ_!+Q!\ O@]H_P^\:?&CQ3\0M>MK.,:[XP\6ZBTUSJ=T%'F2B//EVZ%L[
M8HP JXR6;+L >'ZK_P %0[;X<?\ !47P[_P3(^.WPAL_#FH>._!UQK_P]\8Z
M?XN%[;:OY3RC[)+ ]K"]M.4M[EL;G4F-55F+C'T'\?/C=\/_ -FOX)>+/V@?
MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/DUU&FFGGN3:65_<Z?Y0-KIMY<A8H+CSGD)G@>2&%)-X^:_^"-/QK7X[_\
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M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
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MUKN^_H>IF'$>,J^S<*\^9+WG&4HIZ*VE[)IWO9)/3?5F7_P\J^)?_0H?$O\
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MXR;X<Z T&L6BH=$M=BM;DD#R5P.M;?V+QO\ ]!NR_P# 8_XU%\+O^29^'?\
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M>&--^('B7X7>'_!5MX6\&&:2UTS3-/3?ONKF=(WO+V20HK.(HTB2!(UW@;J
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M\<1W_@_Q1X1'QAM;N'Q9?K:->66HSRF$[=1B-K<A[R0-)<)<,LC,5C*_6/\
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M6J"OCOXA_P#(_P"N?]ABY_\ 1K5]B5\=_$/_ )'_ %S_ +#%S_Z-:OM^"?\
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L[QC_R*.J_]@V?_P!%M6C6=XQ_Y%'5?^P;
M/_Z+:M:'\>/JOS,<1_N\_1_D?&E%%%?NY_-(4444 %%%% !1110 4444 %%%
M% !1110!]LVO_'M'_P!<Q_*GTRU_X]H_^N8_E3Z_!'N?TVM@KX[^(?\ R/\
MKG_88N?_ $:U?8E?'?Q#_P"1_P!<_P"PQ<_^C6K[;@G_ 'FMZ+\S\Z\1/]TH
M?XG^1CT445^BGY2>6_M#_#W]H+Q/XI\%^./V?/&GA[2[SPS?W<NK6'B6VGDM
MM8M9K<Q_9"82&B^?;()1NV-$OR."17A_[,?[&7QO\0?'/P3^TO\ M-:3X7\/
M7GPT;Q;#X3T+PS=3W=Q=2:OJ$S2SW=U+%"#"D3-Y,*QG_7F1F4DQC["HKEJ8
M.E4K*I)O>]KZ75K/Y61VTL?6HT'2BEJFKVUL[IKYJ36O38\?\:^&/VRM!\<>
M+]2^$GB[PGK>D>)H;9O#\'C"\FM#X0N$MQ#(8H[:TD_M&)V59_+DE@8.77?M
M8%&_"[]B[X;_  __ &*(/V']8U"[UKP]-X2N]$UN_G CGU WBRF[N,#(C>22
M>60 9V%A@G&:]BHJUAJ?.Y/6]UKKHW=KY_\  6AF\75Y%&-E9IZ:7<59/U2_
M-MW;N?-WAK]EGX_^,K[X6^$OVB_%GAF_\-?"#4H=4L+[19KAKWQ9J-K;O;6-
MU>0R1(EB(ED:=XHY;@23A&#1JFP^O^(-/^/4OQN\/:CX9\0^&HOA[%I-XOB?
M3;RRF;5)[TE/LSV\BMY:QKAMX89],Y!7LJ*4,-"G&R;Z===-EZ:?/KJV%3%U
M*LKR2V:M;36]WZW=_+2VB2/ ],^ OQZ^!GQM^(_Q,_9]C\(:[I7Q/U&VU?4=
M(\6ZQ=:=)I&JQ6<5H\T4MO:W/VF&2."%C"PB*NK8DPX"]=^R%^SK_P ,N_ V
MR^%MYXI_MS4WU/4-7U_6%M?(2\U&^NY;RY>.+<WE1^;,RHF20BKDDY)].HHI
MX:E3GS+SMY7=W;U?_ LAU<96JT^27E?N^56C?T7W[N["BBBN@Y0KZO\ @3_R
M230_^O4_^AM7RA7U?\"?^22:'_UZG_T-J^.XU_Y%]/\ Q_HS[[P]_P"1K5_P
M?^W1.MHHHK\T/UX**** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7K
MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
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MM:^RZ+0[XYWBXXMUU;6UTTG>R26K3=[+5]7=G)_VAJ/P=^'&AV6NR^(O%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9WC'_D4=5_[!L__HMJT:SO&/\ R*.J_P#8-G_]
M%M6M#^/'U7YF.(_W>?H_R/C2BBBOW<_FD**** "BBB@ HHHH **** "BBB@
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MK>#\)A\/CZDJ<;/E[ONCV:BBBOAC]%"BBB@ HHHH **** "BBB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[QC_R
M*.J_]@V?_P!%M6C61\0+ZUTOP'K>I7TNR"WTBYEF?:3M18F).!R>!VK6A_&C
MZK\S'$:T)^C_ "/CJBO./^&MOV?/^B@?^4J[_P#C5'_#6W[/G_10/_*5=_\
MQJOW+V]#^9?>C^</JN)_D?W,]'HKSC_AK;]GS_HH'_E*N_\ XU1_PUM^SY_T
M4#_RE7?_ ,:H]O0_F7WH/JN)_D?W,]'HKSC_ (:V_9\_Z*!_Y2KO_P"-4?\
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MORQ[G[&M@K\/_P!IK_DY'X@_]CQJW_I9+7[@5^'_ .TU_P G(_$'_L>-6_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCXW?\
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M\"EZO\CAZ***^N/B HHHH **** "BBB@ HHHH **** "OV2_X)Y_\F8> /\
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M "BBB@ HHHH **** "BBB@#]\=*_Y!=M_P!>Z?\ H(J>H-*_Y!=M_P!>Z?\
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MGG_R9AX _P"P._\ Z/EKY[B3_=(?XOT9]1PI_OL_\/ZH]FHHHKXP^\"BBB@
MHHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?
M_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N8^-W_ "1CQ?\ ]BOJ'_I-)73US'QN_P"2,>+_ /L5
M]0_])I*TI?Q8^J,ZO\*7HS\+J***_4#\?"BBB@ HHHH **** "BBB@ HHHH
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M )(QXO\ ^Q7U#_TFDK2E_%CZHSJ_PI>C/PNHHHK]0/Q\**** "BBB@ HHHH
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M*;B1S'&GF-Y>%5B%RWRQ4YY24X)IZ=K;ZW^7_ U+I.G&$H3::U[WO;1KY_\
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MB4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
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MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
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M">?_ "9AX _[ [_^CY:^>XD_W2'^+]&?4<*?[[/_  _JCV:BBBOC#[P****
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MBBB@#]\=*_Y!=M_U[I_Z"*GJ#2O^07;?]>Z?^@BIZ_+'N?L:V"OP_P#VFO\
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M4[MRW"[/*D /:Z\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
M0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH
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MY/)^+?\ V4W7O_3C/7K91_$EZ'BYU_#AZL\RHHHKW3YX**** "BBB@ HHHH
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M_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W:
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MKX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH ****
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M.+Q3JGA'PI+J ^T1:==$E+NW1F\PI(A41%AY9^>:OUX;3?@I^UY\!+"3QGX
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MJUGK=IXIAM[5)[N%O(FAEM7O'BC2*+9Y<B_,B1A/M6@#Q#_AV5_P3<_Z1\_
M_P#\-/H__P C5ZMXE^'7P^\9Z?IVD^,/ FC:M:Z/J%O?Z3;:EI<4\=E=0',%
MQ"KJ1'+&>4=<,O8BMFB@ K)\)^ _ W@)-1C\#>#-)T5=7U:?5-672=.BMA>W
MT[;IKJ;RU'F32$ O(V68C))K6HH **** "BBB@ KB?VE_P#DW#X@?]B1JO\
MZ1RUVU<3^TO_ ,FX?$#_ +$C5?\ TCEJH?&B*GP/T/Y=:***^R/A@HHHH **
M** "BBB@ HHHH **** "BBB@#^K70/\ D!67_7I'_P"@BK=5- _Y 5E_UZ1_
M^@BK=?&/<^[6P5_,9^VM_P GD_%O_LINO?\ IQGK^G.OYC/VUO\ D\GXM_\
M93=>_P#3C/7K91_$EZ'BYU_#AZL\RHHHKW3YX**** "BBB@ HHHH **** "B
MBB@ K^C+_@D7_P HWOA-_P!BZ_\ Z4S5_.;7]&7_  2+_P"4;WPF_P"Q=?\
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M0 4444 %%%% !1110 4444 %%%% ']3N@^)=6&AV0_X1"\_X](_XE_NBK?\
MPDNK_P#0H7O_ 'TM7= _Y 5E_P!>D?\ Z"*MU\8]S[M;&/\ \)+J_P#T*%[_
M -]+7\T/[9TCS?MA?%>:2(QLWQ*UTLC=5)U"?@U_3M7\QG[:W_)Y/Q;_ .RF
MZ]_Z<9Z];*/XDO0\7.OX</5GF5%%%>Z?/!1110 4444 %%%% !1110 4444
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MO^%']K?\%-?^DDO_ )AW1?\ "NYHKJ_V3_H&H?\ @BC_ /*SC^O9I_T%5O\
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M;XI^(+BU\<:SKUSIT&H:!/:7J:4VCZ@LJ"T2-FM8TBC*$R!2=\AD5?T+\/?
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MSU_3G7\QG[:W_)Y/Q;_[*;KW_IQGKULH_B2]#Q<Z_AP]6>94445[I\\%%%%
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MY"M?3-%%.C1]DY.]W)W?W):?<37K^V4%:RBK+ONWJ_5OY604445L8'3?!O\
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M=_R3/P[_ -@*T_\ 1*5YQ^V%_P @71/^OJ;_ -!6O1_A=_R3/P[_ -@*T_\
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M:V_:#_Z*!_Y2K3_XU1_:-#L_P_S#^R,3W7X_Y'VK17Q5_P -;?M!_P#10/\
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M#_D!67_7I'_Z"*MU4T#_ ) 5E_UZ1_\ H(JW7QCW/NUL%?S&?MK?\GD_%O\
M[*;KW_IQGK^G.OYC/VUO^3R?BW_V4W7O_3C/7K91_$EZ'BYU_#AZL\RHHHKW
M3YX**** "BBB@ HHHH **** "BBB@ K^C+_@D7_RC>^$W_8NO_Z4S5_.;7]&
M7_!(O_E&]\)O^Q=?_P!*9J\K-OX$?7]#U\F_WF7I^J/HZBBBO /I0HHHH **
M** "BBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH
M [KX7?\ ),_#O_8"M/\ T2E?+'_!7WXI>._A?X*\%7?@77?L,EWJEVEPWV6*
M7>JQQD#]XK8ZGI7U/\+O^29^'?\ L!6G_HE*^./^"WG_ "(/@'_L,7O_ **C
MKU,EE*.9TVG;?\F>/G\8SRBJI*ZLOS1\9?\ #6W[0?\ T4#_ ,I5I_\ &J/^
M&MOV@_\ HH'_ )2K3_XU7G%%?HOMZ_\ ,_O9^6?5<-_(ON1Z/_PUM^T'_P!%
M _\ *5:?_&J/^&MOV@_^B@?^4JT_^-5YQ11[>O\ S/[V'U7#?R+[D>C_ /#6
MW[0?_10/_*5:?_&J/^&MOV@_^B@?^4JT_P#C5><44>WK_P S^]A]5PW\B^Y'
MH_\ PUM^T'_T4#_RE6G_ ,:H_P"&MOV@_P#HH'_E*M/_ (U7G%%'MZ_\S^]A
M]5PW\B^Y'H__  UM^T'_ -% _P#*5:?_ !JC_AK;]H/_ **!_P"4JT_^-5YQ
M11[>O_,_O8?5<-_(ON1Z/_PUM^T'_P!% _\ *5:?_&J/^&MOV@_^B@?^4JT_
M^-5YQ11[>O\ S/[V'U7#?R+[D>C_ /#6W[0?_10/_*5:?_&J^G/^"3_QT^*G
MQ*_:5U'0/&WBG[;:1^#[J=(OL,$>)!<6R@YC13T8\9QS7PY7UM_P1E_Y.MU3
M_L1[O_TJM*\_-:U66754Y/;N>GDV'P\<UHM02?-V1^H5%%%?FQ^L'SU_P5/_
M .3'O%W_ %\:;_Z7V]?D97ZY_P#!4_\ Y,>\7?\ 7QIO_I?;U^1E?:\.?[C+
M_$_R1^?\4_\ (QC_ (5^;"BBBO?/FPHHHH **** "BBB@ HHHH **** /5_V
M&?\ D[[X=_\ 8T6_\Z_:&OQ>_89_Y.^^'?\ V-%O_.OVAKX[B3_>8>GZGW?"
MG^YU/\7Z(*XG]I?_ )-P^('_ &)&J_\ I'+7;5Q/[2__ ";A\0/^Q(U7_P!(
MY:^>A\:/IJGP/T/Y=:***^R/A@HHHH **** "BBB@ HHHH **** "BBB@#^K
M70/^0%9?]>D?_H(JW530/^0%9?\ 7I'_ .@BK=?&/<^[6P5_,9^VM_R>3\6_
M^RFZ]_Z<9Z_ISK^8S]M;_D\GXM_]E-U[_P!.,]>ME'\27H>+G7\.'JSS*BBB
MO=/G@HHHH **** "BBB@ HHHH **** "OZ,O^"1?_*-[X3?]BZ__ *4S5_.;
M7]&7_!(O_E&]\)O^Q=?_ -*9J\K-OX$?7]#U\F_WF7I^J/HZBBBO /I0HHHH
M **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
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M\C*^UX<_W&7^)_DC\_XI_P"1C'_"OS84445[Y\V%%%% !1110 4444 %%%%
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M^@BK=?&/<^[6P5_,9^VM_P GD_%O_LINO?\ IQGK^G.OYC/VUO\ D\GXM_\
M93=>_P#3C/7K91_$EZ'BYU_#AZL\RHHHKW3YX**** "BBB@ HHHH **** "B
MBB@ K^C+_@D7_P HWOA-_P!BZ_\ Z4S5_.;7]&7_  2+_P"4;WPF_P"Q=?\
M]*9J\K-OX$?7]#U\F_WF7I^J/HZBBBO /I0HHHH **** "BBB@ HHHH *\H_
M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
M8"M/_1*5\<?\%O/^1!\ _P#88O?_ $5'7V/\+O\ DF?AW_L!6G_HE*^./^"W
MG_(@^ ?^PQ>_^BHZ]/)O^1E3^?Y,\C/?^135]%^:/SKHHHK]!/S(**DM+2[U
M"[BL+"UDGGGD6.&&%"SR.3@*H')))  '6O2M>_8_^/WA[PD?%]YX%FDB@CO)
M=5MK6>.:;2XK:-9))+E48F !6/#X(*X(!908G5ITVE)I7-(4:M1-PBW;>QYC
M172_"OX/?$GXV^(Y?"7PM\+2ZOJ$-FUU+;Q31Q[(5959RTC*H 9U'7JPI_Q4
M^#7Q'^">MP^&_B=X>72[^>W\^.T-]!,XC)(#,(G;:"0<9QG!QTH]K3Y^3F5^
MU]?N#V57V?M.5\O>VGWG+T5ZYH/["/[67B;0K'Q)HOP=NI;+4K.*ZLI6U"U0
MRPR('1MKRAAE2#@@'FO,_%GA77O _B:_\'>*;#[+J6EW<EK?VIE5S#,C%70E
M"02""#@GD4H5J-234))M=F.IAZ]**E.#2?=-&?13HHI9Y5AAC9W=@J(HR6)Z
M #N:U/%O@7Q9X#NX].\8Z,^G7<B;FL;IU6XB'!_>Q9WQ$@@@.%)'(J[I.QFH
MR:O;0R:***8@KZV_X(R_\G6ZI_V(]W_Z56E?)-?6W_!&7_DZW5/^Q'N__2JT
MK@S3_D7U/0]+)_\ D9TO4_4*BBBOSH_4CYZ_X*G_ /)CWB[_ *^--_\ 2^WK
M\C*_7/\ X*G_ /)CWB[_ *^--_\ 2^WK\C*^UX<_W&7^)_DC\_XI_P"1C'_"
MOS84445[Y\V?47B;X.?"KX!^!9K+QM\&[[7M.U/P-I.KOXPCU9XGO6N;FU,J
M6+!6AB$7F;?F5W;;EB%?%>6>"?AK\/\ X@?M?VWPQ\,RR3^$+OQT]O;R"<L[
MZ2MRQ+;QR3]G4G</K7MOP1\=?&[X':!KGP*^+OP[NO'W@F32=.O-)\+:GI[2
MI=0W5S;!7LWP2K;9R0JDJL@/ 8$UYC\1/AEJ?P]_;5U_X:?LG^(YTN=,O[N/
M0+JWU-8YH<6CO/ DS,#YB S0J<[RR@ EB*\BA.=ZD7+6S:E?39:^37W=MCV\
M13ARTYQCI=)QM[U[O3^\G;UVON<]\;/%'P?GTM- \$?LMWG@C46F64WVJ>)K
MR[D>#G 6*545<G'S'=P"!ZUM? KP=\-].^#.L?%?XA? _4?'<K^);?2]+TZP
MUBXLOLR+;2S7,S- CE@-ULN",#=G([W[#Q;XP\??L;>-]3^,_B&_U:.P\2:6
MG@B_UNY>:9+]VD^V0P22$L4-N TB [01&< G)XKPSXE_:)\"_"BP\0^!?'FN
M:5X:NO$L\%O#H>M/#G4EBA9B\<+!MY3R]I8<A#MZ&NA*4J3IIV:E;XGKHGH]
M_P"F<S<8UE5:NG&_PQTU:UCM_2.6\>ZWX5\0^*KK5?!7@A/#NF2$"UTE-0EN
MC"  /FEE^9V)R2< <\ 4SP1X+\2?$;QAIO@3P?IK7FJ:O>QVMC;(<;Y'8 9)
MX [DG@ $G@5Z?^VEIWVSXY6-O%IJ#Q/?^&-'?Q=964(!_MR2UC-RNQ!@2%RI
M=1_RT9N^:TOV-=*\3?"C]K6+P_XCTF72?%=CI6K6VCV6I1;'CU5]/G6V0ANC
M,[*%]2ZXZBM/;VPGM([\MTF[]/O?J9?5^;&^SEMS6;2MN^VR?D<A\=_ ?@SX
M07__  KK1-$U'4+V$;;WQ7J4<L$%W*I&_P"PQ84& '*B23>9!\P$8(%><5[A
M\/\ 4/$^N?LY?%V3XMWM_<V5N]@^FRZQ([R1Z^UXHQ$9.1*UO]I\T#DHN6Z"
MO#ZO#RDTXRU:=K]]$_UV,\3&*<915E)72[:M?/;<****Z#F/5_V&?^3OOAW_
M -C1;_SK]H:_%[]AG_D[[X=_]C1;_P Z_:&OCN)/]YAZ?J?=\*?[G4_Q?H@K
MB?VE_P#DW#X@?]B1JO\ Z1RUVU<3^TO_ ,FX?$#_ +$C5?\ TCEKYZ'QH^FJ
M? _0_EUHHHK[(^&"BBB@ HHHH **** "BBB@ HHHH **** /ZM= _P"0%9?]
M>D?_ *"*MU4T#_D!67_7I'_Z"*MU\8]S[M;!7\QG[:W_ ">3\6_^RFZ]_P"G
M&>OZ<Z_F,_;6_P"3R?BW_P!E-U[_ -.,]>ME'\27H>+G7\.'JSS*BBBO=/G@
MHHHH **** "BBB@ HHHH **** "OZ,O^"1?_ "C>^$W_ &+K_P#I3-7\YM?T
M9?\ !(O_ )1O?";_ +%U_P#TIFKRLV_@1]?T/7R;_>9>GZH^CJ***\ ^E"BB
MB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
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M&7_DZW5/^Q'N_P#TJM*X,T_Y%]3T/2R?_D9TO4_4*BBBOSH_4CYZ_P""I_\
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MWG_(@^ ?^PQ>_P#HJ.O3R;_D94_G^3/(SW_D4U?1?FC\ZZ***_03\R"BBB@
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M %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
M+_\ H:T =U\+O^29^'?^P%:?^B4KXX_X+>?\B#X!_P"PQ>_^BHZ^Q_A=_P D
MS\._]@*T_P#1*5\<?\%O/^1!\ _]AB]_]%1UZ>3?\C*G\_R9Y&>_\BFKZ+\T
M?G71117Z"?F04444 %%%% !1110 4444 %%%% !7UM_P1E_Y.MU3_L1[O_TJ
MM*^2:^MO^",O_)UNJ?\ 8CW?_I5:5P9I_P B^IZ'I9/_ ,C.EZGZA4445^='
MZD?/7_!4_P#Y,>\7?]?&F_\ I?;U^1E?KG_P5/\ ^3'O%W_7QIO_ *7V]?D9
M7VO#G^XR_P 3_)'Y_P 4_P#(QC_A7YL****]\^;"BBB@ HHHH **** "BBB@
M HHHH ]7_89_Y.^^'?\ V-%O_.OVAK\7OV&?^3OOAW_V-%O_ #K]H:^.XD_W
MF'I^I]WPI_N=3_%^B"N)_:7_ .3</B!_V)&J_P#I'+7;5Q/[2_\ R;A\0/\
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M_P#T-: .Z^%W_),_#O\ V K3_P!$I7QQ_P %O/\ D0? /_88O?\ T5'7V/\
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MKJ>$4L5OI=4\I"T=HPRMR\ ;SDA*_,)60(5^;..:\^\!?#[QC\3_ !-#X/\
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MBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
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M:_I'K^;C_@EY_P I"OA#_P!CO:?^A&OZ1Z\'-OXT?0^CR7^!+U_0*XG]I?\
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MC/VUO^3R?BW_ -E-U[_TXSUZV4?Q)>AXN=?PX>K/,J***]T^>"BBB@ HHHH
M**** "BBB@ HHHH *_HR_P""1?\ RC>^$W_8NO\ ^E,U?SFU_1E_P2+_ .4;
MWPF_[%U__2F:O*S;^!'U_0]?)O\ >9>GZH^CJ***\ ^E"BBB@ HHHH ****
M"BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3
M/P[_ -@*T_\ 1*5^;W_!S9_R2?X4_P#8Q:E_Z(AK](?A=_R3/P[_ -@*T_\
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MEUHHHK[(^&"BBB@ HHHH **** "BBB@ HHHH **** /ZM= _Y 5E_P!>D?\
MZ"*MU4T#_D!67_7I'_Z"*MU\8]S[M;!7\QG[:W_)Y/Q;_P"RFZ]_Z<9Z_ISK
M^8S]M;_D\GXM_P#93=>_].,]>ME'\27H>+G7\.'JSS*BBBO=/G@HHHH ****
M "BBB@ HHHH **** "OZ,O\ @D7_ ,HWOA-_V+K_ /I3-7\YM?T9?\$B_P#E
M&]\)O^Q=?_TIFKRLV_@1]?T/7R;_ 'F7I^J/HZBBBO /I0HHHH **** "BBB
M@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\
MDS\._P#8"M/_ $2E?F]_P<V?\DG^%/\ V,6I?^B(:_2'X7?\DS\._P#8"M/_
M $2E?F]_P<V?\DG^%/\ V,6I?^B(:[,!_O</ZZ'#F7^Y3^7YH_'VBBBOJ#Y$
M?'<W,,4D$-PZ),H65%<@. 00".XR >>XIE%% !1110 4444 %%%% !1110 5
M]^_\&X?_ "?EKG_9,M0_]+;"O@*OOW_@W#_Y/RUS_LF6H?\ I;85S8W_ '6?
MH=6!_P![AZG[AT445\H?9'R)_P %U/\ E&-\0/\ K[T;_P!.MI7\_5?T"_\
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MP<V?\DG^%/\ V,6I?^B(:_2'X7?\DS\._P#8"M/_ $2E?F]_P<V?\DG^%/\
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M3_T2E?F]_P '-G_))_A3_P!C%J7_ *(AK](?A=_R3/P[_P!@*T_]$I7YO?\
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MLO\ KTC_ /015NOC'N?=K8*_F,_;6_Y/)^+?_93=>_\ 3C/7].=?S&?MK?\
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MB@ HHHH **** "BBB@ HHHH _JUT#_D!67_7I'_Z"*MU4T#_ ) 5E_UZ1_\
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ML_\ XU1_PR_^S3_T;QX%_P#"2L__ (U71_:V)[+\?\SF_L;"]Y?A_D?S-_\
M"J?%W_/71?\ PIK#_P"/4?\ "J?%W_/71?\ PIK#_P"/5_3)_P ,O_LT_P#1
MO'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5']K8GLOQ_P P_L;"]Y?A
M_D?S-_\ "J?%W_/71?\ PIK#_P"/4C_"WQ8C*IDT?YC@8\26)_/$W%?TR_\
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MKX6U"SL+?[+=)YLTMM(B+N:(*N68#)( SR17OG_#+_[-/_1O'@7_ ,)*S_\
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M#HJO';HKK]AO#@A0"/\ 4U9_X>W?\$Z/^CI-%_\  "\_^,UZG_PR_P#LT_\
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M]B;X>_"+XK?M!Z+I7B'0]&:#5-/\N>?R)#/*X7S(8W1OE8'*L1S7U]_PR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>(C^TIIW@?Q)=:MX)LK9+-3I$XD\R2S@OC=;E'V9@Y&T, K/N /U:HK\I_\
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M*_VOOV(]4U_P787%QKO[15EHVO2&':=4TXQ>:;.YQC[1#OC4^7)N7EAC#L"
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M$^K>'--TJP@MRL,,,E[!"LEQ)</;JD*!@(DG8[=BY /H*BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20220630_g8.jpg
<TEXT>
begin 644 biib-20220630_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
MM#^-OBK\ 5>'XN_ _P""_A'XA_"R^MX]TQU#3M>UZ66U4#EQ/ )$$></((<Y
MQ75?%K]K3P)_P5__ &6/!.E_"UDD\&7GPCN?BK\6;))/,6TDM([B+2]#F/0L
MVLVMQ,P(PRZ#(IXE&0#ZO_X)N?MD>)OV_P#]DGPQ^UQJOP<@\$:9XRMY+K0-
M'_X2;^TKG[,LTD.^<BVA2)F,98*ID^5ADJ<J/>*_';_@W9\5?$[]L#]FG1_V
M>-2^,?BGP9X(^"GPN\.V]CI7@O4187>LZKJS7]Z^H7%TJF4Q0QI%#% I$3.)
MS*LF%5?JGX,_M(?M$_%O_@F]^T"/$OQDU&S^(/P6\2^.O"%O\2=%TVQCN-6D
MT0RFUU P2026R2R1>4DRI&%$JR^6(_E"@'W!62OCSP<_CM_ABGB*V/B"/25U
M2320^9DLVE:)9R.R&164$]2K8Z&OS@\'_%?]J;X"_P#!.']ES]OOQK^T_P"+
MO%7BWQ?J?PY@^(&FZI=QOI>J:/KTEG:26XM=FV.XB2\CF%TA$TD\3%W=',==
MU\%/@?HNC?\ !P%\9O$=KX[\9O))\$/"NMRVUSXNNYK=Y9]4UB,V_E.Y5;5%
MC4QVZ@1HQ9E4%F) /HW]D7]LI_VJ/'?Q>\!W?P>U3P?=_"7Q^OA>\AU;4[>X
MEO7:PMKU9\6Y>.,%+I %$DG3)(/RCVZOSE_8\^ GQ"^-/[;/[;YL_P!H/Q;X
M.TJV^,EG'H,/@Z^2TEBU9O#6F;KVX<HQN5C3[.([=_W!/FF1)<IY?+>%O^"A
M'[3'Q,_9)_9Y_;4^.?P\^(6N?"SQ!\)KJ3XLZA\#[B2+5O#WB1;B.*/6[BSM
M'2XFT[9;7K>7#YD499S+%(%C  /U#KRO]MC]H3Q;^R=^RUXW_:9\*_#&U\7I
MX!\-7OB#6-#N/$!TUY=/L[>2XN&AE^SS!I1'&Q5&"AL8W XS;_8Y\:^&_B)^
MRA\./&7A+XWCXEV%[X+TXQ?$'8$;Q"RVZ))?.FU?+DE=6=T*J4<LI52"!Q/_
M  5@_P"46?[2O_9 /&7_ *8[R@#C?@%^VO\ MV?M(_ 3P?\ M&?#C]@;P=_8
M/CCPK8^(-#AO_CFT5S]EN[=)XED0:,5238Z@C<0#GGO7O_[/OQ5U/XV?!O0?
MB7K_ (#O/"NJZA:LFN>&+^X6:;1]0AD:"[LVE0!9?*N(Y8_,4;7"!EX85\%?
ML$?#S_@JSKO_  2G^ A^$G[1GP?@\/R_"GP?+9:+:?"_5+77?[(%K9M);+J;
MZY);K=&U#Q^?]D56<Y58<AD[#P<GQ^^//_!8#XV? 35?VR?&[?"KPU\-_#FL
M6OAS0-1M;&2TU*ZN]2A-O#=6D,<L<,;6LOF*6,SO'$LDK(C1N ?>]>(W'[93
MVG_!0C3_ -@J\^#VJ6[:C\+K_P 9V?C2XU.W^S7,=K?6=H]O% A:7.Z\!+R>
M7@QX"N&##X\^&O[<G[4?Q6\.?"O]C2Z^+U]IWB?Q%^U#X\^&'BOXJP6-JNH3
MZ+X7_M*Y+Q#RO(AO[NWM;:W,PCPI,TB(KE2G1^"OA1XJ^#G_  <+>'M#O/C5
MXC\6>'[G]DS7KO0=.\57JWM[H['Q#I23Q+<E1-/"Y2-T\YI'5C* VW:J@'Z'
M45^3W[-/[2G_  4A_;M_8IU#]L_X;_#_ ./2?$+QE<:QJ'PLE\)Z_P"#(/!^
MB0P7D\%CILUA?:O%+>1$P*EU-=0?:-[S>2R!(S7T9XA^.7[4GQX_:>^ G[&7
MQ)DU'X0W_B/X*:A\0_C'8>&=3@:\EO;673K+^PK2_B:411+=7LDLDT#^:\<$
M861 SE@#V?X,_ME/\6_VS?BS^Q]>?![5- N?A;HF@ZG_ &[J&IV\J:S#J9O1
M&\44)?RD7[$2"[ASO^:-".?;J_/_ /X)X^ /&/PQ_P""RO[77@OQ7\7M6\9P
M6O@3X=MH>H:^\4E_:6+IK#I:3RQHGGM&[2!9'!D:,Q[V=@7;] * "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /$OV_/V&/ 7_  43_9ZU+]E_XN?$_P 9
M>'_".N/$?$%IX,NK&"74DBGBN(HY);FTG9%66%&Q$4+<ABP.*ZW1_P!G/P=+
M^SH_[,'Q4UG4_B%X;NO#;Z#JS^,EM7GU.P>'R&BN#:P01MF,E2P16.<DYYKT
M"B@#P'P%_P $\?AOX6\5^!O$7CGXO_$'Q_9_"^1I?AKH'CC6+6XL_#T_D/;)
M<KY%K#->W$=O(\4<]])<R1AV96#LSG2\4?L1>'/%7[:6@_MQS_&_QU:^(_#G
MAFX\/:=H-H^E_P!D_P!F7$\,]Q;NCV+3MYDEO$Q?S@XV81D'%>V44 %?./PW
M_P"":'PP^#_@OXF?#SX9?&_XF:3HOQ,U35[Z73$UVTGM_#SZI.\]^NFQ3VCQ
MQB61V;,ZSO'N;RV3<V[Z.HH ^5_%'_!)_P"&'BS]A[PK_P $_;_]HWXI1>!?
M![:4-*GM[K15U!H=,FMI]/@DF.F%62"6TA=2$#L01(SC '7WO[!/AG3_ (L:
MU\=_A3\??B#X"\9>+=/LK7QYKOA9M(8>*&M(_*M[F[M;W3KBT6Y2/]WY\$,+
ME $)*JH'O->%2?\ !1K]F*+]L-?V"GO_ !9_PM)]*_M5?#W_  @.J^6=-\PQ
M_;_M7V?[/]FW@IYWF;-WRYW?+0!ZY\/_  1IGPY\(V?@[2=0U&\BM%8O>ZM?
MO=75S*[EY)997)+N[LS'H!G"A5 4:&LV%UJFDW.FV.M7.G33P-'%?V21--;,
M1@2()4>,L.HWHRY'((XJS10!\J?LW?\ !)_P#^RQX(^*_@/X8_M4_%V2U^,G
MB#4=?\83ZM>:'<3#5[\*MY?P-_90$4LJ($((:,#E4# ,%\1_\$F/A9XF_8/\
M/?\ !.R^_:+^*4?@#PT=,33YH+K1EU%K?3KBVN;&W>8Z85*0S6D+@A [$$.[
MKA1]544 >$>'?V$=(T/]L2']MW4/VC?B+JWBY/ J>#Y[+4/[%73[C25O#>")
MXH--C8-Y[%_,1U?G;G;Q4.B?\$^_!GP]\2^)]3^ GQW^(OPWT7QKXBGUWQ3X
M/\(7^G?V;>:C<'-U<1?;+*XN+!IS\TGV.: %R9%VN2]>^UX?\4?^"BG[*7P8
M\977A/XC^,=;T^TT[58=+UKQ</!6JR^'=)OI618[:[UB.V:QMI-TB*PDF41L
MZK(49E! -;X[?L8?!WX\Z9X).IS:UX?U[X:7XO?AWXR\-:EY6K>'Y_(-NYAE
MF65)DDA)CEAN$EBF7_6(^ 1T7PD^"][\-+N]USQ1\9/%_CO6;Z-(6UGQ?/9J
M\$"Y(AAM["VM;6$$G+,D(DD(7S'<1QA>A\?>/O!7PL\$:M\2OB1XIL=#\/Z#
MITU_K.L:G<+#;V=M$A>261VX554$DGTKB/@;^U]\#OVA?$=]X+\!ZKK-GKNG
MZ7;ZI+H'BOPKJ&B7\FG3LRPWT5O?P0R2V[LC+YJ*55P4?:X*T -_; _9+^&O
M[:WP1NO@7\4=7UW3+.35;#5-.UOPOJ(M-1TO4+*ZCNK6[MI61U62.6)6&Y'4
M\@J:Y7X*?\$^OAW\#OVE=;_:LT/XR_$C5O%'BOP[I^F>,H]=\21RV>O360G2
MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'SC^VA^W9K?P$\:VO[/'P(^$Y\=?%'5? >K^+H=
M)N=:BTZPTC1K QQ2:A>7#J[%3<3PQ1Q11R/(Q;.Q5+BU^PQ^V9\1/VG+C6/
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ME'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\
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M0[_HX/\ \M/2?_D2C_A[M_P4._Z.#_\ +3TG_P"1*^;:*_K;_5KAS_H"I?\
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MC/\ Z&6(_P#!U3_Y(^DO^'NW_!0[_HX/_P M/2?_ )$H_P"'NW_!0[_HX/\
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M$5_/O^UE_P G3_$O_LH&L_\ I=-7Z]X0?\C#%?X8_FS^=_I$_P#(IP'^.?\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<E\?O^2$>-O\
ML4=2_P#262NMKDOC]_R0CQM_V*.I?^DLE=.#_P![I_XE^9QYC_R+ZW^&7Y,_
MGDHHHK^SS_-,**** "BBB@ HHHH **** "BBB@ HHHH _H_T;_D#VG_7M'_Z
M"*LU6T;_ ) ]I_U[1_\ H(JS7\4R^)G^FM/X%Z!7\^_[67_)T_Q+_P"R@:S_
M .ETU?T$5_/O^UE_R=/\2_\ LH&L_P#I=-7Z]X0?\C#%?X8_FS^=_I$_\BG
M?XY_^DH\_HHHK]X/Y2"BBB@ HHHH **** "BBB@ HHHH *_=+_@F3_R8?\-O
M^P&__I1+7X6U^Z7_  3)_P"3#_AM_P!@-_\ THEK\I\7/^1'0_Z^?^VR/WSZ
M/7_)4XK_ *\O_P!+@>[4445_/I_7@4444 %%%% !1110 4444 %>4?MS_P#)
MH_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2M
MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7Q^_Y(
M1XV_[%'4O_262NMKDOC]_P D(\;?]BCJ7_I+)73@_P#>Z?\ B7YG'F/_ "+Z
MW^&7Y,_GDHHHK^SS_-,**** "BBB@ HHHH **** "BBB@ HHHH _H_T;_D#V
MG_7M'_Z"*LU6T;_D#VG_ %[1_P#H(JS7\4R^)G^FM/X%Z!7\^_[67_)T_P 2
M_P#LH&L_^ETU?T$5_/O^UE_R=/\ $O\ [*!K/_I=-7Z]X0?\C#%?X8_FS^=_
MI$_\BG ?XY_^DH\_HHHK]X/Y2"BBB@ HHHH **** "BBB@ HHHH *_=+_@F3
M_P F'_#;_L!O_P"E$M?A;7[I?\$R?^3#_AM_V W_ /2B6ORGQ<_Y$=#_ *^?
M^VR/WSZ/7_)4XK_KR_\ TN![M1117\^G]>!1110 4444 %%%>3?M&_ME?"O]
MF^[MO"NH:!XJ\9>,-0MOM&E^ /AWX<FUC6;J'<5\]H8L):P;E9?M%R\,&Y2O
MF;N* /6:*^/F_P""@_[?[W']L6__  1%^+9T#[_VJ3XE^#TU#R^.?L/]I[MV
M/X-^:]C_ &<_VT_A?^T5JDW@K_A%/%_@3QI:6IN;WP!\2?#<FD:ND (5IXD<
MM%>P!F56GM99HE9E4N&(% 'KU>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^
M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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MG-V5HOV:?V==1^/.LZOJ5_<WMGX9\+V OO$NH:=8-=7(1FV0VUO$/];<3/\
M)&I('WF)PAKDOB/<>'CXEFT[PSX"N?#UM9NT*V>HW<D]X<'K<,P5?,]=D<:_
M[/>O9?AAXL\2Z3_P3O\ 'VD?#35+BWU%_B)I<GC!=/D99CHQM)UB+E>?)^U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ5K+8S<YRO=[[^?J:/A7QCXN\"ZNOB#P3XIU+1K]$9$O=*OI+>95;@J'C(8
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M>6<5P8<G!.TR;<D G&<"N\_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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MH]?\E3BO^O+_ /2X'T51679Z]J5S=)!-X9NH59L-*[+A?<UJ5_/I_7@4444
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M-V7@WP1X:T_1M(TRV6WT[2M*LTM[:UA486..*,!8U X"J !0!H4444 %%%%
M!7)?'[_DA'C;_L4=2_\ 262NMKDOC]_R0CQM_P!BCJ7_ *2R5TX/_>Z?^)?F
M<>8_\B^M_AE^3/YY****_L\_S3"BBB@ HHHH **** "BBB@ HHHH **** /Z
M/]&_Y ]I_P!>T?\ Z"*LU6T;_D#VG_7M'_Z"*LU_%,OB9_IK3^!>@5_/O^UE
M_P G3_$O_LH&L_\ I=-7]!%?S[_M9?\ )T_Q+_[*!K/_ *735^O>$'_(PQ7^
M&/YL_G?Z1/\ R*<!_CG_ .DH\_HHHK]X/Y2"BBB@ HHHH **** "BBB@ HHH
MH *_=+_@F3_R8?\ #;_L!O\ ^E$M?A;7[I?\$R?^3#_AM_V W_\ 2B6ORGQ<
M_P"1'0_Z^?\ MLC]\^CU_P E3BO^O+_]+@>[4445_/I_7@4444 %%%% !7Q_
M^WI^QI^PW^TO^V!\((OVI_V$O$7Q4U/Q%HNM:%9^*[7P^;K0O#-M;K%?*VK3
MB1#;&1Q)%;'#!GFF7'((^P** /QP;X,?\$@[G4]4LO#G_!LC\?M:M]*UR_TJ
M35-(^%VFRVL\]G=2VDYB<ZX-Z"6&10V!G&:_07_@E+IW@/2/V&O#.E_"_P"
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MOZ"*_GW_ &LO^3I_B7_V4#6?_2Z:OU[P@_Y&&*_PQ_-G\[_2)_Y%. _QS_\
M24>?T445^\'\I!1110 4444 %%%% !1110 4444 %?NE_P $R?\ DP_X;?\
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M%X;+7_'WPVTO5]9T^QM%A6XOY9IX!.L2 *AG2&*4A0 6D9L?-7>_'OX :_\
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M +W3_P 2_,_=<Q_Y%];_  R_)G\\E%%%?V>?YIA1110 4444 %%%% !1110
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M(+$ ^I*\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
M),_#O_8"M/\ T2E?"G_!P%_R3?X<?]AR_P#_ $3%7W7\+O\ DF?AW_L!6G_H
ME*^%/^#@+_DF_P ./^PY?_\ HF*OL> /^2OPOK+_ -(D?G'BW_R;O'_X8?\
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MO^0/:?\ 7M'_ .@BK-5M&_Y ]I_U[1_^@BK-?Q3+XF?Z:T_@7H%?R_?MM_\
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MXA?]B/JW_I'+7Y51_C1]4?OE?^!+T?Y'\L]%%%?M9_/@4444 %%%% !1110
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M3_T2E? G_!Q!XGT/PS\,_AI-KE]Y"RZ[J C/E,V2(8L_=!K[[^%W_),_#O\
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M,T4?ZV9C_)#[G_\ )!_Q#7(O^?E3[X__ "![-_PM?P!_T'__ "5E_P#B:/\
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M?[S5]%^9\'QY_NM'_$_R/,****^^/S0?<7-S=R^==W#ROM5=\CEC@  #)[
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M$O\ V+LG_I5-7\X-?T??\$@?^4:_PE_[%V3_ -*IJ^3XP_W"G_B_1GVW O\
MR,JG^#_VY'TE1117YV?J04444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O
M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2OS6_X.>O^
M23?"?_L8M2_]$0U^E/PN_P"29^'?^P%:?^B4K\UO^#GK_DDWPG_[&+4O_1$-
M>UP]_P CFEZO_P!)9X'%'_(AK>B_]*1^.M%%%?JQ^+'Z'_!7]HKX)_M1_!K7
M_P!FG_@HGX/D\)ZUX3\):7HL/QAT"-?M\>GKJ%HMG!?1$,L\:2- QE&28PV
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M_=:/^)_D>84445]\?F@4444 %%%% !1110 4444 %%%% !7]'W_!('_E&O\
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M*L6VME)-_F>KD>69E1S>C.I0FDI*[<9)+YV/WFHKYS_X>W?\$Z/^CI-%_P#
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M^1S%%=/_ ,*?\;?WM%_\*BP_^/T?\*?\;?WM%_\ "HL/_C]']IY;_P _X?\
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M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
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M*%7)[G % ''_ /#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\
MC5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S
M10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!P
MW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!PW_#+
M_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!PW_#+_P"S
M3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!PW_#+_P"S3_T;
MQX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!PW_#+_P"S3_T;QX%_
M\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!\N?L(_L__  &\1_![5+[Q
M#\$O"-_.GC75XDFO?#=K*ZQK<$*@+1DA0. .@KVK_AE_]FG_ *-X\"_^$E9_
M_&JU?A;\*?"/P>\.S^%_!<,Z6EQJ5Q?2"XG,C>=,^]SD]L]!VKI* .&_X9?_
M &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\
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MQ>&_%VI^&[6XU324;6;,,MM=/&98 0[Y",H.]O4U]ZT %%%% !1110 4444
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M"M#_ &;/@]I/P=T'QIXG\2QZ89Y+CQ'XTU@ZAJVISS3/-+<75R54RRL\C<X
M PH "@#MZ* "OF/]KK_@F)X>_:^^.6A_'S6/VR?COX$U7PSI$NG^'['X:^,[
M33+2P6;_ %\T:M92/YTH"J\A<DHH087BOIRB@#Q;]F#]BW3_ -E[P5XH\.6'
M[2?Q8\<ZSXJE#7'C;XE>*X]8U>R1(?*AAMI'@6*.*)FEE2,Q,OF32,P8-BO
M/#/_  0I\(>#M)OO#_AC_@IO^V!86&JZA=7VJVEA\8;>W6\N;F1I+B:1HK!6
M,DCLQ9P0Y)SD<5]T44 5M&T?3/#VD6N@:)91VUG8VR6]I;1#"Q1(H5$ ]
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M' SDXJQ!J]MXG\./JO@CQ#I]P+B"0:?J,>+JV\P94,1&Z^8JN.5#J3@C<IY
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M]_ /0OA0?@/H?P/\(6?@9HVC;P9:>&K6/22C2>:R_9%C$.#(2Y&WECGKS3_
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M_P""KW[8/P?\*16UAH$>F_#WQ)%HMBBQ00ZE?:?J$%Y<+$N%5Y4L+0NP +%
MQR3FO>K#]B']B[2M7TCQ!I?[(?POMK_P\H70+ZW\ :<DVFJ!@"W<0[H0  /D
M(Z5L^%_V9?V;O!'Q'O/C%X+_ &??!&D>+M1+'4/%6E^$[.WU*Y+ JWF7,<8E
M?()!RQR#0!\Q?\%_K/PXO_!.#5/$7B2TLO(TOXD^!9IKV]C3;:0_\)9I(E<N
MWW$V\,<@8Z\5RW_!6'PG\%_CQ\1?V+_ PFT?5_".H?M-K%-::=/&]E>1VVBZ
MQYMJPC.R2)I(C!+%RK!GC8$$K7W1XW\"^"/B;X2O_ /Q(\':5X@T+5;<P:IH
MNN:?%=VEY$>L<L,JLDBG ^5@17'^)OV0?V3/&JZ"GC+]E[X=:L/"MI%:^%QJ
M?@FPG_L>",YCBM=\1^SHI/RK'M [ 4 ? W[=MY\7O@[^VI^TUX(_8FL6TCQ/
MXD_8-7Q)::3X9A$4UQK=EJVHV<%]#'$ 6O%M93%&P&XF*%1G:HJC\,?V%M5^
M-?\ P3\^ >O_  F_;5^!G@C1=$E\-ZW\,_'WA/X%WL6NP:INB+0BZ?Q*WVBZ
MNV,UM=QO&S3M-,KIO^[^BD'[,7[-=M\4?^%X6W[/7@:/QKC'_"8)X3LQJF,Y
MQ]K$?F]?]JF>'?V7/V9?"'Q*F^,WA/\ 9T\":7XPN7D>X\5Z=X1LH-2E:0$2
M,UTD0E8L"0Q+<@\T =W7YTZSKNF?LF_\'%^H_$GXXW\&@>$OCQ\!+/0O OBG
M4I1#8W&O:=?!Y=*:9\*EPT'[U%)&\%57+'%?HM6'\1/AC\-OB_X5N/ GQ9^'
MNA^*-#NB#=:-XBTF&]M)B.F^&961L>XH ^8/VQ/VB?@O+^UU\%]*/Q)T9;3X
M,ZUK?Q'^*VKG4$-IX5T0>%]9TF&2]E!VV[SW&JQF*-B'D2WG901&Q'4?MF?%
M/]@;XN>!/ 'P$_:Z@\'^)?AM\>EEM_#FH:]?Q#3+ZX6U6\M/*G) 1Y8M[PS)
M(KAU0(=SK7KG@K]F;]F_X;?#C4/@[\.OV??!&@>$=6CDCU7PKHOA2SM=-O4D
M79(LMM%&L4@9?E8,IR.#D5J>(/@_\)/%GAZV\(^*OA;X<U/2;*Q-E9Z9J&B6
M\UO!;%54P)&Z%5C*H@V !<(HQP* /SD_8[^$7Q/_ ."9?_!5/P5^P+^S+^TY
MKGQ*^ 7C[P%KFN7OP]\3ZJNJ7GPN^P^3]GEBN1\\5E<2S+;Q1-@,?-)#NGF'
M]%-"^.7P=\3?%K7O@-X>^)FBWOC3POI]K?>(?"]O?HU[IUM<@F"66('<BN%)
M!(Z$'^(9K?!S]G']GK]G:PO-+_9^^ _@SP+:ZC*)=0MO!WA>TTR.Y<9PTBVT
M:!V&3R<GDUNV'@+P-I7C#4/B%I?@S2;;7]6MH;;5=<M].B2\O88=WDQRS!=\
MB)O?:K$A=QQC)H UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KSC]KS]I;P?\ L=?LS>-?VG?'>FW-
M]IG@S0I=0ET^R95FO9!A8K="WRJTDK1QAFX!<$\ UZ/7Q#_P<2>$SXB_X)*?
M%35!XGU>P_LRTT^7[/IM[Y45WNU2S39.N#YBC.X#C# &@#Z&^"_Q<_:.UOXK
M:K\)OC[^SU9Z +7PS9:SIOB[PMK\VIZ-=O---%-IS2SVMM)'=0&)'(",LD<R
M."AS&/6*^*]=T_QI\0/^"D^F_L":_P#'#XA0?#_PA\#QX[O#8^,[O3M6\3:G
M>ZS/8QI-J-D\-R+:SCMF/E121AGNX_,WJBJ>@_80\<?$[Q7\0/VD_P!C+QC\
M5?$6MZ9\)?B':Z1X/\=7%\)M473=1T:SU);*2ZD5C/<6;W4D/GR;I2GEERS@
MNP!]:5\M?\%;/V_/BE_P39_9IA_:7\"? _1/'EA%XCT_2=3TO4_%DNE31->3
MB"*6-TM+A9 )'0,I"D!B03C!\9_X(=_!KXF?'+]B[X1?MD_M$?M=?&+Q;XT&
MH:W.L-[\2+]=+N;-;^_LXK2[L%D%O>@*!/YLR-,L@55D6*-(@S_@Z%BN9_\
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M;3=*T?Q-J<L2:MI$\2W&DZP[+ 7MX;VW+R(H23;L)!<$$XG[6_[4.@_M&?\
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M^)OBQIMOX<UR]O-9\=7\VFZCILVNVUK+IMQIS2FUG5[&9T:=XVN/-;S!*NU
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MD.IV\.NVX$>LP13PHBF2<!KIDVC9'!&.X)_4Z@ HHHH **** "BBB@ HHHH
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MS75W(D[1K*?.GGDE<.[#>Q*A=S;G>"/V,OV>?AO^U/XO_;*\"^!8]+\>>/-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M _C7%X/M/".K>,_A5JMKI>MVVFZ+=6.I1F:YME2)6:4*HD*>:I^7/ H \/\
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MFDZKHUQJ*RP"UW+&D-O,1(?DEVE49SD5]+?$W3/%OPF_X*8^'_V^IOAMXO\
M$'PZ\5_ C_A!]0G\/>$;^^U/PU?PZLVHP33:9%"U[Y-RD[QNT<+M'):Q>8JJ
MP8 'O7P=_:N^#GQT^&NM?$[X?7^KW$'AC5+K2_%&BR>';L:OH^HVP!GL9[!8
MS<"=0R,$5&\Q71X]Z.C-XS\-/^"RW[''Q8^$-I^T9X5B\:K\-9-7&EZM\0]0
M\(3VVE:)=M>"T2.\>3$D0,C1[I C1PB5?/>$A@L7["_@OQYX4^*O[27[;OQ,
M^'WB'PMHGQ:\=:;?^%?"5UHD\FJKIFF:-:::M_-8P(\\4]V\+R_9RGG+&L7F
M*KEE7X_\(_#GXF6W_!L%XP_9>;]FCXG6_P 0]0T#Q-IT/@9_A;K"ZE+?WVN7
MUW;D0_9<LK1R1R&49C7< S*WRT ?H/X%_;Z^!7COXC^%OAY!9^)=+C^("W+?
M#;Q%K6@R6^F>+1;P&XD^PSDDG,"O/&)5B\^)&EA\Q!NKT;XS_&/X;?L]?";Q
M%\<OC#XHAT7PMX4T>?5->U6=&=;:VA0N[;4!9S@8"*"S$A5!) KXN_;HU?5/
M$5K^Q?J?PR^"GQ*O(/"7QPT37=?CTKX5ZVTFA:+%HVJZ?.]S&MINMPLL\*&)
MP'*-O"E/FKZ9_;M\;_'?P-^QA\1/'G[+GPJ@\:^/;'PG<3^%?"M_9&5;^XVC
M"- 2K3$*6<09#2% G!:@"]\%/VL?A_\ &KQ_K/PD3PSXC\+>+M$T2QUNZ\,>
M+M-6UO)-*O7F2VOHPDDB/$\EO/&1N\R-XBLJ1L0#RGQH_P""CO[//P/_ &F-
M'_8^\0Z9XSU'XB>(]!GU7PYH&B^#;N4:M'$T8:.VN'1()G D+L5D*0I%(TSQ
M!":^:OV8/^%F0?\ !6;2OC]/\&?CSJ'A7Q_^SA:>'QXT^(7A2:UD&M6NM37=
MP+RW;RX]'40SC9"8K>.1HY/(CD+AI.\^+D&KW7_!<?X4>/C\(_&]YX?T'X*>
M(M"NO%EMX U2?2K+5;[4--DMXC>I;F!=T,-QNDW[$&0[*3B@#M?CO_P4N\+>
M#/V(_BQ^U7\%?A3XF\6:U\*+?5;;Q-X'FLH[*_T34K*S-U(E^D\B".".)HIV
MDB:7?#(KPB;<H/ _'O\ :G\(>-_^";'PV^-'[2GQ)^-7PED\0:EX3FN]?^'&
MFO;:A<W\L]GMC>6V2>&VL+N:98SYS1JZR;.IV'R^?P%\5OB[K?\ P4L\ >#_
M (+>/K4_%WPF(OAE)KO@34],L]>N/^$'CTN7R)[N".+<;R+R\,P+?*PRIS47
M[7GB7XE?&'_@A[X+^&WA[]E;XPP>*H;KX?6G_"*7'PSU&34\Z1JVBW.H2O;0
M122011I;W 5IA'YIA8QAU*,P!]8?\%4_VR[W_@GW_P $]_BC^U[H^D07^I^$
M/#ZG1+6[!,+ZA=7$5G:&4 @M&+BXB+ $$J" 1G(\V_9L_P""2_P9UGX$Z)XF
M_;<_MCXI?&'7]*AU#QK\1-?\17@O[;4YD$DD>F20RI_94$#,8X4M!"%2-3]X
MDG"_;_\ ^".UE_P4K\ ^.O[3_;]_:#\/Z1\0-*BDL?AY+JUI#X9LKF&.)K7S
M=,N-.6Z$2W$$4\D33)(7W89"1MZ?]EG]MGXZ_"WX/^'_ ((?MQ?LE_%>T^*7
MAK3X='U75/!'@"_\0Z%XFEA01IJ-IJ-C')!!'<*JR%+MK=HF=E< +N(!\I?\
M%F/V0/#WP!_X)Y_L^?#;QAK=UXPUK0?VF- T8>-=<NWN-6U/2;[5;Z1X;RZ;
M$DYEBE3SU8E'E!;!P#7J?_!5C]C3P?\ L*?LG^(_^"@?_!.M;CX4?$/X101:
M^]AX:U">'1/$^G131_;-.U/3P_V>XB> NROL$JNBE76D_P""\TGQA^+W[,7P
M:\.>$/V8_B1J_B.V^/'ACQ7K'AWPGX.O-=DTG2;*XN'FDN9["*6W654\L-"D
MCG>^$,J#S#8_X*5_%W]HK_@I5^S;J7[ O[%?[)_Q2TN?XGO!I?C'XD_$[P'>
M>&=(\*Z-Y\;W<Q745AGO9WC4QI#!&V1(QW J%(!VGQ\_86_99_X*%_ R_P#V
MT?VI_'?BRVMM:\ 6WB#P+J=AXUO]-A^'6GG2X[G[1;1VTT<+W"R&2YDN)D=G
M^6,_NHU6L/X8_MB?M1?L\_\ !NE8_MH?M!SW%U\5="^ \FKK=:Q%NFGO7A9=
M-GNE;EY&5[224-\S,7SR37-_M._M+IX3\<Z5^P5J?[ G[37BGX'?#;1M.T_5
MKWP1\'+S4;?QS-:1HD.GF9C&ITR(11M,5W?;' BXMUD%S]#?%3PIJG_!5+_@
MFI\0_AEK'P@\4_"X_$SPIK&C:!HWQ$TW[%JE@P$D-K=WEHI8VX,\:S"+<S&'
M8QVERB@'C/QA^#=G_P $V=/_ &:OCC\/-6OSXHU/XJ^'/ WQIUN[OI)9O',.
MN[K*>]U-F;-S<Q:C);7,4S9:%5DBCVQ.8Z_0"OA3QD/CG^WTG[.OP5\9_ /Q
MEX1U'X??$/1/&_QQO_$OA^>UT^PO-#C>6&PL;MU$&JFYU(6[I+:/+&MO#(TA
M1F6,_== !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'S;_ ,.B?^">/_1OG_EV:M_\ET?\.B?^">/_ $;Y_P"79JW_
M ,EU])45[?\ K+Q'_P!!M7_P9/\ S/F/]2>#/^A;A_\ P33_ /D3S;]GO]D3
M]GC]E7^U_P#A0OP]_L'^WOL_]J_\3:[NO/\ (\SRO^/B63;M\Z3[N,[N<X&/
M2:*\-_X*#_M_? O_ ()R_L\:C\>OC7KUFC@BV\-Z!+?K!/K=^Y"QVT1(8JNY
ME,DNUA%'N=@0,'R\3B<3C*SK8B;G-[N3;;LK*[>NVGH>[@L#@LNPT</A*4:=
M.-[1A%1BKMMV222NVV]-VV>Y45\>_P#!0#]JKQGX+OOV9?BK^SA^TCIR^!_'
MO[0>C>&/%$FC#3[[3]9TF>WU":8B\99#&%>R52T+I@>8&)[?2_PG^//P-^/6
MF7>M? SXS>%/&EG83B"^N_"?B*VU&*WE*[@DC6[N$8KS@D''-8'4=717":+^
MU)^S)XD^)TWP3\._M%^!+_QG;S2Q3^$;+Q?92ZG')&,R(UJLIE5E'+ KD#KB
MKOQ$^/WP(^$.HPZ1\6/C7X1\+W=Q87%];VOB+Q):V4DMK A>>=5FD4M'&BLS
MN/E4*22 * .NHKS#X?\ [;O[%_Q9U;3-!^%?[7?PO\37VMMMT:R\/^/M.O9;
M\_O.(4AF8RG]U+]T'_5O_=..S^(WQ-^&WP>\(7?Q"^+?Q!T/PMH&GIOO]<\1
MZM#8V=LOK)-,RH@]R10!N45Q'@']IG]F_P"*WC*_^'7PN_:"\$>)/$&EJ[:G
MH6@>*[.\O+,(^QS+!#(SQ[7^4[@,'@\U'XQ_:E_9D^'?C^W^$_Q _:,\":%X
MIO#$+3PUK/B^RM=0G,IQ$$MY)5D;?_#A?F[9H [NBN;\=_&7X0?"[4]&T3XF
M?%7PWX=O?$>I1:=X>M-=UVWLY=4O)&"QVUNDKJ9Y68@+&@+$D  U4\0?M!_
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M;^SU\>6OU^!OQX\&>,SI94:F/"?BBTU'[)NSM\W[/(_EYP<;L9P:P[K]MO\
M8QLM<TOPS>?M=?#"'4M<UF32-%T^7Q]IRSZAJ$;JCV<$9FW2SJ[HIB4%P74$
M9(H ]/HKB?AE^TO^SC\:]>U#PM\&OV@/!/BW4])4MJFG>&/%=G?SV8#E"98X
M)&:,;P5^8#D8ZT[XM_M(?L\? #[%_P +W^/7@OP3_:6_^SO^$N\4VFF_:M@!
M?R_M$B;]H(SMSC/- ':45Q'B/]IG]F_P>AE\6_M!>"-+5;*SO&;4?%=G !;W
M;LEI-\\@_=S,CK&W20HP4D@US$G_  4%_8)AU+4]&F_;=^$*7FBW;6FL6C?$
MK2Q)83J&+13+Y^8G 1\JV"-C<<&@#UZBH#J6G+IQUAM0@%H(/.-T91Y?EXW;
M]V<;<<YZ8YKS[1OVR/V0O$6N:)X8\/\ [57PWO\ 4O$KLGAS3K/QSI\L^JLL
MTD#+;1K,6G(FAFB(0'#Q.O52  >D45Q_A?\ :%^ 7C?XB:G\(?!?QQ\'ZOXL
MT7?_ &QX7TOQ-:W&HV&Q@K^=;1R&6+:Q .Y1@D ]:CT+]I#]G?Q1X]_X55X:
M^/7@O4?% FGB/ANQ\4VDU_YD&[SD^SI(9-T>UMXVY7:<XP: .THHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KXW_X. G$'_!(OXN7L@/E6BZ%<W+A2?+ABU[3I)'..BJBL
MQ/8*37V14&J:5IFN:9<:+K>G07EG=PM#=6EU"LD4T; AD=6!#*02"",$&@#X
M"_X+"^)?V?/VF/!O[),%OXT\.^*_!WB']LKPM!]HL]2AN;#5HX[755DB616,
M=Q$7'DN%+*26C/.16+^W7>_%*R_X*<?$7X?_ +,&M+8?$'QA_P $^?%3:!::
M?<+%<W>MV>KQII#J 03-&;N[$3'[NY\<!J^\?$/P!^!/BV&QM_%7P5\):G'I
MEFMIIJ:AX;M9A:6Z_=BB#QGRT'95P!Z4H^ OP,'BB+QP/@QX3&M02QRP:Q_P
MCEK]JCDC ".LNS>&4*H!!R !CI0!^9WP(_9Y^$'[3'_!)OX/?!%?V[O"W@[1
M["R\/OH5EH?@:WA\3^&_%EG+%(\4.;IIQJZ7J31RXB,LK/,"I$AS['^WY\+O
M@YXS_P""S'[#T?C_ ,/Z'>ZDL/Q!OMMW;0^9>SVNE6+VKNIYD\J4>;&#G8\0
M9<%<U]O0?#+X;VWC-_B/;?#[0X_$,L9CDUY-)A%ZZ$8*F<+O(P ,9Z"J?B'X
M'_!7Q=XE7QIXL^$'A;5-80QE=6U'P_;3W(*8V$2NA?Y<#'/&.* /R9_;M_:0
M_9XT;X(?'G0_V=QX%^%P\!_M<^&KWQ9H=U=LWB+7M>MM?T&2]\0JC3J-.LQ&
MHVND<BRQP.^Z'<RGZO\ ^"^LWP^^*/\ P1+^-GC/3&TG7].;P.NHZ#JD0CN8
M23/#Y=S;R#(.58E9$/*MD$@U]AZA\,?AKJUYJNHZK\/-#NKC7;5;;6Y[C287
M?4(%&%BG8J3*@' 5L@>E?/O_  5__9_^+O[3'_!-SXE_LM_LZ_#M=9\2>,_#
MZ:3H]H-0M;*UM/WT3;Y7GD0+&J(<! S9P-H&2 #P7]H_QI^S1\1_AI^Q9X7_
M &!=8T&[U^R^+OA2\^'-AX6EB:[TCPM!$5UTS)%\\%HNF^=!<J^T>:\<;_O-
M@KRO]@3X7R>,OV-?CG\!_P!K?]JSP'X0\3ZS\1_%T'[0OA_QYX2M7O))[J]G
M$%[+<7-Y$9+>2P-H]M.$$:HJB,GR\U^HGPV\*^&;6V;Q]!\(+/PIK^NQ++KT
M1M+,7KRC^&>:U9UF(.2&WL.?7(JYK_PR^&_BKQ#8^+?%'P^T/4M5TP@Z;J=_
MI,,UQ:$'<#%(ZEH\'GY2.>: /A;]OKX1W_P5_P""97P!2_\ B-K7C/1O@W\7
M?AEKGB'QIXELF@OGT2PUFS$NH7:, T;1P,KS,X#*J2/)C#$)\=OVG?@%KG_!
M>W]F_P 'Z5\4M!FN+/X3>-+1[N+5(6@EO;Z32FMK%)0VQ[ED@,GD F39+$VW
M$B%OT#N+>"Z@>UNH4DBD0I)'(H*LI&""#U!':L;PS\,OAMX+6U7P=\/=#TD6
M4<R60TS288/LZRLK2JFQ1L#LBE@,;BH)S@4 ?!__  2^\<_!'7_@)^T]\!/&
M7B7PY>ZSIG[0GQ3O_$7A/4IX9)K2S_MN:1;BX@?)CB(DB97<!3D$$X./"O\
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M#7QR\)>,-8VZQ96:16&DZE'>3H#<S(7F=8]J*!M)/S,H'(!P/Q[\1_"SXO\
M_!3C]E4_LMZ[X?\ $%]IVB>)Y?'UUX5N(+JUB\"SZ2R0PWC0$I]FFU'[ ;9'
M.UI(G9 0LAKY$T']GGPKXI_X)0?M^7?[/7PUT_6-?U']J;QHUY%X>T^*>\;2
M;#7X))+:T" LA2P^UO!''@J\[-& SY/Z_>%?AQ\.M#\/7>G:%\+M'T6VUM#+
MK.E0:5;1+.\BXD6=804E;!*L<L#SR12>!_@_\)/AC<7%W\-OA;X<\/2W:*EU
M+H>B6]HTRJ20',2*6 ). >F: /BG]J+QM\ _BI\:OV*[']A'Q'X:U77]/^),
M&HZ*_@B:)TT[X>KH]W%JOF>3Q!8.K64(1]JF?[.JC>H @UCXT^%/V5/^"N7Q
MT\2>/- ;Q_<>-OAEX0ET>+0M3TTZAX6M(1?P'298K^ZM]D%W.DETK1,T>YF-
MQY0\EG^Z?#G@#P'X.U"_U;PCX)TC2KK59O.U2YT[38H)+R3).^5D4&1N3RV3
MR?6O@S]J+]B/XN_$O]L/QO\ $OX\_P#!,/X,?M+>%O$!TZ'P!X@UG7[/3M4\
M*:=;VX1].GAO;202*;E[JX\Z*5F;SMK+A(TC /GC]L']A/P%^S?_ ,&_/CFR
M^,GPY\$>'O$GC#XHZ1K#_P!BBS>70;#4?'5C-;:7%J,0!G^R6$OD;T<HJHZQ
MDQ(I/T]^U!XZ_9-^"?[<5I\ _ _@7X<_#[QUJ/[-MU$OCWQ1$(K23PPM^+>'
MP_IUDDT,5U<-,F\C<##&D6$F5]B^P?L<?\$\/@M\!OA%J7@7Q1^S[X"T^PU?
MQ7/K^G^ --@.JZ/X3::UM;=[6QDO(E)5S:^?(RQ0JTT\I$8')]W@^&'PUM?[
M&^S?#S0X_P#A'%9?#VS281_988!6%OA?W ( !V8R!0!\M?\ !#WXA>"OCA_P
M2#^"5A>>*-+\3_V5\-M.T3Q+ ]Q'=K;3V]ND;6=RI+!9$C"!HW^8 KD8(KXC
M^"G@?X1>%?\ @TX^*?B[P9%I=I/>V?C379-5L941AJMKXDO%T^99%/RRQ"UL
MEB((*^7'MYQ7[")\.?A['X7NO!$?@/1ET6^:5KW2!I<(M;@R,6D+Q;=CEF)9
ML@Y)R<UA)^S5^SG'HLGAN/X ^"5TZ6Z2YEL!X5LQ \Z*RK*4\O:7"NZAL9 =
M@#R: /BW]L2V\ ? _P (_P#!/O4?ASJ&GZ8]E\?/#>B:/?17"!Y]-U#PYJD%
MW&),YD6XW1-(<GS'*,Q+$&N*_8:\=>-?@5\3OV;/A+X<\:^%/CW\!/'TVK/\
M"_'$*_9_&/@+;I5U<O;:DL3M#?6R6[/:23?NY$E9!,N\1@_H/>_LU?LYZG8V
M>EZC\ ?!-Q;:=$T6GV\_A6S>.UC:1I&2-3'A%+N[D+@%F)ZDUL>%OA9\,? ^
MJ7.N>"OASH.CWMY$L=W>:7H\-O+.BXVJ[QJ"P&!@$X&* -ZBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20220630_g9.jpg
<TEXT>
begin 644 biib-20220630_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKJPL?#G@SP_=:QK-SQN$$$32,J D;G;;M5>K,R@<D5^;G_!:S]DKQW^T?\
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MVOKB&.! LZ1W,T:QPF.V4,"( RJP]ZIEQ<06D#W5U.D442%Y))&"JB@9))/
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M7:O'<6T-N&%O/.(9'CBN6=!'E&>&9D)D /'_ /@JG>^'-4_8W^!?PZ\(Z_\
MVMX%\=?'SX7Z#JNH?:/-34=!FUFSD!>3HZ3>5 I;HPD.>#6Y^V-=7'AG_@K'
M^QOKOAX^5>Z^/B!X>UMHN&N-*.A)J&Q\?>1;NPLV / 9N.6KU?XX?L/?"_XP
M?L81?L5Z;J=]X?T;1]$TJT\'ZQ9E9;K0KG2G@ETR\CW\.\$UK;R8. ^PJ>&-
M8OPS_97^,GB7]IO1/VL?VM/'?AG6->\%>#[OP]X%T7P=I=Q;6%BUZ\#ZEJCF
MXD=S<7 M;>)8P=L$2.N^8R%P ?0=9WC#PEX=\?>$M4\"^+]+2^TG6M.GL-4L
MI&8+<6\T;1R1DJ00&1F&00>>#7BNAZ]^U/\ \/&-8\/I\3-%UOX-O\.O,G\.
M6_AORKOPQKJ3VODB2_#$7#74,MS)Y!&8T@C8A Z&;UWXHP_$NY^'6MV_P:OM
M%M?%<FFRKX>NO$<$LMA#=E2(WG2$J[QJV"54J6 P",Y !\J_\% _A%H_[6/[
M4/[./[-_@#2X?[3^%7Q5TKXJ>*M8M8@%\-Z-IL=PEM;%EQL?4+HQP1PY&^*V
MNGP1!5C]I6ZN/$'_  66_9@\&ZYD:5H_PY^('B+2HW^Y-JJKI5B'P>"\=K>7
M0!'(%P_K7"_L_?L>_P#!:KX2PCPQK/[6WP!:S\0>(DU'X@^,=-^'6JOXEU<N
M\8N;E9KB]:W%SY""*$&'R(4CBCCC2.-$7Z3_ &K/V7==^,WC#X=_'7X4^++'
M0?B+\*=<NK[PM?ZK9O<6-[:7EL;74-,ND1E<0W$10B1#NBF@@E <(8W /)OV
M>;F?PY_P6D_:1\':#SI>N_"CP#XBUF-?NQ:J'U>Q#G' >2UM;<$]2MNG9:D_
MX*L?"WP9X@_8$\2_L(?"OP)I]YXF^-7VGPYX*\.-'O!U"\G-S=ZQ,3EA':%Y
MM1GN&R=\8Y:66-6]4_96_9=\0?!WQQ\1?CY\6?%ECKOQ$^*NL6=UXEO-)LW@
ML;"RLK?[-I^F6J2,SF*",RL9'.Z6:XGDVH'6-/G"+]E7_@MSHWQY\7?'GP_^
MT?\ LTW.I^(G-KI,WB'X?Z[=S:%HZL&BTRU9+^-$BW 2R,$#S2X:0L$B6, ^
MQO"_P1\&Z-\-?!GPV\16YUV#P1;Z<-+N=2RS/<V< BANG7.&D!'F#=G;(%<8
M9%8?-GA7X5V'[0?_  61N_VOO!%FD?A[X0?"B\^'VI^(K==HU[7KN_CNIK%'
M'^NBT^*+$A^ZMS>&,'?!,J^A_M&?"+]O7Q9^Q=8_!W]G[]HWPOI'Q7N]/M+3
MQ/\ $?7]%F$39B/VV>S@M60V\DDG$7/[E')4[U1AQ'['7[.__!3SX1^*?"?@
M[XV?&GX%V?PK\+6DJ#PK\*O .I6-W>GR72&*2>_O+C$8D<3NR@2R/&-SD.^X
M ^N*^,F_;]_:%^%?[1'PG^%W[25C\.=-G^+'Q%U/PR_PWT&=KC7_  G#]FO[
MK2KZZNTO98;I;B*P7>@MX-K7BA6;R'#_ &;7YV^&_P#@DM^VKX6^&_PR\$VW
M[4WP[U#4/@_\=KKQ_P"'O$.K>!KZ2\\2FZ;4%FEUB1;U3)=>5J+J#'C<88]S
M@= #V[_@J=^V)^TC^QAX!^&_C#]G7X9^$_%5UXO^,'A[P=?:7XFOKF%Y1J=V
ML"K;M",1N3E?-?>L98-Y4H!4U;_]MWXI_LR?M*WOP&_;+U;PCJFEW'P9UKXA
MZ1XL\$^'+O3!;PZ/-"NHV$UM<WMV9F$5S%-'.LD88+(K1J0K-N_\%$/V5OCM
M^U9H/PNT#X2:YX4L3X ^+WASQY?7OB6XN5-Z^D78N4LTC@B;8)F !F+'8 0(
MWSD<_P#M!_L3?&K]H7]MKP9^T!XJLO [^!M%^&&O^"?$OA6;6;UKO4K77%M/
MMLB3+:A$\K[-L1"I\U<DM"7Q& ?)W_!63XV?MW_'+_@AWK_[3OB3PS\.K+P9
M\1-$T'5+KP!:Z;>C6O#^D7VHV4MI,VIM=-!>7"![<S0BS@4"20+(?*!D_6*O
MSY_:3_X)7?MP_&__ ()WV_\ P3%T']KGP9IW@O2+/3-,T_QK?>$;F;6]2TG3
MYX)+&RNHEN%A22-8(1+<QD_:/)QY4/FL5^]_"]OXGM/#UG;>--7L-0U9+=1J
M%[I>G/9V\\N/F:."2:9HE)Z*97(_O&@#QG]LZ]^%GP,_94^(P@^&\&M:A\0(
M;S3[/PE#$);GQCKVHVYM8++#DF5I0(XR6.R*WA);9#"2ORY^V7\$/'/[!7_!
MM?KG[-?_  F4ESK'A3X.Z;X7U_6;25MNRYGMK346B8\B)8KBX"9Z1JN>E=U\
M9OV7O^"OWB3]K[5OVBOA9\?/V?!H]E%)8?#G1/&O@C6;Z3PY9/D2RH8+V&,W
M=PNT33;2P51$A6,L']VT[]FGQO\ &O\ 8OUK]F;]N_QKIGC75?&^@ZGIGCG4
M?#6FG3[-HKPRJ([*)B[0K#$\:1LY=]T0=F+$F@#QS_@J#I6G?"W5_P!D/7OA
MWIT6G7OA[]J+PQH6B)9KL,6FWUAJ&GW=JN/^61M)')7IB%3_  U]1^+U^%'P
MPFUW]H?QO-IVCG3_  V(]>\3:A-L2UTRU::XP[L<1QH9978C&>,YVKCP?P-^
MQ7\??%OQ%^$^O_M;_&K0?%FD_ [S;OPA%HFB36L_B'639R6$.LZGYLKI'-%:
M37 6&$%#-<R2[U"I$N5^W]^S5_P46_:"^*_A+4/V;/B_\']*\!^&&CU&X\)?
M$7PQJ>H+JVL))O@N;D6ES )([<JDD,+$H)AYKJ[QPF( D_X)#_L\:]\%_A#\
M2OBMKWA*Y\,CXW_&WQ!\1]+\(W=L8)M$T[4&ACLX9H>/)G>WMH[B6+ ,<EPT
M;<H:\O\ VP?@-I7A?_@MI^QK\<IOB)XOU;4-;\0>.[&/2=7UUI=,TN >$[Z0
MK:6H54A+-C<_+N$4,Q"C'T]^R%X,_;?\-Z=X@U?]N+XR^!O$^LW]Y FAV'PZ
M\-7&FZ9IUI'&=S$74LTTD\DCMO+2% L<84*=V>-_:L_9<_:!^,7[9?P%_:0^
M'%]X.AT?X+:KKE_<:;K>H7:7.M-J>E2Z:\:M%;NML(DE:0,?-WM@%4 )(!]*
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU>WGF@%S9HS1V]U$;=U81G:P(P/EWO[3^V)^V=\%OV*OAS;>-?BQXJTNVO\
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MK>&SM!"ESY40EGD>-"9 #]5:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
MV K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?$W@
M[PCXULX].\9>%=-U:WAE,D4&IV,=PB.8WC+!7! )221,]=KL.A(K2HH \P^
M/[&'[*W[+>LZ_P"(OV?O@%X3\):AXFU"6[UF]T'P_;6DTY<J3%OBC5O*!4$1
MYVJ<D#FNQ^)'PL^&/QC\*S>!?B]\.=!\5:)<,&N-'\2:1#?6LI (!:*961C@
MGJ.YK>HH Q?A_P##CX>?"?PK;>!?A9X#T7PUHEDNVST;P_I<-E:P#T2*%511
M] *PM*_9F_9OT'XH3_&_0_V??!%EXTN9)'N?%]IX4LX]4E9QM=FNEC$K%AP2
M6Y'6NWHH X3XQ_LN?LR_M%7%A=_M!?LZ^!/'4NE)(FER^,O"-EJC6:R%3((C
M<Q.8PQ1-P7&=HST%'P<_9<_9E_9UN+^[_9]_9T\">!9=52--4E\&^$;+2VO%
MC+&,2FVB0R!2[D!LXW''4UW=% &/X>^'G@#PBVKOX3\#:/I9\0:C)J&O'3M,
MB@_M*[D55DN+C8H\Z5E559WRQ"@$\"G^#? O@CX<Z#'X6^'O@[2M!TR)V>+3
MM&T^*U@1F.6(CB55!)Y)QS6K10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y
M)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X'XK_
M .1IU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T,U\AQ=_ I>K_ " SZ***^& *
M*I>'O$F@>+-,_MGPSK%O?VAN)H!<6LH=/,AE>*5,CNLB.A'8J1VJ[0TTP"BB
MB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\-O\ D1M-_P"N'_LQ
MKZGA/_?I_P"']4!N4445]^ 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"
M_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%
MW_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5X'XK_ .1IU+_L(3?^AFO?*\#\
M5_\ (TZE_P!A";_T,U\AQ=_ I>K_ " SZ^._^"ROBKXC^ ?A'X"\?Q?#[Q/X
ML^%>B_$""Z^.'ASP9+(NH7>@"WG&XK$RO+;1SF*6:(, ZQJKD1F0C[$KR7]I
M3XS_ !9^"_BSP-JO@?X+^)?&GAV_U&\@\;0>%M/CN+K3;46Y:&\5&93)MF"(
M8HR9&61RJ.4VU\=A).&(C)*]NE[=._1]O.P'S1_P2)^'W[,'CP:/^U9^R%\4
M8)?#RZ/XMT;7/!NF^(+AK6UDO/$$%WI\YTUW*6$XM+5E;Y(W=)(LAMN1T'_!
M<[QQ^U=X*_87\977P*L/"-GX9ETZVM_&GB#5-?NH]5BLY[R*WFMK*TCM&B<R
M)*JF62X3:KR (3M:O$/^"?G[-%CXE_;[\*_M>_LQ?!KQ7X#T&VMO'%M\9]7U
MG0;C1;+Q5)/JUP-*M8;2X"/-/"VZ2:01A$\B-&;S 5KZ:_X+.Z/XK\8?\$[/
M'_PY^'_P_P#$OB?7]>BL(=)T;PMX;N]2N)W34;65\K;QOY8$:.VY]H^4@$GB
MO4J<D<VIN_,FUONO>>C]-UY6N@/=_CY\([;X]_!SQ!\%]2\2WVDV'B>P.G:M
M>:8^RX^Q2L%N8HW!!C>2 R1B0<H9-P!*X/Q?\0_^"5O["?P]_:I^"OPY^!7P
M9N]+UY_$LOBW7+]O&FL7GV?1='5'8-%<7<D;":_N--@(=3NCDFQRM?>7A[7K
M'Q/HEMK^FP7L4%U'OBCU'3I[2=1Z/#.B21GV=0?:O(_@/X0\5>)OVEOBK^T-
MXZ\.7NGA[NS\'>"H-1MFB<Z/IZ-+-=(K 86XO[N[PPXDBM;9@2-N//PV(K4(
MR49-))Z7M=O3YVW^0'#?M$W,7Q__ ."A'P__ &-/%J?:? ^E_#?5O'OC#09C
MFVU^9+VUT[3[6Z3I-;H\US.T+YC=XX2RG8!5C]AGQ%J7@?\ :&^/7[&JZE<W
M7A_X;>(-&U3P2EY<-*^GZ3K&G_:!IZLY+>3!=07@B4D[(F2,85% M?M$>!_%
M?PJ_;7^'_P"VWX>\':QKNA0^"M5\#_$"T\/Z7-?WUE97-S;7ME?16D"M-<)'
M<VSQ2+"CR!;H.$*HY%G]BKX9>-+CXP?&?]KSQ[X4O_#\OQ7\2:;'X<T+5K<P
MWEMH6E6*VEI+<1-\T$L\C75QY+@/&DT:N%<,B[-P^J>7*K?XN;7YVO\ *WD!
M[YK^E2:[H-[HD.KW>GO>6DD"7^GNJSVQ=2HEC+*RAUSN4E2,@9!Z5\23^'O@
M7\./^"CWPG^%G["6LVR>([&36)/CSI>AZ]+=P_V$ME(D<NL[I'WWW]H&U$+R
MDW))ER2F^OJ7X,?&OQ7\7?A1>_$;4/@#XN\)ZC:W^H6UOX3\4Q06U_=?9I7C
MCD3]X8PDX0-&S,%(8$G;ACXC^T/9>(OVGOVC_@1J7P0^&?BK3-2^'_Q";7?%
MGC?7_"=[H\>FZ&+&Y@NM,26[BB-VUY)+"GE0>:@$7F.5"(3GA>:G.49;6DGK
MI>SW[^7GMV ^KZ***X0"O</AM_R(VF_]</\ V8UX?7N'PV_Y$;3?^N'_ +,:
M^IX3_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J W****^_ **** "BBB@ HHHH
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M^IX3_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[
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MMGCGA\J[,,)$WF!BKNPZ.>7UB;G>_+%:-<SLXZWUU=KOK;YL#VW]@W_A??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"P%:?^B4K=H **** "BHKZ^LM+LIM3U.\BM[:WB:6XN)Y B1(HRS,QX4
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MC/"L_P"S]_P3,\ _&<CP5?J_C'QGX]32!I6;RV,UAMDL+E6+[;>5"2"=DP4
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M*3T(A3BMS_A,?#'_ $&H/^^JS_AA86+?#7P\S641)T.T))C'/[E*W/[.T_\
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M%^R/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M?_\ U*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NC_6')_P#G[_Y++_(#T:BO.?\
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M:M55UW_D!WG_ %Z2?^@FO7K?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@
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M;QO#>N7^I0Z3-?V4MM-/%::A<V7FM#,B21;S;E]DBJZA@& (-?&O[*'[3/\
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MD4,?G2?:)(8;1XDC,A,S((RWR5ZM7 THNERW<9-+F6J=WKI;1KMN!]#?"?\
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M_P!>DG_H)KZ>M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#(-T[_ *[O_P"@BNB^%W_),_#O_8"M/_1*5SOQ[_Y!NG?]=W_]!%>/G_\
MR**OR_- >94445^7@<3^T=X*^$/Q+^!?BGX;?'N*)_!WB+2)-+\0+-(R#R+C
M$)^=>8SEQAQC8<-D8S7YD0>(OVJ/^"*WQMU_3O'VI/\ 'G]GG2H?"%EK6O\
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M-YK>853W3XX?LT>"/CCK_AGQY>:[K7AWQ;X+N;B;PIXP\-7,4=]IPN(Q'<1
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M1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_P 7Z( JKKO_ " [S_KTD_\
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MN,KL_@;_ ,CA-_V#W_\ 0TKTLF_Y&E'_ !(#UFBBBOU8#FOB[_R(%[_O1?\
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MM/\ T2E<[\>_^0;IW_7=_P#T$5T7PN_Y)GX=_P"P%:?^B4KG?CW_ ,@W3O\
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MO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ?^']4!N4445]^ 4444 %%%%
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MUX9\/O\ D==,_P"OM:]SK[WA+_<ZG^+]$ 55UW_D!WG_ %Z2?^@FK55==_Y
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MP%:?^B4KG?CW_P @W3O^N[_^@BO'S_\ Y%%7Y?F@/,J***_+P"BBB@ HHHH
M**** "BBB@ HHHH *[/X&_\ (X3?]@]__0TKC*[/X&_\CA-_V#W_ /0TKTLF
M_P"1I1_Q(#UFBBBOU8#FOB[_ ,B!>_[T7_HQ:\8KV?XN_P#(@7O^]%_Z,6O&
M*_/>*_\ D91_PK\Y %%%%?,@%%%% !1110 4444 %%%% !1110!L_#[_ )'7
M3/\ K[6O<Z\,^'W_ ".NF?\ 7VM>YU][PE_N=3_%^B *JZ[_ ,@.\_Z])/\
MT$U:JKKO_(#O/^O23_T$U]/6_A2]&!\^T445^-@%%%% !1110 4444 %%%%
M!1110 4444 ?14/^J7_=%.IL/^J7_=%.K]G6P!7@?BO_ )&G4O\ L(3?^AFO
M?*\#\5_\C3J7_80F_P#0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BB
MB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\
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M *&?_P DH/\ XBC_ (A-Q'_S]I?^!3_^5A_Q$#)O^?=3[H__ "9] T5\_?\
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M;'X>>)_']O:ZG'+;17@-M,]O8RW) MH[JX5##:O,2!&DSHTFX;0V17<U\?\
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M;R+9VUBMN+J17*[XXGN)(T7=M4D-(JG8,G@5X%^P'<RZ]XV^-GCKQ)8MX?\
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MG:4TLHA%U=7?E-;0B,MD1R-N=M@V%6)'N/CC4O$^D>#]2U'P5H,>J:Q':/\
MV5I\\_E1SW)&(UD?!V1[B-S $JN2 2,'PC_@K1+%#_P3U^(TDTBHHM=/RS'
M_P"0E:U[_P"(_$GA_P 'Z!>^*_%>MVNFZ9IUJ]S?ZA?3K%#;PHI9Y'=B J@
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MF3;GD'I7U-+\*_AA/*T\_P .-!=W8L[OH\!+$]23MY--_P"%3?"O_HFGA_\
M\$T'_P 173@\54P6)C7@DW'OMM;R.+,<#1S/!SPU5M1E:]M]&GU3[=C\V_\
MA)O"G_0Y:)_X.;?_ .+H_P"$F\*?]#EHG_@YM_\ XNOTD_X5-\*_^B:>'_\
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M_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(K7_6W,OY(?<_\
MY(Q_XA_DW_/RI]\?_D#\V_\ A)O"G_0Y:)_X.;?_ .+KU3]D#XW?"#X6_%"Z
M\1>._B7HEC9R:++ DW]HQRYD,L3!<1ECT5N<8XK[0_X5-\*_^B:>'_\ P30?
M_$4?\*F^%?\ T33P_P#^":#_ .(KGQ7$N.Q>'E1G&-I*VB=_S.K!<%Y7@,7#
M$4YS<HNZNXV^?NHX7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_
M^(KNO^%3?"O_ *)IX?\ _!-!_P#$4?\ "IOA7_T33P__ .":#_XBOGCZ\\'_
M &F_VN?V:OB%\%]6\)>#_C+HEYJ%R]N8+?[08]P6>-V^9P%&%4GD]J^4_P#A
M)O"G_0Y:)_X.;?\ ^+K])/\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__
M ()H/_B*]K+L\Q>64'2I1BTW?5/LET:['S>;\+Y?G6*5>O*2:27NM)63;ZQ?
M<_-O_A)O"G_0Y:)_X.;?_P"+H_X2;PI_T.6B?^#FW_\ BZ_23_A4WPK_ .B:
M>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(KO\ ];<R_DA]S_\ DCRO^(?Y
M-_S\J??'_P"0/RQ^-OQL^&7PB^%&N_$GQ?X@T>[TG2+$SZI;IJD$A:VR!*=@
M9B^$+';@[L8[U^>OQM\%>#?V-?C-K?[2G_!.+XV:'HUO->>%GE^%^B:]!=Z1
MXU.HWEQ!+%;PK(P61%"N#%Q%'YA7RQ7]*&J?!'X+ZY8OI>M?"'PO>6TN/,M[
MK0+:2-\$$95D(." ?J!7!>#_ /@GG^P[X ^+VJ?';P=^R?\ #W3O%.K6L$%S
MJMIX-L8Y$$?F_-&5B!C=Q,PD92#(%0-G8N.7$\18W%6YHQ36S2::]'?_ (&F
MIW8/@_+<"WR3FU+1IN+4EIHURV_57=G>UOR$_:=TOX9>*/\ @H1\ ]7^*6HZ
M!?>&['1O$J:(][J%O):1:^R6;0"3<Q02&".=HMW)>([?F%7OV<M?\&^'OVXO
MC9X?^'GB#2+?P6;/0)KR&SOHEL8O$CQW/VSR=K>6)&MQ9M/M_C*%OF8Y_9_Q
MA^SC^SS\0O#\_A/Q]\!_!FN:5<X^TZ9K'A>TN;>7!R-T<D95L'GD5XE\=/@/
M\#OA9\1?@AX)^&/P9\*>'-&/C::,Z1H/AVVL[4H;=F*^5$BIC/.,=>::XCQJ
MJ^TY(WO?9_R\O?:Q+X-RUT?9.I/EY>7>.W-S7^'>_P"!\'_%+XMGXJ_ SQ?%
M^R+\8/!&H>*[:6?2+.[F\4P)!9WR.J3JTB[]DL:,S*2C@/L)5E.#\>_'+Q'^
MV=X/\?\ [/?A,?!WX+Z9'H'CJ6/PG9:5\3Y[F&29=(O4*W4K6P:)/+,C&4[F
M:3 .2Q-?T1>'?V>?@#X0ANK;PG\#?!^EQWM]+>WD>G>&;6!9[F4[I)W"1C?(
MYY9SEF/))HUG]GGX ^(M0TW5O$'P-\'W]UH]T;K2+F\\,VLLEC.4:,RPLT9,
M3E'==RX.UB,X)J<1Q%F&(E=V6VR?1WZM]33!\'Y1@XV7-+?=KJK=$NE[=KL_
M.B'Q/X9,*&X\7Z&LA4;U76K<@'O@[Z?_ ,)-X4_Z'+1/_!S;_P#Q=?I)_P *
MF^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\175_K;F7\D/N?\ \D>?
M_P 0_P F_P"?E3[X_P#R!^;?_"3>%/\ H<M$_P#!S;__ !='_"3>%/\ H<M$
M_P#!S;__ !=?I)_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_
M !%/_6W,OY(?<_\ Y(/^(?Y-_P _*GWQ_P#D#X#^"?Q(^'?A'XLZ!XF\0^/M
M$M[&RU*.6ZG_ +5A?8@ZG"L2?P!K["_X;N_9#_Z+QHG_ 'U)_P#$5W7_  J;
MX5_]$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $T'_Q%>/F.9U\SJ1G5232MI?]
M6SZ')\EPN2494J$I-2=_>:?2W1(X7_AN[]D/_HO&B?\ ?4G_ ,16;XR_;>_9
M/U7PAJNEV'QST22>YTV>*"/>XW.T; #)7 Y(ZUZ9_P *F^%?_1-/#_\ X)H/
M_B*/^%3?"O\ Z)IX?_\ !-!_\17!&3A)270]:<%4@XOKH?FW_P )-X4_Z'+1
M/_!S;_\ Q='_  DWA3_H<M$_\'-O_P#%U^DG_"IOA7_T33P__P"":#_XBC_A
M4WPK_P"B:>'_ /P30?\ Q%?3_P"MN9?R0^Y__)'Q'_$/\F_Y^5/OC_\ ('YM
M_P#"3>%/^ART3_P<V_\ \71_PDWA3_H<M$_\'-O_ /%U^DG_  J;X5_]$T\/
M_P#@F@_^(H_X5-\*_P#HFGA__P $T'_Q%'^MN9?R0^Y__)!_Q#_)O^?E3[X_
M_('YM_\ "3>%/^ART3_P<V__ ,71_P )-X4_Z'+1/_!S;_\ Q=?I)_PJ;X5_
M]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,11_K;F7\D/N?\ \D'_ !#_
M ";_ )^5/OC_ /('YL3>*_"-O$TTGC#1R%&2$U:!C^ #DFG+XH\)NH<>,=%P
M1D9UB '\B]?:G[:_PW^'>D_LI^.=2TKP%HMM<0Z&[13V^EPHZ'<O(8+D'Z5V
MWPT^%GPQN/AQX?GG^'&@N[Z):,[OH\!+$PJ222O)H_UMS+^2'W/_ .2#_B'^
M3?\ /RI]\?\ Y _/;_A)O"G_ $.6B?\ @YM__BZ/^$F\*?\ 0Y:)_P"#FW_^
M+K])/^%3?"O_ *)IX?\ _!-!_P#$4?\ "IOA7_T33P__ .":#_XBC_6W,OY(
M?<__ )(/^(?Y-_S\J??'_P"0/S;_ .$F\*?]#EHG_@YM_P#XNC_A)O"G_0Y:
M)_X.;?\ ^+K])/\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*
M/];<R_DA]S_^2#_B'^3?\_*GWQ_^0/S;_P"$F\*?]#EHG_@YM_\ XNC_ (2;
MPI_T.6B?^#FW_P#BZ_23_A4WPK_Z)IX?_P#!-!_\11_PJ;X5_P#1-/#_ /X)
MH/\ XBC_ %MS+^2'W/\ ^2#_ (A_DW_/RI]\?_D#@;;]NO\ 9&CMHXW^.^B
MJ@!&Z3KC_=J3_AN[]D/_ *+QHG_?4G_Q%=U_PJ;X5_\ 1-/#_P#X)H/_ (BC
M_A4WPK_Z)IX?_P#!-!_\17RQ]PE96.%_X;N_9#_Z+QHG_?4G_P 17Q=\2/'G
M@37_ (B:_KND^.M$EM;W6KJ>VE_M:!=\;S,RMAF!&00<$ U^A?\ PJ;X5_\
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M.FS(=/F879BC\_8A<"&6)W*&5%(!],T5\!_!?_@KW^UO^T)\ /B3^T1\(O\
M@FW8:QIGPN\4ZWX?U[2(OC-&NHW=YI04W0M8VTL)*,-E,NK/C 7. =7]G/\
MX*M?M:?M+_L?:!^W1\-?^"9]UKO@?7M/N+^#2?#/Q5MKKQ"UO!<2P2F*QGL[
M>.:0&&0K$MQN? "@LP% 'V9\2/A]X<^*O@74_AWXNBE?3=6MC!>+!*4<H2#P
MPZ'BM+1M*M-!T>TT/3U8065M'! ';)"(H5<GN< 5Y_\ LD?M8_!+]M[X :!^
MTK^SYXE?4_#/B&%S ;BW,-S:3QNT<UK<1-S%-%(K(Z'/*Y!92&/.Z%^V5:ZW
M_P %!M?_ &!C\*-8@N="^%=EXV/C&6>/[%<Q7-_+9K:J@^</NBD(8G!\N08&
MT%@#VNBOC3]K'_@JQ\5/V:5\4?%;PY_P3U\>^-_@Q\/]0GM/'OQ1TCQ!IUN]
MI]ED,5_/9Z7,_P!IOK>UD5TEF_=+NBE*[DC,E?0GCG]IWP%X8_9RM?VE_".G
M:GXPTC6=*L+SPGIWAFU$MYX@:_,2V,-LDA10TS3Q -(R(@8O(R(K, #T>BOD
MW]FW_@ICXZ\=?M:+^Q'^UW^QOXA^"7Q UCPU/X@\#Q7_ (HL=<T[Q)80.%N%
MAO+,[$N8MP9X""0N6W8V[OK*@ HHHH **** "BBB@ HHKY"_:/\ ^"G'Q%_9
M9_;R^%/[('Q8_9AT^Q\+?&/6)M-\'_%I_'Y73A=1HS"RN(38;X;R3$21P[BD
MCSH%E($A0 ^O:*\&_;-_; \??LX>+_AK\+?@S\#;/XD^,_B9XAN-.TOPNWB\
M:3-;VMO;-<7.I.[6TR_9(%55E<E2K3P(HD>55KQW0_\ @IS^U[X@_;8US]@>
MP_8&\,_\)SX?\ 6_C"^ED^-A%@=.FN1;($E_L?<9?,/*E ,<[NU 'VW17P;^
MR_\ \%8_VQOVK/BK\6_@IX*_X)I66D^)?@KKUMI'C/2_$/QGA@=IYUE>$VS)
MIKQS(Z0EU<L@*NAS@\>Y_L6?\%!? 7[7_B3QK\(-4^'7B+X=_%+X9WT-KX_^
M&GB]8?MVF^<I>WNH98'>&[M)E!:.>)B&&"0NY=P!ZW\+?A3X1^#WAV?POX+A
MG2TN-2N+Z07$YD;SIGWN<GMGH.U=)7BG[77[95K^R=XS^#G@^\^%&L>)/^%O
M_%2S\$V]YI<\:1Z1+/;SSBZFW<NBI;R,57!VHYS\H5J7[5W[67QK^$'B:W^&
M/[+O['&O?&?Q@-(&L:OI=AXGL=#LM*L&DDBA>:]OF"---)#,L4$:NS>1(SF-
M5#, >\45XK^P/^W#\//V_P#X!_\ "Z_ OA76O#=[INOWWA[Q?X0\26XBU#P[
MK5E(([JPN I*[T)5@0>5=20I)46?BK^VE\+?A?\ M:_"S]C*2[M[_P 9_$\:
MM=0Z?#?J)=,TZPL9KE[R6, DJ\B)"@.S<6D8$^4RD ]AHHHH **** "BBB@
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MFT[2M(T*R:9[FY9(+?3[>*,[G+-A8D2,-D\!5!Z"OF[]ESX57GQP_;&\5_\
M!3?Q/HMQIEGJ_@.T\"?":PN[=H;F7PU%>/?SZI<1L T;7MVZ/%$P#);6T#.%
M>9XX^Z_;E_8H\-?MY?"2W^"OC?XW?$/P9HL>KP:A??\ "N]9MK&;46A;?%#<
M//;3[X5D"R>6 H9D4MNV@5RG[-7_  39TO\ 9V^+EK\8-<_;5_:"^*-SI]A<
M6^EZ-\5_B*FJ:;92S!4:[C@CMH1]H$8DB61BVU)Y0!\V0 >._P#!Q1\ /@1X
MV_X)I_$CXV^,O@IX1U?QGX8TS2XO#?B[4_#=K<:II*-K-F&6VNGC,L (=\A&
M4'>WJ:^]:\B_;?\ V.?!O[>/[/NK_LT?$KXC>+/#WAO7V@_MD^$)[*&YNDBG
MBG2,R75K/L421(<H%8X()P2*].\,:1J&@Z!:Z/JOBB_UNXMX@DNJZG';I<7)
M_ON+>**('_<C4<=* +]%%% !1110 4444 %%%% 'YJ_\'&W@;7/V</@QX=_X
M+,_L\ZW;Z#\7?V>-4LH8+N:V,D'B+0]2OH;"?2;Q%93)#YEV)%^;* S;=K2!
MU^X_V4?V??#W[-7P7T_X?Z3K-UK.I74TNJ^*_%&I*OVSQ#K%TWFWFHW!7CS)
M922%'RQH$C0*D:*.0_X*%?L!_#G_ (*2_L_WG[,7QG^*7C70?!VJW,$VNZ=X
M,N[&W?4_(GCN(4EDN;2=PJ311N!&4R5&[<.*].\+?#O7?#'PLMOAN_Q@\3:C
M>VM@+6/Q?J4>GMJ;$#"RL$M%MFD QR8,'&2"<F@#\^/^"&7_ "8?^U-_V<E\
M2OY15Z9_P;:$#_@B-\!23_S ]3_]/%]7;?LS_P#!)OP%^R;\%?B%\"/A'^U=
M\8$TCXEZQJ.KZ]=:E?Z)<7<&HWZHEW=6\ITH>6\BH,@AD4DLJJQW5R_PS_X(
MC_#3X4_LZ67[(7A7]N/]HF'X765C-9)X+M_%^E6<+VDLKRS6[7-IID-V(Y&D
MDW!9P2KLN<'% '#?\&Z]Q:ZS\,_VG_&?@YU;P1K_ .V7XZO_  !+#S!-I;/:
MA9("./)+*X7'&5:OON'P;X3M_&-S\0H/#EFFNWFF0:==:NMNOVB6TADEEB@+
MXR8U>>9@O0&1CWK#^ GP$^#W[+_P@T'X"? +P#8^&/"'AFR%KHNB:<K>7;Q[
MBS$LQ+.[.S.\CEG=V9F)9B3U] 'S?_P4+N-7^,?PHUC_ ()]_!:2'_A,OBYX
M<NM)U6Y2(-%X6\.78>VU#6;D#A?W3S1VT9^:XNF51\D<\D7M_P -/AGX*^#O
MPO\ #?PG\&Z<MMH7@_0[32M$AG8,;>UM8%@B&X]UC0#/UKY.UO\ X(N:%J?Q
M3\7_ !ATC_@I/^U;H.L>.-8.I>(#X<^)ME912R!0D4:I'IP"Q11@1QQ]$10!
MWSZQ\6/^"?W@?XL?L3P?L*S_ !T^)VA^'#ID5AK/B?1/$L/]OZY",FX^V7MQ
M;R^:UT[-)<,$4REW!(1V0@''_#+P%:?MC?MU:1^WP8 ? ?PO\):GX9^$%X1S
MX@N]1EA.J:W&>]GY=K!:VS])Q]IF7,3P22?55?*OP#_X)3Z!\#/BAX<^)&J?
MMU?M(>/[7PO*TNF>#OB'\2X[W0VE\AX8GDM(K2(2&+?OC!.U)$1P,HN/JJ@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45QWQ!^/OPE^%>M1>'O'GB
MS[!>36JW$</V">7,19E#9CC8=488SGCZ5A?\-D?LW_\ 11O_ "D7G_QFNN&
MQU6"E"E)I]5%M?D<%7-<KH5'"I7A&2W3E%->J;/3J*\Q_P"&R/V;_P#HHW_E
M(O/_ (S7HFB:SIOB/1;3Q#HUSYUG?VL=Q:3;&7?$ZAE;# $9!!P0#45L)BL.
MDZM.4;]TU^9IA\?@<9)JA5C-K?EDG^3+5%%%<YUA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !14=Y=V^GVDM_=R;(H(VDE?!.U0,DX')X
M%8'_  MKX??]#!_Y*2__ !%85L5A<.TJLU&_=I?F!T=%<Y_PMKX??]#!_P"2
MDO\ \15W0O''A?Q->-8:)JGGRI&9&3R'7"@@9RR@=2*SAC\#4FHPJQ;?123?
MY@:U%%%=8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\>?\ !07_ )+-IG_8L0_^E%S7A5>Z_P#!07_D
MLVF?]BQ#_P"E%S7A5?K&2_\ (JH^A^!\3?\ (^Q'^(*_1'X)_P#)&?"/_8L6
M'_I/'7YW5^B/P3_Y(SX1_P"Q8L/_ $GCKQ.+_P#=J7J_R/IO#W_?*_\ A7YG
M3T445\$?JP53\0:9>ZSHEUI6G>(;S29[B%DBU/3TA:>V8]'03QR1EAVWHR^H
M-7** /S-_P""77C3_@IW^WK\#O'_ ,3O$_\ P4HN-#U7PK\6O$'@_2K>'X1:
M#/9R1Z=*D<<\Z>5'(Y?=EE22/I@,.M>\_P#!*?\ X*#>,OVMOV8_'?C[]IY_
M"FB:[\)OBMKO@+Q9XFT6X-MH>K2Z8T(_M.W-P[>5!(LZ<,[#<K8(!"C\[O\
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M$WP^_8DO?V.5\+^!/A?H_P"U-J.@>';;5=:$_B>^M'M-?M-2O-1F9U^RQ37
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M6I_'+P?;6T\D"0W$_B:U1)&FC$D*JQDP3(A#H!]Y2",BOB7Q-^S!^SM\1O\
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ML[63X@7&FM:2Z]&L8$5T\333,':+9N9I'+MER<L:]-H **** "BBB@ HHHH
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M_HT2+9P165Q>L(I"93-=QG"^0&;ZSHH **** "BBB@ HHHH **** *VL:?\
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M8]\.>'M;\)>'OV4?AK8:5XE8MXCTRR\"Z?%;ZJ2<DW,:PA9SD _.#R*]*HH
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M?@/X ^"M$U#PUH\FD^'+_2/"MG;3:58.Y=[2V>.,-! SL6,2$(222,FNUHH
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079370624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,113,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078121136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,589.1<span></span>
</td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 5,120.9<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">484.0<span></span>
</td>
<td class="nump">459.7<span></span>
</td>
<td class="nump">1,237.9<span></span>
</td>
<td class="nump">937.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">528.6<span></span>
</td>
<td class="nump">585.1<span></span>
</td>
<td class="nump">1,080.3<span></span>
</td>
<td class="nump">1,099.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">572.6<span></span>
</td>
<td class="nump">637.3<span></span>
</td>
<td class="nump">1,207.5<span></span>
</td>
<td class="nump">1,232.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">67.5<span></span>
</td>
<td class="nump">604.1<span></span>
</td>
<td class="nump">134.4<span></span>
</td>
<td class="nump">702.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(87.9)<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">108.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(428.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(165.3)<span></span>
</td>
<td class="nump">410.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,319.6<span></span>
</td>
<td class="nump">2,192.9<span></span>
</td>
<td class="nump">3,504.0<span></span>
</td>
<td class="nump">4,419.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,269.5<span></span>
</td>
<td class="nump">582.1<span></span>
</td>
<td class="nump">1,616.9<span></span>
</td>
<td class="nump">1,049.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">216.7<span></span>
</td>
<td class="num">(409.1)<span></span>
</td>
<td class="nump">342.3<span></span>
</td>
<td class="num">(364.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="num">(5.9)<span></span>
</td>
<td class="num">(34.3)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,058.7<span></span>
</td>
<td class="nump">1,025.5<span></span>
</td>
<td class="nump">1,277.2<span></span>
</td>
<td class="nump">1,430.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">577.0<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="nump">571.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,058.0<span></span>
</td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,361.8<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.24<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 9.27<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">149,700<span></span>
</td>
<td class="nump">146,500<span></span>
</td>
<td class="nump">150,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">146,200<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">151,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,054.9<span></span>
</td>
<td class="nump">$ 2,236.0<span></span>
</td>
<td class="nump">$ 4,121.2<span></span>
</td>
<td class="nump">$ 4,447.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">436.3<span></span>
</td>
<td class="nump">440.0<span></span>
</td>
<td class="nump">835.7<span></span>
</td>
<td class="nump">829.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 97.9<span></span>
</td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="nump">$ 164.0<span></span>
</td>
<td class="nump">$ 192.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078141280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,058.0<span></span>
</td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,361.8<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="nump">73.1<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="num">(36.0)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">1,062.8<span></span>
</td>
<td class="nump">451.0<span></span>
</td>
<td class="nump">1,358.1<span></span>
</td>
<td class="nump">985.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">576.9<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="nump">572.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 1,063.5<span></span>
</td>
<td class="nump">$ 1,027.9<span></span>
</td>
<td class="nump">$ 1,273.5<span></span>
</td>
<td class="nump">$ 1,557.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761076485552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,646.6<span></span>
</td>
<td class="nump">$ 2,261.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,151.3<span></span>
</td>
<td class="nump">1,541.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,567.6<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">435.9<span></span>
</td>
<td class="nump">412.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,294.2<span></span>
</td>
<td class="nump">1,351.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,645.3<span></span>
</td>
<td class="nump">740.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,740.9<span></span>
</td>
<td class="nump">7,856.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,102.9<span></span>
</td>
<td class="nump">892.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,355.1<span></span>
</td>
<td class="nump">3,416.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">321.1<span></span>
</td>
<td class="nump">375.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,075.3<span></span>
</td>
<td class="nump">2,221.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,749.6<span></span>
</td>
<td class="nump">5,761.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,235.7<span></span>
</td>
<td class="nump">1,415.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,500.8<span></span>
</td>
<td class="nump">1,939.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,081.4<span></span>
</td>
<td class="nump">23,877.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">999.8<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">284.9<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">434.8<span></span>
</td>
<td class="nump">589.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">3,298.5<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,018.0<span></span>
</td>
<td class="nump">4,298.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,277.4<span></span>
</td>
<td class="nump">6,274.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">480.6<span></span>
</td>
<td class="nump">694.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">274.2<span></span>
</td>
<td class="nump">330.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,167.8<span></span>
</td>
<td class="nump">1,320.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,218.0<span></span>
</td>
<td class="nump">12,917.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(110.4)<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,959.9<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">11,872.5<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(9.1)<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,863.4<span></span>
</td>
<td class="nump">10,959.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 25,081.4<span></span>
</td>
<td class="nump">$ 23,877.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761076415488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,277.2<span></span>
</td>
<td class="nump">$ 1,430.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">277.9<span></span>
</td>
<td class="nump">219.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">305.6<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">123.3<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(47.5)<span></span>
</td>
<td class="num">(622.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">269.3<span></span>
</td>
<td class="nump">283.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="num">(1,505.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">104.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(67.3)<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(243.3)<span></span>
</td>
<td class="num">(193.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="nump">634.0<span></span>
</td>
<td class="num">(188.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(65.9)<span></span>
</td>
<td class="nump">171.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(134.0)<span></span>
</td>
<td class="num">(97.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">898.3<span></span>
</td>
<td class="nump">1,996.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(94.8)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,461.5<span></span>
</td>
<td class="nump">1,452.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(2,311.6)<span></span>
</td>
<td class="num">(1,626.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity in Samsung Bioepis</a></td>
<td class="num">(990.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from the sales of strategic investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="num">(217.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(500.0)<span></span>
</td>
<td class="num">(1,050.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings and premiums paid on debt exchange</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(170.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="num">(94.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(488.0)<span></span>
</td>
<td class="num">(1,349.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">455.8<span></span>
</td>
<td class="nump">429.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(70.6)<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,261.4<span></span>
</td>
<td class="nump">1,331.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 2,646.6<span></span>
</td>
<td class="nump">$ 1,742.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069520336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="nump">$ 13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,700.3<span></span>
</td>
<td class="num">$ (14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,430.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
<td class="nump">571.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (163.3)<span></span>
</td>
<td class="num">$ (886.7)<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="nump">13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">10,663.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(174.3)<span></span>
</td>
<td class="nump">13,833.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,682.2<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,025.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="nump">577.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450.0)<span></span>
</td>
<td class="num">(450.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69.5)<span></span>
</td>
<td class="num">(380.5)<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="nump">13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">10,959.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,277.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361.8<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186.4)<span></span>
</td>
<td class="num">(313.6)<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(40.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">11,863.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="nump">14,959.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,872.5<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">171.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">11,220.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
<td class="num">(115.2)<span></span>
</td>
<td class="nump">14,215.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,242.3<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,058.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (186.4)<span></span>
</td>
<td class="num">$ (313.6)<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 11,863.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.4)<span></span>
</td>
<td class="nump">$ 14,959.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 11,872.5<span></span>
</td>
<td class="num">$ (9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077213216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the Financial Accounting Standards Board issued Accounting Standards Update No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024, and is not expected to have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077473792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES <div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recognized approximately $70.6 million and $108.7 million, respectively, of pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $60.9&#160;million and $88.6&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the six months ended June 30, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recorded other restructuring costs of approximately $9.7&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs includes items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079736784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">672.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,160.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,462.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,358.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,351.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,121.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 27.4% and 11.2% of gross product revenue for the three months ended June 30, 2022, and 26.8% and 10.8% of gross product revenue for the six months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 30.2% and 9.9% of gross product revenue for the three months ended June 30, 2021, and 30.1% and 9.6% of gross product revenue for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,690.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(833.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,077.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(391.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(500.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">822.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761081990288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">706.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of June 30, 2022, includes approximately $71.5&#160;million related to lecanemab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June 30, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761163369904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,522.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,598.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,522.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,075.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, amortization and impairment of acquired intangible assets totaled $67.5 million and $134.4 million, respectively, compared to $604.1 million and $702.2 million, respectively, in the prior year comparative periods. For the three and six months ended June 30, 2022, we had no impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and six months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of June 30, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the carrying value associated with the remaining IPR&amp;D intangible asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $119.2&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial or sooner if there is a reevaluation event and may record an impairment charge related to this asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $365.0&#160;million to $15.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $191.6&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D intangible asset from $220.0&#160;million to $28.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized additional impairment charges related to BIIB111 and BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to zero.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077523264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,591.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,727.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,194.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of June 30, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents a portion of our investment in the common stock of Sage Therapeutics, Inc. (Sage) and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. This initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 and is reflected as a Level 1 measurement as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial holding period restriction for a portion of our investment in the common stock of Sangamo Therapeutics, Inc. (Sangamo) expired during the second quarter of 2021 and the remaining portion expired during the second quarter of 2022. The holding period restriction for our investment in the common stock of Denali Therapeutics Inc. (Denali) expired during the first quarter of 2022. As of June 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as level 2 instruments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.96%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 10.9% to certain probability as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$197.5&#160;million and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, chang</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,730.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,066.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,546.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,277.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The change in the fair value of our Senior Notes as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to December 31, 2021, is related to the increase in U.S. treasury yields and wider credit spreads used to value the notes since December 31, 2021. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079247360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,357.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(341.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(351.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,135.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of June 30, 2022 and December 31, 2021, was approximately 11 months and 10 months, respectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $839.3 million and $1,110.3 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in our strategic investment portfolio for the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, were primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761163355760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of June 30, 2022 and December 31, 2021, had durations of 1 to 15 months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,525.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $137.6&#160;million to be settled over the next 15 months, of which approximately $133.7 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of our equity interest in Samsung Bioepis we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,230.4 million and $1,268.0 million as of June 30, 2022 and December 31, 2021, respectively. Net losses of $37.1 million and $49.3&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2022, respectively, compared to net gains of $4.8&#160;million and net losses of $12.6&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077412176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,131.0 million and $2,006.6 million as of June 30, 2022 and December 31, 2021, respectively. For the three and six months ended June 30, 2022, depreciation expense totaled $67.2 million and $143.5&#160;million, respectively, compared to $54.7 million and $103.5&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of June 30, 2022 and December 31, 2021, we had approximately $691.7 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite will be operational during the second half of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761163355760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and will recognize a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income during the third quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078373360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.4&#160;million shares of our common stock at a cost of approximately $500.0&#160;million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately 1.6&#160;million and 3.8&#160;million shares of our common stock at a cost of approximately $450.0&#160;million and $1.1&#160;billion, respectively. Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077276112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077244640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079293104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, compared to the same periods in 2021, the increases in our effective tax rate were primarily due to the overall current year unfavorable tax rate impact on the sale of our equity interest in Samsung Bioepis in April 2022, the litigation agreement in principle and the tax benefit recorded in the second quarter of 2021 related to the Neurimmune SubOne AG (Neurimmune) deferred tax asset matter, as discussed below. These effective tax rate increases were partially offset by the non-cash tax effects of changes in the value of our equity instruments and the current year tax benefits recorded in the second quarter of 2022 related to an international reorganization to align with global tax developments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, compared with the same period in 2021, our effective tax rate also increased as a result of the Neurimmune valuation allowance recorded in the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $500.0&#160;million, including approximately $455.0&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit</span></div>closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077220848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(428.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended June 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(267.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(267.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(288.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo and Denali common stock of approximately $75.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,298.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,167.8 million and $1,320.5 million as of June 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $499.6 million and $664.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077220848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years, and we will manufacture the lecanemab drug substance.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of June 30, 2022, Eisai's portion of these expenses was approximately $275.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third-party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$28.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$210.6&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to $40.1&#160;million in each of the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$250.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $285.4&#160;million as of June 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $46.5&#160;million as of June 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recorded $18.0&#160;million and $37.5&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$77.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in each of the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of the transaction.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $675.0 million and related to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of 15 years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized net income on our investment of $5.9 million and $2.6 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $13.0&#160;million and $17.0&#160;million, respectively, offset by amortization of basis differences totaling $7.1&#160;million and $14.4&#160;million, respectively. These amounts reflect our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating income, net of tax totaling $41.6&#160;million and $30.6&#160;million, respectively, and amortization of basis differences totaling $7.3&#160;million and $14.5&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 713.3 billion South Korean won ($599.9 million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to zero.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2022, we recognized net profit-sharing expense of $58.3&#160;million and $122.7 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $69.9 million and $138.4 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $3.1&#160;million and $4.1&#160;million as of June 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $121.1&#160;million and $148.7&#160;million as of June 30, 2022 and December 31, 2021, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2021 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077235968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.0%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $23.5 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077244640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 (the November 2020 Securities Action) and February 7, 2022 (the February 2022 Securities Action), and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the November 2020 Securities Action, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#8217; fees and costs to the plaintiff. The court has stayed the case pending the resolution of the February 2022 Securities Action. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). Fresenius Kabi later added European Patent 3 145 488 (the EP &#8216;488 Patent, expiring in May 2035) to both actions and no hearing has been set in either.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP &#8216;510 Patent. The EPO has scheduled a hearing on the validity of the EP &#8216;488 Patent for October 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biogen has reached an agreement in principle to resolve previously disclosed litigation pending in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. The litigation was filed by Michael Bawduniak on behalf of the U.S. and certain states and unsealed in 2015. The U.S. has not intervened in the case. The agreement in principle contemplates Biogen making a payment of $900.0&#160;million. The agreement in principle does not include any admission of liability and is subject to the negotiation of final settlement documents and agreements with the named government entities. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description and in June 2022 we filed a petition for a writ of certiorari to the United States Supreme Court seeking review of the Federal Circuit's decision.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#8216;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for November 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for February 2023.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079252400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079337408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text">DISPOSITIONS <div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $581.6&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022, we recognized a pre-tax gain of approximately $1.5&#160;billion related to the transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value based on risk-adjusted discount rates of 3.1% and 3.7% for the first and second payments due, respectively. As of June 30, 2022, the estimated fair values of the first and second payments were approximately $788.1 million and $406.8 million, respectively, and have been classified as level 3 measurements reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any payments due to us remain outstanding after the second anniversary of the closing of the transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the three and six months ended June 30, 2022, we recorded a discrete tax expense of approximately $269.5&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079237136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the Financial Accounting Standards Board issued Accounting Standards Update No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024, and is not expected to have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077277344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069410384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">672.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,160.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,462.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,358.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,351.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,121.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,690.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(833.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,077.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(391.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(500.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">822.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077502048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">706.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of June 30, 2022, includes approximately $71.5&#160;million related to lecanemab.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079589760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,522.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,598.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,522.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,075.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078118224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,591.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,727.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,194.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.96%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,730.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,066.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,546.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,277.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079233808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,144.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,357.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(341.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(351.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,135.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077964592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,525.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079274944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077421440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079275072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077490944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077573472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(428.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(267.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses) recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(267.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(288.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo and Denali common stock of approximately $75.3&#160;million.</span></div>The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation agreement in principle</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,298.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation agreement in principle, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077386352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third-party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079344096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079213200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 108.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761073628400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 70.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 108.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustment</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember', window );">Workforce Reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(29.7)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069109616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,589.1<span></span>
</td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 5,120.9<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,426.6<span></span>
</td>
<td class="nump">1,529.2<span></span>
</td>
<td class="nump">2,821.1<span></span>
</td>
<td class="nump">3,012.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">753.7<span></span>
</td>
<td class="nump">826.3<span></span>
</td>
<td class="nump">1,462.8<span></span>
</td>
<td class="nump">1,577.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">672.9<span></span>
</td>
<td class="nump">702.9<span></span>
</td>
<td class="nump">1,358.3<span></span>
</td>
<td class="nump">1,435.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">534.7<span></span>
</td>
<td class="nump">578.5<span></span>
</td>
<td class="nump">1,072.6<span></span>
</td>
<td class="nump">1,131.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">250.6<span></span>
</td>
<td class="nump">269.1<span></span>
</td>
<td class="nump">492.9<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">284.1<span></span>
</td>
<td class="nump">309.4<span></span>
</td>
<td class="nump">579.7<span></span>
</td>
<td class="nump">626.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">397.9<span></span>
</td>
<td class="nump">487.6<span></span>
</td>
<td class="nump">807.8<span></span>
</td>
<td class="nump">966.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">120.7<span></span>
</td>
<td class="nump">178.4<span></span>
</td>
<td class="nump">237.8<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">277.2<span></span>
</td>
<td class="nump">309.2<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
<td class="nump">626.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">136.8<span></span>
</td>
<td class="nump">90.9<span></span>
</td>
<td class="nump">264.8<span></span>
</td>
<td class="nump">164.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">129.9<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
<td class="nump">164.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">350.2<span></span>
</td>
<td class="nump">400.4<span></span>
</td>
<td class="nump">659.8<span></span>
</td>
<td class="nump">800.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">211.2<span></span>
</td>
<td class="nump">257.4<span></span>
</td>
<td class="nump">393.5<span></span>
</td>
<td class="nump">499.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">139.0<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">266.3<span></span>
</td>
<td class="nump">301.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">258.7<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">488.3<span></span>
</td>
<td class="nump">622.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">171.0<span></span>
</td>
<td class="nump">214.0<span></span>
</td>
<td class="nump">319.0<span></span>
</td>
<td class="nump">423.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">87.7<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">169.3<span></span>
</td>
<td class="nump">198.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">91.5<span></span>
</td>
<td class="nump">89.5<span></span>
</td>
<td class="nump">171.5<span></span>
</td>
<td class="nump">178.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">102.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">516.2<span></span>
</td>
<td class="nump">524.2<span></span>
</td>
<td class="nump">1,037.0<span></span>
</td>
<td class="nump">1,027.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">291.9<span></span>
</td>
<td class="nump">299.8<span></span>
</td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">573.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">224.3<span></span>
</td>
<td class="nump">224.4<span></span>
</td>
<td class="nump">460.6<span></span>
</td>
<td class="nump">454.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">431.1<span></span>
</td>
<td class="nump">499.7<span></span>
</td>
<td class="nump">903.6<span></span>
</td>
<td class="nump">1,020.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">139.8<span></span>
</td>
<td class="nump">149.3<span></span>
</td>
<td class="nump">303.1<span></span>
</td>
<td class="nump">298.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">291.3<span></span>
</td>
<td class="nump">350.4<span></span>
</td>
<td class="nump">600.5<span></span>
</td>
<td class="nump">722.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">194.4<span></span>
</td>
<td class="nump">202.4<span></span>
</td>
<td class="nump">388.7<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">193.9<span></span>
</td>
<td class="nump">202.4<span></span>
</td>
<td class="nump">388.2<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">115.8<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
<td class="nump">243.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">115.8<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
<td class="nump">243.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">113.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">113.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,054.9<span></span>
</td>
<td class="nump">2,236.0<span></span>
</td>
<td class="nump">4,121.2<span></span>
</td>
<td class="nump">4,447.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">894.1<span></span>
</td>
<td class="nump">977.2<span></span>
</td>
<td class="nump">1,769.3<span></span>
</td>
<td class="nump">1,877.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,160.8<span></span>
</td>
<td class="nump">$ 1,258.8<span></span>
</td>
<td class="nump">$ 2,351.9<span></span>
</td>
<td class="nump">$ 2,570.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078411296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,690.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(64.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,077.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(500.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">983.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">137.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">337.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(243.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(98.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">132.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">759.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,346.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(58.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(833.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(391.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">822.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">38.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 29.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079176096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 983.8<span></span>
</td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">137.8<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 846.0<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069492448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,589.1<span></span>
</td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 5,120.9<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">139.9<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="nump">283.1<span></span>
</td>
<td class="nump">352.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">296.4<span></span>
</td>
<td class="nump">261.2<span></span>
</td>
<td class="nump">552.6<span></span>
</td>
<td class="nump">476.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 436.3<span></span>
</td>
<td class="nump">$ 440.0<span></span>
</td>
<td class="nump">$ 835.7<span></span>
</td>
<td class="nump">$ 829.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078149040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,589.1<span></span>
</td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 5,120.9<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">87.1<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
<td class="nump">192.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079208688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,589.1<span></span>
</td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 5,120.9<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">27.40%<span></span>
</td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="nump">$ 128.7<span></span>
</td>
<td class="nump">$ 170.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 97.9<span></span>
</td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="nump">$ 164.0<span></span>
</td>
<td class="nump">$ 192.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078138304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 378.0<span></span>
</td>
<td class="nump">$ 349.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">706.3<span></span>
</td>
<td class="nump">814.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">209.9<span></span>
</td>
<td class="nump">187.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">1,294.2<span></span>
</td>
<td class="nump">$ 1,351.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LecanemabMember', window );">Lecanemab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 71.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LecanemabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LecanemabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069120864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305.6<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">$ 28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
<td class="nump">$ 210.6<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai | Centers for Medicare and Medicaid Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761072947344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,598,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,598,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,609,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,522,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,522,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,075,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,221,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">67,500,000<span></span>
</td>
<td class="nump">$ 604,100,000<span></span>
</td>
<td class="nump">134,400,000<span></span>
</td>
<td class="nump">$ 702,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">130,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">210,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">195,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">195,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">180,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,415,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,415,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,413,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,892,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,024,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,522,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,522,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member', window );">BIIB111 and BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079188400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,761,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(11,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,749,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761074627728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,254.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,433.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 2,144.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">785.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,591.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,228.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">197.5<span></span>
</td>
<td class="nump">$ 202.0<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 226.0<span></span>
</td>
<td class="nump">$ 259.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">220.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">788.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">406.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,890.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,156.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">668.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">668.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,144.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">116.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,727.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,890.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,156.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,194.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">197.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">197.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">788.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">406.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077978176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 197,500,000<span></span>
</td>
<td class="nump">$ 197,500,000<span></span>
</td>
<td class="nump">$ 209,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761173777840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0396<span></span>
</td>
<td class="nump">0.0130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079397776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 7,277.2<span></span>
</td>
<td class="nump">$ 7,273.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">$ 6,546.7<span></span>
</td>
<td class="nump">8,004.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,001.1<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 999.8<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,730.1<span></span>
</td>
<td class="nump">1,895.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,743.8<span></span>
</td>
<td class="nump">1,742.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,066.3<span></span>
</td>
<td class="nump">1,475.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,100.1<span></span>
</td>
<td class="nump">1,492.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,232.2<span></span>
</td>
<td class="nump">1,463.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,492.5<span></span>
</td>
<td class="nump">1,099.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,027.9<span></span>
</td>
<td class="nump">1,457.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,473.4<span></span>
</td>
<td class="nump">1,473.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 489.1<span></span>
</td>
<td class="nump">692.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 467.6<span></span>
</td>
<td class="nump">$ 466.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069428272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">202.0<span></span>
</td>
<td class="nump">226.0<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077793760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2,144.9<span></span>
</td>
<td class="nump">$ 1,632.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">247.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">83.8<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,764.5<span></span>
</td>
<td class="nump">901.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 216.9<span></span>
</td>
<td class="nump">$ 283.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761067767136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 3,279.6<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,254.2<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,137.2<span></span>
</td>
<td class="nump">1,167.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(351.6)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">785.6<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,363.9<span></span>
</td>
<td class="nump">723.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,357.6<span></span>
</td>
<td class="nump">723.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">540.4<span></span>
</td>
<td class="nump">385.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">532.7<span></span>
</td>
<td class="nump">384.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">798.0<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">793.6<span></span>
</td>
<td class="nump">816.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">367.2<span></span>
</td>
<td class="nump">377.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">376.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="nump">131.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">206.9<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,103.3<span></span>
</td>
<td class="nump">1,133.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(341.9)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 761.4<span></span>
</td>
<td class="nump">$ 1,004.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761069426480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 2,151.3<span></span>
</td>
<td class="nump">$ 1,541.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">2,135.6<span></span>
</td>
<td class="nump">1,541.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">1,089.4<span></span>
</td>
<td class="nump">868.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">1,130.1<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,254.2<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 3,279.6<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761080198224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 917.9<span></span>
</td>
<td class="nump">$ 633.5<span></span>
</td>
<td class="nump">$ 1,461.5<span></span>
</td>
<td class="nump">$ 1,452.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761080331840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077416576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 839.3<span></span>
</td>
<td class="nump">$ 1,110.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761073946624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="num">$ (12.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">$ (25.5)<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,525.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,525.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.7<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.6<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="num">(53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,828.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761074501136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,006.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">67.2<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
<td class="nump">$ 143.5<span></span>
</td>
<td class="nump">$ 103.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">691.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 677.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761067806960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.8<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">$ 131.9<span></span>
</td>
<td class="nump">$ 121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionRate', window );">Redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079990352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="nump">$ 1,050,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761074576432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106.7)<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (110.4)<span></span>
</td>
<td class="num">$ (171.8)<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">78.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34.5)<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(110.4)<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(20.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.1)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(20.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="num">(179.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">126.9<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.5<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.4)<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.1<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">126.9<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139.0)<span></span>
</td>
<td class="num">(46.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(79.2)<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(79.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94.9)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36.0)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (175.0)<span></span>
</td>
<td class="num">$ (79.2)<span></span>
</td>
<td class="num">$ (175.0)<span></span>
</td>
<td class="num">$ (79.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761067599264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">$ 428.6<span></span>
</td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="nump">$ 165.3<span></span>
</td>
<td class="num">$ (410.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">216.7<span></span>
</td>
<td class="num">(409.1)<span></span>
</td>
<td class="nump">342.3<span></span>
</td>
<td class="num">(364.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,589.1<span></span>
</td>
<td class="nump">2,775.0<span></span>
</td>
<td class="nump">5,120.9<span></span>
</td>
<td class="nump">5,469.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,058.0<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="nump">$ 1,361.8<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="num">(27.6)<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="num">(53.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Currency Translation Adjustments | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">$ (58.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (58.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761068963264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,058.0<span></span>
</td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,361.8<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">145,900<span></span>
</td>
<td class="nump">149,700<span></span>
</td>
<td class="nump">146,500<span></span>
</td>
<td class="nump">150,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">146,200<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">151,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761067691696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (58.0)<span></span>
</td>
<td class="num">$ (55.8)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">137.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">125.8<span></span>
</td>
<td class="nump">133.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(24.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">36.7<span></span>
</td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">82.8<span></span>
</td>
<td class="nump">85.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 46.6<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">$ 102.8<span></span>
</td>
<td class="nump">$ 108.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761078080768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (58.0)<span></span>
</td>
<td class="num">$ (55.8)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">137.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">125.8<span></span>
</td>
<td class="nump">133.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761068967040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 713.3<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 455.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761074502176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(5.30%)<span></span>
</td>
<td class="num">(9.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis', window );">Sale of Samsung Bioepis</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationLitigationAgreement', window );">Litigation agreement in principle</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.831)<span></span>
</td>
<td class="nump">0.052<span></span>
</td>
<td class="num">(0.463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationInternationalReorganization', window );">International reorganization</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="num">(70.30%)<span></span>
</td>
<td class="nump">21.20%<span></span>
</td>
<td class="num">(34.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationInternationalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, International Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationInternationalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationLitigationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Litigation Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationLitigationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761073124288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity interest in Samsung Bioepis(1)</a></td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation agreement in principle</a></td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(15.5)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">131.9<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gains (losses) on investments, net</a></td>
<td class="nump">78.2<span></span>
</td>
<td class="num">(153.9)<span></span>
</td>
<td class="nump">269.3<span></span>
</td>
<td class="nump">282.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(428.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(165.3)<span></span>
</td>
<td class="nump">410.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized on equity securities</a></td>
<td class="num">(77.2)<span></span>
</td>
<td class="nump">154.3<span></span>
</td>
<td class="num">(267.9)<span></span>
</td>
<td class="num">(281.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) realized on equity securities</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gains (losses) recognized on equity securities</a></td>
<td class="num">(76.5)<span></span>
</td>
<td class="nump">$ 153.9<span></span>
</td>
<td class="num">(267.4)<span></span>
</td>
<td class="num">$ (288.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Litigation agreement in principle(1)</a></td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">983.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">935.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">281.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">216.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">261.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">793.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">3,298.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gains (losses) recognized on equity securities</a></td>
<td class="nump">75.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 846.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 846.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761079999312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">$ (76.5)<span></span>
</td>
<td class="nump">$ 153.9<span></span>
</td>
<td class="num">$ (267.4)<span></span>
</td>
<td class="num">$ (288.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,167.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">499.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 75.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761067517392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080.3<span></span>
</td>
<td class="nump">$ 1,099.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237.9<span></span>
</td>
<td class="nump">937.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CostOfGoodsSoldCapacityCharges', window );">Cost of Goods Sold, Capacity Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.6<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.6<span></span>
</td>
<td class="nump">117.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.8<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember', window );">InnoCare Pharma Limited (InnoCare) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner', window );">Contingent additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
<td class="nump">89.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.5<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="nump">237.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">127.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Payments Made To Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CostOfGoodsSoldCapacityCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods Sold, Capacity Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CostOfGoodsSoldCapacityCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761074386256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> &#8361; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87.9)<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 713,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.7<span></span>
</td>
<td class="nump">138.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.6<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 581.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedMilestonePayments', window );">Accrued milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.1<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077697456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
<td class="nump">$ 210.6<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Neurimmune | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761080962048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation agreement in principle</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139761077763200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 788.1<span></span>
</td>
<td class="nump">$ 788.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406.8<span></span>
</td>
<td class="nump">$ 406.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsFairValueMeasurementInput', window );">Other Assets, Current, Fair Value, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherAssetsFairValueMeasurementInput', window );">Other Assets, Current, Fair Value, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Cumulative translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Gain on derivative used in net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent', window );">Contingent discount on common shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DiscreteIncomeTaxExpenseBenefit', window );">Discrete income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269.5<span></span>
</td>
<td class="nump">$ 269.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscreteIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discrete Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscreteIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsFairValueMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Fair Value, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsFairValueMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>biib-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20220630"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20220630.xsd" xlink:type="simple"/>
    <context id="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2c1009614648486a8d4885185901e0da_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7f0875c34f74569ad7173f706002116_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i852ff350063140c2bb0be923b3509114_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i10419c7fca6040f5b7f54c27a139c129_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d296c26357241e7b67a82ed0b3eb02a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12af56ba242049728b6eb6a1d817a8b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e7eba8131b2470f979b8859ac26fa65_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i655d8f6be57b43f8a4aff100977af6ba_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5d4021ecec514c33b4f46028ea027777_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d0383fdaa1a45b2990dc160ac25e8e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i609e4fab86de4ca682e02c1766083dab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f53af952a05400eb5a03b652b2a5224_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i25bd83dbf18a47969953f960652b7ca8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9f48125dbb64c14aa174f438eb3b529_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7a7a040013e4e578186caffe27ff784_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97a5574cfc654102a3578daabb6da090_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i200e14d4b78f4812b17968b9f9d1aea2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5245b9a67e8448b39d74a04b7e9b1de1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34ba7d8360a14679a9369e90b81fc882_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i281cd7edebd843fe95c846ccd0a8fbe2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i15182190caca498b8e52572e96ba2eba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i40d420575ff241bcb18f34eca21efd56_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d3891d530ed41ce9c40c01229b3ecde_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i67c4af1889714ce0862fe75007a47c79_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icc0a37bdf69449ddaf16a60e03e555ae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id8b532043d004077960b4e7717b3606f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6736d3935f8c47758cb22a7798dd423d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3383d03c85d343899a6760bb144c07cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47198f9003784e62a2d403aa1634c0cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35827c831ea64be78954e395e1202d2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cf823cd6b2f40d2a0cc0697e0186894_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bc3332cac8046689fcf7638658efa23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea41407ff6964211a00be80476455624_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75454f1173a447139f1217b1ed46d9fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19d0784f479f4fc880cb5813d70f6f6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84d4c7b0576941b3878692efd86da487_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i13e6f5e180744036ba354c330621db30_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9bd31dba4354e46bc9629fe6a03d388_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i368ea118836f487388ce043a695cadcd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if25d30d01e8e4db4b897cf36867a25e6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3bbb659071554201aaf22eccd009353e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifea5cd790d23403096957d2bd80ac925_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idb06f06c308249beb439d90fa38b3553_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8b352f1e386449dba581418fff17ab7a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b6703a3087e48768722c1c0f8e42a83_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0a9aca39866e45a586dd764d86c5ed26_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab659fae07d74a4f8df69f5e986830f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i420d4dc476054e95991acdec07455f64_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1857ee2b87204f6d8d339cd56a32cca7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id4d979b13ecb40159fab297299c33759_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i656fd73a858a4b54b51b65e3c1349710_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia2c0db0e45a843e093aa8601c3e476f1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29ab97abf7474573a44451ecae9b1c59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia88b9101790d4b0f86a212c7e9a96706_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14bbc79f38b047a0a22a8ba1a14f35ea_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i052eecd99d764d54aa68dbdd7ecc39a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9bf6535ed584cc8b7699690ed33169c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib469a3e9386544858caebbc51fee96a5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5b1fbe3fefed437397ee703a9770abfd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if28bf8793bb647839d1579d8c2459b62_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i776b02f0e19a4bf1a200745fd79fec21_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i332047e2daed45c5b00fd02fa57e3838_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4a38dad3f363459ea85b6ba15b99fd86_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2455559f227c4f65a8e32a02250a6b37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8e9662a1a044772a5c48f8eb3e4d351_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1552de9fe9a4d07bfa00d31cdf4cddb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea743edaf2fd4b7097146dfcb59ebcc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f0faea6ed6246d5afbb055c576af9f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96d0c433f57848faa5d9ff27e1571aa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fe70259be16496eb27510a3d1a37162_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf7705963176451eab777349e7f86df3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2150fda458e94f098288538ad0da1347_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i298109b8168d4593a326a064ab5b4deb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icbabe3e8841e43538325df1464a51f39_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibab1d1f75f7b44e8878daeee3d01001d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia00b516da2954357b5eb349ac6097259_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9742df769c7c419e858e70601aff7144_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c8021fc79f6416686d187243973ea45_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i0bce0582b9234dbbac96a00b848486a2_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i3729e3a50004440ba3134a7803d8b293_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i3fc13fd60c8140859d72089cfe8c306f_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="id42c682634844c03b11c37f7325f453e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2cb2cf98fd9549a4b68f0d966327fbfd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74bbffe1fc2c4ff4bec0eda9713c2a71_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb931292e9944a83b4a28788d901981a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i093f59a249e8425e8dc9546e07b5d4b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iafb54803dffa43a8b5c152bf9bca7854_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idbc97f4c706c4df984f6691e843d75ee_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2af09c4bc4774ceb8b2aea7ec735f424_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0d2801f94f42429ca36d1bfeafd776fc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0cec06562a4b4440bbb60cef5c0e756c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57475280b3bd4e4f8735035f66af5da2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0ae64ec1886f4842b346a20565644a07_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9cd18c1f363643da8e1eee2a47998423_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e50d0bd0f744b5ba53de911cb87f81c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2b5c3899b1854563ad3c2273433e9b88_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i007d608c419b478cba33ba05d07aced0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d12a48ae2a54cd9bb4249844b6f04e1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8f3d7a22d664d38ae15146f61f0f1c7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie099d88fe35a436897378cba2f7f09f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8bacccfe4b440259bfddc3e626a3be8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3bd6a55e7a084e99a824039b5136eb48_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2f0b5ae9f1c4ab88664e67c1b9d51a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie863f266caf446248389f5d655c80f07_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id0877cfe46ef448c8c7131bfa2927823_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cf00ad995134f4cb48df2bd2c51a7e9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaf5a7668e3e149bb9288945e1b644d4c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic70f6702bb4646988e0ca53e9412cd4d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i439dde2be341406fa6edfa8d2a5fa6f9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if81b6c4e8b0846d2977a5e818273a87c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1d118c84efd5442395adffb3dccb0b7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i549b6fd3d1344466adcf7f2de11e4565_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1fc8989f45f1472695f8f6ed83d3dbf1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib4ed02e892e14d0eaf6fee39773e7d02_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d2c705401ea4f62a8a0412004a979dc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58e8eb6c75ee484da1a9b2899bf4079f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8e7d54a466a485cb541688829066e26_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9874f7ddd2cc4c1598811a920b86b7d7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd19d0a1a1bb4808875dccbdcf6b2e0c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i669f2e9eba26433a84e680686bb0cf63_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieb4a8e4a5df14221807d09956dafea13_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2360a519c23e4144ab123af88aa77ea6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45b67a35dc2b4011989ac9568e54000e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80e14405a5204b01a6ec0d2b6f80a62f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89841ea93b374be7b061906d6d41e52f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38f2ed1ce3a14b0990001afc1dd6c491_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8f89510757554e059925b2ada6c7f286_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1389917b17d40cab84d0dea445f439f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66eadafd646d481f90ae1525ff408940_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i26206d0cd7764127b07966be5f7b1a7b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i246f3bb8b3b94d7a85b72b22eb167658_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18509476d6e74f7a8ad9b9e79de07e3a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i36ccb1c80bf9489c82bec10e689c3e90_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62a2594f184f4ac9b8cbc8aad0760336_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie66d9f7c4dc24480aeac96e047fbb0e3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6db865d77b6d42dbb986db32acfa75e6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4237b443b36c423e87d4bba35a59f794_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i47841ad34b76402897680f541339e3a0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07b428dc01d34c3bbe3425f599b4d465_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id24d8e1260d54752840a81ca4bdcf3fc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibac58ba74b4a4daab4732d74461adb12_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia3a6246e1af94484ac63941a25f762a8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id3b30f603f0e4af5b617750440ab03a1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i787e3c6fe03d41b1af6a449e9505be82_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f6ba2438bad4f1a9522748b9f8c53b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i900bd71ac7a447f2877d1c9ef20a5d79_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1d48220f13a42a9ab30ced0e8f1e5be_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb64f28ce22a4e32865b37fc103092bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5191eac6bdab406a954232524744f872_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifd597660d69548fab84a62c47780e0a4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib35a86579b2d4ccab8f3d3435b134d6e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic64518c9cf9e49b0a60aaee3bd5ed703_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8a92ffd45f3464b9fda8ccf988fe123_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i358cd1acfeee460987aedecf5fb632f2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if05e0a33bc5c4413a51ea40bba76c6c5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4508944e934b4c8cb245dc13c3967cfb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i475aa3cb324a442da54be389e9f9aec0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i236b9b5fed79407ea79107fdd77e4910_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8a3d0fc0b8224db6a7dfe05c6ee94f16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i804d63c72cb74d8a825d0c9196678307_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i54c59c486765442ab29490107dc4c833_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad386a522eeb41e08b1ab49a0355313c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d98e5ebbda3474a97b1805fe5acad43_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1952410e30f040bc853466b15fdacad3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i984ae54db252428cb8f595d9cb4150d9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9acb352dfec4b54bba68898daf102aa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2567373127054bc2a8607a8a0c8a7edd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i72c6c1e9fba1448c8ff10e9636557a4d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3588cab2b9054d38bac088fe429cc890_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7181656e80b44d28b2579ef54642c184_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice7a5aef1a14499eb4bc5e66e0ff9e05_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5196d39fc34746f686749f922c1eddd3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i034c5f0e4d404907bd5ac516daf28b53_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i49329c17755547ba919fa1dda7c1f8d6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8b838ba43c36477982d17fb691b3234a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae90209eddb94ce18a41953fa15d38c1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d5f94ef9b9a43dc8d2c2d02fdcb2722_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibed83b378cc4447ba4b164ca7ba2461e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i81b56cabf17a421f85d3d4f832e08a91_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib039450f31374b54b85c6aededf4648d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i611d28129d4e4e0599f6a9f56f89224e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief3c484378104076849db738ae2ec70c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7866e70096134bd6b4a49b4aa53f2d04_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98bbb070b1424fc2a3a3f4bf953dc517_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i248c0445077b45aa86eba19f300d0882_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7dfd10449e7548ffbe44b55fae3c44b5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90b5463a749b4240884bb2801739ef29_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8c2fc38dd6440378e0da306d5634c8a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c752409708d47fb98286c2172136b6c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d293f205e034c3fa4e0b605f6b06cb8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08b96e7b13fe4cf899501970595d616e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57ef2831201c483a816e081f25fe77b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic75cc49ce6a3424a8ebc26ac92c41122_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i45191a6585d342b19254212fbe8438cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i99502a8cfb3f45729909de9e9445521e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia9efe3047c104850b8e5e3f237c83105_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98ac3e997349402c8283ff022c717a94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9cd308b36c74ad58f3c697827421153_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa62803e94f241bc8d51d00489520d62_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f1762fc48b1448f996169dd0486ad6d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9df119b80ffc480e8399e35f9caf0122_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5cff98a2974c4e18b7621008c47bf431_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe712ea06fb4478e9e58e6a0e0bdc3be_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c298411b25d4e859abbd71121626990_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57e803d9462d4f58ae2c9c760329e8e6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i593120b1e8584eb3b206a368abb95161_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e6113e46ab14f91972e94233f927582_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide944bcb2c8349cf9c7f53fda13e0687_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70ccd22804b741a38a553424e98761d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea4b3c8eb21445db8b85f3ee7225cc7d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c97e3c0924c4cdca1b9f1a53282f87c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idcb92748d73344c199c4d746141d7e10_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e8feeefdefc47759f3ad172a5d47c38_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf198850c37f48fe8acdfb3a8d10b2b7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i48eec3c9dd8649e994f055ef1a743d24_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbfa09326e424881b32a983586469855_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6e6c0ccdcca4ea08f4fbcc8304df01e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i909ed281083841ad97422e6d8e9b5fa2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a1b8097922a4bfc8460acc93072bf50_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff32cab6555f4e67aa1cc62da2fe2381_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28d6bc8eecef46c88940df4fee6d8925_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia0039988350a4be2b2d710515403df71_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic83629e3f3364efa9bef8fbc4e846597_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide698acf03b8401b9aef8d55660fcfab_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i516625dc60d343959f4510e766fb1c31_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i674aeedb6b6245808af71c103fe19496_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i534264b1291c4344a70276b5e63a6910_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iedc015931c1d4d2db4fba3c31bd94986_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if805be58b48f48e48afc88306089f798_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4006bfbe38034523a41e0e68251e4252_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibeedfc78a95049649dab7ec26f21d7ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0d0b53fa1b874bc596af922c5d3014db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3c6e75fff5d48ae9c25b00d31fe330f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07dfa622b4e2449e8b118649dadcb3f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i845528c074714b90896d3a1a295e2d20_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6fa23d5be5be49e894fcbc5ff00c4c1d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5a07137c98dd4524ada1101807817e84_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66ff46c84eb64c11aa952fd2ef0f8162_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i746834edaf31484b8281cd357d15cf15_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie414fbe6060f4736819d0c0a26db0825_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb013e9fb28748ec96b5bd3dbcd9cb36_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if98657545c7442f69f64e667dcb30fef_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if081f6ddaa644634a85c1c8e772b6984_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d58cea04d384f9e962f42524c6c6618_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e33e4e8358e4adda4f14ec95348140d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9743755e37fa419da373d722f34ee542_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c2fcbeae88249a4bcd644491e34cbff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic01db06835d64a3183e66267859801c6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i350ceaa6094d41beb6a43612a28b3522_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8767bf21797c4edd9ed6d33237556b82_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98a4b565eb6a4894a23a82cad310d92d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8586bda14db4b688d52c294e041530e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1be940b30cb4fe585cc5a760d23fa93_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7fa0b6d1982040c4b2eec5d12980a8f6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i55a76cce432a4940a7ee77404de33976_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i267202cf4eae44a18487d9728c2731e5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id895b207466d40dc95e4ccc4a5a688cd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ddce2d7962540e6ac7f7d0e98e969a8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb00137c6dbf40a19194ed758485a9ad_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e5b6eaefce44a1a8296fbd9fad4e46e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e8cf5e156d34a85b0e5038f75d9a1ba_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icf550338832a4a30b4fdd8fec9c03a94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i23f6509df9234368ac66c5aee7ff2450_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i39db4e78f61d4e84a1a5f31a5027bbfb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f6154029d154694ad802b0c0880d594_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i848c2181fc424e8a9cb106ef8274e8a6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41610ed9f98048e6b4b8084998674df6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i272a454e80394786a9fd2275a5ba02e0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5bc86475c9b4c89ab084e88ce485ca1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb45edccfc854e13b231619881ae3579_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i52ff50cb600c4fa6a01c0a4495b88c78_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0863cb79da9045349bba7df17125e957_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i71e411c18d6544dc871cf730df065633_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5acd41d895754f3ab16a2ad37d6b762c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20bdbb4b6e064fc0af141d9e1a0fb2b2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68dfb47e453249e6afb959fc861e7025_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f28371d51c34038bc9822ac4d4329ea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe1ac54ae2734b5f9a4178272d59b625_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04b44e06b1074fe69c010ee1a0eeacc9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9427ad614e3477597e42639edc85a11_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i391f039c06924c07919d530cf6d2dab3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02c880de17294fb3ae9accb52a1997c4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic05034b4dab44684bb680a5b424b3f61_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5991f123dec64a919280b85ffc4ab06e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i411f9e9067594525b9d4f01a9b27f61f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04e83afbbe2445c19ca3bd556f42beb1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d6a7d87e2f44c0db0cd331472ab5e2c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibaecbfefdeba441fafd2b18f0f37475a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6647a216d66c4d41a03fe12ef97207e6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie0008cbf40274fbeb37cbbc7833e345b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4d1e43eb20404d65a4905d84c981be83_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie63936ee597c4dcbb4c197c6cd02228d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id35fad63758942b88c0a4d638d35855b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica2f580e87294d6dbdf0e82006621e05_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93ebb2e335574f1286e06fa26a183500_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2099c0e56b54466bb5a80bc17980d728_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i012225e935554e759f4d02bd7f455af3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i544c9b9c3c2441c5857dc27ac5202a31_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i59cb8ca63113417198b368e0ac0ee147_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd081a6a3bb5485b83c7166fa8c55471_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic484bc958fa842c3893a6412ac12e08c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc85bed201b940878824eb131a5d746d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i73b7e31d17f240a4bfc8076fc48a942c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i77d66fca5ded45e297765f1b445f6c92_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e2d9158b11645f5828f271820b2dde2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62d6c18c9bc14e658bc749d15f2cc080_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55b0b386d72c42c7829f67584a538904_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79b21651141942a69478099c2ccff90f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42e2e6376f304466973b1a306132b804_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i63a0c596128542549c311e01f527d415_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iadcd9c4eb7aa4d43a9535edcf11234db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia15237bd167748dc8935bb2db5aadd11_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6be79ed31c744ac0b8ce99f0b7505404_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iab432a874db444408172f33c16977803_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i43bad9cb88d740469bbafb0fb0cf0cee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33934bee3c5143dd99f1d517165ead05_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if642314400ad46ce8997912ff65d7344_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71f09e81766c42e2bbbe9c2a856ada30_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4b3b5523cb8f4e5288c2afa798269171_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if88580276d234ac794a107b535d8a45b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4d27d16a0e37434c878cd333a5be7789_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icdb9e7fc3fdf4dc9a9ee227b36aeed4c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i86078aa510454a67ac821f531e00d16a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2407978bb6bb465a9a11b59c52630feb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5a019fd8fe4f425ab48dd67d22d37e0e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64a2d4a8e1514e098184d910e5f41721_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if03d8681da5c48ed823c595e3df9cae4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9a918b8fbaf4a098bb0923df21e1a68_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iae9895041a5d4fbf93cb82132c5fdbc5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id39f35171ae547d68317e335f6bc8cc8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LecanemabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i690a67cc5731414a8f9aa06c53540e02_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5c5095f62ab4c62ba0b2a1719784d97_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i635b802dc41d46298f9d8608e9935a23_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia08cc12b77134a85b0419098882728db_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a40683af9114b76a6f0f696d7c173ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i10c90e8d925d40afa3e544318c2a8632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15d560d86969470286de95947d4488f4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i50f82f106e724d23928e954b5d6e3aca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15444f937e5a42c6928f7d30caa9be5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7072613f54844e3ba4de934782cd9535_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d589ef9b9024af5845103efc8018806_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57322b393335447fa049a18be91e5f26_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86265989727740ada4d3803a06691ae4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iacf09d1ffde3467f9d51fd1d72e55232_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0cb1609479343309a6ca0ff24c5fca5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i035bd9bd822646e3ba8f72fa5b2ecab5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie430205c0e8642b399f6ac098c948e1d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i502f935fe0b441bfbca01d697b55e5c7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab21929ee2b44bd3a5f7fcac80a7717a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied71ea253e4b4771947185eb41d0c454_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68ece7d88a2540288a7a78a56600747f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a56ff34c07d4313bcc9ec338711ce30_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3c9311db8dab450889a2d4bef745e3db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6986e53f6f514bc497305cf50bf1d99d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i529693e18f9d4940a0dc51a9656b8e81_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5410a4b7463e4871ba2258c342695d0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5e760801b4e427c8d09b34b65881a0e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icaae543901cf4bf0b0aaf47b428c3c49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1bf903905566403e92f0306b14f21dfe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7bc363fb469e473aaecac4cf8e63ef86_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic86003e21d714ef8a56c54bdd2b57d52_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib9d547ff00df40f989fae1a81b0cda41_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8467e688e67c4414ae5b2d512e027882_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d5a87c8222b415e99b23eb87ba7b373_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94e25682c306442281fbd9b9e82f381c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i439c2171b7ad4a428141db883360f934_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i96a56b8cc106475483c716145966db29_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7e9074ac7fc541f5890093a94bed4d8e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia11ecccfe2884f3db642f3f076602bf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1825b81a7ec14bec968fb3cd13c00522_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314a58abcbd64561923d0f9981338f6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id49be596d72642af812e59dd50890f35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45f635edc8a2430189c968b78a9e8cb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4316a770d24b4d87b85ca16f1e2d0f5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b362d0ab3134007a6f2417677122114_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b867d694211492a993655d5fb259d85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d1446517efc4d939297638bd36ea497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia741396d8ac949ab9d5894b778f1505e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03963bc9f9074822b67815b3e793e1da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9e334b59f08464daa0d2d2f402ad4b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifca26b7ffe0540fc80c3f59dfb576259_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i129644619e6d4f278f61964c9e9f3d66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34bc38e16d5946d6982b6c3c72a07586_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i580eba0699d7484880390868de30783e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2ac8144dad34592a0e0d767e503cd0c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia788a53d2f44480a9c09cb836102cf88_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29b2d699c7994b058ffdc0a2973fe76a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee7f7781b1e446cc8b8a3b615a223395_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4dd86bc5c7e44ed5a9d043c911ec35d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae70c7addbd245e88b9cf036469b0e00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2546b8d042464cf18732132087c7837b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0c1b24834b7c453f887f7958431a260f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i749156c0d2244797891329da8f801076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e095c97d47740e5afa1a5c72b4c260c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05c33ec33ac24977b3efeb593adf8673_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5363dbf017c244debdb2e7604c5291cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fbcb087e76943ca97d22fd15915d974_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3dd69aba81534dac91205bace6805330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0324ddb09a434fee859e03396262f145_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e56bad4fc89492691617ec7457815b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i207ad38739a54d138f6be5e688458503_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7e5238704ed54c3bb7e1f6928897e2c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c1febee2fa143e5976b10c5f25675f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i157163fe40884091bf7820d01b3e22e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5386dbc2d85346818db10319e0a45e26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5c9f2c4702549599568d0e5eb9618b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdb4076d18da4ad79a95ee670fa15bb9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8ef3bd0aea29473b9ec52de86adeb7c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5d591f719add4db891a44f2be40ad81c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if36d266508c34afbaaaeb0f53bd98cce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ae46d4e5ae24b1f999399ec074184ab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1c0efb74abe649dc92a1800ec298d90d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib09e47414ccf4f6b88062930b82b2a81_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i16498989190e4b99abd2625557d367dd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic3a33bb7bfab44b49a33909b6a68a094_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0dbe89693034b608f02372c6ae74cf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i140bb6501b0449349963095a4992952e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i769b78fc374145a2b38b4bb257858d1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90787041e4c649eabc5e9f60954a4d29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i992615614bce4506b32f63aabda86d0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if73106cc97da45d0a1aa9b8366bb2add_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id4d0bd51bc4647dfb2a191cad3986b16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ab0561efd9a429f84f8b4296c82c73e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff853fccd14442ebbb17ab9ef5e1c4be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i18d6800eb2c74fba819c1b070cefdc3b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5c0ffa95ac44d50a2d00434ffc62f9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i921449c1dcd64ae094a4e7206755b28f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i56a4214140a84299923a095d0db68a81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i753e77cb96eb44eb91792a859ab31f61_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i13cb17acde494685b6ba5f5809b645d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7766088e60b94262b048c5f32da60dbf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i199c91171d3f4a2382e5d5cd3f00f2f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaacc3061343b44129f16a08974a6b548_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibff5ba68900c43e69eec8d505e93c934_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ecadcec54794963b50463bd915d2bc9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe39514eee6e4adc9af02f16e10ee4f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7533348289c643f4870127b69ce2e844_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if5cb29af1d6742908ff898b5ebf574cf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5bfba5b1866a471cabbde592da7a1247_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic5e00dff9ecc46b9bdb7d69718e8e77a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0466df147d7942408c489858f169de93_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26725a695f2b478788a442808ce1beee_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e2ff89e7330400e967da0afcc3e2d99_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8e91a04e7eea4c38b6cb6751d4043a2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1bde062c47d49a8a7f0277989d627c9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i743019f676ee466795fa568ff3243842_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb90f3ecd54b4e76b9e9bd9dbdbfe5af_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b82baa8ea8543bda12f9f9de5c4af65_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8929791e27f944c09502d04a25c1b021_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i16c78831bea640a7b02cdd4181f233cf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idfa592716840490d9b21fa9dd5a26334_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia75940771ad54dec84714d53bc3a845a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6cecc0a55d14fafbfae04ffa644a385_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25ca7beff5f2474b9d401734f8a1ec03_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e235045cf98490f8a1e30fcda5c5e48_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3de48898e11f44699c3ee51c8d39f207_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17f3f785472d4636b331649fe366628f_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i6e750febc54343bc90f1a684d4d68e95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f906803044b470f81de0eefb5dba012_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74799976f1b24216a03f17304e960c0c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib6b1a6af29424cb4aa2a50fd11bfc322_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94d5ef31f0fa47a39e2dd83dd2bfe19a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i575d79eb11134ef993a7f0b1f6d269e3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4bc4c2d8c7e943a895789a1697167962_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib02689d9b0b44614b294b3f29ca4964e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cefa532629b41e3b9dc278f0f0761e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6092dc9afba6475196a6884c6298c6f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic958db40215b499a9247ed982bcb0126_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3b36ca2852634efd80fe1a2529739a5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0857062bc899445982d736bffcb52e46_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c530cc918fe4a479490cc9b9876a764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd7a423894c0434db231ce4133ce2fc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c1d25a8fbe4414ba423291d19d37d5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb798cbcdc26425ca390649668ae6b38_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i926408e195f24642b73de23a766b86b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70908e6791334ae48472963b146ee23a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9af4d136402048959dd3e0e8e44a22bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7da619d63a94a4591936365ba7bb51f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8fa50adcc4464c39a7eefd4680d1765c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibaefaf11247247fabd1fe4cc79c22821_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0043843f37f44a84bcc5be0643dee99c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12b4c6baf27c4eba8805276bb5e93dc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65ad03e37af84a41bf8a69fdca5275ba_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="i5299d1d7822041d3b1817887dbd46432_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="i45416e1b26f14f8cb98e144608a14a4a_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i28dde4b51293471682782551de32cb29_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i012f5bd22d3246cab5a94a0bed345c02_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18f30485bd8748f68ef275fcb514e0b7_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i85a73135034a4df7a82a111ed6759cd0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i84ce2898f9b84c02bac44cbb9b1e0305_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i764a683e6bcc4b34bf7d9c79615d5377_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fab60076437436eb30238de33b462fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad2094119ab54aaf9f28c105672c9bb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i182bc48d598f48999740017707097224_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i443555b494964780923c6389a3abfb01_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9e893ee39104e1b816e93ed8a47ede9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia28fc04646c349038aaaf67a779b66d3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i46d16f8649274ffb8a001d8f59f22062_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie252dc547f144a40a6ac6f848a877b7d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a7eb2c1a6e246ada70e7f900be38d88_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe2a159169d54d4286b3396de8a76082_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia331bc87e6e54c62a0a9e2f8480cea82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a78abae937b4e9484720512244a264b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4702937641c1484bb3d3617fa0ba60d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85e1d4e25ace4b32b9de201f21da7db8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5920e9a8348d4b0184a94d22f70f6368_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i812b8492c7e14121b9c263880e2c112c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibe2d434e7672451886a60cab65f8b82c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1938ff3b65564001bf3b50000b46d67e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3bdeffc2747242298d5c74ba9260545b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec879dd434784246ba9689b7523432b6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iced58bff08fe424fb838818157ecd374_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f7ab9eec76f415b9754dece93693c29_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia3b10142df3b467e8bdcbcc59ff9e2e6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e16fe28452c4b27a1b2a84884bb91f2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34aa5eb01fc941468970bfd540a717af_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45d9e723dce441e9bca32cefeba7912d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icef3a7fd90234f2892d851bd89cb2861_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifdd50768ee6b486a869faf383cfec503_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03c42c98806743678d857956f14b201c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05576bec60da463ba40fa81a1d5d6213_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic49a0c322d4a4fa6ad316e2dbcd57859_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i769f963dcd104808b7f557b5bcf509fc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia82614881b654024a0f966982a2e1643_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i064f6c79792847f38bbef18be71b042b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i935112ef58c34d998257dbf55b14da22_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe1fbb5461ad43bea5769749d280c2c6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i59078147fa6f488c8239e033a6fdf63a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ied9be70de8b546c1876a1ef6efccb2b6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ca4330df54e4589a400fd134a2fa6be_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i430d8a3876b04d60b0a0e1af9b6f9375_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iee4c31bfbdd74c94810389e9eb943e18_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e723dda18e341ab87f7edde733b2a16_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieaaccf079a49488eb79a43457781b779_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i404f8659b4894301b106514d8921df0f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i726ad69e44e74f18812d926508d81057_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib613e85a78bc4456893a2ad6a58b3db5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38c01771898e4c6a8325194d609c2081_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58ac757a014e4f9d8ee4cc1b9b4d3350_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4b7dc5fd89d04e4c8378db999b2eda6e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0768cf5b82344dfeb26a9db8c6655c34_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie432e10abc0b47dd9185ef700519fae8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3eccf41bcd3b4ecba3d2a095e0239516_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4da564986d004bf6bbea566000fdb4f4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34df8b39629d46e3a1d76df662efe1ac_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4242bcb1bf68441e915043a252b28f3e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i37c11788c3f940898950aac7349449bc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2087847394724417ae5cd7671bef7634_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06e3f4c497b04721b2a471a9d1462e90_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11e6a4109ed149448f4eb38f7f7a6fe0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd85c59952834082adcd0bda1c3bc397_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c78200de99d4a8992ff379211c1b05c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i598d5781ec294abb97c2fd87cab72371_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idb25232bfbb143b2a5469052ea1aacbb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i070778a5f6bf479290bc275c09f5d25d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib0c2f4968e7d449bbcdba9e0686e5349_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc4229db4a3b479c9d2a9fb092797c6f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4787bd92caad430eade94b63652c8eae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0f165e7c3e24de78375b532ed70ebc6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id383c4b3624c4a3084db5066645c15a6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida0b80c4d4a24c59870003ff1526e308_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03333ee45c754e49b0aae5e5249ab285_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i67d41849f5c049ef858c1b655ecdb83d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1703619476c5469fb6eae667c889633f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd736af6b0704581966ceb888e962dc1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iafdb9d7e53324279ba0597cb20081464_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0af51832291c4232b19c5319e421ca32_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07e91b63836f40969d01256870c0e4e2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i26ef6923e0fd491fb74d065e645dbbce_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7cc7449e1d4248ee94e3a7a6a2b8c0e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fc0bc45a8f34476bd5ce77c28c035ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78027a673ba84f59a729646c29056ff0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if95e48bbaf4a4e799a9ebda77407ebe7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id03a4083cbe14980afe9873df6e01157_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4fdad13d37214d518d991982787c19e3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i231f21da54f240e09322a7c8c9ff9b00_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ccab6bc98574047b1778979662e99de_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie326ff087126492b947c8a627fa90a72_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id33450308aef4ad29feeb06170373827_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66f3123780b4402a90c954338e97580c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b5e346af48c4d1ca76de22d3af2bb36_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1166a4ed6a348088b5ef0d2b05a70c1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ide8a39607aa44c739f29386c64f8a2bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6766574fbd894502b558478062716387_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45e9b008911d4b25964bc84cba645427_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i311cc627d4884000b967bc589ce09d88_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if756749af2de4c4e957db16b485d5427_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e194ceae6f64b65b2349e8df6ab64e9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i32ab1ddc9657403a8db302457fb46496_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i35b2b113cfdd420ebfc7941cfaba6661_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89906910d5954e76b7d9d286e110f422_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dd95981381d46b7a30d0a586d846fb5_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="i994f69bbb09645ee8a7918008c471ef6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89c39215e3534c88835566c3e470d890_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifce6fe69e35a448dbd457279465a317b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i78b272d435084dce9cd4a8f7830ba08a_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="if1139e7fad6c40f48deba330c854be64_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i261e664559194dcfb968a0ed63765c2b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a36bcdc40354faeb9b03f0586021c98_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8xLTEtMS0xLTEwNjUwMg_0a25c26e-e9c8-4e89-966f-69ed4e7c9a8f">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8yLTEtMS0xLTEwNjUwMg_ef8d72ee-5f5c-4109-bc81-d6f80473e5bc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV8zLTEtMS0xLTEwNjUwMg_db9e2284-e5c1-4e66-bd65-993415e9dda5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV80LTEtMS0xLTEwNjUwMg_8a269a95-4d70-4dda-b6fb-8731d7c3211a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV81LTEtMS0xLTEwNjUwMg_c50ec29d-f9c2-4559-9217-7b108480c6f1">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80L2ZyYWc6MzZlODI3M2YxZWE2NGUyNDk5OTE4N2RmMGI1MGE5ZjkvdGFibGU6OGY0NDkyMjFiNGEyNDhkZGEyYWY1ODRkMTUzOWIwYjUvdGFibGVyYW5nZTo4ZjQ0OTIyMWI0YTI0OGRkYTJhZjU4NGQxNTM5YjBiNV82LTItMS0xLTEwNjUwMg_185ec485-4e30-4dae-a657-8c3f5d0b23e6"
      unitRef="shares">145113047</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ied71ea253e4b4771947185eb41d0c454_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82NC9mcmFnOjM3ZDIzMGY5MmY2NzQ1ZTU4Nzc3OWZkYjFkZThiMzQ2L3RhYmxlOjFlNDE4ZTA1OWQyMzQxMzhiMmI0NmMyYTZiM2JhY2MzL3RhYmxlcmFuZ2U6MWU0MThlMDU5ZDIzNDEzOGIyYjQ2YzJhNmIzYmFjYzNfMS0xLTEtMS0xMDY1MDI_c1bab225-0a1d-4845-a51e-7d4f11a37275">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i68ece7d88a2540288a7a78a56600747f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82NC9mcmFnOjM3ZDIzMGY5MmY2NzQ1ZTU4Nzc3OWZkYjFkZThiMzQ2L3RhYmxlOjFlNDE4ZTA1OWQyMzQxMzhiMmI0NmMyYTZiM2JhY2MzL3RhYmxlcmFuZ2U6MWU0MThlMDU5ZDIzNDEzOGIyYjQ2YzJhNmIzYmFjYzNfMi0xLTEtMS0xMDY1MDI_eeae9b2a-3502-4348-b143-9d8e53f547f9">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNS0xLTEtMS0xMDY1MDI_40122220-72c2-44eb-82b1-166676fe7965"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNi0xLTEtMS0xMDY1MDI_d78febbd-bec9-4c28-9a9d-15336229bfa8"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfNy0xLTEtMS0xMDY1MDI_a3112499-02e1-458b-8934-f3f487425b87"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfOC0xLTEtMS0xMDY1MDI_3fb5f975-60a4-48b0-9d46-714f3ada8f4c"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfOS0xLTEtMS0xMDY1MDI_2ae24171-2259-464c-83fa-1c1c8d22ef1e"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0324ddb09a434fee859e03396262f145_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RhYmxlOjVmMWU1ZjA2MGEwMjRhZGY4YWU4MjkzYWZkMDhmYzIyL3RhYmxlcmFuZ2U6NWYxZTVmMDYwYTAyNGFkZjhhZTgyOTNhZmQwOGZjMjJfMTAtMS0xLTEtMTA2NTAy_9f5de7bb-26ea-4c3e-86e3-b58b2b08666c"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetImpairmentCharges
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83MC9mcmFnOjUzODZkNzI2YjRlNjRhMWY5YzJhYzEyOWQyMjViY2RmL3RleHRyZWdpb246NTM4NmQ3MjZiNGU2NGExZjljMmFjMTI5ZDIyNWJjZGZfOQ_dcc81b75-939e-42ff-9ff6-9dc15fa131e3"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMzAvZnJhZzoxNWRkNTIxOTgxMGI0Y2MwODZiMjNhMWRiN2EzYjlmZS90ZXh0cmVnaW9uOjE1ZGQ1MjE5ODEwYjRjYzA4NmIyM2ExZGI3YTNiOWZlXzM2Nw_fb9f081a-f28b-4500-aa41-1374f80a6092">SUBSEQUENT EVENTS</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE2_d7d55a05-8e7b-4be8-9a35-e863c851f5dc">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2RkNzcyZWJlZGY4NDQ3Zjg0ZTIyZDMxMmVjMWQ5NzkvdGFibGVyYW5nZTozZGQ3NzJlYmVkZjg0NDdmODRlMjJkMzEyZWMxZDk3OV8wLTAtMS0xLTEwNjUwMg_fc2810cf-9781-4cd0-b9b6-cae8bb6ca8cd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18xMjM_5219da45-eb68-4ec7-bfcb-058f3717f7f6">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6YjBhMTc0YzFiY2NmNDIwZTg0ZTlmYzMzNDcwNGVlNDEvdGFibGVyYW5nZTpiMGExNzRjMWJjY2Y0MjBlODRlOWZjMzM0NzA0ZWU0MV8wLTAtMS0xLTEwNjUwMg_76a45a24-8836-41fb-a1a0-c4f390e05943">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEw_4b2b46c0-2578-493b-a3b4-8771d496363e">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEx_d6e372a6-109e-4e27-9002-f0cf800e36b5">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2Q4MjY4YjZiZGY4NDllNzhiNGIyNzI4YmU1MThmNjUvdGFibGVyYW5nZTozZDgyNjhiNmJkZjg0OWU3OGI0YjI3MjhiZTUxOGY2NV8wLTAtMS0xLTEwNjUwMg_80ba2d7c-5a8d-4d60-b47d-442899c7b712">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6M2Q4MjY4YjZiZGY4NDllNzhiNGIyNzI4YmU1MThmNjUvdGFibGVyYW5nZTozZDgyNjhiNmJkZjg0OWU3OGI0YjI3MjhiZTUxOGY2NV8wLTItMS0xLTEwNjUwMg_f3d45009-b5de-4c84-809f-b98fcd601072">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE3_ed9fb133-d484-4392-afe5-e6e1c510ab6a">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA2_5318afdd-9c0a-448e-b3f9-1bcb7005d7ad">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEy_8a55ebd9-1ba9-46e8-b6f0-d4fc4713deee">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA3_068d166f-7012-4e86-8577-779847a95c30">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDEz_caa52318-189c-4916-a3fa-ff06f52d1b51">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA4_a5b9e824-c7ca-4fbb-8564-460a3b70febb">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTAtMS0xLTEwNjUwMg_b57e0440-2741-4f30-b4dd-0ee77d7cf026">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTItMS0xLTEwNjUwMg_95590b8c-5f3e-4b73-8b0f-312f56b637bf">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MWE5Mjk0ZjJhNDVhNGNiZmI2NTQ2NjlhYjM2NmU2NGUvdGFibGVyYW5nZToxYTkyOTRmMmE0NWE0Y2JmYjY1NDY2OWFiMzY2ZTY0ZV8xLTQtMS0xLTEwNjUwMg_3e3743e6-f7b4-4b35-b575-636e74890b21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDA5_42afeee1-fdb5-448f-b78c-5aecf410b1e3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE0_39ade907-5d95-4953-bf1f-edf3862d47bf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8wLTAtMS0xLTEwNjUwMg_a154dec4-2ebe-441a-a7b5-8dec863af7f3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8xLTQtMS0xLTEwNjUwMg_b8542a58-3daa-4b75-bf7a-6553f21ad94f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGFibGU6MjA1ODM0OTYzZWNiNDUxZjk5Yjc5ZTFjYzkwMGVjZTUvdGFibGVyYW5nZToyMDU4MzQ5NjNlY2I0NTFmOTliNzllMWNjOTAwZWNlNV8yLTQtMS0xLTEwNjUwMg_d01f95fd-c1ce-4a54-8be9-a227e90bd4c7">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18yMDE1_41e53978-9c9f-4a2b-92a8-ebe16f5b64ef">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i956ac7ca06734caa9a7f77ba4160d3e3_I20220719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xL2ZyYWc6MDE5ZTVlMDc4Y2EwNGQzYzk0NDg0NDFlMWJmOTg2N2MvdGV4dHJlZ2lvbjowMTllNWUwNzhjYTA0ZDNjOTQ0ODQ0MWUxYmY5ODY3Y18xOTk1_185ec485-4e30-4dae-a657-8c3f5d0b23e6"
      unitRef="shares">145113047</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy0xLTEtMS0xMDY1MDI_740a9b0e-a571-4d14-9b26-3adbf54c4efc"
      unitRef="usd">2054900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy0zLTEtMS0xMDY1MDI_3dbcad0d-8721-467b-9971-de97ccad96e9"
      unitRef="usd">2236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy01LTEtMS0xMDY1MDI_3b9df68b-17a9-4055-b39c-36f6315ba91e"
      unitRef="usd">4121200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMy03LTEtMS0xMDY1MDI_11e233d9-e90e-4d5d-b6f4-cebd88693e9c"
      unitRef="usd">4447700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC0xLTEtMS0xMDY1MDI_086d1353-f48a-4d3c-b2b6-8ea4e75d3d13"
      unitRef="usd">436300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC0zLTEtMS0xMDY1MDI_778a137b-f2ab-45a3-a024-2431428b960c"
      unitRef="usd">440000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC01LTEtMS0xMDY1MDI_6491cf43-5530-4604-9c83-b438b873510a"
      unitRef="usd">835700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c1009614648486a8d4885185901e0da_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNC03LTEtMS0xMDY1MDI_9f662bbf-5070-4ee9-994e-c753f6e467b9"
      unitRef="usd">829000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS0xLTEtMS0xMDY1MDI_cdd4709b-2c93-40cd-8af2-ef161784a4c7"
      unitRef="usd">97900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS0zLTEtMS0xMDY1MDI_8d9f6bbd-04be-445a-b8bd-d425254aacc5"
      unitRef="usd">99000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS01LTEtMS0xMDY1MDI_878ad17a-5002-462c-848c-c00bf93bbbfd"
      unitRef="usd">164000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7f0875c34f74569ad7173f706002116_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNS03LTEtMS0xMDY1MDI_a6c4f5b9-108e-491a-a234-5d821547b77b"
      unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi0xLTEtMS0xMDY1MDI_252bfb67-41a1-47b8-9e27-c022e18f9f28"
      unitRef="usd">2589100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi0zLTEtMS0xMDY1MDI_4f7d5fae-f3e3-4001-84b5-27d3e10d4255"
      unitRef="usd">2775000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi01LTEtMS0xMDY1MDI_d0efdaee-5206-46cc-9740-6e548c5d19a2"
      unitRef="usd">5120900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfNi03LTEtMS0xMDY1MDI_5c2e7ea7-7684-4e29-afeb-7d1bfa91601a"
      unitRef="usd">5469000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC0xLTEtMS0xMDY1MDI_5b042497-7a4a-43cc-9662-42b8e8583bc9"
      unitRef="usd">484000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC0zLTEtMS0xMDY1MDI_9a4b1be4-5e39-461b-9f59-12cce1a8bdd8"
      unitRef="usd">459700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC01LTEtMS0xMDY1MDI_c5269ad9-8b37-49d3-9e62-f1088247560c"
      unitRef="usd">1237900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOC03LTEtMS0xMDY1MDI_0283a3f9-284a-4b5c-b4d4-e29578a7fd3b"
      unitRef="usd">937800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS0xLTEtMS0xMDY1MDI_89b6e955-ad7a-4c51-9139-d9f6bea2dcc6"
      unitRef="usd">528600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS0zLTEtMS0xMDY1MDI_dcbfbda3-7b32-4527-b2a3-b4c9532121ce"
      unitRef="usd">585100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS01LTEtMS0xMDY1MDI_04db9713-35dd-4e5e-8d72-3692aef7bfdc"
      unitRef="usd">1080300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfOS03LTEtMS0xMDY1MDI_6a556878-341a-4ed2-b6fb-86276490e8f8"
      unitRef="usd">1099300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtMS0xLTEtMTA2NTAy_53e7311a-9660-4ef1-93ba-d96528ae3297"
      unitRef="usd">572600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtMy0xLTEtMTA2NTAy_0b24f963-93db-408d-865c-b8037fe301ef"
      unitRef="usd">637300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtNS0xLTEtMTA2NTAy_f63c1578-d2ff-49ed-972b-d342fbba2ff4"
      unitRef="usd">1207500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTAtNy0xLTEtMTA2NTAy_409e19e0-8402-4b0d-a2a4-99ed3cb9f1d0"
      unitRef="usd">1232300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtMS0xLTEtMTA2NTAy_27d7621a-90c4-41eb-9c1e-a19334410445"
      unitRef="usd">67500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtMy0xLTEtMTA2NTAy_09d2be0a-a1c1-4806-8c64-4234621585c4"
      unitRef="usd">604100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtNS0xLTEtMTA2NTAy_70744d33-1fd3-4fb7-b8f6-2646c8389db4"
      unitRef="usd">134400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTEtNy0xLTEtMTA2NTAy_a20ba55c-64fc-4c97-a0fe-83a44833fdb9"
      unitRef="usd">702200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItMS0xLTEtMTA2NTAy_6c42e508-4a21-4459-af0b-0fc5bc1e9990"
      unitRef="usd">29400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItMy0xLTEtMTA2NTAy_af189703-9fdc-4378-b552-7d7ef83b33e2"
      unitRef="usd">-15200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItNS0xLTEtMTA2NTAy_4885b701-6f8b-4c79-9dc2-112b7eba93c9"
      unitRef="usd">-87900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTItNy0xLTEtMTA2NTAy_995f8328-1037-44a7-a355-5c5b0cb6bf52"
      unitRef="usd">53300000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtMS0xLTEtMTA2NTAy_141ebcad-9bb8-41d0-b504-418111a7a034"
      unitRef="usd">4500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtMy0xLTEtMTA2NTAy_91cf8a80-2932-49bc-b0db-5d8edd00e34b"
      unitRef="usd">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtNS0xLTEtMTA2NTAy_d5298007-4981-4142-84bc-2a5ece3c941e"
      unitRef="usd">11600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTMtNy0xLTEtMTA2NTAy_f93a32b4-784b-4f39-9f6f-e5647ae03497"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtMS0xLTEtMTA2NTAy_3fc4c0d5-aaec-4fe1-956a-15c8fc9cd71e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtMy0xLTEtMTA2NTAy_a806854e-8497-4073-9ae3-425e505c6379"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtNS0xLTEtMTA2NTAy_9075e630-493d-4877-b05a-20d8ca67f60f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTQtNy0xLTEtMTA2NTAy_1232349f-b4e5-432e-a7a7-3cd96cb049d6"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:RestructuringCharges
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtMS0xLTEtMTA2NTAy_1b9b5b52-58c0-48b1-9ef9-8316c4af4235"
      unitRef="usd">70600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtMy0xLTEtMTA2NTAy_6326ed62-53d7-4b70-9c39-3163cb5db3b4"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtNS0xLTEtMTA2NTAy_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c"
      unitRef="usd">108700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTUtNy0xLTEtMTA2NTAy_5de627c0-31d6-4281-a7e5-b4ed37b39cd8"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMS0xLTEtMTMxMzg5_4b038783-c73a-436c-a12c-6f322c8966a1"
      unitRef="usd">428600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMy0xLTEtMTMxMzg5_26b72504-9e10-4d04-8a36-ab9007374eed"
      unitRef="usd">96400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNS0xLTEtMTMxMzg5_f1391009-f9da-43fb-8bac-7edc058e1418"
      unitRef="usd">165300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNy0xLTEtMTMxMzg5_542d89c4-1cef-4d21-8621-9024f26921aa"
      unitRef="usd">-410500000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMS0xLTEtMTA2NTAy_5d97117b-bdb0-41c0-8ea0-80804fe0cd04"
      unitRef="usd">1319600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtMy0xLTEtMTA2NTAy_d9e458d8-83de-4967-ba75-3c11cfc683a9"
      unitRef="usd">2192900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNS0xLTEtMTA2NTAy_b33713de-906f-46d7-acef-fd9300466e16"
      unitRef="usd">3504000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTYtNy0xLTEtMTA2NTAy_b0e498ee-1837-4bee-a938-8bcbcbc9f442"
      unitRef="usd">4419900000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktMS0xLTEtMTA2NTAy_dd1debf6-0a00-469d-9a97-8a19ef4128f4"
      unitRef="usd">1269500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktMy0xLTEtMTA2NTAy_5805ef70-765e-4db0-a86e-1198380ce986"
      unitRef="usd">582100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktNS0xLTEtMTA2NTAy_93770a4b-7757-44fc-94e5-b238dfb31041"
      unitRef="usd">1616900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMTktNy0xLTEtMTA2NTAy_eee17cac-ad20-469a-9775-a94ce2524c9f"
      unitRef="usd">1049100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtMS0xLTEtMTA2NTAy_770ed739-3325-4298-bc96-0c84ada72cd1"
      unitRef="usd">216700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtMy0xLTEtMTA2NTAy_13d1757a-de59-43c9-bd0f-9d70a161960c"
      unitRef="usd">-409100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtNS0xLTEtMTA2NTAy_d8a80f94-dae3-4690-8de5-4dbb5576734a"
      unitRef="usd">342300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjAtNy0xLTEtMTA2NTAy_98fab727-9675-401f-a306-485d6c4702d2"
      unitRef="usd">-364900000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtMS0xLTEtMTA2NTAy_2546250b-b456-401f-bd8d-489cadacdc60"
      unitRef="usd">5900000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtMy0xLTEtMTA2NTAy_2652f7cd-4a64-46f6-a3ce-29bf9e1df019"
      unitRef="usd">34300000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtNS0xLTEtMTA2NTAy_3fc00b9a-642e-430f-95fc-a03b2f13ec84"
      unitRef="usd">2600000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjEtNy0xLTEtMTA2NTAy_71c6cb88-9b58-4378-af0c-50f89efad3f6"
      unitRef="usd">16100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItMS0xLTEtMTA2NTAy_8f2ed7e3-dc4a-4d60-aee5-6ba3f35c7a6b"
      unitRef="usd">1058700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItMy0xLTEtMTA2NTAy_86bcb419-e09c-4caf-921b-2e64413fded2"
      unitRef="usd">1025500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItNS0xLTEtMTA2NTAy_73a044ea-aad1-45fd-af0a-4e55624e2ce4"
      unitRef="usd">1277200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjItNy0xLTEtMTA2NTAy_a67ed8f9-3406-4c4d-afd6-25592cef7645"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtMS0xLTEtMTA2NTAy_285e130d-87a9-4979-80dd-9fd15fb3b6b8"
      unitRef="usd">700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtMy0xLTEtMTA2NTAy_22073884-fc60-4eda-beaa-57b8b2caa3eb"
      unitRef="usd">577000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtNS0xLTEtMTA2NTAy_0945e8a1-a152-4225-a285-1216e094f93b"
      unitRef="usd">-84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjMtNy0xLTEtMTA2NTAy_66eea830-9948-443b-bbfa-3c7d493c5827"
      unitRef="usd">571400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtMS0xLTEtMTA2NTAy_b3be894f-a7b7-48ed-a34b-f102f30dff42"
      unitRef="usd">1058000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtMy0xLTEtMTA2NTAy_2538cd3a-a0e7-458f-be42-dd5658430d4e"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtNS0xLTEtMTA2NTAy_3af3ad3f-9e7b-4b3c-972a-774ab66520b6"
      unitRef="usd">1361800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjQtNy0xLTEtMTA2NTAy_b7d407b8-4693-4113-8b18-bfb5dd7a375d"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctMS0xLTEtMTA2NTAy_914c2185-ecf3-474c-951b-67a9b6ef3b75"
      unitRef="usdPerShare">7.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctMy0xLTEtMTA2NTAy_08dc768d-bb6a-4eed-973a-757d51f8456c"
      unitRef="usdPerShare">3.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctNS0xLTEtMTA2NTAy_6b06c0dd-cf6c-4d32-92f7-f44e7d01d4f2"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjctNy0xLTEtMTA2NTAy_55f475bc-a34e-4463-8ab5-9d4517a33ab6"
      unitRef="usdPerShare">5.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtMS0xLTEtMTA2NTAy_237401c2-ea5f-42b9-b71b-a2dbcf717649"
      unitRef="usdPerShare">7.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtMy0xLTEtMTA2NTAy_64306c28-ee7d-4151-9a54-453a65198690"
      unitRef="usdPerShare">2.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtNS0xLTEtMTA2NTAy_6925f975-b657-488d-85b8-f38d8efe1ac6"
      unitRef="usdPerShare">9.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMjgtNy0xLTEtMTA2NTAy_54f82b47-528e-474c-afe9-3ad12b3bd4ab"
      unitRef="usdPerShare">5.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtMS0xLTEtMTA2NTAy_f97c16f6-8084-4256-b6f8-3746b529ae7b"
      unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtMy0xLTEtMTA2NTAy_81e84c82-80a8-4725-be66-23382bc0e6da"
      unitRef="shares">149700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtNS0xLTEtMTA2NTAy_35c639fe-0d87-4607-a057-680c4065e9dd"
      unitRef="shares">146500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzEtNy0xLTEtMTA2NTAy_5b5a331a-0d25-4f59-9ec4-044355a314c3"
      unitRef="shares">150800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItMS0xLTEtMTA2NTAy_676f8ce1-11b3-4eb5-89ac-339f50b41678"
      unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItMy0xLTEtMTA2NTAy_29113cbb-ebe6-49da-b0b0-4ceffdb35dbc"
      unitRef="shares">150100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItNS0xLTEtMTA2NTAy_fb7d1add-e4fd-49dc-b2d9-36dea61642a7"
      unitRef="shares">146800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xOS9mcmFnOmFiNjM3MTMzZGM2MzQ0ZmU5ZTFkZjdjNzU0Njc3NjlkL3RhYmxlOjk3MzRmNzM2Njg0MTQxMGZiMGU5MzlkNjYyOTI2YWZlL3RhYmxlcmFuZ2U6OTczNGY3MzY2ODQxNDEwZmIwZTkzOWQ2NjI5MjZhZmVfMzItNy0xLTEtMTA2NTAy_000cc38a-6738-4002-8ea8-d05ac542dbd3"
      unitRef="shares">151200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi0xLTEtMS0xMDY1MDI_f88097c0-da7b-42e5-99cc-a3b0b508ebbb"
      unitRef="usd">1058000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi0zLTEtMS0xMDY1MDI_7dc4454e-620e-4912-aefc-5f0f1a33e44b"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi01LTEtMS0xMDY1MDI_07aa6797-1d4b-48c0-8084-a7e8196645c8"
      unitRef="usd">1361800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMi03LTEtMS0xMDY1MDI_ffd312f2-3c47-4a9f-bd80-89641872e4a1"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC0xLTEtMS0xMDY1MDI_70c34891-7207-46c4-8f2c-128bfbfabfa9"
      unitRef="usd">-8300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC0zLTEtMS0xMDY1MDI_280090d3-ffdc-4bff-aa14-77117b27b77c"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC01LTEtMS0xMDY1MDI_6e924920-aec1-4a2e-933a-c2cce377bd16"
      unitRef="usd">-18000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNC03LTEtMS0xMDY1MDI_3f0b4728-0df4-4b7b-9bb0-bdefcfe74885"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS0xLTEtMS0xMDY1MDI_8e5cf6c2-58d9-4c56-8ea3-6f43be189766"
      unitRef="usd">57200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS0zLTEtMS0xMDY1MDI_5d02108a-29ee-44e9-af9f-c210129c9d21"
      unitRef="usd">-11000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS01LTEtMS0xMDY1MDI_a5ce1e5e-6ab0-4f1c-b3f8-e018f6964b30"
      unitRef="usd">73100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNS03LTEtMS0xMDY1MDI_fb6de167-2640-4bec-b766-c0a75c091edc"
      unitRef="usd">138600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi0xLTEtMS0xMDY1MDI_f7205f35-7fca-478e-8729-67ba0b24e179"
      unitRef="usd">-31700000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi0zLTEtMS0xMDY1MDI_f632f743-c4e5-4fa8-94b3-ccff1e520df7"
      unitRef="usd">-2300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi01LTEtMS0xMDY1MDI_d49bc86a-dc55-41e2-b73f-fe28a5220b11"
      unitRef="usd">-25500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNi03LTEtMS0xMDY1MDI_5d168c9a-8566-4b97-97c7-d3bf61b1ed7d"
      unitRef="usd">20100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy0xLTEtMS0xMDY1MDI_a38a226a-caba-43d3-8734-233c1a5a631a"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy0zLTEtMS0xMDY1MDI_623c67f8-c464-4987-9272-dd6eb0514442"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy01LTEtMS0xMDY1MDI_d44e4c35-0946-4c06-a47d-e15767003367"
      unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfNy03LTEtMS0xMDY1MDI_1c229f94-570f-4c7f-b2e3-7cb6316107d1"
      unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC0xLTEtMS0xMDY1MDI_23d236ed-dd0e-48d4-805c-f8acd5f314e7"
      unitRef="usd">-14200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC0zLTEtMS0xMDY1MDI_0f4c6982-a4db-4f7f-8393-be7df396d2fa"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC01LTEtMS0xMDY1MDI_fd37c94e-6884-4657-98cc-da41aa479593"
      unitRef="usd">-36000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOC03LTEtMS0xMDY1MDI_f9a9d292-1403-45f7-9420-8f60eb083dd2"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS0xLTEtMS0xMDY1MDI_f6877ed0-b0c7-4a2a-9d11-93a65052177e"
      unitRef="usd">4800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS0zLTEtMS0xMDY1MDI_7631ac47-d627-472b-a0fb-bd66fe679119"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS01LTEtMS0xMDY1MDI_88fb0654-cbe8-4c08-bf91-00211f11d8b7"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfOS03LTEtMS0xMDY1MDI_a53f54d5-ff58-42ff-b51d-65cdabca1789"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtMS0xLTEtMTA2NTAy_a980e789-60c3-411c-8b94-98e2d4445a3e"
      unitRef="usd">1062800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtMy0xLTEtMTA2NTAy_1a38ef8a-b726-4fd1-abd6-50b2f5754463"
      unitRef="usd">451000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtNS0xLTEtMTA2NTAy_67f19c20-2ddb-4da5-9067-8f1b3821d1a9"
      unitRef="usd">1358100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTAtNy0xLTEtMTA2NTAy_553c34da-5eec-4b16-97e7-10352a7a1e5f"
      unitRef="usd">985900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtMS0xLTEtMTA2NTAy_7d8b0b80-bbed-45a8-a849-fca30518d389"
      unitRef="usd">700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtMy0xLTEtMTA2NTAy_3a0c22d9-b611-4853-8d5f-4078c7e5a896"
      unitRef="usd">576900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtNS0xLTEtMTA2NTAy_a968b583-2988-4ab5-875d-2162748261b7"
      unitRef="usd">-84600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTEtNy0xLTEtMTA2NTAy_6d2f1bda-0dd0-4b7a-89cb-8b373a5bf43e"
      unitRef="usd">572000000.0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItMS0xLTEtMTA2NTAy_2c6a3c15-8294-4578-adea-fafc00e451eb"
      unitRef="usd">1063500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItMy0xLTEtMTA2NTAy_a15c2713-908a-4453-9ade-08502be1ea1e"
      unitRef="usd">1027900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItNS0xLTEtMTA2NTAy_01afa574-5053-491e-b454-07c0c022da76"
      unitRef="usd">1273500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMi9mcmFnOmNhYmM2YTk4ODBjYjRiMmNiNmMxMzQ0MDEyNTJiYWExL3RhYmxlOjc0NDJkMDg3OGIxZTQ3MGJiMDZmY2MyNzI1MDllYzcxL3RhYmxlcmFuZ2U6NzQ0MmQwODc4YjFlNDcwYmIwNmZjYzI3MjUwOWVjNzFfMTItNy0xLTEtMTA2NTAy_eb20c2dd-0110-48b6-8993-26b123c320bc"
      unitRef="usd">1557900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMy0xLTEtMS0xMDY1MDI_ce568163-38ac-4ec6-9f51-77138fc60f06"
      unitRef="usd">2646600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMy0zLTEtMS0xMDY1MDI_7ddd4e5d-03db-4bd9-9f30-0c3aded4468e"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNC0xLTEtMS0xMDY1MDI_8e60382c-98f7-447b-ae97-74c01b95c233"
      unitRef="usd">2151300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNC0zLTEtMS0xMDY1MDI_41ec96cc-26f6-4f49-94d0-6d62f580ef51"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNS0xLTEtMS0xMDY1MDI_f07bc863-9d8f-414f-916e-3c641b4f9238"
      unitRef="usd">1567600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNS0zLTEtMS0xMDY1MDI_26fad047-1a4e-4857-ac34-e1dd99a47f93"
      unitRef="usd">1549400000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNi0xLTEtMS0xMDY1MDI_1228e42d-8628-4cab-b5ad-2b4f75945e0e"
      unitRef="usd">435900000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNi0zLTEtMS0xMDY1MDI_c7f6aedb-52e2-4034-b703-c32e36f0f736"
      unitRef="usd">412300000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNy0xLTEtMS0xMDY1MDI_d1bc45ac-778a-4ffa-ad6d-84173b58f51c"
      unitRef="usd">1294200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNy0zLTEtMS0xMDY1MDI_b1eb106c-1ab5-4230-b4c5-605c3910fb87"
      unitRef="usd">1351500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOC0xLTEtMS0xMDY1MDI_6efaf9a4-0f82-4608-b468-7ce5701c7fef"
      unitRef="usd">1645300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOC0zLTEtMS0xMDY1MDI_071a8b89-8cec-4df6-8593-c51e549a70ed"
      unitRef="usd">740800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOS0xLTEtMS0xMDY1MDI_e4859d6e-d940-4047-b62a-d8d3f26433a5"
      unitRef="usd">9740900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfOS0zLTEtMS0xMDY1MDI_ca6b4e5a-7e18-4333-8e7c-46254376dca8"
      unitRef="usd">7856500000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTAtMS0xLTEtMTA2NTAy_c37e81c5-b453-411f-ac81-0edf4442fe9a"
      unitRef="usd">1102900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTAtMy0xLTEtMTA2NTAy_2d5334ef-a350-441d-b927-86b11781cde5"
      unitRef="usd">892000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTEtMS0xLTEtMTA2NTAy_8be31b63-5893-40b8-9fa4-dbac74b97624"
      unitRef="usd">3355100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTEtMy0xLTEtMTA2NTAy_89819675-bb91-4a65-8168-2e93e414f89d"
      unitRef="usd">3416400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTItMS0xLTEtMTA2NTAy_e31a1616-65e1-473b-8b5a-75d80e28ac1d"
      unitRef="usd">321100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTItMy0xLTEtMTA2NTAy_89e00683-4daa-4663-922f-033352e92207"
      unitRef="usd">375400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTMtMS0xLTEtMTA2NTAy_1474a265-587c-480f-9ac9-7600210c2f1d"
      unitRef="usd">2075300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTMtMy0xLTEtMTA2NTAy_719f5070-58d4-460a-a600-3a245a8f253a"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTQtMS0xLTEtMTA2NTAy_3da45500-ca5c-4fce-8652-cd4eab697bbb"
      unitRef="usd">5749600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTQtMy0xLTEtMTA2NTAy_089d50c0-c7d5-458c-8e63-d55ed85b2b1c"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTUtMS0xLTEtMTA2NTAy_91273ff7-dfa8-4934-932d-854a1f98004c"
      unitRef="usd">1235700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTUtMy0xLTEtMTA2NTAy_429b2314-2a8c-48b1-9a23-fa5cf22320e0"
      unitRef="usd">1415100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTYtMS0xLTEtMTA2NTAy_193566ef-01b5-4eef-b13b-34f2b1f45216"
      unitRef="usd">1500800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTYtMy0xLTEtMTA2NTAy_7019067d-b241-467e-b54f-d62823260602"
      unitRef="usd">1939500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTctMS0xLTEtMTA2NTAy_c2235642-255c-47a0-9566-8193c73b8cc3"
      unitRef="usd">25081400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMTctMy0xLTEtMTA2NTAy_83face22-a599-4547-9a42-31c07da0ff2a"
      unitRef="usd">23877300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjAtMS0xLTEtMTA2NTAy_1cf25998-3d5b-4f56-93aa-7c4c0faffa85"
      unitRef="usd">999800000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjAtMy0xLTEtMTA2NTAy_bfd0ae17-6f2b-4723-95b7-2ca9ac798bef"
      unitRef="usd">999100000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjEtMS0xLTEtMTA2NTAy_9c2ec648-1a91-4b4e-b2c3-64eb7c5bcbae"
      unitRef="usd">284900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjEtMy0xLTEtMTA2NTAy_d034a66c-c5b2-4fe5-a542-c69b5ef3595a"
      unitRef="usd">174700000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjItMS0xLTEtMTA2NTAy_1445c34c-3f54-4ae7-ba04-e0daafcde0ff"
      unitRef="usd">434800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjItMy0xLTEtMTA2NTAy_b36aa412-458c-4fbe-8605-4b896af2271e"
      unitRef="usd">589200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjMtMS0xLTEtMTA2NTAy_1d4e82b7-fa92-4291-9b86-221a241b6c83"
      unitRef="usd">3298500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjMtMy0xLTEtMTA2NTAy_06689928-4f6c-48ce-bafb-9fc6b670a367"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjQtMS0xLTEtMTA2NTAy_de3afdd7-d5bf-4ac8-9e1a-18b24c24c28f"
      unitRef="usd">5018000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjQtMy0xLTEtMTA2NTAy_f27a017b-84b9-4f11-bb68-bb07454b7219"
      unitRef="usd">4298200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjUtMS0xLTEtMTA2NTAy_ea8eb751-d679-4a20-a4c2-0d0c643635dd"
      unitRef="usd">6277400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjUtMy0xLTEtMTA2NTAy_7aa33ffe-c514-4794-a3bf-dc8e68cdfd93"
      unitRef="usd">6274000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjYtMS0xLTEtMTA2NTAy_5fd459bd-56eb-4dd2-988f-e5d30f43fa22"
      unitRef="usd">480600000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjYtMy0xLTEtMTA2NTAy_edaae6df-6a79-4c3a-899e-b9a37c9b70a2"
      unitRef="usd">694500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjctMS0xLTEtMTA2NTAy_816def96-6b80-470d-9190-12c68c20520e"
      unitRef="usd">274200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjctMy0xLTEtMTA2NTAy_b8ff769f-f0be-42ca-851f-a337b2365ba5"
      unitRef="usd">330400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjgtMS0xLTEtMTA2NTAy_d8c876d6-39f6-45db-a7fa-1410d0306c29"
      unitRef="usd">1167800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjgtMy0xLTEtMTA2NTAy_b9aa5324-4b4b-4d05-81ed-1b1097bdef16"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjktMS0xLTEtMTA2NTAy_e496c6b1-9c74-43d8-9e13-422f9cc1b661"
      unitRef="usd">13218000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMjktMy0xLTEtMTA2NTAy_b291a270-2b05-49f3-a0c8-0e61f41bece2"
      unitRef="usd">12917600000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzAtMS0xLTEtMTA2NTAy_c11e1a9f-c87d-4196-897c-1c7aae10ce13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzAtMy0xLTEtMTA2NTAy_aaec61c0-73dd-4598-bdcb-1f7394954e95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzMtMS0xLTEtMTA2NTAy_5d2a7d80-01f4-478c-b31e-ebc40a3b8d32"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzMtMy0xLTEtMTA2NTAy_fe173fd0-2bba-4030-bcd6-22ace8756281"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzQtMS0xLTEtMTA2NTAy_7e9a0186-cb91-48b4-a15e-2c250a78555d"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzQtMy0xLTEtMTA2NTAy_1a93c8b1-3684-45e2-8401-af00fa3f15ef"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzUtMS0xLTEtMTA2NTAy_f133c4ff-c989-4326-b9f7-58b13626cdb8"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzUtMy0xLTEtMTA2NTAy_fc3798aa-1741-4237-960a-138cc605e058"
      unitRef="usd">68200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzYtMS0xLTEtMTA2NTAy_59840401-5903-4aa1-9a3b-ec445f2eaf16"
      unitRef="usd">-110400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzYtMy0xLTEtMTA2NTAy_31cea787-6529-404d-95aa-38b72fde1547"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzctMS0xLTEtMTA2NTAy_d1757042-fe1e-4841-a768-b1da3e57ea7c"
      unitRef="usd">14959900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzctMy0xLTEtMTA2NTAy_f7d0d3f1-5a82-45e7-a7e1-732e42d753ef"
      unitRef="usd">13911700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzgtMS0xLTEtMTA2NTAy_650c5a72-34d8-41c9-b746-017f81900258"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzgtMy0xLTEtMTA2NTAy_9bc4925c-58cb-47c5-9436-2bb36057bfc0"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzktMS0xLTEtMTA2NTAy_050907d5-5c5e-4b82-9b3a-4f620df92c3d"
      unitRef="usd">11872500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfMzktMy0xLTEtMTA2NTAy_5e88282b-2087-42e6-a4af-bccd92526121"
      unitRef="usd">10896200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDAtMS0xLTEtMTA2NTAy_0b191aae-3134-445d-a079-bb6d734e30a4"
      unitRef="usd">-9100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDAtMy0xLTEtMTA2NTAy_90b8619c-0c36-4fc1-ade7-b78396f93095"
      unitRef="usd">63500000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDEtMS0xLTEtMTA2NTAy_85b56cd4-879d-4aff-8802-c68ff957c67f"
      unitRef="usd">11863400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDEtMy0xLTEtMTA2NTAy_b97f2c9a-90fc-438c-8786-17032b57a976"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDItMS0xLTEtMTA2NTAy_65609c55-a3ca-4cba-a7a5-e4c015d91491"
      unitRef="usd">25081400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yNS9mcmFnOjljN2UwMzRhYjYxNzRiNzRiZjJiYWEwZGM2YWE2MGM1L3RhYmxlOmNiMzE3MmI3ZTkxODQ4NDQ5Yjk1OGE0NjNkMzIxYmY4L3RhYmxlcmFuZ2U6Y2IzMTcyYjdlOTE4NDg0NDliOTU4YTQ2M2QzMjFiZjhfNDItMy0xLTEtMTA2NTAy_4d0556c6-6704-4ce0-9807-cd0459789318"
      unitRef="usd">23877300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMy0xLTEtMS0xMDY1MDI_91317937-3c59-4662-ad02-0f0769977c3b"
      unitRef="usd">1277200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMy0zLTEtMS0xMDY1MDI_5477de2e-01b4-403d-a18d-c795e073a0ea"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNS0xLTEtMS0xMDY1MDI_668a2724-48f6-47df-9cc8-af8a88df4981"
      unitRef="usd">277900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNS0zLTEtMS0xMDY1MDI_7d317cbe-52ab-49a4-b1f5-5707cb1bcc03"
      unitRef="usd">219800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNi0xLTEtMS0xMDY1MDI_82d1305d-fd02-4dee-9b40-7e60902f689a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNi0zLTEtMS0xMDY1MDI_5000ff39-ad45-4100-a8ef-8ac0ac8020e7"
      unitRef="usd">585900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNy0xLTEtMS0xMDY1MDI_1b2cde6c-4b7d-4531-8d0e-61bdb833e564"
      unitRef="usd">305600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNy0zLTEtMS0xMDY1MDI_25f0b9e3-0ece-4356-95d9-c834b69b3066"
      unitRef="usd">8300000</us-gaap:InventoryWriteDown>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOC0xLTEtMS0xMDY1MDI_2e6d13e3-5188-45e1-a587-790ec8d7bd10"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOC0zLTEtMS0xMDY1MDI_3d3d561e-0d0a-471c-a8ef-ae0f205fcd92"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOS0xLTEtMS0xMDY1MDI_27a4fb17-c49a-4c01-b8e0-23f0098f42da"
      unitRef="usd">123300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfOS0zLTEtMS0xMDY1MDI_3fa957a7-fb6a-4b8b-b8ae-b3748e6dae2e"
      unitRef="usd">124100000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTAtMS0xLTEtMTA2NTAy_9adddfbc-4695-4bd3-b3db-e25e629a8cb3"
      unitRef="usd">11600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTAtMy0xLTEtMTA2NTAy_e798043a-0999-4382-9f8a-2548c1d97ab8"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTEtMS0xLTEtMTA2NTAy_ed3aa5f9-8ca3-460e-9f6d-5855c6600efc"
      unitRef="usd">-47500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTEtMy0xLTEtMTA2NTAy_c20ff4a3-2f7a-43c0-bdaf-570afa9315f4"
      unitRef="usd">-622800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTItMS0xLTEtMTA2NTAy_b3fe2f55-d1f6-4d63-9bab-b1613c3098b4"
      unitRef="usd">-269300000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTItMy0xLTEtMTA2NTAy_e4f5e956-60a0-422e-809d-6dd2afa69619"
      unitRef="usd">-283600000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTMtMS0xLTEtMTA2NTAy_9827b8f3-c9a5-4cdb-a9e7-469935ace9e0"
      unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTMtMy0xLTEtMTA2NTAy_c0f242dd-968a-4cb7-a754-179d56b34079"
      unitRef="usd">16100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMS0xLTEtMTIwODg4_cabf57cd-0339-46ef-9019-d8f6d6516c5d"
      unitRef="usd">1505400000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMy0xLTEtMTIwODg4_b1a79659-58dc-4ddd-83bc-770bcaed2c6f"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMS0xLTEtMTA2NTAy_ce4b55ed-ef8b-4a98-8e19-d3cf1e11eb7e"
      unitRef="usd">-112200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTQtMy0xLTEtMTA2NTAy_b61a3676-79a5-41a1-8d52-08e2d4ee921a"
      unitRef="usd">-104100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTYtMS0xLTEtMTA2NTAy_9a8b73f7-bce5-42de-95bf-9525e7ab702d"
      unitRef="usd">67300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTYtMy0xLTEtMTA2NTAy_40f01a9b-a7c6-4d42-ba07-0083645b328b"
      unitRef="usd">-211500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTctMS0xLTEtMTA2NTAy_855f6388-e152-4b08-aebd-f301b8e88695"
      unitRef="usd">23600000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTctMy0xLTEtMTA2NTAy_04e5f0c4-32c0-4f10-be4d-71b00d2482dd"
      unitRef="usd">8700000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTgtMS0xLTEtMTA2NTAy_62167f05-9f2c-4148-a234-6ac3ee54e1bf"
      unitRef="usd">243300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTgtMy0xLTEtMTA2NTAy_f5a0c03a-f5af-41f6-b4bd-30bd49346948"
      unitRef="usd">193800000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTktMS0xLTEtMTA2NTAy_53394028-6ce3-4f3e-9e57-72b4dba41625"
      unitRef="usd">634000000.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMTktMy0xLTEtMTA2NTAy_cc1cd23e-3f0e-4cfe-9bbe-8150b5f67fe4"
      unitRef="usd">-188400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjAtMS0xLTEtMTA2NTAy_c03ba73f-7ebd-4a57-9cad-01311b46d299"
      unitRef="usd">-65900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjAtMy0xLTEtMTA2NTAy_658b2113-e2de-4531-8300-c9a89c3a1e00"
      unitRef="usd">171500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjEtMS0xLTEtMTA2NTAy_d1112f91-2c18-444c-a044-cc5cf5f500b6"
      unitRef="usd">134000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjEtMy0xLTEtMTA2NTAy_b5517605-5612-41d9-be60-9ddd8f147ba6"
      unitRef="usd">97300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjItMS0xLTEtMTA2NTAy_e0044f0d-e636-494f-b5ea-2cfa6606d9e1"
      unitRef="usd">898300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjItMy0xLTEtMTA2NTAy_15662f79-1a6d-47cd-9d36-8f8985efc993"
      unitRef="usd">1996300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjQtMS0xLTEtMTA2NTAy_fbec1d20-bf3d-4def-b02d-f28be50d753b"
      unitRef="usd">94800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjQtMy0xLTEtMTA2NTAy_dcbb6b9e-1fc1-451e-a8fe-25654bf5b4df"
      unitRef="usd">164500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjUtMS0xLTEtMTA2NTAy_6b02ec11-e448-41d0-9e79-6a233ee4ac80"
      unitRef="usd">1461500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjUtMy0xLTEtMTA2NTAy_338fe41f-6864-46f2-a41b-0bd96c80f351"
      unitRef="usd">1452700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjYtMS0xLTEtMTA2NTAy_285590cf-1188-4422-a1e1-ac8c5f9442f3"
      unitRef="usd">2311600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjYtMy0xLTEtMTA2NTAy_55e842d8-e6e1-4c60-9006-0c1e343d40b5"
      unitRef="usd">1626900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMS0xLTEtMTE0Mzkx_8c256366-aac8-4f94-b33c-c92b6e9919f7"
      unitRef="usd">990300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMy0xLTEtMTE0Mzkx_f800bcbb-2063-4773-882c-1ecd7c4a15ed"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMS0xLTEtMTA2NTAy_6aef1fdf-0487-4e4a-a17a-0ecf60074420"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjctMy0xLTEtMTA2NTAy_41328abd-c610-4fdf-810b-8c65dc735352"
      unitRef="usd">28100000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjktMS0xLTEtMTA2NTAy_8107678e-ccd6-49c1-bc7a-803cb99f666c"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMjktMy0xLTEtMTA2NTAy_d1341235-5100-4ab1-9068-b3a714608535"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzAtMS0xLTEtMTA2NTAy_40fb64c0-2517-4e78-835c-4de73937b1a8"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzAtMy0xLTEtMTA2NTAy_a9fa9b1b-278e-459b-bf26-bb648adc5c11"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzEtMS0xLTEtMTA2NTAy_3e5b1fa2-d0d1-4507-b21b-6c7bb6005525"
      unitRef="usd">-2000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzEtMy0xLTEtMTA2NTAy_f6533ee2-b55f-4a58-a231-b97def07b19d"
      unitRef="usd">-2000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzItMS0xLTEtMTA2NTAy_c76ea73e-5b33-4c83-8867-013a39267d4f"
      unitRef="usd">45500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzItMy0xLTEtMTA2NTAy_ca75e852-812c-4828-a24b-8fceff1618a6"
      unitRef="usd">-217400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzQtMS0xLTEtMTA2NTAy_3bd93f9b-0a87-4bba-b1f3-4af74eea74b5"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzQtMy0xLTEtMTA2NTAy_4f38fdf2-88f1-4e3b-bf42-4475b98b8236"
      unitRef="usd">1050000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzUtMS0xLTEtMTA2NTAy_9a379675-e186-4025-b386-0b77cc18b436"
      unitRef="usd">11500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzUtMy0xLTEtMTA2NTAy_f53bb67a-886f-48ae-b502-cacb99693c23"
      unitRef="usd">14200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzYtMS0xLTEtMTA2NTAy_be1d4d7f-939b-4842-9c4b-ce5012b558de"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzYtMy0xLTEtMTA2NTAy_d34734d4-39dc-47b5-842b-b7fe99e0aea0"
      unitRef="usd">170000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzktMS0xLTEtMTA2NTAy_88698b80-528e-4aa2-865e-cca837344205"
      unitRef="usd">12100000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfMzktMy0xLTEtMTA2NTAy_e14916d1-05ac-4498-9569-646b70742904"
      unitRef="usd">-94800000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDAtMS0xLTEtMTA2NTAy_821db42d-f3cd-4051-b5c3-dea72aa845ea"
      unitRef="usd">11400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDAtMy0xLTEtMTA2NTAy_c9ac0f90-e635-4fbd-82bc-d68c8ba6c517"
      unitRef="usd">-20500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDEtMS0xLTEtMTA2NTAy_915d4921-87a9-4f28-a98e-f9a880c41ca7"
      unitRef="usd">-488000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDEtMy0xLTEtMTA2NTAy_0dec2e99-0b62-403e-9976-4ba8a8413f92"
      unitRef="usd">-1349500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDItMS0xLTEtMTA2NTAy_4d8f9f92-16ff-4a56-aca2-c26aa416b86a"
      unitRef="usd">455800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDItMy0xLTEtMTA2NTAy_f92e687a-46e7-468d-9464-e814f980e4bf"
      unitRef="usd">429400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDMtMS0xLTEtMTA2NTAy_1159fd41-cf2f-4ca4-8715-b30b4081a3b4"
      unitRef="usd">-70600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDMtMy0xLTEtMTA2NTAy_9fab2740-2ec9-4e05-9127-8944f1b25cd8"
      unitRef="usd">-18600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDQtMS0xLTEtMTA2NTAy_7eb2b420-af6e-46e3-8b79-4331c6dbf3d0"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDQtMy0xLTEtMTA2NTAy_5e133283-743f-48c1-a09d-f46521ca3413"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDUtMS0xLTEtMTA2NTAy_2bc39381-5e60-43e3-b47f-d3462436afdf"
      unitRef="usd">2646600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zMS9mcmFnOjJjNDEwY2E2NTA0NzQyYWQ4NjM5NDgxZDI5OTg3NGIxL3RhYmxlOmQwZGFhYmY3MmYyYzQxNTViMmE0ODFkNjVlZDRkYTk0L3RhYmxlcmFuZ2U6ZDBkYWFiZjcyZjJjNDE1NWIyYTQ4MWQ2NWVkNGRhOTRfNDUtMy0xLTEtMTA2NTAy_960ce799-d52b-4661-b566-a984c28c89ae"
      unitRef="usd">1742000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xLTEtMS0xMDY1MDI_14b25d1d-dfed-49fe-8b6e-e8e31ac8d632"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i318c3c5e741d4f2787a0ab7d3fd88004_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0zLTEtMS0xMDY1MDI_0c81a046-9f49-414e-8bc0-35e1599291a7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i655d8f6be57b43f8a4aff100977af6ba_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi01LTEtMS0xMDY1MDI_2ba77a37-eddf-4cca-b2d7-a64ef86d8ad5"
      unitRef="shares">171300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i655d8f6be57b43f8a4aff100977af6ba_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi03LTEtMS0xMDY1MDI_50b6fd0a-edaa-4fc4-8524-3e180337f428"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d4021ecec514c33b4f46028ea027777_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi05LTEtMS0xMDY1MDI_af6f8b81-2233-4b79-a718-c04a359d81e4"
      unitRef="usd">119000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d0383fdaa1a45b2990dc160ac25e8e6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xMS0xLTEtMTA2NTAy_b8793f6a-e992-4168-b396-0e10733c688f"
      unitRef="usd">-115200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i609e4fab86de4ca682e02c1766083dab_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xMy0xLTEtMTA2NTAy_cceacdfc-d4b6-47a2-9063-7fa45c7fba27"
      unitRef="usd">14215500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xNS0xLTEtMTA2NTAy_c65a809b-5678-4a3a-b487-c9bc938c528e"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9279ec7e1f6a4d9f8789a6e513b08301_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xNy0xLTEtMTA2NTAy_a2ef20bc-d1d5-4440-93a1-a36d7bd5691f"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f53af952a05400eb5a03b652b2a5224_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0xOS0xLTEtMTA2NTAy_d3ce7b2a-d30d-4278-81c0-fea36320221b"
      unitRef="usd">11242300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25bd83dbf18a47969953f960652b7ca8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0yMS0xLTEtMTA2NTAy_268200e5-0921-4bcf-b9a1-438f22da7336"
      unitRef="usd">-21600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9f48125dbb64c14aa174f438eb3b529_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMi0yMy0xLTEtMTA2NTAy_9e7a67f5-c185-4c1e-81db-d317ee0bd173"
      unitRef="usd">11220700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="if7a7a040013e4e578186caffe27ff784_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0xMy0xLTEtMTA2NTAy_bca244a9-74c1-44ba-9f00-b9d24f9ebaad"
      unitRef="usd">1058000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0xOS0xLTEtMTA2NTAy_93a0d6a8-a775-490e-b8a4-4491bca39ead"
      unitRef="usd">1058000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0yMS0xLTEtMTA2NTAy_9b23fbb8-f6c0-4a7d-9524-50faa256c88a"
      unitRef="usd">700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMy0yMy0xLTEtMTA2NTAy_faf57dbb-65f0-4314-a68d-2cc0c44dc355"
      unitRef="usd">1058700000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i97a5574cfc654102a3578daabb6da090_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0xMS0xLTEtMTA2NTAy_c84d67d5-eccd-4b64-972a-151f74f4e758"
      unitRef="usd">4800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0xOS0xLTEtMTA2NTAy_c045843e-7c9a-4635-b83f-1baf95d66f1f"
      unitRef="usd">4800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNC0yMy0xLTEtMTA2NTAy_be2b5fba-0f8a-4bf3-8ce9-9fce6187255b"
      unitRef="usd">4800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ie95ba7d0554f49afa0b7a133c1e09599_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNi0yMS0xLTEtMTA2NTAy_185c15ee-e95f-4b09-92e1-521f44624767"
      unitRef="usd">11800000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNi0yMy0xLTEtMTA2NTAy_28af49a8-3bb4-47ac-8ea7-794c87ad4e6f"
      unitRef="usd">11800000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xNS0xLTEtMTA2NTAy_0a16b3cc-f6f3-48d0-8472-8240d058bbac"
      unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xNy0xLTEtMTA2NTAy_9f5348f6-bb0c-48e5-9d24-7e3055d62ec2"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i200e14d4b78f4812b17968b9f9d1aea2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0xOS0xLTEtMTA2NTAy_6fa9a40b-1720-4bad-b02b-be1480d3a75b"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfNy0yMy0xLTEtMTA2NTAy_0c490aa6-fb9a-40e7-af44-72d05dfd4bc6"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5245b9a67e8448b39d74a04b7e9b1de1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC01LTEtMS0xMDY1MDI_b7d341c4-41f5-4a52-ab99-59e6c41263aa"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i34ba7d8360a14679a9369e90b81fc882_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC05LTEtMS0xMDY1MDI_60c63916-3c28-44db-97d3-6f2a0b534534"
      unitRef="usd">186400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i281cd7edebd843fe95c846ccd0a8fbe2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xMy0xLTEtMTA2NTAy_d7a28129-0ea1-407d-b088-725ef2770ca4"
      unitRef="usd">313600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xNS0xLTEtMTA2NTAy_5877a858-f317-45f0-afda-4eaaab6d04a0"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i7282361a53a7405193ccfd96de4cb39c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0xNy0xLTEtMTA2NTAy_3ead3307-94ba-400d-a6d9-b54b593709ab"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i99b7018db4714ef7a3f359013b0cafb9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOC0yMy0xLTEtMTA2NTAy_f11a9965-e5cf-44a9-8a47-0a6e3870e098"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i15182190caca498b8e52572e96ba2eba_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS01LTEtMS0xMDY1MDI_acdb1770-958f-49b4-8788-b25a8753e385"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS05LTEtMS0xMDY1MDI_4040f78f-142b-43db-aa69-c9515278c84f"
      unitRef="usd">10000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS0xOS0xLTEtMTA2NTAy_6d58b551-7aee-4033-ae9d-77f90b5c8e88"
      unitRef="usd">10000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfOS0yMy0xLTEtMTA2NTAy_70a54c6c-e6f9-4fdc-aa55-af97a134e9c9"
      unitRef="usd">10000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i15182190caca498b8e52572e96ba2eba_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtNS0xLTEtMTA2NTAy_cb35ca0c-bcf8-4d8b-9ebc-c11a904060f9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtOS0xLTEtMTA2NTAy_682cde58-44c1-4caf-9661-37979122d203"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtMTktMS0xLTEwNjUwMg_bc691f4c-340a-4143-aac2-18fdd6968cb6"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTAtMjMtMS0xLTEwNjUwMg_84f531c7-2c80-404e-a9f9-80ac2841a1b8"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtOS0xLTEtMTA2NTAy_7a0f6e64-ddd1-45ed-8b6c-62a4597ec599"
      unitRef="usd">-58000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtMTktMS0xLTEwNjUwMg_8b47d950-d5cf-47f9-95db-95a3b2f67747"
      unitRef="usd">-58000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTEtMjMtMS0xLTEwNjUwMg_c829c3ad-233d-4645-a0e0-3cab30c983b1"
      unitRef="usd">-58000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i1b38b28d2de64b7b97a6acd6df4dddcb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItOS0xLTEtMTA2NTAy_24fe83a7-ca1d-4dc0-a32f-a24cfd5da7ae"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6d4a5882807c4a71bd25be055ce1d53d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItMTktMS0xLTEwNjUwMg_8a30248d-f3d3-45d6-8f76-29a20a6d6c62"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTItMjMtMS0xLTEwNjUwMg_cde72900-c72d-4d33-9061-0e3564cecd36"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMS0xLTEtMTA2NTAy_4d0be2d5-aeab-4c85-9af1-4e54ea36d767"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMy0xLTEtMTA2NTAy_2c5c1520-776e-4962-a11e-5fe4bfede821"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtNS0xLTEtMTA2NTAy_7ab92f6f-f1d4-4e75-bc3f-086993432400"
      unitRef="shares">169000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtNy0xLTEtMTA2NTAy_f060e94a-db60-41d0-ad39-7327310c64aa"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67c4af1889714ce0862fe75007a47c79_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtOS0xLTEtMTA2NTAy_4a225158-f9ad-4b28-8cf4-d76799575f53"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc0a37bdf69449ddaf16a60e03e555ae_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTEtMS0xLTEwNjUwMg_0b27da45-bda8-4de9-95c2-c7f2244efb99"
      unitRef="usd">-110400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTMtMS0xLTEwNjUwMg_2aaa9a52-0652-42ea-91e5-dfb417623920"
      unitRef="usd">14959900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8b532043d004077960b4e7717b3606f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTUtMS0xLTEwNjUwMg_ef2c1801-2cbe-45bb-ad1c-2b22cd9b6a09"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8b532043d004077960b4e7717b3606f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTctMS0xLTEwNjUwMg_306291e0-ca85-49d4-ba91-34d337a91d8e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMTktMS0xLTEwNjUwMg_e796ebd3-9f6a-41da-a09c-4e4dd3acc97c"
      unitRef="usd">11872500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6736d3935f8c47758cb22a7798dd423d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMjEtMS0xLTEwNjUwMg_01640780-964e-42cc-861d-c25f939278cf"
      unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjg0ZGUwYzAyMjRjYzRhMDc5ZTBjZjI5YWI4ZmI1MjM0L3RhYmxlcmFuZ2U6ODRkZTBjMDIyNGNjNGEwNzllMGNmMjlhYjhmYjUyMzRfMTMtMjMtMS0xLTEwNjUwMg_8f8191d7-2bbb-45cf-8382-97c4f189e642"
      unitRef="usd">11863400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3383d03c85d343899a6760bb144c07cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xLTEtMS0xMDY5MTY_d7d4d3d9-254f-473f-8c2f-60b6535f332d"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3383d03c85d343899a6760bb144c07cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0zLTEtMS0xMDY5MTY_9b9ad3c5-6660-49bc-b569-5286ce0a75b6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47198f9003784e62a2d403aa1634c0cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi01LTEtMS0xMDY5MTY_93b448bb-e3c3-4350-9a70-69263d9d1cd6"
      unitRef="shares">170800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47198f9003784e62a2d403aa1634c0cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi03LTEtMS0xMDY5MTY_734bd339-ba81-4229-a7f9-d0f9583d02f9"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35827c831ea64be78954e395e1202d2e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi05LTEtMS0xMDY5MTY_45500f5a-c9f9-4c4e-adbb-2475e558ce3f"
      unitRef="usd">68200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cf823cd6b2f40d2a0cc0697e0186894_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xMS0xLTEtMTA2OTE2_a76c6d3a-9d97-4357-8e8b-0d3c0f9fe15c"
      unitRef="usd">-106700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bc3332cac8046689fcf7638658efa23_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xMy0xLTEtMTA2OTE2_a193fab3-7243-4b2a-9fa8-3c6cdbcb590f"
      unitRef="usd">13911700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iea41407ff6964211a00be80476455624_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xNS0xLTEtMTA2OTE2_31a7f34a-11c3-4ece-9102-d96923291e36"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea41407ff6964211a00be80476455624_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xNy0xLTEtMTA2OTE2_4060c2a6-b60e-441a-aa4d-396bdbe29dbc"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75454f1173a447139f1217b1ed46d9fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0xOS0xLTEtMTA2OTE2_4f3dddad-d609-4ba2-b623-ea7d4f169d3b"
      unitRef="usd">10896200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19d0784f479f4fc880cb5813d70f6f6c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0yMS0xLTEtMTA2OTE2_8afb46a2-20b4-48cd-b5ca-a497b6d04790"
      unitRef="usd">63500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMi0yMy0xLTEtMTA2OTE2_ea992e93-e265-4314-8c45-8de7c7b15042"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i84d4c7b0576941b3878692efd86da487_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0xMy0xLTEtMTA2OTE2_54077d96-2471-412b-8f22-28df87fba49f"
      unitRef="usd">1361800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0xOS0xLTEtMTA2OTE2_43f43648-e46b-480e-97a4-54cd7cdb79db"
      unitRef="usd">1361800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0yMS0xLTEtMTA2OTE2_1a954ddd-9ea6-4a51-ae22-2042623b5683"
      unitRef="usd">-84600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMy0yMy0xLTEtMTA2OTE2_0971069f-9105-44b1-80fd-56ac33e2a66c"
      unitRef="usd">1277200000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9bd31dba4354e46bc9629fe6a03d388_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0xMS0xLTEtMTA2OTE2_0883fbc2-fd32-4956-ab5b-2634c9b66649"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0xOS0xLTEtMTA2OTE2_e54efd57-5018-4b5b-a9f3-5f3d95e6afcd"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNC0yMy0xLTEtMTA2OTE2_8fc5738c-ba59-4e16-9ba3-ad6743efee1e"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ib837e530f9a64c028cd30ddf4f234461_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNi0yMS0xLTEtMTA2OTE2_88fa97cd-9b00-45c7-9c1b-42c01e3564c1"
      unitRef="usd">12000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNi0yMy0xLTEtMTA2OTE2_ffed1373-aa84-44c5-a648-9f3406b60eb6"
      unitRef="usd">12000000.0</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xNS0xLTEtMTA2OTE2_94e37b11-8241-43e4-8332-3c9f630e9274"
      unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xNy0xLTEtMTA2OTE2_bb10d32d-365d-438a-a81d-c8d8aae7bc50"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i368ea118836f487388ce043a695cadcd_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0xOS0xLTEtMTA2OTE2_4c78ca83-96ae-4392-bc3a-469b850ff2e7"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfNy0yMy0xLTEtMTA2OTE2_63721e10-067b-416d-abd9-da48bea03a65"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="if25d30d01e8e4db4b897cf36867a25e6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC01LTEtMS0xMDY5MTY_81a4b96c-084c-4071-97b1-2cd3b7897cb9"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i3bbb659071554201aaf22eccd009353e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC05LTEtMS0xMDY5MTY_43a137d2-eb4a-4458-8d14-85b272d8b163"
      unitRef="usd">186400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifea5cd790d23403096957d2bd80ac925_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xMy0xLTEtMTA2OTE2_904cc854-77c4-4e10-8917-99ca5a50361e"
      unitRef="usd">313600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xNS0xLTEtMTA2OTE2_b04f8d4c-12e6-431e-a6ac-b07eb4855911"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i67cb639073944a6f9a48a4a01264d980_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOC0xNy0xLTEtMTA2OTE2_058a01f8-501c-49ec-9426-2e28ffe34009"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS01LTEtMS0xMDY5MTY_bee4b808-aff5-4610-b11b-cd505d4dd1e6"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS05LTEtMS0xMDY5MTY_df39892c-e2af-42e6-b734-f43195486faf"
      unitRef="usd">28900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS0xOS0xLTEtMTA2OTE2_b35248c7-8604-43f7-b1ea-88792b6878a8"
      unitRef="usd">28900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfOS0yMy0xLTEtMTA2OTE2_818ee299-ee68-442f-a566-262e64faeae1"
      unitRef="usd">28900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5ff3e54a4ab342ae84c847b6333dc22f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtNS0xLTEtMTA2OTE2_c2640f39-ea19-4201-ae87-aba12fc1f708"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtOS0xLTEtMTA2OTE2_cbf75fc4-e514-4835-9f34-0b6ad13d15fa"
      unitRef="usd">-40400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtMTktMS0xLTEwNjkxNg_fe4ad154-8ad0-4da6-a81b-4034e23ba303"
      unitRef="usd">-40400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTAtMjMtMS0xLTEwNjkxNg_c4596c89-f7be-4326-bd10-f6a86129f9b0"
      unitRef="usd">-40400000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtOS0xLTEtMTA2OTE2_475ade75-f4d1-4fe6-a7d1-041ef457ccbf"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtMTktMS0xLTEwNjkxNg_8906e789-862f-4ae8-9ea9-d136c5360f7e"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTEtMjMtMS0xLTEwNjkxNg_e4346b32-5037-43b7-af96-116df776e32a"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="idb06f06c308249beb439d90fa38b3553_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItOS0xLTEtMTA2OTE2_dcf0e850-41b4-4dd4-b228-f1ccacbaa70f"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i13e6f5e180744036ba354c330621db30_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItMTktMS0xLTEwNjkxNg_df78b43f-1498-4cf1-893e-d718bd6e5be4"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTItMjMtMS0xLTEwNjkxNg_a05d613a-cef9-4781-9a61-378c974ef28e"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMS0xLTEtMTMxODEz_0ffc7d24-5fa8-4468-8bf4-cbef20f377c0"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40d420575ff241bcb18f34eca21efd56_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMy0xLTEtMTMxODEz_797c2a2b-017d-4b92-a6d0-464724748eca"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtNS0xLTEtMTMxODEz_e3ec9fa9-6c96-4af5-9ae4-b680c7d58c7d"
      unitRef="shares">169000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d3891d530ed41ce9c40c01229b3ecde_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtNy0xLTEtMTMxODEz_b65c582d-4f08-4063-bd3a-2d004511919a"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67c4af1889714ce0862fe75007a47c79_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtOS0xLTEtMTMxODEz_c5c27a80-da68-4b44-ab5e-77f1cbcec5e2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc0a37bdf69449ddaf16a60e03e555ae_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTEtMS0xLTEzMTgxMw_b371572a-3bbd-4526-9ff0-e3334be95aaf"
      unitRef="usd">-110400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b2deef427764a7c9fc1e85a3c55d1fd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTMtMS0xLTEzMTgxMw_20123e83-befd-4dfd-a020-471ad08a8d54"
      unitRef="usd">14959900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8b532043d004077960b4e7717b3606f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTUtMS0xLTEzMTgxMw_8271e185-85bb-4076-8e58-bd65bce63710"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8b532043d004077960b4e7717b3606f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTctMS0xLTEzMTgxMw_a51c3541-44b4-4232-9029-83b16c5c3ecb"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5c999d64c7f4aa683e6fe58d18d5691_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMTktMS0xLTEzMTgxMw_056db12e-7d19-4faf-b6cd-d7c6b47922ed"
      unitRef="usd">11872500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6736d3935f8c47758cb22a7798dd423d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMjEtMS0xLTEzMTgxMw_15fad7ff-fd4f-40fd-a4a5-1bae4bf920a7"
      unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmE5YWU0ZWViNTA2MDQzMzg5MDE0YWJhYWY2ZTNhNmRhL3RhYmxlcmFuZ2U6YTlhZTRlZWI1MDYwNDMzODkwMTRhYmFhZjZlM2E2ZGFfMTMtMjMtMS0xLTEzMTgxMw_e385edb5-c85f-4bb8-852f-3df62a486eca"
      unitRef="usd">11863400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b352f1e386449dba581418fff17ab7a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xLTEtMS0xMDY1MDI_5adfbb4d-bba8-42b4-b7c6-d0455b0873fc"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b352f1e386449dba581418fff17ab7a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0zLTEtMS0xMDY1MDI_57ba4098-7f42-4b51-92b1-454abb503aad"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b6703a3087e48768722c1c0f8e42a83_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi01LTEtMS0xMDY1MDI_b17829e3-c132-4074-90eb-efc0861eb2b3"
      unitRef="shares">174400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b6703a3087e48768722c1c0f8e42a83_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi03LTEtMS0xMDY1MDI_bd34fdef-e73e-4c51-8f32-e4ec15a80879"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a9aca39866e45a586dd764d86c5ed26_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi05LTEtMS0xMDY1MDI_fe9b51b2-ac3d-44b3-96ef-5d5f7c59397f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab659fae07d74a4f8df69f5e986830f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xMS0xLTEtMTA2NTAy_3c0ec8da-7602-4f96-8ca0-b75e8a875cc7"
      unitRef="usd">-174300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i420d4dc476054e95991acdec07455f64_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xMy0xLTEtMTA2NTAy_422c6fd2-efc0-4ea0-b82f-6953037cb5ca"
      unitRef="usd">13833500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1857ee2b87204f6d8d339cd56a32cca7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xNS0xLTEtMTA2NTAy_60eb8914-b1e6-40c5-9364-319d07acba81"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1857ee2b87204f6d8d339cd56a32cca7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xNy0xLTEtMTA2NTAy_13bcc863-7869-4321-bbce-1b39305e3e7d"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4d979b13ecb40159fab297299c33759_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0xOS0xLTEtMTA2NTAy_f21d9d3c-e936-4ff4-9246-bf869415c917"
      unitRef="usd">10682200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i656fd73a858a4b54b51b65e3c1349710_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0yMS0xLTEtMTA2NTAy_104852e6-c1c1-44d3-9d7a-75f30c8208f3"
      unitRef="usd">-19000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2c0db0e45a843e093aa8601c3e476f1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMi0yMy0xLTEtMTA2NTAy_4530d72e-eb7f-4c1a-a0eb-7b12c170da0f"
      unitRef="usd">10663200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0xMy0xLTEtMTA2NTAy_4af0fb9d-6d44-47e7-bc3b-0807a37ac601"
      unitRef="usd">448500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0xOS0xLTEtMTA2NTAy_426d22e4-34ae-450e-b475-dd15070f7842"
      unitRef="usd">448500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0yMS0xLTEtMTA2NTAy_0d357633-1fde-4969-b674-51d616ad01aa"
      unitRef="usd">577000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMy0yMy0xLTEtMTA2NTAy_04c7bfab-299b-4217-b5ac-6ad66b1615ad"
      unitRef="usd">1025500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i29ab97abf7474573a44451ecae9b1c59_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0xMS0xLTEtMTA2NTAy_2cdd8b51-5fa0-493d-b4a9-b3adbc95c230"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0xOS0xLTEtMTA2NTAy_bf9c7124-3d2a-499c-9c75-d3a525919d15"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0yMS0xLTEtMTA2NTAy_cf3f4076-640b-4a4f-81d8-59cb09816bef"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNC0yMy0xLTEtMTA2NTAy_398cbe42-34db-467b-81d7-1a708a3a92f1"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNS0yMS0xLTEtMTA2NTAy_a055e68d-d56e-43e0-86bf-3143ef3e7e2f"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNS0yMy0xLTEtMTA2NTAy_b7989dc8-fffc-4df8-bb8b-9b1b914c9e8e"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i9e004a41fda74bc0813d8f024eec0322_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNi0yMS0xLTEtMTA2NTAy_9e8cec67-b75f-4adc-b2c7-d70fa4a00f93"
      unitRef="usd">5000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNi0yMy0xLTEtMTA2NTAy_f8659276-f8d1-411f-9446-f6e0a5024baa"
      unitRef="usd">5000000.0</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xNS0xLTEtMTA2NTAy_e8460c74-8704-4bc4-a1d9-bf2582166f1e"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xNy0xLTEtMTA2NTAy_8aeeb3fb-9789-485c-8313-e0804419c7d7"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia88b9101790d4b0f86a212c7e9a96706_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0xOS0xLTEtMTA2NTAy_bff47f5f-2763-42e1-a7d5-88e6985667c3"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfNy0yMy0xLTEtMTA2NTAy_20f497c6-0276-49d2-b34b-f871dc0f2c1a"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i14bbc79f38b047a0a22a8ba1a14f35ea_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC01LTEtMS0xMDY1MDI_121b1bd7-ae7e-4923-b344-5b2dcd5a8ed7"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i052eecd99d764d54aa68dbdd7ecc39a1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC05LTEtMS0xMDY1MDI_545c592e-ca4e-4e1c-8645-380184b23dc8"
      unitRef="usd">69500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if9bf6535ed584cc8b7699690ed33169c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xMy0xLTEtMTA2NTAy_6fe6b957-c10d-417d-b37c-4c493433411e"
      unitRef="usd">380500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xNS0xLTEtMTA2NTAy_25630b08-c226-40cd-ba2a-e0b59bc32b44"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i36d9086a0e2a4f44805ce185a22f675f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOC0xNy0xLTEtMTA2NTAy_40f4ba72-4c79-481b-ae9d-711a08d6b969"
      unitRef="usd">-450000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS01LTEtMS0xMDY1MDI_2790efa6-f194-4cdb-8c5e-16aa7e280a30"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS05LTEtMS0xMDY1MDI_d310163e-0951-45b1-bc00-440de499894a"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS0xOS0xLTEtMTA2NTAy_928de169-d3c7-4720-9829-a96fb77c9479"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfOS0yMy0xLTEtMTA2NTAy_162c68d0-36b2-4279-9f62-78ac3e086a82"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2d55c9ca04f2451580194c947e6f0a41_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtNS0xLTEtMTA2NTAy_e16cd5ef-3898-4e62-ac6c-b5e82c7f9d98"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6cfb1efda406443fbf9a41646cc1e513_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMTMtMS0xLTEwNjUwMg_1c189e10-dc25-495a-8522-2b2a440c8476"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMTktMS0xLTEwNjUwMg_69cabdbd-bcf0-4c8c-9a43-47ca1379ed61"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTAtMjMtMS0xLTEwNjUwMg_804a1249-6959-4516-9c63-98b35c0833ab"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i048e44a0ba5b4401b388d7c293391e78_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtOS0xLTEtMTA2NTAy_5c60208b-3f47-4fa8-beb7-5fe06e199a6a"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a5b8fbea9234c73bf9060629d85f254_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtMTktMS0xLTEwNjUwMg_89743d5d-5a4c-4e9a-b746-9d6874e3460d"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTEtMjMtMS0xLTEwNjUwMg_df990216-f6ba-43c2-aa31-4532aa7b8a18"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMS0xLTEtMTA2NTAy_fea6c8ae-3eee-4299-a18c-e816fee3717d"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMy0xLTEtMTA2NTAy_81e19a58-2bf8-491c-9917-6c38ea17b276"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtNS0xLTEtMTA2NTAy_4d9d078f-b470-4d10-9d31-ccdb55ad34cf"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtNy0xLTEtMTA2NTAy_8b043c9c-63b7-42a5-83d9-f030702dffa4"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if28bf8793bb647839d1579d8c2459b62_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtOS0xLTEtMTA2NTAy_60544167-3a5d-4739-a5a6-4a856f28874d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTEtMS0xLTEwNjUwMg_a5bda871-447d-4d1f-a4e9-8a6444c8e69a"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTMtMS0xLTEwNjUwMg_eee26a09-e413-4c37-91cb-2f767f0633ae"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTUtMS0xLTEwNjUwMg_9207fbb1-d5a5-43be-a3b0-a689aeca89df"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTctMS0xLTEwNjUwMg_7897a1ea-613f-4e8f-bf89-b6a0960e1cde"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i332047e2daed45c5b00fd02fa57e3838_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMTktMS0xLTEwNjUwMg_2bdcd29a-4ea8-488a-be1c-52b00075c731"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a38dad3f363459ea85b6ba15b99fd86_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMjEtMS0xLTEwNjUwMg_6b97d509-1adf-46c8-a5ba-b9fbe5b1b394"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOjY5YWFjMjdmNjc0MDRkYjNiOGNlNTcxNzFkMWQ3NmE1L3RhYmxlcmFuZ2U6NjlhYWMyN2Y2NzQwNGRiM2I4Y2U1NzE3MWQxZDc2YTVfMTMtMjMtMS0xLTEwNjUwMg_4a0ef294-8510-4c93-bb66-b6678299b456"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2455559f227c4f65a8e32a02250a6b37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xLTEtMS0xMDY5MDE_d7ecff4d-d2e7-46da-9e59-78f3713a3052"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2455559f227c4f65a8e32a02250a6b37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0zLTEtMS0xMDY5MDE_23b04655-4895-454d-bb6d-3dea898a9f2e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi01LTEtMS0xMDY5MDE_cb03e91c-699c-40b2-8024-1722c832ef3f"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfa7e0b3f84b4c7cb7ce33fe0e7d4a7c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi03LTEtMS0xMDY5MDE_24328259-d059-4aaf-a0e3-796d67f7807e"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8e9662a1a044772a5c48f8eb3e4d351_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi05LTEtMS0xMDY5MDE_9afcd71b-b870-4f83-a42b-3a2f64185afb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1552de9fe9a4d07bfa00d31cdf4cddb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xMS0xLTEtMTA2OTAx_455e7709-af2b-4b31-9091-d5f99a3cbe58"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea743edaf2fd4b7097146dfcb59ebcc3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xMy0xLTEtMTA2OTAx_e4cedec0-be04-4c41-82f1-4162174a06fa"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7f0faea6ed6246d5afbb055c576af9f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xNS0xLTEtMTA2OTAx_8ce37f96-b5a1-411a-86b4-5ad0e4c3846b"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f0faea6ed6246d5afbb055c576af9f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xNy0xLTEtMTA2OTAx_ecf0a657-887c-481f-a876-2c46794446cb"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96d0c433f57848faa5d9ff27e1571aa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0xOS0xLTEtMTA2OTAx_7b76ee43-ecaa-4a8d-95b0-a1f739d74eea"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1fe70259be16496eb27510a3d1a37162_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0yMS0xLTEtMTA2OTAx_0f82f083-3de4-4286-9439-04df73e25567"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMi0yMy0xLTEtMTA2OTAx_48180d85-7128-4614-8206-8cd4c7a7f948"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icf7705963176451eab777349e7f86df3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0xMy0xLTEtMTA2OTAx_012cd88e-7668-4455-9b9f-73cb96fcad8b"
      unitRef="usd">858700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0xOS0xLTEtMTA2OTAx_d2afe433-4888-48d0-94a8-ccd42e32b4e7"
      unitRef="usd">858700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0yMS0xLTEtMTA2OTAx_fd97b13f-cb4e-4827-97b0-57e6c94f010d"
      unitRef="usd">571400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMy0yMy0xLTEtMTA2OTAx_9eb91e52-54a8-4117-b99c-b5790fc4251b"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i298109b8168d4593a326a064ab5b4deb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0xMS0xLTEtMTA2OTAx_92261b73-79ad-4683-9485-e08040b9f8d3"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0xOS0xLTEtMTA2OTAx_32f6c31f-4605-4f96-9f60-8ab5dea18668"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0yMS0xLTEtMTA2OTAx_b17e1317-8940-4cad-af13-d118cc02bda4"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNC0yMy0xLTEtMTA2OTAx_ebd75a44-4b90-4a98-bdea-787144c707e7"
      unitRef="usd">127800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNS0yMS0xLTEtMTA2OTAx_aaa75b38-7081-4b90-b5c7-ab068c58d0a9"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNS0yMy0xLTEtMTA2OTAx_3e1e773d-1537-4217-849d-8e6952777deb"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i2150fda458e94f098288538ad0da1347_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNi0yMS0xLTEtMTA2OTAx_65d98ae2-a95e-4b6d-a544-9a655e687228"
      unitRef="usd">5100000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNi0yMy0xLTEtMTA2OTAx_d1ce4bc3-00a3-40bd-93ce-0c41257dbe44"
      unitRef="usd">5100000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xNS0xLTEtMTA2OTAx_4661c782-a391-4960-b65a-b81f2f43338d"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xNy0xLTEtMTA2OTAx_406aa724-f4f1-4e02-80b4-45ecafd6b556"
      unitRef="usd">1050000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icbabe3e8841e43538325df1464a51f39_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0xOS0xLTEtMTA2OTAx_d123df58-5bd1-4f95-93ec-2043cc03ec94"
      unitRef="usd">1050000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfNy0yMy0xLTEtMTA2OTAx_26446715-9ded-4081-8f7c-d7847382ecf4"
      unitRef="usd">1050000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ibab1d1f75f7b44e8878daeee3d01001d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC01LTEtMS0xMDY5MDE_8dd55ec7-80e7-4561-83de-ca9f889702cd"
      unitRef="shares">3800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia00b516da2954357b5eb349ac6097259_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC05LTEtMS0xMDY5MDE_4e41ae86-c167-4ea8-87cb-150fb722e208"
      unitRef="usd">163300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9742df769c7c419e858e70601aff7144_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xMy0xLTEtMTA2OTAx_c9e32dc9-9a71-4948-8334-72182f831f90"
      unitRef="usd">886700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xNS0xLTEtMTA2OTAx_77b281aa-b01e-4d39-9dd7-0616cfa14574"
      unitRef="shares">3800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia0de4cbe974b4ae39886468c3641542c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOC0xNy0xLTEtMTA2OTAx_5076484e-3b88-4b91-91cc-21e8705385ae"
      unitRef="usd">-1050000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS01LTEtMS0xMDY5MDE_951223b3-484d-459b-967c-de58c8242711"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS05LTEtMS0xMDY5MDE_60220493-a7dd-471e-a8e6-dbac7ef5b6f3"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS0xOS0xLTEtMTA2OTAx_733183e2-80a6-444f-86eb-85e7eaf42e3f"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfOS0yMy0xLTEtMTA2OTAx_d19a995a-8d06-4098-aa69-ded21e584646"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1717175c248b45aaa6ac3db65ebdac8f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtNS0xLTEtMTA2OTAx_a982948e-cde8-4282-86dd-cc7af28fc4f5"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icf7705963176451eab777349e7f86df3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMTMtMS0xLTEwNjkwMQ_95def920-7b2a-49ff-8f5c-10d4b3748088"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMTktMS0xLTEwNjkwMQ_0f8bf72b-e5b5-4705-845c-0c650ffe1c60"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTAtMjMtMS0xLTEwNjkwMQ_39ee899a-4eed-400f-83f0-8901a2610bbf"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtOS0xLTEtMTA2OTAx_ec16fbb3-25d2-442a-b694-60bb5a63101f"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtMTktMS0xLTEwNjkwMQ_998b2cf1-4917-420e-a0b4-1cd9ce9bf417"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTEtMjMtMS0xLTEwNjkwMQ_f03457e5-a707-4e29-80d4-b36fb03801bc"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i9232cd4bf2bc4c5cbba889203489d995_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItOS0xLTEtMTA2OTAx_e3ab490a-8e65-4abb-9cc5-0550e9f5957c"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iea6414d6cb554a6a9798773c8f85a1bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItMTktMS0xLTEwNjkwMQ_cd5eeac6-f420-42f7-b877-b3f74c81e8a9"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTItMjMtMS0xLTEwNjkwMQ_acc1378b-030b-45d7-b999-a31564ba07e6"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMS0xLTEtMTMxODAx_c1fc1d2f-eaea-45d9-9bed-63495a2ca854"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib469a3e9386544858caebbc51fee96a5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMy0xLTEtMTMxODAx_6543f6bb-674b-4d3c-a0b6-1a179066d912"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtNS0xLTEtMTMxODAx_415927e6-91d7-4743-908d-4d802da3c3b9"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b1fbe3fefed437397ee703a9770abfd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtNy0xLTEtMTMxODAx_bfe0fa12-5b4c-4971-b56a-1dc41a1561c2"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if28bf8793bb647839d1579d8c2459b62_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtOS0xLTEtMTMxODAx_746a200e-932e-489c-adbe-9b6ee2b0fde6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4a0bb59a5714b0c9d9a2ff18cfe9a17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTEtMS0xLTEzMTgwMQ_f2b47979-f38e-4177-b95f-80dae2a1334a"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b2f16b4a40d457a81d8757b48f78bd8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTMtMS0xLTEzMTgwMQ_d056ad79-d754-49bc-8a36-e1341e89c20e"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTUtMS0xLTEzMTgwMQ_4a037eb7-a613-45d6-aaad-3f4a3b99e477"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i776b02f0e19a4bf1a200745fd79fec21_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTctMS0xLTEzMTgwMQ_5f16a800-7278-4e4a-8ccd-b6aa19c3f47b"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i332047e2daed45c5b00fd02fa57e3838_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMTktMS0xLTEzMTgwMQ_499f9f76-dfbc-42c5-835a-2eb0cf1185e5"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a38dad3f363459ea85b6ba15b99fd86_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMjEtMS0xLTEzMTgwMQ_e1e05d77-cf6f-4641-95f6-f4c0785c09e5"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8zNC9mcmFnOjQ5ODdkYjlmZDJiMTRkMGNhYWI4ZTQ5NTBmNzgxZjNhL3RhYmxlOmFjYWZmMDIwZDNlMjRlNGNiN2RmMDRhZjk5M2YyZWIwL3RhYmxlcmFuZ2U6YWNhZmYwMjBkM2UyNGU0Y2I3ZGYwNGFmOTkzZjJlYjBfMTMtMjMtMS0xLTEzMTgwMQ_992cda22-d559-4540-b6f0-4edb125eae57"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODAzOA_ce99c2cb-e44f-4385-ade8-f5fe1128c6e6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022 the Financial Accounting Standards Board issued Accounting Standards Update No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024, and is not expected to have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA4MQ_ccdf9462-d4e5-4c4d-96e0-3dad7e90865e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA0NQ_773e8e35-75b2-4f74-8f38-4ae618118d9f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfNDI5MQ_2517cf27-117c-4102-b0b0-524e5bb5b322"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA2NQ_f3f6fe76-0cca-48b8-bb9b-20a40214c3c6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfNDgwMQ_b003055a-8981-4455-91fd-eb46f9fb2f5c"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA4Ng_2cc773ae-1e5e-43dd-bcb0-0b9227f08182">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80MC9mcmFnOjdmODFlN2Y1MzlmMDQ0NmY5ZjU2YjZkZGFkODllYjRjL3RleHRyZWdpb246N2Y4MWU3ZjUzOWYwNDQ2ZjlmNTZiNmRkYWQ4OWViNGNfODA2OQ_777a1254-3554-4881-915b-1961585185c6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022 the Financial Accounting Standards Board issued Accounting Standards Update No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024, and is not expected to have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMzQ5Mw_5bc55828-e956-452b-9c5c-377304e4831b">DISPOSITIONS &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale, the carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our investment in Samsung Bioepis totaled $581.6&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, we recognized a pre-tax gain of approximately $1.5&#160;billion related to the transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value based on risk-adjusted discount rates of 3.1% and 3.7% for the first and second payments due, respectively. As of June 30, 2022, the estimated fair values of the first and second payments were approximately $788.1 million and $406.8 million, respectively, and have been classified as level 3 measurements reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any payments due to us remain outstanding after the second anniversary of the closing of the transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, for the three and six months ended June 30, 2022, we recorded a discrete tax expense of approximately $269.5&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDY4NA_c9e0aefc-ddcd-4bbb-b940-e655b42de12c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture
      contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDY5Nw_7a21c978-d96f-4ba4-ab49-534bfc1b329b"
      unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i0bce0582b9234dbbac96a00b848486a2_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcwNQ_74b91707-5750-444f-bcd8-66b6f887893d"
      unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i3729e3a50004440ba3134a7803d8b293_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcxMw_0ebc0d84-6263-4981-9891-fe9599c61249"
      unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i3fc13fd60c8140859d72089cfe8c306f_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNDcyMQ_0b3c464b-8df7-4504-812f-a222d66f4d98"
      unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:EquityMethodInvestments
      contextRef="id42c682634844c03b11c37f7325f453e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMjc0ODc3OTA4NDIwNA_95ffbf8d-e30e-4cfe-af6d-81e9397a7194"
      unitRef="krw">581600000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MDU3NA_7b8f8f03-b95d-4c99-841b-978b9491ae9e"
      unitRef="usd">-1500000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MTUwNA_be0a21f9-11e4-4445-8d15-20440de7e642"
      unitRef="usd">-58900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTY0MTU3Ng_ccbec429-c472-4849-887c-1e4e523dab20"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <biib:OtherAssetsFairValueMeasurementInput
      contextRef="i2cb2cf98fd9549a4b68f0d966327fbfd_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTAyMzA_49516697-e1d1-4596-aaba-465ba20f1e15"
      unitRef="number">0.031</biib:OtherAssetsFairValueMeasurementInput>
    <biib:OtherAssetsFairValueMeasurementInput
      contextRef="i74bbffe1fc2c4ff4bec0eda9713c2a71_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTAyMzQ_8f63d0ce-f83d-4dbe-ad4b-7c4b7c8c640c"
      unitRef="number">0.037</biib:OtherAssetsFairValueMeasurementInput>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTE0OQ_42500476-d823-4ac6-bb3c-e6f59571462c"
      unitRef="usd">788100000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTE4Mw_aaa784e1-accc-4fde-ade9-c6465a134a61"
      unitRef="usd">406800000</us-gaap:OtherAssetsFairValueDisclosure>
    <biib:AdditionalMilestonePayment
      contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNTMzNg_00c50cc8-f513-4c3b-96a3-9a140ac3e3e3"
      unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent
      contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzOTc2Mw_5c891711-fec0-4c49-9fe6-e7168e5e112a"
      unitRef="number">0.050</biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent>
    <biib:DiscreteIncomeTaxExpenseBenefit
      contextRef="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNzg3Mw_2e84832a-4d8a-4878-a3e1-87c0e8201e40"
      unitRef="usd">269500000</biib:DiscreteIncomeTaxExpenseBenefit>
    <biib:DiscreteIncomeTaxExpenseBenefit
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80Ni9mcmFnOmY1MzM1NzE3YjU4ZDQ5Y2U4YjJjODBiNzhmNzI2OTA2L3RleHRyZWdpb246ZjUzMzU3MTdiNThkNDljZThiMmM4MGI3OGY3MjY5MDZfMTA5OTUxMTYzNzg3Mw_433ff21b-a7c7-4fbb-b8ee-dd692d58e626"
      unitRef="usd">269500000</biib:DiscreteIncomeTaxExpenseBenefit>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTc4OA_5df79605-8acd-48d8-bb32-8f7205907af3">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Cost Saving Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, we recognized approximately $70.6 million and $108.7 million, respectively, of pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $60.9&#160;million and $88.6&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the six months ended June 30, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, we recorded other restructuring costs of approximately $9.7&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs includes items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNTkz_3aba3de6-061c-4a43-afe8-91099cc65ac5"
      unitRef="usd">130000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNTk5_adfdb999-8023-47f3-8d78-db4bff8c327c"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTk5NA_1b9b5b52-58c0-48b1-9ef9-8316c4af4235"
      unitRef="usd">70600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMjAxMQ_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c"
      unitRef="usd">108700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfNzY5_21d50c17-f0a6-4ace-90f3-ab7ef4d352ee"
      unitRef="usd">60900000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYyOTYwNw_341b08c3-780a-4968-aaf4-d3cfe99ac21a"
      unitRef="usd">88600000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTUxMg_7bb2cdc5-cf4f-4328-a374-1717a053fd8f"
      unitRef="usd">10400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:OtherRestructuringCosts
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTM2Nw_69606ba6-a436-46d1-bb6b-26336d96b45f"
      unitRef="usd">9700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTA5OTUxMTYzMTM2Nw_c1bdf8b4-5d16-4ece-9b61-9b14d616a3bd"
      unitRef="usd">9700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RleHRyZWdpb246OTE4YTU5NzcxYmRmNDA4Y2E5MTc1ZTRlODhlMTcxODJfMTc4MA_d9aed38b-39c4-481f-aab4-ca3673e0da9e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ifb931292e9944a83b4a28788d901981a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMS0yLTEtMS0xMDY1MDI_dc1606bb-bae4-453b-8e39-b6679e5e5267"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMi0yLTEtMS0xMDY1MDI_ad96b6e9-21fc-4280-8c1e-1cfdf0f3b37b"
      unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i06ef1f0100884cdfa3c7e9ad1d2249db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfMy0yLTEtMS0xMDY1MDI_153ef6a1-5a3a-4fab-bbea-bd555f043c17"
      unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i093f59a249e8425e8dc9546e07b5d4b4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNS0yLTEtMS0xMDY1MDI_c0e9d225-b7e5-4b2a-b330-8de3f34ee3e4"
      unitRef="usd">21500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNi0yLTEtMS0xMTI4MDA_817f7b1b-9fac-4dbd-814d-c81d89e7a71d"
      unitRef="usd">60900000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6b24ab73c62742b9a54ff7fd01bea43b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfNy0yLTEtMS0xMTI4MDA_dafff149-edbb-4629-ba24-b0b6049ff0d5"
      unitRef="usd">29700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfOC0yLTEtMS0xMjg5MjY_3d88232b-c4a0-4aef-bee8-6167604d1027"
      unitRef="usd">-500000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="iafb54803dffa43a8b5c152bf9bca7854_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV80OS9mcmFnOjkxOGE1OTc3MWJkZjQwOGNhOTE3NWU0ZTg4ZTE3MTgyL3RhYmxlOjE5ZTBlYzE5MTExZTQ4MWFiZjhmMDlhZmQwNTA5NDIyL3RhYmxlcmFuZ2U6MTllMGVjMTkxMTFlNDgxYWJmOGYwOWFmZDA1MDk0MjJfOS0yLTEtMS0xMzE4NTg_dcf4c6ab-0250-4640-b6ae-f69f6de6e7d1"
      unitRef="usd">52200000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcxMQ_889a0763-0206-48e2-8f5a-919f8a4fda3a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;672.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;894.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,160.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,054.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;807.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,037.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,462.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,358.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,012.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,570.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 27.4% and 11.2% of gross product revenue for the three months ended June 30, 2022, and 26.8% and 10.8% of gross product revenue for the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 30.2% and 9.9% of gross product revenue for the three months ended June 30, 2021, and 30.1% and 9.6% of gross product revenue for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,690.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(833.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,077.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(391.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(500.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;835.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY5MA_eb1db6fe-6845-45f0-9e93-bd5ee044e0b2">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;672.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;894.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,160.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,054.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the United States (U.S.) in June 2022 and will be commercially available in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;570.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;807.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,037.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,462.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,358.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,012.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,570.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the U.S. in June 2022 and will be commercially available in July 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="idbc97f4c706c4df984f6691e843d75ee_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0yLTEtMS0xMDcxNjM_e77219b7-c7de-45c8-b7c9-023378cece76"
      unitRef="usd">120700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2af09c4bc4774ceb8b2aea7ec735f424_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC00LTEtMS0xMDcxNjM_4ad4259a-bac5-4848-9828-068c078cedda"
      unitRef="usd">277200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d2801f94f42429ca36d1bfeafd776fc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC02LTEtMS0xMzE4ODI_5739e8b4-2275-45b0-8ec0-6df40aaada0f"
      unitRef="usd">397900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cec06562a4b4440bbb60cef5c0e756c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC04LTEtMS0xMDcxOTU_8391f9ab-48ee-4741-b367-a3a518849397"
      unitRef="usd">178400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57475280b3bd4e4f8735035f66af5da2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMC0xLTEtMTA3MTk1_730fc4c6-05c1-4b2e-8952-dc7dfc690791"
      unitRef="usd">309200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ae64ec1886f4842b346a20565644a07_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMi0xLTEtMTMxODg4_c2931aaa-3af2-4ed7-984b-44f82d81e580"
      unitRef="usd">487600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cd18c1f363643da8e1eee2a47998423_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0yLTEtMS0xMDcxNjM_9f9e2e4e-bf20-4250-bab0-5d0c01b27515"
      unitRef="usd">129900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e50d0bd0f744b5ba53de911cb87f81c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS00LTEtMS0xMDcxNjM_987f7c03-4ff2-4384-a5cd-b63bb66ecbc8"
      unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b5c3899b1854563ad3c2273433e9b88_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS02LTEtMS0xMzE4NzM_51b19371-bc0c-487e-86f0-6711037b3cfa"
      unitRef="usd">136800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i007d608c419b478cba33ba05d07aced0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS04LTEtMS0xMDcyMDM_d2351db1-a3e7-49cb-9ce1-5955590fb8e2"
      unitRef="usd">90700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d12a48ae2a54cd9bb4249844b6f04e1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMC0xLTEtMTA3MjAz_90c323f7-ca38-42f6-8d90-032ed42417fb"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8f3d7a22d664d38ae15146f61f0f1c7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMi0xLTEtMTMxODg4_1626346b-4a87-45bb-974a-0d0bf2d1af72"
      unitRef="usd">90900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie099d88fe35a436897378cba2f7f09f5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0yLTEtMS0xMDY1MDI_429203bb-39ff-47c3-a320-716f89b77ff8"
      unitRef="usd">250600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8bacccfe4b440259bfddc3e626a3be8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC00LTEtMS0xMDY1MDI_872156b4-744a-4430-b5ed-9771a6109b77"
      unitRef="usd">284100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bd6a55e7a084e99a824039b5136eb48_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC02LTEtMS0xMDY1MDI_b8a78e42-16ad-4b2b-aafa-4832d65a435f"
      unitRef="usd">534700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2f0b5ae9f1c4ab88664e67c1b9d51a3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC04LTEtMS0xMDY1MDI_da4c9ceb-619f-4cab-8e18-2ca5feb22e3e"
      unitRef="usd">269100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie863f266caf446248389f5d655c80f07_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMC0xLTEtMTA2NTAy_eb1241bb-211e-4557-9820-3ee6f6384bc6"
      unitRef="usd">309400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0877cfe46ef448c8c7131bfa2927823_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNC0xMi0xLTEtMTA2NTAy_ecf7b297-3b0f-4988-aeaf-ba40a2da6185"
      unitRef="usd">578500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cf00ad995134f4cb48df2bd2c51a7e9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0yLTEtMS0xMDcyMjI_e699b82b-4810-45d1-a91a-0188e3fa48e8"
      unitRef="usd">171000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5a7668e3e149bb9288945e1b644d4c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy00LTEtMS0xMDcyMjI_2c000893-53e0-41b6-8d59-282605b5510c"
      unitRef="usd">87700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic70f6702bb4646988e0ca53e9412cd4d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy02LTEtMS0xMzE4ODQ_7c7f8233-ef99-4003-8b6e-c0cfdb8620a3"
      unitRef="usd">258700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i439dde2be341406fa6edfa8d2a5fa6f9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy04LTEtMS0xMDcyNTM_bd1edd5f-892e-4c92-bf71-52f8cbaceb9d"
      unitRef="usd">214000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if81b6c4e8b0846d2977a5e818273a87c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMC0xLTEtMTA3MjUz_807604fe-aec9-4d79-b6c5-132901de0821"
      unitRef="usd">96900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d118c84efd5442395adffb3dccb0b7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMi0xLTEtMTMxODg4_fb2429b0-a36c-4701-9ede-6d25d6fb65ea"
      unitRef="usd">310900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i549b6fd3d1344466adcf7f2de11e4565_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0yLTEtMS0xMDcyMjI_1a945619-772b-4938-9984-9e182f61c2e6"
      unitRef="usd">40200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fc8989f45f1472695f8f6ed83d3dbf1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC00LTEtMS0xMDcyMjI_7ced6bbc-6ad3-48ef-9422-e856cc5fa890"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4ed02e892e14d0eaf6fee39773e7d02_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC02LTEtMS0xMzE4Njg_cd7b5d0b-4b3a-4f42-9c56-007b237c68d3"
      unitRef="usd">91500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d2c705401ea4f62a8a0412004a979dc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC04LTEtMS0xMDcyNTM_e9304e37-db2d-428d-b7ef-6725e3528594"
      unitRef="usd">43400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58e8eb6c75ee484da1a9b2899bf4079f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMC0xLTEtMTA3MjUz_a383e05e-dede-4f8e-b3ae-83cfb0fabcbe"
      unitRef="usd">46100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8e7d54a466a485cb541688829066e26_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMi0xLTEtMTMxODg4_94593f2c-69ed-44b6-8bde-039cb354814e"
      unitRef="usd">89500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9874f7ddd2cc4c1598811a920b86b7d7_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0yLTEtMS0xMDY1MDI_4bf454e7-8279-4681-9a26-4d3c394378e1"
      unitRef="usd">211200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd19d0a1a1bb4808875dccbdcf6b2e0c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS00LTEtMS0xMDY1MDI_dfa53b8c-6b4b-4184-a8ff-7ee539778b39"
      unitRef="usd">139000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i669f2e9eba26433a84e680686bb0cf63_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS02LTEtMS0xMDY1MDI_6ef7c5d7-2b20-4c66-8ad8-a2b42f590337"
      unitRef="usd">350200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb4a8e4a5df14221807d09956dafea13_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS04LTEtMS0xMDY1MDI_da13550f-57f3-47a7-ae7b-bf6c8901fcce"
      unitRef="usd">257400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2360a519c23e4144ab123af88aa77ea6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMC0xLTEtMTA2NTAy_093c927c-3968-4270-88c2-7ea325a71c84"
      unitRef="usd">143000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45b67a35dc2b4011989ac9568e54000e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNS0xMi0xLTEtMTA2NTAy_79c5609b-45af-4cbd-a485-c5704db1491c"
      unitRef="usd">400400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80e14405a5204b01a6ec0d2b6f80a62f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0yLTEtMS0xMDY1MDI_c7b56dae-f413-42df-91b0-8d8dbae7fe0d"
      unitRef="usd">291900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89841ea93b374be7b061906d6d41e52f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi00LTEtMS0xMDY1MDI_978b6b96-ba64-4023-9d3d-9ab624b6e2ee"
      unitRef="usd">224300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38f2ed1ce3a14b0990001afc1dd6c491_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi02LTEtMS0xMDY1MDI_9e4931d4-a393-4cf4-8037-298587223c6c"
      unitRef="usd">516200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f89510757554e059925b2ada6c7f286_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi04LTEtMS0xMDY1MDI_4f5440bb-102a-4b1d-b809-164b2fc662fd"
      unitRef="usd">299800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1389917b17d40cab84d0dea445f439f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0xMC0xLTEtMTA2NTAy_8dcc34ae-b04b-4a02-8156-7999468641ec"
      unitRef="usd">224400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66eadafd646d481f90ae1525ff408940_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNi0xMi0xLTEtMTA2NTAy_e8c83591-22c3-407b-beb2-18cdb9c9e784"
      unitRef="usd">524200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26206d0cd7764127b07966be5f7b1a7b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0yLTEtMS0xMDY1MDI_7f20c2d4-a793-4d38-9db4-1a3e7674c889"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i246f3bb8b3b94d7a85b72b22eb167658_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy00LTEtMS0xMDY1MDI_88c4d0fe-7922-42aa-99e7-54cb7fec6217"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18509476d6e74f7a8ad9b9e79de07e3a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy02LTEtMS0xMDY1MDI_4c03dbbb-2dda-4f3b-b585-ae64367ff7dc"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36ccb1c80bf9489c82bec10e689c3e90_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy04LTEtMS0xMDY1MDI_1868b230-1d10-42e6-b8dd-d109cdd74796"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62a2594f184f4ac9b8cbc8aad0760336_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMC0xLTEtMTA2NTAy_49d419f5-ee41-432c-9e2a-7cc1a8ea0e33"
      unitRef="usd">26100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie66d9f7c4dc24480aeac96e047fbb0e3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfNy0xMi0xLTEtMTA2NTAy_15000c08-c4f0-4e39-b1f4-d5734df8e845"
      unitRef="usd">26100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6db865d77b6d42dbb986db32acfa75e6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0yLTEtMS0xMDY1MDI_79b67c76-9295-4976-9bbd-0e248eae4527"
      unitRef="usd">753700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4237b443b36c423e87d4bba35a59f794_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC00LTEtMS0xMDY1MDI_eca190c3-58e6-4a3b-b418-17bab4ad6477"
      unitRef="usd">672900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47841ad34b76402897680f541339e3a0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC02LTEtMS0xMDY1MDI_ba746c47-8a5b-4d0e-8ec6-af08acb6f0e3"
      unitRef="usd">1426600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07b428dc01d34c3bbe3425f599b4d465_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC04LTEtMS0xMDY1MDI_1079e8cf-ce0b-4211-90b1-e3042cb8290a"
      unitRef="usd">826300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id24d8e1260d54752840a81ca4bdcf3fc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMC0xLTEtMTA2NTAy_dcb94655-7d67-4675-aab2-280e419e7b7d"
      unitRef="usd">702900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibac58ba74b4a4daab4732d74461adb12_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfOC0xMi0xLTEtMTA2NTAy_6db8497d-9785-4e6f-b39a-e20eed71abe4"
      unitRef="usd">1529200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3a6246e1af94484ac63941a25f762a8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMi0xLTEtMTA2NTAy_78ed68d3-7e6c-4e65-8b15-7956607939e2"
      unitRef="usd">139800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3b30f603f0e4af5b617750440ab03a1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtNC0xLTEtMTA2NTAy_d04c9cb2-9b67-43ed-b36d-9d68b4445291"
      unitRef="usd">291300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i787e3c6fe03d41b1af6a449e9505be82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtNi0xLTEtMTA2NTAy_c32944f6-85d5-4abc-a2e3-3f6e1fa23ed3"
      unitRef="usd">431100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f6ba2438bad4f1a9522748b9f8c53b1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtOC0xLTEtMTA2NTAy_a55e7823-f672-4df3-b0ce-9effff2cabea"
      unitRef="usd">149300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i900bd71ac7a447f2877d1c9ef20a5d79_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMTAtMS0xLTEwNjUwMg_6022ace7-b058-47a4-83d6-5dc08c4b9fb3"
      unitRef="usd">350400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1d48220f13a42a9ab30ced0e8f1e5be_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTEtMTItMS0xLTEwNjUwMg_82d250ff-0e7c-4a03-ba3a-f20bd98925a8"
      unitRef="usd">499700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb64f28ce22a4e32865b37fc103092bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMi0xLTEtMTA2NTAy_fb872379-2756-4d3e-95b1-2ae9ffdf84ff"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5191eac6bdab406a954232524744f872_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctNC0xLTEtMTA2NTAy_978ac0b6-d291-470e-9b07-8f9bfc1c8c3c"
      unitRef="usd">115800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd597660d69548fab84a62c47780e0a4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctNi0xLTEtMTA2NTAy_f37c6feb-0be0-41a1-abd2-94d91e27e889"
      unitRef="usd">115800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib35a86579b2d4ccab8f3d3435b134d6e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctOC0xLTEtMTA2NTAy_7b678c36-e45f-4efa-a883-613163fd491c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic64518c9cf9e49b0a60aaee3bd5ed703_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMTAtMS0xLTEwNjUwMg_a2fdeeaf-750e-4d53-bdbd-adcaa5fff38b"
      unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8a92ffd45f3464b9fda8ccf988fe123_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTctMTItMS0xLTEwNjUwMg_8a64a4bc-c22d-4ff3-8bfd-70fd6f72b53e"
      unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i358cd1acfeee460987aedecf5fb632f2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMi0xLTEtMTA2NTAy_6d5df807-7696-4c0d-bad5-927b8b59c9b4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if05e0a33bc5c4413a51ea40bba76c6c5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtNC0xLTEtMTA2NTAy_920204cf-f9ee-4b2c-9bf8-6553f79f2ace"
      unitRef="usd">57600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4508944e934b4c8cb245dc13c3967cfb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtNi0xLTEtMTA2NTAy_c4a8aa71-a0cc-4add-9803-d66201ee3f19"
      unitRef="usd">57600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i475aa3cb324a442da54be389e9f9aec0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtOC0xLTEtMTA2NTAy_d1b495b5-4ee5-4d6f-9c9a-95740a16afb3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i236b9b5fed79407ea79107fdd77e4910_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMTAtMS0xLTEwNjUwMg_3a8dc33a-55c1-4868-8d35-bb8b079fd1dd"
      unitRef="usd">55600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a3d0fc0b8224db6a7dfe05c6ee94f16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTgtMTItMS0xLTEwNjUwMg_c49eb235-acc7-42c4-a013-bf8ec542adb4"
      unitRef="usd">55600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i804d63c72cb74d8a825d0c9196678307_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMi0xLTEtMTA2NTAy_86492c76-85bc-4d59-8783-70b1c826aa4f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54c59c486765442ab29490107dc4c833_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktNC0xLTEtMTA2NTAy_e9c6991d-98f7-4ef2-be0e-9d80038208ea"
      unitRef="usd">20500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad386a522eeb41e08b1ab49a0355313c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktNi0xLTEtMTA2NTAy_8df7f28b-4cdc-49da-8804-9a55e4365d29"
      unitRef="usd">20500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d98e5ebbda3474a97b1805fe5acad43_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktOC0xLTEtMTA2NTAy_ad298b53-ac59-465b-b650-2864462a8012"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1952410e30f040bc853466b15fdacad3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMTAtMS0xLTEwNjUwMg_aace7e14-e753-4780-8dba-7d5370090d45"
      unitRef="usd">25300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i984ae54db252428cb8f595d9cb4150d9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMTktMTItMS0xLTEwNjUwMg_43606e7d-581b-4d85-9ac3-91626591ee10"
      unitRef="usd">25300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9acb352dfec4b54bba68898daf102aa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMi0xLTEtMTE1MDg2_a884aeaa-229f-43e9-835b-d7e13f0304b8"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2567373127054bc2a8607a8a0c8a7edd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNC0xLTEtMTE1MDg2_6ecda5ba-719f-471f-b9aa-585069bab541"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72c6c1e9fba1448c8ff10e9636557a4d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjEtNi0xLTEtMTMxODY1_f24c18ca-4703-4bd3-a256-f3ef1efadaee"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3588cab2b9054d38bac088fe429cc890_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtOC0xLTEtMTE1MDkz_adfa745c-eed1-4dc4-9e0c-3a53d4e56b84"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7181656e80b44d28b2579ef54642c184_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTAtMS0xLTExNTA5Mw_65b7542f-3df0-4292-981c-91125fd50c32"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice7a5aef1a14499eb4bc5e66e0ff9e05_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjEtMTItMS0xLTEzMTg4OA_d20e57ed-039d-4512-9fb7-59708543dd17"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5196d39fc34746f686749f922c1eddd3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMi0xLTEtMTA2NTAy_cedea667-160f-4e62-8723-79a8f94e4906"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i034c5f0e4d404907bd5ac516daf28b53_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtNC0xLTEtMTA2NTAy_e8b36dad-b0de-4f73-acdd-0c53304a1864"
      unitRef="usd">193900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49329c17755547ba919fa1dda7c1f8d6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtNi0xLTEtMTA2NTAy_1cb0097e-1b1d-4175-9238-3cc7485b1264"
      unitRef="usd">194400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b838ba43c36477982d17fb691b3234a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtOC0xLTEtMTA2NTAy_6d19097e-2a78-49e1-a170-6ecfc9d8ce6a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae90209eddb94ce18a41953fa15d38c1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMTAtMS0xLTEwNjUwMg_42c6fc74-d227-4d00-967d-9d506ab6dade"
      unitRef="usd">202400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d5f94ef9b9a43dc8d2c2d02fdcb2722_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjAtMTItMS0xLTEwNjUwMg_f690c8ff-06b1-4e75-b9ad-5aa89ad4342f"
      unitRef="usd">202400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibed83b378cc4447ba4b164ca7ba2461e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMi0xLTEtMTA2NTAy_95252f2e-3fc0-4e5d-afdc-8535387cf5e8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81b56cabf17a421f85d3d4f832e08a91_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtNC0xLTEtMTA2NTAy_2a54e839-49c9-40d1-8c5d-15a1078802f8"
      unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib039450f31374b54b85c6aededf4648d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtNi0xLTEtMTA2NTAy_d6416089-68ce-4ee9-a99e-17baca301a00"
      unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i611d28129d4e4e0599f6a9f56f89224e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtOC0xLTEtMTA2NTAy_b33cd1bd-3291-431a-8553-d00fc3902c05"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief3c484378104076849db738ae2ec70c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMTAtMS0xLTEwNjUwMg_24fd21b4-4cd7-4348-b466-4580ba02f449"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7866e70096134bd6b4a49b4aa53f2d04_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjMtMTItMS0xLTEwNjUwMg_e0faa141-a6bf-4fcb-a280-23ad91a0d901"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98bbb070b1424fc2a3a3f4bf953dc517_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMi0xLTEtMTIyNjky_3179d8e9-280e-4086-a99e-08d4ad81b85b"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i248c0445077b45aa86eba19f300d0882_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktNC0xLTEtMTIyNjky_9475c5a4-907a-4175-8b13-886551f97fda"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktNi0xLTEtMTIyNjky_bc171013-2783-4eb8-aa83-7e3d9d6ecf5c"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dfd10449e7548ffbe44b55fae3c44b5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktOC0xLTEtMTIyNjky_a765135d-91c0-4158-b866-3d831673d727"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90b5463a749b4240884bb2801739ef29_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMTAtMS0xLTEyMjY5Mg_62d296f2-a129-4661-845b-fa5113036f79"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8c2fc38dd6440378e0da306d5634c8a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjktMTItMS0xLTEyMjY5Mg_d4461306-6059-4c28-b4b2-a565b64d5922"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c752409708d47fb98286c2172136b6c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMi0xLTEtMTA2NTAy_c98ff1f7-b78f-4384-8236-7f06050a5e99"
      unitRef="usd">894100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d293f205e034c3fa4e0b605f6b06cb8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNC0xLTEtMTA2NTAy_20301e90-ff7f-4523-b46f-afc03ff32f8b"
      unitRef="usd">1160800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69df4e8424154620af74fafdc94f8c4c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtNi0xLTEtMTA2NTAy_7f144613-e18c-4d27-9048-0a2b4cd72b4c"
      unitRef="usd">2054900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08b96e7b13fe4cf899501970595d616e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtOC0xLTEtMTA2NTAy_db478d2f-8420-4f18-acc0-593c00d31e21"
      unitRef="usd">977200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57ef2831201c483a816e081f25fe77b2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTAtMS0xLTEwNjUwMg_03873e34-dfbd-41d4-8ce9-badcd681d3dc"
      unitRef="usd">1258800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38c21c1035c24c5898d3a7c2ae487fd6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjcyNzEwZDQ0NDQyYjRmYWY4Yjk1MjBjZTFkMTM0NzBiL3RhYmxlcmFuZ2U6NzI3MTBkNDQ0NDJiNGZhZjhiOTUyMGNlMWQxMzQ3MGJfMjQtMTItMS0xLTEwNjUwMg_7c4481c5-4ada-46b7-bec2-ce4dbf4a2494"
      unitRef="usd">2236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic75cc49ce6a3424a8ebc26ac92c41122_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0yLTEtMS0xMDczMDc_3fc9c83f-0e60-4774-b419-ace2b6ae3471"
      unitRef="usd">237800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45191a6585d342b19254212fbe8438cb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC00LTEtMS0xMDczMDc_de30d9f1-c820-4934-990d-622b1cb7e24a"
      unitRef="usd">570000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99502a8cfb3f45729909de9e9445521e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC02LTEtMS0xMzE4OTA_0d9d1361-d06f-4c1b-aa56-186f3c86e16a"
      unitRef="usd">807800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9efe3047c104850b8e5e3f237c83105_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC04LTEtMS0xMDczMjc_3bef8cd8-de23-4e95-b345-238a61c8a2f5"
      unitRef="usd">340800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98ac3e997349402c8283ff022c717a94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMC0xLTEtMTA3MzI3_d527d94a-73e8-45de-85b1-e159fee241c5"
      unitRef="usd">626000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9cd308b36c74ad58f3c697827421153_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMi0xLTEtMTMxODkw_f1a948de-ca25-4246-8d9f-04a2c0d98de1"
      unitRef="usd">966800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa62803e94f241bc8d51d00489520d62_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0yLTEtMS0xMDczMDc_c84e1fcb-7e63-4185-9327-9bc7d633de4a"
      unitRef="usd">255100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f1762fc48b1448f996169dd0486ad6d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS00LTEtMS0xMDczMDc_47592c7b-4e24-4c96-83cb-d9a6e878922a"
      unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9df119b80ffc480e8399e35f9caf0122_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS02LTEtMS0xMzE4OTA_56b573a8-19d9-4a9c-aa54-1f52dcce42ce"
      unitRef="usd">264800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5cff98a2974c4e18b7621008c47bf431_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS04LTEtMS0xMDczMjc_4becaac3-ebcd-4e9e-bad9-d68447896ea0"
      unitRef="usd">164300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe712ea06fb4478e9e58e6a0e0bdc3be_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMC0xLTEtMTA3MzI3_766b4d23-3942-46cc-b491-61018f85f852"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c298411b25d4e859abbd71121626990_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMi0xLTEtMTMxODkw_57dd2b05-3096-4057-9609-30970c4b77bb"
      unitRef="usd">164600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57e803d9462d4f58ae2c9c760329e8e6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0yLTEtMS0xMDcwNDk_05d721f9-f14c-4618-b39c-2c870ea34dc3"
      unitRef="usd">492900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i593120b1e8584eb3b206a368abb95161_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC00LTEtMS0xMDcwNDk_404581c2-504a-4a3e-bdab-5cfe3d6c2312"
      unitRef="usd">579700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e6113e46ab14f91972e94233f927582_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi02LTEtMS0xMzE4OTA_58d75fe3-baf2-482e-9e9f-9b3715fedd9d"
      unitRef="usd">1072600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide944bcb2c8349cf9c7f53fda13e0687_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC04LTEtMS0xMDcwNTY_f5dace19-7b26-4f00-bcd8-75d6086f3f32"
      unitRef="usd">505100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70ccd22804b741a38a553424e98761d6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNC0xMC0xLTEtMTA3MDU2_19cec32c-4569-4745-8feb-71f1ecfe47ba"
      unitRef="usd">626300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea4b3c8eb21445db8b85f3ee7225cc7d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0xMi0xLTEtMTMxODkw_9f5d7a14-6071-4f66-b19c-efbcd430f66b"
      unitRef="usd">1131400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c97e3c0924c4cdca1b9f1a53282f87c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0yLTEtMS0xMDczMjk_a787a26d-dbaa-422b-a0d5-324934aa4854"
      unitRef="usd">319000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcb92748d73344c199c4d746141d7e10_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy00LTEtMS0xMDczMjk_9e81a2de-0dce-4944-9021-759fe84bc028"
      unitRef="usd">169300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e8feeefdefc47759f3ad172a5d47c38_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy02LTEtMS0xMzE4OTA_0071931b-3ac2-415b-8007-d6c3a78b1a54"
      unitRef="usd">488300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf198850c37f48fe8acdfb3a8d10b2b7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy04LTEtMS0xMDczMzE_0e875a65-f10a-44bd-a744-2bb7f087305a"
      unitRef="usd">423200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48eec3c9dd8649e994f055ef1a743d24_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMC0xLTEtMTA3MzMx_06813280-9b9a-43d0-8af4-7e385ec55c7f"
      unitRef="usd">198800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbfa09326e424881b32a983586469855_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMi0xLTEtMTMxODkw_2bf874c7-171e-4fb3-8ffb-2d9bc6b16234"
      unitRef="usd">622000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6e6c0ccdcca4ea08f4fbcc8304df01e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0yLTEtMS0xMDczMjk_c149b26b-ac6f-4d18-a1a7-2cd0f255f051"
      unitRef="usd">74500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i909ed281083841ad97422e6d8e9b5fa2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC00LTEtMS0xMDczMjk_88be6a92-a3f2-40a3-bea6-c97dd0d03f48"
      unitRef="usd">97000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a1b8097922a4bfc8460acc93072bf50_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC02LTEtMS0xMzE4OTA_0121b86b-248c-42b8-926f-9afa40d16e87"
      unitRef="usd">171500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff32cab6555f4e67aa1cc62da2fe2381_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC04LTEtMS0xMDczMzE_51aed4b6-6fff-456b-b79c-6ec7e8467e19"
      unitRef="usd">76000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28d6bc8eecef46c88940df4fee6d8925_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0xMC0xLTEtMTA3MzMx_41489df5-90d5-4644-bcaa-bd9f8a5cecae"
      unitRef="usd">102900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0039988350a4be2b2d710515403df71_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOC0xMi0xLTEtMTMxODkw_a6d36f7b-ac4a-4f99-8748-bd5365fdf2d7"
      unitRef="usd">178900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic83629e3f3364efa9bef8fbc4e846597_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0yLTEtMS0xMDcwNjI_5d0d9775-c9b1-44fa-971a-87758b55c251"
      unitRef="usd">393500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide698acf03b8401b9aef8d55660fcfab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS00LTEtMS0xMDcwNjI_17a0318d-fdc8-4c32-8984-0406716b0cca"
      unitRef="usd">266300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i516625dc60d343959f4510e766fb1c31_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOS02LTEtMS0xMzE4OTA_e4ad0f5b-0398-4e42-9841-5fc2bccf6221"
      unitRef="usd">659800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i674aeedb6b6245808af71c103fe19496_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS04LTEtMS0xMDcwNjg_b286dcf4-39cc-4efe-b492-236e7be8f49b"
      unitRef="usd">499200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i534264b1291c4344a70276b5e63a6910_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNS0xMC0xLTEtMTA3MDY4_4662cc0f-b5b1-4192-974b-dd7514a4e225"
      unitRef="usd">301700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedc015931c1d4d2db4fba3c31bd94986_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfOS0xMi0xLTEtMTMxODkw_f5a0cbb7-aebf-4a2a-8166-bff84d2bf52e"
      unitRef="usd">800900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if805be58b48f48e48afc88306089f798_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0yLTEtMS0xMDcwNzQ_540ffbcc-f154-4dd9-afe1-ecc1fd8197e9"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4006bfbe38034523a41e0e68251e4252_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi00LTEtMS0xMDcwNzQ_6bf533e8-5deb-45e4-86eb-7752413d894e"
      unitRef="usd">460600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibeedfc78a95049649dab7ec26f21d7ed_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTAtNi0xLTEtMTMxODkw_02b2f550-84f5-4850-aa7c-b57adaa93e1e"
      unitRef="usd">1037000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d0b53fa1b874bc596af922c5d3014db_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi04LTEtMS0xMDcwODA_079008a5-da63-458d-93b1-a997a7c2b77c"
      unitRef="usd">573100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3c6e75fff5d48ae9c25b00d31fe330f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNi0xMC0xLTEtMTA3MDgw_f3ac7032-94cc-4ead-84f8-24541c9d32be"
      unitRef="usd">454400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07dfa622b4e2449e8b118649dadcb3f0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTAtMTItMS0xLTEzMTg5MA_6169acef-b860-4560-9380-a5fffc055d9f"
      unitRef="usd">1027500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i845528c074714b90896d3a1a295e2d20_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0yLTEtMS0xMDcwNzQ_59a8ba1e-1968-4296-8245-e63bc5d18f43"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fa23d5be5be49e894fcbc5ff00c4c1d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy00LTEtMS0xMDcwNzQ_6a482f6e-f5f3-45d9-be6b-c5b9d38c6234"
      unitRef="usd">51700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a07137c98dd4524ada1101807817e84_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtNi0xLTEtMTMxODkw_e5cd1bf5-90f6-4b43-8b3c-dc715def2093"
      unitRef="usd">51700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66ff46c84eb64c11aa952fd2ef0f8162_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy04LTEtMS0xMDcwODA_01b858ef-e17e-4a00-ad24-b0a2e20b93b8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i746834edaf31484b8281cd357d15cf15_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfNy0xMC0xLTEtMTA3MDgw_3d354432-80e2-43da-aa96-abaa77b6ca5f"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie414fbe6060f4736819d0c0a26db0825_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMTItMS0xLTEzMTg5MA_fbf6a87f-3844-4736-9ace-84d2ce43ad0c"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb013e9fb28748ec96b5bd3dbcd9cb36_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMi0xLTEtMTMxODkw_e00befd4-2652-4d7c-96a9-bd93c40a3dd2"
      unitRef="usd">1462800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if98657545c7442f69f64e667dcb30fef_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItNC0xLTEtMTMxODkw_76dc678b-d434-4d89-8b2a-9749ae8dbb3c"
      unitRef="usd">1358300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if081f6ddaa644634a85c1c8e772b6984_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItNi0xLTEtMTMxODkw_29dab2e7-a121-422a-82b6-f0c61830ef3f"
      unitRef="usd">2821100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d58cea04d384f9e962f42524c6c6618_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItOC0xLTEtMTMxODkw_5278de2c-b5ee-4068-8a42-91cc409aab52"
      unitRef="usd">1577400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e33e4e8358e4adda4f14ec95348140d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMTAtMS0xLTEzMTg5MA_e1e72fa5-0b15-415c-bb22-39072b56b641"
      unitRef="usd">1435100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9743755e37fa419da373d722f34ee542_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTItMTItMS0xLTEzMTg5MA_bed74c0b-9c12-471e-b3d6-1ab4e74ad747"
      unitRef="usd">3012500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c2fcbeae88249a4bcd644491e34cbff_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMi0xLTEtMTA3MDg2_3364ee86-8137-40ad-be6a-a32d8658ccb6"
      unitRef="usd">303100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic01db06835d64a3183e66267859801c6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtNC0xLTEtMTA3MDg2_f438ca5b-90b7-4bc2-8111-4ae717e99c85"
      unitRef="usd">600500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i350ceaa6094d41beb6a43612a28b3522_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTUtNi0xLTEtMTMxODkw_a390adcb-0e52-4b44-8412-5f24635ccd6b"
      unitRef="usd">903600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8767bf21797c4edd9ed6d33237556b82_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtOC0xLTEtMTA3MDg4_1149e14b-2c02-4c3c-98a4-be1f7115164d"
      unitRef="usd">298000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98a4b565eb6a4894a23a82cad310d92d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTEtMTAtMS0xLTEwNzA4OA_1a03dfd6-2b8c-4912-99a8-9fc06f2fe875"
      unitRef="usd">722200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8586bda14db4b688d52c294e041530e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTUtMTItMS0xLTEzMTg5MA_da9d2ec0-b85c-48d3-957d-57e5a3ef0af2"
      unitRef="usd">1020200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1be940b30cb4fe585cc5a760d23fa93_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctMi0xLTEtMTA3MDk0_868e7c62-0e50-4cc2-afeb-832a2c273a3e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fa0b6d1982040c4b2eec5d12980a8f6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctNC0xLTEtMTA3MDk0_d4d21d2e-fd71-4f14-bb31-707fc9499a27"
      unitRef="usd">230500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55a76cce432a4940a7ee77404de33976_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtNi0xLTEtMTMxODkw_3ad4dc32-09e2-4caf-9661-e90db1a4bdbf"
      unitRef="usd">230500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i267202cf4eae44a18487d9728c2731e5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctOC0xLTEtMTA3MTAw_fed7a0b2-0e1d-4338-96b9-27906dadf4cc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id895b207466d40dc95e4ccc4a5a688cd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTctMTAtMS0xLTEwNzEwMA_c86a17bb-481b-4cf6-8d7e-ed3ac715ee06"
      unitRef="usd">243200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ddce2d7962540e6ac7f7d0e98e969a8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMTItMS0xLTEzMTg5MA_72f424c1-13a2-4b8e-b55e-bdc36ffe4eda"
      unitRef="usd">243200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb00137c6dbf40a19194ed758485a9ad_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMi0xLTEtMTA3MDk0_6acb3bb7-3da3-4041-978f-f9f3163c760e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e5b6eaefce44a1a8296fbd9fad4e46e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtNC0xLTEtMTA3MDk0_4091189f-59f2-4e9a-83c9-94ce3853fb10"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e8cf5e156d34a85b0e5038f75d9a1ba_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktNi0xLTEtMTMxODkw_6030b4c2-1dfa-4112-82e2-caa9a0246f4a"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf550338832a4a30b4fdd8fec9c03a94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtOC0xLTEtMTA3MTAw_cfd26702-9d57-47b0-a58d-cd0f463bb7e2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23f6509df9234368ac66c5aee7ff2450_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTgtMTAtMS0xLTEwNzEwMA_c8464514-7962-426e-b6b7-dfa4313a9543"
      unitRef="usd">113500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39db4e78f61d4e84a1a5f31a5027bbfb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMTItMS0xLTEzMTg5MA_8b0aee5e-8beb-41b0-b713-2bb887047e4f"
      unitRef="usd">113500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f6154029d154694ad802b0c0880d594_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMi0xLTEtMTA3MDk0_f45930b8-241b-48bb-90c7-3750c3b9ee1d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i848c2181fc424e8a9cb106ef8274e8a6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktNC0xLTEtMTA3MDk0_7d781fc7-043d-4835-8c84-56330a042593"
      unitRef="usd">43000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41610ed9f98048e6b4b8084998674df6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjAtNi0xLTEtMTMxODkw_62fa3ab4-4693-4264-ad9f-1173aa9e80c9"
      unitRef="usd">43000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i272a454e80394786a9fd2275a5ba02e0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktOC0xLTEtMTA3MTAw_8d1115c7-e1ff-48b8-adc9-c9385335fb94"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5bc86475c9b4c89ab084e88ce485ca1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMTktMTAtMS0xLTEwNzEwMA_d1005e5d-e381-4316-848e-b15a6209e02b"
      unitRef="usd">50800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb45edccfc854e13b231619881ae3579_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjAtMTItMS0xLTEzMTg5MA_2b7980fa-ed57-45ac-83fa-a554f2c35af5"
      unitRef="usd">50800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52ff50cb600c4fa6a01c0a4495b88c78_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtMi0xLTEtMTE1MTYw_a9e148ac-0610-47c2-845b-dc92421b0e78"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0863cb79da9045349bba7df17125e957_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtNC0xLTEtMTE1MTYw_87f48376-f6ef-45ed-ba52-8aab6120a901"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71e411c18d6544dc871cf730df065633_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjEtNi0xLTEtMTMxODkw_6d26230b-5015-49bf-97d3-e6ccc1d03622"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5acd41d895754f3ab16a2ad37d6b762c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtOC0xLTEtMTE1MTY2_3ab7aec0-0c1c-4db8-bebb-a8b7b35fc1f5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20bdbb4b6e064fc0af141d9e1a0fb2b2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjQtMTAtMS0xLTExNTE2Ng_792db46d-9ed8-4a15-87dd-f3bdbe484bb2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68dfb47e453249e6afb959fc861e7025_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjEtMTItMS0xLTEzMTg5MA_f7de5755-23c7-4467-a369-b5968bb32f57"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f28371d51c34038bc9822ac4d4329ea_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMi0xLTEtMTMxODkw_087fc3a7-6510-4bcf-bce5-d8bb633855b1"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe1ac54ae2734b5f9a4178272d59b625_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItNC0xLTEtMTMxODkw_9444a7ce-bafa-4422-a976-4f968bd55205"
      unitRef="usd">388200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04b44e06b1074fe69c010ee1a0eeacc9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItNi0xLTEtMTMxODkw_425e4ce7-61bd-44c0-8194-01470a680575"
      unitRef="usd">388700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9427ad614e3477597e42639edc85a11_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItOC0xLTEtMTMxODkw_d328dbb1-c529-4df5-9a28-b738a98689f8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i391f039c06924c07919d530cf6d2dab3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMTAtMS0xLTEzMTg5MA_3b71b87b-5bb0-41cf-87dc-49149f582549"
      unitRef="usd">407500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02c880de17294fb3ae9accb52a1997c4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjItMTItMS0xLTEzMTg5MA_141f0d38-1eab-4a87-a970-0507172ece10"
      unitRef="usd">407500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic05034b4dab44684bb680a5b424b3f61_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtMi0xLTEtMTA3MTA2_9070e544-3b52-43c7-b7c2-fd79593fa001"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5991f123dec64a919280b85ffc4ab06e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtNC0xLTEtMTA3MTA2_20b778bc-ba0b-4a2b-8b5d-1662599eb7e9"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i411f9e9067594525b9d4f01a9b27f61f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjUtNi0xLTEtMTMxODkw_6b0b2535-58c0-4597-84a1-07175eb623bb"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04e83afbbe2445c19ca3bd556f42beb1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtOC0xLTEtMTA3MTEy_5d50c8eb-a492-4a06-a6bb-86a3c807e503"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d6a7d87e2f44c0db0cd331472ab5e2c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjMtMTAtMS0xLTEwNzExMg_0ed46021-4251-4426-9970-f2261d22e036"
      unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibaecbfefdeba441fafd2b18f0f37475a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjUtMTItMS0xLTEzMTg5MA_efda5b2f-8d7c-49ab-9070-9a5a15c708a9"
      unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6647a216d66c4d41a03fe12ef97207e6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMi0xLTEtMTIyNjQ3_77a6f37e-2213-4a4e-9168-3e25e9735fb3"
      unitRef="usd">2900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0008cbf40274fbeb37cbbc7833e345b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktNC0xLTEtMTIyNjQ3_884e7905-748d-4c6c-8bd0-c437007ebc26"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktNi0xLTEtMTIyNjQ3_26ffaee6-0fbe-4bf9-9deb-4edf0cf0a5eb"
      unitRef="usd">2900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d1e43eb20404d65a4905d84c981be83_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktOC0xLTEtMTIyNjQ3_bc698e33-fa26-44c1-80b8-ce69044e8817"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie63936ee597c4dcbb4c197c6cd02228d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMTAtMS0xLTEyMjY0Nw_06903755-93af-494c-982a-d13a876d49c4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id35fad63758942b88c0a4d638d35855b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjktMTItMS0xLTEyMjY0Nw_e435f7e7-50a6-4c95-b6e1-96fcc8d4c8b0"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica2f580e87294d6dbdf0e82006621e05_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMi0xLTEtMTMxODkw_e1b21eaf-4380-457d-891a-27d9b31d9af9"
      unitRef="usd">1769300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93ebb2e335574f1286e06fa26a183500_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctNC0xLTEtMTMxODkw_729de87c-31ef-4265-929b-7fa4afdaeaf5"
      unitRef="usd">2351900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19d9f94234df4575a86912bd4239ad72_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctNi0xLTEtMTMxODkw_d18f13fa-2ae1-4dc3-8c1d-5063ffd51b89"
      unitRef="usd">4121200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2099c0e56b54466bb5a80bc17980d728_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctOC0xLTEtMTMxODkw_970a3eb8-8d17-46e3-b35e-9b54b183d6dc"
      unitRef="usd">1877000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i012225e935554e759f4d02bd7f455af3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMTAtMS0xLTEzMTg5MA_9b723664-4e91-4544-964b-c285160adaa6"
      unitRef="usd">2570700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ffb04fe9a184b539f6a44bca71b3b0b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjE5NTVlMjQ4NmM4MzQ3NzY4MzM4ZjljNGQ3NWFhZDJjL3RhYmxlcmFuZ2U6MTk1NWUyNDg2YzgzNDc3NjgzMzhmOWM0ZDc1YWFkMmNfMjctMTItMS0xLTEzMTg5MA_5ae5da90-6da2-4ae5-ade4-c8701f4a479f"
      unitRef="usd">4447700000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjE3_30689567-4c75-48e3-b3fd-7582567cda8b"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjE3_cde3c04a-3199-40b9-a2cd-e73357fb3421"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i544c9b9c3c2441c5857dc27ac5202a31_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjQ3_d384d381-eb38-4b2f-a016-ceede49379dd"
      unitRef="number">0.274</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i59cb8ca63113417198b368e0ac0ee147_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNjU0_f7d3fde9-1c7c-4ca2-8546-523a57444e9f"
      unitRef="number">0.112</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="idd081a6a3bb5485b83c7166fa8c55471_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYyOTk5Mg_10d8ed5a-17fd-4ae8-902d-2b7cd48415f7"
      unitRef="number">0.268</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ic484bc958fa842c3893a6412ac12e08c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDAwMA_257c73da-d463-4f37-896d-bde878ac12f9"
      unitRef="number">0.108</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDA5NQ_30689567-4c75-48e3-b3fd-7582567cda8b"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDA5NQ_cde3c04a-3199-40b9-a2cd-e73357fb3421"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ifc85bed201b940878824eb131a5d746d_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNzE0_2ba7abd8-649d-4c94-b500-d3dc0ef8525e"
      unitRef="number">0.302</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i73b7e31d17f240a4bfc8076fc48a942c_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfNzIx_b213dfd6-fb5a-485f-bdb4-d8cc6a6b77ec"
      unitRef="number">0.099</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i77d66fca5ded45e297765f1b445f6c92_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDEzMg_47fbcc6b-76c6-4212-8e3d-e8e876da9867"
      unitRef="number">0.301</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i0e2d9158b11645f5828f271820b2dde2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTA5OTUxMTYzMDE0MA_583e32e6-47af-4287-917e-893eb49b5973"
      unitRef="number">0.096</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcwMA_a6dbd964-e03b-4f76-89fe-fbeb63120fee">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,690.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(833.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,077.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(391.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(500.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i62d6c18c9bc14e658bc749d15f2cc080_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS0yLTEtMS0xMDY1MDI_ee663c4c-e7a0-4eb4-9b55-dcb7b0e97cf1"
      unitRef="usd">137700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i55b0b386d72c42c7829f67584a538904_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS00LTEtMS0xMDY1MDI_f371194b-00e0-4769-87bf-cc757fb470dd"
      unitRef="usd">759600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i79b21651141942a69478099c2ccff90f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS02LTEtMS0xMDY1MDI_88b03bdf-7973-4a74-86de-2442dbc182c2"
      unitRef="usd">38000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMS04LTEtMS0xMDY1MDI_1efe0125-8e18-4c1e-8950-a6c82ea09904"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi0yLTEtMS0xMDY1MDI_e5ff1303-db96-4132-8091-c8cc95696e2c"
      unitRef="usd">337700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi00LTEtMS0xMDY1MDI_818fb4bf-b844-4c9b-abef-918dc2a67228"
      unitRef="usd">1346100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi02LTEtMS0xMDY1MDI_723ec62d-7569-4ed1-8590-fa4351c6a5ea"
      unitRef="usd">6400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMi04LTEtMS0xMDY1MDI_a9475636-23a2-47e5-a3fe-934f80dd915c"
      unitRef="usd">1690200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy0yLTEtMS0xMDY1MDI_dd034180-ff1a-4a1a-b2c6-c7c0ea94cbd2"
      unitRef="usd">1100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy00LTEtMS0xMDY1MDI_8eff0bd2-3276-42bc-a714-eccc3b959c0f"
      unitRef="usd">58600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy02LTEtMS0xMDY1MDI_411b8848-af49-4fa2-bec1-6f1eca080418"
      unitRef="usd">4600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfMy04LTEtMS0xMDY1MDI_54385c97-cf09-437b-87c9-4c9e375c8c5e"
      unitRef="usd">64300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC0yLTEtMS0xMDY1MDI_099382f7-64fd-48f0-bbf1-f768895ac6d4"
      unitRef="usd">243800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC00LTEtMS0xMDY1MDI_b9f74850-9a7f-4b82-8fb2-1228a0a77b96"
      unitRef="usd">833300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC02LTEtMS0xMDY1MDI_5422df33-2e85-4fa7-9e42-62863bb76bc9"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNC04LTEtMS0xMDY1MDI_ffb735dc-a837-4452-b8b3-84062cb87bdd"
      unitRef="usd">1077100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i42e2e6376f304466973b1a306132b804_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS0yLTEtMS0xMDY1MDI_ee6bb631-2d7a-4d51-ac02-dad9465177cf"
      unitRef="usd">98400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i63a0c596128542549c311e01f527d415_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS00LTEtMS0xMDY1MDI_075bd12e-3ad8-4475-b35c-540575ae4085"
      unitRef="usd">391300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="id22fb72faa854cd2882f3e46c7944b8d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS02LTEtMS0xMDY1MDI_7bfd3246-a4cc-47f6-80d5-52fd6f38c57b"
      unitRef="usd">10600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNS04LTEtMS0xMDY1MDI_57c9d6c6-2e31-490c-9978-7aebeec9cdcc"
      unitRef="usd">500300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iadcd9c4eb7aa4d43a9535edcf11234db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi0yLTEtMS0xMDY1MDI_b1a6f0ad-4285-44f3-a4cd-c037236a479d"
      unitRef="usd">132100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia15237bd167748dc8935bb2db5aadd11_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi00LTEtMS0xMDY1MDI_b2e41de1-73c0-4739-9d28-365fb31269c1"
      unitRef="usd">822500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6be79ed31c744ac0b8ce99f0b7505404_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi02LTEtMS0xMDY1MDI_07b98d5a-dd62-45fa-abec-2db7c62de022"
      unitRef="usd">29200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjNiMjQ3ZDA2M2NlODQ0YzhhN2Y2NDk0Njc4Y2FmZjAwL3RhYmxlcmFuZ2U6M2IyNDdkMDYzY2U4NDRjOGE3ZjY0OTQ2NzhjYWZmMDBfNi04LTEtMS0xMDY1MDI_bfa173af-f411-4df8-8c0e-a4c72186383e"
      unitRef="usd">983800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY5Ng_575ffd3e-ffc3-4b58-8f2c-85f3dda3f906">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iab432a874db444408172f33c16977803_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMS0yLTEtMS0xMDY1MDI_0e03f038-b1ea-437f-8457-256f608f8ec3"
      unitRef="usd">137800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i43bad9cb88d740469bbafb0fb0cf0cee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMS00LTEtMS0xMDY1MDI_55a935e7-678b-4885-97c5-e0127f2dcfc4"
      unitRef="usd">133200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i33934bee3c5143dd99f1d517165ead05_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMi0yLTEtMS0xMDY1MDI_ee59b2c0-daa5-462c-90c4-2337dcef3305"
      unitRef="usd">846000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if642314400ad46ce8997912ff65d7344_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMi00LTEtMS0xMDY1MDI_526746d5-1585-4750-b659-1aa01c1c8e41"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMy0yLTEtMS0xMDY1MDI_63038ff0-d1d3-471c-8d57-1e3c9b4a7d67"
      unitRef="usd">983800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOmNkMzJmZmI2NDJmZDRiYzQ4ZmMwYjRhYjhkN2YxMTdjL3RhYmxlcmFuZ2U6Y2QzMmZmYjY0MmZkNGJjNDhmYzBiNGFiOGQ3ZjExN2NfMy00LTEtMS0xMDY1MDI_caadd61a-b1e5-4d8b-8215-5ccbc976cc4f"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTY4Mg_584a84c5-463c-400c-a43b-51701ce61bb3">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;835.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi0yLTEtMS0xMDY1MDI_bea823cf-59d3-443e-b09a-f2fc6d005be2"
      unitRef="usd">139900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi00LTEtMS0xMDY1MDI_8836f7a5-e0f0-4106-938a-c28316143ba4"
      unitRef="usd">178800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi02LTEtMS0xMDY1MDI_45694de6-4d5c-49f9-8bfc-55262faf7bc0"
      unitRef="usd">283100000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMi04LTEtMS0xMDY1MDI_5cd31e20-3056-4093-9f81-27be9ee51647"
      unitRef="usd">352900000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy0yLTEtMS0xMDY1MDI_8485599c-81c4-4080-a225-be259d97faa6"
      unitRef="usd">296400000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i7fa862e89a654f11b633e511ec9153cc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy00LTEtMS0xMDY1MDI_fe50d9f3-3a77-4cfc-b0e2-69b0b819706e"
      unitRef="usd">261200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="iffa96c500820439eb38f5cfbc4394e9c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy02LTEtMS0xMDY1MDI_a4624c8d-7ac7-47af-8a04-f6b84316a0c1"
      unitRef="usd">552600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i83f8b22f78cc42d6a39a0f49568f081b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfMy04LTEtMS0xMDY1MDI_35e94819-27aa-4e1d-9eaa-d04985d7695d"
      unitRef="usd">476100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="i31754e9830d94758bdf3cc43372c87b0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC0yLTEtMS0xMDY1MDI_47c7e836-231a-4bd8-a209-aa989990c0c7"
      unitRef="usd">436300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9714631aac949d8b63f4a096b5ada97_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC00LTEtMS0xMDY1MDI_446083fc-bde9-4cd3-b75d-13d2b996ed45"
      unitRef="usd">440000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia167f06d2f5b4bcda61d51a7d893b2f4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC02LTEtMS0xMDY1MDI_e45aa86b-6fa6-4506-8b05-ab3ae602904e"
      unitRef="usd">835700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c1009614648486a8d4885185901e0da_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjRhMzYyMDY4OGJlYjQwMTZhYTg1MGVlYjAwMDUzZWM5L3RhYmxlcmFuZ2U6NGEzNjIwNjg4YmViNDAxNmFhODUwZWViMDAwNTNlYzlfNC04LTEtMS0xMDY1MDI_24dfa311-e351-4504-8f4d-cfff39259e66"
      unitRef="usd">829000000.0</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RleHRyZWdpb246ZjQwZjQ3NTU2YTU4NDE2YTgzZjZmNWE5OGJmN2EzZGRfMTcyMQ_8bc1ae18-b6f2-44df-a84d-a1e49facae0e">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="i71f09e81766c42e2bbbe9c2a856ada30_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy0yLTEtMS0xMDY1MDI_02155e25-f6ba-4c1c-befd-bfd4f063dd6b"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b3b5523cb8f4e5288c2afa798269171_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy00LTEtMS0xMDY1MDI_00a223b7-49f7-4e6d-81ca-2cdce43d3598"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if88580276d234ac794a107b535d8a45b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy02LTEtMS0xMDY1MDI_13eaeb03-23c3-448d-97be-46ad9a27f190"
      unitRef="usd">14400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d27d16a0e37434c878cd333a5be7789_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfMy04LTEtMS0xMDY1MDI_db82a637-5d78-49fb-973a-6ba32a81d97a"
      unitRef="usd">9400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdb9e7fc3fdf4dc9a9ee227b36aeed4c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi0yLTEtMS0xMDY1MDI_faa208be-642c-4266-90d8-d88a73313e48"
      unitRef="usd">10300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86078aa510454a67ac821f531e00d16a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi00LTEtMS0xMDY1MDI_f4423de2-b271-412e-8a3c-b38e0c93cd82"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2407978bb6bb465a9a11b59c52630feb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi02LTEtMS0xMDY1MDI_61821f3f-59da-4e41-bb70-7c0c75737f3b"
      unitRef="usd">20900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a019fd8fe4f425ab48dd67d22d37e0e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNi04LTEtMS0xMDY1MDI_70c1eb89-ea6a-4028-9c4e-cbac7b97708f"
      unitRef="usd">12600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64a2d4a8e1514e098184d910e5f41721_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy0yLTEtMS0xMDY1MDI_91bca108-acb7-43f3-a6e1-d47f6c226e16"
      unitRef="usd">81200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if03d8681da5c48ed823c595e3df9cae4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy00LTEtMS0xMDY1MDI_a5a43093-e26e-4c2e-b32c-b7ba5f00e965"
      unitRef="usd">87100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9a918b8fbaf4a098bb0923df21e1a68_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy02LTEtMS0xMDY1MDI_b49983ac-b12a-4013-884a-79e99a7e5a1f"
      unitRef="usd">128700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae9895041a5d4fbf93cb82132c5fdbc5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfNy04LTEtMS0xMDY1MDI_447289ca-b254-49aa-8489-27acad13309a"
      unitRef="usd">170300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i824c82797eb04c2e9a81491089d967fb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC0yLTEtMS0xMDY1MDI_632401a2-ac7b-425c-8bcf-97d86491055f"
      unitRef="usd">97900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e815c78953b4e43a68c9224835aedb2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC00LTEtMS0xMDY1MDI_68b3ba95-9df6-40df-882c-a0396fc0a27d"
      unitRef="usd">99000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb7ac80f93964006bcbb3c64a77692bb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC02LTEtMS0xMDY1MDI_eaaf633e-fa00-4259-8bbb-f95222bb0142"
      unitRef="usd">164000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7f0875c34f74569ad7173f706002116_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81Mi9mcmFnOmY0MGY0NzU1NmE1ODQxNmE4M2Y2ZjVhOThiZjdhM2RkL3RhYmxlOjg3NDFkNzViOWJiNzQzYmY5M2ExOTZjOWZhZTI2ZjAzL3RhYmxlcmFuZ2U6ODc0MWQ3NWI5YmI3NDNiZjkzYTE5NmM5ZmFlMjZmMDNfOC04LTEtMS0xMDY1MDI_8f372499-01e2-419c-9317-4f7319a70805"
      unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTM4OA_ae4d8098-e647-4c0e-835c-658a3d56b7d7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;378.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;706.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Work in process inventory as of June 30, 2022, includes approximately $71.5&#160;million related to lecanemab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#x2019;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of June 30, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTM5OA_8548d90f-71a2-4297-b414-6b6777f6cc23">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;378.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;706.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Work in process inventory as of June 30, 2022, includes approximately $71.5&#160;million related to lecanemab.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMS0yLTEtMS0xMDY1MDI_8207240a-4c98-4da7-8498-0d3602472fc3"
      unitRef="usd">378000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMS00LTEtMS0xMDY1MDI_6641c799-b194-47f1-b268-8b44d26a3449"
      unitRef="usd">349600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMi0yLTEtMS0xMDY1MDI_81497d62-0dda-45a9-ac9c-df246f29a0d5"
      unitRef="usd">706300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMi00LTEtMS0xMDY1MDI_91610b28-5a0d-4de5-ada1-a897e8b4be39"
      unitRef="usd">814000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMy0yLTEtMS0xMDY1MDI_222db4f8-8f38-42c5-a0f0-73bc0b74856c"
      unitRef="usd">209900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfMy00LTEtMS0xMDY1MDI_34a1f610-4512-4139-bc54-aa699e9bc061"
      unitRef="usd">187900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfNC0yLTEtMS0xMDY1MDI_026881ec-cfe1-4bd2-80ca-a2459b398211"
      unitRef="usd">1294200000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RhYmxlOmM0NWZmMTgzNTJjMjRiNGFiMzlkYzlhZGI0ZmUzZGE1L3RhYmxlcmFuZ2U6YzQ1ZmYxODM1MmMyNGI0YWIzOWRjOWFkYjRmZTNkYTVfNC00LTEtMS0xMDY1MDI_38b8f092-11dd-461f-ab53-67c92955a461"
      unitRef="usd">1351500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id39f35171ae547d68317e335f6bc8cc8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTA5OTUxMTYyOTY3Nw_531b2e8b-8dac-413e-9cfe-554f527bf4ba"
      unitRef="usd">71500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWriteDown
      contextRef="i690a67cc5731414a8f9aa06c53540e02_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNTg3_b68f7228-21f5-4ba3-bc7b-e654b29204e5"
      unitRef="usd">275000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic5c5095f62ab4c62ba0b2a1719784d97_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNzU0_4ad9941a-8800-4d74-861d-b550d358dbb9"
      unitRef="usd">136000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfNzYw_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:InventoryWriteDown
      contextRef="i635b802dc41d46298f9d8608e9935a23_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfODI4_5200727f-295c-4bf9-a393-cfdc33498f13"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia08cc12b77134a85b0419098882728db_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTAyMg_f57a7979-cc38-4bfa-a6c2-67b98e77341c"
      unitRef="usd">59000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTAyOA_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:InventoryNetCurrentAndNoncurrent
      contextRef="i3a40683af9114b76a6f0f696d7c173ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV81OC9mcmFnOjBjZjU5NjA1OGI5ODRhNGRiM2JmNjBmNWJmOTU4MDc1L3RleHRyZWdpb246MGNmNTk2MDU4Yjk4NGE0ZGIzYmY2MGY1YmY5NTgwNzVfMTI2OA_35b649c4-60c6-46c7-9baf-58fa92373a2d"
      unitRef="usd">223000000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE3NA_4f9f6745-5831-4922-83d7-1cd8bdacde4f">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,522.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,598.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,522.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,075.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, amortization and impairment of acquired intangible assets totaled $67.5 million and $134.4 million, respectively, compared to $604.1 million and $702.2 million, respectively, in the prior year comparative periods. For the three and six months ended June 30, 2022, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and six months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development (IPR&amp;amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of June 30, 2022, relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rst quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the carrying value associated with the remaining IPR&amp;amp;D intangible asset for DPN &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $119.2&#160;million a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial or sooner if there is a reevaluation event and may record an impairment charge related to this asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111 and BIIB112&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;amp;D intangible asset from $365.0&#160;million to $15.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $191.6&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;amp;D intangible asset from $220.0&#160;million to $28.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized additional impairment charges related to BIIB111 and BIIB112, reducing the remaining book values of these IPR&amp;amp;D intangible assets to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE4NA_73cba80e-d200-473b-9a06-c2e73569b06a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,522.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,598.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,522.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,075.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi00LTEtMS0xMDY1MDI_f1109da6-ddfc-4856-95ab-62dde744bf00"
      unitRef="usd">7415000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi02LTEtMS0xMDY1MDI_7b4448bc-3cb7-43b0-9bc6-19b0989ff0d3"
      unitRef="usd">5522900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a3dde39e57d44fbb6636cbe0cda7dc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi04LTEtMS0xMDY1MDI_f4bcf4d2-c28d-4f7f-9519-349861101b77"
      unitRef="usd">1892100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xMC0xLTEtMTA2NTAy_3742af8a-fec0-419e-b03f-7ee7ea3ce631"
      unitRef="usd">7413100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xMi0xLTEtMTA2NTAy_0febaf1f-a4fb-47e2-9813-5d09f8f69fc7"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i10c90e8d925d40afa3e544318c2a8632_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMi0xNC0xLTEtMTA2NTAy_595c904f-ef1a-43db-a9b4-3ba4e06d3d31"
      unitRef="usd">2024600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i15d560d86969470286de95947d4488f4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy00LTEtMS0xMDY1MDI_7d20e746-eab5-4f32-ac0b-43067cd3c794"
      unitRef="usd">119200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i15d560d86969470286de95947d4488f4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy02LTEtMS0xMDY1MDI_e05fb0d5-b3df-45ef-9f99-f1bae34d5734"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i15d560d86969470286de95947d4488f4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy04LTEtMS0xMDY1MDI_6b49ec70-658e-49ea-9c7d-5e4cc017dc92"
      unitRef="usd">119200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xMC0xLTEtMTA2NTAy_c1a27037-1fb4-4761-b699-a93dea98a9a4"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xMi0xLTEtMTA2NTAy_d7b896ac-c421-4f84-82f6-09ff1b788ec4"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i50f82f106e724d23928e954b5d6e3aca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfMy0xNC0xLTEtMTA2NTAy_24d7c623-9dd5-462f-a21b-0f2efe86523d"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC00LTEtMS0xMDY1MDI_232a9511-f500-4cde-a1cd-4b7379136373"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC02LTEtMS0xMDY1MDI_97d89b2b-a168-497f-a954-39c8123d34a6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib59fa5f039be4ee7af1c04bb03f0b740_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC04LTEtMS0xMDY1MDI_e6a8ca1b-5426-4277-998c-e54884e24898"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xMC0xLTEtMTA2NTAy_49d29229-d7b4-47e0-bd4e-8762072b07eb"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xMi0xLTEtMTA2NTAy_4ef4a1de-8e36-40d5-a27a-376e0859f07e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i15444f937e5a42c6928f7d30caa9be5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNC0xNC0xLTEtMTA2NTAy_95b895ab-261f-4eb7-b34f-0bd96c5effd2"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS00LTEtMS0xMDY1MDI_0e71d8b1-0f3f-42b6-af7b-128ba61c4cde"
      unitRef="usd">7598200000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS02LTEtMS0xMDY1MDI_c06b7b72-161c-473d-b25b-d8a9f28393f1"
      unitRef="usd">5522900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS04LTEtMS0xMDY1MDI_c53c1ba5-db74-4b7f-9f9d-d0c220aacd72"
      unitRef="usd">2075300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xMC0xLTEtMTA2NTAy_1db19349-ca40-43da-b87c-1795d48359ea"
      unitRef="usd">7609800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xMi0xLTEtMTA2NTAy_4cd709fe-04fd-4e37-ab3d-5bbc941675dc"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmM2YTVkNDFiZDM2OTQzYmE5NGExYmY1MmI4ZjRjODg0L3RhYmxlcmFuZ2U6YzZhNWQ0MWJkMzY5NDNiYTk0YTFiZjUyYjhmNGM4ODRfNS0xNC0xLTEtMTA2NTAy_719f5070-58d4-460a-a600-3a245a8f253a"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjcw_27d7621a-90c4-41eb-9c1e-a19334410445"
      unitRef="usd">67500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMDk5Mw_70744d33-1fd3-4fb7-b8f6-2646c8389db4"
      unitRef="usd">134400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjg2_09d2be0a-a1c1-4806-8c64-4234621585c4"
      unitRef="usd">604100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTAwNQ_a20ba55c-64fc-4c97-a0fe-83a44833fdb9"
      unitRef="usd">702200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7072613f54844e3ba4de934782cd9535_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTUyOA_1fb393a6-5fc2-4e2a-a3b3-0ec29ba7b8aa"
      unitRef="usd">350000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i2d589ef9b9024af5845103efc8018806_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTUyOA_7760a89a-56af-454c-8aab-0bd6cb5b43be"
      unitRef="usd">350000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTU0OA_04387fe5-523f-44de-b97f-4859e9177237"
      unitRef="usd">191600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i57322b393335447fa049a18be91e5f26_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTU0OA_eb3cc616-da13-484f-93ce-1bdcb329ccc1"
      unitRef="usd">191600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i86265989727740ada4d3803a06691ae4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfNDk2_936fb08d-69a7-4dbd-b303-1bbbf3a7a364"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i86265989727740ada4d3803a06691ae4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjM1NA_936fb08d-69a7-4dbd-b303-1bbbf3a7a364"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iacf09d1ffde3467f9d51fd1d72e55232_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMjUzMw_dd85d0b5-7742-4253-aabe-df9f5217f7a2"
      unitRef="usd">119200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7072613f54844e3ba4de934782cd9535_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTkzNg_1fb393a6-5fc2-4e2a-a3b3-0ec29ba7b8aa"
      unitRef="usd">350000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i2d589ef9b9024af5845103efc8018806_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMTkzNg_7760a89a-56af-454c-8aab-0bd6cb5b43be"
      unitRef="usd">350000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="ic0cb1609479343309a6ca0ff24c5fca5_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjU2OA_4459f5f0-9651-46b5-9178-a93823396412"
      unitRef="usd">365000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i035bd9bd822646e3ba8f72fa5b2ecab5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjU5MQ_8550d89b-cf78-454a-a95a-968e2883eba6"
      unitRef="usd">15000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia10a1de7945449fb8efbfa684e7e5167_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjQzNQ_04387fe5-523f-44de-b97f-4859e9177237"
      unitRef="usd">191600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i57322b393335447fa049a18be91e5f26_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjQzNQ_eb3cc616-da13-484f-93ce-1bdcb329ccc1"
      unitRef="usd">191600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="ie430205c0e8642b399f6ac098c948e1d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjYwOQ_67f7c486-867b-4691-8748-836da8fc45d1"
      unitRef="usd">220000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i502f935fe0b441bfbca01d697b55e5c7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMjYyOA_9d6a2828-d0c9-4431-b1c0-08ca39a59014"
      unitRef="usd">28400000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="iab21929ee2b44bd3a5f7fcac80a7717a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMTA5OTUxMTYzMzUzMw_39f01559-a3f7-48c8-a22a-08a4e305ddc2"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE2Ng_60b75e62-f10c-476d-b6dd-cdeaa758da71">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMS0yLTEtMS0xMDY1MDI_ab972535-e0fa-453c-8831-ea1a3915278a"
      unitRef="usd">130000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMi0yLTEtMS0xMDY1MDI_c5541a44-eaff-41b3-a484-3de766ab34ca"
      unitRef="usd">210000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfMy0yLTEtMS0xMDY1MDI_0d252c41-d50c-41a1-bda0-3088d063a108"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNC0yLTEtMS0xMDY1MDI_ed44ac3b-7913-4f37-953c-7b126eca3aea"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNS0yLTEtMS0xMDY1MDI_c293bca0-ae85-4164-90ec-b6f0fff0e017"
      unitRef="usd">180000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOmVmYzY5MzI0ZDkxZjQ3YTliM2U0MGY5MTdkNjZiZjBhL3RhYmxlcmFuZ2U6ZWZjNjkzMjRkOTFmNDdhOWIzZTQwZjkxN2Q2NmJmMGFfNi0yLTEtMS0xMDY1MDI_f33ecb1c-64c9-4bd9-b9c1-d29b5e5969b6"
      unitRef="usd">165000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzE5OA_7e1a6c19-80e2-4514-954d-15c03ab69ac9">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfMS0yLTEtMS0xMDY1MDI_089d50c0-c7d5-458c-8e63-d55ed85b2b1c"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfMy0yLTEtMS0xMDY1MDI_59f9448f-16a7-489d-b0a1-447be0a542a8"
      unitRef="usd">-11500000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RhYmxlOjljNGQwYjk0ZjJhMDRhY2NiYjRkZjE0NmZkOWZiNzc1L3RhYmxlcmFuZ2U6OWM0ZDBiOTRmMmEwNGFjY2JiNGRmMTQ2ZmQ5ZmI3NzVfNC0yLTEtMS0xMDY1MDI_8a91327c-3401-421a-ab23-9b73ff165665"
      unitRef="usd">5749600000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82MS9mcmFnOmMyYTZiNjVkYzY2OTRiMDhiZjc3MTY2OTU0YzQ3NzUxL3RleHRyZWdpb246YzJhNmI2NWRjNjY5NGIwOGJmNzcxNjY5NTRjNDc3NTFfMzAxOA_775c4a87-78e0-4d03-bd4d-6a8deb1c0e5c"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMzk1MA_fffdede5-218d-48a1-9478-b92abaa6621c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;785.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;788.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;788.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,727.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,194.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMzk3OQ_3c078a84-e639-4ad3-8b9d-51dc3b6a8749">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;785.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;788.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;788.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,727.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,194.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of June 30, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents a portion of our investment in the common stock of Sage Therapeutics, Inc. (Sage) and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. This initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 and is reflected as a Level 1 measurement as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial holding period restriction for a portion of our investment in the common stock of Sangamo Therapeutics, Inc. (Sangamo) expired during the second quarter of 2021 and the remaining portion expired during the second quarter of 2022. The holding period restriction for our investment in the common stock of Denali Therapeutics Inc. (Denali) expired during the first quarter of 2022. As of June 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as level 2 instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 to 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 10.9% to certain probability as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of assets or liabilities into or out of Level 3 as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$197.5&#160;million and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, chang&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;es in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,730.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,743.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,066.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,546.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,277.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The change in the fair value of our Senior Notes as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, compared to December 31, 2021, is related to the increase in U.S. treasury yields and wider credit spreads used to value the notes since December 31, 2021. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy0yLTEtMS0xMDY1MDI_8cd41b7b-e1b5-48f0-b145-c69436dd3625"
      unitRef="usd">2144900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy00LTEtMS0xMDY1MDI_52efda17-e35d-47f0-bd4f-f13c357ea389"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy02LTEtMS0xMDY1MDI_4d80ac01-4acb-4f63-976d-9f00e5650db4"
      unitRef="usd">2144900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMy04LTEtMS0xMDY1MDI_ad7ff019-cb0a-4050-837c-d9bddd0f64d2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i529693e18f9d4940a0dc51a9656b8e81_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS0yLTEtMS0xMDY1MDI_140ddaa2-4541-488e-9be9-33bf0ce9ad23"
      unitRef="usd">1890300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5410a4b7463e4871ba2258c342695d0f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS00LTEtMS0xMDY1MDI_c6f67324-8c44-4f0b-bdaf-de9fa0c2987e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5e760801b4e427c8d09b34b65881a0e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS02LTEtMS0xMDY1MDI_ee0fe996-51a1-471a-a822-8eb671f141d5"
      unitRef="usd">1890300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icaae543901cf4bf0b0aaf47b428c3c49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNS04LTEtMS0xMDY1MDI_dc2b607a-888b-4a72-ba3d-37cc1a04db06"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bf903905566403e92f0306b14f21dfe_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi0yLTEtMS0xMDY1MDI_72cc06ba-be6b-443c-8e55-93aee07dfd82"
      unitRef="usd">1156900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bc363fb469e473aaecac4cf8e63ef86_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi00LTEtMS0xMDY1MDI_d386f91e-17bf-4382-935c-750ebbf4a06e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic86003e21d714ef8a56c54bdd2b57d52_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi02LTEtMS0xMDY1MDI_d6daecbd-cf23-4418-ab12-5bf668593012"
      unitRef="usd">1156900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9d547ff00df40f989fae1a81b0cda41_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNi04LTEtMS0xMDY1MDI_25896829-82c7-42e1-9dc3-281fcfe74037"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8467e688e67c4414ae5b2d512e027882_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy0yLTEtMS0xMDY1MDI_a42e26ce-9195-40c5-88fb-de404bf1c9f3"
      unitRef="usd">207000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d5a87c8222b415e99b23eb87ba7b373_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy00LTEtMS0xMDY1MDI_037418e1-b6cb-4acd-8046-8bd04596bc01"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94e25682c306442281fbd9b9e82f381c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy02LTEtMS0xMDY1MDI_ef5bd977-fb63-4ef9-be63-586239b3961e"
      unitRef="usd">207000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i439c2171b7ad4a428141db883360f934_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfNy04LTEtMS0xMDY1MDI_d413049f-690c-4e32-9b8e-c48a33602987"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC0yLTEtMS0xMDY1MDI_edbdb67d-01d4-4bfa-8518-441c02dbf24e"
      unitRef="usd">785600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC00LTEtMS0xMDY1MDI_7f3aecf0-32cd-4f27-b384-57c195c43f8a"
      unitRef="usd">668700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC02LTEtMS0xMDY1MDI_b1265d8e-ef97-42b1-84e0-8d84bff07e85"
      unitRef="usd">116900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOC04LTEtMS0xMDY1MDI_4c60f68d-dd47-42bd-87f9-d6dd17b9eb93"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtMi0xLTEtMTIzNzUy_42500476-d823-4ac6-bb3c-e6f59571462c"
      unitRef="usd">788100000</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNC0xLTEtMTIzNzUy_92fd6c5f-9f22-4991-9c18-dfea87f1aae6"
      unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i96a56b8cc106475483c716145966db29_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNi0xLTEtMTIzNzUy_77472494-eda6-449b-ba8a-be8a7d9b704b"
      unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i7e9074ac7fc541f5890093a94bed4d8e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtOC0xLTEtMTIzNzUy_adcbf3f1-2485-49bc-98b1-cc892b998f7b"
      unitRef="usd">788100000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS0yLTEtMS0xMDY1MDI_ac77552e-2591-47f5-9b38-57418c175e4d"
      unitRef="usd">180000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS00LTEtMS0xMDY1MDI_12a4b7cb-23e7-445d-bd5c-d9b529d581fa"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS02LTEtMS0xMDY1MDI_4f12dacb-2f2d-4e80-a02d-c358974dc163"
      unitRef="usd">180000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfOS04LTEtMS0xMDY1MDI_28fb0ba0-908c-4e8a-9323-f77d9aa2a969"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtMi0xLTEtMTA2NTAy_ff8ca1dc-6cf1-4eeb-adef-fcad58c3c735"
      unitRef="usd">31900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtNC0xLTEtMTA2NTAy_16a2748c-711c-40c1-af0c-2b383e1bb321"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtNi0xLTEtMTA2NTAy_ac802843-dbc5-4207-a121-b0a3ed11c469"
      unitRef="usd">31900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTAtOC0xLTEtMTA2NTAy_674e27d0-5765-4389-b741-9e2c7edc3fa2"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i7103c26bc6ca4135a94cbebd7e066ed2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtMi0xLTEtMTIzNzU4_aaa784e1-accc-4fde-ade9-c6465a134a61"
      unitRef="usd">406800000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="id0d7ae89e81b4b33ba4799ff5ff7135d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNC0xLTEtMTIzNzU4_efa052c0-b642-49ff-b841-ca5d4273c0d4"
      unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i96a56b8cc106475483c716145966db29_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNi0xLTEtMTIzNzU4_bf90de1d-27e5-40c2-a6ea-f1feaac1c64f"
      unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i7e9074ac7fc541f5890093a94bed4d8e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtOC0xLTEtMTIzNzU4_02193ea8-8ce5-4195-b398-57bfb6fb6c16"
      unitRef="usd">406800000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtMi0xLTEtMTA2NTAy_6618e4dc-4ed9-464b-997a-af0d1889ce52"
      unitRef="usd">7591500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNC0xLTEtMTA2NTAy_6aae2f02-c702-44f4-ba5e-acc3c5df208b"
      unitRef="usd">668700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtNi0xLTEtMTA2NTAy_ba84701b-369b-4163-9cda-50a6771668ab"
      unitRef="usd">5727900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTEtOC0xLTEtMTA2NTAy_d5f1e5b8-7af6-4746-857a-91a41a63d4d1"
      unitRef="usd">1194900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtMi0xLTEtMTA2NTAy_2328d95d-cbb8-485a-b47b-2f96db58cb81"
      unitRef="usd">23300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtNC0xLTEtMTA2NTAy_248039c6-6150-483e-9fdc-787a1339302b"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtNi0xLTEtMTA2NTAy_2c90bd19-01b0-4842-86a7-55a579a641b2"
      unitRef="usd">23300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTMtOC0xLTEtMTA2NTAy_293f1ada-e33d-4d0b-bbb7-f4b5a5ada507"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtMi0xLTEtMTA2NTAy_a8ba0b5f-f555-45ab-87fb-b44706b76ea4"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtNC0xLTEtMTA2NTAy_f258800b-c094-4a45-a8f3-c0dcf6a4ee6b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtNi0xLTEtMTA2NTAy_c99fd124-e33c-4657-875e-c1387fa98e85"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTQtOC0xLTEtMTA2NTAy_416bcdad-2730-42f6-86cb-05672027bd38"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtMi0xLTEtMTA2NTAy_65bc936b-6542-4f58-aec4-b1da437d1a0e"
      unitRef="usd">220800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1a56ff34c07d4313bcc9ec338711ce30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNC0xLTEtMTA2NTAy_08a371ef-88c9-44bf-ac34-589da3d8bdb3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3c9311db8dab450889a2d4bef745e3db_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtNi0xLTEtMTA2NTAy_ce45d0b1-8bc9-47a9-a1cd-a7c02ed7267f"
      unitRef="usd">23300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6986e53f6f514bc497305cf50bf1d99d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmMxZGVjOTRmMGJmZTQ3OTQ4MjhhMjVjY2ZkN2VmYTMwL3RhYmxlcmFuZ2U6YzFkZWM5NGYwYmZlNDc5NDgyOGEyNWNjZmQ3ZWZhMzBfMTUtOC0xLTEtMTA2NTAy_85a6f851-5015-46cb-947b-b97e70bd84aa"
      unitRef="usd">197500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTY0OTI2NzQ2MDE0OA_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy0yLTEtMS0xMDY1MDI_535b0fbc-20c1-4212-a639-b8d3b3fad1ab"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy00LTEtMS0xMDY1MDI_ef60082a-4721-4a33-b6da-9e6fea144f7c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy02LTEtMS0xMDY1MDI_eadbf00c-9576-45d8-95e9-768c07fb7aff"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMy04LTEtMS0xMDY1MDI_38e0cbfa-bb14-4778-8548-d25556baefd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45f635edc8a2430189c968b78a9e8cb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS0yLTEtMS0xMDY1MDI_e230548d-12af-415e-b37f-5d4ecff8af53"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4316a770d24b4d87b85ca16f1e2d0f5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS00LTEtMS0xMDY1MDI_996fb5cb-469e-4493-927d-da4c0ff39d34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b362d0ab3134007a6f2417677122114_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS02LTEtMS0xMDY1MDI_306c8ca3-c536-407d-85a4-a96868463542"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b867d694211492a993655d5fb259d85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNS04LTEtMS0xMDY1MDI_635ee32b-5333-4331-9bf1-59cc56c37bd6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d1446517efc4d939297638bd36ea497_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi0yLTEtMS0xMDY1MDI_c0552669-524e-4953-9897-354421b3524c"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia741396d8ac949ab9d5894b778f1505e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi00LTEtMS0xMDY1MDI_ca495866-00ce-48c3-b257-b1602c10b22c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03963bc9f9074822b67815b3e793e1da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi02LTEtMS0xMDY1MDI_cc8874b5-6f30-4594-b627-37f022fe835f"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9e334b59f08464daa0d2d2f402ad4b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNi04LTEtMS0xMDY1MDI_3813b960-2ad3-4bfd-a27b-5c65a86b7e6e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifca26b7ffe0540fc80c3f59dfb576259_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy0yLTEtMS0xMDY1MDI_693891a4-3757-4e52-ae77-1a14894dda81"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i129644619e6d4f278f61964c9e9f3d66_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy00LTEtMS0xMDY1MDI_3922eb3f-25d3-4bcd-99e9-9073ef6c2a66"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34bc38e16d5946d6982b6c3c72a07586_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy02LTEtMS0xMDY1MDI_f2e559a0-70a6-463c-a296-4f7119d24c0e"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i580eba0699d7484880390868de30783e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfNy04LTEtMS0xMDY1MDI_ac177d19-e0bf-4006-8897-f2d7b9cf7d25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC0yLTEtMS0xMDY1MDI_961bae6c-e626-483a-921e-e25f558be532"
      unitRef="usd">1048500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC00LTEtMS0xMDY1MDI_054193db-6f23-4a3d-8965-7d476bcf7220"
      unitRef="usd">181700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC02LTEtMS0xMDY1MDI_24c09f8c-abd9-4cb0-8f71-aaf76c6caf44"
      unitRef="usd">866800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOC04LTEtMS0xMDY1MDI_336df4f2-cfc6-4959-9ddc-e00f49a13e7d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS0yLTEtMS0xMDY1MDI_e31b63aa-3ed8-443b-8ea0-d09b7ea00e98"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS00LTEtMS0xMDY1MDI_3ed8e0ca-59e7-44ff-9518-be743f230ea2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS02LTEtMS0xMDY1MDI_821276fd-bc2c-4fc7-b2bb-e7907adf7c20"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfOS04LTEtMS0xMDY1MDI_561bead1-d4b4-45f2-8603-1c1628538316"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtMi0xLTEtMTA2NTAy_03d11a8f-3948-49f2-93d8-49baaa067073"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtNC0xLTEtMTA2NTAy_a4d4beea-d864-4dbe-aa64-c123ef074e8e"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtNi0xLTEtMTA2NTAy_e70cd97c-7267-4ac8-ad13-e174d344e66a"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTAtOC0xLTEtMTA2NTAy_a3964826-6cc2-4cae-877c-4db673540f2e"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtMi0xLTEtMTA2NTAy_799d1119-aea5-4006-b41d-143da66099d0"
      unitRef="usd">5228100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtNC0xLTEtMTA2NTAy_762536f8-d1fd-4b4d-b6e7-1d220423b34d"
      unitRef="usd">181700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtNi0xLTEtMTA2NTAy_1f42d6cc-f5d7-4f3b-afe8-188bf2fcc0b8"
      unitRef="usd">5046400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTEtOC0xLTEtMTA2NTAy_23409b10-304f-4c9c-bcd8-9bc3513fe819"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtMi0xLTEtMTA2NTAy_5d7307f7-a065-4fab-820c-98fca7fd12ed"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtNC0xLTEtMTA2NTAy_7936ab10-f581-4e71-a79d-fdd573ceee67"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtNi0xLTEtMTA2NTAy_612f9722-0e17-4c0e-af81-816a4a1026e6"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTMtOC0xLTEtMTA2NTAy_bdf77963-f037-44a0-a0f0-b9dc49b2c46c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtMi0xLTEtMTA2NTAy_31c8ecec-d915-459e-8ce2-84050967544f"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtNC0xLTEtMTA2NTAy_b873237f-3b5f-4763-88b0-67c0e47d5b48"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtNi0xLTEtMTA2NTAy_0f09a6d2-b0f9-479e-8501-4a6e2f6c74ea"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTQtOC0xLTEtMTA2NTAy_b6b358f7-3395-4cc0-b35a-844b5f6d549b"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtMi0xLTEtMTA2NTAy_0600a6d8-7480-4be9-953a-748fb18b7ef5"
      unitRef="usd">219900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1825b81a7ec14bec968fb3cd13c00522_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtNC0xLTEtMTA2NTAy_574b95e7-f1da-41d3-8bdf-5e09da702e33"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i314a58abcbd64561923d0f9981338f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtNi0xLTEtMTA2NTAy_d8f96656-57f3-4030-ba2c-eb28937c64c5"
      unitRef="usd">10800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id49be596d72642af812e59dd50890f35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmM5ZDlhMDk0MTNlZDRiYTg5NDVhM2U3MTg3YjA1YjdmL3RhYmxlcmFuZ2U6YzlkOWEwOTQxM2VkNGJhODk0NWEzZTcxODdiMDViN2ZfMTUtOC0xLTEtMTA2NTAy_d334baca-5c37-4d87-b2b6-7eb26b6b4088"
      unitRef="usd">209100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMjgy_5415e3b4-8ab5-446f-83d7-6686cb1640a5"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMjgy_e89d9a22-b64b-4a62-a9a8-e8d4aba65f0a"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfNDk0NzgwMjM0NTEyMQ_45f084e3-25b0-48c1-9c48-c550891bfd53">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 to 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,730.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,743.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,066.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,546.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,277.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy0yLTEtMS0xMDY1MDI_a8ba0b5f-f555-45ab-87fb-b44706b76ea4"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfNS00LTEtMS0xMjE3MTU_31c8ecec-d915-459e-8ce2-84050967544f"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if2ac8144dad34592a0e0d767e503cd0c_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy04LTEtMS0xMDY1MDI_980f4bcf-3b34-41ef-994c-8fb25aee4441"
      unitRef="number">0.0396</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia788a53d2f44480a9c09cb836102cf88_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfOC0xMi0xLTEtMTMxOTE2_d023c34e-5196-4af0-a7f2-8162e3984c53"
      unitRef="number">0.0396</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i29b2d699c7994b058ffdc0a2973fe76a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjY2Y2IyZmRhYTI2MzRjNjI4OTJhNjc0ZDRmM2VhNGJiL3RhYmxlcmFuZ2U6NjZjYjJmZGFhMjYzNGM2Mjg5MmE2NzRkNGYzZWE0YmJfMy0xMC0xLTEtMTA2NTAy_5e8e51d7-1b23-46f8-959d-6d189f60f42e"
      unitRef="number">0.0130</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzMzE2Mg_26d4aa40-8205-4e35-bdb5-31e91827b07e"
      unitRef="number">0.109</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfNDk0NzgwMjM0NTEyMA_f06d87c6-710c-4411-ab42-e7c0dff894cd">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iee7f7781b1e446cc8b8a3b615a223395_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi0yLTEtMS0xMjE5MTA_0aaeba29-262b-44ca-a923-45f9b20874ed"
      unitRef="usd">202000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4dd86bc5c7e44ed5a9d043c911ec35d9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi00LTEtMS0xMjE5MTA_2174413c-d963-47fe-ad70-0613479a1d22"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia11ecccfe2884f3db642f3f076602bf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi02LTEtMS0xMjE5MTA_8a12ef07-cd34-47bf-bf5d-2232f112f6b5"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae70c7addbd245e88b9cf036469b0e00_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMi04LTEtMS0xMjE5MTA_4ee38905-34d4-46e6-86ef-da69540a89f7"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy0yLTEtMS0xMjE5MTA_141ebcad-9bb8-41d0-b504-418111a7a034"
      unitRef="usd">4500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy00LTEtMS0xMjE5MTA_91cf8a80-2932-49bc-b0db-5d8edd00e34b"
      unitRef="usd">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy02LTEtMS0xMjE5MTA_d5298007-4981-4142-84bc-2a5ece3c941e"
      unitRef="usd">11600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfMy04LTEtMS0xMjE5MTA_f93a32b4-784b-4f39-9f6f-e5647ae03497"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS0yLTEtMS0xMjE5MTA_0a1d215a-a120-4689-88fe-494665f485f3"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2546b8d042464cf18732132087c7837b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS00LTEtMS0xMjE5MTA_49b8e4cf-3915-454e-9279-0be7c0b7f44d"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS02LTEtMS0xMjE5MTA_fb0b1bdc-b4c5-427c-a19d-aa7ebd5a3845"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2546b8d042464cf18732132087c7837b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOjk4N2QyZTdiZDc3OTRlOWFhOWU3OTE0MDg5ZjUwYWQzL3RhYmxlcmFuZ2U6OTg3ZDJlN2JkNzc5NGU5YWE5ZTc5MTQwODlmNTBhZDNfNS04LTEtMS0xMjE5MTA_fc4d20e1-8b97-4dc8-841b-63df95705429"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzNTYzNA_bc6dd326-9ce0-4b10-81c8-c576b6483328"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RleHRyZWdpb246MTU4ZGM4ZTU5MWQyNDRhNTg0MzhiYWE2NTQ1MDM1ZWVfMTA5OTUxMTYzNTY0Mg_00f6cded-836b-4085-b7ce-d1abe00b7497"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy0yLTEtMS0xMDY1MDI_30bfd345-fd33-47cc-b8c9-45db458b940a"
      unitRef="usd">1001100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i0c1b24834b7c453f887f7958431a260f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy00LTEtMS0xMDY1MDI_fede9ccb-3d2b-4130-a32c-b6a095055683"
      unitRef="usd">999800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i749156c0d2244797891329da8f801076_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy02LTEtMS0xMDY1MDI_eb918e86-0e49-43bc-b5f2-4d4700243730"
      unitRef="usd">1020000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i749156c0d2244797891329da8f801076_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfMy04LTEtMS0xMDY1MDI_43ec3ac0-e47b-4484-aeae-a191b807f6db"
      unitRef="usd">999100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC0yLTEtMS0xMDY1MDI_a818f7c1-6812-46bd-88d2-fbcffaae9755"
      unitRef="usd">1730100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9e095c97d47740e5afa1a5c72b4c260c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC00LTEtMS0xMDY1MDI_8d7d5c53-84cb-4f92-bdb2-6987305bba78"
      unitRef="usd">1743800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC02LTEtMS0xMDY1MDI_eeb3f903-3e91-4170-8c95-507bda026302"
      unitRef="usd">1895200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9e332a0d98dc4c47ba6e2773bebfe15b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNC04LTEtMS0xMDY1MDI_80390540-df35-442e-bb12-f58268ab4b1e"
      unitRef="usd">1742900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS0yLTEtMS0xMDY1MDI_6023e273-c59f-4df8-acce-330e5ab06ae6"
      unitRef="usd">1232200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i5c5357e7e48a48bba0ae5f084520cd1e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS00LTEtMS0xMDY1MDI_a75d00b4-d34c-491f-a929-e83cd8286d16"
      unitRef="usd">1492500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i05c33ec33ac24977b3efeb593adf8673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS02LTEtMS0xMDY1MDI_0e53db44-922a-45ac-8421-d17d6076fab7"
      unitRef="usd">1475900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i05c33ec33ac24977b3efeb593adf8673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNS04LTEtMS0xMDY1MDI_778b8332-a88c-4a0e-8282-0e7dc5a3a2ad"
      unitRef="usd">1492000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi0yLTEtMS0xMDY1MDI_e3226d8f-7843-4ddd-936a-44dee9bb6617"
      unitRef="usd">1066300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ib2c55e0cd9e3456d88342437a3fbb3ba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi00LTEtMS0xMDY1MDI_ccba2e43-52ae-4aab-b17d-d6a566ec757c"
      unitRef="usd">1100100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i5363dbf017c244debdb2e7604c5291cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi02LTEtMS0xMDY1MDI_f04b2bc2-bbb1-4d4d-8fe5-fdfbf7800811"
      unitRef="usd">1463000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i5363dbf017c244debdb2e7604c5291cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNi04LTEtMS0xMDY1MDI_d37885d8-9b33-46ed-a2b9-843965095846"
      unitRef="usd">1099900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy0yLTEtMS0xMDY1MDI_9278909f-f9dd-4442-8d24-60c98aa098e4"
      unitRef="usd">1027900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i4fbcb087e76943ca97d22fd15915d974_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy00LTEtMS0xMDY1MDI_d041b815-4237-4340-8245-0c3a5ee00cc5"
      unitRef="usd">1473400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i3dd69aba81534dac91205bace6805330_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy02LTEtMS0xMDY1MDI_3d83a9ec-ae34-42f4-bf96-8fb7ee1d0a31"
      unitRef="usd">1457700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i3dd69aba81534dac91205bace6805330_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfNy04LTEtMS0xMDY1MDI_69633024-801e-4107-9db6-d64d9b7b4dae"
      unitRef="usd">1473200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i0324ddb09a434fee859e03396262f145_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC0yLTEtMS0xMDY1MDI_1e61f103-16f5-4e33-b87a-3948987d3c3f"
      unitRef="usd">489100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i0324ddb09a434fee859e03396262f145_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC00LTEtMS0xMDY1MDI_9ae0cdb8-62af-4695-9ef5-a71aa6d085b1"
      unitRef="usd">467600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i6e56bad4fc89492691617ec7457815b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC02LTEtMS0xMDY1MDI_ad57c59c-44b0-4f4f-86c2-6898862563ac"
      unitRef="usd">692900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i6e56bad4fc89492691617ec7457815b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOC04LTEtMS0xMDY1MDI_468a5de2-3d23-47f4-8181-3dddbd0ada68"
      unitRef="usd">466000000.0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS0yLTEtMS0xMDY1MDI_1d14b3a8-0bd0-40b7-a3ea-77c4453fe019"
      unitRef="usd">6546700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS00LTEtMS0xMDY1MDI_f2e50757-acda-45ab-a2d8-2eb808ebe991"
      unitRef="usd">7277200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS02LTEtMS0xMDY1MDI_84bedef3-e229-4b38-b360-2261a5e6d43a"
      unitRef="usd">8004700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV82Ny9mcmFnOjE1OGRjOGU1OTFkMjQ0YTU4NDM4YmFhNjU0NTAzNWVlL3RhYmxlOmI2ZTliMmRhYThkZjRmODFhZjhiMzUxNjJmYTRmZGJhL3RhYmxlcmFuZ2U6YjZlOWIyZGFhOGRmNGY4MWFmOGIzNTE2MmZhNGZkYmFfOS04LTEtMS0xMDY1MDI_874da353-4d8c-49ee-a846-6d4cb1dfb86b"
      unitRef="usd">7273100000</us-gaap:NotesPayable>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ2Nw_fc76300b-3e03-4697-be1f-0b923555b23f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,357.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;540.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;532.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;367.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(341.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(351.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;785.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities classified as available-for-sale as of June 30, 2022 and December 31, 2021, was approximately 11 months and 10 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;917.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,461.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $839.3 million and $1,110.3 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decreases in our strategic investment portfolio for the three &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, were primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Sage and Sangamo common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ5MQ_6bf8c50d-d182-48ae-8160-89c4a88913ae">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i207ad38739a54d138f6be5e688458503_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMS0yLTEtMS0xMDY1MDI_31f5f50f-a222-47ed-93fd-9967162449a9"
      unitRef="usd">79700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i7e5238704ed54c3bb7e1f6928897e2c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMS00LTEtMS0xMDY1MDI_8ed89030-e82d-4f55-b8c4-2d0e4fb2b97c"
      unitRef="usd">247600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9c1febee2fa143e5976b10c5f25675f0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMi0yLTEtMS0xMDY1MDI_0ddc3350-2314-4f03-9a75-7aa8ea2d008d"
      unitRef="usd">83800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i157163fe40884091bf7820d01b3e22e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMi00LTEtMS0xMDY1MDI_11800465-2f21-4f65-b9ca-6f43d4b44258"
      unitRef="usd">200000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i5386dbc2d85346818db10319e0a45e26_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMy0yLTEtMS0xMDY1MDI_40d1c29e-26bf-4358-8e22-aa2a60402c01"
      unitRef="usd">1764500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia5c9f2c4702549599568d0e5eb9618b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfMy00LTEtMS0xMDY1MDI_30d4f8dd-3801-4dd5-86f6-d5df258f1e66"
      unitRef="usd">901600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ifdb4076d18da4ad79a95ee670fa15bb9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNC0yLTEtMS0xMDY1MDI_ed9b6603-c43a-429a-9d63-65339400e4af"
      unitRef="usd">216900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8ef3bd0aea29473b9ec52de86adeb7c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNC00LTEtMS0xMDY1MDI_752b5e45-943f-48fa-84d1-c773e5d1ecca"
      unitRef="usd">283000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNS0yLTEtMS0xMDY1MDI_5bc58bfe-49ea-4856-a118-c5d276e3327d"
      unitRef="usd">2144900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOmY5NDg3ZDBlZGRmNDQ5Mzc4ZjNiZjEyZjgxODFlYjRmL3RhYmxlcmFuZ2U6Zjk0ODdkMGVkZGY0NDkzNzhmM2JmMTJmODE4MWViNGZfNS00LTEtMS0xMDY1MDI_c25e17eb-9da1-49ee-91cc-06553b9e30bc"
      unitRef="usd">1632200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ4Mg_c2033e19-f964-4904-9867-beba29adc1b3">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,357.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;540.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;532.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;367.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(341.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(351.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;785.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC0yLTEtMS0xMDY1MDI_b2096554-f602-415b-9047-2aa5eb08ecd5"
      unitRef="usd">1363900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC00LTEtMS0xMDY1MDI_e5325275-2bc7-40e9-928f-69044d68cb34"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC02LTEtMS0xMDY1MDI_a54ddb9c-2122-4c6d-9850-e23136723472"
      unitRef="usd">6300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78fcd21227a3446a8f60d00a5c0e5e04_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNC04LTEtMS0xMDY1MDI_47e515b1-7f48-4a29-b1a6-558106fa6071"
      unitRef="usd">1357600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS0yLTEtMS0xMDY1MDI_8cd3f94b-c7b9-4516-8645-78a6408410b0"
      unitRef="usd">540400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS00LTEtMS0xMDY1MDI_04b7d52b-4d59-48a5-a13b-77fc3e0e5c5d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS02LTEtMS0xMDY1MDI_e4d53323-e136-4df4-92aa-95a7da85cf33"
      unitRef="usd">7800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d591f719add4db891a44f2be40ad81c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNS04LTEtMS0xMDY1MDI_6729d127-7559-411f-8543-5cc053a87560"
      unitRef="usd">532700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy0yLTEtMS0xMDY1MDI_05d96db5-f7d5-486e-8adf-90050bb193a1"
      unitRef="usd">798000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy00LTEtMS0xMDY1MDI_dacaeac4-2f24-4a50-92db-7a08f78d3c57"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy02LTEtMS0xMDY1MDI_d5a28ec7-0857-4473-828e-ba94deedd173"
      unitRef="usd">4500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if36d266508c34afbaaaeb0f53bd98cce_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfNy04LTEtMS0xMDY1MDI_16026d8c-9239-4a37-af58-97bf5152006a"
      unitRef="usd">793600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC0yLTEtMS0xMDY1MDI_75cf8510-762f-465c-bc26-3b8855005a80"
      unitRef="usd">367200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC00LTEtMS0xMDY1MDI_5694f117-6bc0-4a11-ad8d-1c7221ad0b53"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC02LTEtMS0xMDY1MDI_705acc75-05d9-4a2a-ad21-155a7a2cff6d"
      unitRef="usd">4100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibccb7fd6d8954a1d9580e3e122ec4201_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfOC04LTEtMS0xMDY1MDI_1e32bb13-9be5-4e3d-aece-9b1cc28c104d"
      unitRef="usd">363300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtMi0xLTEtMTA2NTAy_a06515bf-58b2-4465-8bc2-403977201f20"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtNC0xLTEtMTA2NTAy_2811073b-ccb9-420b-87e1-8a7620fb05f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtNi0xLTEtMTA2NTAy_5e5c0c45-b209-4636-9e04-d140e7e3e4c3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ae46d4e5ae24b1f999399ec074184ab_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTAtOC0xLTEtMTA2NTAy_e0becac2-003d-49fe-85d0-68b144e2e31a"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtMi0xLTEtMTA2NTAy_a91d4d6a-da6e-4dcb-9bdf-67bf9266c904"
      unitRef="usd">210000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtNC0xLTEtMTA2NTAy_708794c9-d4ba-4f6c-9ff5-fd18fc997bea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtNi0xLTEtMTA2NTAy_e559d3e3-f29e-4614-8e88-4fd25b00107c"
      unitRef="usd">3100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c0efb74abe649dc92a1800ec298d90d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTEtOC0xLTEtMTA2NTAy_44697ccf-130e-42a5-a126-c0edeb1e13eb"
      unitRef="usd">206900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItMi0xLTEtMTA2NTAy_70e8a51d-4d33-4103-8f82-fb1a5b4892a9"
      unitRef="usd">3279600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItNC0xLTEtMTA2NTAy_3d289515-397e-4c5f-b0e5-e99083566e7c"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItNi0xLTEtMTA2NTAy_1427aeef-8065-4e94-844d-2ac567d46614"
      unitRef="usd">25800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTItOC0xLTEtMTA2NTAy_533e942c-051c-462f-a063-3df3ae51f7aa"
      unitRef="usd">3254200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtMi0xLTEtMTA2NTAy_7a591618-0880-4369-aa95-739c91e3cd8c"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtNC0xLTEtMTA2NTAy_45d10429-8778-4cc0-8354-b574a96033bc"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtNi0xLTEtMTA2NTAy_72416d13-3c77-4493-a368-5af42423c19a"
      unitRef="usd">-9700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib09e47414ccf4f6b88062930b82b2a81_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTUtOC0xLTEtMTA2NTAy_c6c4c10d-1e49-412d-a301-301b625e2ff4"
      unitRef="usd">24200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i16498989190e4b99abd2625557d367dd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtMi0xLTEtMTA2NTAy_2ae1b8bf-d600-4ca5-b25b-b602240d960c"
      unitRef="usd">1103300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i16498989190e4b99abd2625557d367dd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtNC0xLTEtMTA2NTAy_c99cce3e-de22-404d-a2dd-0ce5eceba01b"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i16498989190e4b99abd2625557d367dd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtNi0xLTEtMTA2NTAy_b18ce7a9-6d9b-4b52-8f1f-c0b53c2a2c73"
      unitRef="usd">341900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i16498989190e4b99abd2625557d367dd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTYtOC0xLTEtMTA2NTAy_081eaf47-0d58-414d-88cc-47718eb09748"
      unitRef="usd">761400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctMi0xLTEtMTA2NTAy_c60b12fc-0ce2-4307-8b01-f8a2f6ea851e"
      unitRef="usd">1137200000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctNC0xLTEtMTA2NTAy_56c3d778-94a1-4e93-ab4c-81156a4e2399"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctNi0xLTEtMTA2NTAy_a6ee8cbe-b398-40f8-acd8-8a03fecb14d0"
      unitRef="usd">351600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjI1ZmFlOGNjZjYxMTRkYWFiMmEzZjNkNGQzMTI0NTM3L3RhYmxlcmFuZ2U6MjVmYWU4Y2NmNjExNGRhYWIyYTNmM2Q0ZDMxMjQ1MzdfMTctOC0xLTEtMTA2NTAy_4da414b6-53eb-48ad-a64a-016805c9d5b0"
      unitRef="usd">785600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC0yLTEtMS0xMDY1MDI_31ac29e3-6b2f-4bce-90b5-35de287c63b5"
      unitRef="usd">723600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC00LTEtMS0xMDY1MDI_d42ec81b-801a-4ed8-8d92-18c5cc18d78d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC02LTEtMS0xMDY1MDI_436d2ed0-7eb9-4e7b-846b-d7c6f5f95780"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3a33bb7bfab44b49a33909b6a68a094_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNC04LTEtMS0xMDY1MDI_53898ac0-977a-4a84-9f63-f2dd725c5848"
      unitRef="usd">723400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS0yLTEtMS0xMDY1MDI_f4fbed87-2bc8-4556-be51-8c670268af17"
      unitRef="usd">385400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS00LTEtMS0xMDY1MDI_7d6306fc-1053-46a6-80d1-94e0146521c8"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS02LTEtMS0xMDY1MDI_4eded8f0-1133-4ca4-9310-76aab4ed4c03"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0dbe89693034b608f02372c6ae74cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNS04LTEtMS0xMDY1MDI_9a26b8a1-e0ab-424a-b132-c978696b75e5"
      unitRef="usd">384800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i140bb6501b0449349963095a4992952e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy0yLTEtMS0xMDY1MDI_570d0b35-cc09-4ff3-b50e-6ac94dc3b39d"
      unitRef="usd">817000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i140bb6501b0449349963095a4992952e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy00LTEtMS0xMDY1MDI_b7c8c3e2-26db-479a-8681-16b87e851de3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i140bb6501b0449349963095a4992952e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy02LTEtMS0xMDY1MDI_e5ca8e77-c7d0-4b4e-a512-f16fa5ff72ee"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i140bb6501b0449349963095a4992952e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfNy04LTEtMS0xMDY1MDI_d9426891-d6a1-4bb4-8cbd-f51aaca60abf"
      unitRef="usd">816600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC0yLTEtMS0xMDY1MDI_6478d47f-07fa-4efc-84ed-3d944ce3226c"
      unitRef="usd">377000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC00LTEtMS0xMDY1MDI_ac733c32-c3f7-4278-8949-8bb02130f73d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC02LTEtMS0xMDY1MDI_4b53a382-4fb4-4264-9deb-d21e88dac835"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i769b78fc374145a2b38b4bb257858d1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfOC04LTEtMS0xMDY1MDI_db3caf97-d99a-479f-880f-b27d7b1c388f"
      unitRef="usd">376100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtMi0xLTEtMTA2NTAy_3046fcdc-3d9b-44a0-a596-6dcb1173faf0"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtNC0xLTEtMTA2NTAy_c9d72187-67fe-4352-85f4-a9bd0fa3d889"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtNi0xLTEtMTA2NTAy_705ac18a-a34d-4e71-b5bc-924a665a0c33"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i90787041e4c649eabc5e9f60954a4d29_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTAtOC0xLTEtMTA2NTAy_a561e2ea-14eb-4c63-84e5-cf8512cc85e9"
      unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i992615614bce4506b32f63aabda86d0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtMi0xLTEtMTA2NTAy_0413907e-99a5-414a-aea5-bef4bc606172"
      unitRef="usd">131800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i992615614bce4506b32f63aabda86d0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtNC0xLTEtMTA2NTAy_d53723ba-06a3-40a7-b244-f7e273fbf32d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i992615614bce4506b32f63aabda86d0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtNi0xLTEtMTA2NTAy_527c9122-e585-440b-8aad-67889bc337b9"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i992615614bce4506b32f63aabda86d0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTEtOC0xLTEtMTA2NTAy_eb0af1f7-19de-44fc-9952-cbe99fdeae76"
      unitRef="usd">131100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItMi0xLTEtMTA2NTAy_7e286949-efa5-4b32-9579-4e4a35eb73a0"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItNC0xLTEtMTA2NTAy_04325a40-ce74-49b7-9b05-e3be4b3458da"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItNi0xLTEtMTA2NTAy_a11602db-a626-4964-96cb-d7b4420f8823"
      unitRef="usd">3200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTItOC0xLTEtMTA2NTAy_492bd886-b312-4c72-8fba-1124e4fde17e"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtMi0xLTEtMTA2NTAy_49218ea2-6d4a-4e90-a849-c1936e284663"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtNC0xLTEtMTA2NTAy_e7fdecb1-9f60-4b9c-8c25-193d73b1f257"
      unitRef="usd">9900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtNi0xLTEtMTA2NTAy_db98d457-c885-4394-b80b-861dc4619fa6"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic6de03dc2f124e3eb2faeff9d62268bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTUtOC0xLTEtMTA2NTAy_7ecac38f-609c-469d-abb5-7eaa426fd709"
      unitRef="usd">43800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtMi0xLTEtMTA2NTAy_739fe23c-e43e-4d14-b6ad-a7a54dc40f45"
      unitRef="usd">1133100000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtNC0xLTEtMTA2NTAy_78f08b75-29e6-4c39-8532-ceb4e5263e39"
      unitRef="usd">151000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtNi0xLTEtMTA2NTAy_154745c7-e8d8-4cf2-bdaf-3bc74e790063"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifc42164b6dfb4ab99074f1af3080e5ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTYtOC0xLTEtMTA2NTAy_0c32c971-7696-429b-94ea-66f4e3fb973c"
      unitRef="usd">1004700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctMi0xLTEtMTA2NTAy_045ab6a1-6a3c-402e-a913-f3dc9f8364ed"
      unitRef="usd">1167000000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctNC0xLTEtMTA2NTAy_1a96fd38-6100-445e-a338-87723648be2a"
      unitRef="usd">160900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctNi0xLTEtMTA2NTAy_7eaa718c-d0ee-498a-b5a9-27d7a161027f"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjE1MjQyY2RmN2YwMzRjMTE4YzNkYzI4MjYzMTFmNjdiL3RhYmxlcmFuZ2U6MTUyNDJjZGY3ZjAzNGMxMThjM2RjMjgyNjMxMWY2N2JfMTctOC0xLTEtMTA2NTAy_7e65bb94-323b-4066-ba48-fb343520e104"
      unitRef="usd">1048500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ3Ng_b4285db9-005f-40a2-86fe-2c777abedf6f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,254.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi0yLTEtMS0xMDY1MDI_ee82c496-36ac-454d-9796-89a58c067fa5"
      unitRef="usd">2151300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi00LTEtMS0xMDY1MDI_f2f476f4-765c-4e66-8cb7-7d8ad94b49f5"
      unitRef="usd">2135600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi02LTEtMS0xMDY1MDI_61e61dc1-0e28-44c3-a5d3-93aaa9f43885"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMi04LTEtMS0xMDY1MDI_06173a2b-9367-4aad-84f2-d2523ca6ed85"
      unitRef="usd">1541700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy0yLTEtMS0xMDY1MDI_1f7178df-2b6b-4d7e-afae-1ddbf2d92b97"
      unitRef="usd">1089400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy00LTEtMS0xMDY1MDI_4f232374-f279-4d18-9c76-6aefcc4d2731"
      unitRef="usd">1130100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy02LTEtMS0xMDY1MDI_c5b154ed-89ba-46be-9ad6-07430848874d"
      unitRef="usd">868200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfMy04LTEtMS0xMDY1MDI_86dc6923-5f06-4555-991a-1a0f107e450c"
      unitRef="usd">870200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC0yLTEtMS0xMDY1MDI_e2b97208-4d87-4a58-ba2f-9a95560c5e0d"
      unitRef="usd">13500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC00LTEtMS0xMDY1MDI_cd1d6460-e375-4c90-b1d4-d4fd7464848a"
      unitRef="usd">13900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC02LTEtMS0xMDY1MDI_86427b61-3a13-44b4-9701-e385e0a605f6"
      unitRef="usd">23800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNC04LTEtMS0xMDY1MDI_987effae-90c4-4ed5-bd64-0b1eb09f165f"
      unitRef="usd">24000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS0yLTEtMS0xMDY1MDI_051fb93b-c182-4bc3-8938-6810a3226860"
      unitRef="usd">3254200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS00LTEtMS0xMDY1MDI_1f0fbb06-8426-451f-81f2-1e381743e5bb"
      unitRef="usd">3279600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS02LTEtMS0xMDY1MDI_21a35d7c-2109-43a4-9781-1f094219fd96"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjMwYTJmMTg4MmU3YTRjNzlhNTNkODA4MjJiYThiMmMyL3RhYmxlcmFuZ2U6MzBhMmYxODgyZTdhNGM3OWE1M2Q4MDgyMmJhOGIyYzJfNS04LTEtMS0xMDY1MDI_c54b99d2-c386-43a2-80e6-1249a85ea4fb"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTAyMw_b06c7beb-5af9-4e9a-85f9-3d0f4ce8ee2b">P11M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="if73106cc97da45d0a1aa9b8366bb2add_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTA5OTUxMTYzMDI3OA_cffa279f-391f-4695-b783-a93bfa6d4f5f">P10M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMjQ5NA_20a843ce-f9be-4dff-a8e8-23a81aa08edf">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;917.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,461.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi0yLTEtMS0xMDY1MDI_79202ec7-9eea-472a-bdeb-b34b12575258"
      unitRef="usd">917900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi00LTEtMS0xMDY1MDI_4e96d11b-cfe1-4a91-a14d-29967cf31994"
      unitRef="usd">633500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi02LTEtMS0xMDY1MDI_fd45d323-9261-497f-9c29-5fdca6b032ba"
      unitRef="usd">1461500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMi04LTEtMS0xMDY1MDI_c61aee43-6240-45b3-8601-cf222bcdc8ea"
      unitRef="usd">1452700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy0yLTEtMS0xMDY1MDI_78a6f575-2bdf-4972-821f-4c314a5bc4fc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy00LTEtMS0xMDY1MDI_0a89938c-a997-4f90-88a2-bc6d5ff6adde"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy02LTEtMS0xMDY1MDI_c3867e2c-ac53-4cc4-82a6-615e88a3b6a0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfMy04LTEtMS0xMDY1MDI_ab600a1f-5b84-495f-bad4-501751daf411"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC0yLTEtMS0xMDY1MDI_a28a41e1-389b-447e-b814-48b20a89ed6d"
      unitRef="usd">-800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC00LTEtMS0xMDY1MDI_42f8950a-77e9-4fa3-a889-75f12f27a62b"
      unitRef="usd">-500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC02LTEtMS0xMDY1MDI_8a0f6cce-8d00-4a55-b26c-f4638df23c9b"
      unitRef="usd">-1400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RhYmxlOjQ1OTVhYzIyYzI5MzQ3M2FiOTBkNzk0ZDE3M2M2MzJiL3RhYmxlcmFuZ2U6NDU5NWFjMjJjMjkzNDczYWI5MGQ3OTRkMTczYzYzMmJfNC04LTEtMS0xMDY1MDI_a1d25da8-8da2-4dae-aa9f-2b42f0ad2eb8"
      unitRef="usd">-1200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTQ4NA_24ec6155-03b4-4cf7-ae3d-8597ccf3c9ff"
      unitRef="usd">839300000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="id4d0bd51bc4647dfb2a191cad3986b16_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83My9mcmFnOmQ5MjFmMTRkM2EwZTQ4NmNhOThhMjQyNWM5ZGI4MGY5L3RleHRyZWdpb246ZDkyMWYxNGQzYTBlNDg2Y2E5OGEyNDI1YzlkYjgwZjlfMTQ5MQ_11d9b3e7-077d-47df-a092-8e6f7af27597"
      unitRef="usd">1110300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTg5Nw_686adbd2-78cf-4e13-94c8-bbbf23095b25">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of June 30, 2022 and December 31, 2021, had durations of 1 to 15 months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,525.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized gains of approximately $137.6&#160;million to be settled over the next 15 months, of which approximately $133.7 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale of our equity interest in Samsung Bioepis we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,230.4 million and $1,268.0 million as of June 30, 2022 and December 31, 2021, respectively. Net losses of $37.1 million and $49.3&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and six months ended June 30, 2022, respectively, compared to net gains of $4.8&#160;million and net losses of $12.6&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i3ab0561efd9a429f84f8b4296c82c73e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNjM2_52e0bbd3-5454-46f5-98a5-ba2c32213b3b">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="iff853fccd14442ebbb17ab9ef5e1c4be_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNjQy_974ac3ce-61ea-4254-b0ac-917c00286a28">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkyNA_c06e459c-98fe-491f-a71f-ff8c2a70ad56">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,525.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i18d6800eb2c74fba819c1b070cefdc3b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMi0yLTEtMS0xMDY1MDI_a66764d1-34fc-4782-9c2c-8dbe8d352208"
      unitRef="usd">1285400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if5c0ffa95ac44d50a2d00434ffc62f9b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMi00LTEtMS0xMDY1MDI_8096bae9-c9c0-488c-b1a2-cc6c95a820e3"
      unitRef="usd">1828000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i921449c1dcd64ae094a4e7206755b28f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMy0yLTEtMS0xMDY1MDI_4e446546-230c-4a5f-9da3-e3ca33f131b2"
      unitRef="usd">87000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i56a4214140a84299923a095d0db68a81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfMy00LTEtMS0xMDY1MDI_42721103-454c-475f-befc-692e9d547863"
      unitRef="usd">166200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i753e77cb96eb44eb91792a859ab31f61_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNC0yLTEtMS0xMDY1MDI_ea9a0c75-0fe1-4e49-acbf-69864d55d604"
      unitRef="usd">78700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i13cb17acde494685b6ba5f5809b645d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNC00LTEtMS0xMDY1MDI_6baa69d2-9400-47bf-adf7-f4899918a27b"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7766088e60b94262b048c5f32da60dbf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNS0yLTEtMS0xMDY1MDI_481601a6-ebe0-4f66-a04f-3aa36d0eab39"
      unitRef="usd">44600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i199c91171d3f4a2382e5d5cd3f00f2f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNS00LTEtMS0xMDY1MDI_1344dfa0-4713-482e-8d74-0bd2bd99cadc"
      unitRef="usd">72700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaacc3061343b44129f16a08974a6b548_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNi0yLTEtMS0xMDY1MDI_38c50fd8-81c6-4c10-a7f7-2d96ee7ac828"
      unitRef="usd">29500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibff5ba68900c43e69eec8d505e93c934_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNi00LTEtMS0xMDY1MDI_af5354b4-99ee-4553-9163-01f46ebaa528"
      unitRef="usd">59900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ecadcec54794963b50463bd915d2bc9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNy0yLTEtMS0xMDY1MDI_c8016cf9-47c2-40d2-b244-b223858fe28f"
      unitRef="usd">1525200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibe39514eee6e4adc9af02f16e10ee4f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmExNDQ5MmE5Zjk0NzRmZTE4MTgxYTFmMzYxNGNmZjE3L3RhYmxlcmFuZ2U6YTE0NDkyYTlmOTQ3NGZlMTgxODFhMWYzNjE0Y2ZmMTdfNy00LTEtMS0xMDY1MDI_7f720ab0-bab9-4e54-beee-b87079b12b7a"
      unitRef="usd">2126800000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkwMQ_de244f05-f62d-41a8-80e7-362abbc80052">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives
      contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMi0yLTEtMS0xMDY1MDI_9f2e37d2-cd42-4105-86ac-9bb596aa31d1"
      unitRef="usd">140700000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives
      contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMi00LTEtMS0xMDY1MDI_ad6fa76e-15c3-42bb-b347-0731ff604e67"
      unitRef="usd">60800000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMy0yLTEtMS0xMDY1MDI_0531dfb6-acbc-4e22-aa1e-ff4f003d1f0b"
      unitRef="usd">3100000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfMy00LTEtMS0xMDY1MDI_87f760e7-36c2-4f43-91e1-7852d5ded979"
      unitRef="usd">7000000.0</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfNC0yLTEtMS0xMDY1MDI_11b3be11-cb71-4903-8e34-b121e43a64c4"
      unitRef="usd">137600000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ic2f77816467f4a04bf60bdfbc3e9b431_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmEwNDY1MDhiYzE2MjQwY2NhMzdiZThkZmU0Zjc0M2YxL3RhYmxlcmFuZ2U6YTA0NjUwOGJjMTYyNDBjY2EzN2JlOGRmZTRmNzQzZjFfNC00LTEtMS0xMDY1MDI_dd2cb134-0890-413d-a977-ae365a0a6b62"
      unitRef="usd">53800000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i7533348289c643f4870127b69ce2e844_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzkxMg_11b3be11-cb71-4903-8e34-b121e43a64c4"
      unitRef="usd">137600000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="if5cb29af1d6742908ff898b5ebf574cf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTg2MQ_eb3f119e-62bd-4713-a51e-f5241ebbacbf">P15M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i5bfba5b1866a471cabbde592da7a1247_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTg3NA_330a016e-78b1-47cd-81ae-565a90841ac0"
      unitRef="usd">133700000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ic5e00dff9ecc46b9bdb7d69718e8e77a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTk0OA_609ff910-ff82-4a0d-abd4-fcaeddcb69ec">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkwNQ_c21824bf-1cb6-4135-ab19-a85337ef76dc">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i0466df147d7942408c489858f169de93_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy0yLTEtMS0xMDY1MDI_4616c379-31e7-42a4-9db2-280dd0089b59"
      unitRef="usd">44600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i26725a695f2b478788a442808ce1beee_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy00LTEtMS0xMDY1MDI_ccff7d86-0391-4238-a651-4c8f6f5a005a"
      unitRef="usd">-30700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i0e2ff89e7330400e967da0afcc3e2d99_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy04LTEtMS0xMDY1MDI_a0784e58-c5c8-4b50-87ed-63f17c280f97"
      unitRef="usd">-900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i8e91a04e7eea4c38b6cb6751d4043a2a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMy0xMC0xLTEtMTA2NTAy_f67d1d98-825a-404a-9f91-c5e8539fd397"
      unitRef="usd">-800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic1bde062c47d49a8a7f0277989d627c9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC0yLTEtMS0xMDY1MDI_3a787ca8-d07f-4d9b-a2a9-0a0100557cb9"
      unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i743019f676ee466795fa568ff3243842_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC00LTEtMS0xMDY1MDI_581dd151-237d-4ba0-a7b0-f8679633c7f9"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ibb90f3ecd54b4e76b9e9bd9dbdbfe5af_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC04LTEtMS0xMDY1MDI_55cdfca2-7cf7-43b3-9a4e-7820fc9d590c"
      unitRef="usd">-200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i1b82baa8ea8543bda12f9f9de5c4af65_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfNC0xMC0xLTEtMTA2NTAy_1fd37743-b19a-4b75-8874-22f0231095ca"
      unitRef="usd">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8929791e27f944c09502d04a25c1b021_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS0yLTEtMS0xMDk2OTQ_b5c91257-5e42-4757-87c2-b086ec42d32f"
      unitRef="usd">65500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i16c78831bea640a7b02cdd4181f233cf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS00LTEtMS0xMDk2OTQ_cb821079-f226-42ca-98e4-ef92ef90638e"
      unitRef="usd">-53800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idfa592716840490d9b21fa9dd5a26334_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS04LTEtMS0xMDk3NzM_4cc26fcd-1abc-4e02-bc37-7bf4b3213499"
      unitRef="usd">-7400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ia75940771ad54dec84714d53bc3a845a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfOS0xMC0xLTEtMTA5Nzcz_74b5ce17-8857-4e62-a3e7-7c88bddc1795"
      unitRef="usd">-3800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if6cecc0a55d14fafbfae04ffa644a385_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtMi0xLTEtMTA5Njk0_c2fc00a5-7056-44e8-b74c-58165156245a"
      unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i25ca7beff5f2474b9d401734f8a1ec03_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtNC0xLTEtMTA5Njk0_fa9d98a5-b017-4c57-a8c6-16806718ff27"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3e235045cf98490f8a1e30fcda5c5e48_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtOC0xLTEtMTA5Nzcz_a2524504-44ef-435a-970f-c7b39699a840"
      unitRef="usd">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3de48898e11f44699c3ee51c8d39f207_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOmY2ZGYxN2UxYTY5NDQ5NWViZTZlZmJmZjVhZDAyNDJjL3RhYmxlcmFuZ2U6ZjZkZjE3ZTFhNjk0NDk1ZWJlNmVmYmZmNWFkMDI0MmNfMTAtMTAtMS0xLTEwOTc3Mw_0d453c96-4925-43f3-95a1-b1e78908ca7e"
      unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i17f3f785472d4636b331649fe366628f_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMjkxMA_b3579220-a663-4607-b024-5fcca6f1170d"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMjkzMA_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzAyMw_7ad82036-3c71-421d-9ddd-7e97c504f6db"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ieb60c40ec1b5400fab3008a74dd584f3_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzA0NA_3802d612-0807-4c22-b388-e7ec4ab80144"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzNzQ3Nw_c9e0aefc-ddcd-4bbb-b940-e655b42de12c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzODA5MA_897ee35b-4163-4c42-84ce-a26f27e77b6c"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i6e750febc54343bc90f1a684d4d68e95_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMzc3Nw_5f34378b-774e-4897-8ed7-3c314defd52f"
      unitRef="usd">10600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i3f906803044b470f81de0eefb5dba012_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNDIyNA_ce36cea2-1c91-424e-b244-59cea775a27f"
      unitRef="usd">3600000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkxMQ_fd98563d-95e4-43b5-a2bb-d28031c6a186">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0yLTEtMS0xMDY1MDI_d2ae851e-43e5-4cd5-87c4-d664ea993bb1"
      unitRef="usd">10300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy00LTEtMS0xMDY1MDI_b4b98459-9ee8-480b-9cb5-ab3d40a99db3"
      unitRef="usd">-2500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i676123d5a2a34deb8ee98080a6e25df9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy04LTEtMS0xMDY1MDI_5637cb50-ef03-435f-b431-c13eccf8bc98"
      unitRef="usd">100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i8bf0907927d74ccebbe41442fb9f174f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xMC0xLTEtMTA2NTAy_ccd6023a-a019-4e1c-9089-59d856276aa4"
      unitRef="usd">300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i74799976f1b24216a03f17304e960c0c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xNC0xLTEtMTA2NTAy_921e239d-ddce-4b6d-b041-2c56f186957a"
      unitRef="usd">-3500000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ib6b1a6af29424cb4aa2a50fd11bfc322_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfMy0xNi0xLTEtMTA2NTAy_293ed262-c87f-4716-9dff-f4bc53194867"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0yLTEtMS0xMDkzOTc_600e39c4-133a-41c4-84b1-2158ff644de6"
      unitRef="usd">20400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC00LTEtMS0xMDkzOTc_d30adfae-6ed3-46e5-b807-98fc54d15d08"
      unitRef="usd">21300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i4b988b6af7514c9c880185f8b00c9b0b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC04LTEtMS0xMDk0MDQ_38896ce7-c197-47f1-ba6e-9b798b3957db"
      unitRef="usd">-3200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="if7fa33d901424302ab1b0495f6e98157_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xMC0xLTEtMTA5NDA0_39e35df4-69f6-4f45-ba5d-b13c7aa0ede7"
      unitRef="usd">-1100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i94d5ef31f0fa47a39e2dd83dd2bfe19a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xNC0xLTEtMTA5NDEw_62985bef-1f91-4dd4-a924-d40ed2de3222"
      unitRef="usd">-4600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i575d79eb11134ef993a7f0b1f6d269e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjI2OWMzMTQxYjhmMjRlMjI5OGE1NjgxZWYwNmE5NmU3L3RhYmxlcmFuZ2U6MjY5YzMxNDFiOGYyNGUyMjk4YTU2ODFlZjA2YTk2ZTdfOC0xNi0xLTEtMTA5NDEw_bdb9feca-9968-45c1-bffb-f1ea9ab54d21"
      unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzNzA0NQ_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4bc4c2d8c7e943a895789a1697167962_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTEyOA_8513b94a-8ce0-4890-a95d-d5c75c2cf5fc"
      unitRef="usd">1230400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib02689d9b0b44614b294b3f29ca4964e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTEzNQ_c4473992-8f6b-45ea-8838-2b0ca92e3749"
      unitRef="usd">1268000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTE4Mw_99ca5746-4827-449d-b845-55556e93de73"
      unitRef="usd">37100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzczNQ_1d4f8718-bbce-4985-9896-72a3bdf2b7dc"
      unitRef="usd">49300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzc5Mw_c91607b4-57c0-4661-b1ef-e223c38c27c7"
      unitRef="usd">4800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzMzgxOQ_dab24aff-52bc-4c40-bcbe-7989a89422c9"
      unitRef="usd">-12600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfNTkyNw_538618fb-c693-4a22-b102-6d942e81d45d">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5cefa532629b41e3b9dc278f0f0761e4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMi00LTEtMS0xMDY1MDI_5cebf2f6-b1c4-4020-b639-a9b2060bf6ab"
      unitRef="usd">142300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6092dc9afba6475196a6884c6298c6f1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMi02LTEtMS0xMDY1MDI_14c400f2-5288-432b-a545-00b5e8e8c772"
      unitRef="usd">66200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic958db40215b499a9247ed982bcb0126_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMy00LTEtMS0xMDY1MDI_05baff69-1370-497e-b0a0-2b3ddabca0b8"
      unitRef="usd">4100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3b36ca2852634efd80fe1a2529739a5c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMy02LTEtMS0xMDY1MDI_2230f4f2-aac1-49ad-b5f1-8a3cce6e19bb"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0857062bc899445982d736bffcb52e46_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfNC00LTEtMS0xMDY1MDI_15b6193f-bfd0-440d-ad1b-1930d3ad2b14"
      unitRef="usd">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0c530cc918fe4a479490cc9b9876a764_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfNC02LTEtMS0xMDY1MDI_047d695b-80b3-436c-a4bb-500723fdb590"
      unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibd7a423894c0434db231ce4133ce2fc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfOC00LTEtMS0xMDY1MDI_f50c6f13-af4e-42fb-994d-aeb90cf7ef6a"
      unitRef="usd">21400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2c1d25a8fbe4414ba423291d19d37d5f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfOC02LTEtMS0xMDY1MDI_7ab97c50-f191-4708-a119-08146f50c10d"
      unitRef="usd">4100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ieb798cbcdc26425ca390649668ae6b38_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTYtNC0xLTEtMTA2NTAy_f8a763a6-37c0-475e-9f31-c96d75869546"
      unitRef="usd">12200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i926408e195f24642b73de23a766b86b6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTYtNi0xLTEtMTA2NTAy_ea046686-ce17-4701-92e7-7de7a7de0191"
      unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i70908e6791334ae48472963b146ee23a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTctNC0xLTEtMTA2NTAy_93892902-a7a7-4fad-9110-310f1ee1b8b6"
      unitRef="usd">18100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9af4d136402048959dd3e0e8e44a22bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RhYmxlOjFhYjAyNWJjZTZmZjQ0YTM4MWI3OTA4ODJiODZiNjFlL3RhYmxlcmFuZ2U6MWFiMDI1YmNlNmZmNDRhMzgxYjc5MDg4MmI4NmI2MWVfMTctNi0xLTEtMTA2NTAy_b1bf4f2c-21e7-4649-bd81-c38f0db0bdd0"
      unitRef="usd">4200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV83OS9mcmFnOmZmYjYxZTAzYmI4NTQxMWQ5OWJhNGFmOGU5OTRmMjc5L3RleHRyZWdpb246ZmZiNjFlMDNiYjg1NDExZDk5YmE0YWY4ZTk5NGYyNzlfMTA5OTUxMTYzODA4Mg_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTE2MA_2c29fcbc-2a77-4764-89ff-87bdb287f5ea">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,131.0 million and $2,006.6 million as of June 30, 2022 and December 31, 2021, respectively. For the three and six months ended June 30, 2022, depreciation expense totaled $67.2 million and $143.5&#160;million, respectively, compared to $54.7 million and $103.5&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of June 30, 2022 and December 31, 2021, we had approximately $691.7 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite will be operational during the second half of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTcx_269b2382-d24e-45cf-93d4-e1715b324424"
      unitRef="usd">2131000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTc4_1fd4ff7a-b789-4430-8b46-148bdf0c4484"
      unitRef="usd">2006600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMjY5_19077e88-bb89-4f56-bb6b-153491de4f5f"
      unitRef="usd">67200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA5OTUxMTYyODk0OQ_7c10df8f-0ca3-457f-8abb-4316da92b38f"
      unitRef="usd">143500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMjg0_50e0c6f4-c41c-42bf-be40-3ee79ff9ba38"
      unitRef="usd">54700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA5OTUxMTYyOTAxOA_3b14b470-53d6-4c7b-8767-5e14e58c839c"
      unitRef="usd">103500000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="ic7da619d63a94a4591936365ba7bb51f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNTc0_e5dc664b-1b6a-4777-a584-22227a8b6151"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i8fa50adcc4464c39a7eefd4680d1765c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNjQ4_25c28039-4db5-4ba6-b0e2-87fb2289f0d4"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ibaefaf11247247fabd1fe4cc79c22821_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzA5_3583300a-8f51-4f2d-a051-c477c0b17f71"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i0043843f37f44a84bcc5be0643dee99c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzg3_73115022-ee48-4f45-9fdb-d629747ad304"
      unitRef="usd">691700000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i12b4c6baf27c4eba8805276bb5e93dc8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfNzk0_c5ec0250-c0db-43a2-a8a5-8ec2680d1472"
      unitRef="usd">677000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0043843f37f44a84bcc5be0643dee99c_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84NS9mcmFnOjc5YzcyYjBmM2MzZjQwYzI5ZDAwNzc5ODhmYmZmZmQ4L3RleHRyZWdpb246NzljNzJiMGYzYzNmNDBjMjlkMDA3Nzk4OGZiZmZmZDhfMTA3MQ_3bcc813e-fbb3-4819-b74a-c81a6db59301"
      unitRef="usd">1200000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTgwNg_de744866-15a2-4fd8-8914-1a6310ad76f9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and will recognize a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will be recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i65ad03e37af84a41bf8a69fdca5275ba_I20150915"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU1MQ_c4269836-adb5-43fa-8e47-6cbb435b26ec"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU2NQ_c76cc7cf-8331-4df1-80e7-c662bb99fd51"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU2NQ_cef9d2f5-e2bf-4578-bea4-110727b64305"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:DebtInstrumentRedemptionRate
      contextRef="i5299d1d7822041d3b1817887dbd46432_I20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU5MQ_cb50925d-1efb-4fe9-b8ae-34f23b36b0f9"
      unitRef="number">0.99920</biib:DebtInstrumentRedemptionRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU3OQ_c76cc7cf-8331-4df1-80e7-c662bb99fd51"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU3OQ_cef9d2f5-e2bf-4578-bea4-110727b64305"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU4OA_c76cc7cf-8331-4df1-80e7-c662bb99fd51"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDU4OA_cef9d2f5-e2bf-4578-bea4-110727b64305"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i45416e1b26f14f8cb98e144608a14a4a_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTY0OTI2NzQ0NDUxNQ_630c2bd3-8076-4524-a202-ff94113c3412"
      unitRef="usd">2400000</us-gaap:ExtinguishmentOfDebtAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMjYx_3c42bef3-665d-4c05-81a3-1ecbad72ca9b"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="i28dde4b51293471682782551de32cb29_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMzU0_69e75d1a-c2bc-45c7-b411-dd936e1db445"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i012f5bd22d3246cab5a94a0bed345c02_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfNDI3_1fbed40a-69af-4d89-9eb6-6c042304ca8b"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfNzM4_8ffb18dd-2d54-4d13-8d21-6128b40de145"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="if77b9dae64374e43ae8ef1a6047d80d4_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfODEx_6456ff70-388d-4451-97b5-64238b81fafd"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfOTYx_bdf27121-0b1e-4eb0-b1e5-bdf8d10b767f"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTQzOQ_3faa3ee2-3ddc-422c-8cf6-c14b251d4ae2"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="i02a0dec4de1247dbacbb7aea8672ca5b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV84OC9mcmFnOjRkOTU1MzIyNjkyYjQ3YTM5ZGFmMTY2MzUzMmQzOTQwL3RleHRyZWdpb246NGQ5NTUzMjI2OTJiNDdhMzlkYWYxNjYzNTMyZDM5NDBfMTYwNA_d1a6cfdd-d0b7-4407-ba37-03baf70ecdc8"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTM4_7fbabc88-6e39-4f02-a420-096d3323b9e7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.4&#160;million shares of our common stock at a cost of approximately $500.0&#160;million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately 1.6&#160;million and 3.8&#160;million shares of our common stock at a cost of approximately $450.0&#160;million and $1.1&#160;billion, respectively. Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i18f30485bd8748f68ef275fcb514e0b7_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTEx_010390db-4712-4d4e-bda4-2ef450bd1efa"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyODczNw_8f8fab23-6628-44f8-bd88-a170979ec677"
      unitRef="shares">2400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i664a69bb49ec49769ef8a497eab25fb1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyODc5NQ_601d7a32-2406-46e8-a11d-7f7b89e254ce"
      unitRef="usd">500000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTExNw_65ccb61d-a5b2-4417-8e00-eed1ea4a91fe"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTEyNw_51fb2f38-95b0-4049-8e57-79e7fd6d2c78"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i17a77a2f0f23466e9ffe9ed45abed8a4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTE5OA_0839d4b9-cb1b-4fcd-98b1-a6b93e568ebc"
      unitRef="usd">450000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i53c5fe19d7864691bb2700735d7c6417_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTIwNg_c397bde2-bec5-48de-8a9b-9dbedb41cd37"
      unitRef="usd">1100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i85a73135034a4df7a82a111ed6759cd0_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfNTg0_389900fc-78df-477d-a5e5-c330aa5f47c3"
      unitRef="usd">2300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTQ4_8baa1034-a97c-4b05-be8a-337c304ed0d2">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i84ce2898f9b84c02bac44cbb9b1e0305_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0yLTEtMS0xMDY1MDI_fc245c79-198d-42a6-af80-e36e4643c72f"
      unitRef="usd">-2200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i764a683e6bcc4b34bf7d9c79615d5377_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS00LTEtMS0xMDY1MDI_6595a212-a531-4f1b-a6ed-7bf7ac743502"
      unitRef="usd">53800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7fab60076437436eb30238de33b462fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS02LTEtMS0xMDY1MDI_221a4304-7fed-41a2-9208-92f927b697fd"
      unitRef="usd">25500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iad2094119ab54aaf9f28c105672c9bb1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS04LTEtMS0xMDY1MDI_3e9317c4-bc21-439f-8ed0-795cbe28d568"
      unitRef="usd">-44800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i182bc48d598f48999740017707097224_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0xMC0xLTEtMTA2NTAy_ccb200dd-0fb7-4e37-a24a-7c75c03119dc"
      unitRef="usd">-139000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMS0xMi0xLTEtMTA2NTAy_31cea787-6529-404d-95aa-38b72fde1547"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0yLTEtMS0xMDY1MDI_ff40dedb-2926-4894-8e59-7f4aca56e3bf"
      unitRef="usd">-19100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi00LTEtMS0xMDY1MDI_eb8e0b23-6ef6-4728-ba22-fd0a6c7a8130"
      unitRef="usd">129500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi02LTEtMS0xMDY1MDI_884ba03b-348d-4cb7-bdf8-ebe9adc72a07"
      unitRef="usd">12600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi04LTEtMS0xMDY1MDI_86177276-b9e9-4aee-b986-0b4a117b72a5"
      unitRef="usd">2700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0xMC0xLTEtMTA2NTAy_da294062-2f7f-4619-8a91-9b044470a7cc"
      unitRef="usd">-94900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMi0xMi0xLTEtMTA2NTAy_7aee907e-ea9d-4a1f-9799-a854fb0d9aa6"
      unitRef="usd">30800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0yLTEtMS0xMDY1MDI_77aa4be6-575a-498a-b25e-d786446c8c30"
      unitRef="usd">1100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy00LTEtMS0xMDY1MDI_90bbfd70-ecbd-4cda-b8e5-a8f0228702e5"
      unitRef="usd">-56400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy02LTEtMS0xMDY1MDI_573dc8b7-a4c6-4fc1-8f25-662be7b72da1"
      unitRef="usd">-38100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy04LTEtMS0xMDY1MDI_0d41b05b-4e06-462d-ac24-96f52d4b4477"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0xMC0xLTEtMTA2NTAy_7dcd70fa-9cef-4dd7-986b-efe2e798a0b2"
      unitRef="usd">58900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfMy0xMi0xLTEtMTA2NTAy_9820659f-6bff-4891-99c7-9cf0a80e9bf4"
      unitRef="usd">-34500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i443555b494964780923c6389a3abfb01_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0yLTEtMS0xMDY1MDI_57f3afa0-dfd3-49c6-913f-d2735db2b20d"
      unitRef="usd">-18000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4053edb282f049da9c7c9a2169434a90_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC00LTEtMS0xMDY1MDI_527a4bc3-7b9c-445c-adcc-30582ae516c4"
      unitRef="usd">73100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26abd2370bc44d6289d92aa9639e48ef_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC02LTEtMS0xMDY1MDI_d87019fb-8615-4674-9dee-1334f0234d5c"
      unitRef="usd">-25500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4428b36e6474a55b570f0f6d41fc419_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC04LTEtMS0xMDY1MDI_ca51ba32-17e5-4ce5-bc9d-32fe1840805e"
      unitRef="usd">2700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic11ee4aa753b4237bb4560b38884efc9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0xMC0xLTEtMTA2NTAy_98e4f3ad-89a8-4e0a-90ef-dfa884b9c268"
      unitRef="usd">-36000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNC0xMi0xLTEtMTA2NTAy_f6582f2a-9ea7-445a-bcd7-54a2e5570156"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9e893ee39104e1b816e93ed8a47ede9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0yLTEtMS0xMDY1MDI_c1946ff7-c261-492f-a54d-717fa08ed5d6"
      unitRef="usd">-20200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia28fc04646c349038aaaf67a779b66d3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS00LTEtMS0xMDY1MDI_d99db966-3068-46b6-bc9d-3b81bf0ec6f4"
      unitRef="usd">126900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i46d16f8649274ffb8a001d8f59f22062_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS02LTEtMS0xMDY1MDI_ca4e9e04-080c-412e-993c-d40ce5de06c2"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie252dc547f144a40a6ac6f848a877b7d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS04LTEtMS0xMDY1MDI_85493d25-b564-492f-96f9-9cae4d60afb7"
      unitRef="usd">-42100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1a7eb2c1a6e246ada70e7f900be38d88_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0xMC0xLTEtMTA2NTAy_1cdaf3b5-f404-4719-ac56-136dc631796f"
      unitRef="usd">-175000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjMyZjc3MmRjYTFjNzRmMzBiYjAwZTQ3NjAwZmJkOGU3L3RhYmxlcmFuZ2U6MzJmNzcyZGNhMWM3NGYzMGJiMDBlNDc2MDBmYmQ4ZTdfNS0xMi0xLTEtMTA2NTAy_66ee0996-1c74-4b6b-b7f1-8e4dc474622a"
      unitRef="usd">-110400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTYyMA_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe2a159169d54d4286b3396de8a76082_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0yLTEtMS0xMDY1MDI_719d94a0-e6f1-4fea-9858-53461e19dcca"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia331bc87e6e54c62a0a9e2f8480cea82_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS00LTEtMS0xMDY1MDI_1e050e51-c8f3-4a3a-b72f-2ceb439d2db7"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a78abae937b4e9484720512244a264b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS02LTEtMS0xMDY1MDI_22aa954c-e0dc-4e14-9c06-eacfe2f39e7b"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4702937641c1484bb3d3617fa0ba60d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS04LTEtMS0xMDY1MDI_7a5e63ff-a646-44f3-984e-c6ee3851a599"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i85e1d4e25ace4b32b9de201f21da7db8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0xMC0xLTEtMTA2NTAy_0f6cbff5-33d2-41aa-b7ec-798f0ebb9a68"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMS0xMi0xLTEtMTA2NTAy_2ff5964c-d1c8-4a30-9eee-c20dcd1365a6"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0yLTEtMS0xMDY1MDI_3b48b6e2-9ebd-4957-8732-5c51c3b012f8"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi00LTEtMS0xMDY1MDI_f01e39be-bec9-4aa7-ade0-08ac8cc12710"
      unitRef="usd">90200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi02LTEtMS0xMDY1MDI_14296708-e538-420c-bc65-2c14e936a8b2"
      unitRef="usd">20200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi04LTEtMS0xMDY1MDI_48a472f7-bbec-427b-bf7f-5f28732717dd"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0xMC0xLTEtMTA2NTAy_a321aac7-c55c-4ceb-abdf-bda2c0973248"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMi0xMi0xLTEtMTA2NTAy_c3497782-e99c-4ab5-8588-8eaec7d7347a"
      unitRef="usd">78200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0yLTEtMS0xMDY1MDI_a74c5bc9-ee3c-4a18-ac0b-5d38ac0a63eb"
      unitRef="usd">700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy00LTEtMS0xMDY1MDI_5292e089-a4fb-4589-af66-7f0c3513af4f"
      unitRef="usd">48400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy02LTEtMS0xMDY1MDI_913c407b-9fb7-4200-81dd-ec839339c51d"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy04LTEtMS0xMDY1MDI_74362644-2539-4c95-aa16-367f5dfb5b30"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0xMC0xLTEtMTA2NTAy_0dcd96d3-4f39-4d27-b798-5a9cde8226df"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfMy0xMi0xLTEtMTA2NTAy_ba4cd243-8164-4e04-ab95-cde1bb97efd5"
      unitRef="usd">49000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i69d007d9c5464067815c8eba277e5d3c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0yLTEtMS0xMDY1MDI_cd1c67da-5b99-4824-bc06-f303a6492fee"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i90b6a5860b4345d6877fe3ef7fad8372_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC00LTEtMS0xMDY1MDI_dbd2c5bb-e753-47c8-809f-ba1d210fb785"
      unitRef="usd">138600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7a5a20750d24c9da3e5a4b21525108e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC02LTEtMS0xMDY1MDI_79a376cf-756b-48e0-87a7-7100c097a7d0"
      unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie2d401419ba14492ae5d7474901127cd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC04LTEtMS0xMDY1MDI_20129e6d-5b82-4c9a-9765-c076071a214c"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5ff5150548314d28b8fd403572ad777d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0xMC0xLTEtMTA2NTAy_3f89d32c-394b-4205-a2e3-0cb71e47bc81"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNC0xMi0xLTEtMTA2NTAy_81e02ff6-eba9-4a75-a68c-56b27b5bc800"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5920e9a8348d4b0184a94d22f70f6368_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0yLTEtMS0xMDY1MDI_cbde7d9b-7370-406c-9113-066b9b099925"
      unitRef="usd">100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i812b8492c7e14121b9c263880e2c112c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS00LTEtMS0xMDY1MDI_bf26aeae-d7ee-4d45-85f7-3e343993b12f"
      unitRef="usd">-40400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe2d434e7672451886a60cab65f8b82c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS02LTEtMS0xMDY1MDI_56348970-3d59-471f-8317-43c84f325e76"
      unitRef="usd">11600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1938ff3b65564001bf3b50000b46d67e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS04LTEtMS0xMDY1MDI_520b895b-974f-4676-91b0-143673c975d4"
      unitRef="usd">-63900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3bdeffc2747242298d5c74ba9260545b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0xMC0xLTEtMTA2NTAy_6051ac56-38b9-4c5d-8783-85ef29c282ef"
      unitRef="usd">-79200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e7eba8131b2470f979b8859ac26fa65_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjcxZTQ5NjU2NzQ0NTQ2ZTE4NzkxNWM0ZDMyOTlmZjQyL3RhYmxlcmFuZ2U6NzFlNDk2NTY3NDQ1NDZlMTg3OTE1YzRkMzI5OWZmNDJfNS0xMi0xLTEtMTA2NTAy_d215b349-1d8d-4c76-a849-a24731b83504"
      unitRef="usd">-171800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfOTM1_7fa77229-af80-476e-b69f-4affccc34ede">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy0zLTEtMS0xMDY1MDI_fa155031-3eec-4d47-b210-71ab3222e1ec"
      unitRef="usd">-800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iec879dd434784246ba9689b7523432b6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy01LTEtMS0xMDY1MDI_2d13d4da-f9a8-407a-b134-f7acd6471123"
      unitRef="usd">-400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy03LTEtMS0xMDY1MDI_1708f1a5-6960-4246-877c-2f2edac128c1"
      unitRef="usd">-1400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMy05LTEtMS0xMDY1MDI_5d594a2b-329b-46c4-9c9c-ff8b26f2a4cb"
      unitRef="usd">-900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd8dbc025139416bab59cd7e75a63895_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC0zLTEtMS0xMDY1MDI_12f6ea72-0e1f-44da-b515-29ce9901d7ba"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iec879dd434784246ba9689b7523432b6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC01LTEtMS0xMDY1MDI_16988caf-2f9e-4362-9684-964d3ccc4ee8"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i11bea6e61a654994914f1f7787b7afc2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC03LTEtMS0xMDY1MDI_d2ed686b-fe0f-4cd9-b80a-ab18a54aa439"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie86b4ebba6ae44d4b0f0b1094644b687_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNC05LTEtMS0xMDY1MDI_8863b78d-032a-41a4-894c-11aa4c4eaede"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi0zLTEtMS0xMDY1MDI_a1a5ce60-fb32-4002-a414-4bce997191eb"
      unitRef="usd">44600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi01LTEtMS0xMDY1MDI_f5139ea9-f27e-466e-a947-84f3a26eb9b4"
      unitRef="usd">-30700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi03LTEtMS0xMDY1MDI_5c994de6-03f0-4f51-9c5b-f87b0f2b4cdd"
      unitRef="usd">65500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNi05LTEtMS0xMDY1MDI_c3049800-f665-4b77-8f6f-34e6f35ecbf0"
      unitRef="usd">-53800000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy0zLTEtMS0xMDY1MDI_89fbf79b-336f-4a47-a9d4-b54ae57c025a"
      unitRef="usd">2400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy01LTEtMS0xMDY1MDI_061dda8e-350f-4197-b3ac-45964e328074"
      unitRef="usd">-400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy03LTEtMS0xMDY1MDI_c96dfb9d-2796-4a7a-8f0a-dd26c94f4a6a"
      unitRef="usd">2700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfNy05LTEtMS0xMDY1MDI_cb85c491-6f33-4ca5-a12c-c6242cf9f777"
      unitRef="usd">0</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC0zLTEtMS0xMDY1MDI_28c0d4f8-265d-44ef-9b7f-69cf8e3d9545"
      unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC01LTEtMS0xMDY1MDI_f146a503-7852-41bb-8fbf-b6adea96c560"
      unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC03LTEtMS0xMDY1MDI_ffd95543-940c-4154-8601-d1f01c01c6bf"
      unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOC05LTEtMS0xMDY1MDI_7b453b71-4619-4749-8f08-3a382bf28ed2"
      unitRef="usd">100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i54c4a485301442d1ae31b1b5999b04bb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS0zLTEtMS0xMDY1MDI_598a822b-ba34-4027-a98c-2920d6e2e229"
      unitRef="usd">-4200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iced58bff08fe424fb838818157ecd374_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS01LTEtMS0xMDY1MDI_36dd36a5-f710-4fc5-91b8-f2cfc85e3bbd"
      unitRef="usd">3000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i40c03edd960148f9b745ffdccc70b495_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS03LTEtMS0xMDY1MDI_b6d8359f-1035-4e15-99af-efa2b67ad371"
      unitRef="usd">-6200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id8359480c83b4b2486fe1bf4c83927bc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfOS05LTEtMS0xMDY1MDI_6bb1a572-6680-4ddd-a202-c4c7fe944e99"
      unitRef="usd">5300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4f7ab9eec76f415b9754dece93693c29_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtMy0xLTEtMTA2NTAy_827372ab-34d8-47b8-b2dc-b668e9aea209"
      unitRef="usd">39200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia3b10142df3b467e8bdcbcc59ff9e2e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtNS0xLTEtMTA2NTAy_325d4433-c3e3-4dba-aa86-50f6cc0aa60f"
      unitRef="usd">100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0e16fe28452c4b27a1b2a84884bb91f2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtNy0xLTEtMTA2NTAy_8dc99271-f218-4a11-9fa5-79d30a81c5ec"
      unitRef="usd">38100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i34aa5eb01fc941468970bfd540a717af_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTEtOS0xLTEtMTA2NTAy_b48c93fe-342e-45fc-b2d3-390b4caaf7c8"
      unitRef="usd">100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i45d9e723dce441e9bca32cefeba7912d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtMy0xLTEtMTMwMzU5_c2a0fa9a-59c9-499b-83be-150c8626cf91"
      unitRef="usd">-58900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icef3a7fd90234f2892d851bd89cb2861_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNS0xLTEtMTMwMzU5_0faadffc-1c79-4682-a9a4-9f85cb8305ad"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ifdd50768ee6b486a869faf383cfec503_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNy0xLTEtMTMwMzU5_445a0e19-8baf-4a3d-9174-3fe4978fccf5"
      unitRef="usd">-58900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i03c42c98806743678d857956f14b201c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtOS0xLTEtMTMwMzU5_89031eab-9aa9-456b-aff8-5d53eb52f121"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="i05576bec60da463ba40fa81a1d5d6213_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtMy0xLTEtMTA2NTAy_996d9d2a-bb21-49e7-b77a-37e150bed05f"
      unitRef="usd">17600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic49a0c322d4a4fa6ad316e2dbcd57859_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNS0xLTEtMTA2NTAy_09deaa87-de3f-4187-afde-f74ccaba47e1"
      unitRef="usd">-27600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i769f963dcd104808b7f557b5bcf509fc_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtNy0xLTEtMTA2NTAy_8a1ac859-6c52-4d09-941f-c953cc9abc4d"
      unitRef="usd">34500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia82614881b654024a0f966982a2e1643_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RhYmxlOjdhNmJhYWYzYTI5NDQzM2Q4M2U1NjI3NGFiMzVjMDgwL3RhYmxlcmFuZ2U6N2E2YmFhZjNhMjk0NDMzZDgzZTU2Mjc0YWIzNWMwODBfMTQtOS0xLTEtMTA2NTAy_971c41ba-6da5-435f-b9f2-561df97cc397"
      unitRef="usd">-49000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV85Ny9mcmFnOmY5NDE5NGVhOTFhMTRjN2Q4N2MyM2EwZTJlZjc1MTk3L3RleHRyZWdpb246Zjk0MTk0ZWE5MWExNGM3ZDg3YzIzYTBlMmVmNzUxOTdfMTA5OTUxMTYyOTY1Nw_eaf44043-7fb2-43b6-994d-a1e086faa999"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90ZXh0cmVnaW9uOmJlYjI0MGE1YjU5MjQ2MTJiZDQxNzE5ODZlNzg3ODliXzI1Nw_7401577e-0e5b-4f73-9236-2ff344fb19cc">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90ZXh0cmVnaW9uOmJlYjI0MGE1YjU5MjQ2MTJiZDQxNzE5ODZlNzg3ODliXzI2MA_06aa1a9f-20f3-4c47-a688-f8b56ec94a6d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtMi0xLTEtMTA2NTAy_b3be894f-a7b7-48ed-a34b-f102f30dff42"
      unitRef="usd">1058000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtNC0xLTEtMTA2NTAy_2538cd3a-a0e7-458f-be42-dd5658430d4e"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtNi0xLTEtMTA2NTAy_3af3ad3f-9e7b-4b3c-972a-774ab66520b6"
      unitRef="usd">1361800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzMtOC0xLTEtMTA2NTAy_b7d407b8-4693-4113-8b18-bfb5dd7a375d"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtMi0xLTEtMTA2NTAy_4836b745-ca16-4de6-a091-6322a630e82f"
      unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtNC0xLTEtMTA2NTAy_66711d85-b677-45a7-a479-acc990f19fe7"
      unitRef="shares">149700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtNi0xLTEtMTA2NTAy_46cb6ef0-29ea-4e38-bd62-5199149f5618"
      unitRef="shares">146500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzUtOC0xLTEtMTA2NTAy_50d7827b-6d6a-47d8-9747-8972779830f0"
      unitRef="shares">150800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i064f6c79792847f38bbef18be71b042b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtMi0xLTEtMTA2NTAy_e1f8d085-2841-4548-9405-20c37f2d86c6"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i935112ef58c34d998257dbf55b14da22_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtNC0xLTEtMTA2NTAy_241c4aa5-aa3d-40ad-85fb-4497dda0bd8e"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibe1fbb5461ad43bea5769749d280c2c6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtNi0xLTEtMTA2NTAy_ccb758bb-d102-45cc-8a87-4d6ae21b5953"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i59078147fa6f488c8239e033a6fdf63a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzgtOC0xLTEtMTA2NTAy_0a0f1b8b-7dd4-47a5-8aec-348e911e1f37"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ied9be70de8b546c1876a1ef6efccb2b6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktMi0xLTEtMTA2NTAy_1999998f-5805-4741-8c42-bff9b58c332f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9ca4330df54e4589a400fd134a2fa6be_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktNC0xLTEtMTA2NTAy_55cd46b2-e3a0-48fd-aeac-c3d17dd2a7bd"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i430d8a3876b04d60b0a0e1af9b6f9375_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktNi0xLTEtMTA2NTAy_8367351e-11d9-4eb5-8386-f8b22de25309"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iee4c31bfbdd74c94810389e9eb943e18_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzktOC0xLTEtMTA2NTAy_4e7a12db-c9d3-4ed8-91c4-afd59c5bcede"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0e723dda18e341ab87f7edde733b2a16_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTItMS0xLTEwNjUwMg_bdaf5fae-f3c3-4e5b-bbc0-d8b96e09392b"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ieaaccf079a49488eb79a43457781b779_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTQtMS0xLTEwNjUwMg_7e231cb1-e62d-4bec-a685-15b2e5b0cd06"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i404f8659b4894301b106514d8921df0f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTYtMS0xLTEwNjUwMg_12281334-f68f-4561-844e-95b0f9586425"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i726ad69e44e74f18812d926508d81057_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEwLTgtMS0xLTEwNjUwMg_f4eddc93-f748-480d-af77-6d37ae651cd7"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTItMS0xLTEwNjUwMg_37b53ba1-529a-437b-a2b8-28f755f80ac6"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTQtMS0xLTEwNjUwMg_1a30c7f0-3d14-4b1a-b17a-a9370e3083ea"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTYtMS0xLTEwNjUwMg_68cfd099-1cc3-42a7-93b7-62600a4ca670"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzExLTgtMS0xLTEwNjUwMg_5359cb84-dd35-4a91-8952-c43a2b30f973"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTItMS0xLTEwNjUwMg_96b74e01-eede-4660-988a-54c7b147831d"
      unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTQtMS0xLTEwNjUwMg_6553bf5f-c5e3-4897-ab5d-34fb53dc2805"
      unitRef="shares">150100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTYtMS0xLTEzMTk0Mw_6043c306-5bbc-40a0-88a0-b71b7c215fe1"
      unitRef="shares">146800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDAvZnJhZzpiZWIyNDBhNWI1OTI0NjEyYmQ0MTcxOTg2ZTc4Nzg5Yi90YWJsZTpkMTBmYWNmZmY1NWU0YmVmYWZiMDRlYjI0NjEyYjc1OS90YWJsZXJhbmdlOmQxMGZhY2ZmZjU1ZTRiZWZhZmIwNGViMjQ2MTJiNzU5XzEyLTgtMS0xLTEzMTk0Mw_7ede2052-eca2-4e12-ba68-ffa7f59e8324"
      unitRef="shares">151200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY3Mg_63682b08-9fc2-45f8-b500-55f6603e8101">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY1MQ_20af3933-fcef-4757-bf41-8267ee992055">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib613e85a78bc4456893a2ad6a58b3db5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItMi0xLTEtMTA2NTAy_41ec3d5e-f69c-466a-bc43-72877d059843"
      unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38c01771898e4c6a8325194d609c2081_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItNC0xLTEtMTA2NTAy_0f34cc4f-8dbc-46da-8a4b-188d7c6d9138"
      unitRef="usd">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58ac757a014e4f9d8ee4cc1b9b4d3350_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItNi0xLTEtMTA2NTAy_da72a1d0-a373-4a9c-9d3d-e0b3aee333f7"
      unitRef="usd">48100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b7dc5fd89d04e4c8378db999b2eda6e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzItOC0xLTEtMTA2NTAy_63a1849e-4174-4c82-9beb-f67948135131"
      unitRef="usd">52700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0768cf5b82344dfeb26a9db8c6655c34_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtMi0xLTEtMTA2NTAy_e7400d60-d90a-49e2-b45a-5cd3af67e43b"
      unitRef="usd">36700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie432e10abc0b47dd9185ef700519fae8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtNC0xLTEtMTA2NTAy_789bfa85-b8de-4c3a-a979-8d3e4fb9279a"
      unitRef="usd">40300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3eccf41bcd3b4ecba3d2a095e0239516_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtNi0xLTEtMTA2NTAy_19f87180-ae59-4a37-8966-c66c5edb12e7"
      unitRef="usd">82800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4da564986d004bf6bbea566000fdb4f4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzMtOC0xLTEtMTA2NTAy_8c7eb7b6-ef0b-4b94-b31f-be92017c0b86"
      unitRef="usd">85200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtMi0xLTEtMTA2NTAy_ee317d42-1577-42fe-8a49-3830058b571f"
      unitRef="usd">59100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtNC0xLTEtMTA2NTAy_f9fc723f-1ae6-4f7f-83ac-1ea4e68cb423"
      unitRef="usd">59400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtNi0xLTEtMTA2NTAy_23bb314d-c353-4697-a1f4-51588120b04a"
      unitRef="usd">130900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzUtOC0xLTEtMTA2NTAy_b18455b1-f98f-4e54-876b-4c1cb9a6e7c3"
      unitRef="usd">137900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtMi0xLTEtMTA2NTAy_866e7714-8f80-4ec1-81ed-134de95a753d"
      unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtNC0xLTEtMTA2NTAy_b037d017-f6fa-4596-a6ac-d25ebc4e5cc2"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtNi0xLTEtMTA2NTAy_2e0aadc7-5613-4036-9102-a88572558357"
      unitRef="usd">5100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzYtOC0xLTEtMTA2NTAy_88523a2d-f709-439a-96e0-397e04279af5"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctMi0xLTEtMTA2NTAy_e8816dd5-f14c-49e3-a4f4-d66bfb8aa3ec"
      unitRef="usd">56800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctNC0xLTEtMTA2NTAy_56764f58-7cee-403e-818b-781017c096a6"
      unitRef="usd">57700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctNi0xLTEtMTA2NTAy_af5183e8-95f2-408e-8c38-89ad291330ac"
      unitRef="usd">125800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzctOC0xLTEtMTA2NTAy_3fa0820f-9acb-47ec-b42c-9edb9ab24cdb"
      unitRef="usd">133600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtMi0xLTEtMTA2NTAy_5141fa87-3164-47c3-a4a6-447298f115df"
      unitRef="usd">10200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtNC0xLTEtMTA2NTAy_a40f8428-5905-4569-8f7d-0cc590ca3a47"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtNi0xLTEtMTA2NTAy_1a77349b-38a7-4107-9c05-76d6012c98a6"
      unitRef="usd">23000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzgtOC0xLTEtMTA2NTAy_504fb566-7d88-40a8-81dc-02ce2ec803c5"
      unitRef="usd">24900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34df8b39629d46e3a1d76df662efe1ac_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktMi0xLTEtMTA2NTAy_a3fee7a6-fab9-42a1-b4f9-37d81bbdc182"
      unitRef="usd">46600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4242bcb1bf68441e915043a252b28f3e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktNC0xLTEtMTA2NTAy_3fc9624d-b180-4f0a-a4f3-142f0fdc8d39"
      unitRef="usd">46800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37c11788c3f940898950aac7349449bc_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktNi0xLTEtMTA2NTAy_f7c023d9-1cf8-4172-8412-2e6908073639"
      unitRef="usd">102800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2087847394724417ae5cd7671bef7634_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTo0NGNjOWI2ZmM2ZTE0YzNkYTg5ZDU5NDM1OTYwMDMzZC90YWJsZXJhbmdlOjQ0Y2M5YjZmYzZlMTRjM2RhODlkNTk0MzU5NjAwMzNkXzktOC0xLTEtMTA2NTAy_842b09cd-79a4-4aab-bb29-c30481a771d9"
      unitRef="usd">108700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90ZXh0cmVnaW9uOjk5ZmZhMGE5ZmQwNDRiNzI4Y2M3NzI0YjE5NmI5NmE3XzY2MA_97e45962-e064-4d71-a552-80a1a70164be">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06e3f4c497b04721b2a471a9d1462e90_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItMi0xLTEtMTA2NTAy_1a263b83-1f5c-4efb-8e04-6fa96947c329"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11e6a4109ed149448f4eb38f7f7a6fe0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItNC0xLTEtMTA2NTAy_17de2dac-611b-44e8-ab17-34235df359fc"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd85c59952834082adcd0bda1c3bc397_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItNi0xLTEtMTA2NTAy_8850d4bb-ab53-4164-b6e5-8feabfe16118"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c78200de99d4a8992ff379211c1b05c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzItOC0xLTEtMTA2NTAy_7ff78f80-aa5d-4082-b395-3f44767384e1"
      unitRef="usd">25800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i598d5781ec294abb97c2fd87cab72371_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtMi0xLTEtMTA2NTAy_1c2d3a13-947c-47bf-b7d7-a271e615483e"
      unitRef="usd">50400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb25232bfbb143b2a5469052ea1aacbb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtNC0xLTEtMTA2NTAy_c575c606-c693-4440-b355-5dabad11e34b"
      unitRef="usd">40400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i070778a5f6bf479290bc275c09f5d25d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtNi0xLTEtMTA2NTAy_fd8cd2bc-e992-437c-81d2-007712090aa3"
      unitRef="usd">101700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0c2f4968e7d449bbcdba9e0686e5349_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzMtOC0xLTEtMTA2NTAy_8506aadc-4cb0-4c9d-94c9-48d066e1fba1"
      unitRef="usd">83200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc4229db4a3b479c9d2a9fb092797c6f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtMi0xLTEtMTA2NTAy_a0debd36-d311-4085-8181-b0f3d3a9630a"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4787bd92caad430eade94b63652c8eae_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtNC0xLTEtMTA2NTAy_da7a52d5-b22f-4b1b-8c1b-c8459409846c"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0f165e7c3e24de78375b532ed70ebc6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtNi0xLTEtMTA2NTAy_3492ec41-4516-45ca-9d22-5e8d394556a7"
      unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id383c4b3624c4a3084db5066645c15a6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzYtOC0xLTEtMTA2NTAy_f1d71ea7-27dd-4ce6-b880-a02fc447a224"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida0b80c4d4a24c59870003ff1526e308_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctMi0xLTEtMTA2NTAy_4fc5969c-3970-42de-94ab-95689ca239b7"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03333ee45c754e49b0aae5e5249ab285_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctNC0xLTEtMTA2NTAy_1c39114d-9718-4492-9bf5-0e3112c3dd5b"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d41849f5c049ef858c1b655ecdb83d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctNi0xLTEtMTA2NTAy_d79d527e-f37f-4ebd-a282-ed07db777c7e"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1703619476c5469fb6eae667c889633f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzctOC0xLTEtMTA2NTAy_721bb479-18ae-4261-b451-5b13dd6ec851"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd736af6b0704581966ceb888e962dc1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtMi0xLTEtMTA2NTAy_0c9eb837-7ee7-45c8-8785-ab23130a184f"
      unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iafdb9d7e53324279ba0597cb20081464_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtNC0xLTEtMTA2NTAy_ccbfdb25-1ae4-41e7-b51c-51ebb073ff12"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0af51832291c4232b19c5319e421ca32_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtNi0xLTEtMTA2NTAy_79893ee5-b253-415f-8498-ccb1048c021f"
      unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07e91b63836f40969d01256870c0e4e2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzgtOC0xLTEtMTA2NTAy_e98b8c56-45b3-4c63-84a0-de0622915d36"
      unitRef="usd">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTItMS0xLTEwNjUwMg_e009a248-e780-4ae4-bbf9-b7473a524bfa"
      unitRef="usd">59100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTQtMS0xLTEwNjUwMg_330da492-15c6-4813-b042-9eb3737c12b4"
      unitRef="usd">59400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTYtMS0xLTEwNjUwMg_0eb4d94e-478f-41b4-8a14-7470b33148a6"
      unitRef="usd">130900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEwLTgtMS0xLTEwNjUwMg_25ff75a4-f0f3-46f8-ae67-3d7e3fce67ff"
      unitRef="usd">137900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTItMS0xLTEwNjUwMg_7105d0a2-43e6-4e95-8f5d-4701a83af1ab"
      unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTQtMS0xLTEwNjUwMg_0e7c8b28-fa12-4b35-8a3b-9ae23e12a264"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTYtMS0xLTEwNjUwMg_036653d3-5bb9-46c4-9287-565d855c6979"
      unitRef="usd">5100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzExLTgtMS0xLTEwNjUwMg_7f0c381a-8646-407e-b6e2-896089987e77"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTItMS0xLTEwNjUwMg_52aac256-f6fa-45fe-a034-5184ec2bf915"
      unitRef="usd">56800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTQtMS0xLTEwNjUwMg_d04fd73b-b820-4216-a4cc-ecaa60c3dbd8"
      unitRef="usd">57700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTYtMS0xLTEwNjUwMg_ae741ab0-6123-4b23-8d63-3d5513d27d5d"
      unitRef="usd">125800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDMvZnJhZzo5OWZmYTBhOWZkMDQ0YjcyOGNjNzcyNGIxOTZiOTZhNy90YWJsZTpkMWU1NTRhMDNhNTI0NTEwYjQ1NGI1MjQ4MGE5ZDUxMy90YWJsZXJhbmdlOmQxZTU1NGEwM2E1MjQ1MTBiNDU0YjUyNDgwYTlkNTEzXzEyLTgtMS0xLTEwNjUwMg_1646892b-b25f-4a9b-b0a4-adb9fa300d92"
      unitRef="usd">133600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzM0NjI_cd670749-0cac-4cad-ae9c-1b0cceac8d9d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2022, compared to the same periods in 2021, the increases in our effective tax rate were primarily due to the overall current year unfavorable tax rate impact on the sale of our equity interest in Samsung Bioepis in April 2022, the litigation agreement in principle and the tax benefit recorded in the second quarter of 2021 related to the Neurimmune SubOne AG (Neurimmune) deferred tax asset matter, as discussed below. These effective tax rate increases were partially offset by the non-cash tax effects of changes in the value of our equity instruments and the current year tax benefits recorded in the second quarter of 2022 related to an international reorganization to align with global tax developments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022, compared with the same period in 2021, our effective tax rate also increased as a result of the Neurimmune valuation allowance recorded in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For additional information on the litigation agreement in principle, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 19, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For additional information on our collaboration arrangement with Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 18, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $500.0&#160;million, including approximately $455.0&#160;million related to the unrecognized&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit&lt;/span&gt;&lt;/div&gt;closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzM0ODA_7a5c8fca-2e6a-4231-a38d-04f745a11fa0">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItMS0xLTEtMTA2NTAy_fcb7ce6c-6cda-4138-962f-05a27f774429"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItMy0xLTEtMTA2NTAy_112f522e-e79c-4dd6-a011-0d9ee3a9e369"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItNS0xLTEtMTA2NTAy_3007ce72-e1ce-41dc-ac72-0b3af18bca81"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzItNy0xLTEtMTA2NTAy_3e1afdad-0ab4-41dc-992b-7f9290cdd280"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtMS0xLTEtMTA2NTAy_505328ce-83c3-4c24-95bd-fac9fc7c81e7"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtMy0xLTEtMTA2NTAy_2971f69e-b41a-4903-80ab-d22836386b65"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtNS0xLTEtMTA2NTAy_155b84ae-2c86-4e9c-a27e-aa84fb351888"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzMtNy0xLTEtMTA2NTAy_b58324c7-b8f9-4772-b716-cd6a9a20742a"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtMS0xLTEtMTA2NTAy_ded297de-8f47-470f-8da0-bbe315bdede5"
      unitRef="number">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtMy0xLTEtMTA2NTAy_bb1497ae-4ed0-43a3-8d85-7bd52c116841"
      unitRef="number">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtNS0xLTEtMTA2NTAy_46fe4893-993c-4772-b068-00b735ac9b6f"
      unitRef="number">-0.053</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzQtNy0xLTEtMTA2NTAy_2431fcc2-3aee-4258-af23-7c08613075d4"
      unitRef="number">-0.091</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtMS0xLTEtMTA2NTAy_0414cd74-5d48-404b-8757-7069127c326c"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtMy0xLTEtMTA2NTAy_cf933cdf-e7a4-48fd-85ae-df0afce88112"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtNS0xLTEtMTA2NTAy_65b08941-49d7-464a-a0e4-bdd51f0cfa6a"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzUtNy0xLTEtMTA2NTAy_1350e55d-e8e3-48aa-985e-44deca9e05bf"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtMS0xLTEtMTA2NTAy_eeaf48b1-1a5a-4c20-8304-dea9786ba5bc"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtMy0xLTEtMTA2NTAy_8959143a-7239-4731-82b4-a1d55707c1dd"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtNS0xLTEtMTA2NTAy_da2fd11c-6d2f-4d55-8f02-b2d4f85ccf83"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzYtNy0xLTEtMTA2NTAy_8bfe5e59-e4b1-4edf-ad05-e2d3fb2d0c3c"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTEtMS0xLTEwNjUwMg_cc279179-e761-4cb9-a063-86a2c24d7a2b"
      unitRef="number">0.002</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTMtMS0xLTEwNjUwMg_30a5b520-9c3e-48be-97c1-195567ca7db4"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTUtMS0xLTEwNjUwMg_47d8fd67-a60a-4555-beeb-cf2ee4677c71"
      unitRef="number">0.002</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzEwLTctMS0xLTEwNjUwMg_b684a998-864b-4e88-8f1d-6af4ebc70eb9"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTEtMS0xLTEyOTgxMg_49ea5514-6d04-4119-b75a-9fc7b5eeb39a"
      unitRef="number">-0.037</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTMtMS0xLTEyOTgxMg_c0c7d1ed-074c-4f03-8be7-5234c688176d"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTUtMS0xLTEyOTgxMg_7dbc1aee-3a51-486e-99a6-359eccac5e25"
      unitRef="number">-0.029</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTctMS0xLTEyOTgxMg_22b3ad6c-3d52-43e6-8cdf-2d7de2afb37d"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEzMjE4MA_d92ae294-e060-4a18-81ce-c3a79b07e7aa"
      unitRef="number">0.085</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEzMjE4MA_b7ce85fb-2750-4c21-8104-0c0ef5248dd7"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEzMjE4MA_a634b4e5-db62-4da2-b1cc-f36c94b1cbc3"
      unitRef="number">0.067</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEzMjE4MA_f1c9dfb7-ed51-4bcd-87ad-f66997f184f9"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTEtMS0xLTEzMjE4Nw_e323011d-1882-4c0c-ac95-e2bf5638be20"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTMtMS0xLTEzMjE4Nw_621bc553-6b2c-4a41-85b7-7bc82f7ab64b"
      unitRef="number">-0.831</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTUtMS0xLTEzMjE4Nw_6ca43db8-5788-4e61-9dcb-1eb814c802c9"
      unitRef="number">0.052</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE3LTctMS0xLTEzMjE4Nw_aceb8d9c-d724-4532-b9e2-3414754e8a81"
      unitRef="number">-0.463</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEyOTgxMg_5f1a095d-b04f-4018-ad57-3cd3d6623462"
      unitRef="number">-0.040</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEyOTgxMg_a8073e83-2f7e-4a4a-be77-8f368070082b"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEyOTgxMg_df509a9a-b04b-446c-bcbf-e5bafb6cf9a7"
      unitRef="number">-0.031</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEyOTgxMg_874e8e6a-dac3-4738-a72e-4aea5ffdf47f"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTEtMS0xLTEwNjUwMg_ff0fd7a8-7b78-4cbf-9397-e5de4e06970a"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTMtMS0xLTEwNjUwMg_3ed7d2ca-afcb-4f99-9bb7-21a453791a33"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTUtMS0xLTEwNjUwMg_8a7bbeae-3c1c-463c-9661-67d60af54204"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE1LTctMS0xLTEwNjUwMg_af60b237-edbc-4972-9ad0-c77a0af59cfc"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTEtMS0xLTEwNjUwMg_e0266d25-612e-4b6d-85ee-4b8832ec5272"
      unitRef="number">0.171</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTMtMS0xLTEwNjUwMg_f78895c3-6524-43aa-b077-3e7a6a30eec4"
      unitRef="number">-0.703</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTUtMS0xLTEwNjUwMg_5c2dac61-8998-4b34-a9d1-4d83ed6bc0b4"
      unitRef="number">0.212</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90YWJsZTo5ZjdiNzM0Yzg4MDc0MzE4ODk5ZGQ1MDE2ODRlYTRhYS90YWJsZXJhbmdlOjlmN2I3MzRjODgwNzQzMTg4OTlkZDUwMTY4NGVhNGFhXzE2LTctMS0xLTEwNjUwMg_74ae0d4c-fab9-4fe5-9810-e64ff67921f9"
      unitRef="number">-0.348</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzI4NDE_6fd45d02-6f14-4d18-b610-ae68ba08b2d1"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzI4NDE_a84899e0-f424-46c4-8ade-0eea1fc0865f"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzMxMjI_cb9a9ccd-20df-4848-92e0-6d688659b783"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzEwOTk1MTE2MzMyNzU_7277a262-d932-4818-baf9-b1f319851af2"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i7cc7449e1d4248ee94e3a7a6a2b8c0e6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzI3NDg3NzkwNzgzNjU_5d9de7a4-66b8-458f-b9c7-dcc708f43675"
      unitRef="usd">500000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i4fc0bc45a8f34476bd5ce77c28c035ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMDYvZnJhZzo5OGEwNDg1MTYzYmY0MGU5YmM2N2RjYzRiNDQxMmE2YS90ZXh0cmVnaW9uOjk4YTA0ODUxNjNiZjQwZTliYzY3ZGNjNGI0NDEyYTZhXzI3NDg3NzkwNzgzODE_afe2f8ff-637f-45b7-b6b8-e5a3dc79a49a"
      unitRef="usd">455000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMTQ_c210e3f0-c801-4e94-b80b-057d4f63f551">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(428.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended June 30, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; For additional information on the litigation agreement in principle, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 19, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gains (losses) on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(267.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses) recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(267.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(288.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo and Denali common stock of approximately $75.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,298.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation agreement in principle, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,167.8 million and $1,320.5 million as of June 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $499.6 million and $664.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMjQ_d5f00e1d-b10f-45e9-b794-79301612c5f0">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(428.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItMi0xLTEtMTI2MDI1_7523f6ad-2bf8-40e2-a449-299bde8975f4"
      unitRef="usd">1505400000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNC0xLTEtMTI2MDI1_d1a14689-4779-4340-92bf-583e20ee93b0"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNi0xLTEtMTI2MDI1_efaf9d73-d1a8-495f-a320-ce37702ef9bc"
      unitRef="usd">1505400000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItOC0xLTEtMTI2MDI1_a7e19e02-61eb-4ea4-b88f-f99d59933c5b"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:LitigationSettlementExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtMi0xLTEtMTMwNjY0_7d7d458b-130b-4066-8e53-ad40f24e427f"
      unitRef="usd">900000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNC0xLTEtMTMwNjY0_ed0f362e-7380-47f8-bf32-a282e5f6e8bb"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNi0xLTEtMTMwNjY0_91960898-ba14-40be-b48c-0cb7d21b9021"
      unitRef="usd">900000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtOC0xLTEtMTMwNjY0_9af5c264-1990-4219-bd89-a78c5bb3899e"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItMi0xLTEtMTA2NTAy_43ec6b53-06bc-4ba3-afc2-3e7be4412932"
      unitRef="usd">12600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNC0xLTEtMTA2NTAy_52924097-b632-45a5-9b4a-23493fff59b5"
      unitRef="usd">2700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItNi0xLTEtMTA2NTAy_4c137482-dcdc-4e7f-bce0-1d04bb153959"
      unitRef="usd">15500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzItOC0xLTEtMTA2NTAy_4bdec16a-53b1-4cdf-a901-ee2200176a3a"
      unitRef="usd">5600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtMi0xLTEtMTA2NTAy_6160115e-cb46-4e2f-8dfd-71f7ba5d3706"
      unitRef="usd">65800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNC0xLTEtMTA2NTAy_a793421c-7ce3-4bb3-b879-f22d6fd441d4"
      unitRef="usd">56400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtNi0xLTEtMTA2NTAy_35af5c26-07fe-4732-b73e-9df16e9bd6ba"
      unitRef="usd">131900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzMtOC0xLTEtMTA2NTAy_63de7274-f9c8-49c6-b8d7-afba9a8e0ed8"
      unitRef="usd">121100000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtMi0xLTEtMTA2NTAy_e48fc09c-7c76-4881-ba35-87a2b7d60293"
      unitRef="usd">-78200000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtNC0xLTEtMTA2NTAy_d94fd433-2a13-4150-9ec1-d755a9059d9b"
      unitRef="usd">153900000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtNi0xLTEtMTA2NTAy_c4e0744e-b605-4371-8f20-ddaeffb7628a"
      unitRef="usd">-269300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzQtOC0xLTEtMTA2NTAy_0bf7fe1f-f747-48dd-816c-0c57457a9950"
      unitRef="usd">-282700000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtMi0xLTEtMTA2NTAy_594cf521-50dc-4cad-b488-32758afa37f9"
      unitRef="usd">-19200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtNC0xLTEtMTA2NTAy_76ab5b01-bdb6-4cd1-86ef-c76bb333369f"
      unitRef="usd">-800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtNi0xLTEtMTA2NTAy_1b6797a0-9ee9-44e5-bc65-d0fc54c19f8c"
      unitRef="usd">-27500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzUtOC0xLTEtMTA2NTAy_a3242632-daeb-4c07-8241-0eaf21de38ba"
      unitRef="usd">-9400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtMi0xLTEtMTA2NTAy_4455ae72-2353-4cc3-9e78-d8432744b736"
      unitRef="usd">-26200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtNC0xLTEtMTA2NTAy_86ce69f3-34ec-4ff7-9bb8-81530177f098"
      unitRef="usd">-3000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtNi0xLTEtMTA2NTAy_9b88a622-37d5-4de0-84dd-a0ddd3ca1cce"
      unitRef="usd">-26900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzYtOC0xLTEtMTA2NTAy_2b7bc2ca-b0bd-4889-84e7-e0205695a715"
      unitRef="usd">-2900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctMi0xLTEtMTA2NTAy_141d4691-1525-4230-927b-4b81d509c6bf"
      unitRef="usd">428600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctNC0xLTEtMTA2NTAy_1a860420-8c19-4170-af57-6d1de80c4974"
      unitRef="usd">96400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctNi0xLTEtMTA2NTAy_fb02f824-01a3-4d19-bc3d-58ef268f8e81"
      unitRef="usd">165300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpmYjBlYTc5Mjc0MGQ0MzhhYjk0ODRmYWZiZTczZTM5Ny90YWJsZXJhbmdlOmZiMGVhNzkyNzQwZDQzOGFiOTQ4NGZhZmJlNzNlMzk3XzctOC0xLTEtMTA2NTAy_a8bf830c-7292-4b6a-95ea-08eb99f4fa33"
      unitRef="usd">-410500000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwOTk1MTE2MzExNjY_c9e0aefc-ddcd-4bbb-b940-e655b42de12c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LitigationSettlementExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzQ5NDc4MDIzMzE2NTc_15907a59-f314-4dfc-a134-f09ea70172bd"
      unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMDY_f6bc6ea4-f611-4cf4-9927-3e1a20974aa4">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gains (losses) on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(267.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses) recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(267.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(288.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Sangamo and Denali common stock of approximately $75.3&#160;million.&lt;/span&gt;&lt;/div&gt;The net unrealized losses recognized during the six months ended June 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali, Sangamo and Sage common stock of approximately $277.1&#160;million.</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItMi0xLTEtMTA2NTAy_706bda13-8a41-45a8-b265-cd883096dfc5"
      unitRef="usd">-77200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItNC0xLTEtMTA2NTAy_e41ee933-09ef-4dbb-b694-37bb6e5b9bd4"
      unitRef="usd">154300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItNi0xLTEtMTA2NTAy_1822e4d8-5b22-4a93-b91c-913f4eb8b702"
      unitRef="usd">-267900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzItOC0xLTEtMTA2NTAy_6f07b58b-a605-4eda-8d1f-0d6efc46bd84"
      unitRef="usd">-281800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtMi0xLTEtMTA2NTAy_a5847d77-03c9-44dd-8a26-4d8322c7f0fd"
      unitRef="usd">-700000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtNC0xLTEtMTA2NTAy_1b7c5b8c-65b6-49eb-b67d-e62dc0c224c9"
      unitRef="usd">400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtNi0xLTEtMTA2NTAy_e6bb6df5-e91f-4505-85b3-bc94ff2465bf"
      unitRef="usd">-500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzMtOC0xLTEtMTA2NTAy_279256bb-5b77-484a-a9cc-1e407a609db9"
      unitRef="usd">6600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtMi0xLTEtMTA2NTAy_fc3c95e9-3ecb-4a15-a82b-4c0e1263393b"
      unitRef="usd">-76500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if2cfdfa3aed44d7f889c00cd4b19d8e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtNC0xLTEtMTA2NTAy_b7f12ddf-95c5-4752-b98a-f561554c5331"
      unitRef="usd">153900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtNi0xLTEtMTA2NTAy_dc0d088a-3ba8-4460-a626-3904ac8156a4"
      unitRef="usd">-267400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i61c808ce7a9d4767a7b186aeb890902f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTo0MDg3MjExZDlmZGI0ZWVmYjVhMjY4NmYxZGE2MzgyOC90YWJsZXJhbmdlOjQwODcyMTFkOWZkYjRlZWZiNWEyNjg2ZjFkYTYzODI4XzQtOC0xLTEtMTA2NTAy_8942610c-bcaf-46b3-b92a-f910e3fe59cc"
      unitRef="usd">-288400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i78027a673ba84f59a729646c29056ff0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwOTk1MTE2MzA1MzM_a047a02e-7418-4ae6-b618-021e485e00b3"
      unitRef="usd">75300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzEwMzE_ca31d9b6-a289-40e4-9d6e-1e5fab6cacbe">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation agreement in principle&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;846.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,298.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to an agreement in principle to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation agreement in principle, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtMi0xLTEtMTMxNjkx_b8deddd2-0f59-47c5-8dfe-9c1131ea643e"
      unitRef="usd">900000000.0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtNC0xLTEtMTMxNjkx_6f4c4e1e-9d94-4489-b3f0-824672ed828b"
      unitRef="usd">0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i33934bee3c5143dd99f1d517165ead05_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtMi0xLTEtMTA2NTAy_f14d0131-235c-477a-923a-60d65bf9f482"
      unitRef="usd">846000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if642314400ad46ce8997912ff65d7344_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzEtNC0xLTEtMTA2NTAy_8f8b8e2d-3445-4598-8136-4b45a2eff63e"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzItMi0xLTEtMTA2NTAy_b64b7c7c-e640-4310-a5df-3138cba9a100"
      unitRef="usd">261800000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzItNC0xLTEtMTA2NTAy_3b5d39c8-83e5-4ca6-976f-ea7cf092a352"
      unitRef="usd">324700000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzMtMi0xLTEtMTA2NTAy_1cda7e8b-bc76-40c7-9b89-9cb32314e553"
      unitRef="usd">216200000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzMtNC0xLTEtMTA2NTAy_10d06abc-af5f-49f0-8e34-822ef2499471"
      unitRef="usd">234700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzQtMi0xLTEtMTA2NTAy_c71de29c-6e55-49cd-b547-701e57eccf95"
      unitRef="usd">281500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzQtNC0xLTEtMTA2NTAy_bdf17c3a-a14e-43df-8cc3-a7c8a3ef6c27"
      unitRef="usd">345100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzctMi0xLTEtMTA2NTAy_dadbaa29-0aa1-46a5-9649-09db6c130198"
      unitRef="usd">793000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzctNC0xLTEtMTA2NTAy_cb711fcf-7481-4a4d-b57e-37bc785830a7"
      unitRef="usd">828600000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzgtMi0xLTEtMTA2NTAy_382a5aec-fc01-48d3-a4f9-26e61e0d3b98"
      unitRef="usd">3298500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90YWJsZTpiZTViZjhiNTFhZDk0ZGEyOTRkNTY3MjE3NzI0YmFiMy90YWJsZXJhbmdlOmJlNWJmOGI1MWFkOTRkYTI5NGQ1NjcyMTc3MjRiYWIzXzgtNC0xLTEtMTA2NTAy_334deb3f-1d10-4ab3-bcd3-5c5c5965c319"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzQ5NDc4MDIzMzE2ODg_fb22b722-e07a-4d3d-b065-7ea951867e47"
      unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzg5NQ_d8c876d6-39f6-45db-a7fa-1410d0306c29"
      unitRef="usd">1167800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzkwMg_b9aa5324-4b4b-4d05-81ed-1b1097bdef16"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzk3OQ_e18bd63d-060e-4723-bcc7-780ce2a932a8"
      unitRef="usd">499600000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTIvZnJhZzpiMTcwN2VjOGEyODk0YWIxYWIyOTgwNTM3NDc0Y2YzZi90ZXh0cmVnaW9uOmIxNzA3ZWM4YTI4OTRhYjFhYjI5ODA1Mzc0NzRjZjNmXzk4Ng_5e793162-bdee-42b8-8e5f-e1c25c849b9d"
      unitRef="usd">664500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njcy_876c1c69-559c-4453-8633-ee63d98535fc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lecanemab Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years, and we will manufacture the lecanemab drug substance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our Lecanemab Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of June 30, 2022, Eisai's portion of these expenses was approximately $275.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#x2019;s economics beyond these royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third-party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended June 30, 2022, we recognized a net reduction to our operating expense of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$28.9&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$210.6&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, compared to $40.1&#160;million in each of the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended June 30, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$250.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $285.4&#160;million as of June 30, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. Amounts payable to Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$56.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $46.5&#160;million as of June 30, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the ADUHELM Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sangamo collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;InnoCare Pharma Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#x2019;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ex&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;that was recorded as research and development expense in our condensed consolidated statements of income. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2022, we recorded $18.0&#160;million and $37.5&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$77.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in each of the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $675.0 million and related to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2022, we recognized net income on our investment of $5.9 million and $2.6 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $13.0&#160;million and $17.0&#160;million, respectively, offset by amortization of basis differences totaling $7.1&#160;million and $14.4&#160;million, respectively. These amounts reflect our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating income, net of tax totaling $41.6&#160;million and $30.6&#160;million, respectively, and amortization of basis differences totaling $7.3&#160;million and $14.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 713.3 billion South Korean won ($599.9 million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2022, we recognized net profit-sharing expense of $58.3&#160;million and $122.7 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $69.9 million and $138.4 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were $3.1&#160;million and $4.1&#160;million as of June 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $121.1&#160;million and $148.7&#160;million as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2021 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="if95e48bbaf4a4e799a9ebda77407ebe7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDI_90567a85-eecb-43fb-981f-34a416b27c34">P5Y</biib:CollaborationAgreementTerm>
    <biib:CollaborationAgreementTerm
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDg_32577ec9-4897-4ecd-8e18-8be6ae174045">P10Y</biib:CollaborationAgreementTerm>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njk0_6ba370d2-3a67-4475-8f83-09d85df6ecdc">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItMi0xLTEtMTA2NTAy_5c5a86e4-122d-45c4-a54a-db5387d9925c"
      unitRef="usd">78600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="id03a4083cbe14980afe9873df6e01157_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItNC0xLTEtMTA2NTAy_1eb11542-181b-4d08-92d1-e23b8c477fa2"
      unitRef="usd">62200000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItNi0xLTEtMTA2NTAy_ec2c2379-6aa1-4bf9-9322-b9cf86a11d37"
      unitRef="usd">155600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i4fdad13d37214d518d991982787c19e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzItOC0xLTEtMTA2NTAy_8594151c-0a14-44c1-ae46-3db6594f1557"
      unitRef="usd">117700000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i7e853894fbfe475eb7c2797ebb92a568_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtMi0xLTEtMTA2NTAy_b3ce30b4-0fff-4237-adab-4689bd18b038"
      unitRef="usd">39300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id03a4083cbe14980afe9873df6e01157_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtNC0xLTEtMTA2NTAy_af45ba32-37a1-4655-bec0-6d39a4d15d96"
      unitRef="usd">31100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if48e7d80b31e4260893e3d5f2d103544_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtNi0xLTEtMTA2NTAy_724d7c3a-0196-45fa-8f4d-8e77c342d279"
      unitRef="usd">77800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4fdad13d37214d518d991982787c19e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzMtOC0xLTEtMTA2NTAy_fa874574-e6cb-4e5c-8668-79597db9f286"
      unitRef="usd">58800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtMi0xLTEtMTA2NTAy_e89522fa-75d1-44ad-a435-2ac5d46fbe47"
      unitRef="usd">23400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtNC0xLTEtMTA2NTAy_4a1ca1f0-b49f-4090-bc8f-e108762e7763"
      unitRef="usd">4300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtNi0xLTEtMTA2NTAy_5120c2b6-2b51-4a2b-a123-b47cc745e78b"
      unitRef="usd">39300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzQtOC0xLTEtMTA2NTAy_25319eeb-0112-440a-be07-b60d0d6b6661"
      unitRef="usd">10000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic63ccf56bba84511ae3e733419b79c88_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtMi0xLTEtMTA2NTAy_73dc56c9-3516-43d1-832c-a5be722874dc"
      unitRef="usd">11700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if6989fd0f67f47038f58e8d6b10c6088_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtNC0xLTEtMTA2NTAy_fb3659cf-6ebc-4665-83c7-70f5f12ee585"
      unitRef="usd">2100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i066644127ec74aee800ed0e8a26aa660_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtNi0xLTEtMTA2NTAy_c001fbf4-e518-43d5-bdba-bb968ee6f34e"
      unitRef="usd">19700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i616588dff6e947b8b25fa42ea368d565_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmOGU4MDhiZWI1ZGM0OThjYTVkOTgwY2Y5NGQ2ZGJhNy90YWJsZXJhbmdlOmY4ZTgwOGJlYjVkYzQ5OGNhNWQ5ODBjZjk0ZDZkYmE3XzUtOC0xLTEtMTA2NTAy_d77f797e-956f-42fb-bbb0-993820dc29ee"
      unitRef="usd">5000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzIwMjU_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzIzNDM_95c0ab1b-f6d8-4a94-ba3a-9d14458899d8"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0NTY_5e0b93b2-f2a2-4402-81f0-5f387bfa03b7"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0Nzg_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i8d619108d16c4f3195965f6d07c40e0f_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI0OTQ_95c0ab1b-f6d8-4a94-ba3a-9d14458899d8"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i231f21da54f240e09322a7c8c9ff9b00_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzMwMzI_fbe206df-3225-4a45-9910-537f16daa1aa"
      unitRef="usd">335000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i30ff4924fb8e4b93b7f08ff5e5eedced_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDUzMDU_c9339fd2-a8a2-428b-9d79-314787a9ad5d"
      unitRef="usd">275000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2Njky_2813ab9e-7235-4d90-8422-bc21cb603435">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third-party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i3ccab6bc98574047b1778979662e99de_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItMi0xLTEtMTA2NTAy_16c38078-2f71-4d2a-9774-4068fd6b6efb"
      unitRef="usd">37200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItNC0xLTEtMTA2NTAy_fc2ed524-3860-4282-8121-a08c81f48ffa"
      unitRef="usd">42100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItNi0xLTEtMTA2NTAy_09343d6f-830e-4c17-b933-20a1a974a5d2"
      unitRef="usd">81400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzItOC0xLTEtMTA2NTAy_edca1aa4-ed79-4097-adf1-a09f19f63700"
      unitRef="usd">89100000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3ccab6bc98574047b1778979662e99de_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtMi0xLTEtMTA2NTAy_5df8ae4f-5802-4e5b-9da7-59e13bcc9e77"
      unitRef="usd">20500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic5065c6b474c4a72b16c829daa5c0e75_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtNC0xLTEtMTA2NTAy_43c70e5e-ac17-474d-8229-f7f26c7e28a5"
      unitRef="usd">23200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i35e20c6e1b454ee586ff38fe6c059aa2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtNi0xLTEtMTA2NTAy_26416ccc-6cff-48d3-bab2-756c82943fdc"
      unitRef="usd">44800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i053f6ad4caf543b08c32a393a4c0aa9c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzMtOC0xLTEtMTA2NTAy_9111d5bc-f5d6-48fa-b5ec-2beee4db42fa"
      unitRef="usd">49000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtMi0xLTEtMTA2NTAy_fd4cb46d-42a8-490f-87a7-2fc3e99bf5f6"
      unitRef="usd">40800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ie326ff087126492b947c8a627fa90a72_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtNC0xLTEtMTA2NTAy_c96c50f3-3ddc-4cd9-8aa0-003119fe3939"
      unitRef="usd">125600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtNi0xLTEtMTA2NTAy_4e729131-a252-41c8-b1cb-bd3cd80d917c"
      unitRef="usd">135800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id33450308aef4ad29feeb06170373827_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzQtOC0xLTEtMTA2NTAy_f265293e-5e45-4017-aca0-a24839fa809a"
      unitRef="usd">237400000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2e5be185a3194ffd851b5165a6da498a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtMi0xLTEtMTA2NTAy_c9f6fa61-5fc8-482a-ab4b-370563d2584d"
      unitRef="usd">21100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie326ff087126492b947c8a627fa90a72_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtNC0xLTEtMTA2NTAy_0f44f9d5-ef48-4348-8d02-0725ce7792bc"
      unitRef="usd">67600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i462b942bac024e14a4ed7fa804a88a2a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtNi0xLTEtMTA2NTAy_8edc778b-2899-46d4-bb63-f25d21305700"
      unitRef="usd">72000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id33450308aef4ad29feeb06170373827_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzUtOC0xLTEtMTA2NTAy_0f20f582-646a-4b5a-abd4-0aa51f21f47a"
      unitRef="usd">127900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtMi0xLTEtMTA2NTAy_5082d9c4-02b2-4013-8ec3-ad8261c766a3"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtNC0xLTEtMTA2NTAy_b3fd5df0-b286-4746-a0f0-6d05717e583c"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i66f3123780b4402a90c954338e97580c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtNi0xLTEtMTA2NTAy_55a74324-4bf6-4035-ae5d-9816c0f7451f"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzYtOC0xLTEtMTA2NTAy_975f27bc-4006-4c41-a2a3-04ce903c7f40"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctMi0xLTEtMTA2NTAy_1f64af70-8bb4-4216-a516-bd8b572eab69"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i05f75aab17f34a08b32d477a900caa92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctNC0xLTEtMTA2NTAy_b8ff4403-4981-4c6c-ad5f-51786c186843"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i66f3123780b4402a90c954338e97580c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctNi0xLTEtMTA2NTAy_7acbd98e-c290-46d3-bffd-953a9e8349cd"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3fe0c832152342f18eb8b1db5bf1d0e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTowMDdlNTYxOWQ2YjA0NzE4OTUyYWE4NTVjOTBiMTRkNi90YWJsZXJhbmdlOjAwN2U1NjE5ZDZiMDQ3MTg5NTJhYTg1NWM5MGIxNGQ2XzctOC0xLTEtMTA2NTAy_3d524a80-6eb8-4a0d-830a-e94baafd31bc"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzM3NjI_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6b5e346af48c4d1ca76de22d3af2bb36_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQwMTM_b27f05e1-2278-46c7-9f66-ae1a22827816"
      unitRef="usd">28900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg0MDc_331917b3-5558-4c86-bc58-b818b39cc02e"
      unitRef="usd">210600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQwMzU_f3f0cb38-ce8e-457b-9ff9-23520125d4c5"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i93fa5ba115534b88ad53c2b7bff98846_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTcxNTA_544308ea-2a02-4cfd-ab96-926277dca7ad"
      unitRef="usd">40100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie1166a4ed6a348088b5ef0d2b05a70c1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTcxNTA_6857bc77-6221-4b22-a2c8-bff5e95c9b82"
      unitRef="usd">40100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib1d1c0ace8b44803b59ba3b9854f51fd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQzNTk_971beb38-6dde-4d38-9dd1-b1ccf3f019c1"
      unitRef="usd">275000000</us-gaap:CostOfGoodsAndServicesSold>
    <biib:CostOfGoodsSoldCapacityCharges
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ1MDY_444714d5-762d-4a79-8e96-ea0281f69e18"
      unitRef="usd">45000000</biib:CostOfGoodsSoldCapacityCharges>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0af311005c9b4595b8ad09d11086ca10_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ2Njk_5687cfee-0f0d-4fda-91f6-46fbf641ea4e"
      unitRef="usd">160000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ2OTE_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:DueFromRelatedParties
      contextRef="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ4ODk_63243683-6c4e-4e23-8874-09d7b59428d9"
      unitRef="usd">250800000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="ide8a39607aa44c739f29386c64f8a2bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzQ4OTY_cebbe120-5241-4556-b3e4-a15ae75dc296"
      unitRef="usd">285400000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ic96abd1338e241ba8e4aa764ac2f21d2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzUwMDI_9422b353-77a5-49af-bcb2-8c1d3c4b0cd0"
      unitRef="usd">56000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ide8a39607aa44c739f29386c64f8a2bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzUwMDk_68cc81cb-55d0-4353-946b-8aca257bedc2"
      unitRef="usd">46500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <biib:Expenseincurredbythecollaboration
      contextRef="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItMi0xLTEtMTA2NTAy_aaae7587-2c53-4ca8-8da4-7e97bd87cbbf"
      unitRef="usd">15600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6766574fbd894502b558478062716387_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItNC0xLTEtMTA2NTAy_e4a39a55-5d5d-4dbf-acee-550e628eca2c"
      unitRef="usd">16100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i45e9b008911d4b25964bc84cba645427_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItNi0xLTEtMTA2NTAy_15777019-aba3-431b-8a8f-6646ea58be36"
      unitRef="usd">33200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzItOC0xLTEtMTA2NTAy_36249b40-37b0-4f69-b461-8c10c7998e99"
      unitRef="usd">33000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i627965cdd93e4945b44535a2a29104e9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtMi0xLTEtMTA2NTAy_b938e436-f2bd-4ade-af9e-89ba9bc2a09c"
      unitRef="usd">7800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6766574fbd894502b558478062716387_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtNC0xLTEtMTA2NTAy_b22672d1-deb0-454b-9907-a6b61ce1d129"
      unitRef="usd">8100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i45e9b008911d4b25964bc84cba645427_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtNi0xLTEtMTA2NTAy_7c5ae784-60fc-46ee-962e-69b1ffc026a8"
      unitRef="usd">16600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ide2f0a24ed4240f8b544d4248cdb8f2f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo5MGZiZTYxZDYyNGU0MDlhYTBmZTkwMGRkNmQ0NmIyZi90YWJsZXJhbmdlOjkwZmJlNjFkNjI0ZTQwOWFhMGZlOTAwZGQ2ZDQ2YjJmXzMtOC0xLTEtMTA2NTAy_2ee6576e-4c73-455e-a71b-e533c6321537"
      unitRef="usd">16500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItMi0xLTEtMTA2NTAy_32be4baf-56e5-484b-93d8-4aefdf7c5c11"
      unitRef="usd">50800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItNC0xLTEtMTA2NTAy_a04d9932-5191-480f-891a-bb22c0269ff6"
      unitRef="usd">54000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItNi0xLTEtMTA2NTAy_2cdb4020-c44c-4a50-832b-3744dc1e14ba"
      unitRef="usd">89500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzItOC0xLTEtMTA2NTAy_5c6d2a66-d00e-4531-bb63-278e12608b5c"
      unitRef="usd">93800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id9dba5e7efb640dda74fb7f9d91398d5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtMi0xLTEtMTA2NTAy_51d5b31f-1011-450a-88c7-e7fa79e997df"
      unitRef="usd">25300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2c61f73fecf64f18901a9051594fa766_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtNC0xLTEtMTA2NTAy_1740743c-dc79-4021-851b-f449ff1ef17e"
      unitRef="usd">27000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if7057994e0704f11a1af174e0e7213cd_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtNi0xLTEtMTA2NTAy_d68e982c-32c7-4021-9a00-eae18d485324"
      unitRef="usd">44700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ifebc955a7baa4c83b848c5b2dd3c654e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzMtOC0xLTEtMTA2NTAy_dc25e0c6-d27c-4680-9b62-2d83defdb968"
      unitRef="usd">46900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtMi0xLTEtMTA2NTAy_fe4f4079-38c4-4def-9e68-2f4887f161fa"
      unitRef="usd">23000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtNC0xLTEtMTA2NTAy_512bc838-1ef2-44f8-903b-89093d8b1353"
      unitRef="usd">10500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i311cc627d4884000b967bc589ce09d88_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtNi0xLTEtMTA2NTAy_81b775d1-9dee-4fcc-a7f0-174de70d582b"
      unitRef="usd">41400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzQtOC0xLTEtMTA2NTAy_974feb7b-f9ef-47c8-bd2d-d05b785cf55c"
      unitRef="usd">15800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i8232db4b00fb4aa48a07e5dee55fbb26_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtMi0xLTEtMTA2NTAy_8e5d23ae-9a85-4276-9c81-62b10079dca1"
      unitRef="usd">11500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id08b16e98a4941bc9b5ef5bcdb07dc16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtNC0xLTEtMTA2NTAy_34d87569-fe78-4424-aee9-23b5e406a890"
      unitRef="usd">5200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i311cc627d4884000b967bc589ce09d88_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtNi0xLTEtMTA2NTAy_69e44076-b569-474c-a4bc-d008fed3d6e8"
      unitRef="usd">20700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i95c04a7b5fb546e6a869dbdfd613cdfa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTpmNDZkMjc0ZTZjNTA0NmI2YTRlMjg3ODkxNDc3ZTdhOC90YWJsZXJhbmdlOmY0NmQyNzRlNmM1MDQ2YjZhNGUyODc4OTE0NzdlN2E4XzUtOC0xLTEtMTA2NTAy_29df4b99-7a33-4690-8ae2-7d45121acd41"
      unitRef="usd">7900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NjU5_c77e35cf-3040-4b56-b6e6-78a24cc7cac4">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItMi0xLTEtMTA2NTAy_5783eb62-fc20-4f9c-97c0-01610201b1f6"
      unitRef="usd">23200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItNC0xLTEtMTA2NTAy_1d48b1e3-c041-4b2e-89d0-0b8e7fa88cf0"
      unitRef="usd">10400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="if756749af2de4c4e957db16b485d5427_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItNi0xLTEtMTA2NTAy_2ca44996-d503-432a-bd30-a13eaf755d70"
      unitRef="usd">38100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzItOC0xLTEtMTA2NTAy_29fd9d32-2c86-4a88-9dda-f51086cca98d"
      unitRef="usd">18700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2dde54580b57440c9fdcbe2ce53ca150_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtMi0xLTEtMTA2NTAy_7b95ca07-8d83-44e3-880f-4f79dac57e0a"
      unitRef="usd">13200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3acd59c20e1d4c7ab724b3a11d48d66c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtNC0xLTEtMTA2NTAy_6063eaaf-8360-4bf9-9a0f-4fe51398bbf2"
      unitRef="usd">6200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if756749af2de4c4e957db16b485d5427_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtNi0xLTEtMTA2NTAy_0cc58865-3c80-41c2-95bd-4bf5c175eb43"
      unitRef="usd">22100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6b0b9926e0f249d19e11cca3f3b4e991_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTo4NzZiMzI3ZmM4MDg0OGI1OGQxNDkxOTgyYWYzOTg3Yi90YWJsZXJhbmdlOjg3NmIzMjdmYzgwODQ4YjU4ZDE0OTE5ODJhZjM5ODdiXzMtOC0xLTEtMTA2NTAy_6bad6503-e871-4b88-946e-0a13327ba9cc"
      unitRef="usd">11200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Termofcollaborationagreement
      contextRef="i3e194ceae6f64b65b2349e8df6ab64e9_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NjYz_da388bc4-e2c8-422e-808f-671a4df2b8b8">P5Y</biib:Termofcollaborationagreement>
    <biib:Expenseincurredbythecollaboration
      contextRef="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItMi0xLTEtMTA2NTAy_afce82f7-fd72-4326-8488-73488e014ccc"
      unitRef="usd">2600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItNC0xLTEtMTA2NTAy_797e91c7-7891-419c-a2ab-33cd94faf446"
      unitRef="usd">5400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItNi0xLTEtMTA2NTAy_d623ee1d-362e-4061-b96e-283d274a04c6"
      unitRef="usd">10900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzItOC0xLTEtMTA2NTAy_d4399cb3-4601-43db-af38-2df80411a63e"
      unitRef="usd">10200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if3ebc7b01f374e1b9bbd2822d85e6714_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtMi0xLTEtMTA2NTAy_e71d14cf-e5c7-4641-9e8e-002cd4369e5f"
      unitRef="usd">1600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id564f1111e4a4bd898dc104779e63e4a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtNC0xLTEtMTA2NTAy_9b23e84e-86b3-4e8d-abb8-f2a36e8e58e9"
      unitRef="usd">3400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i90d99ee924fc426f8efd896b3579a8ed_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtNi0xLTEtMTA2NTAy_5b309a03-674f-4371-8851-c8ef9fb10b75"
      unitRef="usd">7100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i06458671b8ff4b88810e919c9a1ea62e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90YWJsZTozNWRhZjcyOWY1NGU0MTIwODVjMzhlY2JkZTMxYzAzYi90YWJsZXJhbmdlOjM1ZGFmNzI5ZjU0ZTQxMjA4NWMzOGVjYmRlMzFjMDNiXzMtOC0xLTEtMTA2NTAy_36e00efd-1a93-459f-ad1c-c646ffe5282e"
      unitRef="usd">7600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5Xzk5MTI_59fb0bf9-ebf8-4c83-846b-2020d6e57aab"
      unitRef="usd">125000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:ContingentMilestonePaymentsMadeToCollaborativePartner
      contextRef="icae6c642aec54607830f8b3a015ff42e_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwMDY2_e660df52-a3b4-4975-a687-83f111a0ce91"
      unitRef="usd">812500000</biib:ContingentMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i32ab1ddc9657403a8db302457fb46496_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwNjc0_8a832e82-e400-4079-b65d-a6de7bce0b4b"
      unitRef="usd">18000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i35b2b113cfdd420ebfc7941cfaba6661_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg0NzQ_2452b977-182a-465c-b520-7809caef02e2"
      unitRef="usd">37500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i89906910d5954e76b7d9d286e110f422_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwODQ4_8a22cbc1-ad3c-4b9d-892f-2996d82b2b00"
      unitRef="usd">77200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NTc2NTY_c9e0aefc-ddcd-4bbb-b940-e655b42de12c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture
      contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ2MjE_7a21c978-d96f-4ba4-ab49-534bfc1b329b"
      unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i0bce0582b9234dbbac96a00b848486a2_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ2NzU_74b91707-5750-444f-bcd8-66b6f887893d"
      unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i3729e3a50004440ba3134a7803d8b293_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ3MTU_0ebc0d84-6263-4981-9891-fe9599c61249"
      unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i3fc13fd60c8140859d72089cfe8c306f_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NjQ3NTI_0b3c464b-8df7-4504-812f-a222d66f4d98"
      unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:AdditionalMilestonePayment
      contextRef="i7008f57ab0074faaacfc6e73447d8489_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzI1ODcz_00c50cc8-f513-4c3b-96a3-9a140ac3e3e3"
      unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i0dd95981381d46b7a30d0a586d846fb5_I20181107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzExODM4_2a881b76-08f6-4560-8318-535734de84ac"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i994f69bbb09645ee8a7918008c471ef6_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMDMw_1a3e767a-0214-4c22-b31a-ca1cbae5d6e3">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i89c39215e3534c88835566c3e470d890_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMTk4_f43ee309-ee4b-4f51-917c-4fcfee381fe4">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMjgy_730ce4d5-daa9-4d38-b6c2-5493c5eb5844"
      unitRef="usd">5900000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg2NzM_dc576cb8-b4b8-4f9f-8892-5a60e75bd4a5"
      unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyMzY2_63f90801-d155-4fc9-acfb-f289194423fd"
      unitRef="usd">13000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg3MjY_d8ffc544-ec60-4975-aa5c-2f7c75c78cfb"
      unitRef="usd">17000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNDIy_3ff39b71-6e8f-4bad-a464-fa7d2f283f3f"
      unitRef="usd">7100000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg3NjA_7fbb97a8-67fb-440a-be20-c742f94dfbf5"
      unitRef="usd">14400000</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNTAw_e9feac9c-ee53-43d5-9313-0c98580790c2"
      unitRef="usd">34300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg1NTI_90b09031-c809-4e86-9b6f-7e67808b766e"
      unitRef="usd">16100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNTgz_25f6d243-65dc-4780-958e-fec49323fd5f"
      unitRef="usd">41600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg4MjE_e8f12d5f-f4ac-4ca3-a45b-75f6953d0d8b"
      unitRef="usd">30600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNjMz_881c03a7-97fe-4b6c-9e77-70927858f593"
      unitRef="usd">7300000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NTg4NDA_a820b28c-415d-448a-88b6-b0918edacef4"
      unitRef="usd">14500000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="ifce6fe69e35a448dbd457279465a317b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNzQ3_9ea34dd2-4a0a-4685-a871-78e90a63f3a5"
      unitRef="krw">713300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifce6fe69e35a448dbd457279465a317b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEyNzY4_c1ef8905-2f97-4430-9641-0be15c23948a"
      unitRef="usd">599900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3c8021fc79f6416686d187243973ea45_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2NDkyNjc0NzE4NTA_f5bbef57-bc85-4c1a-ba75-54ea83d9eaf9"
      unitRef="krw">0</us-gaap:EquityMethodInvestments>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEzNTc2_d2dfd2d0-f68f-4778-a728-eb7c2e6e08cb"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="i51756137bedd4e98a13762e4f59e5766_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU3ODM_7b75a52e-215c-40a1-b37f-4421ee9a6766"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MDQ0_a2f5b56a-2f98-4e16-bb57-d7bbd99b6540"
      unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id46a16c51d8a4b2f99effd941c815995_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MDky_d95b94f7-c0aa-4117-be49-890ca9b0fda3"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i78b272d435084dce9cd4a8f7830ba08a_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MjA3_f260d952-c261-4c7b-b05c-51456bce2340"
      unitRef="usd">37000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AccruedMilestonePayments
      contextRef="ic0ca111dfefc4822809d3271f8ea6e9d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0MzQ4_79910970-996f-4f63-85db-1ef975100f88"
      unitRef="usd">15000000</biib:AccruedMilestonePayments>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0NTk0_ccd1d2a8-a37e-4cf3-9a9b-356a886d4151"
      unitRef="usd">180000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0Nzkz_3c16a467-14e9-4a63-b272-df9efc6ad56c">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE0ODQ1_d8a235e3-db4f-4df0-8b6d-93669715e080"
      unitRef="usd">60000000</biib:ContractOptionExerciseFee>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1MzE1_448b4761-fe5b-43b3-9c93-b9ddd999866b"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NTgx_791fefe2-09f8-4b75-bb2a-068f9a74b517"
      unitRef="usd">58300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="iae55f2ae057948359e2632d936d3fd68_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU2OTk_e706bc1e-5055-4345-8b90-b3bf2fbba8f9"
      unitRef="usd">122700000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ia41cd503232e431e962e56b719d08e2c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NjEy_448b4761-fe5b-43b3-9c93-b9ddd999866b"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="if73d1b52fa93440db2e1eb444bcb5ad8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE1NzAx_af80aaf1-38e6-4bc4-88c1-d81a1a61d603"
      unitRef="usd">69900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i7bdc25853d954b0c92ba45c8734a1a06_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzEwOTk1MTE2NDU2NzU_8703e371-87bf-4290-b9dc-68c57205ee01"
      unitRef="usd">138400000</biib:Collaborationprofitlosssharing>
    <us-gaap:DueFromRelatedParties
      contextRef="if1139e7fad6c40f48deba330c854be64_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MjE5_c85ef29a-bda6-4517-8345-d0528e82cb91"
      unitRef="usd">3100000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MjI2_6b2a503e-1dc0-4b56-a35a-e9551bb14127"
      unitRef="usd">4100000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="if1139e7fad6c40f48deba330c854be64_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MzQy_19626a1b-3efb-46ce-8317-7147691a8757"
      unitRef="usd">121100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i1ec1a576b7c14af2b7f1f25bebe59d9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMTUvZnJhZzpjMGY5YjY3Y2QxYTc0MTEzYWRkMTNlNjBjYjk5NzcwOS90ZXh0cmVnaW9uOmMwZjliNjdjZDFhNzQxMTNhZGQxM2U2MGNiOTk3NzA5XzE2MzQ5_65281d32-32e2-4d6b-82e9-d7a553f79d8f"
      unitRef="usd">148700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzQyNTQ_1987706d-235e-468c-a67a-0d9cafe6ac64">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $23.5 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4Xzc0Mg_b0171aea-e319-4bf6-ab73-4ba622a1a099">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="i6b6e3f0fa03147b69eee7b9a9a264e00_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzEwODU_a6483068-e155-4c45-9ac6-e394749d65fd"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzEzMzg_41a09d39-293f-4a54-a19a-e26f3b0c7864"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE0MzM_41a09d39-293f-4a54-a19a-e26f3b0c7864"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5a36bcdc40354faeb9b03f0586021c98_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE2OTQ_8be9b8a6-56c2-4e97-8baa-4eac79a28020"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i604ecca217f343a480f5c79431fe9b16_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE3MTY_bd644626-3c0a-4486-b743-28754bd95245"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i261e664559194dcfb968a0ed63765c2b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzE3MzI_41a09d39-293f-4a54-a19a-e26f3b0c7864"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MDE_6fd45d02-6f14-4d18-b610-ae68ba08b2d1"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i26ef6923e0fd491fb74d065e645dbbce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MDE_a84899e0-f424-46c4-8ade-0eea1fc0865f"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MjY_cb9a9ccd-20df-4848-92e0-6d688659b783"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzI0MzM_7277a262-d932-4818-baf9-b1f319851af2"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i10419c7fca6040f5b7f54c27a139c129_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzM0Mzc_257c5ca7-620a-449a-88e1-64e33a57eeeb"
      unitRef="usd">23500000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i2d296c26357241e7b67a82ed0b3eb02a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjEvZnJhZzo2NmM2NTAxY2M5NTg0ZTBlOTYwYzlhMGRmZDdkODhkOC90ZXh0cmVnaW9uOjY2YzY1MDFjYzk1ODRlMGU5NjBjOWEwZGZkN2Q4OGQ4XzM0NDQ_86c85f61-4f58-4077-917d-d21433b95027"
      unitRef="usd">24600000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzEyNDcw_155e27c8-8f1b-4d4f-b493-9595e8ba3bc0">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 (the November 2020 Securities Action) and February 7, 2022 (the February 2022 Securities Action), and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the November 2020 Securities Action, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#xa7;78n(a) and 17 C.F.R. &#xa7;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#x2019; fees and costs to the plaintiff. The court has stayed the case pending the resolution of the February 2022 Securities Action. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#xfc;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). Fresenius Kabi later added European Patent 3 145 488 (the EP &#x2018;488 Patent, expiring in May 2035) to both actions and no hearing has been set in either.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP &#x2018;510 Patent. The EPO has scheduled a hearing on the validity of the EP &#x2018;488 Patent for October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Biogen has reached an agreement in principle to resolve previously disclosed litigation pending in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. The litigation was filed by Michael Bawduniak on behalf of the U.S. and certain states and unsealed in 2015. The U.S. has not intervened in the case. The agreement in principle contemplates Biogen making a payment of $900.0&#160;million. The agreement in principle does not include any admission of liability and is subject to the negotiation of final settlement documents and agreements with the named government entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ERISA Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#x2019;s approval and ADUHELM&#x2019;s marketing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TECFIDERA Patent Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description and in June 2022 we filed a petition for a writ of certiorari to the United States Supreme Court seeking review of the Federal Circuit's decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#x2018;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court with respect to the judgment in the West Virginia Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for November 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021 the EPO revoked the EP &#x2018;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#x2018;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#x2019;s proposed natalizumab biosimilar. A hearing has been set for February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in the General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzQ5NDc4MDIzNDE3NTY_03b286c3-b594-4466-b929-e787940399eb"
      unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i12af56ba242049728b6eb6a1d817a8b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xMjcvZnJhZzo3Y2UxOGQ3YzJhNzk0YTAwODRjMTJiZWY5NTllMTYzNC90ZXh0cmVnaW9uOjdjZTE4ZDdjMmE3OTRhMDA4NGMxMmJlZjk1OWUxNjM0XzYwMzU_0155e341-0999-463f-939c-cdd2abf16dad"
      unitRef="usd">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:RestructuringCharges
      contextRef="i679a9034f0b94dc897213c23a3d84280_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzY0_3aba3de6-061c-4a43-afe8-91099cc65ac5"
      unitRef="usd">130000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ibd8a756ac4f94f4ab8837703d8abf063_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4Xzcw_adfdb999-8023-47f3-8d78-db4bff8c327c"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1ODE_1b9b5b52-58c0-48b1-9ef9-8316c4af4235"
      unitRef="usd">70600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1ODk_20ba8020-04b6-4ee8-aa57-bbbac52b4e5c"
      unitRef="usd">108700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI1OTg_21d50c17-f0a6-4ace-90f3-ab7ef4d352ee"
      unitRef="usd">60900000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE2NDkyNjc0NDI2MDY_341b08c3-780a-4968-aaf4-d3cfe99ac21a"
      unitRef="usd">88600000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzE5MA_7bb2cdc5-cf4f-4328-a374-1717a053fd8f"
      unitRef="usd">10400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:OtherRestructuringCosts
      contextRef="i852ff350063140c2bb0be923b3509114_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzEwOTk1MTE2Mjg1NDQ_69606ba6-a436-46d1-bb6b-26336d96b45f"
      unitRef="usd">9700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8xODQvZnJhZzpiNTc0N2Y1MDIzOTA0NGQ3YjAzZDk2ZmM5YzFjYzVhOC90ZXh0cmVnaW9uOmI1NzQ3ZjUwMjM5MDQ0ZDdiMDNkOTZmYzljMWNjNWE4XzEwOTk1MTE2Mjg1NDQ_c1bdf8b4-5d16-4ece-9b61-9b14d616a3bd"
      unitRef="usd">9700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMTc1OGYwYjA3ZjQxMDg5MTVjYWVjZmZmMzI3YzdhL3NlYzphZTE3NThmMGIwN2Y0MTA4OTE1Y2FlY2ZmZjMyN2M3YV8yMDUvZnJhZzphMzIwOWQwNjZhODU0MTM0OGJjMjkwYzMzODJhNzA3OS90ZXh0cmVnaW9uOmEzMjA5ZDA2NmE4NTQxMzQ4YmMyOTBjMzM4MmE3MDc5XzI3NDg3NzkwNzM0MDc_8c256366-aac8-4f94-b33c-c92b6e9919f7"
      unitRef="usd">990300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$"L=$*OE@&81#T,R2A.XG=CK+:Y3.4W#XQKRN:7Q<6L9G_M(J*5IF.] 0:_
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M&?A&?H)OCZ&T-@C$9)<?>P:)+68A]!$SP" #X8B;<'^+:G.JN"R1.*C!CBT
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MU:L-X/<; =U&?Z*_:NZ_8J__ U!+ P04    "  0@_14-1H)Y)P(   J)0
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MJI;/$!DB_>'D'MO%XB*P@L%AA8/%6"QWXAR^(L[TN?F!H7^4JU1-]3&O"6B
MC;9"(C5R#(FHE+ID-M.,EL2AK<93;(NVTRP:#?I.LT._9G]C^X:HYK01$B:
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MH&V@!W!_Z3$0-5]H@^Z'8R__!U!+ P04    "  0@_14T#?;T( &  !>$
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M.OTT_OWF/5\0>$E_(<!'E=CC#/ "*@#>GDTG[Z]G.\XW_X579$*X(D,J X*
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MH4&. @6+ 6>$"U#,-&CQWQU]2'E>>PR<B0*"T.02L<H0.(VSWD'8DJ0S>)P
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M ZZ0Q\-!R8%DMH+;5(YRV\["'I-B]20N]/:>6_D,;E6CB$?.O<M0O.30A"'
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;+U86V_;.!;^*X0G&"2
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M"T;'8S\^<6LC"HC?9'6:-B=&2> G+/!#=CSQIR=L!'1.V*\6563%O6PF9U.
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MN 6%GSFNG6R\ 9YG6KO]PA_07F1G_P%02P,$%     @ $(/T5 U/"T9-!0
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MW>,4[HUH-$Z'T$-9N15+8GT74(&J>N/Y0S QRD%Z4:W:\=@8<N/(82MR4^H
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MJ6D!_4JS)9S\:*X-N6[C*,)4+/11BO\@R@7L#X-'Z4$H5^*YE?4!N#M/<[K
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MAF6HC&[ [Y,4ZW%?:(+R9>%/_PU02P,$%     @ $(/T5#V2>"0G"   ;!<
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MF"KNSF'->KSW1<P&=,)</)D>CHX[#B>SGTR/1D_3&V:D.AY\2IQAZ6!=272
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MN^ _FZ(O7AWTQ/!@.'QFO5?A<*]XO5=/':XT1IR#1EW,5)$\]L1U87',@)@
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M@^>.T3UK E/$/WF3RXF8:/CS7 .D/J+B'$'FIL%4D*,6VL4SCC8"%7.VHGA
M_V[C_\NFXLC*1SP&%J2V='**H2KRNZQ-=BC(=4+_7"+WA=Z=BJ.!\W67M^(%
M/=@1/83I"UTYWW0C"9VOCO;ZZXC(*-S!X2@E6=^$-C@2AZ>G80/6I^,W].K9
M;3B*1_C7\1-%B<A0\ECBQT2!,=!]FJ@TA8I] C#2>F4UB5&CDGF!\"6S-I=Y
M,5J R$SLWI^-]KP^K9/^A8,*L7MY^P7HP4.5.X6NU+),9*R_[;E:]EF+@-G6
M'L"HI8UU9OX(I45:&Q6O+]8RB=7G"_R$\W;#SD$/UD6R707!I0M5("%]>&'
M:#(QN75.YP%8XDHC5;(8WPKE"&JL)K+09AZ#+3K&B^@ ;%3]<!@_CD[S,E59
M?]WH()VE!2P1%3.-*6@3!%ZMLXC/@HB7#BIU(#7=P"R)1#((:'%KRZ.3D[J0
MGZD"QWA-5F(+G3BF8$EDCU82$5/<R8.K=Z@C^#PX*&WCA]/[#8I3=G0590QK
M=HM#T.\?T&WV?<GW81RV*)J'<'SBP6M8P50!RG<(M<@0?'X$ _\F'_ G#'(
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M<6+A"!+/VD;'.@5+F=@L@&@ .?Z62M2:=,7L_Q\YW__G>'1V%YJ0=VU7)0J
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M;W)K<VAE971S+W-H965T,C4N>&ULC91=;],P%(;_BF4DKE"=IET9)8G4CB)
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MSRWZVV [V3(7#B^,^B8S7YP,#@>082YJY3^9Y=_8V+/'>*E1+OR%9=P[W1U
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MD+;(-+:A>4T5AJY'D(CP0" S!/!X\4B=#%PA<Q^-79)#HQ<$3>[O5"28Y]R
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M?+BTQA=OJG!1G!M/U\[P6- ]'RUOH.^YH6 U+ZR@^\_!Z?]02P,$%     @
M$(/T5'TY=+>R#@  (2<  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
MW5IK;]O*$?TK"Q=M'4#Q*\_>/ #941+?VHXKQ>G-+?IA1:[$3<A=9I>TH_SZ
MGIGA2XDDW #W4X$@LDCN[#S/G%GJ^9T/GV-F3*6^%KF++_:RJBI_.3R,268*
M'0]\:1SN+'PH=(6O87D8RV!TRHN*_/#DZ.CQ8:&MVWOYG*]=AY?/?5WEUIGK
MH&)=%#JL3DWN[U[L'>^U%Z9VF55TX?#E\U(OS<Q4-^5UP+?#3DIJ"^.B]4X%
MLWBQ-S[^Y?0I/<\/?+#F+@[^5F3)W/O/].4\?;%W1 J9W"052=#XN#5G)L])
M$-3XTLC<Z[:DA<._6^FOV7;8,M?1G/G\WS:MLA=[3_=4:A:ZSJNIOWMK&GL>
MD;S$YY'_5W?-LT=[*JECY8MF,30HK)-/_;7QPQ]9<-(L.&&]92/6\I6N],OG
MP=^I0$]#&OW!IO)J*&<=!656!=RU6%>]G$DPE%^HF5TZN[")=I4:)XFO767=
M4EW[W";61/43C^ZW?]U[?EA!2]KK,&DT.A6-3K9H]%A=>E=E44U<:M+U]8>P
MKC/QI#7Q]&2GP%]K=Z >'(W4R=')R0YY#SJ7/6!Y#[;(VV3P?\;S6 6DV'\W
M&2SR'FZ61V7W2RQU8E[LH:ZB";=F[^7?_G+\^.C9#FT?=MH^W"7]Y;M;"$0N
M;])K]\I3ZY?&*1N55LO<SW6NYM:7F48Q)*:N$/Y<);XHM5NIA4>RFE2AT%(;
M$X]=X: 1"N06A5^2L[1+\36W<HNJ-4^1[$99Y_RMINI456:"+LFCP!M5&E_F
M1F$)+[!5IN >Z^NHG*F#S_V2E2#)?"$UT!@26!;T,*A7J!_5'<J>/H/)=04U
M91\V0NGT$^QQ%,<#]6^C,HW%6N6 .-JV]*%:(,Z>$K\P*0+N(+3RJ@(*5JI
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M'Z0^Y22";!]2XI421]T/6^@ED((X1B4L/R?2FU"1"&Z1:VX< ]Z,-@(1OSE
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MGBUY4&:I_.Q ,$BAHTG.NZ6GB,YYXD *FEN=U\0"^)3T#YC'>4UONM97$$<
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M<&^BLB5"1AV)WQ;U2WIVN\8X),SD@-S#J>3-)9^"@/+HYCR$MN-^T5V1-\4
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M#/854?1J9A1(K^ FHX%$E=)6XZ,Y;8;ON)HY+^;5Y"9)RYS>0^""7./PK!>
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MXYV^WV)' >OCWAG[K"1H6_^_XIEBVT;9<,R%5$NIB,M;*\?LHE(*'+#^":+
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M+X,RJP?TW.3O]T+?OQ>ST'?;;!B@ZX?-Q%B$[AEX^-T<-B3!392I9<814[*
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MI)!OJ^;O0S.Q>NF^^&?:6EVZ88$N\HH$\/E<HZ_MA QL?@&-_P102P,$%
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M4Q8W0S=<PD2A:0&^SQ5L;5Y(0'NY/_T+4$L#!!0    ( !"#]%39=@3CJP0
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M:H(FU^\HO0GN#1/4O7=,H9'\YX<M/7A@7 #MUUKC8>(2C$]H_A=02P,$%
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MVH<<>E-*=H!*:\$F'U2Z%%H(G&!968^<BF\3@>/> V*<YA'/:8)75V">,V'
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M=V]R:W-H965T<R]S:&5E=#0T+GAM;+6=6V\;R;6%_PJA! <)D"-UUZ4O/K8
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M<M]STQY:;E)*:ZUDVEHY[:'3:*11O2<A=$\-2B,4S2^*M7]RJ)2EA'I!*,U
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M))Q%^OK>$P^ZFP:E$8KF5\+Z/#U4H%)#S1^49J T0M'\$CEGJ1P?J-PAO)5
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MD]$OB_5Z\?#\V_MF<MLLMX+-WW]9+-;[/VR_P;?%\M?GX9S_!U!+ P04
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MA*D'Y/TMI>+E1 6HQ\SS_P!02P,$%     @ $(/T5'%,G;". @  5@<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULK55K;YLP%/TK%JNF5EIY)B3K
M"%*;:.HF58K2=?OLP$VP:FQFFR3[][,-1:2ET:;V"_AQS^'<>_!ULN?B418
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M+L[1^6,$> U4&HCW&T+XL2$=5-<SLR]02P,$%     @ $(/T5)E-20@I!
M,A@  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULM9EM;ZLV%,>_BL6N
MIGNE#3#A(71)I#8PK=.Z5>F]F[9I+]S$2= %G-E.<BOMP\\&0GAP6;JZ>=%@
M<_Z_P_&Q3[ [.1+ZF6TQYN!+EN9L:FPYWUU9%EMN<8:8278X%W?6A&:(BR;=
M6&Q',5H5HBRU'-OVK0PEN3&;%'WW=#8A>YXF.;ZG@.VS#-&G&YR2X]2 QJEC
MD6RV7'98L\D.;? #YI]V]U2TK)JR2C*<LX3D@.+UU+B&5S'TI:"P^#7!1]:X
M!C*41T(^R\;M:FK8\HEPBI=<(I#X.N Y3E-)$L_Q=P4U:I]2V+P^T;\O@A?!
M/"*&YR3]+5GQ[=08&V"%UVB?\@4Y_H"K@#S)6Y*4%7_!L;3U;0,L]XR3K!*+
M)\B2O/Q&7ZJ!: @$1RUP*H'3%;C/"$:58'2I![<2N)=Z\"I!$;I5QEX,7(0X
MFDTH.0(JK05-7A2C7ZC%>"6YG"@/G(J[B=#QV0(?<+['#'P+?N%;3$'=\3["
M'"4I^R!N?7J(P/MW'\ [D.3@+DE3D6,VL;AX (FQEI6SF]*9\XRS$;@C.=\R
M$.<KO%+HHV&]/Z"W1.!U],XI^AMG$/CC/C?!R/X&.+;C*)YG?KD<JL)YG??X
M?WMO#<:HG@JC@C=ZAA<E#&TV%&]0L83)^C07P)\_"5-PRW'&_E)EO>2Z:JXL
M=5=LAY9X:HA:QC ]8&/V]5?0M[]3#;E.6*03%FN"M9+CULEQA^BSCX2C5%3F
M(B&J')1ROY#+7X?#S/'&H2DFQJ$YNJ59T#0+ J]M%/59'G1L,VR;Q7V6Y_IG
MHU:<7AVG-QCG@CRAE#^I(AP4OG26Z81%.F&Q)EAK]/UZ]/TW*@&^SN3HA$4Z
M8;$F6"LY09V<X'4EH)2/&^L1VN:H4P#Z1K[I=M9_WT:Q^A7>'--7K_YQ'>)X
M,,3R%61)Z(Y0Q/$I6.6KQB#II3-.)RS2"8LUP5KI".MTA&]4#D*=R=$)BW3"
M8DVP5G*@?7YUMU]7$"I]<XV.H>ET*H+**C#ML/GI% B%!#IC,^B4")59T"Q)
M[< ;>Q;XWV5"&?"@[J7S3BLMTDJ+==':&7#.&7#>J#)48%TITDF+M-)B7;1V
MBLZ[.3BX'[F@.HQZJS,,S-!N?+J[ATKB-26]VM"W@;[;K0Q]WS!TGJT,YUT2
M'-XFS4F:HD?Y\I <,$"4HGR#,YQS\ _XX_;GF\7O'Z^58S&(??&LU$F+M-)B
M7;1V@L[;.^B]5>'0NO_32HNTTF)=M':*SGM .+B+N:!P^+WS@=X>8JXP\LSN
M08/""+I=5*RP"AM&99A6XPPTPW13'#XSL9?8Y[P\ ZM[ZP/NZ^)8M]-_ Z_F
M4-$?R0/QXLSUC"]/T^\0W20Y RE>"U>V&8C\T?* NFQPLBM.8!\)YR0K+K<8
MK3"5!N+^FA!^:D@'];\)9O\"4$L#!!0    ( !"#]%1@<4S4700  .X9   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+697X_B-A# OXJ5GJH[J25Q
M @EL >G8I.I5MW>KW5[[4/7!P #I)3&U#5RE^_"UDY#_I*S.\+ D9N9GSXP]
MZ[&G)\H^\QV 0%_B*.$S8R?$_LXT^6H',>$#NH=$_K*A+"9"OK*MR?<,R#I5
MBB/3MBS7C$F8&/-IVO;(YE-Z$%&8P"-#_!#'A/V[@(B>9@8VS@U/X78G5(,Y
MG^[)%IY!?-H_,OEF%I1U&$/"0YH@!IN9\1;?!=A3"JG$[R&<>.49*5.6E'Y6
M+^_6,\-2(X((5D(AB/PZPCU$D2+)<?R30XVB3Z58?3[3?TZ-E\8L"8=[&OT1
MKL5N9HP-M(8-.43BB9Y^@=R@D>*M:,33O^B4R0X] ZT.7- X5Y8CB,,D^R9?
M<D=4%!SG@H*=*]@-!=N^H.#D"LZU/0QSA>&U/8QRA=1T,[,]=9Q/!)E/&3TA
MIJ0E33VDWD^UI;_"1$V49\'DKZ'4$_,G.$)R (Y^1!\(8T2%#;WV09 PXF_0
M*Q0FZ"&,(AE4/C6%[%'IF:N<OLCH]@6Z@QYH(G8<!<D:UAWZ?K^^VZ-O2DL+
M<^VSN0N[%_CK(1D@Q_H!V99MHT_//GK]Z@TZ[6@$G$3 .H9X?ST1GXE=EFH?
M6/#- ZNYT"EFC)-RG0M</^1DNV6P)>E*IQN4SR'TYWLIBMX)B/E?77,EXPZ[
MN2HCWO$]6<',D"F/ SN",?_^.^Q:/W5%12?,UPD+-,%JP1D6P1GVT><?Q0[8
M.2"="S;3=U-]]5_D.+='X\D 3\UCU;V9F%<5\[Q17<AOLT;8M@:3NEC09HV&
M;BE4,W14&#KJ-?3#(5Y*2^7L*]<(1U_[5\PB8XZJ5C7L[NWUI=/J?[L+-'57
M<Z%;N-#M=:%<R(*%RX.@#'U,H,M?O8"7KEB=,%\G+- $JT7!*Z+@W2B=>CJ#
MHQ/FZX0%FF"UX(R+X(Q[E\@CL!4D0NZ856#8>:^T8326F["_Y<)9EXNH,]UF
M?(PK.< :V-ZPD78ZQ1RKD2[\;IH[;F25"S3<G7(GA3,F5^>+WTZTR]I>P$NG
MI$Z8KQ,6:(+5HH"M<L=NW2ACY&!-\=%*\[72 EVT>H@J116^<=[(.VBL88R;
M^Y5N.6O2V(/Y%WA6,W5<XKG=N0/;I4OL*W:F*\KV5%:94#BET_A>U(OGJ4Z:
MKY46Z*+5@U*6<OA6M1S66LQII?E::8$N6CU$94&'O[6BP^TR;(P'K431(>6I
M1%'Y-'-&6P7;XX'73!D=8I[<;US(&&6%A_M+O-3R3H-U%FGW6FF^5EJ@BU:/
M0%D@8O=6Z4%KY:B5YFNE!;IH]1"5U2/NK7^N20]>:WE.O,'$JGR:AS^Y2O7$
MIIT<VC+8'3930[MO/+%;J<&LG%_'P+;IQ0&7FX5#(K*#R:*UN)QXFQ[)-]H7
M^.X>=[3[ZC(C/2\O\=E-R -AVS#A*(*-[,H:>'+%L>QR(7L1=)^>GB^I$#1.
M'W= UL"4@/Q]0ZDXOZ@.BBN>^7]02P,$%     @ $(/T5#V8"W?5 @  =0D
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MHKKDJXGB17E/SKC2MVXY7.GO(A F0*\O.%?/$W/U-E]:Z6]02P,$%     @
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MV-A<7$BVRK?)/C,I69*?+H&&P+,&ZOF<,?E^D06HMI=/_P%02P,$%     @
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M 3U["O@U>LK*/%I73QN-@W8"0FD!E,:@- ZE"11-KY&3K]SS (L':#\@E!9
M:0Q*XU":0-'T2E'YI7?A2_V@BP=HX@FE!5 :.]!.#_">9_JJ. [5%2B:7BTJ
MS?3LEQM_%A_(G^3_;"NULWM7!S3EA-(8E,:A-(&BZ16D4DYO C@S0=-+*"V
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M>N_1#-4TL28PLG)]8"8-=A4W7&+?!V43<'TNI=D$MK5T_R2RWU!+ P04
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MI&@"3>,$=K&Q7]S3%U"S/8%&>U:QPI;:\!HHL$!VR0)910M;:D/S"BZ01;I
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M>X9JHU\@.IZ>8#18X3$R@XR/(&,GR)LTJ\!CFN^9"5>LC8@1);TQ#\!T,['
M> S-T)(CM,2W[-BW?<9_G"F\)&3A!0JF)#X])CY]9N%-M0F'$"?:NAS,J&(6
M)^95F1W!S3SNZB_RKGYO*[N9-GIT@F^FIQ%'-EZ D12J:!C$OZR%UT52:XI"
MC<),=@W562@"]D05GJ^_K[;ZZYS[PR93JJ/3S6!$IF-J02>%#SH%9G%55KNR
M2KDF?.!J7U5B V $'50!0T539T!J(,0!M1\Z%75PZH&BJ:E+?85N@3U/0U!7
M38ACW*O@+A'=+D&X=QNK"*7 PH$*:]T"=(%<9 1U>8UL$@:EO$*WO@[8!$!=
M1B_B,3Z%:;"*>E8J3JFUT*EH9_8!G;.ZT#31B4BW:Q;:QI)2$*%;$>T\]'=9
M7"P=7.2,.[@@ T539T$J+YR%Y"*GC@]./5 T]0 F)1VY)?T\%R%=H2G1]_D&
M,RP4U7*'(JGCR*WC_E2$=+'N\TP'TV1DV>JCWCG6+><#R*B+I-!,HIU(3%91
MSTK%*447N4^>;C+JG)65QFB<G&+3S?"46,%)641GSIWE(ZN*IOOAN1]RQQO<
M$0@43<U>2BZB(7LA3OT>G'J@:&KJ4LJ16\H]."C6=AG)3*L9W6@*+8<R)/4;
MN?5[ /_H&FW@G\2Q7U(A2A%';A$?PC[Z ?>"](XS'4B#E;5K@Z3,(O<)]PS[
MZ(?69(:UG9#!; ICVY872R'$9\ZV1O8YLPMRQQQ:AJ&BJ3,@E1;#@ R$G;(]
M./5 T=34I7YCMWY[=&1U0<:QWACJS/KEC1,+!^%>O]@MV_X<A'5MCG20)B/+
M@0Q+^<8#V\9V%L+ZL56PT"E5=E;]N;RPH90RB]TG6S<'8?VHVAR[3X^*)K,D
MMDZA%$+L%L*/XBY<IVL&TF(%2KYA%4C%'')PERX?Q(SZ;8O<@PRNS$#1U"F1
M\HN]>]4^I!2T51TJFIJZE'7\W&XUUG5:WW$8C*#U5I5:CGVZU5Z4=+Y=[311
MGV%)/2<^O6HO.NHBN1 Z352$4F^)1X?:2D7$YS1K,+*N+9%J2-QJ.("&SNR/
MW ,-K<=0T=1ID2I,0G:L2=".=:AH:NJ])\+/[5@37:P1U*K(U-:&MLX!D:).
M0K6KR?EVM=-$!2B%G01K5A-#&QKKA6]L5ELVFD2J+7E.LYKH!UP4Q=I#"8-9
ML\HV6I)Z2-QZ^/OA6?7ML>Q>NW9![F"#Z^__:% 3J;;$NT'M]<2>!&U1AXJF
MONPAE9P^MT5-#;UG_6'9.2L5GI1QZM.@]GENWP5RD0_5!7UFA2@%G?JTI[V>
MVU/]G#L;QS/EWREF_<QK(4PJM99Z-*JM3^^I?H!%^LLS!BN";6)#I192MQ8:
M:*C9!3FHR!UP:#6&BJ:FWWOWRKM/[45%-&BG.E0T-7FIX_2YG6JJ"S.$D=Y"
M,-K97^VB4L*I3[_:BXY<K>@.I6X"J0VB%'+JTZ_VHR-#)QH3J'.[P<[Q&A&5
MRDL]>M9V(CHX]]_ 3&*H/1LUF,$H(MI^;=)[B;AY@UO4VEHL'LC9O7 4^SNQ
M$-7AI>C#!2]W[7O%=R7GY;;]N&'IBE6-@?C]OBSYSXOF5>7CJ^F+_P!02P,$
M%     @ $(/T5"%9;ZHU P  . H  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C$N>&ULK99O3]LP$,:_BI6A"23(_Z0I:R-!.S0F(2$JV&N37EH+)^YLIX5]
M^ME)"&F3L@[QIHV3>\Z_YRYV/-HP_B26 !(]9S078V,IY>K<LD2RA P+DZT@
M5T]2QC,LU9 O++'B@.>E**.6:]NAE6&2&_&HO'?+XQ$K)"4YW'(DBBS#_.42
M*-N,#<=XO7%'%DNI;UCQ:(47, -YO[KE:F0U6>8D@UP0EB,.Z=BX<,XGCJT%
M9<0#@8UH72-MY9&Q)SVXGH\-6Q,!A43J%%C]K6$"E.I,BN-WG=1HYM3"]O5K
M]JO2O#+SB 5,&/U%YG(Y-B(#S2'%!95W;/,#:D.!SI<P*LI?M*EBP\! 22$D
MRVJQ(LA(7OWCY[H0+8'C[Q&XM< ]5.#5 J\T6I&5MJ98XGC$V09Q':VRZ8NR
M-J5:N2&Y;N-,<O64*)V,KTB.\X1@BJYS(7FA.B0%.IZ"Q(0*Y)Z@,W0_FZ+C
MHQ-TA$B.;@BEJOYB9$DUO4YB)?54E]54[IZI?A:YB3S[%+FVZ_;()^_+IY H
MN5/*G6VYI4PWSMW&N5OF\_;DFU4O+F(IFK!<<O5"%:H,-U@6G$@"XAQ=K%41
M\".%,[5>SF:8 II!4C_N*T UH]\_HUZ1YV*%$Q@;:LD)X&LPXJ]?G-#^UE>.
M3TJV51RO*8[W7O9X6H!N-LL!O0#FB'%$08A3A#/&)?D#<Y0P(?MJ4"4.R\1Z
M$UG'KA,XIC>RUFUWW3 G\!W3:<*VN/V&V_\8-PA)U*)7W"DF'*TQ+:"/ODH?
M;=%[@1GNT'?#2OI!/WW0T ?_I,>I!/YF0"XY*Q9+E*K-KKQS4 ^"+IX=#4U_
MQT4W+ HCT^TW$38FPL\P<6A#PJX5Q[-;[TEEI1L6#>Q]5@:-E<&!5OZO_(,N
MLV<&.\3=(-<SHW[@J &./@!\:*FC/NSA#G85%+2Q_7[H80,]?!?Z>X-WI?$>
M]N$-.WB>&_BM'E> W3#7][Q]&XMCOWTH[7<Q+YJV3_:TO4X0;A$.AIW-HR=.
M(0:M4E>(5NNSKL]4-Y@O2"[4CI8JH6T.5!=X=4RI!I*MRB_](Y/JW%!>+M71
M#K@.4,]3QN3K0!\>FL-B_!=02P,$%     @ $(/T5&0PE*P" P  J0D  !D
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M+&;!QX#EL.:UQ$>]^PRMG@O'EVEI_2_;-;X7%#&K+>JR!9-="M5\^;ZMPQ&
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M_I(^\3X6=5ULMO^\29/F;YMV@^;[5T51/W[1#G!?E']L#_/R_P%02P,$%
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M%_)T6S[B8Y[F>1J7+]<\7/*L:"#??TCE";U:* 0.S]*9_0=02P,$%     @
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M<(\=P:L=2NJCBGL9N !Q-)]1L@>TL!9HQ449_=);Q"O.BD*YXU1\&@L_/O^
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MM 0  ',:   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;*V9;8^;.!"
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M9WO$M;2BZ8/2^Z6V\A>A.E&>)5=7B=*3BQAS2NA:H"UP]+S!'-#[""0FF?B
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M^HT:_49>IKF -572Y"FF"RM=0NG8T *BC$N)"J6SWE>3]FR"^KE[..P[!.T
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ME@;Z^X9S]?)2=M!<RLV^ 5!+ P04    "  0@_14&1K1>&<'   ?+P  &0
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M(-U6EZ:6T*FY;",2V ,E?!$ETG;O1/*\ WF>EKS[)OV*NJ.BJ@+P.UD"AYY
MEL(*#B<"7RHH=^@*C"FL7#%>I.W6B:1-#J1-^I&&JR*M8FTB=<)SA[Y FFSD
M>N+L"V0CV[&'4X$TA16TA[; FK9?)[+F'UCS7RR %)REA%+,-T5\NB;9(V>Q
MF*_T F3J9<Z7^C7QAU#@43;B>>6(' 6R&?2F0T=@4F'E2ZD<:?MZ(I/3 Y-3
M+9-<)G 1D/'TBS<H6V.P[E![E,NIG"-3B4O9R!+S-I!MX$2:QK+15,SM2-O/
M$UFTK68[;VEY+'=<1]FJG;OI(M%56[7KNY!0@1I(G, J*]$HTG?H5,):^L=^
MF3!P5JT5Y[KR5P-UIN08^M*RH;*;\AIHM?YLD4^%C\VKJSB1%79CVQ+S--+W
M^51.8<,IU&[[PVH?N,#Q/N<[&<Q+8?3Y\OW]!2AWC&=O^:3F4_HVY6M.AHJC
M!?#W[0-E.8K9/TKJH4EE8!0M,(H6&D6+3*%U\Z!1?[96?<RXS!/J.,AQ3-99
M\B]>%JME+1CH(5&4@^_(<V,RD:N6;&:[8W$&!2HTZ$WDVJ6R\VUQW8CT%)Q*
M<:/ ;+T$>XLIO0)*HE'Z.IK'<H<M<8\P5UA9TO9.#24NI@HK3]H3Z[M_*KV-
M#K/U0JP@=I\=N#20S*XBF3V1FWEMYG626=[]J="*9!;5K@*.)[,O[5WT;)S*
M=B/<;$^[;MS&<;[G9-8'112@; G*!5I)I2&]5#-N$BTPBA8:18M,H74'N1&:
MMEYIOGBV<>2,J(;5GV_H8[]Z%'N$#(V&C&HT]<%4E_%&I-IZE?H1/^)LCR]S
MG)8'_'4S*%B1'"P3&I,]EZOE9$-I2IY0%A\I7K*.G/J.= 2@;\ZK!Z%7T-!H
MT$@5U&EOQ[M#T:A<6R]SYR1-T0/)J_S7B0V%'N6[#VF=,*0V:ZI[!0V-!HT4
M09VQVSKFZ3[%:90PU"OAC^0[2HMEN$SL-(F+QZ'9&JRP.KFA0JS:LCC61WTM
MX_V"AD:#1JJ@SKBUU>LRWDAIJ)?2O9,;RBH6>M+6>JX/]VJJ>P4-C0:-%$$=
M>)SJ1F%#K7*;'=T4U7[M)6LR=41BC0K@/B%#HR&C&JU-J]\YB>G2V@A6J!>L
M?Q*&4H#J;6B=P67]($<)EW6B Z>^5*GUD5_->;^HH=&HD2(J=/FR"(_PWJA8
MJ%>Q]R1+Z 58H&R-MN0"!#CCBJLD?H'6ZAIB2!C6HV,2+3"*%AI%BTRA=4>Z
M$=30_7^/!J$AR5KG@4FTP"A::!0M,H76S8-&ZD/]0UKC!RM0?L0ZD<[/Y_I6
MO7I\C:I\HVB1*;3N^#8J'^I5_IQL=R0KI#U9B0LJ?6%%-2FHYT;1 J-HH5&T
MR!1:=\2;4P;H&SR\@R;E^MPH6F 4+32*%IE"ZPYR<WX!]><7QHZ2ZCCM<RY_
M+#Y)U3?FU</:(V1H-&14H[7/W7T+2F<;H];[NUN<K\LWK2DHR:Q>MCS</;S-
M?5N^PRS<O[.OYK;B?F!?A=6[V@U\]>KX.Y2OBZ4WQ2L>RAI.^+8@K][&KBX8
MV95O#S\0QLBV_+K!:(GSPH#_OB*$/5\4 0[OQ,_^ U!+ P04    "  0@_14
M[AD/E+H#   T#P  &0   'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6S%5VUO
MXD80_BLK]U0E4H*QL0U) 2G!H+M*::.CUW[>V(-9W7J7VUU#KK^^XY>X8(Q%
M>DC] KOK>9Z9>788,^.=5%_U&L"0UY0+/;'6QFSN;5M':TBI[LD-"'RRDBJE
M!K<JL?5& 8T+4,IMM]\/[)0R84W'Q=FSFHYE9C@3\*R(SM*4JN^/P.5N8CG6
MV\%GEJQ-?F!/QQN:P!+,E\VSPIU=L\0L!:&9%$3!:F(]./>+46Y?&/S)8*?W
MUB3/Y$7*K_GF4SRQ^GE P"$R.0/%KRW,@/.<",/X5G%:M<L<N+]^8U\4N6,N
M+U3#3/*_6&S6$VMDD1A6-./FL]Q]A"H?/^>+)-?%)]E5MGV+1)DV,JW &$'*
M1/E-7RL=]@#(TPYP*X#;!'@G (,*,#C7@U<!O',]^!7 /Q<05("@T+X4JU Z
MI(9.QTKNB,JMD2U?%-=5H%%@)O+"6AJ%3QGBS/1WLP9%9E)HR5E,#<1DP005
M$:.<+ T>8!49<A6"H8QK\@>\FHSR:W)+OBQ#<O7AFGP@3) GQCE6BA[;!J/*
MN>VHBN"QC, ]$<& /$EAUIK,10QQ"S[LQ@<=>!O5J"5QWR1Y=#L)?\U$CPSZ
M-\3MNVY+/+/SX4Y;.C_F??YCWA?=\! BA#MM\ ,M!W5Y#0H^[P3?;]@:$VQO
M&IM0)!/!_L8"PX:"58=5$V$KU/F"K"A39$MY!D2N"'S+F/E.-$298H9!:U65
MCH/"<=X^M]/;8=#SQ_9V_ZZ.K1Q_T+L[M I;N-Q@V/,.S>9M9J-1TVS1*4G^
MIKC7&QK!Q,)7@0:U!6OZ\T].T/^E0W"O%MP[4_ K+K4&?8W*4U[H'J.:(BFT
MWX!BLKB)L[0N?8[V$^_WA@VIO2-U^DUIPE:BQIW-CXF"7M#0N%.%_ZBQ7VOL
M=VI<]DPN17)K0*6$,_K"^$GQ_*.<'0>+:]20K]/G^1F5.I_G<WY)GPO_^*<V
M</=O]T#LH!8[Z!3[(8I4AL6+W4*F0 Q];5<Y.,K8N[MKELVLT]=[10Z.$FYQ
M.;^DR\6QRR#P3DD\K"4>=DK\20JF;\B2BH2F\H:$(+!C$"IB/$N@3>U.PG<F
M-;LD67A)LODER187(CNXXE%]Q:/_ZST\.BK)H=\;-'YWG=&]]XHO23:_)-GB
M0F3E%=M[_^I34$DQ?VD2R4R8\A]8?5J/> _%9-,X?W3N9T[+>>C<S\L)[E_Z
M<IY\HBK)BX7#"EWAJQY[NRIGM')CY*:8*5ZDP0FE6*YQK 65&^#SE93F;9,[
MJ ?EZ3]02P,$%     @ $(/T5-$AH!,7%P  #&<! !D   !X;"]W;W)K<VAE
M971S+W-H965T-S@N>&ULS=UK<YM8GL?QMT)YI[;25;VV0$*2LXFK''._32J9
MWGTPM0^(1&RV=7$CG,M4O_@%&1L=.#X6G6_*VP]F' <^!R/__Q%'/PYOOFZ+
MWW<W659JW]:KS>[MR4U9WKX^.]LM;K)UNCO=WF:;ZF\^;XMU6E9_+*[/=K=%
MEB[W.ZU79\9H-#U;I_GFY.+-_GOOBXLWV[MRE6^R]X6VNUNOT^+[NVRU_?KV
M1#]Y^,:'_/JFK+]Q=O'F-KW./F;E;[?OB^I/9X_*,E]GFUV^W6A%]OGMR:7^
M.IE/ZQWV6_Q7GGW='7RMU3_*I^WV]_H/_O+MR:@^HFR5+<J:2*O_^Y)=9:M5
M+57'\4>#GCR.6>]X^/6#[NQ_^.J'^93NLJOMZK_S97GS]F1^HBVSS^G=JORP
M_>IES0]DUMYBN]KM_U?[VFP[.M$6=[MRNVYVKHY@G6_N_S_]UIR(@QT,XXD=
MC&8'X]@=QLT.XV-WF#0[3([=P6QV,(_=8=KL,#UVAUFSP^S8'>;-#O-C=SAO
M=C@_=@=]]/#*C8[>Y?'%/OK5UA]>;OWHUUM_>,'UHU]Q_>$EU_>O^=G]K^_^
M=]]*R_3B3;']JA7U]I57?[$OH/W^U:]\OJEK_6-95'^;5_N5%U6-K-)/VR*M
M2TY+-TOM[^5-5F@?LE5:%^/N)K_=:?^A'6Q7?5-[965EFJ]VOVA_T_*-%N>K
M5?W]-V=E=4RU?+9HQG]W/[[QQ/BZ%F\WY<U.LS?+;"G9WU'O/WYN_UB]_U2Q
M_UEU+A]/J/%P0M\92O#RMCC5QJ-?-6-D&-IO'RWMU=]^D1S7U3/,W77%Z'M&
M5S"6F@GN-H]'HV)L-6-EBX>CT<^UVV*[O%N4LA=+S<1I\?A#C15'XQ[_0ZE.
ML7?\T:@8_^ASHSS%@9KYF-T>]4J%S L>'7]N1@HF9EZIY(=_**%6QX_-;[QW
MQT<UO\NB2#?76?5&IMPWPL,_WS?%\B;=:.)._XPJ4_/+;+W['UGWNS^ B?P
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M-/'XM5O4T."J1C.(J&:CFH-J;J,)M\\9O1N"/'10O]$.?Y'UR?S@GKVFLM&
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MU7Q4"U M1+4(U6)42RA-Z#?S-CTY?_$U)^=HOA+5+%2S4<U!-1?5/%3S42U
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M(8KF#O6_W^5Y]?Q+,\&WO/A]^S!O_P-02P,$%     @ $(/T5"1X=FCZ!@
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M+IC("JC[2ZY>JO(D<U!M3Y_]!U!+ P04    "  0@_14>"?LA.4"  "M"@
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M<0)#1Y=1"6(+3O3VC1]Z'YN">4RR^)ADDV.238]$]D<2=*LDZ+:QU^L'3@6
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M;&.9N;T\L\/1XHZJ\SSJ/5R &FV@M "4%H+2,!3-C(;&;7-?F=WF@OIMH+0
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M/_9=?=6\WOT%:??WJ7?_ E!+ P04    "  0@_149LT1.G0"  !M,   &@
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M<' N>&UL4$L! A0#%     @ $(/T5'H_)%'M    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $(/T5)E<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  0@_14H!ZM9K\%  "Y'@  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $(/T5&J76'XB
M"   R2<  !@              ("! 0X  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( !"#]%1L2),4SP0  )D3   8              "
M@5D6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  0@_14
MA2I.8" '  #1'@  &               @(%>&P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ $(/T5#4:">2<"   *B4  !@
M     ("!M"(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M !"#]%0D9@0+514  ,T_ 0 8              " @88K  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  0@_14@@;0&,<.  !$)@  &
M            @($100  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ $(/T5- WV]" !@  7A   !@              ("!#E   'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !"#]%2_%BUA1@H  /49
M   8              " @<16  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  0@_14TV1+- \%  "1#   &0              @(% 80
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !"#]%3KE?4,
ML0D  #@;   9              " @89F  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ $(/T5#J:+V[%#   <R@  !D
M ("!;G   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  0
M@_14T=,?=UD(  "@%P  &0              @(%J?0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !"#]%22DS8_1@P  &TJ   9
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M970Q."YX;6Q02P$"% ,4    "  0@_14B@TFNH($  !S"P  &0
M    @(&"IP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M !"#]%0,UY25:@@  ',5   9              " @3NL  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ $(/T5!GSMO0<!P  '!0  !D
M             ("!W+0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  0@_14MZX89<@9   X7   &0              @($OO   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !"#]%0]DG@D)P@
M &P7   9              " @2[6  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ $(/T5$$REN95$P  KC<  !D              ("!
MC-X  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  0@_14
M=LBO.P,"  "=!   &0              @($8\@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( !"#]%2J2K"4G@8  $40   9
M      " @5+T  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ $(/T5'TY=+>R#@  (2<  !D              ("!)_L  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  0@_14[ALYY?D"  ">!@
M&0              @($0"@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( !"#]%2#/D<[B0D  !<9   9              " @4 - 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ $(/T5.W"7-N\
M @  \04  !D              ("! !<! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  0@_14V\R\_C($  !I"@  &0
M@('S&0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !"#
M]%0?5EI\4P@  (X7   9              " @5P> 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ $(/T5+P#A:]'!@  91(  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( !"#]%1:L+98<0,  *4'   9
M  " @0]" 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M$(/T5*Z&@G,W!@  Z \  !D              ("!MT4! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  0@_14V78$XZL$  !E#P  &0
M            @($E3 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( !"#]%1(8+" 5P(  $X%   9              " @0=1 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ $(/T5 M!C+8C!
M(!D  !D              ("!E5,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  0@_14ZR6@W_(#  !K%   &0              @('O
M5P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !"#]%0,
MI*0'"Q,  )3G   9              " @1A< 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ $(/T5,FSB[FA!   <A8  !D
M     ("!6F\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !"#]%0]F MWU0(  '4)   9              "
M@0>$ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ $(/T
M5(R&T*EI!0  :BX  !D              ("!$X<! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  0@_14*GJI\Z()  #6:@  &0
M        @(&SC $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( !"#]%2N6-;KD@(  %4&   9              " @8R6 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ $(/T5($0^>9L#P  @=4
M !D              ("!59D! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  0@_14YZ6L^>,"  #M"   &0              @('XJ $
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !"#]%2$#LHW
MA@(  %4(   9              " @1*L 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ $(/T5)&XLH,;!0  KA\  !D
M ("!SZX! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  0
M@_14-FP1 $P#   D#0  &0              @($AM $ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( !"#]%2XQ2G0C ,  /P0   9
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M970V,RYX;6Q02P$"% ,4    "  0@_14UW!Y8VT"   \!@  &0
M    @('TRP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M !"#]%301K(:&A(  +4  0 9              " @9C. 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ $(/T5-5'O,OF!   !B(  !D
M             ("!Z> ! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    "  0@_14>(W6CO<&  !71P  &0              @($&Y@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( !"#]%0N=I2TC0,
M /,0   9              " @33M 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ $(/T5(01$W"I"   OT<  !D              ("!
M^/ ! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  0@_14
MFF=JPW,&   S*P  &0              @('8^0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( !"#]%2%A6/,M 0  ',:   9
M      " @8(  @!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ $(/T5"^(L^BA!   (AD  !D              ("!;04" 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  0@_14CI%'H#4%   ^(0
M&0              @(%%"@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( !"#]%0>OR,B,@0  *$>   9              " @;$/ @!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ $(/T5*Y,$025
M!   H!,  !D              ("!&A0" 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    "  0@_14&1K1>&<'   ?+P  &0
M@('F& ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( !"#
M]%3N&0^4N@,  #0/   9              " @80@ @!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ $(/T5-$AH!,7%P  #&<! !D
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M=#@R+GAM;%!+ 0(4 Q0    ( !"#]%3>,?</=P,  ,\7   -
M  "  3M= @!X;"]S='EL97,N>&UL4$L! A0#%     @ $(/T5)>*NQS
M$P(   L              ( !W6 " %]R96QS+RYR96QS4$L! A0#%     @
M$(/T5#$;H:3@!0  PC4   \              ( !QF$" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( !"#]%1FS1$Z= (  &TP   :              "
M =-G @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !"#
M]%02 6)0(0(  " O   3              "  7]J @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !: %H K1@  -%L @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>735</ContextCount>
  <ElementCount>384</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>144</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2139108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2154113 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2162115 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2166116 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2170117 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2172118 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2174119 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2175120 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2355310 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2363312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2367313 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2464436 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2465437 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2473441 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2476442 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20220630.htm">biib-20220630.htm</File>
    <File>biib-20220630.xsd</File>
    <File>biib-20220630_cal.xml</File>
    <File>biib-20220630_def.xml</File>
    <File>biib-20220630_lab.xml</File>
    <File>biib-20220630_pre.xml</File>
    <File>biib-2022630xex311.htm</File>
    <File>biib-2022630xex312.htm</File>
    <File>biib-2022630xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20220630_g1.jpg</File>
    <File>biib-20220630_g10.jpg</File>
    <File>biib-20220630_g11.jpg</File>
    <File>biib-20220630_g12.jpg</File>
    <File>biib-20220630_g13.jpg</File>
    <File>biib-20220630_g14.jpg</File>
    <File>biib-20220630_g15.jpg</File>
    <File>biib-20220630_g16.jpg</File>
    <File>biib-20220630_g17.jpg</File>
    <File>biib-20220630_g18.jpg</File>
    <File>biib-20220630_g19.jpg</File>
    <File>biib-20220630_g2.jpg</File>
    <File>biib-20220630_g20.jpg</File>
    <File>biib-20220630_g21.jpg</File>
    <File>biib-20220630_g22.jpg</File>
    <File>biib-20220630_g3.jpg</File>
    <File>biib-20220630_g4.jpg</File>
    <File>biib-20220630_g5.jpg</File>
    <File>biib-20220630_g6.jpg</File>
    <File>biib-20220630_g7.jpg</File>
    <File>biib-20220630_g8.jpg</File>
    <File>biib-20220630_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1543">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20220630.htm": {
   "axisCustom": 5,
   "axisStandard": 33,
   "contextCount": 735,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 711,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 16
   },
   "keyCustom": 74,
   "keyStandard": 310,
   "memberCustom": 76,
   "memberStandard": 63,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154113 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162115 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166116 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170117 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172118 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174119 - Disclosure - Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175120 - Disclosure - Dispositions",
     "role": "http://www.biogenidec.com/role/Dispositions",
     "shortName": "Dispositions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355310 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367313 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserveAccrualAdjustment1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues - Revenues by product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "shortName": "Revenues - Revenues by product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i47841ad34b76402897680f541339e3a0_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "iab432a874db444408172f33c16977803_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "ibd11859d947e4dc8bc77e57e9ba6ded7_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Revenues - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues - Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "icdb9e7fc3fdf4dc9a9ee227b36aeed4c_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Inventory - Components of Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "shortName": "Inventory - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Inventory - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i690a67cc5731414a8f9aa06c53540e02_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i0fd7a7d2f9364202b4b43cc6593f0fb6_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "if2ac8144dad34592a0e0d767e503cd0c_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "if2ac8144dad34592a0e0d767e503cd0c_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2455559f227c4f65a8e32a02250a6b37_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2455559f227c4f65a8e32a02250a6b37_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i555cfe30ceb9456ab09f4c3dbf21fcf0_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i65ad03e37af84a41bf8a69fdca5275ba_I20150915",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i65ad03e37af84a41bf8a69fdca5275ba_I20150915",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i18f30485bd8748f68ef275fcb514e0b7_I20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i12af56ba242049728b6eb6a1d817a8b8_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i05576bec60da463ba40fa81a1d5d6213_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i06e3f4c497b04721b2a471a9d1462e90_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i10419c7fca6040f5b7f54c27a139c129_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i7cc7449e1d4248ee94e3a7a6a2b8c0e6_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464436 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465437 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "ia1cd448e6abb45bd9d62ccf5ff57bffb_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i0dd95981381d46b7a30d0a586d846fb5_I20181107",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2d296c26357241e7b67a82ed0b3eb02a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i852ff350063140c2bb0be923b3509114_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473441 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i12af56ba242049728b6eb6a1d817a8b8_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476442 - Disclosure - Dispositions (Details Textual)",
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "shortName": "Dispositions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i2cb2cf98fd9549a4b68f0d966327fbfd_D20220101-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "biib:OtherAssetsFairValueMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220630.htm",
      "contextRef": "i201a6d2ab6b448ba991a559e95939ec5_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 144,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share Repurchase Program [Member]",
        "label": "2020 Share Repurchase Program [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "A2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ADUHELMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADUHELM",
        "label": "ADUHELM [Member]",
        "terseLabel": "ADUHELM"
       }
      }
     },
     "localname": "ADUHELMMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Milestone Payments",
        "label": "Accrued Milestone Payments",
        "terseLabel": "Accrued milestone payments"
       }
      }
     },
     "localname": "AccruedMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111AndBIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 and BIIB112",
        "label": "BIIB111 and BIIB112 [Member]",
        "terseLabel": "BIIB111 and BIIB112"
       }
      }
     },
     "localname": "BIIB111AndBIIB112Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BYOOVIZMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "terseLabel": "BYOOVIZ"
       }
      }
     },
     "localname": "BYOOVIZMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CentersForMedicareAndMedicaidServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centers for Medicare and Medicaid Service",
        "label": "Centers for Medicare and Medicaid Service [Member]",
        "terseLabel": "Centers for Medicare and Medicaid Service"
       }
      }
     },
     "localname": "CentersForMedicareAndMedicaidServiceMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "terseLabel": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_ContingentMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Milestone Payments Made To Collaborative Partner",
        "label": "Contingent Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Contingent additional milestone payment"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CostOfGoodsSoldCapacityCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods Sold, Capacity Charges",
        "label": "Cost of Goods Sold, Capacity Charges",
        "terseLabel": "Cost of Goods Sold, Capacity Charges"
       }
      }
     },
     "localname": "CostOfGoodsSoldCapacityCharges",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Rate",
        "label": "Debt Instrument, Redemption Rate",
        "terseLabel": "Redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionRate",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DiscreteIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discrete Income Tax Expense (Benefit)",
        "label": "Discrete Income Tax Expense (Benefit)",
        "terseLabel": "Discrete income tax expense (benefit)"
       }
      }
     },
     "localname": "DiscreteIncomeTaxExpenseBenefit",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "terseLabel": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationInternationalReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, International Reorganization",
        "label": "Effective Tax Rate Reconciliation, International Reorganization",
        "terseLabel": "International reorganization"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationInternationalReorganization",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationLitigationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Litigation Agreement",
        "label": "Effective Tax Rate Reconciliation, Litigation Agreement",
        "terseLabel": "Litigation agreement in principle"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationLitigationAgreement",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "terseLabel": "Neurimmune tax impacts"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis",
        "label": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis",
        "terseLabel": "Sale of Samsung Bioepis"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationSaleOfSamsungBioepis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Expected Profit Share",
        "label": "Equity Method Investments, Expected Profit Share",
        "terseLabel": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InnoCarePharmaLimitedInnoCareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InnoCare Pharma Limited (InnoCare) Agreement",
        "label": "InnoCare Pharma Limited (InnoCare) Agreement [Member]",
        "terseLabel": "InnoCare Pharma Limited (InnoCare) Agreement"
       }
      }
     },
     "localname": "InnoCarePharmaLimitedInnoCareAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Net Current and Noncurrent",
        "label": "Inventory, Net Current and Noncurrent",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LecanemabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lecanemab",
        "label": "Lecanemab [Member]",
        "terseLabel": "Lecanemab"
       }
      }
     },
     "localname": "LecanemabMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Capital Contribution",
        "label": "Noncontrolling Interest, Capital Contribution",
        "terseLabel": "Capital contribution from noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestCapitalContribution",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_OtherAssetsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Current, Fair Value Disclosure,",
        "label": "Other Assets, Current, Fair Value Disclosure,",
        "terseLabel": "Other current assets, receivable"
       }
      }
     },
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OtherAssetsFairValueMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Fair Value, Measurement Input",
        "label": "Other Assets, Fair Value, Measurement Input",
        "terseLabel": "Other Assets, Current, Fair Value, Measurement Input"
       }
      }
     },
     "localname": "OtherAssetsFairValueMeasurementInput",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "decimalItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PLEGRIDYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "terseLabel": "PLEGRIDY"
       }
      }
     },
     "localname": "PLEGRIDYMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables To Divestiture Of Interest In Joint Venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "terseLabel": "Payables to divestiture of interest in joint venture"
       }
      }
     },
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent",
        "label": "Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent",
        "terseLabel": "Contingent discount on common shares"
       }
      }
     },
     "localname": "PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "terseLabel": "Payment Due At First Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "terseLabel": "Payment Due At Second Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "xbrltype": "stringItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentAssetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Domain]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetDomain",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "verboseLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGainOnDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "terseLabel": "Unrealized Gain on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedLossOnDerivatives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "negatedTerseLabel": "Unrealized Loss on Derivatives"
       }
      }
     },
     "localname": "UnrealizedLossOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VUMERITYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VUMERITY",
        "label": "VUMERITY [Member]",
        "terseLabel": "VUMERITY"
       }
      }
     },
     "localname": "VUMERITYMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WorkforceReductionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce Reduction",
        "label": "Workforce Reduction [Member]",
        "terseLabel": "Workforce Reduction"
       }
      }
     },
     "localname": "WorkforceReductionMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20220630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r145",
      "r313",
      "r318",
      "r324",
      "r485",
      "r486",
      "r493",
      "r494",
      "r570",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r145",
      "r313",
      "r318",
      "r324",
      "r485",
      "r486",
      "r493",
      "r494",
      "r570",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r67",
      "r69",
      "r143",
      "r144",
      "r330",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r215",
      "r401",
      "r405",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r329",
      "r367",
      "r420",
      "r422",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r664",
      "r668",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r329",
      "r367",
      "r420",
      "r422",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r664",
      "r668",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r215",
      "r401",
      "r405",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r401",
      "r403",
      "r611",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r401",
      "r403",
      "r611",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r329",
      "r367",
      "r411",
      "r420",
      "r422",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r664",
      "r668",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r329",
      "r367",
      "r411",
      "r420",
      "r422",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r609",
      "r664",
      "r668",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r143",
      "r144",
      "r330",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r160",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r160",
      "r165",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r401",
      "r404",
      "r666",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r401",
      "r404",
      "r666",
      "r691",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r160",
      "r165",
      "r307",
      "r421",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r584",
      "r586",
      "r589",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "December 31, 2021"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r31",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r28",
      "r617",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r77",
      "r82",
      "r90",
      "r91",
      "r92",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r72",
      "r82",
      "r90",
      "r91",
      "r92",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r92",
      "r93",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r82",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r92",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r80",
      "r81",
      "r82",
      "r645",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r79",
      "r82",
      "r90",
      "r91",
      "r92",
      "r152",
      "r153",
      "r154",
      "r492",
      "r669",
      "r670",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r72",
      "r82",
      "r90",
      "r91",
      "r92",
      "r492",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r435",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r432",
      "r433",
      "r434",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r128",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r424",
      "r429",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r231",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r128",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r138",
      "r200",
      "r204",
      "r210",
      "r248",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r485",
      "r493",
      "r547",
      "r571",
      "r573",
      "r615",
      "r642"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r65",
      "r138",
      "r248",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r485",
      "r493",
      "r547",
      "r571",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r222",
      "r255"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r226",
      "r229",
      "r638"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r226",
      "r228",
      "r637"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r219",
      "r223",
      "r255",
      "r621"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r221",
      "r255"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r221",
      "r255"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r425",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r471",
      "r472",
      "r474"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r471",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r125",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r125",
      "r552"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r476",
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r306",
      "r624",
      "r650"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments, contingencies and guarantees"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r86",
      "r88",
      "r89",
      "r101",
      "r630",
      "r658"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r88",
      "r100",
      "r483",
      "r484",
      "r502",
      "r629",
      "r657"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r88",
      "r99",
      "r482",
      "r502",
      "r628",
      "r656"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r412",
      "r419",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r106",
      "r611"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r343",
      "r350",
      "r351",
      "r353",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r137",
      "r145",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r355",
      "r356",
      "r357",
      "r358",
      "r565",
      "r616",
      "r618",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r326",
      "r355",
      "r356",
      "r563",
      "r565",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r341",
      "r355",
      "r356",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r137",
      "r145",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r355",
      "r356",
      "r357",
      "r358",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r137",
      "r145",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r382",
      "r385",
      "r386",
      "r387",
      "r562",
      "r563",
      "r565",
      "r566",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r139",
      "r452",
      "r458",
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r128",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r128",
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r510",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r510",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r69",
      "r509",
      "r511",
      "r518",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r529",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r507",
      "r509",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r516",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Dispositions"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r142",
      "r316",
      "r318",
      "r319",
      "r323",
      "r324",
      "r325",
      "r569",
      "r622",
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r142",
      "r316",
      "r318",
      "r319",
      "r323",
      "r324",
      "r325",
      "r569",
      "r623",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r102",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r166",
      "r168",
      "r173",
      "r174",
      "r175",
      "r179",
      "r180",
      "r531",
      "r532",
      "r631",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r102",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r168",
      "r173",
      "r174",
      "r175",
      "r179",
      "r180",
      "r531",
      "r532",
      "r631",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r140",
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r442",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r182",
      "r249",
      "r381",
      "r388",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r530",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r669",
      "r670",
      "r671",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity, ownership interest",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r103",
      "r104",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis(1)"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r45",
      "r201",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r243",
      "r660"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "verboseLabel": "Less: Net gains (losses) realized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r243",
      "r660"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Net unrealized gains (losses) recognized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r534",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r341",
      "r355",
      "r356",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r535",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r534",
      "r535",
      "r538",
      "r539",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r341",
      "r412",
      "r413",
      "r418",
      "r419",
      "r535",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r341",
      "r355",
      "r356",
      "r412",
      "r413",
      "r418",
      "r419",
      "r535",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r341",
      "r355",
      "r356",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r535",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r540",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r341",
      "r355",
      "r356",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "verboseLabel": "Fair Value, Measurements Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r508",
      "r513",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r240",
      "r241",
      "r242",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r352",
      "r379",
      "r529",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r271",
      "r273",
      "r276",
      "r280",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r276",
      "r613"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r276",
      "r612"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r69",
      "r412",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r509",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r128",
      "r359",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r263",
      "r264",
      "r573",
      "r614"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r265",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r507",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r128",
      "r281"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r200",
      "r203",
      "r206",
      "r209",
      "r211"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r96",
      "r128",
      "r198",
      "r244",
      "r625",
      "r653"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "(Gain) loss on equity method investments",
        "terseLabel": "(Gain) loss on equity method investments",
        "verboseLabel": "Income (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r288",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r445",
      "r446",
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r443",
      "r447",
      "r451",
      "r456",
      "r462",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r163",
      "r164",
      "r199",
      "r441",
      "r457",
      "r463",
      "r661"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r123",
      "r239"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r175"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r272",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r272",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r270",
      "r274"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r94",
      "r196",
      "r561",
      "r564",
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest Expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r38",
      "r261"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r63",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r261"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r39",
      "r261"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Excess and obsolescence charges related to inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r108",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52",
      "r138",
      "r205",
      "r248",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r486",
      "r493",
      "r494",
      "r547",
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r138",
      "r248",
      "r547",
      "r573",
      "r620",
      "r648"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r138",
      "r248",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r486",
      "r493",
      "r494",
      "r547",
      "r571",
      "r572",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation agreement in principle",
        "verboseLabel": "Litigation agreement in principle"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r27",
      "r340",
      "r354",
      "r355",
      "r356",
      "r618",
      "r644"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r308",
      "r309",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r138",
      "r248",
      "r313",
      "r318",
      "r319",
      "r320",
      "r324",
      "r325",
      "r547",
      "r619",
      "r647"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r125",
      "r126",
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r84",
      "r87",
      "r92",
      "r97",
      "r129",
      "r138",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r172",
      "r200",
      "r203",
      "r206",
      "r209",
      "r211",
      "r248",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r532",
      "r547",
      "r626",
      "r654"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r87",
      "r92",
      "r163",
      "r164",
      "r489",
      "r501"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r388",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r27",
      "r618",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other assets.",
        "label": "Other Assets, Fair Value Disclosure",
        "terseLabel": "Other assets, receivable"
       }
      }
     },
     "localname": "OtherAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r74",
      "r75",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r93",
      "r553",
      "r555",
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r73",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r80",
      "r83",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r71",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "negatedTerseLabel": "Cumulative translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain on derivative used in net investment hedge"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r85",
      "r88",
      "r90",
      "r91",
      "r93",
      "r98",
      "r381",
      "r553",
      "r558",
      "r559",
      "r627",
      "r655"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r85",
      "r88",
      "r482",
      "r483",
      "r491"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r78",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r508",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r53",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other (income) expense, net",
        "negatedTerseLabel": "Other (income) expense",
        "terseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringCosts": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.",
        "label": "Other Restructuring Costs",
        "terseLabel": "Other restructuring costs"
       }
      }
     },
     "localname": "OtherRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r113",
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r122",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payment"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r110",
      "r114",
      "r220"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "terseLabel": "Proceeds from divestiture of interest in joint venture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "terseLabel": "Net (distribution) contribution to noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r110",
      "r111",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "negatedTerseLabel": "Proceeds from sale of equity in Samsung Bioepis"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of investments classified as other.",
        "label": "Proceeds from Sale of Other Investments",
        "terseLabel": "Proceeds from the sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r84",
      "r87",
      "r92",
      "r124",
      "r138",
      "r155",
      "r163",
      "r164",
      "r200",
      "r203",
      "r206",
      "r209",
      "r211",
      "r248",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r482",
      "r488",
      "r490",
      "r501",
      "r502",
      "r532",
      "r547",
      "r633"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r291",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r23",
      "r24",
      "r287",
      "r573",
      "r639",
      "r649"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "Gains (losses) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r93",
      "r553",
      "r557",
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r438",
      "r610",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r295",
      "r298",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r128",
      "r292",
      "r299",
      "r301"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r295",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending",
        "periodStartLabel": "Restructuring reserve, beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Accelerated depreciation expense"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r295",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r388",
      "r435",
      "r573",
      "r646",
      "r672",
      "r674"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r249",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r530",
      "r669",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r95",
      "r138",
      "r193",
      "r194",
      "r202",
      "r207",
      "r208",
      "r212",
      "r213",
      "r215",
      "r248",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r547",
      "r633"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r82",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r227",
      "r230",
      "r233",
      "r234",
      "r235",
      "r237",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r509",
      "r518",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r424",
      "r428",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r424",
      "r428",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r12",
      "r138",
      "r247",
      "r248",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r271",
      "r275",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r22",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r295",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r135",
      "r183",
      "r184",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r374",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r485",
      "r486",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.",
        "label": "Settlement Liabilities, Current",
        "terseLabel": "Litigation agreement in principle(1)"
       }
      }
     },
     "localname": "SettlementLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r423",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r132",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r90",
      "r91",
      "r92",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r182",
      "r249",
      "r381",
      "r388",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r530",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r669",
      "r670",
      "r671",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r182",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r381",
      "r388",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r30",
      "r381",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r381",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r29",
      "r30",
      "r381",
      "r388",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r29",
      "r30",
      "r381",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r35",
      "r36",
      "r138",
      "r218",
      "r248",
      "r547",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r138",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r248",
      "r249",
      "r388",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r480",
      "r481",
      "r500",
      "r530",
      "r547",
      "r553",
      "r554",
      "r559",
      "r670",
      "r671",
      "r722"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r388",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r560",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r560",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r560",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r574",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r240",
      "r241",
      "r242",
      "r352",
      "r379",
      "r529",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r60",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r30",
      "r381",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r30",
      "r381",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r60",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r381",
      "r388",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r412",
      "r634",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized Gain (Loss) on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r146",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r175"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r166",
      "r175"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r709": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r710": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r711": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r712": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r713": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r721": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0000875045-22-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-22-000025-xbrl.zip
M4$L#!!0    ( !"#]%0HF9TPT)8$ /KW-@ 1    8FEI8BTR,#(R,#8S,"YH
M=&WLO6UW%$>R+?S]_@H__GPTSI?(S BO&=^%S<O1N4AX -L#7V9%9$9"8[UP
M6A(&?OT3*1 &#Q[;8]'551+V JFKNKJZ]L[<.S(C(__Z?U\>'GSV0M<GJ^.C
MOWWN_^(^_^S_?O77_V]GYQ]?W[_[V<WC>G:H1Z>??;-6/M7VV4^KTZ>?_=#T
MY,?/^OKX\+,?CM<_KE[PSL[Y>[XY?OYJO7KR]/2SX$+XQ<'UEXV<DY+23DV0
M=R"UML.AZ4YFC:G%"#&X_WKR9=:,N;2R$[O''8 4=K!YVO&5(G/U,=7\7^U+
M5E\2=B>N=/ .R:?*6GOO,91:SC_VZ:E]._N&1R=?KDZ.(?CRM\^?GIX^__*+
M+W[ZZ:>_O)3UP5^.UT^^",[%+]Z>\?F;-WQPXD_Q_#1/1%^\'!=]>]*7XPIM
M]>[<]R^8OWAS\-VI!ZNC'W_]JN/H^U==_;L[/3HYY:.J%^>O7O[:R7Z<;)?6
M >?%Z4U_<<<G6O_RY/C%%W; WA/\_\+%J?7X[.AT_>KCI[\]>/Z6BS><K$_?
MG=SY1,[OPUX\/VG'^9WX[M27)ZN//0[[AOZ+?^S=?5"?ZB'O_/*[UK/U6H_J
MK]W2VZ,?W-._//@/G^8X+'SR[A/.3M>_>C9]84<O3I352CXX4U;'3_1HU>QF
MZO'AN(?@<G0_PW2Z8S?ZP5LN;OQGE+XX7?/123]>'_*I-<H!8MIQ^-Z#.SO9
M><+\_%^?\]L#'WG6]M$?_T[_[G.#VW%AQX?SBWQYP$=/_O:Y'NU\]^!S:UG*
M[:N_'NHI?S8NNZ/_>[9Z\;?/OSD^.K7^8N?AJ^?V/.N;W_[V^:F^//WBO-U\
M\=7_^3__YZ^GJ],#_6H\OYV+A_37+]Z\^-<OWEQ:CMNKK_[:5B\^.SE]=:!_
M^[RM3IX?\*LOCXZ/U&Y@]?++<:*NW_RX:DV/SG^TX_O6::U7]<WGOSR]K_UO
MGZ_L.7)N@24+  H3>4Z)E!)%TIK^>?/\5KP]MY^!.^+#\=&Z^O+6D=W?JV_L
MZZSY8/>HZ<O_IZ\^_VS5[-(M?O]*;AZ_N!ONOW@4]\[:LULO'M^A9_<.;Q_L
M/:S^WIU'/SUZ=B,^?O;WEWLWGZ2]A]\_>_3#]\\>'SX^W'N]&Q^];D_OQOV#
M1Z^?/WW\\%;<?_CT<._.[D_[X9';>W@#[CV\Y1^%VP>/@KWCV=ZK_; 7'WV/
M[FYX_.K1#S7OO7Y\<._F;MP+CUX^_N%6V+_SW:O]FS\F>Q_LA_OC6G[OSJWT
M^-F/+]J=VRNY\UVV>W)VSJN]9[=7^W=NV?E/?WQL_S[ZX9&_=_/^CWL/OWM]
M[X==N^_OWK[G>SN6CAX_/ ;['N[>P]U7>S_LND</=]V]._=_?/3P?YX^?O8=
M[-_Y^\O]AWOIT;.O5_O?X\N[#V^=[CUPX]^?]I]]]]/>DW\Z#JF&K#M*U3IX
M1=JAG/M.)FV@I1)C__PK9W^P) ?IKU]\ .NG1/F;\_[C]/;JI/+!(^7UK:-V
MTY3O\\_>- S[A)>G7S9[9>?0/O;I3N-K$OPF"5Y]A 3:L96@NI-ZJCLFX+0C
M%?U.RQT=E*A)ZN=?^?!%]!O$_\+P_$R V_;*R37$OP7QZX] W(0T!(0=3=5;
M.\]Y1UI..T01?%)JC=/G7PT8)D/X6[O^<;O&^'=A[#Z",7+(Q)1VH!5G?S7>
MD=QE!TOTK=08O.?/O_K[)MOP#8.WG4-\P$^N4?TM5/U'4*W):0W4=CK58)%:
M,H6VT&BGB 5:@*[F[C__JO/!B?X*L+?77(>-_.SL:/4&UI.GO-:3SS^$FE+F
M6BJ[7")49N+22Q$&GUV+&O^Y>XYP\?3Y9V:K5X?VD7_[?'?_]D>LV?&A2?*#
MT^/ZXX/SC[IW=CI"A[8Z>O*A?!^='>ZTX].=MQ?\_+/1$]BUW#59?HLLX>[#
MW5^2Q6/2"FA=@,;1!;#N<$YE!VOLJ3D)4;,I.:3_\C[^EVG[!64N./)O.P-M
MQ:L9QJ@@4(P(4,8'"OCF*B3X-YW!VW#HR]LKXZ#>7;W0MGMDC'BRD@.]<7*B
MI]^=:#\[N+OJ'QJ\$:5]V<[6KTS_I^5$V/^&#NOA[:-[S_;BXYN[K_?N/$I[
MAX_"_NN_^\</#9_7-=[[X?&/CY[=_O'QPZ>KO==_#W?C_:>/#E\>W'MV^V#_
MYBUX_/"&O_?#WU_9L9=[K^V<PUVW?[CWZM'#QZN]\#]/'X6]UQ?OL<\Z>QR^
MRWL_?&?W]?1@[^9W:7RN7>?UO3N[KQX]^WMX]/I_GNX?[KY^='C[V:/7^_TM
M'\YYL7?SD=^[N?O/ZH4E!(M<V;<=0$@[G+SNE ;=)"&64$S[X8_(0D:M6AJ:
MY"1PP?XM7)!3SLX5*/V:"=,S8?6O3%!E)0F\$Y,S+8F .^(A[E!#3=9#&')D
M+A!_MY!8]RVZ_H60."-< (P@Q7J%V!%-2"@A1&\.Q?6W0G+.B8\*R05%;JJ<
M[AZ=G*[/7:*Q1$U*3N];Q/?@= R!FF.L=H"?Z#O=V G34B/NO:.&=?(W'_^X
M_WHW/'IV_V#_V?VG>S\\2@.F1Z]OO3J'_MGWJT<F(C]3X_M#@]@_?G8CF*C\
MM&?O>7SG$3SZX3O8>_;CZT=&J;V;3P\?O=Y]]4MJ[/]@ O70WG_3OM?#&Z_V
M[QCUGCVU>W_RZM[#_:>/#__^T[T[=J?/_J?O?Z23 .>#_7$[)0R; 6J^,8C?
M\3GGDKL6RM9)Q+_DD'Y-,WXG/4@=I4K6^Y0"3A-W-D]92Q"H1H]Z38^IZ?&1
MGJ,5["K2=D0K[1A0N&.A1MOQ*<8< DEG- WYBTON3](CU113T:* ;!&'L&--
MW:QN"JXVK]?TF)H>K_Z5'AR]#T"TXX)Z"U+0>@^*L--C!RP0DF#Y_*OTE^#^
M+#TDU)34F$ :(66S(!$"Q,*QBT3A:WI,3(][W_PK/0R;U*FDG>P8S(&*,\L!
M>:=XZ)$;8X=JON,OX4_W'M"EBD/K/S)!K&PR$T)O/I%/C0I<TV-J>GS$>P36
M +Y8K!"2B4N&NH.Q\XZOOJ+AI]WK\![^3]/#Q0"MB2,V\]M5,9D;B9%RR*%;
M6'Q-CXGI8?=_^BZ&?7@C[-OY_Z2>FA:1G9"5S7Q$W<&L<4=,9X*U=K.H=?#C
M#W4?9R?M%^3 %'JWR,C@]^!J$'&B%*+8:^3]Q? &?!#4_LR2?XEPSX/9W</G
MO%H/DGSSE-=/QJC;=@QQ_:=T.-#_OO_J\0_MN<5X>?_A'NP?_CWN/7N\VK_S
M7=B_<^OEXV<'S_8L"-U[N#N"U%?[/_S/L\=W'O=[?_]GJQ6]F Z,P>,=L,>]
M0[UG$X/JDX4!T6O\_*M?!?&R1Z@O@'IP)B?ZOV>&T:T7]M?)0[OXUP?']<=I
M$7JY]_K&B\='__/T\>OCE_L_W/]Q_^'NRWL/G[RT][I'8>\G0VVU]VS?T+J_
MV@^W7C]Z=G#X^ &YQ_]XZNKA]T?\ YW=>W;+/[[S=[_W[%:Z=_.6W>?]9X]>
MWS#4=E_M!4/KCMW?P_W5O1\>'_SC]5[8_^F?7<C\MN>='LS'@36('6:P4# 6
MZ.@X.[*N3(W&S^TA6A=HG?.#[[Y^<.OOW]W:?_C9K>_M[P?_,H3PQ8>I 6OM
M.M)#].0C&0TC#>3+D_.D$P/YL_.$G"]/7XV/.UD=/C\8^2'GKSU=#PY\D+SP
MEY?6L.WC/KS&F\__^4/?WL/)\=GZ_+?S-)\OWQ+K#>K_";$N+J3GP^ 7OZW:
M^+VO=/W9^0WI1]-.OMG]?Q_.M/_RS5]=O/3AU9^?SYM=_'9RRNO3,4U^/IDW
M,D^<OWC?S\?>W69[[]2\,U(_/CQR\?O%AWSQP8/ZZ'/[ _,(TS^N-RE-IV^?
M0-GQ].Y";X_\OB<P9.7\Z[^=6KEX_5#YY&RM7[T%X/S@Q24NCEW\/J[QT2>:
MJ750M#C')\C!<;>&R+U5LO98H7Y,F#[QHWW[??3)4+8WOS;[L)?/#U9U=;JG
MPWM]UE9V]$TVX\GZ],MOU\?MK)[>6S_0]8M5U1LO5_:@+CKAMT??O/6O7WST
MBN\>U;L/_@]:!&RB1;SCP]EY;_0AX&^S&[_\[L'-/\R%B#68+W8QU0 U(6&+
M7*I9: NT>\OG7/ 77/#77/AU+OC?SP5_:;VCIT:=($2P-IU*8LSD@S1[A;B5
M,(&JS!6_2=2M]"[.0D=BCR I4L\,()6+EV@!P]OVYZ_;W^]I?[\7O\MK?]&7
M!$H872,H%D"V'FN%&$NH6,3-6DN'$?[ROEH0<Z8G8U& &9A5;<&=/M6UN?4S
M^^WY^OC)F@]/%B*T'X"K5#Q8],YLUH@:2HX=V%&6Q(VIS%H<MPC<2923?2[=
M6436DUB'VSC[ECR7AA0E](]FGUR#.Q-9#69IK9U:ZP4$S(P-$)/'1,ZK:SQK
M6=TB<"?17+1(!4.AHF:=:C#OA!YHK!-K9&U:9JVYO_!,-X[:V\/W!KI+5%FO
MZ%,M2"D**$3.6"F,C)_$VB3,6F4GA7,2754I7-%UBI3!N2Q5)-8,7$JF(#)K
M79VZ=6Y>2=5,DCW9&J$72'D,*O@2>W'9&6M\GK623MTZ)]#._V!2<OIA]>E%
MJH?:6^=HB@302D>DZEQM('YDNTXQ3CH+-<C>M "K%J8&)1<NXLV/JR Y<J%/
MT'UL:SM]?XS_6UV?KW1Y]RS:ZH5]A_=//9\)Y=/C=QWB'YP.^)?WCQ=OZM'Q
MX>KH8Y=]^^U_<\KI@TM\\>'=_]9LA#4@3[7TRMF:D@7FI2=S^(5]I.H#O9=/
M,SU)/ISK>Q_W/S;7]V'@V@+E&G),)8#7(M9D,&AS$BW:"6_R$;T/T6_7$_ [
M/NQ$?PE/P ?N*0L',!FB$E"R2F;?T-NC$#Q_ F[[GH"[M"< :I&MQ;1QK'LH
MYJ0+"6(B-EYTSF^RRK:EJ_R  Y?5"J+'&FO2 KY!#P4+.Y;28F^(SEVD7<9/
MSX$_ZC7?Y0"-M+WQGEO_>_9F!>/SXZ.1#/1+XSE22-;:SA<W7K[A_+"/BI?#
MSYQ2PYY%4Q&('1FX]S'>5@K;R[P8=-Y;=SH3:%(#:X=:M28/-4:!#MD%5':A
MV)_%0'.CM=7(Y>.#;WG5=H^^X>>K4SZ8"4RQN8C6F3%[AB2!R+7JL[,>/NF(
M)A8#4ZUGAV<'(X7Y/*0>YZWUZ;C:"]T]JL>'.A/(LB.%SH*Y*9@_-5/F0O4E
M9X>QL2P&LOMZRJLC;;=X?;0Z>O()9A ^"3X4"FDMZD<"1:..!8FS)A_% ')^
M,?@\7)\'7:_F)$NAI\B=4F"7P#F5Q"Y*3D$"IQ 6Y.=XU)B:"RI)FO5=TKU9
MN$*9*,5.V0U<2F5<#"K[QT?CBZ^/#PZL1[M873,3E"IU0!]2$\E0/9AG*.;J
M(JI$2>_&1#: TE1/H!>V^,_Z#1\5+.A C[E:R*&A]%YPBC'KV6OP]"/JN0$G
MQ("N5!CICLWZ(W4I5?4MQ;8\5#^5.$R/I5(2+LW LYZ)N+.3,68;JQ_%&8B6
MA^6F)&5Z;*EP2@5JKSF!=X&C]< 6N9H<-78TAPS7.02MTP-= H:8/9M5+^"2
MIUAK;W0>[TJD.2P+>@?TF*6ZK\_/UO4IG^BW;Y+AWLN>NS$&[#]^UF] .[-P
M;GI:!8OW/#20@N=&5KR%&BC4J7E6#M>T^A2T6J[7()+B/#:!XD'[J-021UIO
M%&=!@<S*:WPZ/LT2VA0@"7$NBF.)=*16P (_*4KBF_HY07O9,TS7I/I/5VC!
M"$TP9L<><B&FF$G)"?I>+?Z<$ZGFHS\;FY^;GF !?6U%FTI#B-UBX8J0:VV.
ML8M>$^R3$.PJ#)'YY#%X,E]3&0@%-854@M)(CU+A.3%K"S(NM@!0B2@!6VB:
MS=8(%<Y<6VX=6FMU#BN7KG7@5]/V7(/@4DF]!_!2Q6./H)6#U]Y2WESRZB?&
M=+-):Y>54M@BTIA8<-K 5Z4*KHXBQ211:]/%H+/!I+5+@B:/":#N$<=R^ZH.
M<^AJC\\5AE++!K.^E](9?A*8:G4<B[2>"6#L\--]YNS414TI\7):T!8DK5T2
M9$7,:6B'4,I8@%FI5Z^8.-:4FN]M,9!M.FGMDO!I*"F:WXO-F>DKA;(3T%)\
MD9A=[HO!9Z-):Y<$CJ9*1"U#+1V8,T;-71,VC^;FR"\&G,TDK5V:68BY18II
ME"HL)6&5$-B:#K91]&PY7=HT26N7Y;8CCASWBJE%,.,]!O6M;Q,/4%VI;7/+
MV)83"UW>$CLHGK"3<[$@: X<&KC([',T>!:$SJ9BH<N#)B8,I6+TRAE$1U44
MT$A)O7U,"[H8:*:(A2X/IE [AEA;'I7"7 OL+#K*5-1YS$BP')@FCH4N#[(L
M-<88ZBA. ]E ZK67'#$GU,XA+@:RC<9"EX>/,GB+@7K/E&'L+>N<Z-@O.D-*
M.2RG26TN%KH\<$J"-'9W+)'!W$.D[H,%J5X;Y$9]@V4)YA\+76*I!&K.'%R'
M0AU&,H.KDM#'5ES//=?%H#)!+'1Y*"$TJ$5<&GM(C1G @IF"]H:Y,6"904&T
MK5.@7\[V;;XNFA^C06;+T16PX"D+QS16W+L<?)/HEH?JIE)*-X^E8"R:HNMD
M05=U 6N+KC7K4T,$R'YY6$ZU?&6"^H4D+5J+9+#VJ6!1 .5 73.[,26,R\-V
M*Y:O;![H7*KD2*Y$ N!L;7GL^,K.APR-<%8=\GS2\#:\?&7SM(H9E;U'C'GL
M/6L]1E4WBA13JMQJNZ;5G)>O3-!-9>N<2 1(*Y"%!#H*:%%1EI"ZS,IK;/5*
M@\U#VT,:OM%Y184F($BE=NM <N&0WM:(G0FTU\M7MH14441R,EOC4X*QAR3W
M$'2L+G 44]0YD6H^^C-9VO($O99RJJV0:Q;LNNC(G$UI01HZKA2FV)?T"A#L
M*@R1I=ZC)K @3"($5H2*4"Q(B['5\+;V]TR8M07Y!M,#VL3E[G*-#@.0J$"D
M1JYS1(DIQ>4!>H5T8$ 8NM>(>:1W"R?TX+'W[@M+>3O%MX!J<!M-V;JT6GV2
MBXML+:^,G7DSEA"JKZY;J!$8XV+0V5S*UF5!XYBX<B3,62%9L\FME0P-<TW:
M0EX,--.D;%T63#S"J,[JRJ@J 1W'0I:>U'##Z'I9#DR3IVQ=%F06[S9H%4IV
M8Y/=1.2Y-JVN0$H]PV(@VW#*UF7AXS$5U2 F1@YZ;MABI-I2YAAJY>4TJ4VF
M;%T6.-9RQL8A/FH5<'[T?1*H!*(:8TFT&' VDK)U>7MGY-Y*9$S((,G^]Z9+
M&JN/0,6[Q: R2<K6I7F%4)T%N\/.(41U%)DQ.U^CFAAUOSF4)N-I[3+*%C X
M"P=CES&?[O.H:^-'4?T9;,JZ=1K\08P_R6Y\%IW(J$G$%"+4$@U5EUT.U##U
MD&!YJ&YD(GD2+$F=LSC&6QLM(-6-O%_L+H":08YA#MLF;ZFD3(]M(!ZU@:07
ML%#G/.D>DM?*HQ!B3;0\;*=/6IL$Z)@;.<SL-#!T '2C_#TF#J'GDOJ<@)[/
MY-LFD]8FH14C"GGGQZPNB.O&L.!#+4I,N;@I=BN^ K1:KM?PA4OAT-U(B,]9
MJ7<E;18>B38+9*_Y-%]H0:06ZA'%P=AF-01&8<\>>DS*<X+V.FEM2TCE4K H
MI!&=3X2E\^HY35HK6FLD]G,BU7ST9YIDA4D(UDEZ3M8_M810*TK)1)F<MAA]
M?KM7R37!+IE@5V&(++24*E5VT(/%W F=)Z@$17-W#+/JNK8@XV)Z0!V@ K 3
M3@(&FT3$5FJ@&,EKP>4!>H5T0" 31Z51Q@4 $U96\[/)=U7*G-Y.U,P?T\TF
MK5U2%;@DOHO&;K?>()9(175DL5$ICN5M^=$EH+/!I+5+@J8'E(Z%XMA5MF"D
MYE.AAM5$CR2'Q4 S4=+:)<$T%C"+).)4+%!WE1IQZ-UC[6IQ5%D.3-,GK5T2
M9""A^RS 8S^ 5!A]LZ=:!+ 7E(:+@6S326N751.[9'&A._7$(-US<".?L+="
M76OPB\%GHTEKEU8W-C@+M4+C,;I<DSC7FZ%E_9]&C,MI/)M)6KNL+HTC-FZQ
MQQS-'BACDBSLDQ"-,E:+066:I+5+0LF<F_VA'D*IT'-BU!C8A9 <9XEOO();
M0#6X#<9"[M*JP-7.19W$CB!02Y52-5IHY+2TL37#8M#95"QT>=!80Z&< WMV
M *4$3M7,&JI$A1:37PPT4\1"EPB33RDTI1'Y0'-%.CO7HJ^M0VU-E@/3Q+'0
MY4&F7"!JXQ[ZV #<C0V><NO5(EJ56N-B(-MH+'1Y^)3N.BMG;3D8,(F[B$OF
MNTOF3GTY^&PN%KH\<"@W5\$\0BIH>L2<&O4>BOI4/'->##@;B(4N#Q7?M;B0
M2-1GH*P22O*.8_,<BW\[<+H$5":(A2[3;9?B$N7H1_EXKRREE BDI:,)T,7R
M%;^<2;_-S\W_WA(5ES?;-_9$\="R^8<$G)D*H<%:S:PG]M*7A^JF4DHWCV7P
MR8WE9<F"+^B.,""FB-Q<8Q^A+ _+J9:O3( MH7<DZ#,V2!0YALPN TL2:"K+
MPW8KEJ]L'FAV3:&*4@$!UDB(&3+6:/UT@E#G!/1\TO VO'QE\[2JPJ)1$<$K
M1%.%&%+K'JP'2;Y'NJ;5G)>O;)Y/*=;4U5,KHWLB+Q:T.5=B:J5:3S4KK['5
M*PTV#ZWU%+[Y7E(O F!=1L'&JAJ;P>E\FQ.TU\M7MH148^NYY'/C0,GTITA2
MB4!<LZ,2TK7^+&OYRN8)9GXYM%XRU5+!DZ)%P<5EY[GWX@&N";:,Y2N;9Y8O
MX[]4 Z! 8N;,-;918DH:5US@$-E&EZ],T%6$&&H#Z4$JU%1%&)&"BX#4B-+R
M %VV#IP=K=X@^_9.WX%U>![4ZYM.\^W!BVM<'+OX?5SD7RYX=#:>Q+]<[^U-
MV8^_YVH?9F-6M&_;Q_)P"Y-RQMP\E@"12E2&-ZMKMK+,]\GZ],L']HGM[$#O
M]3=\V]/3I\?&IQ=Z<OHS"]]_576?#_4][7K AR=G1T^^7AV?K Y7![R^\62M
MYQ3^I/-@X?*2G>VA]E181HYS-SFHO68M$: TM![D;<5VN*C8#ML'Y;M1KU?/
M#<H;ZS4?/3F'8"*</N@UPN]?]'9^ZN6L:)2J+F&04<6MF2!4RB-D,4!A5'IY
MVRS]]DY!;PN6'[8Y?SESS[$$TLC)GAP ..'H(W!!%QM*H'A%X?G-3S^__.VS
M4Y.F;^QYFD,?%UT=6,=L-F'<T\E[]_$MOQH?>O-,;YS>7JU/3F\<':U>Z/J$
MUZ_F0I1>?>PMNXH>'"9J)3BDVA5K=+E?$^6RB?) #8 V/Z8T"#5CR&;Z :J+
MXGV-I9<84H>Q"=@;IFQQU>#M[/'_\V*Y[USWC^N?_L5RKTZ.(?CRY?^[_\,?
M]MP,OK;DHH5]"M$KY: I2_'4'.K;*=5Y[+&S+9C_TK%M?F^=4"743M@;)1C+
M#C-VURCG&$H?"^&W']2-J?/6QW:_F_][;]K\N.3NT?.ST_&0/ASJ^.49-U<G
M]?CLZ/2^\6R)[:" 2._J>PT5>@?1ZK0Q%1]KX#*'S6\W9SZN&\*"&X)WQO@L
M-5<3_)B81AJ5M*(N9VUA>T?6+A"[S:OU]WQPIE^_>@^\VVO]WS,]JJ\^A/?=
MR>^=>G)?Z]EZ;0UH[NU@6P;[JJOLO6]=>P4, 1TU,QB^XUCB0^V7@WU;S*YM
MM8Y_8+#OLO:++\3D(G0G!*TBE3#$,G)L" ;Q.:CQ0C+C-L: HWW>'T"^ 7'\
MNK<Z6AV>_>D)X/.6?S&K]*#J$=MS_?E3+EZY?;S6RI\\USK^?B6)'\:>?R8!
MJB&7E-G\%$$'%L18RAAK9.G6Q&?*#WYYS8]+X4<7BCY04"( QBC  0MB(^<)
M_=MM7;=YO=I]$^OU637';5[AF^,12S9[3=<OWE?O'X[7/_;C==7[Y@/JF#_^
MI*KM+VVIFLO:?1_9BHA06^=X7J>_^1;"V(?WES'1%C;@[4/J3SC\2VIWCF)/
MQ :AFDXGQ58I0597)#40V/XAV^U!\[(&;3\T5A),+4NL.10(0IR@]]*;\Z(,
M46;DEK<'J>G],G=),.9:>S<4&255GX)TDLH%$VQ_9+T]:'Z2*+5)I=*A%I<K
MM$X(/6?RUDO&5I+J#-K=![;RCHY<UN=/5Y4/WN!S/G*U?O7E=P_^G'/]=GT\
MH+VW?F#8K^K[Z#^\]<WMW9NW[M]88A,.W!U5D JE0%5!":Q<M):8.@28/T/>
M6Q+\W6^E(5]3Y=^YK!;0^?/(-T"@RC$W+UVYMU)RKS.ARI6%KVIU.>7 YHA'
MKI1(MM=ZJDY+RG/8QN/J:,$T.]86*,G:N$1IH-#1-,"9#.3,/36>PRZG5U +
MIMGH@S6#5H^8.UC,+1$R!Y>L?QG[?Y294.6JPD>U>:Q^U!C.%@HPJE<=VZ(6
MLA@AQ)E(^;1:\/UW>[?N[SY\M$2S4#2YYJ2Y7@ D":?8E+RO@J6CGXO7VQ(I
M6#)3@J0:D4@\)D@Y<HLUA!(A1B5!G E3KBAZSI66'8Z%T0(%JW",PBXU5[AJ
M<S/1\2LA!--LFMZ\V0)D,P<):B,1"_[-(X#D[D#GL$7?U1."B?9![[$5#J'E
M#"T:97SRD'OVW75?%Q 2+!D]=40-L6M,##$CE7@N!Z&7[JBGF<CXM$)P^^R0
MUQO)HMV\4^@H7&OM.D8/SXLR]]9JU!PR1]&Y^+PM$8(E,R5*RYR2%G8(2L08
MP$62Y&-6@;DPY8JB5T-WDEC)-/L\P]'47'.I7J@ESW$F,GXEA& :IX Y]I!S
MY0Z0 Z!%_SVUG%)%UV<S]'NUA& 2IC2#K S'D-6H@A5K\=%+YT"A8)A+5W)%
MT</:G>-1]LI'Z%!-N5L/TD(U&2CZ+^5LMA2]:87@QO?W]F_]8XD^@7OBDC-J
M5 \D0@&1(*F7#-#@>H;@FB=O_&1Q/1<71&#4@T945SE%)?"CUMX<%LI=6>P@
M4FL:1"-X<+F/S<LZ8PN<[.=.,Q'P*R !DSB$CM;95U 4"_1S"U0*)T6/H43&
MLH",LL5)P"0\\<U[<_^@O26 $"EQZUUBJU6<S(8G5Q*[9-XN]Q:;!0$6[F=N
MM9<>FGJOD/+UO,#OH<>W=V_=N;][<Y$9!+Y7)*0.J7LH(5/JV,TG8#322/?S
M)\@F16#)3!'0YH(B!8L8FU/NN:M&<PU1BQV9"5.N*'KF^BV42X:.,O0<&-E9
M".<<C*TAVUQ$_$H(P31. 175XH&QKA 0&GLF"2,SL(,KU.=/D 4*P4290M;?
M)^!A)P%3E00^(V*@49 KY)DPY8JB1UB@E]9,#RI4GPC16U,/3C!+:64F,CZM
M$)SO2-MUO<RZ +6-"KHF %X$T*$A-V)]"QVS!'77<P/77/FY-$BF'I14.&2(
MD1$TH\O6EX@SOLQE*=*5Q4\%3,^!SS>-#<&CLUB.*.7&7=G/99+_BLC!)(XA
MQ.PX>:HA*G@ %A\B=T3F4I3GXO>NFAQ,PA5(D@M'\PM!C!">D+A:;X*:P!#5
MF7#ERN*'3JV%N\3)-%N<YZS5M2"YH^,<^OSE_.&K$Y;UZNT9E]'8_YSVS-(U
M((W]YIFBQ *B15SV%OVWW.SE=$V33Z@_L^1+1 L2FJ\:V5NW0F10>N[5MY8K
MT%QFF2Z++[/$$#M2\JZDDA*H2T0A2>#&N98><"XV<%O:_ :D81('4?TH)^"+
M^-+ 51:$YIHR0.H09S./L"TTV:0T3,*7G-7ZD-XRF'E W\F-E<<A]0X.">92
MPF!;I&&:$8)LDMU<'84$P0>S@X5R%DW=N@$N<Z@///T@TNT;>]\^6F;MP@"Y
M1Q&4.#;F*(Q)2I 05'PN.<UE2>F6C" MF"@>DR,H%DCJF*5DY$9"6JBI*Q8\
MS(0H5Q.\F&L57]%))T"J&$2K=YKMYZ@T%R6_"BHPC=,+'!)!]S@VWZDD6*4B
M<W,ENQCG$D!>*1689HEZSHUZJ=!J $ +"(PM61V4+N)T+G.25Q.\W 1SLDA
M+)X+38307HJ!:^>2-,]?PO<>O#UX7U_HT9E>2DN_@I,($&(1@"AF'.QGQ=)
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MUIULBBMG1ZLW1/GIZ?&!GO"!KM_!?ZA\<K;6-Z;LY^,75[HX?/'[N-3')SK
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M>I<GOC@_?>8)",PA+T6'%6$B6)E02*)J)C@36M!I;XV(.3=G89X 8:PG1J8
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M3/;2MFE?R<H!8C$;D5%%R4,.*5D5O7*<2>?18_!*(G=K1K%0#;& ^$63P)2
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MED<1XE$GEF*<WQ"^NK3A;77&I(;&+.V?'H=![Z?AMT0JOS@BILTCLCM=0V]
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M9';MPD2GT8[3+UVE*EE$4VM_0$JZ?TA*_@61T\Y/+P]>_/RPLTNW?=1Y O6
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MS8<?T$W#?Y_F]ODB@P0PAU<AR:UK,W?8;?XP;Q?G7PJ#U6*PO2F;Z%I$PG!
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M/"'D0DP^1<6U%@#;&A)YB2-)*^CS>]L_;J1V]VOC.(:/L5_<_ 6G-_V,N5[
M9+V$N?IWGJI7,)<5G>4#D>^B;]M^OY5@&/,E;W5"8:^:['4PZ>#K*'(W8(J$
M#@9Q+V0^R\Z03)RY2+11,K?T5*5(TXHIC\6X^06_#XO?"5=?A#QYVB)J8F[)
M&PVRR21P&D!34N--H 34!ZGA-"P%0I^PP9UY%DP![.( .^'E6^$CB2(B:7.Y
MM40\<BQI%#'121K)'4SGIF)UZZX5@_O(<D(*:A>'VLF4$B=#)%(A*CF@UD5
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M,LER%&!9*^Z,DI2O;;)U)D3=8TA%!3P.%5#0.3=TCHL!;30Q4H%&=X8@;J5
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MB,5"KCP2V@%"S3F5S+]M;%J+8[]?LD4ZZ;M"0YW+N"W*E50J]7-%,,BJ!:)
M,@"K@W?!2=5Z6SS@>AE3I3#4W_"!Z;3OC?(I3G+J38:]_GA\40E?ODQ9J3._
M3?S>^ 1'F05L>U)Q>-;Z]W9G=7HX&K4>/=W74 ^>6R423R^5>#P\QK>_]R<G
M)\/3)LU6N*!I[W%3WI-/=$>HM11J+2A9YE%9;ZQFN2X_#+C4+*CZC =K8Q0N
M0(=:B^J5$;NX?^R"#/2F#70NIJ55"*:EICM3&#BL:YCFDD5LB>K&JRA;,7Q8
MD-]"G.+K+*WRY\OIW@A$&(Y&PS?U7B[+H)Z/\EG_XFS<.\=^ZE4K3#E,>OGM
M99^_>\D<;I,X?%#5^*C\>SAX>9Q'9_-5C2@#]BOQ:$$ALI!%@F0+JQH+%8^J
MA^,C!!:SYD(&K5W*E &[3G!VJ\3A:@,E0US.$.>.R"BP"A(PY5-D8(-FU1@#
M"[9D[S/'C%UGWS7;;=BXT[T;-^"-YEXMF^B'>M.343]<M+GZCPZ@WO_5MG>J
M*+J7AJ>G+:;7K_ URN/[N6NS+N>0/AZ5/.@/AJV$=></-O<PCRBO8#FP7W1>
MV9FVA<R9ENV4 Z)DSNAV?!F=JLL 2-[*2,IERSD0Y;H+E.NJ_&,RT!LST%DV
ME@5X89)@7&-E8^ =\]IX9L $RRU(SV')[E&T34,GD#9CU?]Y..J4\?/[1"M*
M*?PJ9#G<77#DV$F1 K1&="HF!EP+%G14+&6T$M&!SMA%:.8S"FGIIZ6?K/1&
MK'0N\==CY,7SUJ)<,R@A,2=#9,FX6&'71"WLUH[DZ]^I[@X=.UJ4^$O'CFXY
M\V.Y4PH$5M\*5@O.,GNA$W@IF*LK3P6K=DK!N\R*1^=X!!&Q@A4XMXJ<4CI\
M=)^)R#)F3>FI*[3Y68+"JR1E]I[Q8&1U(U1FWEO#(*"K3H10Q<N6GJK +Y/K
M16>3OH*W] >QG5S)O1^J4KIG[8CT)9UI22;=D]:MYL\ZY[^QQ-K=Y"RWN0/2
M\*S]?^^C@I[F%K"*DYS:&X\&Z?,7/OGDK_6&6RN-2[7O3M6_]S:>7C1-[$T3
MB9[B).^5DB,%RI=#O@7'K2&YXBNZ,6%*5Q7",(PH690&$80)=:5KQZWU@KU9
M.F^]293G-A-="!76&Q7F\FJ]S*;Z/PQ,MO7!)>;! ,M.0/&.9PBM"(/T2^^K
M$B5:TFPOIW37H6\ZT7NMSFSO\OFX9=G>"#7:6/:S'CLVEVH[*I^BT]'@FW"0
M8&TI6#N8)SM":%\2"!:+K&0G(C!G13O4PP-P)U %V-JQG)H$WS;JK<?^#!GQ
M&ACQ+#?Q!8.TP)G,T3/(7#,OI&7. Q01I([);>T(MX01$_&XJD[,(E;QH!?R
MR_Y@T#7U*UT1_/..HM]+NK$,VTC2F^I8*VTEB&S;R34G<^)!Y< EOMAO^"2D
M$C?H3=%.\NK0:4%%$IN##" YPV)R<Y\4<\%6G%)*1)-"48EO[<@'TE!.RGK@
MW!(&+"06;0+*JF#P5KI@<C HDA/5DH/K#)B3 6^2 <_2"YV%4M(I9D&U(\51
M,.0^L0)&2Q%1@5!=*$AM0-7\S:89N;[Z18)QS:WFR[M\J*K(T_"B->][?W/?
MMM.[K$2_$R/YWUL4TQUC;(*#\-&6B(8#+SK8HB%*BT+Y**3O /^FHV($^*L#
M_ 5%7F2(RBLGF,Z&5YY6&5L 6UA28"0H@R65QM@,F 4NY3?%P%9@<=^'[WV^
M>[\N>/J=5J@K\71-8'/]>#+DZ@:A$TH$"987;WUP3GNLSF]!HR\=78+-38+-
MN6TXPV.VWK.D9:B.KFDG+XQIN9)UA731><R-)UM8ONW+K:-CQ[)_G&#]T?IO
MZO^Y\\_Z\'Y\9SAZV1]T/Z\^1["8VWGKJ9GN_#.,?MSY<(_T+7?V6U8+R(+_
M'1[+AL?/<NYA;,4:<?"N[<4.AI,\;C4 JL,TSA6?\2+U)UU!QT'*@\O2CH/.
M6+IBD-,# 'A:AU]?Z([!;%\IBNEO*U,'=SZ\[(G^L*LKV?\S__2FGR8G[Q>*
M3ZZ:VC#_> F&.H*+R=67K)60W>?R^/2Q#;E;.C +JUWA@=L"@CLO=,0<2RE*
MVFCQA8*M]Q>=C#Y2K9>9A5'&UPQ+O<N'>/H&WXVW?OQ\ M;9-QU0Q='N[.FL
MW*Z43BE?SPG^KI)\%<ZE-=3U=#CJJMD]K#0WC]JGZKAPK<;3.QDU7O(_?Z\J
MN[5SW%"_[3L\:92FRZ+ G4738/DY*Z)&F[Y^SLIKB&%KY_'^T2][A[W]PR?;
MO4>'N[UGOSU^MK^[_^CI_MZS*\U[K>[@R5&E(X?/]G9[]=FSHW_O[SXZKG\\
M.Z[_'.P='C_K'?W<V_O/;_O'SS?CAG[X ,8/6BYS_9G3.D/'_UAZ]'^S7BVZ
MK&,Q,]2JWOPIGH_SP_=/?GI?2J<_Z$;?7?33=/F;@G@#GQG6U/W>Y=M37/)^
MVUC=H&FZ23G]X2EJ;7>H-</WIN_5*Y6[\FV^+:Z^] M?J[:5OOK*+WWKE]]3
M(&]@K,;:C1DKR?4FQ@K;SFZ*7.VV\; A8]7;6JH-&:O:MDYOR%AAV^A-F0-F
MVTFS(6.UV]IMRECUMN#7FZ_3\.6,4RF@VVU>^Y#FM?IK+=[:^G!C_CHW=DG>
MUN[6?JUN5!Z-<E/PEWI*+9% LLGBN&P?LSI9U(^.AF^^E%BS&7)Y5 ?</' \
M[;R55@R<]0?=\XCG_4E]G:3U45HQ7IQ==)T#.A$-N\I=G;"&9^>C?)('X_Z?
MN7OE=#B^^E#'/93=TSS!^N*EX#*.6D[J2@2TR;!T?+W&?_=PNAP/)U-,>MP?
MOLR#WOX@;G=_CS^I]]B59[<_7<ZI_U[T)^](AI\<T?^LP' GI/=%A@F:%LZU
M!7-H,0V6_/[0X&OT;UT0S-T O7>58Z]C"=>Z[V_I?[N9\GMT-KP87%VO?+4M
M@C=31#3%UF^*W?I'[YB.:([?O3F^.6<7KB7BQWC:&JD^Z!W@*)[TE'C0:]G@
MFU6/2@7\:C'9;?UMF:.=US6>21Y5PD45=;8@$A1IG46.P295DG.<PS3G7OWM
M(:N/S9TOP>3H8C*>X*#)<.T[H!T^>9\6^A]]M)M>/W]U>O;'[K_Z!\=/7Q_\
M<GCR_/=]^./X/_KP^/'9X5\OW_[QZO#D0UKHJY?\CU]^>_/\KT?O#EX]??7\
MKZ<G![M1_W'\^-4?K_9U=^W9OCAX=3"7%GJT^_1U^]S![OZ[PU\.7QW^LO?F
M\*_3T_J;9P>O3D^>OSHY>_[JMW<'?STM!_UI2N@S7N_]N:C7O! 0I$XBL52J
M2,&7S-HA.99=5@*C2T;)53= NZ5<^;\]CGE5$OW-&/]7'$;Z'K;_M8>1OL-9
MHUN%OOFD^57A7H=XTZVLO6[K87\P+97UZW#41O%H<MDRJN7X' \_W]#9G^[E
M$$*N!B'_FD5('IU #H;Y IZ!@(:0D3.EL]#>2R]:>>'[B9!$E9:C2D;KY(H)
M6=L JC@$+*5^D;<6Z\NX&JI$!K^,P8M9@Y<!JSJ493FE5G0J(@LR688&<G$F
M.4RM.YD5V^J>F3L1(B)$7ZKKM2)T6Q4A(AQ<!@?5+ YJ'DQ)'"L.(C(H$9C3
M$IC*PE4EV@+2;>WPE35I)!0D%+P#**@3<"ERS%$+B$H%*&"X=!FYM/4_0L%U
M1D$]BX)UY2HN.,&D5(I!*PV&5C@6.:#2/CF1H36L\TL?FB8<)!S<-!Q<ILRK
M2EPY52IY$ @Z2.]YBM4@,$J=7397 ^$5U5T)$6\E9#!7@"<XZU4QE1AZ+QD(
MXUA0WC">!;=*1>-<:9"H%]1;VY2&6X2&A(8K]8VYSU P.),R1#1.9BZCL,9P
MIQ*&VPP6K&NIG8T!R+GVJ3%C3"6R!,$PL"B9YT8Q6^I"&&T)*&T%2'@@*T;.
MMR>[V[218@97DZB%00,OK<_19E&77$B^..L\FJR%"A4[N*"@P2W8_.$L*8I&
MH^,^,&VL8]4W1!; 619]B%ZYJ*7+6SM2+6C+19R(.-&=X43+>(A?CVPW["$2
M.UHA4LZR(Y2Y2-ZZR8ND&0!PYA4*ALHD&Y(V7G3U6[VU"V(+!)8$EG<&+)?I
M15*TPN*U1*[KE^6@D:M@M P2M92WFFU&$/EM$'DT2R:3BME6Q;*D>&(@*Z-T
M(G)6<@5)U10M0MMA>R!!4A8* >6=!\JE>D3JD)Q*H0B'8+WQ7JOB#6]8:2,Z
MBCML!"J^FR_\;YRL*Y]FW$O!(,3"@J_$$90K4B:T2IE*',4JND$2&!(8KBL8
M+H&%T1=P0NH4@H$H %%8*-5@<E!!?^B'0JQQ$_%QKL)_MFALT2P*5QWK*')E
MC2E4$BELSCPD8=4E:Y1\VVX*:]S80ZB+C?<P3WK]:AQG>>VZ;WX/[)J>DUFW
MOHDW&L4B99&R2%FD+%(6*8N41<HB97V%)ULL6N3U:X3*D+5UPIF(I61I2[$.
M7NQVGBQPP:[7XO/7T;#T)_\>CC>D\=Q&N*7O%F3#A8@2 #VSU25E  &9+YRS
MX).$XG- 3*WQ'-=N96<HR) )=4E9I*S-5]8R.>8)4#LG';<1T(J0I Z9:QVS
M2%HE6B+79(F<B_=[A3P9= RMU0P\SRPXA+I8>E&73^4S+9'WR)"SUP%MJI8+
M!3P6Y*%UL%=19.ZU]]]DR&2KR]CJ?!3:!ZE*"(X5$SFK.)N8;V41-"^(4IOH
M'+:R"*L*L)"=KJV=.BU+49I7 Q3 HPR!A^RE"O4U+P3YI&MCQ+,^:<&B;0J!
M&5VJ$5?U,30N,1DCCP I*JW?+[CK9,AW+!AZU%KG]#YKFS,-CO9^:*US_O&@
M-\B3UMMW@F\I7DI+!RF+E$7*(F61LDA9I*SO[.YXBUI;B"4:#8)+5-JZA!B"
M2<@]7]K=Z>C?DT_9WWY'_IH#=)@G1^48WY*OLX2O<_AD0;F>Z" 9FS3+,28&
MP0#S5B(36I26#)RM=EL[L.!@.EGP)E@PP2TIBY1%RKKGRKK-0"D1F1L@,G-1
MTLA!.U"9V>B1@5&:!:<*$Z$=C$_&E%8X@HC,IEHPP>T&*>LVPV0$MZN'V_D8
M6<@RZ!*0\>(JW(:BF(O9,U]B-L)9J758-[C]F_A8ZH_/3_%=&VS^LM'3)^F3
M],G-^>0="XP_P?/^!$^[=;0[5M^6V#(:GO4&GYVL[_6G1^LI.$Z$D91%RB)E
MD;)(6:0L4A8IBY1%RB)ED;)(6:0L4M9:*NLV#@6&?C\\7%R@<;KM].2372>*
MHRP31UE4ME8X'87.F54-%@:!>^9E%DQ+40",!&M:-RBQ5H$4,N+U#H62$=^L
M$<\&0Z7#AKJ.J1"@M72+S&6TS'J(SF*";,K:&?$="XH\S><7HWB"X]Q.!,:N
MG5D=QS"^[M4WQA<XF/0FP][D)/>J\?!>U^6L]\E5OXZ&+T=X]J"'DWHY!4UH
M:2%ED;)(6:0L4A8IBY1%RB)ED;+65UE+-HZVTDEE!&J%%K@67L58DN\ZT ?E
MX])YU\>CC..+T;M/>D@_BO^]Z(]RHAV&9788WBUH(,U1F% UQ(HIBH%+G#FP
MDCD)/''M0IW/6SMR&[Z]N179[;K8[?P.X<T:[?_AZ45^;[-/AN/)09Z<#,EZ
ME[;>N=Y+12MPQ; 0>*S6FS5KY:V9S8IKG8S,46[M:,X7U.\D^[U#]MLZ% I(
M$*SK6J\%8;UQP1>?!&:49+_K8+]S9TM-08_  Q-6<@8!$PM<!A:J,AU/%8S;
M82>RWXVT7W)R-DA9RX"M]\%RX5( *R 7BZHH[;E0=1'&$I8OE$Q@NWJPG0^F
M\@B>(QI6580,>+8,"U2R)*NCDTI=/*-9*["]<X'429W29WDPH4 JK2JD+%+6
M>BEKR7U.+4'7A<38[ !<4#Y90%X]L.R#2%DLS0*ZU?\CW*5'@W0)F6GW8E0E
M^FN]KV%Z-AT+L8%KLX&C)UQT3*"Z7P>[ST6]YD6P28&(P$ 4S0"U9!B\9]IG
M$T%(HQ!IWW,C[9A =X.4M8S?I:"EHCME. HPUJ-7QF?/@Q,E.O>-FUQ3K/WH
M<3TZJX*>$-(NA[1Z%FD-CT9Y89B*TC& %)BOX,M,D<B#5E#_M[4CG"&LW3SS
M):S=(&4M%5!P(B:;4P[)@2K9Z^C Q)@XNA(R8>TZ8.U\U]MDL6I.>L8S"@;<
MMH""<\Q*G8NTED>L8*N$VC8$MIMFO[><AT/^Z0U:\EQBCG;6HM..%24L@]8P
M#$M"!AD1@TD<D"]V4&DQWFACOI'DG'&]Z_J,%N7O8<JSB[+*F)3BEOG6A;Y.
MA\30),^"AJ"]LMSCE5%^,N9-,&9R@TA9I*S;;A1UHVD95ZZ.GW;,+?VW.;&_
M\FA(J^9RJ^:"9KE"H/=&LZQC80#HF4.PC*/)REF>N7<?C'F-ULT[EK6Q/VZ9
M&7'^\'N57AY-GP_/.^/$0?J8T'&9LW%^6G^:$C5HF2%ED;)N91],:%%UZRL'
MB C>!9=U':?,W@24.>#7[8,U6%RT\37#&?K=QX@,+$,&GLUG:V!,05C+F=>N
M<@$?@#GK' M2H[-:54*@MW;XME@C'D 63?![)Y6UA$LF@G)!NB13-A!L\!9-
MM663"J248E@5]G8Y\P2]*X#>N?0-J-HIMJ*N !D8J!08HO$L>BVTM"XZ:"7(
M:.]R4\V9L)>41<HB99&R2%F;HJS;[+I,%/2&*>B"8_))NZ"U8!9S9L"58IA]
M8M86SX..+CM'''2#[9G =X.4=9L]F E\;QA\Y^.PEJ.&:"++IG@&)46&J#7#
MXELG",@^^K4#W_L8A,4W.$I=P)7BK;2&D+)(6?<@WMJ]>=2EGXSWWN91[(_;
MHD])6=],!NKX)W.G$F)E;A%Y9"$6QR"YP'P.D<66K%5U:GCQZYB41>9.V'PG
ME;7,F<X51&.O.$?R);?L"H0F)%X*B>?WQ)R,*>MVHCX*!A$+\\8(IJRW7DB9
M)%<M)<;2.<]-LVD"8%(6*8N41<HB96V*LI;AH2L(R1(/O24>>G#\>C+M-?SF
M\-5O;PY>O@C1>%$@,@4<&0A0##%*)EQ)R7CC8C#$1#?2J@F"-TA9RT#P"@*S
M!,&W!<&O#F8AV$'12D3+9'2< 8?,T!?/'*] [$"@"&Z-(/B.16>?#,_.\V",
MG=&-\BE.<FJ5S+OP" NM5E+O'-^URN=T%):6$5(6*8N41<HB9:VSLM8BKO;H
M]'08&YWHDAT>-R;Q*=G8>]N>9F+02S'HO?E@FD5>3%4>J_H2#'1.S 43F9$(
MVML<M?=;.]JM58XC63-!+RF+E$7*(F61LNZ>LM8BHD8,]$88Z((PF@M@D]><
MI:[>H2V>>=V:I6A4019C+5CBH!MLSP2^&Z2LM8BE$?C>#/C.!]"BDSXJ3$PJ
ME1@8T QYYDQ%#(I'[U00:P>^=RR,=C0YR2.*C]'*0,HB99&R2%FDK#56UEK$
MQ[J$LI/A:<JC\=Y_+_J3=QV)($:\%"/>GP^(22C9*;0LHJA\.$7.4,G"4$(L
M22>TF*G@\N9:+T$M*8N41<HB99&R-D59:Q$/(\:Y&L:Y* "&BDMPB165% .=
M#'/%&B8]2HXFF6@D<<[-M5\"VPU2UEK$OPAL5P2V"P)>*5OI.6?1RN;@*\4\
M-X+QK+2!F&-29MW =F/C77:AB3W&TU;3\T'O7Q>#W%/\0:^9Q[<$P,)P5$V%
M7=[90U7%G(87X33WV@V]?W<R/'_8-# >GO;3Y3MW#Z465B8$GD!R;74I$D2(
M0;BB($>4(I>DS8O]ZQ4D?-)58.W Z;((X='%9#S!09,AE1Y<"69]P*N/6Y*0
MZK(BDV:8,3"(3C./13#(&C(JDZRQJRX]N J#NF6V<FN8L2SF?B?(^-_;F -+
MZ'X-P72>\JT*2><)WOX@GEXTN?TZ'+51/)I,1OUP,<$J\>/AX7#0QC$:GM;A
MO]RO(ZKH2SVX5X:YL[7?9=11:,F9M28S\$8R%"(S73*$DE.N8$N8^TT>(G&V
M+W(VE93S;<^.YP0B9A^KB\F%E#ZHZJ3DU7 VPHFE<&*N++3%X&4QA161H#(R
MJUF(JC#NC/<*E*Q386M'&+^R_,D[@!+$S(B9K9R9K0HO5\7,"%F70]99!E:X
MX=D#LA0,9R 29YB49U9)JP2/!A!7N4]'N$JX2KBZ(*+< LE%..>M@)@KL9&E
MTAS.+8*-UI/'NY%X.Y?X""BE%MJQXC$Q"-(Q%PNPMKOH?=OQT(H\7L)<PMSO
M4*4T1H[*AE2,!_ I50 V6/D05UEKC5\@L]<.*!.K_1[[B@UA/X\_\R!M0M L
M)&R-I'([[1XEB[9("9!+:!67A.#;\.TU2PE@"6#O#< N@:\VR)1S 6EM]2-M
M]"6*[#2JJ'42)=TFJ1U<G+$TG+#I[Q+F+HVY<SD_$A$]:LFXJ0\@,S(OLF:I
M!!#62.5EVZ6%!U[[;4_DEL(YW\3G%L9SD@M:20XJ<0[<6F]X@&RML$$9;@K%
M<VX%*WZ;Q8I<9!2NI6S&D!GH$!@F$9D,4L;D@T%>^9E4VX[H&=$SHF<WXO]^
M/5C>L/]+1&V5X!MGP5=Q(RLSXRRBTPQ\ A;0"Z9:GK:MSY++%7P?>&L7!'X(
M?PE_"7]7X!YG';WWR4"T!1"-4]F4K%T2+FGC!;G'FXRZ<^</<UU?<TB*^6):
M'[N$K)+<R"!#2@IC]#:V+<D'SLIM3>XQ82]A[PTV";7*).65+BZ"M=K%ZGEB
MY< N)9#J"WN3%/M9*Z!]-1_[$:9Z,XXS;R SD#$R9T2U"JF+5UY:%\O6CB=J
M2_!*\'I#)=DX"%]I;43#@1<=;-$0I46A?!3R5M.9B-I^*^+.]P<M3GB1+),A
M! :MP+Q33K+*:*$(Y[,!>4EMC5H0<-\\:ML=%?^QFW3UW]3_<^>?]>']D#_Y
MKIC;')R:[<X_P^C'G0_W29?199MZV6H+&@C^=PN0; O0LYQ[U4\>GM4!O*LF
MW!L,)WG<6N%.3O(XUP4)Z]+0NN/612"UVO7=L\[VNZ:YI3_ 0>SC:1U^?:'K
MF+M]Y;U/?QODMFT+Y/EPW&]P];!KP=O_,__TII\F)^\7QT\NG$(2_W@)ACJ(
MB\G5EZR5G/WG(OGT\63TL1S&R\S"*.-KAJ4.^"&>OL%WXZT?/[NOL_Z S<AQ
M5@17WF@I-U<AH][G)>17%C <=>T.'M8E)H_:I^JX<*W&TSL9-5KU/WW,HKJJ
MA0=N"PCNO- 1<RRE*&FCQ1=V:^>XK4J]8>D]:8RLZPF-.XLTNOST$U&C35\_
M_>0UQ+"U\WC_Z)>]P][^X9/MWJ/#W=ZSWQX_V]_=?_1T?^_9MP+5][F#)T>'
MNWN'S_9V>_79LZ-_[^\^.JY_/#NN_QSL'1X_ZQW]W-O[SV_[Q\][K/=#4U1_
M<)'3/S;C]G[X +0/>O5[Z\^<UODZ7G[T7['X=)SK(]!V)*_>_"F>C_/#]T]^
M2OWQ^2F^>]@?=*/O+OKI#$<O*QQ-T;E!T0S'ZW[O\NTI2GF_;:QN0#6M"S3]
MX2F&;7<8-D-8I^_5*Y6[\FV^+:Z^] M?J[:5OOK*+WWKE]]3(&]@K,;:C1DK
MR?4FQ@K;SFZ*7.VV\; A8]7;6JH-&:O:MDYOR%AAV^A-F0-FVTFS(6.UV]IM
MRECUMN#7FZ_3BH$S#J. ;H/];E017+PW]^'&_'5N[)*\K=VM_5J=JCP:Y:;@
M87Q]Y3W.*^_*#.Y-%L=ERO/J9%$_.AJ^F<ULWSRY/*H#;OXXGG;>RCGV$^L/
MNN<1S_N3^CI)ZZ.T8KPXNSAMVVV=B(9=U[U.6,.S\U$^R8-Q_\_<O7(Z'(])
M=A]E]S1/L+YX*;B,HT$=_DH$M,FP=#S*.+X8O2-@FI/,<#+%I,?]X<L\Z.T/
MXG;W=W<T9AHV[6H)V)\NYU070B49?I3AYP'C3DC]:=28H&GA7%LPAQ;38,GO
M#PW^)/_FJKCS@M#S!NC]\O#;JN[[2V9R-^7WZ&QX,9BL"$GNIHAHBJW?%+OU
MC]XQ'=$<OWMS_*ZV"]G-,9^%/.HIT;4,$2MH&?+W\W"CBA(L66-:.96XBDXG
M!<IYC\8:'H( B-S&RZ,&0D@EJ"_(XNS6LSW]_/??^!^__U__\/B1/-C]SU\'
M?]6Q[>[QY[__JUY;?^WX\.3P[.G);';K\^/3.LZGIW_\OB\.=I^_.=P]^.MH
M]_6;^KOU<S^?_/'JC],#N2?_^.7G<M"?5NM[QNN]/Z_W_OQ%L@F22IY)#86!
M586Y* NK"C1:Z:*43#=4L.]:X+T!1P>^TOCOV/F :TAAHZ%O0:WH%>$>U31=
M)X3\:Q8A??"85-3,F%9"VH?(@C:>:>E,S!RM#N:^(B11I25;J%GA7?&<*^L@
M&XDR 5>(PJB*&:NB2F3PRQB\F#-X%0!<""RKJ!@HS9E'RYGQTE2FE$1,U>"%
MY0N*-]UM<R="1(3H2VW-5H1N=-3\-G!0S>*@51"24IX%=(*!E)ZA+9XE7KQN
MU%<6?P.],P@%UQ$&" 6O[19J)VUT2F0T$+)U7D-67F=1T2_)3"BXSBBH9U$0
MM.:\:&315^R#")EAJN10@M59:Q>S*EL[QFU+@D&"P3L.@\M4()*Q.*FJKQ1D
M 9XD\ABY\39SX8SS<#4.4@6B-0+$MY]V$J_W(E^@-=$DA<PG;YM_;)G++C">
M5*S4L&2A6Z$W;K;MRBH0$1JN(QS<<S1<IAQ;B$HI&3$Z#J;"7XG%&N6,=KF@
M5+<9*[B3!8.^)T"^FP5(X57!H)B5H%H3M J5!1U3T<048M">5\HHU ,OQ *,
MO-NTD4(&2[9\R @"N"W%> ,5(Y#SD"N*6%-=$R._P*,H9G!C-G\X2XJ40%L4
M(!.B!0URS,P++EGRQDO5RI$KL^*&#VMOZL2)[A\G6L9#_'IDH_X,FX.4L^P(
MN.%1HF'!\,P !#)$2$QY4\TA2U\ITNJ[,Q!8KB-:W'.P7*;7H 8-10BK$, *
MY8N0P@:1$YA4O0MR(#<7(H]FR204E5+"Q)+AOCJ0*"M82L4RVE0G@?%)A;;#
M]L!Y0W$' DH"RD]*<_O$K8,"UA<HT3D>@W9")<N+*292^'6=L?#=7+3!80E@
M*@)*'H"!BXD%'2MG!&^#2=5;\'QKQZA5MY0A'%Q'(" <O';X-4EOHC1*6PDB
M5UNQZ&1./*@<N"3"N,D@.>M39_1>9E\9HC2:@1+ 7 3-7,HV5B]!\ZY! >]:
M4V],Q&%C3Z N-M[#/.GUJW&<Y6\Y<;JQ88_I"9FOFVMKM.Z2LDA9I"Q2%BF+
ME$7*(F61LF[8DW60H#HQ7%OC003EK#/5VRG)F83@[(O=KMF>X()=K^O>KZ-A
MZ4_^/1R/R2U=F5OZ;D$BG 9N;?*F'980#(0,S!4IF72I.%L"@F^)< ^4$2L[
M2TN&3*A+RB)E;;ZRE@EZJ6R*SL)Q"\"5":@T1*6XD2(%Q6F)7),E<C[4KPHH
M XYE,(&!XYEYB\"J^I*-*5B? BV1FVW(R^1$!J=LUHH7CP8BERXFQ5,J4*0"
M,.(:EGQ%<N2G)DU6NXS5S@>E!7H-*27F,QH&J 7#W(@M!VFD"MHXM;7C8-M\
M>P(C6>O:+KO5#M$DB<%T%8/0>X%:^^RU5SY'3<ONNACPK&?*O17<^-(.:6@&
M$ 1SO"2F#5;:E"4:T\ZP/I#6KBS!CD*B<[9VU+KG]#[KG#,-D?9^:-US_O&@
M-\B3UNQW@F\I:DI+!RF+E$7*(F61LDA9I*SO?F#3AZ1$"@A*0]NPBMY(7[)!
MKI)R[NLW)SHB^.13'KC?T<#F"AWFR5$YQK?D]2SA]1P^65"YASNG2HB2E:0D
M Z\-PZ #DZU IP_&&/!;.VH5=7O(C ES25FD+%(6*6M-V<P*@J;$9KX?FYD+
MG>;*04O2EFDN'(-&9- 7Q711R>M*2DM,Q&8VTHP)<S=(64L5A?WVB!EA[G?#
MW/FXF2NQ3BH764#M&61AF*_K)L-D+*A<<A9YC3#W;\)EJ3\^/\5W;9SYRY9/
MGZ1/TB<WYY-W+$[^!,_[$SSMUM+NK'U;9LMH>-8;?';<OM>?GK>G6#FQ1E(6
M*8N41<HB99&R2%FD+%(6*8N41<HB99&R2%EKJ:SO>U#P,H 2^OWP<''5QNFV
MTY-/=ITHA+),"&5A05M7T-N8F ^<,]#1,A]%8" C%UGIJDVQM2/D-E^C<T=D
MQ.M]@)",^&:->#8.6DI.0EG%$!TP@*@9ME/\OBC@IG4V"6;MC/B.!46>YO.+
M43S!<6X'!&/7WJR.8QA?]^H;XPL<3'J386]RDGO5>'BOZWK6^^2J7T?#ER,\
M>]##2;V<@B:TM)"R2%FD+%(6*8N41<HB99&R2%GKJZPE&TD;&X-1GEOE = 4
MC^ 0D MI('FW?)' XU'&\<7HW2<]I1_%_U[T1SG1#L,R.PSO%C24]I"5#4(P
M)T$P4!F84THR%7VIFLE>6MC:D=NP'IG69+<W<V#B9HWV__#T(K^WV2?#\>0@
M3TZ&9+U+6^_L_F (@B<E$U-&IVJ]#ADZ46>P2PXQVQ UW]K1G"_8("3[O4/V
MJXS+*(1SRA1P5CD7,P>%QNN(*2:RWW6PW_FRO-&ZB$XQ;S!7^_62A:B0@?'!
M:5Z*S);L=T/MEYR<#5+64F3)5(KD0P"?(WAK?"ZN]8G-&*0NX?HY$02V-P>V
M\\%4HZP467#&C0T,A$D,0_*L=7<)&7E=+?5:@>V="Z1.ZI0^RX,)!5)I52%E
MD;+62UE+[G,6J5LJ)!?994@!@O,VENJ(&8M29[,T"^A6_X]PEQX-TB5DIMV+
M497HK_6^ANG9="S$!J[-!HZ><-$Q@>I^U<_6>W_^P@F$X$UDW$%DP*U@WH:J
MJIA4L$V5P=.^YT;:,8'N!BEKJ4VN$(+1OMJJUM!R6K%(F6-,G'NE5?XVOVN*
MM1\]KD=G5= 30MKED%;/(BTH%,HFR7( 9 #:,9<$,*>#M#*Y((S:VA'.$-9N
MGOD2UFZ0LI;!VI)1QV0]3U(!5]P;KZL1A^0X1B^7[SE$6+MZK)UOA>LYQ.@T
M,&LCM,)IG#DO+/,^HD;-E>D*IPE%+<,VSWYO.0^'_-,;M.2YQ)S H;A4?5,A
MLV&@1&9H,++ ;2523FLOQ&('E1;CC3;F&TG.N:*:*2W*-V'*<UT M:O**JY5
MD(ZL10V9!VF8S-*5DBN_XOZJP!,9\R88,[E!I"Q2UIU4UAT+PN^/6Z ]SI]E
MKM++H^GSX7E'27"0/L;G+T/PYZ?UIRGN3JA!RB)EW<JVABY%90W5_PD*)&8'
MT8&M_I%2*4I9OFY;H\'BHGV,&0>IWWV,/*)E/*)G\\'WD#,$QQW#4C0#(S@+
M0@06D^8Z04HBFZT=OE8MT<FB"7[OI+*6V(A*@9O"353<2? A!U ^>5Y0N:"T
M5JO"WBX%FJ!W!= [%XU/17GG96198F'0]I:#5< **.$U.%.P;.U(M^T)>S?2
MG E[25FD+%(6*8N4M2G*^K[==(F"?E<*.G_JN?H*$ERTS!D.#%2QU?W/R)RS
M7@;CK$-'''2#[9G =X.4=1MUI E\OQ/X+FBM*US.TGN6LW$,0!:&VA@FC<P&
M"F;,8NW ]SX&8?$-CE(7<*5X*ZTAI"Q2UCV(MW9O'G7I)^.]MWD4^V-:])=:
M].OX)W/)Y%$:X$7511^%9^WL)*N:M P#"EFB*):[%G"E9/+--&G"WPU2UC+'
M\%80<;TB]?]+KA>A\"I0>&[?*X9B=8G LA; P"G=-?)A/!A,0B6A"V[MP"(8
MIK-Y:V[4A,"D+%(6*8N41<K:%&4M0T17$'<E(GI+1/3@^/5DVA_VS>&KUV\/
M7[XH&2KEU, <)LX@H6F%XP.KJH4LZ^137!$5W4RS)@S>(&4M@\$K"+\2!M\6
M!K\ZF,7@"-J;Z#PK-K3B_]*PD 1GQ: S0OKB U\G#+YC0=@GP[/S/!AC9W6C
M?(J3G%K]Z2X*PD*K<-,[QW>M7C6=>*5UA)1%RB)ED;)(6>NLK+4(K3TZ/1W&
M1B>ZG(;'C4E\2C;VWK:GF2CT4A1Z;SZ>!E9CRE:S DDP*-DPM/49!Y$+:!MC
M*%L[0CK*:]A0<R;L)661LDA9I"Q2UJ8H:RV":D1!;X2"+HBD.<]-MLXS9V1A
M@-DQG]&S))2)6AE>;"82NLD&3>B[0<I:BW :H>_-H.]\#"V# A.49)HKRT %
MR[!XPX0PJ5AKLI*X?NA[QR)I1Y.3/*(0&2T-I"Q2%BF+E$7*6F-EK46(K$LJ
M.QF>ICP:[_WWHC]YUY$(HL1+4>+]^9A8BH5GISD#$8!!2L""E(X5$2/&@&AY
MBXEMJS6BPV2]!+6D+%(6*8N41<JZ>\I:BX@8,<[5,,X%(;!4K*NN06$"O&,0
MBV#.J\R2%2XDDW7(0)QS<^V7P':#E+46 3 "VQ6![7S$"[E.1BAD,1?/P#K!
M/!K!E'716\A%NKQN8+NQ\2Z[T,0>XVFKWOF@]Z^+0>XI_J#7S.-; F!A.*JF
MPB[O[*&J8D[#BW":>^V&WK\[&9X_;!H8#T_[Z?*=NX=2"VL0 D\@N;:Z% DB
MQ"!<49 C2I%+TN;%_O5*#S[I:JUVX'19;O#H8C*>X*#)<*M7AJ,SG-2?>SMY
M6/IO<V)_Y=&0,&LIS/J 5Y4H'KP]VMW[ZP4O)=HD@>F"K>*P<<R% BR&"E:\
M*&LC_T R5H1:JS"H6V8KMX89RV+N=X*,_[V-.;"$[M<03.<IWZJ0=)[@[0_B
MZ463VZ_#41O%H\EDU \7$ZP2/QX>#@=M'*/A:1W^R_TZHHJ^$\+<56'NNQG,
MM=Y&B3(P+FQB$+QDE>IS!@:L! NNJIPP]YL\1.)L7^1L*BGG1=**YP0B9A^!
M1RZD]$'EF/)J.!OAQ%(X<3C+S7+5A2_HF8G>,,"BJS>9@07C>"5MVM6'ZDT:
MO\T))8B9$3.[,6:V*KQ<%3,C9%T.66<96# Z:B<K^2J\>KU5<2PDA4PFSD$+
MX87'5G)?$*X2KA*NWABN&ALKK1'.>2L@9MZ.Z66K.;<(-EI/'N]&XNW1+).-
M.DJ+CK.$K:]9 & 8=&;6%A%#S%%G21XO82YA[G>H5!HC1V5#*L8#^)0J !LT
M/'.5M=;X!3)[[8 RL=KOL:_8$/82:?\Z.'[Y]N#-BZ"LT%8B4R%4<JNE8;X4
MSK)2"D+V&K$EF(N5E"TE@"6 O3< NP2^VB!3S@6DM0;01E^BR$ZCBEHG4=)M
MDMK!Q1E+PPF;_BYA[M*8>S"+N9(+J;)3+.12,3?5!^22,[ "$W?HDFX)EO#
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MW ,=J!%IE3#N?QKW_;E"LICFG$5-7OP562>7E>HKU.&U5M;O9@G5!,HJM2W
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M JP;'E9:%#RT4F"G>W<>GV_8% "PTO<RV&0C.VMY54W.^27GH8X+QD>]S9D
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M>6$IE=8-W8O@?1&*]4\*6JH@Y?W :$]=_KP-E5(92('/6+!(XWVUP5=C*WD
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MIS;KGLR9U/>D2&(X9_*'D[?A,!S?9L#D./[H+9HHWWM/U;A"4F>/%C)60Z%
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M5#-8)T'X;)Q %]N05V+\9%G1-LU;H,>#YQETH*LUTN?J0:.V%)*UR8127*V
MYC93ECNXQ@Q971$/1HM&H6@118%@BXB6_4@V?*@5<Z)I,TN5TN,>?79P3:<X
MV>?6]8RJ5>S<47/W#+O\P4AP,=;8P34M%7E%/)BB9)HS15 LD74DVZ[HE!80
M(Y&3Z K6F8'KX<:#?_AY[7^6O^_QX$EQ##*Y&)3@,_]C/89,$J),DDAFXR?5
M8;ZKYIMSS^5X<$7CV;TA =B.>2FV1B;)">V,3#KZ4E3N\>!'@E]"2J!(U83
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M\Y,=8H/%&5\Q2Q9TCN6="?4V20V=VR884!SM ^BC VTM"BR>)5UKX. M1I&
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M_6ASH1O/G&XDK87&5,E &;=>&6X)5DXP$;3EPKWTM-$'PY")M%'"HHT.,P0
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MCAEF)1+)4\0C!5L-#AC"T5/CP'1J:V<,VPEM8C(.3"VW26@N"&8Q@4TF&@A
ML;[+LO5*26RUL4A(FRM#<X]@LUT^UB.]$XXS%U?6P!>?<J[GFB#=.66;L)
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M?\QE>ZN1'/6ZX;@"IT[URT'/MON7D#8X!/P].*RYXSY,I]_/<4P'PI5'=;N
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MD&UBA C:<)RL\49:(KWTWEM%Q<K,/'-N #HCS_SGTGM[JD1RZ&<.LQ5JP.#
MZ%XUV5?\TU?YH[V<G/ ] JN(G5HGV]8N<)( MO.T?YX24<4B[;DY!Q/>!\H
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M^U8,BTA@]G,1B:W&VQGJZ;P%Z?PGP_!&L^];W?YQ+Q9QO%$<OWZBV^M?.!?
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M#7XBSO"_6W#?*K^Y7_40#C%%T(4\S?91[/2K-H3%.WY8[]@UF^YUWIEA:Q
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M6OS*MK[8R][:KW<Q!0!E>'.I-O(XC@[!O1U-:6Y!936AGP-\"V!8#4R#5Q<
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M?5J4)/SOI$2<T1"]FB)$/]_=A56\=%7\LYVOYP/FM7[S+)\#[:3*^I-F_'M
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M)T%0HS%6(,V:@'KFF=P7Y)I:$7UDWH B7]O,Z9!%4R]24\\BSI)XC;6/RIK
ME516.:*EC0[\3X-I&JIJ\AU57<1Y)<1Y+,J0#+.,.HX42#'BB1EDDDPH"LF5
MC6!U&[6VR=@,AG=AZGD65ZYL NZ/4[%B.SQE$M;PV P#60B=BWP(IZY\-%T-
MU6>Y=3C'X7E6NXJEJLYJ:-+&P:34+1(H$1990C'B4AND=8I@)W,I1>):)#;?
MJCKSD)]%;#@N'@^782]R@;"W;*%"*KAT.F!.N>0^$:T8)2RG.WJEF7+#7+ "
M>XN'O;$0'S=.1Y[K10PJ_O"(#%4&89>/ISN5. ^#7+ 9@WRKAV[%#"QF8#$#
M7Q8>CL5'D\..N."1XQ[PD"H/!J$)R%H571"6:2Z*&;@<>%C,P&(&%MA[".R-
MQY$]#Q1'@K0S"O'@-=*<."192$8H+#@U*V<&SH^!<?$T2UO3,J&M9V[$;N=K
MS5_8NKR:EML-'U=%J?[SVY/VJ)K4M"=MP?^; =P(YL1XE;R5F.,DP#,2W%-E
M"3.>4/.(-EVCT\[;:O#]6B:C@GF%]GSMOVI?G*'0Z:/AXU8= ^?"V=C(_V]]
M<EZ&P*A$QD>,N",8:0*8YH623G+-&-7?M^*&9!^UC,VR3FB@1GHJF5"4DZB<
M5%;3&+!CT6%Z3SFOLDZ>?IW@O>-/&"?I0PQ(,^D0QUH@IWQ$@5@7,7:JWCZ=
M?)3DB@]FO>K&7BYZU/P;\'9]G"?NBB:NW^G;UE1D<=47VX.[IM:@E)+-7'2^
M<W;>:0\9[0 ! ?);G?8QZL?NV0B5YA4I'>BN3(N7'Y,5ZY"6MV4SNU[O)&8:
MSIJOS[8OX6EGMEG3&PRO&&O \FJ2.T-CO>]>0)OCU_/<_5J Z^':J&ZE?_\$
MDU]-X=>-/ILN(=_KEV,8N7_ ;/1ZF>_XUL3GS(GK!(J:B?"^^W]_TGI]^&?
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M:J9U.7)YSYOJGM=F4 EAS@W$)QQ )X%PQZQ&&" ;<>P4LBQ:I)3GF6\]8F+
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M-580,+.D!F<\RC.*N)<!&2TPBI01)A5E7-&U3;G!QJ!J;+>HH%1!J>=N:]T
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M6,1CWN<.AB*BO?">Z*!T>$"1^((B+Q%%9LF9632,/,>DF2>#$3H*(YS)0&/
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M TZV9<C"1"(E$J&)*BOS(6\\Z_[C4HC@"]:;<W"RBVP^L6R.T\Q;G*3W$>F
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MU@26J\OEGL>^;^<I6'DF5N]TC(9YP%Y^X;;EP^W;7=^/=A"K+YYU8Q]6?5J
M?IC3*^UA'OXWO>ZJA./FX-%;H;@[RJ/QIM,@5&)):<$5#5PRZ1@CDIL4F922
MZI1'CQ*-!2/709C=F#RZ_7\CV-3=.#SJA2L";4X>X<.W)ZCLNTW@\[PRV_DP
MZOLC>.064-*@6NXW;$;T98+SX\=*?CT^W]T\<$PH ]HHLE(RQ"568*I1CD3R
MWLI$B,)A;4.LXQE@_5>FHN^A!>8U"-SDE4F2$RFU#$0KRIE1+%HNYH^A9=-B
M^,'D\$N?]26<=;2@ 6'.D$J.YH)NB8SA 8&A@K5,UIH<ON1F3D^^?ZT7>=+?
MX"B/CCT=\U$QO&*DXLP.RN&AG3BLZHP:O7^JX9@E5@&PO2I&I_!!WP%<ZQZ^
MRO!U:MOA=JHY[I]-D4QT$GN.HR=. *8GZQC&VBH>@M \E3XDHDFES.5?II0Y
M/4T\'^Q%*<%:O4T/=-2/\ZGI@0/-S:]&5Y>;%Z"<*1LTQ4PBYO,0<TH",B$$
MI*)1'JRI)(-;VU#"S$GC!#%732S>ZXU I/Y_ -@@-\_@A=\6&6G]O80QXUQ<
M+F&\4,W_>P@#YU'6 /!!$HJPQMG[1RER3&L45?3<.HT)YVL;4LDY;>LG)8GE
MV.$936N]:(+:TKY23]O52.!8GE(>_3FMNO1C->88K@;JXV &N^+Y:6\P>3]>
M&U':&>6)P.4DX,E=IFEUO;BI >=GR>39[E9?O*$3CU50GJ>#PBU+W>1UN3JP
M'\=#0<?.]6O?&I=0XZNO6#?H=4;#V[\R4S'SG+HVU5-;=.WG4?_**#N,R,&V
M'B.;8,6O;>?,7@S6_GW3J@"38GQQJ=;S/DYOP:T/FM*/*P*"YZPL'.#^7K\\
M^->E*IX_!>NR*[6>XJB?D?._VC82)73"#JO$"=:&"&^C3[G;F/+*'JBUC58Y
M$A>XZFT&W=+BLQL/F:I[%^$1+ZP*RR.\^6;LFYWF^^U&L=-XNUYL-K:*O<]O
M]G:V=C8_[6SOO8PG: "J[U6AD%:S>-L$X&WL;6_EW_::?^UL;;;@CW<[C<W&
MVYW-OXJ]%KRPN]UHO9#'^VW4M2,PT2(HB&/0C.'W>6@QA:ICD1JH2)J"ZDHE
M=TP:IXUGMNQB$Z*5:U<7W<Q26GJMB63"6@(6J#.@N5@*M@=/3BBOQ=K+<F"4
M>3E9:)V 5#@$"7>']')Q>!9C)<(^K^^M%R$/L^Z73H=ID?9JQAGR@.GTV48
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M:E&O1]T0^U6'BO^Q*[6>XJB?T?:_[@_MJ;6-5MEB!KCG;0;JLM>=W;C5[_U
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MK^4%Z+//P"+7FS+[R\;9@4XZP8'D"#K5H-LFG8?F:62)PD;!T4FE'I+T6Y'
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M1($\8]A:D;CR+!M@[':/115*SEKK/[;=*<NX'NHUF#.YZV5.R;@^ +%9AD,
MND[[\2AV![F']DX5VO@MYX?\_J2.>'\4PZ@#6'IMB>4*;RRP6E]>75F']^NZ
MYS_R ]AH2P"LD#7*(^ZP "C5%C$&O(!Y##C0:?<\J$1:4Y>\8YHKRUU2!/0X
M!_I2)-;0QXX.?7;'=L[>2KU.IW=6&KB9.'(^UDDNFKZLNL56@<-R+O3U":%5
M5-#?8(-QA.^W3F:#;W-%<Q*7N[A*#GZ]4%5AN::IJ?>P11U[.HBO)[_\$=J#
MTXZ]>-WNEL]8?NF/\<Z/"Y_%[/#W\G[5V^,"8&/6M6"Y!C@/M1^&R8W'Y<'K
M97EP.?5^^CT&UIV1M[Z-U\DCWQ.,/NJ;=RW6K%,C7LQ:,7[<5>M]O6NM!*^#
MQ?="%ON2-E8#A)@'7?7?)<A40 -0EE'Q_UUC:U>]#,J4A-?T]+P@$]%1(5?.
M4IA&LPK(?H@TN;=30-DWX;>=[F18P#4M:+P)=SP?SD^W]J"/SMF*2E*LW&9\
M[O;C>#I"F3I<*8=Q\'O.]MK+W;*JP3R;W[3JG!BS!Z;*JZ)1"<Z6/:]W\8Y=
M?)O3,M^![E+\;PR'N>G+,VS<G9SXY+U4'K:KLUN9-VZG^T\<5UO=OI_+7[)8
MOS<#"A8]I]%-UJ@17=>S>IT#([1JF?(;F>X#43/2877ZG:O3SPE]V=1WL1M3
M>WBMB5^-15=;^#:GV>99,2VX\J!3)5=L?BM1'/SJ^]/*<])O;,(]^LW8FBM3
M,$^'19DW6DS6NKK*SXPE73[]FZIBXM7LP+3OH(O)1EE_?-COC;H!C1\IE/_[
MX\$[B(LE[",5RGKW@_?QOZ>W:WE[</W9^_F6*_?PORWB=^<^4FUT,@Y^Q10V
MB'/OG'$D8H;%+1/5!! =/"O\-NU+?* '$01",X$X>.FANJ/]D_-.$ZX#K['=
MDT]?]UOOOC8N/\%:WK1AG?#YCZR1_SWY\[CY_O.W[\"]1E_H9[E[^>=)X])?
M?'G?.-K]>Y<UWN]?[K[_L[V[]:;3V/(4_CW9/_G(O^1 SAZ^^*NU/81_X=GW
MR>[6SD'R-/=_,(B87*I)K40V:8PBDS%W-O>*INR;GZV*FS&NEL8C^=T%>>4.
M6)NS'I?_[X\:[VJ\*QTH#X<[E1/T-(O2><\=RR[X8(![)!%!,*5NA[L:Y9X0
MY? TRDEAA*6$(BMRX^A$'+(R!J3@ *U7G E,US;$[<DPOQ[65=_[M;%NT3WX
MN; N62<Q5F4;#= &',.4Z1 9<US2%&NL6PFLH]-81RFQG&&.5 *$X\129"C6
M\".9W%#=J-Q\@XKUV7[JBV+=@ORQLEA7ZW4_HUZWB!UK \6Y!;RQ3G!KDTE4
M>X)%KCTWSI':CETMU./3J,>B841YCIRGH.$QDY". 2-EA'>1ZB"D7MO@?(Z&
M5QNR->#]<H!'-'6> UL8G;@VQBBX)E$*YYHX2GD->*L%>.>[;_%Y"7JM3=IH
M;5X<>.\HQB$@G'++CL@4LI1;I+P2'C.092'/2&5F3F;^"X:\:CTUY-60MRCD
MT4"-]%0RH2@G$4RA7"8 2H)CT6%J:\A;-<AK3T$>(SY:I162@II<TA:0$=8B
MIIVB*40B>"X[P7).W^K5@[S%$N\J/*+K5+R .'3SOKSLPL74*]M ^(X=#+XU
M=%Y*_@)]N,I\*]2_?+CCG DA'#?<2*XT-I1YR;2QS+KD\$.:"=R">W>!W9OR
M7#]-'VN-@8_!P/:<>&W*O9>#0]10B4!SY[FJUR"5N/56R,A< @@T<TKO%D#
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M=!0U!V4U#5)(E;0U)H. ;+)/5AA^#3A6%*X(A3/+6)DR$"X "1 =*95LB$]
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M"=TZ;6;T??O ;[>#9CU9;?TCM"MOW8"WVK_,NL!C8E&;Y(D*#O4*RR4))4%
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MLC'6!.-SY'.7\2MKW3MKB9D"T(;:S+PBVFE*BL AUIA(>.:0?&3<1E;R<"[
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M<M9;S@,)7D@B*2_+SS82[CA-&CAP[C:V9%47'HRZL 0KND+O#J W8S4+G9)
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MF%/VPD.2,IELK8N4QB0#<\G>(,/L6@:J/1C2:/\R11I<"1N3\,130-)0-I,
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MA-S'*7!6UFH;<Z@U')]@H_$FPXEE<#&OX]?S&B;SNE@3$Y,#&]4?#\ID3N5
M.;W76&U^D@H>?S4D6#2BB0GR;$;6HH4X:< W1B+V1]>?#N'9Y8>?+[/K=WK-
M"S47_7S1SQ>F0M%PI^R_IN<GA[\HOYMTH@!?+,M?//GB\&9S:,ITG1Q3>M,X
M>>5ANLEN>$R)JQ_ZO2N_UUB[J9VJ;7WB;37T>NVY9IC*,HJ6N.MLO)FHVROT
MALZ(_(8R?NT/&A?+(1J%T-K'\X^'K=U>X<+?QCUH"?K3,@)<'D,7O>I\O$8'
M/=BM6?-?_E][O1;>NHO2<OC?RY@)B]6F_M9K.NTRO=WD6?)*Y/S^*^KM-;KM
MQZ^\6'WMN^RW>YEW93&E3K<ZW58UW7Y XXLL[*P1Q\]?$7T)0_"#>-SRO=1*
M\ ]T^Z?%RFG= H!WNU=GT6Z\EZ"3_WMG.RX66!5<NXB;\3!-UR;13(!5WM@0
MI53:.N&Y3]HK&T0*:N%-QA>^GXO5\QG7T(7S:HU6TF_F 9JLI/=I&X\?O-G#
MN^YS?"Y]>][^\/;P2+W;>:W:._OLX/#M&3[C_-TO4ROI[_'^?%^]Q3=X>_X.
MW_'E^WW^\OA@I_NA75;*S_'Z]]MG^WB_O\[W9A."2P91) 4D:Q=+;*XG.(*"
M&&Z-250Y*P52*5]XR\(#V9*TE&U(:RD!KJ2N^V&HU<;]S#*4L)$R8YAU%F34
MW@JNF"MIEUWDU+*%MTE7AKH3AIK)?TZSD#'*3&PJ48 Z>6*]#(19FTS4R3%1
MBIN[&P8(KQL15>6J*E?3E:2LCP;;1)D$F<O6!F2PR((+,@FAZ,([P"MUW0UU
M32M7R1ON6:+$"R/*=M!(7!*)  W" P@ALMG8DG9I^>'6E-.J<O7(E2L93(HJ
M)^L218Z*5AB4ULZYP"%Y#0OO8:\,=2<,-9/B7@O/K'1 )#.2X,!QX@($M 9-
M*6(@%!-L8TOQ3;-FRM6#79*Y8I<Z=/'+HY]:1]"#@>\V;CN?3CJ]SG T:$*0
M:\+[)9$5-24-BPJ6"RE3AL"U=RG8J+5242R>$*^2U1V0U?Z<2O0&QQX-=I(<
M]019BY,@E2<J)N&1L4"*L+$E],)D5=/MKA20.&X<&/4ATB!-0HO>*LB&4L5<
M]F"K:V8] #GCFC'6A>RM(L&6Q Y1E$QUQA&;!!JJP7'C/-HW"^>S6@O</6$)
M*2#&+%E 7@T28O B<4^= LJ%4VSQ2O,5D'<#R-GRKMD:9BGQH!R17AABG=8$
M59NH( 7&P6QL6;ZT#=-K@=3'+R%E\DI+9W6B5(:L0P#\0I<M9RG(+*M]O1Z
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M\Y3C;7D]$%W3DV&3L[U8'93ZC=P\_3&[>7D@2] C"6QF!0+/P@'TGX]D2GK
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MUTE:?-SUHA1HI77?G6K:&[$FHYC-NOO)E 3)-:G2$$0$!;Q%66Y&I1SB3I,
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MK-BONK$%YO9;_"./%M$U/2G.SO9BO@$ 9'*)A)[QD>YU830+9 'NJ15]OU>
M&RE.NUE;OY>E<.6F0M%)1?_JV"FL="^3RG2C[QRV<R%HD;J=D_+:'KB9_/'.
MH%O<ZAC;@Q,'AN2Z;V3@&BE)7IDD.9%20[BM%>7,*!8M%U^VI\4"[&%=<G?/
MVK';.VJ>_AF[V8S9PZO]/T27U"D>_.L(^Y._VO9O,]@]V?[>N("Q_;W#]_>V
MX;L^@F-\"_]MB]W-#;)SX7'CXN/QP7'CY%\76V>[>U_)SMX6W;G8^MXXWO_B
M3<0V)H]"\"$3%#KD#,<H2B$<IR$2ZL&_F2F;>?]5Q'+.B^95^YCBDSWI#=J'
MQ>MF)YXV0:XZXR^][QPV?2]_;N.TVVP5>677BFGJ\9Q:\+;3+;+!RD]E6S"Z
MJJM3%EWX_TWIOO^A5XO35@3]!T6QX3F>KKSKJV8?3(]_P/,V.OU8T-6B:AA=
M/C:,^:57 20%IAIF#:Q#R/@U>Y9VZ:UL/YN:9MNV?1,6J->'%TJ"J[5+<%6Z
MDZ&$-@8G, )_FWN1HP"KF;^G_XKR-24F7,Y\'IW@!SW[_2Q>JX7M@3R5UAHF
MHUG)907(K.M\B]DL@U>*6>-"=.#GHQ]T87$CW& HLU<O96'VX+'@>PO7!'GP
M1VUXX,-SF/,3F(7RJF_P[8,N+(@]S;)5)'!6O>(, HY8?CO\&KNM<W#TX\,M
M++P-MWW,=Q:V'0I8003+]3563S=QGQN+O@R+3"@L\B:,'Z:JM"<Q"WGQ[X'M
M@A7)$Y,M87$62]\*B"T4]M(=^R-XK-+\_.?"MFT>[X,'7AZ%3A\-;[;T,>CC
MW>T' ??A.YO;%^!N(9[T7X@P6%EA4&*Y[60 QVL)XRAA$ZV"H(6Z<'?;29#.
M%OR6?<R@5X#2P1R7YC$.U6=X*J0W,@@A6P1[6YOT_":XL4[K&]@1$,@FV)23
MHG757;W"NEEN.Z5E'OA^OAI<)KQ ,1%KQ=X1./JAE#:S=_>M01;ALR9H3ONN
M4RMY*-FGWF+RKPQ]EO[J!EG42AUZ 5#]0$7O'\%,EVOQ=#[U@4/I-;\O[CP5
M)_"1(Q#B=I:6?P[:L6!XM0*%+SYSQ?VH<$Q+IBO7<P'!JT=Z.!(L'[)$@L2L
M%E?&_<4G?K68 Q*\!@3GL EUW16.ZB]WVU>19F\/ON%UJ^.__G)N;NML9W/_
M2Y+.2PC849(D-[%)'!E#%6*16(J-XM;R"J,TVX,8-C):H$G2H*WC)!$.\:96
M.E$=<M,;9A(%#!(!/)SF=&1W$%>6 ^R5B'[O*'NJ5JMS5OK.*G$Z.(%!PTUZ
MI=,[O!?T@QK8_ABN'PL_QV#U46R%(ER!RZNO/86Q=T+OU01@?NY4+LF IMHT
MF367*^2:,OQ12=>[WQ/L]B]];"I7KTGSN 1Q/=:?9ZR XV?)YC]5OGW\H^8A
MY>+5/L\+[K.JVZC:2KNV5\+JG0HS;EW#C/.H)/\9INA3\_L#)FAI"06F/_QO
MV^UB&!7W)@Z=_)A>W7=697)S]N;.[(\)SYQ/<$V?OXQR'S!M]S_R0R;T>>;M
M6>0NG]2HQ:T6MY<2MWO,^"SG1Q;(QD\_:]6 8.A&O#2V"]V9LMOP] 5Q]1GG
M7_ (\]-1[50'&#Y="O#;;XWF*-&T]'LHU3F^#H:QL)WCK>\'FZV3@W?;^.#O
MOT[VC_\ZVCG>YXV3_>\'[_+1A,/SW3<WSO$=?SC;W?3G.WMOO^[^??!U__AC
MZ^#O@V;C[ZWSQO$A/3A^^W5_;_]B=W.;YQ;+$U5M"DL7<M<);3E!7%B-')4"
M^: UPT:&Y,7*NE)3B'8>>Y!Y,<\I_T+'D'^U4\9S+SBK3=(<3=)$N5GD)$;#
M&,(F)L1#/GHE#4=,.2>C<,;EWK!$\)D;<"RF_:GA5 VGGH^6J;9=\[1=$R0!
MFM+(@T;"48JX-0PY0SPRA"4>G78*TTS*I&;HY%7CJ9?&&K\"GIK%.CU=V59M
MG>9HG28;$">LG- .V;*U60P6Z4 2PD'&Y#E$@IKG1DID2B^$>RKYG[@<:QEW
M9:;KV?O8Z[TJIN;MJB9B\\[:_0)\EXN;J!IUAJMMV*-LV,YDPLH*S550"F'F
M<[^(W S.4@EQHF:4>I5P"KF;RV0KN)GQ54UX^?.D9VI%_$%%G&0%<LH+ISV2
M(K=5,C&G:51 4=+@P;!2[DU6Q!?H#%$[R*5)/=1Z^:-Z>=-!1NF<#$F@: #:
M<P%(7PO'D/.&IT0YJ&O9[FR2EZ%VD(OI(.<0;M>*^.2*.$D'K0P5H(Q(.)7;
M%G.+K/$>D<BQ@@C<! <.4DZA"UU$.FA5E@XL?'B= ^M!^S*67K2S,8O"AK70
MNSTO3I.U<)CL>9,6GR_UIW8&CW(&'R;3%LDS;T0TB$7O$+=$(*MIV5$O$BH9
M,\RMK"LY#UCV\A1:-6%@31BXO+FBVO[]L/V;R!8YE0@-(2$CO$!<"8J<T18E
M(8D0W O&,F.J8#.W*UI28U<#Q1HH+GORKC:4/VXH;P+%X'' &BPC<U8CSB5&
M5E*)F,'<>DV$M+PZ030#VWZ-%&ND^#,@Q<4]I%2;PA\VA1,)5&TXE01[Y+Q-
MB,N\B6$H8$9#<&0I"N-]/JZDEZKQR(/I?B?86^C: I"WM*\G6*O,ZGAB=8QQ
MI2+\NIW-:C530F7JE];YB,.QL%D'NR4[U)#,T1X>=N-AIGI)MMDMOMG6X))T
M=)Q?L20<;1_:DT[),;89VS#&S*$( X#IZOBO^2I[>MKM?"_)X>!;9V$.5!I3
M9:7*CIDG8:RB1G+IJ<%"IH1G9@Y\J!VI203OX^S-[^U\L9@KBVE$BA. 3C9*
MY"3\!-8]<BTBQHZMK*MI33FN<0C>PYYZ!YOJ4%MXWBF99,6^Y/SYK^N,34-C
MA*\NL0[LSJ!_^R736.A?S"PP<6/"QOX^ZEYANL.('$CW5V03C/B5;9W9\][*
M/Z[;/S!^PYL#Q,WS>',*;GW0E)ZNTCS3G)=S'C(/:4D(]ZJB>2VYS/_'+M1X
M"K"[8+'^HVDC44(G[+!*G&!MB/ V^I02H\HK^T6!42\9K\ ROLG&#@SI__S#
MKM]*)?M P2->6!7F)WC3)F!E_?4VF)A&L=UXLU9L-#:+3Y]??]K>W-[XN+WU
M:3F>H 'V]%-E?/9VBS>[C<VMQJ>MS?S3I]WWVYL;>_#+V^W&1N/-]L;[XM,>
MO+"SU=A;DL?[;="V@]#LQ[!ZQ7#W^S1K 39U^(&*.+)R9E(KQS!3T1*NG+)!
M&LHEYX%+I:A]./'=BT.GZ0]X+\_?S)"KU_S^G("K EFKUX#7)S#T]\$NJM0:
MN>ET;TS1[4;H^DK?FIH#H/:4U*'317[#^RX(>3&D@"YGI&Q&])Q$G)_\40R#
M5MQ-P^&\;UK7;)4HL[3WOS0IY\76%V\9"<9)9*DVB./(D0DR(A)%@HGWUKNX
MO"2;(QF,8S)8L4UGOMAFK^*-OL:)N=Q<F'I-<+,D/(A$KS&^+,2=Y6 ?UC%J
M:>NT%H$]K_RSA*1E&Z4EN88QYCM7R\='5DW)9O0Q-W4J&"FGY>4IRNX*G9^^
MZO$^2OBGHU=_0!,S/(\F9L-H9MEY0#"5P<<%W?!_\DVLYWCX&5+.!'-BO$K>
M2LQQ$DXEP3U5%L)#3ZB9W@-N,M-\U9EF+!!X,^AVX96E3R$/>Z$V#_;^:AX<
M'S4;>V^/#N":@WSMWL>OC;W]O'_%&A?;>/_D;7-GHA?J/UN-O_]YLOMNF^S\
M_?9KO@;B"-%X]X$TCO/^E8?K/S;A^R\@?A@[V[GSO7'\]?L7IR'0#H$B6"$(
M)I072(<4$2P1821:R5F\NWE-S?SQXBCPUV7^F.5X4:!&>BJ94)23J)Q45M,8
ML&/186I+>T0(9>1'[-'X?E=J?H\!7<1NI[93,]JIJS.80SLE$_<\$C!,P7#$
MN3;(L821IEPJ6$5-M5L!BZ0IH7\L&+7:TD:7TW7N8_P6VX.(1JW(NA'N\RWV
MRBY>H=GS8/3[5=\RFS,TMNV7F 1DT6!5KK;@+D;F!>$L!&,2"8(H(D6T =_2
M6G?2C/UE6U6J>N-RC3;:X>-P+5_;5GZIMEN/QE>CVAG" P8DA2@3'O"5LLA0
M9I'$(1<SF\0U75G77,X-7]6%S<]3S2$Y0 4.][&!2Q^U,<H0FI(403'.'PHG
M:CU\6OPP.H^7M-.1!@1+(Q 71B--F$3<<6%IA&7+<8[&=(TL>DGSP@.$-WE[
MQ0V/=HPV<FH L"!Y%==LNE?7EFC47=;FK;>?X%S>\QJ;*<3T3G*GO/(H2HX1
M9P0C*T)"C##MG346%CW704SC*JR=_@([_1_-(=2Z-V_=FW#TS(D AA#<.XO@
MZ,%*(J-D0M$JG["AE@D W"R?=*@=_8]F CKGME7V*\W!?JOI093S8:[<M[SV
M]POB[T>!QO!@S>6:U5LHC[$X4U@]B0]61>V0\PH""NP5,DX;9+QC.42,0C#P
M]D1.Z4-3>_N?V-O7FC=?S9ND\<0!2^L\LDDDQ$W>#XB,H]S((%%N#%<$-(_5
MOO[']6;KY+35.8_EZ>@,68<'8L#ON]B.J=FO/?ZB>?S1DGVL-FKJXQ,_:(&F
M4&-Y14*DQB,)7AXLD _(":Z0PB0*%;U/1E1="2:YL6K?_POX_EH'YZV#D_1,
M(1'EF446L#;B+"2DO6<( GYM64RPC HB?BX6,+4_*D" ,<6[M7/Q/OGK/MJR
M8;?K-5PU/%L,>%:NRF2-6^T7'N,7_"0V"S8X:ZE!V%J"N+0"&<GA5Q.<](1A
M8O3*NC*L/GJQ #;J!;!9K8!S5< )8.:=(B3YA!37H("6Y^!(Q=P,URLM-,,6
M@)FF>DEHY(E9 E^_U^G;5F%OJZ+]=6CB%[H8Z.4I[WYF4'7?P?R?C8CJ>2W]
MX2348II:8:-'R6.P]#I ],V3051&22(.S&6HQ5:IT7-+A+T\&U[-_UGS?RX^
MP*V-X=,:P\D32(R'Z%A")! ,L+?L7P8647CXGY'",V)6UNFJ8&+F$P$O;O/N
M9@"=1N#UO$PLQJQQ(AY#Q,+8&B8/HPN9Z;9DC6 Q_]O2-:'T+.0FHP\,C1(K
MG=.=' [#>;]=D&;@P'CL1Z?+VX.M^%[S)/:*1CPK/G9.;/OQ- OT1V@6BJ=C
MB+C7]Y2D2IMC)&L17$TH_CVP7=#/3/>1@75Q%DM2MFZF7;/%:3>KX/?"'X$&
MEOQILY#-SJ'CTW4_=L7 <55\.^0H^[E]V>.IPCX(N _?V=R^V+G8HKN;AU^2
MH]0I2E'$RB(>6$ .2X%4M$80+57DZNY*_R&ET&IQVAKTBMCKEY1XH3SN6688
M1H>95XM1;6@_T^K=0IN2W^Q&L"S?(HC<OP?-HF]/BM85VTJE9EEN.UG PL#W
M\]6=;GZ!8B+6BK?P2S8;^?.V!;>OI"%?W:D( 5OWL;?DQRD9!+O1AN?0U/*N
MTTCYINMNH]./!3&KQ946O+0Y6<T+ )/;B^6ZY#4/)3U;]A*52#3;%J87EJ37
MAQ=*SL5[J(FG,]3Q1>-(+#%U\;[3/D1@/T^*,7C]0,['16/<JYZH=?E$K:LG
M K?0C3/9_J?*XS0Z;?\K1"^/M_B'HO'A2]!>*QERRY4D$1?!(:N2183GLY(,
M9\;WE76R2J2:4GLT(HTKC?DLJ_Y4 6N]ZO>M^M>SG<,OSE@K&.6YFM6!:\]M
MLTD,B#B"C7(A)B+SJC,ZK77VU:I/$N(-NQ'<X(/+_KUW&GW&P*WSU?)#X$U;
M@Q(]#K<>X(7."3AY^QWL2#_O2F17_A*V9+C%MUT.:"^/IY:K>^6*[7[X$HEV
M00)0Q!)'Q!7-F0ROD-+81VH-HU:OK'.(N2<W\%[<EM2K_HA5YXW#+R(JPXBD
M" P'K#IU&NDH$HK$4^$U-\Z$E74I^1VVY+J%F(+\KI-E9ZQ43O6]I/^$B)6[
M$1;AN8%%E4M .1W^BJH;H OE5Z9#+J$T,?+QD.MF(F$ZB"1JK0JI)O]^L_O^
M_<;KW8\;>]M_;96= 7;W_G?K8_%QZSV\M-OX]+_;?WXJKD_HTQ)RC]6K?HL;
M79B,PQ+0;S9[OM7I#;H+Q,C]>:0PQSOO]L7^\3[;IQ^^[^]YN&[K8O_OCU]W
M]AJMQO'KX_WCKZ)QX<]V/]U4F)VS@^-6LW$<C@\VWQXU+F",>XVC@W?P+_U,
M=]XUFKM[7QDHE?@7A-8Y)?P%,)<G7AH$4^L1YX(A+1E#,8+U-%HPD?S*51>!
MC6QX(!17SGI#$V><!JZ%=ISE!GI1IN3%PRF\%RM VFKV;+-XTUF#B+4?UAX2
M%-T:  FF*1-/^0S30Z+WT=MV/+&NN%:LO:0!WM^Q.+)EDL5?8^:XRH><-?M'
MQ8V%*WXK7_@]Q_K'G6:[WSH'?POFO'-:^O3<)2%V<XP/0RE:ES/VV^N-!N68
M_+Y:IGY Y)$].6]UFJ'\Q77"$#'&5FP[@)8Y0[!:YFI@8*WB]<:;K>*WG#\M
M1M?Y5K3?,GJ,[8OSD_@[8,NCIFOV.UVX[JPS'/EIMU.FB& @H4Q#5(QD^<:G
MG=P=)J<C^MUHRQ80&>INM"Y@HN I_KN7B<O*+-!O^?.WK/_O:\5VN_@43_L5
M'@:[:7+F-#]--8:2_FRHY>4W'[8Z#K[VSZ-\;P;+/P@YKH8O'W_\G)"*M@LS
M/&5(#U*A!12[:D:&W' 06Y39N)QC@X>_$I>A2)5+DN>Q&P\'+0M+>U[T!NZD
MV>ME%O/A/,($E:+J8(QE(9IMY]GT'30NC5E2*@E%(!,GG?XH]SV4D-6Q!3NJ
M!"OGJUHEG,Q?AT[LU_(F@_Y1I]OLGZ_!NK3@?KU^;W48Z>3W,_.=[?JCU?&G
M6"UZ@!ZKA"@LT-=8?OTP-0I?W8U%[PC^!@7X]Z!\)!?[9S$"*.Y=#0PD;7R6
MNB HS3R/5W<LNY)\LZW5ZQ)XUBQ'.GSR<<7,GRF_.<]#+M@;#:"4ZIW\()=[
M 2!)50N6W#>E-S@]A6%>F8NQ[.[5[1-\87$7%$E&1( @SB9N.6!,8TUTP2K%
ML8HNJIM0)'?5OI4W8V,TF+W8/;D&YT%<_:LPZ)YUNJ$7V[\>)#G;V=S^DOOZ
M0=PD ()XASA+#AE-$F(P]T0Z -.,KZPGD*GB'&2X=S,=F]?VKL6$B#QZ;RE1
MB7%FN8;XW"O#&4G1."+OP)7U8LZVF(=?&& Y%;U!7!N%8.(#1&0$PC(798Z8
M..80%8'&3E_+RMZ!5I>VX<2V!PG"-<#M0Y-\:8J[@\-L=,$CM?TCW<Z+-ZLJ
M3=EY9<@JBYC]1"OVAP[YRJF4K9V*UTT8W6'3]XKW)7])+#; VC5]!9%^>_U^
MX_?A;D?Q=G/C$E%8[\&!=TLS.++$UQQ;:53_.6@-AS*Z/E]W.AH+W+Q<FD.8
MA?S:GWES"]Q-\3%^:\:SRM=9>!DB@6[SM!S19EZDSS YQ=L(8\U-L*J42D8\
M9?X.UM>"]Y1EKHXMZ3+NW8[""MOJ=;(/^];,'FKD]O)4P9I6L_0@S+JQ^?E_
MM][O%+]90 4P:_!-OQ>_C5[=/;V"?+N^WQD"/C7\PO@]WRAO?&5/>OVBD;Z5
M1V#*5&C>!RW:L*2W(?"17)6CG@!%X^,>[FZFJ^'GZT:_7)^I2\/Z^\,WWW[1
M/J"R[@.Z4..I^X#6?4 7XO%^L _H_6F^ZVE!'&3"TB:9G.=4,>.CEYH9 -#P
M"O5W)0(7+0.P 6CKY"2#$5#-FS[MCBAY/,"\(QU3-,N\0M4'L#>M"^#3),;+
M .93]62=M)$W.0"T#1D>^ITM*K&!YQKFP:X-><$:6+Y$NOPK_B*=90H'BIB5
M$,]P)9!.FN7*7"U"DA#@^(GT]_)T=)1K$ @O29-$O2;-XTXGUV/]><:J\,/&
M\\"BV7F<"S=+W$;Q[3"8VP,,&XN=3MG2>NM:2^MYL''\#%/TJ?G] 1.TM'PL
MB].?]=;*H"7LW/K 5JWW/_)#)O1YYNU9Y&ZBEVLM;K6X/:.XO43KX)?EX1@/
M>D?!;;,ZA1@*=UZZP.LIX1NAKPW?\F;,Z,3"]=W<\2,$3T_L\4P5Z7-6Z>5J
MXOLL#S_#85P5M6#:\.12A# ].N6I,BHZ9Z@54C^XE*_,F0QK]K:'"O#Z_%IN
M9('.W3XN+S*L/#_9??>9[VP>-0_^WB8'[W;P[M[1\?[>7U_S6=U]NI\KR>G!
MNW\>-28JS_?Y 7QF]]T_6_O'?WW=O_@@=M\UCAI_P[^;KX\/CK_B@\V#K_LG
M6VQJWQGAA=4R<D0H#8@+SY$5W*+@8!%5,(8*O[*N9N9;JGOYOK0WJ7OY7C-+
M 3/+L6;>1<*-QC9%HQ7+J4-,B*B.$I&162*U67I.LS1)TQ\=+ JGB&A2EB=I
M9&@@*%+FM.=*)4M7UB5])!O&HEF?&D;5,.IFLU"NHPH:.T8BIQ)KPR(+(H$6
M8"8XG[K95-NK9[)7-V%4]-13I@R2)7&L2P891BERQB<M+2&!J95U(D2-HVH<
MM7C/.(-=XBG80!C(,R4\"*(A1B!&4Z65)R:R(8XB-8YZ ;NT.]'#6!A.!/$(
M6\(1YYX@&[E$+#@);R6P2-DN$35KNZ/G80U;QOV;Z1KVNMDYC.W_[@W+*>[,
MRTU- 79C@BOZY='0RRJ2\M+I"<.R#.,6JI4K@I4\D*KJ?FFY_A<-N#U)_NMR
M]?.AY6;[:@$[J5J^VE3.9"JG]&1TS$>&'4<XI80XH#ED@X7@4VKC M$.LTQ(
M:]983?W_XN;TI1,_M3[.6Q\G4D V<>$LHXBILA>'$ @<)$8R,&-Y("(8"?I(
M7J)%4^T?%RRQ4>OCW/7QIG]4E(>R9QHF)O.$)8MTXKFL4.7*4!H Y:RLJVDD
M8;5_7&#_^"0!?:V/\];'B= ^6:VX4!Q%F<NUH_!(2ZF1,L*HX$RB&ORCT+/J
M8QV\WW(PYZ[JDYL'=.YC@ZE!Q(\9+2^9]TE(YZSF@A ;652,<6*<,EX_+L@>
M+:([AR7T=2+RT=9J2M?CJ(V@%#"#$@'0/+<!6<X$HM:+P&5R)94T96N\1@\O
M;N]F0?/2:),"3E(EKC#32>BH@W0$>\#V^E'1=:V(<U/$B;":6^(M21@Y;A+B
MV,!/7F>J1JR5I #F)5M9Y[-FN19"W7YAAXBEE)P3JJ)7W,:H,8X!1VVIM%9*
M_*BHNM;#^>GAQ,%+0G.?"XFH$[G3)77(DLR6RY6')111:5>GFY?/(4HBA=8A
M)1D-5TX[*I+E-%HF=1!2/"J<KA5Q;HHX$4=3P8B)T2%," 5DBBUR$2OD) X8
M@ P85K*R3F[O<5+'T4^R"7XWV</89G@OMC)/_&H!]XZ9#C1?8\-)L]WL]2L*
MXGI?_.4-XY.$['6><;[V\?-DY*Y8\$)Z@Y@@$G$&X;MFU",K7%24:L6#ST>(
M9CY!5 .5GR]RK_5QWOHX$< GQZ0P/B$9G4=<2@'ZF#MLX"02H3$*+5;6:;TM
MOESN\4D"^%H=YZZ.-]VCQY@DESB*@NCL'@4"@848PAFI8Y2)\0CNT=3N<;G<
MXY/$\;4^SEL?)\+YH%3*QVV1$3(?XTP.5-%A9 S3% =/(=9?61<O%LU?-B:^
M0:>[7%S+=S=1S2'V+3O@S]4Z]=%]7*K>J7IU?-C?JFX)5=?+DK0QTS =-4][
MS_$ ]_=5':8T[NZE>M5N;Y@$R68K=\,]*0A&__<@TF^S:%UW[N&P7M(V*)\S
MI7&Y1DUP4'D9[WG.LJ''66?0"E6[E+(S3ONPDW-FX^4A5Q3@EP3_8VU RNO'
M^H",OG3(*=^-A[G126ZS$X;]0(K>::O97RM>PUOM=OZV$95\V?8QMR >WMOV
MX/KFB1MT>_EC@[+1SM#BWN:4VX/<,N>F7WY,%XDKO[S=>'O-,?\9NYD*R1[&
M3DJ#W.%@;+[*[BW=2Y+6_"27#AK1)?70CZ=BW3[;.?[\Q06(4R25B'EL$>=:
M(J<X0U0KP5TP@N;.$GR:A_VO:L%O,/N6LWP/Q=%E#X7KW$:7?/:C'Z;40OV^
M5BRI&2B[0;1C9:@OE1$T:=3\86I'B>'\C7>>N+>#538"1[;J2Y":W5Y_K'U
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M(D\-SCOI#+F4(. 7S)JH&3<^U*YS*5WG? /^VG4^D4I.A/\LT_-:C9&$!4,
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MK%7.TPD?@?][$+%,ZE!D4/.MV3]?*Y93,39:K6$)_*C\O93420%;'1JT/"4
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MK,#S(W EDRC/$5D6V1:<^G$:,YLSV"VSNLQU[8TN^XZZ; X,F'EN'*<)MB&
M-?'<+#%9[D:FD^61Y=DV VN:=-E7UZY\+[ML;9-#]V\]*(*(FUJ_-3;ZODDH
M[J<!3W\G?;F@UH^'=F9[:6YR'WQ9+_!L,^81-RW+24&7!C'W<]"7CQ:16XE:
MAJ7*_,<O<O@F<:;-/GWL?3H7;HH3\-$BCYM1@,8-CS*3)4EDY@YS ]BP?L3C
M9R_<1PLWK>@^_6G.TV\21-GLTT??IW/$D8EKQ<QRS2#T<O _0MN,(M\V4UC
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M[3\OQJU=<L[-!&3VD\ER&/%O;'#%KNMG_]/5(* ^Y,V#$#7&W!0L?=$\_W;
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ML0?IMGM/,1(-&3*><ZPQ%Q'DR575QJ@QL_'%DN2&3LQ=YL,)#D.U$N;:KL?
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MTCPQ<R>*[=CS'- 2<(J[CPZK?AK%M)&&>^@>]^#CA[,LRO/4]SR3I^ -BTI
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M4YPCX_K*IHH,[)#,MUS'!>?-M7D,3ARHJ=".,ROB3GKO<B?AQBE.CI:V3VT
MI*7JMPQR1[EFN\#YTL9CFJVSV3-+]\SAZ2?K+$TS.W-89#(WY'#0Y$CN%R>F
M"Z9P% 699_LV]C2ZU>PM.CR/G3:(8WX^A6U320I6:E-HBH9S&M'?#\:<^5XR
M8S+9Y 4=R&HTD1X"O .7&@&)V57* >ECC?3)X_,M$6/;W %#1R_W#O?>]M_L
M]XS]@^/^F]U]6L]7;_;_TW^Y3[6T'2&XC3[GB]1%)P"K-;!LPN>G,)<+&7)^
MVJR?=7CSZ>;,3>V >4%HVAZ/38_!J8CFO9GEX$.F <O\('WV(L=X.]'BS)+E
M](QZFGR4K.Y:^*.5:?X9)09\E)SS!S/(/.K1@:%Y?.@1#6Q/CNL5WWBT2V7D
M:/<O^RR+F./ZW#6SQ /+*<LM,TJ"S(S=((A#V^=6!.Y&<-LA( +C58)TKK,:
M3^K!>V1V1&JPB4*#8ML!*XBM;0+0U1)^Z]X=Z#UOJIO'<,274RIA;1H/WWY
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M"D,SML/,S!S;<]TD]BWD;@$M'-R3SFW;P+J1(?M<#*=##.)1U10>9+/4R^)
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M (^1/VQ52#?S0  (F7UXQ0:@/'<$,*.?"M>7\&&8C>@$YX2RU<:(;(M-0N4
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M>C9"X 3NC1&OD*X +J$+4.W@NV#CL)*#PTA1-YELIP\R+FS_B>PUQ*F8$WS
M*SX8&$PK1*/GT$N '?T1WH?::FC.*O@53# OP=X%)5E4J%:&C<??)*>&:-+C
M,.MTP,=@\X*&.SAYWA/W*:0<2+<W+\;U1-9:X$=-)!I?MQY1_G<X!3V,5,4,
M+AU=7!M;)QA3T-I(=V^&&@Q!]0ONBF&++!N3HX-D\@5IRQ&;7%!K>2(_&]S
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M*U4T=Y=\&_W :V54JB]4RW9PUE4C)BD=", 5N;AN&^'&$% !+T+ 5^ TMB%
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MVC(%LW/T]_ZN:<<&YHOQ>S)ML-5E=<UQ_%3Q+G0Z9@RK8>O$RU("L@RT^6J
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MXS#7D%19T<@01NPGC0J\;VF?7M1,\M1,!!7P%K0MKP6$MAQ71+T%Z_)?<#M
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M"$#3.4.Z(<_)N8T%[.^('3S [%@0QPEM.SJ^5S?G?_?CTP^TP4[*(XBP/O(
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M.9-E A,;SOJU8ZK**;OXIB)IFIT2I&:6$#@7"0$\<LG*9DS*,L+=@?R.>;B
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MDY#>(^NSFVXV&3>FY.OQ:4*^)IFPX1RI7HW1''KN[.,-7<60%/9FMOA%\..
M.H/OC%VVJ*+^+O#W:,+*,R7><KTN2]?R6C1WW&JCP!+R[$\K=[S#?I*6SP^.
MYSX3.WB.GW>=Y%1\NKB[^N/+/>>X1;V!"@F)K2!E9EX0A_3)<F/32@C>0MUW
M1?WEP4+;X)8^*7?NF#@5&*\X=P7;\<%DNDBOWK:QV/G!:3>:EYN0<&6I[RYW
M/#UJNL#>L5%ET4D=K&RH!2[P4_CYE=[5U([("&:/OFHVXK+RZ/>\A9_&]BN]
MV195@)G7-%HMU9C[&DO(=12J*'*B%_-.O4+*5A2% C=Y3@MBN\>TC$@J4S\
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MSRCN*#,A0] W0%Y_/R,#6/%;8C^19Q]U\S1C JZ4 V0>!C-W>KBY\)6>4_\
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MV \G$]<+F/;9]\*A K@P7=CQ<[YJ4Z$#4#E!!065S V'(Z9*);8<TYT /-8
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M# [T)L7!ETU]1H<_\>\I+,Y))=GZ%*52KM>^!B"VQKW0\[DMQAQNW)Q",%D
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M<[PT^[4X$\&/5'FNA[$1(J)@)DIQP'$@/+=ES9GS!Z?7!TZLPJW&\8%^L)G
M&I&(/*.ZH2QQ;@69-5[<09*4L)H82A/E]9 B+RL\7."-G>%[78*DHMP^GHI6
MWC".YP?Y1*LMJJWEV&-A<5:!5E\TW-&CXRC3+Y&1>2/_J">VE@.%>."001\\
M)(L-3%YI6E?5<]FUY3WBD3*9\A#$?)I1+VX)C=>4OLC\^*@"H_&/Z3;,+D\?
M%B:NGRPV*AE?X_LS[60K3GWEAB':#G;HIWB^ZPQ=?"@O63W%=\%Z$16$8J15
M8I=@+.%15.MR_1=3-HHY?(J7)[NOIJ8K(L*X[2AB6]%0WF4B)F>D_;+*20<.
MD<ET!L*'N DUX?[A_"XJ0TWU5.I;W#\UID#?2+P\Y><92>H[?8X^A3^ $C;!
M.DX_<D5Q6J;%1R:I8<WDK*6\K(RP^'*XG;E8Z2C(!N@O HK0,OF7>201SX7(
M1XU6.T=D,<_ *Z/5S'\;3L<K+?]K50/%FU&7_HNA_/?Z[OK+?9["]-D4)@CJ
MG3)RG] %5E-XW!$LF\AOP)+0W![K1@"$8;(B#^$N$SR09Z>)H"R-.I1B0GF)
M:+<@NV1OM*OK4^<&:5?OJ(VCH-W(&0!O\PK)U@]97QDL' D]9EIG&F@XD6,N
MSCW-H%UTET!;-#T)/?'^LX**R#=G"A]][(02J3(X SM*DKFD)AT+OWN$Z*S9
ME2H#+4JVG,IW2DFW&B<005F)5MX#.',R%_7[_CS:874(/ZGG5I4JYM?31CD7
M\[*3YH<KJU%GVZI-Y^NSK?[NNGU42FL'MQ.4+=;7ROR8^?DQ[?GP6;*VI:V?
MR*R:RF2DR*R:@TQF/509UT6F#O-S5(?YD=5AWO,ZS%4*MEIS"K9:LF!K"N#%
MA:])'4TDN7SE'C3-$"Z]MUPZL?R_*VC<ODXJ<R,[!%\&B@R^+E^ U;- "L&N
MB.>G:S3)T*.I)DRY[W"7?V^Y0N*H&]S??:71S"R.%^?&N<31%'A179WU']&X
M-C0+J7.QSHJ&=%:OX<HJ^0X-(@2?"3))-2EXU>RHAI+M2 ![;HN?\OT4@CA;
M?AYE11D2/)<A**S9SB;AD47+;'75;FZ9!MB5LY8940G+4N F$?\:S\R+PKEK
MAE4*64$Y',M96CFXREU(K.5UR\\]1IQ"$Z=(Q!RC),XLM1X<\.ASZ69\+N6%
M.CO-)8"85L\YSF:POO)"$IGR#$$ZS851TE,_+4ZSQ;^'QTBCKFJY2BQL.VN.
M$K5E+G>7S'W_S#U7E_=$18'=/'4DTO)8OD=1]$,H'(*VRWL"V:D[.&:RROTK
M9IYF@0K_IGZ ::@3\LQT^#'ILV3$6QJ"#3%&-.:T:YN$#C][VVJ.?7B;:O->
MB 5FSW'V1SP\5>_:?UN%_*!E/:>=JG4%.OV=6,X;!?U'>/0^8*ST#Q8KO:-1
M+R<1+[E@"?%#_"_XJX_U]8Q.5W$WM>>XF]K2W<3<32G0HIA@'7LPZ\N$+1,K
MSE0O;)B3^)^B4I)(SD0%/$E=PS"N3@FFJYO3E10\JRBN+X\"["*WR.T!^/E2
M<8E^:([2'S#SF^%K@96D@_)B)$1<#,4*I-B7X *FGD8W<BY4_/)D)3Y75CG+
M8=XYIIAFZ@6F\P*6?7DMGFU*G+C8(II,(C98B_HI)48L)FN=#ME1LZ.CEOJ\
MES]J,Q>R1H>]+3I;2NY_6ZZ'DKD-*EAF-$T\[0X+_WGM3.B+8D3^11ZD3[^7
M%_6DJQ:2Y/FX HH?EY$%1S*FF(@Y)/D J1P($,ZQYCGE9DYG<XL4"=EY?WZ<
MM;.5.&NG(>.LU8E1RCCKBXJSWE'1!Q69Z07/S5I%U>W,474[!U%UR]7&@/7/
MO<#F0?=\VM-UTL6VHBK+M9/D_K'D1)3F-^0Y[A6<)-BBY,6Y17[4<=&.T@YQ
M,E=4[#6K:7JJ5SKK3>33N!$PJIT]R@KUN'J0]-<D6!79X['?3+_@]."LZ%N^
MT UP&!/H]2:OL5RAD7#BJDHW%(YJC6*5-7HVT5WPO4R)!2W93&E$J6A/5-MN
ML@IHGC",WUZF_3+/Y9U16#T O%2ZY^@7,</)IUD$)SVJN88:LO+X%'.+$T\Q
MCQ#'KF%6<:Z+_J_6C[>.Z\"R.36&\(4[%#RAWS]A*C- @_U@M=I=TJT;#1!%
MW4;?['3;NF:8ND&,?J>A=^I_70+I&G6MKIVQOQB&=L+2<,?$]O]Q<M8\41S0
MW/'59T-")F\SK#CBQ"<*=QG"]WX$;X&TS_HNDY#X%N"LP"_A#:T3KHOUC3^>
M>Y?NXT?][O&K<1/VOUT]_OE[]]NG\0?[YL'4/OW^]>GKMW/CSV___G%S.6S>
M//SQ[>M__OCVY_C/\<W/:^/KS_[HHW%K?_TY&?WY<&7</HS&-[]?/]WJ7^LW
M#^>-3P]7VE?]@_U5AR>^W3S?ZC?&US\Z/SY=_OOQ3^=?HS]_3JS;![,.]VLW
ME]<_/SV<UV]__[<!W_SYY^5W>.JF^?7GAV]??_XQ^G31K?_YWU'='/_AD/]T
MPT_C:^WVY[]A;5^>;K[=-&\N_UW_\[)OW5S>?O_T\.?XZT_[V\U_;K_=_N>J
M\=^?7^M_&:0'H*:MLWI+,\\:I&& )DD[9UVMWNV:9JM)S.;);YH!0OW77[)H
M_6TZBWP%Q/?Z'=)NMHC9&'0;@P;I=3I&NUT'M)/> "2?1/P.$6\^_47Z@WZO
MV^V>=0"Z9XWVP#CK]-N=LWZOT1L,.B;J@8#XYD+$"[$B&M&06:V">:D&NHU$
MO7BNU'NJ(QZZF7C;O@FQCJ@ O-!;L:+O_L$: Q>^I4_*G3LFSH9N^X,'#I9/
ME5I?UG2:.M@WS3IP%ZU1-_5>K]ZC7=WHP6]=36LPEJ/7&YSE,/5;LIQML9PK
M_?;R^_/M-_C6Y;7VZ?+J+ZW7[35[3?VLV3'K9XU.3SOKT@$P)$-KF0TR:("E
M<?);NZZVIAA0-LEL!1+0ZQII]772:_4:\$72[6JDV>S2;K-K=*G9C$A DR2P
M!Q+X_I=>[Q&0/_6S>J/7.FM04#P(:;;/>KT>Z!UZKT&;*(3J';4]DP;R&4 @
M&B8>/0O(CUF::]:ER<RMU(24K#Z, PI8W5V)V,Z]$*1H$/N:)+>ER.UA^)>N
M]9MU4VN?#>H$R(V8]*Q;!\6']-ITT.@;39W2D]]:=;6[0-<].-N1)+ Z">@W
MEU__,AI:KP[:[5F[4R=GC6X+.<Z@<=8WS 'M=HFI:^3DMTZG0.C,S3MDP1^?
MC44;*'0\L=UG2E,J+^M7)U1EWKR.1872PS**V15<J&HB1.GZSJX<#OTTY?]
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MV;8S._5H/\2);S@=)EXVTZU2"^6C.77V/O8&!E22T9I)'TC%IV)86C2\)QI
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MP . MPFM)S,:2XP/9">;ZZ!\NB\SU!+Q6WJZO0:\*]JY>G!B+2-P[H LE ^
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MO2__:N/*UOU7M/*Z;Y*U!!>,L4W[O;L6P7::[F#<0)*7_N6MDG0$99>JU#6
ME;_^[?&<?:I*@ <&)>IU;[<!J88S[+.';W\?[<V_@!WW!B[IEZ3<')S!03,F
M848\VC[9N,*)U3+3E/7IW C,=V(+.Q.NE7PU$ H]XJ=A(B!036!FR3DJIM,*
MO@R?[%3K/^\,I4KP0\[^H?<$K/?$[;_>B>E/DHR2C/REZL+AAY<L'<U?.IJM
M<5*6"QQ?6#*-GS?CCO1,&58R=O?VX!B6&M-F;[#7Q6!/Z3\O[WD\!_NP?#-?
MXT&7(7-4[FJMUJ?P2G^]S9J%#6!^]5-QGHZKS<'/: ?IHO#-&0T3!6@UO%.%
MRU<RU'[+1 [+ Q?Z(;+L5*<>[Z2JR4,SAL&Z5J5#"5L&^1&.\4XTQH]XYZ2A
M2C+"&&WJ2O2T,?0;U%=% .+ 0G]LP_QB^XFV0,\>_4#CF0H+F2I<:5DA6B:G
M0#,I.3I\;*/[=.?Y2HZNH"KL\)*1=MZ(R(_&9&_>&O1WHQ_Q.,;C5T<E7JH\
M.O",TY&".]AB-G/%@81:Q%]VV[ 2^)@4Q)+Q!0(!R%F X=,ZA4DY^1HP')*'
M8"OR1; =XD\VZ$EBP@4.XKJJ$RZ 4M#YV3/GR\$N:QT*Y"N2W>H<X_3<!4X9
MA!"X;I+![N;67P<088PIJP./F*6N(:/']E'>Q5>I^47H^3D1!.^X.9"V<T2=
M7+70$UQ6_ "_NBB*2?]C39,T$W#-+/G@J'R<F7'D,=1'X!OSZ%**>%;4GYE4
M>G"'^.:2[*=%'(^YSO5$Z7P'$)"]@J!6LDOPT ]N]K]>@?81COF*[HTS L5@
M0P[9!@[RFQG&ZK\[3D:#X2CCX"YJ\+'6+D1]/>T]__._Y?)1:QJA4.:5^YO^
MXV4K%4-?>BF#*%E3S!"VDS,XK/SGEYU$CW31QWF@3?I3JV&._[:SL_EB:W?I
MG[<VMS_K;W#+W>>?^\VE?WNRM[GUXL6*/.S.]N:3O9U;779E.?\Z.4_FXSC,
M-=M1=3@Y[HCP[YHQX@K")XW2DV>3L;OC48I2BE]WE+[N8-S'DNEDWCZ%8&EI
M9^]UJ^)1MO&_<N"VI0_!J7T'O =?=Q/=-:'VUR0[N(\WW]G;OJDC_LO&X'$0
M:?\Q^3CN=OG=QPON[FY]KL#A5UEE*^LR]0_G:9*?)[-B9<GU[L7D;8>&K36]
MWCU2P#W?>70<<"NPH<]75U[J?G;SB[6XU ,LS"<[VS?PP:UW<V?0#HL\75WF
MVWLZG&\BTEYOYSL8]A?/[X&^_):[^0ND+6X9LO:SNZVS&E]E>!Z_C7G^8G?S
MV1UPF3[BC,@C6/&/(%_RD O[7D*LX=;3G9M4OA]P!2]AEER%LN_UD BNTGMV
M  21ER4"Q;DH3]U4'4R$)&N& T[7$^P,X[W50$ML/Q\.#F)"!'C^8X).GU O
M3Y%7%^E\C:-8XRCN9D-1-+4BF^7%+3?+@V\5RPKQ"5L$OX'UU@%,ZVRPO;7Q
MS]:R7&66H$?8P\UT/J\-$]SJM:\R/T".;>?C"UX]5[@Q<O"[QT((AE2&A+0<
M-6F&!&Q(>H-T5@BT*I,YM@SGS309UTSD!O]"@2%$(PY.SMX-!V_!:%\,#I(2
MUG*>$/U00YPY=/GH2O-T[O !!\FX+*IJ,&NRFFG8Z .NJ9'?!^Q,Q:U@^"CA
M?I5T0G!C[,@%F@\4NEX0,,SE$^&5VPG\98$FC@DW32-0&^4_^,N3#MG<)C;T
M81OWV-/QT7D5/=W(G<.=)H'L;@IO#[>/R>ZV5Y/1X(>NBOA*G82P!=ZX4=D@
MPEIW0>B8PF7Z^J.T'1Y/I\PDD%?"_"88;(](7).$WP,;ZS,PG,]B;/[U+(1\
M/#[=C9D-L<W3R=0R1<5?8(5KD>Q3KKR['5^YT\$R^,OV[K9&AGIE-"_^XA97
MO^;UO3>N<BVB?.DZ\C2:Q'32FOHG*H=]\\P/<45ZJKUQV0A3;9,C=Z@'^:]H
MT&$[4[>(6J^J\ TK'LXFIW9M^ 4QM AKS$T,HSN;6[YW_#NZL)V=[]?F^J$W
MV?;F;FCNOW8NGVSVTL\>)8L! 4IWMM:6\=%-VL[F]K63MKNUHM8J;C5!X@;I
M-%GH63#6#K>HAV^)-1-;1W3:V[MHJK;C@^3[M36ZEX6]=>N%?5LV[+5FR;U,
MW//;FJ2GFUNWFKC=]7%R;Y.W_>26D[>["1>Y8?+8G497?%5YXXXY8[O5#1PY
MR-AN!QDH1B9'"/5H:WLVTLZGXPON<)\590T/,4$FG"B[+[W!(B4@C!9!F("H
MC/#JQ*:C+-S*U[>J8TPU#GMF^^Y0UO.P/$"5GNGV)!_YU)90"T7=7G25'K*A
M5:B(/!\.WN! _$)MLD?PP(U0SP\?O 9R=\38:T[$%B?BTS4GX@KS":XY$>^2
M$_'1%5H.F-OWC5255C.H/LP'_TAR+;90$I#,()EN9.$9V AM"-;^TFTL7%)V
MP^K271;9)>FQ\,CX>ANM1?&+KIC\!QR=65I+>7!2)E<LVD,YQI:L"YWKK-F3
M&=;H>0/_0I9%JCX:PCMWS9,H\6!BCJTQ>%\Y4E$0%8YP9%=(9I,71-KC/B+3
M)(D\?4QGS2P^_S*DGP:3/*"-MSGH82!>YID(+W%>+/5R4..+/$TF&F8Q%:F5
M9N'1*QEB.FKU95>S?/FK3+X4]5?4U?VUM81A6B9N2CI4X+E*GDHY-3/4]]'?
MP12/</I8MZ=U&2QMQ.2LL$#^LK/YK,76>JO5!XL<*_0DW-%F<VUO03A!D,(*
M5R3NH9(\ZE1%,5OOTZW3;P]?O'BZ^=1+-E)![IH+F4'HN=KS[;T@_[BJP1".
M]XTCV6*^+6&N<D5/$)78O \5T1%M9FY>Y+AE1G@1W<-9D"L5Y43J,8EPE+'$
M%<:A/51@G:+:XR7?^\OS%R\VMW4T'CZ8PAE-REJ/JD_D*D[S:\09_T 8LQ78
ML'VVJI>INF4RM8RLN9] L<RB2(3;PGUW2WE-]@WRW#'BB7V#FT7",!\ROH#G
MF-RD^7E;"_NX_(A38N,^"9H@[\KBO(3MM+)^^O&X+O $)S\=[<4/15(2@NX5
M.*RDNS1(FOJB*"GE6/B,YI*1T$PE5=+F_#OFJ/2?9";.O^R:&HV6V@QMV^;@
M^*9[#2:%8W^:]5)S7/ZI8)G1CP:_&?S9#H6Z^+4WO@MKL8[PNS4JW"@7]FT&
MP=Z0T1URD=89]T0;JW7C!1+/]HAP2GA<5'W'\VYW"YL]6$.TSD:A2C\.X(KU
M185(27B<R*N+Q'IO^:7M3WC;[0ZD"SZZT\9,?>80/.VRN9(GNZW('!]OQD[J
M?@O^"6Z.KDOF/,77N$S2C+R7VZZ='I^YQ^:ED__SS<TIE"=;N]_<D-Y\S-$7
M"6&]R8H5U!B_#1UEK*PM@@Z+&^O\DE?FV;I?$LJ]O<W=9]N?PT&YN[OY_,G7
MIW7<VMS=>?K5:1V1+'WWV?IA[^AA;[<,_F#T$OU]GY_3:;^]N\(DD&^$D?L4
M/(,C]@Q>1Y[!IY!"/MXU<#-I*F%YW;S&W#/.57+N[H%(E?ZSO)%XJ]M+_&5K
M"CR'9#RZXV&]);GJK=[Z-L-Z;Z-W+XNRP\2Z'KU/&+V_LET_H%SU5R&TO6$<
M'N7A]G:I8-EW347%N^][I<L>@@6W/;Y?A4#C*]NYNR;"[8S!%]%GW,O+O]A[
MH5)1=S8,CX,.]TX6Z+V8@4]FQ/VZZ_!>WG%[N+?W[*:5^+@67!\SW1<MOL<Y
M,]_M[FYN=5SH>YB2AWKAO_XQ8J7/=RFX&_^KN10/R^!X+Z?HT]TU@>,#6*8G
MV\\WGRXS3>N1_8+3^,G6FNGV+DRK !+7IO7VF_SIBQ?7^!]KNWH'0[X]W'FZ
MM[F[MJQW,+;/=C9?W.7 7L\W>4=(_M[QW-UY\61G]_Y[K8Y]1FR_:V-7J])]
MX(\3 HOUY?H0Z5&ZBM59+X391&"CC"V'>1TU925-6]1?Q8A\!)<+J,-<CV%J
M]04AVGP@D$]ZSZ[-P:].Y="94T6/O>4/3"B>,;Q[FC-V#HG#D/>,,'4+""*;
M<DQ ..X6@$_PK9VY7N[<I)*60D8O.T,,YQ5JX7]A;!SC7!O\VZI"B<.J#CX&
M <X1+TQ>1C)YWPCC"HPF H'3?%S,:!#6+ =WWV^=%_D&S4U8I6GM9M6@:K!5
M&.<*=NHX%< FHN.Y=3AA&>ET-D_2DC"<C 6MAH,F+QV8/83ZG:-L]7=9457?
M#PA_A0TRY_ N1D]U"/N,.ELF@\-W)_^5S.8O7S%B#&%1&Z.$&SMG"$JENZY)
M%.Y^77##!<&ZC3UD[#_.C<$6*UI3.C%0?AL_/$F1 \^!!:S 6-97SN51=P!>
M1>7!41L=%R'<H,"U!A-.:.$_%FR\9SD^Y.(S<O#2SW7!4[08,-9U7)SGM(O3
M7!#@C*=4OLSJ)4?;:V:,>]Z17>UJ]DS.<2]YV?OV9F*7"2RMZ*;C]T9-!;>N
M*F&4\-\U#E?$[ERMJB>B6*/KH<M#.F>2DM^<NV!FGON"")D0JHQ_F+C0.)$O
M3:+T^Y)]O1CP?_!E%_E ?$-X*C&I,&%A=F&Z+N %XV]@3X;_B'R=^OIN?JTO
M:Z9XJ+CIT'O[*Q\W??4E:GM[EB_1OL))_Q*%;XTI@N$^/(V7/J-9#/N%_G?Z
M\6_@?<(X<GM0DZ?U"=(!--7D&S)H,#WTB_3)UG;R;/(D&3T;/7WZ8I3L[6TG
MN[M[;F]W;V?/C7?_WRL<F:WMK>T-^L>SG:UO<(/"\V?5__EF8_>;00Z#A)?>
M.$^2^=_>R9N\@><_A4<_GKZFASYR]44Q.0R^Z3<#9KN'A_A8_RUO9AN3@L@,
M\-+?#"IP!>"RS[YA#/YDYY?%Z%5Q^=.3D\O?=HZ:R?O7E__^<>_]\>Q-=G0V
MWC[^\;>KW][O[_S[_;\^'KTZWSTZ^^7];[_^\O[?LW_/CGX_W/GM]\G%3SMO
ML]]^GU_\^^SUSMNSB]G1CX=7;Y_\MG5TMO_T^.SU]F]/WF2_/8%OO#]:O'UR
MM//;+R\61Z]^OOQW_H^+?\/WX#I7Q[_^Z^KM^W]?'+_Z&;YWM'7\XS_>'[W_
M</7;[T>_'[_ZQ\7;W_=WCD_WMO[]?R^VQK-?\N37O>9X]OKWH_?[N_]^M?_D
M[>SUT[=G\(R__^OI;[.CQ?'9#^^/?C]Z>C1[O7/T:KS[?^%9W[XZWWG[^X>K
MM[\?;<'O_M^+\9/=9SO/GFTDR?C%QM/IWM.-T<[.>&.\]V3TS,&,[4V??_,_
MU #ZO_\[GOK_Z?7SUN0KGGQE=TV^LL+$)6ORE;LD7UGJD=S/WIQI.UBGA_V.
MNU<?RN%ZXQ.J:X?K]C&!U%)[T]%+>K,'YW M7"[@=8QXU4A/HVV3E/OW^?C\
M,ZO81$_[9'.P[RG_L@6U7KJ/;MSTRQCXB#,MP9MK*5&$Y _F!_B!_*L738UO
MS_[>]O..(L;GMS*^Z,O8F-6V_73IOGG^8GOOV><OK2>WL+K?_ ^:2O1NFB0;
M'(\R:7CGJ T&=>.')*/:P.F%@\':-Y))*]G2ON1U5]0N'#.EH'^CPDQ@V*="
M%N_9(,V'N+V74^LPRQDW_89< -$^PA&1%?GY!O)#@>48U=$EJ 8FO#PCE\._
M:L/'X!N%S5<B00#B2(W2."C54]:8CJ<<@7C"\"VL5U&%IIC-4LW(FWS2Q%VZ
MK)CC'[#I^;R!2Q;E@LM8\!U7$E<53 8$3048SJ!0T)N5HJ_YW],H3B2A:)\7
MQU2S4WB?$5A.>6*J2E3C,AW1X("%65W>\-(Q[\ (T^-Y@4RJ<"WDVS$)^&O6
M(PP0F)$.A])J,FR=%(LDJQ>#=[)8ON@E'LI!.OOM=/^'D\,5M7V_,@F>+#'>
MBK/D@^O=RV#ZME]L;OUU0*7!'-?F55%F$_#<'7D!F!:BC\F@*&W'$TNM#@;A
MR>XG787H\(3[SEYK<Z K*)B;N))!;A(;;;YJV%Y]#+*&-Q:^P3G6+]M:#[4J
M3]\=OCW9__?^ZBY+6H5E>WYO7#/ZX@,\2^!D'(#+39R0<B5B;-3ZY#;VJ].*
MW,85:1FSUXOHF__YY>>CUR>'9[^MZ"**F(JV]RBH>?-JGRE@,)VM[^>1.#6&
M8%JA/CDZC:AM^J7YPD4PK/.7[K\B7%*CJ]>;/V\.!Z=7:?V[*S,"6@@)WL^;
M_[2D08$TBZIZ^]D'<"!A$;Z#X'"6# [1AX)O_I2"-^<F0^(U'X&/E0JUN?_"
M/!L/OM.?OJ<HL'^/@<7V7RKR91O-O[=NM&B'X5%QKUMJU<$"CWSO=-EX4<<2
M)3LA- I+E %#G%7!^00[XZGEQK%L</^R)JP>><@N\Z*=:0[!"ZXJL.9N?)'#
M0)PO!H1GP'P%7'QHN'82_@O%.Y((&;);HX*D+BQ>V*9T-_\+\RD&K"&5;3DA
MJL0%\^3BP^7GR3EG/U0HD+8\["%&(OIB7.OD:>VM)(=]A_@JYC-C]-^-.X[\
MH;3J/&M3X?O@N$.\!$O0N<W!%\@YQS.S&O(%MQ9T?E1J!E]3T'E%8K^#$%\<
M+,L)_*#Y@ .3#UA=9Z3-C=D"Z$C)!4Z1<T31R0$_)GGC)*L&?R^R"7%Q_U1/
M-HF]'$UHB-C,+O='.8,IFWG!3D<RODC=I?,8/,D0A5P._!&^MJJ@GU\C'X-S
MXDLR3Y8KM0V<(NYR.S$),K*[M(Q 6#JBX6,3.J*(QY _ Q^(<W8#9#H5!1(\
M)_ATHC-OEI ')A%SFZ40"VN61YDY!O$2?NZB[%_[%5;>1KRR6<F3."MY$+*2
M1WXE?TI.Z1$NY1]HX\H);5*R(KS>0Q0Y9'GJ)H,%4*;GYY@V+K!^B^,BCD4W
M:2N+11P<83GO78-[@=M]*"<2N3HM?O7-/9_I@?&P3QY6ZK#]K:W HLZKV\^O
M6=X]VLG/XKOUI:<Y?ZQ$USB:EPELNJ9J 1WM.['7JBTET>@+=>^F7U]>[P"W
MNG=J*Y6)R%#CG:!Z6.<3S"5S@J)17F*0E^7@B[+_'3<'/[AQTE2NS\KSHYF!
MQ$ 5"7#5(L)"@_<:T5/U+BSJ#?"F=(RKA+Q@O @ELIFW/3@H?5[,YF"_6Z4P
M]KEG;6+0V'K097GQI I(9G-1L=+P F/P(Z9-]M5&_)8&];'9E</PRF/X*WH6
M2RL[/ $S5TNNP!Y0?]G9:^NA6T<B@%$#]:U7%/";9%7]C"^(J2IV,5ZG59*N
M2$3U?.4BJC6\\%IXX;,UO'"%H7EK>.$?&%[X]94M5R34X_/DC6!3#@(V945=
MA![MM:'/'E<DU 8.;'Y>$!1'/;&JA@"$G2<?I>C?ZE+F_QS]?<0LS;""@GG>
M= J?P!1'_-FHV1Q=.7&XT7]& )]+2O#KB_(\R:6_MQI\=W!R7'TO(ESR6?%9
M\"]TF1#:&+C3D#\$[CH$3T-,F1!*:D[9A\&O+L0(;=F9'I&N%W$\>$UE:"3
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MT&YE1279&H-4Z>=:!"\;PP1?*1@E54HA)"$,*59$!J9;O!Z=EB/*J=EO8*0
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MZ1%/&!A-9GZ4IBLZ8N#4Z42G$T&OT#%41H\ &Q*_'+*'-Y9XVB&Q'S:NGWU
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MY5EC$DT$]$J8#VYS+ER+A$TEWVU=:+X7PCL1*@D)YN!0@:=<6C%K81FNG/O
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M7J-G500NYV^I\Y#C3P6 !2 />9]T>?A_KB54L/.YX\FCU;ZS;6]ET9Q?Z+?
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M,,#&.9P@C#]SMUQ'C\9?!H[+6<J>',$T>Z"-%A'N*<$MCI/. DE9=%2# V^
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M$7T2.O@XJTE5X-"BG!=DY)G[N\MT9/8EK3]:9B)6UFZ>P_4FQ.YQ:R-#EPW
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MNSO=+0L^5M+]V!=O3GQJ<0TYEV]467/:DI3$X@]>)65.58BNB&B26Q*+'EY
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M'I&)VU:L.IE.A9MR:(1Q&0.%,&?_*]\[Y8E+X5"<JS#;2-D#/<]<A.9A@JD
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MA3'L="8LZ7F]<@G=GL@)JZ%($*$+;_;NH(+GJ4E\,13IEC4W=*H#7L=)_:H
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M4KUH(260'BTQRHA_T =)<T',^-06KSX-XUB;IA6(P%N535JS.92^>4U[*K$
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MLD@FV4([B@.CU^FF:L=8W\ODB;3098)Q"%H06!ZE><C^%03=$Y>: =I#@KG
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M;)2@\1W5D6,=A.3\G]%:ES SZSFY^SDIFAJ#&@K/L2WB/*CT"5$E:MESLHJ
MI*31?BGL3PXO5T5*][.DKA6?C(3B\O-Z+N]^+H516M3"\EQZ^YAU =7I&4M$
MH&#J:ZE]HI'GVN>%K(MD<D2L9C4A^M*QW\%QQLNS/:RG_#Y4JP)#-0'>M11$
M9=6$];^9M5>TI=;,_O?(["\IV*6=_?^_O2M_;MNXPO\*QO6T=D-1)$CJL-+,
MZ*!3I;'E2'*;_@@2$(D4 C@ J2-_??==NPL2H"A9!R%C,DDT) @LWNZ^?<?W
MOG<'!PG4))B ,US$' B<1M$Q7S\ 'RC%V+>5KM!D[%5->9T8GD32-)+HM#Q
MPZ.,$3>L+;$BE<O;N.6"EW;TC05MN';R\0)BI)""$4R=<I5@?N;U[<$W*6DD
M5Z-'%]"CG1H]^OVB1Y=D=YYC\0FG&9*V2]?6IK-O8'P-LY5SZL.[3+C&+PTD
M\RU7FHXD?_U+>ZNUYX/-E#8LVXNO9#0(TY@KU9X8JXSX>4TJ;B%- YU(E,3A
M!K.8D\ X&; Q2&=9>0Q=BF=R$Y8&-$I,XB0<)9\+@V,UW7S4;D'KC@,?FB\
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M(JL<_^D%$HC"R3-2*\..F#3*;;C&TA99N=$IH=XF+ ;IM6V#('TE#8B?!%=
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ML?&!@'-!7[,6W-UM=K$]RH_35/WKRX-91S911VY._<7OW'9S=V>G].M6L_W
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M %6PU6G=!#>==IN4UB$(W&X-"Z&QPW$8P.D>#&=(<'8"S%-$CY(!]11HH;,
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MMXAFI]RYV1PD_JWZWWAZ&?WT?U!+ P04    "  0@_14@QQDK<@:  "U- $
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M MF#-#7)M7!6OY(7%G"R(*H$VY*"?ZOX^>48FN_;2^RA7W_Z7U!+ P04
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ML9SC<KRI!3I+R[V;T.AO,3R1V&<+!U9"/2HEDV80:# I%!FL=J!%.;C:WF-
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MC*J/!?N"84C7%AR(%8\40$,#=#K'-%[/"/T\P?5T3_/12>VN]*^-\^5R*NB
MH"1MF184^9$K%AAR4<"6[%VG&R&W03>DBPX.9HH:"ZVCQWQ^Q6D=LW5)H-6!
M%%N@,4?KF#?",M"Q2!&LS:F/-;H7UC8$"M^\7_Q8.76DSB9A\&4'Z\=//X]'
M40 B< K_#$<:M7"LMJIBP15M ;G'3K?9;X=OJ_0A_^;9M+?H.M+JYB7KHR"E
M<*KV\2,7GFFM(XN:9H \>:LX(IG@;JG#!]%M12GQS5-J3[&UN^ -QM/JK[V=
M;HJ$+J<R702)&B2#&"@&#*[6!T7'K)'96F53DGWV>^X!M15]OK7,<RLA-6/-
MCS">KT_N_K0^RKL^.?K;>/GQU^DL+G"^YO/KZ>EJS>_9-(TG&_?N?56A<YJ8
M%[ 8+RYZ<IV/;],,M<[@^6GQD8HR: V**44SIO/ZB@ZO&4= ITPI9,F[</!@
M0]R*T4]=\]J:T<,D4$<S_6J%==?H/:X['[R#^7H*N=/<%J]8$;XPG:QA7I;"
M1 DAR91CZ52SL27 K;CY[6?9]Q=>7P>P[FY?N:E*9 J3D;.DN:XVP3.O7&3K
M$V:VF!#U@2L3=KP[3'QCV?;F4FO(ITV@_/DW"FWPU>R/Z8A;5]MN.&92"DP+
M4[N+\\R<MQ&A@/:RST&_FUBVXLHWEEG?4R+MF'%R2D:Z&N;J<%ZM^7X]S5C&
M4\(W&7_"?/.R:H_:\^04"ZK6A*MH6."D*KT4A#RFX&6?8NM]4&_%MF\L8W\P
M*;=MH%M[MM+L;'8OS[8N:1Z*B0XTL[["<<$P$!%8L+:(2//B5,<KBV^#M!6C
MGKKBM36EV@CH*?HP1&=DT87"A"0,\5G%NFFI68&BM#-9F'30 M<'^S \OJ#\
MS)?],/L ?]; J[;WH@?5$X>WERP5%!KJ+5[11EZ;M)'8R,]E%J)51A$E?)^&
MG8]%O&/IZY,LO7U)>%>Q>5?I=CG#=>DTQEI_W#8SQ8*6CF)W!4$Q;0E?4/7N
M&TT!F,HI%-?G=HT=@7X%!^6;$Z^C*!N6%YV>07M;KEPHPCWZJ)VHMRA%ICWA
M"I$G5DHJ1@;D6O<AUEV(OH9C\*TIU$0Z7773A]GYY5EK+7K6$7.D4,>2LV41
M:QZ(2\5B,H[Y)!(YP;R(TB=%O3W&K^#\^R$T4@,!]CA*2LQ?S=-',LIORZ6N
M[:. 2@FLO?4")UR03>VRAV29+<; :X%OG^* A[%]#2?A>SE7C236N8_M>_R$
MTQ4NSO]?I^UHNAR_?"7Y![+*<(JKY3C1I!W/X63QJK9IGBRN@MNNE>TCG]2F
MFVV+839J:'L.8:23]C)RLE4IRUKQ&AA8@0R=-EI;P66G2^G/$3Q6-U79;HZL
M5%K3G)W,JDPV59VD)[F64KK,? 0@I\U%<MH@,)=(?9I(U+^^%WN3+/<_8DC'
M%1\ESG.=T7 F.^N)BW1SC0=GTTT+Z(L7]U +VWUQ&RWPB$'LN>C7 KYXPA27
M9U=(P31/O]PG)4B6Y#P@^1,^U.;FBOE2.^RH:(Q/*EL>MEHQ#SVIV3;0>_CC
M)UCB? R3S8T.M=!__HF6@4$OT+O$G(=J/^N)(DD+HD@3)2^@E.J\+70GMB&H
MC?:$N'-CJ(V,.FPASN:_7YP N0I,"*VX)#@\U7A?1F1>><X$-ZYH%8!W:AVP
M!;@AI&L.R)Y&4FI/'_+7QXN/F.OVTC5@)3B-4--%NMY1K;AB02K)2$\B$,)Z
MSV=?^MP-;@BGF@](GT92ZN[57-W*I(DXW[7<RZ5Y\%M;^3.[P6\4P5Q_+(GW
MYJ:O"LGH*"SSH$C*/B46*:@F>>?LM;-&ACX;0=N@V[NP=;W=_:9N=U]_W*6+
MBZZ>3,)@*0S@3/G:CM/40];<!):BU#130DGL5*&Z,]9!;8DU)]N-&M.^LFQH
M *^"^^=\MEC<G(HD=0Z@$C,R^DW,2"JU[M +'T50'FPO_WL;?$/PH@Y&K0XB
M:U>;?S?MUXTA1/89D2C.H?9-+/4"6 06M-4E&(0H^G2"OA_7$RANJYU,"2PK
MG'Q<G2#3)!3))#C)T:4 N<_5,%^YXFY(L 8J>Q<I'F*-K57!*$J0'A5G-L3$
M=,;"HD^&"7!8$D9C2Y\+O!]"-B0U_31$VEU G6.5V\["[+,?<^_WM8E/MH?<
M*#*Y5"=_\>Q7XT6:S.KC1[HHGWD-9>LQ7 U:,1 H64I1@,'B1*<=E_MQ[:MF
MSF^9>#D[B>/I6E(O9]-:JDGS7:]O)*G,SP1X=A)JA#&88@*-G<O,M%2D#PU&
MAJ8XS-D"QCZ:YQ%@AY"W[<"PZ\JHMQC;F;79G*9Z^G*=+TJ?*\@YI.67<W:W
MS4R][%5'I1D$(9FNJ1]?-[XA(,F!O%R!G=RH1Z =DOGKR+CN@NQM$C>E&S!Y
M/5TLYZO+YD4\RB3>]WV-3.+6D!N9Q-N:4KR<+98D1P/2.D/A+!BF"VD-;YUC
MZ$6H729SQ#['(.Y"M%<YPO4OO7XYSJ6X8.W9_3J=(TS&_\)<#P2_P$)+H=Y*
M'X20M9"0)4]AN';)$[&#)X4:8S(BBYC$0S1J"6A(MJ\)E:Z4/CR%U/8V@WLB
MKX?0OR"7J?"P;@J3/048TFGFDTO,2V]"R<H+SCOS[0J@075L'A+A'B^V9G[7
MK?V%N(DJR7I.*M9[Y50,+ ;)R3 K&1/%Q27TV3)_;".H0[5N;DJ>9B)H1H;K
MS*TU\)=XO<E]U>,[B^6Z"<9(HTNJ4(!@+*]9YI3K><S"""ZO28Y45)]^AKLB
M;3TS5^_%NW0W4!*^D ZEI:M4(>&IR,#7+6^=<RB0$@GQ(#-R%\(A&?^N?+N^
MS+J(\%!+;TL38CTZ'FTM?G"Y9J0I<)/ 6>9&:%^X4;Q/0-P$_J#\A"?E9G_I
M/SEQKSK;D>L271+,20GU_J'(HBB:25E*$3YA2,,B[LX!U:%<E*^"MX\7_M-E
M?Z[U^-T[^R/[9W^N06Z4_=G:D(84D9N2&,> 3 /9T,@#L((^2R@RR-1G/^!Q
MOE#KF3B[19)^J^?@Q].W4_Q_"/,K2W $UA++O6&T^'P]%48ZNX!G,BJ4)H%3
MT"=CMC_V(7N233BYFP?97-QMDDK;@CXJRWI>_M,:]%4[,3+*.I$R.19D#9B6
MDB:MH&6.IBR1E1 ZZ(<T82LP0]I&Z<JZ)Y%>-[?P7N"T5#Y\G,]6QQ_O&(+U
M24)TDEFK:=DXY9C7)C(?HT&GE':E3UOIIL,8LIOXI JS/0F>+B7&@PRY<,<X
M8"T**Y9%!84!)@5)1FL.E !ZVI38'=;P8O-WE#%XQ3DPQ$!:R<5ZXRQ)4RJ9
MM<[&QD[=E??#/62GIRDWFS@_CQ/W8(S0%_BB)#2B..:LU^2WA<0\Z3^65?+1
M%NY3IT.$S88P9+]I$,1M2X*G=-XO(=:TQK@0]>HK8.3G^7JO0V"YJ)IK"=$5
MV=%QWXE\@TV0/89\!Y=>Y[S8>4_[4]RT\=NC1OBNKVJ3#=L*:*-$V&]KNF(^
M^H1S.,:?5R>1-$AY-9ZLZ-7UXQ=O5\M%/0M+F$9:VWJ0N3#N"]G ' P129(K
MFZ+7(G,)JL]1XAV![FMV[WC<C>?4Y95&CB,"6L]*-((\ X'UZ&YD"K(I'B'R
MV"<#MA/,(?E]/7EWW7KVDV4S+^]6B'=-QE'^[]7F_II12BAX4HDAMV3.Z4<&
MPE5%&Z.'8I7O= ':(P$/R8-[<@HVEN^3DQ%I8M!YSY*WDGQ+H9G7DL(E'L%*
MA1Q-GV,D3<CXF)/':7-V!R9G7>S6SSI:+N?CN%I6K^G#[$O'X+,&>$?S.4R/
M-V=^**14H:2"-*+:.#C[R$*F&91:67+29!2\3P9A?^R#MR:-&7OKI22'DWYG
MY_@&T'V.T-W]96T<Y"W!MMHKGJP_<\:D&\V_S[KSKWNYU$H 0 &&N,,42N(4
M!A(JR9-EB5P:C,2J/@T^=L.Y=]$M$6'V&2D@G'\:)[S]F6>0Z*?:YR;-CJ<U
M+'V'\_%L'9PN7L+I>+FIIZ"H=45+,GB1.(? I _U&I\@&1C/F5$&K <1:&'V
MJ=OM,Z AJ<F.3+Y1$#P >K3)7]T[5U]NS%OC/9KFLS<6([0 3B3'0JR9-@Y
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M\[;A3?@V>--+"H>@Q\\KG+\^.5E-Z]NO3TYK_\&1MBI&3]&O2*DV72^211N
M.<X+6$PQXW9[2KL_>ZL,+?^WX<W>XCFHY?MY5O=D5O2Q.,&S7:]7>#K'=.9
M3J]V!1<*(!2/C+Y:,VT+UC2SJ_>Z"B.\#3[VJ?+M,)BMB/MON+?0DQ.=]TC7
MVR*U\^]L,LYU6_FB?\3:^M>\SV9S<H\=U)V?T69_=;^A=>R-6MOTU)8G(XNY
MT#P5XH$E0YF=)R67,CGZ5@<0PH+ITQ'C/E0]6@B^O]2@:#WRH+/2 DB?UUO
MUK4GWI?,A#.Y9/(BL^@4HFZ!;E [J*WXLTV;P;W$U+4'Y=4>5V>#-\DIQRNB
M>L,U!A:2TRQ@3"Y$'YPZW.*YB6]0VZ>')-&>HMK2WIV]7O^)L,!__.7_ U!+
M P04    "  0@_148" W.(*@  #<Y08 %0   &)I:6(M,C R,C V,S!?9&5F
M+GAM;.R]:7-;.9(N_'U^1=VZ7R^ZL"\=TW-#WFH<X>VU7=W3\X6!)6'SEL3C
M)BF7/;_^35"D%HJ4#DF E.CJF7"5;=4Y#S*? V0F<OGW__OM[/2GKS">#+O1
MWWYF?Z$__P2CV*7AZ-/??O[MXPMB?_Z___%O__;O_XN0_WKR_M5/S[IX?@:C
MZ4]/Q^"GD'[Z8SC]_-,_$DQ^_RF/N[.?_M&-?Q]^]83\Q^P_>MI]^3X>?OH\
M_8E3SI?_=OS7Y"@-1BD2E=1$JI2(YPF(]B!4$D(*3O_/I[]JT%:;9(C(S!(I
M%2<V,4=8=,+[R(2*>O;0T^'H][^67X*?P$^XN-%D]MN__?QY.OWRUU]^^>./
M/_[R+8Q/_]*-/_W"*16_+'[ZY_F/?[OU\W^(V4\SY]POL[^]_-')<-4/XF/9
M+__U^M6'^!G./!F.)E,_BE<OP->GZ>5_>!V-^N7B+_%')\._3F;__:LN^NE,
M/?<NX:>U/U%^1Q8_1LH?$<:)8'_Y-DD__\>__?33A>3\.(Z[4W@/^:?YO_[V
M_N5MI,/1])<T//ME_C._^--31#Q[PO3[%_C;SY/AV9=36/S9YS'DM>@72RZ@
M5('SO\O3?MD9TV<$,H[G 0C^*8P*P2MB7/7TW3%?/HLDR/[\=%H1\>UG5\7;
MG?EA30'?>G0%M+,'D3,X"S"N"?7&<Z_A7(!<1E@>&8;=)Q@-$\2_Q.[LEQG
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MPU$W1N,'?3H8X_Y67+X;3WF./M_T^VN8?N[P;[[BC\SNTP810M;!1V2S0W>
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M>_%L-QQ'2[ ]JJ?VS>"B9=I[F)Z/1Y.3+U].AY!./J%T)]/[EG+]\\C*F,"
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M)9% 2S.S6!:1/26"9A]LRM&K'RD^N)%.[VT"NH%L]Q8;Z@/JAXL/;J2I?DU
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M4FQ3Z'0WKL,PI;8V-R+,1JIH8 I=N:RK/YH+A]1K1_%P#R1%P(-=0B0N<4]
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MDKA###0Q$@S^S@60>/!DW+MV.:][:Q7?V=^97D_ZZ^K<5W05#^U;#/]X\V'
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MFR0>U281ZYT@:!6@KZ*Y<5X_=0QN>?;9Z+&&[!KDY* O6J[BYI;7+V6#N9S
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M% T>)\4+=0SM#^D$([[,&3,V6R^X-<S(O3[+U9//_RQ]E@PK^O2/P*QJB3K
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M"?..2<FE]\IV.A=VO>5E*[>N$)N4#M_']LMH!A.8S@JR^9R@] $F$?_"7\(
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M$., !?1+$2V=R<I%(KCW)9\2]U)6TBLA4^I$I(:V.4/ZIL83 XKZ9L8^<F_
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M,G<,T"XDU);<&J. ./1+24KX_43P ==Q/ ;NQ/Y*S[X4OX&[!\]RNTC_?;,
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M37ATZIX('8Y=R_C0![JK\;S?-A R3[H4H'#@9MFU06='&(W*65R0B6TF4^T
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MF:6^ZP7TJ>0>M%5Y17E63,0M:_Y8+.?%*94-NE0L$>-+-KG$O29HY\NL-)N
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M:<GY+JBJU[-NQ]-_06L=?3U!@ .$7;FJ=0>Z*%G.9<BV@(Q;%4.G%KT?W+G
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M)-/#,!S.+]#,2+<N,*( SK0IC%Q0A L77I)--<.SD@.ZY;CA10=_\J_O/7C
M-2\ZJ&)"49A2UMCE5K$EK]J*L?*,FGGPDHNW-B_,#F?!-+ 2[4 6^.'\<';1
MP6WNAT%_/0P?/+!-DG@7'236-PX,A.X!*HJM ]@%I4-&$4$.5"H7(&6L4D$>
M?  M(BA<!/\KAY#R8:QR&*T>N*T=!,OMOS V[<,2S=ZV&KBZZ.!MYTK3](*T
M=$$4.S!2J]767%#T$* X-,_#1,L.A?,SMWD<84);<R-VIXD;A0?6UYH>+9*+
M#AZ\C;-IW,%XNHC];;:F 5N^%5AA,@="0^ CW/9?:!J'[2@.M.1B-] <"YY,
M+>="^,[1.Z@2-_&M(Y='-D'XM]V][=IWU\L?]K70N>A@=LBT;&WA)P<O)MW(
ML<)'M"(G>@2"%DM(^4+X"/WMW."[L-M>_<[5CMP]ZL1_LAB YNZ0PST:SE&$
M=3YP_G=B!W8#YPZQ@2F'!6 BII9HM)98%P/EEP\AZ*$BIB#%P^7:8;0(^H>+
MQ0OAWZ,]BD5DNG;^>PRP;0;5T6US[R2Z<R856V#@3UGZ*,J[38]B)8K\BX^8
M-N_[BWD2KT</4'+EP'F"9KCAVD4?=!2?VZ;<R4@9+P(]U%Q__D=L8_TVU>*Y
MI>13ZZ*#DC6/%K%A';R=;IO=6@V'4]=,QA>C6&5[W:.&?H]R;+G..+D8Q^^D
MO&WH]TAO,^=&EZG?27RTC1]-O.T*%\.U"5PF"%'V1@W)(4C"8<@6P<P)@H:K
M(C'OU<=+LUY;:?5:RM/"0B"(LNCY;0(J$MN-) #]NC'$UB8AKF>")A(D#/&"
MROBTB-3$GE>KR[V,!50DN"O(3#;5 YQBP(6N8D7#;W"B2P[5?N20.-B/0S0
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MOLX%P\K24'K1J*%"* :R3)E.60&+>Z.5'XS82E<I2Q.''^.)AL 9NO88S&V
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MA/O#=QMH& CA\850J3W$I#:=+;2(A-_Q 46=\\S;1$<MCCL<2U>8F,R=HA?
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M'A#5<9[#[B^MG3;0/?M/D&ZZO)<8!T:#$  >9)-?;ICLV^E%2FVLN9;S$V=
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M).-$S9_N@AQ1BAB C2>6I#!(_3S.!GVL5Q^#VB*:,./Q>RG^# J*0]%U%!@
M9!+SRG,H[Z()-=Z!SG+\\T__B(]*E4 VP1RY2#=,J(JLVT=8A#"L?9#>P0!\
MB.&_2>&BBJ"<*5J]7^#"3E/)?GY.NPDMDT@=!B#*&[99"5MA_O1LZGY @DJO
MQ'BJ0&VY1%W&2L[&Y(Z@1Z@.)_N0JWF\C8\GO^CH:@3:D@ ?R) ZG*9?'V0
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M;:OQ-]-9"(A =YB#3R/V>WVJ8XSCD979/>'%<C"Z9K1:<WD4_#^>&PI,CV<
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MJ;'?F#X924_Z8TKBZ#_:O2A-U (V_LU9K5,D5J.7#(!!(V;E1US0%ZOM<O(
M(AOZ ;.(I%[))^37TCZ#7!Q_U02G-OQJ ;:3GS^(_W&SZ>69C3'RR<J>W6?B
MHA<A[ECZF4(1U2(SJ=FB0.5]Y] =9"=I3KV[/<)4Q3!PZE;(*.R-"4Y+DRFF
MR2KT4#8:CKDP=B0#$Q9Z*XS#;1G>YUR3#^7EZYL9%&O/:>[\3-=L &.1;;#P
MH/0>KE@M(5Q"4D$MUT5(E\/%[OO!O\]XT_LJ'N>T&<%T<R[@:A'O0L0+UC/<
MH,:(_"D=!U<@\4;TR6M4'AVHX6*AFF0XA[C53(N^=2@1YD5&1*BHJHU7>KY(
M@;K/TB8@@07_VQV>8WMM!D!$ T0+B:2GP$>]__]M\?#H==J+C%*O?Y[=S"@_
MJL@LW,#?)2J#[T3EUL?K,NOH"0O.U4^+*![GEC.X07IUF?WT1H-5^JF9V5EC
MBDA]] GI[6# "63G/.F6+/5RM2VM.@2B%)\W&/@E1'74\<9(AY?>.+\)+^\U
M7XV37]]<"*K3)WOP8[-TO2!)PMLB>,/ZI-UYSZ;C.9%% WXCSD#*:'J',-VS
MR@Z=RZ03%.EVTXZO/W;^/>[+Z\+GR9W$"<HG='D9IQPKY4U8%N+C4WGJ%BD2
MK]P)NQ*BKU2Y&.]MB3]3K#S?,'8[9_%AT,E.K-Y3.<!&3$<>ZO,^5+AU)>58
M[EOUEG@9HI1V)4=OX4==:/Q B?=BD>^(U .D#GEOE;DJP4X)?_I/-L.*_7L<
MFQ/DB,Q WZ)YF^])[)G.-K=RGPVGIKPOFA&@)!.8P? >&X#&ZLSFQ.)57^+K
M(_9%Z,-\ K49RV]LP[\#G"([LFAT><C987M[YZ2% P'[?EZ6V^B2P^#\D7[O
M./N31;7M@UU'=L"22<2(>#LP+H>?=+2@#KH4H/>X&G/7%DMIC/6CE,FG^(+N
MJ* E6^5VI;XBU_8(HK1ZJB6%FVH,?SS\(GB'&Y^J&"J@SS:]*1]$G)0\J/OK
M#A>KI+7)+FR; <#O=<!J>MK+%;J%+S=37B87%\T^/3U1Q87B*$VNNZ]Q,<OG
MVL=[(/0,N-VR*B@+3RPV=/;;3T>L$0LH]>QXRZM3".GFJ<HY32HF?86H/#6L
MP[//.L%RQ]KJ;(8^O^F%*R\=WG[V%1W=VI^GLS,]G 78U(PYX@K+81T3F&L?
MX-,PAYUZMENP]R).[4:":-OQ/RDJ;%A:6:0(,F-QXDI$MNUZ.FS?SGII[=,X
M1S4;7K%V/=V* LM<3R@E[/U9W6F2%IW8CCK355@0>D[^24 &]G1=I=Q"[&,T
M]T?82CXUZW7%61?J."D?']L%$0PQNEFYN'?!9>[&V!=Q(A$C<^LO6/@)+.^P
M!4"^E6=P&#+\2?;\PIL&%Y57P;,OCI*/Z3$_Z; AE4C!3Q:KG2:S&SPX9/KF
M;GN,5 G)""?5#1&J+1RE"F+C73O339<&;-EU4Y^RYB:^G0J;C>+9L2AE\_+^
M.F+H-YNX-%JDEO2H,-,S;SRKG.<H/1*T$,T U' V/JT>Q#:+Z+\$1"$5,V$*
M0,)@%E>NZMHF"X@?UL8/>@4\.UG;">6NGG"P9.G.+IE^L(7)4RB5WR#>VSKJ
M2?B>>>O-\N-_(%1#*MH:M_LJ?P!W4$^"' .EAVV%U4C^2*HLGJ/!)/JN'?BO
M\>LK.XKLX+I/>@ZUK2J:<.W'1SM_>R6MQC8XP27Z9-,,!I@%(^_O&(H@X0)S
M9<TW0/5<[1B\$+S+,%1XL]O;M7A#6UN9]\J=%RF]"I\E-@ZDWKWWE[5\JI7V
M"[8P)\LR#2=]HM[':ZZQTC7=/M>10_<4J&1P[]+W:8FV\52V<:"&7<9*^K$M
M7BO_5-N/BMLIKL.%/UY4(.["AM;&@3ACM#"LO9L6">7=A#Y-3+_WOFM>59K0
M.BVO1<E3)0X&ZP3.;S=25%XQZZ)G6[EZ*_E,;MFFC7&Z]$C;S2+I-\8M;O$B
MMQWNVS5.1AU[H\WMHR%#GU(-+.5]71Z1KG[!Y+LC6^EO^XO'BSX4L,T+Q)B,
MB\$ZI581TP@ZF_>"Y^^J(2,E729JI'>/Z#6<YQQYQ,'/#_Z1G,B6]?X,^[=K
MX3T#*B8DR4CJY5W@I+IN<AN4,T,0&=60W;)Q<_'!X=DG(54JZR^?OHG2!5R?
M%G%!+;VL+9\+2 8WC"FRE\9N;4W:!,?&1G,DH46N5BMP&\J+)IG84.B<"WKP
MF.ZEW6*?A"%[J"D58B@#:<=["DI?SN$ZY61>.JO7/TAG'UQO+B+D,;<D)L22
M5K9W6P3/&U4A[:,:S9Z[X3;1$(0D6I\8^'Z4\D.H<J1)+4:*L'V3,^)*1G[D
M^SCP_3*H0DRW5>>8KQ?WF^3-V?:8BP)@2TOI@=< ?M&) <1YJHYPCJS@O8FT
MX81AU<H479/"G>_;,,GUU <]BR_E/Q3@\@5B)$I$#TTF]PA5I'"*#"G<E^LT
M*?/1"'B V\01-5#5N)$H?3[%[5W<TFNALQJ8S;WM4\PP#\'U[(#]G;"P*QVN
M6*"0T8?PTY$4$!CV@#_!C%F^-+*2 J:&WK N'DF;U7"7)5:+Y'*4%;$\6+^'
M3%_DO-2Z^@TZH5&K9N1YL-N$Z,W?N'-;HGLEV7[HR:\MWOK^Z@.(.F+4C@>G
M3.46H;-Y>N%7)X 14*T6[H#V[I,^V<8OCVN_/O*^^N'HNPX_VOHR-]11K.48
MN1:R=*O3\7OQ,R\IR^IUC&X3@GH>/5^5-1'A$)$@SGD8JE8T#@*10O_($^E#
M>!N39AD ZA=Q9NF%3C-+KRC/07/H1>;-09A2YP/5D"EUIF$TT?<M_LC-[4BZ
MSC\P,I&+)@;L/YZGQKDR  DPLCD;+8VY<^RPWH_VL-_H0":/N&_A"U&.J(7W
M\_LO>!$$A3G8>F;0,819])>-& #/GB,M1 ?J6) !F*ZB<56TB(3H#&M=) F:
MX66C%:5"Q;6'L<J\_MY9TH:CFX^3+DN<KKX $'T'B4?A'G&1I)QB82[9N@<=
M],LYE'88UP_X]C J/;!4U@C#673=A+IO7L^Z.O/7C3TJSQ*=C45Y1Q5OX,E"
M>DE#80&X\@Y= 5YUQ<S:8WN_GO,"5\M"=>\P )T TLAW%9'WQ<^*]8 )\9N:
MSQ&3=G?I'BWV19[\7N$/=?2??C.K5<QWW=%J8 !DU];_Z(8<J,>?$ADJ1KD"
M:WND=0/:TQ!>_L$_*2"S[95??RYDP/J9\>J<\4-IU05'3F.+'+WMHNT.BEF
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M8P#NQI,(9 ZVWWDQY(R[SB.1U067TQUSK^M<MOK\?Y_EA>3_6Q8A4.CLU@R
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M;E!<TG;>5WN:>4KQ*-FJ%O41H-QDPX8#ZC7RXL8'@O$B1=ZY5BOU\G<8^L9
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M5A$;-EDTRX9E>A-9'&U0AB1/8+UH(<QN,X&?C-40.A]X]A#=A@V[:1)!6$E
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MB*Q<<G$93.N1@X56_;A K>T(1G!C&E!TN3O?J=AP+UKWBI+[]X'?8,#$Q]X
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MH7@73"[M+C[EX.RC?93R[J=9)'9WA>R-O<?7C$,6.B^9"Z?Q3[@<=XH?52A
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M0]WWET[S5NQ?DC$Z1G[S,@/?2A@K4V@KEYHR#Y5[V7+WG+,],%G.Y<UK$NJ
MYBD$ZW,U'&T<,T55>L,4P7><:=/)L+OP0"?I$V^KZ2GDZ9G*62@7\WN$_JM_
MTYNX7U4EX?-/S"^QDEG<ULSBF\Y[B<KC)L-=5(L] RNVV@AQW&PKVM%YOXL=
MN%!HOJ:+,4%PV.M(G2^2^DDF3\22O!/L-8\=L5%[S:N-)SH*@=R9%/@-VW8X
M#UI*(O:"6H_3P)7MK;!!IJM5XKCS6U" CN+&UJL)468#]4JETNQ^#&8R1?3T
M@J@F^^*6;;4)BG'3[49\^UUDP.U*_55=T&/G"(@-CB[:W(0?VC<SIC?A72F6
MTEI3G4*"]=\YO!;S#GME]<IN\9[F=OEXUCE6*&$\$N!EPYY*A5HZZZ/HNI5/
MG6X'9Z+JCHRU-/MX73+2FN2=_LC_WD09GWT._^Y7Z:)\^^-YU&#M.A9E4L$4
M6/(M1M9>\?CK3D[93'E;>O(@1FZGNR*]9]&O%#6D.?D+R[C$Y*?RA6\TC3[]
M.BQL+/C\6F^#?X@@&V8W\GWVRR\D;, =]1G2KQ>$QN/A(A-Q]2M<M2+2*C-?
M73-')3];6YP5?;CMYW249?#'I*B^S+Q=7M)4VU$"GVP"^-E@&X2C:YYNN.B-
M22&-EPA',,Z8WXA33$W&7;1)'_H1*;2IHG?CRJ6# M/FM^7SC\;1G]RH@>N_
MU)8(2PX!TU(T#G_)-# .,=9^'H7XM&B<:%8><W)J=-C7;%V3*:!)$XFF_:'3
MR]W7=)TGX'Q-)4-+5$JG\'.Q\J3.\[MM\K-^M-SG6Y1KX*.+#=2@@A4OUGM3
MB+?R;)_P-\O&S-AUG^. 17.<=HU8/GYM#24/U%8>R\5)U+%AP4<N9CMDW?H^
MA+QJ,VM[2L*TZ1J'*&&S:YZX_IC .9E[NCE[S-#.\(/@5;'6H5'QL<2535-6
MO=]+:8'6)\;9(DKZY%&) CL9'XN5,@H0!JDFD>A_K+U3/)3D?-PVNP$G,UM2
M[G_EY*Y@5)JFK,^K$U0\&[9GR=9_V+E11L]$E>-KDQ8<I4+0RL#SXH[;?!B0
M=N&;2=XY+&F?OF>JQS.&<]41HPM/P%%YF[!LF+H!E/;6'@*HVPC2R7 X&)(&
MT86?**0E&]N:ZG9@E0UA_2 T?1#FK(H#"_>TV3 U(9!3#M1BCD#2[G$9V):,
MQX%[H]DP;+\G)/3CH]8,84<)4H'O5T-RQ-K.0:= UD9I:P2AKF_;3EV9.O,J
MD44 =?C V_KCZ,@L'SYF/(H923=B((%:<? "IEW%J"G'_=NP5TI]_Y?*H=AW
MY!?%<U=&I>]F2<+D8X?T7KP<[>P09"F:D&R81WQHS[H1-KBA1F=5A,.!@/!)
MG5U9,M_.YTM9A)-/M+Y^<3C&[(+RGILPV"[4-PKJA%%[EJ^.L&#GL][8N.+Y
M7-J KFKDUNS1%T^ER[$#%Z+0<05("]0SG%/\X@PZ7/VPR7S@K,2\$/-X(U72
M 1!FJE/<HF)+*O*+^Q^&)8EX?:X_ U_A?MS)>)L.]'YG A#F^SJ*.@]S- KX
MLWHQO*7A"5WQM)]OZ&3G5L)#J:W.ACMZ 9YZS=]#,<4E<\#U%P>TD>)^<9JB
M57) KU0[P8XP*% #%'6^A9B3Z9#<[#/UEJ9#UPIA("6RU&4O5>TQG+;@D'2Q
M2E!'.\'YC?W5S<,^6Q?;#:8L9DW,]Z?-&X=\L)K/2L.H@CT Y28VB+A_.5>N
M&CXZ[+6I+FQ=(ET<_UGD=PI<]B[OW$0$WT\5DZ9J-3J*A/0WK[<#)2A@T01C
M6M3[6/B'V/P3GKMJ?FZ>,%G_:KC1R6?JA;OG<^U.4^?]PNB5&Z[[.H[[&KT1
MW-8P(6%4P@POOC<2<E\F)(4CRN!),U;'QQ>U.[F5D&TDE(P!R@?Q:5MJ>S]5
M8HF3HM,8?3D.QX/FF[GJ9%/2_;C81O5S]-$'T4FN_65SA/%85 %3B?R2L+\0
M<3%85-CIF-HK9H N(5UP_3?5 #90I>&Y.@U\5_.P$GZ"7^[SKW98MQE/=48C
MZ 8D;.@Q_!^TW,2H:X/)I^;HM#\M;I,+_/>XRD@$=*4,@Y,I2''-,F7*4"[]
MK,SJ3*E_N>![2RM;<]RAMS#Q6.?U/!V+XQ8.4J9T+4>2Z20J.:,F5]HDI#>*
M#7M67\R&58D2=N-F(MJ5 @2/LV&VN5'@ H$TQ,3^1 U&@WN1U.,DR]&JS8;C
M;:A=<SF!/@];/#/;J]\<_#CY<WG93'N:[RQ!%_$,_F>S!I$O]"XB9KSJR%5M
M"2.A^'>SOZI[]\X]C1,6R=SWY;3HA(;N*W_!K1G/QD\1=LLD"5M V@W;F;55
M[#NC6[>%,5NY'S[+[#0!=:;>0Q%VS:;K[P@+^1P%\N'7:JI49_($54"_NU*
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M*.XK;>0X2*E"?N'WR(75G(!=U>]2!Z[B"/\[31W^L=$#>_!_ %!+ P04
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MEOWW&1;_?\NR_\.P_].N.6"W !]O\ 0D !C 9CU//0S\_UP$5O"@YB:UB^(
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M]0($9.G*UUP%?'*CLDMO\'/7KP]W7="Z%&TQ>&-L\$;GBL_!&SIJVC8NQ[D
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M<UG9I$?A#O*TIX5QP857A6$Z:MDU&]]VN7ZVCDUK=$T_ZMUS1[AG*1VRNTT
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M<)&R% LUE);%GC?-5QG-RL.-,M1/>[,%18OYGQQ\HI1XQJ]PQP[U$!(JA9[
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M$#@%G8Z7U+<(.?LVE(L^ZO?]=.*KA*=)HBW!QTG^<(-A)PL2=0:X1^6B6'7
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M[PR5T#N1/D![0*&;RW'>K8J5IQ\'?8LZ50(2W4XL[,[CT]6!A7QW5Y"[>VT
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MA<57 ^74#("#DKW2 1/45R/N&&FQ]!;:S-2E/K![:J'W&E.J5F/WL5&&R^0
MU021WPN.TV@"=(:3L+L1+J3\Q!85DI7(5T%?G0EG]Z=/WX4C,KIL^OU5@X0C
M+MU=F?["MR0Z*FV] [ZD03N+V)B[/9C*W(T, <R]9UF0!#3_>HY+D)2SKVU8
M9NCRM4!)/%7\<V(?KS%W=[R)U8.H;:MP:4-1I 8YB"[B/<N9JK^73# :KJ]$
M;71CJQ8E S';Q9WO\>VY.R%4&/<@ZNWQZ[?RG:DK_WB!ZC&<,.QR)904VA/$
MB0S" 1FDVWJV9!7W(]%>3[7OUI\+V1DU^[H&__I'4+)GUN:MJI$!R"W+8+0(
M2@X()>K$?*8$5OMJCW75*%0]?.K8([EB]_+*YI&[!^20J<')=\MT]$1-+DMC
MELW(H5WY$EH$[F], 0HLX8:;A2DE(.]9T+.ONI.U4:().(3ZR+&F^)YWV_>>
MW9C<72AV,0TD[,K#*!C][ A*>0%:9]8-Y87[;(7C?>W;^"@B8O;4<L6M":.
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M,7'QU7M$P9/TWO,US/ZLTTTCWS\E6'1_P9^9;#IY,_&D_8\/@<9K&2"U+^E
M@[]IE0 +2, %XO"GT3S?=-MRR"2K[0"L/8]W+#!$Q45%+VD2&Z2AKE$54.E.
M\KW4V'@R)6#N5/K^+Z9W,Y916L=I7OU>54#HK&5C9]\]N_I+0_K&I!3G'_@
MKAF#F+QW4N;W; 3;O&SF\2O;3T[??)@S5OJ8?S\C WTY*6CR'O4H&;[41+Y^
MGL))WV,HW#A<U[2^.%[K=MIG8C[35R[5$Y)^XON)HJ6/$3M%!Y&"# S2^"ES
MR+ED.8=V!O%]I!LGI%YW<TC_4,!3)^TVS.R 1.ZE]'ZK5%/O=-]<FRJ-2_O,
MDWW*[O84[ETY;\V9/_,-73>-&J'JOLLG83FQ[>OD\\\7=%6;0]HGX%T[ONZ>
M-X\.V_?>Y?-I01Q:/XH;P$7A+D/Q@U1;((5RDP6AV@3%H?:1Y[MQ4A\0[XZV
MA%?"?3<,=X]_KWP<M1137_=",K>\M26XPF19AD<?=9'#S; 45*4LJCCC_AIF
M,HEJ10Y:PA4A&N;@LKNK<Y:;/P_4=.!CEKO?-H8Z;%.0/XF]IO^V.FI:-"/T
MB.9MOU\EP(*N<0!A\TAK.+-YB@7Y=MZ.[';[&RT0%-#Z1<+Z^" +<KH0&_7U
M+]^-9I2B-!;@$)@W7))^9:CE:$@XC@<(7+%I&*DY\99BZF2<]MK(U#'U1*SV
M:EP[09HYZJY'N0(300FC1IVM,&N5YDC1:UB\&;&T[<T-6NL)Q$I,?$Q[/<)#
M*'"U90)?(1UKHK+.V<N?@!('CI&SW$$O/-PNQV2HPK*G*EG3<."N@L?!4$A,
MZH?@Y%#L(#J9!>&_P3\),K#]E30S4-2/,96F?,AN,X C:/BJA^JW-P_K7PE1
MZ8^73\0+O-T>:>=VQM4T[Z+E?;8M-8HB:4<"&=>>E:<UD>[KV; SDWHS7C9\
M.D':C*].):W-Z=*E%'$YU;FT\98LJC302GE)>D0061M,W=BZDIT?@]H_^&0*
M_\U^X>[D-"/JS:R+2H1DD-IW&>3X9KY$QR<E#/4^J#O+<>&4EYUYZL!>\N(K
MI@+Y>_23EO$&]P,4@^[HX^6OATTW]#P:[Y^RG;R3G'Z$48B,.IVQF@_L3VVD
MF2Y )9AZQRGG7KF+C=SX9KC?S;+<JFBQUK5_5S55YA!J4+)%29;P>I,^;!RT
M>=,S&[+5WZV;6ED$>-N,U?$)UNO17"2*:T;L+TJ\?&A]/_X8,?0@SPORX>S-
M\%Z8 "Z ,!5,(G3"!9$N0"L1*X,X1])(#=!7J0""+<CQ(_G'FUN<>(6=WBJ$
M*<9('N&?]TJLNLKC99A,[NV!QKAKO0_!B(*W[$]!/T7<8B[TNHVJK>_$\_ D
M!7JG>K^;?.O)46/*-GC6_]4-#%Z'Z@5L4"S,@+DY:.J,0'0G2O#%?;H^>6UF
M;X/_@"G3[LC\^? +7RP_RQ#KHX,>)N2=>%F<X@G92OR/D,ZN>:HW2'YI1 T:
MGS%]<>TL3@]V&;VIT28$(NHH[!WNY-?_VY+ L8]P03! V7LIA079/CR!%,$U
M:*1\!WD]"R)M7*:>3SJZEM0/$%_6T@Z(K? ]TNRG=;VXN4O<[\%5%"#W%0_*
M'1[M#N-!AA300RE62XUE2+,A.NSIC+-Q*4+OC)N%,YG<[,/755Y2S1_*&X47
M<)ZXW>'I$WLR] :$7D@QHXOH,'<&D,!1_$E6RXJ_-,/98A32)70PVJ_5Y\CS
MG95Z[B-UTPBYFH8[7'OO&64-/#"7+O!25.&*W1L)A:'0[0+, W1NH)^L0PK%
MP"Z# ^63H#UP+E>Z1Y,EK!<GG&U<YJ[IDZW9!UU16R:\26D_^9'7F^<]@WJ[
MER[&@C!W]C]]2Y7=SRC35WN\($@YDD*"\_A)7BX0OC$YWFB?]K8R[\C]=XBJ
M1JHOHY0I@?2EJ%> *QFZM$HZ@(214A#^H*.:18+N_(@(-TJ?G6Z_LNI2O'3U
MP\*Y.OLAI1][?^SNL?A@>NK#/Y4&T@3%6U#C0:\S?'BMU8(I "HY>EDE8=\4
MHX"*UO"(?K09]&@>W[SRV_SH60+9UFI3M$6-!;G(D\]@4V*',65=0/[IP(*H
MPYA?BGYSA<WT><S_#$?\C%LW0?^88T&^^\%^?;%Y.1&RE?-O-D#5*A7!>(XF
MWD9\07. ^/N2V??CQI0Z<X2!G9_W[WEY<]-\ A6<]_$8-LY_!C:;!_OABD4O
M.8-LT>RX$=3OESWM3RQ(PPH]Q[V5!7&[PH*LE2D#ZFUKC$;T)_SZRM8BB /%
M-@[M-_ZR_[VCN/A;]L"];\T]N1P?6QZLJGV_Z"3X_+B$_79I ?Y1!PEBT%3.
M+&<4:C\<>9&<W\&_RY<I/[HG]<"ZBZ78SB]L^N_L,MCL+\IQ[OG\RCJXSB'$
M!")J;$INC$4>NX8.):[L<G2T*)O)&;!U4=%*P*ISETD4*[.EGRA-:JVY6G8X
M0IDAPA:GT<D?6PL$VY*1H"'2TAG6?O8YWW$XW_S.--SBP$?5>R:-5RKF,U6Y
M//L&@G4UEN[1E!%!CK]$;-"7X7$-DC$Q;UP="4X(]9X#E5],>=--%P4N>5W8
M>>'X]FTJ[TO_"B'_#0$0/-@J10(7Y7J*[]*3S52F,:=#_KFB:NP.%B0J'?VZ
MDAA$V^D*\F\N]]X_*?XDKP!*J&BO(L"_4].Y7T^\[07GNP>-9,4S[SG?K/VR
M5SE/@+;!)I&@"6LVP,1\_Z5AQN[%Z%-D;-QR8%'$C.NF[9EE^1KD\VYI&[V7
MQ'@(A_UE[ML[6H+^\>3<^^P:5&]&69LBW8J2B^V$)J'9O]^0,5VUG A1<;O5
M:YLX?^8%QFK,H]H?,>D!UT:N?6S3VJ[D]8ZN:#F7CU?L.I(OM(Z^0^ T%(,E
M:V-X?9[[Y1TPKE!(OGEM$+=$K=:32ZCZ[/@D)'[31^1 V+E;\U\(_UPJ<+CX
MTH-:%]0HKBXFM39_^0CER[UKF0OC&@53E=70I93TT@U[F11(.&>'52**'_A(
M'C$!JF=YIA2'M1>W-]>$%1[8%]UIMD_6]N2%UV_"[.UERGHQ=*M*A$7G=3^4
M%-EK)5Y;/&-O]7!%KJ?FZ^4(=X?-BRFF3KG-RKD%#\ITDD#"IYEYF9'EO"7-
M@EQV1]"Z'21W+JG"75L/@7)UB?[6X('L^LH&CY[1HO\^^>*=*9].O*E,Y8(D
M)U-?#Y;^T@;$G&:\@-($2BKI.X <\C+]P)R:^*F&L>YDW3+"U(+DE1_F0A^F
M/VQ/>:!:K1^(D=1L^+"#E^]6"'*$?'.Z^Y<N)E'10,D)8*Y\"HCK;E,"0O@V
M8O1-BB;K,W+S$GS#/P\\33)+MT\\'GRC5B+;5Y^X9S?F#1Z5^?\J1NL<DPO$
M4H4W&\SN9R#8W1"=75\&]4$]*ZB<[M?2T!1F9Q;G?<'C[K/!7,YKZX_Y&WTJ
MT,#Q-<SF)HB/KQJ*F *WY9BH(#19K91]\ ]8?#?M,L+E[ C:.^ Z=28\\T;F
MR#:+V(L#;XT+L'%_6GC'WL1XR()\:@,LF)W6+(@N0QC[#C/U;ER/D)HG5I?Q
M0#6[ZWCB$7[WWGH0#'Y=:SO*5NV($X)]RET$G1F.9A9D2.WL;^I(>X"XV0%E
M*,3_GL( \4#1A[M\(X)=ED;01_?_1H( J@BD][WW8>M]Z P+1_N_6:@*F?Q]
M063<KZM_43?I[C%J;:J(PAG-T[TDE3';7L5MH=+9D/D_JV'[PQ#'#*YF_LX:
M>!4AN_ME-NFK5J;J*8M,&V;U%IN1+-;$:PJPL*QNMG@1J)YD.F6]H6I&4K']
MEY2F(G3H(O>8)D$\Z,D3\RR(T>F-_/^*97S*_N6WB"@MU"!3&""&$AGGX!3Q
M>*T<%H2'T!]>L& H/89_%^X?EU"@T71\1K\Q1&FVB'-O1DPHZ-,F,@?SJ]%Q
MAKL0J002-)E^&XN8Z**RGXLS'=,_?DT0<[JQM24\(1._TR/QZ*>L0YLU >K=
M5[F?"MP Y>#R("] Z]&!"FAAI!#W.FZ]*RKBDW,=U5<)Y]4H<RS7DS\<]OP-
MF['\R_W)\I3-*C&3':UBB9"Y=?Y()@<Z<@0UZ+[;@K +<0- ?!TW[LQ*\;]V
M,>!SV.D+][W2QL)XKP?WO3L;J-'IHH2"?D.QU5#.-K$-5:H11]8+2L.RWKSO
MD7/*,Q?-]);3HW=[7>^]_FC"W 1R=68;P$G$<"!/C*(T_/+VCNN;DUJMSB19
M9G5)TI\_O/@\Y6V2/^]-B@GOH<UDMP93B6F._@#74*W_*.H*[Z4+]S(M,E88
M2>= 0_)5I7WQ?YW&_&%JWP?F6] ZPI$*X&LL1>>B$B;FO9= #5?8Z(!3)>,V
M)[[F0D23*'),\QD<^.I=L RAL?J?E<\(^K#N[U6L7TIT_K_S_[-Z\I"#@ .*
M],09T&MX'C/(C,A8@?TFE-:.FWV2_T,%X<+L$(=M;;/F[-/ZLU2D%2C9"KJI
M[H"CJH$J7_08RXE%@ @/'GW7P3=9[8=FR'! ;C\S$;'FO/>[+2W:"/4C"!3^
M$[C%RGQFA@F<XSV;B>@7%J1.<=F-[$GU'7:?)VG$/UI0/)M-'3D^$G"IN?5%
ME*'L<9'3;].BC#3;)MN/JBJQ#RM5P8GPGOP8F-2:Q: @78$RDX^=_+85[4AP
M_;8:Y!)>G'C,69RYE)C>VV2E[.+;OIU?*H?)/0$ZBBL1>KAEE9+[R;G#3U-*
M-:^-QHI]$NRUOF8$-;5QW4@R5$'JDQ4CQ4GPY)9S04]],-(:,LM???H?)L:G
M6:<LR]4J5UP,K3UH_>31>>@N0TWZ40"K7N0]FWO[<^O0YU0#^&G<\[PW6]U/
MW(8VQQL/2 ]QNF:H1AS<_NRH%MNHC;L#!4/]P+B/]B;LGD:PSRGV\DD='_MN
MJT.3&3DU<^+4-:EWKRL:%KJDM8K9VO>06D\,?Q]GCJLL2CWX$N4S?NIR0J=\
MO*GQ 6D!LSV)D/3$-Y3&5'TY,J%C(N\(A1 ?<*-2T2K9X./ZIQS;@Z?L9)?>
MVMF96ASF@*1SV #!%.]74#'5%74Z7Y5VY[=&^.71I:J*IW4OJQ\4OD@-#[]C
M7N"17,%>F%ZQ^Y* #WO1G]BXP:E\IL7*'=R2-O\J=DCW_Z+"Y[_:LI\-#-;A
M]U7F$7K8OVU25&90OXY-.T2CV\UAG^S)C8P[ZNBU[8_YT_^R+&6-^"^8I_ I
MWUNQ);PZNO<'1.\(G6)WU>T9UGS,W"<H$R]S/V_,[_=6<0,#*&+H62H$FE@)
MB&+O':(G6M#M^NA/3>[@8]?#F*E1$8:C_TC<$AN/GBV"[\+Y#D;/Z% PRW"R
M0^=-]T/D_(0VZ5[B"A3P\VUI-;:,^O@%L5+Q@+(/^^AS@82J^>QW/NCTV"IV
M&48NHF+;,"3#<G+L1J?DES@2CM?86_Q.O5.@VO?"IE1%LQ>Q1,&1X%B[0YH7
M-D\AN_I$V&IILLA+O\B8'YP-Z.]%;X]9@I'3$9&$7N<=Q8%75NJ63TZYX,U%
MAJIX ST:,//V%QR/\=\],<DHJ0M0='RO+TA31'B>B1KO[;GU02R4*I:V/9'0
M2>56QUKO(U?K7S/VBCA*\V.<Q-5L+$V3^.^TZ0))%!Q)@9J*=*' G.I:QROT
M=:232AQ-?(.HB'T)3]B^7.?IDW_[K/43;-]<7KDEX%8Y0#-9R)=L,;_MKU8A
M*]HXI*_BRW,H?4SV<MZ6D^;C'0^'!ZX^H3<D6BE"V-_B9@NM&/E$;"Q*>?A0
MZ>(69W>EBBV9$#T*U>F:."#3%> E"(G_)-"ONJA".HK_<+A&W=$;R36A#?_E
MWR6-6J[-8:"(LQNOFC]C.P,.6PRWB);W\V9E9SYJO/<67]L7()_Y/4D+YVV7
MZB2IK_.P]JW1;3EJ,B!!@B5L340R]],-QBLJZ';DE2Y;OV;56V5-M6VI_DX!
MZ@&7E7A,Y6,O3RN7/Y@ZOWPQ0PO)1;8B':FFF9O3K.@>62>?XVK)X4!0)U.:
MO+PV<=?%I3]89J"[:^*P,;N%7,O!LL<)8MK&_5FO(59XM#%P<59CJI?$!T)]
M%'',BY)2/\I?M+G/!2.PT'AM4VR\,U133^>>D'?\L/9G>_W4:.IYP Z+Y&-D
M(SG)H=V2S]M&6PX3]61TF9]=:^J&3I01N3X]WE/&@M1PA(EWP6)Q9)N/#M2H
M5J"$J,3DFOF*]TTGO-H*3:B7<<NWB(E6^9 1RV%5?R;.'S;P^:EG<L2P5ELI
MWFK9G@6I+>[)TW>:[0+*M9]@=SU6#90ZV?C"-TE9^=KADVD"D3FJISX<[W.&
M$'%7I!*T<7A^:BC@78I^+6<'9(0^@S^CU5B6^&PTVI?./#[[; ]T)L'*6BD\
M01\TJ1RF26>'#4\A;<B:_BE^2H"0Y<7RCLR1HU\=%=8[V">V[XIZ:86!;]<W
MIZ#;F>*C-SZB.GI[\G@FEM89G#;AH30IN+%4KY:FDEYW"\5"7RW*Z61D+"EB
MMZ$(79+2C 0MH2\T.=WW$( Y][[RAHR<V?L@A:;Z8:W77F%3)W]T\UBICKQV
M^] 5H7IM#Z?O9<CZ:5#_]?)_"\/TI9^1^G^:J?Q',Q5W/O -RK,@:2X=!*H
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M71M?D#\/-&LU/,PT=>5?>X#Q V[^(X$F//-=L'D 9:1CI#MPN,9?4#1!M]&
MXR^!W?_L@5)/5OPY^.3YVSX\GDACBEBY8H3V:T)':+R461-'DCKG]YSL/V^=
M^(?,;)BF(;30\4Z0!=D9,[]5S%18>X;^=;^7NO],8GO,BP;,0]!;(AKHE6)L
MK*$B70PHKD!:4,2P_L3#G]W\&X/-FJF0FW7O.O?@I"5IS!;^;O0/K04X52 '
ME %MHG=3GIQJ"9>M^<?6E2TM3A"IR 6&JN",GH&R\AY->0,CGD Z@8M^C@51
M?,R"S&6LQ8BNHA<O>]+OTG[Y[S/.@;_G%A%TY4/,#^/O:/I=*&A".NX M>"J
MEC"MCK,@O4HL2 P7Q9L98T7/BV9!4AV&16R8#9=A??R@$/\P0A)8$&YATB"#
M.W_3@),%D2YBBBAVYV^)PG[<XF<>@Y^R,=N:>@ ^BB$H@'ULJVBZDE42;$T9
M_6D-2K^. :SSQ=!?SX,??84!GV_O-8'^2Q]>98D%F1JW$D*<FRV):S%XACCQ
M==#_LKUE>A'O9C)BS]U;$VSN1/(T\V2 #O,%>JFGM0*CVWT9\?!<^>XG&6M6
MS6XNV[KS6I^Y?I071EQ>$+W<>7KI!3S8^;X-_.R_HIGR'^S[K?YV'[]%BLEM
MSH+L:XS!+>T%AW^L $'>^[,6#G^DI.1;/]MR:T[\+WL98;"?L1K;"OO9E/]I
M8#84]IML\)#-*=IA</*WR5F,V )FR):B$8?=!/H39Q@+XIZ._KJ_TLXME&D4
MFK_^39$9Y:]+Z,@J8I_'*Q7BI/X4O;^6HL<T:(6YEG$,6Q:D^< 837=RVT\:
MLI(QBP(]F;02\!O/[Q"V)+!II)59VW7T78DU&Q/DP3_LPA8>UQFT*5A'V"*"
M;JLD>6N#/Y;P0\X7M]X)TB?M=7U%)@-&9I;RO5$J;*/_;W:"_ABJ_V!/[N>X
M\&/^^E\L^@_T="C3$@NRMJH&]):=*%(<?@OUNT*'/Z-.W]&_-<F+J[4_6>T(
M[O(J%N3UKE5F*SC!]Y;.9<TK](@5V.*P%6/[> @N1L.4<[#.Q@1UY,\:CW .
M@;RO#+YAHIO#OU7,@MPX5TX-><Z!@()V^)/O*"CV.LQ8?X+**SIH7>3.@M^X
MR(5;.PR7ZR:\*EY@0?8<_EK8A$YB02118DAVLFN^0-M!!+[_^+ 0226DJ<7#
M.3Q!ZLI5$\FHU=/+'=V2M=6S['#^W6_.]KE%CMJX'Z(=9A+@M=!EMW+8'4,Q
MNA&&*>13N<Y3CMFY8/_#>2&3>C.K<.![<4.&_:E"7UF#XHC!AXTK<F7?D3Z,
MYS!OV-2B/;,3>$F1N?$R?LED_6N2Q<N7EKKO:Y4_NANTV*K=YTA[E1TL"54C
M$U0\S4XT/WM-6L'C([_=<-";XT]"\^ESD$ML@#D25M+1!6%V^OV3\: 6HWMA
M#?T7TB2RB<X&,QYAGE</Y'9*!:?!80@S)H\%J.%]E)4DK7QVA#&UJ*YMK/[C
M6<+98=5"\GB9Y,)"F)B2ARL^LNECAIF!I2X":7+^PQZ\R]01SM$;YR4SBTM\
M\"$]U17P=E]??Q[+D)!@I=2CGM9.N5/QW(^WF>M#5/B)6=VXN'R)&\(D7*RL
MG)OW*8VD (_A&7CUC+JF?$/N?;,0*$,K(?=PS]*X:XT?]?VNU,0NX!Y%JAVV
MTQ#JCQ9%*2 2^>0Z9Z2'2T;K*\]^.F3AXNBI:;Z7FT=:^5X$EP%$/A*N!\"8
M/&;@3-Z 8)5T [,- ?O+5-:7P:D,+7G\YU1LQQ\'AGK9W!L=KR.O+W2_$0A0
M[WMN6%28J"+ _5NU):Y_A_+A/IF.H!?CF&_]%Q!6C"TTD6$M!6+=;>"?:;\=
M\E\A<?C@;W=YYE$&H"KHG 5U;07\/''N[2&T3<=IG-IF0/'RF,9!F'XI]KD2
M-HL%<0'AM9=IR8+@(RD,42H':,- -095>C\+LFP$,!-IVQ)AX^!C7 .1!DU]
MC$2;W(X$32.:<10$61S-VA!6V/:J$+..8SY"?R(P2J'0(?@%T-*"QO@L[$<0
M<Y0?\[MM/_<TM_Q7A$WI_;^P4]#6^+H=-53<FE$6N9W1E(L=0#/J^)W A5UX
M-8OV_:76K2.$[&)/[J7&3:&&%)I6Z96TFX-2MS\DK_4Z;YHQ)<R8)00ZJ(U4
M/ U*6J''B^-63$#@$6OQ:-.)/^R*XI22O*'H]2:O;S'TXT%]]*]O@!'OHQ=
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M.F^A,1;H4K9L-]-R2K,&E.5 #MZ;HT-Q+&'-M,K!^5!FABAN\B0'\EN_<K6
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M09J##ZA!UFTR+TO*#6J6MN4RCGQOJ14P6*ET>*BK7<WSZ,KJ\C^>N.P*YT!
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M071J4$'2@?OK#@97SW7O*/C%U 4'&>;,$[2\3@?RB 50F4H9E #MMSKSL&*
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M/G-T!'V:2>#-P2BF:A?UL[/!*?SL^M\%.T"M)SVIB7J&\"MKLQJNJZ2IRZQ
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M#&3;8!V;WPU+OX"?&_(+>BUY'ADHG$@[D/+B0N&LW"_TPNXN4CQ1B ?$7.#
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MP/7F5CM/>Z''0;@ ,4X$;2[+6L T@_M@P@@-9IIVAP[4?TF-*DVV6!E+4-0
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MY&Y]?:H)T-'7D=+K[[DQ6=[0$$/^"E6_;F7;\[95/ZC!N)F3>* 49S"@AAW
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M,!5UI\8\J\89NC8Y!_5WHI!_!6N30T2/M>1:* >E2SQ_$#9D7$]%/\%1G%&
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M/ VF7J'/MM]Q;Z0 @SC8,EZ:""6+4C#$"+*J%V75#D,:Z'6W[]&A+)\KJ.5
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MFM=W_D'CSWPVE-FN5DZ0%'[ O_1]4WI<RSF^]9:NIRLG93T&7V2#,/G+#,&
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MY1&A@:^M[Q6[=_E7WW2+]8WMICEGXUG.W?5^Y&_ISY7%0-?0DAP\*@]G@VR
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MFLGT>W-FK4_4AO>&P[.Y:)CKD]PGQUIF2Y$W.@8S3W%R:@1S9JS!'=^T54F
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M@(Y@7JL&RL>(8<G-<P6Q5!.4J+U;BG+>[,CTSZD"S_JP0QLDYHZW)=SV?AB
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MLJR8N+[M+1?VJ)W=8<:%A7S@O$).9N)_'( &,ZKS3Y<C'<D@S'XJ![&0<6]
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M10X(-E $ZY1FWDWC]I&)ER(MR(%MRG'7MV3[>@89(CX298P.ZVBEN0\JCB\
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M$=$ETM=#; X'"K3CU1@;L)$??Y*SD?20QH6M?L13.7;K':&4195\$-FY^9^
MS;'<7R)KUM+$H'P&69)GB0!N[Z03F:T +T.RE0LKYYU=H.[5:@5Y&80&MQI%
MAF&#J*B4]=M7#O9M=V3L8]):PZUPG?LQ6TP$6M'?I52SD*.IE)*^V226#:#8
M0I8DNVQ;N%7@NR"60@ESVML[NSDQ/=/=Y"K:A7&YGA#[Z=CMN/I4NZ"@$_L#
M%[FP,IMZ^!#>,I+66TY'7*![A6MKCN&W#/6?'G7T=,\UZ5<]$&@T,CTRK1ZK
M:500=@7SP6L_//GYE?O$ 6GFX5Y0".@;$VTUC]9,WE%W!!C+';P,9!O3(\XG
M6Z=ZH)V9QY6I]\ZT:0?;V\E6.$>UR;P*<JQ9_W;((FVS0NFG$NL9^I3L>-54
MT7=XB'FX!O776R.114_H4J]P OB&5O 3LF3A.9RIR42P9? >X @+@E!S<*U/
MG([4\0<I7[@P8Y9Y_%+?)''.G$'%[4%7:3;">3'MY[JPSF.5+F5T#IA[1Z ^
M:\A :'BZ:-M6&Q.?V&/I-+N?Y6$) DDH"%6%[.2\"9TUX<)V?952H]NP%<FS
M1 #B4M1KG((9EC?(_QE@(9FN W4=3'(Q.#:'O#E '%D[P1D.6&@Q[R<Q33D9
M/G.\)L J2Q=CTW('X]0Y5[*!YG% J_&Z8%ACGLNI<_/\AD3'QSKR3=:-9AEW
MAY+-3;T"[*I7/&Z6##GWZ$)P,_!>/WLO -G)9E%.EJX$^S##+/7.5=%0+"P9
M[>BD]7QEFTCKQ8#G@Z;-!0?1>[.2]1)=8U-C;)-=V:)\HV I#?7POFAS(O!C
MS&0OLI$LH"U9_C[9AWG$;3"J"Q/R15"G;UVAZGF"Z\?LP4VG:='LVH_&LWAG
M<T#6]3UIP)O9 Q!8)H#T:.M#GP>*=MTE#OA0ZZI=<0>JODI(.CSS/<";F+NU
M0JV5J)R"T:L6@S&1=$O5@;$QKSESEDXCW7OT*4XX9A$E/%E5.KP049J28D0S
MU;I82N9_65[ZHO+)T+,V+3_/X26?S*$NNX233Q+Z*OWF.F587%CCH^7-OY8N
M-N_\ZLLY2O.?Y3"6+GSU6L'S8(\#6<<RQW+WZGXT>5T4,69<6U3ZS4GLV_/,
MDLHT3;\+YV_^/+_9X.H<0LP#[Z;C.NI)\J!K7:"7A3)$'AS>*?$ WU';E>^Y
M6+FT7>:NL9CDPRL1WH$V.2EU*E[1%S ;1X;>7P"<)IH%3N_QM[G?U+>[__3^
MJ(74:^%.QD]UMSYL$W<^?E1!7%M==O9U5K:5^ZHU/HU0@9##R@(S]#$FE-\"
M>Z?MR>^1NYOSW>J$."\DS1F$,/6:VH1O/UK*=_3N5GKI\:Q5PNFPKU+FY]@-
M'V[K#I(.<1(A])PJR;Q3R! -T_ 2'0:*6YV.?PO)'5O8<]-Z1FB]MNMEC(Q1
M3T)Y:>#A X'#QK9/?%U<_5;L,3E/)RP.!<@DY9>S_18A_J/X[*^?O/B-\-39
M/ )(H$&J"=@@B)]TJ3.,)#\R^0:><NW4%Z:__\LG0N81.\GC!MWXF5#PDWOC
MS'==2?R'Z-<0[8!SGO7UT(FL96C.UE]JRF=$L.C_F?H<V51BI+8FO)$ ;U0I
MW%[DEACQT?S,?C/%9O+H2_N1A%R,>R,Z&V5XQ&2J?9..KC[)%[AZ]1IE)U;[
MLS._G%Z)S+-69.4Y!@*0]R@MD1*G=P8.[TYA13T]=711.4 ;R85)1SB1%EV_
MW/%BQW_CB()/"0F_:CN>9\LO4<3 -HBEH @UIAD N9G"@U5\\,9-=.>Q%)W6
MT+D7Z4>JKOS8]4.R'8;9(1RZ3V)9V$I_:P2,![:A*S'B6<-NCV;[G_&YUAGG
M+#V'4.F? /_1['K25DS!3&N: &!,C5:]7-LQY)NJ=;H\<'Y,FA?[X1&%8.EN
MC]H&V.,%],<4V!K9=84["\M#K0+4-8\T&!_42)(,O!%?LN>N^YD(H?W"-X(/
M)<C,#SW0/7V9F40G4 U":0/8!QG8(_25M.HC\5]Z\WULI:OC[[7//[]PXOO]
M\:61*@F%BN;YH"SY;-=*/6LZ*7AESL2\U[=C9[_3"/IHR:#5M^%D8]FG>5GB
M-)=-+<W&EC:; @W/D?6%[/8?&RR6Q[@VU(G1K2-%0VHDJ>T[Y<P>I;[L7FY7
M+P]4F^\Z<>F4D(B?R_$]Q0+W#I(Z];?)Y#TJE_,3GD.]"\FZGL5VKJGH4;&6
MT46DZIT8T_79@TN@E<Y1WJD?[F"\7I$+OXQOT#K16&"X/JGX^0MYW,J!+5?:
MB%_4@3P]' %]>9U*6-]YF@M[8,&%;2.$("<U>#DK-LCB$@@I,D)!SO9_^)/]
MC+.\B!J"-R6+I+-TW?T2[5]8&G79S^EKO[C<Y$Z[SPIEMA<7AS+]^F0B>C6N
MRKX6OPYAT]9/5O057'@#:E$Y":#\$&3,0\81VX.<&>3"NEX),R" *72]$55D
M.'>$2I;"2@"%KZ?>CG%AH:"(J7=#'\7+X8'9UI^&SFG?'NWX4'2F?FRM>S_?
MC@32.\4HH)RE@Q4$IJCM7!@?VPJXGN%^;/!I@(K3ZOD08^]R-U\_RX^C5[;L
MB;KC!*I$%0KM$3#C2'6L^_GKVJ@V-6Z+B+8>+/NB\OEF'4<E_R<&Q19$M2 E
M\U<($5S8!ET%K",^;!#>:"X($1Y!(/I.Z>N>C,0><XV\KK<'T/F1!G$G9,NK
M-V)@4FJ<+*0S85"5MCFK(PKIAM_8C]4"\ 719UO?  5?#C)V%;HUM1YL?<+O
M[+Y/39&?M=8ICO?=C09C.VLVCZ)V 6>Q2#H4QY93]F[V2!OV,=$Y*9^_266K
M&SOA0HJ9F8W8B1,SE\^C"KUFO3=%JB.+O!K5?:Y\F!G5T1:63N=MH[U;+SL@
M)'U.69T40*GMFN\:<IPE]4ROS^]Z?<AW0E1DSM/!K]AO0+,N^>!PE<;DH"^G
M(#>[/L?NJ)CG5;NKJH+2PE>V?GRW(YLW'19#JX/27N"==J$JT9:+0A']G SV
MM5W=+Q!E$>L'YKMZP5X'R1FWGX%N@R?2$WADP@RVO]/>;;A)XCT=4<^%!1'Y
MI.;-0Y!\-2>H+>3X3W4>O&?+BS7AG"GM5XX3WW]6N9I9YF]CDFEW+N9OO9IS
MT;\FWROA"P^S\?J8!T\CJM@Y75FNB<S?G'WS0_;\Y!.%ZI[V^S*)])3+7-A]
MAHY[5TW V (/6X'NS(41P - 6JO>U^4WVL-Z%WOD^$][/M_.=V3T[BFI5P]/
M?AM8WKMKQKZ,(?LE&GTPT]5+2<1_T>%M\M:L(R6%F;&55I\L1"[<;E'_XA>E
MV>0D25^(7#8A[@"*3Q=]4Q_JC_)/QF7>C*\_*97#J#C4V!]XJ%(F2T$N=^A'
M.6U MU<@:%]?50'%;ZB7(I/TH? J_GI.?V,..BGVLL/EIJ*A[V>H<9>N;"^*
MK=^T^_1>;Y0VOOZX; QJ%_OZ$:,\WCG1L</G7HR!![?4A229=F=WIQ@E-XB6
M8,ZKWNSDD30PZ J^$U@QMO>(+8X'0-*3J-<=D8WPX)$]=.JO\3RY*WPS<1#!
MZOAQ8$%W0N-HMH)U$ O%.)3JIK?3,JT\(7^QLM-"7[CRHQ^^N+E)A"C)/N+M
MO<^HVR:L6NJA2]T2-$6MC8AEB<?@.NDQV57&6/<DQD[FU$??L**M'[3[*.2!
M03P;@"(#+AC+*\J%U5WDPN#3';U87<AA?;T88%CV/P0)*U^B".#I*#4OOQ)F
MHE'RZ)2.\45[RO^YA%6?DI*H?HUS41"_^\&M47B?OE9K4*A6?'7B$93U@/Y_
MKV*P%$,T2OOP@0N^;W"3"V;_T.9<"_0@_BEY\C '(HA*P5HL+7,NC"B&7_A*
M&NA]?_$?>R? 4"K\CB%<2!/=00A0E-XU6KFOKX8+<T5S84MC<,ZZ,%5*P<I<
M<%H^ B:Z!(--+26O2:F FU5MUC:<B9 GA?QUS?.K=-[P93Y57EO[X9N%A@?T
M0@RT8TPQ*P&HQA1%!6W^;.W$V*-B)Y3%9-@M==E!7!@E&T1\VY#E02/ 1\S*
MRJKRS*5?'% 83R9;R$8_O26E=3PA]$SA0WV3_Q?7+[W)$ (8E\S&]_E#W^LC
M!BG]^+GO+]BIJNX4T]DY\O4OGXL@1'^^ZK5H2E+RX""SV-R]8+CCT1M2KGP.
M%Q8&N?D%Y)H-%U9)W,:%[9X!,\B+YN#W-;.(]:(().TPO@<.6G%A\U?_V[_\
M\][5_$PQ( GADB *$PZ!(GF<'!?FSH45<BXF#:+QZ !LI3"X[/>C9B>'2,@.
M7V_5E*ZM5,83C[()=AD1A\S)VN5,: +B??KP,_G98((^:D??=TH9GIWRNIH+
M<_1 +N<< ES(9ZFJ:R+M;*_%<& 5 <W&-&)E#C]E":&RNI? P[^P*YZRW\EK
M!^6/]!;8!9D ]I<Q$?. !US8@6G*&&?W/Y'\U9TLIV=-=I#_4Z*_]VQH>J7-
MLKBPJ]O(RT>=UGY;S?\W3R'J"__ EXK.Z;_&?3DV(O359V'S,)#9#.HR#DPZ
M;:.7IHY;MX +'Q)I!HGWS#[LBQ"[$3N^/PRVV=#%"LF_]=RKRNL54F_UL9]9
M4N 04ARGQCY3!&@RNIFWJ^DM^?A,(,FFF'$L);?^7J9C8];,[:E\=\'HXGM3
MS&>K]V);MIZ:B=U_J9AU&C>(+$$$(MT"* ,4YC5.A*JN,FHR3:"[E"*(.LW@
M->^4[A99IZU+NAG5(&K\6)LZ%M.VJ)T0ITPGU&:&)*U8S]7.52",+&PI<%^\
M^ S(VU5*#DO;];AQ\,=PG,G;2>O!-W4FVVQO-#*#SPHD3-I=4CE=+[T#8XI@
ME@)W:.9#?!<YT5@-W\T@^24@CC6DB<^1K%I>R%09[2^-A1U/Z"FI4-K^4J\D
M?$.>U8FV:L6AVSJ6$0SD$ \S!PAE:4_CMM(UZ_$#(Q,T?!36/V?$ 8V3*&/H
M%\06C?1VSGNJV-,FQ=Z?DG;,%E>+VC,JU<CT8ZRV(L.E8+H' 2Z,A6RE]]D'
MM$E'-NHU]ZY_BMP^JE1DZADID'ABOS"1+]!(YDVV0<:K'"V[M5Q.'_G+>_^G
M-@C&*BV+4H]\G+8/(&8!!UE-?>M6X1YRC?>O;Z[XMI":J.A^O#]0^'7J6-B1
M32KLV$<H34=\_2F\)WDKT%Z?MA> C'U3436].32JQODJ=<C1"E1W6ZT[VZ?4
MU#;N(-UVH'6']WFJX3:^M"/).;8W2S,_2V('47<]4..\_>H6^E<V.%'I0^!9
M#TVP C_;4J/[QXV>!^906"&;LY$Y/'>A0$S^+WF+D8T68P$\7>7/\<=S-MGH
M_U$,6DDAX!=W=I-GH'Y-'JC!<F&@OC .E<SSZ4U&!+OF+S>GJI&/R(O'(6^X
ML@JUH*OBXRRX!7)UJB;G,06Z_[GE(J\U"0A0"_#TND&<QQ9^G).WK&S31-ZP
MDBJI7[I4X!S7TRJU<IE&4[MWC?>4^QCQCQ5N6)FT!7:8*'E!GPO+%*FY5L.V
MV>/R7>/B=(7M&0OWE!%+SP6S.'NW*H1F"KT.E7HMX?YB'%IVOB0AWBL/Y3VQ
M\,_KY<Q,2BBF@ <Z^+FPCAP4L ."]U=_X)N0;>2)'^9U2/:CI=5_4B+(=WFG
M$+[)CH9<6S&!8#(12L5P('1-D\U^N]K*A3W1Q?W3RD1UCS((0*2V(1>F^Q8_
M>I0+^_'H;TJD@U J3]"%;'J1MX/R6TVB/Q;PZ?NJ;O%+B!3&A4U\4V5OP?]-
MB31.65K,IB# 4VNL/U9"^N-8K&^!,H82 \'^)<UZV/%W&5(*B+O$&ON;# G_
M+\HRG>K\I4*2AEI[B4P7AYK[-QE2/+[C(Q&+7^-IQVU@RP#!F5@7^DCN6PR^
MO?RQ5?2/^+D[>W/@EWEE^H:^48EP\KAO-W)FSOW[#)FOJ6+^X&-21-2UL?F"
M2UUEG,N$]+;%RRK&!I?>G#,UIHR@E\O/!O[3AZE+?SU,G5;_GWB:^C^^3;L&
M><5V7M9^K"*GE"U,I02-R 'I>1CIEF3/$M^%$-P1^OA/'3VC;\K73Z1)/Y&Y
M$(=EB%BV?TRXL8M\RB89_$HLHCPBN[$6^&:<Y!BH"!\=\_KD%X.$D!6O;3.D
MJ]YH7YF=/,:5IP7@"N-ZDB'105%[Q:[ HQI[?'(5WMH/XTFM'^#AY-%GQ%*;
M.1VZUUAV,/(J<@A%_1F=;TI[S0@B;L>IN1T)HUQV5S:[Y^L04 %G!WSH,G#1
M=>IY_\BO?)=N'!#,VGH3/ )0&;QC"XWP(2T:(A!K0PM3GQ3H:[1$DZYFZR2D
MM5O<\;CCKGBY8$TV(=/?ROE%\':<MSL3LIW  (S)*#S2 Z>(/0VDT[S"TM2Z
M6@J]J!S79LT+8B4.IF= D]R@DO+R$+%KB;>:)TS?53\])'Z]Z7H&\)@EC-%L
MD3K&\(JID678M-3Q5@*/W;UX">ETWY57BJ2M^UCJED:K(MTF'O+E3;H>N?7[
M]<U3[DJK^F)-Q:]=?EOGD.]3Y;DZ,)OOF;)L_$B4+5C,C&)XS3FS1 "H+X22
M&1,/?X>N'P1[1VU^+^7ATD^]\:9;M<->823.BA^WL8COK7$8;:U7?8S82!XM
M 67HE'IXD),8W3,5SSHRM=K7*R7\5;EDTM.3V.2?T_TA<3)B4?BLY;C(?B'!
M]Z3\.C'V4;I</3'TOEP#/D1*O*RS1HLZK+87:= UMV%Q+I]V*NRQ3/S#$]=,
M!..,99*76,@!WM/%')(G_A:5@6^QQ$3,-*"ISWW0"#/PDX2]HTZ70Y#(M:ME
MZ+U!:5[/_*\4B@D'*5Z\F-O^ZD9J4H?^(H\6\PF'4 *1Z3'SQ[B#EW%?ZS3H
M3F]'A_FL2[N4:_CQ:'?MM@#9[$%9_[1MS]Z(O)/O%Y7L%]G_\06B7Y"VVDSB
M!T)IJ[,3#&(KG#9W<90+:Q+J5-)&:[PX;)H[U7?R03ZG?-!ZDU'T=^.[5Q,R
MSUH?R?78''U?KKEC@-A $:K;[T846R:*NX_L_E_MO7DXE-__/SX1LB5D7Z:B
MR%K9$ID4(17)DG42LH46,C+-6+)O(10Q12+;V/>,G4A"3$:6&<J2Y1[5N#/;
M;WP^O^]UO5^O]^OSOEZ?SW>_KN\?-]=]S<RYS_/<YSP?C\?SG/,\9&S,SY:W
MZI?( 5&$C]/\!LNDM% SN=:&QH;L(VE[G+CBGDD>LWRCFC-;L[6Z 7RGW *B
MMJ(,H(4_-[]+3G^H(ZGZ7FO5$2-\*+IMF+?YS8KSMY2/VGZE0X<.*>67Q%$J
M$?YF>FW9?N5;:P$]OP_HE0".'U%:3$B'H:I*S$:@182!D,Y=)N1.JTE9J;$8
MO;9^[ 9&CMK<^6MM"5VSU9[+10D"V&EZP&*2_E6LHP$VM#AG0]QWU$?'==W3
M._NXRO/83TW6+@.Z\@LY:%[47H0=474V/DA=8-KERPRBK\=.]@!>/4@BXVOF
MRC52E*6(#=O)%Q%[Y)R$Y*)VJ=SM.SFP_TO91F'6,+IS+NC)_XV@39L'0ZBV
MC%%<_7"OKS.<*+;F6@"J.P-,2"],&'2!1MT#?92?UCY=U:2;^7V=V->?97=D
M?I7ANKD0+S]SEEW^<.EW)H0?S*(4X^A)^H?+H7N7T4##KP"NI3=EYTJF-&U/
MW<?>X>,-O:.I9)-HN_[CPG5;VSMBF1+FG#)!E?=>C*;;/=0: Z8N?91M,4;Z
M <,D_%H759,QZ\)-3X>Q3$AR4.C!\"(=@+:Z8M"M>T*6/^%<VT=L;5VT>>SA
M:&Y97=4\O=A./1GJI"'LJ/H,F$*:[84FH^N'XV$> E$X(07 (!Q8['"PK2'A
M]GEG.Q=^*$*CWPP&JJI>I]ZZ:BC2;.PIU]^K$.PM:-U76W/4]; 8^4CYT$,_
MWZFZK3&_]NT3\8# 9R:$4D2&I:!D:18U(#VXZ$@3 ._+QD:W7JE8KB_GJ"CD
M*&S52?7AY?;<-"<X=;LG:G"DNA/NK[&_4V$IIUF"9R>NNB\"/5>(WH>T]]<7
M(0W!S=[B&9(RAZ9O?*2IECKW!'@&<8QB";+;XNM^_IXG],X=>I9ZB,52KYVJ
M\#_EGU4:ZHAG2 O4%^>W/:#7P/R*#=C Q4Y8#:XK@0GA2XE%Z=K[^_FWNA8G
M/%3H:K96*34H19XK.,45&*\<%.@;]_1 (,]ZXVCAJ;&O\9\$7GJ56<1D6\1J
MHGD<#4GHV!-@WJ:-T&#IV^>BRT?F]AY*YN"I"K;LF>+*0M4U6([GABG_00XJ
M)U8,SP70DH71GT\S(3\UL28L2I):""4?.'V3U:G'P[[M[.?L#P]E_(1O'_?M
M59YD_/'^QXPRZP=/T)TX71;BBOPX\%=A_5NTG5@*_B(+R^NP][!\.W).KN(9
M$P+W=5F$AW;"UX-@/=L'_M4J=/S8!&/_6W&HP;^,HD"-S_T[T-_Z=]S?"9&(
MS*%VJEC$TGR5CV:W);!(+#L93DLZE45_Q#+VXQ R10S-EE5*"QMFZ49BV%]N
MW_KC1$0,OA&IS2I3BL4@*J#4X]@W1-C6,A,2\^N,_T[2E;G_(>=2+:)8G_7K
M7&8]8X,)>1&_]"\\10J+D?;G8P=_G G)8#&BK/#??M3K2"EZ"NX66A+4H[RG
M9[7I+>-V,]0-20^#+Y!-NE,$?*NFAEY/>S>C7KC(.!P8P$JD#=GD&=NE<4E7
MBSAL=U&.TFN"AAP9W)%SZ*ESE*_C9<B#(>J1O86DH0L4:(W1TF$$L4EP5Y=3
M[\&,0\:#6ITEZDIU2PQ]>AS,/26N37TGETIK$%47H6SUB:9Q]\>RCHZ+>.W=
MQ!']4,= S[LIQRJO=C:7)EM+KK;)T0Z#=N2$+A@0A70&/8E,B(A79^!3;UGY
MD1=M=3^$]: #SR1TU"[O/7'BCDO2+6?)3ZZ77H^&MCBK!EJ4C ?4U7\1R&9"
M/"V2H37P'AQ!5)T [\/(TOCOS0_O]Y[O@O.WLA>"U8.6;1]K8]"U[X2-_52B
M-OPE#S<VNP^<DVF]LZ[L_\.LB>J!".Z UO0E5N#\<[GF]?.XR4X,J90NL68?
M$.E[='Z_O7OFP("JKD>\;Z[AX<PK_JZICL*G^F6/;S[(ZMKXO$4Q!<U)I6@9
MI!(]DR$->CK6VCDZ>W8Q]E16MSPZM?]V^CF>YFA;CY/Z$89S> ^="'VQ>Z3/
MR(=WB#)JE^[/?"1,?;<HZO4GA:5=-#_NO/(H[7YD8GJ?UO.J_>,>BO#,B?J<
M^ROE6]\KYI OJ7L9/6B)5A:F[/X%AL^IITA^B2$%]_&F"((IO=5?WDEI91:6
M3OWFYM4\<V3INGF@J_@>&6F% ='6+))%O"I#&]W!9R"#>D^0=X$GMWH4(1R)
M\:#78[5RK4&]4G-G*[&4C?-^0A\V0S224MNO/3[F^_-^4ZE )(SK)RX6#Q</
M'(Z29<EUOY^RQAOQUS^6CUUI3.#1/MUOH87G*>"(_6WRHB19EVIBY>OB<=BO
MHOF!WQ:D30/L ;!$?#Q29RY%%FDX&ICDUJNS:8]PO/1)W>IHG6/L_ E]2V7I
M_@Y.4]D700>@F4@M8(PX4\Z$<!2!J21X,DI\#*N5@(E R:80+V8/-5_ OBZ<
M>*$5U?!CE]1H</T/-MI >@3*7G=[UA& 1[::EWH_V(JE*;SV$2/(#'[Q:FBH
M%QQ4PV@<3'H5_EE8>/]-JP%#)=,E7SV27<?P([C$SV)-]408#TV'-"CEW?K=
M%R:T='^+;'SD^%NKP.OER2<X[UP;*9<T*T2'V-.WQM9K?H?_&*8)/;B$$T"I
M+.<)W)[=>\M #XR?(AJ&UW@U*_V6=;_OCL2YF?] I=[ZS58A]I47;F/C)V<R
MBH05.GHY<&;YN;EYLG5Y>WJR]>P7+.[,/Q0F<@8"X82(W*S!VDW9W*O#TM%=
M87:>@ [#A!NW*KOC->PDG#'ML[^E65ZKDL4IEKR=FW1H28I,2-RN[YI7C%%E
M7%KD8(81[^Q6/A,RDN!RW&7XC_?P/);C2RQ@B/SN9VOC8!'\:,9GC. &"H8\
M0T]$'B13H%$!Q(V(^1X':_+GLX2B1+6;:4197EW_$ZG&_H_9&%;/IG/CJU4N
M6LS: #$TD7N=T,K9M5 B+ X.0>EXGS*""[>)(]1@@J".%6/4T?D&X>A\:MJW
MH0Z[0/OK'FGJ>?JQDUDJ3S=/?!4HJT!,/W AE-_:6OO1"#5G# Y3+98S\TY_
MQ/E ]RTW_YI(FK_9 "0WY",>UBY\J@U8?6MP;>'8,_GWLUYIZSH>-UZ;?E:T
MV27V+8!0,Z].VS]+T0-N9E'O@/.DX4=:6"YLO&9.@ 1R;QW@<W[;-K<8?NYF
MG'=)7+9OZ><\TH'W U6F4\^NV)S5.<<:0<GDQ35!7RSR%OU9VPE:(#I!5A(T
MGI=25>B BJS7MV[7:MCS/ENM4+ R^C&9&:\KG>FW><PMRE( BL+#JH+7',EG
M>S?ZT'4670\UB/!.)D2(W[JK!"1TBI%MW[J_OY$U&'*.W^"#I;NM'/T(23.(
M_IX'+]7Y_,V-A>?6^>6AJF/.FB,X94U:.OMWG QBOA/'KR]5@C0D]]:(8@J6
M)DZX^-A51]@JNEF]O[U+Y?9)2VX%")NIR(^ 55VJ&6,4+0'SA:= ^1GZ#E/>
M#P*B5EL5BD&3SJK)\UF2,O5%?J'*CE\&FC2<]D=S9GU33'LF=,*2T\]BRLZ0
M7LF07\'QMYZC*B/U %@"\GB1LUGY=P(T&6D27% ^OGJ#:W3!5::L_)!1K_?[
MRR5&9$?8M4JD H.;3L)-A5JS.D\YZJ,YN6ANJVOMD/);X8Y9(%<[G$0MK2FZ
M-58GL,J$5'.KNE%-LH-#6F@X=79_VH3U;3+B0MI]G.J6G6V:8T P=JXY_/ML
MW<S. ;['WH[J>Y +*$'@;R*4S1O%5]O4!.##Z["[^]Y ]Q\N,_X:^KWWF</(
MS:#4&]?$E,5-@K]\E:/ /F_-?V)"ZA16L< 6);$9&/,:0^ [126[MQUU7?WD
M@=)J95E[=N&Z9%ZUL?!L,G9*F/(:9"?K]4CVK2K UHX2!;A-@MPK:=?P03!1
MPK6AU][WWLR^)ORN/NK[O3CAX,ZDFY=SX0V9\E$+=V"K#ST9T(ZI>007HVF0
MU;LD SJ'^;V_3>"[M1N*LR^5EY=AW'GW%RQX9<QO/GFI9+K+C)1?=A,8N2P:
M/#I <,2&KF.Q[\(%UM!4:Y"7H@-*%=-\R%_+MGKUGJIHJO(,&#GF>EYMO"-2
M_N1PO^6FZ1D5E+7E^JR2I.=J33G-EKP13@0Q9#L2/NI7RY"#2JYP^WF)6F?Y
M!>@AO;)6_-VB+R$)^;J[RP1O*W?"YE[G28)HL@8)M_JF@F9;7SG>)ES4"ZOS
M_3&]/^>R[[O T)X1]QS=\U$;DB>[=/H=W.'SD.^@4-\%8(,F*M?]0*##5\_7
M>2\Z_/8T\FK-J*#5B-;PFI'S$;,)6$: [/!:EXI.[?$^S!,3Z^*KVR4-W6-^
MVWJ.[W[]+OPD4,82(S_:)__ \5PD "K#Q%F#T3;Q]D/;UB/<EQ5TPL\S_RH!
M*+;HO[Z#_S\1S-]OU_77IZC]B>$)8&^#?DS((>T<)L0)1G&#7^U$;XSMS!2&
M?6'5<*/]GRCC?REITX>=SQ[[LT:$\RP38B@R\L?9KHK@^5E:9.#&]CH+#_9@
MH3MK"HSA6=_"?B@IYN/4_W("[X\$O^+$G\*X;U5R&.>?H+O#?F6SBK!ES]X)
M=1_BV*".H)=ZL.)8SS_=#R.PC/-7F! >VL(N)ZX^Z*0G)83^2E_A#:@S;]&Q
ML?<[);O646WA4R#B<([>?>6RY*B,\=LB'0-SU_%H8^073\4+Y/O7;WC!^!C2
M"+OV0:"+Y3(%?E[2Z3+W/EP"/NBZ$"TER!XA>Y!-,<6-\U;%%YD^N>P?_>@Y
M#+K2IO7=G0"J(/)@LM'U_F4 ;\YANK#/2%KRUXI2@6U9@+<6^AC/^S&DV-R:
M6'=S4>)/-/=R9G9O_>,C-:6.UTQDAK;;RRJYOUK*7I%L><1W^6,WG_M$KHB8
MEX R66!5F2H(-L#;R';Q3(@;)NI!WILWT^^"WO@XQ'1-:_LF-"W<V#172=GE
M+?,T\^8-,_FTN[XU%H_0/&[@;8.]?4!?UR!1I)HJ"=H$7N/,5F5"%E,FZT-<
MX%2I.VO._"+^Y?8.FP]"PC$5")/./ 7@$X.7K!ZM23<Q::ZG:DVD/_20GA@[
MEQCB)QR1^'3>6[P$NK=-!*D.PEY@>%C4.. %PM'<FW!S#*E;T.'F[W[+@]9H
M8W>G_5WO9654?+*W _XC6[SB*\[AKHW?,H'#VU2'K5/ S@+04\N87Y2Z]:"M
MUL.,Q:LT>#[D'R75>,D?]=;#T__5!)7_1^Y\,7[HZE;B8%:T<O^*D^- BT<$
MHJL@Y6Q1A"([]%]/#R,XL2Q:8$U_\BO7X;M=(QA)-M!56Y?U-$5ZG3UZ4^5L
MBG+X,%LI$]+U&.<^NZTXNY\) >IA-)_&'WP*^,JTET/^OKZ^ORSZ]Z[$$]'$
M?GAU 'U_0#P:=(0RM$QHNKR42SL[T,@63 BO&Q/26_J5"1D7V$:SQCD30FD/
MMK9CR<&]9^GIZ*4"Y%4FI/,S$T(N@?VYH.V73 BKB$TXX_/??% Q$V(-8ZE4
MACD3,K5K^@I<#V2I.RVJK@\+08/CV_9.([9(QT9KT7S79@D#>>JN>N;*E=>'
MO\YAI?GX[(K0?[8WY=<Y!DMV+N#HE3+C(IW_W" IX%VQU9R=W74D#$.TCPE)
MNL(H1K.:G);%A-2S-^<WPO_Y&W]E^S\VC\TDC9_E]3H#J%PX1G0&"0XLJ$_J
M,.)U>F TU10F1+* (1U%95'DD?-@$1,25<6$S-N,11)32FZ\="3,9LQ\J6>9
M'T:5C <7__F;UO]D95N90#'JCS&/*);2/XAZA_MYI>TH$T*\A0;'H7^N!39O
MZ"YT3?]"Z9KNK7)?>.E#_&V]DK_W2PVZ)1/"JM!O5D>^Q15D?!OW-TRT1I=
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M[338)8FHV.S9"-S@ U.,VD:"^,].ZH:4^_T2/Y"VHB5=TUU1HBO/ Z'X*'?
MO-&@D@*-18LH>F""!Y!#R:2_T=<APO;-&O,57,9Y.Q%ZE$7BS8OB9%3F[^[%
MYQ;8=AQXS!]:D?/&F_ A-Z!T60R8)CAWICM,.UZ03_;ZS&EWWNK<T=W[3'9+
M?^3B)@Y'GLJ+HYHATN<3FS\)>%<@'@Q?CN]Q<Y6_Q"ODE/=(&O\"+T(.I22
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M\Q=H]S2&WBD*21 ,>*+K_(K\_"/7F*;=P,QN5@NSNGF'EH%B6P6&'V6P@CK
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M2=TH]_4?J):7=;4_S+/))F<$X69ACCL]5PL6 :^Q2-&W4(BJ:%4N0#J!PZ0
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MC1UQ8JRWP6,(GZB*5/>6?:/]BX>Z/G%<V=]RU^!="&>8@3LY+R<?+&7PIA2
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M4)[I95GAFOJL\W5/TS5%DZ2O3_4=E*\^;W,M_?$]<S3U!&.(@.TYB=)=P;
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M2#^(/8USR.M5^EY;7G59)[;OV:3S<%=CN$OGA]0*$^UKU3-H*2X09\W2&[6
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MJY>/9<YTUB;G'B_;77HC1-3PP6-:#DNJA7-:DB4KQAE2H^ XF5.3,DR3'UQ
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M60VB?T DY^N/-X@CNE7-:["VX[\G<LZ.S*O*M#VL+"J]=-K.Q!2F1Y8UW%D
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M-G5Q=*SRWIP&;;:2.;W-4DHQW^2 "$!_<+RJ=M?5II1@*N5BNJS6/KUML>V
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MI&2"=)OZ@&HY)06Z:^\P6@$I(7(V<R5"*>?+B%C*8OWIB6._!O?-S+9&I;P
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M?5B)OCB*X(R_ULDYN<<W/3XDH<D >^ /S!K3H<<RI<MT8NHF*E^"HPR388Y
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M"EK4V4Z)KL\HILC<:Y7JY'RO"B@431E$#*N\O/5-]R6W<Z_JKM>Q6>?XO=M
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MC&]O7'NPMDF3@4<EVN65Q6U\@X38[]D8\D07L_MDT3H;N//[LQA,6[G;W /
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M=W2F_<I]OT]+CBF.]V=<\LY]50B<>+_O.V@C",3:]B_HO>L+K835S=.DY2\
MCN^TE?S'^41?Y(%6=UFN!CN+J $;]X/VIZ$UQ]T,?(NLQ0DC 8,PI?Y2.WK:
M"%]=C-GG1*R 2RS?.(F+(?S89\<#U4ER8ZWIT0STSZ_9*^O&> <P#??1  !&
MU/L_0W!IJ CAJV\O=';>;?3G'L<8+965":,'1V[\R2)]]?7/!NJEY?^.UOV
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ME66$]IEX#UY#?^- >'M!ZRK,"+*NOP>12"\4R;=\0^- >FK$_V[#LH7?-AG
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M)$'U^V-455)G*6B*$![)OZ/5>98\(WLD)Y%GM25ZW69<?RGZ.^-"M*^N!S%
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MM<L_PRY^V/=N9-BRO?Z(U2<!97,Q&TC$;TF@AKI%@8+:001X'%$,'S 2C6R
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M\5ZU9LC\J)^]QG56=?H$06L=,</:S+E.T^" P-IL+55M_L\2+ZX+N?OT6YR
M'L%V!78HHZUIT\Q]2RY<"1*ZZ 2P<RF.3).P1?DL]T,=8TS=D B?V2P;(3&U
MMS9."A>25*":(_(3.[OUP1LX.2+Z'@L',_'!-TYWKN_ATD/9US5,%6.B0(?
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M3U=V- ?#NC4)F?^UYG+$VW]-8XHTR#.[SU;F^[ 4TXL.GAKEQ7AI>/Z@<I4
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M5U8CBZ43,@R*N/1QUKDBA5W/BS[<Y]?KEQ?^OV]#]?_;15C_\#]02P,$%
M  @ $(/T5 :&+E\HC0$ M_@! !4   !B:6EB+3(P,C(P-C,P7V<Q,RYJ<&?L
MNP=44UVW+AR:*"B]" A1BH@TD:80"8J B @VJA"17J,B$" D"M+!" @H*%'I
M-704D- 1$.D@04@(*M(3E; E[>;][KEEO-\Y8]Q[__N/\_UC_(LQD[UWDKW7
M7&O.9S[/W@OV9S8))'+1PLH"Q,7-!;K%^0.Q-T%"9SWAM[U 7B!.XV+/@<Q
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M==XY3JR3C<.9G29^Z2J#$<CF.#SI-;BAOV=D5I46P6PT.<V  ''52 TJ?U=
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MCT[4B9P;4QL05Z^[9[*;;^T&?2OX_+;9"S%TIN?JOK,F+N>JZBX%PG/17C!
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MZ7$[)#,&--9"95(&?^Z4OV9>>?/ Y :S!>\SDMI"["+&0 \R9#Q"EFP/,?B
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M<(E5JP#YFQF %O@WB_TP P-6'FY$;/H*8CJ)V67^K[F\),.8^017SMHU,S3
M4)*U&UHIR&- *F58YT/'_?6,0YU.9WCN=KDT0\0TA0U8K[&LB'0?&+6-N(+
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MB@W#MA$7?>O$(=9S&S<Y0.@\\L]J\S5Z#P15@O*L6@13G2?O$1N0=<'GZXM
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M=ELWV9C*U;4J5_?=V70'CF #X1SH M;#D!\S960ZCF5,R"1>((;<"IB5H>N
M!U:-P4A:P_?FU)UQ#@.XU_XQ-ZF=!>B[ZMK>[60_986:GBU%ECE)7#85![8*
M>G_L9(A8-\-Q@Q#%"R[!#K1EP]9#H>9\Z'&<8"T,.9KJV*\M0>\I<QFF'\2V
M(* ,XGZVKA<KA<99U="XBZ45B>-(B9FU6_VU!5P*N96]&FX)@5LU58M]A=-<
MRR2U.*8?_W=5MU_ G,%M,J9V-EEAK&)'&/NJQ =ITLY&G:+V@1JK=Z9?)")5
ML$<WQS^SG7/%&%+A\31=\FHU=;A)U,GX F6'],SINH2NAO>O.D5/3/!MXN2Z
M'GQ,JI4G"\!J,4Z#EG0HH=9S8]4NCVHP4Q8ZYX3I!Z9@?/,:C&/4]E;)*'^+
M+:"5\]&@=+4CDPE)-R<[OHG%\T9$"ZDRENRF/.9DJ# R&V"(V8VM->"$/S-N
MT#SN+N<R3+/1WQL=DD(SR\I[%Q18'RN][4.<#?>WAE8N10B7A ![[;PN3 S%
M,80=R;$5%!6++>CPU22P+(\A7TX]BY5)(?MF45:2^:JWS8O8O$I>>:&S:/_X
M:"%'91OGI06-/4A#S$WF8ZPD(Y"Z%GJC\ P)C3M#E:WF+AE#;$6[IP4O- YT
M'=M=9>K[NEF!"Q.9%9J6N$?.[4&8P=T[0EN9C^"[,#Z@)AO@XJ1!6#I,\6CI
M\*8@PPOADE.R<"HBDF$M7MROE:N.FE^F/]^_>-LSW33MV_ O:8\S1#8'&'D=
M#-876AVG+438D8,69FNI>_O[9RBH9@%%^FEJ<TKVA>[S3S$%M=>H&B.E9:*!
M]\WY>[3V[5E2<H#0%P*50:6W, #C2NF,*D;CFV15:9VQF660B"]IE56O"C8[
MOB%SUJVLG,^'7V)UE5K0]GK;KAB=D_/USP?CPAA&D*<>\41LA>N#C:OW7T-W
M$:Q>N.1 C?=UF>D'H %%_W'HRX-=DG3M1YK9J:<<CRKX24M<Y*O6](@?N2,T
M[$'.F1V@"^+JQ?4LJ9S-;$!P14,2HT?%-PPCN.O)H$9__X*M%R/F8*],3*9C
M^^X/GZHMRNY=:3$KK/!:Q$DP])AY. AHAG16C]-:&6*ZX^8A-$?CUS1-JD=X
M>&C-D8T351KWM074OZGX."QA>@1<]QGX>W^3&U0U\_N^SF\NOP$E>&8DG+>5
M+O>%U8P3<1O [D0;G^V>?UEC&#A>Z[Y0IN_YY<.2F=_UF]4[<O:_<SJ5PKO/
M*N6FNB9#A;X9/-)#@874R6,<0#)-B.+3VICGAG\K(:O?^]*]O$L]E;N"?MY1
M5_=F3=56O7BUYG&GD\'&[N?G/Q[5'R(>0KBB!G.:265)<Y'TB]C^Y(&Y7>/X
M+6 J+#H!<XAZEUJ4MMTT[?-D<E!Q^=/TA(..=Q9'VS3+G^A72ZB?*4T)'UXC
MEE2$:Q"]Z+"A? M9=+VVMQ"7*?D)0ULR8L*9]Z1"E:3BU*SQNX$+8?4'KY=,
M["2?I.@%T3>A19N(PGJN-'GR0 LR B&H7B??R(LY44*5+?#:++L+_4)BRF]G
M9=GS.77LQX)?*DN\ Y\*[Y_(,#JS!3>6A"M=B"5>07W6( _,"='@[S_"1+P=
M?#K*:S9N&*H5H507?%4O58::WVP^,*SUKO+0.:"MQ9OD_1PTI":1.]^B0C=X
MZG'WX*)EGVHTR$%[=^@<[U:M7YSS23\:<:=8M94S\>*YR-V1"LF3N7__A*"-
M#?B0U@_6WF95#;*!J;,V5.>@*;HO&V@KFR&M]$/*ZU0Z(7CR+__W6PQR]1L8
M1T%*>D$BB1/A,4,00Q]"E]AT*?5F],^EU_5?>E51Z7W7%;6+K\R]XBI!M7@]
M;+_X4?=;RSM0JX_Z<>0G-3HT^ELD3YG%5F]9]>[EE.><]<(NQER]2T@%JRW2
M'C+RBQD!"<97]KY4-P<(CUC[69TX:<0EB_O20G,_"EI V@WLWJX:&TJMQ;D4
MLD2M?%"8V;&7ZD/SWE+';(.-8SPLA=^*B'\<*Y!F!M+E&?[4N#D-N@[:8#S@
MKM[!C8-)15['"I?#;6 7/)^_2. H!6QDE6QV C;'WGX$>%+1=JM5S!S2N&0(
M2QQCRPS+H3Z":Q#?5%3TX2E&>*Q:-U] ZCD'&7^/O?EWKUW5.1G]P-YVK7EA
M"+$:2B4UT1?"_UJ>5&A,$4]]Z.$[5%ZEY^Z>6<_U)0T_FZL>YNX>_3X^*@%X
M>JQ^!D6&D"$T@VZ/;J4XLI;,J!(IL)!E13W"\"5AY.4$C=S6U1N'=T@/6::^
MN(G? 5=V9$B"" HBZH!]2J66C_JYE[.B"RXCPN5\[I Z.Y=\:&"D&;B.?%W1
MVKF#]0DN1>,N@=1I<.=8= =/TYJT0O)U,&R'Z<=$+HO#_?9BBA)&GK%\&-JA
M0\VW8OQP)<0&>EP(D@NC3UVPKI6\]?AY7$H14F@=TYM],W5Q?&;WAX<FT&@7
M55CW:(UXF[WI*GL.YZO6?2,K4VWZY%Y\A\RFE[$OM[CO?'!L+"0*(,.E6%UU
M/& )+:.5R(.1TM-)P,#-#NJ[6E94B2@-S2>2DX>!\UJFO+ZZ<1V[K,32.M/L
M/B"*6QM) $:-68[P)')C]E/A<>0.V1',SM4-V]!L0P\?4?ASW</VZ38VJDT)
M1[\FF 7I_X53[>B<_;&@OM: 7)4.7Q^8?(Z]B?T )5LD9C<;N)"+>XZ-_,1A
M3Q1!?'T^PP96N:H@,:'F:!-'$V*=$+C.>KN&V-B3KV0\L^\&RM?=>[4NS#^K
M[935[-/U.,,KELCGN*8B7"^)#4#RDEX,+FP,LP%SW"**U=N:7JZ<P=I]G97-
M!M8A2C82PO1A SF(=1UH.%R[',4LV8!()1NPQC&@0)FO9Y6S@1X\(P5B%IJ3
MA5'*;"#2B0WD$5F.;&#M/!MPQ$UULB !./1DV;99[->O?84K)"Y#<NE'L=WI
M6RH7HQ 4.\0T]$I(WC(_(_I)&]<A+85;S=87+S:$T53P*U 3VG&L6=@,BGD8
MBF(BW7KY8RM++PVBR::,?(?8=I8>Y:_7IY@[U&U<5VWR>1DDL#5K :REY"S1
M\"+([3\Z$[Y&Z.9E3(/UD(&]FQ&KFB3<Y%K1,P3WU0&IMNZ/RK?M>_I5DOU*
M;B&"+8D?OS?26G3%[S9:/O[E7/E">I!>SV&A6?P&&A+NB(WE']OR][2RH/8,
M%#RRLV,<[>1#3$*T^K$W-%@]2_B5$*C5>.*Z*NY=S@]!:P$#H3Z[Q/W]-ZQ<
M@SK.C8:T_G&(>11 CR:&;]1#]NPD,1(17ZU9$(SEQ#$@6Q",5RV8>KAQ//-6
M)6003CU5-I"&8]D0(+,8,,]WL('O"RQ3V"(DX?_1J RZ$BL50>MDU3JEQX%W
M4R5PGR#"O7> #4RDL5Y!^6]I#;)"W+H8&WB-FX)":SL;F.GZ54N++(U_[M0G
M-F!_ +=.AQ1%*R,*-XA8IK&!6-S*Y*]::@?YT$Z/4/RR!AMX#_&!=4_<2RDB
M@PF-FBO+$/&/SF_PT/<:?F5UNDA$W_3+2?5C V:R=5L(=3AWP@^/X\<-W(4<
M.\[^HMZ1L5'!J&8W$.ENA9W!K.Q&+WB;7W/,RK>#MP=?U[NIJYG'NU1UIJ[-
MWSE!=T,YO5*HYY^^2_SOD.<UA-5AL)XF0Q8,>3'*T*5)KF(J*A[N;@]*D*K(
M3W^@N??@8:5L9<XOGH2[1'(9S@O_EZ.3('(SKH5KO,SJ0?SU"";W'T<P_=@1
M9^DA98 AEC)N5Z\1=F2MF10!DW 9-J1^2])F9:G>$D]Y$Z6M>ISP<$FS!9@_
M*4YV,&9(E+!X15UIPJKPG1CYNM=45DX ^;;CGM+!Y92"&"6ZRZJI_7>B)6^H
MT^S[QF^S[O478=< [#M+)'Z(,-='/S[IX-Y2481QKB@I*0W-KJZNZE%UC=K6
MZ_Y\,)WC+&"B,,;AA)J%X(#+#)RCGV;LZ,%J@[H43L/,&<FDJ6R)[I=/.KAJ
M9U?;=!BW[P=&;WGH"W>F7_-+X-CP,,0:HZ-9?-9T&T?/.EWP\5BA]'<G*J+1
MV7;)@F9;CA^DCIKN?M!!_SPD8Z5N1?K.[Y8HTB$:T3@F.I<JRZQ%>&J(3TK
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M]T0(FGJ!-MUD22OTGL8H/;^-A1 /CV8EP\:OQA=1#>>-",T>/',WZH=%7(I
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M(VP%$RF^=STSTO0!U"T-WZ'76EXUC4UN+C8['B56T%274GCW1)UC(QBU5%0
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MLNTXJ3<=-&J!)B[[L082C*JW+L8 P9TI82\N+5])2C*8&6@VO63_%)!<BF!
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M:<'U=9_]KEMSDUA&D5]2(U!9V];"\#T?S7R(%()M.RF#C1@3C?F,03%@/VY
MT%M8H;T$*$H7:P>CGUOID-CRDZNDK^DPEA)9KH:SX@H-NO!WF1O]4I,?.MI%
M6)A 00$'FDU:@:$M#G!D>P.CD?U9W?3)<G' 3(=R[*?4O=3XH[A-=[V;-TWJ
M%NE]ZO]9A[U^]/&4?PC5K;0 ^/7"2/+-J[Y=--3&6W$/$Z>X&-+X3Z0W+?6D
MS1Q#I9UA(_;4#KHBP;ZZE3J2&TVDIJUHT3HAU2&NQ=_MY0<!JUZS_19WMSU$
M/,[16W.Z>SKR,W&0C:B:Z0M9E*>YPEQL U,K7)]&NE^J^HD4)#^5BONM]K5&
M"_RF 28@GGSQDZP6']1!XF5*41C([>,)Y=DI#OWB84?G?M8;W?+O>J/\M!"*
MQ'>]40_T/Z$W2C00"$TSOV\\H]S5Y=6M\W7*;L*+NPGU6J**$$1>2QI(11>$
MP&0ID+ E'[EA]' 7M#JJ[R3M8^3:H!?G5FP&2V0.'DB)O6KZ\(AH=+,WB69,
M#,"NTY*&*LE\I;IT/0I_L(;>'R"&8A Z4RH/$$?YNJ/MET[HQ=]=)"HH6C04
MJ_;YV5@<RFAI//393YSUT -U%\C'1J(=_!5AIGF_0/\:5<UA@FJI:.*O^OGU
MFZ"!_.VBA]T:^&.C#E(-GCPM'[0TF$+2#,ZP4LLWX:('L/=*KV6/)AB$S?LF
M29L5TQ@6LA]BO;>5*A[/=EO3F/CHL\NFMYXFZ_*2]VE8'\BXGNI-/!G-?"+$
M74T(<V=R=OVX@E@JBQ2P@-W>1"$%%ML^7W?G>9]2]ZW[C\8>*53NV)_'Y[7J
MU"J1(Y5UTG.,Q7#6N_)-YJ-HKND%%(R.^(D:<*+=(O\,1Z*N>Y?A)]B5A;GX
M3L_I;;^T=@+">OOSX$V^-K(2CU9'QL=\AM*8O*"%,TV/8A)(BS.@XXDY9J"W
M7N"YUZ1N_7?%3KAKIH.8P[2J^\<E!0M7WXK2M_'S9CUE;F"<T!\(9=[TSZCH
M7T5?" F?QT[VW;VO"]A'B^H>GG=NW:X^;=Q;S[7Y4/,5NNHMX\2G%OIE1D5C
M++_;DZ5'<LQ!0G67L.B;HG=A6XY_E'YRM;3(WO;D(ZX@W.=UIQ #&8C A[<P
M8@P]IFT1*[E\%2YO4*G8@40XUFI#T&_?QEP)H@O*.N]DO<L1EL2P,M:J4[TK
MDKBIZ9%,)'VG\5^E7]7^1OKU,"3K)T0CUOGJ<^O3'W3.?)Y'\IKB J2ES6*N
MEA;G1G\LU*V6DM]];O]3R0-^[T6.5!S 428?4X>+L+.,VXVL&*W-EZ 64EY]
MD-9.QX2'I$Z/KP=UJ7O. A].&"?U4J%)1K.WS"S!1_J3?4J*^^-O0TN7>7\,
MXW48.YH*I+.!-"G\_?+"Y_\+85UZ  M*NDZ%TH67!I=JD)_KJU"H*Z )) S*
M:1BG&>RY*_L*5_7-06[[0%[LH!2/R1A"?E@JJ>=SYOZ:&M8"=CU0B='8Q]@"
M=9?O!&-HW(->T2^TZ>J4D(!!.BK04WY*K*!+-B7YB(#<]2^\WMJQZ\SV+P^^
M?Q#OWA I(G=^I7'D07?:U*NN%CQ9_<Y\]^1KM -#LM2;TM(;4E-L4N3Y ASH
MP^E8MLZO:[_:X7'MI<-LO?1QZ^BE%*I%_J.8L+@'A4'GM_N54".G)G+,88ZL
M7;X-7YN\AL8?G@7'QVU8IUF05-,[$D"4\>CKS&USL8EH;!R?YM'+&]GUTL<Y
M7-)T\/RDJ(U0$7.'8CTV_Y+P7K";<<CO*C@L44O8PA2EQT0\&@#"B@2M_*T$
M)F.IOE+?+FC7+ 91(W3$$OWN9^'.JZ%Z(7LC:*,K U4U^X=W*?U;K6S3M:,"
M%3/FOI(Z_*KZ$M.%V2F@X+FNY3Z]@UJ/P?#!KX)P[\PP?:A;%,U+\]I3D,K$
M$#]UGTRKAMB-:TQB#?4TZF44M@MRR=QX=9I&!L4)4VZ#!GTP,X\HE\'55R6D
MA[154S\6/1_M%^[V:'E#'O,RL=V5&C"^GTO'K<3W=&2LCM?9ARGE]XF/@8'H
MO!,JP1!ZEPVFCV$"SA_N^HA<O$=]EU&76-7A[)C0L0E%,W+MZ[9@/=1 OL !
ME.[;I9;^5& [F'BBG=(]I<'KHQ6::F'E>*-/5[GKV:=$)?>TP=-G@XU$W^RY
M8ZKLKX^%F4RE_<M@Y&='3((QS!$VJ50*Y5U+#YUO XX:4+"G_?1! FUN@'2[
M !V&YM.P2\?Y5A<KDPBO)M2R&ZM=G80'GB?UW8FUX>IXR"W^E")PQ>%MO<E0
M&5X0[[NJ M_9OXF5@Q<Y02%QXQL)@DKD8 9QI(2N<Y_(5'3-*K;0X?N<E9*?
MU&DV''O^V]G;X=>KC]S('D;G)A&G2!1RGU$->0->!>J-92-X_&0IKJO,K<;I
M?4REUY^@YDSLE_>R5\A<[]MX"PN2,9=RUM:^.[(%>P$=IJ&:+*"EY.S5SMAK
MZI\_?M7SH'^B7?R(*[?@8;^^O/LWK8XP$ YJL7DT6\9B*%WY_FLG]"ZFMMN@
M^A\YV[)>FWZ1<7,PF48>:'6X87JJT2V4[\2=**GV5X/!40X6SC'39%^L]<HB
MUY<_4L(&N>S^PFAQ=M4SRWL\6CC*3VJ,?A@(WLR Y%L1OX DRZ#?8*E%'';I
M%4#%Q@=+LWHY-_@]58-9.!$YO/?OYBM7KOV(E#J=_PJC .$FJMW"8_SO>%,C
M.8) ,T6#&)*@W[4!%&@'% )7P,SS[5 WC Y<XT:6511T2*X]6[],?51P>VJ]
MD+/9=:,=TYA73SIU2FR+S<SQPP;:]$:596$7AR2;>"41#9MSVK)\4;Y D.*D
MH_0 &_&W'!;-8;#W2-\9K#V,I:KK.!P6P^&PNO"_$OT\F$H8X_P-D?W.8K<#
MWUELZY\L]@:1PV*CO[-826(@&_&W3)9#8_?#) SFL:E_\E@*]CN/E?C.8PVQ
M<*E_SV4Y1%;[3R*K\R>1K2)])[(&<.=JT5+*X<P=TL-&=.8!PR-LQ!>/GW@Q
M%0F&LQ%'T<LFD1RUV86)(&!4!(:"!!CP^5.T_5 _33*,_EQ<#8K.#]T&9K-1
MD"EJHGLCW!(=2!<-G614E553BICW>EU9-]B(G@=X@Y_:P9)G/2B7@2'@/&?S
M"=V)P<609[CJPY:3!W6.+*O&M O;UGQ=NIF4FNTY /*'O35/K?GV!+#;('=Q
MF2)=-F7?:&"]8CJ?^U&D(2_A8^Q6HE)4R:5<<ZNO%Z9O.?,86CV:^D5E_W]"
M:)D<"<QN^5.C=71_L?P_G@T;A/MD5C)SEOE)V 9.F<._R(M]9_O_..FF_:\D
MW=O@($,&:D'GA]Q=0*]C.H":E*_X=I-PFR\)$9%K\NQ<:CT??<HMSEG]]LBE
MS;MG1HF)]X<W6,E]V$Q:AQ.I!+9J*#L-D$*2M[7-[Q&NW6@ZIB9'V)-=4!RE
MNX'GS!^!HD\11Y1#8/#9,S' 7X/:U>-WDCY3,<,]D;RW_0V+D#,."12\*RVH
M-Y!S$)%+0M\-FY1\?L[AJ^;1L,7&)J/<Q',=SOO?%KT-34W>,+@U2F2S0F[R
M^KT/CPT$7FJIQMYF([C*-^OZRE?.!%KQT!(=+RPGA,/HO+!KW1@;42;Q,+R4
M4:COZ7'A0I2)P=$CD:%LQ)KRS7[.[5/SG&W2ZTL/42?TCFR.C>V7^"1+'+SS
M4>%]7NI:":Y'HYH'H S:7,5N<H UZ)2-$]0II0T5!K19KIXX&Z8G<1NQYM0Z
M(X%C=V8'A3RRPZ3F&ANPEZ7&\4*TQ0+*1.0&)S7>F/X8;^M%;W.;YE>ZKLHE
M^TX%#5XV3I4\$R.R1N@:[]6NKJZZ+G5I:7M*\*ZJ$YM/\QH>K3C/C5A5L?I%
MRLOI[S,^UYD_T-?-G+,P(CGQW^6P1["^5=AI3W3MRMZ-,".R!Y;W"A]A(]ZH
M&[$1;;K2KW^=7FS9!"T8,/7F#M8")0:MD,Y<"&PJ"Q3FB[]3*0'.WI)GWLE&
M3W2A66N,$[)38(O9W0Z57>-,_I@1!WO\SD*YG$O.DH#>)>A<$S6$]5C?E8W0
M^T8<3?G-PTX_*38"7\.1UHU?#H%'8AH'T/5F=9(X:NT.X,!O)ZQGO)D[^J"S
M7)1(UFTXO)RQ)5;N9DW#Q,(":+CM=PC. SOAE'.V<SDR#)@5@V,A%KW8@TH%
M;>"N"B,O3,$?&FJNP"2ZRJ#OEUL[_DLN1QTAAI-F]_[')7AAB\"/_S.7.)LI
M;5 TXL>C\##ZO?^MHB\:21KR;$=S=-8GJK7^,F?23XMC),'LZ=[JMVQ$+PHZ
MS1T!3)[K@%L;=692.I+U'"[\-FX$JIF"0[.N*#&O"JX9-KH=S ^'L-/M\\ C
M)H6C X(#I-;RVIUJ+7#=[MBUPA>4KN_MXWV@UMG))2@9(['JXM87G8X8S.O)
MJ1LI85+W?EYG@)[,8Y>YS('N+&!E?:;RSQ.I];E@/,L&%;064&,C"F:827&U
M2(9D AF*:\:V:O_FX2O0"&*%<H2>%>>0L,5\H;$1U+BA2'6X2Q?;Z;_<@O)]
M@J5_!A0K8C[AKD8Q5J&AQ\W8 &4&/.QK"F&;08"P&UR&LVU;?.8<B@?N%#T=
MCFI%+EJ'U@3I\)(F^N#/4GP7> RQ=PF%_Y\G%1J**:3-L50*@17BB63MY/6\
MG(M<2.45(O;ZHIW2E=]EN_HZU3$L/'S,^NU8D3$==>XWW2WT>I<<7.W(;^:=
M>4&TMK\$4X_$@N/-+)S7/=%P-]Y+8R/.$Y:-.!@/)TFLY"P6A'JS$1D$R!!V
M8-@8MNM!S]&SZ7 (PM,,L8&<!8$=L.T;H9FP,WX] >V/8QT'A@V@3ZR!%!+W
M:"HD1H9> LLP[B@.86K+K]QE(QH)K.>,2FT\LE7GK_4CP3#LP@886Z$9)Y8"
MPIBHE$@P#EB!X]\P"AI'T7E(X_!('@ 60V9^FFD$-&,6V0CF-A1D@#%C(W*]
MX<"9%JO<$DX[P<)6ZRE GT86]1+C>MS[O\I/[2G_=DL <P_H]7D@(]_YSN<K
ML<77[QTO-+=X& X;\>@S/SL<G%A<.:"SF9Q;= \Z"&,1658>*TX9=CL[_Y+)
M?M=$G\W8B<-:7UQ;OAZI4_WH-/?SLDG\_0$Y&6I8)G_LE;(TI7<6(^DH'\?.
M-,FRA*ZN#EJ>EEB#N]_QU/#,)G&BBYFFH%.*4^I_CLJ&.<LX5/D_EW'0S-?P
MP^X<WC\7<@!FZ%(0+PWX!VLYK9R%G!KL]X6<?.#[0H[TGPLY< C;.;/Q'R'A
MU)^ <,5_!QR,/O[7J>1O\I-P!1Q/#*IGG,8I4ER9DLC)F:FOMP0-BH JXQ$?
MP8\JUQD'INM?4A:([:_F;_C))]/R]VQNB\Q[2E:XU!K3U5UJ(U8\D3%E$U]G
M^;0MYJS0<BJ_7:KY3.?>7Y)UR>]R>L=_1-J/'S",?!9J"%#U,-0&K%"-.E^Q
M-/V9->-:JJ!*FBY#"5=]YC48E (N$_%['7;D&SHFY 0-U^QCR$2H*!UZ_;CT
MS*G%FR6BI[)GV8@I%3JJMAQ-Y[OSDJE-VS\J+$&K#P'>,'5<64'""4O\>O[>
MZ"31[:]62450#TY>5%3@._+1( 4/!^)-?BH98!$EL@:[RN\J#8JG3F#Y3BO[
MP[G,BD_E^)H8C<1[U@^SK%\K[+NO]N[S"VD7\1=PW@Y@>K27'[(G;58B[ 1+
M=.@&->@MH"VUO;Y<]E.26%&9UUM9!^[DV[+5M>N7A\X^][%P$G8:.OC&XVW8
MI<PDW3+S? I]&NK8D\TWY50KG9;>==5F2F']G)8.3_XY.J$REZ&(*3'O;W-I
M'B=M\).G\9(N8^\G2\*^>L^5Z>QJ1QGU-"O0%]_DI"[H4V!J6GV]P4WZ@QEE
M[0O/R+M'>?QZ9LFW2?F1</2Q;?!,\J:<SLWO+O ]G=5N7OPZ>"Q;]F2 [@75
M=!W]-H43<7MC+E[F;G[4#[4<&M-C"#)=6^5+;2A-LCK8D.J)%(>$R-#K4SFN
M^H7/; C6%QISO.KGW-=-AT?7XEQ#Y@.)$UUJVSJ<G;7Z?'A)O3/IVX]M7=I4
MKN.R?9V[*0TA7J8AN]'8[GX:EAR9?ZZMTZ*GW:NP2U_9.=^!;/2AIBOSC.J9
MQ_X-[LHO$^::K1A?7R8QVRV1*6@'0J_WH'=-9(]!93(OV#RXOD#?H-:\L^7>
M-O%(!_NN%>=W3NJ&4"2/;VE#U_*]Z_3-)SV)1T&Q''PK?B,K'A+"22R>!\L&
M+.6Q,'?.+Y#%5A='9*3N,3I?$COUK#!H?YG)Y3I!:^M+.6R$ZJJW-"T'ULM2
MMV?@R*#P"VCS6P7<3>V(+3NKICX=3K+9T7=,7%TI')703Y06UFUV ;D'" $%
M/4S^0132S^>3QX3*!I7[T\IE%S8)$I%?=-P9=TVF)))NE9^IW:^T?CB^\>&+
MJV]?#8.FPX\')>LV-+3$5">H.)J$A^6V*I7VFG2FYL:B=\K4O4B5TI_]XZ94
MK\DYE:CHDJ[F9?&9% UR79RP3#$].--ML*M4;=!Q)W =L)?:&9XTTKQCW9"J
M7P#R1*TE:#>(YL,)UFYX!6[]**6<D<HX'*?R^>Z<1>/D,]W5#X\F"FA?WU'2
M<$G5!'L4S,L!U1<+606E.E1-Q5IS3. \6@!7/N[K;%=S[DIAWIVO\>)/_U#?
MA-@P*;"LVD \TJ:!$BZ@"I*VF(/INKK/Y0J]53 !FYSJ,%R;E$HN'&R*W;+O
MZ-&Z8WM1+DFFQM6279'2P^<,G;3QD6DQ"4Z%*\*:9VZFA;JGR=E\:(M9\)KH
MGQXC:A9H5B_6Y])Y"94&P3N8WFW)W=3:QG&C">SU_.V..T8_T,*Y2;LVV\K(
M>?&S1F+YO06E1\SA+!B>+$9;O,/8CU,9<"%1RU2LZ%Y)U"D=X]#\LE/JH_FR
M<O9['UPO;]^I=-8F7OBFD$NE6F&7NW2-M%"R0C R9O[Q5*ORA]YA2Y$>KYX"
MVX5F&P'J<IQI%<O<+T.]/'>:,1W]"<9K"TBE_X?8?D%LY7 ^#+Q'&HIG*L($
M@0.64JX225H_7*E0 =#<^)G1Z&!@<4\'>OZL\<)3F.>+60EV85?.1L8.8I?%
M#VD]XKP8WL00AM4' ;7?[LOS)\'-A)-==&<7,)E$!L9L'O@=P\+$JQ).Z$,+
MG@2&A#=YQ>P:]D@MG)+/4DD5+<\HV&5)&FE09](9;G)3_?SS63*3[R9DV#U(
M6%EI ^9'G+'!"PRX\K5/V8C'GN (5)Y/8!WIPU#*\,N<O0&=Z(E)TOP35# 8
M _.5<6!A&KURD:/[W89L^=T5B4A'. &X PT+?C)P6JN#@\QQXNA&$H$,2D@P
M"9BJ%H:0,S!_ +J=26OA10\YGV"B&#?1#O#P:'NR$; E%3[[YU+EW'5Y1B>:
M+O\!QL'0%%IG&?5Q#]S&[I#9APS?T"EQBT2S_B/;<Z-.U2@0SNN<L?F;TVKS
M]3]RWE>]?R7$D&9<3<N$)%-2>KF;102&)LLE@9Z373!3*G>$PG[SD(6I(BQ-
M&H#7E@E/< 1H!&X(#TG4YZLWP(5?U\^T3K3J=-70=7T.^E;=.M2IH9_SI4^C
MJHW<?/K1!4G(P<9'].3%]VNB] X$Z&RP*F"(XC^5J[/BF?I9.,8)FE82%=AB
M-19XADX,\7P2V.O(ITA:R> 6VV"]C%TC-1"P*Q-?'1E[0%57 UW?MFCII3_F
ME8]I6RP/&0)W4=+"PFK\]GC[JWAU-<PX._LZ.N!;T7DJU9$APMO?@9&THD'9
M\J(K#G^,%OM_#/5-;W+.L&CP?ZF+DWAT[MIL8H-_R9[W,L9O\F3K\<TDA(8-
MXRSS<AM^!TY!P$1O3(^,37L3(R-[WB664B$R;+QFX-&[PASWJO(H5E$Y%W,;
MIW@L*X-D"_"/FUO?V@AZ:OC2!HW=)UYN2I1,?9W0;P@5K$;'JKA<7TYWGTV'
M^RS U$\?C*; [+2OBH!40MY3&XZXDV79KY7]O&>\7=ON5E65G\!SDPW[!#%K
M[]2UCEGQ;F[9J26<?2]-?/RX_*")F^-&$P=IK;')=O,%S>(>+^$C"S*:I]/.
MN6.YBJ/<'<>G)_+&$VYY:+FWY2]U%N@Y'U#/Q.T>I^PWRQG9KBU@RW6SY$:8
M8E3];06G]@543U-5 KE:?H>?-JA"#T/QJ 2*!+CR.+2-NG\NMM [4"$WI9<G
M>.]D3EAMS05)SVO"BI&2Q!3\*DL<II:4VUV+#4%O5/+]RE_;BKNPQZY6K3 =
M7^3FM%LSJ4-6,^FM*97!/R,L\+K?[:%VWBUDV<0W8R<*9>/CH;9O8;>DS1K$
MA_V]^N+L,MM=I>733I4.GW-0:1(O*NNPT+707RJ?T,Z!G&D6 S,!3']G;RH0
M1A;(9R-6X]P_>A3N3NN/UYQ?PLAL\CEO<52EH>#4B+OQ>07KX4_*,(98O-Z-
MMB7RCR6<A&3:_712<"$G0TQI1:'Y_F2[CDD;&;ZC62JG!C*E3WW)V%.Y9E9K
M%0T=6BX&QO95)@L\,#?3>S][Z:Q(47XHQJ-HQ[OEJZ';]=23>8TDTKP(!<BZ
M+?S4<T64EK7@_G$SIOP :K,%Z%N]=+/FFN_P@V1=H@!2:L1 -.(/GXN',H9U
MTR3"S9Y>M,,I+:?:V!-SVPNFR=ZV1.LLU2SIIA?#FW25FZ1+BCJ5?<WD&L=Z
MI[[,;9Q>0-\65FA%V_DB>U4L@BWTI3%T=?L5#<4^7I7$O0H-:H<T4IZ*']U;
M2'GZG+<*TT;: 8DS3X,P?UW3]6F!!"><;9XMV_M[F2[E!84EW04.1+'@M:W9
M E<Q,4]>K;/==ZQ"YMP19=PX&*8L^<HK_^7CDMX6UQ)@[-3&H(T=$VIQI9=[
MIWRS(39B@MA\T5#[%O?_>5-86#@C5-9@9\]" FS$9^_S\+-#&#+AAXT> VA0
M-1S.9=5HQM9QU(KX@96/,*Z/(FZ9D&>)ZS2Y$9G1NP@<"5]#M#2<_Z$GZ*35
M85,DVYD@-: >'5F.!#4S<;<=3,I%Z5MR"&Y W15=T8UG BO=M_((;]HF/8H,
M%][$2O3;2?'!"_H9LA(]#;@<;_G0[^[>TPX&&^2SRKNJ^'-5RMVWNT>]O[9I
MV$?WW>-G!R8%/]3:/G[]]LFG8?=H3&YAN*6G(T.3.%),2@UJ<J3>:"-^2.69
M\O:W2K!/*K+HHWDMBX<M$'H8E) [!80@] [\$7!$Q]\1O>JS ^D*;: 8M[_T
M;5GQ+)]9_W[1;2=7R;S)552O*^G8&;UX![PRX"](T:EVC4A>UTK6CJR/58OK
M*U5U2<9E3<ODE ;'?AT6-]A_ON+5^X^-8WO[*S8[L9[K3%A5?61^*6K[\N7I
M8C\;L;6HH-AJ18!UO*BSK*PSN]FEM/1+7"^9+[9LI;<^VM#JJPU#Y3-3@47(
MGXDD\S+W94_P6XF&YF@<HO2M?Q'6M8GW*J%W]_W1M"B)&TT\DH9#&UN^[;^-
MJI6SB?"-EPCKV8=Q;]JL'5:W@9'J)L&5+DJXX'1)2RY6JJEG/*67I)?=-G_+
M:](&NPFS.75*R1U39*&9N,!@W$\I+!<&^4W!1]0)@_6CN2=V?G'U#6]*EUZ;
M5.IHG4 U04R%J78.70L,,KIMP#N.+O2N(@:2-L,4W)S,Y'G=L;_=3Y_63S8N
M?MLQ(J\\7%E6>ON+PM"]\!?K^R\P,YY:S]8Y7I-LKSVQ=:99>D5:?&$AK^CY
M15J,XY5T2XO8PPO>#@YCGH!1+6PS$T>.EY-A+X!!4L/X!'KQW QI/K>N?"^Q
MB(T8N V#E%O%+:SHDAF6S!OB4RH;L2SNAAVP^W2#R'R,P])3O\_.# ^NG%]V
MA3;!J5]R@M["\G= K]PL)%;?8KWGW/(--*IQY!JQY@;0TZE,6C_)CP/0Q@D+
MBS"X0E;[G8%I_@)Z90G%.L!1'1[C'GFN[8],P]>AD$Q-BO/QID%TO9[K%O U
M>.ULUY7VH=9IL;RV*V5OB[8)]GSB^])Z[L4+0U*LZ)K"BVD^4")#$6RJ(13P
MCDQF4V3-JY9,"NGZT_>+4]]?R[_B))HIVWYX@VG R=GD#;U;5VE@"'K*%9TC
M;K&/] O;SS2(]SJ;92J_6O@\DQ%[S4%52L=,*4I?Q:M7]\5T<J3.V+L1'DPZ
M&+@(T#J7JF:V^9F#ZG1EIEXZ3N=\00%=2:58Q&'N:)Q<:Z7GQGCKG1;Y]XQD
MKCTRB_:X?/@8#3-@4 T(V8=321Q=&+D8&D.ON-Q)4UPO>_>(X=NRF./Q0B=<
M%(4VE*V*>;\V=*-0YE31DRO&$A>F&WIRS(Y8=1?)OB/:)O<YO=G$%>IY4:8
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M2IM#F2+"[$LS#"[8SB9(L[/RVO&*7(YPJE,*P+C2OG>* *TTP4_SZKWVE6W
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M<*Q?M*RS"U,U"2FJMCHAGW?-34U/5/.+F!+8@HIC[_]#72 LM\%5B/A>1X5
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MP..9710UIY^H_K)NG O^G<-TOS:IGKET?%/B0BIRN/V[(7=;WWE+ NU5"#C
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M:XN 3'RJ:LCKPE"]X/;_8GG_=S3-W^UD?V9>F#1J=@3% 96+N?S,0$8C;G-
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M0LI\"W07CLO3/1$T/=T6:W6HL)$7.VSI>C>AB'4H>-D14!_I0J>7-. I#F\
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M)+IJ=0G<-AT2@:?\WUSCW/_ -: E8$4S>\9U1& 3U;'',0U?C^E+I.EVARV
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M1RK5]GXZ\'1/8%EPIM2SL@,ZSVUNH>Z[H';RE?E#9" ,MKK,6J&1DBJ7^08
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M5/FUC$4ATODCD-^O/D*V0\K2(0,C& DJ06*%TI_>;D'E&79?9$GT7%CY^Z
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MUT)<IP/NJS*>"./=VX3(X99+OY.0 OR6 1DNO"QN,,N?+[K"PO?D"+[,/LZ
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M?,7L#C;G588N-7D3XM@B977+Y#X0\W+^V#=#.8$0:#(]D4)?FUYG;/0-Q<.
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M>+455_Y_F!;Q_^_;YLS_!5!+ P04    "  0@_14/F/TSCEX  !HI@  %0
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M<S<Z+',PZO+'7-<N^Z2'QHA%4[?!Z\ZQ.SL.-!.A\><1YL0K$+XM;&J!(>U
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M3HWHPU%_]9FA4Q,H3=@O%H7KF1WTFG<-7W0WO)3S[=)</%(?Q C2?BQ%=7.
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M;EIHEZ_)53Y;3M3?D MJB#FIJ"3::I(->" KDK^D#SDW=NWP47#KA-78=H^
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MUBOV 5NBA)B*@='O%RVCN<XA,69D_->^A:]FON<>#0>)QG'7T:JU6B;&Q1I
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MA/D1TQ/9AR=\?GF-:4RV:6MB27DL,T+/LUMG4S6^/CTV;]!?>K+X] !"L6]
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MC*UWTU2?OYS@^=T^R^MGA3,LQ>R^(<5!70FCYU=?!*7*T\5>(M'_,2OD5G"
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MW\R*UMK2GCDX%'"AXX/F4?JL9\?C#_IUM18;IPKVG_+HG"L>TK/JRN[XKF;
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M11>[9O40/+0^C2]^(6/!UYA_W_LG]^8V8" -]D,@JH.E1U*Z$Y)I9G4ZKY%
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M#NPG4B.CT"KO7T]DR+*3M>/5J?D-U $A!DNJ^1W!-O;ZU_A]7Z+&778'%+B
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MBC@-#=S'S:'KUVXRU"88P5"'Z'APO04-/MI>H\E4 98864!O,(W4>B3 H_8
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M.ZXZ,AX#_\V?;?@_\"?$Z?]_ %!+ P04    "  0@_14&CC:F8=R  #CH
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MN[=28^-#Z5%)FZXS_$S9#-+(" [<,TP"_8)V@\F6+%"\@CHCH56-K0X#QRA
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MA71"G?0Z@:Q#*FF#3/<Z42 /0PC)3.6Q'92$WP/)[@SWF>0IO$%M?62RL[V
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M@;YRE?)FC397F/U5Q.,._[/9&QQL?O&)LK3A2'-$N%"6>F;0 I!.FR3VT<.
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MMA+T;*8("]!.S'XVT\+/<U,F>X?B]H3+2Z,*!JTMSN<ZUSV3SB@HG+_&[UK
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M0TFN@T<'%VJJ:VN;:/KH8I?")Y]OQ>BHR1S:S((]_HI_.*'[JT-KVI$I$%R
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MH>Y2JX9J(Q0L]J#9WZ-*4)OTO)T]#;.0UBC+Z\'IV!K4Z7*UW>W-ME^]U"%
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M-]VI6CIJ"A"Y,.?I+O^TX,3S\?Q7V.+*Y_N*N@T6-MW5?=-TZ=D$>H%C$%*
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MU)-]6GD555'*RI?/'GU6HWC_UH<A-/QA/;+\AC)MF:5!E-%F$/,IN%!SYF]
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MJBH4E)*_(87 2)F]<K%^PMTY]#I3[>)6BW?GC'>^U-NZ7,/[(-)@,0(*L/,
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MKDY;);4;C"Z>:#SA?#R;5L>Q"0"S(3&> 'W,4CUX4(RUYW/+."/$2O<V5"S
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M^^[]\,CHV/C$Y!210IW__.7KPK?%)?KW'S\W&)O@KZT__.(!>'G^U_*7?DE
M?FW[8PX$_O"+9UO$'SM(\/'OT=LN><)1P.NFU-[#=P2E3SYZ7MTAI*I_CB9S
MY=:0L*R: 46=_H=K?_/LGW,L]O_(LW]Q[/_UBPCLX.6!)H]7 H #;-:+Y/W
M?_'!NX '#ZRO=E$=0 W=E32J^/2V?G*%\M$AM%H0J=O-#2Q@&BT=\6V.GU*+
M,QI1Z[8UR7+2HYQ0J?X5:$CP1X+[Q_IB^A[\U 4UTN(V#+-/RXW?]L'UQ>A4
MW4G[X/+0KJ#PBC4?S^NQ6Y&7C^)UN$!<%O:+($P9NR)1B%U<=\ ?9;=RM+ =
MEPG>!%##$E?OD-!FQI*>"%WG]7>S?AGY#(6E!%<6S,VXQ<<;B$>8OXY0M-J=
M;J5%3RPXW"5=JF0<=%E\R"%^[LA(FP;:Y).YVC=&MBPC7V4H*$S318=Z0,MQ
M4/)]V5*D$T^,RD^59"(^"6/JP4*Q8^IQ,?"=5]@EK0@Z#RN$'G&")MX]J]L3
MTF%8W!!V4XWW7&W\D<?^P],S=S.O-$P)Q0TX6^_Q\,.,JC*>T =9LJJ4P94)
M\CIQH;=-%@RCXF-S.2W4-+%O<*\[!8&FJ^9\1B'L)_W2-6;?%)S]E53][^Z3
MI#SF7<O]P042876Z"69':>=[X?+F2OY2J%FT0O/CB&;K.Y'!Z?T15SYF.W7:
M)3PP1,T9._??<(S9T7Z@D0R/.X\R)5^%\6[@4_+UZ0?23N$<\GH5OM:45UW2
MNM/W^X334%=#F'/G^^0*(\VKKV8P$EP@UIJE,V(.XP(=^SFZEQ;S#]+5O\.3
M,?LFB]H:J8HID_-V08%.J5<=]?5^7-KQ;H]Z(3(GR>R3P#07J-%=Y?5G.G/Z
MX6)<P'\:)O+NQ0FZ0,=M9*+7T-<6J3?IL]-J5"F5BV(7S&<[K&_^+OSS-.LI
M.]^0"Z3!JO$L"6?&-79]*"F-HTX8K6,Z)#C=;KSG286OV.%W+#F/*_@R;DVM
M$-.+ZF=N19?"S&:L;;'[?ZD.A<*)SHP2=A7V.HPHU65$$L>8>("J%/C]>9I#
M7-UZ+$>=UIO&</]6\;RI>11?.&9HZI[RNC J\8/>XRC#I.WG;'Q5>'^&MT;-
M#_8-IGF*@44%:#7V4^RU/"2,=.E;M@(^L5[)N3?PA<NWAT+G-"]$FO??&.Z_
MT;EP9>\-;34M:^>C7(#VV[H$9XJSA_TD=)* 3$M8?8ZV'C&TFQ9Y_1EG[SM^
M_<73>_D%:K>#NAGCWP=X[O?ON"7CZF3__&RI\OQQ&"]+ 0IZ,V:<!,/L1GN!
MV30\1ZBG>"F+"_!A]@3FB]+#<PD*5Y+7%AR'G31:C )UGE3W*T^=L(Y4U8X]
M),:S16"8L%]4<(% _)0S96'5H@1T\A 3AX'6?9X)UKDKEXZESW36).8>+]M=
M>CU86/]!)BV;)='".27.DA;A#*I2<9STJ0DIIM$R%U"&>R/!/;@5.O.6/P+&
MLHLJ^Y;E"<1S@<YXJM[S613R[-AU@]KBE&-Y3E;UK:Z8,1Q\5= =E;(S1GS\
MO2:9E$)$KNK3O3DBMO"52B_F512S"RNRQ@6NT:D#=B=HG[.,&G>2E&Y6I)NZ
MWVWXL>=D68W!?4_D[&-7&34?/ \[&0.5>H<%(8 P.>@&CE :V,6M%M3&,<-*
M38IN<AU2$K576]\^P:XYOW,TP"DB-[,@P%G2/F P2GVL+/OPD4:7A];=O!N=
MR:QE=A'V.FF:PCK/W,=YC]D'ZE-QPJAE:E]"6'3(O'4*;<3I4YY3XJ)LUM=H
MXS,MH[KGWAOD4LFF[S/JZ--5JD&?7VVL3^+/L5OK8$1\3SX?F$<+I!JFM?</
M"DPOF4N,8[10V5V-6Q]3JXK:D^?M7 W>G%Z+:K'U\FFRK;)%S1WUUJWKW<^[
M'*#YE@L$(R4",++LG+!5A!W[166;C$1$B578O'_=8(-]X/7-3VHTMZYW4?V)
M.:N5G>4$G)F[Q'0 3AE*B=OHVW0ND$P(Q!,U&3X3^^@I*&_*#Y3=1=IU<W@S
MT[H\$%F^N"FNY:#Y3FU (NO#AZ0;O2C.I[<=VRK\>#9696A9>'^F#=H1.M48
MV,\(&(52!+%[BG6P%A0H1-4XB/AM.HU+]I1>"M@<3^*3<_ID8W#V>L-A_6#]
MVH.Z3[^LI[:N=^$:-5:MJ##>;_ :+9C<^FJK;2EF:@N:I')\<OHD\:FMV;'B
MCI RK7F]:!SSM/M^:JWK?4NDKE$G-<:\B^Z[^I@CQ7YCIL@4]V0IC\EQI'3Y
MECA[7]%_;W[:5.\S,C>D?D?EY'#MM;5#;B=V[C*U>!#8QG[&,44?93_!"*!J
M&0E@2]D['PJ._YN<25OCS1W[;&7G!/M?6>YN:3 J2VO](' ;Q#J"<"HNCD1#
MP&.;KY)VH^VH.#$$>CO]\99.&G76"EGU,^I.1%'E.[MB1[.''_A;#IX>K)[/
M]A+ND%N%$]/:<?SF!SB#YH= #Z:-Q8[\[72C!*,,JD^^=2JF_Y99W(^2 ?G^
M6+5=^V],[7H+T'X1D.O$J$XW>&QK-)3G0@L5B^92]/44ENGS16)^&GU;U[F6
MH>W5I<0I]YFEAK)'*:'G0^^U#:C/*0J?XGO;-LT\R?GDA*W]F$E)==JDZ#YH
MO63F.!]DVN4O$,,R"3M@T-<:[HA%/9]X6YT2[(-[>B?[B]H=1![FT!B6_ Q'
M.YXF^FV 'M+K1*K+7HDH6M[RS \3EVA_.2^>X+0>N</IG/Y\/R%6*!=(4-RL
M"(B=.CDQ#J<YBR?!=G$D42+DS?MM.]'>$V8Z2+@?GO>;&SO^<=:<4VT)8MGI
MDP/2U%;D?=G91\R7JF^OB3;M!L0KON$'N "HI=$#2X6]PO>N\V"&, +@)GX&
M94.]WCC'^P:,+&>=R',8J4O;23I.FLK?:[-#_<%'H1/N=4YZ/;N3]MHT7683
MF'HL2;I NVX<$=ZUKH#VHSMT:]\F?M2K KMZFE/L0U[.\BM??6'V*_R;N^F5
M^T#Y_:SK+0 *4\X%^"T:P)O0+RO:.DM*=;ZQ4Q$N%J!L2@OK)= V>TVP*?=6
M&_!?S I6TML9K][4?=%><U=\:IMZT37E?K0 _<=\1!<7F,*3LU/@?K#DYE?5
MM(4X,WA81:"Q6?#.$U*GWL<\>CT=/.99\>'9+2M,,+8C$'X5K\09X@)U\-2V
M@RP>YP3J>CM4/1P),(%6LS5W;$3)XK>)^D6?^K-';YIMLY18$%=).-H3AI E
M!#ILPW8@N(!/&M\B5L15C>:ST&F*2R;(7D]WT M2JWM U=:U>/)3BSA0V?U!
ML$LG;F^^NCRP1> (O890,H_!!=CI:#WFI0""@ K-.F=>,U*G3A3&D42N:N)J
MM88MVFYI/S^5<]\G]F7&%Z_TDH/'J 0E GD6)X/^C?T*?NTIC($:;=,#2SKR
M!<$#M):N!H:)<^R&A%=$Q5)S+6*N[?G-T#(?/0L%JQUG#TCH)WTHWR?CO(2+
M@]<EK$K1D1RA-\SC:9*LJZ/7.2HL63J4EWN0= VKD>O>36.%0SN*)\X>LN7+
M>J?U*-+V<*&79;ENENJODS'1':Z:\X,"\ <D2C(J>1*,/:8>9FOP\%>.%M$I
MR5>U1E[FL=1HN?=S_$=Q 98S^V7;-@@XCF!]!J?7>PEU7""E]2*5)+>$%;L,
MWBE>RK[9EEWFM_4S*SS=/<4CS[LI25?UB<<>*5NS,QZSN_L\)CH<[FSII'(!
M 1[T-;H2_@'KVG=;FD5G\TS#A+E.2^[L%]R%<54CSOG7%^NM4L^$+_'Y]>1<
MD+URW#R5_0A[O81=9A9!CVJ/P K4.PC,LM3I6Z#G=R7W\XU-61O$3N*&;\]K
MU#R_SD-^2=L1M;CO:<'XCXC)'V2-;MU4>,/@:MMU+N 'EP5-3S> [WR5X\3C
M\.G#+O77:.,YS0S*>[W7+B,K5-,(=H>Y_R/U]Y'HQGL$\G-875_WX)0&(Y)=
M;WZ490;>JT)KT04Z U^::RW!>-?44IQHFTFRU",%XVM:JTHZ^T8:W#T;L\5S
MI'U^[Y>^XPWP;HBUXAF3[.=F[DP-3+^G,;L8K4GKG>A9),-$/<$XET]K9L=#
M)[(=:AO3J93GV2L_MC^V492Q%E;<-2.FCV0<I>/C.7LQ[V%B9CX4W=1YJL>]
M]=B?\W+=2G<4N[4:OJ4C3((0.K8>KK/"+VVTBB[$"DA!]7:9"SQVY0P3&,?-
M?+A L>E[8![#@R%R@4;?556:5 =4(+Y=:9.*':1)\R.TRK1$@R-(SM$Z9[A/
M2Z,MU76G7\\Y^P?/4KMY\Z,F")Q!@DP8/!6W_2<LZ387B%DWTRQ;DJW(78C7
M79/UKXL^*:\@TF*4";BBRQ._I'UPK._<[KG+N0/QRJ9K$#SXL05B026@($82
M,X03(--8!&$T3#LKQ9]&N% _@:WAK\RSO=Z<MYSN7CE4+P[#,:R<0C)=;LF;
MB@MH]*VGP6DNXJDX'D/$M$;O*JV\"R'*.EKA!H8<'PVZ?K5NM*IJ8[]]J['3
MPSZM&[WC-;^273ZL[[93JT@<:A*8VZ :PQK.$[$=)PVXP.3!'V3&RV!B6B?$
MDN2GP.'Y\XU,PP_AC>/A:4AI0;=+:ZU\K?F>.U#"E#CQ-',%S@RN'M:#%$-K
MLE-UVG01_G,:=+E5B_G!>&5-L)P_M6Q)ZEN;'&?XM>[.[ZV)R+75U:#*#YUF
M!_1/)59=*+$AX^\I'P0A9BD@@HJR: 7'J'!9%&:!<6:BZJ>2:8]S>514035=
M['%&=Z.ZY4CG%]70'[DV3H=CIL/+8C )CH@,4JW#Z@%H*O>P6[!7GEHP!D$D
MC0O,#Z-/TC-[JTO16MF=T&3$J= P23OD,CJ\BP>\HLM[M#];MK\,,QR%^<W]
MB-2ZHVKXTS<1<Q0SBE.&^Z_'X*JSNW,,87>-.:K@@5*T!=CG17GZV_;6+,:X
MATD_4WB8L^^QE>2LYSNMC..<P#X^KZO'/[KP3G%V<*8<Z$C& %C+A'FBE<<,
M1'#WFO?%O82HT9+"T]:7%5TO\X84>Z35686(:DF1IA#"UU3!A>ER2/1PA.;)
MXKM8>A (O^=,>(K0$3VK[KTWW$ IRK3?[?@VNBW6_\IBA8F;@Y9??I3UJHKK
M;GD%?65&./_TSVTQPOM?_+L,,SL&BQUOQ@_%4XJ=7Z\[A:4N=$-I@,)VFLQW
MHT_XD_O+=ZF/IA^@-B4?57]=]_21DXMCM<3)F7@M,<U*J)_XP@7LF";PE0[Z
M>==1SAY4\'(7\MG2X+QZ?>2&J4#"6[\JT8J=UE/W,[4D7!;4%G)_"N_G;4=#
MU^.C@T@*4@94[/8\"A+H GT,K,AG?XS"-^4CX]K!6JQC\(>,=[?:K"KT/6=L
MD*H]NS>'+[W;%>YS>>5C:*LC4P(5TH-HR(ICWARD$_J<VE1I"_'!9L=*_(S2
MBKC 58B77W+8L2F[EG9EI#%'O?4,XJ.8D9>\@,SJX[,\B",L8RCL?NA#()Q,
M2,*)F\NCD6!.X3>"E*&]YY:'GN&T[2K+;*MP_=C68K6#'[U7_=%4K<E'^AI2
M.R,D>,LD&?B%Z('1;+E O+(6.Z%5$W*'36 78 Y8D1$"#8\-7JZNU5T<55 Z
M'.C_$U1[LGC/525K6.[<3M.=EO?G@;!-PBN'^%"H2RA,]&'OP6$8%5"DUU-[
M9*42'5D%NM;%*^\//,4JC\IK<9\UH0X%GX//_J)9B#SF$3I8)M Z<0^Z,+\"
M^\D+]JL)AG 4%Y#%=@Y':S(OHH]Q 4&Q\B]/C3_HL0FK"%\F?*HQ-C\BIS:B
M_RE)&[B] -$&/G^<&%K5E[RJ<784N;?.23>J'/%F;.Q#U9?/6:Z7TM?6/O0]
MD^^\=U;:+]!(SJTX(Z1X<MG9)'2D?:@'>_61P?@':[Y$=9O[KY:,"W1L5!X<
M')#F^5ZR,@N=&$<37ZDFIR5S>$%OY@661_K$O$:BH1*V5VII(E>IN\N9(-R8
M33-FG)6P.ZAR4M"O_<O90SODNK$TV[1[^?O8<2S(?+Z5-O8+S@$;LKBHDI[!
MKV?-0]F.@=$F5.+7WMFO)E[G'@[XB\1"<;1HJ9*.OF@%H&P2L%Y*JA;LZCWL
MQC!QHC%5IY+ZF78091ZE;<&4"66FJB-%R4G4./O4N,@5Q <;YX7@</K9;SB:
M V$[^AA=-VD#'H-3XNQE&0^A ZD'-DC2(+Q3;BN"$?2UX$9(V$VY::TJ'2V%
MD!^VC*//^-\]"G^MZ\GTA-%M.,('F ?0N^B9$W<AU.AS'UDU6'52TG6CWZ Y
ME>LFA.8MNLJ:!KZY8GJMNB$C-+%"+<?R^E*-]+6SQPW;3#&], &,V6*^D,GO
MQ(F$C?7X;.HFA72_U?!EI%MCPL)WT98G/CD^MNFG;!^X!$NZ%",V$D&^4(20
MN<@<RZ#ES829(SVCAV,ZCBPXY>Y*1S,":,=?[]T5M*)=&>3%]WNMVEY;083>
MC,TNSX2^.7.:<^<@7P!)LDT-5=QG0>/$E=AC*Y85GG9V(7V#).72796:+E[D
M2X_63 05F0BT&/LYVB::3.!9:A[(;RE9#-\J;!9(9FF6^F5_]Q^IU3(><B=U
M[$B?;E'5S4V^>$DZNDKX$R_VNOB4+@6_6DFS7B8C>I00'B-:G\>N&]J;NM/:
M7F@;*NF>K6E^L#2^1G2RN9A^](J3XJ/1[\*Y7S#"V [S-B66&+LHC$"LM0#[
MZ:I.=)MDEFG)8O[A- ^ZVJVIY1%7H6'B%G47^7AM882^=76G=\/9]D3>@Z\V
MRWQZNF4?'AL;791VW!.I]BBV;+^\6D8[$/%,7'*8X#4@8,.NV2!-8T;F)]+2
MDLU.4 31>A&%IXBV(WM']C3E4N=VS7,&?YQ(#DSRN/3^8X17_P/-1%HC2]*!
M_%L<!2X/VGF"C72I;I%YW>0:]&D/FPNC=:"N@:ZL?F_7Q9&2FIH[JY\1!RY8
MVW6]:C:X7F-2#S4>!,T%!FHT]A'2G&"U$)EX,*B;;/CV*U:XJH3R]'1G?W>*
MX(?*8L^9Z3XD1GK;B7@;,<)AI&?@5-L1=#3HRC0!?YONA<F@3V@7*L27;\\N
MF')9')F;6\K^(;FGKJZ^T2;WJR^Q6\VO^Z#I[P?U 7'93W!R%D&DDG =+L:9
MG3.'1*86V$>%Q]<=^!EXS,Z=KEY46=$@:7*D(<K>:'B<1Z&Y-LCRQ)[,#W/(
M_D8BUL_ACB<ONY@CC,HF"_3PO<&*@8UVT:9N:;^U!D86-J"1EID8OW>[@R\=
M^GA"@$^C?3V-"XA &DO$ ZRE>!(,1V]?JS3/K'1!+(Y,(?R=::L_@G16@R7V
M->18J%Y_)/TX-.R]234][3Z!YH(%-1)6N "]E"4(UM-7%DTJ3+K=K O*&^,W
MY$/M]1T?'K SK70R#:]IR-MAK);!"V/531T7'X.3G\SQT0D,>'R;$68$L<M\
M+TKUY)C6AB(L0=F0KOWT8X9A3V&Y8;G'.YG?(YIC^P[;[+=KR7F4;Z"#3UXA
M7,=/-G82&AH3T'H4A"+:G8Z+O\XZ,*]DW*-P&W72P]PH[]RKI\'::IE5*VM"
M+E^LHE/J7>X?\NJY+=!#N@_;T<:+UA_CZ+$0],S\.,I3X9%5A>)*5%]_D@C_
MV6VQ'U=62A/O/)T=NZ!_2* ?>Q4)'G!>"6'>0)5TFP-L7-N^V1E47F=UG]$;
MBH,$*H +6(UI!WU6L;G)L#\IZ./GKIDD<SIU:=?+R_MY[X/+?R H&,FT0Y7T
MM&F"LTP'M-,$J8<DJMLJ="SU<[/X5.C 7CHU"E]M:?"P85.R3B^K2?[AKYLL
M4DN:[VO,1QQ_,-PW[:X)O&,3)%"Y@.+TM_!JXF0@YFAS'<Z1:7:SS$8ZP]V]
M?1^QG%-CY;\KW75RXB8$H&N/F##W15C]6A'36YPH1Q7MQ9>! >+B,Z!;I %^
MQ:O$(L3PPR$MN\L:_.I-3Y+,U@\E['D: ]Q ;.<"Y'12K=P*B:9/+6F'3_6Y
MT.%W0DDI'+71#:QTP&V9G@S/Z91)HG%-752*ZSD1OZ&<*_;WA]:NP$)DX0Y#
MQV%*F ]<@&8%%0VA>B&A;E:5<8-=BCD$7ML\0R."86']T3:6N4O+I^Q24IY<
M7Y,-.D#&O<M="D^.2)RQK#'P/]@;[OS*A=.%$VS59JHN(:JS.]G(;F5)VGAU
M\9)L;G%EX5S7S;+9^E^9^"J?IK;X^8&FIPM9-CEC>2'IPF1O+*.87<[AY_3"
M!/$8$\R0IW;3D)E^2;^TLS-CZ]C8HLVC\2,==GZ%/CM6DIIBGC7'6@<.E?)^
M65? =FB9*Z$6&!8T@97S+SG#,.G+M+2NJ%19A/@,\9)?.6:YT+!EL7I T_^>
MQ^5 ER=>,K_'?36( \(5<"ORM!_GV15U:=/Z'%E\6A#:PX>\#!<-?+5(G#$:
M-]]75_<Z?0D2]LG\,_1!@S1FAO"A$,6"WM-.L%57J.E?8=_%7B$HP1*P=1J]
M(@/&C@WQ0AL-PRR-ETM96]+Z]!VY=QE.WWNNJ)%+<S*37UTV8HVMNQFGFL&H
MNMN)+,M/Z/,EGGYRQ"L!1K=GZZG'"AG(79DZLF?##:P/[SYB>OKW!6D>*HF7
M"UQ.U2<+W#<_ /[H@-=-=+^L1Z3D?AHWLPU[B?5ZQX#P0[1YAEBVF%S]*G;N
M2.P1%./^8^T?SJI,0VS' 32,J89R[\*(@W),#_35X166)B72[%BQVB91ICWH
M6-77%I<OMJ%9MA[[\D^FU^3LU#L[[1IWV[G#8;J%<8W]#(WP)J?%<PZ/>FZZ
M#ZN/M6KNPU/RV":D[MS0,RGJ7W..S>CUE9XL/O4.)=_[3C6#?:FZ17?5GQF.
M&8!5ZV04!\!@K3[8P+#*G(^I+_R4=[>-&VJ.WCV0[[*JY96%/*BRV';NA<'<
MG2=R9X^;D*;6R1I=XE,19'P"W'<]3H%GQ$R/XF%XO2[/^&E1V'$[_99J]=G9
MG*DTIRM1X\ZK/DRC;Z1Z4KNX%.8CI&'2J-@=WSP/#0<;X'?.HDZ['UE;J]#9
MB_)M((4%F;RP5:RIW9O004DXVL@TX(P0>+#7=>-RG?O6I_!4CX04,_5*37:"
MTRLQ@HF><_*ISQ?3Y2_>$=V=7%52*O-R/NT^3HRS&QSIP(F;>5#Y&\;-50(C
M%!SN:5E>'XP,V8X+*WUO?C;\X+3KQYYID8<I3S\^BT'_H+5PA (KT3*@SS.T
M(HB TF4?N\ @313E;M4P;"!Z4-2A2ZLAW(FN=;:S8DOJJ'!RF8@DZG.&&[QF
MDR6YT ZK\>U)1<SK=I&(YZG%116!<SMK:8Q7:-OH0H_*&2."/TI'S:NX(NV6
M1LOK)G^[#*V:ZH<F3^M_KD+\KS'V#RR ;V.IDK61[1.X7>:J@8>7L#)K'/5%
M3Y71,&T3;;NNN8.O<[[BSKW*'>[=>8_H:F%QL%]$K<9ZZ''X^0*R ZA.ZL0+
M<Z;"<8U]R1PSUD4ZMKL%*0)/N#IFR 4DIT\$F>=>LQV?JC1@NOO)&CSB39RW
MM+EV[='5:]J(,X['87"4#4=H@9QV+^+V7"8--C_8C4O@[*0K$T(JEKB ..M
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MQPSK!IN9$0MKW7O3Q7_ZB5W=_]WT_:.ZX[T?]BFEI6+)3W%U.H_(NFD$'G,
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M7(!=E?;'LP<;!["?N< ?;^[ILKW><8&%=8Z=[G?>H5+\42YP[X\MY[(Y#ER
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MA6ELKO>$LX5!AX,\0[V)]WMA\\E]U7[A(W>/K^>M_@F-3">=R"M.-V+#Q&/
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MN1G!WD)XN].7+:[>NO(='/FJ%X)]. &X0A BS(&C?E># 6KGYG(9VN!0L4=
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MMBY'GY%Z#CVL_[!"8M.7+3A2C1\.DF8/L(]3?5^CY!&L,J8?9IKO^E>^BLH
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M4Q[T57I[_O+UKPUE?_\]O?_5'\[H_P)02P,$%     @ $(/T5*<#XG7V;@
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M/#^'R.VH[C5XOVPGC/!E 183&@&?#UO=I=J>X?7T=E%[*'X^=?W@FQM'.5/
MC3\]*!A&LT&4=+>J@?,T.Z3]U&+WHH!6R[Y3J9^;A&;N#\E3B!&XZK-ZCQMV
M1.JT,]]*/?Y]E[[8C/%ZA_J(Y0Z$>F$>&$';=T \D07(S'X+J29,^Z%.-M5A
M+]%,[I9:B:6[N+0I$\J8-18^!].<IJ?NLAWHUA,:Q&4-4K]51/,0(D@2!7IP
MI:"OD- <Z!RFA]MT+S$/TA\\KFYS0X5;Z>VSAR;;QQ..Y$4!=V![6<!2VF*M
MY.8B69=8T@:=Z76D0*/O+R8S%<=_H<5\P\6[T]UFDZ<)AC5U$<E.E_F]1[)O
MVJ:,;-V$!$E [49.0V11@RR ;,$V&GSU:D+=O +U#N,UZCAX>^<"F0 &!P]$
M6IW-6=\X9Y.<_,Q_2R+@V!*V+V<])"DT<>YLC9Z/:D^(0Y4CLQ/+VZ)!4UB'
M56=U,.!=<B+DR>KB=8F<XHK"A<Z[I?/UOS-PE9YO6^-7AM[FK69:94_D!J7Q
M+7F@J<6,,B8WLP?"BT,9H4;<--Z.F.B6#(@Y.%!W3TVL63V9/-%NXUWHN7_S
MX=NH%TTQEGXCKSF_;$NCV]5-91&K5',RS^:5-\Q1B-@-,J8S(E4")C1'N.Y=
MAMHHU&]>JQY2\XESO>'G^,Q=_'GL5[U8($0:NRE%_G&%45Z'F=5E2N P 4A7
MSZ4-J(!?U1IASF#25+FN[EW:.KNP3^*>HPSK86CI?,>#9 IZSMM#2$[LH'^3
M\0!]$R\+24#7J?3P#QE>:HC?]ZMAE*[R9CUS5TR7LC_G =7^>_=-Q:77V1E)
M53<,Z!/;SH:I)A"BUEX"_>PGY)42-V])PDU?@_#Y>N*I0BK\8(:FQ,40/4N=
M0R>,SS]?%>,@+G*R@!NINDL\*:;'P!_MT+JIKC?UL.2<3Y,FUL%OT.Y]5+;_
M$&B:(Y2N)557Q2R<B#F!H*8\U?CAH$#31[<?0T)HB@B73I00*$ES1=X:W:2K
M+8>9G"I6W"&(MP6<JOS:[/C%^GZFM:MR_IFTFNP#VA=GG6+#'=KM9INIMQDO
MD#"/)4P\4V?<;<=E5&FB14T9MYS+,%KLRKE_(5GI:_:I.>W>UV>*S_4AI'KZ
M%-(9UZN;M4@^M!#4$*1:,[W8%P)I\43[!5=D?TQ]Y2UWJ'527VW\P;%\1Y*Z
M>R9<]?!:Z^57>@O1SR0OGC9:G-E>4ND4F@E=PB5 O;9CI3G&3+277?7]ZW(-
M\XJ"3]OH-E<KS<]GSV#L;T9,.I \:0;?%NL7VX1$41_9-0R&B-[_S>WX:* >
M[L \XKS+B:VM<DUYA%?#8G" T2MKF9I:^83VY823C30]YAB> ^VO%9OCT+L]
M@R.Z)B2;*%6H,1+LJP3Q1MH.2><^7TN3NA8M<"BILN2U^)L53 I6D'D('&O'
M"IFX$KD;)DT/^X5*V\6IG_4?#@O:BPU^W6]Z,41UUNEC]RS_X^2\CR^BD#_(
MS<Q]?A5(<=#S!5(&A+'AHLPHT,,((%PL&D;U!%0%[#K5&T+L*>H7.\IW14_R
M)97RBR ^ISM#:W;H(JMMD!JO[E38BE;G(N$*L;BHW&_A0"V96H6TCBQTK9@S
MP/L@-!7=B\LQ]U2:W[WUL4E7KZE^;)17_Y/$SO\:8_[T!= ]=(4E#7C;%/:@
MJ8*?SCI:?(NIM.9V>#Q8PTC#IG-!]5WV5^SEJIS1G@-Q!"=S<]4!?L4:RY&G
M(5<*ENQ I<4.'!]S)@3;V)O$-*%?HZ"[FN'\T(1;$_HL0&36+, TY[;UY$R%
M'LW%6T+O"6?BREFKV[>?W+JM ;MPZ30$BK!B[EM=PL2%AB]DD"$KPUW8!.8!
MBAP^J'R=!0C1CY4Z*F<&;A7JS-?794E<7O 9T$OYV.<5M*>L6>^FP4V_,K;'
MA=#UP)%24+?'GO"U>5E( FGLTQMCXKDL\]H#/_HR7RF>.,W_K"2&N."XDF*B
MVZTJ*@:O,_$>6!^_R/,16VM'%X4N;6_VT2Z *]3F3TPUNC7%\%&KPLQ,YXJ&
M57?^,:<;XVX3M\YY^ODAW./.6QU)5;@J;/GR[-UBM6]-1U_L2?HO(+Q)\(.6
M=*9@;IS>[X*D(!KGB7BG5SKR4+JR5EU-_.6V0[?V2JT]F6Q=!6>6[$21%T%C
M(C:>R0]FO$$8.DZU0,/<BQ"-5JEN&Y9O,R7.;<O;+^<;W%@Z=*M2QPB#91=9
MB],.Q-4$?( +9G:#^A),?^'7:I*\E)E+[F\WT7!7EZAU:D<KOV3#55FQ?$I2
M0.I I;UX2NKWP/XH=_H!1B/>!Y:$KBXA\5!BKR2W3;;J@/H4T5ZW0Z.KL9U3
M"1?&;WY2S)#/=/&(_%I@^X4^Z]6QM7)B-9&"I8MAJ>/8#DCU'[7DDF589VXS
MEA![I@HN(GMI.VI4*]#$A%!8Z]*3)O336_#6T>_&_4_J3O<,*LMB4M%+>=@Z
MS2=+6A@\ARF A),_/ES"87*8C3B8KU'E0Y,F? )</\(BX5+\=&&,5)K/M:)'
M#GR37Y>9UM37E6AS=MEXCSF%$AB#WM+@&R,Z=.:%:\T$#IKKSTUF[7J <= J
MK,6YLQXD^?DT'AVIG1,9E$3W2W51_D@S]I58,(MZ<KP5BC"G]M=\JF]>C(7P
M_QQ.E+:O7HI4CM31$O;)&G4E%)7,! 8&IM9WN!'"C.D[5I+"K:)^&G<-V)'2
M7B@5+73?+GY1E*GD!]UOXE4"#L#&]+:ED:? NR_7/5S(MQPV7S?:!"L-]I4I
ME35IM+GX7;Z"?-CA?RJ+Q,'.+_HIJR0'F@/2F;+:,XOEAW;:);'/'@:](@I]
MPHOZUZD2U)VIT,>^3SY0>R2P0TV*9RS'CR8,1A;!IEMYD8:,)A.IEPB7Y9)N
M2*H;UT0=3J 3#G\#=EX@DP;#\8DO&OE*Y1:<W!;ZG<Y@C"Q\V@54,A]G6J5P
MSFVLP$&-XB**ZB)U+QA-QK?#]MYJ)L.33$X%^5!4>@UP7 4=TH>VT'7U5\=B
M]_W:YQY=C!U(YCG<:GVY@FJ+@)"LR!!J*>.%J3@X3+T[8JH!7CE'[GVTJ:77
MO"UA77!AMR>CR+6L]VZ P%MWN E12NY$I=,GJZ=>\;?/W (H+ !4S=M.T+>;
M7ER"=>)XV9D688&;,M4['+<K6/8ZLF#(ULHLUZGVL61Z0>'"53Z7@GV""/UW
M- _7ZP@O)E\O36:C5<[TVE:KZ6%$A(OW6[_4H]^L7_LC(S^[-/,; &2IMU_*
M)I@G4)V+_,SCJ!YA5'=X8$GD,D/&:D2OS(YG0\+3L^E3Y?V2&%>=[Z?HQNWZ
M%2W/3@A5O5E.O4G7960P=1!9U-P1J!^$,-:+DIK4W^9&F&YW+G"/(&6+YEP<
M'>LWVG8S7W\E6@7=O:,10'1LG^4ZM]'J<>0.QT]9+T1GAYLL9>=!O=T>$&]C
M0U)Q'BNIFE OO,U_%ZX7<.A)6N$!*:EX,YY\ 41E @XUSH81)=6C<XVB:S')
M%,!WXG30@BX@O+^9W-.43O@M;T/NNJX_KC/7]UGXV2CO] /!>+@K6"#4U8Q-
M<)['MY>1)*:Z[_G4X!(J6ZRX:J;-0ZXF+MQ_4-;B.ZUT]<V-X[P?3_/TX\D7
MH0^<H20/VD7F1V@M.DKO+;J.*8Z\-MJJBBASK$_D)B^D%O?>R9SLSI*!7&S2
M;C]T4H;8T(04YG9D% 56FK"MA3N3\<Q$IO*6CS.T$YLH)S]:@'YG4%I6Y)C0
MOM02TIAU6OB#I-#&=:U-!DV.!;3[MHITF&B7,R<7 >?A+CEY6RNB4,K]Q03G
M,C#+09.2G)N10_Q5T3W\..:H6<*'.(6D$ROG5L[""EF [_!,J"LXM"*4@)9%
MB8$UO69@,KGD>E,KN9Y9=GM'PK A*[-GZN*8YA.IZ^9WA<\HFC<=>Q%S\="1
MU#:37&K8.VPGENQL1[!J)P@9N363"]I,Y2<]8,T2I1"':L&[;6$: 0'MI\[/
MEGB^@2Z50?B14D2A:=$N?%5"!WZ/STZ^,CA!Q0HBU#I3Y<C!_'U#0PO5VB?=
M95^&U4MMR:@@/3(S'2?>7Z':,[*09N307H@PRA3I1/%\U$P1)596>P4378:4
MAY:JJVIJ&FD&V&+GPI2/-V-TU:0.;67Z/?Q,B)[4^]VA->/ Y \J0(910GNQ
M0G\^!JJU_5A"5#%HNK!P!$17S@^]]%YO?S6FX:2U<C;YCLB'=LXA3>DS[?*.
M;:8];&N%[/VV*("4(L]VV:^ZQK9+[-X9W0I6KSTU]'S/T<"\H/C'PE\%9F8/
M.QR\90\Q0#@LNR:0>-@K^*29@6L1OOT$C%CFZ4@>3B!@$RNFO*?J-YK!K>)J
M*\C&JS%BL@BDJ=$P_GAHNP[N)7,$RXN'PR10W9-0'K37-L&P8]>J.^*]Z>A8
M%PL0_L60<!>]K4"=V5RJOV7PW5I%.(CV]-[5[:ON7:A>6"V>+O9C&9*$5%G:
M3L5*H[AGZ&KD^L+7)FKDLC:CC-3YM>^N1Y*LM[<UM0\^Z=KJYZHQ\0AZO/V6
M<R,)[,/#%PF2RS"2,!F['$I2\B"OVF*)O5VN=IU:Y$6SO$IV"K*OD^I'JU#=
M72=I><:O!<I7N7[36"),)8GG?KC#CH13J_#X?RF(&G!QK3)T';)M(\F6O'UQ
MW%2('M+$]D$)+>9E".E=FV&1W.)Q"9_@AQ*_+F2YV;]:WX^8<\<$17_BG,4O
MO5EL4"$IT XB>);Q*5 O6#Q*E')M*IEY'!'1/D6 /<15NH=9EH14J<[6*0B_
M.PG3WRGWC V[''5U L]H1!UC#F+K*K;;X+-:]N1';XKFD%*3K4?6Y-3)=@F:
M/]OA@A@]M=?3M@%!$2&WW<4'KU@9]1V\4:-F6:AFL$T7,Z?:@R2:O3>4OT[H
M0<YJG+I=E*D6(J@W:ZI5Z>V[*^&[%M/O;/0>\>;>R([:>[/W!A?OXLE#+(#$
M0Q-%^C)>H@-P>U&?Y%1KR,:@C 7HC@-5NEK%<YW>^[T_/W7=Q:[A0[K&Z[/?
M6X>J#[SYX:!8IT0YR-.W2+:W2\4VHGNUP",+>-H?8'HG5+"\18HB>O93L T.
M<%YK+' F,Y]$OIZQ\='U#;C_R>WZX8@@/?F/W'NL]WQ OKC%N(D;QA+LF/M<
M:7?H<':4#9UENP/M^Q#":GM.:,S/Y%.Z%\;H?I'+,MGU[VVLQU9C;&347F<N
MNULK.!X1F>NQ(Y@\#[OXN]QA&\T_"^:/=4Z&+.A-;.H+.&F,^THVN3VGAOP8
MP&07Q%@7>S_-3_*\!VWQYNQ!^V\LQF$YH9YVB1U"\60_YX0N7K@>#;K/_$#F
M:H\1M2 PX$9-9YJGS^E'.HZ;20LB+K>.I^$U43-H+I,@&C>ZO7YW=7.*#:JG
M64:]<::":ZV24[]RK5T"![))%?H2#S'R2DG$)>5PR[+\C'GD;486?@FWH,C
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MHL$]YTC]A8\[NEX\"ZNLI'3<!-*9^X1H)GZ+W,P#]/-@!0YQ?K53807=LW@
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M EQTMC]CY_"_#YM^>]7*1G:\-.,Y^ML^(II^@L#6HO(("]BO3SO!AKQH%PL
M[]8/,VT+&/X#^#3T/?:T4;17_U&Q,/\U4M67+6V#*CR;4Q2>:Y$B82WP8JZH
M(6KJGR\I?3UTP !K1+3H'<K/7@J:,EY^F\Z9U&69HJ#6-WNUXG<T-4_\.Y9^
M<H/JSO:XL13VK()*\Q#R*FXF@9DDU VEG\@*_@E$.ED@9Y8@H!*^#1V/.M9(
MP3XP541:)U^L%SP2L7CP_><;1F+^W7<P,LCRNQDG3%(."(2KT'68>2S (J@;
MO_,QEP5\"!ZV=WP[L',QV>V>'_D2^ID<UB(LX6\'W4=W:JTM_G0P<6$!R#4\
M/<$IXD(O,[*3!7"BZ>5"=J]:.IE2Z#_8O+XC+M)6;=GZ,8(N9_W<WE7+UV !
MK?<7F>8%A-O0'UL04(8%?+D1'BG^%4(>V UEB ]+L(!%(S@+./+G@N)+T"/7
M*7#&CV)V;2 K-Z;- K!WV%%ND06H<8Y]PQUGXP VAO]6B6AD_AY#_Q;$@)X,
M8V;2:C)Z.\^0!3S^1LW&T&D)S+TLX+?C?TP8J[I!].H<E,R^O+_MYZ[:X-^Q
M_G?"G2KV8 &FRRP@&L^TYRD9<3,CXJ97.A;TR%]6XTS,*+ >N">:T_Q^YI2]
M_7>Q4R%]XJ5-D. ;D1N#^.5A6*T00PR2A ;O:FZ\2BGK0U&/0947O[[BF7CJ
MT(_^ZT667:6+R%!OCI5_&9?LA8HI';<<Y2T"'X;54U.62(>75JIYYJ[UG]<.
M^,FYP?<?!.YOW#^-^#]3JLLP4&%[LV,=PF3SDF2N< (BK D6L:<XA1J$_KR(
M.L:^:U<SKL0Y^I?G/[#JNT;836':">_=C)['.:%)JQ*U+?)A3/D-E\^$\UL!
MC>[W[J9'[0WG&&W9[-7M_/(XI;1XF[!8=CJRVP*I]8^4]_?*<K/;G<E"*S*_
ML,7AV+$0)^/_@?;^7EL;MUWIZ;0L=C3BF1=SZ&#?[>_5]P_459$=^MUN"T9_
M#+E_"<:NZ_^!^OX.!,P&S\4^Z#OT]].1(_]AL:S^JZ3:U!,"%:<V^X@5THM=
M.HAFXK5<5^4? 5X4$5H_YKD[LC>D5W9Z"N6:YQYD5)EWM$\/5^J6)\.YD:2V
M"HW#DB]HS="6A;I.*1"]XI%^%!$B"[!LEC2H6L\_\>YM8RB08BUS9V/8'&;I
M4,5A(7;QK\CM$HVMH[X"<(?9QE;#RXKP]W^SL5#',?_7Z6IEZ,HB/?;^]NX6
M"]CEK4S^F_0H",_.G3[+E*"G0MD*M4#\9@'T)%4Z7H\G^Y*%^&\$M_A76$-H
M;P6,>IV1WBJ/&G&#D)],P5NDEF5(SF/6 ]QOTPYF/SWI=O9&U$>K(^*):S E
MY!XPG>9%OT#IQO>@H_$-J 2*U=F)K.7YJ23UF^04Z$VC:\RR((E"O1'X8;]C
M&LM.R6%,9.ZEK@<FWGT35OQ&=7DVA9DYBY'08=SOZ%UN"T0O*8"2#B,WO"=O
M4Q%@V)M3V"24.OCF9W/ &1&3(=WS]0UI.U?>7R KNGA?T-;^.+/U\N;!8U?J
M:6>0?TPR)4&K/\ P<M+HPDH/4\FABAR9-^WC7B]LN7\W]</'E0 _*1'3<S\.
M=?.Z*U)6E2P#K(:_;Z_AY]I^$M0Z\$O9Z$.F"JA1;)55Q_ C%B"IC\#1;8@8
M?HN(\@4SGT/[U >W^'E7."[>$ 3VX%A NUFK'F)X26@S@;B=R ($Z@<"=+O>
M5H_2#5\ON!2.S/I*Q_UZ']=2<0BK%I?Y1<;O3LB/;L,S?L*;X0L+#N^CJ+YJ
M[2S@EE "OJ[R"1J]8I<")5],%DK9U>ANG/G9["K49N26[A=PW+\%HU^>KC<(
M\(D9<0_<TE9K6.W>3I;&MPD1,,MS1A4T?&RK^N+P<O*SK\C*7"(OR;.Y.D>7
MKA;$73\NHF6N&%(4DGXDY!N*TJ'S1_\NK/C]9724W(R%F#T@/D,78 %/.N T
M'C:8,GH<O,B&3*M]^$VY/_>H'(K2T1]&,>!CN5H+,8?UMG_;O<-Z$7$"ZW**
MK>3(1^\"-,N*75SF?*6109P:+5>RN30W)JX-ZL2IX#(7,KY"&TDE)%DT381^
MK8;QN%).Z^$H*'D9QF7-E90N<+IM 98V]+U\A@78NWP1\5=)F6+;+UW4PXX1
M@P^$IDY)8&L9JXFM0G17\JG5SHHK7?G[*%9)^@+&789-\9ARNV <8?VXM59V
MA>(3R^C"[%L<GZ.Q_7>NG89ZO<:E00,J;J^L.)!FR))4H8FMVVAN1.PYBE9J
MJ\*:<'^?W#NO(J6B]YEY=^N8WR>V?G'G.-H-'*T[>^?#QR+HS<C;*TLEI'G*
M*E5P5/.V';>W-#2>#B>O6(4YK7PBZ9]M:7P_5K$#F2<4+>2/6?#^EI<,3!07
M%P,B[UJ8OR8,198,>\)?V_HH?JI1FJ@R5U2,X:S\Y3EGE-IO:77XD=J/8>)4
M# OPPL:R%UPH"L^+7\*V'L4P)>416S:85'MGAX=?6]^UD)VGV1[(>PY,K,-]
M[0]TZVI7FKRMV_3;2N8UY\_S?UE)E&[@OW.VL "<-?2GJ'UI93,+.&P\O/LS
MG068Z>?!EVU&HG^0Q"[!4J/^)[O1'#^O0M>S&"-_%'<RWZ#GQ=89>?X<;CQ$
M_&_I8"T:+SO+>9FSTT^&BK,SIK$WZ.DS<,;^J0^44/*Q</R'_;M'7[4>_(<E
MSOO.Y49Z(@'.8&=M,ZF(R(B$3OAOX;K%77:R5"N]F\_VS2@LB+ZZ]PN;.]3_
M!P[P-OTZN;69&"%S]+XQY-2K#(+9U]*E ]H[B3@UXY++E0Z7#]@V!DC@[O,\
MN>0*H:O"$J$_V1-_GH/172'D-ZC#;*^)9X>MNVA*\.]A:N"?>9\7"XABJ[\/
MSXYE*7+[04ZR;M>BE*F"4SE3CLQ\-N6\&=C\U"F>7U>\?4Y"9] !8J"]@%=#
M>T/CW XR8E#0#6P]GB[BMV*:]\(%MF[*#P>OH" 3(CMGP"3">\9\796S2\*-
MFM+2#_%R\I@A[=_!-(LR^GZ*7:+>;[W4B';[J<DTTH\ N-P^#^2!3M5!LW8
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MGX4*+&0&E.:WLZ4U:H^)2%QT/5-,FC^] \?@A=$>F$1L[4Z"21"E55:H!RV
M=,)]LRZ8F_/!$\*O?=YIO&15,JP:YTW'&#EBLH]^_Y2A;K;G/=Z"D=4;3Q>
M= H)TA5'RDWTQ9.=+)9GU?S.E5^>B1;@C3Z78FE^X$H@K\HCGS6:WIS54CT(
MAW3,*R&-<A!5MAPWZB5L?$5O-![P&A#FY@CQ"#S1H^J[K%U_5Z=B4QFGMB;9
M./\6(@8:+F]W8F.Q9(<*:#ND!O?@/D[()SRAW6]C."5<*-Z_H'[L53:\XHK%
MNYR#9WJR*@5VU0XH(H2;2F.,H*"JB:1T&FI86C"3WU<27:\2^[GV+*U;8^'K
M^F>,NQ]WN^D,[@U3!O5AU["]0AXF1#\,0I87^1SM3N9$0 36J/;'^XX=U.S;
M.Z$1M??<L/@@(I9Z$DRG\%#3R#L]:&GO2WF&;=+!<RB!,?OO(BZ7WZ=8!+VV
M_D&^O!A<9_Y:4M(B>EYN]I&,W$9/8 IC8E*3M.&W-C_;QS'V_VB%G8S<9RQ@
M.)N-=BUZU*I:[9\EI<*#1:H0FB&@!F6*:W5!=MFEQO= +:9F$SS.="_%+K[%
M6HE97_3[>'WN8?0IF:_J)0?M5:IQYJIM'F^^7BTRNFQ]:LX5?_B48-)1W&C;
MOVZW_< 1AGNP!UME41_SU2C#FXPE%XP88MAF;'*ELU6F_JJ.;Q:_ZLUQR=]7
M!J7.D**BDT4,/J/LV5G"Z58^9_:7-=2WPNX: XN^-9R4?X#Q\J</4VX>U.K-
M&8[5U(.#9EW2J;1U0^GX%^<:\CF\#\J;JS/O5Q].0/7V;KZWD,UX[G /UNTC
M,JRC:JO3P]E4&1(3_MC0@&/M[>XGGD%80T*GE@RH2WT'*M#"$ KMSHV)]UD
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M//2;/@_CEP.TMHX%_*8D,!E\?W$(E/S%&"NZLNE!%O!B'+(S<9WYD9TEK/9
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M2O\!BYIOIBWYYFW$O(J[/8CK7 T^*EC.DZQ5'#Z4P^LUM$[OZ.@(UW]U=<I
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M-983?#Z82='^O@G]_]:)8G\C"OY?HNU_A33WD(.),#%@D>9-3;Z+4BVP1K^
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M!@*X6892 1H(?6!1P+/3"95^9#;AY5'UJ"\SW;*RL$]\;=NW\2G)X?,B3)6
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M6F5?05QJQ6]W1.H%!74>/357ZE,.)55 1)'R%/",5 ^^)JD+O\U_LW ?,,G
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M6MQV]:_B:6?@<VH4-%4YDFY &J'JT'0<:> ^<$+[GKIZ(.7:B],:X[],6AK
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M^#65/P;N(N^)[2#^5MK',V:>L_CF[Y7#2U[53D$IQZ*&> 9:\7\^A)+Y3&R
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MU.+?+JU?A>."NN3V_2X0:V9\X6SHE>ZS31OZ(7#S<RW&VR(/M+GUWP'W?TO
M?1%[D*5!PN\ _D=[WQW6U+;MNU 0*1*:("!$!"LE2A%%)#9 9"-@H4-4E"H@
MTH*$!%1ZB:"(PH8H111!NB@MTE6$T)%00H@B")$$,"Q)>\M[W_?>.=M]S]WO
MGN^<=^[]]A_Y"%_F''/-,7]CS-^8<\PU8;]DF3+\8^E!HT[))Q>L<\1.W- 8
M=W$V#PS8JTPV+T@S/=29B1)!'VSF"?8I'69@X]<1+JVLA);X^KVT,IZ>LGA
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M68]4+_@6DA^IO<\TTY25WKCNNW*:7JBUA!)+F%MKK(*EH 0*P2XJ7&3.56Y
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MH=MEE%+>H5Q?TKVF1H:MR >:S*HI9#%6+#-TWH=MBNTDKS25)C9*,S@J6_G
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M(D^?=#<JGQGK_*H8M)EM97\L<C:D+!(59P=[0JBU75/E3.4A9@OZ1JXY;0B
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M(+6(#?+@\/)KMGNVI=93;XPU/E=N/0_[)&+@+L,ON?;T(A?L.,.0,^P^R*,
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M%=HKX,E+OS:3)&)F#F6@PT3374.JUJD#??@59[D>5JJ8DA:6V5ME+_DH^4?
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M7D)WX7K^^]/2"_?*R,2>XL\31E3%85'CG&5$3;[9M435M9AD">.ZL,?0(BX
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M&?)37L+^LG,%?!8<82NN1(-2G&'\\RMO74S-:;Y3_JTFH\S)EE2W,:46CB*
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MKUPB]@WUSD5'[G*UQE6!-07?OZ.L=,'&S3KO\BD7*RQQ2B5'&% KFCYK/6J
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MJS>JDH,F][E<5A)5&1^.NOAB6L[<33O1%\_PF\;N1FI17 NH4+)(C.:2@.'
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M?]L*WMT)""AEG*E.<T2)(D]74[.C3LN9,<[ZE9:YQ=R19H0OJ0"B/8<".OR
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MA&=70N6XF?)K"GNV9KH(UXYGG'/9%*>5+UA:#/C$/V:UNBHP8V%>Q>6[?8:
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M&R3WH,#U0)WNLP= V%[!U_6GDA4;I(>2G]U>@:*)'+<R&^BF0$/OJ?4TY21
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M1B=N<\66J :/>AA3P603JB5+4)_23%NFY)/M2>D").O'K'V^*..9W?D!7>]
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MJ)#MOY!GRFQ ![I#2>+EE#@:#V52B#)!RJA;ADA48*G-[[QJ_/JD[GG.E9U
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M/>64O.>\(*>K<4R-\JZ2Y6)I)#E@Y  R: J\V:2657GK-,0,4<H2:J6D#G$
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M-5#\85#;)NCF4;>SGA,Z==<?5_6;O9&RX:YY]^%5Z:;_O^_!U__V(*P(NMR
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ME<WZG5N>P?^8NY(AI; ,S<!Y8V;72>@!$1SWZ K3E938CY%%7AXW$PH/;F1
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M&;[OSA2J$:**)QQ]_\YCS\FAD<N>ET5<W^XJ;0EM(46^0M422WZN!%6,;-?
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MM+T3RS[P))Z.#21U-B-#B!0MYU $PH\;(FCW(&W1_%X)#<EG0L;<1Z+#'K"
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MAE0!W\H-:SA8J)K!K?3#8*E]"Q^42X*B&4PD"9V 3*F2@!FM:Q;#-XX9#5]
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M6>0D7BVS^)-G1SAB(%;[*<_,GF>[PV>\>*XR/RFT?XHE<]NF!N>*'RM+95+
MRU=LXW6G<2/6\2GE[1$"!SNH3!.>W<KG?"_@G7ICJY90>-?IQF.=0;<1P.'V
MJ=#)V2S]V]F*NNZ2TB)QLFS,ZW1>H=YUG\TK5OW;.V>;VE:"'L('H)W8YYWT
MAP)O?RS0U!"?-?H75W/_'YRDY.T^_^-U64I[9[[I==7S\86Y_)A6C;R$7B7Y
M1][8!@HV/*U(=]8I-]>=K)P$,R@(>\#59)K/?%!4.$0X1%)[,J$PG:K94R02
MMWFMTWU!3\/1*V##[GY,._.\48O_](7[:1$MSU8?7Q'"J:@+X#-@<AO"HY_S
M0M.;RDST$^97AE=,?(>6[4"$I&!>>ACFV$LGAAL<Z_B>./';1*JL[986+4$B
MSTD^=%WR>2SQ1-+':$FI1^[;;-/=!ODF1S1^7/%J+522O6OS-J3FV5D(9Y2Z
M\$V'XZ4=I8$?Q.<+497E- 9DNLLW#3_?%B';@&\(2C5(M3OWS8;4=-VDU).(
M5AV7[67)%[Z]+IZHQEZ5@!ES.3Q(-JCCJA8LRB\JB^ZRG-NW\26.6U&0-2-S
MNG V%:\_-^)4^7PL4_&'<LX(N9+BN-K=;.=>O8><Z#MZPFK3HI"0%^8GMV[
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M,N-$U3G=[;-O]YA0E7Q*UWRBC%-S%$1IPBEP(3";[!YZ,2"_ ^8N6APP.8X
M@_?>3R )&8>;0OB!Z<\,'Z694>![@2]@T'+/^O\1BQ<E4#0PLR>?><_0ZY9
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M!AY%#KJ:R]H2FE!:1BG<4-V-T:F&&WT;&0:]$W0;-.3-$&([+02/ID=K6P:
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MLFG>+C=+%_$*B3,0.7,RJB554%;9VB>B_P4I@&PV!F?U=OL&Y4$>QQLXCHU
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M1$Z$[S>\YI</>'>>OCJ3T5SF)K;H--,1]3FU/MQ2  H1?0BQZL80P$$9!BC
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M3)T\Y=JQS$M-]%7<'O8%%+7VUL<&J+_.AO9-C<T8M=J\$]G?88 RJCO)E"M
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M*J2I#0FZ+!L?HON7A[QUNOYNTD6#H.[Z+,/T<Q>#_>J$IQIFC6'=+2== ZR
MN!HQ[L\V\Y @L>5/_S6/R?1YLXCG7WX/"S@YF[;[H6?\#P*@B>K&0;B3,RGM
M*$!9?_47K12V'V/):.A!0%>R/^2\<-480Z,ZFS!?:!O76GP2PK)U=^S<:$_7
M:E"Z>T:/NY]]GM.$U<&U.X&-9/OQ)7RVM^LA+((H#5[S<"C:JYJN%>/5HG*E
MX;M7N*]2I5>JW6/^LZ7(0]HW!0\@@*-375K $?BJ"$L>8\LI,A8!A1W*\(H?
MA;#7N;_&D:X?S9[3=T#:7HQU^?!DFI ESG08M83P,PQ%M#73D0=0D<9[V5(
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M ^O"(B\+'J[7$[>BKI[$:;.!^&S,EST01<RZ2!%F9<L6=Y+9SM+$=%XE>!-
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MDWC@%&<(J-;23\APA#1PP,3]89U4_;=?,?PUI8OYY[L&>]+VO*\N\?@TVX]
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M%E,X9&-IFN?2\$ JJ[!H_C*_6^%>(:3^:[JW^Q6D+XN_GRZWAE<T<=C$FQQ
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M*D6O:([PG73ZGJ;>^5RX]C!.C<E)YOXP$?0TI!X;C_'/$&6H87@&E[1._A*
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M\)^JN<24W'/PW)BQZ FR^5D[@/SL<->-<FU$@GL4_1WZ>4R#QT%J%HO?DB[
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M1$2:4E500 0L%*7%1A,!0>E"5*0&1'J 0 1$E"H@H"A$.DB)=(1 Z$COO:2
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M>LOJ6FKHN;\DX+UGQPF?BV.G<.76T@&\2*#8<ACY%$1D6B- F2V3-%WG?Y
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MWK!79TN35IX^EA!]:G3K4=N7*R>'?<E DC)8]33LV)3:.]EE[VN1?%;]ZR>
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M>=7*+N-:6^U+HQ/[A)J1L#LQ>J,)+>W8I2R16G]1)'"T^.J.N_G0U0NQE(M
M44_F^48RFPVIH5Z1/9(BYXV5X33);XK;/'LU344CC6DTH(ZY$#!LQ(.T5SB4
M6&^.:$7(]:^.%H<(!B=!/K]-^GS3!-4E0RX:I20.BMQ&LC?!UF470<2C'^B
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MUF2=]TLN^%Q<+$)?H0,TW_IFU_N?4_,I]1L2V^8Z%6).,=@"JZV#PFSC ND
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M2;%$:!R_CY>%/9*N$A7N^NQ9/C(IU=Q;UH:C_2G?1?-:4*%+NHME];QL2=/
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M&YZG!([/:3U_^?D*W($G/FU[#=5*$\>W>3#7IKUVJ]A1M?^-E53,]Q(&_D#
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M=+?Q\V."RZ<;XN9<'.R6DVV4QQX],=Z@?&W"D3\+]_2!+#[1:\%/WB76*G5
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M7T%DFVM0:I"#*I+CYCPY8=P/]\0K?S%!C6K0HRC=VGA_E"HZ0'T7NRXO\'(
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M[Q4J BGDS>EN2>Y/L@.BWIY;3R[\>6Q2M>@+3V$5Q[V:W, NK,'<;88Y@W?
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M!/)L2KP!.9>OR^P]M:VF,T0^LDVNOH]P-;!>M^.$^!JF**KJ6X+781J[<'(
M+:')GVD*7J##-:<GQ(%"ZFUB?.'W(ZSU;^Z8R14>K][_XDF_R87>9M./*T;
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MTY36#'[9V=E1\D_*K/)9FF[[KN<ORO)[$B!Z]%QA/[FU=>DS'P,>Z/'?)93
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M(J+R"ML4E32UM'?MWF-D;&)ZX*"9U3%K&]OC=B?.G#WG[.+JYG[)Q_>RGW]
M8.B-L/ (5.3-N-MWXA,2DY+3'CY*S\A\G/4D+[_@>6'1BY>O*JNJ:VKKZE\W
MM+5W='9UO^UY-S0\,CI&^CA.IM)F/WW^,O=U?H'Q[?N/->8Z^'/CEUY\ #_?
MOQU_5R\I2*]-O_9 Z)=>?)LB?@V0$A#<L6^S]!$G(>]K,CL-;PG+'GWPK*)5
M1'W_:;K<Q>N#HO(:1E1-QB_5_J+9/Z98[/^69O^NV'_H10;$^?F@S>.7 N
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M?VZ4S?)V-Q5%I?UJS'#!B1^;8D1WY?T?:1;V3#8GWD(0LJ<,)[?&8!Q+F^N
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M6];MYF*AV3=AOP@]X 'M6S#]\!\"##A7)1B*L(?^?SL3J<S)EIEQB0? BWC
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MZ>LTRRR6+5IER$*.L("070G;M73#0&'!C%.SM#_ W=OTDN,(=DC?[8O,9EW
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M1U*@C.E)%4OVK=#\BLZCKW,7Y9X(:NV9,7F<?HZV<:E(?16R>NN:Z_U,ENT
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M"$SU3X_!H85MDFS9<2J,';?.P>)D^%%YZAHV:@OTS0BYSK%@/SYSSY5C>;=
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MF\K;_*,W,/\?=G!M3?\+4$L#!!0    ( !"#]%3FI683$F\  .B4   5
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MZH< =^)6Z,QKP3 (RRGFY=<L'R"1"W0D4HV?S2 1+J.7S6J+TP[DNAZM:_%
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M:S9Z+Y<4RW,6$HV^*0838@\KJX@U6SP$/%!ER9^Q[T_5=6SUV>;6#JMRZ!P
M]WQHYK&@$E 8+8L>Q G-T5A$413$("LMF$8\6S>.J1&LR'6\W)2[G.E5,5@G
M!<$QCKJ&/W2_IFPM):33NX:%TMRETG%\YK IG9Y56EDG3(*UO]P3##\X$GK9
MGS!26;F^^V2+I>N]7OTK/6,UOU+=WZ]M=](J3QYL%)I=IUI"ZL^0,.V'S;C
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M4=E6PR$WSC;!>RH4FBNJ4K2#^2&6,1<4#HKL@!P?/"H/G/KO\E]6W$SIV=0
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M)ZI:E/E1V78'"4-?X*;%P8QE?L_)E^V*;PV*^?M<MDEWA5W2^41.Y?!S@;@
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MW&Q!2&$=+BP'PT?S_6+\JH_H4*8&-]'DU+L@KXZ!< VE)_=/-R82]K 3.?Q
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MU5/J&YZU%P9H+[,5.UMZ6"J7\SA2FBRI-4[B'-F;LZ/BM-#00_@;'.T9=)9
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M7'LB/ITL%S'^UFI\7L-^<DY3EO"8HB.H#S[YV,>2:A)VAC7.?^ ?-"S4Q_]
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M!:E%N'S_A:T=>[8@O6Z?&?A\RLJT'<7_=K?S>!>DY+FPBFJ"TX<KVZ6.>4%
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MYZ@<93EX_\Q!$-(S^(S7K3.0QX:/0-\"@$,RL]@&N@A'N'8.%_.%>1R]<GP
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M#%H/^5<\V?/_XR;&'?L?4$L#!!0    ( !"#]%0':7F:EBH! (>" 0 4
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M\BOJ7:9(>-X9V2NII$]2IOYQ[1^>_;<Y%O,_Y-G_X]C_ZQ<!V,?-Q=D\;A$
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M=C P4L8N3N-LT/#=T-W8\-(!LTL11V>=/_;."CQ.R?OXXC[R!Z65Q1]8A90
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MUOU1[1!34T)AO6M?NO!//R%OM>\F T\:3O5]4)''I*&)>=@&K2=$;0R>RPQ
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M8RDN=@2K3H*PL7LKI:##[/"D%ZQ5LASB6"MTN^.N9G!PY\GSLR4^95!B!40
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MB<CY_1&>/3D =1@\*I19@M2<8 />)Z-("WF2>5&D+4)*MXQD8E9@36_QHE.
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M]+^(K?\$G.ZX?_(9B(0)X#\_!R-9'0[8'67UB)IV*?1[/<H6\WX5].=YAPU
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M(E,HOF5%^R7K4O3T_3FIVP%1!ZY/R!7;YLOLGG2^NP.SVH"\'!-&V>W *J%
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M#1]WA)GDGAF6WV!IU:ON"7V39FKAT;;B8UE28EAC]WUT*CW\\\_=FXVK-]A
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MUT/A9CK2?5?70?0F'N/T?H,25JO!^<";$$KA+:A5R33.=3UP0-#2XD5P2(;
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MRX_M#HW4AW:96S^)N&+\5]*'SE0DKEH63XYZW2$>RS5*/58K^\F]RS3.<#
MUAK6BF1U__ 9: ]V!UBY>1%3XL'!%*+?(D_D>ORV5DIN5#?Q\YGZ&'74Q<H<
MZ#XRTQNL-FK\'A&!+&T-*V3^/^R]=U13W:(O&A5%442I(DB0WE&1)B4V0$!
M::%'1:1$0$":A$1!:8)(%Z0H56I$FK0$J2("TGL)O9-00@(I;_'M<_?=^_O<
MYYY[QWGCOOON^<,Q'(NU5M9:<\Y?F>4WA0FOZULSEKP5ZJ<D!7,M#?A#H@]=
M"-(:/,;(4YS,:\]>^PIEN^H+EO53\=]CV8-*F@?WJM6HU:)7R!F=+I2$N8J4
M K=>T[0@U7-3KMRZ?BQ!3T-E1O1[1'MERR\<Y'& /HV.OG7F$$'H^0$AII\%
MPXY6*R; LQ_++QPP\4<OL9ON-*P'V2B0LO)U,WP$-;D,1RS?OZY\5!4V?MPA
M\/"F<-*C6U/6/_,K!P_^S,@]&#,EVR#+!SRSH(_6E&*0S--\ H-'"W/=X4>O
MF@T=QK2U;>__J&(M'$Q"VQD-;6Y@;(@]ZQ=WUYBG,/FK@JO22,LBN/=L[6I>
M?S,'^]T[3U_Y \J3 024Y6 _:B4%AEJTBT"HP-Q0WT"0&:)\VIXH=&+7W-:F
MDP7U?2V8%$7&O@:DYN,2V.ZF["]J-$ ".W*4"M4&(J U8WP'(,N%.;38)MAI
MZ BV'$)YWP%H,&MGR%:V!"D, PZ%3$S3.,@ENSSU*+*H!&I@"+5X :C#& 3U
M+SN?[?];A=C#R#(V@)3Z7 /KP)#0+P"B_.<CI;BT'8"H7V]I32*E@;8SS0)8
M,3J(.,?Q)P*KD&290E%B#$ZC!IG6@>I>ZV\*)N&W88ED#M2D;A=-:]8?\(9=
M6I,OK#L;.B-VQD\$:G=YNAY;O%*>F+G$[,T ]<J\':ULO1*=(9E['AJ^2M8T
M'F#6L+5Y)75364(2O7BVJ]#T)?G#2CM@X6\,(/R$8Y^%<Y;'6]A5#&W5RAD$
MMU64AA<_.IH9K7M1ZF=C"5NKJHGN!/L2%,/Y&>^G=<+KF7_OSL60WJ!H\^M'
MO)5G5B/8G];QS?0[LT]KQ@ID<*2/$.@@!7'3?&6%<31J>2:@W#.-=_GL?.!3
MV"&;&RY26]PRJ:W3UX5LGWSOK(F^]NU:^($WS_KE.=Q?BO3 [3UG5@9FABXF
MIR<9^(/'T^:BT%,LW#:DUUI=6Y81DOH5>F?[/@3 )>7#S!N4_;L_TT%F=<D'
M_9 B%>OJ*J3RI3DZR%)/]G:P5=_CX9&[!/8[K<3*Z8='Z:!G-W@?+UWH""FX
MIKKAT=AEKGL\.%J[!4Z369\9+WP,Y]7S*>^MJ)@LP#@ZI.(TV$WG_AAL7E8+
MIOA\HX.LH&2F^'3@UR+/0);#Z*#SA@.;@:-4ZF,.RC)M +OA!6.'K*3#_[9-
MXU^/(0MQ!GM$4<I%2F?;?L^#1P,=% :+5ET+$T./&+3\MHL!ZX>=C)_8N <^
M@5IA^-LV0T<'UKTIK".TVX=PD=3G@ [2>83^B=CW"-+@73(=5/Z="FZ0)?.:
M MK,%?CKWZ9+L"*'_U-RA4B':"<!T(^VP[?1&H:#::%A&#KH3U$',!#J6Q-D
MXS:&&S7H=P<X<A':23"@A$CNRE+%P84D#CI(%"9%!P&(OM5W8R,5>/_&SJW>
M590]^+4;@(B;.'!XSX)XGA8N!3ER)\; Z_A\@<N9O.B3_<U>Y2?/'!K&U)/B
M]E2&23N3[Y&_Z""\O@&?[I0>DQ#A-D80GUU\/MBB9]53\A9_3>"/[WN&-U^]
MF6R,)DRW\Q>3VB8CPVN$\7M3Y:^GP7PD)VM[C>(JV3S'"]]/H_G%?OP*4I69
M]%J;!\TSGD%_5.>B]:)*4"OMN$+&*:UODA-GG?C$NQ\26!TPX/X'96'C[>A5
MY]6&<3VV&,^S(&N.!Y$_?6BN4F)C:[.>GR18<VRT-7=6Q9;!SX#/V5"XVN.Q
M,:[<MJF36,AK8Z[C4A4IG6248:+41^TS>8I[M)(W+B&1@=RN-+A ?:\N@&#&
MVS=$AO)QD!H^^42/&W N/O-*?#A^I@>7Y''0)FN&[)AY4T,6[B*WR5:]%A5]
M">L ?F$!KJ=*UJ>=1O+YU/NCOHTK]SRJQM,^^M^3=L%%'PM75$@X+5E54'P+
M)&P>%]?W8OZ0("Z^$N\N>V*9=II4B!O9>F^D\,6!)M[-SZ5HH5O?\3#<4A7?
M<ME#<O5QU9=W7;&IQBN(9Z0^');/1_<;["B-=Y&K',.)YTST.)*BD/_9>HD+
M:I2X5C1K+%7LZA]6+*ET,T*3J"S?U*GC(ZD_H#M6MHZ$EU(*1FJKX7X9"_W@
M<S="_;,YC._DJO09SA)=F +"[1CAN1[-IV=KMSZ-^OIR+TU\WFFTEJ<Q4IZ0
M[COC*QKN6-%!]8E]KBX(LRAKA7RW+VM]I@?756[PFKV/"Q.2L@TO?E )D86B
M:3_H("X,&T6P"R,P@M"H)' -J]KA:3L-IL?3%T]9"3&KEF^$SCBZ/% R.C+V
MW)U')>BBE4']>VR@!2K\4<*T>A1ZZ0H+T;_[&^<+-W8ND9GF^K'!ULKKC,-F
M[FX]2M\\L_-Q"]=:)45JY9?OM3W9;)-[W',J5R_W!YMEA4)N)MDJ)36O522Z
M2U(0W)"W&]'MX[3<%.7(R57RL?IKK=S[AV(\CZ.%C@F6C_T\TOM D?>DGE_P
MZC=7SM!).BB0=AQ/75K&G.M"@'XMI"J'(.=AEV!6>I!8GODW*KX/X6[L'X5A
M4O$:X^DUL'K)R>.!;G;3;2D6[4*#_<-O8N#GVNHUO26O"44Q,D=UOLORVGH<
M99W0PA+!=Y: !O#F$.(,R3]K0@,W<6#(IK"05G#:99NGNK5Q0)&%]W$KTZSM
MS1"Y5;,-Z]>\&MSU9W1"R[SBJBG:PV-5$U4ZNZ5/'RD]UA0,N6 BWJQ_>591
M,C,])DLI+\RR<BP/40&/-XP)KN:6O0R0[,O=)^BOV,GGX V_LYW4F/QUJE0Q
M.AB^)DOB9Z2D-I?000^7]N@@72GX$&Z=? YHPZP010**IA</!_C0;A?\93\0
M8@X5/_\..0@@DNN5>:HG@"W=[_*G)/:\_\+>#031/0JJ'JN NN$#(*O0K,'N
MGBQ5!$!O:&=:SF&./@?(8=IY4N1U?Y3>KW,9&YR6M\QC];RRKR:&J:Z[Q?2>
MX+W'ZE/ C5 KTD!C7UGJ)"_='7MO^N56F_;\D>$[!Y++<>%,W<9Y32)3?41E
MQ^DGGCEBUS,MWRS*Y^3JAPT.(!BGL"?-48Y.50]>>Z:U1OOYO9N[E=6,J+A8
M<G0"1"D,_#8=UMZSM4<U)4HKZGY)FINR/W[BE*;U6.2]C&@G*U%N][+< LE?
M^0:IK/IJ/7K^,Y=-4J ZF"Y7'H->VYN)ZA2X1.6-!:^8 )7 [VOB\9Q<PX4K
M%BZ)@&1MW#@Z&< NM7%1B0DT$^UG..M=5B:M?Y)W<;%V]U27Q>[Z<XH)KDUV
M51IZ^^"HWDRK6NU/#R'#:77+=T,!Z@?(EHR!+1Q1^G=CSV46Z$GTYK<D)<<F
M/%TG'V:_:^C@E5:"IB3( CPP:",[#T- Z^B@/QT9?M*YEPG8B5U!/(23#IIQ
M"P9(![7G\1N#WD(#2GGCJJK'WS,ZH7VX.,(I&_@FY'RCROTY2MH,\GX7+&T+
MN@TF0G;H(!:2Z":,V+(# 9,8%PYS -2F 08JPP0%,AG\O^_P5N<_]/+G#<M2
M7A1"EOLA5 :3))II0F/GXCN*V/^?>_VOI/U^4P'T"^PD+L55IP]Y%G%9[\JN
M<AB\ZL6]X)RU!^A?L"!.3FG\0,//_KNL3U6N:X=[[,6BDU&3N:C#F#,4$WSP
M2V=57]S#VC>=AI5^GKJ)]X?;SQ[T8!-78[0:"&Z,S8()%QY=Z][/#=R%!9+C
M3F0TAF.YS!7/Z'CK#/0G]R<X>JXASW7!_/9C]GX"3[Z?L^?W]YR]1$#(_!&T
MM[._$]T,;$@I=9FP'RI(!]$$D-?H(/4\.FCR O">G0$.Z%HL[C7J$>J/+,#:
M_2S O]R4UMJX XLD,U)N4@)I_B9T4!U0(UK3&/YC#W"7&A.ZA@5OL)!"@5OL
M I;R.8#+,>K'TC'$WYS]1Y2?'-"$_LCR6]_/\ML391M#0F; !+8-%O(VE XZ
M -0;$02;AO_J;\[>3_ZS_V_)?Q,T-2VBOF@5!?4=,B4Z ]Y<0M,.L=!NDT3"
M]D;^<B;EHNM*Y[^%&RIB*<\B5Y(-/$ETT%M4H\%WR'P?C'($3$G$Z_D#AI^!
MI;?@*79$R^QKKXRI$(1%-E8N58[8)@/1&?E-(>R+MML30VV3+0TLPT?HH$;U
MHWB+H7%M'#R$SQ3S]=V9G\05S:&']_NTE#HYEA_Z.C\SK^4N+\@$L"0*CQ3U
M>1'S" F>4[(P7A+7C]%94EBLS08*= WV#ZGED/^^LT+>/-$+@"-UH(@G/FK]
MP_]AQ6GSH;/@LHG0R](W)D^6.=KE-@E%"!?U&K4V_7R$N8 NASQ645%"V;>[
MW"JT-66UP,5?8*$@FF!L _\^X_!M9RZ.LU,_U%QT<YN,>.R(E-5C^M&\K(.)
M:0N "=P*T&8(7(OY+ 8SO&+K-D5AS(>1_*9G5P<:O:SEC"IC[H1-34VN6NJV
M3L697G=_\G$4,53'Z.76KFL_U1FHF)_G!/"GJV/TJ-EP07EY/EOB[!LS\U11
MJ6R%!Z]"SA='7U,Z;H6-I#S!LM$$8:21QM.U24Z*/&/2MJREM_(XV \:7V3*
M._:]4W2XUFD;MV:LIYQ=/C14:[% !W5^)Q5@91J5H0TZEXR%N65]_7ZY7+ J
M1KDH8+5<C(O6[08 X<<GB ^NE^5;PLCTM!=FEGO%EW?I3))W1!:YSUW0G\PK
MNG'RJ"C#IA[>'-_R7/WHJ$^+43Q!WH!UR="Q/]KL,6N+/6ON>WBYEXL]4^/!
M6P=\3NBY(\4)O5<2@E=53^-2+I92.3MLE5_-3DB/?>.YO7D!Q-G"].&^UB&A
M:/N>&FO<*K3.BW: $#ER7T_E3OSR[5XI?NU$AKQTLR3%IPRL8=\"'Y[R49X6
MM@A_&'M%(W/":VWOJ;.LW!>?$\X6ABG^>2:&T6$E,^'&AF6S?C\NQD8[#Y45
MAJ%.J7*F,O=*T9H^O:]F-M(#K)U>I4.Y7#WYC&<KT]*/'U>%[-Q/,CM2CO67
M%K),7>8Z6[;E]<!/LAH.7WSO9&D@71/5<AY2?^@"N=I>+2_A38UC-JG:K$>@
MHB<',.5;I,=2DY<"Y:Z^+)%3N%B;F/+U#,_S>8X;%JY'K'V*O']![Y1V6=@2
M/5,,X2]O>Q^(T^[$&MB0/*ZG"@X;E<68P@8,&K=,KI *RG#%VN-/HIV%<S3\
M'-OM_83A.;_65<4G(T^3;N 8(^4-N,QX+,T+'Z\Z?TQ\L;F&[ U_\PYRP>3D
MW\K#QMH:'%;C>3('MV? 0+*_[0S1*(GMG*FIGJW^*GC$]QWHN.TK$"CC17*T
M[X_DFXMM\1>&)29>(ZW;+U6=R4/V%PF,]@FW/RQ\F'&F"&V:X9T_/@;XTR*/
M7A7P$''JN$$$DKNR\JV08[ZF=>15.=A30*;;XB)WF0%T]8<V@$OJA=)X52]$
M\]M=J3%G>,@'7X>LK$)H"  XL=<Q/4&H,5&:;!?X!0E $L%P"!7 SI%$@_^^
M <I7.FB8I0G#DS I&C$5:?:RQ.>&$=.!);V"N''4WR.X.0")4<YY',_8(E5^
M)T 5G#L9TD+9;869OP*,_Q\Q8V\?8,=R@'HN2&[='P[ TPS_98YC%C-7,]^9
MLVH?KO1""*M@%%'#XA_V9\E9J/)*HT8XT@)9*'Y:=)!4\(Z&.:VCAPZ:;P;O
M;4F2B# V2$$&/CV-(K+/U!]ZP3M]*%4ZJ*RF>!39E\:6\ZI!D'*]/_&,]Y'=
MQV=IH?\0>4[SAL#+C*D%ZJ+I8B#$C?[G(.!K&B1A3?[>C3O']P_=N+[_7C=N
M]3[.LK M<,(^:S7H6A::BLWH,3<(\FGMWBPC78/50O"Z[R7%(?=D@PR$,V^W
M7$?$A[.BNO\'_0EK\7]-ZF<U&]+\-ET2:O94\@R#<1E)>\_A/R7OLPDU^1&\
M(45RI6'G ?G!69O_IZYA'S2%79"FD<9,!PU0Z*#=@P,)*:CO7W+:-K4&G[!0
MX@9AYJA%5G4+H+PW2W;?_C9"801R#TN6VDDCR@)(GO$!S89^3 T Y$#).&JP
M%D)[$U"]@2:?Z=Y6MP_'SL0WT4$OTN[=U>#8U::D^P:O1@+DNUF$&K TH(J'
M8030%:C'*+)BB@>M:ABU>-N$P(& L**P+13)3?LMQ9? %] W!K[D%T#-W&._
MJX$@[S[Y3=;C@6%D!W;#J@;X*/=]L"G^!-@AVI\..#9 UF( F[L064>Q!$JK
M&4P#],KJ3\E(ZD?@X9_[S-,:5X$7TA8JJM]O/V#:+<8WJ']+;M;9_2F[U_='
M3&0@!VT5HD4&=YP#9.= \,;;?Q$_>8!Z<0&[<02HIV@SX!:G39W*7]-!_'"#
MW6W@$USC>(2-M"/([?Z ,/V'1R;^197^/VADXJ_5K^R?5[N@.>B@@)>H[R4X
M["X=!"B/JQ8;FV@RIS$9Z;!W\@!P:O7Q95FJ@%;;ON/U0AD>UA6.&S6-FM!V
M63[1T<:>A83:-4^R(%RLJ!IPRF444POAD&9,RU&>6V?#M>Z<. :3?-*QX@X=
M&)%?IH,XA4E1^)V&[S0176N/F[V"???+>J56IN+[E7)>& Y-W?OZ/$#_8%3=
M/<63M;$7\@JYC5TUAFQ&G"B1;!?:9P-;NNOKC_UP+/-N\Q/-?.K8:FD\/.;M
M["/,,8'@*DW=N4&XJ<Y9?HF4:79]^%2$W(5PW?<Q+)G5%\,1(]ZK<Y$1G#%#
M#DBNX";3<6A8Q,O.HF-L;&=^5I;+/6LK\=(FEZ^,M6OUI7TF5BRBI%?A.\LN
MPX <=-+:TUU*KAH?6<9[;+J/3.ZI#I"VBNNZ;$KP.]/HQD)X4Q7RA5WAM>P%
M4[>@I'YFA3%:IZTKWSS/^*6?XU;VT;ZV(TIH>8(FUG,*S0HCQ9--[+#5T=XW
M><4?B3H0N>N('/+BW1'R8MJUSF7E9.ROGF-AS7V-/^*>W8V(?J;7NC2L770K
M<\M/X4YZE>LA"I0 ;?"_M-3S[<LUN(??%?GVE?BNG[.G3A5_BC(3:[LHY(ZT
M>3?O,6T0B3"94CO4D,3RVE.^$O/F^Q+7F_*NIM+1>XTO-?.47MDB$W\V)^5H
M=[G/>5M+9^_9T$%J 3X%CR]V9:UDM(ILSR/Z[U8C:N++MDB[1415XCZ/=C,1
M.P=E:;IJ\]370,5:6)!L7/X3+!51\FF:EVL-$J=ER<+%J$G[00 ^D-$HL=3[
M>[8 B-8LIVWW ]?J/$"'Y*\:C'C107MR1/@ &E&X)UQ"]K95K@KQ1 .X]H_1
M@#^;GP2?MM]&%C__V,E0:3D7T >'ZVBO#.B"/SV!AM3PU)L;XWW+)8>,8T>[
M9W)E/3]EKA_5=N7*6L]NN:8!0#<^!=4+0)(@'42\C*H'6O@=+ 5 @\$!4<H-
M&P6 ^&"45*#2B_BC*)H3)R +$#I('' LL_;_[M5==-"I@0CL N X10$?VQK\
M7Q?;Y_V9$%+22B#AR!'"7KUIVM (HMU)>&S>GI<JN:5?*\5Y[?T3JJ(6V"#:
MT%N'\,R9:&F9ED3 <N)WN*9S'UP*&^\_%2F)*(E(&2G+.5.;IG?PKP2Q\E<>
M01L=IVWOQV"KL_P79_Q_B3/.IC)]_E5FP#[D."[2:]I1[^@U9JVL].H6!,*;
M[-F">% ;@TL+ >,, L\'-X[+=Z%K9*\LA:)RKB$!(^G@$G:>M8EKPG3<5XK+
M0=3KDN2WQ=O1EXXFMIH(Y<74B:(W./J"FOPMS0K]J,/JRWJ1//(_.!_'2NC_
M6BI(TX9S$>V*(BW-+Q=YI;%LJUUQ#48*X^TP^:XY2\.Q\6A7^=YE)NMKW!["
ME7$AQJT/4>^>CUS0OWH8R>_T["GX9(W\9%N$Z<2=OM(AE\RO2?V>B=+WWGY\
M,WHK,W\R'_OCEC6)46B 3<.@7WBE4KI[0G)B';O=.[)W"6Q%I$S 4R?&9V8F
M*F3UJ<X?NWW\[A3_4CU0:-/BRT5\DR]D\?14,,]TQ?=XQXN]!PV%&+_:GXNP
M]S%H(&*$^RSU:@CGWL0'C&LC^SXIF[6:2+'Q@Q.+7YC'FB*[U"T+N2C*W9_7
M)#)>%HI73^A=UC97[]];<R#=N-TC'\ENYI@TGG4N);;BEJQ,UI-TL9*$QZE[
MU^K6GJCTU-A-*2.LI_+I(%;=HR$V5B4M1Q?9?>LUU>*NWEV1O!1FM1Z3T $4
M^O1.DA\[@6^HUMENMG!BPFZ'/SU,@CF@MH0(R.+H3E\ZZ,$64"^N,!&N_)D5
ML!+[D4"R1G,^;33MQS 2-_$PT (STWZ(1M+&81MPS'DZJ*@?M@ME1OH.+-BO
MS@)5O'H*O+MJ!]3B)P/S*<B*.M2&:!II@A;#MK$F#]RM%%*'5=Z_BQ/BA7SM
MJ]6^FAVO_B*");]?L,GW"-W##+L'?S+VA@5A/M9VU]RWQ8>0EB>%FU)S<0_Q
M[>'N#N7Q=T=5N5JE1!:LZXP3=0\(<MY#&CX3,T0B!V;2IEP;J9KK#6>OAI:U
M._D6K-09GY;Z4O)*==7DCJ]R'2AY$IKPXB?RZ]Q*K*W?<EY9:?27DH$>@\2%
MZ0M@DSM0YQ]CE[TQQ=[>L/D-Y5W)082&8E#+2F7N N9, +=S*9;7K%[^_$FA
MVK?#5HDB0A'?CH$$DN]SN"MRBH:1[A<A[H9M(^3P\3]FRWAR&ZH=XY%V/_,N
M')2[%W5*-:H^94+AR=?AU$LFCOI."K->?2.ZHM[926H%=D9,N;TOK= _T>E8
M3[NB:MX4CE%:UV>2^\347)8K[KNTP,94A;6.RN'C+A7U[%P"_#6'-RNVII5;
MSA1IW>CRE#V]1-SEC'*=&QW3$0Q5!%WRB_:YPRB4"F)(/>RJ6>.$FS;/%XD9
MR$ZX6*C1C9;0-4TI72X,BX5^]HE' 7C0(.UT5C&(/TC76K;%](Y,YOG&A&X>
ME1BAQJBW!74,1N$"V9JKC22J)A?;=IQH&UP%>6RBS3^L\3ZM: KMET^#SY?C
M !R\V^%-!WWII"0;!&)75%@VT=W#E&YJ/&IF"G$.H(]!5 HR?F 6X0^P$!-L
MDFJ^"V- ?>W;MQ(!_S$>>%U/!]4:_9%-4]2$JM[?:&LS&/CA;1PE\U]%RZ%N
M/_O'OO+"= !KS_;0:@'I\DO#'#T]A+A-^Q)9'X!-00WOT/3;IH*IL7J W]2=
M0R^D_^9@'P) :V0C'10$220'A])!:SXH@NZ&5DJ7!L>>(VGRMQLN_W7D_-M9
MZAJ MI:HUN?[78>?V>B@Q=M]Y,@PU(9P!AT$@Q"'P!G[LXX$PR:V5X$_WE7;
M#1-#UQN,7/_S6/U?5L)O/_MG=G X5/6GD7(;23KH\%&@$=HWH+;I( CM>=GJ
MOV^ :VJ6:1IQZK D]8;GJ)FB^MTV.NA6U$8?T'Y3TGI_2W\V0WL $[7:U]!!
MQ<]0U'.'?5+\[%< G2&<NDEK6@1*^2G'1!SJ>W-"[J8J\*9"Y;*4$WO *Z&[
M#6;96N@@5UFR_,0I +C@LE3)(*SJ\I8<<0-X4VL""]5KW\A^A6]V8"TG(62V
MSOVD(>U0LO=9H'B'P9.PY(#]+2;4K^ZDO=HU 2IX"M22X/H-&\X'+G^Y&*_O
M(B/_*MRB^.OS-O:NUD"!P#D98Z5[5QD]'E1BN1%P_*/W>U=)Z"F6@!J6[*4D
M]<\EEM<</[4(N7U1NB;T0]#.[A('\I*ZN=GI5H[9UU(A!:&"A]V"0?@&Y?F!
M)&=?XXTJY+")1%MB6=M06?:JRU8/W'I'37S.B'@W1\\]<WU,M*AUI6S ;\A+
M#;,Y#6L8,R*Z#UR&N[Y"<O2XNGB2! -OEZ?Z3\H7+!.;3&.+'5I!X.K-#1:.
MF22N()FR!<28(K0G/46XH<$_5\/)V"V864[B<X?F 2';J !FNR[K,PCV"U%)
MF1,UZX43-ZNP,G/RA)@FI:K7.-/NML)=P5K2XA0+"ZEGZDAJE68%<\_(0C_G
MV?*OWUYZ)[@UYDI_$W*QZ^3YWL8PUN%TCK'1"WP(R;]$?#ODH'ZA7,%]T'=.
M6Z_@^^QQU<?A$3\"@I-/=2@?^1HFD1'XTD%"NH*AT(7F;0J?_7BI2:_?,[KT
M?>V>K_GZ9B]QCPZ*@+&4P88:++H*D9P^4/W:2L()\9.)<-6]7A[SEA$3"\.F
M#"$QB/?\#)]DHUAZN,C)>):T:-HFIA 3ZNGZ^8&;YT6K&N*.2:DV\AK0XLU_
M_-\--=ZH0\@CXY2'[VWZ7%6U73^2_.J?7>Q3U2L:'5&M[YYHOQ5E*$9SM/,5
MNFG\G2%:5R) :Y4CWZBAQU-"19@..E$SXGHSOG A\KM85ZY-^DN.$1I&6]IR
MX0UK&+%S6)3XB.2&GZY7A)RF<5+L*OI7I.7/<1E4=LD^)3N72?K*EK;*,FR(
M_T0:^<I6V%8>#BM7L /:^&1"O9KMM'VC+OB@8U+L682<DK\NM(;Q>T]AH$3-
MAFWT 3N3NYLJ50*S*=?JXR''+4\0C@U+^F4G=>_)^Z=U?JRU.BD2+WS':<//
M/,??N<IK#)78VF7=V<CRXME\(,JA%D[TZ/&$^U\'2H=@U_R*[Z.(-"YQ*N7C
MYKOJTZR(ZE#;5U;13XX5[0?\%">\=,4P^P1/#=2Y#AM=)U!2C]_*(L1'V&58
M#[;;,[P1W-.KK#11O!.L),-QBS>J_?:F%(<\H[BCBOG0R'BWHE>IRUB"?-&6
M1=P)+/?==LTK]3M0:(^?Y+BI!<9R"%X\N04UP,_7\QTFG*KIQ0@@M U.+O8C
M+0"OO)A-W)C3&GL5-*IZ/Y;A04='&%:L]9')%<@YVM$E&(/JC:RABI!"^4+!
M1@MF3!FNUKU9\=9ZP2.9O#G% ^F>/C,1TRXFT_>C+^C30>;I^7N<U/F9E=V%
MU4>4F,JP!M.G:E]LEC:A-GD[NAW]2L\DM>K5.?L0KE,1D/HK9UZO/HL;MJP;
M8)-R.V\;T;%:+[#]2(GI0TP=VIZ@N&*/XYD(5#]/JL3S$&-_U2!IQ\T>$N(C
M__Y!N"[X9QF/7>>=_,IT=>93 >',B@RGVRMS\]:L$CC4SBLNPSN]&OI,8.%>
ML=(['>.^[NHQT?3J+RYK;="'*V7V@0#U];N_^M\^1/SGA6&;.Q3V-B-,#T(<
M9_HE[;[_]1G%'R=17JGIF!=_GCD&7//M#FK&$)] ?>F"VK* EC5\?:P@IYRE
M6<,^.5(5K:?&TZ?&/6>O-.IB'6_<B)/XD7)KN#L\^6%1=U=V4E=9QB!9\)^B
M&OXA>$)2/8QJ3X7BTG8/ ,P> "#-][14%!KA!G#U;0,:"Z#;6\^"_V52A7'A
MZIK,&FMW-V.\N9707<VLQ,%DT/ZD"R@\']F1QG49Q0(^-4HRU;IE.*=+XH\3
MBFY6.FT][FFJ?N>;JL)108:#5Y7Z<#36#*&\^V(BQ-HK3G30BS+UR]-+K5\?
MF<7'$PL!GQ^MC/JGE(K_GD!1L-M','A!,9],^\S"L>!AEF)@H#O"D<8=/];*
M1&+D9\T)#&S1Z<(/'-?4D3VLN>XZU@"K:W=K.:=4*=7)9H==SZ.#-F["_N7;
M04O3@FRN#%R&D&Z58EFTI?.%T,<V[VA?:983U."^MY'G\37]LQ7O-$>@CJIB
M?8FS%J/&"&JLP:#.?1JI$J!OGBH,<YT ^'TF@N5?/'\^WU$2:EHV9/?;KYK3
M./+V\:R05@&-Y\4?^#F]'G <N<4M=.*M2@_"<1+&1;DRD-:@KHBG=KSW/\NH
ML",>8+QE)QADU,D?]6TKEPZ"^A@,[\GF_IH;'^](61WOKX0MH_GV9!VI6:&S
MP[3A0O0PI?_\OY.5TIE>1@>9D.QISQT N/R$VA"!+4_PHG[U .(O<']IFF;P
M/YV_,T$2%2G+78*<6_]04SD>V*!XXD@3+YE("\"XHS\ MT@"KH$!7+$"!4BM
MB[@]:Y^L]O:^>U*? TY<\VY$C_%D$E)/,N/7#U+#Z^*A""EUT0OH*^Y>;G$6
MT:^MD]P=T49K26+IV/,0S3]"'#I0/ZY0/ #Q:6% 2U[-QX]CW2&3)6D;;["\
M@ CKCZ&#<E2<*(KH"=7];H-G.53_!%K,(?P$*W;&WX!6"R@VG7?[XQ/7R N_
MZY-9A>'U#<CJZ%=I1*5AP%6:4 ] -P%EP# #:+HEDCD=9!N!IKV"_>) <D_E
M4"(^H0+I(!?[575NU/<B['[R>"_';V;SW+="K;( K?E0"X0HZH3:U19&.O]]
MY"W][R-O#?^CD;=LM7_<2=>T"S7#[ C 4C'PI (% X05C C*7 MW#=:!704@
M1]2.<(/V0V2_DV83NG7W=T>7,.QT$/8!J@'\D]( L/B.*H2411;L6.['/HP<
MYFI!E4!"RR+!#DC&GAH#7/[8!4<;>?Q:R2D_O>O-@+HQX9_Y*)4F.?E*]=0-
M#E?AHAX<5PN$'<%3-G!YC.W:KS(5,*NYEGVA&7S78JS![:".\+&RD$'O/(7M
M\[T?)'[ B5+^AT/K=6("DKRJ7 :@T(&,\MR=8K+"D9*&J8R[>DWY0UE^*BJ.
M?3"M68_%M!&_2<@WEA ZZ+@G((_>$^T)R*QLK0_H8*,6[$EYJ$S5O<HO82K'
M"F?!RW<$R;9><YU)WK(2'IB3M%::@OIQ/ /D)$V HLI)X\=V X:"8]0:<;5G
M=5U$_4&K:PZ912S*E%TE\>CA>8^W]6<B?+E:7(?78:02')ER& <^Y)#*@I\E
M]&3U;8TQ'4.TZT]U]_&'%HDD:0M%"3:0W=:8/GZYH6Y%=@V6'^D\3@IJ:*QR
MUQPXZ[D"O2.5I\,5T?#IWE&AAR<V).OK[1+3VSBXC4L,-(1_KOZ(-G3,+Y,L
M7=N:K7:V(A:;O['8Y#*]O);4U[21OZDP:J3?VMR:+^U;^'#%#T)A1]59S#>@
M1XRF&))2"[/U/3O9EBP*<[L]S8INWS'P?<+@X?L8D7O5J$JD04Q0,"D'UWEZ
ME-:.+:&#0K=TRR^2*J:R8YP?E#,&]UP&R\OP.0;C6Y^V'HU@4=>I"3YH]MJ=
M"\OG6>M*?%5+S:@QF<2>7+Z2^G%*)<)I1Z-W)2M&+VG*_.SUPE.Q<IKGOIRJ
M9'1@_OH0?)- !U'8&1NQI^[U%[E"'J6]/(LL+OKV)$%=I <!YN]-]XV+FW_C
M* -^_-4V]().JN;1(U7JZ,@@+I:@.'EY#C[[IV41!6757YS6:PO[,EA<7Z2*
M8 3D>7F3*TW>=T.K%XIZOJSZ;6F%D![,-R@D;9=UAI?ZK=ZXK26RUJG7:]CM
M"V4\(.+SR%CY6VO$5P:WY$@XM3(<*?@:E];$<NR%\V2*:]UI2Q_1FY[J7A&N
M]AYJ-<3H2J&.J=E';SLWR!BOU=P=QK<^NLU>M+-A?M)&WY+4J^U5)-^K68L<
M$+)ZOBA<4ZR3S,H4S#3JPI 7AR583C.^1LHN7?'L#.GN[N_4Z)[N>7H.?/MY
M$SQ[Z.,CLP>&YL658T-CB6,IB8FA[<\X'$QR(W-,),7&5VO/PM,7)4=L!J#>
M2H[0'(-#AC'/?O3W&/<L[38/]-2FQ+VQ4!8*K= 0%/_&;?3FZ#=PB!+:'K\3
M*@-YM#ZTTT@#5]N"7R/%%TW+4?=4U1,^A!K.9L>B3B3<?AOR:^.\Z=M)W=.J
M'5E[-YV>333[2T[KE^$KOBG*+5ZP: $'-P?.+$(A]B^U>/1<C^>\T_^UNGG_
MW;T K+0W$@(@ZG.?A*G#F JU@94>?*!!O_R@C& 50>']Y.*1++:.@B\&O-U6
MZD-/VD,OW!(59#AD12J+*%K\UE7SU'TG?C$[?CBS;SQI=73B*/XIA_:>I:X)
MV'.E[_V&LXKTTXGB2>.[&GZ,T1Q[^UL8E ,("B(!/N.>Z/ZN6/EXS=],X+>=
M2J.$ LPST$DMUUJ@ :@Z54'U0^T:&R !;,3'$'_]9<.\_X7</6@''80W!I/9
M:P *N\^31N6,V]+ZY[G\Y D:$P#M @DOL2N"^WF=W9C@5Z@9U W H"U*X;^^
MI]WTK-U?/?4&T'[4&LJ3"9+EM#')C<!SDS":Y#0N$Y.KX4[\Z39W^-XMQN*6
M&X.3 U]]T+B7ZD+X Z2T/6E2Q+:U&I>9OY$FYD$"\=?8-5Z/EA((QMC0EX$Z
MV[QQ"2&*HU6GD^R;3<^NAVSE8#Y7O'M?+38JGGHID[UU\:U;ZE"G_&+J:5(M
MO@2G$)?CDU_'=7:[H_CA</J@8\(BD\:!RB"Q!@.!BYMQ5Z4^"*S9S;L<04CU
M1WB'1.B<=O$J'P@O3:B6F9CJ'E@N7K4K<\ACS;'0C=^?D7\.BM)S=7F?#&E
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MFR")BE+2H/6=>[S.J"T)VO-\?"<'9,;Y!@6\YP%QQ+?1-#SI(("@RC\408B
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MC-IZJQ"\@X\'^?(K&L?2BMTZCAIAV0,J]DD:J7WX9@KV2T4GV".LCN!JAS6
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M.O.F0*)$0R83?-K":]G.)B^CZJY^Q!4Y*C=SOAS[^NC\NU;'?E"82?D6.D]
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MW80FM O,;6\S0:MS*JSDEF *5MO1QT:('E3?&Y^'*W^TZ)&'D%<3,IODH@+
MK\-@.[]#E5C\%RBT:FR'^2\$V0U[21%*'NXL0-L6GBUT2K+^^478>',O/F!O
MOS528Z#Y[7DOT02N3>NK6B'NCGZ662A6@!2(4T*5N8CXHCR. Z\9N.Y9*SHR
M6;/)9 2(M1T+M+YP^;QRW)V2':>_="1\->ZWX=_'7P1V6(L9Q(FU[<>\0XC
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M)K_?EH^0Y#<QC]P+Z%#QB;_@Z3S(+J)757")8-8%#2:^)K0X8WM-*2'4=Z'
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MA#%\EB$]D?.D_OJES$USTF[;L#T")\^'+(\'CR^I]M]VVG-Y[L78*:%V*ST
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MM0GS>2G%WB]^""AIOG32:B8Z>5P5*/1YYZ:D'#M_C:_1R6.+E^>-6>WF?E)
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M*30V_GI N1OQ8M'+_]8V:_* @T7BX54="DR.+<"I8LM2>9"I)X/,6 Z!J,:
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M2[04/2]G6??K(;(7BM05TW+[P)%>+TF:J9L6_RW#=GP>G(+'*L$O0Q/F8*1
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MX!).:G'4>]T@[0K;N.E^![/Y\OWBOPJ0AJP39]TY4RT^=[2*)222E6%.Z&.
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MV@WB39J+$-LP0BAXQZGO^GE/;:D&HN2EZJB!'>ZW?'H3W@I0'LQKC>.JV'Z
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MEZ?UTX?NIQOZ!$XT;)-/$-^ADKYV%'874;^VW,&R7"+1[9#3]MUFR*X9"?T
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MEWW^X^5?+KONXW;YADQXN]=.Q-YX,U:?ISM\7<&!N;9PY\Z%H <MZ:._D)Z
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M*CH28820"J8CR"<8+Z,"4Z,O77S!O^VX-20W-*^;%(_8AC$$8H8[>! YS$[
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M*_3G?5WW=:G)R;>0ED':!9%/W7_=/K4">=M.C(4]J?*I]\Y,<S@-UXV29^@
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MTMMD#*6WJ^$Z3,:KDEB1=(NN#UQJ=W;CV]4;V]-RH],5[,4,S=O# F(V?/M
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M:F",]*#CT'PH:)#<MF ?.*%,EEZ:6+(88P>1!>Y-.28)W6FZI]5I\MI[7BU
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M3V6180C9@?2QXS[&RF"'V[8Q&[H1$@N<+;699 J^F[ 9S-5K=2C2>/'IG>#
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M\( 9;6K/1T_^1Z9-#$2RE6;P4[3YO=^L%Z;C-S[TNJ\P;6[\,&DY3J]_>"5
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M\$I]?UC8-KI&1OYQ)HL.8(AL>RP95>O;19[]CIL19GEPXY? NC)_PI9:'J"
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ML:WVPPD.;GOWLEZEXA^J3>631CSQSZZ?\'O,]:'PCV$BE!5*DOX5<+P#M%#
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MB#L39%\*D*PS19AU6,-9Q$U=W%7H,V@%F"!.M-6A;,^&@<U(R Q?=SS=0!!
M(^4EQAC; MZHZ_>$CH4(62T3$&I,4.4:[4U&*Q=5,A/+R.B%?J0X1^;%M>%Y
ML@:E?6YM)!\OM;CPY89ZG$WGVF(RC F*^D#A9H*T,(Q;Y]&4$3!Q&+D?L0A0
MRRYG# "M4,F+*$#]_FG*Y[ 38]G=)";HX@H7Q<,D'+)Y&?%3 1!,XE[EA3Y1
M@A&-HGVT0Y ^41AQD/_YT55Z<>P*&KRA^>T?:"N'*G%DB@&> _]G; ?^B=&<
M_=L S9HJ09%HL3FP,"&S6E$5?'9]7(5+[>KK"ZP/N4RA_1;P;42C+'KNFR9
MD\> A;7YT8,VVU+'*Z-LJF/J8_,&T2PGNLEUE%3IJUI\NU/N21XE9SYTB\<4
M&H?\_"]1^ =[UPQ(DR:M*=4S<L=AJA341[<&KL'S 6R4<%PWFJNXMPW-DSXI
M>^)PQ,S$*5?Z[#'!'FA&4N4/<X$W%=LU7JUOBC<FNA6//O_1]K9"QOSQC @'
M>W:8),L&NEWD'!VMR4])66C<NQ1A9@8UGM4\49E#J!FL['^:Z97;PSXPFV%G
M>6N+=PNZPH>'QC1(462#"F#&]'+8/M*0*?28B4!P-ZXMWL?!@?6:I,%X1>!V
MD('S->OND,=IK]@&'IO\W%[1(NDR#AH2:V<L\AJ3DY&?R=$D:'OVT?JO@W7N
M)*L;]#>K&@'NL\+&JJ_O>'Q?6G9Z,/1AW?M9X6?Y<L6[O%=Z=_?.82&1@E9\
M9DW"@S*K5U2)1\'1FD>A)^YH![QM)E:9'.20:[G +T'E21_]N?U;)(SP5"6C
MVG?\\;[5K9_@:@@M$Y*,6-G/!.T*8 HQ?]JSO"*,^4,6<I'<[VFC"3ZZ#16%
M8).5E6L0#\Z@*DO_$E"WH@H-^3B#GL<\CYE)^E)\SK30_GV>P7FS4+$2;"?_
M2*%!I(I:BFG<5+7S=GG!^[K4/]6O_K',N!9=6IZ\RU[ !#TVI"5!"/<+&1&_
M,4'A@,TQK?]>861RLVRD4EAD%+]LE#8W5.):;94R,BZ@[#:6\$ZRYT,)AZ7H
M.R6/?Z"=Y)7[LXSP)<3,B;^52'6A%\^ *4*(GJT:Z<X_5<HV^S.Z@&5KCEZ/
M#0.,FR2CK0^R*)+'V">W5Y[UOWIH^X^,\#]%R[S?:4KT7#@'#8J9(Z*;T0((
M-ZRV!T:.G>S5<RG6VKSJEY/I""9A(3/NE;VK3M8; VY3VVI^L8; \]G.&1:9
M3Z6O5I>9&:%;5O/?Q\VH7XO;0$Q,MD_+4IR(?-:DO/ MG\]+@2DV\:'(,ZJ!
M[%\2!7\^MS:VB)D+0B6B@8YX)/^M(Z5['=FT-N&<W7A]$:5CJJ_N,;6:$G:&
MFGW4O>6V3-ZQ_-&$+(]=<:^))8S3IDX<;?4?*(^[1=?J@RS\A#1 :;'S3%#)
MN-6ZR2KP1@P>,P!]@_U#,1[D][WA0>2'M--H>=O=3-!SKJU)*88^?8 )FDL>
M$)#>J/W?UC0F;W%=8H*0+Q@[B/7?&+7.T$Y(#83V?%=4&QZT-]4CX+_-M-/>
M3/]I*(QW"^"-=216CG$=@KE?N".QK<L$I4"NNZ'ZUO[MBD+(L,8L WZ+^I,)
MZHC>):0AQ!B+@/;K+B;R[DS]24(Y?QK&;O1K1'\7 H;>.<8$V96AYI!3 *ZB
M'W_?($PY0+W+&( K4?IQ* Y*%EYBPI^N91$G6(M8B5?<.):M,Q=S83?B2%@K
M%)(U-U:47N%NY?Y5FEH=YC4B^J.K_+ZRCX&%Y,>4P-'I>L%#LP# 1^R<%E%E
M@DK5;S%!@_K2GTL@Y&A@F/MFD53N2@A=+.7+ _0:@.];T!>K>1D$B.X.N$\8
M<!68Z/5G?R^5@2Z_B%YGJV""4( X-H];>E3% PK@:;*[!8SW*J\+.MF9='&W
M"W+H$ / +I[8'76Y.##95 E-E\M$OX_[BX<6Q#PZE9MQBN$Z+R+!!'W%,4&M
M<ITB0=H\5H2\V?"_W+ZKQQ(-?78N<$5!R/L1]'.9:%;/[5H&!V#7S^XCMC.^
MF3!!N1>MYC7/ ;.4GDP'@,KD/7@R+H.6)(W 5 ,OKV\O2;Y'<T"\_F6W/MIL
MB* 4IC9K@(Z'\=W4N/76445T_\&.N0<F!IEQ(-H/>H*F)*+1#N*$',<VH\NF
MTP ?8HVT(6Z'%T6EX2Y;:&H&N_3->RDKP")K8JV__Y#RLCZKL]_UR/F.[A?@
M^XQN, _"S20>>62!I$N0I<KV$N-;CB\-3C;B0NI<G4M>>5E>&C_?,.!,K?S1
M>R8$$(6E":<4JF7O6%,QBC[>,_D S()>"N>EN%J7/\N=?HX'Q]AXI0US7C"H
MNV5<DO>\4;@U ,D!5X'Q4:BX6 TOH@1^.Y+FF:,=3$Y98IS $"JES;]86+K=
MJ%I=%))^)_WZ\9)OQ]NC[_\=^\I0P(TUWD3,F1$SZ$^]$9LV5@/@WP5!%Q 4
M*2Y:G#U@&C\G]C/B#79%> $=IW,!%O5#>1/>9^?XZ"9TUTSSTOLX:?(&Z=M?
M[32CWC)!,YF :D%]  )K!1"0 ?+6QL\P=D#N  Y+H2*8(,?Z=D9R-8HO!CVG
M"P#:PY=AT0Q=14A+<HW;^SB:&/T# ,XFNQE&02V0K0G S!C@4/UJ=$YZ'7H.
M ],"]*\(O5DB0-M C5*X&-<WF"!!0%$<X79MZ'7E: K?PFF@?P239W^5W0'(
M8-R582S1B"4+1^]@?GG!W>'=D'5?S:/ H%<@?6A#S_4&36#4D7)$>!%=+@+R
MPX,)BM^\>@=!X +$R=(.(4MX(';UQ0-YVQG?@7%>T? #1A28!\@HQ:H5AY@&
M_'8LW!7CB)[*VRL;VVG>2P\A,LS^;E71Q\M\C"NCR*UE,"-"JO>/G("T G "
MZSU.T(<FA#)! (W78G2=W=.&#:M-T[]ZNM3 PP2A'1'-X!Y:<PL3M*T!H>3N
MB/;MI1U5T![\9=K17^CA3.)?H=;V5LC."<#@HY#4^\D#- 5 5JT^NV3@97XV
M'5!^G 3A7ZJ-;GH$8E3V<&?:ADVOS-'G=]ZS72@U8WD<+";R($SJ$1$[:0&9
M^3!X.S@$,O-&!<WB4+=18A(7W58;YJ@W(:,[%Y9*E1^.ZL]"]W0T&M4OLJP#
M/'N(>@?16(_E0CC3V7$0@A/1LU$@N@5Q)+98 SHKQP/OGTBJEHA'72\:]#P7
M=CY#9K"XTT?%N5'?:=I)<O\A^K6_!5>-Z4\9,K#CM205&O=0<[;P(.T(.":O
MNJZ*V/[X)Y'P=3C]E("E<MFD;;J?X!7.K(-W03\"9X+YQM$S"^!=3D83F")#
M F9<!/41<6\?U;N96#++$&2LX6YD*S,F,E:2B7!A@\O25(WV8S&7AE]]I.J^
M6O!N'*]H3PJZR5[X[\J6^[-RBOZAB ZVQ@0=N I,AV$3E'S\*Z!X[E"M)O0Z
MY-T2,#GIP7>,F* S:M. W3?0;><QU89/PR_]Y?[6)IC&#648$I@@>MPV>%=S
MN@'VEUJ-)_'18DA@G"OJ&6"OYZ,IS[>- #?T%%F1#:&&(#I+*-&,6FO$KSM*
M.PO0=\CJ#%KF6@QBN3*#D=8,S0[8Q>X#/LM&S")V;YAT?\$P= !UVD^; _H0
M5K#^5_D?[ BJ#""D%HHZH_DS$Z1&ET7UROU!G:W:L>L7<AE<(\A<HBXU$4J"
MQT@G[]VP,_<X>('10@"6MKY82=.? R.4.CGJ"(0DU[.[8D6MH(/G$)?\3;41
M]N"NJW_GA$[VS?;WP @$AACU %SYKFW]:4*.%EX,61Z%T%DM,AF7,UKZER5I
MDM([&#H*,;?2((D8OSX*--;@P8C[BX=TJR;D]HH)Q6D'^3(8R5@ G#X/6BQD
M"I!I%3+IKPL#_T)!CZ.FURCBU;27[,U@ZCX(XT4O]"4%6*QG;"!;@*WT>KX+
MB8*N7RH&3 R6D<:-S?^;S:WX%TO0NQ<7'K?"Y1%4/[HCB1D>\#/? [!<W3+3
M?*2,)QI7-3.*W 8->)TOW+FF8W8E1BS"(H7_FF2*RH3\+_.;[.W5Z-(@&N\3
MW1>_X"! U_JB!RU*O1F*]&Q%+Q,SO?4+ O.C\UT2]_>KG%+MTSM;"PYG@H@F
MAEA."O4&981JR1B!0RBSLT8"B JW5$J);9BZUL"J<AKW^.($S-=&K%'_L&*W
M8F=JE79G_Z#BOZN.$?4&6,OYD/5SP8:,)A7(KJST8O+O:=X&FL;+SM"6XT",
MZ0!>5CLWC.L0,-&,Z$+ SUCC?%5H,<N/Y.CGP$*FVKS4$ IN"<F&=NV5:"4?
MHV3@)1*\%+T@ID-*YS;C80;;*A"7"!UW<EMBE9B_:N<!LD*^!&^_$5&]]19-
M9Y A%.QC-A006_EET$N*"3*NF?)1E/VR\_29P(5W=\K*HNSRDEYMHL>I;1C+
MP$<^X7 IF(**Y87@6[:UQ-7B>7VOAU4FG@\VVA*[NI(LK^1&=]B*?D9!*.4S
MO5PX>G]TG2>QVF;$:4A#/[=R_G5&WXGUX5@1?E&7Y'U1YK@H%9:AKSN[EXIL
M>Z1NO2#X[_@;JW>-ND^3;?)JC0(O=WVY+_6MZ8-3J%)OH=F$RI0-YI%2F6?/
M*&!J7/M9@JO-LAJQ1^"JUI[VXG&J D=D*T*\9NJ#A\O;?1[T:%7MF_QJKGSI
MTOQG& LQ:JA%D[>6$CF+XF_&H;DF[.-_"Q7/^F'DYV_E&W7*/&+N_.$372#1
M["]+#2)N1'@O&U<\\MCXK1;LO2 B*M)D]V?(L4]34UP[S@)1XC=IJ[[?0)DS
M&MPX.3#,;,2J2>14$GYM(?15NCYY<I(3MM'1$ZCS-L OV>2J[:V"F!<>2K;;
M'M-4TXWYJCA9+Y<AJP;RD-2+19V;QLD-:ZL2<N=MEWZ&K:;:V'HN%Y*X<4?R
M(NO..9'X&K,O/FFQ%T+7>BH-BU:$AGBMI@6]=(GLE&R%.T3=O2)Q^:+G#/B;
MK-5L=NW9[$R:VN47WH -=/O1=._$'<T;#\Y$'%:U"%QN>B=1Y0\+*@IV 7,L
MHLNAS4;>1PS$,=JKI:@.AD7]=,Z9&+XNV<3/.A]*R&TKZ=^$P^)QU<U0;DK0
M;$8X[1P.LE*@(8&+SWB^=I?$&Z]?8-=YF*.DYYS\LSG<\<"4_"<?C1XZ;LCH
M",JE+;A7JO!)2W0+9]F<=WUOT!TZJ9-4=!ZJ=3S),G+FM?D+;\S%*8G"GS95
M:X.8D8MSO_#K+L'Z?6W2R#L"R[0#1/1U$E=4"<QW%A%S,EMDH'BU];V>5^;2
M_/S#VBKM_<?T#G>Z2.6<OI?]<EJ-F/1U!GF\_QTE2OW>%W!=:S%-Y5QEK.A"
MY+@?X772)H#F&O/<K-+A$J3^<-36Y:.!Z8I)TA\K;#,L&CDTV_FO=>F!R.S\
M*.^BGU9'<PU"5T:RPKP$ 3(T'9UL(/4FU")I,L\_P\BK."/]([8%\509?H)8
ME44ZW#A],;I%4WCD_+W*.+K,],3M\S?9W)QC8\<FC77XPX5V76-1KI0"2#3-
MG:KJ;G^6XN!P-AI'X&Z1=4?@:J,V7D]WGV2"*L/>;BA;!,Y\(BRRJ:).%95-
MC'@Z8"O@ZZDV$TO]AI.&$Y/N8Y@+.<:) 2NCB1*YA$^CF%%,P^[VH5VNO^VD
MBP,PA]$:FDP'^T UK;XCB$:('3D <Y&E?R 6J8_F\'([Q_&0IK[7_\%X%G65
M(C_#=6A94QC#$*/TM3%!-TN)<U7Z]-2//:4:ZW?TNHK%(J'=L8%"SSZD="E(
M]Q<. O;H,+XG99I2/8.*$[ALWW0[IV9 !J"_!C65#X/TSCA4N0U'<J+E^=F%
MCX1I.IW393^;VUU5/.Y=43-!A>:NPN;W2]W.SQ/QVC2@BU0M>Q%&1V7A0V3(
MP?>DU8;LPV7U@P&A<MQ3-M._C"T-]1V/8M&1:7R=.U&<NJ?W7_AQJS+,A.Q.
M"<VWI:AJ[)-(2)<\PQ@AR3RBC3+N%;U[;=/V\DJ^,?O+4RE'?4=KL1,;AJ%3
M@BV9"RW@ []VC5%\B3;8)I51<OR!T6+G5["V-%V%]^''K?7FJA0>^G4'N\Y$
MKC46'H8*T_0H806>F9LQ$@-UHCX.,L^O/?J Z?MT[7'(,9:O7XY4G)!N;L*[
MF9S/[5>%.O->OK=2E>(^'E)[=B*]@^Q[Z='W]N&YIUZUWI!#M=.R2D%S)8-&
MWCT$Q,Q"TUHT5$@)>SAXN35(HGE7.5-)4$]+)B@S)C@G1?"*[]-G.X\O.KV7
M!]USV!6))B)FH5$P$ZZG#$%#G!&T.1N,M*[,QEIGKA[.=Y">UY;,$K\3)6BM
MQTI>>2!3MX^4M7=_\+(G7>KG5G>[2F;%;H+1?ILVWU?W.G9$64 @M;N2&H=^
MP;R.,$'-"!8/"">#FR)MESY!VD<RB5]3='_GN9D\O_[>$OK#=K^*$*T_.0OD
M6.,R7_]&Q;IF-)(@K6V#237HW/"\-^23FS:Q$/&$G$K6-ZNKMDI=21TIL3L_
MI!]06P;3;?+9/Q9<:_5U%'9+,9TA_+V8,8Z:TFT.N8)SN!:\X0S3>3*<.F#D
M#A]D'"96-S-!"7P,?J)+)CG3/S#0[ZJ7>+/!S6Y/GB(5%8EY/]OE(AC[< /7
M(IJ+&^]2^KZLD[QV[(/F23Z(5[WHX0SJ-?BJN/AQWZFL0M]W5&=*:',&6N"I
M"!_IP$]&>2C;&Y9?7KDQ:?O*PQVEY5X&E=/0YP<J7M^;5?(GI4ED:9MDROMF
MEIL93CVHR$['V/G<R[11*3(Y;*QJ^_.GUR7UO)-;9C4V6"/%I:%'N7GQMK9W
M[.^TN[JS=,N4G)#,,>M9,0:! L3(*$= !1M1T8Q#%*[0$*&'=RCEUS'%,I7=
MPS5G3^5FGA,+O7<E$"GM(:TB]N7!I?UE>QFW3;)$3[Q(H40;^["B79!!Q;F<
M X.1V+$U(5_U]OG33@)ONBXFMH!QC2M%%5Q/3S!Z[,6.P^Q'5HM=2 $?AI:X
M@VWOH]W6Q2>RCG3^$!3+F&I3$QKLD2^W^+7^5?*<EOF'X1*,>:;[^8P1M*P]
M.P>[#JSKO)&ASJ!OV<K4&KS^Q,;0PI+D^_J-EO]FK/\_&>O_Q?D8_P]PY2\(
M.\0=PD<[7^FU?[MK1/%>6;WA94UR%W]KQ="U17[..(/? @]\/U:BLO^HD?,O
M)@BL$>I#TFS']Y4ITJ%F0TX<3CX%MPLJPZ^E:>OEC.5S!_X\G'"AWP:?7P)9
MH?%5O*9GUJ5E9Y6@P[;6AI=WR?*W$E2GWJ]6CF]2B_.<A@)\)AQG[8?S1@/0
M$9K[:FN_/NOT]?/+Z5O7:R^\R+]N9$Z4(/#CN4"4L]LX.O(Q32XLST,E:GY+
M25C3TCU9T#3.H/:Y[WI!WT7[4&T3LO?A\?6'[A\SPI27OR,F3O6[]_>6U//9
M[0:HH85H9M6DJF>9-Z"':>?>O_AR@H[2&KH7Y=+T><SZ@T/%:N>II9S,?HKO
M+,$3AT@$, 8X.% P1,Y_/"']5V!DCE@!].4Y5F+[ER(#Z8"HM_DUEMMV0[9K
M#?-RQZU'+7S6I*T)5>W:Q V\<2$1VZ(B(C:XZ:5 ]LQ2]9H6-AON/5'TLOO
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ML 3FO+"8SBEG9[F(@V+'@D]C5+6YCD1[T^)7KY3R#E:K4\<LNON/!S\Q'<%
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MIULE!]>Q0B_NJ%Q>OGY?1R:U]YKY0I^?B)'(E]IQ1'V^U?N"Y4&,NL?W=:D
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M]$8SC=%OSDIO*F"]N*MHYWTDC^Q6+GH_O'$P5T-):B\8TQ0I7T=]>$?(O/K
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M*UWD:-9S4V\.Q&0.NY#[FY=#R",<"&K+=<(S-J*?<B _ M$TDU6C;)!K,MR
MJ=_>Y;L2P!0:9U_F(B6RPC <R*6[V";)WU55;R3&H%?E\S@0!)P^!LT#0 20
MC2&N4< /KYW>C%'"-IN-_U=<P(;8QH$TM2)6+[,E.)#1 % @?<>MB9@_U5E/
MP0&=6+8QI@7.V+<(W510WNS9"3(^[-XE$!^-NGRPS!1QS,6MD<%5E')CV'_
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M9TUY'#@ZN7@GD[RH9'-;)<VFU?/4L\L&SV8>KDD"ONP]G0PID 9<Y$ \H1*
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MO6E2DUO] -$L^]Q_:0;"^ZD5HH,]]Y)_6V(CIK2 N5^C!2$.]TB4!IKY^<8
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M3QYZF##NWNSV#O$J:[^HR^.Q_81R_V'#<)VORF^;WXI#@LW[_MF8_@]]H'K
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M<'R!TV8TQ<AZHYOIF0K5^;US9_UX'SJ?/LLMHGS&V5FY4> ,Y/M?,]6K'(@
M:@Q3[A)9N43D6\(+Z<=23OTPL?\$+UV1ZDH[J;14<^L@Z9$$=\3HD!G@A1E#
M_.MF674\T(;4I3'8)OAX_++7(/[7^TLS'FN7X5S.6J[GO'SKC%=D"IF*<ZE
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M;QQRU"2_QK:$L_&7QJ2]L#Q\"_<" V8*5B/10:)*H^ZP]/:BA@;A1-0ACN'
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M0EZ.PJ<.M:6ND1C9Y8K(D@CB)KH/"/(W[(R\_NQ.%8&N%K# P;.7-VWX53V
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M7H>3OF1N6YBI@$0/;_L\57(7QP@"X7>\26\Q)J)[Q;/GN@<H0YL)O)7<RG3
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M'#@T3#_AROD K:)5@0\,ON<#O^A./"W<7_PA/-Y7PE-3C>0#UHO<$>B83FY
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MH=LKQ&AZ!GY)YZ?7?73%\6E*/]I<*A*\_.S0 4+!#U.SO:(7 H2C%$[H3O.
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M>PLS33_J-KG?^)KG\U!%_8>W?,S #IV#X*N_,QL+#H@;%0Z9T>1BK=M 2@%
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M'"!^N3@<O4=>_E!)6'ULD>,Q^+3-]8:=J_RW& [P!U1$PQ#_+K@NW:XO"N
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MEC7JH:LL>G7 Y(5_PTJ66(IBKN+95M3%&=?<146?U1$BSF+5-'FC)XODM3?
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M^4/W;G:1(%L"-I;$VH?;- .F1_9%X$V9!P"K ,C=L4H(\SYJ\7L2.P2 RS'
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M*"$W)!K(]*MZW<?(10[*.L >5WR2,Y]LVV^<I?Y<1?7.O5!+5AJDH"?[>]U
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M-@6V;$2HD5#O/V!2$']HQS<@YEXB)A$<4-7,/X_:(#>2#6L"FUC M#B@WW<
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M\,+0G='G*^K%(9#M2NM3.(NQ2RJ7CL"L3WK8^JY!^RF+XE?P9J:X&>$V^$,
M7X^1^1G"Y?RL(Z^JD_\4OF$>]K^JZNL@S]"AOS*:!G"3U=Q%%6IEDRA8@&E"
M.7F>'I.^WU/[2Y9-Z4O/+.TGPT5=^= =;0GG8YUV5? ?3SREN#]Y'?=<EO2=
MFR2M1NK+<T%H)F)O__3C53E%R&Y'#:JDW<BXN\GL?WL]-+;U 0C$?XSUJ0P&
M*%RR-8J$B9 Q*"TQ%PDP-W0P/U?-N(*DR;V\7O#I.%Z87WPO6GWBF&Q"H=H
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MPU&>NB^44CK^C;HS6##-<[TFS\^J_("#6*)U>?DN*3/UK(R;4W*[>KQ^>/?
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MZ.2:9>&1:?J]AD$#WX9$MTW?6]'67\[[IW\8Y=;?H^EU%MF/EJQHWHW$(T\
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MCL.L@T6_EY>V'[\_9"D=E-)8-=..(F5(;5LEEJ.NA@@B[L>,+[: J=_,51J
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M>R4DOVA-S-_F)/W?Y;]61';&_@]02P,$%     @ $(/T5.YD5$1^<@  +90
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M+>Y\WFAQB!B_,P](5MZLNAX_>W)Z"DYW@:1"=W.E46*4S7L=N] ^TS #)#R
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M@S]@OKO585UEY/7)%JG>MV=S[/*[W9%^5U8_A+<[L:1087V(YIP$ULT1!G'
MN4.=OI04"CM6'F"**^4!OGQ=?ME1?%-^'7=UO.6)9OM9Q =)4V]%$;FU1^<$
M$$?89OQI#T ?!.$48BH>8JF(1H)/2KX194P<O+8\#YG,V:VQ85LE&\>VENL<
M QC]F@]G&\P_,-:1^EEAH5OF:< ?1!^4;L<#DE3U.,GMNGQW.$1.,>: -04A
MTOS(N&)MO?'2A)+*X:# 7Z#&X^5$M[TY8PKG=UGL.G5O$8C8)-8Z)H7SLX32
M]  V$0[%[ 7%^KWTQU>KT=$UH%MCDNK^H-/LRIC\-H]Y<]IHZ'GX_!^ZE=@C
M@9TZ+T7:IQ/Y)Q96XCPNXM1.,T5C>( \MGLL5I=U"7V,!^R0K/Q28/;^$(>X
MAO!GP6=;X@NCGC1$#160]8';2WS9(!2(ET2K^U/6M,]-(-4:G0UC*A%O)B??
MUWSYG.-V.7-]_?W ,\7NQ'.R 4&F"NYE66%E,]]=S,/'.T?[L+X/C:?>VPBE
M:-K>JUTQ*S:PW7M?9UA6X$?YZCS_P'@Z9+6.@DOC"H(^K(MLS\SI1>T4$Q5L
MO\S*=)Y*;X\+4;0EEV[&/"=EK[/WY(Z SB_G#HHK]&+I=KC$0BU. IMOOM!J
M!Z>(>\"6 I%0.63\YUGK:*Y34*PYC?2U?_ZKN??Y!\.!8O'\>;1JJY&-O60-
MH&R3L=XJZE:<NGV<E@@(R8QF4$W[3-=!6<;H6['DPED9FD@)2BHMP2$C(7H5
M\=[692DTDG'N&Y[N2-R./L8P3/T-C\.K<-789J/H(-J!WV19$-ZML!7%#/E:
M?",LXJ;"G%Z-@9Y2V$\[YM%GPN\>1KXV]&)Y01FV7-$#K /HW8SLZ;M\UACP
M&%\S7G-6,71GW* [5QHFA^<ON\E;!+VY:G&MKCDK/*5*X\FIX)5ZV6OGCIMT
M6&#ZH2(8V'+A3O.GI.GDWQM)N;1-*OE>NTE%M'M+\M(/B;;'?D_\[#)/V]UW
M#95V+4/\3@&%PA$[+<46V,9M;Z9A3HRL/J[%%++XM(<; \V\3C_^6FUWR*I^
M=8BWT-,&#36['8A#GVQW>R4/+%C27;I'A*Z3I3LT4&4#5G1N0KD#MNJ[4D%W
M#](_1%HATTWEU:5+0IFQNBF@,@N!EN0\1]O&4H@"*ZW#A6WERY%;):TB:6S=
M%P&Y/P+'&_3,1CW(7>*9<VWJAGEIER[+QM:(?A3$!D-F#:F$M6JZS7<*HD\%
MX3FN]WDRV,3!PH/>4:1OHF)XKK[U_LK4.LG9]E+FT:O.R@\G?HCF?<&(8KLL
M.U38DIS2""*IP0H<8J@[,VS3V!;ERX6'<9X,C5NSW\?==HZ1MFB[*<<;2J*,
M;.JZ?9K/=:8(ZM1NOO3KZY5_<&QR8EG6:5^TQL/XE_L5-;(Z@:AG$.DQHO>P
MB"VG_C=Y#C.^.(W#I<%.4'>@#T65G";9C:N-[WN51UO8O<@=^7DB+2C5\_+@
MARCOH?NZ*?06MK0CY:\$*EP1M/<"6Q@RO6*+AFGUZ#.>MA<G&D%#8T-YH_Z>
M2^/E]?5WUCXC#ERTL>^I;34.KC=OXB<>!-T5"FJW#!!QSM &OIBX/V*89O+V
M*U:TIIQ:<*9[J#=]Q_OJ,J]/<P-(C.RV$TFVDL3#2*^@V8XCZ%C0C64._C77
M#Y5#G] O44JJW)Y;/.NZ/+ZPL)+[4WI?8V-3BVW>5W]2KT9 KX[%4QTC "+_
M$4[)(8I5$X/ADMSY!4M^D:D'#M#@28T'?@4=L_=@:)965S5+FQ]ICG$P'9L2
M4&IM"#EU8E_V^P7D4 L)&^!XQTN04\851>521/J$WF EP1;[6 MWW%_M0=$E
MS6CDJ6Q,P+L]H9</?C@A(J3=N8'C 6+\&DO,$VR@>A%-)FY?J[;,KG9%+(_/
M(@)=Z&L_0PS60J6TFI]8J0<_E'T4'C%H7L? W2/27;&@=O(J#V"\8.\ FQBK
MR^95YKWN-L65+4F_%<,=C)P>'+"WJ':VB*QOSA<WT\@2A+(;9X]#)N&4QPM"
M#"(3GM1ABAE'[+940ZF?G-3[K0Q-5C5AZ!=\R#+I*ZDTJ?1\)_<TJC5^X+#M
M?ONV)P\+C0T(::O$8,),2S>QN249?8B*4$9[,/!)P>P#BRIF?4JW42<]+4WS
MS]<6A.IK9->LKN]T_6(=F][D>N^@=]]MD3[R/:AXAR#::))[B(U@9!<F4 M$
MQ]>4RJI1 T.I8L+GML5_6%U]D7*G8'[RHM%!D2&L+Q(\X+(:QKJ!*N^U!#CX
M#JWY3ZC\[KH!TS=41RG4=1Y@/:D?\GFO[4VFP\D=?@$>NJER9S)6=E=<V2]X
M#_S^-X."T2Q[5'E?ARXXSW)$.T^3^\@2ANT[CV5\;H7,A@^K,6@QA+I3Q@^:
M-Z4;#^6\4GSPYR:;W(;S?XWY@!<.A?OC[IK#NS9!(HT'*,]]BZPCS01ACK8V
MXIU8L)LO;66S/#PZM4B5W'KKP-V9;C/3-_D$NOZ0!?58AC:ME[)\("0%FD0_
MX25X'0+Y!+I'&Q-6O<NMPDS>']2SOZ(MK/GJ<2ILXV#ROH(XX 9B.P^@9)(;
M%%;)="-:>2=\=L"5 ;\33D[G:DS\QLI>ORW7E^4UESY#,JMOC$EW.R\6,/KD
MJL.]T?6KT#!YN./H<:@*YCT/H%OS04.L6TING%=GWN"\P!P$KVV>I9/ B(BA
M6-M3>2O?3]NGIS\.7I</.4#!O\M;B4R+2OETJMXX4*<_TJ76E=N#W]&NSU)?
M0=3E=G.0O:K2]*FZLA7YO++JDH6>FR_GF_YD$VK\7G4D+0Z_*EC*L7TRF1^6
M*4KQP3++.)5<86X_= <!8XX9]=)_-0HS*A^2=7%A;AV;7+9].'6DRSZ@Q$]\
M-?55W+/6>)N@T1>"7S:4L%UZEBJH):85763U0@5W#"I[A8[KB<F01T ^D2X'
M5&*^EYBT+=<-ZP8F>EX)<GWL+?<TX:MQ A"IA%]5I/^\P*EJQ,T9<>4)N!"T
MIQ_E.UPBJ':9],ETRE*KL?%UY@J_L$\3_L08,<:QLD0/ABD7]Y]QAJZY\9/^
M5<Y=[%6B"C09VZC=+S9LYM2<M/-W\QA;NV(E9TO6B"&>=Y?I_*/OJ@;EQ9/L
MM-HKINS)#7>S#!B49KB=Q#[U$7VAW"M @73UNNGM^2;:L1(F<G>V@?RY2&.;
MPWN.6)QYNB0K0",+\H K&484D7N6!\"?7?#&Z=Z*)D1ZWL<IF%U$!=;['9//
M'Q*MGT@OE]/J:N,7CL0?03'O/=+_Z:+.,L%V'4!#61HHCQX,!%1@>:)]QU;9
MNM1HV+$RC4V27&?(L9JO;:Y?[,)S[#RU"D]FUC_9=>C<G%O";9<NQ[DVYC7.
M,S3"AX)+XAZ>\-KT&-.<;-?5(E#S.>;DWKSPL^F:7Y\<^W1HX,7)LM/O4(K]
M[]2S.)?KV@S7 EF1F&%HG4%6V74HM-T/&Q11_>1#1E& ZIZ.*1/=B;L'"EW7
M]+QSD#I[ESO.%QDOW'FL<.ZX.7EV@Z+= YF-HA"2X?X;"4H"X[!#5$^3X,9\
MLX+2B./V1FUUFO/S3V9QSE=CIES6_%BFW\A-Y$Z(#.8#OX;!T;#BW[P.CH4:
M$W;-H\YX'%E?KS)00_DWDR-"S(OLE.L;U)*[J,E'6UC&W'&B #;8,"'/96!C
MED#S3$Z':5;K<I*=:R6)YH=<TDY_OI2I>.F.Q)ZTFO(7<A6+N'MX2>X><+P+
M#X%YTH2;IRSW!D4I.2;JG0H>B0[;CH]X,6AY+E)GSNU#WYS8@_2"#\_BT#_I
M;=R=0=5H.=#O&5H91/##18M3;(R30'E8-X\92^A(./;H-4<Z,_3.=5=MR1P5
M37LI)HWZG.4.K]]D2R]U0NO]^S(0BX8]9-(%6EEI5=#"K@8ZLQ9M%UOB6?W)
ME!B(,M#P+JO"W=)N>_TJT#Y+K[[N@7E!TZ\UOOYKB?^;"^#;V.H4?63G-'ZW
MI7K0X16LW#I7<]EK[T2$OKF^?<^"SNLG7_'G:_/&^G<EDMRLK'2&Q#3J;48?
M15XHICB"FN1N@BAW-A+?,I#&A;$O,;"];4@Q>++OI D/D)X[$6*9=\UN:K;:
MF.41(&_\4#!E\93MM6L/?:_I(\XZ'8?"4;;<G4L47&+4[85L.G1QI!>?S-W%
M4"6&5:WP  C[P$M7K9S0]9+#\TV-N?+G%P*'C.]]>.<?MJVRS?BJZ=6@2C[C
M0MG&X.A+T*C?F?2UC0J11UL$#L3#_*C*+WR(8\\+-9-H,V*/R^-I"ZZ+]V!&
M?3HRLLA&6,#0RL0YD0_X!D>V#)RRL?J.=19<9+9]Y.JR[1AF]SO49V=[%O5M
M^PH/N%V9\)KT/>T7%(3R3CQCNR]#_:*4S?-3-\MTO[7N?[8M[7]!)\(B[K9G
M<27S$XW_%*>%L02/)+D5'5:#L[4,&^N3SG?N\=VNN/QPJF,)G*4XRJ#/@18T
M?!)7#,RN0)FY3K?#H[U+42VV&5[?;5[ER)_>4'.F%II>H>SQK3ELCL/SBRSR
MC MM*9D8XH&;^\Y\#F8]"^J I5-R\NF#73!];SWY!K<NK-9S?KAJ:51-*T@H
M[JIQEKN7\2-T,,Z;O8O30@Q$I&'KRM=$& D7TCNG.@Z#)@R9 :\]8TL)/=/)
M9R>N?M3(5LOQ\(G]6NSPA3WGW[V^>&0IA8%GR^*9$_AN:-U?#?1R*J(GOPU/
M2CA9BY16<=J(&S,,A<%()0T>_9F07P&2OOM_6 P^;#S>_UY+!9>!I13@&PT>
M4@QQ1 %+ (VD?TBE$'!YW!8"XKIY32JLE9B,-(FQ3G9*FBF)5\P,O%1ZWT5T
MZBN5:\=\48.UXI>-M[C3&(EQN*^^Z#C-I:?@MN%LZ'LKDT]3N5L^8"*\%F]]
M^I3/FMI\ILAAQ<TCV8P4;Z?&N&#T"?Y(/)C+/#K1 4=9,0?K/S:UD1.@8K]&
M4I2<ZRBQ6K&'#:4"<\<\2:7ELZ&AH1E-W5ZD: OVIJV"5(=,D/Y-4WZF=(9D
M8"'ACDED&:YF$%P<YE\.#B'&C3>4T,? F\]7?#SHOBZK+UKL(S3?OZO4K&S5
M[_0(.G\!G=H=?"QW38"O+P892VLN+!>T.V.I?PXO!N]Q3.-OW0OZQY0$WBX=
M7&'*,S>GHQY<?_B6V2^/'V[5.&DSL3_Y?6PI8J9C!]J,TPI3?([RH);W03.\
MA"8;"1(]2&0%V'.6OO;^-C'E68OH2]4%-Z^%0;>3.'/KP"X)[9P'.;;W!#]]
M7T2"^F6E#!TR<SMXAT[L0FSW;:,CTV#'P@(9V@.F!*'B;J4]Z]C&IHOC"3M_
M[_2^4X8?2A?9VV%WOIKI@(*NV=*AS)><9Y9RX CSYJBE/GCA-'W@_JJA<=N&
MO%WQV:W^[%+/RH&;(1*OO)$PFJ+JD1JWC[:/_).NG?0%&#P U"G82#9QG"%3
M$#V$'7RE15H09DP/C"1N25:^B"T>=K ]D>_6\$ AJ[ADX:*H1_%.293):Y:/
MYV64/U=T@*7\O4/5\M)ZA^5>5(Q'P*N@C/W?[%X$HV,_>[2)F0)TQ5=?*B>Y
M1S ]9#'N04R_%*;O=FAY+)6C;#MJ7.DH\EW>SZ_U8TUX>;SGX1_'V!9=)M7M
MCX] :BNH&5?91IQL[F%4+C-_%!X$)8T/8!2G3#:$498;/0O"HVB5TD\>KJY-
MWSNW<EY\I=F&W;RA'T)S[9H3.OV]PV??#8%?*OZHGFXO%<;FW2;';2#1WGY-
MVWV\O'92K^2:V$VD<<B>AYDENQ05DTZ(%$J@:I()F E^&#$R?'J6&4;64UP)
M8@_A,%;2 T0.MM'[6[-(?]3LZ;V7328.?WKW6>KQV(Z9NY))2$^P&-+;AD]V
MGR=V5:[)3_?="JPG)->TVPK5SUA%7DQ9"+];V7Y]1O-BQ96#.SX<%QDDTL_!
M[[K#UWQ8Y[@?X W8..-7V$:N'/K26(<.JM*U*468OI!1-G C9ZHO5QEZKO50
MUYZCRK3F5K24L"NG-+0&QD>+< [G,4RYQC?0'=Z#3U%5&RO&OC9]65GJFMQ%
M:8]LR3TN]58!\OVRX2J'I<H#NJYW2'?##E5QI\B ^TBOJIJ#+0UR+YR<[%X)
MYKH8,-+SL_-HOZO[1A[$[S^1_#91/>W(XNG%4X@2'G!]9#;*$QQ>A"1C53"R
M8/W "3"=7GZYM8/>Q*V\MBEOUIR;TS]];MS@H>)EJYM2)S6L6@\\BS^W9U]&
M)RR?&?T:WX.GNSN2;+M($'.O-GIQIZ7:E ^B3?XEU*5.\F9GM'Y(2->Q,W/E
M?A5P2B54#*U(@\S(]!)KD[N)VP(W"[7 229>$J7;DZ%*CQ![-SR\4'?HJ+?*
M\^@FQ75E;;1/3H[KY)L+3&=.+OH$/6H *H6Q1+LQ_.ZW,61H-77^$32/8:UA
M2EUM?7T+RQ1?YEYR[\/5>"-=Q3WK.4&IGTEWIHS_=!O.NG#%PHK1T8RH 3SD
M[]M #0X?RFG:IJUG%_:!V)KYX><!*UU%X_INAHNGTF](O^T2'#90.MFEYMII
MV<]'*W3[-[($6I$^U^N\Y)G0);]U8VP]0J_AV/#3;?M#"\*2'DA]E9B=V^NR
MV]<9:HIRH7HFKXGP5_!A&X?0+G7M(1A#%>E.'TDFX5.JIP.FF[ZW@>ME=;;0
M[T7CM'1I:&N+6=+!J*[#A.?<4?P.(A(AC^F;@HM@_3=(9MU;MGTQ;RS'QGMY
M@-1OCKRWS#5UYNPJI<G7](>=ME08Z]&MBQL7O7LQ X@&(EOV)Q6:AM:F;&3@
ME3#"LVQ=>E/)"Y@NO;+3/#MC?OF'Y[XTNXT-@T.['_:N#PK5PWS"'FR\$OR>
M!KXC(LDD!2IB38J.IT:M:?K0EQSPM(%>3\<>0SKY1$$-7X+L[&$&L:IUME;6
M#/V2ED/5:CV_Z5-(TVER^6]O\#/A]!(RZ5\*HF9"8H<R^S#=H67-@;YQ;L(2
MPHYLY7-0<KM5)4IIRWY$.K]L0CXP(E7^]]E<+^>B%7'4)V]<V)V/@G-$2@6Y
M67M-G;4;)4(EWH/[(Y(P,HQ+T^G<@ZB8KFD2(I50XQUM4QY9JS/7J"[U^BC"
M9+/*+R'Z?-S%22*G!7. ^Q[?6+W1B9PS=*;?KRC]A%:<ZMBWK*I'=TPV^-6%
ME,09Z[Z8<0@)BXF\YBWW_H*M^;O=5^IU;4IT33?8LE9,9W"-Y1P %VN$W,U;
M2M1SC+,T1(4-Y$YW:+YZ?>'VEO7,:WOC^SORKSR)VWYUX(K0#O+1/3Q@380E
M@[[.>8X-(6S'?%35J:=;@,K6H#<!U.[MD,MW>Q/TYLST90_'YK=9^B]._>@8
MKMM5\=-%HU&3L5OD'9GN[)B!;\$.&(+[%HBLO\"L'KAD5;LB0^;4QPA[ N"^
MW%+L3N<^C'TQ:Q]H=#TD_*/7Y;TQ8<9J'X2WV6U[BW[FR[E*&,&3'+D[/5DW
MV$A^EHV:X]/!H7 H::DK+RK^5_HQH[/C[*!8JO*3IC?V=N-+\?;*NB]RJ-YV
MZJ[[I#_U.Y)@3Z//_:ERV<"*S8&%XSU3D0O&DZLF$F[Z$]<56KV>,B-_#N&>
M%,?;E04\*DSSNP5O#Q#LQP9_)R?B!>%^CBG=D"1ZD'MR[PZD,0N^TVI7SE*_
M.;,X-.1*?4^F7^#Q^X==5],6I#U\#V82#3"S6"%8&$L8V]6TM;0ZS0^J1[GF
M XF6DLL="M._\^T\0H>>K%6;R*?BU#33:!2MVS:5A=GSZ&N<7"*%L*#!(30A
M2;I4_X&167H T\G.F[YTBD&(-\E?AAWU_2,]F"0VXV,6)=;H8#K6=?%4HH\>
M=+YQ8[:\GP<H\8"KG"!^?=7&#BI#35]B="14+!<>G4";E!58#A>U'WYQ?U#+
MX&/5(5B@\M&H^5V15WOS ,8(J".978[6G^0!OL=BJ L%\@4QU U2>H^2?$I.
M4&U?&=GUNE+L_,M%KINRW9[LY92+/$ BUI;V&W2B=X=$,9,9[:3(^^'\C2F_
M-V2NRP3;>QZ>+'O5T[;'5DG1+U)=<?$HZ14=*XCIPT+1'@P%JB61Y<&^_A'M
M5L*6_!G*WB>?6N00!$^)R/+7O&O^H?SKX/*>47>'&_*[3UB9O,_<.%<A_05#
M)C>XL&4]F/$@@:IOQ0P&B73L&3HT2>F8S6(W0@I]J&)%K#)HIQ9H$&I=^G[;
MZ;7!D@?=O<\>1]?4,+JO EG<G1 6+(@LS-W%/@-6$U!GEGK4%[']Y%UHVS&V
M>E3PE?Q3XTW;DRR.7$O&:46U--^GN=:*W[IL'#*H](,'S(E03+.I6%"_?#6(
M,8A,*32<;)) ]JI:U.'L)G]/Y9X=HZC*=#RH+GUQZ;2]J1G<@"IKM*L8ZHAY
MZR7.:6&;E:,27#BO^,)7N7=KF/-YY_,9M#E]LC^_+'#J87_4(87SP\99[]2;
M?XS)BNWQ/EDPNXCEYZLPYAVPC^7'%N:46.Y!H,Q5H)3FRAK$I\#6A>>1N>;C
MUV]?; WJKY9KJZY-U0P4A)K%7)$[OG,O],RHM2S@]!_]_UAW,6+DTOQP7<1$
M$KE/PO%L'I-L76]VF-1)]3J^8[<0'6(R[O((\XD'_ C@'N,!M6(\X%O0<=5L
MZO U0RGP=D_OP9.CI9Q'+CN5GSZ2O!-GN6@26=NA@'UG1-_@Q%7#?YUQ7@-D
MG:S_*;O<%V@+G)T'QV%7M_& +:7IRNE_ZZK*=/?&'RV,"G^#7#DW]<Q\E6$B
M^<=9M@4/N*+KR)'.;CLN+.OTS]FC;==&>( 6;I', HC<I*:5W__@\4>1"'H;
MUPZ?C%T5#N0!1>=;@L2H4>RLOY\IG1$=YP&G2D,_"EC+GONG[%Y.K# >\*X8
MW.1V&O* Y]6WW_R#QXT"\V@#'I#I3R6S!-RQWQY5D[I!3QZ@,=)#9&YKY &C
M!SP:_X]C\-_%YK^)1B_"O_$9B$*($3\_ :.XG<[X+4W=_X#?/TW_#_C][X<?
MXAAW%$N_:#@SS;P"YOO0TVF(/F/N7-:EEH;I9^-ZVFVXGG23QFFID1=#XB$J
M>8^IG^2=772HW8^$DZO9,)!,3Z -=+^U/((^ CXL_JXJV=I2^'6Z3S[J[92,
M1_=ZYE]92SXGQ4/1'R/EE._HG-BKXB!'(?+5GIP(<QNG%J.Y A6!7_M;CQ8>
M8%CF!TS?^C95;6SD&"PIT4<L4!)[=4+]<+?G49$C:F]6XD1UARP-N21B [R3
M(/\))4,SZXU*=ZT=<[DT%<Y1M^J8^#SZBZDGSV2[61G.Z*?:]FZJ7O8?0IL-
MSOQ"B*/P/1@3^GSR/;0R34S?X_1D,*UM[+>#Z;)V2UO+0ZL!X_/[=-4./Q@<
M/+TW7@+P^A]]^81@"&Z1FQ!IGC !UN%Y5%#WL+%'DV.*I4%MK(T%<-O6O]Q:
MSV8=?<LKL"CIV+L[-Z+Z"Y]; VAL! \0(G*>HQWY$;(3@H-3ZK&-$WE#TN^Y
MBJWTJ:SRI+7FP6,J$_NYRSX#%Q;:R D\  )'0F>7W%K&N'NY'^7A*C!EW92E
MMBFT24@16&SO%>^D63BG;R>B7'R0-"AKI)=E.9.?SBDC4DJ]X*  O<>3<3^;
M==3M>^N':L8)C"I:FCY/N$<<AR%KE,N;PM24S[7&MI^WOO7ARV<+?=]@G4?7
MF/A9#]I&'RZM4'+*> 2'AX0[BJ.6NMTWF69IC41Q\,[O8V9K$OY!,7MRIJ6M
MA.YE(&,$=#5.O_TRO21:?T2D_)^0G3&6W*E6_!I_,H50G"H39 ;7&+P [X//
MX@=X0",,+UW31-AAH\F )_ZVSS"@B54>U5?,77,>DE:PN=!\I/K^DN,K['&B
M;PQT!L\LXB3^\G"<+>..])*WP]Q;<LUC'SD]7OO<DG\NC[;X5^:VE/.RV:7-
M,?Y.*1.]U*2P1;BLI0"VRZD=0GNC-4+MQ8MR]Z+0:/0DVH/:.-VD;WOV-7TR
M>XE9DHJ,T'#>W/9#UBRF1:WWVYC>7G,!G4UX@\*J%:.%*<"OEU$KB(:-U0(:
M5/@Z#Y"MV8@X=DW"I<]T4PF;G.4V@52*GK_2[%::-B:PS_79Y=Q=:@UES A@
M"7X=GW#;<.WO9RJ=.4\A/<>T=C0AXQC?+;49&ZG!1:(DK]P8;\V,^_?'#!E>
M9T?VWRW<5Y_]5GD<2Y*CEZ]FT2%<,0=Z*.L4W;%7'\GT:Z%_V4PMFK34!'M.
MO&((;Z8V+1ED1-W,?W%^ON;:Z:E=KCN>I5^U5M(X9$.\]/TV8LU,>TW_^76N
M*L,E@0;:*R36+#+D<1'EETU;3&O]K)!Z,MM_Y'RRV7.X=AY_.3X.>H M"W;1
MOS-%."^(UX?MF1^G\#T9B]@44ZX1'9?^VUZQD-R+@2JI9%2YQY:D93#3TX^&
M&/B8!CV)RU8Y5W('9\=?XVU9+NW\Z7) &TQ'2*@N.31,:4__=I0,C/*!^!5[
M!I$2^PMV\ #OX,\) 7N$2"* RPO,% ]H0/0CYB3[%RG0E(Y],Z 55;6\'JZH
MG6R@G>7%\$QU^KJ<=+6N+#=DW_R>$<5"MR)-N>K-0X1 >DLB^R@%)[Z\($;'
M) >5!2I9WS5U]\KWV=8G7-IX6CUM]^@-*3FYB_LI@#" ^)]YV>WG!HT8;VG
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MT68>0 CGIP5KUY=;_PI&NDR3.N;W*T5I!^[QP0/L+R+"B91*> NT%RJ,^<C
M=*M*@W_\Z?&&N]C"#.@]?72@*5Y\>F'?1,C0B>V)Y79AK/QHYLY0C=CZ,Q=M
MZH2N>L7!CP<0"OGU)97E%V@^D I39SFACX_#/)Z[@S$]TP@(V[$,#%@>\SH!
M,]-:-H1'J]FA,HLJ'P\^Q[V]N2=$7; +0X+3G49VH94Y=5QA[@!9G+L'-6N
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M()Y7J&Z"_[:>V$*=<:S>+$(P_0&P$_7S*!0I/A*FV<<M$%J0 ->]7BQ@F"\
MWH/#D'H6_PKP*52$:,7"M?>@*YHYBBW/%BH"@M(9*F1-*:0RWV*+<$(Y7 P
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M/F7J^)XAVZP+N%VF,IO\P_KW+):N8='NQ/=H*;@TH?>T\C <5!WN)G;US+T
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MOYQ'P"]/!!DTE*6>*G"T;&IW04U@H!1!-T3JW@?BDP.:B\14 IRB3_-BB]A
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M-YIZ:755LZ3)B>9H.Z/121Z%UH;@<V<.9']:@ ^V$-!^]@\]>%EE;&%$[J)
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M\T?[]L837"PLC@Z*J-5;C3R+N%J\: ^J$[NPPNR9"$Q+?PK;C'F=ANYI@XM
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M&;+87%D#F_-O77@9D6LR%G#_6FM@7[5,6W5MLKH_+\0X^J;,::']D LCEM*
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M273>['\D;2 S)V%,,)'-"_DA3FE?9\<&H!?O<0!];I8DI(%#', BEWVUF@.
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MU7B6))@V08CR58$UC82YO_>HGJXV=B<=<*[:^W.X[+3J@1]7DG[CEWH@.H4
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MKT^>7?X2]E"X X)\@I,"G+U<+08U7@&LO1\&UV9J\7Z[EWS)W"TL49$A?]4
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M(C;2@U'OMK2C%3&0K?]\\ @# U/HL :JPB2\"1=W%7F#.OZ4PU5F!Z;,><&
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MIWTZ(4&SJ>=VQ2O*W3VQS>'[XJHI;83C\,\8AZF(1C9DQ,<&K*-H3?KAHJ9
MSTGH=J0>%@@;X5A;.IUF^E2NUI-0OKD-DQ^M$^7-%>2.$,Z^<^!.$ 1FH<^-
M-'L\"6^ <S.<L7U0\YB6>I'^]7=+<B\N#'7X>4F2#DWPM9S/#+CA*O:Y]&U]
M$.>>5QF>E+8V!*B ;\3L!RW/4O>B?\N<B%.^D*4J"*(FS=)GL!_"3LO%GQZT
MOV ;FUO(H[V:&[TE_@_E9D0<^CUZ*8!NV)WW@^'.S*@5(!WQC;OK,?1@(4ND
M_%5]_XQZJ6WMG>KVY<Z%P </AC46U:]PZY$(3] \2("R#'^BKP,Z$\F(1I]1
M0R^M\/50$=Y7VA=N.;M->KKO:[;@.6BE'*Z8>WO[1_/?@ 88QT-6(J65WE/Q
M3=W?,XG2CTO=;93OYRUJJS9Y'1M:_N9,+S-4OZ+<VE1^9(=-J<T7 L4*/NK3
M#"_;FTY):!17:-:3_2S"AHB@%!J(CI8D]-.*]4\?*'DU]M>O![7(.<=TI[RY
M<-L](2ESW'C/AQ09J"GC'.A)623-/EE&[J3"/VLK1*TIC^'N]B(-\@Q"W/6'
M]M00T^TD]FP3X][!90GZ-#CQ40*>D)%<1.AN]PSK\-LN*D<K'#4;3ZFHD#^/
M'+I@<>[0MM8>2)L'N,':7:=*[L\'"89E8"9UAD#2:HRSO$ =R+'#4?K.%MDM
M^F<=B1@?5*@)KXUZDSJX(JW8IU@9]$"U,^J .=:-JQE&'(93S+JWC+L_LR$,
M]2W8K^:E18%I1'S3BMC\EG_R)/]VMQ%L:<([!\*\YDAJFA!UV/&,S\YFI87S
M#UJ#C*^?I!VJ='N]O0S)H4Q<@;LU#C#X)KH4#!WAUNAK@VDF_=F5HE7]E?.E
M;U<'@I(OG%&5=7X1F^1I_SM1&L7D2+.I'_HRP/?$0C9D7A([:K.?;LJ&?/F(
M/,.&?)"UXB3OTQYOJ-E*2/X>EJ-;=C1=EOB71.!7B7\!S[GHF7 :,]CX5Y6Q
MRDJ=?W.;'8#/!;9V%?E1$WR6AQK^JKJXY8.94:,-<=+7%["*#7'6<F)#^F/7
M%YVAS6EO2+/PIL@BW:\<PN"[^:=&6?]!'OZJOLB8P:]QR,^.&#;D.0+)T=(?
M_#C2[ZW':CEBPAB_IH?,9,XXH0OUXSF<ZK/^\]]K=5!U K_$&6\G 'J*/KW[
M'S31D@)$Z.KXD<A.LTWZO)^8Z)+UI[Y>^J:;&6,'/VGG"NX,C#:=>G9U_Y'H
MX^^B<Q;,OT]^QE7P-R&&V1 S2@#9A'J8T"I]NFK(KT C8;^]K4JN?>R#A2H?
MAXNI"\LJ_4M]9W8<S.R '+[\ Y^"_-6GH1]H4*_G8IP;1 F#&[38C%"?<_4A
M*A[XQG%NO,;4AVJ#*)7IS$ME'Z/DC7;:GVQ(?&0-"5/F,!G.M2,!Q&YR D7A
M(C,;)2C12AG_!!08Y'8!SBH5_2WN[ZX/!Y7L:4\RK!U-&SY4].[&@>U\D&"-
M?Z&%B0D%WVQ?#-_KNRNY,<U;]#QVVV#:'MV4F4HVA"@_R.&85SC6K$_-_E.[
M@VT)G-Q_C$,.SX6O,->P<5312]#]]5!/'%_M6:+C51W^?7-X>^>UU*36LF*U
MYM[3YSX_;+@^\<SH?L.\8YS0-DI6#L>.(13]*I*$^:[ R$GCUE!SHGQ56 [E
M!X'73_5 F[JH_XD?<D4W-1;/(:8^*#VRY_))^JUKW.EJ?;M#S:@>)##@#"5N
M)F6'->!2IHV\A_G><WA@M3?EV=T#(WD7*=MVW'>4?P"3J-=#2C,S&=RJS=WQ
MTK#WE)D8J0'K@H#@3GO2C/6H<.V)U^X*Z:-/HC5<?1H+7O,?8R;@G/FT:&J/
M6RNS^*B1S=#]!I/=D@M.JD/95-^M.X\TO,Y9J/SHE3#5>1"]K#:=U(YK%,'6
M G1-4)3$AK0X2I#0K?"]8%I+3I/XR^"T)[4G2N"&S+@<>#915;!/[OS'CP:I
M\0X8/:++85DQ#6/:98Y;)+*^P"NMRUB[P;-4)1AH>K-R8.58K7#AJ*E[T:CM
M,#Q&M#9UZ([=H:BIP,JT*^;I51))AI>K)A/( %T;]4T<6_F(&DG2=J_:T+XS
MDFEG/Y]FTV\_W_/>#LO['!MMA"V/>\%=_4)NUV6Q%H@_G)*TP D914XP$DR=
M$)/=#YT$P"CZ):0>LTB#P ]&Z7(\PA#OV[5]?&19N#Q5RLYKYY=7/"+^V[^I
MA#N>Z9C2--*#&P^IH_?-:U:S'A4ZP&WA#O(M*>27BT>U]E5'F @,I/@YRT3L
M"-MUZ!,NGB"%VH_J).SVP\2CI73=$<25W:#_F.N07^:[W$25Q%S;@90HN^]I
MOE>$3>0CA;9]&6=(E-<S\Y< CP)59& &-C(LC]*)$H]I+JX6>F;B>\RL_WM"
M8FD37]C=6=>O9QL3/U";&K2!-LXBUA\'^2<1>SR/SXUK4NK?O%[XZ=[?)M5H
M/^Y@@E ^WUE<)&-RH$#ILZ0@_\4IX X&5"0LN=/]/();4^B*C)L(T2^OSTI6
M=U:.2PZ4O,$*GA H,O-!2(:,[CGWVX]S)[AX+M"V($26$!C,_QC'6ZO!25OC
M(H-Y_;HJK^WFQ>^FE1O]U!7ID3N1+G8NXL&[DV<@+R?VIO0 C:8<_=?SAL/H
M0U7N6IPYP(;\?OF-&7+5.":/*&ZC;ZA%Z(\!5?&/UTH[T\]Z!L?--L9=')]L
M2M.<Z_[-.3&-:Z,]Q.:;\+HH68$3GP'7V)#25$Y@ZRE/CS!ACV%35JI4W%>%
MR2P9-J1] ;I.!N:O<@A"?05X R/.?%]K3#_F$8R(A+FB1R8->C!(5:HF*U1I
M3-?XI+$'_L,YUV@]<L(QHUTLAR+E*.%SKSJ5ASV56YQV4LSC2PPCXVJE\CSW
M[1H_L;<HO^7>(TG(8I10['$NV?K?/)5Z4BYZ*XULV#BY;Y7PO5^7O5CV$I/O
MZH(V0B</,"8YYO)S8T.$@#L)HUP-N'*%ANZXC:P3H-FDI^H!1SC(;UDMFARX
M3;W+R,W+6S9-GE3U$7%,WOIS@+MMQ WQ^@VJ%X&L"GWJ;?FYFO^12Y^!ZO>I
M06S(]^4#7A)5Q?Y+.3-CL2<FA=@0C@(O!SYW#]><_429Y>3C\&IH1 D&(?^I
M3MPHC:_FNHD<1O5;;V$:SQWG,SX?[N5 MCG6/;CQWJ>1R,Q,<QC6$XDQ1*7A
M9]]&^M]^82 60RO4ZNO"%F.]R<<JRQ9#'!>"\D=Q=\VW1/3%@8F-*YRD:[_$
MX%-MWNVKQX8(+E6X:<!.ETN'^QWM"4)ZZ>2=]QI[<"(^Y8.AOU%F#$[-=<?"
MD:('>7-"%H9N=WX=3/:%[7Z;-$JRCM&U)BL??B-FFUSDTV,S /S>9>#'&1(<
MO9?_F@WY?A$V"W>PF6%XLIBF#%@1S('RDV6(Q;5MR4)9@HYP5C@O@3[O&<W,
MK34L_$+7!K>T**](OU&L"WE%KO.OF01AS/ZJ5-':-&E,N 9"WS"J>PV%:<9-
M_^S\,G1@^3')T=;-WX EP-L-KB6 :?1L#@GXO=\Z_E6UXA^B -[%3WXEVT6_
MB;3)N!![ER"([6L?N_;J'(H/N#S(:$6-$%:#8!QVN/1VD;!U/ZON;@Z8M*9[
M?1&\M^Z:;F$HO(S6_<MN8$Q^H.&P!ODBGK6[EU(X#MTS=JF(N+']FG,3D-O5
MK\&@_$M40F^AVVF@U#MI=ZV:'T_YS3S_ZZJ?2B[^H<SQ3G90_0OV=(4M]H#X
MZOBNV:Q>%\NC]R]\^U!S[(%P[-6=<C=>?.>OOJ^'/$N_Q5%%I_"T-6:Y-^M@
M((+%(TL%B#O&14 @?\X^XC'%LHW_S8+- XG1Q42]C:\M9-K7[/U5GB<R^583
MST@&++VA7^(,8,':"XI:@CK$;E#6J: 4M&RL/SKDV[T;3%6-S8+VNPZJ'!PH
MO?W3M?*C'W"\NMY[KWX_J_90U FX/:H)$$ =9-@R7]Y%AE)O3V0CM:E2&U'(
M\QH).TL86JZF&7H/M@XEZ.YHT8U[K],AIKB\]/7"H7K.32.W!1:QDA_3 SBT
M@ ZPC#&YN)NXQ\$!2Q)T+5"-9@Q&41MG6[)D$NSQ0)E?G#^ENRCPT3$-SP[B
M?46YVOY=I1;Y:3NMJM3V[77C(OS_VWZ:)%3EX<EBGD3"7O0P@1;^J_F_+[Z<
M#7'_P7$Z!=>BT#*]F ^:/ZC2_<DI4[-9*4NP/Y3ZO\'NJFYNGT.OKVNQPK#+
M%+PJ;5K:K?7BBHFA"<QO1>PPN@NJT^)38!ZY^/7E2\?4#]XJ(1TN&9Y3W<DX
M+&[B+6XM"<YHJE8%+9@<+]_)$92Y26S(C%0OT%B3H4Q3I9EO_?:&@VR*;,AJ
M.86 <4&O_6K]SLUAVU/?).@.+!Z.#C619T,Z=;(Y<P_D<#.*)XNG@VI@0H&W
MJC[!5>EGDA*DD8>I9ZG0L#4I!)&6EF_OZ*A1/%1VQ-<ZMOU&EI6!4LK.[BXQ
M'?PBSRIA!$I<(>\D 4*@:ANT?#9.5R]O/-"%M>QHW]1<V?_%J]B^R_LV_>#Q
M9[U(^AW!N%%Q^4U)0>4T"=/=#GR*NAHJ7I3>'#%$M<?N>5Q6FQ/WR<[Y6SFP
MDFM];(BP?5E,O\O++'H0XNUL"YIBQC_*3XL!J51O0L.X#+,4"XV 2^M"\P*S
MOC!4,8R#?<Y!ZDP#>U/R>;NQ9R(T5>Q(\YA0CO'AEN%/"1C6URT,>7T2-_*3
MEDCM1%==' V,[FZNUGJ"=3RW2/1/>8"H6#0[K%QTQ_;EW:H85,Z#<?L].A>^
M#:LTH\NA2\Y47#-4DL'1+ZQ^>_-PAEX0I;?6@?_)FNJ>,?. ^WZ',>\N]74'
M^!V]\ICG?-=4XP?T^HR1LURKGE8+;%O]*88V2)V$Q0/E\H1PA3224<)M[J@*
MC.CX]=$6YP*[\ST.'L^PM2?3?W+)77702JEU:+9V8]W=_&ZK8?2\D%B@;P)T
M1YM\U8T[YOREJ&9X&:^1K'?=11\A8*U^W\I&%YA=-S[0\4HS>[/BLK)Q'R/-
M[2<,E,=% 1-O=M,/#0>*$C?("UO02*0PJ7M?(+QI)(1QLF]ENYW[%G:P0D<^
M;?:[R/'")\^BWW#S*)<P*WZ=]&JPU3^%E.^OEPZTH4WVUIK5M&8<+@C)#WS\
M6=L[S:T@'][RKDTN:;3I:.S.EEQH]:Z&GQ&;6C;W*7A:,#5@:8PNW43AI850
M'9_4*_;IPGPS8$]U+3VZ$'[%E_O,Y<F=]Z5&[U2GFMA=>XF0<96<!SDW9$,J
M4'64HL;\1KA@Q2NM-G'YY4R ),!79)RW2!:\M=H0(U<VZM!I][7]S51LL>M>
M+F6_<W&[)F3/!7K86)A@C>(8S&73JMF0NA6?^+?.\:DWE=:H5J>OCR4760^-
M.>D.F78X8XN#M!I61II8///%J%[[[J5\ZB(-WZ][FE0#XS4F.?ZVT43@5W]E
M?'FH(@<VG)<H[> F%^'FZM9+NJ-[,;;8X#X9-D*@6,*W3%19-\=$&<JQH!T=
MQC"K9[[#FH^L3&+'(SU+H+\IA.N>(*+WC'<%>>;-STPY7N^0'Z!\WMC??=*@
M[\"0^J-K"#ELB#,B_)J59GY$3@V6(VVJX1L Q:L^7U]+*L[/,C^ZL,(&ZU&)
M<^"@$$4UQ/UV!(NC7\,R.'K9!/BY=PY'-*95,83PK"2.FGX18,B&\"R[E6+^
M$/D)B\/YS%\MPAL&@4VU/PW@](7.#T=]Q\-$ER=!.MT): S*!FYTWNS%$2']
M:[ACDUV1=\?]JK[=J\'?G%CIOJ+\'&/.3(9-O;W. 4MI.%-,.$AL8Q#WH6B5
M.&^X6G?;Z+G]VOTPST&U46*GRTW=#7XQDL>7T\KYUCGF@Z?566Y;FAR)W=(]
M?EF4ELPA#CJ% -X48$JGK))##>DF;,@7J4'88AZ.E7!QTQ]G/M&]*6S*0*Q&
M@;-/8:O:D<P0^-:U,,X()?H'\M^!D09]?A)\LI:#K\,6K5X1^[VFGW%_2I0-
MLKL"" CD?. J2QXIM9EB19((82P99GGR!#=#2.OR$$.!ZHV(1LE\Q%);RS'7
MYWL\Q'?0T@KR-!/>'7VG(JCI:=NG^'6_S-6 ]CM63%[*QF=^D6%4^[@(,P.#
M.N)A737B^F0ME/\ZU2@MZ-#X]1:O/0*.M6H4:H>V\:&H""G=L<5("R?__5)'
MX3JQ_CA'Q-LX]6(V!*,VU.;\ON'!$3/Z4$!EG,ZB2&9U_Y?%5:<B0Z3IA.IP
M31,;4L;/$/KYN7X;,W'%KT2GT4D5#"KU@ DC#_I@Q@C##KSN*I/]Z_N.Y27F
M9#E$W8FYATB_F<RUDLQ/WB"BG^ XG.0N&\(?:$J+![FI"FU.NRCH1GKF=R\&
M[YM%T7T-!80% 4SZT0S/@^.I6SZDDRU/T0</3#R:+#2*??GZ^?-/7J':.C\=
M//5'WX9+5C^G"L2Z_'"6]ERECUE]"BH)P<P,OPUM, S"+(4CZ)H&=!W0&SXL
M.:SU4*$R2/WT4>?TIADCP:"XTVIBYQ\--N=WVEA;-USE]IP$=H^ *XUIX_RX
M0:R$<N@YZ.&929-:3\\$Q<0Z0:M-TH]/Y^:L!DXHMG\^3G[R8_Z(L@<FIWI3
M?]Q?=^O9E>*)Y23_03O&X!K*1L,-$Z_/W4))YKAY6.S9"=QW'^OW^GOZZJ&$
MA-B1@$@-6<T$KP)L"XYF\[6X]]CK<X2@<)3//N:LCO)2<#<_?+2EYBXYIQJ5
M8&Y^K;=4F7_=O07NFU78!:^NJ?(K+<@?4,R.GCM].7."P$C1XV8U6K AVELC
M]2:@%ALB;WZ6#7G_'/A67XGI O',K300L$95$6<9,9Y PMK9/V^GE8Y\1(_
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M!)+I0_1>\%%]JBQ53+6($%)TH+KKG.HS\U]>G;("=M5.V4-.VE8FLTI;@1Z
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M(P=AUIR&A*%3D%RYM; "_V.>A_PAC@;5$4*_9&5A_46R0)PB@L&>BV#O\%7
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M4^W#E@&TP'X13*<6"GGX&V$-IT3H D+0#)1*ZC\D&R+=)?F-D'>R^3KKUG.
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MFVMYFC35G[ DM-I,85LC63YY9L4FT-\AY;:]_O%?-X7[#ZL6(%XE0K_PSW-
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MUZ)Y<:1Z)<M#L$.& IO#MN/XS#38(V;' #>&E;EPWCZ:4;Q1.MD[SS(%/?@
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MYX8JNC_O[]*-.9*G*@O:); %/G!1,H?. ;'24,<9-^\2^ ]1+5^M:$7HUHE
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M<^Z/3\\'Y J?[G,^<>MQE9B?V"#\,'SFU[)ZMUX*K&&$TA;  ?G"I '3BPU
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M#T(4I<5*T6W3@_LMJ=-D*.8K(W%*6D 97\K[=8D?;3+LL0]Z!WZV)B"V*)3
MBL^=4 W]"PF5UXNMEO&Q2IH EUGR"R$CS5N!23),&HE>I5^:KORM:-KC6!89
MF5]-$WV1WMVH>GZ\\YMRR*]L*X<34?-A[Z/0\?;P=&*M+46#Z\K#K!:,9ZXY
M?01 4#F@E3'4.5I&;W4)2CNKD^N,F$-4=**P3'J'5]&0QZ.R'IVOY]M+0PTG
M(+Y+OR*T'RL;_O9)0)]"3^"48'[;4;CJK.Y7AI GQFQE0*,$90[T>9!RK^QK
MS:1/N9D,,@3'V&HO+,07W?NUT\^P_?OV>MP^,^S$.\L69L_:TA#T(:"6 7%'
M*4T:".%BF]5B2KG4:%TNM[6TO*LT9U2^1U*560"O%A=J"B9\3]F_.E_&;7K8
M BO+X(/,XUP0'F!/NPO1X#T4U]Y[+H $:=[W85P;S1KCY[E6;N)BJ^V;%VE)
M.>2L("NGKT0/XYO_O2=*\.B[_Q"!VM"9K#@H']>>$JR\>KU9#'FUFQL&2$RG
MR4HWZJS?\F#90=6)- UR4](IU0]UN:D.3O;58N<6XK1%M2JX]<0'QF_#,(%M
M=M"N.4^P#R.#-KH0;]9'5E3K(_Z8\L=_\JT4*3]@.?LT0UO,:55E-?NWX%'>
M=A1WO;TT $%"2 'RW>ZG  *-OX^.$?KJAY;[H71R2B=(FWD:]IS>_Z#-HES?
M?<$*H=RC\'?L9O_!,.];F\,AK?8,,61P#[PA,X9Q?X1&Z'-H4Z:NQ@5!3Q?[
M&F$+.:#;7%Y^TU;XK_06UG.\\95JZR7XL*B1ARR_%.6%'0_\)-.8:W9?U#$
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MMK':YP-&(H+WX4)+!LSLPC3GG8=[YH6>)^<.OXE"_:*VL 7\*U!2@/<;E#P
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M9D0\IVA"VB\T4?K/I2QWAW?KPL@%#VSPXR^\\X3E4F*#.D69<1#)3R(\A?G
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ME"EA]%'LD='VM;'*L74A_QY0NE#-PP,'#Q^*L@#!6;F$Y1(.J#J+HD^38A]
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ME8,H_<1>G%KF(&3.*T!5!+8R=Z6IKC"+ =C_:?[^P-1*9I;_(-FOW#[42L@
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M1:)H*"F.EA7&"I^50E>U1GSA^G0NXH.BP4O^_"E\Q_'YP0[Z1UKBW(NQ#O"
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M0B#VUM_\"YU'?>6:Z  5FI^H*YVF<]$R,A*RA&(UOB26""UXO1T49UW!#^!
MQ8VI*2BJR;QXBW"N6]VD4;WB%>3JYD%+<@EP!H1Q];YA$P93A2W%3>OHXH:,
M#%'+9"3C]EO8$S+\09=?I67GX,>UA2JA/#R#?355-T1J6=VPBSZIAJX@4)^#
M#E#@!8!H#EK! 7KE3!Q] '2,W>.DK53R27K/(AK6P.\#  N$ S(VZ#_T;C"
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ML./[OCX49MOB*[A'1DWZXR$D.9HFG!7Y/! /4V68RB\(+P^,W?NQ&Z'QXTA
M7HA_0*61-C)@2[5 PO1B\741T--@%M5!QZ(JC9^C^0+0<3;.BM\#-[C@[[U[
M$"[YG3!_;Y72Y+R")NJFKN&/4U_E[-3UQZ0=\.)+6$\8#MJ*.DI7)#?B(<]=
M* >D#P!.[QW'EW'EGRHL2IS#RE=)HC>J38EG/[?)VA OBMP%?0D6TH^YN7JC
MNTYXQVG2LK"S%)JU7+[A.EUF$W^U0K''OT1V>)8P9-[CHV(H7%,_B6R%2.E[
MXB'Q3#U&)5,>2%A<-1YNDB_I)%8$RJ_3+X1^L+=@3TNSS<M0%9,[R,8EDI_X
MI(+"BJ@#^$2:20<KZ.AR)<\*X:@.R,% 'XV.%O6[N6H\N*;:(95?;U_>B^L7
MOJYIM6AW!%_J18HPB(IEGD*URC7=(I X6[W=:4;C *K]XS.?=Y[476&KJ:E*
M#$YU,2AUHO#UV^GCWT9N7KIE.L*9@!S 5O,_1TK@$!<!_[E$;J>Z9\B3'C)7
M1]X-WN<++GB-.=%4\^G9M[-9O6G"'#J!6P(?50MY.;EL"JVMGEELEI7E/G9H
MM&^9/'XJZ9W-*S<K,U7W@(U@N3*:_+W&#16QGUCI7U)*+/^A'^[^W,(.A!%7
MP=(>MJC#@1:V-I261.%!N^7,%+L+^Y8517[X.>95GPE[EV.:9Z?>XKP'4OE"
M0-U%'0*@W>AJDZ<#'>C$M!RAZN]:?6*:K4C?S-#X=!5=W$1#UYVZ^^D0_<U6
MH6I:'S@S8VXC <(7 )O(5)MPQW?8+S#1H7.R%)T7369$\X,/ENH_Q>#,O;WA
M/BZ9@9&:9N_O^RM5QQ\C[+NS!>5;8&0E+UT912I:S!W,;'/SN6'R?4WE?>*M
M6V'C#AGN\:7;Y0+H4V'YHF)?XH,CSI5J$C=*@H+&G&LG^V"?EHIL^$6YE#SR
M H-]=*'!L\&81U#<L"VK8I27Y8N9XY3"<'#;;NV[N7B;56OR_.OI]_UR4PG4
M^82C[^XV1G&*28K/TWF(%FIMTLJ5E),U>"?YCMK1Y"/I1F/.RSZJE?ELQVLR
MQ3YR\6V:UI]B^]*+-J8$=P_L0W['UFH7TBXRAY$B(^#VF9,435SBBVH8U[1L
ML-5D2Y#1@>3X_ \'&[/8G^9<."?M$LP(UWDA1Q-LK!N:H32EG"@=[O2%QCVQ
M<FJC?9 -XFA0>%]TZE%\\TBHS\^<7<G4-TZ>-Y]C0O2@81M!M6/T@0(LOB1'
M>0_T?(LXU@Z51+7I%/R<G02ST>5#&4GO)H\^*&V:5&=>%:PZ8YH2-&+]]>(3
M]<=C?34D5&U4U^RS6<D:EK8$<Y?KFZ.YZ9J#""44^$5 :"A,ZQ<-)4\2?.W[
MGGCM4!L;=$,+7G"-XU".D*#7Z.6,>&-;B7.%H<UM,0KE>2^8%0'\.VQVJ+'\
M/Q,Y@3?.[X%>BJ0S'O_/':'KH"\,!GX&?K3]NY$PYEOO'22CEI64MIBJ>Z )
MRS$6"Y@S"$OD1#6-_()FD!$AS%43NN6F_I^5W2T03;"?OW^P6G;PP\V6$:?-
M<ZY/0/OE/X+8UA1?_<VW9_^]:,M.&>NI!JB>DX E"^^/%.R!<H]CAM#_CD+>
M4=AY?_,1EL64R6?SF)>TFD69KQ*[[15RL3:0(]Q*RR0P]1#@24CD] H"2T,\
M0J$\\.^ B=G8G6&Y[^OW*P;O8.MK'/Q1?D=5ZG,_7;X7HZA?<4RY(T\.KM9E
M&:4#YFQ1 S $N=$JV(<^ DP(ZBGD=>3)B_),'(&@_E8_XFY65(5(A+*%^)#?
M,SHX;:!\R>*!'$)?^'W=EJW#S]'EG]OG&I0&D?+(?J0N8$:&L+"E"R/>JO4&
M*N@V C8>+E?AA5'UC!Z4!"8_LK'-;HO/6WAQ6EGR;GK;;!26BVY2T%=.MP=P
M.2*U.D]'>V>Z+X9=VW3'B17 ;4P[KBNX]:5-=22)FU50A\HLVK/URFS20_4,
MFK[ 'Q<7RJ9FIXP4Y-G:-VM92!J(S"+\&-F(0++.W,W9_;_/J=3$7^A_DVFP
M&&=OJN4=^BDO<PBN<ZK"SC5-G8TMW"=_WT&,<0,CPN<DD%'&[&<>!88]BQ&W
MR+]3I^IF1*-,W#[6-U1'+#8,E\&:VNXWQKN^\O%PC<XY>3,U87J(<E-&1%Y%
M'-N'31X+<GP(S[#H-+E)&D;.P"R2MA:$;3\ 8"I\L-R05XW$18DB"K<<)7>N
M8T_&OCN)SD-Y>(F735GEIU1?U_Q^[*E(FIJZS2O$4'%N_92HV8\(K1"Q&P6Z
M91_*:DA 5=^'\E7J$X ?0P=1(A+"BU:#[%NRRSVT,Y<B:TAGSSZ[.>Q[LUJC
M^(O(]P4GJ:/[DB^O^,?E''DC+YYD'3L84W!N*.MY:B;WW["DG1WH6Q39!T-'
MMS2R6$'[=59XD R;IC:8QEK8ML=-++XG4PPFFJS_F55*0G\"'T.ULA+[@NBL
M '9UPW@/-%Q3@#(881QDZ;R_^7\7<A#UI1(ZAWIEV0N?8UXF[X'VL6K(%_DE
MNE9%DX#;$GW3":AHM%2+K#D!S0,OZ;(@;/!/>NXZ3,]ZBYY1AOE]=+,^Z'KX
MTGO;N\&&(F!OUZ4_<Q=<A32['O*,)1?S*ZH:W.H .8HX2X'&V5J3F]<P"[-P
MU$W>C\T+K_*^%V]$U*X/7"]O97QM"UPFO"F";3:74EO2&6H_=J8J<\3?JUQN
MF58+=5X9JZU=7O7^B9BDG:<+#B)YG.#.,#Z$[1#"]3V\JFW.<?BWA30.;GVV
MGS1=F'3B6O&R>DT>S/HTSYTC( US,HWJ31E+;-D'WP-1XV.XRA Z^+.E0J$3
M*EP)U,T5JD1 C<D7ME39D-OQXP??AB_N,^"D_F*D,<%TGAHR?R?D"59TX\]1
M[$3IV,! ?&BS/425VNJS?F5JXNH;!8_%5PNI-S6JT0K'TI:9[ @[H&@."ISL
M)O'@H6*(JQ2.LESXX^XVKK<>N)PJ?6K#W>P[^VHI>J^>"Q0?/&_X\U?IS$D8
M#_>KZ0W9+*]OW[Q4["?+<KI*N"Q<Y:^4^GCTY&>/_)!,:::&EOW2#Z7Z 3+D
M2>(4;IU%=N9(4>WH0QXV5IJ9"XO1AKECHOY7CDC<+B,-O%[[4F5Z^]ZISQV4
M+ZLMNLQ>;-4>J'W@R2#"'SA'@[;/ >\I5WYZ%G;C]:85,I#?AGL)ZV]\;P_W
M3M=<XZ4L292T>D] O-6 .IQM..J^-RRIZ3"AIHG"Z]K26/2\L7&:.64EH:>]
M76G@;9]4]OL%SG>@(+4TK5FMN>'WZ8)3X%MH+:V %J7>;=BU6AQ#N@T(I=J1
MWV?C^=GA<W.PK@!R-!"W5?>\S.6[/<VMU)9C?!9Z.DW#Q_>^G<A5;_WGET@+
M<YXP"-!-SNI"[3,\!3S#SW;H*9!^8_F\JCQW7SWL:8&H:Y^RDXC_,J7^AO<I
M7Y@9!H[%0UO1SU!58Y$0[XW(!DQB((^/,)!BPFP;%;6TT&FO"][2UQ;5RWNY
M<B[MW-+X^_&W6;U;IN<LQ?_L( _W)XJRI,.#/= +&Z@PW05&Y/-===*-[ZKQ
M]/*9:XI9EVUX:OPB9?X9[R!R5=Y]NF<R)4U"T*8 :6< UJH=':JL<ZK#.C@8
M(9S%(Y357QTI2:--.^L@IK5"'7*#?RRBW >>/*[K;D8YU"5VV#2HQA.@?([
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M*2!TB+ .K"3]'A!>0K\!I!,5?_N$.K6$-M^P^@32'*KH.7M=Y#R>_?J?W99
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M'I\S,^<:N;EPRTTY/N[T 2&N5BFO[L0F&!$2G7-N%"D#;P.F6(!4XO=A)?@
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MRQL!?I'?",7H=D+)C\#[>0%UGH%;AFKQIU^7VHC'Y%V[X=DXH3/\A=+[;W1
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M\0=XL'WE2Y- EX?"J3//2_;QGUHQM;X2"Q%!^:A%8%D:U!L:@:YXE1ZTS=0
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M,R/#DQY@8(P[-T6%B_)=Q2 %MC_\!#<#Z- N=#1> 1\$![4^OEJ$"WZ?GO#
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M9U>]GNF.D R&N#$#O8];=P5I';GFZY]<# RRE#[_W=ZK&VXAL,8/,E(@,JI
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MM_+QL:)ZZ"WD47Y^N?$?"SJ#4H..PZEAVF@V/01A<! !1C$M;8 3*SRMR:!
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M#I.\V9-K^-0XQ9MN?N[T6]WKKB4%UUQC S0J['5(&RKOYN,.GE&,8H?]G;?
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MYNEC"C9ZE89#Z*<=8%V\.[D/)'\6F<5\9'^\E54<%V+X3K!_7Z*ELP0_<>U
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MQ?JFCFF.%)VA.[-JS H3CC7Q$S1TOO[CW<JR^WO=6Y/%!BTZ[@1^H9]%1^Y
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M??Y58[X)M4,Z7\[VUD0;38.#EW[&:=]5,?H5E(X\A9S&*$%"MA,Q386#3XS
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MFVTG'L9<*B<Z 6J$?JP@:SX&TS&2R3)G7*&B!KM@0I"TZS-&;)#XPND(RZ)
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M]1 XQX=GIA4K/ "#U0 #%RB;[^_@TI]V"+Y06O+P67KG<09M:A/2)ZQ1\*#
M+IO[\_HR#-"IJJ1J$FA\P%T*K@_*=[V+ LLTMX@*H6J,&&-YROOE%+90K6V7
MIY(%=@1\[U9A1K/X#_?87ZRG.<+!FW84,.T%\ZFE%#!.NSEAJ0-<.D<9N;^A
M9]BU+6U??F%O^%&E=^W(S0CAE[XP<[*LTLD&CX]V#X-2 \]<!U'9($"S9#O-
MR.D3@0@=P.[G*"W\$B]U;F0\94^D]GE"^9BCW>EBCY8',OGE%4N7!;W*!43@
M1J_H_MY7X4$LP1&Z_'J/DN65K1[+P_!XK^"783E'O]L_#T<D?/'J$C(&461?
M?JV=89U$#A"$6,>1PV+(H3N1U0DDIKS=A&&M$_^Z=$! Y\>&V]5)WB=^6##,
M^HSJNQ^?%&VL(>7X,0R8CU@GX(6TX@E(&!@_-8*4G37:YH5;;@\L\4X@%"L_
M>[F[MZWW[A4\_T:VB[IY0R>"[-ZWP'-NO<?_R VN7XI!\(%^'T7J[KTVIWT
MSL%A4\-SJKIQ1KLB4.@FS#!"(3>OXJ"L;.II_E)A>$,:%CG-*2-JCO_ *M7
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M"_)<[2CWI+!R$Y[/.X08A$;<_NAS]7!\E*'R!]Y]]OO>()Y>9_IAQS%X)Y:
M-_T& \9AV=@%#ASHWP;C5_J*8I-^95D87)ABA"60Y)^TO7:PGUI)<I#7>EY
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MW%^76%-T/^0\@1?GATTS7C("FLCUNG@VR OG;= OI\AJ@_GMS3Y;_G(WX&7
M?4GNE8)8Y9/^![:L%'[/,21^#H);+#K2S:_(I+!!(=M<" =@@"JRRH!2(1<I
MMCB^,CE)=VUB!_IM['$/SZ$OG@NJE3XVF?;'/TP=Y-K&';)4"R;P68K#JY=%
MTS>KBITHF#2]MF(@8O@Z/")B*?8*>$GSGN@=()[CI]O&-ZLI4); ,DD/T!(=
M1&7=B:D)JG'_KJ1.Q?0+H40]U1\%D!9=XZ]%;.@^XMU>V*S?FK0VGQH],'EF
M[7#VN2[+<0IZ")J(:XTNS.X6(&(5 -301WB\6Q<%=__VJ/R;+9N<M6'>H91W
M23$G/8Z_6:I02L69_)G6>16RS) %E%/=8E#:+69U&UB*H4G!9K26V)'OE^@F
M2^;#(?URB-7HL&>A<OUO7#TJ@^M)+:T'*\<?'2R(4S)4MQ*=\?POW=CT [V
M83F"1W T+A13.&QF_1TD$O7;$*7$44:\''@U>BJR_H]2:5:F?_NW.E*1 Y%2
MU:R,\XO_/A?D_U6T(!R)V_N!V0\69L,^4E/18?" $S9\U?Z*_2J/ET[T73TH
M8*]Z80>_82JN=3X3]%,T$=*4ME%/UUGGH$$Z+F@[T4>"4E!&CCCC]3IP]S2%
MV58Q5:AYP8N<X_6.][382NC?#TXUC)#M^L=3(8<86B9WD7J(4Q\15YY=/1Z6
M QXL.FLRV_Q@/^^S)QZ'B*7EK^K7CG++D-B@ 70:1H"A%4&$II1R3R",GGGH
M+EC(#^Q=-79M%#V;*779Y=>^QE;L?#$-]A%YU(F*LV9B$&(!RPY/5.,Q,GCX
MQ0\6%UUOMLTW%.AK22N(>^7.=MTYRGT/&*'K(M_C6J\,I1 V>>FF@,3(Q55[
MY9!;P&B_L6>Y1UW*A225*(G' Y*.?3=+RBUXP?R0@/'Y0EKT2UP7$X,*<MH'
ME_:^HN)X$<H'V(XZA UE-V6?CWAF??CBEE7X\LV12]Z+DEQHTG9:*8B2%;I-
M@G '[WE0^<K5R["*9A<R13>U7DFY.F3E9)JO>ERY4O)C\"@/Y1A+F**79*GP
M71_P(FTGM];S7\B8)T^U1EAJN8L]_II^7^T*3ZG]B%'M_P%S?05W0!A%$#1J
M8Q\;M"<W5SOW+]3\W#\46IU>"N''!889&W1-RXDI_JC+BE?2Y=\_X.!,-NA+
MR#1NXX@)*S6,H-7+X!@)E;\JV2!? =PO ^B1(4)O)4>-'#;X_BP3N":H69C6
M;?\4WG*!-4_YT 1#!4>J)U[U?*=H_B8 7GGA_KJRJ=BG&L47F\*&O4>?98+^
MT]#Z;"F/>I-3Q0;-B3(?SZ7-O41P #97WI$-:@#3];$U),CN*AN4MF,5Z6(C
MM4O\_\O$KB_C &UL9H\*P$\")W:C9 :V)?[<5Y-%W2>$O:^D0+G>K%L6^U0H
M;IC<=**[?>*#7T%P,FA=KC97]@&Z2>LM*L0IFPV21@H!+;UX[%V6$% X7*J(
MFX8=IK8J24\MO^R<BK!Y%0R3DGWXMOU:NE_V$]GKMYY_-9X;\54EI6?GO>[T
M633[E="]P3\&IIS#I!%:^-%\:+HK\@U4\EKAP&@YT&$[9RY?!221ZB.N=U-Y
M9.X@5AQCC_F>;&T+@.69W,[33EW(_8CJB^J^27>#:]%DJ(_F>FM%]\\#@=ZF
M>,)PZ>$9(_KS'?>ZE>[,I; PK7.;<AHG5%]4>>A*A'8G'C'S[+9F"?RF&[H#
MA30Z!;L93]='R%&AB;_DPV *7HB@F9T2OF6;9NKE_+4Y[O-MJ9-$E3%SG4[[
M"K%[3LJ&@3^Y//?"6$)FY0!V&$SY:QS,. 6@*&S08(_&W,[WNB.3MV%"\,CM
MBR]+IES:'OUHI^(*>((W7]'0#Q/MR:_/_YT[5M/U4WV6CHW[SC3Q<>WD7F19
M(E3:@5U*U""8=T=/G!!BK*31:!I3'U=E.8IN.M\7Z9?3QV>2QZWJ=_J=K GH
M/)%#S*(L 2^Z ,."^0(IR!F %"5PVV$.,]@,=%S%P>3"9#!!$[>C[:Y-7/5^
M*R^ W3+\M#_:K#PO_%;;;F%:VSI8XGL!GE7,N^'L;==S=$?1--Y^^HZYP3-[
M65HT/[X;383<,[]"AN&]R-A-X66LB,\J:6N#H4A\;B0?F/$!75WN8#2IQ97"
M0<>N 1'5S-GYNRJ1Y@QCY;;];VT=54L+VQ:F5B)85C<(K8[OH6".1BT#B[)!
M_D[2U7B$:"7#9*8[?EF8S[\X GG]==M4*]VK8M6HTWS.H%7O\>+RO>:2Q"OH
M3T&#GH5W.=0-0T.;7JRYF?B @0BRL/QERGF?JX;8ZE7380SM;G7M*9TO?=&\
MQ Q[,^7KV;XN5FWTLW#P$$H0%X%*8X/:"6G=BG5AG9*6@C,(4>J^*0Z7S.W.
MNKJ9&,^UNTUX6M4;]=M%A5//-9:_D?Y^\LSS+Q[,S!Y9^.3R,O\P"O]SI$<2
M1V'@I!CV52.D,2'7CN-+7L&>5S+QG@XW)1 ?'<QSHF]^>2DJYRCWTNU 5LN-
MO>I"S0[@5=MOCO32BN/:+F(]4N]ZNO3]P=KNG?@E3_M]T-6M6HNF:$VU[.;F
MM*M;%R]GWWUPQVTP'X@G0@?0P-'=?E0*IK&@);Q4I2G?/7_Y0V'9^N3B /->
M^T756^MF%0F[!#S?])D?^;?L"U6K]O8*B2/#G.%Y R[Q5'EG@)N\+;!FW+&7
MTH:[Q[@D*3VW"PU\M'S_+).4K4KBMGW?=^Z:_4*JI0K=>AZ>12OE*$V>4"B/
MI2Q0>V&Z!\PX$Q$[5&HRQ]"(+Q^I^NXW_$VH7E^M*U,E9B[/03#..>XYCX__
MH_WW5E*^59^R]?*T7Z_<V-W^NM)QS1+[+%/KWK[7 Z0.1CH>QKS!!LWGP!/B
MTP9@O\5:"7L<;F^1VROE. LD!D!=YOLJZ0)%<ME(.O]G\4\&\<[K.+M-CC%1
M1R\3Z" <*[65:Q&ARP;E!9$(="Y/U/>']?A^P)L-4AT?P-'VM;)!$\>\6O_[
M7%:["V!9MB4.K'X)U/? US^Z18=0/PS7H+2#Q6R0M=$/!6^&H _V![=EYE%L
MZCXS+P>'0\CQ@ @%_:W >7%>^2=9^KU;]JI[>8[V_^K@_\!5HM@;0 0;I&S,
M.?95",T?>JD?M<W1D*)KB9\Y$[_]S^3WC^H3ZX8]RGS%X8@)!L?T7Y/AN/_9
M1#/L/Y"5^S_X\?]F]_Q;2ORY%P&Y4&H&)- =X78T:0IN)!Y\[R!\A01-9]C)
MH+<-/VETSNIM,%Y&_-(YU1#%8R*B6A";.VFWH!!RR.V!T1T,0Z('NG!F6'Y;
MA#6%$;N]?0CNBP3#'9P!%#D,(EPLE)5\4WA[H>PU3'\V_B5>*V%<:5"_6^=K
M;=<*QUPE57\G4)P(^*H%3V8R*@(B"(_<]2HDU1.R+94LVY[7UR]\'HP\\O#3
M><%S^8-ON4^4@XW4CN3F*H#_?)M8%EY,*P+LJ6S0"+01G8D*\2+D@ 491R@#
M THJ%&Q6=(;XLC.E\NN>,<(L^M:]WPU-Y>?21XZ)VZ58T4'\G1PW2W'!'41P
M,ZMZ!)#O, =Z%. +=#LR_["BS!FJ278#@S<>G%;WZW=Y?(:.W_368>E"DTO/
MPL46NKI#\POTNZ^!&Z*]W1P^MG:51'E-/VUI;NF(V];3K7(G)ZE>'%?I.BAU
MY;1J?B*7>@]'F"3U./%8:C(?#$XI2S.;S75EHKCRF4_JL@6W4<1*L"@JC W*
M1 DRS(B8>8?>4@&J12OK6"H*#,!&E-1>3M:W):@?_1+=8G :9G:HXI4TZW;
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MCXSC':=T-UH/C!9N; HOD"V^?-HP5[7F2(9?Q-3PQ, KD 68)3!%=P;HM%+
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M30Y()>&$-ZN6Z>K2[&6P.<EQ@M>RW^D\BNI:V2*R/>/O.>T@?P;8OZ6'N_J
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MVD'F9V5\GFW5Z>,CIS%UL#W(S/V2U[ISK7KI)AD5"VG(XKB$[BD5%>B2OI2
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M)*FK7Z>ZUJD(7?-Z86HV[5FLX!.M+1XJ+C$LN/EQ^T6(."SF1/46:FAQ'3X
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MS^H%&VC(4CRC%3(_O7K<]-+9/"1#3$R)+%F#&[A#)/0VIC+BX"-I>*@HJ3A
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M=VDO5W0/QG$@'8@&19WWSWTB:]XX'_7U@)B,UL'S0FO%(_@P4".YB%!+84'
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MW0SLI)\EE$%Y+*^_21Z%[Z$F?>60W5S_)>6,QH2F,U;2YA;?>_>:Y(N3#KZ
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M"GC_M',?=AO.-Q^TH1M SQ$3NF+V,^4>]4.?1&AX%VB+34<TWIM814S:LV*
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M!:5?.>;,BLHG_E5].COI#F,ORT/UIR\X[KOE[NP:+Q @6,7W10SO0SYEI0I
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MVS?,II;[%>._HV^/7X9=QC>AIJ>_MJ[VM^8-9ML(_QE3$W.5WD<X.X'3X1P
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M#-,3IHW952H-*XPD*6FE9/-(!5C@_RSFR[+]C68E'RHCIMY#_@_;L4<AJ)Z
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M'NG&(HA '">*43SL^P&1D4B->.340%,CD%I4L"VKQ5%2%Z(&IWJ.<!J8+ Y
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M!Z\CN8_18SD+48PI45NWE(<Q1)X70:I>0<A%DN H\C$-:(]*J,8"&'U8XY=
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ME//Z@]\H:FGL#CS59J;P="9P8-K>]O;NA9IM=-VRGQMMP;:ZNI/\KL*@U7B
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M^AX35L7CAQ!R:DM#)>E9==6&F$E#HO_.\S,PZ]M,C3UM#XB=6PX?0M!Q"7U
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M<^;!S$YWC^[ 2X<;8,]IS6J TU!-6+N&_E[M5@W@Z&BL:G)W?[I:J$E]:>)
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M&:=;^:%;-2]T<NB6T);!WR<0-[-9'>(X\/IQ'H3V(>!FP+@- C\QYKAAX&8
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MU3ZO-&-]D7][4$KH].RBG 6IS^,4IY"$4C$,2D*81AQ#)E+*J)"(F)7'/3;
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M'7M(7:<FZ\X HUJGAU1[;8@>O,;QGG8FDU"2.*!08E:UN \@B82$:HL;!4G
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M(+V0)1"G<00100+22""%O8AE%%$6BF2VU$ND&2V=&M"*DM;##KWZSS=25Q9
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M :D(0HB$5#L0GV.(.?5B1% <652*.33"U-Q_VS):AT@?Q]' 'C\7G8&_^H&
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MU8+I2%OQ3M3_.R->E)(@D3"B.*X;M>,$(TAB[K$DB7CB6\6CN1)L:H3WRVZ
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MU%0TD&%32[VTH<MU^9]-5<!" 497Y0J(K5^N[4)#S9\=E;W&K Q,>Y=T[>_
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M9V1#=9)@%)CEZG/U_I?I@+<I5S],Y/19O9-L/4LC'G.2QS!)L:FFU:1+6%[
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MIZ!A%=2\ND>OSH-Z.7(5!*J1/_E!*'E%K"ZB,#A:=?[)DT6J+@IW&*6Z?/%
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MI^P!#[C]_/:C7TCABI5SBSM,LQXC[TX'2_%+O12?NJ5H10&=+(?=I>H&GS>
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MU/DU^Z90?DIKP#JXJ;!QT1U9H5D6#SJ7W8"=-%"7:U@QJ^?&& TT'+6@ZFP
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MM69W77=%AEA"DXQ H3/SY:M809HB 15.E51Q0G6:NP9U3E*8W^<O:KY $M\
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MC*DL4\SX,@ER/GGJIS4W173$+6C8!3]9AG\&+<L>QS$7<'8XJPJ'WMC6R)3
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M>?*!DWR<?:)TWV?O-4-Z>?W^Z_NO'[__5ZO9M4HDE9GY)(7MD4]L^E^:&5L
M,4YUGG'S!;LW\CIZ]MP^T(X[GY95QV YV '#(1CY>^P8&]2YZQ@&G[9=@^&8
MJF?7I9?"LV'727G[NW4=WS)AJZZ3O![WZ3I]R<#>.Z4HWJEU\<,LZ0_UGUNV
M+/13L;J[K?Y#R3O53%EM AOERLX)T48K?&=_+KB0&F&,(4HB!#%&MHI<)S#&
M*<)(Q%'.O8I0AS(R-X6VEP'\<R<$8%5]L%BL?JAJ4T<O[ZU4-T"U<M7QZUHP
MS_8]0]?/+;8\Q:J,[6U]?OOQ!APLRW\>+<M_-.O020)VHMP 9H6QQX\!V_M<
MB6?8-C]#F9FVW<^5D+UH^W/M\P8JVKH%["*.-&'*6'6Y1!G$B>"01TK )),,
MDYAPHIE7Z[+ZL?/,DVF:/WOJLP8F1^WD+?S8NJ9?8G]U<21@V(^_>?2TG_*1
M."\^S.-_'=I HSGW^[C;:7]AQ:JR:0*J6G""-66Y@HQ)!G%,"<P1,GZ6R@BW
MD586YXN5NK,GP]]]&FCT$'5Z/6GS>KX@/=ZK6G/89#VIZF=0K@Z,DZI.@_+M
MF]$'O-OW?#V.4W7*:/@$>T9!BV?#Z_FI&0,:9#A@$K@S1A_%B5MB. C_LA>&
MRTW^9ZWO_[DM-D^_JLU]V3Y;J=_,6])VW:6Y%CIE&J8X(Q#G&86Y3;V,64J2
MC#/)I7-;K7Y2<W-Y]D#? ,NE9T-C!VS[U4=8Q$;6'?Y@>1W2NN%P]6'M!3*3
M'=JZB7MX>.MXQX @[A>UUN7ZP<YU^+8IQ3]^7Q6;ZIO:;)9*%JNWK+IO0W69
MRAGA/((I90IB217DVC@"A.>)RFF,44Z<P[NN5.>F- [X!I5E'&PMYZ!J6*\S
M]@SS'@%19_P=(L9CH#JR8CD$M.89U$R#;WM +=]#0LW.R'H$H<= >*+P=#"D
M_<+8OHCU!KB='S9=Z-M7OJ.@N/?-0Q1\DWCZ;JMN;:/H<B5O5ZOBAU&6;/W4
M?@%1I(4PM\)46BM0UTEW(H5,VQ%@62JQV^&Z*\'9J?4V.=?P#&[K-NJ&:W#
MMH_:<<#;19>'17%L-7X)P$$*W %)']T=%M&IU/;@5]-33[NCTZ^B'9XSH79V
ME^I8,7O<-RSD]YO:[&N!=J.&58QRG"D)<QYC:!SQ#%*"$ML*)$<HB],\IWZ%
M-2?I^+SGTQ3%_&:^I;5]/__=+X!W&D:WP-W5T(RL5&TEX5%QX9DZPJ#CFYW
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M::LK%62I,<5SFBB12<:$EC[J^#RIN2E7RZF-0E=L:9U]]:<M5JGG'1SF_=E
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M_BUR_437VU\?]7?D_F>Y63"*>2:% (30!"#!,*"D2 "3 O$L+?1=4AMVN33
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M *1B'2=!E@!2(*1_PYE CO)W-]DS/^XT!M8/+#<_R+VICH*:-\T2H2*E.:<
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M=5VQM-^'6W &]?HQC0%G7 '$,@%H2AE0$"90ZG6D2$:<^[0:>X;!U\U'.^U
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M]K+1JJMK2<WQV>;_WU6?GN2Z[F'ZBCZ5.B#9??TY1$AD!0.(4K.]AC%@,I:
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M>X9'K>51:WI4VQ[MC3\1&/Q,[4JCW%,&H^#TFR)P,V':E, H>$Y2 ./N,BJ
MW.T4/6^D**M*/\F[P/71J*GJ?UFI+?TI?_+ELW[T=;S[M*J,)%?%UY+JJV3S
M_XLB3C.6*PI8 3. 9"V#2A6(.9<PHVF"[*C2NV5S8U$C4+N)?EOJ58/4ZTT=
M,S0GKCKOHL=&';ES+-IYYA29>9Q:J]CW928L>*R\<RMZ;DY&79BMJDD+:/_.
MS5S4^1C]UGGYIY>:3:>X_&5F=;(X_@5FUW4-X'\&KJP9/ XXY1K#/TY':Y(
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MW7&ZG9A1GAYLM8R[PZ7W0G\"=9#ZCW_[E^Y?]'\8W<A_^Y?_!U!+ P04
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M)'3264WB>?1&Y0"ATB4MTUBE 9WA@<3< % N;"HY>Q)5-O4Z8+T7BCE L"Y
M+K63E4C:FW'@<4%!(Q'2@9I<#2#6@^'P!==Q-1 @GJTVG6%]\<?GFM3:7&83
M)+J4K/*0<LJ@C.VJ\!VHZ$I6T=-N_%B=ZN$ >8BB1JS(,( 91.S- .A-^<MJ
ME:_OS^]7BSSS.I=DHH/DL@!5R-0&S1&X(BM;M,E!C0>A^VF:UNH,H_5[H#2
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M^3FL_X9=\[&KTI)9=,+ZVI[8Z52G.P?:$$KFX+)$'J119K3.-'N2VN2UT-%
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M4Q^MG"S#XNMY,_1N1CK]O<S//M7K<Z^6;]>K>DBPXW+G VYN<8N"<>OK'*7
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M,/WYX^K+C[LGG@-D]TV'CPX95^^;$ ;#*&UUE 0;\#Y^62U_O0BL,$GR@T4
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M+CW^AJJ"Q6ISMKZPX;2+H\8 S)0 2C.RX29Q2$IRD0+67HM/Q/PMTJ;SIT?
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M6%<<TVU:: W)Q;BIC?:X'EWS':3@'IKCW._C>U:\%\0+TL8M2!Y)O5DC'Z1
MJ/=K*83:(:<IB#<0-6Z6Y/R8/%4O+]1)/.G=R;-?;>\FMGR)<FCP$A13PD$@
MZP,J\T3XDXK.8>U8RG4&7)OL^5F#Y(?MLL.$W][/D0/""Q=DF[EAM'MJ=W=?
M:K-W)0+M*.;W>XAP@E5[CL:7Y% >@J_M1FY0K8V=(JX/1T.M.)CF1XGO4+E9
M54]:;6M+>%T8,>0U'0DL<'!1>F:34 'WZUW]S$+CPJB5<F>-)-T+:FC;_?3
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M_UGJ:%4!)8KTCBD%KB0/BMFX&LSG)#<R!FMYF]NTYVGKQ6X=I_V=8#I9%1V
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MU$M'I!8XF#502J?@6O7.<UDGR5. PD0M06(!8LP(@25-'D>6,;6)5[?3-"[
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MA O)M+%$:6">G*6L$H1<"_]B(?5)EPSN%9#OI_['2X_C50RF_J.EV$%@4\_
M=^75?%X%<3^=/@4KF0T:F#>$87*?($3#H0CK2!;D5>LVQ6T;R=G/.K!_$1]C
M.,UU +]'Y-<F].2+AX??68Z\)QG6VM3[4@4MHX[$7E'$GJHCHRU+L,R(\BSL
MGD?4X9GGPP@=-]X> !KKN>B&>NH AH\V]OUN__5^3KE'[Z71 HR-% U:12>Z
M9PZDX"7Y'"53;3+5.\G:#V+_*DW]A]=D5[#\@#7/42OI5YW.^87A042%%KRJ
M55O>"HC:*K!2Q%2D+VJ]R__@J'Q*52]EF2<K?RNL3M3$^$/*G@ZZPL6[Z:I
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MZ&3%>+YC7*'5)1'Z$LD;5&*^CK>5@!2$EEKJAVJ_D>A#4K4?7E_0-=*X>NO
M%N]L^TLGSNQR6K-^OTQO#Z=?IE@*IOKWW\_F2\5/\^VMR%U>Y2VI[>>[OS3%
MQ>(3"9)"3]KH%]I'U%QJ2#Z6.M>J@%=1U)?E2H;( I>MP[,SL+G?+GG1%V*]
M@65LT_]C?OSQ9?3B(HGZA"\@11YUA([/!:*N;62$L,QX%XH^IACEAT7V@]P+
MNA<;5*K]H&.]5&%QX9!6<Y(\=H4D',\#":?4^7%.F"1L'?%Y(#J>++(?.E[0
MM=2@4CT<'?X6'5.\K,G53TWO2A]S56=^IIPD),Y813H'9Z4%K5*TED5+M)WM
M0O1@?+W JZ0A%3*V$=J[PN VK_ JY\EMT<O[FWGZ3*[MH_KY"XV1=I>*D'6I
M<VX2@X!&TG;3PF 1R7B[E]4:DJK]8/B";G[&U5L'T<G[\'WI8WZ:O4HDACEN
M%L:"?$59N"\&-'?D \1H(5JTP T7JD036@T:W9?"_;#Y B]_FJBH ^CM2L\^
MS6(]GZ/E3 5OI2<9\P0*DX>@"@,L"H42/A1LTQYC8$;VJVI_@==)8RI\,+S_
MKW]_HA:2SM^7?[3\D_JO/F#YO^J/?WSXY8?OQ\GL$J>3C.G?B/';!=[/Z\25
MZ^_OKP)];YKK[OY:I? CZ8O)EZ]7S^8CMW_LWQ\H7*=]]<TG*#J!6OSK&J<9
M\_]]XNGT>+57CU9[%1?+]V,7%K4)-GK0V=1+;T4G;2!/D>48DU%!L=#F6<"S
MI)U\,F];X*?)(EW-%C>T"4C,K^G?_/TB&)U1L@!!N]I0,FGP>MECT"<*UH-+
MJ<TUY"%4COLF;%@L/3FD6VGK!1JNG_ Z3*X6@]JONV^V-F,;:3^;-2ND>1>P
M@&4Z@BJ8"!C& PN6\9R#T[Y-Y[CFUNQC^HSYY@K?E:U+W;[YS1*302\A<E[J
M:"@&7KH(SK.BB\-D4YLX8U\*>[=BAV#HR6CP%EH:.RWS-J1EE=+=._1E#X3(
MR.*2^PHNB@ J) $A^ A89VN0-<)HXW/&:NO7QX5(&R7.AI1H;Y!8=0\4S',=
MB86B7&7!T]:)B@&Y T&E;'GP^TT4W?S]<6 QD,9VZ?\(\8V-@(^SJ]GUYYOY
M]..?D^O_P3GMD/N>CW32BY@U,&MK,6-F$)P@7U#K9+.3"IG8"P7;U^@("<?H
M;C:\(,?&PYU8:D.2VX$DEBRCLAD\-PR4EQPH%M!@77%!"F>Y50?9@KLOC]NT
MX'R'PU&2[ D&=YW[B\D9%0):0SNC#MH*7B1"L=".1<-,VF^D\--O=V &CM/2
M-GT?(;*Q-?YZ0@;L<I(6OX7I32$'^F;^,*>V("]*)J1 O38@2JC ASJD2"OM
M @E&E[27[G>MT@D*CM'=K(4@QT;$?Y'</L]N%OC']6K<!EG'CS=?O\[FUQ^_
MAG37)C)Y%S)SOH[AL\03G99!90?""BYX]BEGO1<X]EQPG(-C<)RT$._8D'F5
MOTRFDQJ UWN3QUP@&A_J.]<4?'WVZA"B1ZS=YR/9V,"]V\^";%UBG+XS@\-B
M&!%V<*VYU:]ZN$2S24E4=,PRX6O^5RN(L7#(W&5> O.NT4/VYVD;MXM14^^T
MD8(Z@-RKE&Z^W%S54KF?D(A(D]O0#K]>X4-1\/QZ\C_+W]\J@ LE;*JMS<$&
M)\D)1 8Q20K@<JWID\EDU:;QT5 <=)J</1)93^> G5_-'<#[,;,7F>4HBB5B
M4^TC43N>1%LB\)R-0).B6Z_F'>R!PP,5X\;PC6%VM+C']L)^OZG^PKOR\1\W
M),>WB-<7KGC%; H075:@:GSK AT;PCHLQ('UP>SE?CW]]K@G92,,#"''#BS&
MF]GR]<RR(O.7:@@O23V+O\UGB]K].CDCBX,H&86BAH*+J)D&LGTB<VY]<6UF
M,N\@:MS^?HWMR5#*Z !76R5URPT*$6-F 0K6<U41!BCVT6"C"AY%#5G;-/?;
M3=>X'?T:HVM E?1;:O/+-&,DMZ^^WSNFK.:'?S]0"<UVF@8JE_F)/O]0/75?
MWZ"]XZ6^4I2!"U#%"W!<)_#*6J,XTRRV:G>^B9[3G=NXL48,<Z"C-M6)A;&^
MOE."]@3S('C,2DK#2J,YW5L(&KNA^\E8>.KFGB[XEV$Q3JC'V_29!O:C9=7=
M%NA0H!L"5PBE%/(\;"G@6 Z0F R,)U%"LQ[/K<S(PY/QVR29=DY%X\EIM\:#
M2E%"9"&#%8%4K#WWIDUM] 9BNC0?AV!@D_DX1> =>+,_LK"\!;;!&1&U!ZXB
MQ7G>*?"1V @JB)QDU(JU&EV\3LOXB#E)O3OA<K"LNT/+[^'+W94/YFP-CYK"
M-^MKZ1#M(J(=.!V5(1GC>:,6:-LHZ@DYAVMZ)W".%/O8F;F/=/C/YK_/KG'Q
M=MFK9$)[ZL_9ZF7M3S?XZ4_Z\?O;&05R]2_<#6(T,MB($ERL4^>16W J& A.
M\Y"L#T'NU[GAN/5[PM&QBI^=5PMC ^V5%)H]XI.8>HMQ?A/FW[DF&\U7/#FF
MB(5()L5K47<D.?G>.4A9%!&9=EGNU_MKSP7'GE0T-)1:R'GD&;@?21_+*88?
M:3>$^62V--U2:9V$J.-';&6 U7FNVD#R3#H6C%/K9:";#[>]9N%N)*$GZ!SO
M!PTCX;$ALJ+[C^GB*Z9)F6!>;:3B'-.1XH=@Z]RM&!W$X#R$H!&UUJJ(O:+)
M_6"RC8SQIF</H-K9T'+N!"RUE7P*B^N[LK:H.7<B08P8B -/OF"QM;9-9*Y$
MDDD--UM],PTCPF08Q6Z R@E2[B"V^G@3%_B/&Y+>S]^JF;TKRG8RL,"D!)\"
M U4SG2%%!C(F=)A1)6[V <OACR$W$S3VC+MA8_(AI-XG>%:;RABK5.U:[6K!
MM4HE EE> \QC[=$>E7)MZ@RWDC3RR\@A%/X\B(Z0?G\PNC.DSL?L1 ;FZA'.
M PDIQ^4+,;1.ZJQXFX9X&\GI#C['J'HW@(Z0>P?@^=$T_WI_LY^9EA0/DDQ8
M#3!1D8C09LB>F$LH0]*M)J9O)&CL09HMD\K'2;T[\+P-"5=30(/PR0E?FTW5
MZB!1ZD01'2'*E(1T#K4\QP76 T4]902/5/=."!TI^[&S?C\R\8%.["]?JU(^
M4%!Z$6DU2YQ T*Q6L$8.$74!'CQ72BB*,-9&6&QM\[]]E9Z2-*<!8UB!=F==
M?IG2EW%Q73E9)BWRH\&O*#/%G$CGK:G%8C:3'V@U&0A=M/<4G[K0IH/@_C3V
M%(&UL$"#Z:<#Y/W\5VVT?S-9?%[VDRV5TY5UU3':(J*C$$.9.JO-D,/(&'#G
M0T;:84&WN6??3E-/KM$PR!I(_AT@Z0-^736!?5=N;UTJ+Q>&CF%K?0+A,])^
M\!R\+G6^9$03#.,2VZ!H,SUC3PX?'D$#R+U7WVBU$0J6S)RA\"/K^A2,0DS'
M;>W]@*QD[K,-^[49W[W.V%.[S^0?'2'4L?'QZVQZ^0GG7RI+/_^5/H?I)>:[
M&" I'2P3@"%:4#$7<"502,"9EXDL953[S579L<C8,[('1L90XNS@T*D-F!>U
M S,NWDTWG:4729GH..$\E=KKWJ1(#)%%9#YX8C%[%]O4T#Y+VM@3JH<_BH;5
M1@?P>GRV+NF7.G*>;("218TK!8*W*D$20;JB.)K8YO74.B5C3Y%NZ\<<+.L.
ML'(7%?[\UU><+O#"FDRA7M0072U>2IZ!Y[I>W63,WGC/<YO',6N$C#[Y>7BH
MG"+J?I_#W([,^)'._5[ K/[E0(]>-M$QT#N7VT_?OVV0P@O2O@"=2FW$P\G9
M4(Z#YD7:6GX77)N;EQ_I./E6\GJ6_OYY=D4[:7'[Y5ION.G=EHZ9&$-27U'D
M=(?:7KUVL:O7N4$4P;)H4X:^-XGCWAZ<@(\G5Y9-E-*O]7C4>&77#)/EA=Y1
MS^P.6V @6W0"5VU,5E0N\OH2BZ*AY?PB 2Z)"-IEC*A0)A=?@LFZ;V)UB(0?
M]DR1CD[8.G=3NUHUF2WXHBW($C *.MA5:F.Y3R2\*_-V"):V=\%OK\ .G.OU
M 4OO;J[WXGR-:VTL=\IKP)A$'<M=)S6J )B"1649_6^;6L5AZ!_W!G= ](Z@
MSGY/[H^?2?P4_:X&-9[R%'[;IP8ZC?>BM,VYJXO-UG':6"K4N]6@(*!WH$W0
M#E$K$5[6N;OT3U]_?U/WP6V5E=(R)3+"4+ARH.I_(O(,M:^]]XJEV.AF?P=1
M79V7AV!@^WEYFN [. O7=N&R657XLBP2YBY)+ZR$F&I2Q3@-WIH"D8F0,9B4
M=9N<TW::>IDS<Z+:U^$TC ZZ1=.J9E@ZCEEZ!LYI1:XB=_4VB$14')W\IF2]
M/FRF*9ZZJ,\?2/-[ >H(-8Q]5_N*-,HV<W,W<D4KSE!*,+3G0 E+7ALW%F(1
MTA0>"@KYG*.SWU(](N48E<Z:R;<# [2TR"O[_' ]@"C0!4F'.]>F1A<%?";7
MOE#887+)@?ZOB>792$XO\W"&/<1.EWP'\%E2_]0>WUQ_GLTG_W-7U\ OG'!6
M%V203(RTX4R&R%,&'DUA3D96@FMSE.U'X+BV:@ H;,J_#ZR7#N#V:8YA<3/_
MOF1O:887JXGW^<(&C260.;><6U E,8BR!&"849>@R %H\Q1D!U'C6J[A8364
M_#N TOM5N</;V?QAG[PK;V9?OLRF2_XN3/8B<EU &.%K2VL#SKH"UAA;C$D1
M39M\Y?.TC5OD/SRP!M9&!_C:;($_8/4_)]/+!U/\\'?NC'(JT2OTU2C706NI
M=B600H*63A2%PL;<Z%'VT32/^S3@7.?GX-KK-RV^Y[W6"=GR U<X[Y7V&7/K
MM;)7.Z080M48PM#// 8.&FTJ*0KC&K5Q'C:W?LA%Z(7A63,1&&1)VT,5)+=3
M! ,6@] VH_"BS<EZ")5=9=\/0<F.J4##JJ:+8W;55NI67I6UV;1Z$K?SJRW7
MZ;8U-ZNVF"$$6ZURS,6C]Y'+-O=6.\D:%UCMT/#D#!U*-1W@;(V'51XQNDPB
MP03"AOK<5%L(W"'8E,@W-:5$TZ;WR49R1DZX#J?N]5>:)\N^ P ]VG:_X_4?
M4XJDKZH#^<OT&RZNE^-(B*NZ\U:)Y"PH8%9!@Q*IEFA+#<$I#JB=\UQ9Y1O9
MKD,I[>&</ D<VX_+X375%Q+O&"$^WX3%Y[=7LS__ _,EOE^*?L6>XID9S H,
MR@(J8X#(!7DB1M-94"1FW=Q9VX?0'NJS&N%P<#WU!</=D=A\\FTY\?=_W] ^
M+-]K^+U8<O_S7^GJAN*Q>Z'3OZ+?H+_POLZX)+U?7\\G\>9Z6;<V^WU&'YU>
M$QM$TN7=*Y:5\#2=2+K0@52"#:"X1/!:.XB&'.ZHG2"%C1F1G$<,XZ85FVZA
M\85[$,;ZVJ _89E,,;_&*?WDN@Y26[S*_^?F]C2\&\*=O2TY<7!))U#,:(B8
M#$29#:O=[[AIOH/VH'/<3&53B ^MI;XP^&E._%S=:FJ=*V\\"R$SVDK1@5+)
M@>=<@TFR!"&"MXW&*NY'W[AM3YIB;BBM](6U78?%PP5#L5R@1@N1N3H@0=1V
M'HK5[)S1HC"919OH_U!*Q_6,SY9P:JK EP-0"A+>E4_AKPN=M??2U$#4<E"A
MEJ*%*,&)(%22UK)&S9\.)/1%Y$./1,UQ$#U*A4<C]"NYO[/\\3K,KT?!J?'<
M2<<R!$_NB K!@O>TYZ-73.BBM;6CQEX'X71L,SH.3@]180>6=!=/K[',:GGO
MCV_D'E@5V0@=N:GG4@8EG8-:0P=9(4=6) ;6QM<\@>AQX_JS(O=<JNT Q>N,
MO"7)[R'K-S?SJK7W2ZM_S[NUTI!WY0A]+()* <$5\MA1*Y]R'?55VC3'&)*+
M<8/[L^)\-.5W /R]CB0AA7")4;A9F^6KZ#CX(!5$:X5SWIB0SF^G#P)JLXQ
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MQ]KDVAHR-?+;]!&QNOZ>IA/@=+N''I4F6>Z,-C&#"2J#2EF33Y04A!+YLG%
MU(V>P#]#V<C=Q'N!T%[0/E*?8U<.?II\P?^LM7+Y _UW/DGTL^7$YC^FD^O[
MJ6Q1DE!2 "\U(Z==,0@Q,M LZIS0IF#T<U[NWJOU"+ICE3MK*>D!PZ,CP?-;
MF/\=KY\P(8T*&#4GTNN 2A8BQ)PD<,&+TL8E-,\&13N^/W+O^&8 &4":XT."
MK&^9S;^$:<('3C[B]?45YLET^5LKOE*.R=EB( DMR2GG%H+)MJ9)2V8F,BO<
M7BC9>\F16[<W TX;F7?K.>WM 3S<[DD6E='DOV*2MF;+$[$<&/"$V:$H29DV
MF=.A.!C7YOWSQ!7'06)L)VTMI;HUSR%"LC8R\F5Y2* D(Y[0&0@D4BS".N_3
M7B9USP5[=-5:0V'66"^C'N$;JVWNV3#DB1I/?FEA=:!8I/#)&\_!:1.,RD*8
M))I8T8WDC-@,M8G>=Q4\':6"_I!$87=U9E&#DT@[K=A 7FW@4'+.+N= _D>;
MB[O#R^N:F:T!%+NS-NX0&7?@X_T73BX_TR9Z1:@+E_C[3754WY7E1EJ\N[E>
M7(=I[;GS<&MII6>8R4WVM2F$SL2?9 )0)A2:6Y$:U9P?2NDX/MO9#%13Q75A
MN_;E<"GM"QM]B<'4(OM4GY4JBJUJCX4L9,I6EJ)\F_8P!Y$YKNUKBYDC 7JX
M^CHPFS\]S6L_%)PE$ZRKC5G5W7OX4$7HK/ A&A-XF[OV[32-&[Z>%74#*:8+
M TA>Q7SYTCU<42CU93:]%=F/?>_NBGXPOP_?ZU_^_]K[MN8V<B7-]_TO.8O[
MY64C9+O[C"?<;8?M/OO(P"5A<U8B/235ISV_?A,D=1>E(EE@E=33#XZV;!<2
MF1\2"2#SR[/%(LR^K?_=<I(B1ZX,@F<NU\HV4\LJ'3CG9-:>Y91#$S >+_NP
MKK(O'#VL0#RE24<!XT?7_S8T>N@$KBL*)EX(Z851P%Q$4*$XBHXP@%=%^%QX
M3N&$D>;S @_K91L!]A3&.WP_G],Z:AEK[IKH).9:LUZI1NH[@9*T'(.E_\,D
M1.;::E_:W&CO*>BP;RYCB#=[,6%O".T]$78]KWAKKS@H!_:1K_24_OJ<?#UE
MOKZ;+M/Y?'FYP(^E7COC;+D6]S.NJ]'>SI>KY4-1KG&7!2\Y%@Y1N (JD;=R
M2.!SRM<"D1"T;!,F'2?W\:>8CJ/?#D:6-]GD065K2^!@B@NT7(.FXUOME<YD
M"1@8;]6SX4C!APXM3X;5AZ>CTQE\S.4#C\SQX,*GG=_JTX,^*^LX_*A1C&=2
M#0CT$11Z#H&S DXH5F2R6C+["OWHK6H<0LS\)U(4OOASFO#&=K>%.CM??W+]
M+/H9T_S;K#;^V30R7TMZL^!825)%Q2&O%[NBJ,ACJ@&US,&SR%@C,O=F4WK1
MOG<??#]1LC4@2$9Q(W"CBMLSKK/Z=;YX\O;CME8>U]M:-V]^?CH/LWNU;U'$
MF+17X#G6!"^NP1M+X(\8/&86=*,\[T&F._1MQ C6V5C!];(BHR-**W=_K%EL
MU+*\\DA0ZV)#S*4 -YR<LT0/7A@!FOM 4"F*YS9%AJ\L.%HG,3(5HA:I )*C
M( _!+#A#&LV,AY1RL+P14U23Z;SHH&@?7#</BO8&QP@>DS?90]>=;3]LI[BN
ME$K**A-I*J9VB%!69XC6:6 E9A-XD9JQ5@]XNX0:2Y7E8)!YE%;T>/N-%XK;
M$@F6@XO9A9JE5%=Z<#5=(X&NMT)6)18;Y7X]*=:P<.S-^-U =8 E1@"KSV03
M$N![S8G#/_%\_F/=5F)#7;DMCD%AI?-D^Y E*2LKVD9<J*S0@705K?:Z57^O
M9X4;)<0.@<(#LMI^[3*.VP5<MX#\!\YP$<YI:F?Y8CJ;UFBE/I!?$:9>M=6.
MT7-G-;A4IQ>*A"A- %>"$5X'IF4C,J-]Q!SV--\.@.UL-0HHWNF<'8OWVD82
M5\@$JC+>.R8BT"X1C6>9%]OFR+)W^_)F"0'M@'2PID>!DWXBV0_7)57:V9B#
M-"""IX7"A(/ **0M7/(BO"RL4=?CGB<REKK+L9PTAL3)",+(Y^9+^\?;._S$
M[V>_3F=AEJ;A_-KIW%Q<E*Q8<,9!22I6&FM5'4: 7**HC,,L->H@T^\\!F;]
M&A*2]Z.)X? QBFUD.]-MMML#16RCJ8FU.DC/,Q25:L,=1L=2QA0DC"$9%PFT
M;>Z4NLDW\/72@!BZ7VS?OSE?$$Q_Q]7'\C7\-4%%T9QG&DAE%!;:G,!GY)!2
MHJ.GL@5C(_:(O>0<.%9Y:; ]R+PCR!3O9[][&WY,2:+ZT[.+^>5L-8E.FJ1#
M A:5 N6T "\L;7Y<*9]9-LZ/.61_,*%A#YHC6@YC ,SP_7XVO5R?<@CO9QOF
MD/>;+ NRT'5KHZ*C1R,L*+%FRBYK@C9R$3(6X33C271LGWN8 ,/VGQH!ED]F
MO1$<,CNM5]JXMLT#KXAN[D=ESO@@HG= $5AEM5&>HK)2@%DC PHALVZ3"MN/
M_,/VP!H!Y >$P['>>I#\L'L9ID<FB/'F&6+WY!U'BIBTQ>I(!S@96 #%44)T
M!4&BSU9)9C&U>2)XC2EB6@ITRC"@%1YJKPLZ%V>)H*WAQN?(A6KSH/P_*6+'
MX/HT*6+[@&,$0<G9O\(B?Z6_O,XKT99I+G2&G",#I;%VMY(*B@Z&(BJCO&ET
M@7=;C->8!K87+.[?>QQLHQ$ ;(?6;F7'O_GY,'F^SOAFVK-<$^-O4>I&KR+7
MS(()5M6D> <N,04Z:T/'5-3V_KFM[0/+4;,9F&WS<'!U>R0YG:6'IG/=1?3M
M*#SW :$8GT 9C+6NUD(0A6%)-C+=C67_"-KT4[]JG-#H7:C6][# \%3KG1H*
MH.=*8>$@C/>@;*239Z S*&TC6GAE&4;;"52]M6XX]0O$0!#KW3K# ZX[SWQ,
M1:/)#I"73/.2'*+A$4(4T@C,4@C>"74OA-M_7-!K8Z>A=\VG9_4V++]O)Z5*
M8:($.NOEVG!7N_J>IQC$%*-P48AT_R'K(/#=C#C*V_E18N] *PT-O>L#7IW1
MI\M%^DZJK!K;SD4X8VLK%D!=#VU.&'"6?LF\8 F.Z8#=$/?,0*.\$Q\(:'W:
M9!1)*7WGL?$0HXXZ *VR2F6F667HB6"Y#IXS14NL#5O__Z3@-KWE&1(G0SOB
M+Y<7%V'Q<Q<[PO:MZVRYG*=IO1;^O]/5]W?30H*2J3\MYM\6X>+F4AAM(A=!
M>XY)3(!2=/"KN9^@BN<V.<>C"IW<=J]BO:YLVKW0-1^%J4=P&=HQ\5*P@B:2
MW\C2:@K?K8%0/)TAG111ZNB9:?/$/^8\VJ'1<U@.[3ZF'$6XLF>29<[">^,#
M)!D**,,M1,\]%%ZL4DQRR]K<Q+^$'-H7"=F#3#L*Z+9*B$QTIK7!U>K0>GU,
M>H8HL$!(P0=D=)K)>L01]T@R:$>V&,8 EA>>/1MK[V)?^^L)1E-U1D,D4]&1
M7SLEG _L/N_=:\B>'0F.3V:YWL+FWE,&-T7?M%4=QJ][^Y_WE!2X4Z*>L@"O
MOW^3-G5#;9@#YTIX"*@Y*$^.)]3W>^T]1QZ=8ZD-"^430O7#&G3GTS?,B!R1
M,U&;G.D8*X@-.(\".,M%EYQ4:%38\I148R!T.1X?CW,&]6"',3-4WEJ\AY-V
M/_Q(_ZZE(4WW4P!R0I)Q,R?$5(YV61AXQFC3T"'1'P4,NEG+IU8.YM8U,.U_
MJ5+#7(_VF3;N&O3-TO1\NLW&OT/-JD1.-ND(F:.B%54X>$=!'Y?1><F3$J5-
MMN0Q4H_70>V#KR=R>=O:\84XL&TM0IWC93@_TI'=^UC_#NTI:4_@V*QEG/ZC
M,UKAM9BL-HM$47,@*0Y.C'&*CU^:8[O^]-OY;#6=D?;3S\T;E2$K:U,<&&2.
MCAA:4NSO-2@4*D;IY8-'[;YG>U^D\;JD?9"Q,V8ZR@(#/EHL%ZO)=<W;EX2S
ML)C.UUG"MI!?]MJ#TAY!99_!"?*?S$N6Z?2H(^_T/D$CW((/_>X^=':*,!+(
M'&?:>9]Z'AHH6[G_F"U_8)J6*>9M)DCAPFJ&$4C:7)-O225,"U!,,I]Y+B)T
MJI;J!I9=8@P#F)Y,.^];SR,!RZ_S!::PO&+7TUKHDK0&9)5XP&@#T5D/43NG
M<XK&Z4Z,F7LAY:X, \*D'\,^ I4CM#PX3JZC^O^ZG*Y^_H:K[_/\?O8G;IJ!
M/OPI8LU!6Z\P5#+E$!*@8[1W>R_!1]J[2V19^& #[U:EV1%-ATLZ!@K67O>R
M4UEM8'3NFL?5LBU:")$UF%R?3Y.2$ P68$IFRS.3/';JL-4)?T_+,J17.Q46
MYDT,,WAB7+A87LZ^O9G.Z=0^/0^+LV\+7$<36V_N9"H^N@(.>4V'S0:"MQE$
M=%(;Z5#%;L5ESXTT'(;Z-.>\E6X']D6?%O-\F58?%]OG[/7Z484.J2HKL$Y*
MBC'MNIC34."09>W3[;+O+YYZ3((Q<$+WN;,=K>5QH*0^!6]GL-PN(IU$YIXF
M$6U]$-;1@S/&0O:, L2<BQ&=&N[N Y6'8@SG8XZW[$.8'*GFH;>>LW=__/LO
M'WZ[9LCGT?KD(=%1I)X:"GA:16!CLHR'NG!2IWWFSF<'-_BQ-IKWHK 19"8_
MYBP_W&1[>U>DBPF$*)[V6)\@J%1 H+:8T*:"C7,+'A-KV/J\?K>7_NTP E"]
MVPY+TSE;+G&U_&<XO[Q.K/M7+2:<,&F$BU&#9(6"K!(=!!T4"(K=>(S!A]"H
ML_/SPHWOEOE *-SOUMZS748 M<>/EY4C4B2I="5\=[5C1W#@I24U,:>4CPG1
MMNG"LT.@\5WV] .I/O0_ A@]6!D?IB%.SZ>K*2Y_Q]5$:"XM1840G.*@0FTB
M$'.!I)S(3'LA&9[&6]T5;'PGK4:>Z@A[C )>:8&AIN;^,5M<YY/?D'PNWR\_
MTY_/9Q1'_/PT7RZG-9Y( ;U(6=8*:E*@J?VJT3"(S*1HA0RJ4<7O0>*.+RKK
M"XJM;?<B,JV/Z-K]R%>:Y1*=/(DH,B><<V398.K;G-+@=*B7U3PK1(K_0\L6
MIDV2B![/I=NLK$M:7!]_X&)MK^6C:78WJ<>2>]KH,RA7#"BE#3B>(FC%HE-1
M2>;;--KH:0(C.0<<B;H'(=L UAU'G6"'%-&SU:^8:^O(FKYQ2=_[>><O3W2)
M)5OCZWSI9*^+K=VD$((7KC+**<?;+/<>A!^8B6 (V'6"?CL$O!C8KY.5SF;Y
M WWM_-:N.G':AH3<UZ8@6.^T%$0N&4AI*&R*I*G0IL[[&*F'/6R_%*#W8O,7
M@_":#37]-KOS-ZXK,Z?A?!*<]$4D"59EFC4=(VE)U[91+G&MZ+20;*>GL"9(
M?T[Z8>\!7@KB>\7 BT%^/123;'12G=17+,><A:3KRJZ+.F9'^EX_42"7QG;*
M36J"\1LYA[U*>"EH/M"N/3:#:8O;W^?UZ'Y)?RV>7S5N?X<D<]HJ>E:Y%Q:K
MZ7^O?SL1-&\;6 0F2J&IUSJR@!%*9B;:++,T;7J=-)C,L,R0+V4%M$3(\/3,
MUQIX=.[_>/_AZ_M5^&NBDBVR& 4IU#1Q(2-X[3GPS(IB.OOLNS&"=QNO$S+-
M:T1F*Z,,G?#S])2^A)K%>Y,SB3]J%8N(@<X& 2*KI?_&:*"S+X<L7?'>"4NA
M4P^8>VSL3OBS?U/\'6VL<6/QPW0U_;91Y%7*[@0C$[2T-!A17P)%R1!4Y056
MZ(J-7 FG>H#B(T-W0J+[FR+Q6%.-&XB_7^+B_<7%Y:S^\?N+'Z3(Y:08#"I(
M3?%WU)NB8><U@U2<CBJYHG0?3O&QL3M!T?]-H7BTL<:-Q?<S&F:V_M]P_AE)
M@C"["GB+3K3D8H!0';XRV4.0AM7"&A<4XZEKZX2#1>CVYL#^IM#LRW8C2''I
M<E[[N/J.B[/\GY=766*.)<5"LE![C(%"Z2#2,JSI]K;DB-[JX>ZC[DO;#<I_
M^_>SHXP\XDO5QS0],=9CQ%BKQ%#64D4$E[4"[YCRVB:>U2D!_)B,W6#[-WP-
M.]J@AWO=^2J<M\S;6J]!FM]R?C[-]=+V83/S3;[4(>E<W3_>4Y;7@;/I*?GK
MXZU-^4:(S>WBIUNS^EB>ZAAO19(Y%T?K>(UA)BKS:B%<Z<B=%(9.Z4T<12_B
M'TTNG_-T$^1<#_)^MNXK57_Z&+ED1&M8I$7N3;&@HJ?X7(0(TF#&R$VRV*;7
M]MZB#IM5<WIT/F"7;VK;,?/N=?9+A].*[CO$J3UN0TK2?I M(\L,&46;)E<N
M"3I%^>PXI-JI,WF*0T6;.J!1^-T;&HZU17^?S^:;4&?V;1,*;1_-[A%C2L:M
M09>!95.K*RQ"2"R!*3RCCB++U"85YC!Y7X,'W@>GNTE0FUEY%.>R?X3I[,-\
MN?PXNU5I=C,?'8P)*6E(Z&D3R_5ZV=!.AJ:$(@S3/+19ZD_+-6PRXO#H[-%J
M([CFNEEK9RDM+FG\F\*T>^O+UM9_W&F0P=.)U6("YY"!T;IX%4)AHDWJ;'<9
MATT;'!Z;C:SY*H+6(PJ^]A[CU&%KRV*Q?E"-4CKC2@"1<V6>,19"-AI8DCJB
M1QOR*[XON/[BAE@C"W0)@X043'VQRPI<" 9<BC)R'0.M_S:>](X<KR'.W =7
M#[SEX589P<[])IRONYA_1UQ]V';W6M,]96DMC[PR/3%2B? 4!W.9P3&)L3BC
ML=%5TRZ)AL79,5:>-U#Y2*&S98TRRMNB?0(I0J#U%!$BYQ8X%L:\3,RR-JYI
MMTS#PJ<?FW< T@$&& &4-B'*Y:*J\E:P>=7DWM?\*!F *>5)1P+!*4<!;8D\
M>9%41R;L_7?]I\0:'Z .L?V\E2$&1%7&Z>0#?@OGO\Q6T]7/#7NA*%*+R""P
MQ.@\A((.U"&#CD)'%IQ5\2EBK24%U-_F?_YO^O0:/O^EZO_"YG_7F'EDT&'O
M.'K8L8Y5Y, 8V$A]1628,\M%,/"H(ZAB"_@Z#3H:N]K!-\C\%&U,-P#<'G$8
M_W"TR>8]Z&_HU,#W\]ET^27,OH6+^3N<A?-I);8,WW#KQXH*V;K:?)PT4+O2
M%H@E(0@IA;98&]G<RT_9D0#XS$##0>!PT\T;Z7$$4<:U1_QP38$4C2'9%>V0
M2M?V#XZ!\S6Q4$@N0RPVQC87"@]E&?;6L<?SS9%J'@%0U@FHN%S=>2?Z'5?7
M]P4B('>:HO9@,P5"3#@*V*T$SW)*%-";&%LU?WQ:LI$<D@^T_ /VUQ[-,(JW
MNL=Y(3_CIF?ZS9O0N^GRQWRY+KU7-C =P$56N\DR3UNWS37G6=)OF*&=O4TF
MY9Z2#DT*U2=2.I%Y]F2TX9O>7TWSIC;I"ZY6Y^MUO-7D1-+"Y8KB1J=K[Q%.
MYTK/ZGU%ML$YVNSE_7*RGF#XA%!#<\<V1%Q?IAC%5GJU8#::NM+;)- :\9H$
M%[;2@NM L:/"1 !(7!L3*U%\HRWT<8F&)HUMB*=>C# >3W4E_M624 &15&.!
M,Y7JA9<"FA@']+QD*;+3IA64[@@R--=K4P0=KO)11%Y7V_7-4J@;][+NW+B<
M*!^DLC232N4.*A0)D:L"6:>DM%0L^S;\A4^*-2S=25,\]6>.\;BE+8_6YO8\
M_?RZ"+,EZ:D28&QCQ#=8Z.]\#7]-, DK2G; $2N97*YS=0Z,3U:;7(14;>X=
M]A!R6$Z3IO!K9:I1L$@]G>XZ\2:'( L#$90$)4."4"DP,"<ZG6BF FMS=_&T
M7,,RF#1%6X\&&8^W6T_JXZ,SJJT(Z@6A2'3\S96%69G*O>;7G )8O'"<XH8V
MZ2-/RS4L.TE[E/5CD/&@;'/W\@73Y6+]$/WKG[]/KUSTV?F6)N#/&P9PZYV+
MK%!<&DJD TUM4D?+"RJECTU.<,D:L=WM)^A(GH;[N:=M::017&$\-;V)0<<S
M<@%8.V<H61+XD!1(XY FQH*3C?AQGY!J8$KSEG#8 WI[V::WJO5^<7;_EGG"
M4I$6Z:3MG*S\)YAKP;^F;8+3 K:1]H\VT5L7Z09F&!\8=T?9:A27)(_-JK;W
MN3<O]#IBRARBL!1 )!T@VB0@>471*S>.A]-A\*%\ [-^#XS"(^TU"AP^+#O:
MIB1>:RU80_X[(!C%:S]92X%+;7,>!=/!)>LYMGD7?5:TD:1Q]!/9]6N(46#K
MYD7MX:PF4DK.L\V@#:^')&_(60<'*B@F0Q!%-BJ6?4JJ8:.YGB%P/U>H+VN,
MX)SPL&UL[:?]F<RU^!.7VX3M290Z)Z4]"*SOMYK\<!08083B-'IF@V[3_:N3
M>,-&<&VQUK]]1N'0?KGX<3[_B?@9S]=7R _7$2+GL2"#HDREW781*-:@_5\8
M&PM3SF,C.K;G1!MVLVP+MW[M,@+_ME77Y_G/<'['33LA=8F,(E@Z:RL*+>G
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M%/IAD8?6O0]NYZMK^5L!^ZN%G;\!4$L! A0#%     @ $(/T5"B9G3#0E@0
M^O<V !$              ( !     &)I:6(M,C R,C V,S N:'1M4$L! A0#
M%     @ $(/T5(,<9*W(&@  M30! !$              ( !_Y8$ &)I:6(M
M,C R,C V,S N>'-D4$L! A0#%     @ $(/T5-C3YAB])   RVP! !4
M         ( !]K$$ &)I:6(M,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M !"#]%1@(#<X@J   -SE!@ 5              "  >;6! !B:6EB+3(P,C(P
M-C,P7V1E9BYX;6Q02P$"% ,4    "  0@_14I#+#TJ.^  "B]   %
M        @ &;=P4 8FEI8BTR,#(R,#8S,%]G,2YJ<&=02P$"% ,4    "  0
M@_141T\_X4S4  !>"0$ %0              @ %P-@8 8FEI8BTR,#(R,#8S
M,%]G,3 N:G!G4$L! A0#%     @ $(/T5$!3BWNLNP  2.<  !4
M     ( ![PH' &)I:6(M,C R,C V,S!?9S$Q+FIP9U!+ 0(4 Q0    ( !"#
M]%2$@[.9I>P  % 9 0 5              "  <[&!P!B:6EB+3(P,C(P-C,P
M7V<Q,BYJ<&=02P$"% ,4    "  0@_14!H8N7RB- 0"W^ $ %0
M    @ &FLP@ 8FEI8BTR,#(R,#8S,%]G,3,N:G!G4$L! A0#%     @ $(/T
M5#YC],XY>   :*8  !4              ( ! 4$* &)I:6(M,C R,C V,S!?
M9S$T+FIP9U!+ 0(4 Q0    ( !"#]%0:.-J9AW(  ..@   5
M  "  6VY"@!B:6EB+3(P,C(P-C,P7V<Q-2YJ<&=02P$"% ,4    "  0@_14
M:9#:(IMQ  #*H0  %0              @ $G+ L 8FEI8BTR,#(R,#8S,%]G
M,38N:G!G4$L! A0#%     @ $(/T5*<#XG7V;@  8*   !4
M ( !]9T+ &)I:6(M,C R,C V,S!?9S$W+FIP9U!+ 0(4 Q0    ( !"#]%2K
MEK;GGV4  !&1   5              "  1X-# !B:6EB+3(P,C(P-C,P7V<Q
M."YJ<&=02P$"% ,4    "  0@_14JMH(@$)S  #,G0  %0
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M &)I:6(M,C R,C V,S!?9S0N:G!G4$L! A0#%     @ $(/T5.6-KJD>P
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M,C R,C V,S!?9S@N:G!G4$L! A0#%     @ $(/T5"\H!6BIL0  /^0  !0
M             ( !*0P5 &)I:6(M,C R,C V,S!?9SDN:G!G4$L! A0#%
M  @ $(/T5&TTH:&650$ Q^T- !4              ( !!+X5 &)I:6(M,C R
M,C V,S!?;&%B+GAM;%!+ 0(4 Q0    ( !"#]%3X/K_?LM@  "NZ"0 5
M          "  <T3%P!B:6EB+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4
M"  0@_14UJV^KCT(  ! *@  %@              @ &R[!< 8FEI8BTR,#(R
M-C,P>&5X,S$Q+FAT;5!+ 0(4 Q0    ( !"#]%2-3D0U.@@  -,H   6
M          "  2/U%P!B:6EB+3(P,C(V,S!X97@S,3(N:'1M4$L! A0#%
M  @ $(/T5*XDJNZ/!0  $"$  !8              ( !D?T7 &)I:6(M,C R
D,C8S,'AE>#,R,2YH=&U02P4&     !\ 'P /"   5 ,8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
